Program Book - Confex

program B O O K

Pre-Conference Courses: Friday, November 4 – Saturday, November 5, 2011 Annual Scientific Sessions: Saturday, November 5 – Wednesday, November 9, 2011 Exhibits: Sunday, November 6 – Tuesday, November 8, 2011

to the premier meeting in rheumatology

IMPORTANT LOCATIONS ACR Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . W177; Telephone: 312-808-2100 ACR Resource Center . . . . . . . . . . . . . . . . . . . . . . . . . . . Concourse between Halls F1 & F2 Announcements Boards. . . . . . . . . . . . . . . . . . . . . . . . . Gates 43-44 Business Center (FedEx/Kinkos) . . . . . . . . . . . . . . . . . . Level 2 Concourse Career Connection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F1 (Booth 1205) Child Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Call for location; Telephone: 858-397-8909 CME/Internet Center . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F1 Entrance Coat /Baggage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gates 43-44 Exhibit Hall. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F1 Fellows-in-Training Lounge . . . . . . . . . . . . . . . . . . . . . . W375e Pre-Function First Aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gates 43-44 Graffiti Wall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gates 43-44 Hotel Reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F2 Entrance Industry-Supported Symposia Information . . . . . . . . . Gates 43-44 Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F1 (Booth 789) Lost and Found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . W177 (ACR Office) Membership Booth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F2 Entrance Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . W175c; Telephone: 312-808-2104 C20c (Hyatt McCormick Conference Nursing Mothers’ Room. . . . . . . . . . . . . . . . . . . . . . . . . C Center - First Floor) Focus on Philanthropy . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F1 (Booth 601) Poster Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F2 Prayer Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . W472 Recharge Stations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . H alls F1& F2 and back of selected meeting rooms REF 5K Run/Walk Registration. . . . . . . . . . . . . . . . . . . . Hall F2 Entrance REF Booth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Concourse between Halls F1 & F2 REF Donors’ Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . Level 2 (270 Degree Restaurant) Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F2 Entrance Replay Café . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F1 (Booth 180) Restaurant Reservations. . . . . . . . . . . . . . . . . . . . . . . . . Hall F2 Entrance Ribbon Distribution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall F2 Entrance Shuttle Bus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gate 43-44 Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . W184a Taxi Lobby . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gate 40 Visitor Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gate 40 (Information Desk) Wheelchairs (complimentary-limited availability) . . . Gates 43-44 (Coat/Baggage Check) Wheelchair and Electric Scooter Rentals . . . . . . . . . . . Level 2 Concourse (FedEx/Kinkos) Special Needs Contact Ron Olejko in the ACR Office; Room W177; Telephone: 312-808-2100.

program B O O K

ABOUT ACR/ARHP EDUCATION

The American College of Rheumatology and the Association of Rheumatology Health Professionals, a division of the ACR, are organizations of physicians, health professionals and scientists serving members through programs, including education and research. Through these programs, the ACR and the ARHP foster excellence in the care of people with rheumatic and musculoskeletal diseases. The 2011 ACR/ARHP Annual Scientific Meeting programs have been independently planned by the ACR Committee on Education, the ACR Annual Meeting Planning Committee, the ARHP Annual Meeting Program Committee, and the ARHP Clinical Focus Course Task Force. This program is sponsored by the American College of Rheumatology for educational purposes only. The material presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed, but rather is intended to present the opinions of the authors/presenters, which may be helpful to other healthcare professionals. Attendees participating in this medical education program do so with the full knowledge that they waive any claim they may have against the ACR for reliance on any information presented during these educational activities. The ACR does not guarantee, warrant or endorse any commercial products or services.

PROGRAM OBJECTIVES At the conclusion of the 2011 ACR/ARHP annual meeting, participants should be able to: • identify recent developments in the diagnosis and management of patients with rheumatic diseases • outline new technologies for the treatment of rheumatologic problems • d escribe potential challenges in the delivery of care to patients with rheumatic diseases and to specify possible solutions • utilize new research data to improve the quality of care of patients with rheumatic diseases • summarize recent rheumatology research findings Printing of this publication is supported by Amgen, Inc. and Pfizer Inc. This publication was printed by an FSC validated printer on eco-friendly paper.

ACR/ARHP 2011 ANNUAL SCIENTIFIC MEETING The American College of Rheumatology and the Association of Rheumatology Health Professionals are committed to providing comprehensive education to improve the knowledge and performance of physicians, health professionals and scientists. Through evidence-based educational programs, the organization strives to enhance practice performance and improve the quality of care in those with or at risk for arthritis, rheumatic and musculoskeletal diseases.

• Diverse formats of education delivery, including: didactic lectures, debates, and interactive sessions, such as poster tours, Meet the Professor and Workshop sessions;

The program is the result of a planning process that identified educational needs to change or enhance the knowledge, competence or performance of rheumatology professionals. The program’s content was derived from both needs assessment and practice gap analysis, based on professional activities, practice setting, core competencies and ABIM recertification requirements.

• Clinical management sessions, including the Thieves’ Market, Curbside Consults – Ask the Professors, Medical Aspects lectures, the Great Debate and the ACR Knowledge Bowl;

PROGRAM HIGHLIGHTS • Educational tracks to help attendees identify content targeted to them. Tracks include: business of rheumatology, clinical, clinical and research, clinical practice, educators, fellow-in-training, pediatrics, pediatrics and clinical, and research; • Latest science and best practices presented through peerreviewed and selected clinical and scientific abstracts, and invited speakers providing clinical, evidence-based and quality focused content;

• Extensive learning opportunities in the basic science of rheumatology, an area of the program developed by a subcommittee of US and internationally prominent basic scientists. Offerings include: Basic Science Symposia, Stateof-the-Art Lectures, a series of Immunology Updates for Clinicians, and a Basic Science pre-meeting course;

• A specific pediatric rheumatology track, plus content integrated throughout the program designed to provide a high-level educational program, to pediatric rheumatologists; and relevant updates to adult rheumatologists; • Formal presentations of new practice guidelines provided to alert the membership and explain, in an open forum, the data supporting the guidelines and propose approaches for implementation; • Over 40 workshops designed to provide hands-on skills training. For additional details, refer to the session level learning objectives at www.rheumatology.org/annual.

TABLE OF CONTENTS POLICIES Copyright Materials Policy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Embargo Policy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8

MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices . . . . . . . . . . . . . . . . . . . . . . . 9 Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Child Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Nursing Mother’s Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Exhibit Hall. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Meeting Room Capacity/Important Fire Safety Information. . . . . . . . . . . . 9 Photography and Videotaping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Name Badges. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Emergency Contact Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 No Smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Session Descriptions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Meeting Navigation Guide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

MEETING SERVICES My ACR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 ACR Resource Center. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Membership Booth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Lost and Found. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

CERTIFICATES OF CME CREDIT OR PARTICIPATION Accreditation Statement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 310 Designation Statement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 310 International Physicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 310 Health Professionals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 310

MEETING EVALUATIONS, CME CREDIT/ CERTIFICATES OF PARTICIPATION Conflict of Interest/Disclosure Statements. . . . . . . . . . . . . . . . . . . . . . . . 310 ACR Disclosure Policy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 310

PRE-CONFERENCE PROGRAM Friday, November 4, 2011 ACR/ARHP Musculoskeletal Ultrasound Course for Rheumatologists – Day One. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 ACR Certified Rheumatology Coder Course – Day One . . . . . . . . . . . . . . . 18 ACR Basic Research Conference: Bone Pathophysiology in Inflammatory and Rheumatic Disorders – Day One. . . . . . . . . . . . . . . . 18 ACR/ABIM Maintenance of Certification Learning Session – 2011 Update in Rheumatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

Saturday, November 5, 2011 ACR Musculoskeletal Ultrasound Course for Rheumatologists – Day Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 ACR Basic Research Conference: Bone Pathophysiology in Inflammatory and Rheumatic Disorders – Day Two. . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Announcements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

ACR Clinical Research Conference: Comparative Effectiveness Research in Rheumatology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

ACR Career Connections. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

ACR Review Course. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

ARHP Clinical Focus Course: Targeted Approaches to Complex Pain Management. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Shuttle Bus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Speaker Ready Room. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Wi-Fi and Recharge Access. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 REF Booth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 REF Donors’ Lounge. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 REF 5K Run/Walk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

SPECIAL OFFERS

ACR Certified Rheumatology Coder Examination – Day Two. . . . . . . . . . . 24 ACR/ARHP Opening Lecture and Awards. . . . . . . . . . . . . . . . . . . . . . . . . . . 24 ACR/ARHP Opening Event. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

ACR/ARHP ANNUAL SCIENTIFIC MEETING Sunday, November 6, 2011 ARHP Special Sessions: First-time Attendees Orientation . . . . . . . . . . . . . 26

SessionSelect. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

ARHP Special Sessions: Moderator Orientation . . . . . . . . . . . . . . . . . . . . . 26

ACR Career Connection Networking Reception . . . . . . . . . . . . . . . . . . . . . 14

ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

What Would Make This Meeting Better?. . . . . . . . . . . . . . . . . . . . . . . . . . . 14

ACR Special Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Medical Bag. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

ACR State-of-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 ACR REF Special Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

POSTER SESSIONS Poster Session Presenter Instructions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Guided Poster Tours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Poster Hanging Service. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

ACR Meet the Professor Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 ACR Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 ACR Practice Issue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 ACR Immunology Updates for the Clinicians. . . . . . . . . . . . . . . . . . . . . . . . 28 ACR Medical Aspects for the Rheumatic Diseases . . . . . . . . . . . . . . . . . . . 28 ACR Poster Session A and Poster Tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 ACR Practice Issue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 2011 Program Book

3

TABLE OF CONTENTS ACR State-of-the-Art Lectures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29

ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57

ARHP General Session I – Keynote Address. . . . . . . . . . . . . . . . . . . . . . . . . 29

Exhibits. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58

Exhibits. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

ACR Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58

ACR Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

ARHP General Sessions III: Distinguished Lecturer. . . . . . . . . . . . . . . . . . . 59

Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30


ACR Plenary Session I: Discovery 2011. . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59


ACR Plenary Session II – Discovery 2011. . . . . . . . . . . . . . . . . . . . . . . . . . . 60

ARHP Special Session: Networking Forum. . . . . . . . . . . . . . . . . . . . . . . . . . 32

ACR Practice Issue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60


ARHP Special Session: ARHP Networking at Noon. . . . . . . . . . . . . . . . . . . 61

ACR Meet the Professor Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32


ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33



ACR Special Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62

ACR Special Session: Medical Education: Year in Review. . . . . . . . . . . . . . 33

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62

ACR State of-the-Art Lecture. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33

ACR Special Session: 2011 Updated ACR Rheumatoid Arthritis Guidelines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

ACR Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 ACR Basis Science Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34

ACR Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

ACR Concurrent Abstract Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34

ACR Basic Science Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

ACR Special Session: Great Debate: Is too Much Suppression of Turnover Bad for Bone?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 ACR Concurrent Abstract Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64

ACR REF Special Session: REF “Within Our Reach”: Finding a Cure for Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

ACR Special Session: Thieves’ Market: Show Me Your Best Cases. . . . . . . 71

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43


ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 ACR/ARHP Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 ACR Concurrent Abstract Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 ACR Meet the Professor Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 ACR Special Session: Legislative Update from Capitol Hill. . . . . . . . . . . . . 51 ACR REF Special Session: ACR REF Clinician Scholar Educator. . . . . . . . . . 51 ACR/ARHP Combined Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 REF Industry Roundtable-Supported Symposia. . . . . . . . . . . . . . . . . . . . . . 53

Monday, November 7, 2011 ACR Immunology Updates for Clinicians. . . . . . . . . . . . . . . . . . . . . . . . . . . 54 ACR Special Session: Clinicopathologic Conference: A 40 Year-Old Male with Dyspnea on Exertion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 ACR State-of-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 ACR Meet the Professor Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 ACR/ARHP Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 ACR Medical Aspects of Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . 56 ACR Practice Issue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 ACR State-of-the-Art Lectures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56

4

ACR State-of-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 ACR/ARHP Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 ACR Concurrent Abstract Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 ACR Meet the Professor Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 ACR Special Session: ILAR Global Health Project. . . . . . . . . . . . . . . . . . . . . 80 ACR Special Session: Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . 81 ACR Special Session: The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives. . . . . . . . . . . . . . . . . . . . 81 ACR/ARHP Combined Abstract Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 ACR REF Special Session: ACR REF Marshall J. Schiff, MD, Memorial Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 Wine and Cheese Reception. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 ACR Study Groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

Tuesday, November 8, 2011 REF 5K Run/Walk. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 ACR Medical Aspects of Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . 85 ACR Special Session: Gender Issues in the Rheumatology Workforce . . . 85 ACR State-of-the-Art Lectures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86

ACR/ARHP Poster Session B and Poster Tours. . . . . . . . . . . . . . . . . . . . . . . 57


ACR REF Special Session: REF Memorial Lectureship in honor of Lawrence E. Shulman, MD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57

ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

2011 Program Book

ACR/ARHP Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

TABLE OF CONTENTS ACR Immunology Updates for Clinicians. . . . . . . . . . . . . . . . . . . . . . . . . . . 88

ACR Basic Science Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117

ACR State-of-the-Art Lectures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88

ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118

ACR/ARHP Poster Session C and Poster Tours. . . . . . . . . . . . . . . . . . . . . . . 88

ACR Concurrent Abstract Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119

ACR REF Special Session: REF Paul Klemperer, MD, Memorial Lectureship. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89

ACR Special Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123


ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124

ACR Practice Issue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 Exhibits. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 ACR Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91 ACR Plenary Session III – Discovery 2011. . . . . . . . . . . . . . . . . . . . . . . . . . 91 ACR Practice Issue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92 ARHP Special Session: Networking Break . . . . . . . . . . . . . . . . . . . . . . . . . . 93 Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93 ACR Meet the Professor Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93 ACR Clinical Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94

****ARHP Concurrent Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . 123 ACR Basic Science Symposium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125 ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125 ACR Concurrent Abstract Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126 ACR State-of-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 Industry-Supported Post-Conference Symposia. . . . . . . . . . . . . . . . . . . . 130

ACR POSTER SESSION A (Abstracts # 1-717) Antiphospholipid Syndrome (Abstracts #1-26). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131


Cell-cell Interactions and Adhesion (Abstracts # 27-41). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133

ACR Special Session: Education Redesign for Teaching Rheumatologists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94

Cytokines, Mediators, and Gene Regulation (Abstracts # 42-82). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134

ACR Study Groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94 ACR Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94

Education: Medical Education (Abstracts # 83-98). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137

ACR Concurrent Abstract Session: Leadership Town Hall, Business Meeting and Late-breaking Abstracts . . . . . . . . . . . . . . . . . . . 95

Epidemiology and Health Services Research I: Rheumatoid Arthritis (Abstracts # 99-149) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138

ACR Basic Science Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95

Genetics of Human Rheumatic Diseases (Abstracts # 150-171) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142

ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 ACR Concurrent Abstract Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 *ACR REF Special Session: REF Edmond L. Dubois, MD, Memorial Lectureship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104 ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105 Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 ACR Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 ACR Basic Science Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 ACR Clinical Symposia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107 ACR Concurrent Abstract Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 ACR Meet the Professor Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113 ACR Special Session: ACR Knowledge Bowl. . . . . . . . . . . . . . . . . . . . . . . . 113 ACR Special Session: Insurance Roundtable . . . . . . . . . . . . . . . . . . . . . . . 113 ACR/ARHP Combined Abstract Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . 114 **ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115 REF Industry Roundtable-Supported Symposia. . . . . . . . . . . . . . . . . . . . . 115

Wednesday, November 9, 2011 ACR Immunology Updates for the Clinicians. . . . . . . . . . . . . . . . . . . . . . . 116 ACR Practice Issue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 ACR Special Session. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 ACR State-of-the-Art Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 ***ARHP Concurrent Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 ARHP Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117

Imaging of Rheumatic Disease: Ultrasound, Optical and Preclinical Imaging (Abstracts # 172-206) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144 Metabolic and Crystal Arthropathies I: Pathogenesis, Epidemiology, and Diagnosis (Abstracts # 207-223) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 Muscle Biology, Myositis and Myopathies: New Developments in the Clinical Evaluation, Immunology and Treatment of Myositis (Abstracts # 224-253) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148 Pediatric Rheumatology – Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis (Abstracts # 254-293) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151 Pediatric Rheumatology-Pathogenesis and Genetics (Astracts # 294-310) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155 Rheumatoid Arthritis Clinical Aspects: Rheumatoid Arthritis Classification, Disease Activity and Remission, Biomarkers and Predictors of Response (Abstracts # 311-363) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156 Rheumatoid Arthritis - Human Etiology and Pathogenesis (Abstracts # 364-391) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy I (Abstracts # 392-464) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163 Sjögren’s Syndrome (Abstracts # 465-498) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171 Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I (Abstracts # 499-552) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174 Systemic Lupus Erythematosus – Animal Models (Abstracts # 553-576) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178 2011 Program Book

5

TABLE OF CONTENTS Systemic Lupus Erythematosus – Clinical Aspects I (Abstracts # 577-631) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180

Vasculitis I (Abstracts # 1500-1537) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I: Susceptibility and Pathogenic Mechanisms (Abstracts # 632-664) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185

ARHP Epidemiology and Public Health (Abstracts # 1538-1556) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics (Abstracts # 665-717) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190

ACR/ARHP POSTER SESSION B (Abstracts # 875-1586) Epidemiology and Health Services Research II: Osteoarthritis/ Osteoporosis/Gout /Cost (Abstracts # 875-924) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195 Fibromyalgia and Soft Tissue Disorders (Abstracts # 925-943) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198 Imaging of Rheumatic Disease: X-ray, Magnetic Resonance Imaging, Computed Tomography and Positron Emission Tomography (Abstracts # 944-974) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199 Innate Immunity and Rheumatic Disease (Abstracts # 975-1012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202 Metabolic and Crystal Arthropathies II: Anti-Gout Therapy and Outcomes. (Abstracts # 1013-1037) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204 Miscellaneous Rheumatic and Inflammatory Diseases (Abstracts # 1038-1059) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206 Orthopedics, Low Back Pain, and Rehabilitation (Abstracts # 1060-1069) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208 Osteoarthritis – Clinical Aspects (Abstracts # 1070-1096) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209 Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis (Abstracts # 1097-1129) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211 Rheumatoid Arthritis – Animal Models *(Abstracts # 1130-1153) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213 Rheumatoid Arthritis Clinical Aspects: Cardiovascular Disease in Rheumatoid Arthritis; Infection and Rheumatoid Arthritis; Drug Studies and Safety; Risk Factors for Rheumatoid Arthritis (Abstracts # 1154-1206) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215 Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy II (Abstracts # 1207-1283) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220 Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II (Abstracts # 1284-1336) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227 Spondylarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology (Abstracts # 1337-1366) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 Systemic Lupus Erythematosus – Clinical Aspects II (Abstracts # 1367-1422) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233 Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II: Innate Immune System and Organ Damage (Abstracts # 1423-1446) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237 Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics (Abstracts # 1447-1478) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239 Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics (Abstracts # 1479-1499) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242

6

2011 Program Book

ARHP Rehabilitation Sciences (Abstracts # 1557-1571) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249 Clinical Practice/Patient Care (Abstracts # 1572-1578) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250 Education and Community Programs (Abstracts # 1579-1586) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250

ACR POSTER SESSION C (Abstracts # 1733-2426) B cell Biology and Targets in Autoimmune Disease (Abstracts # 1733-1769) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251 Biology and Pathology of Bone and Joint: Inflammation and Osteoarthritis (Abstracts # 1770-1804) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 253 Cytokines, Mediators, and Gene Regulation (Abstracts # 1805-1845) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256 Epidemiology and Health Services Research III: Connective Tissue Diseases/Vasculitis/Inflammatory Arthritis (Abstracts # 1846-1895) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 258 Fibromyalgia and Soft-Tissue Disorders (Abstracts # 1896-1917) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262 Genomics, Proteomics, and Genetics (Abstracts # 1918-1938) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263 Infection-Related Rheumatic Disease (Abstracts # 1939-1952) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 265 Miscellaneous Rheumatic and Inflammatory Diseases (Abstracts # 1953-1976) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266 Osteoarthritis – Clinical Aspects (Abstracts # 1977-2006) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268 Pediatric Rheumatology – Clinical and Therapeutic Aspects: Pediatric Rheumatology Systemic Lupus Erythematosus, Juvenile Dermatomyositis, Vasculitis and Other (Abstracts # 2007-2047) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270 Quality Measures and Innovations in Practice Management and Care Delivery II (Abstracts # 2048-2079) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274 Rheumatoid Arthritis – Animal Models (Abstracts # 2080-2103) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276 Rheumatoid Arthritis Clinical Aspects: Clinical Features of Rheumatoid Arthritis; Disease Severity; Outcomes Research and Metrology (Abstracts # 2104-2154) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277 Rheumatoid Arthritis – Human Etiology and Pathogenesis (Abstracts # 2155-2186) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 282 Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy III. (Abstracts # 2187-2253) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285 Systemic Lupus Erythematosus – Clinical Aspects III (Abstracts # 2254-2308) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291 Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics (Abstracts # 2309-2330) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295 T-cell Biology and Targets in Autoimmune Disease: Lymphocyte Biology and Targets in Autoimmune Disease (Abstracts # 2331-2364) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297

TABLE OF CONTENTS Vasculitis Poster II (Abstracts # 2365-2402) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299 ARHP Pediatric (Abstract # 2403). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302 ARHP Psychology/Social Sciences (Abstracts # 2404-2412) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302 Health Services Research (Abstracts # 2413-2416) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303 Research Methodology (Abstracts # 2417-2426) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303

REF Industry Roundtable-Supported Symposia and Industry-Supported Post-Conference Symposia . . . . . . . . . . . . . . . 304

RECOGNITION 2011 ACR/ARHP Annual Meeting Leadership. . . . . . . . . . . . . . . . . . . . . . 311 Exhibitor Listing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 316 Supporter Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320

INDICES Invited Speaker/Moderator Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322 ACR/ARHP Abstract Author Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339 ACR/ARHP Abstract Keyword Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388 ACR/ARHP Abstract Moderator Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . 396

Abstracts sessions denoted by an asterisk (*) are not in sequential order. *Abstract # 2487 can be found on page 104. ** Abstracts # 2547-2552 can be found on page 104. *** Abstracts # 2559A-2559C and 2560 can be found on page 123. **** Abstract # 2609 can be found on page 123.

2011 Program Book

7

The most comprehensive online collection of rheumatology-related images. Serving as a centralized resource for clinicians, researchers and health care professionals, the Rheumatology Image Bank provides invaluable assistance in self-study or the education of others. Start your visual exploration of rheumatology today! Stop by the Resource Center, located in the concourse between Halls F1 & F2, to grab a copy of the 2012 ACR Calendar featuring select images from the Rheumatology Image Bank. While there, ask to view a demo or visit http://images.rheumatology.org.

COPYRIGHT MATERIALS POLICY

MEDIA

The annual meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without written permission of the American College of Rheumatology and the presenter. Any use of the program content for commercial purposes, which includes, but is not limited to oral presentations, audiovisual materials used by speakers, and program handouts without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it.

Credentialed media attend the annual meeting to cover stories for consumer, trade and other media outlets, and are easily identified by their black press ribbons. Media has access to all general sessions and, at the discretion of speakers, limited access to Meet the Professor and Workshop sessions. Media may use hand-held audio recorders and still cameras; moving video recording is also permitted with the permission of the presenter(s). The exception to this policy is that an exhibit may not be photographed or videotaped without the permission of the authorized exhibitor. Annual meeting attendees who have questions about the ACR’s media policies should contact Suzanne Forte at [email protected].

The names, insignias, logos and acronyms of the ACR, the ARHP and the REF are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the express written permission of the American College of Rheumatology.

8

2011 Program Book

EMBARGO POLICY Accepted abstracts are made available to the public online, in advance of the meeting, and are published in a special supplement of Arthritis & Rheumatism. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract online.

However, the ACR continues to require that information that goes beyond that contained in the abstract, e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional new information that will be available at the time of the meeting, is under embargo until 5:00 pm Eastern Time on Saturday, November 5. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy.

MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices As a courtesy to meeting attendees, electronic devices must be operated in silent/vibrate mode within educational sessions; devices that beep, ring, etc. are prohibited. Cell phone conversations are not permitted in meeting rooms. Children For safety reasons, strollers are not permitted in the exhibit hall and all children must be accompanied by an adult. Child Care KiddieCorp is providing child care services for attendees during meeting hours. If you did not reserve space in advance, you can inquire about space availability by calling 858-397-8909. Nursing Mothers’ Room During scientific session hours, a staffed Nursing Mothers’ room will be available in room CC21a of the Hyatt McCormick Conference Center. This room will have private seating areas, a refrigerator and a bulletin board for information exchange, advice and suggestions. Exhibit Hall The 2011 exhibit hall is located in Hall F1 of McCormick Place West. See page 315 for more information. Exhibit Hall hours: Sunday, November 6

10:00 am - 5:00 pm

Monday, November 7 Wine and Cheese Reception

10:00 am - 7:00 pm 5:00 - 7:00 pm

Tuesday, November 8

10:00 am - 5:00 pm

Meeting Room Capacity/Important Fire Safety Information Attendance at scientific sessions is on a first-come, first-served basis. Rooms which have reached the maximum capacity may be closed according to local fire and safety regulations. Standing in the aisle or against the walls is not permitted. If overcrowding occurs, staff/security personnel will close the session. If space does not permit you to attend a session, the session may be available on SessionSelect or replayed in the Replay Café in the exhibit hall.

Photography and Videotaping Photographers will be present at the meeting. Registration and attendance at, or participation in, ACR meetings and other activities constitutes an agreement by the registrant for the ACR’s use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions, and audio tapes of such events and activities. Visual reproduction of sessions is prohibited without prior written permission of the ACR. The ACR reserves the rights to audio and video reproduction at the 2011 ACR/ARHP Annual Scientific Meeting. See copyrighted materials policy for more information on page 8. Name Badges For security reasons, your badge will be required for admittance to all sessions, exhibits, social events and shuttle buses. Please wear your badge so it can be easily seen at all times. Lost badges should be reported to the registration staff immediately. Emergency Contact Information Space is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder. No Smoking All meeting facilities at the convention center, hotel meeting rooms and other venues have been designated as non-smoking areas.

SESSION DESCRIPTIONS ACR Clinical Symposia provide instruction to improve patient care. Developments from other specialties and practical patient management skills will be emphasized. Included are Clinical Reviews. ACR and ARHP Concurrent Abstract Sessions are the main forum for didactic presentation of original research related to rheumatic diseases. ACR and ARHP Poster Sessions feature poster presentation of abstracts, facilitating one-on-one interaction between the presenter and the audience. ACR/ARHP Poster Tours Guided poster tours, led by experts in the field, will guide small groups of attendees during the poster presentation times to highlight novel or recent developments. Selected posters from various abstract categories will be included in the tours. ACR and ARHP Pre-Conference Courses are designed to offer attendees, with a specific interest, a unique learning opportunity. A separate registration is required. ACR Basic Science Symposia provide an update of the most recent scientific developments in the field of rheumatology. ACR Immunology Updates for Clinicians is a series of three one-hour lectures designed to provide clinicians with an update of the new developments in immunology. 2011 Program Book

9

ACR Medical Aspects of Rheumatic Diseases are sessions that cover topics in other subspecialty areas in internal medicine that are of importance to the practice of rheumatology, presented by experts from other medical subspecialties. ACR Meet the Professor Sessions provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. Several sessions are designated for trainees only. A separate registration is required. ACR Plenary Sessions: Discovery 2011 – three plenary sessions will be offered and each session will have a separate focus and will highlight abstracts of significant novelty and importance. ACR Practice Issues are sessions that address the major changes in the practice of rheumatology with the introduction of new medications, devices, and diagnostic and ancillary services for patients. ACR State-of-the-Art Lectures present current information about topics related to rheumatology and are presented by leading experts in their respective fields. ACR Study Groups are designed to bring together attendees with a common interest in one disease, a group of related disorders, or a specialized field of study for discussion and dissemination of information. ACR/ARHP Workshops are designed to bring attendees together to foster hands-on learning, and provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. Several sessions are designated for trainees only. A separate registration is required. ACR Year in Review highlights publications of major interest to the membership that have appeared in rheumatology literature since the last meeting. Both basic science and clinical perspectives are represented. ARHP Concurrent Sessions offer educational programs of interest to various health professionals. Concurrent sessions include invited speakers; peer-reviewed programs and lectures; and research and special interest abstract sessions. ARHP General Sessions are interdisciplinary sessions scheduled without competing programs. The topics are of expansive interest or the speaker is of such status as to appeal to the membership at large.

2011 SPECIAL SESSIONS ACR • 2011 Updated ACR Rheumatoid Arthritis Guidelines. . . . . 63 • ACR Knowledge Bowl. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113 • ACR Leadership Town Hall Meeting. . . . . . . . . . . . . . . . . . . 95 • A CR REF Special Session: Clinician Scholar Educator Presentations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 • C areer Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123

10

2011 Program Book

• C linicopathologic Conference: A 40 Year-Old Male with Dyspnea on Exertion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 • Contract Negotiations for Physicians. . . . . . . . . . . . . . . . . . 62 • Curbside Consults - Ask the Professors . . . . . . . . . . . . . . . . 59 • Education Redesign for Teaching Rheumatologists. . . . . . . 94 • Gender Issues in the Rheumatology Workforce. . . . . . . . . 85 • G reat Debate: Is too Much Suppression of Turnover Bad for Bone?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 • ILAR Global Health Project . . . . . . . . . . . . . . . . . . . . . . . . . . 80 • Insurance Roundtable. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113 • Legislative Update from Capitol Hill. . . . . . . . . . . . . . . . . . . 51 • L everaging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives. . . . 81 • Medical Education: Year in Review. . . . . . . . . . . . . . . . . . . . 33 • R heumatology Roundup: Highlights from the 2011 Annual Scientific Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 • T he Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . 81 • Thieves’ Market: Show Me Your Best Cases . . . . . . . . . . . . 71 • Year in Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

ACR REF • A CR REF Edmond L. Dubois, MD, Memorial Lectureship: Interfering with Vascular Health: Inate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104 CR REF Marshall J. Schiff, MD, Memorial Lectureship: • A Multicenter Orthopaedic Outcomes Network - A Prospective Longitudinal Cohort of ACL Reconstruction Outcomes. . . . 82 • A CR REF Memorial Lectureship: From Shulman’s Syndrome to Nephrogenic Systemic Fibrosis: Exogenous Factors and Systemic Fibrosing Disorders . . . . . . . . . . . . . . . . . . . . . . . . 57 • ACR REF Oscar S. Gluck, MD, Memorial Lectureship: Everything a Rheumatologist Should Know About GlucocorticoidInduced Bone Fragility but was Afraid to Ask . . . . . . . . . . . 26 • A CR REF Paul Klemperer, MD Memorial Lectureship: Osteoarthritis - Quo Vadis - Where are We Now - Where are We Going? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 • A CR REF Special Session: “Within Our Reach”: Finding a Cure for Rheumatoid Arthritis. . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

ARHP • ARHP Networking at Noon. . . . . . . . . . . . . . . . . . . . . . . . . . 61 • ARHP Networking Break. . . . . . . . . . . . . . . . . . . . . . . . . . . . 93 • ARHP Networking Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 • ARHP First-time Attendees Orientation. . . . . . . . . . . . . . . . 26 • ARHP Moderators Orientation. . . . . . . . . . . . . . . . . . . . . . . 26

MEETING NAVIGATION GUIDE To navigate the meeting by track, look for these icons. BR Business of Rheumatology

Look for these specific areas at the Resource Center: • A dvocacy Get the most up-to-date information on the legislative and regulatory issues affecting your profession. We have talking points on all ACR legislative priorities and tips on how to get more involved with the ACR’s advocacy efforts. You can also receive information on RheumPAC – the ACR’s political action committee.

C Clinical c/r Clinical and Research cP Clinical Practice Ed. Educators f Fellow-In-Training

• College Showcase Throughout the week, recordings of sessions will be replayed. ACR staff will also present interactive demonstrations of educational resources and practice tools.

P Pediatrics P/C Pediatrics and Clinical R Research

ARS AUDIENCE RESPONSE SYSTEM

Audience Response System will be used in selected sessions to allow attendees to actively participate. PM PAIN MANAGEMENT

The ACR designates certain sessions for pain management credit as required by the Medical Board of California (AB487). This designation is identified by the icon shown and will be placed next to the session title. PS PATIENT SAFETY

The ACR designates certain sessions that will satisfy patient safety/risk management requirements of the Medical Board of Pennsylvania. This designation is identified by the icon shown and will be placed next to the session title.

MEETING SERVICES MY ACR – The Source for Syllabi and Abstracts View, download and print speaker syllabi and abstracts during and after the annual meeting. Use MY ACR to identify recorded sessions and create a list of sessions that you would like to view on SessionSelect. See page 16 for more information on SessionSelect . ACR Resource Center – The Spot for All Things ACR! ACR Resource Center Hours: Friday, November 4 Saturday, November 5 Sunday, November 6 Monday, November 7 Tuesday, November 8 Wednesday, November 9

questions you may have. The Resource Center has it all in one place and with longer hours! See page 12 for more information.

6:30 am - 6:00 pm 6:30 am - 6:30 pm 6:30 am - 6:00 pm 6:30 am - 6:00 pm 6:30 am - 6:00 pm 6:30 am - 1:00 pm

Stop by the ACR Resource Center, located in the concourse between Halls F1 & F2, to learn more about the exceptional services the College has to offer and the exciting new initiatives under way. ACR staff will demonstrate popular ACR/ARHP online resources, provide information and answer any

• L upus Initiative This educational initiative, designed to reduce health disparities in lupus based on gender, race and ethnicity, will offer demonstrations of educational resources for health professionals in training and in practice. Lupus experts are encouraged to drop by to participate in our online discussion. • P ractice Management & Coding Visit with ACR certified coders and practice management experts for any coding, billing, insurance or practice management questions. We have all the resources you need for an efficient rheumatology practice. You can also pick up the latest copy of the ACR’s monthly RheumWATCH. • P ublications The editorial office staff of the Arthritis & Rheumatism and Arthritis Care & Research journals will be available to answer questions concerning online article submission and article review processes for the journals. • Q uality & Informatics Learn how enrollment in the RCR can benefit you. The RCR provides hands-on measurement tools and reports that enable you to comparatively assess the quality and outcome of rheumatologic care you provide. Plan on attending interactive demonstrations of this tool offered throughout the week in the College Showcase. • R ecertification Need help navigating Maintenance of Certification? We have answers to help steer your route to success with the American Board of Internal Medicine’s Maintenance of Certification program. An ABIM representative will be on-site throughout the week to help answer your questions. Membership Booth Located in registration at the entrance to Hall F2, this is the place to go if you want to become a member, pay dues, reinstate your membership, learn more about member benefits and awards, or volunteer to serve on a committee. Lost and Found Found items should be returned to the ACR Office, room W177. If you are looking for a lost item, go to the ACR Office or call 312-808-2100. 2011 Program Book

11

ACR Resource Center Located in the concourse between Halls F1 & F2

Visit the ACR Resource Center to see what’s new with the College! Within the Resource Center you can: • Demo popular online products and receive daily giveaways • Get details about educational activities in 2012 • Speak with key representatives from the ACR and ARHP journals • Learn about the latest advocacy efforts • Take advantage of annual meeting-only discounts • Get answers to your coding and billing questions ollect complimentary product brochures, publications and • C patient education materials • S peak with ACR staff about health information technology, new initiatives, CME, MOC and much more

Come discover all the College offers you, your patients and your practice at the Resource Center— where the resources you need are all in one place!

ACR Resource Center Hours: Friday, November 4 . . . . . . . . . . . . . . . . . . . . . . . 6:30 am - 6:00 pm Saturday, November 5. . . . . . . . . . . . . . . . . . . . 6:30 am - 6:30 pm Sunday, November 6 — Tuesday, November 8. . . . . . . . . . . . . . . . . . . . . 6:30 am - 6:00 pm Wednesday, November 9. . . . . . . . . . . . . . . . 7:00 am - 1:00 pm

Newsroom Located in room W175c, use of the Newsroom is limited to media representatives with press passes. Announcements Located at Gates 43 - 44, display boards will be available for posting announcements and events of interest. Posted materials are limited to 8.5” x 11” in size. ACR Career Connections Employers and candidates are encouraged to take advantage of the ACR Career Connection located in the exhibit hall (Hall F1, Aisle 1200) to post position openings, search nationwide rheumatology career opportunities and much more. Employers that post open positions with ACR Career Connection will receive a 15% discount on any job posting package through November 14th. ACR Career Connections Hours: Monday, November 8 Tuesday, November 9 Wednesday, November 10

9:00 am - 5:00 pm 9:00 am - 7:00 pm 9:00 am - 2:00 pm

Registration Registration counters are located in the registration hall (Hall F2 Entrance). Registration Hours: Friday, November 4 Saturday, November 5 Sunday, November 6 Monday, November 7 Tuesday, November 8 Wednesday, November 9


Shuttle Bus Shuttle service will be provided to and from ACR hotels and McCormick Place West beginning Friday, November 4 – Wednesday, November 9. Service operates 6:30 am - 6:30 pm daily (regular service ends on Wednesday, November 9 at 1:30 pm). Special service will be provided on Saturday, Nov. 5 to and from the Opening Event at the Field Museum of Natural History. Full shuttle service information will be posted in ACR hotel lobbies and at the shuttle bus entrance at McCormick West. This service is complimentary for attendees who booked their rooms through the official ACR housing bureau. Attendees who have booked their rooms on their own in contracted or noncontracted ACR hotels may purchase an ACR shuttle bus pass on site at the ACR registration counter for $40. Speaker Ready Room Located in room W184ab. Check-in is expected of all speakers. Plan to check in 24 hours prior to your presentation time. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual technicians will be available to assist you. Computers in the Speaker Ready Room will be

configured with hardware and software exactly like the ones in the meetings rooms and will allow you to preview your presentation, identify problems and make corrections as necessary before your presentation. Speaker Ready Room Hours: Friday, November 4 Saturday, November 5 Sunday, November 6 Monday, November 7 Tuesday, November 8 Wednesday, November 9


Wi-Fi and Recharge Access Complimentary Wi-Fi access is available in all rooms of McCormick Place West. Recharge areas will be available in the exhibit hall (Hall F1), the poster hall (Hall F2) and in large meeting rooms. REF Booth Visit the REF Booth, located in the concourse between Halls F1 & F2, to find out more about what the REF is doing to ensure the future of rheumatology. View and order the latest poster in the Rodnan Commemorative Gout Print poster series, learn more about REF programs and initiatives, and even receive a gift just for stopping by! REF Booth Hours: Friday, November 4 Saturday, November 5 Sunday, November 6 Monday, November 7 Tuesday, November 8 Wednesday, November 9


REF Donors’ Lounge The ACR Research and Education Foundation Donors’ Lounge is located in the 270 Degree Restaurant on Level 2 near the Food Court. Qualified donors should plan to spend time in the Donors’ Lounge and take advantage of special perks! Enjoy a hot breakfast each morning and gourmet afternoon coffee service; catch up on work and check e-mail at one of the private computer stations; or relax by watching some television and catching up with your colleagues. An official 2011 Donors’ Lounge Access Pass is required for entry and will be distributed to qualified donors at the meeting. A minimum cumulative donation of $500 to the REF Annual Giving Campaign during fiscal year 2011 (July 1, 2010 through June 30, 2011) qualifies. REF Donors’ Lounge Hours: Saturday, November 5 Sunday, November 6 Monday, November 7 Tuesday, November 8 Wednesday, November 9

Noon - 5:00 pm 6:30 am - 6:00 pm 6:30 am - 6:00 pm 6:30 am - 6:00 pm 6:30 am - 1:00 pm

2011 Program Book

13

2011 REF 5K RUN/ WALK Tuesday, November 8, 2011 6:00 - 8:00 am Soldier Field

Enjoy a brisk trek through the Windy City while supporting the REF’s commitment to advancing the field of rheumatology. This year’s course will start and finish at Soldier Field, looping runners and walkers through a breathtaking course along the shimmering waters of Lake Michigan. Participants may register at the REF 5K Run/Walk Booth located in the registration area until 5:00 pm on Monday, November 7. On-site registration is $30, subject to space availability. Complimentary shuttle service to and from the course is provided. All participants will receive an official REF 5K Run/Walk T-shirt. All proceeds support activities, grants, and awards provided by the REF.

SPECIAL OFFERS AT THE ANNUAL SCIENTIFIC MEETING SessionSelect – no need to miss a session! Within 24 hours of virtually every live session* at the annual meeting, video recordings of the presentations, including oral abstracts, will be available through SessionSelect, your source for ACR education, online. As a scientific attendee, you get FREE online access to hundreds of hours of annual meeting content–over $500 of added value. See page 16 for more information. Select sessions* will be recorded and available to view as webcasts during and after the meeting. Therefore, if you missed one of the designated sessions, you can watch it the next day through SessionSelect. You can also catch replays of select sessions from SessionSelect in the exhibit hall at the Replay Café and in the ACR Resource Center at the College Showcase. Check these specific areas for a tentative playback schedule of sessions. *Recordings of individual sessions are subject to change. Ticketed sessions and pre-conference courses are not included. CME credit is not available for online viewing.

ACR Career Connection Networking Reception Take advantage of the exhibit hall extended hours on Monday, November 7 from 5:00 - 7:00 pm, to meet with potential employers and candidates during the Wine and Cheese Reception. During this time employers are allowed to distribute handouts, flyers or business cards to potential candidates at the ACR Career Connection in the exhibit hall (Hall F1, Booth 1205).

14

2011 Program Book

What Would Make This Meeting Better? You’ve got ideas to share, and we’ve made it easier for you to share them. • Post a suggestion or thought on the Graffiti Wall near Gate 43 & 44 for all to see • Tweet your idea using the #ACR2011 hashtag • Drop a comment into one of the Idea Boxes around the convention center We can’t wait to see what you come up with. Medical Bag Don’t forget to pick up a Medical Bag prior to visiting the exhibits. Each bag contains special offers and invitations from our exhibitors and will be distributed from the exhibition entrance while supplies last.

POSTER SESSIONS Poster presentations facilitate one-on-one interaction between the presenters and attendees. Posters are grouped by topic and will remain displayed in the poster hall area in McCormick Place West, Hall F2, from 9:00 am - 6:00 pm, Sunday, November 6 - Tuesday, November 8. One poster session will be held each day. Presenting authors will be available at their poster from 9:00 - 11:00 am to answer questions from meeting attendees as well as poster tour participants. There is no poster session on Wednesday. The number on the poster boards refers to the abstract presentation number, and this number will change for each poster session. Poster Session Presenter Instructions In order to ensure a positive experience for both attendees and poster presenters, it is important to make sure that all posters are properly mounted and presenters are present from 9:00 - 11:00 am for poster presentations. Please note that the ACR will be monitoring posters during the presentation hours in an effort to make certain that the ACR is meeting the educational needs and expectations of attendees. If you are presenting a poster, please set up and remove your poster during the times listed below. Poster Sessions: Sunday, November 6 - Tuesday, November 8 from 9:00 am - 6:00 pm Set Up: 7:00 - 9:00 am Presentation: 9:00 -11:00 am Poster Tours: 9:00 - 9:45 am 10:15 - 11:00 am Posters to remain up until 6:00 pm Removal: 6:00 - 6:30 pm Poster presenter ribbons will be available in the Speaker Ready Room in room W184ab. Posters must be removed by 6:30 pm. Posters not removed by 6:30 pm will be removed and discarded. ACR is not responsible for lost, damaged or discarded posters.

Guided Poster Tours Guided poster tours, led by experts in the field, will guide small groups of attendees during the daily poster presentation period to highlight novel or recent developments. Selected posters from various abstract categories will be included in the tours. Although there is no fee to participate, preregistration is required and each tour is limited to 20 registered scientific attendees. If you registered in advance of the meeting your ticket was included with your meeting materials. Once you have your ticket, plan to check in at the poster tour desk–located at the entrance of the poster hall–to collect your headset and meet your group 15 minutes prior to the start of your tour. Please note that your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register for a tour and would like to participate, you can check tour availability at registration, located at the entrance to Hall F2. Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on

a first-come, first-served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset and it will be registered against the participants’ registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour. Poster Hanging Service As a convenience for ACR/ARHP abstract poster presenters, this year we are pleased to offer a complimentary poster hanging service to all poster presenters. Poster presenters can drop off their poster at the Poster Check-in Station located in the poster hall (Hall F2) by 5:00 pm the day prior to your poster session and one of the ACR’s friendly staff will hang your poster for you. We will also remove your poster and store it for you until 6:30 pm on Tuesday, November 8. Posters not collected by 6:30 pm on Tuesday, November 8 will be discarded. Poster presenters who had their Mira poster orders shipped directly to the meeting may also use this service or pick up their posters from the Poster Check-in Station.

ACR/ARHP 2012 Annual Scientific Meeting will be held in Washington, D.C. – November 9 - 14, 2012

Call for Proposals and Study Group Applications Submission Deadline: Tuesday, December 6 at 5:00 pm ET Don’t miss the opportunity to share your ideas by submitting a proposal for the ACR/ARHP 2012 Annual Scientific Meeting. To view instructions and submit a proposal, visit www.rheumatology.org/annual.

Coordinate a study group and create a unique opportunity to network with peers that share your interest in a single disease, a group of related disorders or specialized field of study. To view the guidelines and submit an application, go to www.rheumatology.org/annual.

2011 Program Book

15

4 ,

FRIDAY

N o v e m b e r

ACR/ARHP Scientific Sessions

ACR/ARHP Registration 6:30 am - 6:00 pm

Hall F2 Entrance

ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS – DAY ONE C 7:30 am - 5:00 pm

W470b Admission to the ACR Musculoskeletal Ultrasound Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: Ralf G. Thiele, MD; University of Rochester; Rochester, NY Faculty: Rany Al Haj, MD; Shore Arthritis & Rheumatism Associates; Ocean, NJ Marina Backhaus, MD, PhD; Charite University Hospital; Berlin, Germany Peter V. Balint, MD, PhD; National Institute of Rheumatology and Physiotherapy; Budapest, Hungary Herbert Baraf, MD; Arthritis & Rheumatism Associates; Wheaton, MD David A. Bong, MD; Instituto Poal de Reumatologia; Barcelona, Spain Alessandra Bruns, MD, MSc; Université de Sherbrooke; Sherbrooke, QC, Canada Amy C. Cannella, MD; University of Nebraska Medical Center; Omaha, NE Arnoldas Ceponis, MD, PhD; University of California, San Diego; La Jolla, CA Juliet A. Coquia, MD; Presbyterian Medical Group; Albuquerque, NM Jurgen Craig-Muller, MD; CentraCare Clinic; St. Cloud, MN Paul J. DeMarco, MD; Arthritis & Rheumatism Associates PC; Wheaton, MD Amy M. Evangelisto, MD; Arthritis, Rheumatic and Back Disease Associates; Voorhees, NJ Janak R. Goyal, MD; Raritan Bay Medical Center, Perth Amboy, NJ Jay B. Higgs, MD; San Antonio Uniformed Services Health Education Consortium; San Antonio, TX Gurjit S. Kaeley, MBBS, MRCP; Ponte Vedra Beach, FL Eugene Y. Kissin, MD; Boston University; Boston, MA Minna J. Kohler, MD; Yale University School of Medicine; New Haven, CT Gary A. Kunkel, MD; University of Utah School of Medicine; Salt Lake City, UT

Daniel G. Malone, MD; Now: Family & Sports Orthopaedic Center; Beaver Dam, WI Peter Mandl, MD, PhD; Medical University of Vienna; Vienna, Austria Bethany A. Marston, MD; University of Rochester; Rochester, NY Esperanza Naredo, MD; Hosptial Universitario Severo Ochoa; Madrid, Spain Midori Jane Nishio, MD; Walnut Creek, CA P. Scott Pollock, MD; Swedish Medical Center; Seattle, WA Anthony M. Reginato, MD, PhD; The Warren Alpert Medical School at Brown University; Providence, RI Johannes Roth, MD; University of Ottawa; Ottawa, ON, Canada Jonathan Samuels, MD; New York University Hospital for Joint Diseases; New York, NY Wolfgang A. Schmidt, MD; Medical Center for Rheumatology Berlin Buch; Berlin, Germany Darren Tabechian, MD; University of Rochester School of Medicine; Rochester, NY Mihaela B. Taylor, MD; University of California, Los Angeles; Los Angeles, CA Ralf G. Thiele, MD; University of Rochester; Rochester, NY Alvin F. Wells, MD, PhD; Rheumatology & Immunotherapy Center; Oak Creek, WI

2 0 1 1

FRIDAY, NOVEMBER 4, 2011

Upon completion of this session, participants should be able to: • demonstrate the proper probe position and ultrasound machine settings to reliably obtain images of shoulder, elbow, wrist, hand, hip, knee, ankle and foot • identify and describe normal sonographic anatomy for each joint area applying standardized protocols • explain how fundamental sonographic pathology of rheumatic diseases is distinguished from normal findings • assess standardized sonographic scanning protocols for each anatomical region, according to published guidelines • apply appropriate indications for the use of ultrasound in rheumatology • explain the requirements for billing, report generation and record keeping as they relate to musculoskeletal ultrasound • demonstrate evidence-base and technique for ultrasoundguided procedures 7:00 - 7:30 am Continental Breakfast 7:30 am Introduction Ralf G. Thiele, MD; University of Rochester; Rochester, NY 7:45 am Principles of Musculoskeletal Ultrasound for Rheumatologists Wolfgang A. Schmidt, MD; Medical Center for Rheumatology Berlin Buch; Berlin, Germany 8:30 am Ultrasound Findings in Rheumatology Esperanza Naredo, MD; Hosptial Universitario Severo Ochoa; Madrid, Spain 2011 Program Book

17

4 ,

FRIDAY

2 0

1 1

9:15 am Ultrasound in Pediatric Rheumatology Johannes Roth, MD; University of Ottawa; Ottawa, ON, Canada

N o v e m b e r

9:45 - 10:00 am Break 10:00 am The Shoulder - Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Gurjit S. Kaeley, MBBS, MRCP; Ponte Vedra Beach, FL 10:30 am Live Demonstration: Scanning of the Shoulder Gurjit S. Kaeley, MBBS, MRCP; Ponte Vedra Beach, FL 10:45 AM Hands on Scanning: The Shoulder Faculty Noon - 1:00 pm Boxed Lunch 1:00 pm The Elbow - Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Amy M. Evangelisto, MD; Arthritis, Rheumatic and Back Disease Associates; Voorhees, NJ 1:30 pm Live Demonstration: Scanning of the Elbow Amy M. Evangelisto, MD; Arthritis, Rheumatic and Back Disease Associates; Voorhees, NJ 1:45 pm Hands on Scanning: The Elbow Faculty 2:45 - 3:00 pm Break 3:00 pm Hand and Wrist - Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Peter V. Balint, MD, PhD; National Institute of Rheumatology and Physiotherapy; Budapest, Hungary 3:30 pm Live Demonstration: Hand and Wrist Peter V. Balint, MD, PhD; National Institute of Rheumatology and Physiotherapy; Budapest, Hungary 345 pm Hands on Scanning: Hand and Wrist Faculty

ACR CERTIFIED RHEUMATOLOGY CODER COURSE – DAY ONE BR cP 9:00 am - 5:00 pm

W194b Admission to the ACR Certified Rheumatology Coder Course requires a separate registration. Registration includes CRHC review materials and a boxed lunch. This course is not eligible for CME credit.

18

2011 Program Book

Speaker: Antanya Chung, CPC, CPC-I, CRHC, CCP; American College of Rheumatology; Atlanta, GA Upon completion of this session, participants should be able to: • discuss anatomy, physiology and medical terminology necessary to correctly code provider diagnosis and services • identify key coding guidelines and regulations for evaluation and management services • discuss selecting appropriate diagnosis code(s) as it pertains to chief complaints, signs and symptoms and follow-up services

ACR BASIC RESEARCH CONFERENCE: BONE PATHOPHYSIOLOGY IN INFLAMMATORY AND RHEUMATIC DISORDERS – DAY ONE R 1:00 pm - 5:50 pm

W196b Admission to the ACR Basic Research Conference requires a separate registration. Registration includes networking reception. Upon completion of this session, participants should be able to: • describe the techniques for assessing bone structure and function • identify the ontogeny and regulatory pathways controlling osteoclast and osteoblast differentiation and activity under physiologic conditions • explain the mechanisms involved in pathologic bone remodeling in osteoarthritis and inflammatory rheumatic diseases • state the role of the immune system in regulating bone cell differentiation and activity • describe the mechanisms underlying deregulated bone remodeling in Paget’s disease of bone and genetic and pediatric disorders of bone remodeling • identify the role of vitamin D in skeletal homeostasis • explain the rationale for anti-catabolic and anabolic therapies for treating bone diseases

Session I: Ontogeny and Regulation of Bone Cells Moderator: Georg Schett, MD, PhD; Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg; Erlangen, Germany 1:00 pm Introduction: Pathophysiology of Bone Remodeling in Rheumatic Diseases Speaker: Steven R. Goldring, MD; Hospital for Special Surgery; New York, NY 1:25 pm Ontogeny and Functional Regulation of Osteoclasts Mary Beth Humphrey, MD, PhD; University of Oklahoma Health Sciences Center; Oklahoma City, OK 1:50 pm Immune Cell Regulation of Osteoclastogenesis (Osteoimmunology) Hiroshi Takayanagi, MD, PhD; Tokyo Medical and Dental University; Tokyo, Japan

Session II: Cross-Talk between Bone and Extra-Skeletal Organs Moderator: Steven R. Goldring, MD; Hospital for Special Surgery; New York, NY 4:10 pm Bone Fat Connection Clifford J. Rosen, MD; Maine Medical Research Institute; Scarborough, ME 4:35 pm Anabolic Pathways of Serotonin Gerard Karsenty, MD; Columbia University Medical Center; New York, NY

1 1

3:45 pm Role of Osteocytes in Bone Remodeling Lynda Bonewald, PhD; University of Missouri - Kansas City; Kansas City, MO

2 0

3:20 pm Ontogeny and Regulation of Osteoblasts Thomas L. Clemens, PhD; Johns Hopkins University; Baltimore, MD

4 ,

3:05 - 3:20 pm Break

Upon completion of this session, participants should be able to: • assess strengths and weaknesses in rheumatology medical base knowledge • state major developments in rheumatology over the past ten years • satisfy a self-evaluation requirement for the American Board of Internal Medicine Maintenance of Certification program

FRIDAY

2:40 pm Feedback Mechanisms Regulating Osteoclastogenesis Lionel B. Ivashkiv, MD; Hospital for Special Surgery; New York, NY

Moderator: Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH

N o v e m b e r

2:15 pm Innate Immunity: Role of Immunoreceptor Tyrosine-based Activation Motif Receptors Mary C. Nakamura, MD; San Francisco Veterans Affairs Medical Center/University of California; San Francisco, CA

1:00 pm Introduction Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH 1:15 pm Session I Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH 2:30 - 3:00 pm Break 3:00 pm Session II Mary Chester Wasko, MD, MSc; West Penn Allegheny Health System; Pittsburgh, PA 4:15 pm Session III Robert A. Kalish, MD; Tufts Medical Center; Boston, MA 5:30 pm Conclusion Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH

5:00 pm Pediatric Bone Disorders: Bone Muscle and Body Composition Interactions Mary Beth Leonard, MD, MSCE; The Children’s Hospital of Philadelphia; Philadelphia, PA 5:25 pm Osteogenic-Angiogenic Connection Dwight A. Towler, MD, PhD; Washington University in St. Louis; St. Louis, MO 5:50 - 7:00 pm Networking Reception

ACR/ABIM MAINTENANCE OF CERTIFICATION LEARNING SESSION - 2011 UPDATE IN RHEUMATOLOGY c/r ARS 1:00 pm - 5:30 pm

W192b Admission to the ACR/ABIM MOC Learning Session requires a separate registration. Learn in an interactive environment as clinical experts lead you through 25 case-based questions from ABIM’s 2011 Update in Rheumatology Module. After the session, submit your answers online to the ABIM to receive 10 medical knowledge points for the Maintenance of Certification program. 2011 Program Book

19

SATURDAY, NOVEMBER 5, 2011

ACR/ARHP REGISTRATION 6:30 am - 6:30 pm

N o v e m b e r

5 ,

2 0

SATURDAY

1 1

Hall F2 Entrance

ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS – DAY TWO C 7:30 am - 4:30 pm

W470b Admission to the ACR Musculoskeletal Ultrasound Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. See Day One for learning objectives and faculty listing. Moderator: Ralf G. Thiele, MD; University of Rochester; Rochester, NY

1:00 pm Foot and Ankle - Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Ralf G. Thiele, MD; University of Rochester; Rochester, NY 1:30 pm Live Demonstration: Scanning of Foot and Ankle Ralf G. Thiele, MD; University of Rochester; Rochester, NY 1:45 pm Hands-on Scanning: Foot and Ankle Faculty 2:45 - 3:00 pm Break 3:00 pm Ultrasound Needle Guidance - Lecture: Ultrasound Guidance of Procedures Eugene Y. Kissin, MD; Boston University; Boston, MA

7:00 - 7:30 am Continental Breakfast

3:30 pm Live Demonstration: Ultrasound Needle Guidance Eugene Y. Kissin, MD; Boston University; Boston, MA

7:30 am Introduction Ralf G. Thiele, MD; University of Rochester; Rochester, NY

3:45 pm Hands-on Scanning: Ultrasound Needle Guidance Faculty

7:35 am Billing, Coding and Report Generation Herbert Baraf, MD; Arthritis & Rheumatism Associates; Wheaton, MD 8:05 am The Hip - Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Wolfgang A. Schmidt, MD; Medical Center for Rheumatology Berlin Buch; Berlin, Germany 8:35 am Live Demonstration: Scanning of the Hip Wolfgang A. Schmidt, MD; Medical Center for Rheumatology Berlin Buch; Berlin, Germany 8:50 am Hands-on Scanning: The Hip Faculty 9:55 - 10:00 am Break 10:00 am The Knee - Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Marina Backhaus, MD, PhD; Charite University Hospital; Berlin, Germany 10:30 am Live Demonstration: Scanning of the Knee Marina Backhaus, MD, PhD; Charite University Hospital; Berlin, Germany 10:45 am Hands-on Scanning: The Knee Faculty

20

12:00 - 1:00 pm Boxed Lunch

2011 Program Book

ACR BASIC RESEARCH CONFERENCE: BONE PATHOPHYSIOLOGY IN INFLAMMATORY AND RHEUMATIC DISORDERS – DAY TWO R 8:00 am- 4:00 pm

W196b Admission to the ACR Basic Research Conference requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. See Day One for Session Overview and learning objectives. 7:00 - 8:00 am Continental Breakfast

Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases Moderator: Steven R. Goldring, MD; Hospital for Special Surgery; New York, NY 8:00 am De-Regulated Bone Remodeling in Inflammatory Arthritis Georg Schett, MD, PhD; Institute for Clinical Immunology, University of Erlangen-Nuremberg; Erlangen, Germany 8:25 am Uncoupling of Bone Resorption/Formation in Inflammatory Arthritis Ellen M. Gravallese, MD; University of Massachussets Medical School; Worcester, MA 8:50 am Bone Remodeling in Spondylarthropathies Rik Lories, MD, PhD; Katholieke Universiteit Leuven; Leuven, Belgium

9:15 am Bone Remodeling in Osteoarthritis David B. Burr, PhD; Indiana University School of Medicine; Indianapolis, Indiana 9:40 am Glucocorticoid-Induced Bone Loss Nancy E. Lane, MD; University of California Davis School of Medicine; Sacramento, CA

11:45 am Cherubism Antonios O. Aliprantis, MD; Brigham and Women’s Hospital; Boston, MA noon - 1:00 pm Lunch with Speakers

Session IV: Assessment of Bone Structure and Quality Moderator: Georg Schett, MD, PhD; Institute for Clinical Immunology, University of Erlangen-Nuremberg; Erlangen, Germany 1:00 pm Bone Structure and Quality Mary L. Bouxsein, PhD; Harvard Medical School; Boston, MA

ACR CLINICAL RESEARCH CONFERENCE: COMPARATIVE EFFECTIVENESS RESEARCH IN RHEUMATOLOGY c/r 8:30 am - 4:00 pm

W375a Admission to the Clinical Research Conference requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Upon completion of this session, participants should be able to: • restate why comparative effectiveness research is a powerful method to develop evidence-based treatments for rheumatology • describe the importance of standardization of treatments and decreasing variation in treatment • promote comparative effectiveness research and the development of evidence-based treatments through participation in registries • clarify how rheumatologists can get involved in collecting data for comparative effectiveness research 7:00 - 8:30 am Continental Breakfast

1:25 pm Imaging Clemens Lowik, PhD; Leiden University Medical Center; Leiden, Netherlands

8:30 am

Session V: Therapeutic Targeting of Bone Disease

Moderator: Daniel H. Solomon, MD, MPH; Brigham and Women’s Hospital; Boston, MA

Moderator: Georg Schett, MD, PhD; Institute for Clinical Immunology, University of Erlangen-Nuremberg; Erlangen, Germany 1:50 pm Anti-Catabolic Therapies R. Graham G. Russell, MD, PhD; The Botnar Research Centre, Univesity of Oxford; Headington, Oxford, United Kingdom

1 1

11:30 am Fibrodysplasia Ossificans Progressive Eileen M. Shore, PhD; University of Pennsylvania; Philadelphia, PA

2 0

11:05 am Genetic Disorders of Bone Remodeling Matthew L. Warman, MD; Children’s Hospital Boston; Boston, MA

3:55 pm Wrap-up Steven R. Goldring, MD; Hospital for Special Surgery; New York, NY Georg Schett, MD, PhD; Institute for Clinical Immunology, University of Erlangen-Nuremberg; Erlangen, Germany

5 ,

10:45 am Paget’s Disease Margaret Seton, MD; Massachussetts General Hospital; Boston, MA

3:30 pm Targeting the Wnt Pathway Alexander Robling, PhD; Indiana University School of Medicine; Indianapolis, IN

SATURDAY

10:20 am Vitamin D and Bone Disease John S. Adams, MD; University of California, Los Angeles; Los Angeles, CA

3:05 pm Anabolic Pathways-BMPs Vicki Rosen, PhD; Harvard University School of Dental Medicine; Boston, MA

N o v e m b e r

10:05 - 10:20 AM Break

2:40 pm Anabolic Pathways-PTH Serge Ferrari, MD; University of Geneva; Geneva, Switzerland

Session I: Introduction and Overview of Comparative Effectiveness Research from the Perspective of Government and Insurers

Welcome and Introductions Speakers: Daniel H. Solomon, MD, MPH; Brigham and Women’s Hospital; Boston, MA Carol A. Wallace, MD; Children’s Hospital & Regional Medical Center; Seattle, WA

2:15 pm Atypical Fractures/Osteonecrosis Elizabeth J. Shane, MD; Columbia University; New York, NY 2011 Program Book

21

8:35 am The Government’s Agenda for Comparative Effectiveness Research: What Does It Mean for Policy and Funding? Carolyn M. Clancy, MD; Agency for Healthcare Research and Quality, Health and Human Services; Rockville, MD

N o v e m b e r

5 ,

SATURDAY

2 0 1 1

9:20 am How Payers are Using Comparative Effectiveness Research to Make Decisions Edmund Pezalla, MD, MPH; Aetna; Hartford, CT 10:00 am Question and Answer 10:15 - 10:30 am Break

Session II: Methods for Comparative Effectiveness Research Moderator: Carol A. Wallace, MD; Children’s Hospital & Regional Medical Center; Seattle, WA 10:30 am Methodologic Challenges: Why Comparative Effectiveness Research is Tough Sasha Bernatsky, MD, PhD; McGill University Health Centre, Royal Victoria Hospital; Montreal, QC, Canada 11:00 am Methods for Reducing Confounding Sebastian Schneeweiss, MD, ScD; Harvard Medical School; Boston, MA 11:30 am Weighing the Pros and Cons of Different Databases: From Registries to Claims Data Daniel H. Solomon, MD, MPH; Brigham and Women’s Hospital; Boston, MA 12:15 - 1:30 pm Boxed Lunches and Roundtable Discussions of Registries with their Organizers 1:30 pm

Session III: Developing Standardized Treatment Algorithms for Registries Moderator: Carol A. Wallace, MD; Childrens Hospital and Regional Medical Center; Seattle, WA Introduction of Afternoon Session Speakers: Carol A. Wallace, MD; Children’s Hospital and Regional Medical Center; Seattle, WA Daniel H. Solomon, MD, MPH; Brigham and Women’s Hospital; Boston, MA 1:35 pm Importance/Value of Standardized Treatment Algorithms: What Has Been Accomplished in Oncology? Deborah Schrag, MD, MPH; Dana-Farber Cancer Institute; Boston, MA 2:15 pm Developing Standardized Treatments – How to Start? Carol A. Wallace, MD; Childrens Hospital and Regional Medical Center; Seattle, WA

22

2011 Program Book

2:45 pm Break

Session IV: Successes in Rheumatology Comparative Effectiveness Research Moderator: Daniel H. Solomon, MD, MPH; Brigham and Women’s Hospital; Boston, MA 3:00 pm Registries/Cohorts that Have Made a Difference in Rheumatology Jeffrey D. Greenberg, MD; New York University School of Medicine; New York, NY Kimme L. Hyrich, MD, PhD; Arthritis Research United Kingdom Epidemiology Unit, University of Manchester; Manchester, United Kingdom Thomas A. Medsger, MD; University of Pittsburgh; Pittsburgh, PA Laura E. Schanberg, MD; Duke University Medical Center; Durham, NC Frederick Wolfe, MD; National Data Bank for Rheumatic Diseases; Wichita, KS 4:00 - 5:00 pm Networking Reception

ACR REVIEW COURSE

C

8:00 am - 4:00 pm

W375d Admission to the ACR Review Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: Mary E. Cronin, MD; Medical College of Wisconsin; Milwaukee, WI Gary C. Gardner, MD; University of Washington; Seattle, WA 7:00 - 8:00 am Continental Breakfast 8:00 am Neuropsychiatric Lupus Speaker: Michelle Petri, MD, MPH; Johns Hopkins Hospital; Baltimore, MD Upon completion of this session, participants should be able to: • describe an appropriate evaluation of a patient with possible neuropsychiatric lupus • recall current proposed pathogenic mechanisms of neuropsychiatric lupus • devise a treatment protocol for long term management of neuropsychiatric lupus 8:45 am Large Vessel Vasculitis 2011 Speaker: Philip Seo, MD, MHS; Johns Hopkins Vasculitis Center; Baltimore, MD Upon completion of this session, participants should be able to: • describe the basic immunology associated with large vessel vasculitis and its implications on clinical manifestations • develop a diagnostic plan for someone suspected of having a large vessel form of vasculitis

• c onstruct a therapeutic plan for a patient with large vessel vasculitis 9:30 am Peripheral Neuropathies for the Rheumatologist Speaker: Julius Birnbaum, MD, MHS; Johns Hopkins University; Baltimore, MD

11:30 am Lessons Learned from Fibromyalgia Regarding the Mechanisms and Treatment of Chronic Pain PM Speaker: Daniel J. Clauw, MD; University of Michigan; Ann Arbor, MI Upon completion of this session, participants should be able to: • describe a diagnostic approach to the patient with chronic pain • summarize the current knowledge on the mechanism of chronic pain • manage patients with chronic pain with a focus on the possible mechanism of pain in an individual patient 12:15 - 1:15 pm Boxed Lunch 1:15 pm Enthesopathy: Spondylarthropathies and Beyond Speaker: Dennis McGonagle, MB, PhD; University of Leeds and Leeds Teaching Hospitals; Leeds, United Kingdom Upon completion of this session, participants should be able to: • d escribe the basic anatomy and physiology of the enthesis • d escribe the immunology of inflammation at the enthesis • d iscuss with a colleague or patient how inflammation of the enthesis is important in the clinical manifestations of disease 2:00 pm Sjögren’s Syndrome: Not Just Dryness Speaker: Judith A. James, MD, PhD; Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center; Oklahoma City, OK

2 0 1 1

Upon completion of this session, participants should be able to: • d escribe basic ocular anatomy and interpret ophthalmologic examination terminology • f ormulate a differential diagnosis for common forms of inflammatory eye disease • c onstruct a diagnostic evaluation for patients with inflammatory ocular disease • d escribe the current treatment options for these illnesses

5 ,

10:45 am Inflammatory Eye Disease and the Rheumatologist Speaker: James T. Rosenbaum, MD; Oregon Health & Science University; Portland, OR

3:15 pm When Your Defense Can’t Go on the Offense: Immunodeficiencies for the Practicing Rheumatologist Speaker: Troy R. Torgerson, MD, PhD; Children’s Hospital; Seattle, WA

SATURDAY

10:15 - 10:45 am Break

2:45 - 3:15 pm Break N o v e m b e r

Upon completion of this session, participants should be able to: • d escribe the classification of peripheral neuropathies • o utline a diagnostic approach for patients with symptoms of neuropathy • d iscuss a therapeutic plan for patients with autoimmune related disease

Upon completion of this session, participants should be able to: • outline an appropriate work up of a patient with sicca syndrome • discuss the current proposed mechanisms pathogenesis of Sjögren’s syndrome • employ appropriate therapeutic management of the patient with Sjögren’s syndrome

Upon completion of this session, participants should be able to: • describe to a colleague the basic components of the immune system • describe symptoms and signs that might suggest an immunodeficiency • develop a focused evaluation of the patient with possible immunodeficiency

ARHP CLINICAL FOCUS COURSE: TARGETED APPROACHES TO COMPLEX PAIN MANAGEMENT c/r PM 8:00 am - 4:30 pm

W190a Admission to the ARHP Clinical Focus Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Upon completion of this session, participants should be able to: • describe the advances in the understanding of pain pathophysiology, especially the mechanistic characterization of pain • identify how current pain research pertains to conceptualizing and treating patients with rheumatic disease • conduct a comprehensive pain assessment including addressing medical and psychiatric comorbidities, as well as cultural, gender and age-related factors • incorporate the use of validated pain assessment instruments and outcome measures into clinical practice • formulate evidence-based pharmacologic and nonpharmacologic treatment strategies based on pain mechanism and unique patient characteristics • demonstrate how concepts and strategies presented over the session can be used to address even the most complex cases of rheumatologic patients with pain 7:00 - 8:00 am Continental Breakfast 8:00 am Introduction and Overview Afton L. Hassett, PsyD; University of Michigan Medical School; Ann Arbor, MI

2011 Program Book

23

Pain: Pathophysiology and Clinical Assessment Moderator: Afton L. Hassett, PsyD; University of Michigan Medical School; Ann Arbor, MI

N o v e m b e r

5 ,

SATURDAY

2 0 1 1

8:15 am Pain Pathophysiology: Advances in the Basic Science of Pain Yvonne C. Lee, MD, MMedSc; Brigham and Women’s Hospital; Boston, MA 9:00 am Pain in Rheumatologic Populations Daniel J. Clauw, MD; University of Michigan; Ann Arbor, MI 9:45 am Clinical Assessment of Pain Elizabeth G. Salt, PhD; University of Kentucky; Lexington, KY 10:15 - 10:30 am Break

Complex Pain Issues: Comorbidities and Special Populations 10:30 am Medical Comorbidities Leslie J. Crofford, MD; University of Kentucky; Lexington, KY 11:00 am Psychiatric Comorbidities Lesley M. Arnold, MD; University of Cincinnati College of Medicine; Cincinnati, OH 11:30 am Pain in Pediatrics Laura E. Schanberg, MD; Duke University Medical Center; Durham, NC noon - 1:00 pm Boxed Lunch 1:00 pm Pharmacologic Management of Rheumatologic Pain: A Mechanistic Approach Kam Nola, PharmD, MS; Lipscomb College of Pharmacy; Nashville, TN

Evidence-based Non-pharmacological Interventions 2:00 pm Physical Strategies: Physical Therapy, Occupational Therapy and Exercise Jan K. Richardson, PT, PhD, OCS; Universal SmartComp; Washington, PA 2:30 pm Verbal Strategies: Patient Education, Cognitive Behavioral Therapy, and Complimentary Alternative Medicine David A. Williams, PhD; University of Michigan Health System; Ann Arbor, MI 3:00 - 3:15 pm Break 3:15 pm Cases Presentations: Targeted Approaches to Complex Pain Management Daniel J. Clauw, MD; University of Michigan; Ann Arbor, MI Kam Nola, PharmD, MS; Lipscomb College of Pharmacy; Nashville, TN

24

2011 Program Book

Jan K. Richardson, PT, PhD, OCS; Universal SmartComp; Washington, PA David A. Williams, PhD; University of Michigan Health System; Ann Arbor, MI 4:15 pm Wrap-up Afton L. Hassett, PsyD; University of Michigan Medical School; Ann Arbor, MI

ACR CERTIFIED RHEUMATOLOGY CODER EXAMINATION – DAY TWO BR cP 11:00 am - 5:00 pm

W194b Admission to the ACR Certified Rheumatology Coder Course Exam requires a separate registration. Fees for the examination include a boxed lunch. This course is not eligible for CME credit. See page 18 for learning objectives. Speaker: Melesia Tillman, CPC, CRHC, CHA; American College of Rheumatology; Atlanta, GA

ACR/ARHP OPENING LECTURE AND AWARDS c/r 5:00 - 6:30 pm

W375d Moderators: David G. Borenstein, MD; Arthritis & Rheumatism Associates; Washington, DC Nadine T. James, RN, PhD; William Carey University; Hattiesburg, MS 5:00 pm Presidential Address David G. Borenstein, MD; Arthritis & Rheumatism Associates; Washington, DC Recognition of 2011 ACR Masters Recognition of 2011 Distinction Recipients Recognition of ARHP Merit Awards, Lifetime Achievement Award and President’s Award Recognition of Fellows Award 5:45 pm Finding and Interpreting Your Inner Fish Neil H. Shubin, PhD ; University of Chicago; Chicago, IL Upon completion of this session, participants should be able to: • trace the comparative anatomy and evolution of the spine • describe the importance of fins in the evolution of limbs • review the developmental genetic evidence and paleomorphology revealing the “inner fish” in humans

ACR/ARHP OPENING EVENT 7:00 - 10:00 pm

Field Museum

5 ,

SATURDAY

N o v e m b e r

Admission to the ACR/ARHP Opening Event at the Field Museum is ticketed and requires a separate registration. Purchase your tickets in the ACR/ARHP registration area before 6:30 pm – while space remains available – to ensure you have access to this VIP event. Tickets will not be available for purchase at the Field Museum.

2 0 1 1

2011 Program Book

25

SUNDAY, NOVEMBER 6, 2011

ACR SPECIAL SESSION 7:30 - 8:30 am

ACR/ARHP REGISTRATION

W375d

6:30 am - 6:00 pm

Year in Review

Moderator: Joel A. Block, MD; Rush University Medical Center; Chicago, IL

ARHP SPECIAL SESSIONS

7:30 am Clinical Perspective Leslie J. Crofford, MD; University of Kentucky; Lexington, KY

W195

First-time Attendees Orientation

2 0 1 1

First-time ARHP annual meeting attendees are invited to an orientation to learn the ‘ins and outs’ of the annual meeting. The ARHP Membership and Nominations Committee will provide advice to assist you in how to get the most out your first annual meeting. This session is not eligible for CME credit. Coffee and tea will be provided. Moderator: Linda Ehrlich-Jones, PhD, RN; Rehabilitation Institute of Chicago; Chicago, IL

6 ,

SUNDAY

PS

Hall F2 Entrance

7:00 - 8:00 am

N o v e m b e r

c/r

W194a

Moderators Orientation This session is not eligible for CME credit. Coffee and tea will be provided. Moderator: To be announced

8:00 am Basic Science Perspective David A. Fox, MD; University of Michigan Medical Center; Ann Arbor, MI Upon completion of this session, participants should be able to: • discuss selected recent publications on the pathophysiological basis of rheumatic diseases by literature review of important publications • describe selected treatment modalities for rheumatic diseases from the recent published literature • enumerate how these new advances may impact the practice of rheumatology

ACR STATE-OF-THE-ART LECTURE 7:30 - 8:30 am

W183a

2011 Hench Lecture: Resolution of Inflammation

ACR BASIC SCIENCE SYMPOSIUM 7:30 - 9:00 am

W196b

Epigenetic Changes in Rheumatic Disease

R

Moderator: Steffen Gay, MD; Center of Experimental Rheumatology, University Hospital Zurich; Zurich, Switzerland 7:30 am Epigenetic Changes in Rheumatic Disease: Focus on T cells John J. O’Shea, MD; NIAMS/NIH; Bethesda, MD 7:55 am Epigenetic Changes in Rheumatic Disease: Focus on B cells Hans-Martin Jack, PhD; University of Erlangen; Erlangen, Germany 8:20 am Epigenetic Changes in Synovial Fibroblasts in Rheumatoid Arthritis Caroline Ospelt, MD; University of Zurich; Zurich, Switzerland Upon completion of this session, participants should be able to: • discuss epigenetic mechanisms in different cell types • describe pathogenetic pathways that are activated by epigenetics in rheumatic diseases • identify therapeutic options that arise from modulation of epigenetic changes

26

2011 Program Book

R

Moderator: John Varga, MD; Northwestern University Medical School; Chicago, IL Speaker: Charles Serhan, PhD; Harvard Medical School; Boston, MA Upon completion of this session, participants should be able to: • describe the cellular and molecular basis of inflammation • appraise how inflammation becomes pathological • describe a family of novel mediators that restrict inflammation and restore normal homeostasis

ACR REF SPECIAL SESSION 7:30 - 8:30 am

W375a

ACR REF Oscar S. Gluck, MD, Memorial Lectureship: Everything a Rheumatologist Should Know About Glucocorticoid-Induced Bone Fragility But Was Afraid to Ask c/r Moderator: Michael J. Maricic, MD; Catalina Pointe Rheumatology; Tucson, AZ Speaker: Nancy E. Lane, MD; University of California, Davis School of Medicine; Sacramento, CA Upon completion of this session, participants should be able to: • d istinguish how glucocorticoid-induced bone loss differs from postmenopausal osteoporosis • d escribe how glucocorticoids influence bone cell lifespan, activity and cell fate

• identify how glucocorticoids alter bone quality and increase fracture risk • e valuate how effective bone active medications can prevent and reverse glucocorticoid-induced bone fragility

ACR MEET THE PROFESSOR SESSIONS 7:45 - 9:15 am Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual.

Behçet’s Disease (001)

Controversies in Sjögren’s Syndrome (002) Speaker: Alan N. Baer, MD; Johns Hopkins University; Baltimore, MD

W185d

Pain: Evaluation and Treatment of Back Pain (003) PM

Speaker: David G. Borenstein, MD; Arthritis & Rheumatism Associates; Washington, DC

W186a

*Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (004) P Speaker: Murray H. Passo, MD; MUSC; Charleston, SC

W186b

Spondylarthropathy: An Update (009) Speaker: Daniel O. Clegg, MD; University of Utah Medical Center; Salt Lake City, UT

W187b

*Systemic Lupus Erythematosus: Lupus Nephritis (010) Speaker: Frédéric. A. Houssiau, MD, PhD; Université catholique de Louvain; Brussels, Belgium

ACR WORKSHOPS 7:45 - 9:45 am Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual.

W178a

Dermatopathology of Rheumatic Diseases (201) Speaker: Lynne J. Goldberg, MD; Boston University Medical Center; Boston, MA

W180

Musculoskeletal Ultrasonography: Basic (202)

f

Speakers: Gurjit S. Kaeley, MBBS, MRCP; University of Florida College of Medicine; Ponte Vedra Beach, FL Janak R. Goyal, MD; Arthritis Center Inc.; Perth Amboy, NJ

W179b

*Pulmonary Hypertension in the Rheumatic Diseases (005)

Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (203)

Speaker: James R. Seibold, MD; Scleroderma Research Consultants LLC; Avon, CT

Speaker: Stuart L. Silverman, MD; Cedars-Sinai Medical Center; Beverly Hills, CA

W185bc

Rheumatoid Arthritis: Challenging Cases (006) Speaker: Jonathan Kay, MD; University of Massachusetts Medical School; Worcester, MA

W186c

*Rheumatoid Arthritis: Difficult Rheumatoid Arthritis (007) Speaker: Nancy A. Shadick, MD, MPH; Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; Boston, MA

2 0 1 1

W184d

W187c

6 ,

Speaker: Hasan Yazici, MD; University of Istanbul, Cerrahpasa Medical Faculty; Istanbul, Turkey

Speaker: James R. O’Dell, MD; University of Nebraska Medical Center; Omaha, NE

SUNDAY

W187a

*Rheumatoid Arthritis: Early Rheumatoid Arthritis (008)

N o v e m b e r

*Sessions denoted with an asterisk were sold out as of September 12.

W185a

ACR PRACTICE ISSUE 8:30 - 10:00 am

W192b

Health Information Technology and Informatics to Promote High Quality Rheumatologic Care BR C cP

8:30 am Bringing it All Together: Adoption, Implementation and Meaningful Use Charles M. King II, MD; Internal Medicine Associates; Tupelo, MS 2011 Program Book

27

Upon completion of this session, participants should be able to: • explain the forces in the current healthcare environment promoting adoption of health information technology • appreciate the types of problems in clinical practice and healthcare delivery that may be amenable to improvement with appropriate use of information technology • explore the technologies and related initiatives that are improving patient care • discover technology-driven opportunities to enhance care coordination and workflow efficiencies • explain workflow systems and patient care software that you can implement within your organization

ACR IMMUNOLOGY UPDATES FOR THE CLINICIANS W375a

New Targets in Rheumatoid Arthritis: Syk, Jaks and Btk c/r

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

9:00 - 10:00 am

Moderator: Jeffrey D. Greenberg, MD; New York University School of Medicine; New York, NY Speaker: Iain B. McInnes, MRCP, PhD; University of Glasgow; United Kingdom Upon completion of this session, participants should be able to: • define the basic factors and cell types involved in these pathways, and the inflammatory responses they control • explain the rationale for the development of new agents that target these pathways • review recent clinical trial results and appreciate the potential benefits and toxicities that have been reported

ACR MEDICAL ASPECTS OF RHEUMATIC DISEASES 9:00 - 10:00 am

W375d

Lipid-Lowering Therapy 2011

C

cP

ARS

ACR POSTER SESSION A AND POSTER TOURS 9:00 am - 6:00 pm Poster presenters will be available from 9:00 - 11:00 am (abstracts # 1 - 717). Poster tours will be held 9:00 - 9:45 am and 10:15 - 11:00 am. Morning snacks will be available from 9:00 10:30 am.

Guided Poster Tours HALL F2 - Poster Hall Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Hall F2 Entrance). Alternatively, you may go directly to the poster tour desk and wait for a standy ticket. Standby tickets will be assisgned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants’ registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour. 9:00 - 9:45 am Antiphospholipid Syndrome (301) Tour Guide: Pojen P. Chen, PhD; University of California, Los Angeles School of Medicine; Los Angeles, CA Fellows Only: How to Navigate the Poster Hall (302) Tour Guide: Calvin R. Brown Jr., MD; Northwestern University; Chicago, IL Pediatric Rheumatology: Clinical Aspects (303) Tour Guide: Balu H. Athreya, MD; duPont Hospital for Children; Wilmington, DE

Moderator: Ian N. Bruce, MD; Manchester Royal Infirmary; Manchester, United Kingdom Speaker: Neil J. Stone, MD; Northwestern University; Chicago, IL

Rheumatoid Arthritis: Clinical Aspects (304) Tour Guide: John J. Cush, MD; Baylor Research Institute; Dallas, TX

Upon completion of this session, participants should be able to: • describe current concepts in lipid pathophysiology and its impact on cardiovascular disease • recognize the various approaches available to manage this pathophysiology • identify best practices in management of lipid abnormalities in their rheumatic disease patients

Rheumatoid Arthritis: Treatment: Small Molecules, Biologics and Gene Therapy (305) Tour Guide: S. Louis Bridges Jr., MD, PhD; University of Alabama at Birmingham; Birmingham, AL Systemic Lupus Erythematosus: Clinical Aspects (306) Tour Guide: Barri J. Fessler, MD; University of AlabamaBirmingham; Birmingham, AL 10:15 - 11:00 am Rheumatoid Arthritis: Clinical Aspects (307) Tour Guide: Deborah P.M. Symmons, MD; The University of Manchester; Manchester, United Kingdom

28

2011 Program Book

Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy (308) Tour Guide: Martin Aringer, MD; Uniklinikum Technische Universität Dresden; Dresden, Germany Sjögren’s Syndrome (309) Tour Guide: Jacques-Eric Gottenberg, MD, PhD; Strasbourg University Hospital; Strasbourg, France Systemic Lupus Erythematosus: Clinical Aspects (310) Tour Guide: David A. Isenberg, MD; University College London; London, United Kingdom

• integrate the ACR’s public relations campaign, and its tools, to educate people in their communities on the value and role of rheumatology (nationally) and the value and role of their practices (locally)

ACR STATE-OF-THE-ART LECTURES 9:00 - 10:00 am

W375c

New Auto-inflammatory Syndromes

P

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s: Clinical Aspects and Therapeutics (312) Tour Guide: Maureen D. Mayes, MD, MPH; University of Texas Health Science Center at Houston; Houston, TX

Upon completion of this session, participants should be able to: • summarize current understanding of the pathogenesis of auto-inflammatory syndromes • identify clinical patterns consistent with new autoinflammatory syndromes • discuss available treatment

Utilizing Media Relations to Build Your Practice BR

cP

Moderator: Alan K. Matsumoto, MD; Arthritis & Rheumatism Associates; Wheaton, MD 9:00 am It’s All in the Planning: Determining Your Goals, Objectives and Audiences Jana Leigh Thomas, MPA; Porter Novelli; Atlanta, GA 9:05 am Establishing and Nurturing Important Media Relationships Stanley B. Cohen, MD; Metroplex Clinical Research Centre; Dallas, TX 9:25 am Media Interviews: Moving From Local Rheumatologist to Go-To Expert Jana Leigh Thomas, MPA; Porter Novelli; Atlanta, GA 9:45 am Panel Discussion Jana Leigh Thomas, MPA; Porter Novelli; Atlanta, GA Stanley B. Cohen, MD; Metroplex Clinical Research Centre; Dallas, TX Upon completion of this session, participants should be able to: • d escribe the basics of media relations and how working with local media can help promote your practice, and rheumatology as a whole • identify different ways to use media relations tactics to promote their practices in their communities • d evelop and maintain communication with local media e.g., building relationships, pitching stories, writing Letters to the Editor, etc., and position themselves as a go-to resource for media and other constituencies in their community

Pain, the Brain, and Osteoarthritis

R

PM

2 0 1 1

W181b

W375b

6 ,


SUNDAY

Moderator: Kathleen M. O’Neil, MD; Oklahoma University Health Science Center; Oklahoma City, OK Speaker: Marco Gattorno, MD, PhD; University of Genoa, G. Gaslini Institute; Genoa, Italy

N o v e m b e r

Systemic Lupus Erythematosus: Human Etiology and Pathogenesis (311) Tour Guide: Mary K. Crow, MD; Hospital for Special Surgery; New York, NY

Moderator: Najia Shakoor, MD; Rush University Medical Center; Chicago, IL Speaker: A. Vania Apkarian, PhD; Northwestern University; Chicago, IL Upon completion of this session, participants should be able to: • summarize regional changes in the brain associated with osteoarthritis pain • review the complex nature of osteoarthritis-associated pain • explain the current data on pain perception in osteoarthritis

ARHP GENERAL SESSION I – KEYNOTE ADDRESS 9:30 - 10:30 am

W183a

Sleep for Success! Everything You Must Know About Sleep, but Are Too Tired to Ask c/r Moderator: Kori A. Dewing, DNP, ARNP; Virginia Mason Medical Center; Seattle, WA Speaker: James B. Maas, PhD ; Cornell University; Ithaca, NY Upon completion of this session, participants should be able to: • determine common causes of sleep deprivation and the consequences as they relate to thinking, performance, health and lifespan • identify the five different stages of nocturnal sleep and their importance to daytime functioning • explore recent brain imagery research data on thinking and performance • establish strategies to improve sleep quality

2011 Program Book

29

EXHIBITS

INNOVATION THEATER

10:00 am - 5:00 pm

10:30 - 11:15 am

HALL F1 - Exhibit Hall

HALL F1 - Exhibit Hall (Booth #789)

Join your colleagues in the Exhibit Hall for morning and afternoon refreshements from 10:00 - 11:00 am and 2:00 - 3:00 pm. Visit the Replay Café, presented by SessionSelect, to view a session you missed during the meeting. The schedule will be available in the Daily News, at the Concierge Center and the Resource Center.

The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Genentech, A Member of the Roche Group. Please visit the Genentech, A Member of the Roche Group exhibit booth (457) for more information or see page 304. Seating and light refreshments are subject to availability.

ACR WORKSHOPS

Rituxan for the Treatment of Microscopic Polyangiitis and Granulomatosis with Polyangiitis (also known as Wegener’s Granulomatosis)

10:30 am - 12:30 pm

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

Admission to the workshops requires a separate registration and ticket. To verify which session you registered for - check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual. *Sessions denoted with an asterisk were sold out as of September 12.

W178b

Designing a Website for Your Practice (204) Speaker: Peter J. Embi, MD, MS; The Ohio State University; Columbus, OH

W179a

*Joint Injection Techniques (205) Speakers: Atul A. Deodhar, MD; Oregon Health & Science University; Portland, OR Kenneth S. O’Rourke, MD; Wake Forest University School of Medicine; Winston-Salem, NC

W180

Peripheral Magnetic Resonance Imaging in Rheumatology Practice (206) Speakers: Mikkel Ostergaard, MD, PhD, DMSc; Glostrup Hospital; Glostrup, Denmark Philip G. Conaghan, MD, PhD; University of Leeds; Leeds, United Kingdom

W179b

Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (207) Speaker: Edward Keystone, MD; Mount Sinai Hospital; Toronto, ON, Canada

W178a

Synovial Fluid Analysis and Crystal Identification (208) Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic; Cleveland, OH Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical Center; Philadelphia, PA Gilda M. Clayburne, MLT; Veterans Affairs Medical Center; Philadelphia, PA

30

2011 Program Book

ACR PLENARY SESSION I: DISCOVERY 2011 c/r

11:00 am - 12:30 pm

W375d Moderators: David G. Borenstein, MD; Arthritis & Rheumatism Associates; Washington, DC E. William St.Clair, MD; Duke University Medical Center; Durham, NC 11:00 am ACR REF Industry Roundtable Awards 11:10 am ACR Abstract Presentation Introduction 11:15 am 718. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate, in Patients with Active Rheumatoid Arthritis with An Inadequate Response to Tumor Necrosis Factor-Inhibitors: A 6-Month Phase 3 Study Gerd-Rüdiger Burmester1, R. Blanco2, C. Charles-Schoeman3, J. Wollenhaupt4, C A. F. Zerbini5, B. Benda6, D. Gruben7, G. Wallenstein7, S. Krishnaswami7, S. H. Zwillich7, T. Koncz8, J. D. Bradley7, C. A. Mebus7 and the ORAL Step investigators9, 1 Charité - University Medicine Berlin, Berlin, Germany, 2 Hospital Universitario Marques De Valdecilla, Santander, Spain, 3University of California, Los Angeles, CA, 4Schön Klinik, Hamburg, Germany, 5Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 6Pfizer Inc., Collegeville, PA, 7Pfizer Inc., Groton, CT, 8 Pfizer Inc., New York, NY, 9Groton 11:30 am 719. Reduced Cardiovascular Risk with Use of Methotrexate and Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis Rasa Bozaite-Gluosniene1, Xiaoqin Tang2, H. Lester Kirchner2, Jana L. Antohe3, Stephanie J. Morris4, Mary Chester Wasko5 and Androniki Bili1, 1Geisinger Medical Center, Danville, PA, 2 Geisinger Center for Health Research, Danville, PA, 3Geisinger Health System, Danville, PA, 4Rose Tree Medical Associates--Riddle Memorial Hos, Danville, PA, 5West Penn Allegheny Health System, Pittsburgh, PA

11:45 am 720. The Value of Periodic Echocardiography Screening to Detect Pulmonary Hypertension and Predict Mortality In Scleroderma Ami A. Shah, Shang-En Chung, Fredrick M. Wigley and Laura K. Hummers, Johns Hopkins University, Baltimore, MD

Best Practices for Collaboration in Research and Clinical Practice c/r Moderator: Elizabeth G. Salt, PhD; University of Kentucky; Lexington, KY Speaker: Holly Falk-Krzesinski, PhD; Northwestern University; Chicago, IL Upon completion of this session, participants should be able to: • d escribe how collaboration can be used in clinical practice and research settings • d escribe The Input-Processes-Output model of effectors for collaborations • d escribe the facilitators and challenges of collaboration and how to maximize the benefit of collaboration

W190a

Rheumatic Disease Update: Calcium Pyrophosphate Crystal Deposition Disease C Moderator: Peter A. Simkin, MD; University of Washington; Seattle, WA Speaker: Frédéric Lioté, MD, PhD; Centre Viggo Petersen, Hôpital Lariboisière; Paris, France Upon completion of this session, participants should be able to: • discuss the signaling pathways that are activated by calcium pyrophosphate dihydrate crystals • review potential therapeutic targets related to calcium pyrophosphate dihydrate crystal-induced inflammation • develop a treatment plan for patients with chronic and recurrent calcium pyrophosphate dihydrate arthritis

2 0 1 1

W474b

Upon completion of this session, participants should be able to: • describe the four compartment model of the immune system • review what happens to immune cells when they are activated • review each immune compartment in detail • describe current and emerging therapies that target each immune system compartment

6 ,

ARHP CONCURRENT SESSIONS 11:00 am - noon

Moderator: John A. Goldman, MD; Atlanta, GA Speaker: Troy R. Torgerson, MD, PhD; Children’s Hospital; Seattle, WA

SUNDAY

12:15 pm 722. The Intensive Diet and Exercise for Arthritis Trial: 18-Month Clinical Outcomes Stephen P. Messier1, Barbara J. Nicklas2, Claudine Legault3, Shannon Mihalko1, Gary D. Miller1, Paul DeVita4, Mary Lyles3, David J. Hunter5, Felix Eckstein6, Jeff D. Williamson3, J. Jeffery Carr3 and Richard F. Loeser1, 1Wake Forest University, WinstonSalem, NC, 2Winston-Salem, NC, 3Wake Forest University School of Medicine, Winston-Salem, NC, 4East Carolina University, Greenville, NC, 5Royal North Shore Hospital, Sydney, Australia, 6 Paracelsus Medical University, Salzburg, Austria

Immunology 101 and Targeted Therapies for Rheumatology Healthcare Professionals C

N o v e m b e r

12:00 pm 721. Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis Carol Wallace1, Edward H. Giannini2, Steven J. Spalding3, Philip Hashkes4, Kathleen M. O’Neil5, Andrew S. Zeft6, Ilona S. Szer7, Sarah Ringold8, Hermine Brunner9, Laura E. Schanberg10, Robert P. Sundel11, Diana Milojevic12, Marilynn G. Punaro13, Peter Chira14, Beth S. Gottlieb15, Gloria Higgins16, Norman T. Ilowite17, Yukiko Kimura18, Anne Johnson19, Stephanie Hamilton1, Bin Huang9 and Daniel J. Lovell9, 1Childrens Hosp & Regional Med, Seattle, WA, 2 PRCSG-Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Cleveland Clinic, Cleveland, OH, 4Shaare Zedek Medical Center, Tel Aviv, Israel, 5Okla Univ Health Science Ctr, Oklahoma City, OK, 6University of Utah, Salt Lake City, UT, 7Rady Childrens Hosp San Diego, San Diego, CA, 8Children’s Hosp Regional Med, Seattle, WA, 9Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10Duke University Medical Center, Durham, NC, 11Childrens Hosp Medical Center, Boston, MA, 12UCSF, San Francisco, CA, 13Texas Scottish Rite Hospital, Dallas, TX, 14Stanford University, Palo Alto, CA, 15Schneider Children’s Hospital, New Hyde Park, NY, 16PRCSG, Columbus, OH, 17Children’s Hospital Montefiore, Bronx, NY, 18Hackensack Univ Medical Ctr, Hackensack, NJ, 19Cincinnati Child Hosp Med Ctr, Cincinnati, OH

W470b

W476

The Osteoarthritis Initiative: A Database for Knee Osteoarthritis Research c/r Moderator: Nadine M. Fisher, EdD; The State University of New York at Buffalo; Buffalo, NY 11:00 am Overview of the Osteoarthritis Initiative: Study Design and Current Results Michael C. Nevitt, MPH, PhD; University of California-San Francisco; San Francisco, CA 11:30 am Collaboration with the Osteoarthritis Initiative: Obtaining and Using Osteoarthritis Initiative Data and Images John Lynch, PhD; University of California at San Francisco; San Francisco, CA Upon completion of this session, participants should be able to: • describe the background, purpose, study design and data collection procedures of the Osteoarthritis Initiative • discuss types of investigation the database is designed to support • identify available public data • explain methods for obtaining and using Osteoarthritis Initiative data for research

2011 Program Book

31

ARHP SPECIAL SESSION

ACR MEET THE PROFESSOR SESSIONS

12:30 - 2:15 pm

12:45 - 2:15 pm

All ARHP attendees are invited to this kick-off forum for the annual meeting. A box lunch will be provided for the first 250 people. You will have an opportunity to meet and network with other health professionals and the ARHP leadership. This session is not eligible for CME credit.

Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual.

The ARHP thanks Amgen, Inc. for supporting this Networking Forum.


S102

Networking Forum

12:30 pm Boxed Lunch 12:35 pm Membership Recruitment Award Presentation

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

The ARHP Membership Recruitment Award is presented to one ARHP and one ACR member who have recruited the most members in the current year. Kristin D’Onofrio, PharmD; Mount Airy, MD Sharon Stotsky, MD; Rheumatology and Internal Medicine Associates; Wilmington, MA ARHP Graduate Student Recognition Award Presentation The ARHP Graduate Student Recognition Award recognizes creative research or clinical project efforts that merge theory and clinical practice in assessing and/or improving the lives of patients with rheumatic disease, broadly defined and encourages the interest of non-medical graduate students in the field of rheumatology. Andrew M. Galica, Bsc; Hebrew Rehabilitation Centre; Roslindale, MA Jennifer Mei Ping Wo, BS; University of California; Loa Angeles, CA 12:45 pm Presidental Welcome Nadine T. James, RN, MSN, PhD; Hattiesburg, MS 12:50 pm Program Overview Benjamin J. Smith, PA-C; McIntosh Clinic PC; Thomasville, GA

INNOVATION THEATER

W185d

Adult Inflammatory Myopathy (011) Speaker: Mary E. Cronin, MD; Medical College of Wisconsin; Milwaukee, WI

W187c

*Ankylosing Spondylitis: 2011 Update (012) Speaker: Desiree van der Heijde, MD, PhD; Leiden University Medical Center; Leiden, Netherlands

W186a

Cutaneous Vasculitis (013)

f

Speaker: Nicole Fett, MD; University of Pennsylvania; Philadelphia, PA

W184d

Myopathy: Issues in Diagnosis and Treatment (014) Speaker: Mark F. Gourley, MD; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Bethesda, MD

W186c

Osteoporosis: Novel Treatments (015) Speaker: Michael J. Maricic, MD; Catalina Pointe Rheumatology; Tucson, AZ

W185a

Polymyalgia Rheumatica (016) Speaker: Bhaskar Dasgupta, MD; Southend University Hospital; Essex, United Kingdom

W185bc

12:30 - 1:15 pm

*Pregnancy in Rheumatic Diseases (017)

HALL F1 (Booth #789)

Speaker: Megan E. B. Clowse, MD, MPH; Duke University Medical Center; Durham, NC

The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Genentech, A Member of the Roche Group. Please visit the Genentech, A Member of the Roche Group exhibit booth (457) for more information or see page 304. Seating and light refreshments are subject to availability.

Toclizumab Redefining Biologic Monotherapy

32

W187a

*Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (018) Speaker: Elena M. Massarotti, MD; Brigham and Women’s Hospital; Boston, MA

W187b

*Systemic Lupus Erythematosus: Novel Treatments (019) Speaker: Mary Anne Dooley, MD, MPH; University of North Carolina at Chapel Hill; Chapel Hill, NC

2011 Program Book

W186b

ACR SPECIAL SESSION

Vitamin D and Bone Health (020)

1:00 - 2:00 pm

Speaker: Karen E. Hansen, MD, MS; University of Wisconsin; Madison, WI

W192b

1:00 - 2:00 pm

W375c

Difficult Raynaud’s Phenomena (Clinical Review) cP

Moderator: Robert Spiera, MD; Hospital for Special Surgery; New York, NY Speaker: Fredrick M. Wigley, MD; Johns Hopkins University; Baltimore, MD

Moderator: Michael D. Lockshin, MD; Hospital for Special Surgery; New York, NY 1:00 pm Publishing in Arthritis Care & Research Marian T. Hannan, DSc, MPH; Hebrew SeniorLife & Harvard Medical School; Boston, MA 1:15 pm Publishing in the Journal of the American Medical Association Phil Fontanarosa, MD, MBA; JAMA; Chicago, IL 1:30 pm Publishing in the Journal of Clincial Investigation Gary A. Koretzky, MD, PhD; University Pennsylvania; Philadelphia, PA 1:45 pm Publishing in Arthritis & Rheumatism Joan M. Bathon, MD; Columbia University Medical Center; New York, NY Upon completion of this session, participants should be able to: • e xplain the journal’s objectives with respect to rheumatology • r eport what types of rheumatology articles are of interest to the journals • o utline how to increase the likelihood of acceptance of an article for publication in the respective journal

MicroRNA in Epigenetic Regulation of Rheumatic Inflammatory Diseases R

2 0 1 1

c/r

W375a

6 ,

W181b

ACR STATE-OF-THE-ART LECTURE 1:00 - 2:00 pm

SUNDAY

ACR PRACTICE ISSUE 1:00 - 2:00 pm

Upon completion of this session, participants should be able to: • recognize the major research reports and scholarship in the field of medical education over the past year • translate results of educational research to their own educational programs • formulate ideas for educational research at their own institutions N o v e m b e r

Upon completion of this session, participants should be able to: • e xplain the evolving concepts of pathophysiology of Raynaud’s phenomena and potential new avenues of therapeutic intervention • d iscuss evidence for pharmacologic, behavioral, and surgical approaches to Raynaud’s phenomena and its complications • identify the appropriate use of these interventions and when simple supportive treatment is warranted • g ain insights into potential therapeutic interventions that are under investigation or in development

Publishing in Peer-Reviewed Medical Journals

Ed.

Moderator: Michael J. Battistone, MD; University of Utah Medical Center; Salt Lake City, UT Speaker: G. Dodd Denton, MD, MPH; Uniformed Services University of the Health Sciences; Bethesda, MD

ACR CLINICAL SYMPOSIUM

C

Medical Education: Year in Review

Moderator: Michael H. Pillinger, MD; New York University Hospital for Joint Diseases; New York, NY Speaker: Steffen Gay, MD; Center of Experimental Rheumatology, University Hospital Zurich; Zurich, Switzerland Upon completion of this session, participants should be able to: • appreciate basic principles of microRNA biology • define how particular microRNAs can increase or decrease transcript expression at a protein level • review emerging data in studies of rheumatoid synoviocytes and other cell types involved in rheumatoid arthritis

ACR WORKSHOPS 1:15 - 3:15 pm Admission to the workshops requires a separate registration and ticket. To verify which session you registered for - check registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual. W178a

Dermatopathology of Rheumatic Diseases (209) Speaker: Lynne J. Goldberg, MD; Boston University Medical Center; Boston, MA

W180

Peripheral Magnetic Resonance Imaging in Clinical Rheumatology (210) Speakers: Ewa Olech, MD; Oklahoma Medical Research Foundation; Oklahoma City, OK Orrin M. Troum, MD; University of Southern California Keck School of Medicine; Santa Monica, CA 2011 Program Book

33

W179b

Rheumatology Physical Examination of Lower Extremity and Lumbosacral Spine: Anatomical Correlates (211) f Speakers: Pablo Villasenor Ovies, MD; Instituto Nacional de Rehabilitación; Ciudad de México, Mexico Robert A. Kalish, MD; Tufts Medical Center; Boston, MA

ACR BASIC SCIENCE SYMPOSIUM 2:30 - 4:00 pm

W190a

Tools for Studying Joint Tissue Changes in Osteoarthritis R

SUNDAY

2 0 1 1

Moderators: John A. Hardin, MD; Albert Einstein College of Medicine; Bronx, NY Joanne M. Jordan, MD, MPH; University of North Carolina Thurston Arthritis Research Center; Chapel Hill, NC

N o v e m b e r

6 ,

2:30 pm Advances in Imaging of the Osteoarthritis Joint Garry Gold, MD; Stanford University; Stanford, CA 2:55 pm Biomarkers for Osteoarthritis: Are We Making Progress? Stefan Lohmander, MD, PhD; Lund University; Lund, Sweden 3:20 pm Osteoarthritis Animal Models: What Have We Learned Christopher B. Little, BSc, MSc, BVMS, PhD; University of Sydney; St. Leonards, Australia Upon completion of this session, participants should be able to: • describe advances in imaging, biomarkers, and animal models in the osteoarthritis field • list the biomarkers for osteoarthritis currently under investigation and relate their ability to detect changes in tissues affected by osteoarthritis • recognize advances in joint tissue imaging technologies that have been applied to osteoarthritis • choose an appropriate animal model for osteoarthritis research and relate how these models have advanced the osteoarthritis field

ACR CLINICAL SYMPOSIA 2:30 - 4:00 pm

W375b

Impact of Environmental Health on Autoimmunity C

PS

Moderators: Karen H. Costenbader, MD, MPH; Brigham and Women’s Hospital; Boston, MA Diane L. Kamen, MD, MS; Medical University of South Carolina; Charleston, SC 2:30 pm The Environment and Autoimmune Diseases – Where We Stand in 2011 Frederick W. Miller, MD, PhD; NIH/Natinal Institute of Environmental Health Sciences; Bethesda, MD

34

2011 Program Book

2:55 pm The Role of Gene X Environment Interactions in Autoimmunity Judith A. James, MD, PhD; Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center; Oklahoma City, OK 3:20 pm Smoking and Silica Exposure-Models for Exploring Environmental Triggers of Disease Glinda S. Cooper, PhD; United States Environmental Protection Agency; Washington, DC Upon completion of this session, participants should be able to: • identify known and potential environmental triggers of autoimmunity and autoimmune diseases, including chemical factors, physical factors, biological agents and others • describe potential mechanisms for gene x environment interactions • summarize new technologies in exposure monitoring

W375c

Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis C PS Moderator: Eric M. Ruderman, MD; Northwestern University; Chicago, IL 2:30 pm Which Kinase Pathways are Important in Rheumatoid Arthritis and How Do We Decide What to Target? Mark C. Genovese, MD; Stanford University Medical Center; Palo Alto, CA 2:55 pm What Does the Data Inform Us About Safety and Efficacy of Kinase Inhibitors? Michael E. Weinblatt, MD; Brigham and Women’s Hospital; Boston, MA 3:20 pm Where Will These Agents Fit into Our Treatment Paradigm? Roy M. Fleischmann, MD; University of Texas Southwestern Medical Center and Metroplex Clinical Research Center; Dallas, TX Upon completion of this session, participants should be able to: • compare and contrast the mechanisms of action of the various kinase inhibitors in late-stage clinical trials in rheumatoid arthritis • summarize the key data on safety and efficacy on these agents • formulate a plan for integrating these agents into existing management strategies for rheumatoid arthritis

ACR CONCURRENT ABSTRACT SESSIONS 2:30 - 4:00 pm

W475a

Antiphospholipid Syndrome Moderators: Barry L. Myones, MD; Baylor College of Medicine; Houston, TX Robert A. S. Roubey, MD; University of North Carolina; Chapel Hill, NC

2:30 pm 723. Involvement of TLR7 and TLR9 in the Production of Antiphospholipid Antibodies Renan Aguilar-Valenzuela1, Kevin Nickerson2, Zurina RomayPenabad1, Mark J. Shlomchik2, Gracie Vargas1, Tuya Shilagard1 and Silvia S. Pierangeli1, 1University of Texas Medical Branch, Galveston, TX, 2Yale University School of Medicine, New Haven, CT 2:45 pm 724. Endothelial Cell Injury and Activation Promote the Binding of Anti-Phospholipid Antibodies and Thrombus Formation Patrick Laplante1, Marc-Antoine Gillis2, Rebecca Subang1, David Salem1, Jerrold S. Levine3, Yahye Merhi2 and Joyce Rauch1, 1Research Institute of the McGill University Health Centre, Montreal, QC, 2Montreal Heart Institute, Montreal, QC, 3 University of Illinois at Chicago, Chicago, IL

6 , 2 0 1 1

3:30 pm 727. Rituximab in Antiphospholipid Syndrome (RITAPS) – A Pilot Open-Label Phase II Prospective Trial for Non-Criteria Manifestations of Antiphospholipid Antibodies (aPL) Doruk Erkan1, JoAnn Vega2, Glendalee Ramon2, Elizabeth Kozora3 and Michael D. Lockshin2, 1Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, 2Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY, 3National Jewish Health, Denver, CO

W193a

Cell-cell Interactions and Adhesion Moderators: Bruce N. Cronstein, MD; New York University Medical Center; New York, NY Zoltan Szekanecz, MD, PhD; University of Debrecen Medical and Health Sciences Center; Debrecen, Hungary 2:30 pm 729. IL-7 Contributes to Monocyte Migration In Rheumatoid Arthritis Nathan D. Chamberlain1, Sarah R. Pickens1, Richard M. Pope2, Michael Volin3 and Shiva Shahrara1, 1University of Illinois at Chicago, Chicago, IL, 2Northwestern Univ Med School, Chicago, IL, 3Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL 2:45 pm 730. CCL21 a Novel Proangiogenic Factor in Rheumatoid Arthritis Sarah R. Pickens1, Nathan D. Chamberlain1, Michael Volin2, Arthur M. Mandelin II3 and Shiva Shahrara1, 1University of Illinois at Chicago, Chicago, IL, 2Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL 3:00 pm 731. Evidence for CXCL16 As An Endothelial Progenitor Cell Chemotactic Factor Jeffrey H. Ruth1, Takeo Isozaki1, M. Asif Amin1, Charles A. Lesch1, Ali S. Arbab2 and Alisa E. Koch3, 1University of Michigan, Ann Arbor, MI, 2Henry Ford Hospital, Detroit, MI, 3Department of Veteran’s Affairs and University of Michigan, Ann Arbor, MI

2011 Program Book

SUNDAY

3:15 pm 726. Effects of Fluvastatin on Pro-Inflammatory and ProThrombotic Markers in Antiphospholipid Antibody (aPL)Positive Patients: Preliminary Results from an Open-Label Prospective Pilot Study Vijaya L. Murthy1, Doruk Erkan2, Praveen Jajoria1, Rohan Willis1, JoAnn Vega2, Giuseppe Barilaro1, Gurjot Basra1, Elizabeth Hsu1, Laura Aline Martinez-Martinez1, Shraddha Jatwani1, Elizabeth Papalardo1, Emilio B. Gonzalez1, Prashanth R. Sunkureddi3 and Silvia S. Pierangeli1, 1University of Texas Medical Branch, Galveston, TX, 2Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, 3 The University of Texas Medical Branch, Nassau Bay, TX

N o v e m b e r

3:00 pm 725. Mitochondrial Dysfunction in Monocytes From Antiphospholipid Syndrome Patients: Implications in the Pathogenesis of the Disease and Effects of Coenzyme Q Treatment Chary Lopez-Pedrera1, Carlos Perez-Sanchez1, Patricia RuizLimon1, Mª Angeles Aguirre1, Rosario Mª Carretero1, Nuria Barbarroja1, Antonio Rodriguez-Ariza1, Eduardo CollantesEstevez1, Jose Antonio Gonzalez-Reyes2, Jose Manuel Villalba2, Francisco Velasco1, Munther A. Khamashta3, Maria Laura Bertolaccini3 and Mª Jose Cuadrado4, 1IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 2University of Cordoba, Cordoba, Spain, 3Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 4The Rayne Institute, London, United Kingdom

3:45 pm 728. European Registry of Babies Born to Mothers with Antiphospholipid Syndrome Arsene Mekinian1, Priscille loire-Berson2, Eric Lachassinne3, Pascale nicaise-Roland4, Eric Vicaut5, Jerome Stirnemann6, Sylvie chollet-Martin4, Mario Motta7, Angela Tincani8, Christine Boinot9, Olivier Pourrat10, Tadej Avcin11, Rapr Tomsik12, Amelie Benbara2, Sarah de Carolis13, Patricia Rovere14, Lionel Carbillon2, marie-Helene Aurousseau15, marie-Claire Boffa16 and Olivier Fain6, 1Jean Verdier Hospital, Bondy, France, 2Service de gynécologie-obstétrique, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, 3Service de néonatologie et pédiatrie, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, 4 Unité Fonctionnelles d’Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, Paris, France, 5Paris, France, 6Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, 7Obstetric and Gynecology of Brescia, Brescia, Italy, 8Rheumathology Unit, University of Brescia, Brescia, Italy, Brescia, Italy, 9Hemostase Poitiers, Poitiers, France, 10CHU poitiers, Poitiers, France, 11University Children’s Hospital Ljubljana, Ljubljana, Slovenia, 12University Children’s Hospital Ljubljana, Slovenie, Slovenia, 13Rheumatology, Brescia, Italy, 14Rheumatology, Milan, Italy, 15Bondy, France, 16Service d’hématologie biologique, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France

35

3:30 pm 739. Nocebo in Fibromyalgia: Meta-Analysis of PlaceboControlled Clinical Trials and Implications for Practice DD Mitsikostas1, NG Chalarakis1, LI Mantonakis1, E. Delicha2 and PP Sfikakis2, 1Naval Hospital, Athens, Greece, Athens, Greece, 2 First Department of Propaedeutic and Internal Medicine, Laiko, Athens University Medical School, Greece, Athens, Greece

3:30 pm 733. Active Non-Canonical NF-κB Signaling in Blood Vessels of Rheumatoid Arthritis Synovial Tissue May Enhance Inflammation by Stimulating Angiogenesis Ae-Ri Noort, Katinka P.M. van Zoest, Paul P. Tak and Sander W. Tas, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands

3:45 pm 740. The Performance of American College of Rheumatology 2010 Diagnostic Criteria for Fibromyalgia Among Fibromyalgia Patients Seen in a Rheumatology Clinic and Diagnosed by 1990 Classification Criteria Muhammad B. Yunus and Jean C. Aldag, University of Illinois College of Medicine at Peoria, Peoria, IL

2 0 1 1

3:45 pm 734. In Vivo Imaging of T Cell Motility in the Joint Draining Lymph Nodes of Genetically Unmanipulated Mice in a Model of Rheumatoid Arthritis Tamas Kobezda, Sheida Ghassemi-Nejad, Colt Egelston, Tibor T. Glant and Katalin Mikecz, Rush University Medical Center, Chicago, IL

6 ,

SUNDAY

N o v e m b e r

3:15 pm 732. Notch Signaling Pathways Mediate Synovial Angiogenesis in Response to Vascular Endothelial Growth Factor and Angiopoietin 2 Wei Gao, Catherine Sweeney, Ceara Walsh, Peadar Rooney, Jennifer McCormick, Douglas J. Veale and Ursula Fearon, Translation Rheumatology Research Group, Dublin, Ireland

W181b

Fibromyalgia and Soft Tissue Disorders I Moderators: Don L. Goldenberg, MD; Newton-Wellesley Hospital; Newton, MA Manuel Martinez-Lavin, MD; National Cardiology Institute; Mexico City, Mexico 2:30 pm 735. Long-Term Outcomes In Fibromyalgia Patients Treated with Cortical Electrostimulation Jeffrey B. Hargrove1, Robert M. Bennett2 and Daniel J. Clauw3, 1 Kettering University, Flint, MI, 2Oregon Health & Science Univ, Portland, OR, 3University of Michigan, Ann Arbor, MI 2:45 pm 736. Incidence and Predictors of Fibromyalgia in An Early Arthritis Cohort Yvonne C. Lee1, Daniel H. Solomon1, Bing Lu1, Gilles Boire2, Boulos Haraoui3, Carol A. Hitchon4, Janet E. Pope5, J. Carter Thorne6, Edward Keystone7, Diane S. Ferland8 and Vivian Bykerk9, 1Brigham and Women’s Hospital, Boston, MA, 2 CHUS - Sherbrooke University, Sherbrooke, QC, 3Institut de Rhumatologie, Montreal, QC, 4University of Manitoba, Winnipeg, MB, 5St. Joseph’s Health Care, University of Western Ontario, London, ON, 6Newmarket, ON, 7Mount Sinai Hospital, Toronto, ON, 8LaSalle, QC, 9Brigham & Women’s Hospital, Boston, MA 3:00 pm 737. Cortical Oscillatory Changes During Mechanical Brushing in Fibromyalgia Syndrome Patients Nick Fallon, Yee Ho Chiu, Xiaoyun Li, Turo Nurmikko and Andrej Stancak, University of Liverpool, Liverpool, United Kingdom 3:15 pm 738. Pain Variability Influences Recalled Pain Estimation Steven E. Harte1, Robert H. Palmer2, R. Michael Gendreau3, Daniel J. Clauw1 and Richard E. Harris1, 1University of Michigan, Ann Arbor, MI, 2Forest Research Institute, Jersey City, NJ, 3 Cypress Bioscience, Inc., San Diego, CA

36

2011 Program Book

W194b

Orthopedics and Low Back Pain Moderators: Jeffrey N. Katz, MD; Brigham & Women’s Hospital; Boston, MA Beth L. Jonas, MD; University of North Carolina at Chapel Hill; Chapel Hill, NC 2:30 pm 741. A Study of Tanezumab in Adults with Chronic Low Back Pain (NCT00876187) A. Kivitz1, Joseph Gimbel2, Candace Bramson3, Mary Ann Nemeth3, David Keller4, Mark T. Brown4, Christine R. West5 and Kenneth M. Verburg4, 1Altoona Center for Clinical Research, Duncansville, PA, 2Arizona Research Center, Phoenix, AZ, 3Pfizer, Groton, 4Pfizer, Groton, CT, 5Pfizer, Williamston, MI 2:45 pm 742. Time-Course and Extent of Pain and Function Improvements Post-Knee Replacement: The Multicenter Osteoarthritis Study Tuhina Neogi1, Jingbo Niu1, David T. Felson1, Michael C. Nevitt2, Yuqing Zhang1, Laura Frey-Law3, Jessica L. Maxwell1 and Jasvinder Singh4, 1Boston University School of Medicine, Boston, MA, 2University of California-San Francisco, San Francisco, CA, 3 University of Iowa, Iowa City, IA, 4University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL 3:00 pm 743. Impact of a Patient Decision Aid with An Interactive Values Component On Decisional Conflict Associated with Total Knee Arthroplasty Sofia De Achaval1, Liana Fraenkel2, Robert Volk3, Vanessa Cox3 and Maria E. Suarez-Almazor4, 1U.T. MD Anderson Cancer Center, Houston, TX, 2Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 3UT MD Anderson Cancer Center, Houston, TX, 4University of Texas. M.D Anderson Cancer Center, Houston, TX 3:15 pm 744. Pain Catastrophizing, but Not Widespread Pain, Is Associated with Poor Pain Outcomes After Knee Replacement: An Analysis From the Multicenter Osteoarthritis Study (MOST) Jasvinder A. Singh1, Cora E. Lewis2, Ke Wang3, David T. Felson4, Michael C. Nevitt5, James Torner6, Laurence A. Bradley7 and Tuhina Neogi4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama, Birmingham City, Birmingham, AL, 3Boston University, Boston, MA, 4Boston University School of Medicine, Boston, MA, 5University of

California-San Francisco, San Francisco, CA, 6University of Iowa, Iowa City, Iowa City, IA, 7Univ of Alabama-Birmingham, Birmingham, AL 3:30 pm 745. Identifying Comorbid Conditions That Affect the 6 Month Recovery Pattern of Total Knee Arthroplasty C. Allyson Jones1, Lauren A. Beaupre2, Gian S. Jhangri3 and Maria E. Suarez-Almazor4, 1Departments of Physical Therapy and School of Public Health, University of Alberta, Edmonton, AB, 2 Dept of Physical Therapy, University of Alberta, Edmonton, AB, 3 School of Public Health, University of Alberta, Edmonton, AB, 4 University of Texas. M.D Anderson Cancer Center, Houston, TX

2:30 pm 747. The Childhood Arthritis & Rheumatology Research Alliance Network Registry: Demographics and Characteristics of the Initial One Year Cohort Marc D. Natter1, Jane R. Winsor2, Kathleen A. Fox2, Norman T. Ilowite3, Kenneth D. Mandl1, Kelly L. Mieszkalski4, Christy I. Sandborg5, John S. Sundy4, Carol A. Wallace6, Laura E. Schanberg4 and CARRAnet Investigators7, 1Children’s Hospital Boston, Boston, MA, 2Duke Clinical Research Institute, Durham, NC, 3Children’s Hospital Montefiore, Bronx, NY, 4Duke University Medical Center, Durham, NC, 5Stanford University, Palo Alto, CA, 6 Childrens Hosp & Regional Med, Seattle, WA, 7Durham, NC 2:45 pm 748. Distinct Phenotypical Clusters In Childhood Inflammatory Brain Diseases: Implications for Diagnostic Evaluation Tania Cellucci, Pascal N. Tyrrell, Marinka Twilt, Gordon S. Soon, Ivanna Yau, Shehla Sheikh and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON 3:00 pm 749. Whole Body Magnetic Resonance Imaging in Juvenile Spondyloarthritis: Will It Provide Vital Information Compared to Clinical Exam Alone? Alisa C. Rachlis1, Paul S. Babyn2, Edrise Lobo-Mueller3, Susanne M. Benseler1, Jennifer Stimec4, Michelle Anderson1, Margaret Reaume1, Kristi J. Whitney-Mahoney1, JoAnne Marcuz1 and Shirley Tse1, 1The Hospital for Sick Children, Toronto, ON, 2 Saskatoon Health Region, Saskatoon, SK, 3Hospital for Sick Children, Toronto, ON, 4Hospital For Sick Children, Toronto, ON

2 0 1 1

Moderators: Rayfel Schneider, MBBCh, MD; Hospital for Sick Children, University of Toronto; Toronto, ON, Canada Lisa F. Imundo, MD; Children’s Hospital of New York; Columbia University Medical Center; New York, NY

6 ,

Pediatric Rheumatology - Clinical and Therapeutic Aspects: Clinical Characteristics

3:45 pm 752. Frequency and Levels of Maternal Antibodies Reactive with Full Length Ro52 and p200 in Umbilical Cord Blood and Risk of Cardiac Neonatal Lupus Joanne H. Reed, Robert M. Clancy and Jill P. Buyon, New York University School of Medicine, New York, NY

SUNDAY

W183a

3:30 pm 751. Brain Morphometric Changes Associated with ChildhoodOnset Systemic Lupus Erythematosus and Neurocognitive Deficit Marisa Klein-Gitelman1, Adlin Cedeno1, Aimee Baker2, Frank Zelko1, Dean Beebe2, Blair Dina1, Anna Carmela P. SagcalGironella2, Darren Gitelman3, Hermine Brunner2, Mark Difrancesco2 and Travis Beckwith2, 1Children’s Memorial Hospital, Chicago, IL, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Northwestern University, Chicago, IL

N o v e m b e r

3:45 pm 746. The Role of Pre-Operative Pain Sensitisation in Chronic Pain After Knee Joint Replacement Vikki Wylde1, Shea Palmer2, Ian Learmonth1 and Paul A. Dieppe3, 1 University of Bristol, Bristol, United Kingdom, 2University of the West of England, Bristol, United Kingdom, 3University of Exeter, Plymouth, United Kingdom

3:15 pm 750. Decreased Expression of Nicotinamide Phosphoribosyltransferase (NAMPT) in Active Juvenile Idiopathic Arthritis Patients Receiving Methotrexate E.J. Fox, M. Gibson, L.Q. Zhang, J.S. Leeder, S.Q. Ye and M.L. Becker, Children’s Mercy Hospital, Kansas City, MO

W183c

Quality Measures and Innovations in Practice Management and Care Delivery I Moderators: Esi Morgan DeWitt, MD; Cincinnatti Children’s Hospital Medical Center; Cincinnatti, OH Jinoos Yazdany, MD, MPH; University of California, San Francisco; San Francisco, CA 2:30 pm 753. Rheum-PACER – Design, Implementation, and Adoption of Innovative Visual Display Software Eric D. Newman1, Virginia Lerch2, J. B. Jones2, William T. Ayoub3, Thomas P. Olenginski1, Thomas M. Harrington1, Androniki Bili1, Brian DelVecchio1, Alfred E. Denio1, Brian P. Oppermann3, Sorina Dancea1, Jana Antohe1, Chad Walker1, Rasa Bozaite-Gluosniene1 and Walter Stewart2, 1Geisinger Medical Center, Danville, PA, 2 Geisinger Health System, Danville, PA, 3Geisinger Medical Group, State College, PA 2:45 pm 754. Generating Run Charts for Quality Improvement Using the Electronic Health Record David W. Moser, Tracy V. Ting, Janalee Taylor, Daniel J. Lovell, Hermine Brunner, Jennifer L. Huggins and Esi M. Morgan DeWitt, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 3:00 pm 755. Rheumatoid Arthritis Quality Measure Bundle – Development and Implementation Chad P. Walker1, Eric D. Newman1, William T. Ayoub2, David M. Pugliese3, Jeffrey M. Barrett1, Shea Mealia1 and Androniki Bili1, 1 Geisinger Medical Center, Danville, PA, 2Geisinger Medical Group, State College, PA, 3Geisinger Specialty Clinic, WilkesBarre, PA

2011 Program Book

37

3:15 pm 756. Improving Adherence to Glucocorticoid Induced Osteoporosis Guidelines Minna J. Kohler1, Matxalen Amezega2, James Drozd3, Susan Crowley1, Barbara Gulanski1, Daren Anderson4 and Liana Fraenkel5, 1Yale University School of Medicine, New Haven, CT, 2 Griffin Hospital, Derby, CT, 3VA Connecticut Healthcare System, West Haven, CT, 4Community Health Center, Inc., Middletown, CT, 5Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT

2 0 1 1

3:30 pm 757. Use of Quality Improvement Methodology to Improve the Safety of Intravenous Infusions in a Pediatric Rheumatology Practice At a Tertiary Care Children’s Hospital Pai-Yue Lu, Janalee Taylor, Moussa El-hallak, Keith A. Sikora, David W. Moser, Terry M. Moore, Julie V. Ranz, Judy Thomas, Grace McIntyre-Patton, Jennifer L. Huggins and Tracy V. Ting, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

N o v e m b e r

6 ,

SUNDAY

3:45 pm 758. Improving the Influenza Vaccination Rate in Patients Visiting Pediatric Rheumatology Clinics Using Automatic Best Practice Alert in Electronic Patient Records Anjali Patwardhan1, Kelly Kelleher1, Dennise Cuningham2 and Charles H. Spencer1, 1Nationwide Childrens Hospital, Columbus, OH, 2Nationwide Childrens Hospital, Columbus

W375a

Rheumatoid Arthritis Clinical Aspects: Cardiovascular Disease Moderators: Jon T. Giles, MD, MPH; Columbia University Medical Center; New York, NY Inmaculada Del Rincon, MD, MS; Unversity of Texas Health Science Center at San Antonoio; San Antonio, TX 2:30 pm 759. Differential Predictors of Mixed and Fully Calcified Coronary Plaques in Coronary Artery Disease-Naïve Patients with Rheumatoid Arthritis George A. Karpouzas1, Jennifer Malpeso2, Dong Li2, Panteja Razaeian2, Maria V. Peralta2, Silvia Munoz1 and Matthew Budoff2, 1Harbor-UCLA, Torrance, CA, 2Harbor-UCLA Medical Center, Torrance, CA 2:45 pm 760. Outward Carotid Arterial Wall Remodelling in Rheumatoid Arthritis: A Case-Control Study Alper M. van Sijl1, Katja van der Hurk2, Mike J.L. Peters3, Vokko P. van Halm4, Giel Nijpels2, Coen D.A. Stehouwer5, Yvo M. Smulders3, A.E. Voskuyl6, Jacqueline M. Dekker2 and Michael T. Nurmohamed7, 1Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2EMGO institute, VU university medical centre, Amsterdam, Netherlands, 3VU University medical center, Amsterdam, Netherlands, 4Academic Medical Centre, Amsterdam, Netherlands, 5Maastricht University, Maastricht, Netherlands, 6VU Medical Center, Amsterdam, Netherlands, 7Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands

38

2011 Program Book

3:00 pm 761. Abnormal Concentric Ventricular Remodeling in Rheumatoid Arthritis John M. Davis III, Veronique L. Roger, Cynthia S. Crowson, Terry M. Therneau, Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN 3:15 pm 762. Expansion of Intra-Thoracic Adipose Tissue Depots Associate with Prevalence and Burden of Mixed (Vulnerable) Plaques in Coronary Artery Disease-Naïve Patients with Rheumatoid Arthritis George A. Karpouzas1, Panteja Razaeian2, Jennifer Malpeso2, Dong Li2, Maria V. Peralta2, Silvia Munoz1 and Matthew Budoff2, 1 Harbor-UCLA, Torrance, CA, 2Harbor-UCLA Medical Center, Torrance, CA 3:30 pm 763. Oxidation Products of Arachidonic Acid and Linoleic Acid Are Increased in High Density Lipoprotein and Low Density Lipoprotein From Patients with Active Rheumatoid Arthritis Christina Charles-Schoeman1, David Meriwether2, Yuen Yin Lee2 and Srinivasa T. Reddy3, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2UCLA, Los Angeles, CA, 3UCLA, Los Angeles 3:45 pm 764. Cholesterol Efflux by High Density Lipoproteins Is Impaired in Patients with Active Rheumatoid Arthritis Christina Charles-Schoeman1, Yuen Yin Lee2, Victor Grijalva3, John D. FitzGerald2, Veena K. Ranganath4, Mihaela Taylor2, Maureen A. McMahon2, Harold E. Paulus4 and Srinivasa T. Reddy3, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2UCLA, Los Angeles, CA, 3UCLA, Los Angeles, 4University of California, Los Angeles, Los Angeles, CA

W471b

Rheumatoid Arthritis – Human Etiology and Pathogenesis I: Pathogenesis of the Earliest Stages of Rheumatoid Arthritis Moderators: Danielle M. Gerlag, MD; Academic Medical Center / University of Amsterdam; Amsterdam, Netherlands William F. C. Rigby, MD; Dartmouth-Hitchcock Medical Center; Lebanon, NH 2:30 pm 765. Familial Clustering of the Serum Cytokine Profile: Comparison Between the Asymptomatic First-Degree Relatives of RA Patients and Controls with No Family History of Autoimmune Disease Hani S. El-Gabalawy1, David B. Robinson1, Donna M. Hart2, Irene Smolik3, Charles N. Bernstein1, Marianna M. Newkirk4 and Marvin J. Fritzler5, 1University of Manitoba, Winnipeg, MB, 2 Health Sciences Centre, Winnipeg, MB, 3University of Manitoba, Winnipeg, 4McGill University Health Centr, Montreal, QC, 5 University of Calgary, Calgary, AB 2:45 pm 766. Porphyromonas Gingivalis (P. gingivalis) is Associated with the Presence of Disease-Specific Autoantibodies in Individuals At Increased Risk for the Future Development of Rheumatoid Arthritis Ted R. Mikuls1, Kevin D. Deane2, Jeffrey Payne3, Geoffrey M. Thiele4, James R. O’Dell4, Lezlie A. Derber5, William H. Robinson6,

V. Michael Holers7 and Jill M. Norris8, 1Omaha VA and University of Nebraska, Omaha, NE, 2University of Colorado School of Medicine, Aurora, CO, 3University of Nebraska Medical Center, Lincoln, NE, 4Univ of Nebraska Med Ctr, Omaha, NE, 5University of Colorado AMC, Aurora, CO, 6Stanford University, Stanford, CA, 7Univ of Colorado School of Med, Aurora, CO, 8University of Colorado Denver, Aurora, CO

2:30 pm 771. Preferential Transmission of Genetic Risk Variants of Candidate Loci At 6p21 From Asymptomatic Grandparents to Anti-SSA/Ro Positive Mothers of Children with Neonatal Lupus Amit Saxena1, Erin McDonnell1, Paula S. Ramos2, Satria Sajuthi2, Miranda C. Marion2, Carl D. Langefeld2, Jill P. Buyon1 and Robert M. Clancy1, 1New York University School of Medicine, New York, NY, 2Wake Forest School of Medicine, Winston-Salem, NC 2:45 pm 772. A Point Mutation in the SSA/Ro60 Autoantigen Which Prevents Y RNA Binding Attenuates a Requisite Signal for Cell Surface Expression and TLR-Dependent Inflammation Joanne H. Reed1, Soyeong Sim2, Sandra L. Wolin2, Jill P. Buyon1 and Robert M. Clancy1, 1New York University School of Medicine, New York, NY, 2Yale University School of Medicine, New Haven, CT

2 0 1 1

3:45 pm 770. Synovial Inflammation and Expression of Mediators of Pain in Preclinical Rheumatoid Arthritis Subjects with Arthralgia Maria J. H. de Hair1, Patrick Leclerc2, Britt N. Sotthewes1, Marleen G. H. van de Sande1, Tamara H. Ramwadhdoebe1, Christiaan van der Leij3, Wouter Bos4, Mario Maas1, Dirkjan van Schaardenburg5, Danielle M. Gerlag1, Marina Korotkova2, Per Johan Jakobsson6 and Paul P. Tak7, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Karolinska Institute, Stockholm, Sweden, 3Academic Medical Center / University of Amsterdam, 4Reade, Amsterdam, Netherlands, 5 Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, 6Rheumatology Unit, Karolinska Institutet; Karolinska University hospital, Stockholm, Sweden, 7Division

Moderators: Athanasios G. Tzioufas, MD; Medical SchoolUniversity of Athens; Athens, Greece Gabor G. Illei, MD; National Institute of Dental and Craniofacial Research/NIH; Bethesda, MD

6 ,

3:30 pm 769. Lung Abnormalities in Subjects with Elevations of Rheumatoid Arthritis-Related Autoantibodies without Arthritis by Examination and Imaging Suggest the Lung Is An Early and Perhaps Initiating Site of Inflammation in Rheumatoid Arthritis M. Kristen Demoruelle1, Michael H. Weisman2, Lezlie A. Derber3, Jason R. Kolfenbach4, Chris Striebich1, Isabel Pedraza5, Annie Harrington5, David Lynch6, Peter Sachs1, Brian Petersen1, Colin Strickland1, Jill Norris7, V. Michael Holers4 and Kevin D. Deane1, 1 University of Colorado School of Medicine, Aurora, CO, 2Cedars Sinai Med Ctr, Los Angeles, CA, 3University of Colorado AMC, Aurora, CO, 4Univ of Colorado School of Med, Aurora, CO, 5 Cedars Sinai Med Ctr, Los Angeles, 6National Jewish Health, Denver, CO, 7University of Colorado Denver, Aurora, CO

Sjögren’s Syndrome

3:00 pm 773. Large-Scale, High-Density Genotyping Performed by the Sjögren’s Genetics Network Using the ImmunoChip Identifies PRKRA as a Novel Sjögren’s Syndrome Susceptibility Locus and Confirms Associations with IRF5, BLK and MHC Christopher J. Lessard1, Indra Adrianto1, John A. Ice1, Jennifer A. Kelly1, Roland Jonsson2, Gabor G. Illei3, Maureen Rischmueller4, Gunnel Nordmark5, Xavier Mariette6, Corinne Miceli-Richard6, Marie Wahren Herlenius7, Torsten Witte8, Michael T. Brennan9, Roald Omdal10, Patrick M. Gaffney11, James A. Lessard12, Wan-Fai Ng13, Nelson L. Rhodus14, Barbara M. Segal15, R. Hal Scofield1, Judith A. James16, Juan-Manuel Anaya17, John B. Harley18, Courtney Montgomery1 and Kathy L. Moser11, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 University of Bergen, Bergen, Norway, 3NIDCR/ NIH #10 1N110, Bethesda, MD, 4Queen Elizabeth Hospital, Adelaide, Australia, 5 Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 6Bicêtre University Hospital, Le Kremlin Bicêtre, France, 7Karolinska Institute, Stockholm, Sweden, 8Hannover Medical School, Hanover, Germany, 9Carolinas Medical Center, Charlotte, NC, 10Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 11Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Valley Bone & Joint Clinic, Grand Forks, ND, 13Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle, England, 14 University of Minnesota, Minneapolis, MN, 15Hennepin County Medical Center, Minneapolis, MN, 16Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 17Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 18Cincinnati

2011 Program Book

SUNDAY

3:15 pm 768. Prevalence of Periodontitis, Anti-P. Gingivalis antibodies, and RA Autoantibodies in a Community Sample of North American Natives with Prevalent RA Isanne Schacter1, David B. Robinson1, Donna M. Hart2, Mary Bertone1, Christine A. Peschken1, Irene Smolik3, Carol A. Hitchon1 and Hani S. El-Gabalawy1, 1University of Manitoba, Winnipeg, MB, 2Health Sciences Centre, Winnipeg, MB, 3 University of Manitoba, Winnipeg

W474a

N o v e m b e r

3:00 pm 767. Analysis of Twin Concordance for ACPA Positivity and ACPA fine specificities in a Large Swedish Twin Cohort (TwinGene) Aase Haj Hensvold1, Patrik KE Magnusson2, Monika Hansson1, Lena Israelsson1, Cecilia Carlens1, Rikard Holmdahl3, PerJohan Jakobsson1, Johan Askling4, Vivianne Malmström1, Lars Klareskog1 and Anca Irinel Catrina1, 1Rheumatology unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 2Swedish Twin Registry Karolinska Institutet, Stockholm, Sweden, 3Medical Biochemistry and Biophysics Karolinska Institutet, Stockholm, Sweden, 4Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden

of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands

39

Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH 3:15 pm 774. Salivary Gland Epithelial Cells Are Capable to Directly Induce the Differentiation of IL-21-Secreting Follicular Helper CD4 T Cells in Primary Sjögren’s Syndrome Yazhuo Gong1, Ghada Alsaleh2, Emmanuel Chatelus3, Christelle Sordet4, Jean Sibilia5, Dominique Wachsmann1 and JacquesEric Gottenberg2, 1EA 44 38, Strasbourg, France, 2Strasbourg University Hospital, Strasbourg, France, 3Hopital Hautepierre, Strasbourg, France, 4Hautepierre Strasbourg Hospital University, Strasbourg, France, 5CHU Hautepierre, Strasbourg, France

2 0 1 1

3:30 pm 775. Functional Delivery of EBV-Mir-BART13 by exosomes in Human Salivary Gland Cells Affects Calcium Signaling Alessia Gallo1, Mayank Tandon1, Shyh-Ing Jang1, Hwei Ling Ong1, Indu Ambudkar1, Gabor G. Illei2 and Ilias Alevizos1, 1NIDCR, Bethesda, MD, 2NIDCR/ NIH #10 1N110, Bethesda, MD

N o v e m b e r

6 ,

SUNDAY

3:45 pm 776. Matriptase Dificency and Primary Sjogren Syndrome Induction: From Patients to Mice Hongen Yin, Peter Kosa, Xibao Liu, Bill Swaim, Javier CabreraPerez, Zhennan Lai, Indu Ambudka, Thomas Bugge and John A. Chiorini, NIH/NIDCR, Bethesda, MD

W470b

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I Moderators: Robert D. Inman, MD; Toronto Western Research Institute, University Health Network and University of Toronto; Toronto, ON, Canada Dirk Elewaut, MD; Gent University Hospital; Ghent, Belgium 2:30 pm 777. Baseline Radiographic Damage, Elevated Acute Phase Reactants and Cigarette Smoking Status Predict Radiographic Progression in the Spine in Early Axial Spondyloarthritis Denis Poddubnyy1, Hildrun Haibel2, Joachim Listing3, Elisabeth Märker-Hermann4, Henning Zeidler5, Jürgen Braun6, Joachim Sieper2 and Martin Rudwaleit7, 1Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 2Charité – Campus Benjamin Franklin, Berlin, Germany, 3German Rheumatism Research Centre, Berlin, Germany, 4Dr. Horst Schmidt Kliniken, Wiesbaden, Germany, 5Medizinische Hochschule, Hannover, Germany, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7Ev. Krankenhaus Hagen-Haspe, Hagen, Germany 2:45 pm 778. Multivariate Analysis Indicates That Fat Lesions Dominate Over Inflammatory Lesions in Predicting New Bone Formation in the Spine of Patients with Ankylosing Spondylitis Walter P. Maksymowych, Nathalie Morency, Barbara ConnerSpady and Robert GW Lambert, University of Alberta, Edmonton, AB

40

2011 Program Book

3:00 pm 779. Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial I. McInnes1, J. Sieper2, J. Braun3, Paul Emery4, Désirée van der Heijde5, J. Isaacs6, G. Dahmen7, J. Wollenhaupt8, H. SchulzeKoops9, S. Gsteiger10, A. Bertolino11, W. Hueber11 and P. P. Tak12, 1 University of Glasgow, Glasgow, United Kingdom, 2Charitè Campus Benjamin Franklin, Berlin, Germany, 3Rheumazentrum Ruhrgebiet, Herne, Germany, 4NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 5Leiden University Medical Center, Leiden, Netherlands, 6Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom, 7 Praxis fuer klinische Studien, Hamburg, Germany, 8Eilbeck Hospital, Hamburg, Germany, 9Klinikum Innenstadt der LudwigMaximilians-Universität, Munich, Germany, 10Novartis Pharma AG, Basel, Switzerland, 11Novartis Institutes for BioMedical Research, Basel, Switzerland, 12University of Amsterdam, Amsterdam, Netherlands 3:15 pm 780. Oral Apremilast Is Effective with and without Concomitant Methotrexate Therapy in the Treatment of Subjects with Active Psoriatic Arthritis Georg A. Schett1, Angela Hu2 and Randall Stevens2, 1University Erlangen-Nuremberg, Erlangen, Germany, 2Celgene Corporation, Warren, NJ 3:30 pm 781. The Association Between Human Leukocyte Antigen and Killer-Cell Immunoglobulin-Like Receptor Gene Variants and Progression of Peripheral Joint Damage in Psoriatic Arthritis Vinod Chandran1, Arane Thavaneswaran2, Fawnda Pellett1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 3:45 pm 782. The Impact of Psoriasis Extent On Prevalence of Psoriatic Arthritis Alexis Ogdie1, Nicole Seminara2, Sinead Langan3 and Joel Gelfand2, 1University of Pennsylvania, Philadelphia, PA, 2 University of Pennsylvania., Philadelphia, PA, 3London School of Hygiene and Tropical Medicine, United Kingdom

W196b

Systemic Lupus Erythematosus – Clinical Aspects: Cardiac Disease/Organ Damage Moderators: John G. Hanly, MD; Nova Scotia Rehabilitation Center; Halifax, NS, Canada Sasha Bernatsky, MD, PhD; McGill University Health Center/ Royal Victoria Hospital; Montreal, QC, Canada 2:30 pm 783. The Protective Effect of Antimalarials On Thrombovascular Events In Latin American Systemic Lupus Erythematosus Patients Guillermo J. Pons-Estel1, Graciela S. Alarcón2, Daniel Wojdyla3, Ana I. Marcos4, Alejandro J. Alvarellos5, Antonio A. IglesiasGamarra6, Maria H. Esteva-Spinetti7, Lilian Costallat8, Nilzio

3:30 pm 787. Predictors of Risk for Progression of Subclinical Atherosclerosis in Women with Systemic Lupus Erythematosus Apinya Lertratanakul1, Peggy W. Wu1, Alan Dyer1, William Pearce1, Kim Sutton-Tyrrell2, George Kondos3, Daniel Edmundowicz2, James Carr4 and Rosalind Ramsey-Goldman5, 1 Northwestern University, Chicago, IL, 2University of Pittsburgh, 3 University of Illinois at Chicago, Chicago, IL, 4James, Chicago, IL, 5 Northwestern University Feinberg School of Medicine, Chicago, IL 3:45 pm 788. Plasma Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) Levels Are Associated with Carotid Plaque Progression in Women with SLE Maureen A. McMahon1, E. Lorenco1, Jennifer M. Grossman1, Lori Sahakian1, John D. FitzGerald1, Nagesh Ragavendra1, Christina

Moderators: Rula Hajj-Ali, MD; Cleveland Clinic Foundation; Cleveland, OH Carlo Salvarani, MD; Arcispedale Santa Maria Nuova; Reggio Emilia, Italy 2:30 pm 789. Immunoglobulin Concentrations and Infection Risk Among Patients with ANCA-Associated Vasculitis Treated with Rituximab or Cyclophosphamide Ulrich Specks1, Peter A. Merkel2, Philip Seo3, Robert Spiera4, Carol A. Langford5, Gary S. Hoffman5, Cees G.M. Kallenberg6, E. William St. Clair7, Swati Tole8, Paul Brunetta9, Shuyi Shen8, Nadia Tchao10, Barri J. Fessler11, Lisa Webber12, Linna Ding13, Lourdes P. Sejismundo14, Kathleen Mieras1, Deborah J. Phippard10, Adam Asare10, Noha Lim10, David Ikle15, Brett Jepson15, Alice Lail15, Mark Mueller16, Nancy B. Allen17, Fernando Fervenza1, Duvuru Geetha18, Karina Keogh1, Eugene Y. Kissin19, Paul A. Monach19, Tobias Peikert1, Coen Stegeman6, Steven R. Ytterberg1, John H. Stone20 and for the RAVE-ITN Research Group21, 1Mayo Clinic, Rochester, MN, 2Boston University School of Medicine, Boston, MA, 3Johns Hopkins Vasculitis Center, Baltimore, MD, 4Hospital for Special Surgery, New York, NY, 5 Cleveland Clinic, Cleveland, OH, 6University Medical Center Groningen, Groningen, Netherlands, 7Duke University Medical Center, Durham, 8Genentech, Inc., South San Francisco, CA, 9 Genentech, So San Francisco, CA, 10Immune Tolerance Network, Bethesda, MD, 11Univ of Alabama-Birmingham, Birmingham, AL, 12 National Institute of Allergy and Infectious Diseases, 13NIAID, Bethesda, MD, 14Johns Hopkins University, Baltimore, MD, 15 Rho, Chapel Hill, NC, 16Food & Drug Administration, Bethesda, MD, 17Duke University Medical Center, Durham, NC, 18Johns Hopkins University, York, PA, 19Boston University, Boston, MA, 20 Massachusetts General Hospital, Boston, MA, 21Bethesda

2 0 1 1

3:15 pm 786. Vitamin D Insufficiency and Deficiency in Systemic Lupus Erythematosus Michelle Petri1, Kayode J. Bello1, Hong Fang1, Caroline D’Souza1 and Laurence S. Magder2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD

Vasculitis I

6 ,

3:00 pm 785. Development of Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: How Important Are Race/ Ethnicity and Geography? Murray B. Urowitz1, D. D. Gladman1, Dominique Ibanez1, Nicole Anderson1 and Systemic Lupus International Collaborating Clinics (SLICC)2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto, ON

W192b

SUNDAY

2:45 pm 784. Non-Calcified Coronary Plaque in Systemic Lupus Erythematosus Quantitative Analysis Adnan Kiani1, Jens Vogel-Claussen2, Armin Zadeh2, Margaret Yew2, Laurence S. Magder3, Joao Lima2 and Michelle Petri1, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, MD

Charles-Schoeman1, Alan H. Gorn1, Michael H. Weisman2, Daniel Wallace3, Bevra H. Hahn1 and Brian Skaggs1, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2Cedars Sinai Med Ctr, Los Angeles, CA, 3Cedars-Sinai/UCLA, Los Angeles, CA

N o v e m b e r

A. Silva9, Gloria Vázquez10, Maria Loreto Massardo11, Marlene Guibert-Toledano12, Guillermo F. Huerta-Yáñez13, Mariano Cucho-Venegas14 and Bernardo Pons-Estel15, 1Servicio de Enfermedades Autoinmunes, Hospital Clìnic Barcelona, Barcelona, Spain, 2University of Alabama at Birmingham, Birmingham, AL, 3Universidad Nacional de Rosario, Argentina, Rosario, Argentina, 4Hospital Interzonal General de Agudos “General San Martin, La Plata, La Plata, Argentina, 5Hospital Privado, Cordoba, Argentina, 6Universidad Nacional, Bogota, Colombia, 7Centro Clinico San Cristobal, San Cristobal, Venezuela, 8Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil, 9Faculdade de Medicina, Universidade Federal de Goias, Goiania, Brazil, 10 Universidad de Antioquia, Hospital Universitario “San Vicente de Paul”, Medellín, Colombia, 11Catholic University of Chile, Santiago, Chile, 12Centro de Investigaciones Médico Quirúrgicas, Habana, La Habana, Cuba, 13Hospital de Especialidades Miguel Hidalgo, Aguascalientes, Mexico, 14Almenara Hospital IPSs, Lima, Peru, 15Hospital Provincial de Rosario, Rosario, Argentina

2:45 pm 790. Association of Ferritin Antibodies with GCA/PMR: New Biomarker for Diagnosis Niklas T. Baerlecken1, Anna Linnemann2, Wolfgang L. Gross3, Frank Moosig4, T.R. Vazquez-Rodriguez5, Miguel Gonzalez-Gay6, Javier Martin7, Ina Kötter8, Joerg C. Henes9, Inga Melchers10, Peter Vaith11, Reinhold E. Schmidt12 and Torsten Witte13, 1MD, Hannover, Germany, 2Student, Hannover, Germany, 3Medical University at Lubeck, Lubeck, Germany, 4Stormarnzing 156, Bad Bramstedt, Germany, 5MD, Spain, 6Hospital Marques De Valdecilla, Santander, Spain, 7Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 8MD, Tübingen, Germany, 9University Hospital Tuebingen, Tuebingen, Germany, 10 PhD, Freiburg, Germany, 11Medizinische Uni Klinik, Freiburg, Germany, 12Hannover Medical School, Hannover, Germany, 13MD, Hanover, Germany

2011 Program Book

41

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

3:00 pm 791. Immunological Signature Discriminates Active and Inactive Patients with Takayasu Arteritis David Saadoun1, Benjamin Terrier2, Guillaume Geri3, Wahiba Chaara4, Michelle Rosenzwajg5, Nathalie CostedoatChalumeau3, Pierre Fourret6, Lucile Musset3, Adrien Six4, David Klatzmann5 and Patrice Cacoub3, 1Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2Pitié-Salpêtrière Hospital, Paris, France, 3CHU Pitié-Salpêtrière, Paris, France, 4Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Paris, France, 5Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Paris, France, 6 Anatomopathology, Groupe Hospitalier Pitié-Salpetrière, Paris, France 3:15 pm 792. Serum Proteins Reflecting Inflammation, Injury, and Repair As Biomarkers of Disease Activity in ANCA-Associated Vasculitis Paul A. Monach1, Roscoe L. Warner2, Gunnar Tomasson3, Ulrich Specks4, John H. Stone5, Linna Ding6, Fernando Fervenza4, Barri J. Fessler7, Gary S. Hoffman8, David Ikle9, Cees GM Kallenberg10, Jeffrey Krischer11, Carol A. Langford12, Mark Mueller13, Philip Seo14, E. William St Clair15, Robert Spiera16, Nadia Tchao17, Steven R. Ytterberg4, Kent J. Johnson2 and Peter A. Merkel3, 1Boston University, Boston, MA, 2University of Michigan, Ann Arbor, MI, 3Boston University School of Medicine, Boston, MA, 4Mayo Clinic, Rochester, MN, 5Massachusetts General Hospital, Boston, MA, 6NIAID, Bethesda, MD, 7Univ of Alabama-Birmingham, Birmingham, AL, 8Cleveland Clinic Found A50, Cleveland, OH, 9 Rho, Chapel Hill, NC, 10University Medical Center Groningen, Groningen, Netherlands, 11University of South Florida, Tampa, FL, 12 Cleveland Clinic, Cleveland, OH, 13Food & Drug Administration, Bethesda, MD, 14Johns Hopkins Vasculitis Center, Baltimore, MD, 15Duke University Medical Center, Durham, NC, 16Hospital for Special Surgery, New York, NY, 17Immune Tolerance Network, Bethesda, MD 3:30 pm 793. In Situ Immune Complex (MPO-anti MPO antibody) and Complement 3 cause Glomerular Capillary Injury in Human MPO-ANCA Associated Glomerulonephritis Soko Kawashima, Yoshihiro Arimura, Yoshinori Komagata, Shinya Kaname and Akira Yamada, Kyorin University School of Medicine, Tokyo, Japan 3:45 pm 794. Increased Frequency of Circulating Follicular Helper T-Cells (TFH) in Patients with Granulomatosis with Polyangiitis Wayel H. Abdulahad1, Nikola Lepse1, Henko Tadema1, Minke G. Huitema1, Berber Doornbos-van der Meer1, Coen Stegeman1, Pieter C. Limburg1, Peter Heeringa2 and Cees GM Kallenberg1, 1 University Medical Center Groningen, Groningen, Netherlands, 2 University Medical Center Groningen, Netherlands

42

2011 Program Book

ACR SPECIAL SESSION 2:30 - 4:00 pm

W375d

Great Debate: Is too Much Suppression of Turnover Bad for Bone? P/C PS ARS Moderator: Chad L. Deal, MD; Cleveland Clinic Foundation; Cleveland, OH Speakers: Kenneth G. Saag, MD, MSc; University of AlabamaBirmingham; Birmingham, AL Douglas C. Bauer, MD; University of California, San Francisco; San Francisco, CA Upon completion of this session, participants should be able to: • define the evidence for and against use of bisphosphonates in osteoporosis • interpret the evidence for and against bisphosphonate use in light of current guidelines • utilize this improved understanding of the pros and cons of bisphosphonates when discussing therapeutic options with patients

ACR REF SPECIAL SESSION 2:30 - 4:00 pm

W196a

REF Special Session: “Within Our Reach”: Finding a Cure for Rheumatoid Arthritis c/r Moderator: David R. Karp, MD, PhD; University of Texas Southwestern Medical Center; Dallas, TX 2:30 pm Methotrexate and JUN Pathway Activation in Rheumatoid Arthritis Nancy J. Olsen, MD; Pennsylvania State Milton S. Hershey Medical Center; Hershey, PA 2:55 pm Autoantibodies, Inflammation, and Cardiovascular Disease in Pre-Clinical Rheumatoid Arthritis Jill Norris, MPH, PhD; University of Colorado Denver; Aurora, CO 3:20 pm Biomarkers of Enhanced Cardiovascular Risk in Rheumatoid Arthritis Joan M. Bathon, MD; Columbia University Medical Center; New York, NY Upon completion of this session, participants should be able to: • indentify the role of methotrexate treatment in JUN pathway activation in the pathogenesis of rheumatoid arthritis • describe the degree to which the immune system is dysregulated in rheumatoid arthritis patients even before there is recognizable synovitis • know what biochemical, genetic, and clinical features predict accelerated cardiovascular disease in rheumatoid arthritis

ARHP CONCURRENT ABSTRACT SESSION 2:30 - 4:00 pm

W194a

ARHP Epidemiology and Public Health I Moderators: Charles G. Helmick, MD; Centers for Disease Control and Prevention; Atlanta, GA Robert R. McLean, MD; Hebrew Senior life; Harvard Medical School; Boston, MA 2:30 pm 795. Musculoskeletal Conditions Are the Most Common Causes of Work Limitation in U.S. Adults Kristina A. Theis1, Charles G. Helmick1 and Jennifer M. Hootman2, 1 Centers for Disease Control and Prevention, Atlanta, GA, 2 Centers for Disease Control and Prevention, Kennesaw, GA

Alyssa B. Dufour1, Virginia A. Casey2, Patricia P. Katz3, Robert R. McLean4 and Marian T. Hannan4, 1Hebrew SeniorLife & Boston Univ, Boston, MA, 2Hebrew Senior Life, Boston, MA, 3Univercity of California San Francisco, San Francisco, CA, 4Hebrew SeniorLife & Harvard Med Sch, Boston, MA

ARHP CONCURRENT SESSIONS 2:30 - 4:00 pm

W476

Disability: Clinical Facts, Legal Fictions, and Practice Strategies BR C Moderator: Donald Uslan, MA, MBA, LMHC, CRC; The Seattle Arthritis Clinic, University of Washington Medicine/Northwest Hospital & Medical Center; Seattle, WA

3:15 pm 798. Trajectory of Weight Associated with Arthritis: A Population-Based Longitudinal Cohort Analysis Orit Schieir1, S. Hogg-Johnson2 and E. M. Badley3, 1University of Toronto, Toronto, ON, 2Institute for Work and Health, and Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 3Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON 3:30 pm 799. Identifying Obesity in Rheumatoid Arthritis: Current BMI Definition of Obesity Does Not Accurately Reflect Body Composition Patricia P. Katz1, Mary E. Margaretten2, Steven Gregorich3, Sandi Kaplan4, Holly Wing4, Edward Yelin5 and Lindsey A. Criswell5, 1 Univercity of California San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA, 3University of California, San Francisco, San Francisco, CA, 4University of California, San Francisco, CA, 5 University of California San Francisco, San Francisco, CA 3:45 pm 800. Does Hallux Valgus and Foot Pain Affect Self-Reported Lower Extremity Limitations in Men and Women? the Framingham Study

2 0 1 1

2:50 pm Legal Fictions: Long-term Disability Frederick P. Langer; Nelson Langer Engle, PLLC; Seattle, WA

6 ,

3:00 pm 797. Does Physical Performance Mediate the Effect of Knee Osteoarthritis and Risk of Indoor and Outdoor Falls in Older Men and Women? Uyen Sa D. Nguyen1, Yuqing Zhang1, Tyler J. VanderWeele2, Jingbo Niu1, Robert H. Shmerling3, Douglas P. Kiel4, Suzanne G. Leveille5, Carol A. Oatis6 and Marian T. Hannan7, 1Boston University School of Medicine, Boston, MA, 2Harvard School of Public Health, Boston, MA, 3Beth Israel Deaconess Med Ctr, Boston, MA, 4Hebrew Senior Life/Harvard Medical School, Boston, MA, 5University of Massachusetts-Boston, Boston, MA, 6 Arcadia University, Glenside, PA, 7Hebrew SeniorLife & Harvard Med Sch, Boston, MA

SUNDAY

2:30 pm Clinical Facts: Vocational Rehabilitation and the Disability Spectrum for Rheumatology Professionals Donald Uslan, MA, MBA, LMHC, CRC; The Seattle Arthritis Clinic, University of Washington Medicine/Northwest Hospital & Medical Center; Seattle, WA

N o v e m b e r

2:45 pm 796. A Population-Based Approach to Establishing the National Burden of Severe Hip and Knee Osteoarthritis In Australia Ilana N. Ackerman1 and Richard H. Osborne2, 1The University of Melbourne, Melbourne, Australia, 2Deakin University, Melbourne, Australia

3:10 pm Practice Strategies: Disability in the Rheumatology Practice Richard Jimenez, MD; The Seattle Arthritis Clinic; Seattle, WA 3:30 pm Panel Discussion Upon completion of this session, participants should be able to: • describe concepts and terminology in the vocational intervention of rheumatology patients • describe treatment options regarding a patient’s disability • identify different disability determinations and compensation systems • discuss how to properly fill-out the necessary paperwork • recognize legal issues as it relates to patients and health providers

W195

Rehabilitation for the Clinician

C

Moderator: Mary Wright, BS, OT; The Toledo Hospital; Toledo, OH 2:30 pm Review of Common Rheumatologic Conditions Treated with Physical Therapy and Occupational Therapy Donna K. Everix, MPA, BS, PT; Mills Peninsula Health Services; Burlingame, CA Victoria A. Merrell, PA-C, MPT; Roy Kaplan MD; Encinitas, CA 3:00 pm Exercise and Rehabilitation for Common Rheumatologic Conditions Donna K. Everix, MPA, BS, PT; Mills Peninsula Health Services; Burlingame, CA

2011 Program Book

43

W178a

3:30 pm Demonstration and Practice of Exercises Upon completion of this session, participants should be able to: • list common conditions encountered in rheumatology that could benefit from rehabilitation interventions • demonstrate specific exercises for common conditions encountered in rheumatology • identify “red flags” for urgent referral to rehabilitation or other interventions

Rheumatic Disease Update: Relapsing Polychondritis C

Moderator: Debra Bancroft-Rizzo, MSN, APNP; Rheumatic Disease Center; Glendale, WI Speaker: Jane Hoyt Buckner, MD; Benaroya Research Institute; Seattle, WA

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

Upon completion of this session, participants should be able to: • describe the symptoms of relapsing polychondritis • describe how relapsing polychondritis is diagnosed • review the medication used to treat relapsing polychondritis

INNOVATION THEATER 2:30 - 3:15 pm

HALL F1 - (Booth #789) The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Novartis Pharmaceuticals Corporation. Please visit the Novartis Pharmaceuticals Corporation exhibit booth (314) for more information or see page 304. Seating and light refreshments are subject to availability.

Gouty Arthritis and the Impact of Inflammation

ACR/ARHP WORKSHOPS 4:00 - 6:00 pm Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual.

W179a

Adult Musculoskeletal Upper Examinations (212) Speaker: Arthur M. Mandelin II, MD, PhD; Northwestern University Feinberg School of Medicine; Chicago, IL

W180 f

Speaker: Eugene Y. Kissin, MD; Boston University; Boston, MA

44

2011 Program Book

Speaker: Megan Troxell, MD; Oregon Health & Science University; Portland, OR

ACR BASIC SCIENCE SYMPOSIUM 4:30 - 6:00 pm

W190a

W474b

Musculoskeletal Ultrasound (213)

Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (214)

Crystals and Arthritis – Mechanisms of Inflammation and Joint Destruction R Moderator: G M. McCarthy, MD; Mater Misericordiae University Hospital; Dublin, Ireland 4:30 pm Mechanisms for Urate Induced Joint Inflammation Robert Terkeltaub, MD; Veteran’s Affairs Medical Center; San Diego, CA 4:55 pm Calcium Crystals and Joint Tissue Destruction in Osteoarthritis Ann K. Rosenthal, MD; Medical College of Wisconsin; Milwaukee, WI 5:20 pm The Role of Anakinra in Chondrocalcinosis and Joint Disease Charlene Williams, PhD; Thomas Jefferson University; Philadelphia, PA Upon completion of this session, participants should be able to: • define how the various types of crystals induce joint inflammation and joint tissue destruction • describe how recent studies on urate crystals have led to a better understanding of the role of the inflammasome in regulating inflammation • relate calcium crystals in joint tissues to the pathogenesis of osteoarthritis • determine how mutations in the Ank gene contribute to excessive joint tissue calcification and arthritis

ACR CLINICAL SYMPOSIUM 4:30 - 6:00 pm

W375d

Management of Antiphospholipid Syndrome – From Controversies to Consensus cP P/C PS Moderators: Robert A. S. Roubey, MD; University of North Carolina; Chapel Hill, NC Fernando E. Figueroa, MD; Universidad de los Andes; Santiago de Chile, Chile 4:30 pm Primary Thromboprophylaxis Doruk Erkan, MD; Hospital for Special Surgery; New York, NY 4:55 pm Management of Thrombosis Munther A. Khamashta, MD; The Rayne Institute, Kings College London School of Medicine; London, United Kingdom

5:20 pm Management of Pregnancy Lisa R. Sammaritano, MD; Hospital for Special Surgery; New York, NY 5:45 pm Question and Answer Doruk Erkan, MD; Hospital for Special Surgery; New York, NY Munther A. Khamashta, MD; The Rayne Institute, Kings College London School of Medicine; London, United Kingdom Lisa R. Sammaritano, MD; Hospital for Special Surgery; New York, NY

Moderators: Jeffrey R. Curtis, MD, MPH, MSPH; University of Alabama at Birmingham; Birmingham, AL Tim Bongartz, MD, MS; Mayo Clinic College of Medicine; Rochester, MN 4:30 pm 801. Initiation of Biologic DMARDs and the Risk of Hospitalization for Infection in Patients with Autoimmune Diseases Carlos Grijalva1, Lang Chen2, Elizabeth S. Delzell2, John Baddley2, Timothy Beukelman3, Kevin L. Winthrop4, Marie Griffin5, Lisa Herrinton6, Liyan Liu6, Parivash Nourjah7, Nivedita M. Patkar3, Daniel H. Solomon8, James Lewis9, Fenglong Xie2, Kenneth G. Saag2 and Jeffrey R. Curtis2, 1Vanderbilt University, Nashville, TN, 2University of Alabama at Birmingham, Birmingham, AL, 3 Univ of Alabama-Birmingham, Birmingham, AL, 4Oregon Health Science Univ, Portland, OR, 5Vanderbilt, 6Oakland, CA, 7Rockville, MD, 8Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, 9University of Pennsylvania

2 0 1 1

Epidemiology and Health Services Research V: Drugs

6 ,

W470b

5:30 pm 805. Switching From Oral Bisphosphonates to Intravenous Zoledronic Acid Is Associated with A Reduction In the Incidence Rates of Morphometric Vertebral Fractures Among Patients with Postmenopausal Osteoporosis? — A Real-World TimeSeries Study Peter Sun1, Jean Lian2, Chris Recknor3 and Julie Recknor3, 1Kailo Research Group, Indianapolis, IN, 2Novartis Pharmaceuticals Corp., East Hanover, NJ, 3United Osteoporosis Centers, Gainesville, GA 5:45 pm 806. Safety of Zoster Vaccine in Individuals with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Disease Jie Zhang1, Fenglong Xie1, Elizabeth S. Delzell1, Lang Chen1, Kenneth G. Saag1, Kevin L. Winthrop2 and Jeffrey R. Curtis3, 1 University of Alabama at Birmingham, Birmingham, AL, 2 Oregon Health Science Univ, Portland, OR, 3Univ of AlabamaBirmingham, Birmingham, AL

W181b

Imaging of Rheumatic Disease I: Ultrasonography and Dual-emission X-ray Absorptiometry Moderators: Wolfgang A. Schmidt, MD; Medical Centre Rheumatol Berlin Buch; Berlin, Germany Ralf G. Thiele, MD; University of Rochester; Rochester, NY

4:45 pm 802. Short Periods of Glucocorticoid Use Are Associated with a Prolonged Risk of Osteonecrosis Steven C. Vlad1, Donald R. Miller2, Yuqing Zhang1 and David T. Felson1, 1Boston University School of Medicine, Boston, MA, 2 Edith Nourse Rogers Memorial VA Hospital, Bedford, MA

4:30 pm 807. Can Ultrasound (PDUS) Easily Detect Erosions? Evaluation of Physiological and Abnormal Cortical Breaks of Small Joints in Healthy Individuals (HI) and Rheumatoid Arthritis (RA) Patients by PDUS Comparison with Micro Computed Tomography (µCT) Scan Stephanie Finzel1, Philippe Aegerter2, Georg Schett1, MariaAntonietta D’Agostino2 and OMERACT Ultrasound Task Force3, 1 University of Erlangen-Nuremberg, Erlangen, Germany, 2 Versailles-Saint Quentin en Yvelines University- APHP, AmbroiseParé Hospital, Boulogne-Billancourt, Paris, France, Paris, France, 3 Paris, France

5:00 pm 803. Cardiovascular Risk Reduction Associated with TNF Blockade: Results From a Large Multi-Site Observational Study Daniel H. Solomon1, Leslie R. Harrold2, Jeremy Rassen1, Huichuan

4:45 pm 808. Imaging As An Outcome Measure in Early Inflammatory Arthritis: Monitoring Disease Activity and Patients’ Response to Therapy Using Ultrasonography 2011 Program Book

SUNDAY


5:15 pm 804. Use of Bisphosphonates for the Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatoid Arthritis — a Population Based Study Diane Lacaille1, Mushfiqur Rahman1 and John Esdaile2, 1Arthritis Research Centre; University of British Columbia, Vancouver, BC, 2 University of Calgary, Calgary, AB

N o v e m b e r

Upon completion of this session, participants should be able to: • a ssess the risk of thrombosis in individuals that test positive for antiphospholipid antibodies • r eview the data on primary prevention in such individuals • identify the options for the management of thrombotic manifestations of antiphospholipid syndrome iscuss the evidence and best data supporting treatment • d decisions in antiphospholipid syndrome • r eview the therapeutic options for the obstetric manifestations of antiphospholipid syndrome • d iscuss the evidence and best data supporting treatment decisions in obstetric antiphospholipid syndrome

Lii3, Lang Chen4, David Graham5, Marie Griffin6, Mary Kowal3, Bindee Kuriya7, James Lewis8, Liyan Liu9, Kenneth G. Saag10 and Jeffrey R. Curtis10, 1Brigham & Womens Hospital, Boston, MA, 2 UMass Medical School, Worcester, MA, 3Brigham and Women’s Hospital, Boston, MA, 4University of Alabama at Birmingham, Birmingham, AL, 5Food and Drug Administration, 6Vanderbilt, 7 University of Toronto, Toronto, ON, 8University of Pennsylvania, 9 Kaiser Permanente, 10Univ of Alabama-Birmingham, Birmingham, AL

45

Yasser M. El Miedany1, Maha El Gaafary2, Deborah Palmer1 and Sally Youssef2, 1Darent Valley Hospital, Dartford, United Kingdom, 2 Ain Shams University, Cairo, Egypt

and Center of Chronic Immunodeficiency, University of Freiburg, Freiburg, Germany, Freiburg, Germany, 4Dept. of Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, Aarau, Switzerland

5:00 pm 809. Ultrasonography Is a Potent Tool for Prediction of Ongoing Joint Destruction During Clinical Remission of Rheumatoid Arthritis Ryusuke Yoshimi, Kaoru Takase, Maasa Hama, Daiga Kishimoto, Kayo Terauchi, Reikou Watanabe, Takeaki Uehara, Darisuren Tsolmon, Sei Samukawa, Atsushi Ihata, Atsuhisa Ueda, Mitsuhiro Takeno and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan

5:00 pm 815. Synergistic TLR3 and TLR7 Activation by Endogenous Ligands Promotes Inflammatory Arthritis Through IRF5 Pierre Duffau1, Tamar Aprahamian1, Hanni Menn-Josephy1, Amanda Watkins1, Kei Yasuda1, Ramon G. Bonegio1, Paul A. Monach2, G. Kenneth Haines III3, Harris R. Perlman4, Christophe Richez5 and Ian Rifkin1, 1Boston University School of Medicine, Boston, MA, 2Boston University, Boston, MA, 3Yale University, New Harven, CT, 4Northwestern University, Chicago, IL, 5France

5:15 pm 810. Does Rheumatoid Synovitis Activity Vary During the Day? A Sonographic and Doppler Evaluation Agnes Lhoste, Bruno Pereira, Marion Couderc Sr. and Martin Soubrier, CHU CLERMONT-FERRAND, Clermont-Ferrand, France

5:15 pm 816. Soluble CD14 in Synovial Fluid From Patients with EarlyStage Osteoarthritis Augments Synoviocyte Responses to TLR-2 and TLR-4 Ligands Anjali Nair1, Veero Kanda1, Charles Bush-Joseph1, Nikhil Verma1, Susanna Chubinskaya1, Katalin Mikecz1, Tibor T. Glant1, AnneMarie Malfait1, Mary K. Crow2, Greg Spear1, Alison Finnegan1 and Carla R. Scanzello1, 1Rush University Medical Center, Chicago, IL, 2Hospital for Special Surgery, New York, NY

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

5:30 pm 811. Sonoelastography Detects Rigidity of Salivary Glands in Primary Sjögren’s Syndrome Christian Dejaco1, Tobias DeZordo2, Daniel Heber1, Rainer Lipp1, Andre Lutfi1, Marton Magyar1, Saelde Baumgartner1, Dorothea Zauner1, Winfried B. Graninger1 and Josef Hermann1, 1Medical University Graz, Graz, Austria, 2Innsbruck Medical University, Innsbruck, Austria 5:45 pm 812. Vertebral Fracture Assessment (VFA): A Valid Tool to Detect Vertebral Fractures in Community-Dwelling Older Individuals. Diogo S. Domiciano1, Jaqueline B. Lopes1, Liliam Takayama2, Camille Figueiredo1, Valéria Caparbo1, Eloisa Bonfa3 and Rosa M.R. Pereira4, 1University of São Paulo, São Paulo, Brazil, 2 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3University of Sao Paulo, Sao Paulo, Brazil, 4 Disciplina de Reumatologia da FMUSP, Sao Paulo, Brazil

W474a

Innate Immunity and Rheumatic Disease Moderators: Richard M. Pope, MD; Northwestern University Medical School; Chicago, IL Susan A. Boackle, MD; University of Colorado Denver School of Medicine; Aurora, CO 4:30 pm 2011 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk Speaker: Wayne M. Yokoyama, MD; Washington University School of Medicine; St. Louis, MO 4:30 pm 813. WITHDRAWN 4:45 pm 814. Circulating Mitochondrial DNA Copy Numbers As a Disease and Activity Marker in ANCA-Associated Vasculitis Ulrich A. Walker1, Nora M. Effelsberg2, Nils Venhoff3, Chingching Foocharoen1, Jens Thiel3, Paul Hasler4 and Dirk Lebrecht3, 1 University of Basel, Basel, Switzerland, 2Dept. of Rheumatology and Centre of Chronic Immunodeficiency, University of Freiburg, Freiburg, Germany, Freiburg, Germany, 3Dpt. of Rheumatology

46

2011 Program Book

5:30 pm 817. Abatacept (CTLA-4Ig) Treatment Reduces Adhesion and Migratory Capacity of Monocytes in Patients with Rheumatoid Arthritis (RA) Michael Bonelli1, Elisabeth Ferner1, Anastasiya Hladik1, Lisa Goeschl1, Thomas Karonitsch1, Hans Peter Kiener1, Stefan Blueml1, Carl-Walter Steiner1, Michael Bergmann1, Josef Smolen2 and Clemens Scheinecker1, 1Medical University of Vienna, Vienna, Austria, 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria 5:45 pm 818. A Novel Autoinflammatory Syndrome Presenting with Chronic Atypical Neutrophilic Dermatitis, Lipodystrophy and Elevated Temperatures (CANDLE syndrome) Caused by Mutation in the Immunoproteasome Yin Liu1, Yongqing Chen1, Yuval Ramot2, Damaris Garcia1, Antonio Torrelo3, Afzal Sheikh4, Amy Paller5, Adam Reinhardt6, Deborah Stone1, Massimo Gadina7, Plass1 Plass1, Dawn Chapelle1, Zlotogorski Zlotogorski2 and Raphaela T. Goldbach-Mansky8, 1 Translational Autoinflammatory Disease Section, Office of the Clinical Director NIAMS, Bethesda, MD, 2Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel., Jerusalem, Israel, 3Departments of Pediatric Dermatology, Hospital Niño Jesús, Madrid, Spain, Madrid, Spain, 4 Medical Genetics Branch, NHGRI, Bethesda, MD, 5Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA;, Chicago, IL, 6Faculty of Physicians of the University of Nebraska Medical Center, College of Medicine, Nebraska, 7NIAMS, Bethesda, MD, 8NIH, Bethesda, MD

W471b

Muscle Biology, Myositis and Myopathies: Insights into the Pathogenesis of Myositis Moderators: Jiri Vencovsky, MD, PhD; Institute of Rheumatology; Prague, Czech Republic Lucy R. Wedderburn, MD, PhD; University College London; London, United Kingdom

4:30 pm 819. Micrornas Mir-15b and Mir-206 Are Key Factors in the Regulation of Impaired Angiogenesis in Muscle of Children with Untreated Juvenile Dermatomyositis Simone Treiger Sredni1, Peter Hendrickson2, Erin Kim3, Gabrielle Morgan3, Sheela Shrestha3, Yi-Wen Chen4, Chiang-Ching Huang5 and Lauren M. Pachman1, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Children’s Memorial Research Center, Chicago, IL, 3Children’s Memorial Hospital, Chicago, IL, 4 George Washington University, Washington, 5Northwestern Univ Med School, Chicago, IL

5:45 pm 824. Clinical and Autoantibody Associations in Myositis Patients with Anti p155/140kDa Autoantibodies - a Multicenter European Study Herman F. Mann1, Lenka Plestilova2, Hector Chinoy3, Robert G. Cooper4, Lara Dani5, Ingrid E. Lundberg5, Zoe Betteridge6, Neil J. McHugh7 and Jiri Vencovsky2, 1Institute of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague 2, Czech Republic, 2Institute of Rheumatology, Prague 2, Czech Republic, 3The University of Manchester, Manchester, United Kingdom, 4Hope Hospital, Salford, United Kingdom, 5Karolinska Institutet, Stockholm, Sweden, 6Royal National Hospital, Bath, United Kingdom, 7Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

Michelle S. Yau1, Laura Yerges-Armstrong1, Michael Doherty2, Marc Hochberg1, Joanne M. Jordan3, Virginia Byers Kraus4, Braxton Mitchell1, A. G. Wilson5 and GOGO Investigators6, 1 University of Maryland School of Medicine, Baltimore, MD, 2 City Hospital, Nottingham, United Kingdom, 3UNC Thurston ARC, Chapel Hill, NC, 4Duke University Medical Center, Durham, NC, 5Sheffield Uni /Medical School, Sheffield, United Kingdom, 6 Durham 4:45 pm 826. Treatment of Knee Osteoarthritis with Intraarticular Infliximab May Improve Knee Function and Reduce Synovial Infiltration by Macrophages Jeremy R. Schue1, Ossama Tawfik1, Donald D. Smith1, Gary Hinson, Rebecca Bolce3, Jo A. Wick and Herbert B. Lindsley1, 1 Kansas University Med Ctr, Kansas City, KS, 2Janssen Services, LLC, Horsham, PA

2 0 1 1

5:30 pm 823. Role of MyD88-Dependent Toll-Like Receptor Signaling in a Murine Model of Histidyl-tRNA Synthetase-Induced Myositis Lisa Harlow1, Irina Fernandez1, Yunjuan Zang1, Makoto Soejima2, Eric L. Greidinger3 and Dana P. Ascherman3, 1University of Miami Miller School of Medicine, Miami, FL, 2University of Pittsburgh, Pittsburgh, PA, 3University of Miami, Miami, FL

4:30 pm 825. Heritability and Linkage of Radiographic Progression of Hip and Knee Osteoarthritis: Results From the Longitudinal Component of the Genetics of Generalized Osteoarthritis Study

6 ,

5:15 pm 822. CD28null T Cells From Myositis Patients Are Cytotoxic to Autologous Muscle Cells in Vitro Paulius Venalis, Jayesh Pandya, Vanessa Stache, Gustavo Nader, Vivianne Malmström, Ingrid E. Lundberg and Andreas Fasth, Karolinska Institutet, Stockholm, Sweden

Moderators: Joanne M. Jordan, MD, MPH; University North Carolina Thurston Arthritis Research Center; Chapel Hill, NC Najia Shakoor, MD; Rush University Medical Center; Chicago, IL

SUNDAY

5:00 pm 821. Pandemic Unadjuvanted Influenza A 2009 Vaccine in Adult Dermatomyositis and Polymyositis: Immunogenicity Independent of Therapy and No Harmful Effect in Disease Samuel K. Shinjo1, Maurício Levy Neto1, Clovis A. Silva1, Julio C. B. Moraes1, Ana C. M. Ribeiro1, Carla G.S. Saad1, Nadia E. Aikawa1, Alexander R. Precioso2, Maria C.S. Timenetsky3 and Eloisa Bonfa1, 1 Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 2Butantan Institute, Sao Paulo, Brazil, 3Instituto Adolfo Lutz, São Paulo, Brazil

Osteoarthritis – Clinical Aspect I

N o v e m b e r

4:45 pm 820. Type I Interferon-Related Biomarkers Predict Clinical Disease Activity in Inflammatory Myositis Ann M. Reed1, Cynthia S. Crowson1, Hatice Bilgic2, Emily Baechler Gillespie2, Molly Hein1, Steven R. Ytterberg1, Shreyasee Amin1 and Erik J. Peterson2, 1Mayo Clinic, Rochester, MN, 2University of Minnesota, Minneapolis, MN

W196a

5:00 pm 827. Prolonged Improvement of Clinical Status and Structural Cartilage Tissue Repair by Joint Distraction in Treatment of EndStage Knee Osteoarthritis; The 2 Years Follow-up Data Karen Wiegant1, Femke Intema1, Peter van Roermund1, Anne C. A. Marijnissen2, Sebastian Cotofana3, Felix Eckstein3, SC Mastbergen2 and Floris Lafeber1, 1University Medical Centre Utrecht, Utrecht, Netherlands, 2University Medical Center Utrecht, Utrecht, Netherlands, 3Paracelsus Medical University, Salzburg, Austria 5:15 pm 828. Efficacy of Tanezumab Compared with Non-Steroidal AntiInflammatory Drugs in Patients with Knee or Hip Osteoarthritis (NCT00809354) Yusuf Yazici1, Evan F. Ekman2, H. Scott Greenberg3, Michael D. Smith3, Mark T. Brown3, Christine R. West4 and Kenneth M. Verburg3, 1Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 2 Southern Orthopaedic Sports Medicine, Columbia, SC, 3Pfizer, Groton, CT, 4Pfizer, Williamston, MI 5:30 pm 829. Osteoarthritis Is Related to An Increased Risk of Falls and Fractures: A Prospective Multinational Cohort Study (the GLOW study) Daniel Prieto-Alhambra1, Xavier Nogués2, M. Kassim Javaid3, Nigel K. Arden3, Cyrus Cooper4, Allison Wyman5, Adolfo DíezPérez6 and GLOW Investigators, 1URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol i Gurina-Institut Català de la Salut; Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Barcelona, Spain, 2Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, United Kingdom, 3Oxford NIHR 2011 Program Book

47

Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, 4Southampton General Hospital, Southampton, United Kingdom, 5Center for Outcomes Research, UMass Medical School, Worcester, MA, 6Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain 35:45 pm 830. Association of Candidate Single Nucleotide Polymorphisms with Radiographic Knee Osteoarthritis in African-Americans: Data From the Genetic Components of Knee Osteoarthritis Study Rebecca Jackson1, Changwan (Larry) Lu2, Laura YergesArmstrong2, David Duggen3, Marc Hochberg2, Braxton Mitchell2 and OAI Investigators4, 1Ohio State University, Columbus, OH, 2 University of Maryland School of Medicine, Baltimore, MD, 3 TGen, Pheonix, AZ, 4San Francisco

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

W475a

Rheumatoid Arthritis – Animal Models I Moderators: David S. Bradley, MD; University of North Dakota School of Medicine; Grand Forks, ND Paul H. Wooley, PhD; Via Christi Regional Medical Center; Wichita, KS 4:30 pm 831. Nanoparticle Encapsulated STAT1 siRNAs Induce Regression of Established Collagen Arthritis In Mice Robert I. Scheinman, Ruchit Trivedi and Uday Kompella, University of Colorado Denver, Aurora, CO 4:45 pm 832. Identification of Microrna-221, -222 and -323-3p Association with Rheumatoid Arthritis Via Predictions Using the Human TNF Transgenic Mouse Model Ioannis Pandis1, Caroline Ospelt2, Niki Karagianni3, Maria C. Denis4, Martin Reczko5, Artemis Hatzigeorgiou5, Jiannis Ragoussis6, Steffen Gay2 and George Kollias1, 1Institute of Immunology, Biomedical Sciences Research Center ‘Alexander Fleming’, Vari, Greece, 2Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Institute of Immunology, Biomedical Sciences Research Center ‘Alexander Fleming’ and Biomedcode Hellas SA, Vari, Greece, 4BiomedCode Hellas SA, Vari, Greece, 5Institute of Molecular Oncology, Biomedical Sciences Research Center ‘Alexander Fleming’, Vari, Greece, 6Institute of Molecular Biology & Genetics, Biomedical Sciences Research Center ‘Alexander Fleming’ and Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom 5:00 pm 833. Why p38 Inhibitors Are Ineffective in Rheumatoid Arthritis (RA): Increased Pro-Inflammatory Macrophage Function Monica Guma, Deepa Hammaker, Meghan Edgar, Katharyn Topolewski, Mary Corr and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA 5:15 pm 834. Superior Efficacy of Ozoralizumab, An Anti-Human TNF Nanobody in a Transgenic Mouse Model of Polyarthritis Martin Hegen1, Els Beirnaert2, Guy Hermans2, Peter Casteels2, Marina Shen1, Julie Lee1, Lori Fitz1, Nilufer Seth1, Yulia Vugmeyster1, Christopher Wrocklage1, Kyri Dunussi-

48

2011 Program Book

Joannopoulos1, Cheryl L. Nickerson-Nutter1 and Mary Collins1, Pfizer, Cambridge, MA, 2Ablynx nv, Zwijnaarde, Belgium

1

5:30 pm 835. CXCL5 An Important IL-17 Mediated Proangiogenic Factor in Rheumatoid Arthritis and Experimental Arthritis Model Nathan D. Chamberlain1, Michael Volin2 and Shiva Shahrara1, 1 University of Illinois at Chicago, Chicago, IL, 2Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL 5:45 pm 836. Novel Small Molecule Inhibitors of Interleukin-1 Receptor Associated Kinase-4 Are Effective in a Preclinical Model of Arthritis Eric G. Vajda, Tsung H. Lin, Bojing Wang, Koc-Kan Ho, Arjan van Oeveren, Brian McGuinness, Jeffrey Letourneau, YongHee Lee, Deepa Rungta, Lin Zhi and Keith B. Marschke, Ligand Pharmaceuticals, La Jolla, CA

W375b

Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy: Biomarkers Moderators: Michael E. Weinblatt, MD; Immunology and Allergy, Brigham and Women’s Hospital; Boston, MA Martin Aringer, MD; Uniklinikum TU Dresden; Dresden, Germany 4:30 pm 837. A Plasmablast Molecular Biomarker for Reduced Clinical Benefit From Anti-CD20 Therapy in Rheumatoid Arthritis Kasia Owczarczyk1, Preeti Lal2, Alexander R. Abbas1, Kristen Wolslegel1, Cecile TJ Holweg1, Wolfgang Dummer2, Ariella Kelman2, Paul Brunetta2, Nicholas Lewin-Koh2, Marco Sorani1, Diane Leong2, Paul Fielder1, David E. Yocum2, Carole Ho2, Ward Ortmann2, Michael J. Townsend1 and Timothy W. Behrens2, 1 Genentech Research and Early Development, South San Francisco, CA, 2Genentech, South San Francisco, CA 4:45 pm 838. Development of a Multi-Biomarker Structural Damage Score in Rheumatoid Arthritis to Predict Radiographic Progression in the Leiden Early Arthritis Cohort Annette H.M. van der Helm-van Mil1, Rachel Knevel1, William C. Manning2, Lyndal K. Hesterberg2, Guy Cavet2, T.W.J. Huizinga3 and Yijing Shen2, 1Leiden University Medical Center, Leiden, Netherlands, 2Crescendo Bioscience, Inc., South San Francisco, CA, 3Leiden University Medical Centre, Leiden, Netherlands 5:00 pm 839. New Assay Generation for Antibodies Against Modified and Citrullinated Peptides Predicts Poor Response to TNF Inhibitor Therapy Lotta Ljung1, Karl Egerer2, Holger Bang3, Eugen Feist4, Gerd R. Burmester5 and Solbritt Rantapää Dahlqvist1, 1Umeå University Hospital, Umeå, Sweden, 2Labor Berlin - Charité Vivantes GmbH, Berlin, Germany, 3Orgentec Diagnostika GmbH, Mainz, Germany, 4Charité Medical School, Berlin, Germany, 5Charité Universitätsmedizin Berlin, Berlin, Germany 5:15 pm 840. Protein Array Screening Reveals Autoantigenicity Patterns Predicting Anti-TNF Alpha Therapy Response in Rheumatoid Arthritis Patients Zoltan Konthur1, Katja Köpke2, Hans Lehrach1, Gerd R. Burmester2 and Karl Skriner2, 1Max Planck Institute for Molecular Genetics,

Berlin, Germany, 2Charité - Universitätsmedizin Berlin, Berlin, Germany 5:30 pm 841. Gene-Gene Interactions in Folate Pathway Contribute to Methotrexate Adverse Events in Rheumatoid Arthritis Thierry Dervieux1, Judith Wessels2, J. M. Kremer3, Tom W.J. Huizinga2 and Henk-Jan Guchelaar2, 1Exagen Diagnostics, Albuquerque, NM, 2Leiden University Medical Center, Leiden, Netherlands, 3Albany Medical College and The Center for Rheumatology, Albany, NY

4:30 pm 843. Survival and Predictors of Mortality In Australian Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Gene-Siew Ngian1, Wendy Stevens2, Jill Byron2, Ai Tran3, Janet E. Roddy3, Robert Minson4, Catherine L. Hill5, Ken Chow6, Joanne Sahhar7, Susanna Proudman6 and Mandana Nikpour1, 1The University of Melbourne, Melbourne, Australia, 2St Vincent’s Hospital, Melbourne, Australia, 3Royal Perth Hospital, Perth, Australia, 4Flinders Medical Centre, Adelaide, Australia, 5The Queen Elizabeth Hospital, Woodville, Australia, 6Royal Adelaide Hospital, Adelaide, Australia, 7Monash Medical Centre, Melbourne, Australia 4:45 pm 844. Prognostic and Diagnostic Significance of Autoantibodies to Citrullinated Proteins (ACPA) in Patients with a SclerodermaRheumatoid Arthritis (SSc-RA) Overlap Syndrome Makoto Soejima1, Zhou Zhijie2, Donald M. Jones1, Danielle Goudea u1, Christine L. Amity1, Lynne M. Frydrych1, Robyn T. Domsic1, Aarat M. Patel1, Larry W. Moreland3, David M. Lee4, Thomas A. Medsger1 and Marc C. Levesque1, 1Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Aurora Health Care Oshkosh, Oshkosh, WI, 3University of Pittsburgh, Pittsburgh, PA, 4Brigham and Womens Hospital, Boston, MA 5:00 pm 845. Detection of Autoantibodies to RNA-Protein Complex in Scleroderma by Quantitative-PCR of RNA Components of the Antigens Angela Ceribelli, Minoru Satoh and Edward K.L. Chan, University of Florida, Gainesville, FL

2 0 1 1

Moderators: Maureen D. Mayes, MD, MPH; University of Texas Health Science Center at Houston; Houston, TX Jessica K. Gordon, MD; Hospital for Special Surgery; New York, NY

6 ,

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics I

5:45 pm 848. A Prospective Observational Study of Mycophenolate Mofetil Treatment in Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis of Recent Onset Fabian A. Mendoza1, Sarah J. Nagle2, Jason B. Lee3 and Sergio A. Jimenez4, 1Jefferson Institute of Molecular Medicine and Scleroderma Center, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, 2 Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, 3Dermopathology Division, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, 4Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA

SUNDAY

W192b

5:30 pm 847. Long-Term Follow-up of Limited Cutaneous Systemic Sclerosis Patients with Anti-Th/to Antibody Erin Snell1, Mary Lucas1, Dana Ivanco1, Thomas A. Medsger2 and Robyn T. Domsic1, 1University of Pittsburgh, Pittsburgh, PA, 2Univ of Pittsburgh, Pittsburgh, PA

N o v e m b e r

5:45 pm 842. Patterns of Interaction Between Genetic and Non-Genetic Attributes and Methotrexate Efficacy in Rheumatoid Arthritis Thierry Dervieux1, Judith Wessels2, J. M. Kremer3, Leonid Padyukov4, Maria Seddighzadeh4, Saedis Saevarsdottir4, R.F. van Vollenhoven4, Lars Klareskog4, T. Huizinga2 and Henk-Jan Guchelaar2, 1Exagen Diagnostics, Albuquerque, NM, 2Leiden University Medical Center, Leiden, Netherlands, 3Albany Medical College and The Center for Rheumatology, Albany, NY, 4 Karolinska Institutet, Stockholm, Sweden

5:15 pm 846. The Significance of Tendon Friction Rubs in Early Diffuse Systemic Sclerosis Patients Adam Doré1, Thomas A. Medsger Jr.2, Mary Lucas3, Dana Ivanco3 and Robyn T. Domsic2, 1UPMC Presbyterian Shadyside Hospital, Pittsburgh, PA, 2University of Pittsburgh Med Ctr, Pittsburgh, PA, 3 University of Pittsburgh, Pittsburgh, PA

W193a

T-cell Biology and Targets in Autoimmune Disease: Lymphocyte Biology and Targets in Autoimmune Disease Moderators: Joseph Holoshitz, MD; University of Michigan; Ann Arbor, MI Sujata Sarkar, MD; University of Arizona; Tucson, AZ 4:30 pm 849. Therapeutic Effects of TGF-β-Induced Regulatory T Cells on the Established Autoimmune Diseases Song G. Zheng1, Qin Lan2, Julie Wang2, David Brand3, David A. Horwitz4, Zhong-Min Liu5 and Hejian Zou6, 1USC Keck School of Medicine, Los Angeles, CA, 2University of Southern California, Los Angeles, CA, 3VA Medical Center, Memphis, TN, 4USC School of Medicine, Los Angeles, CA, 5Shanghai East Hospital, Tonji University, Shanghai, China, 6Huashan Hospital, Shanghai, China 4:45 pm 850. p53 Regulates Th17-Mediated Autoimmune Arthritis Jin-Sil Park1, Mi-La Cho1, Mi-Ae Lim1, Young-Mee Moon1, HyeJwa Oh1, Joo-Yeon Jhun1, Jun-Geol Ryu1, Jae-Kyeong Byun1, Eun-Joo Jeon1, Hye-Rin Jeong1, Sang-Heon Lee2 and Ho-Youn Kim1, 1Catholic University of Korea, Seoul, South Korea, 2Konkuk University School of Medicine, Seoul, South Korea 5:00 pm 851. Citrullinated Fibrinogen-Specific CD4+ T Cells Display Memory and Regulatory Phenotypes Laura Su and Mark M. Davis, Stanford University School of Medicine, Stanford, CA

2011 Program Book

49

5:15 pm 852. Characterization of the Expanded Populations of TH17 and T Follicular Helper Cells in New Zealand Black (NZB) Chromosome 1 Congenic Mice Nafiseh Talaei1, Carolina Landolt-Marticorena2, Babak Noamani1, Evelyn Pau1, Nan-Hua Chang3 and Joan E. Wither1, 1Toronto Western Research Institute, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3Toronto Western Research Institute, University Health Network, Toronto, ON 5:30 pm 853. Contribution of a Kidney-Infiltrating CD4+ T Cell Clone to Nephritis in Lupus-Prone Mice Akiko Okamoto1, Keishi Fujio1 and Kazuhiko Yamamoto2, 1 Graduate school of Medicine, The University of Tokyo, Tokyo, Japan, 2Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

5:45 pm 854. Deficient Ubiquitin Ligase Casitas B-Lineage Lymphoma b Expression and Abnormal Peripheral Tolerance in CD4+ T Cells From Systemic Lupus Erythematosus Patients Diana Gomez-Martin, Maria J., Ibarra-Sanchez, Jose Cruz-Ruiz, Jorge Romo-Tena, Jose Esparza-Lopez, Mariana Diaz-Zamudio and Jorge Alcocer-Varela, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico

W196b

Vasculitis II Moderators: Paul A. Monach, MD, PhD; Boston University; Boston, MA Alfred Mahr, MD, PhD; Hospital Saint-Louis; Paris, France 4:30 pm 855. Prednisone Versus Tamoxifen for Idiopathic Retroperitoneal Fibrosis Augusto Vaglio1, Alessandra Palmisano1, Stefania Ferretti1, Rocco Cobelli1, Luigi Boiardi2, Carlo Buzio1 and Carlo Salvarani2, 1 University of Parma, Parma, Italy, 2Arcispedale S Maria Nuova, Reggio Emilia, Italy 4:45 pm 856. The Relationship Between Systemic Vasculitis and Retinal Vasculitis James T. Rosenbaum1, Jennifer Ku2, Amro Ali2, Dongseok Choi2 and Eric B. Suhler2, 1Oregon Health & Science University, Portland, OR, 2Oregon Health & Science Univ, Portland, OR 5:00 pm 857. Efficacy and Tolerance of Treatments in Patients with NonInfectious Mixed Cryoglobulinemia Vasculitis: Results From the French Nationwide CryoVas Survey Benjamin Terrier1, Evguenia Krastinova2, Isabelle Marie3, Adeline Lacraz4, David Launay5, Emmanuelle Plaisier6, Luc de SaintMartin7, Fabrice Bonnet8, Pauline Belenotti9, Jean-Emmanuel Kahn10, Olivier Hinschberger11, Patricia Rullier12 and Patrice Cacoub13, 1Pitié-Salpêtrière Hospital, Paris, France, 2INSERM U707, Paris, France, 3Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 4Nephrology, CHU Bordeaux, Bordeaux, France, 5Internal Medicine, CHRU Claude Huriez, Lille, France, 6Nephrology, Tenon Hospital, Paris, France, 7 Internal Medicine, CHU Brest, Brest, France, 8Internal Medicine,

50

2011 Program Book

CHU Bordeaux, Bordeaux, France, 9Internal Medicine, CHU Marseille, Marseille, France, 10Internal Medicine, Foch Hospital, Suresnes, France, 11Internal Medicine, CH Mulhouse, Mulhouse, France, 12Internal Medicine, CHU Montpellier, Montpellier, France, 13CHU Pitié-Salpêtrière, Paris, France 5:15 pm 858. Churg–Strauss Syndrome: Description and Long-Term Follow-up of the 383 Patients Enrolled In the FVSG Cohort Christian Pagnoux1, Chloe Comarmond2, Mehdi Khellaf3, Jean-Francois Cordier4, Mohamed Hamidou5, Jean-Francois Viallard6, Francois Maurier7, Philippe Delaval8, Boris Bienvenu9, Xavier Puechal10, Olivier Aumaître11, Marc Ruivard12, Alain Le Quellec13, Ramiro Cevallos14, Olivier Fain15, Bertrand Godeau3, Raphaèle Seror2, Alfred Mahr16, Pascal Cohen17, Luc Mouthon18, Loic Guillevin19 and French Vasculitis Study Group (FVSG)*, 1 University of Toronto, Toronto, ON, 2Referral Center for Necrotizing Vasculitides, Hôpital Cochin, AP–HP, Université Paris–Descartes, Paris, France, 3Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 4Division of Pneumology, Hôpital LouisPradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, 5Service de médecine interne, Hôpital Universitaire de Nantes, Nantes, France, Nantes, France, 6Division of internal Medicine, Hôpital Haut-Lévêque, Université Victor Segalen – Bordeaux 2, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Bordeaux, France, 7Division of internal Medicine, CHR Metz, Metz, Metz, France, 8Division of Pneumology, Centre Hospitalier Régional Universitaire de Rennes, Rennes, Rennes, France, 9Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, Caen, France, 10Le Mans General Hospital, Le Mans, France, 11Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont– Ferrand, Clermont–Ferrand, France, 12Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont– Ferrand, Clermont–Ferrand, France, 13Division of internal Medicine, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, Montpellier, Montpellier, France, 14CH Compiegne, Compiegne, France, 15Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, 16Hospital Saint-Louis, Paris, France, 17Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, 18Hopital Cochim, Paris, France, 19Cochin University Hospital, Paris, France 5:30 pm 859. Surgery Versus Endovascular Repair in Takayasu Arteritis: A Multicenter Study of 166 Procedures David Saadoun1, Marc Lambert2, Tristan Mirault3, Yoland Shoindre1, Zahir Amoura4, Mathieu Resche Rigon1, Pierre yves Hatron5, Joseph Emmerich3 and Patrice P. Cacoub6, 1Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2Service de médecine interne, Hôpital Claude Huriez, Université Lille II, Lille, France, Lille, France, 3Service de Médecine Vasculaire HEGP, Paris, France, 4CHU Pitié-Salpêtrière, Paris, France, 5Service de médecine interne, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, 6Hopital La Pitie, Paris, France


W187a

Crystal: Diagnosis and Management of Gout (021) Speaker: Naomi Schlesinger, MD; University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School; New Brunswick, NJ

W185d

Systemic Arthritis and Still’s Disease (027) Speaker: Rayfel Schneider, MBBCh, MD; Hospital for Sick Children, University of Toronto; Toronto, ON, Canada

W186c

*Systemic Lupus Erythematosus: Central Nervous System (028) Speaker: Jorge Sanchez-Guerrero, MD, MS; University Health Network/Mount Sinai Hospital; Toronto, ON, Canada

W185bc

Temporal Arteritis (029) Speaker: Gene G. Hunder, MD; Mayo Clinic; Rochester, MN

W187b

*Vasculitis Mimics (030) Speaker: John H. Stone, MD, MPH; Massachusetts General Hospital; Boston, MA

2 0 1 1

Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual.

Speaker: Martin J. Bergman, MD; Taylor Hospital; Ridley Park, PA

6 ,

4:30 - 6:00 pm

*Rheumatoid Arthritis: Outcome Measures in Clinical Practice PS (026)

SUNDAY

ACR MEET THE PROFESSOR SESSIONS

W184d

N o v e m b e r

5:45 pm 860. Causes and Prognostic Factors of Mortality in Patients with Non-Infectious Mixed Cryoglobulinemia Vasculitis: Results From the French Nationwide CryoVas Survey Benjamin Terrier1, Evguenia Krastinova2, Isabelle Marie3, Adeline Lacraz4, David Launay5, Emmanuelle Plaisier6, Luc de SaintMartin7, Fabrice Bonnet8, Pauline Belenotti9, Jean-Emmanuel Kahn10, Olivier Hinschberger11, Patricia Rullier12 and Patrice Cacoub13, 1Pitié-Salpêtrière Hospital, Paris, France, 2INSERM U707, Paris, France, 3Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 4Nephrology, CHU Bordeaux, Bordeaux, France, 5Internal Medicine, CHRU Claude Huriez, Lille, France, 6Nephrology, Tenon Hospital, Paris, France, 7 Internal Medicine, CHU Brest, Brest, France, 8Internal Medicine, CHU Bordeaux, Bordeaux, France, 9Internal Medicine, CHU Marseille, Marseille, France, 10Internal Medicine, Foch Hospital, Suresnes, France, 11Internal Medicine, CH Mulhouse, Mulhouse, France, 12Internal Medicine, CHU Montpellier, Montpellier, France, 13CHU Pitié-Salpêtrière, Paris, France


W474b

Legislative Update from Capitol Hill

cP

Moderator: Timothy Laing, MD; University of Michigan Medical Center; Ann Arbor, MI Upon completion of this session, participants should be able to: • discuss current legislative initiatives in Congress affecting rheumatology • outline the Administration’s role in developing health policy • recognize the value of grassroots advocacy in communicating with Congress

W185a

*Dermatological Manifestations of Rheumatic Diseases (022) Speaker: Nicole Fett, MD; University of Pennsylvania; Philadelphia, PA

W183c

ACR REF Special Session: Clinician Scholar Educator Presentations Ed.

W186b

Immunodeficiency Syndromes (023) Speaker: Alton Melton, MD; Cleveland Clinic; Cleveland, OH

W187c

Pediatrics: Dermatomyositis (024)


P

Speaker: Adam Huber, MD; IWK Health Centre; Halifax, NS, Canada

W186a

Psoriatic Arthritis (025)

Moderators: Abby Goulder Abelson, MD; Cleveland Clinic Foundation; Cleveland, OH Michael J. Battistone, MD; University of Utah Medical Center; Salt Lake City, UT 4:30 pm Introducing the Testimonial-Commentator Format to the Musculoskeletal Curriculum of Medical Students James D. Katz, MD; George Washington Medical Center; Washington, DC

Speaker: Arthur Kavanaugh, MD; University of California San Diego; San Diego, CA 2011 Program Book

51

4:55 pm Development of a Curriculum to Utilize Medical Resident Clinic for Rheumatology Education James M. Ross, MD; Lehigh Valley Hospital; Allentown, PA 5:20 pm Team-Learning Strategies in Rheumatology: Fostering Accountability, Reflective Learning and Critical Thinking Karina Marianne D. Torralba, MD; University of Southern California Keck School of Medicine; Los Angeles, CA

N o v e m b e r

6 ,

SUNDAY

2 0 1 1

Upon completion of this session, participants should be able to: • discuss novel approaches to curriculum development for medical students and residents in the musculoskeletal and rheumatic diseases • discuss new approaches to teaching in the rheumatic and musculoskeletal diseases • review important areas of overlap in medical education between geriatric medicine and rheumatology and the impact of this education on quality of care • summarize the unique and important roles of the clinician scholar educator in medical education and training

ACR/ARHP COMBINED ABSTRACT SESSION 4:30 - 6:00 pm

W195

ACR/ARHP Combined Pediatrics Abstract Session Moderators: Rolando Cimaz, MD; University of Firenze; Firenze, Italy Clarissa A. Pilkington, MBBS, MD; Great Ormond Street Hospital for Children National Health Service Trust; London, United Kingdom 4:30 pm 861. The Development of a New Service for the Management of Non-Inflammatory Musculoskeletal Pain Susan Maillard, Swati Bhagat, Charmaine Bernie, Alice Morgan, David Adkins, Ellie Haggart and Clarissa Pilkington, Great Ormond Street Hospital, London, United Kingdom 4:45 pm 862. Development of a Questionnaire for Early Detection of Factors Associated to the Adherence to Treatment of Children and Adolescents with Chronic Rheumatic Diseases - “the Pediatric Rheumatology Adherence Questionnaire (PRAQ)” Vanessa M. Bugni1, Karine Y. K. Okamoto1, Luciana S. Ozaki1, Fernanda M. Teles1, Juliana Molina1, Vanessa C. Bueno1, Maria Odete E. Hilário1, Claudio A. Len1 and Maria Teresa Terreri2, 1 Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, 2 Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil 5:00 pm 863. Characterization of Active Joint Count Trajectories in Juvenile Idiopathic Arthritis Roberta A. Berard1, George A. Tomlinson2, Xiuying Li3, Kiem Oen4, Alan M. Rosenberg5, Brian M. Feldman6, Rae SM Yeung7 and Claire Bombardier8, 1Children’s Hospital of Western Ontario, London, ON, 2University of Toronto, Toronto, ON, 3University Health Network, Toronto, ON, 4University of Manitoba, Winnipeg, MB, 5Royal University Hospital, Saskatoon, SK,

52

2011 Program Book

The Hospital for Sick Children, Toronto, ON, 7Hospital for Sick Children, Toronto, ON, 8Institute for Work & Health, Toronto, ON 6

5:15 pm 864. Predictors of Health-Related Quality of Life in Children and Adolescents with Juvenile Idiopathic Arthritis: Results From a Web-Based Survey Lotte Haverman1, Martha A. Grootenhuis2, J. Merlijn Van den Berg3, Mira van Veenendaal1, Koert M. Dolman4, Joost F. Swart5, Taco W. Kuijpers1 and Marion A.J. Van Rossum3, 1 Emma Children’s hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, 2Emma Children’s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 3Emma Children’s Hospital / Academic Medical Center (AMC) and Reade, Amsterdam, Netherlands, 4St. Lucas Andreas Hospital and Reade, Amsterdam, Netherlands, 5VU medical center and Reade, Utrecht, Netherlands 5:30 pm 865. Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Juvenile Autoimmune Rheumatic Diseases Patients Nadia E. Aikawa1, Lucia M.A. Campos1, Clovis A. Silva1, Carla G.S. Saad1, Jozelio F. Carvalho1, Guilherme Trudes1, Alberto J.S. Duarte1, Joao Miraglia2, Maria C.S. Timenetsky3, Vilma S.T. Viana1, Ivan L.A. França1, Eloisa Bonfa4 and Rosa M.R. Pereira5, 1 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Fundação Butantan, São Paulo, Brazil, 3Instituto Adolfo Lutz, São Paulo, Brazil, 4University of Sao Paulo, São Paulo, Brazil, 5Disciplina de Reumatologia da FMUSP, Sao Paulo, Brazil 5:45 pm 866. Silent Arthritis Progression in Children with Juvenile Idiopathic Arthritis Detected by Magnetic Resonance Imaging Nikolay Tzaribachev1, Marius Horger2 and Jan Fritz3, 1Center for Rheumatic Diseases, Bad Bramstedt, Germany, 2M.D., Tuebingen, Germany, 3Johns Hopkins University School of Medicine, Baltimore, MD


W194a

Clinical Practice/Patient Care I Moderators: Eswar Krishnan, MD; Standford University; Palo Alto, CA Lianne S. Gensler, MD; University of California San Francisco; San Francisco, CA 4:30 pm 867. Factors That Influence Appointment Compliance Rates In a Multi-Disciplinary Specialized Lupus Clinic Pretima G. Persad1, Su Jin Kim2, Kyriakos A. Kirou1 and Doruk Erkan1, 1Mary Kirkland Center for Lupus Care- Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, NY 4:45 pm 868. Identifying Predictors of Medication Adherence In Patients with Rheumatoid Arthritis Elizabeth G. Salt and Susan K. Frazier, University of Kentucky, Lexington, KY

5:00 pm 869. Clinical Decision Support System Improves Bone Mineral Density Screening Rates in 65 Year Old Women Kori A. Dewing1, Basia Belza2, Brenda Zierler2 and Andrea LaCroix3, 1Virginia Mason Medical Center, Seattle, WA, 2 University of Washington, Seattle, WA, 3Fred Hutchinson Cancer Research Center, Seattle, WA 5:15 pm 870. Assessment and Treatment of Osteoporosis After HipFracture: An Observational Study Maria Antonelli, Douglas Einstadter and Marina N. Magrey, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

C

PS

Moderator: Susan L. Williams Judge, MN, ARNP; Seattle Rheumatology Associates; Seattle, WA Speaker: Susan B. Broy, MD; Illinois Bone and Joint Institute, LTD; Northbrook, IL

2 0 1 1

Upon completion of this session, participants should be able to: • discuss risks associate with therapies approved to treat osteoporosis • describe the incidence and risks of atypical femur fractures and osteonecrosis of the jaw in patients being treated for osteoporosis • discuss current recommendations for calcium and vitamin D supplementation and review studies that suggest too much of these nutrients may be harmful

REF INDUSTRY ROUNDTABLESUPPORTED SYMPOSIA

6:00 pm 874. WITHDRAWN

6:30 - 9:30 pm


W375a

Axial Spondylarthritis: New Concepts

Iatrogenic Misadventures in Osteoporosis Treatment

6 ,

6:00 pm 873. WITHDRAWN

W183a

SUNDAY

5:45 pm 872. Continued Tocilizumab Infusion for Rheumatoid Arthritis Is Well Tolerated and Safe At An Accelerated Infusion Rate. Gunhild Bukh, Michael Sejer Hansen, Sussi Larsen and Susse Skalsted Rasmussen, Gentofte Hospital, Hellerup, Denmark

Upon completion of this session, participants should be able to: • discuss quality issues of non-drug randomized controlled trials • describe the elements of randomized controlled trials that contribute to higher research quality • recognize and explain the Consolidated Standards of Reporting Trials guidelines for reporting results from non-drug randomized controlled trials

N o v e m b e r

5:30 pm 871. The Association of Symptomatic OA At Multiple Time Points with Functional Limitation Over 5 Years: The Multicenter Osteoarthritis Study Daniel K. White1, Yuqing Zhang1, Jingbo Niu1, Michael C. Nevitt2, C.E. Lewis3, James Torner4 and Tuhina Neogi5, 1Boston University School of Medicine, Boston, MA, 2University of CaliforniaSan Francisco, San Francisco, CA, 3University of Alabama, Birmingham City, AL, 4University of Iowa, Iowa City, Iowa City, IA, 5 Boston University, Boston, MA

Speakers: Susan L. Murphy, OTR; University of Michigan; Ann Arbor, MI Nancy A. Baker, MPH, OTR, OTR/L; University of Pittsburgh; Pittsburgh, PA

C

Moderator: Mehmet Tuncay Duruoz, MD; Celal Bayar University Medical School; Manisa, Turkey Speaker: Muhammad Asim Khan, MD, MACP; Case at MetroHealth Medical Center; Cleveland, OH

In 2011, there are two types of symposia offered to attendees: CME-accredited and non-CME accredited. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. The non-CME accredited symposia have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Please visit the organization’s exhibit booth, the industry-supported symposia booth or see page 304 for more information.

Upon completion of this session, participants should be able to: • d ifferentiate inflammatory back pain from mechanical back pain • d iscuss how to diagnose axial spondylarthritis in the absence of sacroiliitis • identify the “spondyloarthritis” features in the definition of axial spondylarthritis

W476

Deconstructing the Randomized Controlled Trial: Assessing the Study Quality of Level One Non-Drug Studies c/r PS Moderator: Wendy Marder, MD; University of Michigan; Ann Arbor, MI 2011 Program Book

53

MONDAY, NOVEMBER 7, 2011


Hall F2 Entrance

ACR IMMUNOLOGY UPDATES FOR THE CLINICIANS 7:30 - 8:30 am

W375b

T-Cell Regulation and Autoimmune Pathogenesis: Th1, Th2, Th17 and T Regs c/r Moderator: Jose U. Scher, MD; New York University Hospital for Joint Diseases; New York, NY Speaker: Jane Hoyt Buckner, MD; Benaroya Research Institute; Seattle, WA

N o v e m b e r

7 ,

MONDAY

2 0 1 1

Upon completion of this session, participants should be able to: • explain basic principles of T-cell biology and selection of antigen specific responses • define how the local cytokine milieu can affect biased T-cell responses • review emerging data in mouse models and clinical studies how certain T-cell responses can drive a disease process, while other T-cell responses can suppress the disease


W375d

Clinicopathologic Conference: A 40 Year-Old Male with Dyspnea on Exertion C cP PS ARS Moderator: Nadera J. Sweiss, MD; University of Chicago; Chicago, IL 7:30 am Case Presentation Nadera J. Sweiss, MD; University of Chicago; Chicago, IL 7:40 am Case Presentation Amit Patel, MD; University of Chicago Medical Center; Chicago, IL 7:50 am Case Presentation Aliya Husain, MD; University of Chicago Medical Center; Chicago, IL 8:00 am Case Presentation John F. Beshai, MD; University of Chicago Medical Center; Chicago, IL 8:10 am Case Presentation/Discussion John F. Beshai, MD; University of Chicago Medical Center; Chicago, IL Aliya Husain, MD; University of Chicago Medical Center; Chicago, IL

54

2011 Program Book

Amit Patel, MD; University of Chicago Medical Center; Chicago, IL Nadera J. Sweiss, MD; University of Chicago; Chicago, IL Upon completion of this session, participants should be able to: • identify some cardiopulmonary manifestations of select systemic disorders • describe the limitations of the common laboratory and radiographic testing in making a clinical diagnosis • discuss the clinical, pathologic diagnosis, treatment and follow up of the case presented

ACR STATE-OF-THE-ART LECTURE 7:30 - 8:30 am

W375c

Moving Forward in the Genome Wide Association Studies Era R Moderator: Peter K. Gregersen, MD; Feinstein Institute Medical Reschearch; Manhasset, NY 7:30 am The Power of Next-Generation DNA Sequencing Approaches for Identifying Causal Genetic Variation in Autoimmune Disease David Goldstein, PhD; Duke University; Durham, NC Upon completion of this session, participants should be able to: • describe the gap between the success of genome wide association studies in identifying genetic loci for autoimmune disease and the proportion of heritability that is explained by currently identified loci • summarize current theories about factors that may explain this “missing heritability” • explain features of “next-generation” DNA sequencing approaches that have made sequencing a feasible approach for identifying causal genetic variation

ARHP CONCURRENT SESSIONS 7:30 - 8:30 am

W476

Behave Yourself! Practical Application of Cognitive Behavioral Theories to Motivate Change in Patients with Arthritis C Moderator: Elizabeth G. Salt, PhD; University of Kentucky; Lexington, KY Speakers: Susan J. Bartlett, PhD; McGill University; Montreal, QC, Canada Sarah Hewlett, PhD, MA, RN; Bristol Royal Infirmary; Bristol, United Kingdom Upon completion of this session, participants should be able to: • review readiness to change, motivational interviewing and guided discovery theories • apply motivational interviewing, guided discovery, and goal-setting techniques in a non-judgmental and guided environment

W474b

ICD Coding – Crash Course for Researchers

BR

R

Moderator: Glinda S. Cooper, PhD; United States Environmental Protection Agency; Washington, DC

Speakers: Charles G. Helmick, MD; Centers for Disease Control and Prevention; Atlanta, GA Michael M. Ward, MD; National Institute of Arthritis and Musculoskeletal and Skin/NIH; Bethesda, MD Upon completion of this session, participants should be able to: • r ecognize analytic issues encountered when utilizing ICD codes for administrative database research • d escribe features related to the ICD-9 to ICD-10 transition and how these impact research spanning both systems • a pply these concepts to rheumatic disease research

W471b

New and Noteworthy: Nursing, Pharmacy and Pedorthics c/r Moderator: Linda J. Pine, PharmD; Pine Consulting Services, LLC; Atlanta, GA 7:30 am Year in Review for Nursing and Advance Practice Nursing Basia Belza, PhD; University of Washington; Seattle, WA 7:50 am Pharmaceutical Advances in Pharmacologic Treatments in Rheumatic Diseases Kam Nola, PharmD, MS; Lipscomb College of Pharmacy; Nashville, TN

C

PM

Moderator: Eduardo S. Paiva, MD; Universidade Federal do Parana; Curitiba Parana, Brazil Speaker: Robert M. Bennett, MD; Oregon Health & Science University; Portland, OR Upon completion of this session, participants should be able to: • r eview appropriate investigations in patients with fibromyalgia who are suspected to have a major sleep disturbance • d iscuss common sleep abnormalities seen in fibromyalgia patients • describe management options in these patients

*Antiphospholipid Syndrome (031) Speaker: Graham R. V. Hughes, MD; London Bridge Hospital; London, United Kingdom

W187c

Crystal: Diagnosis and Management of Gout (032) Speaker: Michael A. Becker, MD; University of Chicago Medical Center; Chicago, IL

W186a

Osteoarthritis: Update 2011 (033) Speaker: Richard F. Loeser, MD; Wake Forest University; Winston-Salem, NC

W186c

Pediatric Rheumatology for Adult Rheumatologists (034) P Speaker: Peter A. Nigrovic, MD; Brigham and Women’s Hospital; Boston, MA

2 0 1 1

Sleep Disturbance in Fibromyalgia

W187a

7 ,

W375a


MONDAY

Upon completion of this session, participants should be able to: • s ummarize research advances in rheumatologic nursing within the past 12 months • d escribe recent advances in pharmacologic treatments for rheumatic diseases • r eview recent advances in pedorthics and application of this new information to rheumatology practice • d escribe the significance of these advances for practitioners, educators and researchers

Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in the parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/annual.

N o v e m b e r

8:10 am Innovative Footware/Footcare Can Make a Big Difference in So Many Ways Dennis J. Janisse, C.Ped; Medical College of Wisconsin; Milwaukee, WI

ACR MEET THE PROFESSOR SESSIONS 7:45 - 9:15 am

W186b

Pediatrics: Juvenile Idiopathic Arthritis for Adult Rheumatologists (035) P Speaker: Mara L. Becker, MD, MSCE; Children’s Mercy Hospital; Kansas City, MO

W187b

Pediatrics: Spondylarthritis in Children (036)

P

Speaker: Shirley Tse, MD; The Hospital for Sick Children; Toronto, ON, Canada

W185d

Psoriatic Arthritis (037) Speaker: M. Elaine Husni, MD, MPH; Cleveland Clinic Foundation; Cleveland, OH

W184d

Rheumatoid Arthritis: Difficult Cases (038) Speaker: Stanley B. Cohen, MD; Metroplex Clinical Research Centre; Dallas, TX

2011 Program Book

55

W185a

ACR PRACTICE ISSUE

Scleroderma: Systemic Sclerosis (039)

9:00 - 10:00 am

Speaker: Christopher P. Denton, PhD; University College London Medical School; London, United Kingdom

W181b

W185bc

Scleroderma: Systemic Sclerosis (040)

Moderator: Rebecca M. Shepherd, MD; Lancaster, PA

Speaker: Michael R. York, MD; Boston University Medical Center; Boston, MA

ACR/ARHP WORKSHOPS 7:45 - 9:45 am Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual.

N o v e m b e r

7 ,

MONDAY

2 0 1 1

Joint Injections (Knee and Ankle Prosthetics) (215) Speaker: Gregory C. Gardner, MD; University of Washington; Seattle, WA

W180 f

Speaker: Eugene Y. Kissin, MD; Boston University; Boston, MA

W178a

Speaker: Megan Troxell, MD; Oregon Health & Science University; Portland, OR


W375d cP

P/C

ARS

Moderator: Zsuzsanna H. McMahan, MD; Johns Hopkins University; Baltimore, MD Speaker: Brady L. Stein, MD; Northwestern Feinberg School of Medicine; Chicago, IL Upon completion of this session, participants should be able to: • discuss mechanisms in the etiology of anemia of inflammatory disease • recognize the guidelines for the treatment of anemia of inflammatory disease • develop therapeutic strategies for the management of anemia in patients for which treatment of the underlying chronic disease is limited

56

2011 Program Book

Upon completion of this session, participants should be able to: • perform complex audits from actual rheumatology charts • identify key risk areas that are under the microscope of the Recovery Audit Contactors • recognize how to prepare and survive a Recovery Audit Contractor audit

ACR STATE-OF-THE-ART LECTURES W375b

Cervical Spine Surgeries in Rheumatic Diseases: 2011 Update C PS Moderators: Jon T. Giles, MD, MPH; Columbia University Medical Center; New York, NY Mary Chester Wasko, MD, MSc; West Pennsylvania Allegheny Health System; Pittsburgh, PA 9:00 am Cervical Spine Surgery in the Rheumatic Disease Patient Howard An, MD; Rush University; Chicago, IL

Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (217)

Anemia of Inflammatory Disease

9:00 am Practical Auditing Guidelines and Procedures for Physician Practices Melesia Tillman, CPC, CRHC, CHA; American College of Rheumatology; Atlanta, GA

9:00 - 10:00 am

W179a

Musculoskeletal Ultrasound (216)

RAC and Roll – How to Perform Complex Chart Audits BR C cP

Upon completion of this session, participants should be able to: • order the appropriate imaging studies in the rheumatologic patient with cervical spine disease • repeat the indications for cervical spine surgery in these patients • discuss the current surgical interventions for the rheumatologic patient with cervical spine disease • recognize challenges in cervical spine surgeries in the rheumatic disease patient

W375c

Innate Immunity

R

Moderator: Richard J. Bucala, MD, PhD; Yale University School of Medicine; New Haven, CT Speaker: Dan Stetson, PhD; University of Washington; Seattle, WA Upon completion of this session, participants should be able to: • evaluate the main mechanisms by which inflammatory and immune responses are initiated • appreciate how these mechanisms contribute to immune dysregulation and autoimmune tissue damage • describe how novel innate immune therapies may offer new prospects for clinical benefit

ACR/ARHP POSTER SESSION B AND POSTER TOURS 9:00 am- 6:00 pm Poster presenters will be available from 9:00 - 11:00 am (abstracts # 875 - 1586). Poster tours will be held 9:00 - 9:45 am and 10:15 - 11:00 am. Morning snacks will be available from 9:00 - 10:30 am.

Guided Poster Tours HALL F2 - Poster Hall

Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis (315) Tour Guide: Nancy E. Lane, MD; University of California Davis School of Medicine; Sacramento, CA Rheumatoid Arthritis: Clinical Aspects (316) Tour Guide: Neal S. Birnbaum, MD; Pacific Rheumatology Associates; San Francisco, CA Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment (317) Tour Guide: Atul A. Deodhar, MD, MRCP; Oregon Health & Science University; Portland, OR Vasculitis (318) Tour Guide: Alexandra Villa-Forte, MD, MPH; Cleveland Clinic Foundation; Cleveland, OH 10:15 - 11:00 am Fibromyalgia and Soft Tissue Disorder (319) Tour Guide: Don L. Goldenberg, MD; Newton-Wellesley Hosp; Newton, MA

Systemic Lupus Erythematosus: Clinical Aspects (324) Tour Guide: Eliza F. Chakravarty, MD, MS; Oklahoma Medical Research Foundation; Oklahoma City, OK Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment (325) Tour Guide: Luis R. Espinoza, MD; Louisiana State University Medical Center; New Orleans, LA

ACR REF SPECIAL SESSION

9:00 - 10:00 am

W183a

ACR REF Memorial Lectureship: From Shulman’s Syndrome to Nephrogenic Systemic Fibrosis: Exogenous Factors and Systemic Fibrosing Disorders R

The 2011 REF Mememorial Lectureship is in honor of Lawrence E. Shulman, MD.

2 0 1 1

Orthopedics, Low Back Pain and Rehabilitation (314) Tour Guide: Jeffrey N. Katz, MD; Brigham & Women’s Hospital; Boston, MA

Rheumatoid Arthritis Treatment – Small Molecules, Biologics and Gene Therapy (323) Tour Guide: Eric M. Ruderman, MD; Northwestern University; Chicago, IL

7 ,

Metabolic and Crystal Arthropathies (313) Tour Guide: N. Lawrence Edwards, MD; University of Florida; Gainesville, FL

Rheumatoid Arthritis: Clinical Aspects (322) Tour Guide: Inmaculada Del Rincon, MD, MS; University of Texas Health Sciences Center San Antonio; San Antonio, TX

MONDAY

9:00 - 9:45 am

Osteoarthritis – Clinical Aspects (321) Tour Guide: Joanne M. Jordan, MD, MPH; University of North Carolina Thurston Arthritis Research Center; Chapel Hill, NC

N o v e m b e r

Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check-in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Hall F2 Entrance). Alternatively, you may go directly to the poster tour desk and wait for a standy ticket. Standby tickets will be assisgned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants’ registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour.

Non-Pharmacologic Interventions (320) Tour Guide: Laura D. Bilek, PhD, PT; University of Nebraska Medical Center; Omaha, NE

Moderator: Bevra H. Hahn, MD; University of California, Los Angeles School of Medicine; Los Angeles, CA Speaker: Sergio A. Jimenez, MD ; Jefferson Institute of Molecular Medicine, Thomas Jefferson University; Philadelphia, PA Upon completion of this session, participants should be able to: • d iscuss the current state of knowledge regarding the pathogenesis and clinical manifestations of the systemic fibrosing disorders • identify the roles of exogenous and environmental factors in the development of the systemic fibrosing disorders • d escribe the contribution of genetics, and the interactions of genetics vs. environment, in the development of systemic fibrosing disorders

ARHP CONCURRENT SESSIONS

9:00 - 10:00 am

W471b

Antimalarials for Rheumatic Disorders: Historical Perspectives, Clinical Insights and Future Directions R

Moderator: Elizabeth G. Salt, PhD; University of Kentucky; Lexington, KY Speaker: Daniel J. Wallace, MD; Cedars-Sinai Medical Center/ David Geffen School of Medicine, University of Carolina Los Angeles; Los Angeles, CA 2011 Program Book

57

Upon completion of this session, participants should be able to: • review the history of the use of antimalarials • summarize the clinical trials investigating antimalarial medications • explain the recommended ophthalmologic monitoring for those patients being prescribed antimalarials • outline future directions for the use of this class of medications

W192b

Preparing for Transition from Day One of Diagnosis to Adult Care P/C Moderator: Katherine A. B. Marzan, MD; Children’s Hospital Los Angeles; Los Angeles, CA 9:00 am Introduction Katherine A. B. Marzan, MD; Children’s Hospital Los Angeles; Los Angeles, CA 9:10 am Overview of Adult Providers Expectations of Pediatric Patients Attending Clinic Elizabeth C. Ortiz, MD; University of Southern California; Los Angeles, CA

N o v e m b e r

7 ,

MONDAY

2 0 1 1

9:30 am The “Toolbox” Needed for the Journey from Pediatrics to Adult Care Sandra J. Watcher, RN, BSN; Children’s Hospital of Los Angeles; Los Angeles, CA 9:50 am Panel Discussion Upon completion of this session, participants should be able to: • define what is expected by adult providers • discuss methods in which adult providers can ease the transition during initial appointments • identify key aspects to prepare pediatric patients from the first day of diagnosis through transition • review the tools that pediatric providers can provide their patients and their families

W196b

Rheumatic Disease Update: Musculoskeletal Manifestiations of Human Immunodeficiency Virus C

Moderator: Kenneth J. Scalapino, MD; Portland Veterans Affairs Medical Center; Portland, OR Speaker: Ajay Wanchu, MD; Oregon Health & Science University; Portland, OR Upon completion of this session, participants should be able to: • discuss the incidence and prevalence of rheumatic disorders in patients with human immunodeficiency virus infection before and after highly active antiretroviral therapy • review antirheumatic therapies that can be used in human immunodeficiency virus-positive individuals with and without low CD4 T cell counts • develop a treatment plan for an individual with human immunodeficiency virus related arthritis

58

2011 Program Book

W474b

To P or Not to P? Knowing When the P-Value is Less than Useful c/r Moderator: Kelli D. Allen, PhD; Duke and Durham Veterans Affairs Medical Center; Durham, NC 9:00 am The P-value and Statistical Significance Michael P. LaValley, PhD; Boston University School of Public Health; Boston, MA 9:30 am Time to Beat Up the P-value Daniel K. White, PT, ScD; Boston University School of Medicine; Boston, MA Upon completion of this session, participants should be able to: • define the p-value and statistical significance and identify situations where these are appropriately used • describe situations where the standard p-value is of limited use, such as in post-hoc analyses, multiple comparisons, stepwise regression, and in describing the strength of an effect • identify alternative approaches to the p-value for such situations. These include use of confidence intervals, exploratory analyses, causal models and diagrams, and effect size measures • discuss measures of meaningful change

EXHIBITS 10:00 am - 7:00 pm

HALL F1 - Exhibit Hall Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 10:00 - 11:00 am and 2:00 - 3:00 pm. Visit the Replay Café, presented by SessionSelect, to view a session you missed during the meeting. The schedule will be available in the Daily News, at the Concierge Center and the Resource Center.

ACR WORKSHOPS 10:30 am - 12:30 pm Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in the parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual.

W180

Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis (218) Speakers: George V. Lawry, II, MD; University of California Irvine; Orange, CA Paul C. Utrie, MD; Orthopedic and Sports Medicine Specialists; Green Bay, WI

W179b

Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (219) Speaker: Stuart L. Silverman, MD; Cedars-Sinai Medical Center; Beverly Hills, CA

W178a

Synovial Fluid Analysis and Crystal Identification (220) Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic; Cleveland, OH Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical Center; Philadelphia, PA Gilda M. Clayburne, MLT; Virginia Affairs Medical Center; Philadelphia, PA

ARHP GENERAL SESSION II: DISTINGUISHED LECTURER 10:30 - 11:30 am

W474b

How Do We Get Policy Makers to Take Musculoskeletal Conditions Seriously? – The Bone and Joint Initiative cP

The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Forest Pharmaceuticals. Please visit the Forest Pharmaceuticals exhibit booth (919) for more information or see page 304. Seating and light refreshments are subject to availability.

Strategies for Diagnosing and Treating the Fibromyalgia Patient

cP

ARS

Moderators: Diane L. Kamen, MD, MS; Medical University of South Carolina; Charleston, SC Robert Spiera, MD; Hospital for Special Surgery; New York, NY 11:00 am Scleroderma: Challenges in Clinical Practice Laura K. Hummers, MD, ScM; Johns Hopkins University; Baltimore, MD 11:25 am Difficult Myopathy: When Your Exam and Labwork Don’t Equate Robert L. Wortmann, MD; Dartmouth-Hitchcock Medical Center; Lebanon, NH 11:50 am The Challenges of Fertility and Pregnancy in Patients with Lupus Michael D. Lockshin, MD; Hospital for Special Surgery; New York, NY Upon completion of this session, participants should be able to: • compare their personal management approaches to selected clinical problems with those of the presenters • describe therapeutic choices and management options for several common but difficult complications of scleroderma • develop an approach to evaluating and managing patients presenting with asymptomatic elevation in muscle enzymes • appraise the potential impact on fertility and pregnancy of various treatments for systemic lupus erythematosus

2 0 1 1

HALL F1 (Booth #789)

C

7 ,

INNOVATION THEATER 10:30 - 11:15 am

Curbside Consults – Ask the Professors

MONDAY

Upon completion of this session, participants should be able to: • s tate the achievements of the United States Bone and Joint Initiative • d iscuss the burden of musculoskeletal diseases in developing as well as developed countries • d escribe strategies that can be undertaken at a national level to reduce the burden of musculoskeletal disorders

W375d

N o v e m b e r

Moderator: Kori A. Dewing, DNP, ARNP; Virginia Mason Medical Center; Seattle, WA Speaker: Anthony D. Woolf, MBBS ; Royal Cornwall Hospital; Truro Cornwall, United Kingdom

ACR CLINICAL SYMPOSIA 11:00 am - 12:30 pm

W375a

Juvenile Idiopathic Arthritis: Clinical Heterogeneity and the Genome P Moderators: Peter A. Nigrovic, MD; Brigham and Women’s Hospital; Boston, MA Alexei A. Grom, MD; Cincinnati Children’s Hospital Medical Center; Cincinnati, OH 11:00 am Historical Overview of Juvenile Idiopathic Arthritis Classification and Genetics David N. Glass, MD; Cincinnati Childrens Hospital Medical Center; Cincinnati, OH 11:10 am Juvenile Idiopathic Arthritis: The Clinical Phenotypes Alberto Martini, MD; University of Genova; Genova, Italy 11:35 am Genotype-Phenotype Correlations in Juvenile Idiopathic Arthritis Sampath Prahalad, MD, MSc; Emory Children’s Center; Atlanta, GA noon

Gene Expression in Juvenile Idiopathic Arthritis and the Clinical Phenotypes Lucy R. Wedderburn, MD, PhD; University College London; London, United Kingdom 2011 Program Book

59

Upon completion of this session, participants should be able to: • assess phenotypic subgroups within juvenile idiopathic arthritis • review recent progress toward understanding genotypephenotype correlations within juvenile idiopathic arthritis • discuss the significance of recent gene expression studies for the categorization of juvenile idiopathic arthritis

W375b

Treatment of Lupus Nephritis

C

PS

Moderator: Jennifer M. Grossman, MD; University of California Los Angeles; Los Angeles, CA 11:00 am Clinical Trials in Lupus Nephritis: The Challenges and the Results – Mycophenolate, Rituximab, Abatacept, Azathioprine, Calcineurin Inhibitors J.T. Merrill, MD; Oklahoma Medical Research Foundation; Oklahoma City, OK 11:25 am The 2011 ACR Guidelines for Management of Lupus Nephritis Bevra H. Hahn, MD; University of California Los Angeles School of Medicine; Los Angeles, CA

7 ,

MONDAY

2 0 1 1

11:50 am Lupus Nephritis: The Future: Prevention of Renal Failure, Biomarkers, and New Products in Clinical Trials Brad H. Rovin, MD; Ohio State University Medical Center; Columbus, OH

N o v e m b e r

Upon completion of this session, participants should be able to: • explain the results of large clinical trials in patients with lupus nephritis • cite the 2011 ACR lupus nephritis guidelines • describe the new developments in biomarkers of disease activity, prevention of renal failure, and new therapies currently in clinical trials

ACR PLENARY SESSION II – DISCOVERY 2011 c/r

11:15 am 1588. β-Catenin Is a Central Mediator In Systemic Sclerosis Christian Beyer1, Amelie Schramm1, Alfiya Akhmetshina1, Trayana Kireva1, Clara Dees1, Sonia C. Schindler1, Makoto M. Taketo2, Oliver Distler3, Georg Schett4 and Jorg HW Distler4, 1FriedrichAlexander-University Erlangen-Nuremberg, Erlangen, Germany, 2 Kyoto University Yoshida-Konoé-cho, Kyoto, Japan, 3University Hospital Zurich, Zurich, Switzerland, 4Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 11:30 am 1589. A Combined Fc-OPG/hPTH(1-34) Therapy to Restore Impaired Skeletal Growth and Bone Loss in a Mouse Model of IL-6 Dependent Juvenile Inflammatory Diseases Andrea Del Fatore1, Marta Capannolo2, Barbara Peruzzi2, Alfredo Cappariello1, Nadia Rucci2, Fabrizio De Benedetti1 and Anna Teti2, 1Children Hospital Bambino Gesù, Rome, Italy, 2University of L’Aquila, L’Aquila, Italy 11:45 am 1590. The Absence of CD4+ T Cell Help Underlies the Maintenance of B Cell Tolerance to Glucose-6-Phosphate Isomerase and the Avoidance of Arthritis Justin J. Taylor, Laura O. Barsness, Ryan J. Martinez, Stephanie R. Thomas and Daniel L. Mueller, University of Minnesota Medical School, Minneapolis, MN noon

1591. Identification of Robust and Disease-Specific Stromal Alterations in Spondyloarthritis Synovitis Nataliya Yeremenko1, Gemma M. M. Rigter1, Iris Simon2, Juan D. Cañete3, Paul P. Tak1 and Dominique L. Baeten1, 1Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Agendia BV, Amsterdam, Netherlands, 3Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain 12:15 pm 1592. Identification of Specific Amino Acids in the Uric Acid Transporter URAT1 Required for Uricosuric-Mediated Inhibition Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, San Diego, CA

11:00 am - 12:30 pm

W375c Moderators: George C. Tsokos, MD; Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA Joel A. Block, MD; Rush University Medical Center; Chicago, IL 11:00 am 1587. Evidence for a Direct Role of Anti-Signal Recognition Particle Antibodies in the Pathogenesis of Necrotizing Myopathies. Coralie bloch-Queyrat1, Laurent Drouot2, Jean- Luc Charuel3, Erika Yada4, Dominique Langui5, Saik Urien6, Serge Herson1, Lucie Musset3, Gillian Butler Browne4, Olivier Boyer2 and Olivier Benveniste1, 1Centre de Référence des Maladies Neuro Musculaire, Pitié Salpêtrière, Paris, France, 2INSERM U905, University of Rouen, Rouen, France, 3Laboratoire d’immunochimie, Pitié- Salpêtrière, Paris, France, 4UMRS 974 INSERM UPMC, Paris, France, 5Plateforme d’Imagerie Cellulaire, INSERM UMRS 975/CNRS UMR 7225/UPMC ICM Centre de Recherche Pitié-Salpêtriere, 6URC Cochin Necker CIC901INSERM, France

60

2011 Program Book

ACR PRACTICE ISSUE 11:00 am - 12:30 pm

W475a

The Road to Meaningful Use and Beyond: A Simple Overview of a Complex Topic BR cP 11:00 am What is “Meaningful Use” and What Does It Mean for Me? Speaker to be announced 11:25 am Developing a Solid Plan for Your Electronic Practice: How Do I Get to Meaningful Use? Robert W. Warren, MD, PhD, MPH; Medical University of South Carolina; Charleston, SC

noon An Electronic Health Record Isn’t Enough: Information Exchange for Meaningful Use Laura Zaremba, BA, MA; Illinois Office of Health Information Technology; Chicago, IL

Epidemiology/Public Health

Upon completion of this session, participants should be able to: • d escribe the rationale behind the Centers for Medicare and Medicaid Services Electronic Health Records Incentive Program (meaningful use) and the requirements and criteria for incentive funding • identify the electronic health records Incentive Program’s impact on the practice of rheumatology, including how operations must be modified to successfully achieve meaningful use • d escribe the functionality objective and clinical quality measures most relevant to rheumatology providers • identify the value of electronic health records system certification and meaningful use standards as a path to achieving interoperability of health information and data exchange iscuss the benefits of health information technology beyond • d electronic health records • d escribe the functionality objectives and clinical quality measures expected for future stages of the Electronic Health Records Incentive Program

Healthcare Education Issues: Education Strategies for Advanced Practice Nurses

Extended Role Practitioner: Can They Fill the Gap in Arthritis Care? Forms Exchange for Those New to Rheumatology

Hip and Knee Arthroplasty: Patient Discharge Instructions Infusion and Injectable Therapies Measurements of Physical Activity Medications for Rheumatic Diseases Nurse Practitioner Issues Nurse Practitioner Issues - Pediatrics Office Manager/Practice Administrator Office Nurse Physician Assistant Issues Pediatrics Qualitative Research Research Mentoring

noon - 2:00 pm

Volunteering/Mentoring ARHP

MONDAY

Tuberculosis Screening Prior to Initiation of Tumor Necrosis Factor Antagonist Therapy

N o v e m b e r

ARHP SPECIAL SESSION

Sit down with your colleagues, enjoy a boxed lunch (provided to the first 250 participants) and an open discussion on various research, practice and clinical topics. Each roundtable discussion will be facilitated by a rheumatology expert. All ARHP attendees are welcome. Topics listed are subject to change. ARHP Business Meeting Speaker: Nadine T. James, RN, MSN, PhD; Hattiesburg, MS Inaguration of 42nd ARHP President Benjamin J. Smith, PA-C; McIntosh Clinic PC; Thomasville, GA A Friend in Need: The Value of Structured Peer Support in the Clinic Setting Adult Form Sharing Advocacy and Access to Care Ankylosing Spondylitis ARHP Grant/Award Opportunities Arthritis and Employment Clinical Research Coordinators Community-based Physical Activity Programs: What Data to Ciollect and Why Diversity/Cultural Issues Enhancing Patient Adherence

INNOVATION THEATER

2 0 1 1

ARHP Networking at Noon

7 ,

S102a 12:30 - 1:15 pm

HALL F1 - (Booth #789) The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by F. Hoffmann-La Roche Ltd. Please visit the Genentech and Roche exhibit booth (457) for more information or see page 304. Seating and light refreshments are subject to availability.

Optimizing Rheumatoid Arthritis Treatment Strategies: Selecting the Right Targets to Improve Patient Outcomes

ACR MEET THE PROFESSOR SESSIONS 12:45 - 2:15 pm Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/annual. *Sessions denoted with an asterisk were sold out as of September 12. 2011 Program Book

61

W187b

Basic Immunology for Clinical Rheumatologists (041) f

W475a

Speaker: Antony Rosen, MD; The Johns Hopkins University; Baltimore, MD

Contract Negotiations for Physicians

Crystal: Pseudogout (042)

W186b

Osteoporosis: Applying Fracture Risk Assessment Algorithm Methodology (043) Speaker: Thomas P. Olenginski, MD; Geisinger Medical Center; Danville, PA

W185a P

PM

Speaker: Polly J. Ferguson, MD; University of Iowa Carver College of Medicine; Iowa City, IA

W184d

*Pulmonary Manifestations of Rheumatic Disease (045)

N o v e m b e r

7 ,

MONDAY

2 0 1 1

Speaker: Paul F. Dellaripa, MD; Brigham & Women’s Hospital; Boston, MA

W186c

Raynaud’s and Digital Ischemia (046) Speaker: Janet E. Pope, MD, MPH; St. Joseph’s Health Care, University of Western Ontario; London, ON, Canada

W187c

Rheumatoid Arthritis: Safety of Novel Therapies (047)

f

1:00 pm Contract Negotiations for Industry: How to Optimize Your Industrial Letter of Offer/Contract Gregory J. Dennis, MD; Potomac, MD 1:15 pm Contract Negotiations for Private Practice: How to Optimize a Private Practice or Hospital Practice Contract Herbert Baraf, MD; Arthritis & Rheumatism Associates; Wheaton, MD 1:35 pm Contract Negotiations and the Legal Ramifications of the Contract: How to Optimize the Contract and Protect Yourself Joan M. Roediger, JD, LLM; Obermayer Rebmann Maxwell; Philadelphia, PA Upon completion of this session, participants should be able to: • explain the value of legal advice prior to signing a contract and the legal ramifications of the contract • identify a fair private practice or hospital practice contract and how to successfully modify it to correspond with their individual needs • negotiate a fair academic or industrial letter of offer/contract

PS

Speaker: Daniel H. Solomon, MD, MPH; Brigham and Women’s Hospital; Boston, MA

W185bc

Scleroderma Mimics (048) Speaker: Laura K. Hummers, MD, ScM; Johns Hopkins University; Baltimore, MD

W187a

Vaccinations for Patients on Biologic Therapies (049) Speaker: Clifton O. Bingham III, MD; Johns Hopkins University; Baltimore, MD

W186a

*Vasculitis: Update (050) Speaker: Peter A. Merkel, MD, MPH; Boston University School of Medicine; Boston, MA

62

Ed.

12:45 pm Contract Negotiations for Academics: How to Optimize Your Academic Letter of Offer/Contract Richard M. Pope, MD; Northwestern University Medical School; Chicago, IL

Speaker: Geraldine M. McCarthy, MD; Mater Misericordiae University Hospital; Dublin, Ireland

f

BR

Moderator: Seth M. Berney, MD; Louisana State University; Shreveport, LA

W185d

Pediatrics: Periodic Fevers in Children (044)


2011 Program Book


W375c

Did You Brush Your Teeth Today? (Clinical Review) cP

P/C

Moderators: Faye N. Hant, DO, MSCR; Medical University of South Carolina; Charleston, SC Victoria K. Shanmugam, MBBS, MRCP; Georgetown University Hospital; Washington, DC Speaker: Michele Ravenel, DMD; Medical University of South Carolina; Charleston, SC Upon completion of this session, participants should be able to: • outline the pathophysiologic mechanisms by which periodontal disease interplays with autoimmune disease • recognize what can be done to improve periodontal health in patients with established autoimmune diseases, including scleroderma, Sjögren’s syndrome and rheumatoid arthritis • outline practical advice for patients on the oral complications of autoimmune disease and therapies

ACR SPECIAL SESSION

ACR WORKSHOPS

1:00 - 2:00 pm

1:15 - 3:15 pm

W375d

2011 Updated ACR Rheumatoid Arthritis Guidelines C

PS

Moderator: Ted R. Mikuls, MD; Omaha VA and University of Nebraska; Omaha, NE Speakers: Jasvinder Singh, MD, MPH; University of Alabama at Birmingham and Birmingham VA Medical Center; Birmingham, AL Kenneth G. Saag, MD, MSc; University of Alabama-Birmingham; Birmingham, AL Daniel E. Furst, MD; University of California Los Angeles Medical School; Los Angeles, CA Upon completion of this session, participants should be able to: • d escribe the recommended treatment approach for patients with rheumatoid arthritis • r eview the recommendations for indications of biologic and non-biologic disease-modifying agents in the treatment of rheumatoid arthritis • r eview the recommendations for tuberculosis screening and vaccination in patients with rheumatoid arthritis

Upon completion of this session, participants should be able to: • e xplain what makes a good biomarker • d escribe the current list of systemic lupus erythematosus biomarkers under investigation • o utline the potential clinical application of the current biomarkers

W179b

Diagnostic Errors in Rheumatology: Why They Happen and How We Can Avoid Them (222) Speakers: Alexis Ogdie, MD; University of Pennsylvania; Philadelphia, PA Joan Marie Von Feldt, MD, MS; University of Pennsylvania/ Philadelphia Veterans Affairs Medical Center; Philadelphia, PA

W178b

Getting Electronic Health Record Right (223) Speaker: Salahuddin Kazi, MD; Dallas Veterans Affairs Medical Center; Dallas, TX

2 0 1 1

Moderators: Anca D. Askanase, MD; New York University School of Medicine; New York, NY Susan Manzi, MD; Allegheny Singer Research Institute; Pittsburgh, PA Speaker: Jill P. Buyon, MD; New York University School of Medicine; New York, NY

Speakers: Dorothy D. Dunlop, PhD; Northwestern University Medical School; Chicago, IL Jungwha Lee, MPH, PhD; Northwestern University; Chicago, IL

7 ,

Biomarkers in Systemic Lupus Erythematosus: Where Do We Stand? C PS

Basic Statistical Concepts for the Medical Researcher (221)

MONDAY

W375b

W178a

N o v e m b e r

ACR STATE-OF-THE-ART LECTURE 1:00 - 2:00 pm

Admission to the workshops requires a separate registration and ticket. To verify which session you registered for - check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual.

W180

Peripheral Magnetic Resonance Imaging in Clinical Rheumatology (224) Speakers: Ewa Olech, MD; Oklahoma Medical Research Foundation; Oklahoma City, OK Orrin M. Troum, MD; University of Southern California, Keck School of Medicine; Santa Monica, CA

ACR BASIC SCIENCE SYMPOSIA 2:30 - 4:00 pm

W192b

Fibrosis: Novel Paradigms

R

Moderators: John Varga, MD; Northwestern University Medical School; Chicago, IL Carol A. Feghali-Bostwick, PhD; University of Pittsburgh; Pittsburgh, PA

2011 Program Book

63

2:30 pm Cellular Senescence and Fibrosis Lester F. Lau, PhD; University of Illinois; Chicago, IL 2:55 pm Mechano-Signal Transduction Boris Hinz, PhD; University of Toronto; Toronto, ON, Canada 3:20 pm Innate Immune Signaling and Fibrosis Cory M. Hogaboam, PhD; University of Michigan Medical School; Ann Arbor, MI Upon completion of this session, participants should be able to: • describe the biology and impact of fibrosis • evaluate new concepts in fibroblast biology • recommend novel targets for therapy of fibrosis

W196b

Rheumatoid Arthritis: Where Does It Begin?

R

Moderators: Robert H. Carter, MD; National Institutes of Arthritis and Musculoskeletal and Skin Diseases/NIH; Bethesda, MD Karen H. Costenbader, MD, MPH; Brigham and Women’s Hospital; Boston, MA

7 ,

MONDAY

2 0 1 1

2:30 pm Where is the Inflammation: The Synovium and Lymph Nodes in Pre-Rheumatoid Arthritis Danielle Marie Gerlag, MD, PhD; Academic Medical Center; Amsterdam, Netherlands

N o v e m b e r

2:55 pm Molecular Links between Periodontitis and Autoimmunity in Rheumatoid Arthritis Patrick Venables, MD; Kennedy Institute; London, United Kingdom 3:20 pm The Lung as a Site of Initiation of Rheumatoid Arthritis-related Autoimmunity Kevin D. Deane, MD, PhD; University of Colorado School of Medicine; Aurora, CO Upon completion of this session, participants should be able to: • define the role and supportive evidence for pulmonary and periodontal disease in early rheumatoid arthritis • appraise the role of inflammation in different tissues in early rheumatoid arthritis • determine situations where interventions in non-synovial organs might lead to prevention of rheumatoid arthritis • identify targets for intervention to prevent development of rheumatoid arthritis in those at risk


W375a

Advances in Polyarticular Juvenile Idiopathic Arthritis P

Moderators: Timothy Beukelman, MD, MSCE; University of Alabama-Birmingham; Birmingham, AL Kathleen M. O’Neil, MD; Oklahoma University Health Science Center; Oklahoma City, OK

64

2011 Program Book

2:30 pm Toward Remission in Polyarticular Juvenile Idiopathic Arthritis Carol A. Wallace, MD; Children’s Hospital & Regional Medical; Seattle, WA 3:00 pm Immune Tolerance in the Treatment of Polyarticular Juvenile Idiopathic Arthritis Salvatore Albani, MD, PhD; Sanford-Burnham Medical Research Institute; La Jolla, CA 3:30 pm Newer Rheumatoid Arthritis Treatment Strategies Lucy R. Wedderburn, MD, PhD; University College London; London, United Kingdom Upon completion of this session, participants should be able to: • describe the evidence supporting early aggressive treatment of polyarticular juvenile idiopathic arthritis • review the rationale for designing more aggressive therapies in juvenile idiopathic arthritis • identify the role immune tolerance plays in therapeutic response in polyarticular juvenile idiopathic arthritis • explain how functional genomics can be used to reflect immunologic change in response to therapy, and predict which treatments may be most effective in individual patients with polyarticular juvenile idiopathic arthritis


W195

Education: Medical Education Moderators: John A. Flynn, MD, MBA, MEd; Johns Hopkins University; Baltimore, MD Michael H. Pillinger, MD; New York University Hospital for Joint Diseases; New York, NY 2:30 pm 1593. A Controlled Pilot Study On the Use of Active Learning Techniques During a Rheumatology Elective for Medical Residents Joshua Scheers-Masters1, David R. Blumenthal2, Jeanne Macrae3, Matthew Avitable3 and Deana M. Lazaro4, 1SUNY Downstate, Brooklyn, NY, 2VA NY Harbor Healthcare System, Brooklyn, NY, 3 SUNY Downstate Medical Center, NY, 4Brooklyn VA, Brooklyn, NY 2:45 pm 1594. Rheumatology Decision 2011: Factors Influencing Career Decisions Among Rheumatology Fellows Saira Sheikh1, Michael Smith1, Tony Ning2, Erin Shiner3, Dijana Christianson4, Lisa G. Criscione-Schreiber5, Marcy B. Bolster6, Kenneth S. O’Rourke7, Deb MacDonald1, Leigh F. Callahan8 and Beth L. Jonas9, 1University of North Carolina Chapel Hill, Chapel Hill, NC, 2Duke University, Durham, NC, 3Wake Forest Univ. Baptist Med. Ctr., Winston-Salem, NC, 4Medical University of South Carolina, Charleston, SC, 5Duke University Medical Center, Durham, NC, 6Medical Univ of South Carolina, Charleston, SC, 7Wake Forest Univ School of Med, Winston-Salem, NC, 8 University of North Carolina, Chapel Hill, NC, 9University of North Carolina at Chapel Hill, Chapel Hill, NC

3:00 pm 1595. Knowledge of Clinical Anatomy by Rheumatology Fellows and Rheumatologists in Latin America José E. Navarro-Zarza1, Cristina Hernández-Díaz2, Miguel A. Saavedra-Salinas3, Robert A. Kalish4, Juan J. Canoso5 and Pablo Villaseñor-Ovies2, 1Mexican Taskforce for the Advancement of Clinical Anatomy, Mexico, Mexico, 2Instituto Nacional de Rehabilitación, Mexico City, Mexico, 3Centro Médico Nacional, México, Mexico, 4Tufts Medical Center, Boston, MA, 5ABC Medical Center and Tufts University, Mexico City, Mexico 3:15 pm 1596. Development of a Novel Interactive Case Based Educational Website In Rheumatology Christopher E. Collins, Washington Hospital Ctr, Washington, DC 3:30 pm 1597. Revision of Existing Osteoporosis Curriculum in Response to Fellows Feedback : 2011 Curriculum Thomas P. Olenginski and Thomas M. Harrington, Geisinger Medical Center, Danville, PA

Epidemiology and Health Services Research I: Gout

2:45 pm 1600. Increased Gout Risk Related to Diuretic Use Only Exists for Those with a Higher Genetic Risk: Detection of A Urate Gene-by-Diuretic Interaction in the Atherosclerosis Risk in Communities Cohort Mara McAdams DeMarco1, Janet W. Maynard2, Alan N. Baer2, Anna Kottgen3, Linda Kao1 and Josef Coresh1, 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3University Hospital Freiburg, Freiburg, Germany 3:00 pm 1601. Mortality Due to Coronary Heart Disease and Kidney Disease Among Middle-Aged and Elder Men and Women with Gout In the Singapore Chinese Health Study Gim Gee Teng1, Li-Wei Ang2, Jian-Min Yuan3 and Woon-Puay

2 0 1 1

2:30 pm 1599. Allopurinol Initiation and the Risk of Death in the General Population Yanyan Zhu1, Yuqing Zhang2, John D. Seeger3, Young Hee Rho4, Christine Peloquin1 and Hyon K. Choi1, 1Boston University School of Medicine, Boston, MA, 2Boston University Clinical Edpidemiology Reserach and Training Unit, Boston, MA, 3 Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, 4Vanderbilt Medical Center, Nashville, TN

3:45 pm 1604. Comparative Effectiveness of Allopurinol and Febuxostat In Controlling Serum Uric Acid In a Large US Commercially Insured Population Jasvinder A. Singh1, Bhavik J. Pandya2, Gabriel Gomez Rey3 and Brett W. Pinsky4, 1University of Alabama at Birmingham, Birmingham, AL, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, 3Innovus, Eden Prairie, MN, 4Innovus, Lenexa, KS

7 ,

Moderators: Jasvinder A. Singh, MD, MPH; University of Alabama at Birmingham; Birmingham, AL Hyon Choi, MD, DrPH; Boston University School of Medicine; Boston, MA

3:30 pm 1603. Does Treatment of Asymptomatic Hyperuricemia Improve Cardio and Neurovascular Outcomes? A DecisionAnalytic Evaluation Roopa Akkineni1, Alexandra Lee2, Katherine L. Miller3, Anna N A. Tosteson4, Hyon K. Choi5, Yanyan Zhu5 and Daniel A. Albert1, 1 Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2Veterans Affairs National Center for Patient Safety, White River Junction, VT, 3Northeastern Ohio Universities College of Medicine, Rootstown, OH, 4Dartmouth Medical School, Lebanon, NH, 5 Boston University School of Medicine, Boston, MA

MONDAY

W475a

3:15 pm 1602. Uncontrolled Serum Uric Acid In Veteran Gout Patients Is Associated with a Higher Risk of Diabetes Bhavik J. Pandya1, Maryna Marynchenko2, Hari Sharma2, Andrew Yu2, Eric Wu2, Lizheng Shi3, Jinan Liu3 and Eswar Krishnan4, 1 Takeda Pharmaceuticals International, Inc., Deerfield, IL, 2 Analysis Group, Inc., Boston, MA, 3Tulane University, New Orleans, LA, 4Stanford University, Stanford, CA

N o v e m b e r

3:45 pm 1598. Blog Versus traditional Seminar: A Comparative Trial in Rheumatology Elaine L. M. Bezerra1, Francisco A. Bezerra Neto1, Maria J. Vilar1 and Grupo de Estudos e Pesquisas em Educação Médica - UFRN2, 1 Federal University of Rio Grande do Norte, Natal, Brazil, 2Natal, Brazil

Koh4, 1National University Health System, Singapore, Singapore, 2 Ministry of Health, Singapore, Singapore, 3Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 4Department of Epidemiology and Public Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

W190a

Fibromyalgia and Soft Tissue Disorders II Moderators: Daniel J. Clauw, MD; University of Michigan; Ann Arbor, MI Mary-Ann Fitzcharles, MBChB, MD; McGill University; Montreal, QC, Canada 2:30 pm 1605. Continued Opioid Use in Fibromyalgia Is Associated with Negative Health Related Outcomes Peter A. Ste-Marie1, Mary-Ann Fitzcharles2, Marc-Olivier Martel2, Ann Gamsa2, Pantelis Panopalis2 and Yoram Shir2, 1University of Montreal, Montreal, QC, 2McGill University, Montreal, QC 2:45 pm 1606. 5-HT2C Receptor Agonists Attenuate Muscle Pain in a Rat Model of Fibromyalgia Shinichi Ogino, Mina Tsukamoto, Yukinori Nagakura, Tomonari Watabiki, Yasuaki Shimizu and Hiroyuki Ito, Astellas Pharma Inc., Tsukuba, Japan 3:00 pm 1607. Mechanisms of Improvement in Fibromyalgia Symptoms in a Clinical Trial of Exercise: Increased Fitness or Hawthorne Effect? Steven A. Mazzuca1, Anthony Kaleth2, Chandan Saha3, James Slaven3 and Dennis C. Ang4, 1Indiana Univ Schl of Medicine, 2011 Program Book

65

Indianapolis, IN, 2Indiana University Purdue University Indianapolis, 3Indiana University, 4Indiana University, Indianapolis, IN 3:15 pm 1608. Study of the Measurement Properties of the Arnold Fibromyalgia Diagnostic Screen: Results From a Cross-Sectional Study Susan Martin1, Cheryl Coon2, Lori McLeod2, Arthi Chandran3 and Lesley M. Arnold4, 1RTI-Health Solutions, Ann Arbor, MI, 2 RTI-Health Solutions, Research Triangle Park, 3Pfizer, New York, 4 University of Cincinnati College of Medicine, Cincinnati, OH 3:30 pm 1609. A Multicenter, Randomized, Double-Blind, PlaceboControlled Switch Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Patients with An Inadequate Response to Duloxetine for the Treatment of Fibromyalgia Lucinda Bateman1, Allan Spera2, Robert H. Palmer2, Joel M. Trugman2 and Jennifer Lin2, 1The Fatigue Consultation Clinic, Salt Lake City, UT, 2Forest Research Institute, Jersey City, NJ

N o v e m b e r

7 ,

MONDAY

2 0 1 1

3:45 pm 1610. An 11-Year Longitudinal Study of Pharmacologic Therapy in Fibromyalgia Frederick Wolfe1, Brian T. Walitt2, Robert S. Katz3, Yvonne C. Lee4, Kaleb D. Michaud5 and Winfried Häuser6, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Washington Hospital Center, Washington, DC, 3Rush University Medical Center, Chicago, IL, 4 Brigham and Women’s Hospital, Boston, MA, 5Univ of Nebraska Med Ctr & National Data Bank for Rheumatic Diseases, Omaha, NE, 6Technische Universität München, Munich, Germany

W474a

Imaging of Rheumatic Disease II: X-ray, Computed Tomography and Magnetic Resonance Imaging Moderators: John Carrino, MD, MPH; Johns Hopkins Medical Institute; Baltimore, MD Harry K. Genant, MD; University of California; Tiburon, CA 2:30 pm 1611. Comparative Analysis of Bone Erosions and Cysts in Rheumatoid Arthritis, Psoriatic Arthritis and Erosive Hand Osteoarthritis Stephanie Finzel1, Christian Ernet1, Juergen Rech Sr.1, Christian M. Stach1, Klaus Engelke2, Matthias Englbrecht1, Jochen Zwerina1 and Georg Schett1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of ErlangenNuremberg, Erlangen, Germany, 2University of ErlangenNuremberg, Erlangen, Germany 2:45 pm 1612. Baseline Levels of the Inflammatory Biomarker C-Reactive Protein Are Significantly Correlated with Magnetic Resonance Imaging Measures of Synovitis At Baseline and After 26 Weeks of Treatment in Patients with Early Rheumatoid Arthritis Charles G. Peterfy1, Boulos Haraoui2, Arthur Kavanaugh3, Josef S. Smolen4, Sourav Santra5, Hartmut Kupper6, Tracy F. Nicholson7 and Paul Emery8, 1Spire Sciences LLC, Kentfield, CA, 2Institut de Rhumatologie, Montreal, QC, 3University of California San Diego, San Diego, CA, 4Krankenhaus Lainz, Vienna, Austria, 5Abbott GmBH & Co KG, Abbott Park, IL, 6Abbott GmBH & Co KG,

66

2011 Program Book

Ludwigshafen, Germany, 7Abbott Laboratories, 8Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom 3:00 pm 1613. A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study Cornelia F. Allaart1, Linda Dirven1, Shintaro Hirata2, P.J.S.M. Kerstens3, B.A.C Dijkmans4, David Chernoff5, Guy Cavet5, Michael Centola6, Lyndal K. Hesterberg5, Yoshiya Tanaka2, T.W.J. Huizinga7 and Yijing Shen5, 1Leiden University Medical Center, Leiden, Netherlands, 2University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 3Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 4VU Medical Center, Amsterdam, Netherlands, 5Crescendo Bioscience, Inc., South San Francisco, CA, 6Oklahoma Medical Research Fdn, Oklahoma City, OK, 7Leiden University Medical Centre, Leiden, Netherlands 3:15 pm 1614. Tocilizumab (TCZ) Inhibits Progression of Joint Damage in Rheumatoid Arthritis (RA) Irrespective of Its Antiinflammatory Effects: Disassociation of the Link Between Inflammation and Destruction Josef Smolen1, José Martinez-Avila2 and Daniel Aletaha3, 1 Medical University of Vienna and Hietzing Hospital, Vienna, Austria, Vienna, Austria, 2Medical University of Vienna, Austria, 3 Medical University of Vienna, Vienna, Austria 3:30 pm 1615. Evidence for Limited Repair of existing bone Erosions in Rheumatoid Arthritis Patients Treated with the Interleukin-6 Receptor Blocker Tocilizumab Stephanie Finzel1, Juergen Rech Sr.1, Sarah Schmidt1, Klaus Engelke2, Matthias Englbrecht1, Christian M. Stach1 and Georg Schett1, 1Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, 2Institute of Medical Physics, University of Erlangen, Erlangen, Germany 3:45 pm 1616. Co-Localization of Non-Cartilaginous Articular Pathology and Cartilage Damage in Regard to Subsequent Cartilage Loss in Subjects with or At Risk for Knee osteoarthritis –the MOST Study Frank Roemer1, David T. Felson2, Ke Wang1, Michel Crema1, Monica D. Marra1, Yuqing Zhang3, Michael C. Nevitt4, Cora E. Lewis5, James Torner6 and Ali Guermazi7, 1Boston University, Boston, MA, 2Department of Clinical Epidemiology, Boston University School of Public Health, Boston, MA, USA, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4 University of California-San Francisco, San Francisco, CA, 5 University of Alabama, Birmingham City, Birmingham, AL, 6 University of Iowa, Iowa City, Iowa City, IA, 7Boston Medical Center, Boston, MA

W183c

Metabolic and Crystal Arthropathies I: Pathogenesis of Gout, a Potential Novel Therapy, and Validity of Dual Energy Computed Tomography

Moderators: Peter Simkin, MD; University of Washington; Seattle, WA Robert T. Keenan, MD, MPH; Duke University; Durham, NC 2:30 pm 1617. Diagnosis of Gout Using Dual-Energy Computed Tomography: An Accuracy and Diagnostic Yield Study Tim Bongartz1, Katrina N. Glazebrook1, Steven J. Kavros2, Clement J. Michet1, Stephen P. Merry3, Naveen S. Murthy1, Bharath Manu Akkara Veetil1, John M. Davis III1, Thomas G. Mason II4, Kenneth J. Warrington1, Nisha J. Manek1, Tanaz A. Kermani1, Deana D. Hoganson1, A. Kirstin Bacani1, Hailong Wang1 and Cynthia H. McCollough2, 1Mayo Clinic, Rochester, MN, 2Rochester, MN, 3 Mayo Clinic, Rochester, 4Mayo Clinic Rochester, Rochester, MN 2:45 pm 1618. Assessment of Tophus Size; A Comparison Between Physical Measurement Methods and Dual Energy Computed Tomography Scanning Nicola Dalbeth, Opetaia Aati, Angela Gao, Meaghan House, Qiliang Liu, Anne Horne, Anthony Doyle and Fiona M. McQueen, University of Auckland, Auckland, New Zealand

2:45 pm 1624. Breaking the Law of Valgus: The Surprising and Unexplained Prevalence of Medial Patellofemoral Cartilage Damage K. Douglas Gross1, Jingbo Niu2, Joshua J. Stefanik3, Ali Guermazi4, Frank Roemer3, Leena Sharma5, Michael C. Nevitt6, Neil Segal7, Cora E. Lewis8 and David T. Felson2, 1MGH Institute of Health Professions, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Boston University, Boston, MA, 4Boston Medical Center, Boston, MA, 5Northwestern University, Chicago, IL, 6University of California-San Francisco, San Francisco, CA, 7University of Iowa, Iowa City, 8University of Alabama, Birmingham City, Birmingham, AL 3:00 pm 1625. Change in Knee Cartilage Volume and Incident Meniscal Extrusion As Predictors of Change in Joint Space Width of the Tibiofemoral Joint: 5 Year Longitudinal Study Joanna Hall1, Laura Laslett1, Johanne M. Pelletier2, Jean Pierre Pelletier2, François Abram3, Chang-Hai Ding4, Flavia Cicuttini5 and Graeme Jones1, 1University of Tasmania, Hobart, Australia, 2 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 3ArthroVision Inc., Montreal, QC, 4University of Tasmania & Monash University, Hobart, Australia, 5Monash University, Central and Eastern Clinical School, Melbourne, Australia

2 0 1 1

3:45 pm 1622. Association Between Sugar-Sweetened Beverage Consumption and Gout in the New Zealand Population Tony R. Merriman1, Nicola Dalbeth2, Lisa K. Stamp3, Marilyn E. Merriman1, Ruth Topless1, Peter J. Gow4, Andrew Harrison5, John Highton6, Peter B. B. Jones7 and Caitlin Glue1, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, Christchurch, New Zealand, 4Middlemore Hospital, Auckland, New Zealand, 5Hutt Hospital, Lower Hutt, New Zealand, 6Univ of Otago Med Sch, Dunedin, New Zealand, 7Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand

2:30 pm 1623. MRI-Detected Synovitis and Bone Marrow Lesions Are Associated with Joint Tenderness in Hand Osteoarthritis Ida K. Haugen1, Pernille Bøyesen1, Barbara SlatkowskyChristensen1, Sølve Sesseng1, Désirée van der Heijde2 and Tore K. Kvien1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

7 ,

3:30 pm 1621. Pharmacological Inhibition of Interleukin-1 ReceptorAssociated Kinase-4 Reduces Inflammation in a Murine Model of Gout and Is Consistent with IL-1 Signaling Blockade Andrea Bree1, Kathleen Phillips1, Micah Benson1, Ken Dower1, Marina Shen2, Katherine Lee1, Vik Rao1, Cheryl L. NickersonNutter2 and Melanie Ruzek1, 1Pfizer, Inc., Cambridge, MA, 2Pfizer, Cambridge, MA

Moderators: Timothy E. McAlindon, MD, MPH, MRCP; Tufts Medical Center; Boston, MA Amanda E. Nelson, MD, MSCR; University of North Carolina, Thurston Arthritis Research Center; Chapel Hill, NC

MONDAY

3:15 pm 1620. Bone Destruction by RANKL-Expressing T Cells in Chronic Gouty Arthritis Sung-Ji Lee, Hye-Mi Jin, Young-Nan Cho, Seong-Chang Park, Dong-Jin Park, Tae-Jong Kim, Shin-Seok Lee, Seung-Jung Kee and Yong-Wook Park, Chonnam National University Medical School and Hospital, Gwangju, South Korea

Osteoarthritis – Clinical Aspects II

N o v e m b e r

3:00 pm 1619. A Novel Role for Monosodium Urate Monohydrate Crystals and Gouty Synovial Fluids in Monocyte Migration in Gout M. Asif Amin1, Qiang Shu1, Jonathon W. Vargo1, Jeffrey H. Ruth1, Takeo Isozaki1, Solhee Lee1 and Alisa E. Koch2, 1University of Michigan Medical School, Ann Arbor, MI, 2Department of Veteran’s Affairs and University of Michigan, Ann Arbor, MI

W196a

3:15 pm 1626. Novel MRI Ultrashort TE Enhanced T2* Mapping Shows Subsurface Cartilage and Meniscus Changes Clinically in Human Subjects After Anterior Cruciate Ligament Tear (ACLT) Constance R. Chu, Ashley A. Williams and Yongxian Qian, University of Pittsburgh, Pittsburgh, PA 3:30 pm 1627. Pressure Pain Threshold and Knee Pain in Osteoarthritis: The Multicenter Osteoarthritis Study Tuhina Neogi1, Jingbo Niu1, Lars Arendt-Nielsen2, Joachim Scholz3, Laura Frey-Law4, Clifford Woolf5, Yuqing Zhang1, Larry Bradley6, Michael C. Nevitt7 and David T. Felson1, 1Boston University School of Medicine, Boston, MA, 2Aalborg University, Aalborg, Denmark, 3Columbia University, New York, NY, 4 University of Iowa, Iowa City, IA, 5Children’s Hospital, Boston, MA, 6University of Alabama, Birmingham, AL, 7University of California-San Francisco, San Francisco, CA

2011 Program Book

67

3:45 pm 1628. Association of Knee Pain Patterns Determined From the Intermittent and Constant Osteoarthritis Pain Instrument with Knee Pain Severity: The Multicenter Osteoarthritis Study Tuhina Neogi1, Jingbo Niu1, David T. Felson1, Michael C. Nevitt2, C.E. Lewis3, James Torner4, Melissa French5 and Gillian A. Hawker5, 1Boston University School of Medicine, Boston, MA, 2 University of California-San Francisco, San Francisco, CA, 3 University of Alabama, Birmingham City, AL, 4University of Iowa, Iowa City, Iowa City, IA, 5Women’s College Hospital, Toronto, ON

W471b

Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Moderators: Robin K. Dore, MD; David Geffen School of Medicine, University California Los Angeles; Tustin, CA Karen E. Hansen, MD, MS; University of Wisconsin; Madison, WI

N o v e m b e r

7 ,

MONDAY

2 0 1 1

2:30 pm 1629. Risk Factors Associated with Incident Hip Fractures in 9,720 Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Cohort Study Takefumi Furuya1, Eisuke Inoue1, Takayuki Hosoi2, Atsuo Taniguchi1, Shigeki Momohara1 and Hisashi Yamanaka1, 1Tokyo Women’s Medical Univ, Shinjuku-ku, Tokyo, Japan, 2National Center for Geriatrics and Gerontology, Obu, Aichi, Japan 2:45 pm 1630. The Impact of MKK6 and MKK3 on Physiological Bone Architecture and Postmenopausal Bone Loss Jean-Paul David1, Meghan Edgar2, David L. Boyle2, Georg Schett3 and Gary S. Firestein2, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2UCSD School of Medicine, La Jolla, CA, 3 Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 3:00 pm 1631. Denosumab Decreases Cortical Porosity in Postmenopausal Women with Low Bone Mineral Density C. Libanati1, S. K. Boyd2, K. K. Nishiyama2, R. M. Zebaze3, D. A. Hanley2, J. R. Zanchetta4, Thierry Thomas5, S. Boutroy6, C. E. Bogado4, M. Austin1 and E. Seeman7, 1Amgen Inc., Thousand Oaks, CA, 2University of Calgary, Calgary, AB, 3University of Melbourne, Melbourne, Australia, 4Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, 5INSERM U1059 and University Hospital, Saint-Étienne, France, 6INSERM U831 and Université de Lyon, Lyon, France, 7Austin and Repatriation Medical Centre, University of Melbourne, Melbourne, Australia 3:15 pm 1632. Fracture Risk Is Increased in Young Women with Rheumatoid Arthritis Shreyasee Amin, Sherine E. Gabriel, Sara J. Achenbach, Elizabeth J. Atkinson and L. Joseph Melton III, Mayo Clinic, Rochester, MN 3:30 pm 1633. Incident Vertebral Fractures (VF) 12 Months After Glucocorticoid (GC) Initiation in Children with Rheumatic Disorders (RD) Bianca A. Lang1, Celia Rodd2, David A. Cabral3, Peter B. Dent4, Janet E. Ellsworth5, Adam M. Huber1, Kristin M. Houghton3, Roman Jurencak6, Maggie Larché4, Claire MA LeBlanc5, Brian

68

2011 Program Book

Lentle3, MaryAnn Matzinger6, Paivi M. Miettunen7, Kiem Oen8, Johannes Roth6, Claire Saint-Cyr9, Rosie Scuccimarri2, Nazih Shenouda6, Leanne M. Ward6 and the Canadian STOPP Consortium10, 1Dalhousie University, Halifax, NS, 2McGill University, Montréal, QC, 3University of British Columbia, Vancouver, BC, 4McMaster University, Hamilton, ON, 5University of Alberta, Edmonton, AB, 6University of Ottawa, Ottawa, ON, 7 University of Calgary, Calgary, AB, 8University of Manitoba, Winnipeg, MB, 9Université de Montréal, Montreal, QC, 10National Pediatric Bone Health Working Group 3:45 pm 1634. Does Identification of Prevalent Vertebral Fracture on Densitometric Vertebral Fracture Assessment (VFA) in Clinical Practice Influence Physician Prescribing Behavior? John T. Schousboe, Park Nicollet Health Services, Minneapolis, MN

W470b

Rheumatoid Arthritis – Animal Models II Moderators: Tibor T. Glant, MD. PhD; Rush University Medical Center; Chicago, IL Katalin Mikecz, MD, PhD; Rush University Medical Center; Chicago, IL 2:30 pm 1635. Impaired Lymphatic Vessel Maturation in Mice with TNFInduced Inflammatory Arthritis Qianqian Liang1, Ronald Wood2, Brendan Boyce1, Edward M. Schwarz1 and Lianping Xing1, 1University of Rochester, Rochester, NY, 2University of Rochester School of Medicine and Dentistry, Rochester, NY 2:45 pm 1636. A Distinct Tolerogenic Subset, Splenic IDO+CD11b+Dcs From Orally Tolerized Mice Suppresses Collagen-Induced Arthritis Min Jung Park1, Kyung-Su Park1, Mi-La Cho1, Ji-Min Kim2, Sang Heon Lee3 and Ho Youn Kim4, 1The Catholic University of Korea, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, 3 Division of Rheumatology, Seoul, South Korea, 4Rhematism Research Center, Seoul, South Korea 3:00 pm 1637. Collagen Triple Helix Repeat Containing 1 Protein Is a New Synovial Lining Biomarker Overexpressed in AntibodyMediated Arthritis Mohammed Talha Shekhani1, Toni S. Forde1, Anne S. Cuttler2, Volkhard Lindner2 and Vyacheslav A. Adarichev1, 1Albert Einstein College of Medicine, Bronx, NY, 2Maine Medical Center Research Institute, Scarborough, ME 3:15 pm 1638. Intra-Articular Injection of the Selective IκB Kinase β Inhibitor NEMO-Binding Peptide Ameliorates Collagen Induced Arthritis by Inducing Regulatory T Cells and Alternatively Activated Macrophages Soyoun Min1, Mei Yan1, Yong Du1, Cristina Arriens1, Tianfu Wu1 and Chandra Mohan2, 1University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 2University of Texas Southwestern Medical Center, Dallas, TX

3:30 pm 1639. Inflammatory Arthritis in Mice Is Dependent on the Mast Cell-Restricted Signaling Protein Ras Guanine Nucleotide Exchange Protein 4 (RasGRP4) Richard Stevens1, Roberto Adachi2, Peter A. Nigrovic3, Matthew J. Hamilton3 and Steven Krilis4, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2University of Texas M. D. Anderson Cancer Center, Houston, TX, 3Brigham and Women’s Hospital, Boston, MA, 4St George Hospital, Kogarah NSW, Australia 3:45 pm 1640. The CYLD / IKKbeta Axis Functions in Synovial Fibroblasts to Regulate TNF-Driven Arthritis Maria Armaka1, Manolis Pasparakis2, George Mosialos3 and George Kollias1, 1Biomedical Sciences Research Center ‘Alexander Fleming’, Vari, Greece, 2Institute for Genetics, Centre for Molecular Medicine, University of Cologne, Cologne, Germany, 3School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece and Biomedical Sciences Research Center ‘Alexander Fleming’, Vari, Greece

W375c

Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy: Existing Biologics

2 0 1 1

3:30 pm 1645. Efficacy of Different Doses of Rituximab for the Treatment of RA: Data From the CERERRA Collaboration Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny L. Nasonov3, Galina Lukina3, Merete L. Hetland4, Ulrik Tarp5, Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helena Canhao10, Matija Tomsic11, Piet LC van Riel12, Juan J. GomezReino13, Tore K. Kvien2 and Ronald F. van Vollenhoven1, 1 Karolinska Institute, Stockholm, Sweden, 2Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Cantacuzino Hospital, Bucharest, Romania, 71Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9for the SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 10 Lisbon Medical Academic Medical Center on behalf of Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 11 University Medical Centre Ljubjana, Ljubljana, Slovenia, 12 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Hospital Clinico Universitario, Santiago, Spain

7 ,

2:45 pm 1642. Risk Factors for Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Tocilizumab Vijay Rao1, Andrey Pavlov2, Micki Klearman1, David Musselman3, Jon T. Giles4, Joan M. Bathon4, Naveed Sattar5 and Janet S. Lee3, 1Genentech, San Francisco, CA, 2Everest, Toronto, 3Roche,

3:15 pm 1644. Is Screening for JC-Polyomavirus by PCR or Detection of Antibodies Useful in Patients with Rheumatic Diseases Who Are Treated with Rituximab? Jens Verheyen1, Eugen Feist2, Kseniya Maizus1, Zebulon Tolman1, Elena Knops1, Tim Waterboer3, Gerd R. Burmester4, Michael Pawlita3, Herbert Pfister1 and Andrea Rubbert1, 1University of Cologne, Cologne, Germany, 2Charité Medical School, Berlin, Germany, 3German Cancer Research Center, Heidelberg, Germany, 4Charité University Medicine, Berlin, Germany

MONDAY

2:30 pm 1641. Low Serum IgG Level After Rituximab Is Associated with An Increased Risk of Serious Infections in Rheumatoid Arthritis: Data of the AIR Registry Jacques-Eric Gottenberg1, Philippe Ravaud2, Thomas Bardin3, Patrice Cacoub4, Alain G. Cantagrel5, Bernard G. Combe6, Maxime Dougados7, Rene-Marc Flipo8, Bertrand Godeau9, Loic Guillevin10, Xavier X. Le Loet11, Eric Hachulla12, Thierry Schaeverbeke13, Jean Sibilia14, Isabelle Pane15, Adelina Abbe15, Gabriel Baron16 and Xavier Mariette17, 1strasbourg University Hospital, Strasbourg, France, 2Hotel Dieu University hospital, France, 3Service de Rhumatologie. Centre Viggo Petersen. Hôpital Lariboisiere, Paris, France, 4CHU Pitié-Salpêtrière, Paris, France, 5Hopital Purpan, Toulouse CEDEX 9, France, 6Hopital Lapeyronie, Montpellier, France, 7Paris-Descartes University, Cochin Hospital, Paris, France, 8Hopital R Salengro CHRU, Lille CEDEX, France, 9Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 10Cochin University Hospital, Paris, France, 11CHU de ROUEN, Rouen CEDEX, France, 12 Internal Medicine, Lille CEDEX, France, 13Pellegrin Hospital, Bordeaux, France, 14Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 15France, 16Epidemiology, Paris, France, 17Université ParisSud, Le Kremlin Bicetre, France

3:00 pm 1643. B Cell Repopulation and Rheumatoid Factor Predict Duration of Response to Rituximab in Rheumatoid Arthritis Edward M. Vital1, Sudipto Das2, Shouvik Dass1, Maya H. Buch3, Frederique Ponchel1, Andrew Rawstron1 and Paul Emery4, 1NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4NIHRLeeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom

N o v e m b e r

Moderators: Joan M. Bathon, MD; Columbia University Medical Center; New York, NY Peter M. Villiger, MD; Inselspital-University Hospital; Bern, Switzerland

Nutley, NJ, 4Columbia University Medical Center, New York, NY, 5 University of Glasgow, Glasgow, United Kingdom

3:45 pm 1646. Seropositivity and Response to RTX: Data From the CERERRA Collaboration Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny L. Nasonov3, Galina Lukina3, Merete L. Hetland4, Ulrik Tarp5, Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helena Canhao10, Matija Tomsic11, Piet LCM Van Riel12, Juan J. GomezReino13, Tore K. Kvien2 and Ronald F. van Vollenhoven1, 1 Karolinska Institute, Stockholm, Sweden, 2Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4DANBIO, Copenhagen University Hospital at 2011 Program Book

69

Glostrup, Copenhagen, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Cantacuzino Hospital, Bucharest, Romania, 7 1Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9for the SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 10Hosp Santa Maria, Lisbon, Portugal, 11University Medical Centre Ljubjana, Ljubljana, Slovenia, 12Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Hospital Clinico Universitario, Santiago, Spain

W181b

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II

N o v e m b e r

7 ,

MONDAY

2 0 1 1

Moderators: Désirée van der Heijde, MD, PhD; Leiden University Medical Center; Leiden, Netherlands Daniel O. Clegg, MD; University of Utah Medical Center; Salt Lake City, UT 2:30 pm 1647. Sclerostin As Marker of Bone Formation in Ankylosing Spondylitis Under Anti-TNF Therapy: A 12-Month Longitudinal Analysis Carla G.S. Saad1, Ana C. M. Ribeiro1, Julio C. B. Moraes1, Liliam Takayama1, Celio Goncalves1, Ricardo M. Oliveira2, Clovis A. A. Silva1, Eloisa Bonfa1 and Rosa M.R. Pereira1, 1Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2RDO Diagnosticos Medicos, São Paulo, Brazil 2:45 pm 1648. Serum Leptin Levels Are Associated with the Presence of Syndemophytes in Male Patients with Ankylosing Spondylitis Ki-Jo Kim1, Ji-Young Kim2, Su-Jung Park2, Hosung Yoon3, ChongHyun Yoon1, Jin-Jung Choi4, Wan-Uk Kim5 and Chul-Soo Cho1, 1 College of Medicine, Catholic University of Korea, Seoul, South Korea, 2Research Institute of Bone & Joint Diseases, Catholic University of Korea, Seoul, South Korea, 3The Catholic University, Incheon, South Korea, 4CHA University, Bundang CHA General Hospital, Seongnam, South Korea, 5St. Vincent’s Hospital, Suwon, South Korea 3:00 pm 1649. Eotaxin: A Novel Biomarker in Ankylosing Spondylitis That Predicts Less Structural Damage Walter P. Maksymowych1, Nigil Haroon2, Nathalie Morency1, Richard J. Cook3, Ker-Ai Lee3, Stephanie Wichuk1, Proton Rahman4, Dafna D. Gladman2 and Robert D. Inman2, 1University of Alberta, Edmonton, AB, 2Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 3University of Waterloo, Waterloo, ON, 4St. Claires Mercy Hospital, St. Johns, NF 3:15 pm 1650. Smokers in Early Axial Spondyloarthritis Have An Earlier Disease Onset, More Inflammation and Damage: Results From the DEvenir Des Spondyloarthropathies Indifferenciées Récentes Cohort Pedro Machado1, Ho Y. Chung2, Désirée van der Heijde3, Maria-Antonietta D’Agostino4 and Maxime Dougados5, 1Leiden University Medical Center, Leiden, Netherlands & Coimbra University Hospital, Coimbra, Portugal, 2Leiden University

70

2011 Program Book

Medical Center, Leiden, Netherlands & Queen Mary Hospital, Hong Kong, China, 3Leiden University Medical Center, Leiden, Netherlands, 4Versailles-Saint Quentin en Yvelines UniversityAPHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France, 5 Paris-Descartes University, Cochin Hospital, Paris, France 3:30 pm 1651. The Incidence of Infection in Psoriatic Arthritis - Results From a Longitudinal Observational Cohort Amir Haddad1, Arane Thavaneswaran2, Vinod Chandran1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 3:45 pm 1652. Efficacy and Safety of Apremilast, An Oral Phosphodiesterase Inhibitor, in Ankylosing Spondylitis E. Pathan1, S.M Abraham1, L. Van-Rossen2, Robin Withrington3, AC Keat4, Peter J. Charles5, E. Paterson5, Muslima Chowdhury6, L. Hastings1, A. Fox1, C. McClinton1 and Peter Taylor7, 1Kennedy Institute of Rheumatology, London W6 8RF, United Kingdom, 2 Kent and Canterbury Hospital, Canterbury , Kent CT1 3NG, United Kingdom, 3Kent & Canterbury Hosp, Canterbury, United Kingdom, 4Northwick Park Hospital, Harrow, United Kingdom, 5 Kennedy Institute of Rheumatology, Imperial College, London, United Kingdom, London, England, 6Imperial College London, London, United Kingdom, 7Kennedy Institute of Rheumatology, London, United Kingdom

W375b

Systemic Lupus Erythematosus – Clinical Aspects: Renal Moderators: Chandra Mohan, MD, PhD; University of Texas Southwestern Medical Center; Dallas, TX Dimitrios T. Boumpas, MD; Regional General University Hospital of Herakleion; Heraklion, Greece 2:30 pm 1653. Incident Lupus Nephritis: Predictive and Protective Factors Ana-Maria Orbai1, Laurence S. Magder2 and Michelle Petri1, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of Maryland, Baltimore, MD 2:45 pm 1654. Urinary and Serum Monocyte Chemotactic Protein-1 and Interferon Gamma-Induced Protein-10 Are Good Markers to Assess Lupus Activity Bonnie Abujam, Satyanarayana Swamy and Amita Aggarwal, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India 3:00 pm 1655. Association of Serum-Based IFN-Induced Chemokine Scores with Lupus Nephritis Disease Activity Irene Blanco1, Chaim Putterman1, Michelle Petri2 and Emily Baechler Gillespie3, 1Albert Einstein College of Medicine, Bronx, NY, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Minnesota, Minneapolis, MN 3:15 pm 1656. Predictors of Renal Failure in Systemic Lupus Erythematosus

Michelle Petri1, Hong Fang1 and Laurence S. Magder2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of Maryland, Baltimore, MD 3:30 pm 1657. CD4+CD25-Foxp3+ T Cells Are Indicative for Kidney Involvement in Systemic Lupus Erythematosus (SLE) Patients and Respond to Cyclophosphamide Therapy Michael Bonelli1, Lisa Goeschl1, Anastasiya Hladik1, Josef Smolen2 and Clemens Scheinecker1, 1Medical University of Vienna, Vienna, Austria, 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria 3:45 pm 1658. Serum Cytokines in Lupus Nephritis, Levels of IL-17 and IL-23 in Association to Histopathology and Response to Treatment Agneta Zickert1, Petra Amoudruz1, Johan Rönnelid2, Vivianne Malmström1 and Iva Gunnarsson1, 1Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 2Uppsala University, Uppsala, Sweden

W183a

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I


7 ,

W375d

Thieves’ Market: Show Me Your Best Cases

cP

2 0 1 1

2:45 pm 1660. Overexpression of Lupus-Susceptibility Gene HRES1/Rab4 Causes Enhanced Microautophagy and Defective Mitochondrial Macroautophagy (Mitophagy) in Lupus T Cells Tiffany Telarico1, Edward Doherty2, Brandon Clair1, Walter Malorni3 and Andras Perl4, 1SUNY Upstate Medical University, Syracuse, NY, 2SUNY Upstate, Syracuse, NY, 3Istituto Superiore di Sanita, Rome, Italy, 4Upstate Medical University, Syracuse, NY

MONDAY

2:30 pm 1659. HMGB1 Is An Important Mediator in Cutaneous Inflammation in Systemic Lupus Erythematosus (SLE) Deena A. Abdulahad, Johanna Westra, Gerda Horst, Pieter C. Limburg, Cees GM Kallenberg and Marc Bijl, University Medical Center Groningen, Groningen, Netherlands

3:45 pm 1664. Urinary Angiostatin As a Novel Biomarker in Lupus Nephritis Tianfu Wu, Chun Xie, Jie Han and Chandra Mohan, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX N o v e m b e r

Moderators: Vasileios C. Kyttaris, MD; Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA Judith A. James, MD, PhD; Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center; Oklahoma City, OK

3:30 pm 1663. Altered Soluble Mediators of Inflammation At Baseline in Individuals Who Subsequently Transition to Systemic Lupus Erythematosus: Early Studies From the Lupus Autoimmunity in Relatives (LAUREL) Study Melissa E. Munroe1, Joel M. Guthridge1, Diane L. Kamen2, Jill M. Norris3, Kathy L. Moser1, Timothy B. Niewold4, Gary S. Gilkeson5, David R. Karp6, Michael H. Weisman7, Mariko L. Ishimori8, Daniel J. Wallace9, John B. Harley10 and Judith A. James11, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Medical University of SC, Charleston, SC, 3University of Colorado Denver, Aurora, CO, 4 University of Chicago, Chicago, IL, 5Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 6UT Southwestern Medical Center, Dallas, TX, 7Cedars Sinai Med Ctr, Los Angeles, CA, 8Cedars Sinai Medical Ctr, Los Angeles, CA, 9Cedars-Sinai/UCLA, Los Angeles, CA, 10Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 11Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK

P/C

ARS

Moderators: Diane L. Kamen, MD, MS; Medical University of South Carolina; Charleston, SC Robert Spiera, MD; Hospital for Special Surgery; New York, NY 2:30 pm Image Competition Presentation Brian E. Daikh, MD, Rheumatology Associates, PC; Protland, ME 2:45 pm Unleashed Jeffrey Tsai, Royal Newcastle Centre, New Castle, New South Wales, Australia

3:00 pm 1661. Rapamycin Treatment Normalizes CD3 and CD4 Recycling in Lupus T Lymphocytes Tiffany Telarico1, Brandon Clair1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2Upstate Medical University, Syracuse, NY

2:57 pm Unexpected Outcomes Grace Ahn, Northwestern University, Chicago, IL

3:15 pm 1662. Lipid-Antigen Presentation by CD1d+ B Cells Is Essential for the Maintenance of Inkt Cells: Aberrant B Cells From Patients with Systemic Lupus Erythematosus Impair Inkt Cell Homeostasis Anneleen Bosma1, Azza Abdel-Gadir1, David A. Isenberg2, Claudia Mauri1 and E.C. Jury1, 1University College London, London, United Kingdom, 2University College London, London WC1E 6JF, United Kingdom

3:21 pm A Case of Neuropsychiatric Systemic Lupus Erythematosus... Or is it? Kimberly Legault, McMaster University, Hamilton, ON

3:09 pm Chronic Breast Abscess David A. Kandiah, University of Western Australia, Crawley, Australia

2011 Program Book

71

3:33 pm A Rash Diagnosis Sharon Dowell, University of Maryland School of Medicine, Baltimore, MD 3:45 pm Refractory Rheumatoid Pericarditis Kenneth J. Warrington, Mayo Clinic, Rochester, MN Upon completion of this session, participants should be able to: • describe unique and challenging diagnostic dilemmas • discuss the differential diagnosis • review methods used to identify the underlying diagnosis • develop a treatment plan specific to the underlying diagnosis


W476

Education and Community Programs

N o v e m b e r

7 ,

MONDAY

2 0 1 1

Moderators: Aimee Wiener, ARNP, MSN; Arthritis Autoimmune & Asthma; Daytona Beach, FL Laura D. Bilek, PhD, PT; University Nebraska Medical Center; Omaha, NE 2:30 pm 1665. Everyday Life and Rheumatoid Arthritis - Implications for Patient Education Tine Mechlenborg Kristiansen1, Jette Primdahl1, Rasmus Antoft2 and Kim Hørslev-Petersen1, 1University of Southern Denmark, Graasten, Denmark, 2Aalborg University, Aalborg, Denmark 2:45 pm 1666. One-Year Outcomes of Systemic Lupus Erythematosus (SLE) and/or Antiphospholipid Antibody (aPL) Positive Patients Enrolled in An Ongoing Cardiovascular Disease (CVD) Prevention Counseling Program (PCP) Aeshita Dwivedi1, Virginia Haiduc1, Monica C. Richey1, Sotiria Everett1, Lisa Konstantellis1, Ann R. Garment2, Hassan Ghomrawi1 and Doruk Erkan1, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medical Center, New York 3:00 pm 1667. Designing a Community-Based Intervention to Improve the Health of Medically-Underserved Women with Systemic Lupus Erythematosus Candace H. Feldman1, Patricia A. Fraser2, Bonnie L. Bermas1, Melanie Zibit1, Derrick J. Todd1, Paul R. Fortin3, Elena M. Massarotti1 and Karen H. Costenbader1, 1Brigham and Women’s Hospital, Boston, MA, 2Genzyme Corporation, Cambridge, MA, 3 Toronto Western Hospital, Toronto, ON 3:15 pm 1668. A Randomised Comparison of Interactive and Conventional Education to Increase Adherence with a Dutch Physical Therapy Practice Guideline for Hip and Knee Osteoarthritis Wfh Peter1, Ph van der Wees2, J. Verhoef3, Z. de Jong1, L. Vos1, Wkha Hilberdink4, M. Fiocco1 and Tpm VlietVlieland1, 1Leids University Medical Center, Leiden, Netherlands, 2The Royal Dutch Society of Physical Therapy (KNGF) Amsersfoort, CAPHRI Maastricht University, IQ Health Care, Nijmegen, Netherlands,

72

2011 Program Book

Hogeschool Leiden, Leiden, Netherlands, 4Paramedical Center for Rheumatology and Rehabilitation, Groningen, Netherlands 3

3:30 pm 1669. Development and Usability Testing of ANSWER: A WebBased Methotrexate Decision Aid for Patients with Rheumatoid Arthritis Linda C. Li1, Paul M. Adam2, Anne F. Townsend3, Diane Lacaille3, Charlene Yousefi3, Shawn Turnau1, Dawn Stacey4, Jessie McGowan5, Peter Tugwell6, Catherine L. Backman1 and ANSWER Team7, 1University of British Columbia, Vancouver, BC, 2Mary Pack Arthritis Centre, Vancouver, BC, 3Arthritis Research Centre of Canada, Vancouver, BC, 4University of Ottawa, Ottawa, ON, 5 University of Ottawa, Ottawa, ON, 6Institute of Population Hlth, Ottawa, ON, 7Vancouver & Ottawa 3:45 pm 1670. The Impact of An Evidence-Based Community-Delivered Exercise Program on Arthritis Symptoms and Health-Related Quality of Life Dina L. Jones, Jennifer L. Eicher, Matthew J. Gurka, Ruoxin Zhang, Melissa Himes, W. Lynn Harrington, Abhishek Vishnu and R. Turner Goins, West Virginia University, Morgantown, WV


W193a

Debate: Joints for Joints: Medical Marijuana is Useful for Treating Rheumatic Disease C PM Moderator: Atul A. Deodhar, MD, MRCP; Oregon Health & Science University; Portland, OR 2:30 pm Introduction 2:35 pm Con Stuart L. Silverman, MD; Cedars-Sinai Medical Center; Beverly Hills, CA 3:10 pm Pro Arthur Kavanaugh, MD; University of California San Diego; San Diego, CA 3:45 pm Question and Answer Upon completion of this session, participants should be able to: • discuss the immunomodulatory properties of cannabinoids • review the pros and cons of legalizing medical marijuana as a treatment modality • list the adverse effects of medical marijuana

W474b

Foot Structure, Footwear and Foot Pain - Translating Evidence into Practice C PM Moderator: Mary Wright, BS, OT; The Toledo Hospital; Toledo, OH

2:30 pm Biomechanical Mechanisms Contributing to Foot Pain Howard J. Hillstrom, PhD; Hospital Special Surgery; New York, NY

desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual.

3:00 pm Footwear and Foot Pain: Evidence from Population-Based Studies Marian T. Hannan, DSc, MPH; Hebrew SeniorLife & Harvard Medical School; Boston, MA

W179a

3:30 pm Designing Strategies to Prevent and Treat Foot Pain Smita Rao, PT, PhD; New York University; New York, NY

W179b

Upon completion of this session, participants should be able to: • d escribe mechanisms by which foot structure and footwear contribute to foot pain • e valuate recent evidence investigating factors contributing to foot pain • d esign and implement strategies to evaluate, prevent and treat foot pain

W194b

Rheumatic Disease Update: Paraneoplastic Rheumatic Disorders C

HALL F1 (Booth #789) The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Savient Pharmaceuticals, Inc. Please visit the Savient Pharmaceuticals, Inc. exhibit booth (1056) for more information or see page 304. Seating and light refreshments are subject to availability.

Understanding Crystal Burden and Treating Refractory Chronic Gout

ACR/ARHP WORKSHOPS 4:00 - 6:00 pm Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration

W178b

Systemic Sclerosis: How to Perform Skin Scores (227) f

Speaker: Daniel E. Furst, MD; University California Los Angeles Medical School; Los Angeles, CA

ACR CLINICAL SYMPOSIA 4:30 - 6:00 pm

W375d

Difficult to Treat Systemic Lupus Erythematosus: Case Studies C cP Moderators: Anisur Rahman, PhD; University College London; London, United Kingdom Susan Manzi, MD; Allegheny Singer Research Institute; Pittsburgh, PA

2 0 1 1

2:30 - 3:15 pm

Speakers: Howard J. Hillstrom, PhD; Hospital Special Surgery; New York, NY Kelly D. Krohn, MD; Lilly USA, LLC; Indianapolis, IN

7 ,

INNOVATION THEATER

Knee Braces and Foot Orthosis for Knee Osteoarthritis (226)

MONDAY

Upon completion of this session, participants should be able to: • d iscuss the risk of occult malignancy in patients with dermatomyositis, remitting seronegative symmetric synovitis with pitting edema, and polymyalgia rheumatica • d evelop a plan for investigating patients with rheumatic diseases that are thought to be paraneoplastic • d escribe the clinical features that help distinguish paraneoplastic from idiopathic rheumatic disorders

Speaker: Gregory C. Gardner, MD; University of Washington; Seattle, WA

N o v e m b e r

Moderator: Janalee Taylor, CNP; Cincinnati Children’s Hospital Medical Center; Cincinnati, OH Speaker: Yusuf Yazici, MD; New York University School of Medicine and New York University Hospital for Joint Diseases; New York, NY

Joint Injections (Shoulder and Wrist Prosthetics) (225)

4:30 pm Refractory Mucocutaneous Disease Victoria P. Werth, MD; University of Pennsylvania and Philadelphia, Veterans Affairs Medical Center; Philadelphia, PA 4:55 pm When Hydroxychloroquine is Not Enough David A. Isenberg, MD; University College London; London, United Kingdom 5:20 pm The Value of Biologic Registries: Where are we in Systemic Lupus Erythematosus? S�ren Jacobsen, DMSci; Copenhagen University Hospital; Copenhagen, Denmark Upon completion of this session, participants should be able to: • d escribe management strategies for hard to treat mucocutaneous disease • r eview the evidence for immunosuppressive therapy beyond hydroxychloroquine • d iscuss approaches to severe organ threatening lupus

W375b

Heart Disease and Rheumatoid Arthritis

C

Moderator: Jasvinder Singh, MD, MPH; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center; Birmingham, AL 2011 Program Book

73

4:30 pm Risk Factors for Cardiac Complications in Rheumatoid Arthritis: What Should the Clinician be Looking for? Joan M. Bathon, MD; Columbia University Medical Center; New York, NY 4:55 pm How to Improve Cardiac Health in Rheumatoid Arthritis Patients: Targets for Primary and Secondary Prevention Jon T. Giles, MD, MPH; Columbia University Medical Center; New York, NY 5:20 pm Cardioprotective Effects of Disease-modifying Anti-rheumatic Drugs William G. Dixon, PhD; Arthritis Research United Kingdom, The University of Manchester; Manchester, United Kingdom Upon completion of this session, participants should be able to: • describe the risk factors for heart disease in rheumatoid arthritis • explain strategies for improving cardiac health in rheumatoid arthritis patients • recognize cardio-protective effects of disease-modifying antirheumatic drugs

W375a 2 0 1 1

Total Hip and Knee Replacements 2011: An Update for Rheumatologists P/C PS

N o v e m b e r

7 ,

MONDAY

Moderator: Sharon L. Kolasinski, MD; Cooper Medical School; Camden, NJ 4:30 pm The Changing Demographics of End-Stage Hip and Knee Osteoarthritis Joanne M. Jordan, MD, MPH; University of North Carolina Thurston Arthritis Research Center; Chapel Hill, NC 4:55 pm Doc, What Should I Do About My Knee: Who Should Rheumatologists Be Referring for Arthroplasty Lisa A. Mandl, MD, MPH; Hospital for Special Surgery; New York, NY 5:20 pm Arthroplasty Outcomes 2011 Jeffrey N. Katz, MD; Brigham and Women’s Hospital; Boston, MA Upon completion of this session, participants should be able to: • describe how the population with end-stage osteoarthritis is changing • cite evidence-based reasons for appropriate referrals for total joint replacement • explain the short and long term outcomes in total joint replacement


W475a

Cytokines, Mediators, and Gene Regulation I Moderators: Alison Finnegan, PhD; Rush University Medical Center; Chicago, IL

74

2011 Program Book

Erik Lubberts, PhD; Rheumatology Erasmus Medical Centre; Rotterdam, Netherlands 4:30 pm 1671. The TNFα Induced Microrna-17/92 Cluster Promotes Synovial Fibroblast Aggressiveness by Repressing Key Signaling Pathway Inhibitors Michelle Trenkmann1, Matthias Brock1, Renate E. Gay1, Christoph Kolling2, Rudolf Speich3, Beat A. Michel1, Steffen Gay1 and Lars C. Huber3, 1Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 2Schultess Clinic, Zurich, Switzerland, 3Clinic and Policlinic for Internal Medicine, University Hospital Zurich, Zurich, Switzerland 4:45 pm 1672. MiR-323, a Novel MicroRNA in Rheumatoid Arthritis, Promotes the Activated Phenotype of Synovial Fibroblasts Mary Connolly1, Michelle Trenkmann1, Joanna Stanczyk1, Emmanuel Karouzakis1, Christoph Kolling2, Beat A. Michel1, Douglas J. Veale3, Ursula Fearon3, Renate E. Gay1, Steffen Gay1 and Caroline Ospelt1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Schultess Clinic, Zurich, Switzerland, 3Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland 5:00 pm 1673. The Role of Microrna-34 and Microrna-22 in Dendritic Cells and Monocyte Activation in Rheumatoid Arthritis Stefano Alivernini1, Derek S. Gilchrist2, Lynn Crawford2, Lucy Ballantine2, John Hunter3, Derek Baxter2, Barbara Tolusso4, Elisa Gremese4, Gianfranco Ferraccioli4, Iain B. McInnes2 and Mariola Kurowska-Stolarska2, 1University of Glasgow,, Glasgow, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3 Gartnavel General Hospital, Glasgow, United Kingdom, 4Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy 5:15 pm 1674. Niemann-Pick Type C2 Protein As a Negative Regulator of Innate Immunity: Inflammatory Cytokines and Eicosanoids Andrey Frolov1, Min Jiang2, Hua Dong3, Lihua Yang1, Rahul Matnani1, Bruce Hammock3 and Leslie J. Crofford1, 1University of Kentucky, Lexington, KY, 2University of Cincinnati, Cincinnati, OH, 3 University of California Davis, Davis, CA 5:30 pm 1675. A Novel CR3 Agonist Attenuates Pro-Inflammatory Signaling in Subjects with Common and Variant ITGAM Polymorphism, rs1143679 Manish Jain1, Michael Amato1, Jill P. Buyon1, Vineet Gupta2 and Robert M. Clancy1, 1New York University School of Medicine, New York, NY, 2Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miami, FL 33136, U.S.A., Miami, FL 5:45 pm 1676. Musculoskeletal Inflammation and Estrogens: T-Cell Leukemia 1A (TCL1A) Gene-Dependent Regulation of Inflammatory Cytokines Mohan Liu1, Liewei Wang1, Tim Bongartz1, John R. Hawse1, Svetomir N. Markovic1, Daniel J. Schaid1, Paul E. Goss2, James N. Ingle1 and Richard M. Weinshilboum1, 1Mayo Clinic, Rochester,

MN, 2Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA

W183c

Genetics, Genomics, and Proteomics Moderators: Robert M. Plenge, MD, PhD; Brigham and Women’s Hospital; Boston, MA Nan Shen, MD; Shanghai Ren Ji Hospital; Shanghai, China 4:30 pm 1677. An International Collaboration for the Genetic Fine Mapping of 8,000 Rheumatoid Arthritis Cases and 12,000 Controls Refines Associations to Known Loci, Indicates Multiple Independent Affects and Reveals Novel Associations Stephen Eyre1, John Bowes2, Anne Barton3, Soumya Raychaudhuri4, Christopher Amos5, Dorothee Diogo4, Annette T. Lee6, Lars Klareskog7, Leonid Padyukov8, Eli A. Stahl4, Peter K. Gregersen9, Robert M. Plenge4 and Jane Worthington1, 1 University of Manchester, Manchester, United Kingdom, 2 Arthritis Research UK, Manchester, United Kingdom, 3Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 4Brigham and Women’s Hospital, Boston, MA, 5 Houston, TX, 6Feinstein Institute Med Rsch, Manhasset, NY, 7 Karolinska Institutet, Stockholm, Sweden, 8Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 9Feinstein Institute Medical Reschearch, Manhasset, NY

7 , 2 0 1 1

5:30 pm 1681. Variation in the ICAM1-ICAM4-ICAM5 Locus Is Associated with Systemic Lupus Erythematosus Susceptibility in Multiple Ancestry Populations Kwangwoo Kim*1, and Elizabeth E. Brown* on behalf of PROFILE2, Chan-Bum Choi3, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS4, Jennifer A. Kelly5, Kenneth M. Kaufman5, So-Young Bang3, Hye-Soon Lee3, Taehyeung Kim1, Swapan Nath5, Betty P. Tsao6, Amr H. Sawalha5, Bernardo Pons-Estel on behalf of GENLES7, Timothy J. Vyse on behalf of SLEGEN8, Patrick M. Gaffney on behalf of LLAS25, Carl D. Langefeld9, John B. Harley10, Changwon Kang1, Robert P. Kimberly2 and Sang-Cheol Bae on behalf of Korean Investigators3, 1Korea Advanced Institute of Science and Technology, Daejeon, South Korea, 2University of Alabama at Birmingham, Birmingham, AL, 3Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 4PfizerUniversity of Granada-Junta de Andalucía, Grranada, Spain, 5 Oklahoma Medical Research Foundation, Oklahoma City, OK, 6 David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 7Sanatorio Parque, Rosario, Argentina, 8 King’s College London, Guy’s Hospital, London, United Kingdom, 9Wake Forest School of Medicine, Winston-Salem, NC, 10Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH 5:45 pm 1682. Major Histocompatibility Complex Association to Rheumatoid Arthritis Is Explained by Polymorphic Amino Acids In the Binding Grooves of HLA-DRB1, HLA-B, and HLA-DPB1 Soumya Raychaudhuri1, Eli A. Stahl1, Xiaoming Jia1, Lars Alfredsson2, Leonid Padyukov3, Katherine A. Siminovitch4, Lars Klareskog5, Jane Worthington6, Robert M. Plenge1, Peter K. Gregersen7 and Paul de Bakker1, 1Brigham and Women’s Hospital, Boston, MA, 2Institute of Environmental Medicine, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 4Mount Sinai Hospital, Toronto, ON, 5Karolinska 2011 Program Book

MONDAY

5:00 pm 1679. Genome Wide Association Study of Quantitative AntiCCP Level in RA Identified New Risk Variants Jing Cui1, Kimberly E. Taylor2, Henrik Kallberg3, Michael E. Weinblatt4, Lars Klareskog3, Lindsey A. Criswell5, Nancy A.

5:15 pm 1680. Genome-Wide Association Study of African Americans Implicates Multiple Lung and Inflammatory Disease-Associated Loci in Sarcoidosis Susceptibility Indra Adrianto1, Chee Paul Lin1, Jessica J. Hale1, Albert M. Levin2, Indrani Datta2, Ryan Parker1, Adam Adler1, Jennifer A. Kelly1, Kenneth M. Kaufman3, Christopher J. Lessard1, Kathy L. Moser4, Michael C. Iannuzzi5, Benjamin A. Rybicki2 and Courtney G. Montgomery1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Henry Ford Health System, Detroit, MI, 3 Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 4Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5SUNY Upstate Medical University, Syracuse, NY

N o v e m b e r

4:45 pm 1678. Genome-Wide Association Study of Dermatomyositis Reveals Shared Genetic Risk Factors with Other Autoimmune Diseases Frederick W. Miller1, Robert G. Cooper2, Jiri Vencovsky3, Lisa G. Rider4, Katalin Danko5, Lucy R. Wedderburn6, Ingrid E. Lundberg7, Lauren M. Pachman8, Ann M. Reed9, Steven R. Ytterberg9, Leonid Padyukov10, Albert Selva O’Callaghan11, Timothy Radstake12, David A. Isenberg13, Hector Chinoy14, William E. Ollier15, Terrance O’Hanlon16, Bo Peng17, Paul Scheet17, Annette T. Lee18, Janine Lamb14, Wei Chen17, Christopher Amos17, Peter K. Gregersen19 and Myositis Genetics Consortium20, 1NIH/NIEHS NIH Bldg 10 4-2330, Bethesda, MD, 2Hope Hospital, Salford, United Kingdom, 3Institute of Rheumatology, Prague 2, Czech Republic, 4 NIEHS NIH, Bethesda, MD, 5University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, 6University College London (UCL), London, United Kingdom, 7Karolinska Institutet, Stockholm, Sweden, 8Northwestern University Feinberg School of Medicine, Chicago, IL, 9Mayo Clinic, Rochester, MN, 10Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 11Hospital Universitari General Vall d’Hebron, Barcelona, Spain, 12Geert Groote Plein 8, Nymegen, Netherlands, 13University College London, London WC1E 6JF, United Kingdom, 14Manchester, United Kingdom, 15 Univ of Manchester Med School, Manchester, United Kingdom, 16 NIH, Bethesda, MD, 17Houston, TX, 18Feinstein Institute Med Rsch, Manhasset, NY, 19Feinstein Institute Medical Reschearch, Manhasset, NY, 20Bethesda

Shadick4, Robert M. Plenge6 and Elizabeth W. Karlson6, 1Brigham and Womens Hospital, Boston, MA, 2University of California, San Francisco, San Francisco, CA, 3Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 5University of California San Francisco, San Francisco, CA, 6Brigham and Women’s Hospital, Boston, MA

75

Institutet, Stockholm, Sweden, 6University of Manchester, Manchester, United Kingdom, 7Feinstein Institute Medical Reschearch, Manhasset, NY

W196a

Pediatric Rheumatology – Pathogenesis Moderators: Abbe N. de Vallejo, PhD; University of Pittsburgh School of Medicine, Children’s Hospital Pittsburgh; Pittsburgh, PA Sylvia Kamphuis, MD; Sophia Children’s Hospital, Erasmus University Medical Centre Rotterdam; Rotterdam, Netherlands

N o v e m b e r

7 ,

MONDAY

2 0 1 1

4:30 pm 1683. IL-10 Mainly Derived From Activated Hepatic T-Cells Suppresses Toll-Like Receptor 9-Mediated Macrophage Activation Syndrome Independent of Effects on the Pathogenic IL-12/Interferon-γ Axis Scott W. Canna1, Michele E. Paessler1, Portia Kreiger2, Katharine Slade1, Sheila Rao1 and Edward M. Behrens1, 1Childrens Hospital of Philadelphia, Philadelphia, PA, 2A.I. DuPont Hospital for Children, Wilmington, DE 4:45 pm 1684. Reduction of Annexin A5 Anticoagulant Activity in Children with Systemic Lupus Erythematosus Dawn M. Wahezi1, Norman T. Ilowite1, Xiao Xuan Wu2, Bas de Laat3, Jacob H. Rand2 and the APPLE Investigators4, 1Children’s Hospital Montefiore, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Maastricht University Medical Center, The Netherlands, 4Varies by Investigator 5:00 pm 1685. A Markedly Low-Level of Interferon-Induced Gene Expression Distinguishes Active Systemic Juvenile Idiopathic Arthritis Synovium From the Oligoarticular Subtype; A Difference That Cannot Be Attributed to Monocytic HypoResponsiveness to Interferon-γ Keith A. Sikora, Ndate Fall, Sherry Thornton and Alexei A. Grom, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 5:15 pm 1686. Major Histocompatibility Complex Class II Gene Cluster Harbors Systemic Juvenile Idiopathic Arthritis Susceptibility Locus Michael J. Ombrello1, Elaine Remmers1, Alexei A. Grom2, Wendy Thomson3, Alberto Martini4, Marco Gattorno5, Seza Ozen6, Ahmet Gul7, John F. Bohnsack8, Sampath Prahalad9, Andrew S. Zeft8, Elizabeth D. Mellins10, Colleen Satorius1, Jane L. Park10, Carl D. Langefeld11, Eleftheria Zeggini12, David N. Glass2, Susan D. Thompson2, Daniel L. Kastner1, Patricia Woo13 and International Childhood Arthritis Genetics Consortium14, 1National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3University of Manchester Medical School, Manchester, United Kingdom, 4IRCCS G Gaslini, Pediatria II, Reumatologia, Genova, Italy, 5Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy, 6Hacettepe University Faculty of Medicine, Ankara, Turkey, 7Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 8 University of Utah, Salt Lake City, UT, 9Emory Children’s Center, Atlanta, GA, 10Stanford University Medical Center, Stanford, CA, 11 Wake Forest School of Medicine, Winston-Salem, NC, 12The

76

2011 Program Book

Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 13 University College London Medical School, London, United Kingdom, 14Manchester, United Kingdom 5:30 pm 1687. Serum Follistatin-Like Protein 1 Is Elevated in Systemic Juvenile Idiopathic Arthritis and Is a Biomarker for Macrophage Activation Syndrome Mark Gorelik1, Ndate Fall2, Susan D. Thompson2, Alexei A. Grom2 and Raphael Hirsch3, 1Univ of Pittsburgh Med Ctr Children’s Hospital, Pittsburgh, PA, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA 5:45 pm 1688. Analysis of the Immunochip in a Large Cohort of Oligoand Polyarthritis Juvenile Idiopathic Arthritis Cases Confirms Previous and Identifies Novel Associations Joanna Cobb1, Anne Hinks1, John Bowes1, Marc Sudman2, Miranda C. Marion3, Mehdi Keddache4, Lucy R. Wedderburn5, Johannes Peter Haas6, David N. Glass2, Carl D. Langefeld3, Wendy Thomson1 and Susan D. Thompson2, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Wake Forest School of Medicine, WinstonSalem, NC, 4Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5University College London (UCL), London, United Kingdom, 6German Centre for Rheumatology in Children and Young People, GarmischPartenkirchen, Germany

W196b

Rheumatoid Arthritis Clinical Aspects: Clinical Features Moderators: Jonathan Kay, MD; University of Massachusetts Medical School; Worcester, MA Paul F. Dellaripa, MD; Brigham and Women’s Hospital; Boston, MA 4:30 pm 1689. Questionable Relevance of Subclinical Synovitis: First Degree Ultrasound Findings Are Not Associated with Pain, Swelling or Power Doppler Findings in Rheumatoid Arthritis (RA) Matthias Witt, Felix Mueller, Axel Nigg, Christiane Reindl, Nicola Stein, Stefan Mayer, Christina Gebhardt, Ariane Hammitzsch, Claudia Dechant, Hendrik Schulze-Koops and Mathias Grunke, University of Munich, Munich, Germany 4:45 pm 1690. Patient Reported Outcome Measures: Its Impact on Disease Activity and Adherence to Therapy in Inflammatory Arthritis Yasser M. El Miedany1, Deborah Palmer1 and Maha El Gaafary2, 1 Darent Valley Hospital, Dartford, United Kingdom, 2Ain Shams University, Cairo, Egypt 5:00 pm 1691. Influence of Autonomic Nervous Modulation on Rheumatoid Arthritis Olga Malysheva, Petra Baum, Anke Esber and Christoph G. Baerwald, University Hospital, Leipzig, Germany

5:15 pm 1692. Low Persistence of Serotype Specific Antibodies 1.5 Years After Vaccination with 7-Valent Pneumococcal Conjugate Vaccine in Patients with Established Arthritis Meliha C. Kapetanovic1, Tore Saxne2, Göran Jönsson3, Lennart T. Truedsson4 and Pierre Geborek2, 1Dept of Clinical Sciences Lund, Lund, Sweden, 2Dept of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, 3Dept of Clinical Sciences Lund, Section of Infectious Diseases, Lund, Sweden, 4Dept of Clinical Sciences Lund, Section of Microbiology, Immunology and Glycobiology, Lund, Sweden 5:30 pm 1693. Inverse Relationship Between 25-Hydroxyvitamin D and Parathyroid Hormone Observed in the General Population but Not Among Rheumatoid Arthritis Patients Anna R. Broder1, Amy Skversky2, Michal L. Melamed3, Jonathan N. Tobin4, John A. Hardin5 and Chaim Putterman3, 1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Albert Einstein College of Medicine/CDN Network, New York, NY, 5Albert Einstein Coll of Med, Bronx, NY

4:30 pm 1695. Double-Blind Randomized CAMERA-II Trial: Better Control of Disease and Erosive Joint Damage with Inclusion of Low-Dose Prednisone Into a MTX-Based Tight Control Strategy for Early Rheumatoid Arthritis Marije F. Bakker1, Johannes W.G. Jacobs1, Paco M.J. Welsing1, Suzanne M.M. Verstappen1, Janneke Tekstra1, Evelien Ton1, Monique A.W. Geurts2, Jacobine H. van der Werf3, G.A. van Albada-Kuipers4, Z.N. Jahangier5, Maaike J. van der Veen6, C.M. Verhoef7, Floris P.J.G. Lafeber1 and Johannes W.J. Bijlsma1, 1UMC Utrecht, Utrecht, Netherlands, 2St. Antonius hospital, Nieuwegein, Netherlands, 3Diakonessenhuis, Utrecht, Netherlands, 4Meander Medical Center, Amersfoort, Netherlands, 5Tergooi hospital, Hilversum, Netherlands, 6St. Jansdal hospital, Harderwijk, Netherlands, 7Flevohospital, Almere, Netherlands 4:45 pm 1696. Validation of Methotrexate First Strategy in Early Rheumatoid Arthritis: A Randomized, Double-Blind, 2-Year Trial James R. O’Dell1, Jeffrey R. Curtis2, Stacey Cofield3, S. Louis

2 0 1 1

Moderators: Josef Smolen, MD; Medical University of Vienna and Hietzing Hospital; Vienna, Austria Clifton O. Bingham III, MD; Johns Hopkins University; Baltimore, MD

7 ,

Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy: Existing Disease-modifying Antirheumatic Drugs – Tight Control, Induction and Drug Withdrawal

5:15 pm 1698. Treating Rheumatoid Arthritis to Target: Outcomes and Predictors in Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate, Methotrexate Alone, or Methotrexate Plus Subsequent Adalimumab Josef Smolen1, Roy M. Fleischmann2, Paul Emery3, Ronald F. van Vollenhoven4, Benoit Guerette5, Sourav Santra6, Hartmut Kupper7, Laura Redden6, Benjamin Wolfe6 and Arthur Kavanaugh8, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2MCRC, University of Texas, Dallas, TX, 3Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 4The Karolinska Institute, Stockholm, Sweden, 5Abbott, Rungis, France, 6Abbott, Abbott Park, IL, 7 Abbott GmbH & Co KG, Ludwigshafen, Germany, 8University of California San Diego, San Diego, CA 5:30 pm 1699. Withdrawal of Adalimumab in Early Rheumatoid Arthritis Patients Who Attained Stable Low Disease Activity with Adalimumab Plus Methotrexate: Results of a Phase 4, DoubleBlind, Placebo-Controlled Trial Arthur Kavanaugh1, P. Emery2, Roy Fleischmann3, Ronald F. van Vollenhoven4, Karel Pavelka5, Patrick Durez6, Benoit Guerette7, Sourav Santra8, Laura Redden8, Hartmut Kupper9, Theresa Peterson8 and Josef Smolen10, 1University of California San Diego, La Jolla, CA, 2Leeds Teaching Hospital, Leeds, United Kingdom, 3 University of Texas Southwestern Medical Center, Dallas, TX, 4 The Karolinska Institute, Stockholm, Sweden, 51Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 6Université Catholique de Louvain, Brussels, Belgium, 7 Abbott, Rungis, France, 8Abbott, Abbott Park, IL, 9Abbott, Ludwigshafen, Germany, 10Medical University of Vienna and Hietzing Hospital, Vienna, Austria 2011 Program Book

MONDAY

W375c

5:00 pm 1697. Efficacy of An Induction Therapy with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy in Recent Onset Rheumatoid Arthritis – An Investigator Initiated Randomized Controlled Trial Jacqueline Detert1, Hans Bastian1, Joachim Listing2, Anja Weiss2, Siegfried Wassenberg3, Anke Liebhaber4, Karin Rockwitz5, Rieke Alten6, Klaus Krüger7, Rolf Rau8, Christina Simon1, Eva Gremmelsbacher1, Tanja Braun1, Bettina Marsmann2, Vera Höhne-Zimmer1, Karl Egerer1, Frank Buttgereit1 and Gerd R. Burmester1, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Evangelisches Fachkrankenhaus, Ratingen, Germany, 4 Rheumatologic Practice, Halle, Germany, 5Rheumatologic Practice, Goslar, Germany, 6Rheumatology Schlossparkklinik, Berlin, Germany, 7Practice Center, München, Germany, 8 Düsseldorf, Germany N o v e m b e r

5:45 pm 1694. Do Rheumatoid Arthritis Patients Expect Less From Total Knee Arthroplasty? Hassan Ghomrawi1, Lisa A. Mandl2, Beverly Johnson2, Michael Alexiades2 and Susan M. Goodman2, 1Weil-Cornell Medical College, NYC, NY, 2Hospital for Special Surgery, New York, NY

Bridges Jr.4, Ted R. Mikuls5 and Larry W. Moreland6, 1Univ of Nebraska Med Ctr, Omaha, NE, 2Univ of Alabama-Birmingham, Birmingham, AL, 3Univ of Alabama at Birmingham,, Birmingham, AL, 4Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Omaha VA and University of Nebraska, Omaha, NE, 6University of Pittsburgh, Pittsburgh, PA

77

5:45 pm 1700. Successful Dose De-Escalation of Infliximab in Rheumatoid Arthritis Patients with Stable Low Disease Activity and Treatment Aatke van der Maas1, Alfons den Broeder1, Frank H.J. van den Hoogen2, Piet Van Riel3 and Bart J.F. van den Bemt1, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 3 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

W181b

Spondylarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology

N o v e m b e r

7 ,

MONDAY

2 0 1 1

Moderators: Judith A. Smith, MD, PhD; University of Wisconsin; Madison, WI Nigil Haroon, MBBS, MD, DM; Toronto Western Hospital, University of Toronto; Toronto, ON, Canada 4:30 pm 1701. A Reverse Interferon-γ Signature Is Shared by CD103+CD4+ Dendritic Cells From HLA-B27 Transgenic Rat and Macrophages From Ankylosing Spondylitis Patients Ingrid Fert1, Nicolas Cagnard1, Simon Glatigny1, Franck Letourneur1, Sebastien Jacques1, Luiza Krause1, Robert A. Colbert2, Gilles Chiocchia1 and Maxime A. Breban3, 1Institut Cochin, 75014 Paris, France, 2NIAMS NIH, Bethesda, MD, 3 Hopital Ambroise Pare, Boulogne, France 4:45 pm 1702. Regional Differences in Bone Metabolism in the DIP Joint in Psoriatic Arthritis Compared to Osteoarthritis Support the Concept of An Integrated Bone-Enthesis Nail Apparatus - A High-Resolution 18f-Fluoride Positron Emission Tomography Study Ai Lyn Tan1, Steven Tanner2, Michael Waller3, Elizabeth Hensor4, Alison Burns3, Alan Jeavons2, Robert Bury3, Paul Emery5 and Dennis McGonagle1, 1University of Leeds and Leeds Teaching Hospitals, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3Leeds Teaching Hospitals, Leeds, United Kingdom, 4NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 5Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom 5:00 pm 1703. Evidence That HLA-B27-Induced Endoplasmic Reticulum (ER) Stress Produces Pro- and Anti-Osteoclastogenic Cytokines in Rats with Spondyloarthritis-Like Disease Gerlinde Layh-Schmitt, Eva Yang and Robert A. Colbert, NIAMS NIH, Bethesda, MD 5:15 pm 1704. Identification of a Unique Subset DC-STAMP+ (Dendritic Cell-Specific Transmembrane Protein) T Cells with a Th17 Signature in Psoriatic Arthritis (PsA) Patients Yahui Grace Chiu1, Edward M. Schwarz1, Wojciech Wojciechowski1, Ben Panepento1, Igor Kuzin1, Tim Bushnell1, Sharon Moorehead1, Rick Barrett1 and Christopher T. Ritchlin2, 1 University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

78

2011 Program Book

5:30 pm 1705. The Role of Gut Microflora and Autoreactive CD4+ T Cells in the Development of Spondyloarthritis and Inflammatory Bowel Disease in Beta-Glucan-Treated SKG Mice Merja Ruutu1, Jared Velasco1, Daniel Aguirre2, Helen Benham1, Mark Morrison2, Michael McGuckin3 and Ranjeny Thomas1, 1Univ of Queensland, Brisbane, Australia, 2CSIRO, Brisbane, Australia, 3 Mater Medical Research Institute, Brisbane, Australia 5:45 pm 1706. Transcriptomic Analysis of Monocytes and MonocyteDerived Dendritic Cells (MD-DCs) Reveals Several Genes Differentially Regulated Between Ankylosing Spondylitis (AS) Patients and Healthy Controls Alice Talpin1, Nelly Bonilla1, Félicie Costantino2, Franck Letourneur1, Sebastien Jacques1, Florent Dumont1, Henri-Jean Garchon2, Maxime A. Breban3 and Gilles Chiocchia1, 1Institut Cochin, 75014 Paris, France, 2Institut Cochin, Paris, France, 3 Hopital Ambroise Pare, Boulogne, France

W183a

Systemic Lupus Erythematosus – Clinical Aspects: General Moderators: Maureen A. McMahon, MD; University of California Los Angeles David Geffen School of Medicine; Los Angeles, CA Derrick J. Todd, MD, PhD; Brigham and Women’s Hospital; Boston, MA 4:30 pm 1707. Favorable Prognosis in a Large, Prospective Multicenter Study of Lupus Pregnancies Jill P. Buyon1, Lamya Garabet2, Mimi Kim3, Emily R. Reeves2, Marta M. Guerra2, Michael D. Lockshin4, Carl A. Laskin5, Ware Branch6, Lisa R. Sammaritano2, Michelle Petri7, Joan T. Merrill8, Allen D. Sawitzke9 and Jane E. Salmon10, 1New York University School of Medicine, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4 Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY, 5University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, 6 Univ of Utah, Salt Lake City, UT, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8Oklahoma Medical Research Foundation, Oklahoma City, OK, 9University of Utah Medical Ctr, Salt Lake City, UT, 10Hospital for Special Surgery, Weill Cornell Medical College, New York, NY 4:45 pm 1708. Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus Michelle Petri1, Ana-Maria Orbai1, Graciela S. Alarcón2, Caroline Gordon3, Joan T. Merrill4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Hong Fang1, Systemic Lupus International Collaborating Clinics (SLICC)22 and Laurence S. Magder23, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Alabama at Birmingham,

Birmingham, AL, 3University of Birmingham, Birmingham, United Kingdom, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Toronto Western Hospital, Toronto, ON, 6The University of Manchester, Manchester, United Kingdom, 7University College London, London WC1E 6JF, United Kingdom, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden, 11Northwestern University, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Nova Scotia Rehabilitation Center, Halifax, NS, 14University Health Network/Mount Sinai Hospital, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22Chicago, 23University of Maryland, Baltimore, MD

4:45 pm 1714. Developing a Disease Activity and Therapeutic Response Index in Connective Tissue Disease Related Interstitial Lung Disease: Initial Results of a Delphi Exercise Lesley Ann Saketkoo1, Doerte Huscher2, Dinesh Khanna3, Paul F. Dellaripa4, Kevin Flaherty3, Eric L. Matteson5, Chester V. Oddis6, Kristine Phillips7, Athol U. Wells8, Christopher P. Denton9, Oliver Distler10, Otylia M. Kowal-Bielecka11, David Pittrow12, Romy Christmann13, Nora Sandorfi14, Vibeke Strand15, Kevin K. Brown16 and James R. Seibold17, 1LSU Health Science Center, New Orleans, LA, 2Charité Universitaetsmedizin, Dept of Rheumatology and Clinical Immunology and The German Rheumatism Research Centre, Berlin, Germany, 3University of Michigan, Ann Arbor, MI, 4Brigham & Womens Hospital, Boston, MA, 5Mayo Clinic, Rochester, MN, 6University of Pittsburgh, Pittsburgh, PA, 7University of Michigan Medical School, Ann Arbor, MI, 8Royal Brompton Hospital, United Kingdom, 9UCL Medical School, London, United Kingdom, 10University Hospital Zurich, Zurich, Switzerland, 11Medical Univ in Bialystok, Bialystok, Poland, 12Institute of Clinical Pharmacology - University of Dresden, Dresden, Germany, 13Boston University, Boston, MA, 14 Thomas Jefferson Univ Med Coll, Philadelphia, PA, 15Stanford University, Palo Alto, CA, 16National Jewish Hospital, Denver, CO, 17 Scleroderma Research Consultants LLC, Avon, CT

2 0 1 1

5:45 pm 1712. Systemic Lupus Erythematosus Disease Activity During a 12-Month Period and Risk of New Onset Organ System Damage and/or Death: Observations in a Single US Academic Medical Center Deanna Hill1, Peter Egger2, Qinggong Fu1, Hong Fang3 and Michelle Petri3, 1GlaxoSmithKline, Collegeville, PA, 2 GlaxoSmithKline, Stockley Park, United Kingdom, 3Johns Hopkins University School of Medicine, Baltimore, MD

4:30 pm 1713. A Clinicopathologic Study of Retroperitoneal Fibrosis and Its Association with Immunoglobulin G4-Related Disease Arezou Khosroshahi, Robert P. Hasserjian, Nisha I. Sainani, Vikram Deshpande and John H. Stone, Massachusetts General Hospital, Boston, MA

7 ,

5:30 pm 1711. The Intrathecal Production of IL-6, IL-8, IP-10, MCP-1 and G-CSF Increases More Highly Than the Serum Production in Patients with Central Neuropsychiatric Lupus Erythematosus Taku Yoshio1, Hiroshi Okamoto2, Kazuhiro Kurasawa3, Yoshiaki Dei4, Shunsei Hirohata5 and Seiji Minota6, 1Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigiken, Japan, 2Minami-Otsuka Clinic, Tokyo, Japan, 3Dokkyo Medical University, Mibu-machi, Tochigi-ken, Japan, 4Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi-ken, Japan, 5 Kitasato University School of Medicine, Sagamihara, Japan, 6 Jichi Medical University, Tochigi, Japan

Moderators: Murray Baron, MD; Jewish General Hospital; Montreal, QC, Canada Tracy M. Frech, MD; University of Utah School of Medicine; Salt Lake City, UT

5:00 pm 1715. Better Survival in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Patients Enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry Lorinda Chung1, Robyn T. Domsic2, Bharathi Lingala3, Virginia D. Steen4 and PHAROS Investigators5, 1stanford Univ Medical Center, Palo Alto, CA, 2University of Pittsburgh, Pittsburgh, PA, 3 Stanford, 4Georgetown Univ Medical Center, Washington, DC, 5 Washington, DC 5:15 pm 1716. Clinical and Hemodynamic Features of Scleroderma Patients with Pulmonary Venous Hypertension Versus Pulmonary Arterial Hypertension Jessica K. Gordon1, Kamini Doobay2, Evelyn Horn3, Marcy B. Bolster4, Lee S. Shapiro5, Dinesh Khanna6, Tracy M. Frech7, Kara Fields2, Chris T. Derk8, Laura K. Hummers9, Maureen D. Mayes10, Virginia D. Steen11 and PHAROS Investigators12, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, 3Weill-Cornell Medical College, New York, NY, 4Medical Univ of South Carolina, Charleston, SC, 5Albany, NY, 6University of 2011 Program Book

MONDAY

5:15 pm 1710. The Resting State and Task Based Functional Magnetic Resonance Imaging Study in Non-Neuropsychiatric Systemic Lupus Erythematosus Yongfei Fang and Qinghua Zou, Chongqing Southwest Hospital, Shapingba, China

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics II

N o v e m b e r

5:00 pm 1709. Rapid Surges of Anti-dsDNA Titers Predict Severe Clinical Flares in Systemic Lupus Erythematosus Nancy Pan1, Isabelle Amigues2, Rolando Duculan3, Faiza Aziz4, Stephen L. Lyman1, Mary K. Crow1 and Kyriakos A. Kirou1, 1 Hospital for Special Surgery, New York, NY, 2Hospital Saint Joseph Saint Luc, Paris, France, 3Mary Kirkland Center for Lupus Research-Hospital for Special Surgery, New York, NY, 4Interfaith Medical Center, Brooklyn, NY

W471b

79

Michigan, Ann Arbor, MI, 7University of Utah School of Medicine, SLC, UT, 8Jefferson Medical College, Philadelphia, PA, 9Johns Hopkins University, Baltimore, MD, 10University of Texas Health Science Center at Houston, Houston, TX, 11Georgetown Univ Medical Center, Washington, DC, 12Washington

W184d

5:30 pm 1717. Validation of Potential Classification Criteria for Systemic Sclerosis Sindhu R. Johnson1, Jaap Fransen2, Dinesh Khanna3, Thomas A. Medsger4, Christine A. Peschken5, Patricia Carreira6, Gabriela Riemekasten7, Alan G. Tyndall8, Marco Matucci-Cerinic9, Murray Baron10, Frank Van den Hoogen11 and Janet E. Pope12, 1Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, 2The Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3University of Michigan, Ann Arbor, MI, 4 Univ of Pittsburgh, Pittsburgh, PA, 5University of Manitoba, Winnipeg, MB, 6Hospital Universitario 12 de Octubre, Madrid, Spain, 7Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 8University of Basel, Basel, Switzerland, 9University of Florence, Firenze, Italy, 10Jewish General Hospital, Montreal, QC, 11Nijmegen, Netherlands, 12St. Joseph’s Health Care, University of Western Ontario, London, ON

W186c

5:45 pm

N o v e m b e r

7 ,

MONDAY

2 0 1 1

1718. Ultrasonographic Hand Features in Systemic Sclerosis and Correlates with Clinical, Biological and Radiographic Findings Muriel Elhai1, Henri Guerini2, Ramin Bazeli2, Jerome Avouac1, Veronique Freire2, jean-Luc Drape3, Andre Kahan1 and Yannick Allanore1, 1Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, 2Radiology B, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, 3Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France

ACR MEET THE PROFESSOR SESSIONS 4:30 - 6:00 pm Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual. *Sessions denoted with an asterisk were sold out as of September 12.

W187a

Adult Inflammatory Myopathy (051) Speaker: Mary E. Cronin, MD; Medical College of Wisconsin; Milwaukee, WI

W185d

Central Nervous System Vasculitis (052) Speaker: Rula Hajj-Ali, MD; Cleveland Clinic Foundation; Cleveland, OH

80

2011 Program Book

Controversies in Sjögren’s Syndrome (053) Speaker: Alan N. Baer, MD; Johns Hopkins University; Baltimore, MD

Fibromyalgia (054)

PM

Speaker: Manuel Martinez-Lavin, MD; National Cardiology Institute; Mexico City, Mexico

W187c

Inflammatory Eye Disease/Uveitis (055) Speaker: James T. Rosenbaum, MD; Oregon Health & Science University; Portland, OR

W185a

Pediatric Systemic Lupus (056)

P

Speaker: ML Becker, MD, MSCE; Children’s Mercy Hospital; Kansas City, MO

W185bc

Reactive Arthritis: An Update (057) Speaker: Atul A. Deodhar, MD; Oregon Health & Science University; Portland, OR

W187b

*Rheumatoid Arthritis: Biological Agents (058) Speaker: Larry W. Moreland, MD; University of Pittsburgh; Pittsburgh, PA

W186a

*Systemic Lupus Erythematosus: Novel Treatments (059) Speaker: Robert G. Lahita, MD, PhD; Newark Beth Israel Hospital; Newark, NJ

W186b

Vasculitis: An Update (060) Speaker: Paul A. Monach, MD, PhD; Boston University; Boston, MA

ACR SPECIAL SESSIONS 4:30 - 6:00 pm

W470b

ILAR Global Health Project

P/C

Moderator: Luis R. Espinoza, MD; Louisiana State University Medical Center; New Orleans, LA 4:30 pm ILAR: Past, Present and Future Adewale O. Adebajo, MD; Academic Rheumatology Group, D; Sheffield, United Kingdom Mark Andrejeski; Executive Vice President, American College of Rheumatology; Atlanta, GA Luis R. Espinoza, MD; Louisiana State University Medical Center; New Orleans, LA

5:00 pm ILAR COPCORD Repository Arvind Chopra, MD, DNB; CRD-Hermes Doctor House; Pune, India 5:30 pm Reinstatement of Clinical Anatomy as Basic Knowledge for the Rheumatologist in Latin America Pablo Villasenor Ovies, MD; Instituto Nacional de Rehabilitación; Ciudad de México, Mexico Upon completion of this session, participants should be able to: • d escribe the rationale for ILAR’s reorganization • s tate ILAR’s mission and goals • e xplain the funding opportunities for programs that lead to progress in the practice and education of rheumatology in countries where there is an exceptional need

W474a

Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives c/r Moderators: Nancy D. Kim, MD; Massachusetts General Hospital; Boston, MA Peter A. Nigrovic, MD; Brigham and Women’s Hospital; Boston, MA

5:40 pm Panel Discussion Upon completion of this session, participants should be able to: • e xplain the nature of Clinical and Translational Science Award centers and how they may be used to support research efforts through subject enrollment, specimen collection, laboratory analysis, and biostatistical services • identify funding mechanisms available to early career investigators through Clinical and Translational Science Award centers • d escribe non- Clinical and Translational Science Award mechanisms for research support through the National Institutes of Health National Center for Research Resources

5:00 pm From Studies of Pre-Clinical Rheumatoid Arthritis Towards Prevention of the Disease Paul P. Tak, MD, PhD; Academic Medical Centre/University of Amsterdam; Amsterdam, Netherlands 5:30 pm Panel Discussion Hani S. El-Gabalawy, MD; University of Manitoba; Winnipeg, MB, Canada V. Michael Holers, MD; University of Colorado School of Medicine; Aurora, CO Elizabeth W. Karlson, MD, MPH; Brigham and Women’s Hospital; Boston, MA Lars Klareskog, MD, PhD; Karolinska Institutet; Stockholm, Sweden Paul P. Tak, MD, PhD; Academic Medical Centre /University of Amsterdam; Amsterdam, Netherlands

2 0 1 1

5:20 pm The National Institutes of Health National Center for Research Resources: Who we are and How we can Help You Anthony Hayward, MD, PhD; National Institutes of Health; Bethesda, MD

4:30 pm What Do Longitudinal Cohort Studies Tell Us About Development of Rheumatoid Arthritis Among High Risk Populations? Elizabeth W. Karlson, MD, MPH; Brigham and Women’s Hospital; Boston, MA

7 ,

5:10 pm How I Used the Clinical and Translational Science Award in My Research Tim Bongartz, MD, MS; Mayo Clinic; Rochester, MN Megan E. B. Clowse, MD, MPH; Duke University Medical Center; Durham, NC

Moderators: Vivian Bykerk, MD; Brigham and Women’s Hospital; Boston, MA Karim Raza, MD, PhD; Medical Research Council/Center for Immune Regulation, University of Birmingham; Birmingham, United Kingdom

Upon completion of this session, participants should be able to: • define the different stages in the development of rheumatoid arthritis, with focus on description and definition of the preclinical phases of disease • describe the interplay of family history, genes, and environmental factors in the development of autoimmunity • review data on the biologic processes in preclinical autoimmunity • review the outline of a clinical trial in preclinical rheumatoid arthritis


W194b

ACR/ARHP Combined Rehabilitation Abstract Session Moderator: Allan C. Gelber, MD; Johns Hopkins University; Baltimore, MD Mary Wright, BS, OT; The Toledo Hospital; Toledo, OH 4:30 pm 1719. Effectiveness of Facet Joint Infiltration in Low Back Pain Luiza H. C. Ribeiro, Rita V. Furtado, Monique Konai, Andre Rosenfeld, Ana B. Andreo and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil 2011 Program Book

MONDAY

4:50 pm Using the Clinical and Translational Science Award in your Rheumatology Research Gary S. Firestein, MD; University of California San Diego School of Medicine; La Jolla, CA

The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives c/r

N o v e m b e r

4:30 pm Introduction to the Clinical and Translational Science Award Bruce N. Cronstein, MD; New York University Medical Center; New York, NY

W190a

81

4:45 pm 1720. Health Outcomes From a Residential Multidisciplinary Rehabilitation Program for Musculoskeletal Conditions: A Ten Year Observational Study Peter B. B. Jones1 and Peter Sharplin2, 1Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 2QE Health, Rotorua, New Zealand

N o v e m b e r

7 ,

MONDAY

2 0 1 1

5:00 pm 1721. Risk Factors for Restricting Back Pain in CommunityLiving Older Persons Una E. Makris1, Liana Fraenkel2, Ling Han3, Linda Leo-Summers3 and Thomas M. Gill4, 1Yale, New Haven, CT, 2Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 3Yale University School of Medicine, New Haven, CT, 4Yale University School of Medicine, New Haven 5:15 pm 1722. The Effectiveness of Exercise with and without Manual Therapy for Hip Osteoarthritis: A Multi-Centre Randomised Controlled Trial Helen P. French1, Tara Cusack2, Aisling Brennan3, Aoife Caffrey4, Vanessa Cuddy5, Martina Fitzpatrick4, Oliver M. FitzGerald6, Clare Gilsenan5, David Kane3, Paul G. O’Connell5, Breon White7 and G M. McCarthy7, 1Royal College of Surgeons in Ireland, Dublin 2, Ireland, 2University College Dublin, Dublin, Ireland, 3 Adelaide, Meath hospital Dublin (incorporating the National Children’s hospital), Dublin 24, Ireland, 4St. Vincent’s University Hospital, Dublin 4, Ireland, 5Beaumont Hospital, Dublin 9, Ireland, 6St. Vincent’s University Hospital, Dublin, Ireland, 7Mater Misericordiae University Hospital, Dublin 7, Ireland 5:30 pm 1723. Exercise Training Reverts Chronotropic Incompetence and Improves Heart Rate Recovery After Exercise in Women with Systemic Lupus Erythematosus Danilo M. L. Prado1, Renata Miossi2, Thalita Dassouki1, Luiz A. Perandini1, Fernanda R. Lima1, Bruno Gualano3, Ana Lucia S. Pinto1, Eloisa Bonfa4 and Hamilton Roschel3, 1University of Sao Paulo, Rheumatology Division, LACRE, Sao Paulo, Brazil, 2 University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, 3University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil, 4Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil 5:45 pm 1724. Is Knee Pain Relevant for Meeting Physical Activity Guidelines Among People with Knee OA Who Can Walk Already Walk At a Moderate Intensity? the Multicenter Osteoarthritis Study Daniel K. White1, David T. Felson1, Yuqing Zhang1, K. Douglas Gross2, Jingbo Niu1, Michael C. Nevitt3, C.E. Lewis4, James Torner5 and Tuhina Neogi6, 1Boston University School of Medicine, Boston, MA, 2MGH Institute of Health Professions, Boston, MA, 3University of California-San Francisco, San Francisco, CA, 4 University of Alabama, Birmingham City, AL, 5University of Iowa, Iowa City, Iowa City, IA, 6Boston University, Boston, MA

82

2011 Program Book


W192b

ACR REF Marshall J. Schiff, MD, Memorial Lectureship: Multicenter Orthopaedic Outcomes Network – A Prospective Longitudinal Cohort of Anterior Cruciate Ligament Reconstruction Outcomes c/r

Moderator: David I. Daikh, MD, PhD; University of California San Francisco/Veterans Affairs Medical Center; San Francisco, CA Speaker: Kurt P. Spindler, MD ; Vanderbilt University; Nashville, TN Upon completion of this session, participants should be able to: • describe strengths and weaknesses of prospective longitudinal cohort studies • learn modifiable predictors of clinically relevant anterior cruciate ligament outcomes • explain the rationale behind the design and development of the Multicenter Orthopaedic Outcomes Network 5:30 pm 1725. In Vivo Effect of Bone-Specific EphB4 Overexpression In Mice On Subchondral Bone and Cartilage During Osteoarthritis Gladys Valverde-Franco1, Mohit Kapoor1, David Hum1, Koichi Matsuo2, Bertrand Lussier3, Jean Pierre Pelletier1, Johanne M. Pelletier1, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital; Montreal, QC, Canada, 2Laboratory of Cell and Tissue Biology, School of Medicine, Keio University; Tokyo, Japan, 3Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal; Saint-Hyacinthe, QC, Canada 5:45 pm 1726. Lysyl Hydroxylase 2b Is Strongly Induced During Experimental OA and the Potential Cause of Persistent Synovial Fibrosis Dennis F.G. Remst1, Esmeralda N. Blaney Davidson1, Elly L. Vitters1, Ruud A. Bank2, Wim B. van den Berg1, Peter M. van der Kraan1, 1Radboud University Nijmegen Medical Centre; Nijmegen, 2University of Groningen; Groningen, Netherlands


W195

ARHP Health Services Research Moderators: Donald R. Miller, PharmD; North Dakota State University; Fargo, ND Linda J. Pine, PharmD; Pine Consulting Services, LLC; Atlanta, GA 4:30 pm 1727. Organization of Care Delivery for People with Arthritis: Models and Processes A. M. Davis1, C. Cott2, L. Li3, M. Landry4, A. Jones5, R. Wong6, C. Frank7, L. Bergeron8, R. Birtwhistle9 and E. M. Badley10, 1Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto,

Toronto, ON, 2Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Physical Therapy and Rehabilitation Science, University of Toronto, Toronto, ON, 3 Arthritis Centre of Canada and Department of Physical Therapy, University of British Columbia, Vancouver, BC, 4Departments of Physical Therapy and Rehabilitation Science, University of Toronto, Toronto, ON, 5Departments of Physical Therapy and School of Public Health, University of Alberta, Edmonton, AB, 6 Health Care and Outcomes Research, Toronto Western Research Institute, Toronto, ON, 7Alberta Bone and Joint Institute and Department of Surgery, University of Calgary, Calgary, AB, 8 Canadian Arthritis Patient Alliance, Ottawa, ON, 9Centre for Studies in Primary Care and Family Medicine and Community Health and Epidemiology, Queen’s University, Kingston, ON, 10 Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON 4:45 pm 1728. Capturing the Patient Experience: Patient Advisory Committee At Rush University Rheumatologists Laura Wright1 and John O’Toole2, 1Rush University Medical Center, Chicago, IL, 2Rush, Chicago, IL

Disease Modifying Osteoarthritis Drugs, Glucosamine/ Chondroitin and Non-pharmacologic Treatment of Osteoarthritis C Moderator: Donna K. Everix, MPA, BS, PT; Mills Peninsula Heallth Services; Burlingame, CA Speakers: Carol A. Oatis, PhD, PT; Arcadia University; Glenside, PA David T. Felson, MD, MPH; Boston University School of Public Health; Boston, MA Marc Hochberg, MD, MPH; University of Maryland School of Medicine; Baltimore, MD

2 0 1 1

Upon completion of this session, participants should be able to: • list multiple treatment methodologies for osteoarthritis • describe current research and recommendations for treatment of osteoarthritis • explain benefits and concerns for each type of osteoarthritis treatment

7 ,

5:30 pm 1731. Evaluation of Interprofessional Patient-Centred Collaborative Practice Behaviour and Perceptions Following An Intensive Continuing Education Development Initiative in Arthritis Care Katie Lundon1, Carol Kennedy1, Kelly Warmington1, Linda Rozmovits2, Leslie J. Soever3, Laura A. Passalent4, Sydney C. Lineker5, Rachel Shupak6, Rayfel Schneider7 and Lynne Sinclair8, 1st. Michael’s Hospital, Toronto, ON, 2Consultant, Toronto, ON, 3 Mount Sinai Hospital, Toronto, ON, 4University Health Network, Toronto, ON, 5The Arthritis Society, Toronto, ON, 6St. Michaels Hospital, Toronto, ON, 7Hospital for Sick Children, University of Toronto, Toronto, ON, 8Toronto Rehabiltation Institute, Toronto, ON

W474b

MONDAY

5:15 pm 1730. Patient Satisfaction with a New Healthcare Provider: Advanced Clinician Practitioner in Arthritis Care ProgramTrained Clinicians Kelly Warmington1, Carol Kennedy1, Sydney C. Lineker2, Leslie J. Soever3, Laura A. Passalent4, Katie Lundon1, Rachel Shupak1 and Rayfel Schneider5, 1st. Michael’s Hospital, Toronto, ON, 2The Arthritis Society, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON, 4University Health Network, Toronto, ON, 5Hospital for Sick Children, University of Toronto, Toronto, ON


N o v e m b e r

5:00 pm 1729. The Impact of Advanced Clinician Practitioner in Arthritis Care Program-Trained Extended Role Practitioners on Health Care Delivery: A Two Year Prospective Study Carol Kennedy1, Kelly Warmington1, Leslie J. Soever2, Laura A. Passalent3, Sydney C. Lineker4, Katie Lundon1, Rachel Shupak1 and Rayfel Schneider5, 1st. Michael’s Hospital, Toronto, ON, 2 Mount Sinai Hospital, Toronto, ON, 3University Health Network, Toronto, ON, 4The Arthritis Society, Toronto, ON, 5Hospital for Sick Children, University of Toronto, Toronto, ON

5:45 pm 1732. An Overview of Clinical Performance by Advanced Clinician Practitioner in Arthritis Care Program-Trained Therapists: A Two-Year Prospective Study Laura A. Passalent1, Carol Kennedy2, Leslie J. Soever3, Kelly Warmington2, Sydney C. Lineker4, Katie Lundon2, Rachel Shupak5 and Rayfel Schneider6, 1University Health Network, Toronto, ON, 2St. Michael’s Hospital, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON, 4The Arthritis Society, Toronto, ON, 5St. Michaels Hospital, Toronto, ON, 6Hospital for Sick Children, University of Toronto, Toronto, ON

W476

Improving Adherence in the Pediatric Patient

P

Moderators: Christine W. Kennedy, CPNP, MSN, RN; Emory Children’s Center; Atlanta, GA Elizabeth G. Salt, PhD; University of Kentucky; Lexington, KY 4:30 pm Impact of Non-adherence from the Medical Perspective Rhina Castillo, MD; Childrens Hospital Los Angeles; Los Angeles, CA 4:45 pm Impact of Non-adherence from a Physical and Occupational Therapy Perspective Talitha Cox, MA, OTR/L; Children’s Hospital of Los Angeles; Los Angeles, CA Jill R. Blitz, PT, DPT; Children’s Hospital Los Angeles; Los Angeles, CA 5:05 pm Impact of Non-adherence from a Nursing Perspective Sandra J. Watcher, RN, BSN; Children’s Hospital of Los Angeles; Los Angeles, CA

2011 Program Book

83

5:25 pm Impact of Non-adherence from a Social Work Perspective Alana Epstein, MSW; University of Southern California; Los Angeles, CA 5:45 pm Panel Discussion Upon completion of this session, participants should be able to: • describe barriers to learning and adherence • e xamine methods to overcome the barriers to improve learning and adherence • discuss age appropriate methods to educate children and adolescents regarding rheumatic diseases and medications • identify available age appropriate materials and resources for patient, family and educators to use • discuss perspectives and recommendations from other centers using an interactive open panel

W193a

Theories on Sex Disparities in Autoimmune Disease: From Estrogen to the X Chromosome c/r

N o v e m b e r

7 ,

MONDAY

2 0 1 1

Moderator: Emily C. Somers, PhD, ScM; University of Michigan; Ann Arbor, MI Speakers: Cherie L. Butts, PhD; Health and Human Services; Bethesda, MD Bruce C. Richardson, MD, PhD; University of Michigan; Ann Arbor, MI Amr H. Sawalha, MD; Oklahoma Medical Research Foundation; Oklahoma City, OK Upon completion of this session, participants should be able to: • describe and contrast theories underlying the increased risk of autoimmune disease among females • cite evidence for contemporary hypotheses related to excess risk among females • discuss currently proposed mechanisms of autoimmunity in males


HALL F1 (Booth #789) The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Lilly USA, LLC. Please visit the Lilly USA, LLC exhibit booths (470, 521) for more information or see page 304. Seating and light refreshments are subject to availability.

Pathophysiology of Pain: Mechanisms and Manifestations

WINE AND CHEESE RECEPTION 5:00 - 7:00 pm

HALL F1 - Exhibit Hall Everyone is invited to the exhibit hall for the wine and cheese reception. This is a great opportunity to network with exhibitors and colleagues.

84

2011 Program Book

ACR STUDY GROUPS 6:45 - 8:00 pm Study Groups are non-CME activities, open to all attendees. See page 94 for additional Study Group offerings.

W194a

ACR-EULAR Exchange W475a

Antiphospholipid Study Group W471b

Autoantibodies in Diagnosis and Follow up of Rheumatic Diseases W196a

Capillaroscopy in Rheumatic Diseases W181b

Childhood Vasculitis W195

Geriatric Rheumatology W474a

Hypermobility I W193a

Interstitial Lung Disease W474b

Juvenile Arthritis Workgroup (JAW) W183c

Musculoskeletal Ultrasound W194b

Patient Perspective on Outcomes: Methods of Ensuring the Patient Perspective is Included in Patient Reported Outcome Instruments W192b

Pediatric Rheumatology Imaging W476

Polymyalgia Rheumatica W470b

Spondylarthritis

TUESDAY, NOVEMBER 8, 2011

advancement into leadership • d iscuss barriers to success in research careers • define strategies to enhance the role of women in academic medicine

REF 5K RUN/WALK 6:00 - 8:00 am See page 14 for more information.


ACR/ARHP REGISTRATION

W375b

6:30 am - 6:00 pm

Complimentary Roles for Complement in the Rheumatic Diseases R

Hall F2 Entrance


W375d

Celiac Disease: Immunopathogenesis and Clinical Spectrum Potential C cP Moderator: Bruce I. Hoffman, MD; Philadelphia, PA Speaker: Joseph A. Murray, MD; Mayo Clinic; Rochester, MN Upon completion of this session, participants should be able to: • identify the epidemiology of celiac disease • d escribe the pathophysiology of celiac disease and factors leading to disease variability • r ecognize the clinical spectrum of presentations of celiac disease • d iscriminate when and how to evaluate patients for celiac disease


BR

Ed.

7:55 am National Trends of Women in Academic Medicine Sheila A. Dugan, MD; Rush Medical College; Chicago, IL 8:20 am A Call to Action: What Can the ACR Do To Support Women in the Rheumatology Workforce? Leslie J. Crofford, MD; University of Kentucky; Lexington, KY Upon completion of this session, participants should be able to: • r eview the data on current workforce issues related to gender in rheumatology • identify barriers women face in professional advancement • identify successful innovations that support women’s

R

Moderator: Peter A. Nigrovic, MD; Brigham and Women’s Hospital; Boston, MA Speaker: Dallas Jones, PhD; Harvard University; Boston, MA Upon completion of this session, participants should be able to: • discuss the basic anatomy and physiology of bone • review recent progress in the understanding of bone formation and degradation • evaluate potential novel therapeutic targets for bone disease in arthritis and osteoporosis

W375c

Omega-3 Fatty Acids in Inflammation and Cardiovascular Health c/r cP PS

2 0 1 1

7:30 am Update on Gender Issues in Rheumatology: Analysis of 2011 ACR Data Abby Goulder Abelson, MD; Cleveland Clinic Foundation; Cleveland, OH

New Insights into Bone Remodeling

8 ,

Moderator: Abby Goulder Abelson, MD; Cleveland Clinic Foundation; Cleveland, OH

W375a

TUESDAY

Gender Issues in the Rheumatology Workforce

Upon completion of this session, participants should be able to: • appreciate basic principles of complement biology • define how particular complement factors can enhance immune defenses from infection, or contribute to host homeostasis • review emerging data on unexpected roles of complement, and aberrant pathways in the immune pathogenesis of inflammatory diseases

N o v e m b e r

W194b

Moderator: Gregg J. Silverman, MD; New York University School of Medicine; New York, NY Speaker: John D. Lambris, PhD; University of Pennsylvania; Philadelphia, PA

Moderator: Eric M. Ruderman, MD; Northwestern University; Chicago, IL 7:30 am N-3 Fatty Acids, Inflammation, and Cardiovascular Disease Artemis P. Simopoulos, MD; Center for Genetics; Washington, DC 8:00 am N-3 Fatty Acids in Rheumatic Diseases and the Intersection with Cardiovascular Morbidity Joel M. Kremer, MD; Albany Medical College and The Center for Rheumatology; Albany, NY Upon completion of this session, participants should be able to: • describe the scientific basis for the anti-inflammatory, immunomodulatory and clinical effects of n-3 fatty acids in health and disease • discuss the impact of n-3 fatty acids in rheumatoid arthritis • discuss the impact of n-3 fatty acids on cardiovascular morbidity and mortality

2011 Program Book

85


W474b

An Update in the Diagnosis and Management of Juvenile Dermatomyositis P Moderators: Clarissa Pilkington, MBBS.BSc; Great Ormond Street Hospital; London, United Kingdom Susan Maillard, MSc; Great Ormond Street Hospital; London, United Kingdom 7:30 am Diagnosis and Assessment of Juvenile Dermatomyositis Angelo Ravelli, MD; University of Genova; Genoa, Italy 7:55 am Medical Management of Juvenile Dermatomyositis Clarissa Pilkington, MBBS.BSc; Great Ormond Street Hospital; London, United Kingdom 8:15 am Physical Management of Juvenile Dermatomyositis Ellie Haggart, BSc; Great Ormond Street Hospital; London, United Kingdom Upon completion of this session, participants should be able to: • assess and diagnose juvenile dermatomyositis • explain the core outcome criteria that are being developed for monitoring juvenile dermatomyositis • review of the latest approaches in medical management of juvenile dermatomyositis in children • explain the physical management and the effectiveness of exercise in the management of juvenile dermatomyositis

W192b

Cognitive Function in Systemic Lupus Erythematosus 2 0 1 1

C

N o v e m b e r

8 ,

TUESDAY

Moderator: Mary-Beth Coty, PhD, RN; University of Louisville; Louisville, KY Speaker: Robin L. Brey, MD; University of Texas Health Science Center San Antonio; San Antonio, TX Upon completion of this session, participants should be able to: • describe cognitive function in patients with systemic lupus erythematosus • define the role of depression in the cognitive dysfunction of patients with systemic lupus erythematosus • review the proper cognitive evaluation of a patient with systemic lupus erythematosus • identify potential treatment options for the various scenarios of cognitive dysfunction in patients with systemic lupus erythematosus • outline future research in the area of cognitive function in patients with systemic lupus erythematosus

W476

Mechanical Factors in Knee Osteoarthritis: A Plausible Road to Riches c/r Moderator: Nadine M. Fisher, EdD; SUNY at Buffalo; Buffalo, NY

86

2011 Program Book

7:30 am Role of Mechanical Factors in Disease Development, Disease Progression, and Function Decline in Knee Osteoarthritis Leena Sharma, MD; Northwestern University; Chicago, IL 7:45 am Emerging Prevention and Intervention Strategies for Knee Osteoarthritis that Target Mechanical Factors Alison H. Chang, PT, DPT, MS; Northwestern University; Chicago, IL 8:25 am Question and Answer Upon completion of this session, participants should be able to: • summarize findings of epidemiologic studies dealing with modifiable mechanical factors in knee osteoarthritis and their relationship to key endpoints and outcomes • describe strategies that may prevent or delay disease or disability progression in knee osteoarthritis, and review the quality of clinical trial evidence to support their application • explain areas for future emphasis and the work necessary to move the field forward

ACR MEET THE PROFESSOR SESSIONS 7:45 - 9:15 am Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual. *Sessions denoted with an asterisk were sold out as of September 12.

W187c

Ankylosing Spondylitis: Disease Modification (061) Speaker: Joachim Sieper, MD; Charité – Campus Benjamin Franklin; Berlin, Germany

W185a

Antiphospholipid Syndrome (062) Speaker: Graham R. V. Hughes, MD; London Bridge Hospital; London, United Kingdom

W187b

Crystal: Diagnosis and Management of Gout (063) Speaker: Michael A. Becker, MD; University of Chicago Medical Center; Chicago, IL

W185bc

Difficult Patient Interactions (064)

PM

Speaker: Dennis J. Boyle, MD; Denver Health Medical Center; Denver, CO

W186b

W179b

Osteoarthritis: Update 2011 (065)

Rheumatology Physical Examination of Upper Extremity and Cervical Spine: Anatomical Correlates (230) f

Speaker: Richard F. Loeser, MD; Wake Forest University; Winston-Salem, NC

W187a

Pain: Evaluation and Treatment of Back Pain (066)

PM

Speaker: David G. Borenstein, MD; Arthritis & Rheumatism Associates; Washington, DC

W184d

*Pregnancy in Rheumatic Diseases (067) Speaker: Megan E. B. Clowse, MD, MPH; Duke University Medical Center; Durham, NC

W186a

Rheumatoid Arthritis: Early Rheumatoid Arthritis (068) Speaker: James R. O’Dell, MD; University of Nebraska Medical Center; Omaha, NE

W185d

Scleroderma: Systemic Sclerosis (069) Speaker: Christopher P. Denton, PhD; University College London Medical School; London, United Kingdom

W186c

Vasculitis: Update (070) Speaker: Peter A. Merkel, MD, MPH; Boston University School of Medicine; Boston, MA

ACR/ARHP WORKSHOPS 7:45 - 9:45 am

W180

Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back (229) Speakers: George V. Lawry, II, MD; University of California Irvine; Orange, CA Paul C. Utrie, MD; Orthopedic and Sports Medicine Specialists; Green Bay, WI

ACR CLINICAL SYMPOSIA 9:00 - 10:30 am W375d

Emerging Concepts in the Inflammatory Myopathies C

Moderators: Rohit Aggarwal, MD; University of Pittsburgh Medical Center; Pittsburgh, PA Chester V. Oddis, MD; University of Pittsburgh; Pittsburgh, PA 9:00 am Statin Myopathies: Emerging Concepts Lisa Christopher-Stine, MD, MPH; Johns Hopkins University; Baltimore, MD 9:25 am Emerging Biomarkers in Myositis Dana P. Ascherman, MD; University of Miami; Miami, FL 9:50 am Dermatomyositis Skin Disease: Novel Phenotypes in Diagnosis, Prognosis, and Therapy David Fiorentino, PhD; Stanford; Stanford, CA Upon completion of this session, participants should be able to: • to identify and discuss recent advances in statin-associated myopathy and to determine the appropriate workup for a patient with statin myopathy • to identify emerging biomarkers in myositis and to understand the rationale of their importance • to recognize the phenotypic features of dermatomyositis and their prognostic and therapeutic implications

2 0 1 1

Speaker: Arthur M. Mandelin II, MD, PhD; Northwestern University Feinberg School of Medicine; Chicago, IL

Speakers: Brian F. Mandell, MD, PhD; The Cleveland Clinic; Cleveland, OH Lan X. Chen, MD, PhD; Pennsylvania Presbyterian Medical Center; Philadelphia, PA Gilda M. Clayburne, MLT; Veterans Affairs Medical Center; Philadelphia, PA

8 ,

Adult Musculoskeletal Lower Examinations (228)

Synovial Fluid Analysis and Crystal Identification (231)

TUESDAY

W179a

W178a

N o v e m b e r

Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual.

Speakers: Robert A. Kalish, MD; Tufts Medical Center; Boston, MA Pablo Villasenor Ovies, MD; Instituto Nacional de Rehabilitación; Ciudad de México, Mexico

W375b

Spondylarthropathies: Recent Insights

C

cP

Moderator: M. Elaine Husni, MD, MPH; Cleveland Clinic Foundation; Cleveland, OH 9:00 am TNF Inhibition and Structural Progression in Ankylosing Spondylitis Walter P. Maksymowych, MD; University of Alberta; Edmonton, AB, Canada 2011 Program Book

87

9:25 am Is Methotrexate a Disease Modifying Agent in Psoriatic Arthritis? Gabrielle H. Kingsley, MBChB, PhD; Kings College London; London, United Kingdom 9:50 am Reactive Arthritis: Clinical Insights and Treatment Options John D. Carter, MD; University of South Florida; Tampa, FL Upon completion of this session, participants should be able to: • outline the impact of tumor necrosis factor inhibition on the progression of vertebral changes observed on magnetic resonance imaging in antiphospholipid syndrome patients • discuss new treatment approaches to the prevention of pathologic new bone formation in antiphospholipid syndrome • review the data on the efficacy and safety of methotrexate in prostate-specific antigen • assess if methotrexate is a disease-modifying anti-rheumatic drugs in prostate-specific antigen • state the strains of chlamydia associated with reactive arthritis • summarize the recent evidence regarding the efficacy and safety of prolonged antibiotic therapy for reactive arthritis induced by chlamydia

ACR IMMUNOLOGY UPDATES FOR THE CLINICIANS 9:00 - 10:00 am

W375c

Genetic Defects, AIRE and Autoimmunity

2 0 1 1 N o v e m b e r

8 ,

TUESDAY

Upon completion of this session, participants should be able to: • describe basic principles of T cell biology and selection of antigen specific responses • evaluate how expression of self antigens in the thymus is controlled and under the regulation of certain genetic elements • cite how impaired expression of genes such as autoimmune regulator can result in organ specific autoimmunity, and how this has changed our understanding of autoimmune disease pathogenesis


W183a

Cytokine and Chemokine Regulation of Chronic Pain R

Moderator: Anne-Marie Malfait, MD, PhD; Rush University Medical Center; Chicago, IL Speaker: Richard J. Miller, PhD; Northwestern University; Evaston, IL

2011 Program Book

W375a

Neutrophil Recruitment by Intravascular Danger Signals R Moderator: Christopher T. Ritchlin, MD, MPH; University of Rochester Medical Center; Rochester, NY Speaker: Paul Kubes, PhD; University of Calgary; Calgary, AB, Canada Upon completion of this session, participants should be able to: • define the term damage associated molecular patterns and how these molecules participate in the inflammatory response • list the molecular signals that direct neutrophil migration • describe the multistep cascade that allows neutrophils to sense and home to sites of sterile inflammation

ACR/ARHP POSTER SESSION C AND POSTER TOURS 9:00 am - 6:00 pm

c/r

Moderator: Gregg J. Silverman, MD; New York University School of Medicine; New York, NY Speaker: Mark Anderson, MD, PhD; University of California, San Francisco; San Francisco, CA

88

Upon completion of this session, participants should be able to: • describe how the expression of inflammatory cytokines in association with tissue damage triggers diverse changes in the behavior of sensory neurons in the context of chronic pain syndromes • summarize the actions of inflammatory cytokines synthesized by dorsal root ganglia neurons, associated glial cells, as well as by astrocytes and microglia in the spinal cord • translate the knowledge of mechanisms of chronic pain generation into novel analgesic targets

Poster presenters will be available from 9:00 - 11:00 am (abstracts # 1733 - 2426). Poster tours will be held 9:00 - 9:45 amand 10:15 - 11:00 am. Morning snacks will be available from 9:00 - 10:30 am.

Guided Poster Tours HALL F2 - Poster Hall Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Hall F2 Entrance). Alternatively, you may go directly to the poster tour desk and wait for a standy ticket. Standby tickets will be assisgned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants’ registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour.

9:00 - 9:45 am Miscellaneous Rheumatic and Inflammatory Diseases (326) Tour Guide: Winn Chatham, MD; University of Alabama at Birmingham; Birmingham, AL Osteoarthritis - Clinical Aspects (327) Tour Guide: Timothy E. McAlindon, MD, MPH; Tufts Medical Center; Boston, MA Rheumatoid Arthritis: Clinical Aspects (328) Tour Guide: Iain B. McInnes, PhD; University of Glasgow; United Kingdom Systemic Lupus Erythematosus: Clinical Aspects (329) Tour Guide: Bevra H. Hahn, MD; University of California Los Angeles; Los Angeles, CA Vasculitis (330) Tour Guide: Simon Carette, MD; Toronto Western Hospital; Toronto, ON, Canada 10:15 - 11:00 am Epidemiology and Health Services Research (331) Tour Guide: Liana Fraenkel, MD, MPH; Yale University; New Haven, CT Fibromyalgia and Soft Tissue Disorder (332) Tour Guide: Daniel J. Clauw, MD; University of Michigan; Ann Arbor, MI Osteoarthritis: Clinical Aspects (333) Tour Guide: Roy D. Altman, MD; University of California Los Angeles; Los Angeles, CA Psychological and Social Factors in Rheumatic Disease (334) Tour Guide: Pamela J. Degotardi, MD; Queens College, The City University of New York; New York, NY

ACR REF Paul Klemperer, MD Memorial Lectureship: Osteoarthritis - Quo Vadis - Where are We Now - Where Are We Going? c/r Moderator: E. William St.Clair, MD; Duke University Medical Center; Durham, NC Speaker: Roland W. Moskowitz, MD ; University HospitalsCase Medical Center; Cleveland, OH Upon completion of this session, participants should be able to: • d escribe the chief epidemiologic risk factors for osteoarthritis onset • d efine disease pathophysiology and relationship to clinical presentations of osteoarthritis • d elineate current approaches to symptomatic and disease modification therapy

Moderator: Bruce N. Cronstein, MD; New York University Medical Center; New York, NY Speaker: S. Louis Bridges Jr., MD, PhD; University of Alabama at Birmingham; Birmingham, AL Upon completion of this session, participants should be able to: • describe the major experimental approaches to identifying predictors of treatment responses in rheumatoid arthritis • identify the obstacles to personalized medicine in rheumatoid arthritis and other complex diseases • explain what information may be learned by analysis of potential biomarkers and pathogenic pathways in rheumatoid arthritis

W192b

Daltroy Memorial Lecture: The Role of Cultural Diversity in Patient-Healthcare Provider Communication C Moderator: Elizabeth G. Salt, PhD; University of Kentucky; Lexington, KY Speaker: Maria E. Suarez-Almazor, MD, PhD ; University of Texas. M.D Anderson Cancer Center; Houston, TX Upon completion of this session, participants should be able to: • describe what is known about the effect of ethnic diversity on patient-healthcare provider communication • discuss current and future research on patient-healthcare provider communication in rheumatologic conditions • discuss actions that healthcare providers can take to improve patient-healthcare provider communication

W476

Pregnancy and Child Care Issues for Parents with Arthritis C PM PS Moderator: Mary Wright, BS, OT; The Toledo Hospital; Toledo, OH

2 0 1 1

W470b

C

8 ,

ACR REF SPECIAL SESSION 9:00 - 10:00 am

Adult Pharmacogenomics

TUESDAY

Systemic Lupus Erythematosus: Clinical Aspects (336) Tour Guide: Daniel J. Wallace, MD; Cedars-Sinai Medical Center/ David Geffen School of Medicine at University of California at Los Angeles; Los Angeles, CA

W193a

N o v e m b e r

Rheumatoid Arthritis: Clinical Aspects (335) Tour Guide: Larry W. Moreland, MD; University of Pittsburgh; Pittsburgh, PA


9:00 am Activities for Daily Living and Instrumental Activities for Daily Living Ideas During Pregnancy and Early Childhood Years to Help Decrease Pain and Fatigue Alison Hammond, PhD; University of Salford; Salford, United Kingdom 9:30 am Splinting to Decrease Pain During Pregnancy and Early Childhood Years Carole V. Dodge, OT, CHT; University of Michigan Medical Center; Ann Arbor, MI Upon completion of this session, participants should be able to: • recognize common problems experienced by women with arthritis during pregnancy, childbirth and caring for babies and young children • identify activities for daily living strategies to help parents care for newborns and young children • review and evaluate what types of musculoskeletal conditions are common in pregnancy and during early childhood and how splinting can help 2011 Program Book

89

Speakers: George V. Lawry, II, MD; University of California Irvine; Orange, CA Paul C. Utrie, MD; Orthopedic and Sports Medicine Specialists; Green Bay, WI


W190a

Understanding Medicare Incentive Programs: e-Prescribing & PQRI BR C cP Moderator: Charles M. King II, MD; Internal Medicine Associates; Tupelo, MS Speaker: Salahuddin Kazi, MD; Dallas Veterans Affairs Medical Center; Dallas, TX Upon completion of this session, participants should be able to: • identify the eligibility requirements for the incentive programs • review and evaluate how much are the incentives and how they are calculated • discuss the specific dates and qualifying entities for each incentive program

INNOVATION THEATER 10:30 - 11:15 am

HALL F1 (Booth #789) The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Oxford Immunotec, Inc. Please visit the Oxford Immunotec, Inc. exhibit booth (108) for more information or see page 304. Seating and light refreshments are subject to availability.

Why You Should Be Using an Interferon Gamma Release Assay (IGRA) Over the Tuberculin Skin Test to Test Your Patients for TB Infection

EXHIBITS 10:00 am - 5:00 pm

HALL F1 - Exhibit Hall Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 10:00 - 11:00 am and 2:00 - 3:00 pm. Visit the Replay Café, presented by SessionSelect, to view a session you missed during the meeting. The schedule will be available in the Daily News, at the Concierge Center and the Resource Center.

ACR BASIC SCIENCE SYMPOSIUM 11:00 am - 12:30 pm

W375c

Toward Prevention of Atherosclerosis Progression in Rheumatoid Arthritis: Insights into the Relationship between Inflammation and Cardiovascular Disease R

ACR WORKSHOPS 10:30 am - 12:30 pm

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in the parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual.

W178b

Histopathology of Vasculitis (232) Speakers: Allen Burke, MD; University of Maryland Medical Center; Baltimore, MD Jonathon Heath, MD; University of Maryland Medical Center; Baltimore, MD

W179a

Joint Injection Techniques (233)

f

Speakers: Atul A. Deodhar, MD, MRCP; Oregon Health & Science University; Portland, OR Kenneth S. O’Rourke, MD; Wake Forest University School of Medicine; Winston-Salem, NC

W180

Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (234)

90

2011 Program Book

Moderators: João E. Fonseca, MD, PhD; Lisbon Academic Medical Center; Lisbon, Portugal Radjesh J. Bisoendial, MD, PhD; Academic Medical Center/ University of Amsterdam; Amsterdam, Netherlands 11:00 am How Inflammation Impacts Endothelial Function as Primary Target for Cardiovascular Diseases Erik Stroes, MD, PhD; Academic Medical Center / University of Amsterdam; Amsterdam, Netherlands 11:25 am Macrophage Death and Defective Apoptotic Cell Clearance in Advanced Atherosclerotic Plaque Progression Bart Staels, PhD; Universite de Lille II; Lille, France 11:50 am The Interacting Roles of Reverse Cholesterol Transport and Inflammation and Their Relationship to Atherosclerosis Daniel J. Rader, MD; Perelman School of Medicine at the University of Pennsylvania; Philadelphia, PA Upon completion of this session, participants should be able to: • review the data on the molecular pathogenesis of accelerated atherogenesis in rheumatoid arthritis and other immunemediated inflammatory disorders • identify the primary cellular and molecular pathways that are targeted by local and systemic inflammatory responses • discuss the potential targets for therapy that may reduce the cardiovascular burden as well as disease activity in rheumatoid arthritis

ACR CLINICAL SYMPOSIUM 11:00 am - noon

W183a

Periodic Fevers with Aphthous Stomatitis, Pharyngitis, and Adenitis P/C Moderators: Sivia K. Lapidus, MD; Morritown Memorial Hospital; Morristown, NJ Kenneth N. Schikler, MD; University of Louisville School of Medicine; Louisville, KY 11:00 am Periodic Fevers with Aphthou Stomatitis, Pharyngitis, and Adenitis: Syndrome: What It Is, What It Isn’t, and What Has Been Learned Karyl S. Barron, MD; National Institute of Allergy and Infectious Diseases/NIH; Bethesda, MD Upon completion of this session, participants should be able to: • d efine the diagnostic criteria or periodic fevers with aphthous stomatitis, pharyngitis, and adenitis syndrome • r ecognize the differential of periodic fevers with aphthous stomatitis, pharyngitis, and adenitis syndrome • c onstruct a diagnostic plan to evaluate children presenting with signs and symptoms compatible with periodic fevers with aphthous stomatitis, pharyngitis, and adenitis • e xplain research related to immunologic phenomena identified in patients with periodic fevers with aphthous stomatitis, pharyngitis, and adenitis syndrome

ACR CLINICAL SYMPOSIUM 11:00 am - 12:30 pm

W375d

11:50 am Pemphigus and the Pemphigoid Diseases Victoria P. Werth, MD; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center; Philadelphia, PA Upon completion of this session, participants should be able to: • d escribe the pathophysiology and immunology associated with pyoderma, panniculitis and pemphigus/pemphigoid • recognize and formulate a differential diagnosis for these three conditions • identify new treatment strategies including the use of diseasemodifying anti-rheumatic drugs and biological medications as possible treatment options

11:00 am 2427. JAK2 Mediates the Stimulatory Effects of Transforming Growth Factor beta on Fibroblast Activation and Tissue Fibrosis Clara Dees1, Michal Tomcik2, Katrin Palumbo1, Alfiya Akhmetshina3, Angelika Horn1, Pawel Zerr1, Oliver Distler4, Georg Schett1 and Jorg HW Distler1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of ErlangenNuremberg, Erlangen, Germany, 2Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 3 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 4University Hospital Zurich, Zurich, Switzerland 11:15 am 2428. RNAi Mediated Silencing of the Autoantigen hnRNP-A2 Dcreases Inflammatory Arthritis by Inhibiting Activation of Cells of the Mononuclear Phagocytic System Sonja Herman1, Jessy Presumey2, Juergen Pfatschbacher1, Wim B. Vandenberg3, Florence Apparailley2 and Gunter Steiner1, 1 Medical University of Vienna, Vienna, Austria, 2Hôpital Saint Eloi, Montpellier, France, 3Radboud University Nijmegen Med Center, Nijmegen, Netherlands 11:30 am 2429. A Functional IRF5 Variant Predicts Prognosis in Patients with Systemic Sclerosis Roozbeh Sharif1, Maureen D. Mayes1, Filemon K. Tan1, Olga Gorlova2, Laura K. Hummers3, Ami A. Shah3, Daniel E. Furst4, Dinesh Khanna5, Javier Martin6, Lara Bossini-Castillo7, Emilio B. Gonzalez8, Hilda T. Draeger9, Jun Ying10, Sandeep K. Agarwal1, Frank C. Arnett1, Fredrick M. Wigley3 and Shervin Assassi1, 1 University of Texas Health Science Center at Houston, Houston, TX, 2University of Texas M.D. Anderson Cancer Center, Houston, TX, 3Johns Hopkins University, Baltimore, MD, 4UCLA Medical School, Los Angeles, CA, 5University of Michigan, Ann Arbor, MI, 6 Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 7Consejo Superior de Investigaciones Científicas (CSIC), Armilla (Granada), Spain, 8University of Texas Medical Branch, Galveston, TX, 9Univ of TX Health Sci Ctr, San Antonio, TX, 10University of Texas M. D. Anderson Cancer Center, Houston, TX

2 0 1 1

11:25 am Panniculitis: What Should a Rheumatologist Know? Lela A. Lee, MD; Denver Health Medical Center; Denver, CO

Moderators: Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH Richard A. Furie, MD; North Shore Long Island Jewish Health System; New Hyde Park, NY

8 ,

11:00 am Pyoderma Gangrenosum: An Overlap of Dermatologic and Rheumatic Disease Jeffrey P. Callen, MD; University of Louisville School Medicine; Louisville, KY

W375b

11:45 am 2430. Feasibility, Safety and Clinical Effects of a Single Intradermal Administration of Autologous Tolerising Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis Ranjeny Thomas, Shayna Street, Nishta Ramnoruth, Helen Pahau, Soi Law, Marion Brunck, Claire Hyde, Brendan O’Sullivan, Christelle Capini, Ai Tran, Jennifer Ng and Sanjoy Paul, Univ of Queensland, Brisbane, Australia 2011 Program Book

TUESDAY

Moderator: Shelly P. Kafka, MD; Mountain State Rheumatology; Clarksburg, WV

11:00 am - 12:30 pm

N o v e m b e r

The Three Ps of Dermatologic and Autoimmune Disease: Pyoderma, Panniculitis and Pemphigus/ Pemphigoid C P/C

ACR PLENARY SESSION III – DISCOVERY 2011 c/r

91

noon

2431. Genome-Wide Analysis of Imputed Genotypes Identifies Chemokine Receptor-1 (CCR1) As a Novel Candidate Risk Locus in Behçet’s Disease Yohei Kirino1, George Bertsias1, Michael J. Ombrello1, Duran Ustek2, Colleen Satorius1, Julie Le1, Nobuhisa Mizuki3, Yoshiaki Ishigatsubo3, Emire Seyahi4, F. Sevgi Sacli4, Ahmet Gul5, Daniel L. Kastner1 and Elaine Remmers1, 1National Human Genome Research Institute, National Institute of Health, Bethesda, MD, 2 Istanbul University, Istanbul, Turkey, 3Yokohama City University Graduate School of Medicine, Yokohama, Japan, 4University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey, 5Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

12:15 pm 2432. Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCAAssociated Vasculitis: Which Subsets Are At Greatest Risk for Flare? John H. Stone1, Peter A. Merkel2, Philip Seo3, Robert Spiera4, Carol A. Langford5, Gary S. Hoffman5, Cees GM Kallenberg6, E. William St. Clair7, Barri J. Fessler8, Nadia Tchao9, Lisa Webber10, Linna Ding11, Lourdes P. Sejismundo12, Kathleen Mieras13, David Ikle14, Deborah J. Phippard9, Brett Jepson14, Alice Lail14, Adam Asare9, Noha Lim9, Mark Mueller15, Paul Brunetta16, Nancy B. Allen17, Fernando Fervenza13, Duvuru Geetha18, Karina Keogh13, Eugene Y. Kissin19, Paul A. Monach19, Tobias Peikert13, Coen Stegeman6, Steven R. Ytterberg13, Ulrich Specks13 and for the RAVE-ITN Research Group20, 1Massachusetts General Hospital, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3 Johns Hopkins Vasculitis Center, Baltimore, MD, 4Hospital for Special Surgery, New York, NY, 5Cleveland Clinic, Cleveland, OH, 6 University Medical Center Groningen, Groningen, Netherlands, 7 Duke University Medical Center, Durham, 8Univ of AlabamaBirmingham, Birmingham, AL, 9Immune Tolerance Network, Bethesda, MD, 10National Institute of Allergy and Infectious Diseases, 11NIAID, Bethesda, MD, 12Johns Hopkins University, Baltimore, MD, 13Mayo Clinic, Rochester, MN, 14Rho, Chapel Hill, NC, 15Food & Drug Administration, Bethesda, MD, 16Genentech, So San Francisco, CA, 17Duke University Medical Center, Durham, NC, 18Johns Hopkins University, York, PA, 19Boston University, Boston, MA, 20Bethesda

ACR PRACTICE ISSUE 11:00 am - 12:30 pm

W190a

CORC Forum: Payment Reform Options

BR

cP

Moderators: Alan R. Erickson, MD; University of Nebraska Meidcal Center Physicians, Brentwood; LaVista, NE Raymond Hong, MD, MBA; Ohio Permanente Medical Group; Parma, OH Speakers: Michael S. Barr, MD, MBA; American College of Physicians; Washington, DC Warren Skea, PhD; PricewaterhouseCoopers; Dallas, TX Upon completion of this session, participants should be able to: • identify the various payment approaches including the use of managed care organizations and accountable care organizations

92

2011 Program Book

• e xplain the challenges and opportunities facing the Accountable Care Organizations and Patient Center Medical Home models today • identify how these new payment options will be used in promoting quality, efficiency and improved outcomes

ARHP CONCURRENT SESSIONS 11:00 am - noon

W476

Are You Losing It? How to Deal with Loss to Follow Up in Research Studies and Clinical Trials R Moderator: Laura D. Bilek, PhD, PT; University Nebraska Med Center; Omaha, NE 11:00 am How Does Loss to Follow up Happen and What Are the Implications? Robert R. McLean, DSc, MPH; Hebrew Senior Life/Harvard Medical School; Boston, MA 11:30 am How to Avoid or Deal with Loss to Follow Up Alyssa B. Dufour, MA; Hebrew SeniorLife & Boston University; Boston, MA Upon completion of this session, participants should be able to: • outline the consequences of loss to follow up • describe how loss to follow up affects interpretation of research studies • recognize the analytic techniques used to handle loss to follow up • employ practical methods to reduce loss to follow up

W193a Arthritis and Traditional Chinese Medicine c/r PM Moderator: Leigh F. Callahan, PhD; University of North Carolina; Chapel Hill, NC Speaker: Chenchen Wang, MD, MSc; Tufts Medical Center; Boston, MA Upon completion of this session, participants should be able to: • explain traditional Chinese medicine treatments for arthritis • describe how evidence can be integrated into alternative treatments for arthritis • apply strategies for treatment interventions that focus on mind-body therapies for chronic pain • discuss how alternative treatments can be utilized in clinical practice

W192b

Entrapment Neuropathies and Nerve Conduction Studies C Moderator: Cong-Qiu Chu, MD, PhD; Oregon Health & Science University; Portland, OR Speaker: Hans L. Carlson, MD; Oregon Health & Science University; Portland, OR Upon completion of this session, participants should be able to: • review the timing of ordering nerve conduction studies • assess whether the studies’ conclusions are consistent with the clinical assessment • discuss management options based on outcomes

W474b

Fiscal Management of Infusion Clinics: Academic and Private Practice Perspectives BR Moderator: Joyce M. Kortan, RN; Arthritis & Rheumatism Consultants; Edina, MN 11:00 am How to Successfully Manage an Infusion Center in the Academic Setting Victoria L. Ruffing, RN; Johns Hopkins University; Baltimore, MD 11:25 am How to Successfully Manage an Infusion Center in the Private Practice Setting Karen M. Ferguson, MS; Spokane, WA 11:50 am Question and Answer Upon completion of this session, participants should be able to: • r ecognize how infusion clinics may affect patients and practices • d escribe the steps necessary to manage a successful infusion clinic • identify patient assistance and government programs available to help with patient infusion therapy costs • d iscuss how future processes may need occupational therapy change in order to remain successful in the ever changing healthcare marketplace

ARHP SPECIAL SESSION noon - 1:00 pm

S102 Networking Break


W187b

Ankylosing Spondylitis: 2011 Update (071) Speaker: Desiree M.F.M. van der Heijde, MD, PhD; Leiden University Medical Center; Leiden, Netherlands

W186c

Basic Immunology for Clinical Rheumatologists (072) f

Speaker: Antony Rosen, MD; The Johns Hopkins University; Baltimore, MD

W184d

Fibromyalgia and Dysautonomia (073)

PM

Speaker: Manuel Martinez-Lavin, MD; National Cardiology Institute; Mexico City, Mexico

W185a

Myopathy: Issues in Diagnosis and Treatment (074) Speaker: Mark F. Gourley, MD; National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH; Bethesda, MD

W185bc

*Pulmonary Manifestations of Rheumatic Disease (075) Speaker: Paul F. Dellaripa, MD; Brigham and Womens Hospital; Boston, MA

Rheumatoid Arthritis: Challenging Cases (076)

HALL F1 (Booth #789) The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Novartis Pharmaceuticals Corporation. Please visit the Novartis Pharmaceuticals Corporation exhibit booth (314) for more information or see page 304. Seating and light refreshments are subject to availability.

Challenges to the Diagnosis and Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

ACR MEET THE PROFESSOR SESSIONS 12:45 - 2:15 pm

2 0 1 1

12:30 - 1:15 pm

Speaker: Jonathan Kay, MD; University of Massachusetts Medical School; Worcester, MA

8 ,

INNOVATION THEATER

TUESDAY

W185d

N o v e m b e r

All ARHP attendees are invited to an informal networking event. Bring your lunch and enjoy an opportunity to meet with health professionals. Soft drinks will be available. This session is not eligible for CME credit.

for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual.

W187a

Systemic Lupus Erythematosus: Central Nervous System (077) Speaker: Jorge Sanchez-Guerrero, MD, MS; University Health Network/Mount Sinai Hospital; Toronto, ON, Canada

W187c

*Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (078) Speaker: Elena M. Massarotti, MD; Brigham and Women’s Hospital; Boston, MA

W186a

Temporal Arteritis (079) Speaker: Gene G. Hunder, MD; Mayo Clinic; Rochester, MN

Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered 2011 Program Book

93

W186b

Vasculitis: An Update (080) Speaker: Paul A. Monach, MD, PhD; Boston University; Boston, MA

• d iscuss how to increase training efficiency • innovate processes to help guarantee the preparation of appropriately trained rheumatologists

ACR STUDY GROUPS


Hyperuricemia and Gout: Mechanisms and Morbidity (Clinical Review) C cP Moderator: Gregory C. Gardner, MD; University of Washington; Seattle, WA Speaker: Michael H. Pillinger, MD; New York University Hospital for Joint Diseases; New York, NY Upon completion of this session, participants should be able to: • explain the mechanisms by which hyperuricemia leads to gouty arthritis • discuss the possible long term consequences of sustained hyperuricemia • outline treatment options for patients with hyperuricemia and gout with emphasis on newer therapies

ACR PRACTICE ISSUE 1:00 - 2:00 pm

Mastering Patient Flow to Improve Practice Operations BR C cP

2 0 1 1

Moderator: C. Ryan Antolini, MD; Denver Arthritis Clinic; Denver, CO Speaker: Owen J. Dahl, MBA, CHBC; Owen Dahl Consulting; The Woodlands, TX Upon completion of this session, participants should be able to: • identify best practices on improving patient flow and efficiency in the exam room • outline proven tools, self-assessments, worksheets to center effective workflow for each patient visit • describe new technology trends in the process of improving practice operations and patient flow

8 ,

Clinician Educator Study Group W196a

Economic Evaluations: Measurement of Work and Worker Productivity W183a

Geographic Variation in Rheumatology Workforce W471b

Human Regulatory T Cell Biology W474a

Hypermobility II W476

Interdisciplinary Arthritis Management Group W194a

Juvenile Uveitis W192b

W196b

TUESDAY

Study Groups are non-CME activities, open to all attendees.

W475a

W375b

N o v e m b e r

1:00 - 2:00 pm

Macrophage Activation Syndrome W190a

Myositis Study Group: New Developments in Myositis Therapies W181b

Neuro Endocrine Immunology Study Group W195

Osteoarthritis W183c

Patient Feedback, Treatment Adherence and Disease Outcomes W470b

Psoriatic Arthritis Working Group


Skin Diseases

W194b

Education Redesign for Teaching Rheumatologists BR

Ed.

f

Moderator: Calvin R. Brown Jr., MD; Northwestern University; Chicago, IL Speaker: Lee Berkowitz, MD; University of North Carolina; Chapel Hill, NC Upon completion of this session, participants should be able to: • develop milestones for rheumatology training, from medical school through fellowship

94

W193a

2011 Program Book

ACR WORKSHOPS

1:15 - 3:15 pm

Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual.

W178b

Histopathology of Vasculitis (235) Speakers: Allen Burke, MD; University of Maryland Medical Center; Baltimore, MD Jonathon Heath, MD; University of Maryland Medical Center; Baltimore, MD

W179a

Muscle Involvement in Rheumatic Diseases (236) Speaker: Sakir Humayun Gultekin, MD; Oregan Health and Science University; Portland, OR

W178a

Musculoskeletal Imaging (237)

f

Speaker: William Morrison, MD; Thomas Jefferson University Hospital; Philadelphia, PA

ACR CONCURRENT ABSTRACT SESSION 1:45 - 4:00 pm

W375c

ACR Leadership Town Hall, Business Meeting and Late-breaking Abstracts 1:45 pm ACR Leadership Town Hall and Business Meeting This meeting is designed to provide members the opportunity to learn more about the College’s activities and provide a forum for interaction with the leadership.

2:30 pm Autoimmunity and Lymphomagenesis Lynn R. Goldin, PhD; National Institutes of Health, National Cancer Institute; Bethesda, MD 2:55 pm Mechanisms of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome Xavier Mariette, MD; Université Paris-Sud; Le Kremlin Bicetre, France 3:20 pm Pathogenic Mechanisms of Lymphoma Development in Autoimmune Disease To be announced Upon completion of this session, participants should be able to: • summarize the specific autoimmune diseases that have been demonstrated to be associated with an increased risk of lymphoma development, including the specific autoimmune diseases and lymphoma types, the strength of those associations, and limitations of the studies performed to date • discuss the disease features that characterize Sjögren’s syndrome patients of greatest risk of lymphoma development and the etiologic mechanisms implicated by those associations • describe the genes and pathways that are implicated in the development of both autoimmune disease and lymphoma based on their roles in inhibiting uncontrolled B-cell growth

W470b

Next-Generation Sequencing Applied to Rheumatic Diseases R Moderators: Robert M. Plenge, MD, PhD; Brigham and Women’s Hospital; Boston, MA Paul L. Klarenbeek, MD, MSc; Immunology and Allergy, Brigham and Women’s Hospital; Boston, MA

2:30 pm Late-breaking Abstract Presentations Moderator: Chester V. Oddis, MD; University of Pittsburgh; Pittsburgh, PA

3:20 pm Sequencing of Immunoglobulin Repertoires in Rheumatoid Arthritis William Robinson, MD, PhD; Stanford University School of Medicine; Stanford, CA

Mechanisms of Lymphoma Development in Systemic Autoimmune Disease R

2 0 1 1

W181a

8 ,

2:30 - 4:00 pm

2:55 pm Role of T-cell Receptor Sequencing in Rheumatic Diseases Niek De Vries, MD, PhD; Academic Medical Centre/University of Amsterdam; Amsterdam, Netherlands

TUESDAY

ACR BASIC SCIENCE SYMPOSIA

2:30 pm Large-Scale Sequencing in Patients with Rheumatoid Arthritis Peter K. Gregersen, MD; Feinstein Institute Medical Research; Manhasset, NY

N o v e m b e r

Moderator: David G. Borenstein, MD; Arthritis & Rheumatism Associates; Washington, DC Speakers: David G. Borenstein, MD; Arthritis & Rheumatism Associates; Washington, DC Joseph Flood, MD; Musculoskeletal Medical Specialists; Columbus, OH Nadine T. James, RN, PhD; Hattiesburg, MS James R. O’Dell, MD; University of Nebraska Medical Center; Omaha, NE E. William St.Clair, MD; Duke University Medical Center; Durham, NC Audrey B. Uknis, MD; Temple University School of Medicine; Philadelphia, PA

Upon completion of this session, participants should be able to: • define the role of next-generation sequencing in scientific discovery • recognize the difference between common and rare variants • describe the role of T-cell receptor and immunoglobulin locus in rheumatoid arthritis pathogenesis

Moderators: Corinne Miceli-Richard, MD, PhD; Hopital Bicêtre; Le Kremlin Bicêtre, France Lindsey A. Criswell, MD, MPH; University of California San Francisco; San Francisco, CA 2011 Program Book

95

ACR CLINICAL SYMPOSIA

ACR CONCURRENT ABSTRACT SESSIONS

2:30 - 4:00 pm

2:30 - 4:00 pm

W193a

W375b

The Neuromuscular System in Osteoarthritis

C

PM

Moderator: Jasvinder Singh, MD, MPH; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center; Birmingham, AL 2:30 pm Somatosensory Dysfunction and Osteoarthritis Najia Shakoor, MD; Rush University Medical Center; Chicago, IL 2:55 pm Muscle Weakness and Osteoarthritis Ewa M. Roos, PT, PhD; University of Southern Denmark; Odense, Denmark 3:20 pm Neuromuscular Training in Osteoarthritis Laura E. Thorp, MPT, PhD; Rush University Medical Center; Chicago, IL Upon completion of this session, participants should be able to: • describe afferent somatosensory deficits commonly observed in lower extremity osteoarthritis • explain the role of muscle weakness in osteoarthritis onset and progression • review current thoughts on the role of muscle training in osteoarthritis therapy

W375d

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

Vasculitis: Key Issues for the Clinician in Three Unique Diseases C cP Moderators: Robert Spiera, MD; Hospital for Special Surgery; New York, NY Carol A. Langford, MD, MHS; Cleveland Clinic; Cleveland, OH 2:30 pm Churg-Strauss Syndrome Michael E. Wechsler, MMSc, MD; Brigham and Women’s Hospital; Boston, MA 3:00 pm Primary Angiitis of the Central Nervous System Rula Hajj-Ali, MD; Cleveland Clinic Foundation; Cleveland, OH 3:30 pm Takayasu’s Arteritis Peter A. Merkel, MD, MPH; Boston University School of Medicine; Boston, MA Upon completion of this session, participants should be able to: • describe the similarities and differences for the management of asthma and vasculitis in Churg-Strauss syndrome • recognize how to differentiate primary angiitis of the central nervous system from other central nervous system diseases • identify the role of different imaging techniques in Takayasu’s arteritis and how useful they are in assessing disease activity

96

2011 Program Book

Biology and Pathology of Bone and Joint: Molecular Targets for an Effective Therapy Moderators: Mary B. Goldring, PhD; Hospital for Special Surgery/Weill Cornell Medical College; New York, NY Martin K. Lotz, MD; Scripps Research Institute; La Jolla, CA 2:30 pm 2433. Compromised Expression of the Complement Membrane Inhibitor CD59a Propagates Age-Related Joint Degeneration in Mice Vishal Paringe1, Anja C. Bloom1, Ernest Choy1, Bryan P. Morgan1 and Anwen S. Williams2, 1Cardiff University, Cardiff, ENGLAND, United Kingdom, 2Cardiff University, Cardiff, United Kingdom 2:45 pm 2434. F-Spondin (spondin-1) Null Mice Exhibit Increased Bone Formation Mukundan Attur1, Glyn Palmer1, James Liu1, Yang Qing2, Daniel Rifkin2, Frank Beier3 and Steven B. Abramson1, 1NYU Hospital for Joint Diseases, New York, NY, 2New York University School of Medicine, New York, NY, 3Schulich School of Medicine and Dentistry, London, ON 3:00 pm 2435. Synovial Wnt and Wnt-1-Induced Secreted Protein 1 Expression Induce Osteoarthritis-Like Cartilage Damage by Skewing of Transforming Growth Factor-Beta Signaling From Smad 2/3 towards Smad 1/5/8 Phosphorylation Martijn H. van den Bosch, Arjen B. Blom, Peter L. van Lent, Henk M. van Beuningen, Fons A. van de Loo, Esmeralda N. Blaney Davidson, Peter M. van der Kraan and Wim B. van den Berg, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 3:15 pm 2436. Inhibition of Osteoclast Formation by Adenosine A2A Receptor Is Due to Inhibition of NFkB Nuclear Translocation by a PKA-Mediated Mechanism Aranzazu Mediero1 and Bruce N. Cronstein2, 1NYU School of Medicine, New York, NY, 2New York Univ Medical Center, New York, NY 3:30 pm 2437. MicroRNA-453 Modulates Sonic Hedgehog Gene Expression in Human Chondrocytes by Directly Targeting Its Open Reading Frame Nahid Akhtar1 and Tariq M. Haqqi2, 1Case Western Reserve University/Metrohealth Medical Center, Cleveland, OH, 2Metro Health Medical Center/Case Western Reserve University, Cleveland, OH 3:45 pm 2438. The Unfolded Protein Response (UPR) Is Activated by Biomechanical Stress in Normal Cartilage Chondrocytes, but Priming of the UPR Prior to Mechanical Stress Results in Increased Cartilage Catabolism Matthew R. Husa1, Freyr Petturson1, Ron June1, Shawn Grogan2, Darryl D’Lima2, Martin K. Lotz2, Ru Liu-Bryan1 and Robert Terkeltaub1, 1UCSD/VAMC, La Jolla, CA, 2The Scripps Research Institute, La Jolla, CA

W194b

Epidemiology and Health Services Research VI: Lupus/Vasculitis Moderators: Karen H. Costenbader, MD, PPH; Brigham and Women’s Hospital; Boston, MA Meenakshi Jolly, MD, MS; Rush University Medical Center; Chicago, IL 2:30 pm 2439. Giant Cell Arteritis Is Associated with Incident Coronary Heart Disease-A Population-Based Study Gunnar Tomasson1, Johannes Bjornsson2, Michael P. LaValley3, Yuqing Zhang1, Vilmundur Gudnason4 and Peter A. Merkel1, 1 Boston University School of Medicine, Boston, MA, 2Landspitali University Hospital, Reykjavik, Iceland, 3Boston University School of Public Health, Boston, MA, 4The Icelandic Heart Association, Kopavogur 2:45 pm 2440. Incidence, Prevalence, and Mortality Rates of BiopsyProven Giant Cell Arteritis in Southern Sweden Aladdin Mohammad1, Jabbar Mohammad1, Jan-Åke Nilsson2, Lennart TH Jacobsson2, Peter A. Merkel3 and Carl Turesson2, 1 Skåne University Hospital, Lund, Sweden, 2Skåne University Hospital, Malmö, Sweden, 3Boston University School of Medicine, Boston, MA

2:30 pm 2445. Rilonacept (Interleukin-1 Trap) for Treatment of Colchicine Resistant Familial Mediterranean Fever: A Randomized, Multicenter Double-Blinded, Alternating Treatment Phase II Trial Philip J. Hashkes1, Steven J. Spalding2, Edward H. Giannini3, Bin Huang4, Grace Park5, Karyl S. Barron6, Michael H. Weisman7, Noune Pashinian8, Andreas Reiff9, Jonathan Samuels10, Dowain A. Wright11, Daniel L. Kastner12 and Daniel J. Lovell4, 1Cleveland Clinic/Shaare Zedek Medical Center, Jerusalem, Israel, 2Cleveland Clinic, Cleveland, OH, 3PRCSG-Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5National Institutes of Health/ NHGRI, Bethesda, MD, 6NIAID-NIH, Bethesda, MD, 7Cedars Sinai Med Ctr, Los Angeles, CA, 8Glendale, CA, 9PRSCG, Los Angeles, CA, 10NYU Hospital for Joint Diseases, New York, NY, 11Childrens Hospital Central Cal, Madera, CA, 12National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 2:45 pm 2446. Interleukin-1 Beta It Is: High Efficacy of Canakinumab In Schnitzler Syndrome Heleen D. de Koning, Joost Schalkwijk, Johanna van der VenJongekrijg, Monique Stoffels, Jos W. M. van der Meer and Anna Simon, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 3:00 pm 2447. Proteasome Disability Syndrome: An Analysis of the Pathogenesis of a New Autoinflammatory Syndrome, NakajoNishimura Syndrome Hiroaki Ida1, Kazuhiko Arima2, Nobuo Kanazawa3 and Koh-ichiro Yoshiura2, 1Kurume University School of Medicine, Kurume, Japan, 2Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Wakayama Medical University, Wakayama, Japan

2 0 1 1

3:45 pm 2444. The Georgia Lupus Registry: The Incidence and Prevalence of Systemic Lupus Erythematosus S. Sam Lim1, Rana Bayakly2, C. Gordon3, Charles G. Helmick4, Kirk Easley5, Gaobin Bao1, Neeta Shenvi5 and Cristina M. Drenkard1, 1 Emory University, Atlanta, GA, 2Georgia Department of Public

Moderators: W. Chatham, MD; University of Alabama at Birmingham; Birmingham, AL Kristine M. Lohr, MD, MS; University of Kentucky; Lexington, KY

8 ,

3:30 pm 2443. The Natural History and Predictive Factors of Long Term Outcomes in Systemic Lupus Erythematosus Penny Watson1, Alan Brennan1, Helen Birch2, Hong Fang3 and Michelle Petri3, 1University of Sheffield, Sheffield, United Kingdom, 2GlaxoSmithKline, Uxbridge, United Kingdom, 3Johns Hopkins University School of Medicine, Baltimore, MD

Miscellaneous Rheumatic and Inflammatory Diseases

TUESDAY

3:15 pm 2442. Socioeconomic Status and Survival in Systemic Lupus Erythematosus: Results From the Michigan Lupus Epidemiology and Surveillance (MILES) Program Sarah M. Barnhart1, W. Joseph McCune1, Wendy Marder1, Patricia C. Cagnoli1, Emily E. Lewis1, Peter DeGuire2, C. Gordon3, Charles G. Helmick4, J. Patricia Dhar5, James C. Leisen6, Emily C. Somers1 and MILES Group7, 1University of Michigan, Ann Arbor, MI, 2MI Dept of Community Health, Lansing, MI, 3University of Birmingham, Birmingham, United Kingdom, 4Centers for Disease Control and Prevention, Atlanta, GA, 5Wayne State University, Detroit, MI, 6Henry Ford Hospital, Detroit, MI, 7Ann Arbor, MI

W471b

N o v e m b e r

3:00 pm 2441. Prevalence and Demographics of Systemic Lupus Erythematosus and Lupus Nephritis Among U.S. Adults with Medicaid Coverage, 2002-2004 Candace H. Feldman1, Linda T. Hiraki2, Daniel H. Solomon1, Tamara Shaykevich1, Michael A. Fischer1, Wolfgang C. Winkelmayer3 and Karen H. Costenbader1, 1Brigham and Women’s Hospital, Boston, MA, 2Brigham and Women’s Hospital/ Harvard School of Public Health, Boston, MA, 3Stanford University School of Medicine, Stanford, CA

Health, Atlanta, GA, 3University of Birmingham, Birmingham, United Kingdom, 4Centers for Disease Control and Prevention, Atlanta, GA, 5Emory University-Rollins School of Public Health, Atlanta, GA

3:15 pm 2448. Progressive Multifocal Leukoencephalopathy Associated with Immunosuppressive Therapy in Rheumatic Diseases: Evolving Role of Biologic Therapies Eamonn S. Molloy1 and Leonard H. Calabrese2, 1st Vincent’s University Hospital, Dublin 4, Ireland, 2Cleveland Clinic, Cleveland, OH 3:30 pm 2449. Pulmonary and Extrapulmonary Recurrence of Sarcoidosis After Lung Transplantation Fariha Kausar1, Troy K. Takagishi1, Rochella A. Ostrowski2 and Rodney Tehrani3, 1Loyola University Medical Center, Maywood, IL, 2Loyola Univ Medical Ctr, Maywood, IL, 3Loyola Univ Medical Center, Maywood, IL 2011 Program Book

97

3:45 pm 2450. TNFRSF1A and MFEV Mutations in Idiopathic Recurrent Acute Pericarditis Guillaume Geri1, Pierre Hausfater2, Catherine Dodé3, Nathalie Costedoat-Chalumeau1, Zahir Amoura1, Jean-Charles Piette1, Damien Sène1, David Saadoun4 and Patrice Cacoub1, 1CHU PitiéSalpêtrière, Paris, France, 2Department of Emergency , CHU Pitié Salpetriere, 47-83 Boulevard de l’hôpital, 75651 Paris cedex 13 France, Paris, France, 3Biochemistry and Molecular Genetic, CHU Cochin, rue du Faubourg Saint Jacques, 75014 Paris, France, Paris, France, 4Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France

W196a

Pediatric Rheumatology – Clinical and Therapeutic Aspects: Predictors and Outcomes Moderators: Daniel J. Lovell, MD, MPH; Cincinnati Children’s Hospital Medical Center; Cincinnati, OH Marilynn G. Punaro, MD; Texas Scottish Rite Hospital; Dallas, TX

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

2:30 pm 2451. Predictors of Organ Damage Despite Serologic Remission in a Subset of Patients with Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cailin H. Sibley1, Nicole Plass1, Carmen Brewer2, Kelly King2, Christopher Zalewski2, H. Jeffrey Kim2, Rachel Bishop3, Patrick Kicker1, Zachary Phillips1, Joseph G. Dolan1, Deborah Stone4, Dawn C. Chapelle Neal1, Christopher Snyder1, John Butman5, Robert Wesley5 and Raphaela T. Goldbach-Mansky1, 1NIAMS / NIH, Bethesda, MD, 2NIDCD / NIH, Bethesda, MD, 3NEI / NIH, Bethesda, MD, 4NHGRI / NIH, Bethesda, MD, 5NIH, Bethesda, MD 2:45 pm 2452. Impact of MEFV Mutations in Caucasian Children with Periodic Fevers: Clinical Evidence for a Gain of Function Effect. Silvia Federici1, Giuseppina Calcagno2, Martina Finetti3, Romina Gallizzi4, Antonella Meini5, Agata Vitale2, Francesco Caroli1, Marco Cattalini5, Roberta Caorsi1, Francesco Zulian6, Alberto Tommasini7, Antonella Insalaco8, Maria Pia Sormani9, Maurizia Baldi10, Isabella Ceccherini1, Alberto Martini3 and Marco Gattorno1, 1G. Gaslini Institute, Genova, Italy, 2Sezione di Reumatologia Pediatrica, Università di Messina, Messina, Italy, 3IRCCS G Gaslini, Pediatria II, Reumatologia, Genova, Italy, 4 Sezione di Immunologia e Reumatologia Pediatrica, Università di Messina, Messina, Italy, 5Dipartimento di Pediatria, University of Brescia, Brescia, Italy, 6University of Padua, Padova, Italy, 7 Dipartimento di Pediatria, Univerity of Trieste, Trieste, Italy, 8 Divisione di Reumatologia, Ospedale Pediatrico Bambino Gesù, Roma, Italy, 9Unità di Biostatistica, DISSAL, University of Genoa, Genova, Italy, 10Ospedale Galliera, Genova, Italy 3:00 pm 2453. Development of a Clinical Disease Activity Measure for Juvenile Localized Scleroderma Suzanne C. Li1, Kathryn S. Torok2, Elena Pope3, Katie G. Stewart4, Gloria C. Higgins5, Egla C. Rabinovich6, Kathleen M. O’Neil7, Ivan Foeldvari8, Kathleen A. Haines1, Heidi Jacobe9, Marilynn G. Punaro4, Ronald M. Laxer10, Themba Nyirenda1 and Knut

98

2011 Program Book

M. Wittkowski11, 1Hackensack University Medical Center, Hackensack, NJ, 2Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3 Hospital for Sick Children, Toronto, ON, 4Texas Scottish Rite Hospital, Dallas, TX, 5Nationwide Childrens Hosp, Columbus, OH, 6 Duke University Medical Center, Durham, NC, 7Okla Univ Health Science Ctr, Oklahoma City, OK, 8Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, 9UT Southwestern Medical Center at Dallas, Dallas, TX, 10The Hospital for Sick Children, Toronto, ON, 11Rockefeller University, NY 3:15 pm 2454. Defining Clinical Remission and Inactive Disease in Juvenile Systemic Lupus Erythematosus Rina Mina1, Laura E. Schanberg2, Marisa Klein-Gitelman3, B. Anne Eberhard4, Gloria Higgins5, Karen Onel6, Nora G. Singer7, Kathleen M. O’Neil8, Deborah M. Levy9, Shannen L. Nelson10, Wajeeha Yousaf11, Rubén J. Cuttica12, Lori B. Tucker13, Michael W. Beresford14, Graciela Espada15, Angelo Ravelli16, Alberto Martini17, Edward H. Giannini18 and Hermine Brunner19, 1Cincinnati Children’s Med Ctr, Cincinnati, OH, 2Duke University Medical Center, Durham, NC, 3Children’s Memorial Hospital, Chicago, IL, 4Cohen Children’s Hospital Medical Center, New Hyde Park, NY, 5PRCSG, Columbus, OH, 6University of Chicago, Chicago, IL, 7 MetroHealth Medical Center, Cleveland, OH, 8Okla Univ Health Science Ctr, Oklahoma City, OK, 9The Hospital for Sick Children, Toronto, ON, 10Cincinnati Children’s Hospital, Cincinnati, OH, 11 University of Cincinnati, 12Hospital de Pediatría Pedro de Elizalde, Buenos Aires, Argentina, 13BC Childrens Hospital, Vancouver, BC, 14Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom, 15Childrens Hosp Ricardo Gutierrez, Buenos Aires, Argentina, 16Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy, 17IRCCS G Gaslini, Pediatria II, Reumatologia, Genova, Italy, 18PRCSG-Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 19Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 3:30 pm 2455. Cancer Risk In Pediatric Systemic Lupus: Updated Analyses Sasha Bernatsky1, Rosalind Ramsey-Goldman2, Earl D. Silverman3, Ciaran M. Duffy4, Kiem Oen5, Alan M. Rosenberg6, Laura E. Schanberg7, Kathleen M. O’Neil8, Emily von Scheven9, Jeremy Labrecque1, Elizabeth M. Turnbull1 and Ann E. Clarke1, 1Research Institute of the McGill Univ. Health Ctre, Montreal, QC, 2 Northwestern University, Chicago, IL, 3Hospital for Sick Children, Toronto, ON, 4Children’s Hospital of Eastern Ontario, Ottawa, ON, 5University of Manitoba, Winnipeg, MB, 6Royal University Hospital, Saskatoon, SK, 7Duke University Medical Center, Durham, NC, 8Okla Univ Health Science Ctr, Oklahoma City, OK, 9 UC San Francisco, San Francisco, CA 3:45 pm 2456. Distinct Functional Activation and Connectivity Patterns for a Visuo-Constructional Task in Childhood-Onset Systemic Lupus Erythematosus and Matched Controls Marisa Klein-Gitelman1, Adlin Cedeno1, Aimee Baker2, Frank Zelko1, Dean Beebe2, Blair Dina1, Anna Carmela P. SagcalGironella3, Darren Gitelman4, Hermine Brunner2, Mark Difrancesco2 and Brian Zappia2, 1Children’s Memorial Hospital, Chicago, IL, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Cincinnati Children’s Hospital, Cincinnati, OH, 4 Northwestern University, Chicago, IL

W196b

Rheumatoid Arthritis Clinical Aspects: Diagnostic and Remission Criteria Moderators: Joseph A. Markenson, MD; Hospital for Special Surgery; New York, NY Deborah P.M. Symmons, MD; The University of Manchester; Manchester, United Kingdom 2:30 pm 2457. Patients with a Severe Clinical Disease Course Can Be Identified Using Cluster Analysis – Results From a Canadian National Early Arthritis Cohort Ye Sun1, Cindy Lim2, Gilles Boire3, Boulos Haraoui4, Carol A. Hitchon5, Edward C. Keystone6, Janet E. Pope7, J. Carter Thorne8, Diane S. Ferland9, Vivian P. Bykerk10 and CATCH Investigators11, 1 Mount Sinai Hospital, Toronto, ON, 2Mount Sinai Hospital, Toronto, 3CHUS - Sherbrooke University, Sherbrooke, QC, 4Institut de Rhumatologie, Montreal, QC, 5University of Manitoba, Winnipeg, MB, 6Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, 7St. Joseph’s Health Care, University of Western Ontario, London, ON, 8Southlake Regional Health Centre, Newmarket, Newmarket, ON, 9LaSalle, QC, 10Brigham & Women’s Hospital, Boston, MA, 11 Canada 2:45 pm 2458. Defining Erosive DISEASE Typical of RA In the LIGHT of the 2010 ACR/EULAR Criteria for Rheumatoid Arthritis –PHASE 1. R. Knevel1, Désirée van der Heijde1, Tom W.J. Huizinga1, Cédric Lukas2, Bernard G. Combe2 and Annette H.M. van der Helm-van Mil1, 1Leiden University Medical Center, Leiden, Netherlands, 2 Hopital Lapeyronie, Montpellier, France

W375a

Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy: Existing Disease Modifying Antirheumatic Drugs and Corticosteroids Moderators: Daniel E. Furst, MD; University of California Los Angeles Medical School; Los Angeles, CA Paul Emery, MA, MD; Chapel Allerton Hospital; Leeds, United Kingdom

2 0 1 1

2:45 pm 2464. Successful Tapering of Glucocorticoids (GC) in Rheumatoid Arthritis Patients-Results From the Consortium of Rheumatology Researchers of North America Registry Thasia G. Woodworth1, Elizabeth Thomas2, Jeffrey D. Greenberg3 and Daniel E. Furst4, 1Leading Edge Clinical Research, Stuart, FL, 2 Axio Research, LLC, Seattle, WA, 3New York University School of Medicine, New York, NY, 4UCLA, Los Angeles, CA

8 ,

2:30 pm 2463. Immediate and Delayed Impact of Oral Glucocorticoid Therapy On Risk of Serious Infection In Patients with Rheumatoid Arthritis: A Nested Case-Control Analysis Using a Weighted Cumulative Dose Model William G. Dixon1, Michal Abrahamowicz2, Marie-Eve Beauchamp2, David W. Ray3, Sasha Bernatsky4, Samy Suissa5 and Marie-Pierre Sylvestre6, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2McGill University, Montreal, QC, 3The University of Manchester, Manchester, United Kingdom, 4McGill UHC/ RVH, Montreal, QC, 5Royal Victoria Hosp, McGill Un, Montreal, 6 University of Montreal, Montreal, QC

TUESDAY

3:15 pm 2460. Performance of the New ACR/EULAR Remission Criteria Compared to DAS28 Remission in Unselected Real-Life Patients with Rheumatoid Arthritis Dörte Huscher1, Katja Thiele2, Sascha Bischoff2, Marina Backhaus3, Martin Aringer4, Ina Kötter5 and Angela Zink1, 1 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Charité University Medicine, Berlin, Germany, 4Uniklinikum TU Dresden, Dresden, Germany, 5 Department of Internal Medicine II, Rheumatology Division, Tübingen, Germany

3:45 pm 2462. Title: American College of Rheumatology/European League Aganist Rheumatism Remission Criteria Achievement in Rheumatoid Arthritis: Data From 32 Countries Nasim A. Khan1, Tuulikki Sokka2 and QUEST-RA3, 1University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, 2Jyvaskyla Central Hosp, Jyväskylä, Finland, 3Jyväskylä

N o v e m b e r

3:00 pm 2459. The New ACR/EULAR Definition of Remission in Rheumatoid Arthritis: A Comment on the Patient Global Assessment Criterion Marloes Vermeer1, Ina H. Kuper1, Arie E. van der Bijl2, Hetty Baan3, Marcel D. Posthumus4, Herman L.M. Brus5, Piet L.C.M. van Riel6 and Mart A.F.J. van de Laar1, 1University of Twente & Medisch Spectrum Twente, Enschede, Netherlands, 2Isala Klinieken, Zwolle, Netherlands, 3Ziekenhuisgroep Twente, Almelo, Netherlands, 4University Medical Center Groningen, Groningen, Netherlands, 5TweeSteden Ziekenhuis, Tilburg, Netherlands, 6Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

3:30 pm 2461. RAPID3 Remission Vs New ACR Rheumatoid Arthritis Remission Criteria: RAPID3 Has Similar Utility and May Be Used in Everyday Clinical Care Yusuf Yazici1, Maria T. Filopoulos2 and Christopher J. Swearingen3, 1 Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 2 NYU Hospital for Joint Diseases, New York, NY, 3University of Arkansas for Medical Sciences, Little Rock, AR

3:00 pm 2465. Preliminary Results of a Multicentre Randomised Controlled Trial of Etanercept and Methotrexate to Induce Remission in Patients with Newly Diagnosed Inflammatory Arthritis Edith Villeneuve1, Jackie L. Nam2, Elizabeth Hensor3, Richard J. Wakefield4, Philip G. Conaghan5, Mike J. Green6, Andrew K. Gough7, Mark Quinn8, Richard J. Reece9, Sally R. Cox10 and Paul Emery11, 1Leeds Institute of Molecular Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, 2NIHR Leeds Musculoskeletal Biomedical Research Unit , LIMM, 2011 Program Book

99

University of Leeds., Leeds, United Kingdom, 3NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals, Leeds, United Kingdom, 5NIHRLeeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 6 York Teaching Hospital NHS Foundation Trust, Harrogate, United Kingdom, 7Harrogate District Hospital, Harrogate, United Kingdom, 8The York Hospital, York Teaching Hospital NHS Foundation Trust, York, United Kingdom, 9University of Birmingham, Birmingham, United Kingdom, 10SA Pathology / Flinders Medical Centre, Adelaide, Australia, 11Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom 3:15 pm 2466. Subsequent Therapy of Patients with Biologic Response Modifiers or Disease-Modifying Antirheumatic Drugs After Coccidioidomycosis Susan Knowles1, Sara Taroumian1, Jeffrey R. Lisse1, James Yanes1, Neil M. Ampel2, Eric P. Gall3, Rafael G. Grau1, Barbara Y. Bode2, Berchman A. Vaz4, John Galgiani5 and Susan E. Hoover1, 1 University of Arizona, Tucson, AZ, 2Southern AZ VA Medical Center, Tucson, AZ, 3Arizona Arthritis Center, Tucson, AZ, 4 Catalina Pointe Arthritis and Rheumatology, Tucson, AZ, 5Valley Fever Center for Excellence, Tucson, AZ

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

3:30 pm 2467. Red Blood Cell Folate Polyglutamates Are An Important Determinant of RA Disease Activity In Patients On Methotrexate – Implications for Folic Acid Supplementation Lisa K. Stamp1, Peter T. Chapman2, Murray Barclay1, Joel M. Kremer3 and Thierry Dervieux4, 1University of Otago, Christchurch, Christchurch, New Zealand, 2Christchurch Hospital, Christchurch, New Zealand, 3Albany Medical College and The Center for Rheumatology, Albany, NY, 43Exagen Diagnostics, Albuquerque, NM 3:45 pm 2468. Discontinuation of Adalimumab without Functional and Structural Progress After Attaining Remission in Patients with Rheumatoid Arthritis Yoshiya Tanaka1, Shintaro Hirata1, Shunsuke Fukuyo1, Masao Nawata2, Satoshi Kubo1, Kunihiro Yamaoka2 and Kazuyoshi Saito1, 1University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 2University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

W183a

Systemic Lupus Erythematosus – Clinical Aspects: New Therapies Moderators: Sandra Navarra, MD; University of Santo Tomas Hospital; Manila, Philippines C. Aranow, MD; Feinstein Institute for Medical Research; Manhasset, NY

100

2011 Program Book

2:30 pm 2469. Efficacy and Safety of Abatacept Over 12 Months in Patients with Lupus Nephritis: Results From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study Richard Furie1, Kathy Nicholls2, Tien-Tsai Cheng3, Frederic Houssiau4, Ruben Burgos-Vargas5, Shun-Le Chen6, Richard Aranda7, Stephanie Meadows-Shropshire8, Michael Kinaszczuk8 and Joan T. Merrill9, 1North Shore-Long Island Jewish Health System, Lake Success, NY, 2Royal Melbourne Hospital, Victoria, Australia, 3Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 4 Cliniques Universitaires Saint-Luc, Brussels, Belgium, 5Hospital General de Mexico, Mexico City, Mexico, 6Joint Molecular Rheumatology Laboratory of Institute of Health Sciences and Shanghai Ren Ji Hospital, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China, 7BristolMyers Squibb [at time of study], Princeton, NJ, 8Bristol-Myers Squibb, Princeton, NJ, 9Oklahoma Medical Research Foundation, Oklahoma City, OK 2:45 pm 2470. Active Immunization Against IFNα with IFN-Kinoid in SLE Patients Is Safe, Immunogenic and Induces Down-Regulation of IFN-Mediated Genes Frédéric. A. Houssiau1, Raskov Rashkov2, Eric Hachulla3, Estibaliz Lazaro4, Christian Jorgensen5, François Spertini6, Xavier Mariette7, Géraldine Grouard-Vogel8, Bernard Fanget8, Olivier Dhellin8, Bernard Lauwerys1 and Pierre Vandepapelière8, 1 Université catholique de Louvain, Brussels, Belgium, 2MHAT Sveti Ivan Rilski, Sofia, Bulgaria, 3Internal Medicine, Lille CEDEX, France, 4Hôpital Haut-Lévêque, Pessac, France, 5Hospital Lapeyronie, Montpellier, France, 6CHU Vaudois, Lausanne, Switzerland, 7Université Paris-Sud, Le Kremlin Bicetre, France, 8 NEOVACS SA, Paris, France 3:00 pm 2471. Omega-3 in Systemic Lupus Erythematosus: A DoubleBlind, Placebo-Controlled Randomized Clinical Trial In Systemic Lupus Erythematosus Kayode J. Bello1, Hong Fang1, Laurence S. Magder2 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD 3:15 pm 2472. Effect of Belimumab Treatment on Renal Outcomes: Results From Phase 3 Belimumab Clinical Trials in Patients with Systemic Lupus Erythematosus M.A. Dooley1, F. Houssiau2, C. Aranow3, D.P. D’Cruz4, Anca D. Askanase5, D. Roth6, Z.J. Zhong7, W. Freimuth7, E.M. Ginzler8 and BLISS-52/-76 Study Groups9, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Université catholique de Louvain, Brussels, Belgium, 3Feinstein Institute for Medical Research, Manhasset, NY, 4St. Thomas’ Hospital, London, United Kingdom, 5 NYU School of Medicine, New York, NY, 6GlaxoSmithKline, King of Prussia, PA, 7Human Genome Sciences, Inc., Rockville, MD, 8 SUNY-Downstate Medical Center, Brooklyn, NY, 9Multicenter

3:30 pm 2473. Allogeneic Mesenchymal Stem Cells Transplantation in Severe and Refractory Systemic Lupus Erythematosus-Four Years Follow up Lingyun Sun, Dandan Wang, Huayong Zhang, Xia Li and Xuebing Feng, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 3:45 pm 2474. Abatacept for Lupus Nephritis: Alternative Outcome Measures Support Opposing Interpretations of Data From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study David Wofsy1, Stephanie Meadows Shropshire2, Jan L. Hillson3 and Betty Diamond4, 1VA Medical Center, San Francisco, CA, 2 Bristol-Myers Squibb, Richmond, VA, 3ZymoGenetics Inc., Seattle, WA, 4Feinstein Institute Med Rsch, Manhasset, NY

W474a

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II: Genetics Moderators: Kathy L. Moser, PhD; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Oklahoma City, OK Betty P. Tsao, PhD; University of California Los Angeles School of Medicine; Los Angeles, CA

8 , 2 0 1 1

3:00 pm 2477. Risk Alleles of SLE Associated IL10 SNPs Conferred Differential Binding to Transcription Factors Daisuke Sakurai1, Jian Zhao1, Yun Deng1, Kenneth Kaufman2, Jennifer A. Kelly3, Robert P. Kimberly on behalf of PROFILE investigators4, Marta E. Alarcón-Riquelme on behalf of the BIOLUPUS and GENLES networ5, John B. Harley6, Sang-Cheol Bae7, Chaim O. Jacob8, Timothy J. Vyse9, Timothy B. Niewold10, Patrick M. Gaffney11, Kathy L. Moser11, Judith A. James12, Gary S. Gilkeson13, Diane L. Kamen14, Carl D. Langefeld15, Deh-Ming Chang16, Yeong Wook Song17, Chack-Yung Yu18, Jennifer M. Grossman19, Rita M. Cantor20, Bevra H. Hahn19 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5 Oklahoma Medical Research Foundation; Center for Genomics 2011 Program Book

TUESDAY

2:45 pm 2476. Identification of Novel Genetic Susceptibility Loci In African-American lupus patients Using a Candidate Gene Association Study Elena Sanchez1, Mary E. Comeau2, Barry I. Freedman2, Jennifer A. Kelly1, Kenneth Kaufman3, Carl D. Langefeld2, Elizabeth E. Brown for PROFILE4, Graciela S. Alarcon4, Robert P. Kimberly4, Jeffrey C. Edberg5, Rosalind Ramsey-Goldman6, M. Petri7, John D. Reveille8, Luis M. Vila9, J.T. Merrill1, Betty P. Tsao10, Diane L. Kamen11, Gary S. Gilkeson12, Judith A. James13, Tomothy J. Vyse14, Patrick M. Gaffney15, Chaim O. Jacob16, Timothy B. Niewold17, Bruce C. Richardson18, John B. Harley19, Marta E. Alarcon-Riquelme20 and Amr H. Sawalha1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Wake Forest University Health Sciences, Winston-Salem, NC, 3Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 4University of Alabama at Birmingham, Birmingham, AL, 5Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 6Northwestern University, Chicago, IL, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8University of Texas Health Science Center at Houston, Houston, TX, 9University of PuertoRico Medical Sciences Campus, San Juan, PR, 10UCLA School of Medicine, Los Angeles, CA, 11Medical University of SC, Charleston, SC, 12Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 13Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 14King’s College London, Guy’s Hospital, London, United Kingdom, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 17University of Chicago, Chicago, IL, 18University of Michigan, Ann Arbor, MI, 19Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 20Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK

N o v e m b e r

2:30 pm 2475. A Large-Scale, Multi-Racial Replication Study Identifies Novel Systemic Lupus Erythematosus Susceptibility Loci At IRF8, TMEM39A, and IKZF3/ZPBP2 Christopher J. Lessard1, Indra Adrianto1, John A. Ice1, Jennifer A. Kelly1, He Li1, Graham B. Wiley1, Astrid Rasmussen1, Marta E. Alarcon-Riquelme2, Juan-Manuel Anaya3, Sang-Cheol Bae4, Elizabeth E. Brown for PROFILE5, Chaim O. Jacob6, Judith A. James7, Javier Martin8, Timothy B. Niewold9, Bernardo PonsEstel10, Betty P. Tsao11, Timothy J. Vyse12, John B. Harley13, Edward Wakeland14, Kenneth M. Kaufman15, Courtney Montgomery1, Carl D. Langefeld16, Patrick M. Gaffney17 and Kathy L. Moser17, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 3Universidad del RosarioCorporacion para Investigaciones Biologicas, Bogota, Colombia, 4 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 5University of Alabama at Birmingham, Birmingham, AL, 6Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 7Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 8Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 9University of Chicago, Chicago, IL, 10Rosario, Argentina, 11UCLA School of Medicine, Los Angeles, CA, 12Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 13Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 14Univ of Texas SW Med Ctr, Dallas, TX, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 16Wake Forest University

Health Sciences, Winston-Salem, NC, 17Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

101

and Oncological Research, Oklahoma City; Granada, Spain, OK, 6Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 8Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 9 Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 10University of Chicago, Chicago, IL, 11Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 13Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 14Medical University of SC, Charleston, SC, 15Wake Forest University Health Sciences, Winston-Salem, NC, 16National Defense Medical Center, Taipei, 17 Seoul National University College of Medicine, Seoul, South Korea, 187Center for Molecular and Human Genetics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Columbus, OH, 19UCLA David Geffen School of Medicine, Los Angeles, CA, 20University of California Los Angeles, Los Angeles, CA

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

3:15 pm 2478. Determination of the Contribution of An IRF5-SLE Risk Haplotype to IRF5 expression and Alternative Splicing Using Next-Generation Sequencing Rivka Stone1, Peicheng Du2, Di Feng1, Lars Ronnblom3, MaijaLeena Eloranta4, Robert Donnelly1 and Betsy Barnes1, 1University of Medicine and Dentistry of New Jersey, Newark, NJ, 2New Jersey Medical School, Newark, NJ, 3Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 4Section of Rheumatology, Uppsala University, Uppsala, Sweden

102

3:30 pm 2479. Lupus Nephritis Susceptibility Markers in PDGRFA-GSX2, SLC5A11, ID4, and HAS2-SNTB1 Regions Identified From a Meta-Analysis of Genome Wide Association Studies of Women with Systemic Lupus Erythematosus Sharon A. Chung1, Elizabeth E. Brown2, Adrienne H. Williams3, Tushar Bhangale4, Paula S. Ramos3, Julie T. Ziegler3, Barry I. Freedman3, Robert P. Kimberly2, Timothy J. Vyse5, Peter K. Gregersen6, Chaim O. Jacob7, Marta E. Alarcon-Riquelme8, Betty P. Tsao9, John B. Harley10, Timothy W. Behrens4, M. Petri11, M. Ilyas Kamboh12, F. Yesim Demirci12, Susan Manzi13, Lindsey A. Criswell1, Kathy L. Moser14, Patrick M. Gaffney14, Robert R. Graham4 and Carl D. Langefeld3, 1University of California, San Francisco, San Francisco, CA, 2University of Alabama at Birmingham, Birmingham, AL, 3Wake Forest School of Medicine, Winston-Salem, NC, 4Genentech, Inc., South San Francisco, CA, 5 King’s College London, London, United Kingdom, 6Feinstein Institute for Medical Research, Manhasset, NY, 7University of Southern California, Los Angeles, CA, 8Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 9University of California, Los Angeles, Los Angeles, CA, 10Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 11Johns Hopkins University School of Medicine, 2011 Program Book

Baltimore, MD, 12University of Pittsburgh, Pittsburgh, PA, 13 Allegheny Singer Research Institute, Pittsburgh, PA, 14Oklahoma Medical Research Foundation, Oklahoma City, OK 3:45 pm 2480. Association of STAT4, IRF5 and BLK Polymorphisms with Severity and Outcome in Lupus Nephritis Karin G. Eriksson1, Agneta Zickert2, Johanna K. Sandling3, Andreas Jönsen4, Elisabet Svenungsson2, Lars Rönnblom1, Timothy W. Behrens5, Robert R. Graham5, Ward Ortmann5, Ann-Christine Syvänen3, Iva Gunnarsson2 and Gunnel Nordmark6, 1Section of Rheumatology, Uppsala University, Uppsala, Sweden, 2 Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 3 Molecular Medicine, Uppsala University, Uppsala, Sweden, 4 Section of Rheumatology, Lund University, Lund, Sweden, 5 Genentech Inc, South San Francisco, CA, 6Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden

W192b

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Clinical Aspects and Therapeutics III Moderators: Tatiana S. Rodriguez-Reyna, MD; National Institute of medical Sciences and Nutrition; Mexico City, Mexico Ariane Herrick, MD; University of Manchester, Manchester Academic Health Science Centre; Manchester, United Kingdom 2:30 pm 2481. Effect of Warfarin On Survival In Scleroderma-Associated and Idiopathic Pulmonary Arterial Hypertension. A Bayesian Approach to Evaluating Treatment In Uncommon Disease Sindhu R. Johnson1, John T. Granton2, George A. Tomlinson2, Haddas Grosbein3, Thaolan Le4, Peter Lee5, M. Elizabeth Seary3, Gillian A. Hawker6 and Brian M. Feldman3, 1Toronto Western Hospital, Toronto, ON, 2University of Toronto, Toronto, ON, 3 The Hospital for Sick Children, Toronto, ON, 4University Health Network Pulmonary Hypertension Programme, Toronto, ON, 5 Mt. Sinai Hospital, Toronto, ON, 6Women’s College Hospital, Toronto, ON 2:45 pm 2482. Diffusion of Carbon Monoxide Predicts Survival in Systemic Sclerosis Patients with Pulmonary Hypertension and Interstitial Lung Disease Benjamin E. Schreiber1, Chris Valerio1, Greg Keir2, Clive Handler1, Athol U. Wells2, Christopher P. Denton3 and John G. Coghlan1, 1 Royal Free Hospital, London, London, United Kingdom, 2Royal Brompton Hospital, United Kingdom, 3UCL Medical School, London, United Kingdom 3:00 pm 2483. Digital Ischemic Ulcers in Scleroderma Treated with Oral Treprostinil Diethanolamine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study James R. Seibold1, Fredrick M. Wigley2, Elena Schiopu3, Christopher D. Denton4, Richard M. Silver5, Virginia D. Steen6, Thomas A. Medsger Jr.7, Maureen D. Mayes8, Soumya Chatterjee9, Lorinda Chung10, Mary Ellen Csuka11, Dinesh Khanna3, Tracy M. Frech12, Jerry A. Molitor13, Naomi F. Rothfield14, Ariane L. Herrick15, Robert W. Simms16, Janet E. Pope17, Kristan D. Rollins18, Carl Arneson18, Michael Wade18 and on behalf of DISTOL Investigators19, 1Scleroderma Research

Consultants LLC, Avon, CT, 2Johns Hopkins University, Baltimore, MD, 3University of Michigan, Ann Arbor, MI, 4Royal Free Hospital, Medical School, London, England, 5MUSC, Charleston, SC, 6 Georgetown Univ Medical Center, Washington, DC, 7Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 8University of Texas Health Science Center at Houston, Houston, TX, 9Cleveland Clinic, Cleveland, OH, 10Stanford Univ Medical Center, Palo Alto, CA, 11 Medical College of Wisconsin, Milwaukee, WI, 12University of Utah School of Medicine, SLC, UT, 13Univ of MN MMC108, Minneapolis, MN, 14University of Connecticut, Farmington, CT, 15 School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 16Boston University School Medical, Boston, MA, 17St. Joseph’s Health Care, University of Western Ontario, London, ON, 18United Therapeutics Corp, Research Triangle Park, NC, 19DISTOL Investigator Centers 3:15 pm 2484. Microvascular Damage and Cardiac Fibrosis Detected by Heart MRI are a Hallmark of Systemic Sclerosis Heart Involvement Tatiana Sofia Rodriguez-Reyna, Martha Morelos-Guzman, Pablo Hernandez-Reyes, Jaime Morales-Blanhir, Karla Montero-Duarte, Cynthia Martinez-Reyes, Carlos Reyes-Utrera and Jorge VazquezLamadrid, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico 3:30 pm 2485. Development and Internal Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients Robyn T. Domsic1, Mary Lucas1, Stephen R. Wisniewski2, C. Kent Kwoh3, Michael J. Fine3 and Thomas A. Medsger1, 1University of Pittsburgh, Pittsburgh, PA, 2Univ of Pittsburgh, Pittsburgh, PA, 3 University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA

2:30 pm 2486A. Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis – Results From a Phase 3 Study Joachim Sieper1, Désirée van der Heijde2, Maxime Dougados3, Philip J. Mease4, L. Steven Brown5, Tracy F. Nicholson6 and Aileen Pangan5, 1Charité Universitätsmedizin, Berlin, Germany, 2 Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Paris-Descartes University, Cochin Hospital, Paris, France, 4Seattle Rheumatology Associate, Seattle, WA, 5Abbott Laboratories, Abbott Park, IL, 6Abbott Laboratories

2 0 1 1

Moderators: Luis R. Espinoza, MD; Louisiana State University Medical Center; New Orleans, LA Walter P. Maksymowych, MD; University of Alberta; Edmonton, AB, Canada

8 ,

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment

3:15 pm 2486D. Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging Xenofon Baraliakos1, J. Braun1, D. D. Laurent2, D. Baeten3, D. van der Heijde4, J. Sieper5, P. Emery6, I. McInnes7, J. van Laar8, R. Landewe9, P. Wordsworth10, J. Wollenhaupt11, H. Kellner12, A. M. Wright13, S. Gsteiger13 and W. Hueber2, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Novartis Institutes for BioMedical Research, Basel, Switzerland, 3Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4Leiden University Medical Center, Leiden, Netherlands, 5Charite Campus Benjamin Franklin, Berlin, Germany, 6University of Leeds, Leeds, United Kingdom, 7University of Glasgow, Glasgow, United Kingdom, 8Newcastle University, Newcastle upon Tyne, United Kingdom, 9Maastricht University Medical Center, Maastricht, Netherlands, 10Nuffield Orthopaedic Centre, Oxford, United Kingdom, 11Eilbeck Hospital, Hamburg, Germany, 12Centre for Inflammatory Joint Diseases, Munich, Germany, 13Novartis Pharma AG, Basel, Switzerland 3:30 pm 2486E. Radiographic Scoring Instruments Have High Specificity for Detecting Change in Axial Psoriatic Arthritis Vinod Chandran1, Ali Ibrahim2, Arane Thavaneswaran3, Lihi Eder3, Philip Helliwell4, Richard J. Cook5 and Dafna D. Gladman3, 1 Toronto Western Hospital and University of Toronto, Toronto, ON, 2Queen’s University, Kingston, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON, 4NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 5 University of Waterloo, Waterloo, ON 3:45 pm 2486F. Nail Disease in Psoriasis Is Associated with Sonographically Determined Systemic Subclinical Enthesopathy Zoe R. Ash1, Ilaria Tinazzi2, Concepcion Castillo-Gallego3, Chung Kwok4, Caroline Wilson5, Mark Goodfield5, Paolo Gisondi6, Ai Lyn Tan1, Helena Marzo-Ortega1, Richard J. Wakefield7, Paul Emery8, Sibel Aydin9 and Dennis McGonagle10, 1University of Leeds, Leeds, United Kingdom, 2University of Verona, Verona, 2011 Program Book

TUESDAY

W475a

3:00 pm 2486C. Gender Related Differences in Severity of Psoriatic Arthritis Lihi Eder1, Arane Thavaneswaran1, Vinod Chandran2 and Dafna D. Gladman1, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON

N o v e m b e r

3:45 pm 2486. Race and Mortality Risk in Scleroderma Allan C. Gelber, Rebecca L. Manno, Adrianne Woods, Ami A. Shah, Francesco Boin, Laura K. Hummers and Fredrick M. Wigley, Johns Hopkins University, Baltimore, MD

2:45 pm 2486B. Non-Steroidal Anti-Inflammatory Drugs Reduce Radiographic Spinal Progression in Patients with Ankylosing Spondylitis but Not in Non-Radiographic Axial Spondyloarthritis Denis Poddubnyy1, Hildrun Haibel2, Joachim Listing3, Elisabeth Märker-Hermann4, Henning Zeidler5, Jürgen Braun6, Martin Rudwaleit7 and Joachim Sieper2, 1Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 2Charité – Campus Benjamin Franklin, Berlin, Germany, 3German Rheumatism Research Centre, Berlin, Germany, 4Dr. Horst Schmidt Kliniken, Wiesbaden, Germany, 5Medizinische Hochschule, Hannover, Germany, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7Ev. Krankenhaus Hagen-Haspe, Hagen, Germany

103

Italy, 3Hospital Universitario La Paz, Madrid, Spain, 4Leeds Teaching Hospitals, Leeds, United Kingdom, 5Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6University of Veronia, Verona, Italy, 7Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals, Leeds, United Kingdom, 8 Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 9Goztepe Training and Research Hospital, Istanbul, Turkey, 10University of Leeds and Leeds Teaching Hospitals, Leeds, United Kingdom


W183c

ACR REF Edmond L. Dubois, MD, Memorial Lectureship: “Interfering” with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus R Abstracts in this session are not in sequential order. Abstracts #2487-2492 can be found beginning on this page.

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

Moderator: Daniel J. Wallace, MD; Cedars-Sinai Medical Center/ David Geffen School of Medicine at University of California; Los Angeles, CA 2:30 pm 2547. Type I Interferons Modulate Vascular Function and Repair, Thrombosis and Plaque Progression In Murine Models of Lupus and Atherosclerosis Speaker: Mariana J. Kaplan, MD ; University of Michigan Rheumatology; Ann Arbor Michigan Wenpu Zhao2, Wei Luo3, Anuradha Vivekanandan-Giri4, Bradley J. Rabquer1, Alisa E. Koch1, Subramaniam Pennathur4, Anne Davidson5, Daniel T. Eitzman3, Seth G. Thacker1, 1University of Michigan Rheumatology; Ann Arbor, MI, 2University of Michigan; Ann Arbor, MI, 3University of Michigan Cardiology; Ann Arbor, MI, 4University of Michigan Nephrology; Ann Arbor, MI, 5 Feinstein Institute for Medical Research; Manhasset, NY 2:45 pm 2548. TLR7 Overexpression Drives Autoantigen-Mediated Expansion of Transitional and Follicular B Cells Independently of Type I IFN Signals Natalia V. Giltiay1, Nikita Kolhatkar1, Xizhang Sun2, Jinoh Kim2, Matt B. Buechler3, Jessica A. Hamerman3, Edward A. Clark1, Keith B. Elkon2, 1Department of Immunology, University of Washington; Seattle, WA, 2Division of Rheumatology, Department of Medicine, University of Washington; Seattle, WA, 3 Benaroya Research Institute at Virginia Mason; Seattle, WA 3:00 pm 2549. Dual Regulation of IRF4 Function in T- and B-Cells Is Required for the Coordination of T-B Interactions and the Prevention of Systemic Autoimmunity Partha S. Biswas1, Sanjay Gupta1, Roslynn A. Stirzaker1, Varsha Kumar1, Rolf Jessberger2, Theresa T. Lu1, Govind Bhagat3, Alessandra Pernis1, 1Hospital for Special Surgery; New York, NY, 2Dresden University of Technology, Dresden; Germany, 3 Columbia University; New York, NY

104

2011 Program Book

3:15 pm 2550. BAFF/APRIL Inhibition Induces Negative Selection of naïve Autoreactive B Cells but Does Not Prevent Positive Selection of Autoreactive B Cells in the Germinal Center Weiqing Huang1, Ioana Moisini1, Ramalingam Bethunaickan1, Ranjit Sahu1, Meredith Akerman1, Martin Lesser1, Dan Eilat2, Anne Davidson1, 1Feinstein Institute for Mediacl Research; Manhasset, 2Hadassah University Hospital and the Hebrew University; Jerusalem, Israel 3:30 pm 2551. CD4+ Cells Generated with TGF-β and All-Trans Retinoic Acid From Naïve CD4+ Cells Isolated From Lupus Mice Suppress Lupus in Mice Ya Liu1, Annie Lin2, Justin Liu3, Julie Wang1, Francisco P. Quismorio1, David A. Horwitz1, An-Ping Xu4, Song G. Zheng1, 1 USC Keck School of Medicine; Los Angeles, CA, 2USC College of Letters, Arts, and Sciences, 3Lynbrook High School, 42nd Affiliated Hospital of Sun Yat-sen University 3:45 pm 2552. The Constant Region Contributes to the Antigenic Specificity and Potential Pathogenicity of Anti-DNA Antibodies Yumin Xia1, Rahul Pawar1, Antonio S. Nakouzi1, Ling Wang2, Marc Monestier3, Manxia Fan1, Arturo Casadevall1, Chaim Putterman1, 1 Albert Einstein College of Med; Bronx, NY, 2UT-Southwestern, 3 Temple University; Philadelphia, PA


W194a

ARHP Psychology/Social Sciences Moderators: Carol M. Greco, PhD; University of Pittsburgh; Pittsburgh, PA Karen L. Smarr, PhD; Harry S. Truman Memorial Veteran’s Affairs Hospital; Columbia, MO 2:30 pm 2487. Determinants of Depressive Symptoms in Patients with Systemic Sclerosis, Including Fear of Progression and Appearance Self Esteem Linda Kwakkenbos1, Wim G.J.M. van Lankveld1, Madelon C. Vonk2, Eni S. Becker3, Frank H.J. van den Hoogen1 and Cornelia H.M. van den Ende1, 1Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, Netherlands 2:45 pm 2488. Lifestyle Intervention for Health-Related Quality of Life in Overweight and Obese Patients with Systemic Lupus Erythematosus: A Pilot Study Carol M. Greco1, Amy D. Rickman1, Nehal Shah1, Anne E. Mishler1, Nicole L. Wilson2, John M. Jakicic1, Susan Manzi3 and Amy H. Kao3, 1University of Pittsburgh, Pittsburgh, PA, 2W Penn Allegheny Health System, Pittsburgh, PA, 3Allegheny Singer Research Institute, Pittsburgh, PA

3:00 pm 2489. Sexual Activity and Impairment Among Women with Systemic Sclerosis Brooke Levis1, Marie Hudson1, Ruby Knafo1, Murray Baron2, Warren Nielson3, Marilyn Hill3 and Brett D. Thombs1, 1McGill University, Montreal, QC, 2Jewish General Hospital, Montreal, QC, 3Univ of Western Ontario, London, ON 3:15 pm 2490. The Relationship Between Cognitive Function and Physical Function in Persons with Rheumatoid Arthritis So Young Shin, Laura J. Julian, Margaret I. Wallhagen and Patricia P. Katz, University of California San Francisco, San Francisco, CA 3:30 pm 2491. Cognitive Impairment in Persons with Rheumatoid Arthritis So Young Shin, Patricia P. Katz, Margaret I. Wallhagen and Laura J. Julian, University of California San Francisco, San Francisco, CA 3:45 pm 2492. Accounts of Chronic Pain and Emotional Distress in Children and Youth with Juvenile Idiopathic Arthritis or Chronic Pain: Qualitative Analysis of Interviews to Assess Content Validity of the Patient Reported Outcome Measurement Information System C. Jeffrey Jacobson1, Jennifer Farrell2, Susmita Kashikar-Zuck2, Emily Verkamp2, Michael Seid3 and Esi Morgan DeWitt2, 1 University of Cincinnati, Cincinnati, OH, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Cincinnati Children’s Hospital Medical Center, Cincinnati


W476

3:10 pm Participation Outcomes in Everyday Practice Catherine L. Backman, OT, PhD; University of British Columbia; Vancouver, BC, Canada 3:30 pm Summary of Participation Outcomes with Audience Discussion Patricia P. Katz, PhD; University of California San Francisco; San Francisco, CA

Moderator: Michael P. Davey, MD, PhD; Veterans Affairs Medical Center; Portland, OR 2:30 pm Eye Disease Manifestations James T. Rosenbaum, MD; Oregon Health & Science University; Portland, OR 3:00 pm Cardiovascular Manifestations Joan M. Bathon, MD; Columbia University Medical Center; New York, NY 3:30 pm Pulmonary Manifestations of Rheumatoid Arthritis Gopal Allada, MD; Oregon Health & Science University; Portland, OR Upon completion of this session, participants should be able to: • enumerate the ophthalmic manifestations of rheumatoid arthritis • discuss the etiology of increased cardiac risk in rheumatoid arthritis patients • develop a plan for management of interstitial lung disease in a patient with rheumatoid arthritis

W195

Keep People with Arthritis Working: An Interactive Case-based Discussion C

2 0 1 1

2:50 pm Current Status of Participation Measures Ross Wilkie, PhD; Keele University; Newcastle-Under-Lyme, United Kingdom

Extrarticular Manifestations of Rheumatoid Arthritis: Ophthalmologic, Pulmonary and Cardiovascular C

8 ,

2:30 pm Conceptualizing Participation: Measuring More than Symptoms Monique A. Gignac, PhD; Toronto Western Research Institute and University of Toronto; Toronto, ON, Canada

W190a

Moderator: Kristina A. Theis, BA, MPH; Deakin University; Burwood, Australia 2:30 pm Case Study Nancy A. Baker, MPH, OTR, OTR/L; University of Pittsburgh; Pittsburgh, PA 2:50 pm Case Study Julie J. Keysor, PhD, PT; Boston University Sargent College; Boston, MA

2011 Program Book

TUESDAY

Moderator: Patricia P. Katz, PhD; University of California San Francisco; San Francisco, CA

Upon completion of this session, participants should be able to: • apply a bio-psychosocial approach to the assessment and management of social participation and social roles in adults with musculoskeletal conditions • describe individual and general factors which are important when determining restricted social participation in older adults with joint pain • compare and contrast the multi-national approaches to the assessment and rehabilitation of restriction in social participation

N o v e m b e r

Beyond Pain and Fatigue: Expanding Clinician and Researcher Focus to Improve Daily Life c/r PM

3:40 pm Panel Discussion

105

3:10 pm Case Study Diane V. Lacaille, MD, MHSc; Arthritis Research Center Canada; Vancouver, BC, Canada 3:30 pm Case Study Saralynn H. Allaire, ScD; Boston University School of Medicine; Boston, MA 3:50 pm Question and Answer Upon completion of this session, participants should be able to: • identify solutions that could help work related challenges • discuss solutions for arthritis work related challenges • review a range of issues that patients may encounter, including: ergonomic changes, physical job accommodations, energy balance and advocacy

W474b

Practice Potpourri

C

Moderator: Karen Huisinga, MN, ARNP, FNP; Veterans Affairs Puget Sound Health Care System; Seattle, WA 2:30 pm My Patient’s Irate - What Do I Do? Dennis J. Boyle, MD; Denver Health Medical Center; Denver, CO 2:50 pm Can I Diagnose Gout without Crystal Analysis? Pascale Schwab, MD; Portland Veterans Affairs and Oregon Health & Science University; Portland, OR

2 0 1 1

3:10 pm I Have a Patient in Pain with a Monoclonal Gammopathy - Is This Monoclonal Gammopathy of Undetermined Significance? Timothy E. Caragher, PhD; Rush University Medical Center; Chicago, IL

N o v e m b e r

8 ,

TUESDAY

3:30 pm Hip Osteoarthritis with Limb Length Discrepancy of 1 inch - Is It Significant? Jill Ferrari, PhD, BSc(Hons); University of East London; London, United Kingdom Upon completion of this session, participants should be able to: • review strategies to deal effectively with a difficult patient • discuss exercise prescriptions for fibromyalgia • review crystal analysis in the diagnosis of gout • interpret an abnormal serum protein electrophoresis • review osteoarthritis and limb length discrepancy


HALL F1 (Booth #789) The following non-CME activity has been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals by Crescendo Bioscience. Please visit the Cresendo Bioscience exhibit booth (439) for more information or see page 304. Seating and light refreshments are subject to availability.

106

2011 Program Book

Revealing Rheumatoid Arthritis at the Molecular Level: Biomarkers for Disease Activity Assessment in Rheumatoid Arthritis

ACR WORKSHOPS 4:00 - 6:00 pm Admission to the workshops requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www.rheumatology.org/ annual.

W179b

Patient Questionnaires to Monitor Status and Document Improvement in Standard Care: Practical Considerations (238) Speaker: Theodore Pincus, MD; New York University Hospital for Joint Diseases; New York, NY

W180

Peripheral Magnetic Resonance Imaging in Rheumatology Practice (239) Speakers: Philip G. Conaghan, MD, PhD; University of Leeds; Leeds, United Kingdom Mikkel Ostergaard, MD, PhD, DMSc; Glostrup Hospital; Glostrup, Denmark

W178b

Scientific Graphs: An Alternative to PowerPoint and Excel (240) Speaker: Maarten Boers, MD, MSc, PhD; VU University Medical Center; Amsterdam, Netherlands

ACR BASIC SCIENCE SYMPOSIA 4:30 - 6:00 pm

W183a

New Concepts in the Autoimmune Pathogenesis of Interstitial Lung Diseases R Moderators: Richard J. Bucala, MD, PhD; Yale University School of Medicine; New Haven, CT Carol A. Feghali-Bostwick, PhD; University of Pittsburgh; Pittsburgh, PA 4:30 pm Overview of Pathogenic Concepts in the Interstitial Lung Diseases Carol A. Feghali-Bostwick, PhD; University of Pittsburgh; Pittsburgh, PA 4:55 pm T-Cell Dependent Regulation of Fibrogenesis Matthias Mack, MD; University Hospital Regensburg; Regensburg, Germany

5:20 pm Fibrocytes in Autoimmune Fibroses Erica Herzog, MD, PhD; Yale University School of Medicine; New Haven, CT Upon completion of this session, participants should be able to: • identify current concepts of the immune pathogenesis of interstitial lung diseases • d escribe the role of fibrocytes in systemic fibroses and their biomarker potential • analyze the adaptive immune mechanisms that may govern fibrogenesis

W196b

Osteoarthritis: A Disease of the Joint as an Organ

R

Moderators: Richard F. Loeser, MD; Wake Forest University; Winston-Salem, NC Carla R. Scanzello, MD, PhD; Rush University Medical Center; Chicago, IL 4:30 pm How Understanding Joint Development Can Contribute to a New Understanding of Osteoarthritis Maurizio Pacifici, PhD; Children’s Hospital of Philadelphia; Philadelphia, PA 4:55 pm The Role of Synovial Inflammation in Osteoarthritis Wim B. Van Den Berg, PhD; Radboud University Nijmegen Med Centre; Nijmegen, Netherlands 5:20 pm The Subchondral Bone and Osteoarthritis: Not Just Hard Tissue Harrie Weinans, PhD; Erasmus Medical Center; Rotterdam, Netherlands

Upon completion of this session, participants should be able to: • recognize the cardiac complications of scleroderma and the current evidence to guide management of these complications • recognize the gastrointestinal complications associated with scleroderma and apply the current evidence to managing patients with these complications • discuss some of the challenging complications of scleroderma including arthritis, tendon rubs, neuropathy and vasculitis

W190a

Developing ACR Guidelines for the Treatment of Gout c/r PS Moderators: Liana Fraenkel, MD, MPH; Yale University; New Haven, CT David A. Fox, MD; University of Michigan Medical Center; Ann Arbor, MI Speakers: John D. FitzGerald, MD, PhD; University of California Los Angeles School Medical Rehabilitation; Los Angeles, CA Puja Khanna, MD, MPH; University of Michigan; Ann Arbor, MI Dinesh Khanna, MD, MSc; University of Michigan; Ann Arbor, MI Robert Terkeltaub, MD; Veterans Affairs Medical Center; San Diego, CA

8 ,

W192b

Extra Glandular Manifestations of Sjögren’s Syndrome

2 0 1 1

ACR CLINICAL SYMPOSIA W375c C

cP

Moderators: Laura K. Hummers, MD, ScM; Johns Hopkins University; Baltimore, MD Victoria K. Shanmugam, MBBS, MRCP; Georgetown University Hospital; Washington, DC 4:30 pm Cardiac Involvement from Scleroderma Yannick Allanore, MD, PhD; Paris Descartes University, Cochin Hospital; Paris, France

TUESDAY

Upon completion of this session, participants should be able to: • explain the process used to develop gout treatment guidelines • describe treatment guidelines for management of acute gouty arthritis • describe treatment for serum urate lowering therapy • discuss treatment guidelines for management of chronic tophaceous gout

C

Moderators: E. William St.Clair, MD; Duke University Medical Center; Durham, NC Mary E. Cronin, MD; Medical College of Wisconsin; Milwaukee, WI

4:30 - 6:00 pm

Challenging Complications of Systemic Sclerosis

5:20 pm Scleroderma Associated Arthritis, Tendon Rubs, Neuropathy and Vasculitis Virginia D. Steen, MD; Georgetown University Medical Center; Washington, DC

N o v e m b e r

Upon completion of this session, participants should be able to: • r ecognize osteoarthritis as a condition of the entire joint as an organ • identify developmental processes within the joint that may contribute to the development of osteoarthritis • d efine the synovial changes that occur in osteoarthritis and discuss how synovitis may contribute to disease progression • r elate the changes in the subchondral bone to joint tissue changes in osteoarthritis

4:55 pm Gastrointestinal Involvement in Scleroderma Romy Christmann, MD, PhD; Boston University; Boston, MA

4:30 pm The Nervous System and Sjögren’s Syndrome Julius Birnbaum, MD, MHS; Johns Hopkins University; Baltimore, MD 5:10 pm Evidence to Support B Cell Therapy in Sjögren’s Syndrome Xavier Mariette, MD; Université Paris-Sud; Le Kremlin Bicetre, France Upon completion of this session, participants should be able to: • describe the diverse presentations of involvement of the central nervous system in Sjögren’s syndrome • describe the diagnostic approach to and manifestations of small fiber neuropathy in Sjögren’s syndrome 2011 Program Book

107

• d iscuss the evidence to support the use of B cell therapies in Sjögren’s syndrome

W375b

The Child with Chronic Pain

P/C

PM

Moderators: Tracy V. Ting, MD, MSc; Cincinnati Children’s Hospital Medical Center; Cincinnati, OH Kenneth N. Schikler, MD; University of Louisville School of Medicine; Louisville, KY 4:30 pm The Neurobiology of Pain Michael Henrickson, MD, MPH; Cincinnati Children’s Hospital Medical Center; Cincinnati, OH 4:55 pm The Role of Coping Skills Strategies and Behavioral Intervention in the Treatment of Juvenile Fibromyalgia Susmita Kashikar-Zuck, PhD; Cincinnati Children’s Hospital Medical Center; Cincinnati, OH 5:20 pm Aerobic Exercise and its Role in the Treatment of Juvenile Fibromyalgia and Juvenile Idiopathic Arthritis Brian M. Feldman, MD; The Hospital for Sick Children; Toronto, ON, Canada

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

Upon completion of this session, participants should be able to: • discuss the intricacies of how the central nervous systems networks, the autonomic nervous system , the endocrine system and the immune response system interweave in the recognition of pain • construct a treatment plan for patients with juvenile fibromyalgia incorporating modalities that include measures aimed at the neurobiology of pain to include non-pharmacologic therapies including effective behavioral interventions and aerobic exercise


W475a

B-cell Biology and Targets in Autoimmune Disease Moderators: William Stohl, MD, PhD; University of Southern California Keck School of Medicine; Los Angeles, CA Jennifer H. Anolik, MD, PhD; University of Rochester; Rochester, NY 4:30 pm 2493. Effective Anti-CD20 Therapy for Arthritis Is Associated with B-Cell Depletion in Efferent Lymph Nodes and Increased Lymph and Cellular Flow in Lymphatic Vessels From Arthritic Joints Jie Li1, Christopher T. Ritchlin2, Ignacio Sanz1, Andrea Bottaro1, Ronald Wood1, Lianping Xing1 and Edward M. Schwarz1, 1 University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY 4:45 pm 2494. A Whole-Blood Transcriptomic Signature Predicts Clinical Response to Rituximab in Rheumatoid Arthritis Jeremie Sellam1, Sandrine Marion-Thore2, F. Dumont2, Franck

108

2011 Program Book

Letourneur3, Stephanie Rouanet4, Yassine Taoufik5, Jean Sibilia6, Jacques G. Tebib7, Xavier Le Loët8, Bernard G. Combe9, Maxime Dougados10, Xavier Mariette11 and Gilles Chiocchia3, 1Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, 2INSERM U1016, Institut Cochin, Paris Descartes University, Paris, France, 3Institut Cochin, 75014 Paris, France, 4 Roche, Neuilly sur Seine, France, 5Hopital Bicetre, Université Paris Sud, AP-HP, France, 6Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 7Centre Hosp Lyon Sud, Pierre Benite, France, 8 Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 9Hopital Lapeyronie, Montpellier, France, 10 Paris-Descartes University, Paris, France, 11Université Paris-Sud, Le Kremlin Bicetre, France 5:00 pm 2495. A Humanized Monoclonal Antibody Against a Surface Ligand of Mononuclear Cells Suppress Autoimmune Inflammatory Diseases by Upregulation of IL-10 Secretion Yaakov Naparstek, Rina Ulmansky, Galia Katzavian, Ronit Meyuhas, Alon Hershko, Eli Moallem, Shira Yair and Dorit Landstein, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 5:15 pm 2496. B Cells Enhance the Type I Interferon Production by Plasmacytoid Dendritic Cells via CD31 Lars Rönnblom1, Olof Berggren1, Gert Weber2, Niklas Hagberg1 and Maija-Leena Eloranta1, 1Section of Rheumatology, Uppsala University, Uppsala, Sweden, 2Structural Biochemistry, Free University of Berlin, Berlin, Germany 5:30 pm 2497. The Critical Role of Protein Kinase C Beta in Lupus Development in Lupus Mice Luojing Chen, University of Rochester, Rochester, NY 5:45 pm 2498. Effect of Intravenous Cyclophosphamide Treatment on B Cells in SLE Nephritis Chungwen Wei1, John Jung1, Valentin Marian1, Donna F. Hardwick2, Gema Souto-Adeva3, Youqun Huang1, Bridget Neary1, Gabor G. Illei3 and Iñaki Sanz1, 1University of Rochester, Rochester, NY, 2NIH MSC 1616, Bethesda, MD, 3NIDCR/ NIH #10 1N110, Bethesda, MD

W193a

Cytokines, Mediators, and Gene Regulation II Moderators: Kyriakos A. Kirou, MD; Hospital for Special Surgery; New York, NY Harris R. Perlman, PhD; Northwestern University, Feinberg School of Medicine; Chicago, IL 4:30 pm 2499. IL-27 Receptor Signaling Is Critical for B Cell Differentiation in Collagen Induced Arthritis Odilia B.J. Corneth1, Anne-Marie Mus2, Patrick S. Asmawidjaja2, Rudi W. Hendriks2 and Erik Lubberts2, 1Erasmus MC, University Medical Center, Rotterdam, Rotterdam, Netherlands, 2Erasmus MC, University Medical Center, Rotterdam, Netherlands

4:45 pm 2500. Interleukin-27 Receptor-Deficient Mice Develop Exacerbated Inflammatory Arthritis Associated with Heightened T- and B- Cell Responses Gareth W. Jones1, Anwen S. Williams1, Mari A. Nowell1, Brendan J. Jenkins2 and Simon A. Jones3, 1School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom, 2Monash Institute of Medical Research, Monash University, Melbourne, Australia, 3 Cardiff University, Cardiff, United Kingdom 5:00 pm 2501. IL-22 Restrains the Progression to Severe Arthritis Sujata Sarkar, Xiaoqun Zhou and Swaroopa Bommireddy, University of Arizona, Tucson, AZ 5:15 pm 2502. Interferon-γ and Toll-Like Receptor 9 Collaborate to Cause Both Leukopenia and Anemia In a Murine Model of Macrophage Activation Syndrome by Two Distinct Mechanisms Katharine Slade1, Scott Canna1, Portia Kreiger2 and Edward M. Behrens1, 1Childrens Hospital of Philadelphia, Philadelphia, PA, 2 A.I. DuPont Hospital for Children, Wilmington, DE 5:30 pm 2503. Opposing Regulation of IFN Response Genes and STAT1 in Rheumatoid Arthritis Synovial Fluid Macrophages by TNFá and the Synovial Fluid Microenvironment Rachael A. Gordon, Galina Grigoriev, George D. Kalliolias and Lionel B. Ivashkiv, Hospital for Special Surgery, New York, NY

4:30 pm 2505. Racial/Ethnic Differences in Physical Activity Among Participants in the Osteoarthritis Initiative (OAI) Jing Song1, Marc Hochberg2, Rowland W. Chang3, Larry Manheim1, Jungwha Lee3, Pamela A. Semanik4, Leena Sharma3 and Dorothy D. Dunlop1, 1Northwestern Univ Med School, Chicago, IL, 2University of Maryland School of Medicine, Baltimore, MD, 3Northwestern University, Chicago, IL, 4 Rehabilitation Institute of Chicago, Chicago, IL 4:45 pm 2506. Tool for Patient Selection to Optimize Patient-Reported Outcomes Following Total Joint Arthroplasty Gillian A. Hawker1, Ruth Croxford2, A. M. Davis3, Sheila Dunn1, Joy G. Elkayam1, Melissa R. French1, M. A. Gignac4, Susan B. Jaglal5 and Joanna Sale5, 1Women’s College Hospital, Toronto, ON, 2Institute for Clinical and Evaluative Science, Toronto,

5:45 pm 2510. Projecting the Future Public Health Impact of the Trend Toward Earlier Onset of Knee Osteoarthritis in the Past 20 Years Sara A. Burbine, Alexander M. Weinstein, William M. Reichmann, Benjamin N. Rome, Jamie E. Collins, Jeffrey N. Katz and Elena Losina, Brigham and Women’s Hospital, Boston, MA

W181b

Rheumatoid Arthritis Clinical Aspects: Predictors of Outcome

2 0 1 1

Moderators: Elena Losina, PhD; Brigham and Women’s Hospital; Boston, MA Lisa A. Mandl, MD, MPH; Hospital for Special Surgery; New York, NY

5:30 pm 2509. Sick Leave and Disability Pension Among Patients with Knee Osteoarthritis Jenny Hubertsson1, Ingemar F. Petersson1, Carina A. Thorstensson2 and Martin Englund3, 1Musculoskeletal Sciences, Dept of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, 2Spenshult Hospital for, Oskarstrom, Sweden, 3 Lund University, Lund, Sweden

8 ,

Epidemiology and Health Services Research II: Osteoarthritis

5:15 pm 2508. Incidence of Knee Symptoms and Radiographic and Symptomatic Knee Osteoarthritis in African Americans and Caucasians: The Johnston County Osteoarthritis Project Barbara T. Do1, Louise Murphy1, Charles G. Helmick1, Yiling J. Cheng1, Kamil E. Barbour1 and Joanne M. Jordan2, 1Centers for Disease Control and Prevention, Atlanta, GA, 2UNC Thurston Arthritis Center, Chapel Hill, NC

Moderators: John Isaacs, PhD; University of Newcastle upon Tyne; United Kingdom Jon T. Giles, MD, MPH; Columbia University Medical Center; New York, NY 4:30 pm 2511. Clinical Disease Activity and Acute Phase Reactant (APR) Levels Are Discordant Among Patients with Active Rheumatoid Arthritis (RA) and Contribute Separately to Predicting Outcome At 1 Year Jonathan Kay1, Susan P. Messing2, Joel M. Kremer3, Jeffrey D. Greenberg4 and Daniel E. Furst5, 1University of Massachusetts Medical School, Worcester, MA, 2University of Rochester School of Medicine and Dentistry, Rochester, NY, 3Albany Medical College and The Center for Rheumatology, Albany, NY, 4New York University School of Medicine, New York, NY, 5UCLA Medical School, Los Angeles, CA

2011 Program Book

TUESDAY

W194b

5:00 pm 2507. The Association Between Lifelong Joint Force From Physical Activity, Local Joint Factors and Knee Osteoarthritis Charles R. Ratzlaff1, Mieke Koehoorn1, Jolanda Cibere2 and Jacek A. Kopec3, 1University of British Columbia, Vancouver, BC, 2 Arthritis Research Ctr of CA, Vancouver, BC, 3Arthritis Research Centre of Canada, Vancouver, BC

N o v e m b e r

5:45 pm 2504. Plasmacytoid Dendritic Cells in Human Lupus Bone Marrow Are Primed for Interferon Alpha Production Sarah Nevarez1, Arumugam Palanichamy1, Alfred Rabinovich1, Jennifer Barnard1, Jamie Biear1, Ben Panepento1, Chungwen Wei1, Christopher T. Ritchlin2, James Kobie1, Iñaki Sanz1 and Jennifer H. Anolik1, 1University of Rochester, Rochester, NY, 2 University of Rochester Medical Center, Rochester, NY

Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, 4Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 5University of Toronto, Toronto, ON 3

109

4:45 pm 2512. Discordance Between Patients and Physicians in Assessments of Global Disease Activity in Rheumatoid Arthritis: Agreeing to Disagree Thomas V. Jones1, Wenzhi Li1, Andrew S. Koenig1 and Michelle Stewart2, 1Pfizer Inc., Collegeville, PA, 2Pfizer Inc., Groton, CT 5:00 pm 2513. Development of a Matrix Risk Model to Predict Rapid Radiographic Progression in Early Rheumatoid Arthritis. Results From a Randomized Trial Population Saedis Saevarsdottir1, Kristina Forslind2, Kristina Albertsson1, Hamed Rezaei1, Arvid Engström1, Pierre Geborek3, Ingemar F. Petersson3, Sofia Ernestam4, Johan Bratt4 and Ronald F. van Vollenhoven1, 1The Karolinska Institute, Stockholm, Sweden, 2 Helsingborgs Lasarett and Lund University, Lund, Sweden, 3 Lund University, Lund, Sweden, 4Karolinska University Hospital, Stockholm, Sweden

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

5:15 pm 2514. Derivation and Validation of An Infection Risk Score to Predict the Risk of Serious Infections for Rheumatoid Arthritis Patients Jeffrey R. Curtis1, Fenglong Xie2, Paul M. Muntner2, Lang Chen2, Shuo Yang, Kenneth G. Saag1 and Elizabeth S. Delzell2, 1Univ of Alabama-Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL

110

5:30 pm 2515. Predictors of Work Disability During the First 3 Years After Diagnosis in a National Rheumatoid Arthritis Inception Cohort Tor Olofsson1, Ingemar F. Petersson2, Jonas Eriksson3, Martin Englund4, Julia F. Simard3, Pierre Geborek1, Lennart TH Jacobsson5, Johan Askling3 and Martin Neovius3, 1Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, 2Musculoskeletal Sciences, Dept of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, 3Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Stockholm, Sweden, 4Lund University, Lund, Sweden, 5 Section of Rheumatology, Malmo, Sweden 5:45 pm 2516. Do Rheumatoid Arthritis Patients Meeting American College of Rheumatology/European League Against Rheumatism Remission Have Improved Functional Ability, Quality of Life and Work Productivity Compared to Those with Low Disease Activity? Aarat M. Patel1, Christine L. Amity2, Lynne M. Frydrych2, Derek Sippel2, Donald Jones2, Danielle Goudeau2, Heather Eng3, David Kyle3, Melissa Saul3, Daniel Hal Solomon4, Stephen R. Wisniewski3, Larry W. Moreland5 and Marc C. Levesque2, 1Univ of Pittsburgh Med Ctr / Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3Univ of Pittsburgh, Pittsburgh, PA, 4Brigham & Womens Hospital, Boston, MA, 5University of Pittsburgh, Pittsburgh, PA

2011 Program Book

W196a

Rheumatoid Arthritis – Human Etiology and Pathogenesis II: Pathogenesis of Rheumatoid Arthritis – What’s New? Moderators: Kris. Reedquist, PhD; Academic Medical Center, University of Amsterdam; Amsterdam, Netherlands Maripat Corr, MD; University of California-San Diego; La Jolla, CA 4:30 pm 2517. Unique DNA Methylome Signature in Rheumatoid Arthritis (RA) Kazuhisa Nakano1, John Whitaker2, Wei Wang3, David L. Boyle2 and Gary S. Firestein2, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2UCSD School of Medicine, La Jolla, CA, 3UCSD, La Jolla, CA 4:45 pm 2518. A Distinctive Oral Microbiome Characterizes Periodontitis in Patients with Early Rheumatoid Arthritis Jose U. Scher*1, Carles Ubeda*2, Walter Bretz3, Michael H. Pillinger1, Yvonne Buischi3, Pamela B. Rosenthal4, Soumya M. Reddy1, Jonathan Samuels1, Peter M. Izmirly4, Gary E. Solomon1, Mukundan Attur1, Michele Equinda2, Nicholas Socci2, Agnes Viale2, Gerald Weissmann4, Dan R. Littman4, Eric G. Pamer2 and Steven B. Abramson1, 1NYU Hospital for Joint Diseases, New York, NY, 2Memorial Sloan-Kettering Cancer Center, The Lucille Castori Center for Microbes, Inflammation and Cancer, New York, NY, 3NYU College of Dentistry, New York, NY, 4NYU School of Medicine, New York, NY 5:00 pm 2519. MiR-196a Is An Important Regulator of Synovial Fibroblasts In the Pathogenesis of Rheumatoid Arthritis Maria Filkova1, Michelle Trenkmann1, Joanna Stanczyk1, Mojca Frank1, Christoph Kolling2, Lars C. Huber3, Beat A. Michel1, Renate E. Gay1, Ladislav Senolt4, Steffen Gay1 and Astrid Jüngel1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Schultess Clinic, Zurich, Switzerland, 3Clinic and Policlinic for Internal Medicine, University Hospital Zurich, Switzerland, Zurich, Switzerland, 4Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic 5:15 pm 2520. Epigenome Analysis Reveals TBX-5 As a Novel Transcription Factor Involved in the Activation of Rheumatoid Arthritis Synovial Fibroblasts Emmanuel Karouzakis1, Michelle Trenkmann1, Caroline Ospelt1, Christoph Kolling2, Renate E. Gay1, Beat A. Michel1, Steffen Gay1 and Michel Neidhart1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Schultess Clinic, Zurich, Switzerland 5:30 pm 2521. 9G4 Expression on Antibodies to Citrullinated Residues in Patients with Early Inflammatory Arthritis and Established Rheumatoid Arthritis Rita A. Moura1, Inmaculada de la Torre2, Maria J. Leandro3, Jonathan CW Edwards3 and Geraldine Cambridge4, 1 Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal, Lisbon, Portugal, 2Gregorio Marañón Hospital, Madrid, Spain, 3UCL, London, United Kingdom, 4University College London, London, United Kingdom

5:45 pm 2522. Heightened Immune Response to Autocitrullinated Porphyromonas Gingivalis Peptidylarginine Deiminase Is a Potential Mechanism for Breaching Immunologic Tolerance in Rheumatoid Arthritis Anne-Marie Quirke1, Natalia Wegner1, Bart Hamilton2, Peter J. Charles3, Muslima Chowdhury1, Elena B. Lugli1, Jan Potempa4, Geoffrey M. Thiele5, Ted R. Mikuls6 and Patrick Venables7, 1 Imperial College London, London, United Kingdom, 2University of Nebraska Medical Centre and Omaha VA Medical Center, Omaha, 3Charing Cross Hospital, London, United Kingdom, 4 Jagiellonian University, Krakow, Poland, 5Univ of Nebraska Med Ctr, Omaha, NE, 6Omaha VA and University of Nebraska, Omaha, NE, 7Kennedy Institute, London, United Kingdom

W375a

Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy: Further Insights Into Efficacy and Safety of TNF-Inhibitors Moderators: Richard W. Martin, MA, MD; Michigan State University College of Human Medicine; Grand Rapids, MI John J. Cush, MD; Baylor Research Institute; Dallas, TX 4:30 pm 2523. RA, Anti-TNF Therapy, and Risk of Malignant Melanoma-A Nationwide Population-Based Study From Sweden Pauline Raaschou1, Julia F. Simard2, Martin Neovius2, Marie Holmqvist2, Jonas Eriksson2, Johan Askling2 and the ARTIS studygroup3, 1Clinical Pharmacology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Karolinska Institutet

5:45 pm 2528. Etanercept Induces a Decrease in Left Ventricular Mass in Patients with Rheumatoid Arthritis Claire Daien1, Pierre Fesler1, Vincent Daien2, Guilhem du Cailar1, Anne-Marie Dupuy1, Jean-Paul Cristol1, Jean Ribstein1, Bernard G. Combe1 and Jacques Morel1, 1Hopital Lapeyronie, Montpellier, France, 2Hopital Gui de Chauliac, Montpellier, France

W471b

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III Moderators: Christopher T. Ritchlin, MD, MPH; University of Rochester Medical Center; Rochester, NY Maxime Dougados, MD; Rene Descartes University; Paris, France

2 0 1 1

4:45 pm 2530. Incidence of Spondyloarthropathy In Patients with Crohn’s Disease: A Population-Based Study Raina Shivashankar, Edward V. Loftus Jr., William J. Tremaine, Tim Bongartz, W. Scott Harmsen, Alan R. Zinsmeister and Eric L. Matteson, Mayo Clinic, Rochester, MN

8 ,

4:30 pm 2529. Autoantibodies Against CD74 and Class II-Associated Invariant Chain Peptide (CLIP) in Spondyloarthritis Niklas T. Baerlecken1, Georg H. Stummvoll2, Reinhold E. Schmidt3 and Torsten Witte4, 1MD, Hannover, Germany, 2Medical University of Vienna, Vienna, Austria, 3Hannover Medical School, Hannover, Germany, 4Hannover Medical School, Hanover, Germany

5:00 pm 2531. How Does Disease Duration Modify the Association of Radiographic Damage with Ankylosing Spondylitis Metrology? Roozbeh Sharif1, Pooja N. Patel2, Shervin Assassi3, Lianne S. Gensler4, Laura A. Diekman5, Thomas J. Learch6, Michael H. Weisman7, Michael M. Ward8 and John D. Reveille1, 1University of Texas Health Science Center at Houston, Houston, TX, 2 University of Texas, Houston, Houston, TX, 3Univ of Texas Health Science, Houston, TX, 4UCSF, San Francisco, CA, 5UT Health Science Center, Houston, TX, 6Cedars-Sinai, Los Angeles, CA, 7 Cedars Sinai Med Ctr, Los Angeles, CA, 8NIAMS/NIH, Bethesda, MD

2011 Program Book

TUESDAY

5:00 pm 2525. The Risk of Solid Cancer in Patients Receiving AntiTumour Necrosis Factor Therapy for Rheumatoid Arthritis for up to 5 Years: Results From the British Society for Rheumatology Biologics Register Louise K. Mercer1, James B. Galloway1, Audrey SL Low1, Kath D. Watson1, Mark Lunt1, William G. Dixon1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium1, Deborah pmSymmons1, Kimme L. Hyrich1 and On behalf of the BSRBR2, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2 British Society for Rheumatology, London, United Kingdom

5:30 pm 2527. FUNCTIONAL MRI (FMRI) IS Much FASTER In Detecting RAPID Symptom CONTROL by Certolizumab-Pegol In PATIENTS with RA THAN the Conventional MRI Juergen Rech1, Stephanie Finzel1, Silke Kreitz1, Matthias Englbrecht1, Arnd Doerfler1, Marc Saake1, Andreas Hess1 and Georg Schett2, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

N o v e m b e r

4:45 pm 2524. Opportunistic Infections in Patients Exposed to AntiTumour Necrosis Factor Therapy: Results From the British Society for Rheumatology Biologics Register James B. Galloway1, Audrey SL Low1, Louise K. Mercer1, William G. Dixon1, Andrew Ustianowski2, Mark Lunt1, Kath D. Watson1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium3, Kimme L. Hyrich1, Deborah pmSymmons1 and on behalf of the BSRBR1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Manchester, Manchester, United Kingdom, 3British Society for Rheumatology, London, United Kingdom

5:15 pm 2526. Safety of Infliximab Therapy in Rheumatoid Arthritis Patients with Pre-Existing Hepatitis B Virus Infection Xuewu Zhang1, Xia Liu2, Yuan An1, Ying Ning1 and Zhanguo Li1, 1 Peking University People’s Hospital, Beijing, China, 2China-Japan Friendship Hospital, Beijing, China

111

5:15 pm 2532. Selection of Patients with Ankylosing Spondylitis for TNFInhibitor Therapy: Comparing Responses in Patients Selected by BASDAI & ASDAS Karen Minde Fagerli1, Elisabeth Lie2, D.M.F.M. van der Heijde3, Marte S. Heiberg1, Synnøve Kalstad4, Erik Rødevand5, Cecillie Kaufmann6, Knut Mikkelsen7 and Tore K. Kvien2, 1Diakonhjemmet hospital, Oslo, Norway, 2Diakonhjemmet Hospital, Oslo, Norway, 3 Leiden University Medical Center, Leiden, Netherlands, 4 University Hospital in Northern Norway, Tromsø, Norway, 5 St. Olavs Hospital, Trondheim, Norway, 6Vestre Viken, Drammen, Norway, 7Lillehammer Hosp for Rheumatic Diseases, Lillehammer, Norway

4:45 pm 2536. Anti-Fibrotic Effects of Microrna-145 in Systemic Sclerosis via a Multi-Step Regulation of TGF-Beta/CTGF Signaling Serena Vettori1, Matthias Brock1, Naoki Iwamoto1, Britta Maurer1, Astrid Jungel1, Renate E. Gay1, Maurizio Calcagni2, Gabriele Valentini3, Jorg HW Distler4, Steffen Gay1 and Oliver Distler1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Division of Plastic Surgery and Hand Surgery, Zurich University Hospital, Zurich, Switzerland, 3Rheumatology Unit, Second University of Napoli, Napoli, Italy, 4Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

5:30 pm 2533. Obesity and the Risk of Psoriatic Arthritis in the General Population Yanyan Zhu1, Hyon K. Choi1, Yuqing Zhang1, Lindsay Wall-Burns2, Alexis Ogdie3, Joel Gelfand4 and Thorvardur Love5, 1Boston University School of Medicine, Boston, MA, 2Arthritis Research Centre of Canada, Vancouver, BC, 3University of Pennsylvania, Philadelphia, PA, 4University of Pennsylvania., Philadelphia, PA, 5 Landspitali University Hospital, Reykjavík, Iceland

5:00 pm 2537. TLR4 Activation Enhances Fibrotic Responses Induced by TGF-ß: A Mechanism for Maintaining and Amplifying Fibrosis in Scleroderma Swati Bhattacharyya1, Kathleen Kelly2, Denisa S. Melichian2, Kohtaro Ooka3, Carol A. Feghali-Bostwick4, Robert A. Lafyatis5, Timothy RD Radstake6 and John Varga1, 1Northwestern Univ Med School, Chicago, IL, 2Northwestern University, Chicago, IL, 3 Northwestern University, 4University of Pittsburgh, Pittsburgh, PA, 5E5 Arthritis Ctr-BUSM, Boston, MA, 6Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

W183c

N o v e m b e r

8 ,

TUESDAY

2 0 1 1

5:45 pm 2534. Frequency and Duration of Drug-Free Remission After One Year of Treatment with Etanercept Vs. Sulfasalazine in Early Axial Spondyloarthritis – 2 Year Data of the ESTHER Trial In-Ho Song1, Kay-Geert Hermann2, Hildrun Haibel1, Christian Althoff2, Denis Poddubnyy1, Joachim Listing3, Anja Weiß3, Bruce Freundlich4, Martin Rudwaleit5 and Joachim Sieper1, 1Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 2 Charite Medical School, Berlin, Germany, 3German Rheumatism Research Centre, Berlin, Germany, 4University of Pennsylvania, Philadelphia, PA, 5Ev. Krankenhaus Hagen-Haspe, Hagen, Germany

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics I Moderators: Marco Matucci-Cerinic; University Florence; Firenze, Jordan Robert A. Lafyatis, MD; Arthritis Center, Boston University School of Medicine; Boston, MA 4:30 pm 2535. Transforming Growth Factor Beta Mediated Activation of Canonical Wnt Signaling Is Crucial for the Development of Fibrosis In Systemic Sclerosis Alfiya Akhmetshina1, Katrin Palumbo2, Christina Bergmann2, Paulius Venalis2, Clara Dees2, Pawel Zerr2, Angelika Horn2, Christian Beyer3, Jochen Zwerina2, Ormond A. MacDougald4, Oliver Distler5, Georg Schett2 and Jorg HW Distler2, 1Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2 Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3University of Erlangen-Nuremberg, Erlangen, Germany, 4Department of Pediatrics, University of ErlangenNuremberg, Erlangen, Germany, 5University Hospital Zurich, Zurich, Switzerland

112

2011 Program Book

5:15 pm 2538. Tribbles Homolog 3 mediates Transforming Growth Factor beta driven Dermal Fibrosis In Systemic Sclerosis Michal Tomcik1, Katrin Palumbo2, Jérôme Avouac3, Angelika Horn2, Aisa Khodzhigorova2, Pawel Zerr2, Clara Dees2, Alfiya Akhmetshina4, Christian Beyer5, Radim Becvar1, Ladislav Senolt6, Oliver Distler7, Georg Schett2 and Jorg HW Distler2, 1Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of ErlangenNuremberg, Erlangen, Germany, 3Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 4 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5University of Erlangen-Nuremberg, Erlangen, Germany, 6Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 7University Hospital Zurich, Zurich, Switzerland 5:30 pm 2539. Inhibition of Glycogen Synthase Kinase 3β Induces Dermal Fibrosis by Activation of the Canonical Wnt Pathway Christina Bergmann1, Alfiya Akhmetshina2, Clara Dees1, Katrin Palumbo1, Pawel Zerr1, Christian Beyer3, Jochen Zwerina1, Oliver Distler4, Georg Schett1 and Jorg HW Distler1, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3University of Erlangen-Nuremberg, Erlangen, Germany, 4University Hospital Zurich, Zurich, Switzerland

5:45 pm 2540. The Nuclear Receptor CAR Mediates the Pro-Fibrotic Effects of TGF-β and Contributes to the Development of Experimental Dermal Fibrosis Jerome Avouac1, Michal Tomcik2, Katrin Palumbo1, Pawel Zerr1, Clara Dees1, Alfiya Akhmetshina1, Christian Beyer1, Oliver Distler3, Georg Schett1, Yannick Allanore4 and Jorg HW Distler1, 1 Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 3University Hospital Zurich, Zurich, Switzerland, 4Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France

ACR MEET THE PROFESSOR SESSIONS 4:30 - 6:00 pm Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview, learning objectives and updates on MY ACR at www. rheumatology.org/annual. *Sessions denoted with an asterisk were sold out as of September 12.

W185bc

Dermatological Manifestations of Rheumatic Diseases (081) Speaker: Nicole Fett, MD; University of Pennsylvania; Philadelphia, PA

Psoriatic Arthritis (083) Speaker: M. Elaine Husni, MD, MPH; Cleveland Clinic Foundation; Cleveland, OH

W186a

Systemic Lupus Erythematosus: Lupus Nephritis (088) Speaker: Frédéric. A. Houssiau, MD, PhD; Université catholique de Louvain; Brussels, Belgium

W184d

Vaccinations for Patients on Biologic Therapies (089) Speaker: Clifton O. Bingham III, MD; Johns Hopkins University; Baltimore, MD

ACR SPECIAL SESSIONS

4:30 - 6:00 pm

W375d

ACR Knowledge Bowl

c/r

cP

Moderator: Zsuzsanna H. McMahan, MD; Johns Hopkins University; Baltimore, MD 4:30 pm University of Kentucky Team Carlos Gadea, MD Robert W. Lightfoot, MD Christine Chhakchhuak; MD 6:30 pm Ochsner Medical Center-New Orleans Team Elvira Lindwall, MD Anika Alarakhia, MD Robert Quinet, MD 8:30 pm The University of Minnesota Team Patricia Hobday, MD Theresa Wampler Muskardin, MD Bryce A. Binstadt, MD, PhD Upon completion of this session, participants should be able to: • recall factual information related to the rheumatic diseases • integrate basic principles of rheumatology into clinical practice • identify key images that are important to recognize in rheumatology clinical practice

W474a

Raynaud’s and Digital Ischemia (084)

Insurance Roundtable

Speaker: Janet E. Pope, MD, MPH; St. Joseph’s Health Care, University of Western Ontario; London, ON, Canada

Moderators: Rodolfo Molina, MD; Arthritis Associates PA; San Antonio, TX Alex Limanni, MD; Arthritis Centers of Texas; Dallas, TX Speakers: To be announced

W185a

*Rheumatoid Arthritis: Biological Agents (085) Speaker: Larry W. Moreland, MD; University of Pittsburgh; Pittsburgh, PA

W187b

Rheumatoid Arthritis: Safety of Novel Therapies (086) PS

2 0 1 1

W187a

W185d

8 ,

Speaker: William M. McClatchey, MD; Piedmont Healthcare; Atlanta, GA

Speaker: Michael J. Maricic, MD; Catalina Pointe Rheumatology; Tucson, AZ

C

TUESDAY

Effective Use of Technology (082)

Rheumatology Practice 101: Starting Out in Practice for the Graduating Fellow (087) f

N o v e m b e r

W186c

W186b

cP

Upon completion of this session, participants should be able to: • discuss key areas of the claims processing systems to improve efficiency and reduce denials • identify ways to minimize the prior authorizations administrative burden for physician practices • discuss strategies to improve the management and guidelines for the use of biologic drug therapy

Speaker: Daniel H. Solomon, MD, MPH; Brigham and Women’s Hospital; Boston, MA 2011 Program Book

113


W195

Moderator: Howard J. Hillstrom, PhD; Hospital Special Surgery;Yuqing Zhang, DSc; Boston University School of Medicine; Boston, MA

Moderators: Nancy A. Baker, MPH, OTR, OTR/L; University of Pittsburgh; Pittsburgh, PA Yuqing Zhang, DSc; Boston University School of Medicine; Boston, MA

2 0 1 1

5:00 pm 2543. Severe Foot Pain, but Not Milder Foot Pain, Is Linked to Falls in Older Men and Women: The Framingham Study Alyssa B. Dufour1, Virginia A. Casey2, Thomas J. Hagedorn2, Jody L. Riskowski2 and Marian T. Hannan3, 1Hebrew SeniorLife & Boston Univ, Boston, MA, 2Hebrew SeniorLife, Boston, MA, 3 Hebrew SeniorLife & Harvard Med Sch, Boston, MA

8 ,

TUESDAY

ARHP Research Methodology Abstracts in this session are not in sequential order. Abstracts # 2547-2552 can be found on page 104.

4:45 pm 2542. Physical Activity and Frequent Sleep Insufficiency Among US Adults with Arthritis Jennifer M. Hootman1, Dianna Carroll2, Lela McKnight-Eily2 and Kelli D. Allen3, 1Centers for Disease Control and Prevention, Kennesaw, GA, 2Centers for Disease Control and Prevention, Atlanta, GA, 3Duke and Durham VA Medical Center, Durham, NC

N o v e m b e r

W194a

ACR/ARHP Combined Epidemiology Abstract Session

4:30 pm 2541. Does Medication Adherence Itself Confer Fracture Protection? An Investigation of the Healthy Adherer Effect In Observational Data Jeffery R. Curtis1, Jeff Lange2, Huifeng Yun1 and Elizabeth S. Delzell1, 1University of Alabama at Birmingham, Birmingham, AL, 2Proctor and Gambel

5:15 pm 2544. A Prospective Study of Alcohol Consumption and Risk of Rheumatoid Arthritis Bing LU1, Daniel H. Solomon1, Karen H. Costenbader2 and Elizabeth W. Karlson2, 1Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 5:30 pm 2545. Baseline Co-Morbidities Predict Risk of Infection in An Inception Cohort of Rheumatoid Arthritis Patients Receiving Anti-Tumor Necrosis Factor Therapy Joanne Homik1, Nguen Xuan Thanh2, Arto Ohinmaa1, Cheryl CM Barnabe3, Liam Martin3, Susan G. Barr3 and Walter P. Maksymowych1, 1University of Alberta, Edmonton, AB, 2Institute of Health Economics, Edmonton, AB, 3University of Calgary, Calgary, AB 5:45 pm 2546. Giant Cell Arteritis Is Associated with An Increase in Both All-Cause and Cardiovascular Mortality Gunnar Tomasson1, Johannes Bjornsson2, Michael P. LaValley3, Yuqing Zhang1, Vilmundur Gudnason4 and Peter A. Merkel1, 1 Boston University School of Medicine, Boston, MA, 2Landspitali University Hospital, Reykjavik, Iceland, 3Boston University School of Public Health, Boston, MA, 4The Icelandic Heart Association, Kopavogur

114

ARHP CONCURRENT ABSTRACT SESSION

4:30 - 6:00 pm

2011 Program Book

4:30 pm 2553. Developmental Trajectories of WOMAC Knee Pain and Their Predictors Over 3 Years Among Subjects of Osteoarthritis Initiative Bin Zhang1, Uyen Sa D. Nguyen2, Jingbo Niu2 and Yuqing Zhang2, 1 Boston Univ School of Medicine, Boston, MA, 2Boston University School of Medicine, Boston, MA 4:45 pm 2554. Proteomic Identification of A Panel of Novel Osteoarthritis Biomarkers In Serum and Cartilage Patricia Fernández-Puente1, Jesús Mateos1, Carolina Fernández-Costa1, Valentina Calamia1, Cristina Ruiz-Romero1, Carlos Fernández-López2, Natividad Oreiro2 and Francisco J. Blanco3, 1Osteoarticular and Aging Res. Lab. Proteomic UnitAssociated Node to Proteored. INIBIC-CHUAC, La Coruña, Spain, 2Osteoarticular and Aging Res. Lab. Rheumatology INIBIC-CHUAC, La Coruña, Spain, 3Osteoarticular and Aging Res. Lab. Proteomic Unit-Associated Node to Proteored/ Lab. Rheumatology Division INIBIC-CHUAC, La Coruña, Spain 5:00 pm 2555. Development of the United Kingdom Evaluation of Daily Activities Questionnaire in Rheumatoid Arthritis using Rasch Analysis Alison Hammond1, Alan Tennant2, Sarah Tyson1, Ulla Nordenskiold3 and Rachel Gill1, 1University of Salford, Manchester, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3Sahlgrenska Univ Hospital, Goteborg, Sweden 5:15 pm 2556. Internet Versus Mailed Administration of the Health Assessment Questionnaire Disability Index Bonnie Bruce1 and James F. Fries2, 1Stanford Dept of Medicine, Palo Alto, CA, 2Stanford Univ Medical Center, Palo Alto, CA 5:30 pm 2557. Using A Novel Approach to Estimate Effects of Depression On Changes In Knee Pain Severity In Osteoarthritis Initiative Ke Wang1, Bin Zhang2, David T. Felson3 and Yuqing Zhang3, 1 Boston University, Boston, MA, 2Boston Univ School of Medicine, Boston, MA, 3Boston University School of Medicine, Boston, MA 5:45 pm 2558. Relationship Between Accelerometer-Based Measures of Physical Activity and the Yale Physical Activity Survey in Adults with Arthritis Pamela A. Semanik1, Jungwha Lee2, Larry Manheim3, Loretta DiPietro4, Dorothy D. Dunlop3 and Rowland W. Chang2, 1 Rehabilitation Institute Chicago, Chicago, IL, 2Northwestern University, Chicago, IL, 3Northwestern Univ Med School, Chicago, IL, 4George Washington University School of Public Health and Health Services, Washington, DC

ARHP CONCURRENT SESSIONS 4:30 - 6:00 pm W476

Designing Exercise Prescriptions for Individuals with Arthritis and Other Comorbidities: What are the Considerations? C PS Moderator: Nadine M. Fisher, EdD; State University of New York at Buffalo; Buffalo, NY 4:30 pm Risk Factor Stratification/Guidelines for Exercise Testing and Prescription: General Considerations for Individuals with Arthritis and Cardiovascular Disease Mary E. Christenson, PT, PhD; Regis University; Denver, CO 5:00 pm Exercise Prescription for Individuals with Rheumatoid Arthritis and Comorbidities Maura D. Iversen, DPT, SD, MPH, PT; Northeastern University, Brigham & Women’s Hospital, Harvard Medical School; Boston, MA 5:30 pm Case Studies Considering Comorbid Conditions: Osteoarthritis and Obesity, and Osteoarthritis and Pre-diabetes Mary E. Christenson, PT, PhD; Regis University; Denver, CO Maura D. Iversen, DPT, SD, MPH, PT; Northeastern University, Brigham & Women’s Hospital, Harvard Medical School; Boston, MA

W470b

Metabolic Bone Disease

C

Moderator: Kori A. Dewing, DNP, ARNP; Virginia Mason Medical Center; Seattle, WA 4:30 pm Male Osteoporosis Shreyasee Amin, MDCM, MPH; Mayo Clinic; Rochester, MN 5:00 pm Paget’s Disease of Bone Michael McClung, MD; Oregon Osteoporosis Center; Portland, OR 5:30 pm Osteomalacia Clifford J. Rosen, MD; Maine Medical Research Institute; Scarborough, ME Upon completion of this session, participants should be able to: • discuss how to differentiate osteoporosis from osteomalacia • order appropriate investigations in a male patient with osteoporosis • develop a management plan for patients with Paget’s disease of bone

8 ,

Improving Health Measurement in Rheumatology

Upon completion of this session, participants should be able to: • discuss the differences between classical and modern test theory methods for health measurement • contrast advantages of modern versus classical measurement methods for clinical and patient-reported measures in rheumatology • describe recent developments and current projects relevant to rheumatology

4:30 pm Introduction to Item Response Therapy and Computerized Adaptive Testing Measurement in Health Research Peter Ten Klooster, PhD; University of Twente; Enschede, Netherlands 4:50 pm Multidimensional Computerized Assessment of Fatigue Stephanie Nikolaus, MSc; University of Twente; Enschede, Netherlands 5:10 pm Developing an Item Bank to Measure Physical Function in Rheumatology Martijn Oude Voshaar, MSc; University of Twente; Enschede, Netherlands

REF INDUSTRY ROUNDTABLESUPPORTED SYMPOSIA

2 0 1 1

c/r

Moderator: Afton L. Hassett, PsyD; University of Michigan Medical School; Ann Arbor, MI

TUESDAY

W474b

5:50 pm Question and Answer

N o v e m b e r

Upon completion of this session, participants should be able to: • identify consequences of physical activity for persons with arthritis in combination with other comorbidities • e xamine the current evidence related to prescribing exercise in individuals with arthritis and other comorbidities • d iscuss recommendations for exercise testing and prescription, based on risk stratification

5:30 pm Item Response Theory Analyses of Joint Counts in Rheumatoid Arthritis Liseth Siemons, MSc; University of Twente; Enschede, Netherlands

6:30 - 9:30 pm

In 2011, there are two types of symposia offered to attendees: CME-accredited and non-CME accredited. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. The non-CME accredited symposia have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Please visit the organization’s exhibit booth, the industry-supported symposia booth or see page 304 for more information.

2011 Program Book

115

WEDNESDAY, NOVEMBER 9, 2011


Hall F2 Entrance

Upon completion of this session, participants should be able to: • list research highlights from the scientific presentations • discuss the clinical impact of selected research reports presented at the meeting • evaluate the therapeutic potential of selected clinical trials presented at the meeting

ACR STATE-OF-THE-ART LECTURE

ACR IMMUNOLOGY UPDATES FOR THE CLINICIANS

7:30 - 8:30 am

7:30 - 8:30 am

W190a

Platelets as Inflammatory Cells in Arthritis

W196b

Apoptosis, Phagocytic Clearance and Autoimmune and Inflammatory Diseases c/r Moderator: Gregg J. Silverman, MD; New York University School of Medicine; New York, NY Speaker: Keith B. Elkon, MD; University of Washington; Seattle, WA

Speaker: Eric Boilard, PhD; Université Laval; Quebec, QC, Canada

Upon completion of this session, participants should be able to: • appreciate basic principles of immune recognition of dying cells and their phagocytic clearance • explain how inherited defects contribute autoimmune predisposition • define how clinical features and routine tests reflect cascades triggered by defects in apoptotic clearance, and how better diagnostic tests and therapeutic approaches are being developed from these new perspectives


W196a

ICD-10 & HIPAA 5010 - Ready or Not…It’s Coming! BR

C

cP

Moderator: Raymond Hong, MD, MBA; Ohio Permanente Medical Group; Parma, OH Speaker: Antanya Chung, CPC, CPC-I, CRHC, CCP; American College of Rheumatology; Atlanta, GA

N o v e m b e r

9 ,

2 0 1 1

WEDNESDAY

Upon completion of this session, participants should be able to: • identify the necessary steps for transition from the 4010 electronic transaction standards to the 5010 version • discuss how the new requirements of version 5010 and ICD-10 will impact administrative and business operations • describe how physician practice’s implementation fits within larger efforts by other stakeholders, e.g., vendors, insurance companies, clearinghouse, etc.


W375d

Rheumatology Roundup: Highlights from the 2011 Annual Scientific Meeting c/r cP Speakers: John J. Cush, MD; Baylor Research Institute; Dallas, TX Arthur Kavanaugh, MD; University of California San Diego; San Diego, CA

116

R

Moderator: Peter A. Nigrovic, MD; Brigham and Women’s Hospital; Boston, MA

2011 Program Book

Upon completion of this session, participants should be able to: • review platelet biology as it pertains to inflammatory disease • summarize the data supporting a role for platelets in arthritis • highlight ways in which platelets could be a target for antiinflammatory therapy in arthritis

ARHP CONCURRENT ABSTRACT SESSION 7:30 - 9:00 am

W476

ARHP Clinical Practice/Patient Care II Abstracts in this session are not in sequential order. Abstracts # 2559A-2559C and 2560 can be found on page 123. Moderators: Cong-Qiu Chu, MD, PhD; Oregon Health & Science University; Portland, OR Ajay Wanchu, MD; Oregon Health and Science University; Portland, OR 7:30 am 2561. Does Informing Patients about the Link Between Dental Hygiene and Rheumatoid Arthritis Encourage Better Dental Care? Patricia J. Cornell1, Selwyn Richards2 and Sarah Westlake2, 1Poole Hospital, Poole Dorset, United Kingdom, 2Poole Hospital NHS Foundation Trust, Poole, United Kingdom 7:45 am 2562. The Clinical Utility of Using Both the WOMAC and the MDHAQ Questionnaires in An Outpatient Osteoarthritis Clinic Caroline Jones1, Laurence A. Rubin2 and Lesley Bainbridge3, 1st Michael’s Hospital, Toronto, ON, 2St. Michael Hospital, Toronto, ON, 3University of British Columbia, Vancouver, BC 8:00 am 2563. Work Disability Is Related to the Presence of Arthritis, Not to a Specific Diagnosis Hernan Maldonado Ficco1, Rodolfo Perez Alamino1, Fernando Dal Pra1, Veronica Lencina1, Luciana Casalla2, Mariana Benegas2, Oscar Rillo2, Alberto Berman3, Ana Lucía Barbaglia3, Veronica Bellomio4, Francisco Caeiro5, Josefina Marcos6, Juan Carlos Marcos6, Antonio Catalan Pellet7, Rodrigo Garcia Salinas7, Sergio Paira8, Federico Ceccato8, Enrique Soriano9, Zaida Bendran9, Gabriela Salvatierra10 and Gustavo Citera1, 1Instituto

de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Hospital Tornu, Buenos Aires, Argentina, 3Hospital Padilla, Tucuman, Argentina, 4Consultorio, Tucuman, Argentina, 5Hospital Privado de Cordoba, Cordoba, Argentina, 6Hospital San Martin, La Plata, Argentina, 7Hospital Rivadiavia, Buenos Aires, Argentina, 8 Hospital Jose Maria Cullen, Santa Fe, Argentina, 9Hospital Italiano, Buenos Aires, Argentina, 10Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina 8:15 am 2564. Psychiatric Disorders in Fibromyalgia Patients, Results Patient Survey Robert S. Katz1, Sharon M. Ferbert2, Alexandra Small3, Susan Shott1 and Patricia Kuenzi1, 1Rush University Medical Center, Chicago, IL, 2Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, 3University of Illinois Medical School 8:30 am 2565. Evaluation of 13c-Acetate Plus Lactulose Breath Test, a New Examination to Measure Intestinal Absorption in Patients with Systemic Sclerosis Tatsuhiro Yamamoto, Yoshihisa Urita, Kaichi Kaneko, Nahoko Tanaka, Yoshie Kusunoki, Kenji Takagi, Shinichi Kawai and Hirahito Endo, Toho University School of Medicine, Tokyo, Japan 8:45 am 2566. The Association Between Cardio-Respiratory Fitness and Traditional Cardiovascular Risk Factors in Rheumatoid Arthritis Patients Jennifer K. Cooney1, Yasmeen Ahmad2, Jonathan Moore1, Andrew Lemmey1, Jeremy Jones1, Peter Maddison1 and Jeanette Thom1, 1School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, United Kingdom, 2The Department of Rheumatology, Betsi Cadwaladr University Health Board (West), Bangor, United Kingdom

7:30 - 8:30 am

W193a c/r

PM

W195

Marketing Community-based Programs to Primary Care Practices: An Approach Based on Centers for Disease Control Audience Research C Moderator: Janet L. Poole, OTR, PhD; University of New Mexico; Albuquerque, NM Speaker: Teresa J. Brady, PhD; Centers for Disease Control; Atlanta, GA Upon completion of this session, participants should be able to: • describe findings from audience research with primary care practices on preferred modes of learning and key questions to be answered in an introduction to community-based physical activity and self-management education programs • discuss the marketing strategy and materials developed to promote physical activity and self-management education programs to primary care practices • identify key learnings from a pilot test of this marketing approach • describe how to obtain the materials developed to support this outreach to primary care practices

W474b

Rubbing Elbows with the Higher Ups: Effective Communications with Administration c/r Ed.

Upon completion of this session, participants should be able to: • d iscuss what functional, structural and chemical imaging techniques can tell us about chronic pain pathology • r ecognize that multiple chronic pain disorders share overlapping brain pathology • r eview the ramifications of how brain physiology can impact the development of new treatments and ultimately improve patient care

W470b c/r

Moderator: Barbara A. Slusher, PA-C, MSW; Rheumatology Associates of Houston; Houston, TX

Upon completion of this session, participants should be able to: • identify barriers and facilitators to effective communication • discuss ways in which to provide effective communication as a committee member • practice effective communication

ACR BASIC SCIENCE SYMPOSIA 9:00 - 10:30 am

W EDN A YY W Ne EEr SS9 D N o vEeD m b ,D2A 0 1 1

Moderator: Laurence A. Bradley, PhD; University of AlabamaBirmingham; Birmingham, AL Speaker: Richard E. Harris, PhD; University of Michigan; Ann Arbor, MI

Highlights from the 2011 ARHP Sessions

Upon completion of this session, participants should be able to: • list the highlights from the 2011 ARHP abstracts, presentations, and sessions • discuss the importance of the findings presented in ARHP sessions

Moderator: Leigh F. Callahan, PhD; University of North Carolina; Chapel Hill, NC Speakers: Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute Chicago; Chicago, IL Eric P. Gall, MD, MACR, MACP; Arizona Arthritis Center; Tucson, AZ

ARHP CONCURRENT SESSIONS

Brain Correlates of Chronic Pain

Speakers: Donah Z. Crawford, BS, MA; The Arthritis Group; Philadelphia, PA Robert R. McLean, DSc, MPH; Hebrew Senior Life/Harvard Medical School; Boston, MA

W190a

Mechanisms of Thrombosis in Systemic Autoimmune Disease R Moderators: Jane E. Salmon, MD; Hospital for Special Surgery, Weill Cornell Medical College; New York, NY Rachel Kaiser, MD, MPH; University of California; San Francisco, CA

2011 Program Book

117

9:00 am Mechanisms of Thrombosis in Antiphospholipid Syndrome: The Role of Innate Immunity Joyce Rauch, PhD; Research Institute of the McGill University Health Centre; Montreal, QC, Canada 9:25 am What is the Role of Hydroxychloroquine and Statins in the Prevention of Thrombosis in Systemic Lupus Erythematosus and Antiphospholipid Syndrome? Michael D. Lockshin, MD; Hospital for Special Surgery; New York, NY 9:50 am Novel Immunomodulatory Approaches to the Management of Antiphospholipid Syndrome Silvia S. Pierangeli, PhD; University of Texas Medical Branch; Galveston, TX Upon completion of this session, participants should be able to: • describe how innate immune activation may contribute to antiphospholipid syndrome, including why some individuals with antiphospholipid develop antiphospholipid syndrome while others do not • define the recent data that supports a role for immunomodulatory approaches to the management of antiphospholipid syndrome, including some of the potential molecular pathways/targets • assess the evidence supporting the use of statins and/or hydroxychloroquine for prevention of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome

W183a

Stem Cell Mediated Therapies in Autoimmune Diseases R Moderators: Christian Jorgensen, MD, PhD; Hospital Lapeyronie; Montpellier, France Jacob M. van Laar, MD, PhD; Musculoskeletal Research Group; Newcastle, United Kingdom

N o v e m b e r

9 ,

2 0 1 1

WEDNESDAY

9:00 am Mesenchymal Stem Cell in the Treatment of Inflammatory Disorders Alan G. Tyndall, MD; University of Basel; Basel, Switzerland

W375d

Efficacy and Safety of Calcium and Vitamin D Supplementation P/C PS Moderator: Diane L. Kamen, MD, MS; Medical University of South Carolina; Charleston, SC 9:00 am Calcium Supplementation: Necessary for Bone, Dangerous for the Cardiovascular System? Richard Bockman, MD, PhD; Joan and Sanford Weill Medical College of Cornell University; New York, NY 9:25 am Latest Understanding of Vitamin D Physiology Robert P. Heaney, MD; Creighton University; Omaha, NE 9:50 am Guidelines for Vitamin D Supplementation Karen E. Hansen, MD, MS; University of Wisconsin; Madison, WI Upon completion of this session, participants should be able to: • describe the available data from clinical trial and cohort studies that address the cardiovascular events reported in calcium supplementation trials • cite the latest understanding of the autocrine and endocrine roles of vitamin D and what is known and unknown regarding the roles of vitamin D in bone, cardiovascular health, metabolism, immunology and cancer • identify the current state of the art in establishing guidelines for the cardiovascular system

W375c

Hereditary Angioedema

C

Moderators: Tracy M. Frech, MD; University of Utah School of Medicine; Salt Lake City, UT Victoria K. Shanmugam, MBBS, MRCP; Georgetown University Hospital; Washington, DC 9:00 am Approach to Urticaria and Angioedema Michael M. Frank, MD; Duke University; Durham, NC

9:25 am Different Stromal Cell Types and Immune Effects: Application to Autoimmune Diseases Daniele Noel; PhD; Inserm Institute, Montpellier, France

9:25 am Hypereosinophilic Syndromes Lawrence B. Schwartz, MD, PhD; Virginia Commonwealth University; Richmond, VA

9:50 am Organization of Immunological Memory by Bone Marrow Stroma Hyun-Dong Chang; PhD; Deutsches Rheuma-Forschungszentrum Berlin ein Institut der Leibniz Gemeinschaft; Berlin, Germany

9:50 am New Treatments for Angioedema Bruce L. Zuraw, MD; University of California, San Diego; La Jolla, CA

Upon completion of this session, participants should be able to: • review the data basic biology of stem cells, on experimental models for regenerative medicine and on different stromal cell type (placenta, adipose, bone marrow) • explain bone marrow niche biology • provide an update on clinical trials in autoimmune diseases • discuss the future strategy (allogeneic versus allogeneic cells, number of cell, pre-activated cells) for clinical program

118

ACR CLINICAL SYMPOSIA 9:00 - 10:30 am

2011 Program Book

Upon completion of this session, participants should be able to: • discuss the differential diagnosis of angioedema • evaluate a patient with urticaria • explain the immune mechanisms underlying the development of hereditary angioedema • review the currently approved therapies for the management of patients in the acute, sub-acute and chronic phases of their disease

ACR CURRENT ABSTRACT SESSIONS 9:00 - 10:30 am

W196a

Cytokines, Mediators, and Gene Regulation III Moderators: Shiva Shahrara, PhD; University of Illinois at Chicago; Chicago, IL Pierre Miossec, MD, PhD; Immunogenomics and Inflammation Research Unit; Lyon, France 9:00 am 2567. Immune Suppression and Injury Tolerance in Fibrotic Liver Are Mediated by Induced Regulatory T Cells Which Safeguard Fibroplasias From Clearance Ming Feng1, Yuan-Ping Han1 and Song G. Zheng2, 1University of Southern California, Los Angeles, CA, 2USC Keck School of Medicine, Los Angeles, CA 9:15 am 2568. Activation of c-Jun N-Terminal Kinase and Extracellular Signal-Regulated Kinase Predicts Damage in Systemic Lupus Erythematosus Mirit Amit-Vazina1, Yair Molad2, Eliyahu Yona3, Lily Amram3, Olga Bloch4 and Micha J. Rapoport4, 1Rheumatology Service, Assaf Harofeh Medical Center and Sackler School of Medicine, Tel-Aviv University, Israel, Zerifin, Israel, 2Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel, 3Internal Medicine Division, Day Care Unit, Assaf Harofeh Medical Center and Sackler School of Medicine, Tel-Aviv University, Israel, Zerifin, Israel, 4Diabetes and Immunology Research Laboratory, Assaf Harofeh Medical Center and Sackler School of Medicine, Tel-Aviv University, Israel, Zerifin, Israel 9:30 am 2569. Novel Regulation of TNF-α-Induced-IL-18 Bioactivity in Rheumatoid Arthritis Synovial Fibroblasts by Reducing Caspase-1 Via JAK2 Inhibition Hubert Marotte1, Tatiana Fedorova1, Adam J. Pinney1, Benjamin Lewis1 and Alisa E. Koch2, 1University of Michigan Medical School, Ann Arbor, MI, 2Veteran’s Administration and Unversity of Michigan, Ann Arbor, MI

10:00 am 2571. What Keeps An Autoantibody-Positive Healthy Individual Healthy? Lauren L. Ritterhouse1, Holden T. Maecker2, Hongwu Du3, C. Garrison Fathman4, Joan T. Merrill1, Joel Guthridge1 and Judith A. James5, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University School of Medicine, Stanford, CA, 3Stanford University School of Medicine, Stanford, CA, 4Stanford Univ Medical Center, Stanford, CA, 5Oklahoma Medical Research

10:15 am 2572. Aminopeptidase N/CD13 Localization and Chemotaxis in Rheumatoid Arthritis In Vivo and In Vitro Rachel Morgan1, Nilofar Behbahani-Nejad1, Judith Endres1 and David A. Fox2, 1University of Michigan, Ann Arbor, MI, 2Univ of Michigan Med Ctr, Ann Arbor, MI

W194b

Epidemiology and Health Services Research III: Rheumatoid Arthritis Moderators: Gabriela Schmajuk, MD, MS; University of California San Francisco; San Francisco, CA Elizabeth W. Karlson, MD, MPH; Brigham and Women’s Hospital; Boston, MA 9:00 am 2573. Administrative Definitions of Rheumatoid Arthritis: Rising Prevalence Regardless of Definition Used Christine A. Peschken1, Carol A. Hitchon2, Hui Chen2, Allan Garland2, Hani S. El-Gabalawy2, Charles N. Bernstein2 and Ruth Ann Marrie2, 1Univ of Manitoba, Winnipeg, MB, 2University of Manitoba, Winnipeg, MB 9:15 am 2574. The Association of Ambient Air Pollution Exposures and Risk of Rheumatoid Arthritis: Results From the Swedish EIRA Case-Control Study and the US Nurses’ Health Prospective Cohort Study Jaime E. Hart1, Henrik Källberg2, Francine Laden3, Karen H. Costenbader1, Marie Holmqvist2, Lars Klareskog2, Lars Alfredsson4 and Elizabeth W. Karlson1, 1Brigham and Women’s Hospital, Boston, MA, 2Karolinska Institutet, Stockholm, Sweden, 3 Harvard School of Public Health, Boston, MA, 4Institute of Environmental Medicine, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Stockholm, Sweden 9:30 am 2575. The Performance of Matrix-Based Risk Models for Rapid Radiographic Progression in An Observational Cohort of Established RA Patients Siri Lillegraven1, Femke H.M. Prince2, Nancy A. Shadick2, Espen A. Haavardsholm3, Michelle A. Frits2, Christine K. Iannaccone2, Tore K. Kvien3, Michael E. Weinblatt2 and Daniel H. Solomon2, 1 Brigham and Women’s Hospital / Diakonhjemmet Hospital, Boston / Oslo, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Diakonhjemmet Hospital, Oslo, Norway 9:45 am 2576. Are Biologics Cost-Effective? Analysis Based on Real-Life Rheumatoid Arthritis Patients Hawre Jalal1, Kaleb Michaud2, Hyon K. Choi3, Young Hee Rho3 and Karen Kuntz1, 1University of Minnesota, Minneapolis, MN, 2 National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 3Boston University School of Medicine, Boston, MA


9:45 am 2570. STAT3 Phosphorylation of Circulating Leukocytes Correlates with Disease Activity in Early Untreated Rheumatoid Arthritis Krista Kuuliala1, Antti Kuuliala1, Saara Aittomäki1, Suvi Oksanen1, Sanna Siitonen2, Hannu Kautiainen3, Marjatta Leirisalo-Repo2 and Heikki Repo1, 1Haartman Institute, Helsinki, Finland, 2Helsinki University Central Hospital, Helsinki, Finland, 3Central Finland Central Hospital, Jyväskylä, Finland

Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK

10:00 am 2577. Statins and Risk of Acute Myocardial Infarction in Patients with RheumatoidArthritis: A Population-Based Study Mary De Vera1, Diane Lacaille1, Michal Abrahamowicz2, Jacek 2011 Program Book

119

A. Kopec1 and Hyon K. Choi3, 1Arthritis Research Centre of Canada, Vancouver, BC, 2McGill UHC/RVH, Montreal, QC, 3Boston University School of Medicine, Boston, MA 10:15 am 2578. Quality of Care for Common Comorbidities Among Patients with Rheumatoid Arthritis: An Analysis of HEDIS Data Gabriela Schmajuk1, Laura Trupin2, Chris Tonner3, Amal N. Trivedi4, Edward Yelin3 and Jinoos Yazdany5, 1University of California - San Francisco, San Francisco, CA, 2UC San Francisco, San Francisco, CA, 3UCSF, San Francisco, CA, 4Brown University, Providence, RI, 5University of California San Francisco, San Francisco, CA

W474a

Metabolic and Crystal Arthropathies II: Concurrent Session on the Anti-Gout Medications – Dosing, Adverse Effects, and Economic Burden Moderator: Michael A. Becker, MD; University of Chicago Medical Center; Chicago, IL 9:00 am 2579. Starting Dose, but Not Maximum Maintenance Dose, Is a Risk Factor for Allopurinol Hypersensitivity Syndrome: A Proposed Nomogram for Safe Starting Dosing of Allopurinol Lisa K. Stamp1, William Taylor2, Peter B. B. Jones3, Jo L. Dockerty4, Jill Drake5, Christopher Frampton1 and Nicola Dalbeth6, 1 University of Otago, Christchurch, New Zealand, 2University of Otago, Wellington, New Zealand, 3Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 4Dunedin Hospital, Dunedin, New Zealand, 5Christchurch Hospital, Christchurch, New Zealand, 6University of Auckland, Auckland, New Zealand

N o v e m b e r

9 ,

2 0 1 1

WEDNESDAY

9:15 am 2580. Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators Seo Young Kim1, Craig Newcomb2, David Margolis2, Jason Roy2 and Sean Hennessy2, 1Brigham & Women’s Hospital, Boston, MA, 2 University of Pennsylvania, Philadelphia, PA 9:30 am 2581. Colchicine Dosing Guidelines for Gout Patients with Varying Degrees of Renal Impairment Based on Pharmacokinetic Data Suman Wason, Robert D. Faulkner and Matthew W. Davis, URL Pharma, Philadelphia, PA 9:45 am 2582. Characterization and Management of Infusion Reactions in Refractory Chronic Gout (RCG) Treated with Pegloticase (PGL) Herbert Baraf1, Robert A. Yood2, John S. Sundy3, Faith D. Ottery4, Zeb D. Horowitz5 and Michael A. Becker6, 1Arthritis & Rheumatism Assoc, Wheaton, MD, 2Fallon Clinic, Worcester, MA, 3Duke University Medical Center, Durham, NC, 4Savient, East Brunswick, NJ, 5Celgene Corporation, Basking Ridge, NJ, 6 University of Chicago Medical Center, Chicago, IL 10:00 am 2583. Economc Burden of Gout Patients Treated with Urate Lowering Therapy Anna Forsythe1 and Hyon K. Choi2, 1Savient Pharmaceuticals, Inc., East Brunswick, NJ, 2Boston University School of Medicine, Boston, MA

120

2011 Program Book

10:15 am 2584. Arhalofenate, a Potential Novel Treatment for Hyperuricemia, with or without Metabolic Co-Morbidities, in Patients with Gout: Meta-Analysis of Urate Lowering in Four Phase 2 Studies in Type 2 Diabetes Gopal C. Saha, David B. Karpf, Yun-Jung Choi and Brian K. Roberts, Metabolex, Inc., Hayward, CA

W196b

Rheumatoid Arthritis Clinical Aspects: Risk of Cardiovascular Disease Moderators: Lennart T. H. Jacobsson, MD, PhD; Malmo University Hospital; Malmo, Sweden Eric M. Ruderman, MD; Northwestern University; Chicago, IL 9:00 am 2585. Risk of Cardiovascular Disease in Rheumatoid Arthritis Is Independent of Disease Duration and the Level of Disease Activity Elke.E.A. Arts1, Jaap Fransen1, Alfons den Broeder2, Calin Popa1 and Piet L.C.M. Van Riel1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands 9:15 am 2586. The Effect of Body Mass Index On the Outcomes of Rheumatoid Arthritis Frederick Wolfe1 and Kaleb Michaud2, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2National Data Bank for Rheumatic Diseases and University of Nebraska, Omaha, NE 9:30 am 2587. Inflammatory Burden Predicts Plaque Formation of Carotid Artery in Rheumatoid Arthritis Churl Hyun Im, Na Ri Kim, Jong Wan Kang, Ji Hun Kim, Gi Bum Bae, Eon Jeong Nam and Young Mo Kang, Kyungpook National University Hospital, Daegu, South Korea 9:45 am 2588. NT-Pro-BNP Levels Are Associated with Increased All Cause and Cardiovascular Mortality in Early Inflammatory Polyarthritis Independent of Disease Severity and Autoantibody Status- Results From the Norfolk Arthritis Register (NOAR) Hoda Mirjafari1, Suzanne Verstappen1, Manjari Lahiri1, Paul Welsh2, Diane K. Bunn3, Tarnya Marshall3, Mark Lunt1, Naveed Sattar2, Deborah P. M. Symmons1 and Ian N. Bruce1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom 10:00 am 2589. Reduction in the Risk of Myocardial Infarction in Bisphosphonate and Calcium/Vitamin D Treated Rheumatoid Arthritis and Lupus Patients: A Longitudinal Cohort Study Frederick Wolfe1, Marcy B. Bolster2, Cathleen Colon-Emeric3, Christopher M. O’Connor4, Kaleb Michaud5 and Kenneth W. Lyles4, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2 Medical Univ of South Carolina, Charleston, SC, 3Duke University Medical Center and the Durham VA GRECC, Durham, NC, 4Duke University School of Medicine, Durham, NC, 5National Data Bank for Rheumatic Diseases, University of Nebraska, Omaha, NE

10:15 am 2590. Getting to the Heart of the Matter: The Need for More Aggressive Management of Cardiovascular Risk Factors in Rheumatoid Arthritis Shailey S. Desai1, James D. Myles2 and Mariana J. Kaplan1, 1 University of Michigan Rheumatology, Ann Arbor, MI, 2Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, MI

W375b

Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy: Novel Compounds I Moderators: Daniel H. Solomon, MD, MPH; Brigham and Women’s Hospital; Boston, MA Vivian Bykerk, MD; Brigham and Women’s Hospital; Boston, MA 9:00 am 2591. A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naïve to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors Mark C. Genovese1, Maria W. Greenwald2, Chul Soo Cho3, Alberto Berman4, Ling Jin5, Gregory Cameron6, Li Xie5, Daniel Braun5, Subhashis Banerjee5 and Laura Warner7, 1stanford University, Palo Alto, CA, 2Desert Medical Advances, Palm Desert, CA, 3St Marys Hospital, Seoul, 4Hospital Padilla, Tucuman, Argentina, 5Eli Lilly and Company, Indianapolis, IN, 6Eli Lily and Company, Indianapolis, IN, 7i3 Statprobe, Indianapolis, IN

9:30 am 2593. The Oral S1P Lyase Inhibitor LX3305 (LX2931) Demonstrates Favorable Safety and Potential Clinical Benefit at 12-Weeks in a Phase 2 Proof-of-Concept Trial in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Therapy Roy M. Fleischmann1, Jeffrey E. Poiley2, Rumen Stoilov3, Vibeke Strand4, Joel Freiman5, Tamas Oravecz5, Arthur Sands5,

9:45 am 2594. Longer-Term Safety of Fostamatinib (R788) in Patients with Rheumatoid Arthritis – Analysis of Clinical Trial Data From up to 2 Years of Exposure Arthur Kavanaugh1, Michael E. Weinblatt2, Mark C. Genovese3, Theresa K. Musser4, Elliott B. Grossbard4, Daniel B. Magilavy4, Sally Hollis5, Eveline Wesby van-Sway5 and David Millson5, 1 University of California San Diego, San Diego, CA, 2Brigham and Women’s Hospital, Boston, MA, 3Stanford University, Palo Alto, CA, 4Rigel Pharmaceuticals, South San Francisco, CA, 5 AstraZeneca, Macclesfield, United Kingdom 10:00 am 2595. Comparative Effectiveness of Abatacept Versus Subsequent Anti-TNF Agents Among Rheumatoid Arthritis Patients with Previous Anti-TNF Exposure Leslie R. Harrold1, George Reed1, Jeffrey R. Curtis2, Daniel H. Solomon3, Marc Hochberg4, Alina U. Onofrei1, Joel M. Kremer5 and Jeffrey D. Greenberg6, 1UMass Medical School, Worcester, MA, 2Univ of Alabama-Birmingham, Birmingham, AL, 3Brigham & Womens Hospital, Boston, MA, 4University of Maryland School of Medicine, Baltimore, MD, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6New York University School of Medicine, New York, NY 10:15 am 2596. Discontinuation of Dmards in patients with Rheumatoid Arthritis Treated with Tumor necrosis factor Blocking Agents: an Analysis in the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry Sanne van Dartel1, Jaap Fransen1, Wietske Kievit1, Alfons den Broeder2, Henk Visser3, Andre Hartkamp4, Mart AF van de Laar5 and Piet Van Riel1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands, 3Alysis Care Group, Arnhem, Netherlands, 4Jeroen Bosch Hospital, ‘s-Hertogenbosch, Netherlands, 5Medisch Spectrum Twente & Twente University, Enschede, Netherlands

W470b

Systemic Lupus Erythematosus – Clinical Aspects: Translational Studies Moderators: Jennifer H. Anolik, MD, PhD; University of Rochester; Rochester, NY Anisur Rahman, PhD; University College London; London, United Kingdom


9:15 am 2592. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: a 24-Month Phase 3 Study Désirée van der Heijde1, Y. Tanaka2, Roy Fleischmann3, Edward C. Keystone4, J. M. Kremer5, C A. F. Zerbini6, M. Cardiel7, S. B. Cohen8, P. T. Nash9, Yeong Wook Song10, D. Tegzova11, B. Wyman12, D. Gruben12, B. Benda13, G. Wallenstein12, S. H. Zwillich12, J. D. Bradley12, C. A. Connell12 and the ORAL Scan investigators14, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 3University of Texas Southwestern Medical Center, Dallas, TX, 4Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 7Institute of Rheumatology, Prague, Czech Republic, 8Metroplex Clinical Research Centre, Dallas, TX, 9University of Queensland, Brisbane, Australia, 10Seoul National University Hospital, Seoul, South Korea, 11Institute Of Rheumatology, Prague, Czech Republic, 12 Pfizer Inc., Groton, CT, 13Pfizer Inc., Collegeville, PA, 14Groton

Brian Zambrowicz5 and Lexicon Pharmaceuticals RA Clinical Development6, 1University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 2 Arthritis Associates, Orlando, FL, 3University Multiprofile Hospital for Active Treatment (UMHAT) St. Ivan Rilski EAD, Sofia, Bulgaria, 4Stanford University, Palo Alto, CA, 5Lexicon Pharmaceuticals, Inc., The Woodlands, TX, 6The Woodlands, TX

9:00 am 2597. Members of the Receptor for Advanced Glycation Endproducts Axis Associate with Systemic Lupus Erythematosus, and May Serve As a Brake to Disease Activity Manish Jain, Michael Amato, Robert M. Clancy, Peter M. Izmirly and Jill P. Buyon, New York University School of Medicine, New York, NY

2011 Program Book

121

9:15 am 2598. Regulatory Role of Umbilical Cord Mesenchymal Stem Cells on Treg and Th17 Cells in Patients with Systemic Lupus Erythematosus Dandan Wang, Huiqing Liu, Xia Li and Lingyun Sun, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 9:30 am 2599. N-Acetylcysteine Improves Disease Activity by Blocking the Mammalian Target of Rapamycin in T Cells of Lupus Patients Zhiwei Lai1, Robert Hanczko1, Eduardo Bonilla1, Adam Bartos1, Tiffany Telarico2, Gabriella Miklossy3, Brandon Clair2, John Jimah3, Edward Doherty4, Lisa Francis1, Hajra I. Tily5, Ricardo Garcia1, Maha M. Dawood4, Jianghong Yu1, Irene Ramos1, Travis Boevin1, Stephen Faraone1, Paul E. Phillips6 and Andras Perl3, 1 SUNY, Syracuse, NY, 2SUNY Upstate Medical University, Syracuse, NY, 3Upstate Medical University, Syracuse, NY, 4SUNY Upstate, Syracuse, NY, 5SUNY, NY, 6SUNY-Upstate Medical Univ, Syracuse, NY

N o v e m b e r

9 ,

2 0 1 1

WEDNESDAY

9:45 am 2600. Circulating Mitochondrial DNA Copy Numbers As a Highly Sensitive Diagnostic Marker of Systemic Lupus Erythematosus and An Independent Predictor of SLE Activity Nils Venhoff1, Jens Thiel1, Dirk Lebrecht1, Chingching Foocharoen2, Nora M. Effelsberg1, Marten Trendelenburg3, Paul Hasler4, Reinhard E. Voll1 and Ulrich A. Walker2, 1Dept. of Rheumatology and Centre of Chronic Immunodeficiency, University of Freiburg, Freiburg, Germany, 2Dept. of Rheumatology at Basel University, Felix-Platter Spital, Basel, Switzerland, 3Dept. of Internal Medicine, University Hospital Basel, Basel, Switzerland, 4Dept. of Rheumatology, Kantonsspital Aarau, Aarau, Switzerland

122

10:00 am 2601. Interferon-Alpha Activity Levels Increase Immediately Preceding Clinical Classification of Systemic Lupus Julie M. Robertson1, Latisha Heinlen2, Jourdan Anderson1, Timothy B. Niewold3, Michael P. Keith4, John B. Harley5 and Judith A. James6, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2OUHSC, Oklahoma City, OK, 3University of Chicago, Chicago, IL, 4National Naval Medical Center, Bethesda, MD, 5Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 6Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK 10:15 am 2602. Vascular Biomarkers and Risk of Treatment Failure in the Maintenance Phase of a Randomized Multicenter Trial Comparing Mycophenalate Mofetil and Azathioprine for Lupus Nephritis Robert M. Clancy1, Peter M. Izmirly1, E.M. Ginzler2 and On Behalf of the Investigators in the MMF/AZA Lupus Nephritis Main Trial1, 1 New York University School of Medicine, New York, NY, 2SUNYDownstate Medical Center, Brooklyn, NY

2011 Program Book

W192b

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics II Moderators: Maria Trojanowska, PhD; Boston University; Boston, MA Francesco Del Galdo, MD, PhD; University of Leeds; Leeds, United Kingdom 9:00 am 2603. Intermittent Systemic VEGF Inhibition Induces Pulmonary Arterial Hypertension In a Transgenic Mouse Model of Scleroderma Emma Derrett-Smith1, Audrey Dooley1, Reshma Baliga2, Adrian Hobbs2, David J. Abraham3 and Christopher P. Denton1, 1 UCL Medical School, London, United Kingdom, 2Centre for Cardiovascular Pharmacology, University College London, London, United Kingdom, 3Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom 9:15 am 2604. Overexpression of VEGF165b, An Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis In Patients with Systemic Sclerosis Mirko Manetti, Serena Guiducci, Eloisa Romano, Claudia Ceccarelli, Silvia Bellando-Randone, Maria Letizia Conforti, Lidia Ibba-Manneschi and Marco Matucci-Cerinic, University of Florence, Florence, Italy 9:30 am 2605. Downregulation of Mir-193b in Systemic Sclerosis Regulates the Proliferative Vasculopathy by Urokinase-Type Plasminogen Activator Expression Naoki Iwamoto1, Serena Vettori1, Britta Maurer1, Matthias Brock1, Maurizio Calcagni2, Renate E. Gay1, Steffen Gay1 and Oliver Distler1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Division of Plastic Surgery and Hand Surgery, University Hospital Zurich, Zurich, Switzerland 9:45 am 2606. Heart Involvement in Patients with Systemic Sclerosis Is Mimicked by Fra-2 Transgenic Mice Paulius Venalis1, Laszlo Cziriak2, Alfiya Akhmetshina3, Clara Dees3, Pawel Zerr3, Zygmunt Mackevic4, Ingrid E. Lundberg1, Oliver Distler5, Georg Schett3 and Jorg HW Distler3, 1Karolinska Institutet, Stockholm, Sweden, 2University of Pécs, Budapest, Hungary, 3University of Erlangen-Nuremberg, Erlangen, Germany, 4State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, 5University Hospital Zurich, Zurich, Switzerland 10:00 am 2607. In Vivo Delivery of Alternatively Spliced Interleukin-4 Mimics Scleroderma Lung Disease Sergei P. Atamas and Irina G. Luzina, University of Maryland School of Medicine, Baltimore, MD 10:15 am 2608. Functional Inhibition of the TRPV2 Non-Selective Calcium Channel Causes a Potent Stimulation of Genes Encoding Types I and III Collagens and α-Smooth Muscle Actin in Normal Dermal Fibroblasts: A Potential Mechanism of Myofibroblast Induction in SSc

Peter J. Wermuth1, Sankar Addya2 and Sergio A. Jimenez1, 1 Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, 2Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA


W183c

Career Opportunities in Rheumatology: Making a Choice Ed. f Moderator: David D. Sherry, MD; Children’s Hospital of Philadelphia; Philadelphia, PA 9:00 am Basic Research Career in Rheumatology James N. Jarvis, MD; University of Oklahoma College of Medicine; Oklahoma City, OK 9:18 am Clinical Research Career in Rheumatology Daniel A. Albert, MD; Dartmouth-Hitchcock Medical Center; Lebanon, NH 9:36 am Rheumatology Private Practice Career Robin K. Dore, MD; David Geffen School of Medicine, University of California Los Angeles; Tustin, CA 9:54 am Rheumatologists in the Pharmaceutical Industry Wayne H. Tsuji, MD; Amgen; Seattle, WA 10:12 am Rheumatologists in Government Frederick W. Miller, MD, PhD; NIH/National Institute of Environmental Health Sciences; Bethesda, MD Upon completion of this session, participants should be able to: • identify different career choices available to young rheumatologists • d escribe the work load, work-life balance and rewards of various career paths • a ppraise the pros and cons of the various career choices in rheumatology

9:00 - 10:00 am

W194a

ARHP Clinical Practice/Patient Care III Abstracts in this session are not in sequential order. Abstract # 2609 can be found on this page. Moderator: Eswar Krishnan, MD; Stanford University; Palo Alto, CA 9:00 am 2559A. The Effect of Physician Communication on Treatment Adherence in Patients with Rheumatoid Arthritis Maria F. Marengo1, Richard L. Street Jr.2, Sofia De Achaval3, Hong Zhang1, Marsha Richardson4 and Maria E. Suarez-Almazor5,

9:15 am 2559B. Supervised Physical exercise improves endothelial Function and endothelial Progenitor cells in patients with Systemic Lupus Erythematosus Edgard T. Reis Neto1, Aline E. Silva1, Carlos M. C. Monteiro2, Erika L. Naka2, Patricia Semedo2, Neusa P. Silva1 and Emilia I. Sato1, 1Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 2Escola Paulista de Medicina Universidade Federal de São Paulo, São Paulo, Brazil 9:30 am 2559C. Sexual Problems and Sexual Perception in Patients with Ankylosing Spondylitis Anne Proven1, Kari H. Berg2, Elsa Almas3, Espen E. Benestad4 and Glenn Haugeberg5, 1MD, Baerum, Norway, 2MA, Kristiansand.S, Norway, 3MA, Kristiansand, Norway, 4MD, Kristiansand, Norway, 5 MD, PhD, Kristiansand.S, Norway 9:45 am 2560. Is 10,000 Steps Enough to Meet Physical Activity Guidelines?: The Multicenter Osteoarthritis Study Daniel K. White1, David T. Felson1, Yuqing Zhang2, K. Douglas Gross3, Jingbo Niu1, Zhaolong Shen4, Michael C. Nevitt5, C.E. Lewis6, James Torner7 and Tuhina Neogi4, 1Boston University School of Medicine, Boston, MA, 2Boston University Clinical Edpidemiology Reserach and Training Unit, Boston, MA, 3MGH Institute of Health Professions, Boston, MA, 4Boston University, Boston, MA, 5University of California-San Francisco, San Francisco, CA, 6University of Alabama, Birmingham City, AL, 7 University of Iowa, Iowa City, Iowa City, IA 9:00 - 10:30 am

W195

ARHP Rehabilitation Sciences Moderators: Jill R. Blitz, PT, DPT; Children’s Hospital Los Angeles; Los Angeles, CA Talitha Cox, MA, OTR/L; Children’s Hospital of Los Angeles; Los Angeles, CA 9:00 am 2609. A Study to Investigate the Clinical Effectiveness of a Prefabricated Foot Orthosis in Patients with Early Rheumatoid Arthritis Vicki Cameron-Fiddes, Stirling University, Scotland, UK, Stirling, Scotland 9:15 am 2610. Fatigue in Rheumatoid Arthritis: What Is the Role of Lower Extremity Muscle Weakness? Patricia P. Katz1, Mary E. Margaretten2, Marissa San Pedro2 and Vladimir Chernitskiy1, 1University of California San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA


ARHP CONCURRENT ABSTRACT SESSIONS

UT MD Anderson Cancer Center, Houston, TX, 2Texas A&M University, College Station, TX, 3U.T. MD Anderson Cancer Center, Houston, TX, 4UT MD Anderson, Houston, TX, 5University of Texas. M.D Anderson Cancer Center, Houston, TX 1

9:30 am 2611. Muscle Quality Contributes More to Postural Balance Than Muscle Atrophy in People with Rheumatoid Arthritis Samannaaz S. Khoja, Bret H. Goodpaster and Sara R. Piva, University of Pittsburgh, Pittsburgh, PA 2011 Program Book

123

9:45 am 2612. Improvement 3 to 12 Months Post Hip and Knee Replacement: Implications for Rehabilitation A. M. Davis1, A. V. Perruccio2, S. Ibrahim3, S. Hogg-Johnson4, R. Wong5, E. Schemitsch6, N. N. Mahomed7, J. Flannery8 and E. M. Badley9, 1Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, 2Department of Orthopedic Surgery and The Arthritis Program, Toronto Western Hospital, Toronto, ON, 3 Institute for Work and Health, Toronto, ON, 4Institute for Work and Health, and Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 5Health Care and Outcomes Research, Toronto Western Research Institute, Toronto, ON, 6Division of Orthopaedics, University of Toronto and St. Michael’s, Toronto, ON, 7Division of Orthopaedics, University of Toronto and The Arthritis Program, Toronto Western Hospital, Toronto, ON, 8 Department of Physiatry, University of Toronto and Toronto Rehabilitation Institute, Toronto, ON, 9Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON

10:15 am 2614. Erratic Control of Breathing During Exercise in Patients with Systemic Lupus Erythematosus Renata Miossi1, Danilo M. L. Prado2, Luiz A. Perandini2, Thalita Dassouki2, Bruno Gualano3, Hamilton Roschel4, Fernanda R. Lima2, Eduardo F. Borba5, Eloisa Bonfa6 and Ana Lucia S. Pinto7, 1University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, 2University of Sao Paulo, Rheumatology Division, LACRE, Sao Paulo, Brazil, 3University of Sao Paulo,School of Physical Education and Sport, Sao Paulo, Brazil, 4University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil, 5University of Sao Paulo, Sao Paulo, Brazil, 6Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, 7University of Sao Paulo, School of Medicine, Rheumatology Division, LACRE, Sao Paulo, Brazil

N o v e m b e r

9 ,

2 0 1 1

WEDNESDAY

10:00 am 2613. Physical Activity, Body Functions, Activity and General Health Perception in Rheumatoid Arthritis Birgitta Nordgren1, Patrick Bergman2, Christina H. Opava1, Cecilia Fridén1 and PARA 2010 Study group3, 1Karolinska Institutet, SE 14183 Huddinge, Sweden, 2University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden, 3Boden, Danderyd, Eskilstuna, Linköping, Stockholm, Östersund


W474b

Analysis of Large Databases: Rheumatology Research Opportunities R Moderator: Nadine M. Fisher, EdD; State University of New York at Buffalo; Buffalo, NY 9:00 am Overview of the National Institutes of Health-funded Center for Rehabilitation Research Using Large Datasets James E. Graham, PhD, DC; University of Texas Medical Branch; Galveston, TX

124

2011 Program Book

9:20 am Strengths and Limitations of Selected Large Datasets Anne Deutsch, RN, PhD, CRRN; Rehabilitation Institute of Chicago; Chicago, IL James E. Graham, PhD, DC; University of Texas Medical Branch; Galveston, TX 9:40 am Examples of Current Use of Large Datasets to Address Health Policy Issues Anne Deutsch, RN, PhD, CRRN; Rehabilitation Institute of Chicago; Chicago, IL Upon completion of this session, participants should be able to: • state research involving large national datasets, including specific opportunities through an NIH-funded consortium dedicated to increasing rehabilitation-related research capacity • identify and describe available datasets that may be relevant for rheumatology-related investigations, and the strengths and limitations of these datasets • describe current research and policy activities involving the use of large datasets, and future directions of this work

W193a

Chronic Non-bacterial Osteomyelitis

C

Moderator: Siba P. Raychaudhuri, MD; Sacramento VA Medical Center/ UC Davis School of Medicine; Mather, CA 9:00 am Chronic Recurrent Multifocal Osteomyelitis Sara M. Stern, MD; Children’s Hospital Los Angeles; Los Angeles, CA 9:30 am Synovitis, Acne, Pustulosis, Hypersostosis and Osteitis Robert D. Inman, MD; Toronto Western Research Institute, University Health Network and University of Toronto; Toronto, ON, Canada 10:00 am Autoimmune Diseases Associated with Synovitis, Acne, Pustulosis, Hypersostosis and Osteitis Syndrome, and Chronic Recurrent Multifocal Osteomyelitis Polly J. Ferguson, MD; University of Iowa Carver College of Medicine; Iowa City, IA Upon completion of this session, participants should be able to: • define and develop a differential diagnosis for chronic nonbacterial osteomyelitis • discuss the pathophysiology of synovitis, acne, pustulosis, hypersostosis and osteitis syndrome • review the treatment options for chronic recurrent multi-focal osteomyelitis

W476

Introduction to Comparative Effectiveness Research Study Designs for Rheumatology Health Professionals c/r

Moderator: Robert R. McLean, DSc, MPH; Hebrew Senior Life/ Harvard Medical School; Boston, MA

9:00 am Introduction to Comparative Effectiveness Research Methods and Top 100 Priorities Jennifer M. Hootman, ATC, PhD; Centers for Disease Control and Prevention; Kennesaw, GA 9:10 am Randomized Controlled Trials: Mind-body Interventions for Rheumatoid Arthritis Susan J. Bartlett, PhD; McGill University; Montreal, QC, Canada 9:25 am Observational Studies: Using Rheumatic Disease Registry Data for Comparative Effectiveness Research Kaleb D. Michaud, PhD; University of Nebraska Medical Center and National Data Bank for Rheumatic Diseases; Omaha, NE

• a cknowledge how both rare genetic variants and common genetic polymorphisms are mediators of pain perception and clinical pain phenotypes, in the context of musculoskeletal pain • discuss how TNF-á neutralization affects nociceptive brain activity in the context of arthritis, long before it achieves antiinflammatory effects in the joints

ACR CLINICAL SYMPOSIA 11:00 am - 12:30 pm W375d

Biosimilar Products in the U.S. Market: Fact or Fiction? c/r

9:40 am Systematic Reviews/Meta-analyses: Exercise for Adults with Arthritis Jennifer M. Hootman, ATC, PhD; Centers for Disease Control and Prevention; Kennesaw, GA

Moderator: Eric M. Ruderman, MD; Northwestern University; Chicago, IL

Upon completion of this session, participants should be able to: • d efine comparative effectiveness research • r eview the Institute of Medicine’s top 100 research priorities for comparative effectiveness research relevant to nonpharmaceutical treatments in rheumatology • list the most used study designs in comparative effectiveness research • a pply examples of commonly used CER study designs in rheumatology research

11:30 am EMEA Guidelines for Biosimilars Andrea Laslop, MD; Austrian Agency for Health and Food Safety; Vienna, Austria

ACR BASIC SCIENCE SYMPOSIUM 11:00 am - 12:30 pm

W183a

Pain Pathways in Rheumatic Diseases

R

PM

Moderators: Yvonne C. Lee, MD, MMedSc; Brigham and Women’s Hospital; Boston, MA Anne-Marie Malfait, MD, PhD; Rush University Medical Center; Chicago, IL

noon

Developing a Regulatory Path in the U.S Vibeke Strand, MD; Stanford University; Palo Alto, CA Upon completion of this session, participants should be able to: • describe the difference between biosimilar and generic drug products • identify the complexity of large protein production and implications for biologic activity • describe the general requirements for licensing a biosimilar product in Europe • cite the proposed requirements for licensing a biosimilar in the U.S.

W375c

Update on Safety Issues in the Treatment of Rheumatic Diseases – From the FDA and Beyond

P/C

PS

Moderator: Daniel J. Lovell, MD, MPH; Cincinnati Children’s Hospital Medical Center; Cincinnati, OH

11:25 am Genetic Variation in Human Pain Perception William Maixner, DDS, PhD; University of North Carolina School of Dentistry; Chapel Hill, NC

11:00 am Introduction – Update on Newly Identified Drug Safety Issues Arthur Kavanaugh, MD; University of California San Diego; San Diego, CA

11:50 am

11:20 am Update and Safety Issues of Recently Approved Agents for Rheumatic Diseases Sarah K. Okada-Yim, MD; Food and Drug Administration; Silver Spring, MD

TNF-á Blockade Rapidly Inhibits Pain Responses in the Central Nervous System Georg Schett, MD, PhD; Institute for Clinical Immunology, University of Erlangen-Nuremberg; Erlangen, Germany


11:00 am Animal Models for Pain Associated with Arthritis Jason J. McDougall, PhD; University of Calgary Medicine; Calgary, AB, Canada

11:00 am Introduction to Biosimilars Geoffrey Eich; Amgen, Inc.; Thousand Oaks, CA

Upon completion of this session, participants should be able to: • r eview the rationale and evidence for various animal models for studying pain in the context of rheumatic diseases, both inflammatory and non-inflammatory 2011 Program Book

125

11:45 am The Year in Review- Update on Safety Issues at the FDA Sally M. Seymour, MD; Food and Drug Administration; Silver Spring, MD 12:10 pm Panel Discussion Arthur Kavanaugh, MD; University of California San Diego; San Diego, CA Sarah K. Okada-Yim, MD; Food and Drug Administration; Silver Spring, MD Sally M. Seymour, MD; Food and Drug Administration; Silver Spring, MD Upon completion of this session, participants should be able to: • identify important safety issues in the drug treatment of rheumatic diseases • integrate knowledge of new safety issues into their treatment strategies • explain to patients about the safety issues related to treatments for rheumatic diseases • explain evolutions at the FDA that will affect drug safety monitoring and reporting

ACR CONCURRENT ABSTRACT SESSIONS 11:00 am - 12:30 pm

W194b

Infection-related Rheumatic Disease Moderators: David T. Y. Yu, MD; Santa Monica, CA Robert D. Inman, MD; Toronto Western Research Institute, University Health Network and University of Toronto; Toronto, ON, Canada

N o v e m b e r

9 ,

2 0 1 1

WEDNESDAY

11:00 am 2615. Nafamostat Mesylate, a Serine Protease Inhibitor, Demonstrates Novel Antimicrobial Properties and Antiinflammatory effects in Chlamydia-Induced Arthritis Robert D. Inman1 and Basil Chiu2, 1Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 2Toronto Western Hospital, Toronto, ON 11:15 am 2616. Macrophage Polarization Plays the Defining Role in Intracellular Persistence and Clearance of Chlamydia Eric Gracey1, Basil Chiu1 and Robert D. Inman2, 1Toronto Western Hospital, Toronto, ON, 2Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON 11:30 am 2617. Reduction in Chlamydia Trachomatis-Associated Murine Reactive Arthritis by Novel Peptide Vaccine Candidates Ilyes Benchaala1, Indrajit Sinha1, Mirabela Hali1, Balaji S. Bharatwaj2, Herve C. Gerard1, Alan P. Hudson1, Sandro R.P. da Rocha2 and Judith A. Whittum-Hudson1, 1Wayne State Univ Schl of Med, Detroit, MI, 2Wayne State University Coll of Engineering, Detroit, MI 11:45 am 2618. Bacterial Peptidylarginine Deiminase (PAD)-Dependent Enhancement of Collagen-Induced Arthritis in DBA/1 Mice by Porphyromonas Gingivalis

126

2011 Program Book

Katarzyna Maresz1, Aneta Sroka1, Joanna Koziel1, Sviatlana Shashkova1, Katarzyna Marcinska2, Marian Szczepanik2, Piotr Mydel3 and Jan Potempa1, 1Jagiellonian University, Krakow, Poland, 2Medical Collage of Jagiellonian University, Krakow, Poland, 3Institute of Medicine, The Sahlgrenska Academy Gothenburg, Gothenburg, Sweden 12:00 pm 2619. Influenza A H1N1/2009 Vaccine in Rheumatic Disease Patients Under Anti-TNF Therapy: Safety and Response Ivan L.A. França1, Ana C. M. Ribeiro1, Nadia E. Aikawa1, Carla G.S. Saad1, Ana L. G. Calich1, Julio C. B. Moraes1, Ieda Laurindo1, Joao Miraglia2, Maria A. Ishida3, Eloisa Bonfa1 and Clovis Silva1, 1 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Fundação Butantan, São Paulo, Brazil, 3Adolfo Lutz Institute, Sao Paulo, Brazil 12:15 pm 2620. Serum Vitamin D Status and Polymorphisms in Vitamin D Metabolism-Related Genes in Chronic Hepatitis C Virus Infection with Extra-Hepatic Manifestations Benjamin Terrier1, Frédéric Jehan2, Mona Monteanu3, Guillaume Geri4, David Saadoun5, Damien Sène4, Thierry Poynard3, Jean-Claude Souberbielle6 and Patrice Cacoub4, 1 Pitié-Salpêtrière Hospital, Paris, France, 2INSERM U561, Paris, France, 3Hepatology, Pitié-Salpétrière, Paris, France, 4 CHU Pitié-Salpêtrière, Paris, France, 5Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 6Laboratoire d’Explorations Fonctionnelles, Necker, Paris, France

W192b

Pediatric Rheumatology – Clinical and Therapeutic Aspects: Treatment Moderators: Norman T. Ilowite, MD; Children’s Hospital Montefiore; Bronx, NY Karen Onel, MD; University of Chicago; Chicago, IL 11:00 am 2621. Tocilizumab Is Efficacious in Patients with Systemic Juvenile Idiopathic Arthritis Across Baseline Demographic and Disease Characteristics and Prior/Baseline Treatments: 52Week Data From a Phase 3 Clinical Trial Fabrizio De Benedetti1, Hermine Brunner2, Roger Allen3, Diane Brown2, Jeffrey Chaitow3, Manuela Pardeo3, Graciela Espada3, Berit Flatø3, Gerd Horneff3, Clare Devlin4, Andrew Kenwright4, Rayfel Schneider2, Patricia Woo5, Alberto Martini3, Daniel Lovell2 and Nicola Ruperto3, 1Ospedale Pediatrico Bambino Gesù, Rome, Italy, 2Pediatric Rheumatology Collaborative Study Group [PRCSG], Cincinnati, OH, 3Paediatric Rheumatology International Trials Organisation – IRCCS [PRINTO], Genova, Italy, 4Roche, Welwyn, United Kingdom, 5University College London Medical School, London, United Kingdom 11:15 am 2622. Phase III Study Results on the Efficacy and Safety of Canakinumab, a Long-Acting, Fully Human Anti-Interleukin-1β Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features Hermine Brunner1, Nicolino Ruperto2, Gerd Horneff2, Pierre

Quartier2, Tamás Constantin2, Yackov Berkun2, Tilmann Kallinich2, Riva Brik2, Manuel A. Ferrandiz2, Karine Lheritier3, Ralph Preiss4, Lillian Tseng4, Daniel J. Lovell1, Alberto Martini2, Paediatric Rheumatology International Trials Organisation5 and Pediatric Rheumatology Collaborative Study Group [PRCSG]6, 1PRCSG, Cincinnati, OH, 2PRINTO-IRCCS, Genova, Italy, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, NJ, 5Genova, Italy, 6Cincinnati, OH 11:30 am 2623. Double Blind, Placebo-Controlled Trial with Adalimumab for Treatment of Juvenile Ankylosing Spondylitis (jAS) Gerd Horneff1, Sigrid Fitter1, Hans-Iko Huppertz2, Ivan Foeldvari3, Jasmin B. Kuemmerle-Deschner4, Rolf M. Kuester5, Nikolay Tzaribachev6, Angelika Thon7, Michael Borte8, Gerd Ganser9, Ralf Trauzeddel10 and Kirsten Minden11, 1Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Krinikum BremenMitte, Bremen, Germany, 3Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, 4University Hospital Tuebingen, Tuebingen, Germany, 5Rheumaklinik Bad Bramstedt, Bad Bramstedt, Germany, 6Center for Rheumatic Diseases, Bad Bramstedt, Germany, 7Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany, 8Sankt Georg Clinics, Leeipzig, Germany, 9Sankt Josef Stift, Sendenhorst, Germany, 10 Helios Clinics, Berlin, Germany, 11Charite, Berlin, Germany

12:00 pm 2625. Radiological Evaluation of Systemic Juvenile Idiopathic Arthritis Treated with Tocilizumab, An Anti-IL6 Receptor Monoclonal Antibody Chie Aoki1, Yutaka Inaba1, Tomoyuki Imagawa2, Takako Miyamae2, Masaaki Mori2, Tomoyuki Saito2 and Shumpei Yokota2, 1Yokohama City Unversity, Yokohama, Japan, 2Yokohama City University, Yokohama, Japan 12:15 pm 2626. Efficacy of RITUXIMAB RETREATMENT In REFRACTORY Systemic Juvenile IDIOPATHIC Arthritis Ekaterina Alexeeva, Saniya Valieva, Tatyana Bzarova, Rina

W196b

Rheumatoid Arthritis Treatment – Small Molecules, Biologics, Therapy: Novel Compounds II Moderators: Stanley B. Cohen, MD; Metroplex Clinical Research Centre; Dallas, TX Veena K. Ranganath, MD; University of California; Los Angeles, CA 11:00 am 2627. Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to DiseaseModifying Anti-Rheumatic Drugs V. Strand1, J. M. Kremer2, Z. G. Li3, S. Hall4, Roy M. Fleischmann5, M. C. Genovese6, E. Martin-Mola7, J. Isaacs8, D. Gruben9, G. Wallenstein9, S. Krishnaswami9, S. H. Zwillich9, T. Koncz10, R. Riese9, J. D. Bradley9 and the ORAL Sync investigators11, 1Stanford University, Palo Alto, CA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Peking University People’s Hospital, Peking, China, 4Melbourne Rheumatology, Melbourne, Australia, 5MCRC, University of Texas, Dallas, TX, 6Stanford University Medical Center, Palo Alto, CA, 7Hospital Universitario La Paz, Madrid, Spain, 8University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom, 9Pfizer Inc., Groton, CT, 10 Pfizer Inc., New York, NY, 11Groton 11:15 am 2628. Double-Blind Study of Tocilizumab Plus Methotrexate Vs Tocilizumab Plus Placebo in Patients with Active Rheumatoid Arthritis Despite Prior Methotrexate: Progression of Structural Damage, Quality of Life, and Physical Function At 24 Weeks Maxime Dougados1, Karsten Kissel2, Howard Amital3, Philip G. Conaghan4, Emilio Martin-Mola5, Evgeny L. Nasonov6, Georg Schett7, Orrin M. Troum8, Tiina Veldi9, Corrado Bernasconi10 and T.W.J. Huizinga11, 1Paris-Descartes University, Cochin Hospital, Paris, France, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland, 3 Sheba Medical Center, Tel-hashomer, Israel, 4NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 5Hospital Universitario La Paz, Madrid, Spain, 6Institute of Rheumatology, Moscow, Russia, 7Department of Internal Medicine 3 and Institute for Clinical Immunology, University of ErlangenNuremberg, Erlangen, Germany, 8USC Keck School of Medicine, Santa Monica, CA, 9East-Tallinn Central Hospital, Tallinn, Estonia, 10 Roche, Basel, Switzerland, 11Leiden University Medical Center, Leiden, Netherlands 11:30 am 2629. Postmarketing Surveillance of Tocilizumab for Rheumatoid Arthritis In Japan – Full Analysis Report of 7,901 Patients Hisashi Yamanaka1, Masayoshi Harigai2, Shigeko Inokuma3, Naoki Ishiguro4, Junnosuke Ryu5, Syuji Takei6, Tsutomu Takeuchi7, Yoshiya Tanaka8, Youko Sano9 and Takao Koike10, 1Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 2 Tokyo Medical and Dental Univ, Tokyo, Japan, 3Japanese Red Cross Medical Center, Tokyo, Japan, 4Nagoya University,

2011 Program Book


11:45 am 2624. Developing Consensus Treatment Plans for Proliferative Nephritis in Juvenile Systemic Lupus Erythematosus: Maintenance Therapy Rina Mina1, Hermine Brunner2, B. Anne Eberhard3, Marilynn G. Punaro4, Stacy P. Ardoin5, Marisa Klein-Gitelman6, Lakshmi N. Moorthy7, Suhas M. Radhakrishna8, Mindy S. Lo9, Matthew C. Hollander10, Eyal Muscal11, Joyce J. Hsu12, Linda WagnerWeiner13, Deborah M. Levy14, Carol Wallace15, Norman T. Ilowite16 and Emily von Scheven17, 1Cincinnati Children’s Med Ctr, Cincinnati, OH, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Cohen Children’s Hospital Medical Center, New Hyde Park, NY, 4Texas Scottish Rite Hospital, Dallas, TX, 5 Ohio State University, Columbus, OH, 6Children’s Memorial Hospital, Chicago, IL, 7Robert Wood Johnson Medical SchoolUMDNJ, New Brunswick, NJ, 8Children’s Hosp Los Angeles, Los Angeles, CA, 9Children’s Hospital Boston, Boston, MA, 10Seattle Children’s Hospital, Seattle, WA, 11Baylor College of Medicine, Houston, TX, 12Stanford University, Palo Alto, CA, 13University of Chicago Hospital, Chicago, IL, 14The Hospital for Sick Children, Toronto, ON, 15Childrens Hosp & Regional Med, Seattle, WA, 16 Children’s Hospital Montefiore, Bronx, NY, 17UC San Francisco, San Francisco, CA

Denisova, Kseniya Isayeva, Tatyana Sleptsova and Elena Mitenko, Scientific Center of Children’s Health, Moscow, Russia

127

Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 5 Nihon University School of Medicine, Tokyo, Japan, 6Kagoshima University, Kagoshima City, Japan, 7Keio University School of Medicine, Tokyo, Japan, 8University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 9 Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, 10Sapporo Medical Center NTT EC, Sapporo, Japan 11:45 am 2630. A Multiple Ascending Dose/Proof of Concept Study of ATN-103 (ozoralizumab) in Rheumatoid Arthritis Subjects on a Background of Methotrexate Roy Fleischmann1, Savithree Nayiager2, Ingrid Louw3, Bernadette Rojkovich4, Caifeng Fu5, Chandrasekhar Udata6, Parvin Fardipour7, Bonnie Marshall7, Michelle Hinz7, Amarnath Sharma7, Kathy Shields7 and Gail Comer7, 1Metroplex Clinical Research Center, Dallas, TX, 2St. Augustine Hospital, Berea, KwaZulu-Natal, South Africa, 3Panorama Medical Centre, Panorama, Western Cape, South Africa, 4Polyclinic of the Hospitaller Brothers of St John of God, Budapest, Hungary, 5Pfizer, Cambridge, MA, 6Pfizer, La Jolla, CA, 7Pfizer, Collegeville, PA noon

12:15 pm 2632. Results From a Multicenter, International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-IL-6 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy Benjamin Hsu1, Shihong Sheng2, Michael E. Weinblatt3 and Josef Smolen4, 1Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/Philadelphia, PA, 2Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 4Medical University of Vienna and Hietzing Hospital, Vienna, Austria

N o v e m b e r

9 ,

2 0 1 1

WEDNESDAY

2631. Results From a 2-Part, Proof-of-Concept, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-Interleukin-6 Monoclonal Antibody, in Active Rheumatoid Arthritis Patients Despite Methotrexate Therapy Benjamin Hsu1, Shihong Sheng2, Josef Smolen3 and Michael Weinblatt4, 1Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/Philadelphia, PA, 2 Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, 3Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4Brigham & Women’s Hospital, Boston, MA

W196a

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV Moderators: Michael H. Weisman, MD; Cedars-Sinai Medical Center; Los Angeles, CA Lianne S. Gensler, MD; University California San Francisco; San Francisco, CA

128

2011 Program Book

11:00 am 2633. Anterior Chest Wall Inflammation by Whole Body MRI in Patients with Spondyloarthritis: Lack of Association between Clinical and Imaging Findings Ulrich Weber1, Robert GW Lambert1, Kaspar Rufibach2, Walter P. Maksymowych1, Juerg Hodler3, Anna Zejden4, Stefan Duewell5, Rudolf O. Kissling6, Paul L. Filipow1 and Anne G. Jurik4, 1University of Alberta, Edmonton, AB, 2University of Zurich, Zurich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4 University Hospital Aarhus, Aarhus, Denmark, 5Hospital Thurgau AG, Frauenfeld, Frauenfeld, Switzerland, 6Balgrist University Hospital, Zurich, Switzerland 11:15 am 2634. Higher Frequency of Metabolic Syndrome In Psoriatic Arthritis Compared with Rheumatoid Arthritis May Be Explained by High Triglycerides and Increased Rates of Obesity and Diabetes Asena Bahce-Altuntas1, Julie S. Schwartzman-Morris1, Nicole Jordan1, Jeffrey D. Greenberg2, Chaim Putterman1, George Reed3 and Anna R. Broder1, 1Albert Einstein College of Medicine, Bronx, NY, 2NYU Hospital for Joint Diseases, New York, NY, 3UMass Medical School, Worcester, MA 11:30 am 2635. The Prevalence and Risk Factors of Atlantoaxial Subluxation in Ankylosing Spondylitis Ji-Seon Lee, Jae Hoon Kim, Jinju Kim, Joo-Hyun Lee and TaeHwan Kim, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 11:45 am 2636. Influence of Immunogenicity on the Efficacy of Long-term treatment with Infliximab in Spondyloarthrities Chamaida Plasencia1, Dora Pascual-Salcedo1, Maria Gema Bonilla1, Laura Nuño1, Ainhoa Ruiz2, Emilio Martin-Mola1 and Alejandro Balsa1, 1La Paz University Hospital, Madrid, Spain, 2 PROTEOMIKA RESEARCH, Bilbao, Spain noon

2637. The Effect of DMARD Co-Therapy on Anti-TNF Drug Retention in 1630 Spondyloarthritis Patients Michael J. Nissen1, Adrian Ciurea2, Burkhard Moller3, Juerg Bernhard4, Ruediger Mueller5, Bettina Weiss6, Giorgio Tamborrini7, Almut Scherer8, Cem Gabay- and Axel Finckh1, 1 Geneva University Hospital, Geneva, Switzerland, 2Department of Rheumatology, University Hospital, Zurich, Switzerland, 3 Inselspital University Hospital, Bern, Switzerland, 4Buergerspital, Solothurn, Switzerland, 5Cantonal Hospital, St. Gallen, Switzerland, 6Balgrist University Hospital, Zurich, Switzerland, 7 University Hospital, Zurich, Switzerland, 8SCQM Foundation, Zurich, Switzerland 12:15 pm 2638. Association Between Axial Pain Site and Site of MRI Inflammatory Lesions or Structural Change in Patients with Early Inflammatory Back Pain. the DESIR Cohort Study Bertrand Coutanceau1, Florence canoui-Poitrine1, Maxime Dougados2, Martin Blachier1, Sylvie bastuji-Garin1, Alain Saraux3 and Pascal Claudepierre4, 1Université Paris Est, Laboratoire d’Investigation Clinique (LIC) EA 4393, AP-HP, Hôpital Henri-

Mondor, Service de Santé Publique, Créteil, France, 2ParisDescartes University, Medicine Faculty; UPRES EA-4058; APHP, Cochin Hospital, Paris, France, 3CHU de la Cavale Blanche, Brest Cedex, France, 4Université Paris Est, Laboratoire d’Investigation Clinique (LIC) EA 4393, AP-HP, Hôpital Henri-Mondor, Rheumatology department, Creteil, France

ACR STATE-OF-THE-ART LECTURE

11:00 am - noon

W190a

The Role of Extracellular Ribonucleic Acid in Inflammatory Processes R Moderator: Ulf Muller-Ladner, MD; Justus-Liebig Universität Gießen, Kerckhoff-Klinik GmbH; Bad Nauheim, Germany Speaker: Klaus T. Preissner, PhD; Justus-Liebig-University, Medical School; Giessen, Germany Upon completion of this session, participants should be able to: • identify the potential role of extracellular ribonucleic acid in inflammation and immunity • d escribe the function of endogenous, vascular RNase1 as vessel protective and antithrombotic factor • e valuate the possibility of other extracellular RNA-binding proteins to become influenced in their activity by ribonucleic acids

ARHP CONCURRENT ABSTRACT SESSION

11:00 am - 12:30 pm

W195

ARHP Epidemioloogy and Public Health II Moderators: Marc Hochberg, MD, MPH; University of Maryland School of Medicine; Baltimore, MD Kristina A. Theis, BA, MPH; Centers for Disease Control and Prevention; Atlanta, GA

11:15 am 2640. Physical Activity, Body Composition, and Cognitive Impairment Among Women with Systemic Lupus Erythematosus Patricia P. Katz1, Laura J. Julian1, Jinoos Yazdany1, Holly Wing2, Sandi Kaplan2, Laura Trupin3, Lindsey A. Criswell1 and Edward Yelin1, 1University of California San Francisco, San Francisco, CA, 2 University of California, San Francisco, CA, 3UC San Francisco, San Francisco, CA 11:30 am 2641. Objective Measurement of Levels of Physical Activity in Rheumatoid Arthritis Marie Tierney1, Alexander D. Fraser2 and Norelee M. Kennedy1, 1 University of Limerick, Limerick, Ireland, 2Mid Western Regional Hospital, Co. Limerick, Ireland

noon

2643. Hypothyroidism and Risk of Adhesive Capsulitis in the General Population Uyen Sa D. Nguyen1, Hyon K. Choi1, Christine Peloquin1, Young Hee Rho2, Yanyan Zhu1, Daniel K. White1, Jingbo Niu1 and Yuqing Zhang1, 1Boston University School of Medicine, Boston, MA, 2 Vanderbilt Medical Center, Nashville, TN 12:15 pm 2644. Humerus Fractures In the United States: Nationwide Emergency Department Sample, 2008 Sunny Kim1, Robert Szabo2 and Richard A. Marder3, 1University of California Davis, Sacramento, CA, 2University of California-Davis, Sacramento, CA, 3University of California, Davis, CA

ARHP CONCURRENT SESSIONS 11:00 am - 12:30 pm

W193a

Lower Extremity Musculoskeletal Assessment of the Rheumatology Patient C Moderator: Mary E. Christenson, PT, PhD; Regis University; Denver, CO Speaker: Christopher Bise, PT, MS, DPT; University of Pittsburgh; Pittsburgh, PA Upon completion of this session, participants should be able to: • describe key components of a lower quarter examination for the rheumatology patient • identify common objective findings of the rheumatology patient • discuss interventions available for the rheumatology patient based on the results of the musculoskeletal evaluation

W474b


11:00 am 2639. Is Dietary Intake of Patients with Systemic Lupus Erythematosus Adequate? Ellie Aghdassi1, Ladan Yeganeh1, Amaris K. Balitsky2, Stacey Morrison3, Michael Frattasi3, Jiandong Su3, David WL. Ma4 and Paul R. Fortin5, 1University Health Network, Toronto, ON, 2The University of Toronto, Toronto, ON, 3The Toronto Western Hospital, Toronto, ON, 4University Of Guelph, Guelph, ON, 5 Toronto Western Hospital, Toronto, ON

11:45 am 2642. Influence of Lifecourse Social Position on Rheumatoid Arthritis Disease Severity in African Americans Rebecca J. Cleveland1, Todd A. Schwartz1, Beth L. Jonas1, Graciela S. Alarcon2, Richard Brasington3, Doyt L. Conn4, Edwin A. Smith5, George Howard2, Larry W. Moreland6, S. Louis Bridges Jr.7 and Leigh F. Callahan1, 1University of North Carolina, Chapel Hill, NC, 2University of Alabama at Birmingham, Birmingham, AL, 3Washington Univ School of Med, St. Louis, MO, 4Emory Univ School of Medicine, Atlanta, GA, 5Med Univ of South Carolina, Charleston, SC, 6University of Pittsburgh, Pittsburgh, PA, 7Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

Policy and Environmental Strategies to Support Increased Physical Activity for Adults with Arthritis: Findings from a Centers for Disease Control/Arthritis Foundation Expert Panel C Moderator: Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute Chicago; Chicago, IL

2011 Program Book

129

11:00 am The Process: Defining Appropriate Audiences, Settings and Key Informants Jennifer M. Hootman, ATC, PhD; Centers for Disease Control and Prevention; Kennesaw, GA 11:45 am The Product: Prioritized List of Environmental Strategies and Policies to Support Increased Physical Activity Among Adults with Arthritis Teresa J. Brady, PhD; Centers for Disease Control; Atlanta, GA Upon completion of this session, participants should be able to: • identify settings and audiences that influence environmental strategies and policies for promoting physical activity among adults with arthritis • categorize environmental strategies and policies that should reduce barriers and strengthen facilitators to physical activity for persons with arthritis • list prioritized environmental strategies and policies developed by a panel of experts

INDUSTRY-SUPPORTED POSTCONFERENCE SYMPOSIA 1:00 - 4:00 pm

N o v e m b e r

9 ,

2 0 1 1

WEDNESDAY

For these CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Please visit the organization’s exhibit booth, the industry-supported symposia booth or see page 304 for more information.

130

2011 Program Book

ACR Poster Session A SUNDAY, NOVEMBER 6, 2011

Hall F2 - Poster Hall Antiphospholipid Syndrome 1. Lupus Anticoagulant At a High-Risk Clinic: Results From a 5-Year Review of 2,169 Patients. Christine A. Clark, Karen A. Spitzer and Carl A. Laskin, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON 2. Effect of Normal Pregnancy on the Lupus Anticoagulant: No Need to Establish Pregnancy-Specific Reference Ranges. Christine A. Clark, Karen A. Spitzer and Carl A. Laskin, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON 3. Association of IgG, IgM, and IgA Isotypes of Anticardiolipin Alone or In Combination In Prediction of Thrombosis In Systemic Lupus Erythematosus. Vinicius Domingues, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 4. Anti-beta2 Glycoprotein I IgA in Systemic Lupus Erythematosus Versus Controls. Ana-Maria Orbai1, Hong Fang1, Joan T. Merrill2, Graciela S. Alarcón3, Caroline Gordon4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Birmingham, Birmingham, United Kingdom, 5Toronto Western Hospital, Toronto, ON, 6A, Manchester, United Kingdom, 7University College London, London WC1E 6JF, United Kingdom, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9 University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13 Dalhousie University, Halifax, NS, 14University Health Network/Mount Sinai Hospital, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16 Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18 Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago

5. Risk Factors for Rethrombosis In Patients with Primary Antiphospholipid Syndrome Regardless of Their Oral Anticoagulation Status. Gabriela Hernandez-Molina1, Grissel Espericueta-Arriola2 and Antonio R. Cabral3, 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico city, Mexico, 3Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico, Mexico 6. Risk of Recurrent Stroke in Pregnancies of Patients with Antiphospholipid Syndrome and Previous Cerebral Ischemia. Rebecca Fischer-Betz, Christof Specker and Matthias Schneider, MNR-Klinik, Düsseldorf, Germany 7. Utility of the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index for Antiphospholipid Antibody (aPL) Positive Patients. Medha Barbhaiya1, Doruk Erkan2, Esther Rodriguez-Almaraz3, Glendalee Ramon4, JoAnn Vega4 and Michael D. Lockshin4, 1Weill Cornell Medical Center, New York, NY, 2Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, 3 Hospital “12 de Octubre”, Madrid, Spain, 4Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY 8. Development and Initial Validation of a Chronic Damage Index in Patients with Antiphospholipid Syndrome. MaryCarmen Amigo1, Leonor A. Barile2, Alberto Barragan3, Gisela Espinosa-Cuervo4, Mavis Goycochea5, Laura Aline MartinezMartinez6, Gabriela Medina7, Angelica Vargas8 and Luis J. Jara-Quezada9, 1ABC Medical Ctr, Mexico City, Mexico, 2 Hospital Especialidades CMN, Mexico City, Mexico, 3México, Mexico, 4Research Unit, Mexican College of Rheumatology, Mexico, Mexico, 5Instituto Mexicano del Seguro Social and Research Unit, Mexican College of Rheumatology, Mexico City, Mexico, 6Intituto Nacional de Cardiologia, Mexico, Mexico, 7Seris/Zachila s/n La Raza, Mexico City, Mexico, 8 Instituto Nac de Cardiologia, Mexico City, Mexico, 9Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico 9. Low Vitamin D Levels Are Common in Primary Antiphospholipid Syndrome: A Role in the Pathogenesis of the Disease? Laura Andreoli1, Silvia Piantoni1, Flavio Allegri1, Pier Luigi Meroni2 and Angela Tincani1, 1Rheumatology Unit, University of Brescia, Brescia, Italy, 2University of Milan, Milan, Italy 10. Thrombin Generation Indicates An Increased Risk for Thromboembolic Events in Lupus and Antiphospholipid Patients. A Prospective Cohort Study. Stephane Zuily1, Veronique Regnault2, Francis Guillemin3, Pierre Kaminsky4, Thomas Lecompte5 and Denis Wahl6, 1Vascular Medicine Unit, Vandoeuvre-Les-Nancy, France, 2INSERM U961, Vandoeuvre, France, 3Faculte de Medecin/BP 184, Vandoeuvre-les-Nancy, France, 4Orphan disease Unit, Vandoeuvre, France, 5Haematology, Vandoeuvre, 6Nancy University Hospital and INSERM U961, Vandoeuvre-LesNancy, France 2011 Program Book

131

ACR Poster Session A 11. Myocardial Global Longitudinal Strain in Primary Antiphospholipid Syndrome. Gabriela Medina, Eduardo Gómez-Bañuelos, Erick Calderón-Aranda and Luis J. Jara, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico 12. C5 Inhibitor rEV576 Ameliorates In Vivo Effects of Antiphospholipid Antibodies. Ana Laura Carrera-Marin1, Zurina Romay-Penabad1, Samuel Machin2, Hannah Cohen2, Wynne Weston-Davies3 and Silvia S. Pierangeli1, 1University of Texas Medical Branch, Galveston, TX, 2University College London, LOndon, United Kingdom, 3Varleigh Immuno Therapeutics, Ltd, London, United Kingdom

Hospital Universitario Marques de Valdecilla-IFIMAV, Santander, Spain

3

18. A Systematic Analysis Confirms the Importance of Toll-Like Receptor 4, p38 Mitogen Activated Protein Kinase and Nuclear Factor Kappa-B Activation by Antiphospholipid Antibodies in Multiple Different Cell Types. Katie Poulton, Anisur Rahman and Ian Giles, University College London, London, United Kingdom

13. Pathogenic Effects of Antiphospholipid Antibodies Are Ameliorated In Tissue Deficient Mice. Zurina RomayPenabad1, Ana Laura Carrera-Marin1, Nigel Mackman2 and Silvia S. Pierangeli1, 1University of Texas Medical Branch, Galveston, TX, 2University of North Carolina at Chapel Hill, Chapel Hill, NC

19. Anti-Phosphatidylserine/Prothrombin Antibody Titers Are Strongly Correlated with Lupus Anticoagulant Assays in Patients with Antiphospholipid Antibodies. Makoto Miyara1, Laurent Arnaud1, Laurent Dufat1, Marie-Claude Diemert1, Annick Ankri1, Alexis Mathian1, Julien Haroche1, Du Boutin1, Pascale Ghillani-Dalbin1, Nathalie CostedoatChalumeau1, Silvia Casas2, Jean-Charles Piette1, Lucile Musset1 and Zahir Amoura1, 1CHU Pitié-Salpêtrière, Paris, France, 2Instrumentation Laboratory Werfen Group, Lexington, MA

14. Patterns of Immunoglobulin-G Glycosylation Distinguish Different Clinical Phenotypes of Antiphospholipid Antibody Positivity. Edward Tarelli1, John S. Axford1, Ian Giles2, Charis Pericleous2, Silvia S. Pierangeli3, Yiannis Ioannou4, Anisur Rahman2 and Azita Alavi1, 1Sir Joseph Hotung centre for Musculoskeletal diseases, St George’s University of London, London, United Kingdom, 2Division of Medicine/Centre for Rheumatology Research, University College London, London, United Kingdom, 3University of Texas Medical Branch, Galveston, TX, 4University College London, London, United Kingdom

20. Presence of Anti-Phosphatidylserine/Prothrombin Antibodies with Both IgG and IgM Isotypes May Be Associated with the Occurrence of Catastrophic Antiphospholipid Syndrome in Patients with Antiphospholipid Antibodies. Makoto Miyara1, Laurent Arnaud1, Laurent Dufat1, Marie-Claude Diemert1, Annick Ankri1, Alexis Mathian1, Julien Haroche1, Du Boutin1, Pascale Ghillani-Dalbin1, Nathalie Costedoat-Chalumeau1, Silvia Casas2, Jean-Charles Piette1, Lucile Musset1 and Zahir Amoura1, 1CHU Pitié-Salpêtrière, Paris, France, 2 Instrumentation Laboratory Werfen Group, Lexington, MA

15. Role of Apolipoprotein B100 and Oxidized Low-Density Lipoprotein in Anti-beta2 Glycoprotein I Induced Tissue Factor Expression on Monocytes. Kotaro Otomo1, Tatsuya Atsumi1, Yuichiro Fujieda1, Hisako Nakagawa1, Masaru Kato1, Olga Amengual1, Tetsuya Horita1, Shinsuke Yasuda1, Masaki Matsumoto2, Shigetsugu Hatakeyama3 and Takao Koike1, 1 Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 2Division of Proteomics, Kyusyu University Medical Institute of Bioregulation, Fukuoka, Japan, 3Department of Biochemistry, Hokkaido University Graduate School of Medicine, Sapporo, Japan

21. High Antiphospholipid Antibody Levels May Reflect Chronic Endothelial Damage in Non-Autoimmune-Associated Thrombosis. Anna R. Broder1, Jonathan N. Tobin2, Jacob H. Rand3 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine/ CDN Network, New York, NY, 3Montefiore Medical Center, Bronx, NY

16. Circulating B Cells Subpopulations in Patients with Antiphospholip Syndrome. Lorena Alvarez-Rodriguez1, Marcos Lopez-Hoyos1, Jaime Calvo-Alen2, Rafael Barrio del1, Orlando Pompei1 and Victor M. Martinez-Taboada3, 1 Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3 Hospital Universitario Marques de Valdecilla-IFIMAV, Santander, Spain 17. Circulating Cytokine Profile in Patients with Antiphospholipid Syndrome. Lorena Alvarez-Rodriguez1, Marcos Lopez-Hoyos1, Jaime Calvo-Alen2, Rafael Barrio del1, Orlando Pompei1 and Victor M. Martinez-Taboada3, 1 Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain,

132

2011 Program Book

22. The Role of Fatty Acid Composition in Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Amaris K. Balitsky1, Ellie Aghdassi2, David WL. Ma3, Stacey Morrison4, Jiandong Su4 and Paul R. Fortin4, 1The University of Toronto, Toronto, ON, 2University Health Network, Toronto, ON, 3 University of Guelph, Guelph, ON, 4Toronto Western Hospital, Toronto, ON 23. Profiling Sub-Types of Anti-β2 Glycoprotein I and AntiDomain I Antibodies May Distinguish Between Different Clinical Phenotypes of the Antiphospholipid Syndrome. Charis Pericleous1, Acely Garza-Garcia2, Lucy Murfitt2, Paul C. Driscoll2, David A. Isenberg1, Silvia S. Pierangeli3, Ian Giles1, Yiannis Ioannou1 and Anisur Rahman1, 1University College London, London, United Kingdom, 2MRC National Institute of Medical Research, London, London, United Kingdom, 3 University of Texas Medical Branch, Galveston, TX

ACR Poster Session A 24. Prevalence of Antibodies to Prothrombin in Solid Phase (aPT) and to Phosphatidylserine/Prothrombin Complex (aPS/PT) in Patients with and without Lupus Anticoagulant (LA). Maria Laura Bertolaccini1, Savino Sciascia1, Veronica Murru1, Giovanni Sanna2 and Munther A. Khamashta1, 1 Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2 Louise Coote Lupus Unit, St. Thomas’ Hospital, London, United Kingdom 25. Antibodies to Phosphatidylserine/Prothrombin (aPS/ PT) Are An Independent Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus (SLE). Maria Laura Bertolaccini1, Savino Sciascia1, Veronica Murru1, Cesar Garcia-Fernandez1, Giovanni Sanna2 and Munther A. Khamashta1, 1Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2Louise Coote Lupus Unit, St. Thomas’ Hospital, London, United Kingdom 26. The Value of Testing for Antibodies to Phosphatidylethanolamine (aPE) in Patients with Systemic Lupus Erythematosus (SLE). Maria Laura Bertolaccini1, Veronica Murru1, Savino Sciascia1, Giovanni Sanna2 and Munther A. Khamashta1, 1Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2Louise Coote Lupus Unit, St. Thomas’ Hospital, London, United Kingdom

Cell-cell Interactions and Adhesion 27. Steroid Receptor Coactivator-3 and Angiogenesis in Autoimmune Disease Associated Leg Ulcers. Victoria K. Shanmugam1, Elena Tassi2, Maram Al-Otaiby2, Bhaskar Kallakury1, Mihriye Mete3, Christopher Attinger4 and Anton Wellstein2, 1Georgetown University Hospital, Washington, DC, 2Georgetown University, 3MedStar Health Research Institute, Hyattsville, MD, 4Georgetown University Hosptial, Washington, DC 28. Differential Regulatory Functions of HIF-1α and HIF-2α During Angiogenesis of Human Microvascular Endothelial Cells (HMECs). Martin Hahne1, Steffi Luetkecosmann2, Cam Loan Tran2, Cindy Strehl2, Monique Fangradt2, Manuela Jakstadt2, Georg Duda2, Paula Hoff2, Timo Gaber2, Gerd-Rüdiger Burmester3 and Frank Buttgereit2, 1Berlin Brandenburg School for Regenerative Therapies, Berlin, Germany, 2Charité University Medicine, Berlin, Germany, 3 Charité University Hospital, Berlin, Germany 29. Glucocorticoid-Induced Leucine Zipper Inhibits TNFInduced Endothelial Cell NFκB Activation and Adhesive Function. Eric Morand, Michael Hickey and Qiang Cheng, Monash University, Melbourne, Australia 30. Superoxide Anion Mediates the L-Selectin DownRegulation Induced by Non-Steroidal Anti-Inflammatory Drugs In Human Neutrophils. M. Jesus Dominguez-Luis1, Ada Herrera-Garcia2, M.Teresa Arce-Franco3, Susana Cardenas4, Marta Rodriguez-Pardo5, Manuel Feria5,

Francisco Sanchez-Madrid4 and Federico Diaz-Gonzalez3, 1 Hospital Universitario de Canarias, La Laguna, Spain, 2 Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 3Rheumatology Service, La Laguna, Spain, 4Hospital Universitario La Princesa, Madrid, Spain, 5University of La Laguna, La Laguna. Tenerife, Spain 31. A Concerted Dynamic Real Time In Vivo and Static Ex Vivo Analysis of Granulomonocytic Cell Migration in the Collagen Induced Arthritis Model. Ruth Byrne1, Eva Rath1, Anastasiya Hladik1, Birgit Niederreiter1, Michael Bonelli1, Sophie Frantal1, Michael Klimas1, Josef Smolen2 and Clemens Scheinecker1, 1Medical University of Vienna, Vienna, Austria, 2 Medical University of Vienna and Hietzing Hospital, Vienna, Austria 32. miRNA-126 Regulates Increased VCAM-1 Expression in Muscle Biopsies From Children with Untreated Juvenile Dermatomyositis of Short Disease Duration. Lauren M. Pachman1, Erin Kim2, Joan Cook-Mills1, Gabrielle Morgan2, Janice Caliendo1 and Simone Treiger Sredni1, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2 Children’s Memorial Hospital, Chicago, IL 33. Angiogenic Factors in Early Inflammatory Arthritis. Luana Mancarella1, Olga Addimanda1, Lia Pulsatelli1, Paolo Dolzani1, Elisa Assirelli1, Veronica Brusi1, Stefano Galletti1 and Riccardo Meliconi2, 1Istituto Ortopedico Rizzoli, Bologna, Italy, 2Istituto Ortopedico Rizzoli and University of Bologna, Bologna, Italy 34. Junctional Adhesion Molecule C Regulates the Transendothelial Migration of Murine Synovial Fibroblasts of Human TNFalpha Transgenic Mice. Marianne Heitzmann1, Adelheid Korb-Pap1, Christina Wunrau1, George Kollias2, Stefan Butz3, Dietmar Vestweber3, Hermann Pavenstädt1 and Thomas Pap1, 1University Hospital Muenster, Muenster, Germany, 2Biomedical Sciences Research Center ‘Alexander Fleming’, Vari, Greece, 3 University Muenster, Muenster, Germany 35. Matrix Effects on Cellular Adhesion of Fibroblasts From Patients with Rheumatoid Arthritis, Osteoarthritis and Systemic Sclerosis. Stephanie Lefevre1, Simone Benninghoff1, Angela Lehr2, Stefan Rehart2, Henning Stürz3, Jürgen Steinmeyer4, Andreas Günther5, Ulf MüllerLadner1 and Elena Neumann1, 1Justus-Liebig-University of Gießen, Bad Nauheim, Germany, 2Markus-Hospital, Frankfurt, Germany, 3University Hospital Gießen and Marburg, Giessen, Germany, 4University Hospital Gießen and Marburg, Gießen, Germany, 5Justus-Liebig-University of Gießen, Giessen, Germany 36. A Disintegrin and Metalloprotease 10 (ADAM10) Is Overexpressed in Rheumatoid Arthritis Synovial Tissue and Mediates Angiogenesis. Takeo Isozaki1, Bradley J. Rabquer1, G. Kenneth Haines III2 and Alisa E. Koch3, 1University of Michigan, Ann Arbor, MI, 2Yale University, New Harven, CT, 3 Veteran’s Administration and Unversity of Michigan, Ann Arbor, MI 2011 Program Book

133

ACR Poster Session A 37. Regulation of Synoviocyte Migration by phosphoinositide 3 Kinase (PI3K) Delta. Beatrix Bartok1, Deepa Hammaker2, Christian Rommel3 and Gary S. Firestein4, 1UCSD, La Jolla, CA, 2 Univ of California San Diego, La Jolla, CA, 3Intellikine, Inc., La Jolla, CA, 4UCSD School of Medicine, La Jolla, CA 38. Soluble Junctional Adhesion Molecule-B Inhibits Angiogenesis in Rheumatoid Arthritis. Bradley J. Rabquer1, Beatrix Balogh1, Jeffrey H. Ruth1, Beat A. Imhof2 and Alisa E. Koch3, 1University of Michigan, Ann Arbor, MI, 2University of Geneva, Switzerland, 3Department of Veteran’s Affairs and Unversity of Michigan, Ann Arbor, MI 39. FAAH Inhibition Reverses Glucocorticoid Effects in Synovial Fibroblasts of Patients with Osteoarthritis and Rheumatoid Arthritis. Torsten Lowin1, Elena Neumann2, Ulf Muller-Ladner3 and Rainer H. Straub1, 1University Hospital Regensburg, Regensburg, Germany, 2Justus-LiebigUniversity of Gießen, Bad Nauheim, Germany, 3Justus-Liebig Universität Gießen, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany 40. Design of Peptides From CD2 to Modulate Protein-Protein Interactions and Immune Response. Ameya Gokhale1, Veena Taneja2 and Seetharama Satyanarayanajois1, 1 University of Louisiana at Monroe, Monroe, LA, 2Mayo Clinic, Rochester, MN 41. Toll-Like Receptor 2 Induced Cell Migration and Invasion Is Mediated Through ß1-Integrin Signalling Pathways and Cytoskeletal Dynamics. Trudy McGarry1, Mary Connolly2, Jennifer McCormick1, Douglas J. Veale1 and Ursula Fearon1, 1 Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, 2Center of Experimental Rheumatology, University Hospital Zürich, Zurich, Switzerland

Cytokines, Mediators, and Gene Regulation 42. Epigenetically Regulated MicroRNA-126 Influences Migratory Potential and Apoptosis of Synovial Fibroblasts in Rheumatoid Arthritis. Mojca Frank1, Maria Filkova1, Joanna Stanczyk1, Mary Connolly1, Christoph Kolling2, Beat A. Michel1, Blaz Rozman3, Renate E. Gay1, Steffen Gay1 and Astrid Jungel1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Schultess Clinic, Zurich, Switzerland, 3University Medical Centre, Ljubljana, Slovenia

45. MiR-451 in Microparticles Derived From Monocytes Influences Gene Expression in Rheumatoid Arthritis Synovial Fibroblasts. Meike Dahlhaus1, Joanna Stanczyk1, Mojca Frank1, Beat A. Michel1, Christoph Kolling2, David S. Pisetsky3, Renate E. Gay1, Steffen Gay1, Astrid Jüngel1 and Diego Kyburz1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Schultess Clinic, Zurich, Switzerland, 3Duke University Medical Center, Durham, NC 46. The Influence of Cigarette Smoke on Expression of Histone Deacetylases in Rheumatoid Arthritis. Anna Loeffler1, Peter Kunzler1, Fabienne Niederer1, Astrid Jungel1, Christoph Kolling2, Giovanni Camici3, Beat A. Michel4, Renate E. Gay1, Steffen Gay1 and Caroline Ospelt1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Schultess Clinic, Zurich, Switzerland, 3Institute of Physiology, University of Zurich, Switzerland, 4University Hospital, Zurich, Switzerland 47. A-SAA Induced Angiogenesis and Endothelial Cell Invasion Is Mediated Through NOTCH Signalling Pathways. Peter Rooney1, Mary Connolly2, Wei Gao3, Douglas J. Veale4 and Ursula Fearon4, 1University College Dublin, Dublin, Ireland, 2 Center of Experimental Rheumatology, University Hospital Zürich, Zurich, Switzerland, 3St. Vincent’s University Hospital, Dublin, Ireland, 4Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland 48. Age-Related Mitochondrial Dysfunction Sensitizes Human Synoviocytes to Inflammatory Response. M. Noa ValcárcelAres1, Romina R. Riveiro-Naveira1, Carlos Vaamonde-García1, Laura Hermida-Carballo1, Francisco J. Blanco2 and Maria J. López-Armada1, 1Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, 2Osteoarticular and Aging Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain 49. Regulatory and Anti-Inflammatory Effects of MAP Kinase Phosphatase-1 in Inflammation and Arthritis. Riku Korhonen1, Riina Nieminen1, Tuija Turpeinen1, Ville Taimi1, Antonis Goulas2, Andrew R. Clark3 and Eeva Moilanen1, 1 University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, 2Aristotle University of Thessaloniki, Greece, 3Imperial College London, London, United Kingdom

43. Mathematical Modeling of Interleukin-6 Signaling Inhibition: Comparative Efficiency of Different Intervention Strategies. Saroja Ramanujan1, Daniel Young1, Peter Maisonpierre1, Stevan Shaw2, Jason Chan1 and Kosmas Kretsos2, 1Entelos, Inc., Foster City, CA, 2UCB, Slough, United Kingdom

50. Critical Role for the IL-23/TNF Axis During TLR2/NOD2 Mediated Acute Joint Inflammation. Ferry Cornelissen1, Odilia B.J. Corneth2, Anne-Marie Mus1, Patrick S. Asmawidjaja1 and Erik Lubberts1, 1Erasmus MC, University Medical Center, Rotterdam, Netherlands, 2Erasmus MC, University Medical Center, Rotterdam, Rotterdam, Netherlands

44. Abnormalities in a JAK-STAT Pathway Are Involved in the Aberrant Production of IL-6 by BAFF-Stimulated Peripheral Monocytes of Patients with Primary Sjögren’s Syndrome. Keiko Yoshimoto1, Maiko Tanaka1, Masako Kojuma1, Hideko Ogata1, Hideto Kameda1, Tohru Abe2 and Tsutomu Takeuchi1, 1 Keio University School of Medicine, Tokyo, Japan, 2Saitama Medical School, Kawagoe-shi Saitama, Japan

51. T-Cell-Related Cytokines Are Inhibited in Response to Tocilizumab in Patients with Rheumatoid Arthritis in Contrast with TNF-Inhibitor. Jiro Yamana1, Mitsuyoshi Iwahashi2, Motoaki Kim1, Rie Sasaki1, Keisuke Kobayashi1, Seizo Yamana1, Yusuke Sasaki3, Yasushi Shimonaka3 and Masahiko Mihara4, 1Higashi-hiroshima memorial Hospital, Hiroshima, Japan, 2Higashi-Hiroshima Memorial Hospital,

134

2011 Program Book

ACR Poster Session A Higashi-hiroshima, Japan, 3Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan, 4Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan 52. Increased Plasma Levels of IL17F in Rheumatoid Arthritis Patients Are Reduced by Methotrexate and Biologic Agents. Jeffrey D. Greenberg1, Victoria Furer1, John Todd2, Quynh Ann Lu2, Renita Ramirez2, Michael Lock2, Steven B. Abramson1 and Mukundan Attur1, 1NYU Hospital for Joint Diseases, New York, NY, 2Singulex, Alameda, California, Alameda, CA 53. Decrease of Serum IL-35 Predicts Clinical Improvement in Patients with Very Early RA. Ladislav Senolt1, Mária Filková1, Hana Hulejová1, Lucie Andrés Cerezo1, Ondrej Pecha2, Lenka Plestilová1, Katerina Jarosova1, Karel Pavelka1, Jiri Vencovsky1 and Herman F. Mann1, 1Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1 st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic 54. Vitamin D Deficient Healthy Individuals Have Decreased Activated T Cells and Altered Lymphocyte Responses to Cytokine Stimulation. Lauren L. Ritterhouse1, Holden T. Maecker2, Hongwu Du3, C. Garrison Fathman4, Joel Guthridge1 and Judith A. James5, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University School of Medicine, Stanford, CA, 3Stanford University School of Medicine, Stanford, CA, 4Stanford Univ Medical Center, Stanford, CA, 5Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK 55. Hypoxia and Inflammation Synergistically Promote Bone Destruction. Shankar Revu1, Vivekananda Sunkari2, Akilan Krishnamurthy3, Ileana R. Botusan2, Sergiu-Bogdan Catrina2 and Anca Irinel Catrina4, 1Rheumatology unit, Stockholm, Sweden, 2Stockholm, Sweden, 3Karolinska Institute, Karolinska University Hospital, Solna, Stockholm, Sweden, 4 D2:01, Stockholm, Sweden 56. Anti-TNF Therapy Sensitizes RA Monocytes to TRAILInduced Apoptosis Via Inhibition of Pro-Survival Effects of Soluble TNF. Undine Meusch1, Manuela Rossol2, Dagmar Quandt1, Christoph G. Baerwald3 and Ulf Wagner1, 1University of Leipzig, Leipzig, Germany, 2 Translationszentrum für Regenerative Medizin (TRM), University of Leipzig, Leipzig, Germany, 3University Hospital, Leipzig, Germany 57. Regulation of Suppressor of Cytokine Signaling-1, -2 and -3 Expression in Patients with Early Arthritis. Ricardo J. Villares1, Amalia Lamana2, Coloma Costas1, Ana M. Ortiz2, Mercedes López-Santalla1, Mario Mellado1 and Isidoro González-Alvaro2, 1Centro Nacional de Biotecnología. CNIC, Madrid, Spain, 2Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain

58. Expression Levels of Interleukin-17A, Interleukin-17F and Their Receptors in Synovium of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Osteoarthritis: A Target Validation Study. Lisa G.M. van Baarsen, Maria C. Lebre, Dennis van der Coelen, Danielle M. Gerlag and PP. Tak, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 59. Type I Interferon and Clinical Phenotype in Idiopathic Inflammatory Myopathies. Louise Ekholm1, Anna Tjärnlund1, Clio P. Mavragani2, Peter J. Charles3, Leonid Padyukov1, Mary K. Crow4 and Ingrid E. Lundberg5, 1 Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 2Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, 3Kennedy Institute of Rheumatology, Imperial College, London, United Kingdom, 4Hospital for Special Surgery, New York, NY, 5 Karolinska Institutet, Stockholm, Sweden 60. Comparative Cytokine Analysis Across a Spectrum of Genetically and/or Clinically Defined Auto-Inflammatory Syndromes. Apostolos Kontzias1, Yongqing Chen1, Nicole Plass1, Damaris Garcia1, Elizabeth Joyal1, Robert Wesley2 and Raphaela T. Goldbach-Mansky1, 1National Institutes of Health Clinical Center, Bethesda, MD, 2National Insitutes of Health Clinical Center, Bethesda, MD 61. PGE2 and FGF-2 Upregulate Activities of the Human F-Spondin Promoter. Mukundan Attur1, Yang Qing2, Jinhua Wang3, Kimberlee Mix4, Glyn Palmer1 and Steven B. Abramson1, 1NYU Hospital for Joint Diseases, New York, NY, 2New York University School of Medicine, New York, NY, 3 New York University Cancer Institute, New York, NY, 4Loyola University New Orleans, New Orleans, LA 62. Correlation of Vascular Endothelial Growth Factor and Interleukin-6 Levels with Power Doppler Ultrasound of Synovial Joints in Early Inflammatory Arthritis. Joanne Kitchen1 and David Kane2, 1Adelaide and Meath Hospital, Dublin, Ireland, 2Adelaide, Meath hospital Dublin (incorporating the National Children’s hospital), Dublin 24, Ireland 63. Preferential Inhibition of IL-6 TRANS-Signaling Shows Potent Anti-Inflammatory Activity In Vivo: The Potential of NI-1201, a Novel Fully Human IL-6R Monoclonal Antibody. Florence Guilhot1, Vanessa Buatois1, Laurence Chatel1, Laura Cons1, Eric Hatterer1, Greg Elson1, Suzanne Herren1, Giovanni Magistrelli1, Pauline Malinge1, Simon Jones2, Manuela Gabler3, Thomas Kamradt3, Cristina de Min1, Marie Kosco-Vilbois1 and Walter Ferlin1, 1NovImmune S.A., PlanLes-Ouates, Geneva, Switzerland, 2Cardiff University, Cardiff, United Kingdom, 3Institute of Immunology, Jena University Hospital, Jena, Germany

2011 Program Book

135

ACR Poster Session A 64. Interleukin-22 Promotes Osteoclastogenesis in Rheumatoid Arthritis Through Induction of Receptor Activator of Nuclear Factor-Kb Ligand From Synovial Fibroblasts. SangHeon Lee1, Jung-Hwa Lee1, Hae-Rim Kim1 and Kyoung-Woon Kim2, 1Konkuk University Medical Center, Seoul, South Korea, 2Konkuk University, Institute of Biomedical Science and Technology, South Korea 65. Leptin Promotes Th17 Responses. Yiyun Yu1, Yaoyang Liu1 and Antonio La Cava2, 1UCLA, Los Angeles, 2Univ of California Los Angeles, Los Angeles, CA 66. Differential Regulation of Serum Cytokine Profiles In Patients with Rheumatoid Arthritis Treated with Tocilizumab: Possible Involvement of Macrophage Migration Inhibitory Factor. Tsuyoshi Kasama1, Kuninobu Wakabayashi1, Takeo Isozaki2, Hidekazu Furuya1, Ryo Yanai1, Kumiko Ohtsuka1, Michihito Sato1 and Ryo Takahashi1, 1 Showa University School of Med, Shinagawa-ku Tokyo, Japan, 2University of Michigan Medical School, Ann Arbor, MI 67. Glucosamine Sulphate Reduces the Prostaglandin E2 Production In Osteoarthritic Cartilage Through the Inhibition of Microsomal Prostaglandin E Synthase-1. Mohit Kapoor, Francois Mineau, Hassan Fahmi, Jean Pierre Pelletier and Johanne Martel-Pelletier, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC 68. Role of Transcription Factor Fli-1 in Regulation of Dendritic Cell and Monocyte Development. Eiji Suzuki1, Sarah Williams2, Eva Karam1, Gary S. Gilkeson3 and Xian Zhang3, 1 Medical University of South Carolina, Charleston, SC, 2Ralph H. Johnson VA Medical Center, Charleston, SC, 3Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC 69. Resveratrol Deacetylating Rela/p65 Contributes to Inhibit Transforming Growth Factor-Alpha Induced Inflammation Via a Sirt1 Dependent Manner. Xiaoxia Zhu1, Meimei Wang2, Jianhua Qiu3 and Hejian Zou1, 1Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, 2Division of Rheumatology, Zhongda Hospital, Dongnan University, Nanjing, China, 3Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 70. Fasting Expands Regulatory T Cells in Lupus Mice. Yaoyang Liu1, Yiyun Yu1 and Antonio La Cava2, 1UCLA, Los Angeles, 2 Univ of California Los Angeles, Los Angeles, CA 71. Microarray Gene Expression Profiling of Articular Chondrocyte In Patients with Osteoarthritis. Ying-Juan Chen1, Ci-Bo Huang1, Su-Ping Niu1, Ai-Hua Liu, Bei Lai and Chun-Mei Zhang, 1Beijing Hospital, Beijing, China 72. Progesterone Modulates Interferon-Alpha-Inducible Gene Expression in Human Leukocytes. Michael Cho1, John Zheng2 and Grant C. Hughes2, 1Univ of Wash School of Medicine, Seattle, WA, 2University of Washington, Seattle, WA

136

2011 Program Book

73. Temperature Sensitive Transient Receptor Potential Channels in Human Peripheral Blood Mononuclear Cells Enhance the LPS-Mediated Cytokine Response. Monique Stoffels, Lonneke M. Elders, Heleen D. de Koning, Jos W. M. van der Meer and Anna Simon, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 74. Synergy Between Adiponectin and Interleukin-1ß on the Expression of Interleukin-6, Interleukin-8, and Cyclooxygenase-2 in Fibroblast-Like Synoviocytes. Yeon-Ah Lee1, Sang-Hoon Lee2, Hyung-In Yang2, So Mi Kim1, SeungJae Hong1, Myung Chul Yoo3 and Kyoung Soo Kim1, 1Kyung Hee University, Seoul, South Korea, 2Kyung Hee University Hospital at KANGDONG, Kyung Hee University, Seoul, South Korea, 3Kyung Hee University Hospital at KANGDONG, Seoul, South Korea 75. The Discordant Impact of IL-1 Signaling on Experimental Uveitis and Arthritis. Holly L. Rosenzweig1, Stephen R. Planck1, April L. Woods1, Jenna S. Clowers2, Martin J. Nicklin3 and James T. Rosenbaum1, 1Oregon Health & Science University, Portland, OR, 2Veterans Affairs Medical Center, Portland, OR, 3University of Sheffield, United Kingdom 76. The Expression of the Receptor for Advanced Glycation End-products in Fibroblast Like synoviocytes From Rheumatoid Arthritis Patients Is Induced by Interleukin-17. Young Ok Jung1, Mila Cho2, Hae-Rim Kim3, Sang-Heon Lee4, Sung-Hwan Park5, Hye-Jwa Oh2 and Ho-Youn Kim5, 1Seoul, South Korea, 2Catholic Medical Univ, Seoul, South Korea, 3 Konkuk University Medical Center, Seoul, South Korea, 4 Konkuk University Hospital, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea 77. Interleukin 17 Increased Cadherin 11 Expression in rheumatoid Arthritis. Young Eun Park1, Seong Hu Park2, Seung Geun Lee2, Seung Hoon Baek3, Geun Tae Kim4, Jun Hee Lee5, Joung Wook Lee6, Mi La Cho7 and Sung Il Kim1, 1PUSAN NATIONAL UNIVERSITY HOSPITAL, Busan, South Korea, 2Pusan Nationl University Hospital, Busan, South Korea, 3PUSAN NATIONAL UNIVERSITY YANGSAN HOSPITAL, Yangsan, South Korea, 4Kosin University Gopsel Hospital, Pusan, South Korea, 5Ilsin Christian Hospital, Pusan, South Korea, 6Busan st. Mary’s Medical Center, Busan, South Korea, 72The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, South Korea 78. Type-1 Interferon Does Not Directly Impair Endothelial Cell Function in Vitro: Implications for Cardiovascular Models of Systemic Lupus Erythematosus. John A. Reynolds1, David W. Ray1, Terence O’Neill1, M. Yvonne Alexander1 and Ian N. Bruce2, 1The University of Manchester, Manchester, United Kingdom, 2A, Manchester, United Kingdom

ACR Poster Session A 79. Polymyalgia Rheumatica Has a Nocturnal Rise in Serum Interleukin-6 Which Is Almost Completely Suppressed by Nighttime Prednisone. Samy Zakout and John R. Kirwan, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom 80. Early Growth Response factor−1 Mediates the Suppressive Effect of Interleukin-1 on Peroxisome proliferator– activated Receptor Gamma Expression in Human Osteoarthritic Chondrocytes. Sarah S. Nebbaki1, Fatima Ezzahra El Mansouri2, Nadia Zayed2, Mohamed Benderdour3, Johanne M. Pelletier2, Jean Pierre Pelletier2 and Hassan Fahmi2, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, Montreal, QC, 2Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 3University of Montreal Hospital Research Centre , Sacré-Coeur Hospital, Montreal, QC 81. Circulating cytokines in Patients with Hidradenitis Suppurativa: is there a Clue for new Therapeutic Options? Orlando Pompei1, Lorena Álvarez-Rodríguez1, Ricardo Blanco1, Ignacio Villa2, Marcos López-Hoyos1, Marcos González López1, Hector Fernandez-Llaca1, M. del Carmen Gonzalez Vela1, Carmen Bejerano1, Inés Pérez-Martín1 and Victor M. Martinez-Taboada1, 1Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain 82. Differential Production of Angiopoietins-1 and -2 in Synovial Tissue of Rheumatoid Arthritis and Psoriatic Arthritis Patients Is Associated with Expression of Specific Putative Transcription Factors. M. Frleta, L.G.M. van Baarsen, A.M. Grabiec, D. de Launay, M. Garrelfs, D. Gerlag, PP. Tak and K.A. Reedquist, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

Education Poster: Medical Education 83. Development of a Collaborative Rheumatology and Orthopedic Musculoskeletal Ultrasound Training Program. Minna J. Kohler1, John S. Reach1, Janine Evans1, Lawrence D. Weis1, Joseph E. Craft2 and Liana Fraenkel1, 1Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, 2Yale University School of Medicine, New Haven, CT 84. Educational Efficacy and Durability of Knowledge Gained From a Module on Gout. Bernadette C. Siaton1, John S. Sundy1, Sanjay Garg2, Christopher G. Meyer3 and Lisa G. Criscione-Schreiber1, 1Duke University Medical Center, Durham, NC, 2Center for Arthritis and Rheumatism, Fayetteville, NC, 3Asheville Arthritis Ctr, Asheville, NC 85. Twitter and Rheumatology Based Medical Education – Analysis of the First 100 Followers. Christopher E. Collins, Washington Hospital Ctr, Washington, DC

86. Arthrocentesis Training Using a Knee Simulation Model. Jordan E. Brodsky, Erin P. Patton and Harry D. Fischer, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY 87. Evaluation of a Novel Educational Method: The Rheumatology Toolbox. Richard Conway1, John J. Carey1, Ronan Kavanagh2 and Robert J. Coughlan1, 1Galway University Hospitals, Galway, Ireland, 2Galway Clinic, Galway, Ireland 88. The Gait, Arms, Legs & Spine Exam: An Effective Screening Tool for Rheumatoid Arthritis When Used by Family Physicians and Nurse Practitioners. Karen A. Beattie, Norma J. MacIntyre and Alfred A. Cividino, McMaster University, Hamilton, ON 89. Effects of Simulated Joint Aspiration Training on SelfConfidence. Jefferson R. Roberts1, Jess D. Edison2, Elizabeth A. Mewshaw2 and Jeffrey Mikita3, 1Walter Reed Army Medical Ctr, Chevy Chase, MD, 2Walter Reed Army Medical Ctr, Washington, DC, 3Senior Author, Washington, DC 90. Increasing Rheumatology Exposure to Internal Medicine Residents in the Setting of Limited Resources: Evaluation of A Web-Based Image of the Month. Steven J. Katz, University of Alberta, Edmonton, AB 91. Advocacy in Rheumatology: Implications for Medical Education Based on a Focused Literature Review. Jellena Wong and Mala Joneja, Queen’s University, Kingston, ON 92. The Impact of An Intensive Rheumatology Teaching Programme on the Clinical and Diagnostic Skills of Intern House Officers. L.J Durcan1 and Gaye Cunnane2, 1St James’s Hospital,, Dublin, Ireland, 2St .James Hospital, Dublin, Ireland 93. Hospital for Special Surgery Rheumatology Academy of Medical Educators: Planning Retreat Demonstrates a High Degree of Faculty Interest in Teaching, a Teaching Career and Formalized Education to Increase Competency. Jessica Berman1, Juliet Aizer1, Anne R. Bass1, William L. Cats-Baril2, Mary K. Crow3, Edward J. Parrish1, Laura Robbins3, Jane E. Salmon1 and Stephen A. Paget1, 1Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2University of Vermont, Burlington, VT, 3Hospital for Special Surgery, New York, NY 94. Attitudes of Pediatric Residents Regarding Musculoskeletal Evaluation and Complaints. Ricardo Guirola1, Eyal Muscal2 and Jennifer L. Arnold2, 1Texas Children’s Hospital, Houston, TX, 2Baylor College of Medicine, Houston, TX 95. Anatomical Basis of Rheumatologic Examination: Upper Extremity and Cervical Region. Pablo Villaseñor-Ovies1, Joseph Biundo2, Juan J. Canoso3, Simon Carette4, Francisco J. de Toro-Santos5, Cristina Hernández-Díaz1, Robert A. Kalish6, Dennis McGonagle7, Miguel A. Saavedra-Salinas8 and José E. Navarro-Zarza9, 1Instituto Nacional de Rehabilitación, Mexico City, Mexico, 2Luisiana State Univesity, USA, Metairie, LA, 3ABC Medical Center and Tufts University, 2011 Program Book

137

ACR Poster Session A Mexico City, Mexico, 4Toronto Western Hospital, Toronto, ON, 5Complejo Hospitalario Universitario Juan Canalejo, Universidad de la Coruña, La Coruña, Spain, 6Tufts Medical Center, Boston, MA, 7University of Leeds and Leeds Teaching Hospitals, Leeds, United Kingdom, 8Centro Médico Nacional, México, Mexico, 9Mexican Taskforce for the Advancement of Clinical Anatomy, Mexico, Mexico 96. Impact of Subspecialty Elective Exposures on Outcomes on the American Board of Internal Medicine Certification Examination. Katina C. Tsagaris1, Amber Schilling1, Hong Wang2, Sameer Desale2, Michael Adams1 and Victoria K. Shanmugam1, 1Georgetown University Hospital, Washington, DC, 2MedStar Research Institute, Washington, DC 97. Availability of Pediatric Rheumatology Training within Pediatric Residency Programs in Canada. Roman Jurencak, Johannes Roth and Sarah Lawrence, University of Ottawa, Ottawa, ON 98. Publication Outcomes of Abstracts Presented At the ACR/ ARHP Annual Scientific Meeting. Gil Amarilyo, Jennifer MP Woo, Daniel E. Furst, Olivia I. Lund, Rotem Eyal, Cindy Piao, Miriam F. Parsa, Ornella J. Rullo, Alice DC Hoftman and Deborah K. McCurdy, University of California, Los Angeles, Los Angeles, CA

Epidemiology and Health Services Research I: Rheumatoid Arthritis 99. Risk Factors for Positive Rheumatoid Factor Among 31,207 People without Rheumatologic Disorders. Hiromichi Tamaki1, Yuji Nishizaki2, Ken-ichi Yamaguchi3, Toshiko Kawakita4, Mitsumasa Kishimoto4 and Masato Okada5, 1 University of Hawaii, Honolulu, HI, 2Juntendo University, Tokyo, Japan, 3St. Luke’s International Hospital, Tokyo, Japan, 4 St Luke’s International Hospital, Tokyo, Japan, 5St. Luke’s International Hosptal, Tokyo, Japan 100. The Association Between Rheumatoid Factor and Predisposing Factors for Atherogenesis in First-Degree Relatives without Rheumatoid Arthritis: Studies of the Etiology of Rheumatoid Arthritis. Jan M. Hughes-Austin1, Kevin D. Deane2, Lezlie A. Derber3, Gary O. Zerbe1, Dana M. Dabelea1, Robert H. Eckel4, Jeremy Sokolove5, William H. Robinson6, V. Michael Holers7 and Jill M. Norris1, 1Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado AMC, Aurora, CO, 4Aurora, CO, 5Stanford University, Palo Alto, CA, 6 Stanford University, Stanford, CA, 7Univ of Colorado School of Med, Aurora, CO 101. Exposure to Ultraviolet Light and Risk of Developing Rheumatoid Arthritis Among Women in the Nurses’ Health Study. Elizabeth V. Arkema1, Kimberly Bertrand1, Francine Laden1, Abrar A. Qureshi2, Elizabeth W. Karlson2 and Karen H. Costenbader2, 1Harvard School of Public Health, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA

138

2011 Program Book

102. Is Sunlight Exposure and Vitamin D Intake Associated with Rheumatoid Arthritis? Nicole C. Wright1, Brian T. Walitt2, Jeffery R. Curtis1, Mary Pettinger3, Christine G. Parks4, Anneclaire J. De Roos3, Jean Wactawksi-Wende5, Rachel Mackey6, Rebecca D. Jackson7, Michal L. Melamed8 and Barbara V. Howard9, 1University of Alabama at Birmingham, Birmingham, AL, 2Washington Hospital Center, Washington, DC, 3Fred Hutchinson Cancer Research Center, WA, 4NIH/ NIEHS, Research Triangle Park, NC, 5University of Buffalo, Buffalo, NY, 6University of Pittsburgh, Pittsburgh, PA, 7Ohio State University, Columbus, OH, 8Albert Einstein College of Medicine, Bronx, NY, 9Medstar Research Institute, Washington, DC 103. Prevalence and Incidence of Rheumatoid Arthritis in South Korea. Yoon-Kyoung Sung1, Soo-Kyung Cho1, Chan-Bum Choi1, Jae Hoon Kim2, Jin Ju Kim2, Joo-Hyun Lee2, Young Bin Joo2 and Sang-Cheol Bae1, 1Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 104. Postpartum and the Risk of Developing Rheumatoid Arthritis; Results From the Swedish EIRA Study. Camilla Bengtsson1, Cecilia Orellana1, Marie Holmqvist2, Anita Berglund1, Sara Wedrén3, Lars Klareskog3 and Lars Alfredsson1, 1Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 2Clinical epidemiology unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3 Rheumatology unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden 105. Predictors for Remission in Rheumatoid Arthritis Are Affected by Remission Definition. Cheryl CM Barnabe1, Joanne Homik2, Susan G. Barr1, Walter P. Maksymowych2 and Liam Martin1, 1University of Calgary, Calgary, AB, 2 University of Alberta, Edmonton, AB 106. Expectations of Treatment Goals and Goal-Setting Practices in People with Rheumatoid Arthritis. Vibeke Strand1, Peter Taylor2, Tom Sensky3, Nik Harta4 and Scott Fleming5, 1 Stanford University, Palo Alto, CA, 2Kennedy Institute of Rheumatology, London, United Kingdom, 3Imperial College, London, United Kingdom, 4Opinion Matters, London, United Kingdom, 5UCB, Slough, United Kingdom 107. Understanding What Motivates Patients with RA to Escalate Their Care. Liana Fraenkel1, Meaghan Cunningham2 and Paul Falzer3, 1Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 2Yale University School of Medicine, New Haven, CT, 3VA Connecticut Healthcare System, New Haven, CT 108. Factors Associated with Work Status and Missed Work Days in Patients with Rheumatoid Arthritis. Leslie R. Harrold1, Mary A. Cifaldi2, Ying Shan1, George Reed1, Katherine C. Saunders3, Joel M. Kremer4 and Jeffrey D. Greenberg5, 1UMass Medical School, Worcester, MA, 2 Abbott Laboratories, Abbott Park, IL, 3CORRONA, Inc.,

ACR Poster Session A Southborough, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY, 5New York University School of Medicine, New York, NY 109. Do Patients with Elderly-Onset Rheumatoid Arthritis Have Severe Functional Disability? Soo-Kyung Cho1, Yoon-Kyoung Sung1, So-Yeon Park1, Jeeseon Shim2, Chan-Bum Choi3, Hoon-Suk Cha4, Jung-Yoon Choe5, Won-Tae Chung6, SeungJae Hong7, Jae Bum Jun8, Tae-Hwan Kim9, Tae-Jong Kim10, Eun-Mi Koh4, Jisoo Lee11, Shin-Seok Lee10, Sung Won Lee6, Wan-sik Uhm8, Dae-Hyun Yoo9, Bo Young Yoon12, Sang-Cheol Bae1 and KORONA investigators13, 1Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2 Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 5Catholic university of Daegu, School of mediine, Daegu, South Korea, 6Dong-A University Hospital, Busan, South Korea, 7Kyung Hee University Hospital, Seoul, South Korea, 8Hanyang University Hospital for Rheumatic Disease, Seoul, South Korea, 9Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 10Chonnam National University Medical School and Hospital, Gwangju, South Korea, 11Ewha Womans University Mokdong Hospital, Seoul, South Korea, 12Inje University Ilsan Paik Hospital, Goyang, South Korea, 13Seoul 110. An Increase of Disease-Related Knowledge Improves Adherence to Tight Control. Sofie H.M. Manders1, Laura T.C. van Hulst1, Piet LCM Van Riel1, Liana Fraenkel2 and Wietske Kievit1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 111. Does the Hispanic Paradox Apply to Mexican Americans with Rheumatoid Arthritis? Antonio E. Mancera1, Inmaculada Del Rincon2, Daniel F. Battafarano3, Jose Felix Restrepo4 and Agustin Escalante2, 1Univ of Texas HSC San Antonio, San Antonio, TX, 2University of Texas Health Science Center, San Antonio, TX, 3Brooke Army Medical Ctr, San Antonio, TX, 4University of Texas. Health Science Center, San Antonio, TX 112. Subgroup Analyses of a Novel Baseline Biomarker of AcutePhase Serum Amyloid A (A-SAA) and Serum Interleukin–2 Receptor Alpha (sIL-2Ra) That Predicted Long-Term (18 to 35 yrs) Mortality in a Cohort of Incident Rheumatoid Arthritis (RA) and Non-RA. Alfonse T. Masi1, Jean C. Aldag1 and Jean D. Sipe2, 1University of Illinois College of Medicine at Peoria, Peoria, IL, 2Boston University School of Medicine, Boston, MA 113. Risk of Cardiovascular Events in Rheumatoid Arthritis Patients Treated with Subsequent-Line Biologic Disease Modifying Antirheumatic Drugs After Switching From

First-Line Anti-Tumor Necrosis Factor Agents. Stephen Johnston1, Adam Turpcu2, Nianwen Shi1, Dalia Moawad2 and Kimberly Alexander3, 1Thomson Reuters, Washington, DC, 2Genentech, South San Francisco, CA, 3Genentech, Inc., South San Francisco, CA 114. Risk of Acute Myocardial Infarction Associated with Arthritis: A Systematic Review of Observational Studies. Orit Schieir1, Cedomir Tosevski2 and E. M. Badley3, 1 University of Toronto, Toronto, ON, 2Toronto Western Research Institute, Toronto, ON, 3Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON 115. A Possible Source of Error in the Method of Cancer Risk Estimation in Patients with Rheumatoid Arthritis. Hasan Yazici1, Koray Tascilar1, Yusuf Yazici2, Gulay Kiroglu3, Levent Duransoy3 and Aydin Erar3, 1Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, 2Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 3Mimar Sinan University School of Science and Letters, Istanbul, Turkey 116. Cancer Screening Rates in Patients with Rheumatoid Arthritis: No Different Than the General Population. Seo Young Kim1, Sebastian Schneeweiss2, Jessica E. Meyers1, Jun Liu1 and Daniel Hal Solomon3, 1Brigham & Women’s Hospital, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Brigham & Womens Hospital, Boston, MA 117. Biological Agents in Rheumatoid Arthritis and Risk of Malignancy – Results From the Nation-Wide Cohort Study in Japan. Masayoshi Harigai1, Toshihiro Nanki1, Ryuji Koike1, Michi Tanaka1, Kaori Watanabe1, Yukiko Komano1, Ryoko Sakai1, Hayato Yamazaki1, Takao Koike2, Nobuyuki Miyasaka1 and SECURE study investigators group, 1Tokyo Medical and Dental University, Tokyo, Japan, 2Sapporo Medical Center NTT EC, Sapporo, Japan 118. Prophylactic Therapy for Latent Tuberculosis Prior to Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatoid Arthritis: A Decision Analysis. Glen S. Hazlewood1, David Naimark1, Michael Gardam1, Vivian Bykerk2 and Claire Bombardier3, 1University of Toronto, Toronto, ON, 2Brigham & Women’s Hospital, Boston, MA, 3 Institute for Work & Health, Toronto, ON 119. Primary Care Physicians’ Attitudes towards Managing Rheumatoid Arthritis: Room for Improvement. Daniel H. Solomon1, Katie Garneau1 and Maura D. Iversen2, 1Brigham & Womens Hospital, Boston, MA, 2Northeastern University, Department of Physical Therapy and Brigham & Women’s Hospital, Harvard Medical School, Boston, MA 120. Nudging Patients with Rheumatoid Arthritis towards Accepting ACR Recommendations. Liana Fraenkel1, Ellen Peters2 and Valerie Reyna3, 1Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 2Ohio State University, Columbus, OH, 3 Cornell University, Ithica, NY

2011 Program Book

139

ACR Poster Session A 121. An Analysis of the Use of Lipid Lowering Agents in Rheumatoid Arthritis: A Population Based Cohort Study. Bharath Manu Akkara Veetil, Eric L. Matteson, Sherine E. Gabriel and Cynthia S. Crowson, Mayo Clinic, Rochester, MN 122. Quality of Care for Rheumatoid Arthritis and Osteoporosis: Results From the U.S. Medicare Physician Quality Reporting Program. Jeffrey R. Curtis1, Pradeep Sharma2, Tarun Arora3, Aseem Bharat3, Michael Morrisey, Kenneth G. Saag3, Itara Barnes5 and Elizabeth S. Delzell3, 1Univ of Alabama-Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, 3University of Alabama at Birmingham, Birmingham, AL, 4Atlanta, GA 123. DMARD Underuse in the Medicare Current Beneficiary Survey: Evidence for Socioeconomic Disparities. Daniel H. Solomon1, John Z. Ayanian2, Bing Lu3, M. Alan Brookhart4, Sebastian Schneeweiss5, Tamara Shaykevich1 and Jeffrey N. Katz1, 1Brigham & Womens Hospital, Boston, MA, 2Brigham and Women’s Hospital, 3Brigham and Women’s Hospital, Boston, MA, 4University of North Carolina, 5Harvard University, Boston, MA 124. Patients Whose Global Estimates Are Higher Than Their Physician’s Global Estimates Are More Likely to Be Female, Have Fewer Years of Formal Education, and Higher RAPID3 (Routine Assessment of Patient Index Data) Scores. Isabel Castrejón1, Yusuf Yazici2, Jonathan Samuels1 and Theodore Pincus1, 1NYU Hospital for Joint Diseases, New York, NY, 2 Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 125. What Factors Affect Discordance Between Physicians and Patients in Assessments of Global Health in Rheumatoid Arthritis? Soo-Kyung Cho1, Yoon-Kyoung Sung1, So-Yeon Park1, Jeeseon Shim2, Chan-Bum Choi3, Hoon-Suk Cha4, Jung-Yoon Choe5, Won-Tae Chung6, Jae Bum Jun7, TaeHwan Kim8, Tae-Jong Kim9, Eun-Mi Koh4, Jisoo Lee10, Shin-Seok Lee9, Sung Hoon Park5, Wan-sik Uhm7, Dae-Hyun Yoo8, Bo Young Yoon11, Sang-Cheol Bae1 and KORONA investigators12, 1Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 5Catholic University of Daegu School of Medicine, Daegu, South Korea, 6Dong-A University, Busan, South Korea, 7Hanyang University Hospital for Rheumatic Disease, Seoul, South Korea, 8Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 9Chonnam National University Medical School and Hospital, Gwangju, South Korea, 10Ewha Womans University Mokdong Hospital, Seoul, South Korea, 11Inje University Ilsan Paik Hospital, Goyang, South Korea, 12Seoul, South Korea

140

2011 Program Book

126. Relative Effectiveness of Rituximab and An Alternative TNF Inhibitor in Patients with Rheumatoid Arthritis and An Inadequate Response to a Single Previous TNF Inhibitor: Interim Results From Switch-RA a Global Comparative-Effectiveness Observational Study. Paul Emery1, Piercarlo Sarzi-Puttini2, Robert J. Moots3, Alexandros A. Andrianakos4, Thomas P. Sheeran5, Denis Choquette6, Axel Finckh7, Marie-Laetitia Desjuzeur8, Eric Gemmen9, Chiedzo Mpofu8 and Jacques-Eric Gottenberg10, 1Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 2L Sacco University Hospital, Milano, Italy, 3University of Liverpool, Liverpool, United Kingdom, 4 Hellenic Foundation for Rheumatological Research, Athens, Greece, 5Cannock Chase Hospital, Cannock, United Kingdom, 6 University of Montreal, Notre-dame Hospital, Montreal, QC, 7University Hospital of Geneva, Geneva, Switzerland, 8 F. Hoffman-La Roche Ltd, Basel, Switzerland, 9Quintiles Inc, Rockville, MD, 10CHU Strasbourg, Strasbourg, France 127. Direct and Indirect Effects of Disease Activity on Functional disability in Rheumatoid Arthritis Patients Over Time and the Effect of Increasing Intensive Treatments: Results From Early Utrecht Rheumatoid Arthritis Cohort Study Group. Sandhya C. Nair, P.M.J. Welsing, F.P.J.G. Lafeber and J.W.J. Bijlsma, University Medical Center Utrecht, Utrecht, Netherlands 128. Rheumatoid Arthritis Continues to Improve in the New Millennium Whilst Use of Medication Change. Findings From a Representative Rheumatoid Arthritis Register Over 15 Years. Cathrine Austad, Tore K. Kvien and Till Uhlig, Diakonhjemmet Hospital, Oslo, Norway 129. Perceived Benefits of Intravenous Biologic Therapy Among Patients with Rheumatoid Arthritis. Susan Bolge, Julie Vanderpoel, Helen Eldridge, Samir Mody and Mike Ingham, Janssen Services, LLC, Horsham, PA 130. The Effect of Arthritis Self Management Program on Outcome in African-Americans with Rheumatoid Arthritis Served by a Public Hospital. Athan N. Tiliakos1, Yi Pan2, Kirk Easley3, Steven D. Culler2 and Doyt L. Conn1, 1Emory Univ School of Medicine, Atlanta, GA, 2Emory University-Rollins School of Public Health, 3Emory University-Rollins School of Public Health, Atlanta, GA 131. Effort-Reward Imbalance in Patients with Rheumatoid Arthritis? Jutta G. Richter, Thomas Muth, Birthe Koerbl, Nicole Hoffmann, Tobias Koch, Johannes Siegrist and Matthias Schneider, Heinrich-Heine-University, Duesseldorf, Germany 132. Who Are the Patients with Early Arthritis Who Score States “worse Than death” on the EQ-5D? Results From the ESPOIR Cohort. Cécile Gaujoux-Viala1, Bruno Fautrel2, Francis Guillemin3, René-Marc Flipo4, Patrice Fardellone5, Pierre Bourgeois2 and Anne-Christine Rat3, 11 NancyUniversity, Paul Verlaine Metz University, Paris Descartes University, EA 4360 Apemac, Nancy, France, 2 Paris 6 – Pierre

ACR Poster Session A et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, 2Université Pierre et Marie Curie - Paris 6 - Pitie Salpetriere University Hospital, Paris, France, 3Nancy-University, Paul Verlaine Metz University, Paris Descartes University, EA 4360 Apemac CHU Nancy, Epidémiologie et Evaluation Cliniques, Nancy, France, 4 Rheumatology Department, Lille University Hospital, Lille, France, 5C.H.U. D’Amiens, Amiens, France 133. An Overview of Health Technology Assessments for Rheumatoid Arthritis Biologics. Floortje Van Nooten1, Kavita Gajria2 and Karin Coyne3, 1United Bioscience Corporation, London, United Kingdom, 2MedImmune LLC, Gaithersburg, MD, 3United Bioscience Corporation, Bethesda, MD 134. Validation of Diagnostic and Procedural Codes for Identification of Incident Cardiovascular Disease in Subjects with Rheumatoid Arthritis. Lisa A. Davis1, Grant W. Cannon2, Andreas M. Reimold3, Gail S. Kerr4, Ted R. Mikuls5 and Liron Caplan6, 1Univ of Colorado School of Med, Aurora, CO, 2Salt Lake City VA and University of Utah, Salt Lake City, UT, 3Dallas VA and University of Texas Southwestern, Dallas, TX, 4Washington DC VA and Georgetown University, Washington, DC, 5Omaha VA and University of Nebraska, Omaha, NE, 6Denver VA and University of Colorado, Aurora, CO 135. The 2010 Rheumatoid Arthritis Criteria Versus the 1987 Rheumatoid Arthritis Criteria: Will the Real Criteria Please Stand up! Aarat M. Patel1, Christine L. Amity2, Lynne M. Frydrych2, Derek Sippel2, Donald Jones2, Danielle Goudeau2, Heather Eng3, David Kyle3, Melissa Saul3, Daniel Hal Solomon4, Stephen R. Wisniewski3, Larry W. Moreland5 and Marc C. Levesque2, 1Univ of Pittsburgh Med Ctr / Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3Univ of Pittsburgh, Pittsburgh, PA, 4Brigham & Womens Hospital, Boston, MA, 5 University of Pittsburgh, Pittsburgh, PA 136. Sensitivity and Specificity of the American College of Rheumatology and Europe League Against Rheumatism Response Criteria in Rheumatoid Arthritis for Changes Important to Patients: Is An ACR20 Meaningful? Maria I. Alba1, Lori C. Guthrie1 and Michael M. Ward2, 1NIH, NIAMS, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD 137. Can American College of Rheumatology Criteria for Rheumatoid Arthritis Be Assessed Using Self-Report Data? - Comparison of Self-Reported Data with Chart Review. Jack Chang1, Pam Rogers1 and Diane Lacaille2, 1Arthritis Research Centre, Vancouver, BC, 2Arthritis Research Centre; University of British Columbia, Vancouver, BC 138. Comparison of the 1987 American College of Rheumatology Criteria and the 2010 American College of Rheumatology/European League Against Rheumatism Criteria in Patients with Established Rheumatoid Arthritis. Iman Hemmati1, Maria Victoria Goycochea-Robbles2, Eric C. Sayre3 and Diane Lacaille4, 1University of British Columbia, Vancouver, BC, 2Regional Hospital No 1 IMSS, Mexico City,

Mexico, 3Arthritis Research Centre, Vancouver, BC, 4Arthritis Research Centre; University of British Columbia, Vancouver, BC 139. Association of Funding Source with Characteristics of Clinical Trials of Rheumatoid Arthritis. Nasim A. Khan1, Manisha Singh1, Horace Spencer2 and Karina D. Torralba3, 1 University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, 2 University of Arkansas for Medical Sciences, Little Rock, AR, 3University of Southern California-Los Angeles County Medical Center, Los Angeles, CA 140. Achieving Sustained Remission in Rheumatoid Arthritis Results in Reduced Long-Term Health Care Costs. Cheryl CM Barnabe1, Nguyen Xuan Thanh2, Arto Ohinmaa3, Joanne Homik3, Susan G. Barr1, Liam Martin1 and Walter P. Maksymowych3, 1University of Calgary, Calgary, AB, 2Institute of Health Economics, Edmonton, AB, 3University of Alberta, Edmonton, AB 141. Responsiveness of Health-Related Quality-of-Life Measures in Rheumatoid Arthritis Randomized Controlled Trials. Vibeke Strand1, Kavita Gajria2, Paul Williams3, Amy Barrett3, Ancilla Fernandes2 and Fabio Magrini4, 1Stanford University, Portola Valley, CA, 2MedImmune LLC, Gaithersburg, MD, 3RTI Health Solutions, Research Triangle Park, NC, 4MedImmune Ltd, Cambridge, United Kingdom 142. A Comparison of RAPID3 Response Criteria and EULARDAS28 Response Criteria in the DANCER and REFLEX Rituximab Clinical Trials. Martin J. Bergman1, Adam Turpcu2, Pamela Wong2, Carol Chung2 and William Reiss2, 1Taylor Hospital, Ridley Park, PA, 2Genentech, South San Francisco, CA 143. Patients’ Ratings of Clinically Important Improvement in Pain, Global Assessment, and Physical Function in Rheumatoid Arthritis. Michael M. Ward, Lori C. Guthrie and Maria I. Alba, NIH, NIAMS, Bethesda, MD 144. Employability-Adjusted-Life-Years in Patients with Rheumatoid Arthritis Treated with Golimumab Plus Methotrexate or Methotrexate Alone. Chenglong Han1, Tim Gathany2, Neeta Tandon3 and Elizabeth C. Hsia4, 1Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, 2 Johnson & Johnson Pharmaceutical Services, LLC, Horsham, PA, 3Johnson & Johnson North America Pharmaceuticals, Horsham, 4Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC/Univ. of Pennsylvania School of Medicine, Malvern, PA 145. Single Item Literacy Screening Questions Are Strongly Associated with Functional Status Among Rheumatoid Arthritis Patients. Liron Caplan1, Kaleb D. Michaud2, Frederick Wolfe3 and Joel M. Hirsh4, 1Denver VA and University of Colorado, Aurora, CO, 2Univ of Nebraska Med Ctr & National Data Bank for Rheumatic Diseases, Omaha, NE, 3National Data Bank for Rheumatic Diseases, Wichita, KS, 4Denver Health Med Ctr, Denver, CO

2011 Program Book

141

ACR Poster Session A 146. National and Regional Dosing Patterns of Tumor Necrosis Factor Blocker Therapy in Biologic-Naïve Rheumatoid Arthritis Patients in US Health Plans. Amie T. Joyce1, Shravanthi R. Gandra2, Kathy M. Fox3, Timothy W. Smith1 and Michael Pill4, 1IMS Health, Watertown, MA, 2Amgen Inc, Thousand Oaks, CA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, 4Gemini HealthCare, Westbrook, CT 147. Patients with Rheumatoid Arthritis Who Are in Remission According to the New ACR/EULAR Criteria Have a Very High Functional Capacity Which Is Comparable to Healthy Subjects. Joachim Listing1, Anja Strangfeld1, Joern Kekow2, Siegfried Wassenberg3, Thilo Klopsch4, Thomas Kohlmann5 and Angela Zink6, 1Deutsches Rheumaforschungszentrum, Berlin, Germany, 2Univ of Magdeburg, Vogelsang-Gommern, Germany, 3Evangelisches Fachkrankenhaus, Ratingen, Germany, 4Rheumatologist, Neubrandenburg, Germany, 5 University Greifswald, Greifswald, Germany, 6Deutsches Rheumaforschungszentrum and Charité University Medicine, Berlin, Germany 148. The Identification of Rheumatoid Arthritis Patients for Comparative Effectiveness Research Using An Electronic Health Record and Mathematical Modeling. Aarat M. Patel1, Larry W. Moreland2, Melissa Saul3, Stephen R. Wisniewski3 and Marc C. Levesque4, 1Univ of Pittsburgh Med Ctr / Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3Univ of Pittsburgh, Pittsburgh, PA, 4Univ of Pittsburgh Med Ctr, Pittsburgh, PA 149. Personal Health Records in Rheumatoid Arthritis: Quality and Adhesion Factors. Sophie Trijau1, Herve Servy2, Adam M. Selamnia2, Vincent Pradel1, Pierre Lafforgue1 and Thao Pham1, 1Sainte Marguerite Hospital, Marseille, France, 2 SANOIA, Marseille, France

Genetics of Human Rheumatic Diseases 150. Evidence for Epistatic Gene-Gene Interactions in Systemic Lupus Erythematosus. Travis Hughes1, Adam Adler1, Jennifer A. Kelly1, Kenneth Kaufman2, Adrienne Williams3, Carl D. Langefeld4, Elizabeth Brown for PROFILE5, Elena Sanchez1, Javier Martin6, Luis M. Vila7, Gary S. Gilkeson8, Patrick M. Gaffney9, Kathy L. Moser9, J.T. Merrill1, Judith A. James10, Timothy J. Vyse11, Marta E. Alarcon-Riquelme12, John B. Harley13, Bruce C. Richardson14 and Amr H. Sawalha1, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Wake Forest University, Winston-Salem, 4Wake Forest University Health Sciences, Winston-Salem, NC, 5Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 6Instituto de Parasitologia y Biomedicina LopezNeyra (CSIC), Granada, Spain, 7University of PuertoRico Medical Sciences Campus, San Juan, PR, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 10Oklahoma Medical Research

142

2011 Program Book

Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 12Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 13Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 14University of Michigan, Ann Arbor, MI 151. A Large-Scale Association Study Identified Multiple HLADRB1 Alleles Associated with Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis in Japanese. Chikashi Terao1, Koichiro Ohmura2, Yuta Kochi3, Katsunori Ikari4, Etsuko Maruya5, Masaki Katayama2, Kota Shimada6, Akira Murasawa7, Shigeru Honjo8, Kiyoshi Takasugi9, Keitaro Matsuo10, Kazuo Tajima10, Akari Suzuki3, Kazuhiko Yamamoto11, Shigeki Momohara4, Hisashi Yamanaka4, Ryo Yamada1, Hiroo Saji5, Fumihiko Matsuda1 and Tsuneyo Mimori2, 1Kyoto University, Kyoto, Japan, 2Kyoto Univ Grad School of Med, Kyoto, Japan, 3RIKEN, Yokohama, Japan, 4 Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 5HLA Laboratory, Kyoto, Japan, 6 Sagamihara, Japan, 7Niigata, Japan, 8Honjo Rheumatism Clinic, Kanzaki, Japan, 9Dohgo Spa Hospital, Matsuyama, Japan, 10Nagoya, Japan, 11Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan 152. Polymorphisms in the CCL2 Distal Regulatory Region Are Associated with Rheumatoid Arthritis in a North American Native Population with a High Disease Prevalence. Hani S. El-Gabalawy1, Konstantin Jilkine1, David B. Robinson1, Irene Smolik2, Donna M. Hart3, Carol A. Hitchon1, Christine A. Peschken1, Charles N. Bernstein1, Kiem Oen1, Ye Sun4 and Katherine A. Siminovitch4, 1University of Manitoba, Winnipeg, MB, 2University of Manitoba, Winnipeg, 3Health Sciences Centre, Winnipeg, MB, 4Mount Sinai Hospital, Toronto, ON 153. Is There a Higher Genetic Load of Susceptibility Loci in Familial Ankylosing Spondylitis? Reeti K. Joshi1, John D. Reveille2, Matthew A. Brown3, Michael H. Weisman4, Michael M. Ward5, Lianne S. Gensler6, B. Paul Wordsworth7, David M. Evans8 and Shervin Assassi9, 1Washington University in St. Louis, Saint Louis, MO, 2University of Texas Health Science Center at Houston, Houston, TX, 3Wellcome Trust Centre, Headington, United Kingdom, 4Cedars Sinai Med Ctr, Los Angeles, CA, 5NIH/NIAMS/IRP, Bethesda, MD, 6 UCSF, San Francisco, CA, 7Bichester, Oxon, United Kingdom, 8 Chesterfield, MO, 9Univ of Texas Health Science, Houston, TX 154. Analysis of Genetic Influence of HLA-DRB1, IL4R, and FcγRIIb on Radiographic Responses to Methotrexate Monotherapy or Adalimumab Plus Methotrexate Through 26 Weeks in Patients with Early Rheumatoid Arthritis. Alla Skapenko1, Josef Smolen2, Arthur Kavanaugh3, Sourav

ACR Poster Session A Santra4, Hartmut Kupper5, Theresa Peterson4 and Hendrik Schulze-Koops1, 1University of Munich, Munich, Germany, 2 Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 3University of California San Diego, La Jolla, CA, 4 Abbott, Abbott Park, IL, 5Abbott, Ludwigshafen, Germany 155. Characterization of a New Category of Autoinflammatory Disease Associated with Nucleotide Oligomerization Domain2 Gene Mutations: An Expanded Cohort Study. Qingping Yao, Le Chu Su, Lan Zhou, Bijal Jayakar and Bo Shen, Cleveland Clinic, Cleveland, OH 156. A Putative Functional Polymorphism in the IL21 3’-UTR Flanking Region Is Tagged by IL21 Lupus-Associated Variants and Alters Gene Expression in Vitro. Travis Hughes and Amr H. Sawalha, Oklahoma Medical Research Foundation, Oklahoma City, OK 157. Sex-Specific Genetic Architecture of Systemic Lupus Erythematosus. Travis Hughes1, Adam Adler1, J.T. Merrill1, Jennifer A. Kelly1, Kenneth Kaufman2, Adrienne Williams3, Carl D. Langefeld4, Gary S. Gilkeson5, Elena Sanchez1, Javier Martin6, Elizabeth E. Brown for PROFILE7, Patrick M. Gaffney8, Kathy L. Moser8, Tomothy J. Vyse9, Marta E. Alarcon-Riquelme10, Judith A. James11, Robert H. Scofield12, John B. Harley13, Bruce C. Richardson14 and Amr H. Sawalha1, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Wake Forest University, Winston-Salem, 4Wake Forest University Health Sciences, Winston-Salem, NC, 5 Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 6Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 7University of Alabama at Birmingham, Birmingham, AL, 8Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 9King’s College London, Guy’s Hospital, London, United Kingdom, 10Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 11 Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 12 Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 13Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 14University of Michigan, Ann Arbor, MI 158.

WITHDRAWN.

159.

`Recognition of High Risk and Protective HLA-DRB1 Alleles with Respect to Need for Biologic Therapy in a Cohort of 226 Patients with Rheumatoid Arthritis. Surabhi Waghmare1, Andrew Cairns2, Clare Matthews3 and Gary D. Wright4, 1Musgrave Park Hospital-Belfast Health and Social Care Trust, Belfast, BT9 7JB, United Kingdom, 2Musgrave

Park Hospital-Belfast Health and Social Care Trust, Belfast, United Kingdom, 3Ulster Hospital-South Eastern Trust, Belfast, United Kingdom, 4Musgrave Park Hospital, Belfast, United Kingdom 160. Investigation of Caucasian Rheumatoid Arthritis Susceptibility Loci in African Patients with the Same Disease. Sebastien Viatte1, Edward Flynn1, Mark Lunt1, Joanne Barnes1, Madeleine Singwe-Ngandeu2, Sylvette Bas3, Anne Barton1 and Cem Gabay3, 1Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Unit of Rheumatology, Department of Internal Medicine, School of Medicine, University of Yaoundé, Yaoundé, Cameroon, 3Division of Rheumatology, University Hospitals of Geneva, 26 Avenue Beau-Séjour, 1211 Geneva 14, Switzerland 161. Germinal and Somatic Abnormalities of the TNFAIP3 Gene Support a Two-Hit Hypothesis of Lymphomagenesis in Autoimmune Diseases. Xavier Mariette1, Saida Boudaoud2, Gaetane Nocturne1, Thierry Lazure2, Joanne Nititham3, Kimberly E. Taylor4, Eric Hachulla5, Jean Jacques Dubost6, Jacques-Eric Gottenberg7, Lindsey A. Criswell8 and Corinne Miceli-Richard9, 1Bicêtre University Hospital, Le Kremlin Bicetre, France, 2INSERM U1012 - Université Paris XI, Le Kremlin Bicêtre, France, 3University of California, CA, 4 University of California, San Francisco, San Francisco, CA, 5Internal Medicine, Lille CEDEX, France, 6CHU Gabriel Montpied, Clermont-Ferrand, France, 7Strasbourg University Hospital, Strasbourg, France, 8University of California San Francisco, San Francisco, CA, 9Hopital Bicêtre, Le Kremlin Bicêtre, France 162. Investigation of the Interaction Between Smoking and TRAF1/C5 on Radiological Severity of Inflammatory Polyarthritis. Lily M. Wheeler, Sebastien Viatte, Suzanne Verstappen, Deborah P. Symmons, Jane Worthington and Anne Barton, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom 163. Identification of Clinical and Genetic Factors That Influence the Response to Methotrexate in Japanese RA Patients: Genome-Wide Association Study. Taku Suzuki1, Katsunori Ikari1, Yoshiaki Toyama2, Atsuo Taniguchi1, Nao Nishida3, Katushi Tokunaga3, Hisashi Yamanaka1 and Shigeki Momohara1, 1Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 2Keio University, Tokyo, Japan, 3Department of Human Genetics, Graduate School Of Medicine, University of Tokyo, Tokyo, Japan 164. Genome-Wide Association Study of Rheumatoid Arthritis, Stratified by Smoking Status. Darren Plant1, Deborah P. Symmons1, Jane Worthington1, David Strachan2 and Anne Barton1, 1University of Manchester, Manchester, United Kingdom, 2St George’s, University of London, London, United Kingdom

2011 Program Book

143

ACR Poster Session A 165. Genome-Wide Association Analysis of Rheumatoid Arthritis Patients Treated with Anti-TNF Medication. Marieke J.H. Coenen1, Masha Umicevic-Mirkov1, Judith A. Wessels2, Sita H. Vermeulen1, Erik J. Toonen1, Annette T. Lee3, Remco R. Makkinje1, Wietske Kievit1, Hans Scheffer1, Tim L. Jansen4, Ellen A. Dutmer5, Timothy R.D. Radstake6, Mart A.F. van de Laar7, Pilar Barrera1, Piet L.C. van Riel1, Henk-Jan Guchelaar2, Peter K. Gregersen8 and Barbara Franke1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Feinstein Institute Med Rsch, Manhasset, NY, 4Medical Centre Leeuwarden, Netherlands, 5Gelderse Vallei Hospital, Ede, Netherlands, 6 Radboud University Nijmegen Medical Centre, Nymegen, Netherlands, 7Medisch Spectrum Twente & Twente University, Enschede, Netherlands, 8Feinstein Institute Medical Reschearch, Manhasset, NY 166. An Insertion Mutation in the MDFIC (MyoD Family Inhibitor Domain Containing) Gene Defines a Novel Autoinflammatory Syndrome Associated with Lymphedema. Ahmet Gul1, Duran Ustek2, Gulen Hatemi3, Hulya Azakli2, Zeliha Emrence2, Fulya Cosan2, Aris Cakiris2, Neslihan Abaci2, Muzaffer Arikan2, Atilla Cakar2, Nil Arisoy, Ozgur Kasapcopur3 and Huri Ozdogan3, 1Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Istanbul University, Istanbul, Turkey, 3Rheumatology, Istanbul, Turkey 167. Polygenic Modeling of Genome-Wide Association Study Data Reveals Hidden Heritability of Rheumatoid Arthritis Risk. Eli A. Stahl1, Daniel Wegmann2, Peter Kraft3, Henrik Kallberg4, Fina Kurreeman5, Peter K. Gregersen6, Lars Alfredsson7, Katherine A. Siminovitch8, Jane Worthington9, Paul de Bakker1, Soumya Raychaudhuri1 and Robert M. Plenge1, 1Brigham and Women’s Hospital, Boston, MA, 2Department of Ecology and Evolutionary Biology, University of California, Los Angeles, CA, 3Department of Biostatistics, Harvard School of Public Health, Boston, MA, 4 Rheumatology Unit, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Solna, Stockholm, Sweden, 5Division of Rheumatology Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 6 Feinstein Institute Medical Reschearch, Manhasset, NY, 7 Institute of Environmental Medicine, Unit of Cardiovascular Epidemiology, Karolinska Institutet, Stockholm, Sweden, 8 Mount Sinai Hospital, Toronto, ON, 9University of Manchester, Manchester, United Kingdom 168. DO Carriers of A MEFV Mutation Have Any Selective Advantage to A Pathogen Endemic In the Same Geography? Serdal Ugurlu1, Aynur Engin2, Gulen Hatemi1, Gulay Ozgon3, Elif Akyayla3, Mehmet Bakir2 and Huri Ozdogan1, 1MD,Division of Rheumatology, Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2MD,Department of of Infectious Diseases, Medical Faculty, University of Cumhuriyet, Sivas, Turkey, 3Nesiller Genetic Lab, Istanbul, Turkey

144

2011 Program Book

169. Elevated Expression of Inflammatory Mediators Cyclooxygenase-2, Its Product Prostaglandin E2 and Interleukin-1 Beta by Peripheral Blood Leukocytes in Symptomatic Knee Osteoarthritis. Mukundan Attur1, Alexander Statnikov2, Constantin F. Aliferis2, Zhiguo Li2, Svetlana Krasnokutsky3, Jonathan Samuels1, Jeffrey D. Greenberg4, Jyoti Patel1, Cheongeun Oh5 and Steven B. Abramson1, 1NYU Hospital for Joint Diseases, New York, NY, 2NYU Langone, New York, NY, 3NYU Hospital for Joint Disease, New York, NY, 4New York University School of Medicine, New York, NY, 5New York University, New York, NY 170. Genomic Deletions in Phospholipase Cγ2 define a New Syndrome of Cold Urticaria, Antibody Deficiency and Susceptibility to Both Autoimmunity and Infection. Michael J. Ombrello1, Elaine F. Remmers1, Guangping Sun2, Alexandra F. Freeman2, Hirsh Komarow2, Ivona Aksentijevich1, Shrimati Datta2, Parizad Torabi-Parizi2, Naeha Subramanian2, Neil Romberg3, Tom D. Bunney4, Rhona W. Baxendale4, Hun Sik Kim5, Jason Ho2, Daniel C. Douek2, Chhavi Gandhi6, Alan A. Wanderer7, Hane Lee8, Stanley Nelson8, Eric Long5, Susan Moir2, Eric Meffre3, Steven Holland2, Matilda Katan4, Daniel L. Kastner1, Hal M. Hoffman6 and Joshua D. Milner2, 1 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 3Yale University School of Medicine, New Haven, CT, 4Chester Beatty Laboratories, The Institute of Cancer Research, London, United Kingdom, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 6University of California at San Diego, La Jolla, CA, 7University of Colorado Health Sciences Center, Aurora, CO, 8University of California Los Angeles, Los Angeles, CA 171. Ferritin and Hemochromatosis Polymorphisms Correlate with Clinical Characteristics in a Symptomatic Osteoarthritis Cohort. Lauren M. Kennish1, Mukundan Attur2, Xi Huang3, Svetlana Krasnokutsky4, Jonathan Samuels2, Cheongeun Oh5 and Steven B. Abramson2, 1 Hospital for Joint Diseases, New York, NY, 2NYU Hospital for Joint Diseases, New York, NY, 3New York University School of Medicine, New York, NY, 4NYU Hospital for Joint Disease, New York, NY, 5New York University, New York, NY

Imaging of Rheumatic Disease: Ultrasound, Optical and Preclinical Imaging 172. Patients with Rheumatoid Arthritis On Anti-TNF Therapy; Responders with Major Reduction In Power Doppler Activity Can Be Identified After One Month. Hilde B. Hammer, Britt Birkelund and Tore K. Kvien, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway 173. New Aspects Concerning the Activity of Established Rheumatoid Arthritis Under a Tocilizumab Therapy. Maria Hoehle, Rheumatology, Hamburg, Germany

ACR Poster Session A 174. Metrological Properties of Composite Scoring Systems for Synovitis in Rheumatoid Arthritis: Results From a Randomized, Prospective, Multicentre Study. Peter Mandl1, Peter V. Balint2, Yves Brault3, Marina Backhaus4, MariaAntonietta D’Agostino5, Walter Grassi6, Désirée van der Heijde7, Eugenio De Miguel8, Richard J. Wakefield9, Isabelle Logeart3 and Maxime Dougados10, 1Medical University of Vienna, Vienna, Austria, 2National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 3Pfizer, Paris, France, 4Charite University Hospital, Berlin, Germany, 5 Versailles-Saint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France, 6 Università Politecnica delle Marche, Jesi, Italy, 7Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 8La Paz University Hospital, Madrid, Spain, 9 Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals, Leeds, United Kingdom, 10ParisDescartes University, Cochin Hospital, Paris, France 175. Ultrasonography Assessment of the Hands As a Measure of Disease Activity in Rheumatoid Arthritis Patients: Correlation with DAS 28 Score. Carla Saucedo1, Santiago Ruta1, Javier Rosa1, David A. Navarta1, Maria Victoria Garcia1, Ricardo Garcia Monaco2 and Enrique R. Soriano1, 1 Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2 Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires 176. Sensitivity to Change of the 7-Joint Ultrasound (US7) Score Among Patients with Different Musculoskeletal Diseases Under Twelve Months of Therapy. Tina M. Backhaus1, Sarah Ohrndorf2, Herbert Kellner3, Johannes Strunk4, Wolfgang Hartung5, Horst Sattler6, Christof Iking-Konert7, Gerd R. Burmester8, Wolfgang A. Schmidt9 and Marina Backhaus10, 1Berlin, Germany, 2Charité –University Medicine Berlin,, Berlin, Germany, 3Centre for Inflammatory Joint Diseases, Munich, Germany, 4Cologne, Germany, 5Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, 6Klinikum Ludwigshafen, Ludwigshafen, Germany, 7University Hospital Hamburg Eppendorf, Hamburg, Germany, 8Charité - Universitätsmedizin Berlin, Berlin, Germany, 9Med Ctr Rheumatol Berlin Buch, Berlin, Germany, 10Charite University Hospital, Berlin, Germany 177. Impact of the US7 Score for Diagnosis and Prognosis of Rheumatoid Arthritis In Undifferentiated Early Arthritis. Jörg Kaufmann1, Susanne Seel2 and Anne-Eve Roske3, 1 Rheumatologist, Ludwigsfelde, Germany, 2Ambulant Centres f. Rheumatology, Ludwigsfelde, Germany, 3Roche Pharma AG, Grenzach-Wyhlen, Germany 178. Introduction of a New Ultrasound Score for Large Joints: One Year Experience in Daily Rheumatologic Practice. Wolfgang Hartung1, Herbert Kellner2, Johannes Strunk3, Wolfgang A. Schmidt4, Boris P. Ehrenstein1, Horst Sattler5, Marina Backhaus6 and Martin Fleck1, 1Asklepios

Klinikum Bad Abbach, Bad Abbach, Germany, 2Centre for Inflammatory Joint Diseases, Munich, Germany, 3Cologne, Germany, 4Med Ctr Rheumatol Berlin Buch, Berlin, Germany, 5 Klinikum Ludwigshafen, Ludwigshafen, Germany, 6Charite University Hospital, Berlin, Germany 179. The Impact of Ultrasonography on the Classification of Rheumatoid Arthritis with 2010 ACR/EULAR Criteria: Ultrasound-Combined Classification with Two Different Definitions of Gray-Scale Synovitis for Joint Involvement. Daiki Nakagomi, Kei Ikeda, Ayako Okubo, Taro Iwamoto, Yoshie Suzuki, Hiroaki Takatori, Kotaro Suzuki, Katsuhiko Takabayashi and Hiroshi Nakajima, Chiba University Hospital, Chiba, Japan 180. Comparison of the Validity of Synovitis to Predict Structural Damage in Rheumatoid Arthritis (RA) with Regard to the Joint Examination Modality (e.g. clinical versus ultrasonographic [US]). Maxime Dougados1, Valerie Devauchelle2, Jean François Ferlet3, Jacques Bentin4, Sandrine Jousse-Joulin2, E. Maria Atonietta D’Agostino5, Gérard Chalès6, Isabelle Chary-Valckenaere7, Fabien Etchepare8, Philippe Gaudin9, Xavier Mariette10 and Alain Saraux11, 1Paris-Descartes University, Cochin Hospital, Paris, France, 2Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, 3RCTS, Lyon, France, 4CHU-Brugmann, Brussels, Belgium, 5Rheumatology Department Ambroise Par Hospital, Boulogne-Billancourt, France, 6CHU RENNES, Rennes, France, 7CHU NANCY, France, 8 G.H. Pitié-Salpêtrière, Paris, France, 9Chu A Michallon, Grenoble, France, 10Université Paris-Sud, Le Kremlin Bicetre, France, 11CHU de la Cavale Blanche, Brest Cedex, France 181. Sonographic Arthritis Remission Criteria Jeopardized by a Physiological Anechogeneity in MCP Joints. David F. Ten Cate1, Jolanda J. Luime2, Johanna Hazes3, G.J. Kleinrensink2 and Johannes W.G. Jacobs4, 1Erasmus Medical Center, Rotterdam, Netherlands, 2Erasmus MC - University Medical Center, Rotterdam, Netherlands, 3Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, 4UMC Utrecht, Utrecht, Netherlands 182. No Ultrasound Specific Changes in Trochanter Enthesis in Patients with Greater Trochanter Pain Syndrome and Chronic Arthritis. Julio Ramírez1, Isaac Pomés1, Jaume Pomés1 and Juan D. Cañete2, 1Hospital Clínic, Barcelona, Spain, 2Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain 183. Detection by Ultrasound of Small Calcium Deposits within Cartilage in Patients without Radiographic Chondrocalcinosis. Eric Russell, Humaira Hussain and Angel E. Checa, Drexel University College of Medicine, Philadelphia, PA 184. Feasibility of Volumetric Ultrasound and Automated Analysis for Rheumatic Disease. Ralf G. Thiele1, Kedar Patwardhan2, Kunlin Cao2 and David Mills2, 1University of Rochester, Rochester, NY, 2GE Global Research

2011 Program Book

145

ACR Poster Session A 185. US Examination of Wrists and Hands: A Comparison Between Rheumatoid Arthritis and Psoriatic Arthritis. Andrea Delle Sedie1, Niccolò Possemato2, Elena Sardano3, Elisa Cioffi4, Stefano Bombardieri2 and Lucrezia Riente2, 1 Rheumatology Unit, Pisa, Italy, 2Rheumatology Unit, University of Pisa, Pisa, Italy, 3Immunology Unit, University of Pisa, Italy, 4School of Medicine, University of Pisa, Pisa, Italy 186. Detection of Inflammation in Early Psoriatic Arthritis by Ultrasound - a Longitudinal Study. Axel P. Nigg1, Anna M. Malchus1, Mathias Grünke1, Matthias Witt1, Joerg C. Prinz2 and Hendrik Schulze-Koops1, 1Division of Rheumatology and Clinical Immunology, Med. Poliklinik, University of Munich, Munich, Germany, 2Department of Dermatology, University of Munich, Munich, Germany 187. Metric Properties of Imaging Methods in Osteoarthritis of the Hand: A Systematic Review. Michael S. Saltzherr, Ruud W. Selles, Sita M.A. Bierma-Zeinstra, Galied S.R. Muradin, J. Henk Coert, Johan W. van Neck and Jolanda J. Luime, Erasmus MC - University Medical Center, Rotterdam, Netherlands 188. New Onset Bilateral Painful Shoulder in Patients with Polymyalgia Rheumatica and Rheumatoid Arthritis: An Ultrasound Study. David A. Navarta1, Santiago Ruta1, Javier Rosa1, Carla Saucedo1, Ricardo Garcia Monaco2 and Enrique R. Soriano1, 1Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2 Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires 189. The Role of Color-Doppler-Sonography in the Diagnosis of Giant Cell Arteritis Characterized by Adventitial Inflammation of the Temporal Arteries. Francesco Muratore, Luigi Boiardi, Nicolo Pipitone, Alberto Cavazza, Giovanna Restuccia, Giuseppe Germanò, Pierluigi Macchioni, Gianluigi Bajocchi, Maria Grazia Catanoso, Luca Magnani, Fulvia Rossi, Ilaria Chiarolanza, Lucia Dardani, Andrea Caruso, Alessandra Ghinoi and Carlo Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy 190. Challenges to Expanding the Clinical Application of Musculoskeletal Ultrasonography Among Rheumatologists in Japan. Maasa Hama, Kaoru Takase, Atsushi Ihata, Mitsuhiro Takeno and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan 191. Are Training Sessions Useful for Ultrasound Scan Evaluation of Synovitis In Rheumatoid Arthritis? Andrés Ponce1, Juan J. Alegre2, Manuel Castaño3, Ricardo Gutierrez-Polo4, Francisco G. Jiménez-Núñez5, María P. Macarrón6 and Jesús Garrido7, 1Hospital General de Granollers, Granollers, Spain, 2 Hospital Universitario Dr Peset, Valencia, Spain, 3Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 4C.H. de Navarra, Pamplona, Spain, 5Hospital Regional Universitario Carlos Haya., Malaga, Spain, 6Hospital Clínico San Carlos, Madrid, Spain, 7Facultad de Psicología.Universidad Autónoma de Madrid, Madrid, Spain

146

2011 Program Book

192. The Most Reliable Probe Position in An RA Wrist Is From Lister’s Tubercle to Digit III, the Zorro Study. Noelia Dopazo Gonzalez1, David F. Ten Cate2, Antonio Mera3, S.A. Insua Vilariño4, Nanno Swen5, E. Perez-Pampin4, Juan J. GomezReino6 and Jolanda J. Luime7, 1Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, 2Erasmus Medical Center, Rotterdam, Netherlands, 3General Hospital, Santiago Compostela, Spain, 4University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain, 5Medical Center Alkmaar, Alkmaar, Netherlands, 6Hospital Clinico Universitario, Santiago, Spain, 7Erasmus MC - University Medical Center, Rotterdam, Netherlands 193. Meta-Analysis: Improvement In Wrist Pain with US-Guided Glucocorticoid Injections As Compared to PalpationGuided Injections. Maureen Dubreuil1, Stephanie Greger2, Michael P. LaValley3, Wilmer L. Sibbitt4 and Eugene Y. Kissin5, 1 Boston Medical Center, Boston, MA, 2Boston University Medical Center, Boston, MA, 3Boston University School of Public Health, Boston, MA, 4University of New Mexico HSC, Albuquerque, NM, 5Boston University, Boston, MA 194. Steroid Injection for Plantar Fasciitis - a Placebo-Controlled Trial. Elisabeth M.A Ball1, Helen M.A. McKeeman2, James Burns3, Wing Hoi Yau3, Owen Moore3, Claire Benson3, Joanne Foo3, Chris Patterson4, Gary D. Wright3 and Allister J. Taggart3, 1Musgrave Park Hospital/Queens’ University, Belfast, United Kingdom, 2Belfast City Hospital, Belfast, United Kingdom, 3Musgrave Park Hospital, Belfast, United Kingdom, 4Epidemiology Research Group, Queens University Belfast, United Kingdom 195. Power Doppler Ultrasound Findings and Serum Levels of Pro- and Anti-Inflammatory Cytokines in Normal Joints. Joanne Kitchen1 and David Kane2, 1Adelaide and Meath Hospital, Dublin, Ireland, 2Adelaide, Meath hospital Dublin (incorporating the National Children’s hospital), Dublin 24, Ireland 196. Lack of Correlation Between Synovial Biology and Ultrasound Features of Synovitis in Osteoarthritis. Jeannie H. Chao1, Sanna Rosengren2, Joshua Hillman2, Kenneth C. Kalunian2, Scott Ball1, Brady K. Huang1, Gary S. Firestein2 and David L. Boyle2, 1UCSD, La Jolla, CA, 2UCSD School of Medicine, La Jolla, CA 197. Comparison of Optical Coherence Tomography and High Frequency Ultrasound As Measures of Skin Thickness in Systemic Sclerosis; A Pilot Study. Andrea Murray1, Donna Buckley2, Graham Dinsdale1, Tonia Moore1, Mark Dickinson2 and Ariane Herrick1, 1School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2Photon Science Institute, University of Manchester, Manchester, United Kingdom 198. Sensitivity and Specificity of Indocyanine Green Enhanced Optical Imaging (Xiralite) in Comparison to Magnetic Resonance Imaging and Ultrasonography. Stephanie G. Werner1, Peter Schott2, Sarah Ohrndorf3, Carsten Schwenke4,

ACR Poster Session A Malte Bahner5, Bernward Kurtz2, Marina Backhaus6, Gerd R. Burmester3 and Hans-Eckhard Langer7, 1RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, 2Evangelisches Krankenhaus Duesseldorf, Duesseldorf, Germany, 3Charité University Hospital, Berlin, Germany, 4SCOSSIS, statistical consulting, Berlin, Germany, 5mivenion GmbH, Berlin, Germany, 6Charite University Hospital, Berlin, Germany, 7Duesseldorf, Germany 199. Indocyanine Green Enhanced Optical Imaging Using for Monitoring of Treatment Response. Stephanie G. Werner1, Felicitas Spiecker2, Sabine Mettler2, Gudrun Lind-Albrecht2, Carsten Schwenke3 and Hans-Eckhard Langer2, 1RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, 2Duesseldorf, Germany, 3SCOSSIS, statistical consulting, Berlin, Germany 200. A Comparison of Optical Coherence Tomography and Clinical Assessment of Nail Disease in Psoriasis and Psoriatic Arthritis. Concepcion Castillo-Gallego1, Sibel Aydin2, Zoe R. Ash3, Giusepinna Abignano3, Paul Emery3, Helena Marzo-Ortega3, Francesco Del Galdo3 and Dennis McGonagle3, 1Hospital Universitario La Paz, Madrid, Spain, 2 Goztepe Training and Research Hospital, Istanbul, Turkey, 3 University of Leeds, Leeds, United Kingdom 201. Adalimumab Improves ENDOTHELIAL Function and Microcirculation In Rheumatoid Arthritisas Determined by Simultaneous ASSESSMENT of Brachial ARTERY FLOWMEDIATED Vasodilationand LASER Doppler Flowmetry. György Kerekes, Vanda Pongrácz, Szilvia Szamosi, Gabriella Szücs, Andrea Váncsa, Orsolya Tímár, Zoltán Csiki, Edit Végh, Pál Soltész and Zoltan Szekanecz, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary 202. Development of Early Diagnostic Techniques for Rheumatoid Arthritis Using Carbon Eleven Labeled PK11195 and Carbon Eleven Labeled Ketoprofen. Satoshi Nozaki1, Sinobu Suzuki2, Naoko Ozaki2, Jeffrey Encinas2, Hisashi Doi1, Yasuhiro Wada1, Masaaki Suzuki1 and Yasuyoshi Watanabe1, 1RIKEN,Center for Molecular Imaging Science, Hyogo, Japan, 2Nippon Boehringer Ingelheim Co., Ltd, Hyogo, Japan 203. Pre-Clinical Bioimaging in a Mouse Model of Rheumatoid Arthritis. Michelle Ierna1, Karen Smith1, Kirsty Ross2, Gordon Meiklejohn1, Pasquale Maffia3, James M. Brewer3, Iain B. McInnes3 and Paul Garside3, 1MD Biosciences, Glasgow, United Kingdom, 2University of Strathclyde, Glasgow, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom 204. Development of Contrast Enhanced Ultrasound Imaging and Quantification of Lymphatics in Draining Lymph Nodes of WT and TNF-Tg Mice with Inflammatory Arthritis. Yawen Ju1, Ronald Wood2, Lianping Xing1, Christopher T. Ritchlin3 and Edward M. Schwarz1, 1University of Rochester, Rochester, NY, 2University of Rochester School of Medicine and Dentistry, Rochester, NY, 3University of Rochester Medical Center, Rochester, NY

205. In Vivo Profiling of the Disease-Inducible Promoters Serum Amyloid A3 and S100 Calcium Binding Protein A8 for Personalized Gene Therapy in Arthritis. Eline A. Vermeij, Onno J. Arntz, Peter L.E.M. van Lent, Wim B. van den Berg and Fons A.J. van de Loo, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 206. Molecular Imaging of Rheumatoid, Psoriatic and Osteoarthritis in the Hand. Abhijit J. Chaudhari1, Andrea Ferrero2, Felipe Godinez2, Kai Yang1, John M. Boone1, Michael H. Buonocore1, John C. Hunter1, David K. Shelton1, Rosalie Hagge1, Steven W. Falen3, Ruth D. Tesar3, Stanley M. Naguwa1, Nancy E. Lane1, Siba P. Raychaudhuri4 and Ramsey D. Badawi1, 1UC Davis School of Medicine, Sacramento, CA, 2University of California Davis, Davis, CA, 3Northern California PET Imaging Center, Sacramento, CA, 4Sacramento VA Medical Center/ UC Davis School of Medicine, Mather, CA

Metabolic and Crystal Arthropathies I: Pathogenesis, Epidemiology, and Diagnosis 207. Daily Intake of Skim Milk Powder Enriched with Glycomacropeptide and G600 Milk Fat Extract May Reduce Frequency of Gout Flares; Results From a Randomized, Controlled Trial. Nicola Dalbeth1, Ruth Ames1, Gregory Gamble1, Anne Horne1, Sumwai Wong1, Barbara KuhnSherlock2, Alastair MacGibbon2, Fiona M. McQueen1, Ian R. Reid1 and Kate Palmano2, 1University of Auckland, Auckland, New Zealand, 2Fonterra Research Centre, Palmerston North, New Zealand 208. Validation of the Measurement of Tophi with Magnetic Resonance Imaging As An Outcome Measure for Chronic Gout. Fernando Perez-Ruiz1, Aranzazu Urresola2, Diana Gorostiza3 and Begoña Canteli4, 1Hospital De Cruces, Baracaldo, Spain, 2Radiology Division. Hospital de Cruces., Baracaldo, Spain, 3Radiology Division, Hospital de Cruces, Baracaldo, Spain, 4Radiology Division. Hospital de Cruces, Baracaldo, Spain 209. Detection of Periarticular Urate Deposits with Dual Energy Computed Tomography in Patients with Acute Gouty Arthritis. Juergen Rech1, Michael Lell1, Jochen Wacker1, Georg Schett2 and Bernhard Manger1, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 210. Effects of Monosodium Urate Crystals on Chondrocyte Viability and Function; Implications for Development of Cartilage Damage in Chronic Gout. Ashika Chhana, Karen E. Callon, Bregina Pool, Dorit Naot, Gregory Gamble, Michael Dray, Fiona M. McQueen, Jillian Cornish and Nicola Dalbeth, University of Auckland, Auckland, New Zealand 211. Confirmation of Association of Urate Transporter SLC17A1 (NPT1) with Gout At a Genome-Wide Level of Significance. Tony R. Merriman1, Amanda Phipps-Green1, Murray Cadzow1, Ruth Topless1, Marilyn E. Merriman1, Gregory T. 2011 Program Book

147

ACR Poster Session A Jones1, Andre M. van Rij1, Nicola Dalbeth2, Peter J. Gow3, Andrew Harrison4, John Highton5, Peter B. B. Jones6, Lisa K. Stamp7 and Jade E. Hollis-Moffatt1, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3Middlemore Hospital, Auckland, New Zealand, 4Hutt Hospital, Lower Hutt, New Zealand, 5 Univ of Otago Med Sch, Dunedin, New Zealand, 6Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 7 University of Otago, Christchurch, Christchurch, New Zealand 212. Association with Gout of PDZK1 Variants That Influence Metabolic Traits and Serum Urate Levels. Tony R. Merriman1, Nicola Dalbeth2, Jade E. Hollis-Moffatt1, Amanda Phipps-Green1, Ruth Topless1, Marilyn E. Merriman1, Peter J. Gow3, Andrew Harrison4, John Highton5, Peter B. B. Jones6, Lisa K. Stamp7 and Sara Altaf1, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3Middlemore Hospital, Auckland, New Zealand, 4 Hutt Hospital, Lower Hutt, New Zealand, 5Univ of Otago Med Sch, Dunedin, New Zealand, 6Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 7University of Otago, Christchurch, Christchurch, New Zealand 213. Gouty Enthesopathy: An Important Pattern of Uric Acid Deposition in Difficult to Diagnose Gout. Hailong Wang1, Katrina N. Glazebrook2, Steven J. Kavros2, Clement J. Michet1, Stephen P. Merry3, Naveen S. Murthy1, Bharath Manu Akkara Veetil1, John M. Davis III1, Thomas G. Mason II4, Kenneth J. Warrington1, Nisha J. Manek1, Tanaz A. Kermani1, Deana D. Hoganson1, A. Kirstin Bacani1, Cynthia H. McCollough2 and Tim Bongartz1, 1Mayo Clinic, Rochester, MN, 2Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic Rochester, Rochester, MN 214. Serum Uric Acid Concentration and Physical Activity: the National Health and Nutrition Examination Survey 20032004. Tony Ning1, Carl Pieper2, Virginia Byers Kraus1, William E. Kraus2 and Kim M. Huffman1, 1Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 2Duke Pepper Center, Durham, NC 215. Serum Procalcitonin Could Be a Useful Serologic Marker for the Differential Diagnosis Between Acute Gouty Attack and Bacterial Infection. Sang Tae Choi and Jung-Soo Song, Chung-Ang University College of Medicine, Seoul, South Korea 216. Gout Patient Burden Associated with Flares, Tophi, and Awareness of Uric Acid Levels In US and EU. Puja Khanna1, Anne-Kathrin Tausche2, Anna Forsythe3, Amir Goren4 and Dinesh Khanna1, 1University of Michigan, Ann Arbor, MI, 2 Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, 3Savient Pharmaceuticals, Inc., East Brunswick, NJ, 4KantarHealth, New York, NY 217. Risk Factors for Incident Psuedogout in the General Population. Young Hee Rho, Yanyan Zhu, Yuqing Zhang and Hyon K. Choi, Boston University School of Medicine, Boston, MA

148

2011 Program Book

218. Is Calcium Pyrophosphate Deposition Associated with Vitamin D Deficiency? Sophia Li1, Joshua Baker1, Janet E. Dinnella1, Gilda M. Clayburne2, Joseph R. Perno2, H. Ralph Schumacher2 and Sally W. Pullman-Mooar2, 1University of Pennsylvania, Philadelphia, PA, 2VA Medical Center, Philadelphia, PA 219. Illness Perceptions Predict Disability After One Year In Patients with Gout. Nicola Dalbeth1, Keith J. Petrie1, Meaghan House1, Jimmy Chong1, Wingchi Leung1, Rini Chegudi1, Anne Horne1, Gregory Gamble1, Fiona M. McQueen1 and William J. Taylor2, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Wellington, Wellington, New Zealand 220. Association of Insuline Resistance with Renal Clearance of Uric Acid In Phenotipically Selected Males with Gout. Fernando Perez-Ruiz, Hospital De Cruces, Baracaldo, Spain 221. Impact of Acute Gout Flares on Health Related Quality of Life (HRQOL) and Productivity in Patients with Chronic Gout. Puja Khanna1, Cleopatra A. Beaton2, Jay E. Persselin3, Ronald D. Hays4, Daniel E. Furst5, Harold E. Paulus6, Robert Terkeltaub7, Paul Maranian4 and Dinesh Khanna1, 1University of Michigan, Ann Arbor, MI, 2West LA VA Medical Ctr, Los Angeles, CA, 3VA Greater LA Healthcare Sys, Los Angeles, CA, 4 University of California, Los Angeles, 5UCLA, Los Angeles, CA, 6University of California, Los Angeles, Los Angeles, CA, 7 VA Medical Ctr, San Diego, CA 222. Subjects with Gout Have a Higher Prevalence of Simple Renal Cysts Than the General Population. Eduardo M. Hasegawa1, Ricardo Fuller1, Maria Cristina Chammas2, Filipe M. Mello1 and Claudia Goldenstein-Schainberg1, 1 Rheumatology Division - University of São Paulo, São Paulo, Brazil, 2Radiology Division - University of São Paulo, São Paulo, Brazil 223. Gout Vs Hyperuricemia As Risk Factors for Coronary Artery Disease – A Pilot Study. Victoria Furer, Rennie N. G. Howard, Jonathan Samuels and Michael H. Pillinger, NYU Hospital for Joint Diseases, New York, NY

Muscle Biology, Myositis and Myopathies: New Developments in the Clinical Evaluation, Immunology and Treatment of Myositis 224. One Year Randomised Controlled Trial of SEcond Line Agents in Myositis (SELAM): Late Additional immunosuppression is Ineffective in Patients Who Have Partially Responded to Steroids. Ernest Choy1, Patrick Gordon2, Beverley White-Alao2, Fowzia Ibrahim2, Anna Kowalczyk2, Alan Hakim3, George Kitas4, David A. Isenberg5, Bridget Griffiths6, Bryan Lecky7, Kuntal Chakravarty8, John Winer9, Katalin Danko10, Robert G. Cooper11 and David L. Scott2, 1Cardiff University, Cardiff, ENGLAND, United Kingdom, 2King’s College London, London, United Kingdom, 3 Whipps Cross University Hospital, London, United Kingdom, 4 Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, West Midlands, UK, Dudley, United Kingdom, 5 University College London, London WC1E 6JF, United Kingdom, 6Freeman Hospital, Newcastle Upon Tyne, United

ACR Poster Session A Kingdom, 7Walton Centre for Neurology and Neurosurgery (WCNN), Liverpool, 8Queen’s Hospital/BHR NHS Trust, Romford, United Kingdom, 9The Queen Elizabeth Hospital, Birmingham, United Kingdom, 10University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, 11Hope Hospital, Salford, United Kingdom 225. Clinical Features and Treatment of Dermatomyositis Patients with Anti-CADM-140 (melanoma differentiationassociated protein 5: MDA5) Antibody; Recommendation of Combined Immunosuppressive Therapy with Intensive Intravenous Cyclophosphamide. Ran Nakashima, Yuji Hosono, Naoichiro Yukawa, Hajime Yoshifuji, Daisuke Kawabata, Koichiro Ohmura, Takashi Usui, Takao Fujii and Tsuneyo Mimori, Kyoto University Graduate School of Medicine, Kyoto, Japan 226. Anti-CADM-140 Autoantibody Titer Correlates with Disease Activity in Patients with Dermatomyositis and Rapidly Progressive Interstitial Lung Disease. Shinji Sato1, Masataka Kuwana2, Takashi Fujita3 and Yasuo Suzuki1, 1Tokai University School of Medicine, Isehara, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Institute for Virus Research and Graduate School of Biostudies, Kyoto University, Kyoto, Japan 227. Anti-CADM-140 Antibody, Ferritin and IL-18 Are Associated with Disease Activity of Interstitial Lung Disease in AntiCADM-140 Antibody-Positive Dermatomyositis. Takahisa Gono1, Shinji Sato2, Yasushi Kawaguchi1, Masataka Kuwana3, Yasuhiro Katsumata1, Masanori Hanaoka1, Kae Takagi1, Hisae Ichida1, Sayumi Baba1, Yuko Okamoto1, Yuko Ota1, Sayuri Kataoka1 and Hisashi Yamanaka1, 1Tokyo Women’s Medical University, Tokyo, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Keio University School of Medicine, Tokyo, Japan 228. Transcription Intermediary Factor (TIF)-1β Is a New Dermatomyositis Autoantigen. Minoru Satoh1, Jason Y.F. Chan1, Steven J. Ross1, Angela Ceribelli1, Yi Li1, Yoshioki Yamasaki2, Hidehiro Yamada2, Monica Vazquez-Del Mercado3, Marcelo Petri4, Eric S. Sobel1, Westley H. Reeves1 and Edward K.L. Chan1, 1University of Florida, Gainesville, FL, 2St. Marianna University, Kawasaki, Japan, 3Univ de Guadalajara, CUCS, Guadalajara, Mexico, 4Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Mexico 229. Clinical Features and Survival in Anti-PL-7 Autoantibody Positive Myositis Patients From a Single Tertiary Care Center. Arcadio Agudelo-Hernandez1, Chester V. Oddis2, Noreen Fertig2, Diane Koontz2 and Rohit Aggarwal1, 1 University of Pittsburgh Medical Center, Pittsburgh, PA, 2 University of Pittsburgh, Pittsburgh, PA 230. The Clinical Spectrum but Not the Evolution of Antisynthetase Syndrome Is Related to the Antisynthetase Antibody Specificity: A Retrospective Analysis of 142 Patients. Baptiste Hervier1, Hervé Devilliers2, Raluca Stanciu1, Eric Hachulla3, Yurdagul Uzunhan4, Bruno Wallaert5, Bruno Fautrel6, Bernard Fournie7, Lucile Musset8,

Aude Rigolet1, Hilario Nunes4, Patrice Cacoub8, Daniel F. P. Adoue9, Zahir Amoura8, Mohamed Hamidou10 and Olivier Benveniste11, 1Pitie-Salpetriere Hospital, APHP, UPMC Paris VI, Paris, France, 2CHU Dijon, Dijon, France, 3Internal Medicine, Lille CEDEX, France, 4Hopital Avicenne, APHP, Bobigny, France, 5CHRU, Lille CEDEX, France, 6Université Pierre et Marie Curie - Paris 6 - Pitie Salpetriere University Hospital, Paris, France, 7CHU, Toulouse, France, 8CHU Pitié-Salpêtrière, Paris, France, 9CHU Toulouse Purpan, Toulouse, France, 10Service de médecine interne, Hôpital Universitaire de Nantes, Nantes, France, Nantes, France, 11 Pitie-Salpetriere Hospital, Paris, France 231. Anti-MJ/NXP-2 Antibodies Are the Most Common Specificity in a Cohort of Adult Caucasian Patients with Dermatomyositis. Angela Ceribelli1, Micaela Fredi2, Mara Taraborelli2, Ilaria Cavazzana3, Franco Franceschini4, Angela Tincani5, Steven J. Ross1, Brad A. Pauley1, Edward K.L. Chan1 and Minoru Satoh1, 1University of Florida, Gainesville, FL, 2University of Brescia and Spedali Civili, Brescia, Italy, 3Rheumatology Unit, University of Brescia, Brescia, Italy, Brescia, Italy, 4University of Brescia, Brescia, Italy, 5 Rheumathology Unit, University of Brescia, Brescia, Italy, Brescia, Italy 232. Distinctive Pattern of Myositis-Specific Autoantibody Production Between American Caucasian and Italian Patients with Polymyositis/Dermatomyositis. Angela Ceribelli1, Yi Li1, Ilaria Cavazzana2, Franco Franceschini2, Steven J. Ross1, Jason Y.F. Chan1, Brad A. Pauley1, Eric S. Sobel1, Westley H. Reeves1, Edward K.L. Chan1 and Minoru Satoh1, 1University of Florida, Gainesville, FL, 2University of Brescia, Brescia, Italy 233. Persisting CD28null T Cells, but Not Regulatory T Cells, in Muscle Tissue of Myositis Patients After Immunosuppressive Therapy. Ingela M. Loell, Jayesh Pandya, Sukanya Raghavan, Mei Zong, Vivianne Malmström and Ingrid E. Lundberg, Karolinska Institutet, Stockholm, Sweden 234. Proposal for the Development of An International Minimal Data Collection for Juvenile Dermatomyositis. Liza J. McCann1, Clarissa A. Pilkington2, L. Beard3, Angelo Ravelli4, Adam Huber5 and Lucy R. Wedderburn6, 1Alder Hey Children’s NHS Foundation Hospital, Liverpool, United Kingdom, 2Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 3UCL Institute of Child Health, London, United Kingdom, 4G. Gaslini Institute, Genova, Italy, 5IWK Health Centre, Halifax, NS, 6University College London (UCL), London, United Kingdom 235. Ethnic but not Gender Differences in Disease Manifestations in Dermatomyositis Patients. Anna Tjärnlund1, Lisa G. Rider2, Frederick W. Miller2, Victoria P. Werth3, Clarissa A. Pilkington4, Marianne de Visser5, Elin Forslund1, Anthony A. Amato6, Richard J. Barohn7, Matteo Bottai8, Richard Finkel9, Harold E. Paulus10, 2011 Program Book

149

ACR Poster Session A Gerald J. D. Hengstman11, Matthew H. Liang12, Jasvinder Singh13 and Ingrid E. Lundberg1, 1Karolinska Institutet, Stockholm, Sweden, 2National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, 4Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 5Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, 6Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 7Department of Neurology, University of Kansas Medical Center, Kansas City, MO, 8Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 9Department of Neurology, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, 10University of California, Los Angeles, Los Angeles, CA, 11Department of Neurology, Catharina-ziekenhuis, Eindhoven, Netherlands, 12Brigham & Womens Hospital, Boston, MA, 13University of Alabama and VA Medical Center, Birmingham, AL 236. Initial Predictors of Poor Survival in Patients with Dermatomyositis and Interstitial Lung Disease. Masataka Kuwana1, Shinji Sato2, Yuichiro Shirai1, Tsutomu Takeuchi1 and Takashi Fujita3, 1Keio University School of Medicine, Tokyo, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Institute for Virus Research and Graduate School of Biostudies, Kyoto University, Kyoto, Japan 237. Prevalence of Pulmonary Hypertension in Inflammatory Myopathies. Ashwini Mhatre, James Bena and Soumya Chatterjee, Cleveland Clinic, Cleveland, OH 238. Pulmonary Hypertension in Inflammatory Myopathies: Demographic and Clinical Characteristics. Ashwini Mhatre, James Bena and Soumya Chatterjee, Cleveland Clinic, Cleveland, OH 239. Cancer Associated Myositis: Temporal Relationship, Survival and Risk of Cancer Recurrence. Results From a Large Historical Cohort in United States of America. Christian A. Waimann, Kelechukwu A. Olejeme, Jean H. Tayar, Xiudong Lei and Maria E. Suarez-Almazor, University of Texas. M.D Anderson Cancer Center, Houston, TX 240. Defining Clinically Relevant Changes in Core Set Activity Measures for Adult and Juvenile Idiopathic Inflammatory Myopathies (IIM). Lisa G. Rider1, Julia A. Lee2, Anna V. Jansen2, Nicola Ruperto3, Adam M. Huber4, Chester V. Oddis5, Brian M. Feldman6, Peter A. Lachenbruch7, Rohit Aggarwal8, Frederick W. Miller2 and IMACS and PRINTO9, 1 NIEHS NIH, Bethesda, MD, 2NIEHS, NIH, Bethesda, MD, 3 PRINTO-IRCCS, Genova, Italy, 4Dalhousie University, Halifax, NS, 5University of Pittsburgh, Pittsburgh, PA, 6The Hospital for Sick Children, Toronto, ON, 7Corvallis, OR, 8University of Pittsburgh Medical Center, Pittsburgh, PA, 9Bethesda

150

2011 Program Book

241. Fatigue In IDIOPATHIC Inflammatory Myopathy (IIM): Prevalence, IMPACT and ASSOCIATION with QUALITY of LIFE. Richard CJ Campbell1, David L. Scott1, Patrick D. Kiely2 and Patrick Gordon1, 1King’s College London, London, United Kingdom, 2St. Georges Hospital, London, United Kingdom 242. Fatigue In Idiopathic Inflammatory Myopathies (IIM) Is Not Caused by Peripheral Muscle Fatigability: Studies of NonVolitional Quadriceps Muscle Endurance Using Repetitive Transcutaneous Stimulation. Richard CJ Campbell, Ged Rafferty, David L. Scott, Charles Rielly, Katie Ward and Patrick Gordon, King’s College London, London, United Kingdom 243. Predictors of Experienced Fatigue in Idiopathic Inflammatory Myopathy (IIM): Psychological Factors and Pain Are More Predictive Than Disease Activity, Damage or Strength. Richard CJ Campbell1, David L. Scott1, Patrick D. Kiely2 and Patrick Gordon1, 1King’s College London, London, United Kingdom, 2St. Georges Hospital, London, United Kingdom 244. International Classification of Diseases-Clinical Modification-9 Codes for the Diagnosis of Dermatomyositis and Polymyositis in Discharge Summaries: Evidence of Acceptable Validity. Neera Narang1, David Fiorentino2, Eswar Krishnan3 and Lorinda Chung4, 1Stanford Univ Medical Center, Stanford, CA, 2Stanford, Stanford, CA, 3Stanford University, Stanford, CA, 4Stanford Univ Medical Center, Palo Alto, CA 245. Body Mass Index At Diagnosis Affects Disease Course In Juvenile Dermatomyositis. Anjali Patwardhan1, Gloria Higgins2, Charles H. Spencer1 and Robert M. Rennebohm3, 1 Nationwide Childrens Hospital, Columbus, OH, 2PRCSG, Columbus, OH, 3Columbus Childrens Hospital, Columbus, OH 246. Juvenile Dermatomyositis Is a Different Disease In Children up to Three Years of Age At Onset Than In Children Above Three Years At Onset. Anjali Patwardhan1, Charles H. Spencer1, Gloria Higgins2 and Robert M. Rennebohm3, 1Nationwide Childrens Hospital, Columbus, OH, 2NATIONWIDE CHILDRENS HOSPITAL, Columbus, OH, 3 Columbus Childrens Hospital, Columbus, OH 247. Comparison of Untreated Adult and Juvenile Dermatomyositis Muscle Biopsies: Difference of Inflammatory Cells Phenotyping. Samuel K. Shinjo1, Adriana M. Sallum2, Clovis A. Silva1 and Suely K. N. Marie3, 1 Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo-SP, Brazil, 3 Faculdade de Medicina da Universidade de São Paulo (FMUSP)., São Paulo, Brazil 248. Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association with Clinical Parameters. Adrienne Prestridge1, Gabrielle Morgan1, Deli Wang2 and Lauren M. Pachman3, 1Children’s Memorial Hospital, Chicago, IL, 2 Northwestern University’s Feinberg School of Medicine, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL

ACR Poster Session A 249. Increased Depression and Anxiety Symptoms in a Group of Dermatomyositis Patients. Elizabeth Ghazi1, Mitchel A. Kling2, Kathleen Propert3, Joyce Okawa4 and Victoria P. Werth4, 1UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ, 2Philadelphia Veterans Affairs Medical Center and University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA 250. R577X Alpha-Actinin 3 (ACTN3) polymorphism Is Associated with Inflammatory Myopathies in Mexican Population. Flavio Sandoval- Garcia1, Marcelo Petri2, Miguel A. Saavedra3, Claudia Cruz-Reyes4, Luis Jara-Quezada3, Ingrid Dávalos5, Mario Salazar-Páramo6, Ivan Gámez-Nava7, Laura Gonzalez-Lopez8, Trinidad García-Iglesias9, Esther CoronaSánchez10, Soraya Zavaleta-Muñiz11, Raúl Vargas-Ramírez10, Jorge Aguilar Arreola12, Monica Vázquez-Del Mercado11 and Beatriz T. Martín-Márquez13, 1Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, 2Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, 3Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., México D.F., Mexico, 4 Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., Mexico D. F., Mexico, 5Departamento de Biologia Molecular y Genomica, Instituto de Genetica Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, 6Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, 7Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, México., Mexico, 8Hospital Regional de Zona 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, Guadalajara, Jalisco, Mexico, Mexico, 9Laboratorio de Inmunología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, 10Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, 11Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, 12Hospital Civil JIM, 13Universidad de Guadalajara, Gudalajara, Jalisco, México, Mexico 251. Incidence and Prevalence of Idiopathic Inflammatory Myopathies in South Australia: A 30-Year Epidemiologic Study of Biopsy-Proven Cases. Ju Ann Tan1, Peter J. RobertsThomson2, Peter Blumbergs3, Paul Hakendorf4, Sally R. Cox1 and Vidya Limaye5, 1SA Pathology / Flinders Medical Centre, Adelaide, Australia, 2Flinders Medical Centre, Adelaide, Australia, 3Institute of Medical and Veterinary Sciences, Adelaide, Australia, 4Flinders University, Adelaide, Australia, 5 Royal Adelaide Hospital, Adelaide, Australia 252. Epigenetic Control of Muscle Repair Identified in Inflamed Muscle Biopsies From Untreated Juvenile Dermatomyositis. Min Wang1, Hehuang Xie1, Peter Hendrickson1, Sheela Shrestha1, Simone Treiger Sredni2,

Gabrielle Morgan1 and Lauren M. Pachman2, 1Children’s Memorial Hospital, Chicago, IL, 2Northwestern University Feinberg School of Medicine, Chicago, IL 253. Gene Expression In Affected Muscle of Patients with Polymyalgia Rheumatica and Matched Control Subjects Before and After Short-Term Prednisolone Treatment. Frederik Kreiner1, Rehannah Borup1, Peter Schjerling2, Finn Cilius Nielsen1 and Henrik Galbo1, 1Rigshospitalet, Copenhagen, Denmark, 2Bispebjerg Hospital, Copenhagen, Denmark

Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis 254. Ultrasound and Plasma Osteopontin Improve the Assessment of Remission in Oligoarticular Juvenile Idiopathic Arthritis. Miriam F. Parsa1, Ornella J. Rullo1, Jennifer M.P. Woo1, David Elashoff2, Tina Cunningham2, Veena K. Ranganath2, Kambiz Motamedi2, Deborah K. McCurdy1 and Harold E. Paulus2, 1Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA, 2 University of California, Los Angeles, Los Angeles, CA 255. Measurement of Methotrexate Metabolites in Peripheral Blood Mononuclear Cells in Juvenile Idiopathic Arthritis: A More Relevant Cellular Biomarker for Drug Response? Leon van Haandel, J. Steven Leeder and ML Becker, Children’s Mercy Hospital, Kansas City, MO 256. Malignancy and JIA: Updated Results. Sasha Bernatsky1, Kiem Oen2, Ciaran M. Duffy3, Alan M. Rosenberg4, Emily von Scheven5, Kathleen M. O’Neil6, Laura E. Schanberg7, Rosalind Ramsey-Goldman8, Jeremy Labrecque1, Elizabeth M. Turnbull9, Jennifer LF Lee1 and Ann E. Clarke1, 1McGill UHC/RVH, Montreal, QC, 2University of Manitoba, Winnipeg, MB, 3Children’s Hospital of Eastern Ontario, Ottawa, ON, 4 Royal University Hospital, Saskatoon, SK, 5UC San Francisco, San Francisco, CA, 6Okla Univ Health Science Ctr, Oklahoma City, OK, 7Duke University Medical Center, Durham, NC, 8 Northwestern University, Chicago, IL, 9McGill UHC/RVH, QC 257. Predictors of Disability in Children with Inflammatory Arthritis, Two and Three Years After First Presentation to Paediatric Rheumatology. Results From the Childhood Arthritis Prospective Study (CAPS). Roberto Carrasco1, Joanna Cobb1, Eileen M. Baildam2, Helen Foster3, Janet Gardner-Medwin4, Alice Chieng5, Lucy R. Wedderburn6, Joyce Davidson7, Kimme L. Hyrich1, CAPS Study8 and Wendy Thomson1, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2 Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom, 3Newcastle Hospitals NHS Trust, Newcastle, United Kingdom, 4Royal Hospital for Sick Children, Yorkhill Hospital, University of Glasgow, Glasgow, United Kingdom, 5 Manchester Children’s Hospital, Manchester, United Kingdom, 6University College London (UCL), London, United Kingdom, 7Greater Glasgow and Clyde Health Board and Royal Hospital for Sick Children, Glasgow, United Kingdom, 8 Manchester 2011 Program Book

151

ACR Poster Session A 258. Etanercept in Juvenile Idiopathic Arthritis: Who Will Benefit? Results From the Dutch ABC Register. Marieke H. Otten1, Femke H.M. Prince1, Wineke Armbrust2, Rebecca Ten Cate3, Esther P.A.H. Hoppenreijs4, Marinka Twilt1, Yvonne Koopman-Keemink5, Simone L. Gorter6, Koert M. Dolman7, Joost F. Swart8, J. Merlijn Van den Berg9, Nico M. Wulffraat8, Marion A.J. Van Rossum10 and Lisette W.A. Van SuijlekomSmit1, 1ErasmusMC Sophia Children’s Hospital, Rotterdam, Netherlands, 2Beatrix Children’s Hospital, University Medical Centre Groningen, Groningen, Netherlands, 3 Leiden University Medical Centre, Leiden, Netherlands, 4 St Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Hagaziekenhuis Juliana Children’s Hospital, Den Haag, Netherlands, 6 University Hospital Maastricht, Maastricht, Netherlands, 7 St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, 8University Medical Center Utrecht, Utrecht, Netherlands, 9Emma Children’s Hospital/ Academic Medical Centre and Reade Institute, Amsterdam, Netherlands, 10 Emma Children’s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands 259. Impact of Juvenile Idiopathic Arthritis on Parents’ Work Absences. Rafia Rasu1, Stephanie E. Kirbach2, Oscar Hayes2, Walter A. Bawa1 and Mary A. Cifaldi2, 1University of Missouri-Kansas City, Kansas City, 2Abbott Laboratories, Abbott Park, IL 260. Long-Term Safety of Etanercept Compared to Methotrexate and Combinations in Children with Juvenile Idiopathic Arthritis – Data of the German BIKER-Registry. Gerd Horneff1, Stephanie Bischof1 and German BIKER Registry collaborative group2, 1Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Sankt Augustin 261. Physician Versus Parent/Patient Assessment of Disease Activity in a Large Cohort of Patients with Juvenile Idiopathic Arthritis. Caitlin M. Sgarlat, Christina F. Pelajo, Jorge M. Lopez-Benitez and Laurie C. Miller, Tufts Medical Center, Boston, MA 262. Psoriasis in a First-Degree Relative As An Exclusion Criterion Contributes to Classification of Children As Having Undifferentiated Juvenile Idiopathic Arthritis. Mercedes O. Chan1, Jaime Guzman2 and Ross E. Petty3, 1BC Children’s Hospital/University of British Columbia, Vancouver, BC, 2BC Children’s Hospital, Vancouver, BC, 3BCs Children Hosptial, Vancouver, BC 263. PD-L1 in Systemic Juvenile Idiopathic Arthritis. Susan Shenoi1, Jing-Ni Ou1, Claudia Macaubas2, Elizabeth D. Mellins2, Carol Wallace1 and Anne M. Stevens1, 1Seattle Children’s Hospital, University of Washington, Seattle, WA, 2 Stanford University Med Ctr, Stanford, CA 264. Application and Examination of the Key Clinical Parameters From the 2011 ACR Recommendations for the Treatment of JIA Using Electronic Medical Record-Derived Data From a Clinical Cohort. Michael L. Miller1, Timothy Beukelman2, George Lales1, Sean McKenna1, Jason Ruprecht1, Megan L.

152

2011 Program Book

Curran1 and Marisa S. Klein-Gitelman1, 1Children’s Memorial Hospital, Chicago, IL, 2Univ of Alabama-Birmingham, Birmingham, AL 265. Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis. Daniel J. Lovell1, Nicolino Ruperto2, Andreas Reiff3, Lawrence K. Jung3, Gloria Higgins3, Isabelle Koné-Paut2, Olcay Y. Jones3, Melissa J. McIlraith4, Nupun Andhivarothai5, Hartmut Kupper6, Edward H. Giannini3, Theresa Peterson5 and Alberto Martini2, 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2PRINTO-IRCCS, Genova, Italy, 3PRCSGCincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Abbott, Rungis, France, 5Abbott, Abbott Park, IL, 6 Abbott, Ludwigshafen, Germany 266. Effectiveness of Nonsteroidal Antiinflammatory Drug Monotherapy in Children with Systemic Juvenile Idiopathic Arthritis. Meredith P. Riebschleger, Jasmine Stannard, Matthew M. Davis, Sarah J. Clark and Barbara S. Adams, University of Michigan Health System, Ann Arbor, MI 267. Can Long-Term Use of Tocilizumab Induce Drug-Free Remission in Systemic Juvenile Idiopathic Arhtritis Refractory to Steroid Therapy? Tomohiro Kubota1, Yuichi Yamasaki1, Junko Yasumura2, Naomi Kuwada3, Yukiko Nonaka1, Tomoko Takezaki1, Harumi Akaike1, Yasuhito Nerome1, Hiroyuki Imanaka1 and Syuji Takei1, 1Kagoshima University, Kagoshima City, Japan, 2Hiroshima University, Hiroshima City, Japan, 3Kumamoto University, Kumamoto City, Japan 268. Radiological Cervical Spine Involvement In Polyarticular Idiopathic Juvenile Arthritis. Muriel Elhai1, Ramin Bazeli2, Veronique Freire2, Antoine Feydy2, Andre Kahan1, Chantal Job-Deslandre1 and Julien Wipff1, 1Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, 2Radiology B, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France 269. Use of Intra–Articular Steroid Injection in a Large Cohort of Children with Oligoarticular Juvenile Idiopathic Arthritis - the ReACCh Out Study. Julie Barsalou1, Ronald M. Laxer2, Lori B. Tucker3, Rae SM Yeung4, Kiem Oen5, Ciaran M. Duffy6 and ReACCh Out Study Group7, 1Montreal Children’s Hospital, McGill University, Montreal, QC, 2The Hospital for Sick Children, Toronto, ON, 3BC Childrens Hospital, Vancouver, BC, 4Hospital for Sick Children, Toronto, ON, 5 University of Manitoba, Winnipeg, MB, 6Children’s Hospital of Eastern Ontario, Ottawa, ON, 7Ottawa 270. Perception of Health Status in Young Adult Patients with Juvenile Idiopatic Arthritis: It’s Good to Be Better but it’s Better to Be Good. Elisa Gremese, Graziella D’Antona, Laura Messuti, Luca Petricca, Maria Rita Gigante and Gianfranco Ferraccioli, Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy

ACR Poster Session A 271. Race and Other Risk Markers in Juvenile Idiopathic Arthritis-Associated Uveitis. Sheila Angeles-Han1, Christina Pelajo2, Larry B. Vogler1, Christine W. Kennedy3, Lori Ponder3, Traci Leong4, Jorge M. Lopez-Benitez2, Carolyn Drews-Botsch4, Sampath Prahalad1 and for the CARRAnet investigators5, 1Emory Univ School of Medicine, Atlanta, GA, 2 Tufts Medical Center, Boston, MA, 3Emory Children’s Center, Atlanta, GA, 4Emory University School of Public Health, Atlanta, GA, 5Stanford 272. A Meta-Analysis to Estimate the “Real” Placebo Effect in Juvenile Idiopathic Arthritis (Jia) Trials. Erkan Demirkaya1, Roberta Galasso1, Angelo Ravelli2, Elena Palmisani1, Alberto Martini2, Angela Pistorio3 and Nicolino Ruperto1, 1 IRCCS G Gaslini, Pediatria II, Reumatologia, PRINTO, Genova, Italy, 2IRCCS G. Gaslini, Pediatria II, Reumatologia and Dipartimento di Pediatria, Università degli Studi, Genova, Italy, 3IRCCS G Gaslini, Servizio di Epidemiologia e Biostatistica, Genova, Italy 273. Long-Term Follow-up of Systemic Onset Juvenile Idiopathic Arthritis Patients Treated with Anakinra. Aldo Naselli1, Andrea Accogli1, Sabrina Chiesa1, Jessica Tebaldi1, Martina Finetti2, Antonella Buoncompagni1, Stefania Viola1, Paolo Picco1, Angelo Ravelli3, Alberto Martini2 and Marco Gattorno1, 1G. Gaslini Institute, Genova, Italy, 2IRCCS G Gaslini, Pediatria II, Reumatologia, Genova, Italy, 3Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy 274. Effects of Switching From Etanercept to Adalimumab in Juvenile Idiopathic Arthritis. Gerd Horneff1, Ivan Foeldvari2, Gerd Ganser3, Johannes Peter Haas4, Kirsten Minden5 and Hans-Iko Huppertz6, 1Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, 3Sankt Josef Stift, Sendenhorst, Germany, 4Childrens Hospital, Erlangen, Germany, 5Charite, Berlin, Germany, 6Krinikum BremenMitte, Bremen, Germany 275. Clinical and Ultrasound Outcomes of Ultrasound-Guided Ankle Injection In Juvenile Idiopathic Arthritis; An Analysis of Current Clinical Practice. Eimear Savage1, Laura Pascoli1 and Madeleine Rooney2, 1Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, 2Arthritis Research Group, Queen’s University, Belfast, United Kingdom 276. Parent and Patient Treatment Preferences in Juvenile Idiopathic Arthritis. Gina A. Montealegre Sanchez1, Kabita Nanda1, Steven J. Spalding2, Elizabeth B. Brooks1, Angela B. Robinson1, Nellie K. Coughlin1, Andrew S. Zeft2, Denise Costanzo2, Hulya Bukulmez3, Joseph Sudano3 and Nora G. Singer4, 1Case Medical Center, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3MetroHealth Medical Center (MHMC) and Case SOM, Cleveland, OH, 4Case Medical Center, MetroHealth Medical Center (MHMC) and Case SOM, Cleveland, OH

277. Intra-Articular Infliximab Treatment of Refractory TMJ Arthritis in Children with JIA. Randy Q. Cron1 and Peter D. Waite2, 1Univ of Alabama-Birmingham, Birmingham, AL, 2 Birmingham, AL 278. Utilization of Biologic and Non-Biologic Disease Modifying Anti-Rheumatic Drugs in the Treatment of Juvenile Idiopathic Arthritis: A Cross-Sectional Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Timothy Beukelman1, Sarah Ringold2, Trevor Davis3, Esi M. Morgan DeWitt4, Christina F. Pelajo5, Pamela Weiss6, Yukiko Kimura7 and for the CARRAnet investigators, 1Univ of Alabama-Birmingham, Birmingham, AL, 2Children’s Hosp Regional Med, Seattle, WA, 3Floating Hospital for Children at Tufts Medical Center, Boston, MA, 4Cincinnati Children’s Hospital, Cincinnati, OH, 5Tufts Medical Center, Boston, MA, 6The Children’s Hosp of Philade, Philadelphia, PA, 7 Hackensack Univ Medical Ctr, Hackensack, NJ 279. Health Related Quality of Life and Psychosocial Developmental Trajectory in Young Female Beneficiaries with Juvenile Idiopathic Arthritis. Lotte Haverman1, Eefje J.A. Verhoof1, Heleen Maurice-Stam1, Hugo S.A. Heymans1, D. Gerlag2, Marion A. J. Van Rossum1 and Martha A. Grootenhuis1, 1Emma Children’s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 2Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 280. Enthesitis Is a Significant Predictor of Decreased Quality of Life, Function, and Arthritis-Specific Pain Across Juvenile Idiopathic Arthritis (JIA) Categories: Preliminary Analyses From the CARRAnet Registry. Pamela Weiss1, Timothy Beukelman2, Laura E. Schanberg3, Yukiko Kimura4, Robert A. Colbert5 and CARRANet Investigators6, 1The Children’s Hospital of Philadelphia, Philadelphia, PA, 2Univ of Alabama-Birmingham, Birmingham, AL, 3Duke University Medical Center, Durham, NC, 4Hackensack Univ Medical Ctr, Hackensack, NJ, 5NIAMS NIH, Bethesda, MD, 6Stanford 281. A Cross Sectional Study of Juvenile Idiopathic Arthritis in African American Children Compared with NonHispanic White Children in the Childhood Arthritis and Rheumatology Research Alliance Registry. Sampath Prahalad1, Sheila Angeles-Han1, Christina F. Pelajo2, Christine W. Kennedy1, Lori Ponder1, Jorge M. Lopez-Benitez2, Larry B. Vogler1 and CARRANet Investigators3, 1Emory University School of Medicine, Atlanta, GA, 2Tufts Medical Center, Boston, MA, 3Stanford 282. Development of Consensus Treatment Plans for NewOnset Systemic Juvenile Idiopathic Arthritis. Esi Morgan DeWitt1, Timothy Beukelman2, Peter A. Nigrovic3, Karen Onel4, Sampath Prahalad5, Rayfel Schneider6, Matthew Stoll7, Norman T. Ilowite8, Carol A. Wallace9 and Yukiko Kimura10, 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Univ of Alabama-Birmingham, Birmingham, AL, 3Brigham and Women’s Hospital, Boston, MA, 4University of Chicago, Chicago, IL, 5Emory Children’s Center, Atlanta, 2011 Program Book

153

ACR Poster Session A GA, 6Hospital for Sick Children, University of Toronto, Toronto, ON, 7UT Southwestern Medical Center, Dallas, TX, 8 Children’s Hospital Montefiore, Bronx, NY, 9Childrens Hosp & Regional Med, Seattle, WA, 10Hackensack Univ Medical Ctr, Hackensack, NJ 283. Juvenile Idiopathic Arthritis (Jia) Affected Sibling Pairs Present High Correlation for ANA and ILAR Category. Giovanni Filocamo, Clara Malattia, Ivan Foeldvari, Valda Stanevicha, Susan Nielsen, Troels Herlin, Chris Pruunsild, Francesco Zulian, Zsolt Balogh, Frank Dressler, Ingrida Rumba, Maria Giannina Alpigiani, Elisabetta Cortis, Fernanda Falcini, Ralf Trauzeddel, Giuseppina Calcagno, Loredana Lepore, Maria Alessio, David Glass, Susan Thompson, Alberto Martini and Nicolino Ruperto, IRCCS G Gaslini, Pediatria II, PRINTO, Genova, Italy 284. How Important Is Early Magnetic Resonance Imaging of the Temporomandibular Joint for the Treatment of Children with Juvenile Idiopathic Arthritis? Rotraud K. Saurenmann1, Raphael Hauser1, Silke Schroeder1, Elvira Cannizzaro1, Lukas Muller2 and C.J. Kellenberger1, 1University Children’s Hospital, Zurich, Switzerland, 2Center for dental, oral and maxillofacial diseases, Zurich, Switzerland 285. Clinical and Immunological Effects of Etanercept on Juvenile Idiopathic Arthritis in China. Caifeng Li, Xiaohua Tan, Xiaohu He, Weiying Kuang, Yifang Zhou, Jiang Wang, Tongxin Han, Junmei Zhang, Jing Gao and Chao Li, Beijing Children’s Hospital affiliated to Capital Medical University, Beijing, China 286. Effectiveness and Safety of Switching Between Biologics in Juvenile Idiopathic Arthritis; Results From the Dutch ABC Register. Marieke H. Otten1, Femke H.M. Prince2, Janneke Anink1, Marion A. J. Van Rossum3, Esther P.A.H. Hoppenreijs4, Simone L. Gorter5, Wineke Armbrust6, Koert M. Dolman7, Yvonne Koopman-Keemink8, Joost F. Swart9, J. Merlijn Van den Berg10, Nico M. Wulffraat9, Rebecca Ten Cate11 and Lisette W.A. Van Suijlekom-Smit12, 1 ErasmusMC Sophia Children’s Hospital, Rotterdam, Netherlands, 2Brigham and Women’s Hospital, Boston, MA, 3Emma Children’s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 4St Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5University Hospital Maastricht, Maastricht, Netherlands, 6Beatrix Children’s Hospital, University Medical Centre Groningen, Groningen, Netherlands, 7St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, 8Hagaziekenhuis Juliana Children’s Hospital, Den Haag, Netherlands, 9University Medical Center Utrecht, Utrecht, Netherlands, 10Emma Children’s Hospital/ Academic Medical Centre and Reade Institute, Amsterdam, Netherlands, 11Leiden University Medical Center, Leiden, Netherlands, 12ErasmusMC Sophia Childrens Hospital, Rotterdam, Netherlands

154

2011 Program Book

287. Evaluation of Rheumatoid Factor Isotype Levels and AntiCyclic Citrullinated Peptide Antibody Isotype Levels in Juvenile Idiopathic Arthritis Patients At Baseline and PostTreatment. Brooke E. Gilliam1, Reema H. Syed1 and Terry L. Moore2, 1Saint Louis University, St. Louis, MO, 2Saint Louis University, Saint Louis, MO 288. Current Evidence of Methotrexate Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis. Gabriele Simonini1, Priyamvada Paudyal2, Gareth T. Jones2, Rolando Cimaz1 and Gary J. Macfarlane2, 1Anna Meyer Children’s Hospital, Florence, Italy, 2University of Aberdeen, Aberdeen, United Kingdom 289. Characteristics of Anti-Cyclic Citrullinated Peptide Antibody and/or Rheumatoid Factor Positive Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Alliance Registry. Sampath Prahalad1, Sheila Angeles-Han1, Lori Ponder1, Christine W. Kennedy1, Larry B. Vogler1 and CARRANet Investigators2, 1Emory Children’s Center, Atlanta, GA, 2Stanford 290. Investigating children’s beliefs about Juvenile Arthritis: A Study Using Cognitive Interviewing. Daniela Ghio1, Wendy Thomson2, Eileen M. Baildam3, Kimme Hyrich2, Michael W. Beresford3, Carol Lydon4, Olivia Lloyd3, Gavin Cleary3, Liza J. McCann5, Childhood Arthritis Prospective Study (CAPS)6, Fiona Ulph1 and Lis Cordingley7, 1School of Psychological Sciences, University of Manchester, United Kingdom, 2 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom, 4 Alder Hey, Liverpool, United Kingdom, 5Alder Hey Children’s NHS Foundation Hospital, Liverpool, United Kingdom, 6 Manchester, United Kingdom, 7School of Community Based Medicine, University of Manchester, Manchester, United Kingdom 291. The Impact of ANA Titer Levels on Risk of Uveitis Development in Juvenile Idiopathic Arthritis. Meghan J. Ho1, Rotraud K. Saurenmann2, Pascal N. Tyrrell3 and Susanne M. Benseler3, 1University of Toronto, Toronto, ON, 2 University Children’s Hospital, Zurich, Switzerland, 3The Hospital for Sick Children, Toronto, ON 292. SAFETY and Efficacy of Tocilizumab TREATMENT In CHILDREN with Systemic Juvenile IDIOPATHIC Arthritis. Ekaterina Alexeeva, Rina Denisova, Saniya Valieva, Tatyana Bzarova, Kseniya Isayeva, Tatyana Sleptsova and Elena Mitenko, Scientific Center of Children’s Health, Moscow, Russia 293. Evaluation of the Association Between Ethnicity and Disease Activity and Severity in a Large Cohort of Patients with Juvenile Idiopathic Arthritis. Christina F. Pelajo1, Sheila Angeles-Han2, Sampath Prahalad3, Caitlin M. Sgarlat1, Trevor Davis1, Laurie C. Miller1 and Jorge M. Lopez-Benitez1, 1 Floating Hospital for Children at Tufts Medical Center, Boston, MA, 2Emory University, Atlanta, GA, 3Emory Children’s Center, Atlanta, GA

ACR Poster Session A Pediatric Rheumatology - Pathogenesis and Genetics 294. Gene Expression Profiling Reveals Dysregulation of Innate Immune Genes in Synovial Fluid Mononuclear Cells of Patients with Enthesitis Related Arthritis. Amita Aggarwal1, Arpita Myles2 and Amit Tuteja3, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India, 3The center for Genomic applications, New Delhi, India 295. KIR-HLA Gene Combinations in JIA-Associated Uveitis. Miriam F. Parsa1, Deborah K. McCurdy1, Ornella J. Rullo1, Jennifer M.P. Woo1, Tina Cunningham2, Jennifer Thorne3, Ralph D. Levinson4, Raja Rajalingam2 and Gary N. Holland4, 1 Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, CA, 3Johns Hopkins University, Baltimore, MD, 4Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA 296. Antigenic Targets and Pathogenicity of Anti-Endothelial Cell Antibodies in Kawasaki Disease. Rie Karasawa, Mayumi Tamaki and Kazuo Yudoh, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan 297. Measuring S100A12 and Vascular Endothelial Growth Factor Can Differentiate Familial Mediterranean Fever and Early Onset Sarcoidosis From Systemic Juvenile Idiopathic Arthritis. Yuichi Yamasaki, Yasuhito Nerome, Tomohiro Kubota, Yukiko Nonaka, Harumi Akaike, Tomoko Takezaki, Hiroyuki Imanaka, Yoshifumi Kawano and Syuji Takei, Kagoshima University, Kagoshima City, Japan 298. Emperipolesis and Cell Death in NOD2-Related Blau Syndrome and Crohn’s Disease. Carl EI Janssen1, Carlos D. Rose2, A. Naranjo3, Brigitte Bader-Meunier4, Rolando Cimaz5, Miroslav Harjacek6, Pierre Quartier7, Rebecca Ten Cate8, Caroline Thomée9, Isabelle Cleynen1, Tammy M. Martin10, Gert De Hertogh1, Tania Roskams1, Valeer J. Desmet1 and Carine H. Wouters11, 1University Hospital Leuven, Leuven, Belgium, 2duPont Hospital for Children, Wilmington, DE, 3 Hospital de G C Dr Negrin, Las Palmas GC, Spain, 4Hôpital Necker, Paris, France, 5Anna Meyer Children’s Hospital, Florence, Italy, 6Zagreb, 7IRCCS G. Gaslini, Pediatria II, PRINTO, Paediatric Rheumatology, Genova, Italy, 8PO Box 9600, Leiden, Netherlands, 9Centre Hospitalier, Luxembourg, Luxembourg, 10Oregon Health & Science Univ, Portland, OR, 11 University Hosp Gasthuisberg, Leuven, Belgium 299. Novel Mutation of the LPIN2 Gene in Majeed Syndrome. Response to IL-1 Inhibition. Troels Herlin1, Mette Bjerre2, Bente Fiirgaard1, Gitte Kerndrup3, Henrik Hasle1 and Polly J. Ferguson4, 1Aarhus University Hospital, Aarhus N, Denmark, 2 Aarhus University Hospital, Aarhus C, Denmark, 3Vejle Hospital, Denmark, 4University of Iowa Carver College of Medicine, Iowa City, IA 300. Incidence and Identification of Citrullinated Proteins in Synovial Fluid of Juvenile Idiopathic Arthritis Patients. Brooke E. Gilliam1, Melinda R. Reed2, Anil K. Chauhan1,

Amanda Dehlendorf1 and Terry L. Moore3, 1Saint Louis University, St. Louis, MO, 2Ozarks Medical Center, West Plains, MO, 3Saint Louis University, Saint Louis, MO 301. Familial Periodic Fever Syndrome with Congenital Dyserythropoetic Anemia and Non-Bacterial Osteomyelitis. Sarah Keidel and Nick Wilkinson, Nuffield Orthopaedic Centre, Oxford, United Kingdom 302. Evaluation of An Autoantibody Profile in Pediatric- and Adolescent-Onset Systemic Lupus Erythematosus and Their Association with Disease-Associated Manifestations. Brooke E. Gilliam1, Amanda K. Ombrello2, Rufus W. Burlingame3, Peri H. Pepmueller1 and Terry L. Moore4, 1 Saint Louis University, St. Louis, MO, 2National Institutes of Health, Bethesda, MD, 3INOVA Diagnostics, Inc., San Diego, CA, 4Saint Louis University, Saint Louis, MO 303. Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis Are Marked by Distinct Profiles of Soluble Apoptosis Molecules. Bernadete Liphaus1, Maria H. B. Kiss2, Solange Carrasco3, Clovis A. A. Silva1 and Claudia Goldenstein-Schainberg4, 1Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 2Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 3Disciplina de Reumatologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 4University of São Paulo, São Paulo, Brazil 304. Hereditary Autoinflammatory Syndromes: A Brazilian Multicenter Study. Adriana A. Jesus1, Erika Fujihira2, Mariana G. Watase2, Maria Teresa Terreri3, Maria Odete Hilario4, Magda Carneiro-Sampaio1, Claudio Len3, Sheila K. Oliveira5, Marta C. Rodrigues5, Rosa M.R. Pereira6, Blanca E. Bica7, Nilzio A. Silva8, Andre Cavalcanti9, Roberto Marini10, Flavio Sztajnbok11, Maria V. Quintero12, Virginia P. Ferriani13, Dewton Moraes-Vasconcelos2, Joao B. Oliveira14 and Clovis A. Silva15, 1Instituto da Criança da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, 2Laboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM 56) da FMUSP, Brazil, 3Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, 4Universidade Federal de Sao Paulo / UNIFESP, Sao Paulo, Brazil, 5Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 6Disciplina de Reumatologia da FMUSP, Sao Paulo, Brazil, 7Disciplina de Reumatologia da UFRJ, Rio de Janeiro, Brazil, 8Faculdade de Medicina, Universidade Federal de Goias, Goiania, Brazil, 9 Universidade Federal de Pernambuco, Brazil, 10Universidade Estadual de Campinas, Sao Paulo, Brazil, 11Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 12Santa Casa de Misericórdia de Belo Horizonte, Brazil, 13FMUSPRibeirao Preto, Ribeirao Preto, Brazil, 14Clinical Center, National Institutes of Health (NIH), Bethesda, MD, 15Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

2011 Program Book

155

ACR Poster Session A 305. Pathway-Based Analysis Identifies Significant Enrichment of Apoptosis, Immune and Fibrosis Genes Associated with Cardiac Manifestations of Neonatal Lupus. Paula S. Ramos1, Miranda C. Marion1, Carl D. Langefeld1, Jill P. Buyon2 and Robert M. Clancy2, 1Wake Forest School of Medicine, Winston-Salem, NC, 2New York University School of Medicine, New York, NY 306. A novel mutation in the PSTPIP1 gene is Associated with An Autoinflammatory disease distinct From classical Pyogenic Arthritis, Pyoderma Gangrenosum and Acne Syndrome. Dirk Holzinger1, Judith Austermann1, Peter Lohse2, Ivona Aksentijevich3, Steven Holland4, Marco Gattorno5, Carlos Rodríguez-Gallego6, S. Fessatou7, Bertrand Isidor8, S. Tokio9, Jon Bernstein10, Barry Sampson11, Cord Sunderkoetter12, Dirk Foell13 and Johannes Roth13, 1 University Muenster, Muenster, Germany, 2University Munich, Munich, Germany, 3National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 5G. Gaslini Institute, Genova, Italy, 6Dr. Negrín University Hospital, Las Palmas de Gran Canaria, Spain, 7Attikon Hospital, Athens, Greece, 8Centre Hospitalo-Universitaire, Nantes, France, 9 Nagoya City University, Tokyo, Japan, 10Stanford University Medical Center, CA, 11Charing Cross Hospital, London, United Kingdom, 12Muenster, Germany, 13University of Muenster, Muenster, Germany 307. Cytokine Expression Array Analysis Segregates Oligoarticular Juvenile Idiopathic Arthritis Patients At Risk of Disease Extension. Sorcha Finnegan, Madeleine Rooney and David S. Gibson, Arthritis Research Group, Queen’s University, Belfast, United Kingdom 308. Circulating IP-10 and MCP-1 Levels in Active Localized Scleroderma. Katherine Kurzinski1, Christina Kelsey1, Thaschawee Arkachaisri2, Carol A. Feghali-Bostwick3 and Kathryn S. Torok1, 1Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2KK Women’s and Children’s Hosp, Singapore, Singapore, 3University of Pittsburgh, Pittsburgh, PA 309. Presence and Significance of Anti-Citrullinated Type II Collagen and Anti-Citrullinated Vimentin Antibodies in Juvenile Idiopathic Arthritis Patients. Brooke E. Gilliam1, Anil K. Chauhan1 and Terry L. Moore2, 1Saint Louis University, St. Louis, MO, 2Saint Louis University, Saint Louis, MO 310. Pathogenesis Study of Infantile-Onset, Severe Pustular Psoriasis Reveals a De Novo Mutation in CARD14 Causing Psoriasis Which Responds Clinically to IL-12/23 Blocking Treatment with Ustekinumab. Nadia Habal1, Yongqing Chen2, Catherine Jordan3, Yin Liu2, Dawn C. Chapelle Neal4, Deborah Stone5, Damaris Garcia5, Nicole Plass6, Edward Cowen4, Chyi-chia Lee4, Michelle Lowes7 and Raphaela T. Goldbach-Mansky8, 1NIH/NIAMS, Bethesda, MD, 2NIAMS, Bethesda, MD, 3Washington University Division of Human Genetics, Saint Louis, MO, 4NIAMS/NIH, Bethesda, MD, 5 Translational Autoinflammatory Disease Section, Office

156

2011 Program Book

of the Clinical Director NIAMS, Bethesda, MD, 6National Institutes of Health Clinical Center, Bethesda, MD, 7 Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, 8NIH, Bethesda, MD

Rheumatoid Arthritis Clinical Aspects: Rheumatoid Arthritis Classification, Disease Activity and Remission – Biomarkers and Predictors of Response 311. Defining Rheumatoid Arthritis From Radiographic Erosive Abnormalities in the Light of the ACR/EULAR 2010 Criteria. Cédric Lukas1, R. Knevel2, Annette H.M. van der Helm-van Mil3, Nathalie Rincheval4, Désirée van der Heijde5 and Bernard G. Combe6, 1Montpellier 1 University, Lapeyronie Hospital, 371, Avenue du Doyen Gaston Giraud, 3 4295 Montpellier Cedex 5, France, Montpellier, France, 2 LUMC, Department of Rheumatology, Leiden, Netherlands, 3 Leiden University Medical Center, Leiden, Netherlands, 4 Institut Universitaire de Recherche Clinique, Montpellier, France, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6Hopital Lapeyronie, Montpellier, France 312. Comparison of the 1987 ACR and 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis in Clinical Practice. Ewa H. Berglin1 and Solbritt M. RantapaaDahlqvist2, 1Umeå university, Umea, Sweden, 2Umeå University, Umea, Sweden 313. The 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis: Earlier Diagnosis At the Expense of Increased Heterogeneity. Maria J. H. de Hair1, K. A. Lehmann1, Marleen G. H. van de Sande1, Karen Maijer1, Danielle M. Gerlag1 and Paul P. Tak2, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands 314. 2010 American College of Rheumatology/European League Against Rheumatism Rheumatoid Arthritis Criteria Classifies 67% of Systemic Lupus Erythematosus and 38% of Psoriatic Arthritis As Rheumatoid Arthritis: Implications for Real World Use. Lauren M. Kennish1, Monalyn Labitigan2, Sam Budoff3, Maria T. Filopoulos1 and Yusuf Yazici4, 1Hospital for Joint Diseases, New York, NY, 2New York University, New York, NY, 3Vanderbilt University, Nashville, TN, 4Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 315. Performances of the 2010 ACR/EULAR Classification Criteria of Rheumatoid Arthritis: Comparison with 1987 ACR Criteria in the Community-Based Vera Cohort. Julia Nicolau Jr.1, Patrick Boumier2, Alain Daragon1, Othman Mejjad1, Jean-François Ménard1, Sophie Pouplin1, Olivier Vittecoq3, Patrice Fardellone2 and Xavier Le Loët Sr.3, 1Rouen University Hospital, Rouen, France, 2Amiens University Hospital, Amiens, France, 3Rouen University Hospital and Inserm U 905, Rouen, France

ACR Poster Session A 316. The New EULAR/ACR Classification ACPA Cutoff Levels Are Markers of Poor Radiological Outcome in Early Rheumatoid Arthritis. Jose Alfredo Gomez Puerta1, Virginia Ruiz Esquide1, M. V. Hernandez1, Eduard Graell2, Sonia Cabrera3, M. J. Gómara4, Juan D. Cañete5, Isabel Haro4 and R. Sanmarti1, 1Hospital Clinic of Barcelona, Barcelona, Spain, 2 Hospital Parc Tauli, Sabadell, Spain, 3Hospital Clinic of Barcelona., Barcelona, Spain, 4IQAC-CSIC, Barcelona, Spain, 5 Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain 317. Very High Specificity of Anti-Citrullinated Peptide Antiboldies (ACPA) in a Tertiary Medical Center. Meriem Ridene1, Jeremie Dion2, Makoto Miyara3 and Bruno Fautrel4, 1 TUNIS MEDECINE UNIVERSITY, Tunis, Tunisia, 2Faculté paris 7 Dénis-Diderot, Paris, France, 3Université Pierre et Marie Curie - Paris 6, Pitié-Salpêtrière University Hospital, Paris, France, 4Université Pierre et Marie Curie - Paris 6 - Pitie Salpetriere University Hospital, Paris, France 318. Evaluation of the Patients with Early Arthritis by 2010 RA Criteria in Conjunction with MRI of Wrists and Finger Joints. Mami Tamai1, Kazuhiko Arima1, Masataka Uetani1, Naoki Iwamoto1, Junko Kita1, Akitomo Okada1, Tomohiro Koga2, Shin-ya Kawashiri1, Kunihiro Ichinose1, Satoshi Yamasaki1, Hideki Nakamura1, Hiroaki Ida3, Tomoki Origuchi1, Kiyoshi Aoyagi1, Katsumi Eguchi4 and Atsushi Kawakami1, 1 Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Nagasaki University School of Medicine, Nagasaki, Japan, 3Kurume University School of Medicine, Kurume, Japan, 4Sasebo City General Hospital, Sasebo, Nagasaki, Japan 319. Comparison of the 1987 and 2010 Classificatioh Criteria for Rheumatoid Arthritis in a Population of Patients with Early Arthritis. Ana M. Ortiz Garcia, Ana M. Fernández-Ortiz, Silvia Pérez-Esteban, Rosario Garcia-Vicuña and Isidoro GonzálezAlvaro, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain 320. New Index to Assess the Improvement From the Worst Rheumatoid Arthritis Activity without Formal Joint Count. Naoto Yokogawa, Kota Shimada, Yoshiki Nagai, Takahiro Nunokawa, Shinichi Inada and Shoji Sugii, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan 321. Benefits of the Implementation of Specialized Clinics in Rheumatoid Arthritis for Rule Out False Positives of Disease and Osteoarthritis As a Frequent Cause of Misdiagnosis. Pedro Santos-Moreno1, Felipe GonzalezMalaver2, Luisa Fernanda Amador1, Claudia Guzman-Saltis2, Maria F. Cubides1, Ana Milena Arbelaez1 and Rafael ValleOnate2, 1Biomab IPS, Bogota, Colombia, 2Universidad Militar, Bogota, Colombia 322. Rheumatoid Arthritis Case Validation Strategies in Large Research Databases: The Women’s Health Initiative Experience. Brian T. Walitt1, Rachel Mackey2, Lewis Kuller2, Kevin D. Deane3, William Robinson4, V. Michael Holers5, Russell Tracey6, Yuefang Chang2 and Larry W. Moreland2, 1 Washington Hospital Center, Washington, DC, 2University of Pittsburgh, Pittsburgh, PA, 3University of Colorado School

of Medicine, Aurora, CO, 4Stanford Univ School of Med, Stanford, CA, 5Univ of Colorado School of Med, Aurora, CO, 6 Colchester, VT 323. Evaluation of Definitions of Rheumatoid Arthritis Remission by Assessing Radiographic Progression in the Leiden Early Arthritis Cohort. Annette H.M. van der Helm-van Mil1, Rachel Knevel1, Ferhan Qureshi2, William C. Manning2, Guy Cavet2, T.W.J. Huizinga3 and Douglas J. Haney2, 1Leiden University Medical Center, Leiden, Netherlands, 2Crescendo Bioscience, Inc., South San Francisco, CA, 3Leiden University Medical Centre, Leiden, Netherlands 324. TNF-Like Ligand 1A Is a Promising Biomarker of Disease Activity In Rheumatoid Arthritis. Yoo Jin Hong, Yun Jong Lee, Kichul Shin, Byoung Youg Choi, Hye Won Kim, Sung Hae Chang, In Ah Choi, Eun Young Lee, Eun Bong Lee and Yeong Wook Song, Seoul National University Hospital, Seoul, South Korea 325. Prevalence of Remission in Early RA – A Comparison of New Remission Criteria to Established Criteria. Bindee Kuriya1, Ye Sun2, Gilles Boire3, Boulos Haraoui4, Carol A. Hitchon5, Janet E. Pope6, J. Carter Thorne7, Edward Keystone2, Diane S. Ferland8 and Vivian Bykerk9, 1University of Toronto, Toronto, ON, 2Mount Sinai Hospital, Toronto, ON, 3 CHUS - Sherbrooke University, Sherbrooke, QC, 4Institut de Rhumatologie, Montreal, QC, 5University of Manitoba, Winnipeg, MB, 6St. Joseph’s Health Care, University of Western Ontario, London, ON, 7Newmarket, ON, 8LaSalle, QC, 9Brigham & Women’s Hospital, Boston, MA 326. Factors Associated with Relapse of Remission in Rheumatoid Arthritis. Leslie R. Harrold1, George Reed1, David H. Collier2, Grace S. Park2, Hong Chang3, Andrew S. Koenig4, Katherine C. Saunders5, Debra J. Zack6, Joel M. Kremer7 and Jeffrey D. Greenberg8, 1UMass Medical School, Worcester, MA, 2Amgen Inc., Thousand Oaks, CA, 3Tufts Medical Center, Boston, MA, 4Pfizer Inc., Collegeville, PA, 5 CORRONA, Inc., Southborough, MA, 6Amgen Inc, Thousand Oaks, CA, 7Albany Medical College and The Center for Rheumatology, Albany, NY, 8New York University School of Medicine, New York, NY 327. Current Smoking and Hypertension Are Associated with Synovitis As Measured by Ultrasonography in TherapyNaive Patients with Recent Onset Arthritis: Results from an Early Arthritis Cohort. Gisela Westhoff1, Georg Schett2, Edmund Edelmann3, Matthias Schneider4, Angela Zink5 and Marina Backhaus6, 1German Rheumatism Research Center Berlin, Berlin, Germany, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3 Rheumatologische Gemeinschaftspraxis, Berufsverband Deutscher Rheumatologen e.V, Bad Aibling, Germany, 4 Heinrich-Heine-University, Duesseldorf, Germany, 5 Deutsches Rheumaforschungszentrum and Charité University Medicine, Berlin, Germany, 6Charite University Hospital, Berlin, Germany 2011 Program Book

157

ACR Poster Session A 328. Near Misses of ACR/EULAR Criteria for Remission: Effects of Patient Global Scores on the Boolean and Index Based Definitions. Paul Studenic1, Josef Smolen2 and Daniel Aletaha1, 1Medical University of Vienna, Vienna, Austria, 2 Medical University of Vienna and Hietzing Hospital, Vienna, Austria 329. Combinations of Anti-Citrullinated Peptide Antibodies with Rheumatoid Factor Isotypes Reveal An Attribute Associated with Disease Activity in Rheumatoid Arthritis Patients Treated with Methotrexate. Thierry Dervieux1, Cole Harris2 and Joel M. Kremer3, 1Exagen Diagnostics, Albuquerque, NM, 2Exagen Diagnostics, 3Albany Medical College and The Center for Rheumatology, Albany, NY 330. Disease Duration As a Determinate Factor of Disease Activity and Radiographic Progression in Rheumatoid Arthritis. Tahmina Ferdousi, Andrew S. Koenig and Thomas V. Jones, Pfizer Inc., Collegeville, PA 331. Routine Assessment of Patient Index Data-3 (RAPID3), a Patient-Reported Index to Guide a Treat-to-Target Strategy for Rheumatoid Arthritis in Usual Care. Martin J. Bergman1, Theodore Pincus2 and Isabel Castrejón2, 1Taylor Hospital, Ridley Park, PA, 2NYU Hospital for Joint Diseases, New York, NY 332. Successful Maintenance of Remission Defined by the New ACR/EULAR Criteria Leads to Better Functional Outcomes in RA in Daily Practice, Especially in Patients with Early RA, Based on the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort. Kumi Shidara, Eiichi Tanaka, Eisuke Inoue, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan 333. The Relationship Between Time in Remission and Functional Status in Rheumatoid Arthritis. Femke H.M. Prince1, Siri Lillegraven2, Vivian P. Bykerk1, Nancy A. Shadick3, Bing Lu1, Michelle A. Frits1, Christine K. Iannaccone1, Michael E. Weinblatt1 and Daniel H. Solomon1, 1Brigham and Women’s Hospital, Boston, MA, 2Brigham and Women’s Hospital / Diakonhjemmet Hospital, Boston, MA, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA 334. Using the Patient Activity Score (PAS-2) to Assess Rheumatoid Arthritis Disease Activity: Bias From the Presence of Comorbid Musculoskeletal Conditions. John T. Schousboe1, Peter D. Kent2, Tawatchai Paisansinsup1, Scott L. Glickstein1 and Eric S. Schned1, 1Park Nicollet Health Services, Minneapolis, MN, 2Park Nicollet Clinic, Minneapolis, MN 335. Application of the New American College of Rheumatology/European League Against Rheumatism Rheumatoid Arthritis Remission Criteria in a United States Cohort. Iris Navarro-Millan1, Lang Chen1, Jeffrey D. Greenberg2 and Jeffery R. Curtis1, 1University of Alabama at

158

2011 Program Book

Birmingham, Birmingham, AL, 2New York University School of Medicine, New York, NY 336.

Discrepancy Between Boolean Remission and DAS28 Remission Is Dependent on the Differences in Number of Swollen Joints and Patient Global Assessment in Daily Practice, Based on the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort. Eiichi Tanaka, Kumi Shidara, Eisuke Inoue, Yohei Seto, Ayako Nakajima, Atsuo Taniguchi, Shigeki Momohara and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

337. Comparison of Disease Activity Score Using Erythrocyte Sedimentation Rate and C-ReactiveProtein In AfricanAmericans with Rheumatoid Arthritis. Ashutosh Tamhane1, David Redden1, Gerald McGwin1, Elizabeth Brown1, Andrew Westfall1, Richard J. Reynolds1, Laura B. Hughes1, Doyt L. Conn2, Leigh F. Callahan3, Beth L. Jonas3, Edwin A. Smith4, Richard Brasington5, Larry W. Moreland6 and S. Louis Bridges Jr.7, 1Univ of Alabama at Birmingham, Birmingham, AL, 2 Emory Univ School of Medicine, Atlanta, GA, 3Univ of North Carolina, Chapel Hill, NC, 4Med Univ of South Carolina, Charleston, SC, 5Washington Univ School of Med, St. Louis, MO, 6University of Pittsburgh, Pittsburgh, PA, 7Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 338. Trajectory of Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor Over Time Does Not Predict Disease Activity in the Canadian Early Arthritis Cohort. Lillian J. Barra1, V. Bykerk2, Janet Pope3, Ye Sun4, Boulos Haraoui5, Carol A. Hitchon6, Diane S. Ferland7, J. Carter Thorne8, Edward Keystone4 and Gilles Boire9, 1University of Western Ontario, London, ON, 2Brigham & Women’s Hospital, Boston, MA, 3Univ of Western Ontario, London, ON, 4Mount Sinai Hospital, Toronto, ON, 5Institut de Rhumatologie, Montreal, QC, 6University of Manitoba, Winnipeg, MB, 7LaSalle, QC, 8Southlake Regional Health Centre, Newmarket, Newmarket, ON, 9CHUS - Sherbrooke University, Sherbrooke, QC 339. Patients with Early Rheumatoid Arthritis Determined to Be Inadequate Responders After 12 Weeks May Still Have Substantial Improvement in Core Set Measures. Results from an Early Arthritis Cohort. Pooneh S.Akhavan1, Vivian Bykerk2, Ye Sun3, Gilles Boire4, J. Carter Thorne5, Janet Pope6, Carol A. Hitchon7, Boulos Haraoui8, Diane S. Ferland9, Edward Keystone1 and CATCH Investigators10, 1 University of Toronto, Toronto, ON, 2Brigham & Women’s Hospital, Boston, MA, 3Mount Sinai Hospital, Toronto, ON, 4 CHUS - Sherbrooke University, Sherbrooke, QC, 5Southlake Regional Health Centre, Newmarket, Newmarket, ON, 6Univ of Western Ontario, London, ON, 7University of Manitoba, Winnipeg, MB, 8Institut de Rhumatologie, Montreal, QC, 9 LaSalle, QC, 10Toronto, ON

ACR Poster Session A 340. Performance of the American College of Rheumatology/ European League Against Rheumatism (2011) Remission Definition Versus Disease Activity Score, 28-Joint Disease Activity Score and American College of Rheumatology Criteria. Karla Chiapas-Gasca, Luis M. Amezcua-Guerra and Angélica Vargas, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico 341. What Is A Realistic Treatment Target in Rheumatoid Arthritis: Remission or Minimal Disease Activity? Yvonne M.R. de Punder1, Jaap Fransen1, Wietske Kievit1, Pieternella Houtman2, Henk Visser3, Mart A.F.J. van de Laar4 and Piet LC van Riel1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Medical Centre Leeuwarden, Leeuwarden, Netherlands, 3Alysis Care Group, Arnhem, Netherlands, 4Arthritis Centre Twente, Medisch Spectrum Twente and University Twente, Enschede, Netherlands 342. Consensus Among Patients and Health Care Professionals for Essential Domains to Assess Disease Flares in Rheumatoid Arthritis: Results of Final OMERACT Delphi. Susan J. Bartlett1, Thasia G. Woodworth2, Clifton O. Bingham III3, Rieke Alten4, Christoph Pohl5, Ernest Choy6, Sarah Hewlett7, Tessa Sanderson7, Annelies Boonen8, Vivian Bykerk9, Amye L. Leong10, Vibeke Strand11, Daniel E. Furst12, Robin Christensen13 and OMERACT Flare Working Group, 1 McGill University, Montreal, QC, 2Leading Edge Clinical Research, Stuart, FL, 3Johns Hopkins University, Baltimore, MD, 4Rheumatology Schlossparkklinik, Berlin, Germany, 5 Schlosspark Klinik, Berlin, Germany, 6Cardiff University, Cardiff, ENGLAND, United Kingdom, 7University of the West of England, Bristol, United Kingdom, 8University Hospital Maastricht, Maastricht, Netherlands, 9Brigham & Women’s Hospital, Boston, MA, 10Bone & Joint Decade, Santa Barbara, CA, 11Stanford University, Palo Alto, CA, 12UCLA Medical School, Los Angeles, CA, 13Copenhagen, Denmark 343. Development and Validation of a New Disease Activity Index As a Numerical Sum of 4 Variables, Including Erythrocyte Sedimentation Rate and/or C-Reactive Protein, to Assess Rheumatoid Arthritis. Isabel Castrejón1, Loreto Carmona2, Ana M. Ortiz3, Miguel A. Belmonte Serrano4, Juan A. martínez-López5 and Isidoro González-Alvaro3, 1NYU Hospital for Joint Diseases, New York, NY, 2Universidad Camilo José Cela, Villanueva de la Cañada, Spain, 3Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, 4 Hospital General de Castellon, Castellon, Spain, 5Fundación Jimenez Díaz, Madrid, Spain 344. Investigation of the Relationship Between PatientCentered Factors and Baseline Disease Activity (DAS28) in Rheumatoid Arthritis (RA). Rita Prajapati1, Darren Plant2, Deborah Maskell2, Ann W. Morgan3, Anthony G. Wilson4, John Isaacs5, Lis Cordingley1 and Anne Barton1, 1University of Manchester, Manchester, United Kingdom, 2The University of Manchester, Manchester, United Kingdom, 3NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom,

Sheffield Uni /Medical School, Sheffield, United Kingdom, Newcastle University, Newcastle upon Tyne, United Kingdom

4 5

345. To Screen Remission without Formal Joint Count: Analysis of Routine Assessment of Patient Index Data 3 in Japanese National Database. Naoto Yokogawa1, Kota Shimada1, Shoji Sugii1 and Shigeto Tohma2, 1Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 2Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan 346. The Clinical Characteristics of Rheumatoid Arthritis Patients in Clinical Remission: Many Faces of DAS-28 Remission. Kyeong Min Son1, Inje Kim2 and Hyun Ah Kim1, 1 Hallym university sacred heart hospital, Kyunggi, South Korea, 2Hallym University Kangdong Sacred Heart hospital, Seoul, South Korea 347. Clinical Outcome in Early Undifferentiated Arthritis Is Best Predicted by a Combination of Baseline Clinical Features and Serum Biomarkers. Carol A. Hitchon1, Gilles Boire2, Michael Centola3, Andrew Lloyd4, Richard Kay4 and Hani S. El-Gabalawy1, 1University of Manitoba, Winnipeg, MB, 2 CHUS - Sherbrooke University, Sherbrooke, QC, 3Oklahoma Medical Research Fdn, Oklahoma City, OK, 4Astra-Zeneca, Cheshire, United Kingdom 348. Early Increase In Serum-COMP Is Associated with Joint Damage Progression Over the First Five Years In Patients with Rheumatoid Arthritis. Maria LE Andersson1, Bjorn Svensson2, Ingemar F. Petersson3, Ingiald Hafstrom4, Kristina Albertsson4, Kristina Forslind5, Dick Heinegard6 and Tore Saxne7, 1R&D centre, Spenshult Hospital for Rheumatic Diseases, Oskarstrom, Sweden, Oskartrom, Sweden, 2 Paulinsvag 7D, Bastad, Sweden, 3Lund University Hosp, Lund, Sweden, 4Karoliska Institute, Stockholm, Sweden, 5 Lund, Sweden, 6University of Lund, Lund, Sweden, 7Dept of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden 349. Is There An Association Between Uric Acid and Inflammation in Patients with Rheumatoid Arthritis? Paola de Pablo1, Vasileios F. Panoulas2, Karen MJ Douglas2, Christopher D. Buckley1 and George Kitas2, 1University of Birmingham, College of Medical & Dental Sciences, School of Immunity & Infection, Rheumatology, Birmingham, United Kingdom, 2Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, West Midlands, UK, Dudley, United Kingdom 350. Baseline Serum Levels of CXCL13 Are Associated with Ultrasonographic Synovitis and Predict Power Doppler Persistency in Early Rheumatoid Arthritis. Antonio Manzo, Serena Bugatti, Francesca Benaglio, Barbara Vitolo, Monica Todoerti, Garifallia Sakellariou, Roberto Caporali and Carlomaurizio Montecucco, Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

2011 Program Book

159

ACR Poster Session A 351. A Novel Multi-Biomarker Disease Activity Score (Vectra™DA algorithm score) Reflects Clinical Disease Activity Score and Health Assessment Questionnaire for Rheumatoid Arthritis in the BeSt Study. Shintaro Hirata1, Linda Dirven2, Guy Cavet3, Yijing Shen4, Michael Centola5, Willem F. Lems6, Tom W.J. Huizinga2, Cornelia F. Allaart2 and Yoshiya Tanaka1, 1University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 2 Leiden University Medical Center, Leiden, Netherlands, 3 Crescendo Bioscience, South San Francisco, CA, 4Geron Corporation, Menlo Park, CA, 5Oklahoma Medical Research Foun, Oklahoma City, OK, 6VU University Medical Center, Amsterdam, Netherlands 352. Polymorfisms In IL15 Associate with Progression of Joint Destruction In Rheumatoid Arthritis; A Multi Cohort Study. R. Knevel1, A. Krabben1, Elisabeth Brouwer2, M.D. Posthumus3, T. Saxne4, E. Lindqvist5, A. G. Wilson6, Diederik P.C. de Rooy1, N. Daha1, M.P.M. van der Linden1, René E.M. Toes1, Tom W.J. Huizinga1 and Annette H.M. van der Helm-van Mil1, 1Leiden University Medical Center, Leiden, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands, 3Berenkoog 28, Alkmar, Netherlands, 4Dept of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, 5Lund University Hospital, Lund, Sweden, 6Sheffield Uni /Medical School, Sheffield, United Kingdom 353. Identification of Patients Who Could Require Early Biologic Therapy by Developping a Matrix Predicting Rapid Radiographic Progression in Early Rheumatoid Arthritis Patients Treated by Methotrexate. A Study Based on the ESPOIR Cohort Data. Bruno Fautrel1, Benjamin Granger2, Bernard G. Combe3, Xavier X. Le Loet4 and ESPOIR Scientific Committee5, 1Université Pierre et Marie Curie - Paris 6 - Pitie Salpetriere University Hospital, Paris, France, 2Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, 3Hopital Lapeyronie, Montpellier, France, 4CHU de ROUEN, Rouen CEDEX, France, 5Paris 354. Local Swelling and Prolonged Local Pain in a Large Joint Are Independent Predictors of Damage in That Joint in Recent Onset RA Patients. M. van den Broek1, L. Dirven1, H.M. Kroon1, M. van Oosterhout2, K.H. Han3, P.J.S.M. Kerstens4, Tom W.J. Huizinga1, W. F. Lems5 and C.F. Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2Groene Hart Hospital, Gouda, Netherlands, 3Maasstad Hospital, Rotterdam, Netherlands, 4Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 5VU University medical center, Amsterdam, Netherlands 355. Calprotectin in Rheumatoid Arthritis: Relation with Disease Activity in a Tranversal and Longitudinal Study. Miriam García-Arias1, Alejandro Balsa2, Dora Pascual-Salcedo3, Susana Ramiro4, Patricia Alcocer1, Sara García Carazo1 and Emilio Martín Mola2, 1Rheumatology. La Paz Hospital, Madrid, Spain, 2Rheumatology. La Paz Hospital. IdiPaz, Madrid, Spain, 3Immunology. La Paz Hospital. IdiPaz, Madrid, Spain, 4Immunology. La Paz Hospital, Madrid, Spain

160

2011 Program Book

356. Moderate and Heavy Alcohol Use Is Associated with Less Patient-Derived Inflammation and Better Health-Related Quality of Life in Female Swedish Rheumatoid Arthritis Patients. Data From BARFOT, a Multicenter Study on Early RA. Maria K. Söderlin, Sofia Symeonidou, Maria Andersson and Stefan Bergman, R&D Center, Oskarström, Sweden 357. Plasma Talin Is a New Diagnostic and Monitoring Marker for Rheumatoid Arthritis. Kensei Tsuzaka1, Yuka Itami1, Naoshi Shinozaki2 and Morishita Tetsuo1, 1Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan, 2Cornea Center, Ichikawa General Hospital, TDC, Ichikawa 358. Serum 14-3-3η: A Rheumatoid Arthritis Biomarker. Walter P. Maksymowych1, Robert Landewe2, Désirée van der Heijde3, Paul-Peter Tak4 and Anthony Marotta5, 1University of Alberta, Edmonton, AB, 2Academic Medical Center, Amsterdam, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4 Professor of Medicine/ Director, Division of Clinical Immunology and Rheumatology, Amsterdam, Netherlands, 5 Augurex Life Sciences Corp, North Vancouver, BC 359. Can Anti-Cyclic Citrullinated Peptide Antibody Negative Rheumatoid Arthritis Be Subdivided in Clinical Subphenotypes? Diederik P.C. de Rooy1, Annemiek Willemze1, Bart Mertens2, Tom W.J. Huizinga1 and Annette H.M. van der Helm-van Mil1, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Netherlands 360. Elevated Plasma Soluble TREM-1 Levels Is Correlated with Disease Activity in Rheumatoid Arthritis. Sang Tae Choi1, Eun-Jin Kang2 and Jung-Soo Song1, 1Chung-Ang University College of Medicine, Seoul, South Korea, 2Busan Medical Center, Busan, South Korea 361. Investigation of a Multi-Biomarker Disease Activity (Vectra DA) Signature and Algorithm Score in Rheumatoid Arthritis Patients with Low Disease Activity: The REMIRA Study. Margaret H. Ma1, Saroja Ramanujan2, Guy Cavet2, Douglas J. Haney2, Xiaoyan Zhao2, P. Scott Eastman2, Gabrielle H. Kingsley1, David L. Scott3 and Andrew P. Cope1, 1King’s College Hospital, London, United Kingdom, 2Crescendo Bioscience, Inc., South San Francisco, CA, 3King’s College Hospital, Dulwich, United Kingdom 362. Serum 25 OH Vitamin D Levels Are Low in North American Native Populations with Early Inflammatory Arthritis but Do Not Correlate with Clinical Activity or Outcome. Carol A. Hitchon, Neeloffer Mookherjee, Keng Wong, Christine A. Peschken, Peter Nickerson and Hani S. El-Gabalawy, University of Manitoba, Winnipeg, MB

ACR Poster Session A 363. A New Definition of Treatment Response in Rheumatoid Arthritis: Identification of the Critical Difference in Disease Activity. Frank Behrens1, Michaela Koehm1, Eva C. Scharbatke2, Stefan Kleinert2, Geerd Weyer3, Rieke Alten4, Hans Peter Tony2 and Harald Burkhardt1, 1CIRI/ Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, 2Rheumatology, University of Würzburg, Würzburg, Germany, 3Biostatistics, ICRC, Berlin, Germany, 4 Rheumatology Schlossparkklinik, Berlin, Germany

Rheumatoid Arthritis - Human Etiology and Pathogenesis 364. Characterization of TLR7 and TLR8 in Rheumatoid Arthritis. Nathan D. Chamberlain1, Michael Volin2, Richard M. Pope3, Arthur M. Mandelin II3 and Shiva Shahrara1, 1University of Illinois at Chicago, Chicago, IL, 2Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL, 3Northwestern Univ Med School, Chicago, IL 365. TLR5; A Novel and Unidentified Inflammatory Mediator in Rheumatoid Arthritis. Nathan D. Chamberlain1, Michael Volin2, Richard M. Pope3, Arthur M. Mandelin II4 and Shiva Shahrara1, 1University of Illinois at Chicago, Chicago, IL, 2 Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL, 3Northwestern Univ Med School, Chicago, IL, 4Northwestern University Feinberg School of Medicine, Chicago, IL 366. Methyl Supplementation of Rheumatoid Arthritis Synovial Fibroblasts Attenuates Their Aggressive Behaviour. Emmanuel Karouzakis1, Maria Berdasco2, Astrid Jungel1, Caroline Ospelt1, Andrew Filer3, Karim Raza3, Renate E. Gay1, Beat A. Michel1, Christopher D. Buckley3, Manel Esteller2, Steffen Gay1 and Michel Neidhart1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Bellvitge Institute for Biomedical Research, Barcelona, Spain, 3School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom 367. Endogenous gp96 in RA Synovial Fluid Promotes Macrophage Activation Through TLR2 Signaling. Qi Quan Huang1, Robert Birkett1, Andrea Dorfleutner1, Renee E. Koessler1, Christopher V. Nicchitta2 and Richard M. Pope1, 1 Northwestern University Medical School, Chicago, IL, 2Duke University Medical Center, Durham, NC 368. Functional Changes of Bone Marrow Derived Mesenchymal Stem Cell Through Adipogenesis. A Possible in Vitro Model of Bone Edema in Rheumatoid Arthritis. Satoshi Yamasaki1, Akitomo Okada2, Tomohiro Koga1, Shinya Kawashiri1, Mami Tamai1, Hideki Nakamura1, Tomoki Origuchi1 and Atsushi Kawakami2, 1Nagasaki University School of Medicine, Nagasaki, Japan, 2Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan 369. Dopamine D2-Like Receptor Signaling Inhibits Human Osteoclast Differentiation From Monocytes. Kentaro Hanami1, Kazuhisa Nakano2, Kunihiro Yamaoka1, Kazuyoshi Saito1 and Yoshiya Tanaka1, 1University of Occupational &

Environmental Health, Japan, Kitakyushu, Japan, 2UCSD School of Medicine, La Jolla, CA 370. Downregulation of Mcl-1 by Ursolic Acid, a Pentacyclic Triterpenoid, Sensitizes Rheumatoid Arthritis Synovial Fibroblasts for TRAIL-Induced Apoptosis. Carolyn Zielinski, Maria Beamer and Salahuddin Ahmed, Department of Pharmacology, University of Toledo College of Pharmacy & Pharmaceutical Sciences, Toledo, OH 371. Expression Levels of the Nicotinic Acetylcholine alpha7 Receptor on Monocytes and Synovial Tissue of Rheumatoid Arthritis Patients. Frieda. A. Koopman, Maria J. H. de Hair, Danielle M. Gerlag, Paul P. Tak and Margriet Vervoordeldonk, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands 372. RasGRP1 and RasGRP3 Expressed in Lymphocytes From Rheumatoid Arthritis Patients Have An Anti-Inflammatory Role. Marie-Laure Potier1, Thibault Vandhuick2, Céline Derambure1, Martine Hiron1, Olivier Boyer1, Xavier Le Loët2, Olivier Vittecoq2 and Thierry Lequerré2, 1Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 2Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France 373. Circadian Rhythms of Cellular Immunity In Rheumatoid Arthritis. Cornelia M. Spies1, Timo Gaber1, Paula Hoff1, Jeannine Mazuch1, Bert Maier1, Martin Hahne1, Cindy Strehl1, Cam Loan Tran1, Natascha Soboleva1, Alexander Stoehr2, Ferenz L. Lohanatha1, Markus Wagegg1, Monique Fangradt1, Manuela Jakstadt1, Doerte Huscher2, Gerd R. Burmester1, Jacqueline Detert1, Achim Kramer1 and Frank Buttgereit1, 1Charité – Universitätsmedizin Berlin, Berlin, Germany, 2German Rheumatism Research Center (DRFZ), Berlin, Germany 374. Aberrant Basal and TLR-Stimulated Expression of TSLP in Rheumatoid Synovial Fibroblasts. Michele Bombardieri1, Yvonne NW Kam1, Andrew Filer2, Christopher D. Buckley2 and Costantino Pitzalis1, 1Centre for Experimental Medicine and Rheumatology, QMUL, London, United Kingdom, 2 School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom 375. EBV Infection In the Rheumatoid Synovium: Relationship with Ectopic Lymphoid Structures, In Situ Autoantobody Production and CD8 T Cell Activation. Cristina Croia1, Michele Bombardieri1, Barbara Serafini2, Eliana M. Coccia2, Martina Severa2, Stephen Kelly1, Francesca Aloisi1 and Costantino Pitzalis1, 1Centre for Experimental Medicine and Rheumatology, QMUL, London, United Kingdom, 2Istituto Superiore di Sanita’, Rome, Italy 376. Chemerin Activates Fibroblast-Like Synoviocytes In Patients with Rheumatoid Arthritis. Kayoko Kaneko1, Yoshishige Miyabe1, Aiko Takayasu1, Shin Fukuda1, Chie Miyabe1, Masashi Ebisawa1, Waka Yokoyama1, Kaori Watanabe2, Toshio Imai3, Kenzo Muramoto4, Yuya Terashima5, Takahiko

2011 Program Book

161

ACR Poster Session A Sugihara6, Kouji Matsushima5, Nobuyuki Miyasaka2 and Toshihiro Nanki1, 1Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan, 2Tokyo Medical and Dental University, Tokyo, Japan, 3KAN Research Institute, Inc., Chuo-ku, Kobe, Japan, 4 Eisai Co., Ltd,, Tsukuba-shi, Ibaraki, Japan, 5Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 6Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan 377. α-Defensin-1 Is Increased in the Synovial Fluid of Rheumatoid Arthritis Patients and Induces IL-6 and IL-8 Expression in Fibroblast-Like Synoviocytes. Joong Kyong Ahn1, Jiwon Hwang2, Jaejoon Lee2, You Sun Lee3, Chan Hong Jeon4, Eun-Mi Koh2 and Hoon-Suk Cha2, 1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, 3 Samsung Changwon Hospital, Changwon, South Korea, 4 Soonchunhyang University College of Medicine, Bucheon, South Korea 378. Extracellular 14-3-3η: An Early RA Pathogenic Factor. Anthony Marotta1, Vivian Bykerk2, Katherine A. Siminovitch3, Maarten Boers4, Robert Landewe5, Désirée van der Heijde6, Paul-Peter Tak7, M. C. Genovese8, Michael E. Weinblatt9 and Walter P. Maksymowych10, 1Augurex Life Sciences Corp, North Vancouver, BC, 2Brigham & Women’s Hospital, Boston, MA, 3Mount Sinai Hospital, Toronto, ON, 4VU University Medical Center, Amsterdam, Netherlands, 5Academic Medical Center, Amsterdam, Netherlands, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Professor of Medicine/ Director, Division of Clinical Immunology and Rheumatology, Amsterdam, Netherlands, 8Stanford University Medical Center, Palo Alto, CA, 9Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 10University of Alberta, Edmonton, AB 379. TNFá Modulates the Expression of Circadian Clock Genes in Rheumatoid Synovial Cells. Kohsuke Yoshida1, Akira Hashiramoto2, Nao Shibanuma3, Kazuko Shiozawa4 and Shunichi Shiozawa5, 1Kobe University Graduate School of Health Sciences, Kobe, Japan, 2Kobe University Graduate School of Medicine/ The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, 3The Center for Rheumatic Diseases, Kobe University Hospital/Kobe Kaisei Hospital, Kobe, Japan, 4Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan, 5Kobe University Graduate School of Health Sciences and Medicine/The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan 380. TL1A Induces the Production of Follicular Helper T Cells in Rheumatoid Arthritis. Xia Li1, Rui Liu1, Qian Wu1, Jing Zhao2, Xiaolin Sun2, Zhanguo Li3 and Lingyun Sun1, 1The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China, Nanjing, China, 2Peking University People’s Hospital, Beijing, China, 3Peking University People’s

162

2011 Program Book

Hospital, 11 Xizhimen South Street, Beijing, 100044, PR China, Beijing, China 381. CD15s Expression Pattern in the Synovial Tissue of Patients with Rheumatoid Arthritis and Its Role in RASF Migration. Birgit Zimmermann1, Sebastian Ullrich2, Nina Kesel2, Markus Rickert3, Jürgen Steinmeyer3, Stefan Rehart4, Angela Lehr4, Udo Schumacher2, Ulf Müller-Ladner5 and Elena Neumann5, 1 University of Gießen, Bad Nauheim, Germany, 2University Medical Center Hamburg, Hamburg, Germany, 3University Hospital Gießen and Marburg, Gießen, Germany, 4MarkusHospital, Frankfurt, Germany, 5Justus-Liebig-University of Gießen, Bad Nauheim, Germany 382. Leptin Stimulates Interleukin-6 Production Via phosphorylation of Signal Transducer and Activator of Transcription-3 in Rheumatoid Synovial Fibroblasts. Sei Muraoka, Natsuko Kusunoki, Hirahito Endo, Toru Suguro and Shinichi Kawai, Toho University School of Medicine, Tokyo, Japan 383. Mechanisms Underlying the Generation of Soluble IL-6 Soluble Receptor (sIL-6R) in Rheumatoid Arthritis: mRNA Alternative Splicing and Proteolytic Cleavage As Independent Contributors. Jose Ramon Lamas1, Luis Rodriguez-Rodriguez2, Pilar Tornero-Esteban2, Lydia Abasolo2, Jezabel Varade1, Roberto Alvarez-Lafuente1, Esther Villafuertes2, Jose Hoyas2, Elena Urcelay1 and Benjamin Fernandez-Gutierrez2, 1Hospital clinico San Carlos, Madrid, Spain, 2Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain 384. IL-21 and IL-21 Receptor Expression in the Inflamed Synovium From Patients with Rheumatoid Arthritis. Ditte Tornehave1, Berit O. Krogh1, Henning Bliddal2, Niels H. Søe3 and Dorthe Lundsgaard1, 1Novo Nordisk A/S, Måløv, Denmark, 2Copenhagen University Hospital at Frederiksberg Hospital, Frederiksberg, Denmark, 3Gentofte Hospital, Hellerup, Denmark 385. Regulation of DNA Methylation by Pro-Inflammatory Cytokines in Rheumatoid Arthritis. Kazuhisa Nakano1, David L. Boyle2 and Gary S. Firestein2, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2UCSD School of Medicine, La Jolla, CA 386. A Transcriptional Profile Present in CD4+ T-Cells of Patients with Undifferentiated Arthritis Predicts the Future Development of Seronegative Rheumatoid Arthritis and Implicates IL-6 in Disease Evolution. Arthur G. Pratt1, Dan Swan2, Sarah Richardson1, Gillian Wilson3, Catharien Hilkens1, David Young1 and John D. Isaacs1, 1Newcastle University, Newcastle Upon Tyne, United Kingdom, 2 Newcastle University, Newcastle-upon-Tyne, United Kingdom, 3Freeman Hospital, Newcastle-upon-Tyne, United Kingdom 387. Interleukin-22 Serum Levels Are Associated with Radiographic Progression in Rheumatoid Arthritis. Jan Leipe1, Markus A. Schramm1, Mathias Grunke1, Michael

ACR Poster Session A Baeuerle2, Matthias Witt2, Axel P. Nigg1, Christiane Reindl1, Claudia Dechant1, Alla Skapenko1 and Hendrik SchulzeKoops1, 1Division of Rheumatology and Clinical Immunology, Med. Poliklinik, University of Munich, Munich, Germany, 2 Medizinische Poliklinik, Munich, Germany 388. Serum Cytokine Levels Predict Mortality Among Postmenopausal Women Reporting Rheumatoid Arthritis. Jeremy Sokolove1, William H. Robinson2, Brian T. Walitt3, Kevin D. Deane4, Yuefang Chang5, Russell Tracy6, V. Michael Holers7, Lewis Kuller5, Larry W. Moreland5 and Rachel Mackey5, 1Stanford University, Palo Alto, CA, 2Stanford University, Stanford, CA, 3Washington Hospital Center, Washington, DC, 4University of Colorado School of Medicine, Aurora, CO, 5University of Pittsburgh, Pittsburgh, PA, 6 University of Vermont, Colchester, VT, 7Univ of Colorado School of Med, Aurora, CO 389. Treatment-Related Changes in Weight and Adipokine Levels and Associations with Radiographic Progression in Rheumatoid Arthritis. Joshua Baker1, Gary Toedter2, Daniel G. Baker3 and Joan Marie Von Feldt4, 1University of Pennsylvania, Philadelphia, PA, 2Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Malvern, PA, 3Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research and Development, LLC, Malvern, PA, 4Univ of Pennsylvania/ Philadelphia VAMC, Philadelphia, PA 390. B Cell Activating Factor (BAFF) Binding Receptors (BBR) on B Cells: Characterization in Patients with Rheumatoid Arthritis (RA) Receiving Anti-TNF-a Agent Infliximab (IFX). Lara Valor1, Diana Hernandez2, Geraldine Cambridge3, Maria J. Leandro3, Lina Martinez-Estupiñan1, Luis Carreño1 and Inmaculada de la Torre1, 1Gregorio Marañón Hospital, Madrid, Spain, 2Gregorio Maranon Hospital, Madrid, Spain, 3 University College of London, London, United Kingdom 391. Tumor Necrosis Factor Blocking Therapy Alters Oxidative Stress and Hypoxia-Induced Mitochondrial Mutagenesis in Inflammatory Arthritis. Monika Biniecka1, Aisling Kennedy1, Chin Teck Ng1, Ting C. Chang1, Emese Balogh1, Edward Fox2, Douglas J. Veale1, Ursula Fearon1 and Jacintha N. O’Sullivan3, 1 Translation Rheumatology Research Group, Dublin, Ireland, 2 Department of Pathology, University of Washington, Seattle, WA, 3Department of Surgery, Trinity Centre for Health Sciences, St James’s Hospital, Dublin, Ireland

Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy I 392. Active Smoking Is Not Associated with Treatment Response In Early Rheumatoid Arthritis In a Large Randomized Blinded Trial. Leann Maska1, James R. O’Dell2, Jeffrey R. Curtis3, S. Louis Bridges Jr.4, Larry W. Moreland5, Stacey Cofield6 and Ted R. Mikuls7, 1University of Nebraska Medical Center, Omaha, NE, 2Univ of Nebraska Med Ctr, Omaha, NE, 3 Univ of Alabama-Birmingham, Birmingham, AL, 4Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology,

University of Alabama at Birmingham, Birmingham, AL, University of Pittsburgh, Pittsburgh, PA, 6Univ of Alabama at Birmingham,, Birmingham, AL, 7Omaha VA and University of Nebraska, Omaha, NE 5

393. Effect of Disease Modifying Anti-Rheumatic Drugs (DMARDs) On Anti-CCP2 and Anti-Citrullinated Protein Antibody (ACPA) Levels During Longitudinal Assessments In Rheumatoid Arthritis Patients. Makoto Soejima1, Aarat M. Patel1, Danielle Goudeau1, Donald M. Jones1, Christine L. Amity1, Lynne M. Frydrych1, Dawn McBride1, Derek Sippel1, Heather Eng2, David Kyle2, Melissa Saul2, Stephen R. Wisniewski2, Larry W. Moreland1 and Marc C. Levesque1, 1 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Univ of Pittsburgh, Pittsburgh, PA 394. Adalimumab Added to Methotrexate and Intra-Articular Glucocorticoid Increases Remission Rates At One Year In Early, DMARD-Naïve Patients with Rheumatoid Arthritis - An Investigator-Initiated Randomized, Controlled, Double-Blinded Study. Kim Hørslev-Petersen1, Merete L. Hetland2, Peter Junker3, Jan Pødenphant4, Torkell Ellingsen5, Palle Ahlqvist6, Hanne M. Lindegaard3, Asta Linauskas7, Annette Schlemmer8, Mette Y. Dam9, Ib Hansen10, Hans Chr Horn6, Anette Jørgensen9, Sophie B. Krintel2, Johnny Raun1, Christian G. Ammitzbøll9, Julia Johansen2, Mikkel Østergaard11 and Kristian Stengaard-Pedersen9, 1University of Southern Denmark, Graasten, Denmark, 2Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3Odense University Hospital, Odense C, Denmark, 4Copenhagen University at Gentofte,, Hellerup, Denmark, 5University Hospital, Silkeborg, Denmark, 6Vejle Hospital,, Vejle, Denmark, 7Vendsyssel Hospital, Hjørring, Denmark, 8Aalborg Hospital, Aalborg, Denmark, 9Arhus University Hospital, Aarhus, Denmark, 10Viborg Hospital, Viborg, Denmark, 11 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark 395. Tocilizumab Improves Arterial Stiffness Compared with Abatacept In Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis.An Open Label Randomized Controlled Trial. Kensuke Kume1, Kanzo Amano1, Susumu Yamada1 and Kazuhiko Hatta2, 1Hiroshima Clinic, Hiroshima, Japan, 2Hatta Clinic, Kure, Japan 396. Tocilizumab Monotherapy Improves BONE Mineral Density AS Well AS TNF Blockers PLUS Methotrexate with Methotrexate-RESISTANT Activerheumatoid Arthritis. AN OPEN-Label RANDOMIZED CLINICAL TRIAL. T-BONE TRIAL. Kensuke Kume1, Kanzo Amano1, Susumu Yamada1 and Kazuhiko Hatta2, 1Hiroshima Clinic, Hiroshima, Japan, 2Hatta Clinic, Kure, Japan 397. Efficacy, Safety and Pharmacokinetics of Vidofludimus, a Novel Oral Immunomodulator, in Patients with Active Rheumatoid Arthritis on Methotrexate Background Therapy: The COMPONENT Study. Stanislaw Sierakowski1, Bruno Dietrich2, Bernd Hentsch2 and Aldo Ammendola2, 1 Medical University Bialystok, Bialystok, Poland, 24SC AG, Planegg-Martinsried, Germany 2011 Program Book

163

ACR Poster Session A 398. Rituximab and Methotrexate but Not TNF-Blockers Are Associated with Impaired Antibody Response Following Pneumococcal Vaccination Using 7-Valent Conjugate Vaccine (Prevenar®) In Patients with Established Rheumatoid Arthritis. Meliha C. Kapetanovic1, Carmen Roseman1, Göran Jönsson2, Lennart T. Truedsson3, Tore V. Saxne1 and Pierre Geborek1, 1Dept of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, 2Dept of Clinical Sciences Lund, Section of Infectious Diseases, Lund, Sweden, 3 Dept of Clinical Sciences Lund, Section of Microbiology, Immunology and Glycobiology, Lund, Sweden 399. Genetic Variations within the CD6 and Syntaxin Binding Protein 6 Genes Associated with Response to Tumor Necrosis Factor Alpha Inhibitors in Danish Patients with Rheumatoid Arthritis Treated in Routine Care. Sophine B. Krintel1, Giuseppe Palermo2, Assaf Wool3, Julia S. Johansen4, Laurent Essioux2, Ehud Schreiber3, Tomer Zekharya3, Pinchas Akiva3, Mikkel Østergaard1 and Merete L. Hetland5, 1 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland, 3 Compugen Ltd., Tel Aviv, Israel, 4Copenhagen University Hospital at Herlev, Copenhagen, Denmark, 5Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark 400. A Calcineurin Inhibitor FK506 Suppresses Joint Destruction in Patients with Early Rheumatoid Arthritis and Low Disease Activity. Yoshiya Tanaka1, Shinichi Kawai2, Tsutomu Takeuchi3, Kazuhiko Yamamoto4, Shinya Tani5, Toshiyuki Okada5 and Nobuyuki Miyasaka6, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 2Toho Uni Sch of Med, Tokyo, Japan, 3Keio University School of Medicine, Tokyo, Japan, 4Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 5 Astellas Pharma Inc., Tokyo, Japan, 6Tokyo Medical and Dental University, Tokyo, Japan 401. One Year Efficacy and Safety Results of a Phase II Trial of Secukinumab in Patients with Rheumatoid Arthritis. Mark C. Genovese1, Patrick Durez2, Hanno B. Richards3, Jerzy Supronik4, Eva Dokoupilova5, Jacob A. Aelion6, Sang-Heon Lee7, Christine E. Codding8, Herbert Kellner9, Takashi Ikawa10, Sophie Hugot3, Gregory Ligozio11 and Shephard Mpofu3, 1 Stanford University, Palo Alto, CA, 2Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, 3Novartis Pharma AG, Basel, Switzerland, 4NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland, 5 Medical Plus s.r.o, Uherske Hradiste, Czech Republic, 6 Arthritis Clinic, Jackson, TN, 7Konkuk University Medical Center, Seoul, South Korea, 8Health Research of Oklahoma, Oklahoma City, OK, 9Centre for Inflammatory Joint Diseases, Munich, Germany, 10Kobe - Konan Yamate Clinic, Kobe, Japan, 11Novartis Pharmaceuticals Corporation, East Hanover, NJ

164

2011 Program Book

402. Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: LongTerm Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to Methotrexate) Trial. Mark C. Genovese1, Arturo Covarrubias Cobos2, Gustavo Leon3, Eduardo F. Mysler4, Mauro W. Keiserman5, Robert M. Valente6, Peter T. Nash7, J. Abraham Simon Campos8, Wieslawa Porawska9, Jane H. Box10, Clarence W. Legerton III11, Evgeny L. Nasonov12, Patrick Durez13, Ramesh Pappu14, Ingrid Delaet14, Julie Teng14 and Rieke Alten15, 1Stanford Univ Medical Center, Palo Alto, CA, 2Calle Maiz No 49, Mexico, Mexico, 3 Instituto De Ginecologia Y Reproduccion, Lima, Peru, 4OMI, Buenos Aires, Argentina, 5Pontiphycial Catholic Univ, Porto Alegre, Brazil, 6Arthritis Center of Nebraska, Lincoln, NE, 7 University of Queensland, Brisbane, Australia, 8Centro De Especialidades Médicas, Merida, Mexico, 9Poznañski Oœrodek Medyczny ‘Novamed’, Poznañ, Poland, 10Box Arthritis & Rheumatology of the Carolinas, Charlotte, NC, 11 LowCountry Rheumatology, Charleston, SC, 12Institue of Rheumatology, Moscow, 13Université Catholique de Louvain, Brussels, Belgium, 14Bristol-Myers Squibb, Princeton, NJ, 15 Schlosspark-Klinik, Berlin, Germany 403. Safety Profile of Subcutaneous Abatacept Focusing on Clinically Relevant Events in Patients with Rheumatoid Arthritis (RA) and up to 4.5 Years of Exposure. Rieke Alten1, Jeffrey L. Kaine2, Edward Keystone3, Peter T. Nash4, Ingrid Delaet5, Keqin Qi5 and Mark C. Genovese6, 1Rheumatology Schlossparkklinik, Berlin, Germany, 2Sarasota Arthritis Center, Sarasota, FL, 3Mount Sinai Hospital, Toronto, ON, 4 University of Queensland, Brisbane, Australia, 5BristolMyers Squibb, Princeton, NJ, 6Stanford Univ Medical Center, Palo Alto, CA 404. Efficacy, Safety and Pharmacokinetics of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis, with or without An Intravenous (IV) Loading Dose. Peter T. Nash1, Charles L. Ludivico2, Ingrid Delaet3, Keqin Qi3, Bindu Murthy3, Michael Corbo4 and Jeffrey L. Kaine5, 1University of Queensland, Brisbane, Australia, 2East Penn Rheumatology Associates, East Stroudsburg, PA, 3Bristol-Myers Squibb, Princeton, NJ, 4Bristol-Myers Squibb (at time of study), Princeton, NJ, 5Sarasota Arthritis Center, Sarasota, FL 405. Prevention of Cartilage Destruction by Etanercept (PRECEPT) Study: The Comparison of Joint Destruction Between Low-Dose and Standard-Dose Etanercept in Rheumatoid Arthritis. Masahiro Tada, Tadashi Okano, Yuko Sugioka, Kenji Mamoto, Shigeyuki Wakitani, Hiroaki Nakamura and Tatsuya Koike, Osaka City University Medical School, Osaka, Japan 406. No Change in the Levels of PPD Reaction During Treatment with TNF Inhibitors in RA Patients in Japan, a Country with High Morbidity of Tuberculosis. Shotaro Yamamoto, Shino Takatori, Masahiro Iwamoto, Katsuya Nagatani, Kohei Ikenoya and Seiji Minota, Jichi Medical University, Tochigi, Japan

ACR Poster Session A 407. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, LongTerm Extension Studies up to 36 Months. J. Wollenhaupt1, J. C Silverfield2, E. B. Lee3, S. Wood4, K. Soma5, L. Wang5, H. Nakamura6, Y. Komuro6, C. I. Nduaka5, D. Gruben5, S. H. Zwillich5 and J. D. Bradley5, 1Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Tampa Medical Group, P.A., Tampa, FL, 3Hanyang University Hospital, Seoul, 4 Pfizer Inc., Groton, NJ, 5Pfizer Inc., Groton, CT, 6Pfizer Inc., Tokyo, Japan 408. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, or Adalimumab Versus Placebo in Patients with Rheumatoid Arthritis on Background Methotrexate: A Phase 3 Study. R.F. van Vollenhoven1, R. M. Fleischmann2, S. B. Cohen3, E. B. Lee4, G. Meijide5, S. Wagner6, S. Forejtova7, S. H. Zwillich8, D. Gruben8, T. Koncz9, G. Wallenstein8, S. Krishnaswami8, J. D. Bradley8, B. Wilkinson8 and the ORAL Standard investigators10, 1Karolinska Institute, Stockholm, Sweden, 2 Metroplex Clinical Research Center, Dallas, TX, 3Metroplex Clinical Research Centre, Dallas, TX, 4Seoul National University, Seoul, South Korea, 5Hospital Ntra. Sra. de la Esperanza, Santiago de Compostela, Spain, 6Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, 7 Revmatologicky ustav no 5, Prague, Czech Republic, 8Pfizer Inc., Groton, CT, 9Pfizer Inc., New York, NY, 10Groton, CT 409. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor: Analysis of Infections and All-Cause Mortality Across Phase 3 and Long-Term Extension Studies in Patients with Rheumatoid Arthritis. S. Cohen1, S. C. Radominski2, P. Asavatanabodee3, S. P. Wood4, K. Soma4, C. I. Nduaka4, L. Wang4, D. Gruben4, H. Valdez5, S. H. Zwillich4 and J. Bradley4, 1Metroplex Clinical Research Centre, Dallas, TX, 2Universidade Federal do Paraná, Curitiba, Brazil, 3 Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand, 4Pfizer Inc., Groton, CT, 5Pfizer Inc., New York, NY 410. Impact of Body Mass Index on Response to Etanercept Therapy in Subjects with Moderately Active Rheumatoid Arthritis in the PRESERVE Trial. Josef S. Smolen1, Annette Szumski2, Andrew S. Koenig2 and Thomas V. Jones3, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2 Pfizer Inc., Collegeville, PA, 3Pfizer, Inc, Collegeville, PA 411. Risk of Malignancy in Australian Rheumatoid Arthritis Patients Treated with Tumour Necrosis Factor Inhibitors. Sharon Van Doornum1, Margaret P. Staples2, Lynette March3, Marissa N. Lassere4 and Rachelle Buchbinder5, 1The University of Melbourne, Melbourne, Australia, 2Cabrini Institute and Monash University, Malvern, Australia, 3 University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, 4St. George Hospital, Kogarah, Australia, 5Cabrini Institute and Monash University, Malvern, Victoria, Australia

412. Clinical Response within 12 Weeks As a Predictor of Future Low Disease Activity in Early RA Patients: Results From the TEAR Trial. Jeffrey R. Curtis1, Theresa McVie2, Ted R. Mikuls3, James R. O’Dell4, S. Louis Bridges Jr.5, Larry W. Moreland6 and Stacey Cofield7, 1Univ of Alabama-Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, 3 Omaha VA and University of Nebraska, Omaha, NE, 4Univ of Nebraska Med Ctr, Omaha, NE, 5Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6 University of Pittsburgh, Pittsburgh, PA, 7Univ of Alabama at Birmingham,, Birmingham, AL 413. Association of Tuberculosis with Anti-Tumor Necrosis Factor Therapy in Asia Using a Number Needed to Harm Approach. B. Tang1, S. Navarra2, L. Lu3, H. Y. Lin4 and M. U. Rahman5, 1Pfizer Inc., New York, NY, 2University of Santo Tomas Hospital, Manila, Philippines, 3Jiaotong University School of Medicine, Manila, Philippines, 4Veterans General Hospital, Taipei, 5University of Pennsylvania/Pfizer, Collegeville, PA 414. Rheumatoid Arthritis Bone Fragility Is Associated with Increased Dickkopf-1 Expression and Disturbances in the Bone Turnover Regulating Genes. Joana CaetanoLopes1, Ana M. Rodrigues2, Ana Lopes3, Ana Catarina Vale4, Michael A. Pitts-Kiefer5, Bruno Vidal6, Inês P. Perpétuo1, Jacinto Monteiro7, Yrjo T. Konttinen8, Maria Fátima Vaz4, Ara Nazarian5, Helena Canhão9 and João E. Fonseca10, 1 Rheumatology Research Unit, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 2Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon, Portugal, 3Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 4 Department of Mechanical Engineering, Instituto Superior Técnico, ICEMS, Lisbon, Portugal, 5Center for Advanced Orthopaedic Studies, Department of Orthopaedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal., Lisbon, Portugal, 7Orthopaedics Department, Hospital de Santa Maria, Lisbon, Portugal, 8Helsinki Univ Central Hospital, Helsinki, Finland, 9Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 10 Lisbon Academic Medical Center, on behalf of Rheumatic Diseases Portuguese Register (Reuma.pt), Lisbon, Portugal 415. Effect of Sirukumab on Hepcidin Levels and Markers of Anemia: Results of a Phase 2b Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Gary Toedter1, Sarah Sague2, Xiaoying Wu2, Mark Curran3 and Benjamin Hsu4, 1Centocor R&D, a division of Johnson 2011 Program Book

165

ACR Poster Session A & Johnson Pharmaceutical Research & Development, L.L.C., Malvern, PA, 2Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, 3Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 4 Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/ Univ. of Pennsylvania, Malvern/Philadelphia, PA 416. Body Mass Index Is Associated with Decreased Response to Initial and Delayed Treatment with Dose Escalated Infliximab in Patients with Recent Onset Rheumatoid Arthritis. L. Heimans1, M. van den Broek1, L. Dirven1, A.A. Schouffoer1, I. Speyer2, P.J.S.M. Kerstens3, T.W.J. Huizinga4, W.F. Lems5 and C.F. Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2Bronovo Hospital, Den Haag, Netherlands, 3Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 4Leiden University Medical Centre, Leiden, Netherlands, 5VU University medical center, Amsterdam, Netherlands 417. Clinical and Radiographic Implications of Time to Treatment Response in Early Rheumatoid Arthritis Patients with Baseline Levels of Disease Activity Reflective of a Clinical Practice Setting. Edward Keystone1, Michael E. Weinblatt2, Boulos Haraoui3, Benoit Guerette4, Neelufar Mozaffarian5, Shufang Liu5, Benjamin Wolfe5 and Arthur Kavanaugh6, 1University of Toronto, Toronto, ON, 2 Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 3Institut de Rhumatologie, Montreal, QC, 4 Abbott, Rungis, France, 5Abbott, Abbott Park, IL, 6University of California San Diego, San Diego, CA 418. Rapid Radiological Progression in the First Year of RA Predicts Both Disability and Radiological Joint Damage Progression Over 8 Years of Targeted Treatment. M. van den Broek1, L. Dirven1, A.J. Dehpoor1, J.K. de VriesBouwstra1, Y.P. Goekoop-Ruiterman2, A.J. Peeters3, P.J.S.M. Kerstens4, Tom W.J. Huizinga1, W. F. Lems5 and C.F. Allaart1, 1 Leiden University Medical Center, Leiden, Netherlands, 2 HAGA hospital, The Hague, Netherlands, 3Reinier de Graaf Gasthuis, Delft, Netherlands, 4Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 5VU University medical center, Amsterdam, Netherlands 419. No Deterioration of Glucose Levels During Oral Glucose Tolerance Tests Following High-Dose Prednisolone Treatment in Early Active Rheumatoid Arthritis. Debby den Uyl1, Daniel H. van Raalte2, Michael T. Nurmohamed3, Willem F. Lems1, Johannes W.J. Bijlsma4, Jos N. Hoes4, Ben A.C. Dijkmans5 and Michaela Diamant2, 1VU University medical center, Amsterdam, Netherlands, 2VU University medical center, Diabetes Center, Amsterdam, Netherlands, 3Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, 4UMC Utrecht, Utrecht, Netherlands, 5Reade, Centre for Rehabilitation and Rheumatology and VU University Medical Centre, Department of Rheumatology, Amsterdam, Netherlands

166

2011 Program Book

420. Effects of the Oral SYK Inhibitor, Fostamatinib (R788), on Health-Related Quality of Life in a Phase II Study of Active Rheumatoid Arthritis. Michael E. Weinblatt1, Arthur Kavanaugh2, Mark C. Genovese3, David A. Jones4, Theresa K. Musser5, Elliott B. Grossbard5 and Daniel B. Magilavy5, 1 Brigham and Women’s Hospital, Boston, MA, 2University of California San Diego, San Diego, CA, 3Stanford University, Palo Alto, CA, 4AstraZeneca, Macclesfield, United Kingdom, 5 Rigel Pharmaceuticals, South San Francisco, CA 421. Epistasis in Folate Mediated One Carbon Metabolism Contributes to High Disease Activity in Two Cohorts of Rheumatoid Arthritis Patients Receiving Long Term Methotrexate Therapy. Thierry Dervieux1, J. M. Kremer2, Rebecca Roberts3 and Lisa K. Stamp3, 1Exagen Diagnostics, Albuquerque, NM, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3University of Otago, Christchurch, Christchurch, New Zealand 422. Patterns of Pain Medication Use Among Rheumatoid Arthritis Patients From 2000-2010. Yvonne C. Lee1, Frederick Wolfe2 and Kaleb D. Michaud3, 1Brigham and Women’s Hospital, Boston, MA, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Univ of Nebraska Med Ctr & National Data Bank for Rheumatic Diseases, Omaha, NE 423. The Effect of Anti-Tumor Necrosis Factor Therapy with Two Different Doses of Golimumab on Radiographic Progression in Definite Ankylosing Spondylitis: 4-Year Results. Jürgen Braun1, Desirée van der Heijde2, Kay-Geert Hermann3, Xenofon Baraliakos4, Atul Deodhar5, Anna Beutler6, Michael Mack6, Weichun Xu7, Benjamin Hsu8, Robert D. Inman9 and GO-RAISE Clinical Investigators, 1 Rheumazentrum Ruhrgebiet, Herne, Germany, 2Leiden University Medical Center, Leiden, Netherlands, 3Charite Medical School, Berlin, Germany, 4Ruhr-University Bochum, Herne, Germany, 5Oregon Health & Science University, Portland, OR, 6Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 7Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, 8Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/Philadelphia, PA, 9Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON 424. Increased Visceral Adiposity During Anti Tnfa Treatment for Inflammatory Rheumatic Disease Is Associated with Various Changes on Serum Adipokines: A 2 Year Prospective Study. Eric Toussirot1, Laurent Mourot2, Nhu Uyen Nguyen3, Malika Bouhaddi4, Daniel Wendling5 and Gilles Dumoulin6, 1Rheumatology and CIC Biotherapy 506, Besançon, France, 2University of Franche Comté, Besançon, France, 3department of Physiology, Besançon, France, 4 Physiology, France, 5Minjoz University Hospital, Besancon, France, 6Department of Physiology, France

ACR Poster Session A 425. Glucosteroid Treatment in Early Arthritis Leads to Increased Fat Mass Despite Reduced Disease Activity. Karin Britsemmer1, Dirkjan van Schaardenburg1, W. F. Lems2 and Michael T. Nurmohamed1, 1Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, 2VU University medical center, Amsterdam, Netherlands 426. Anti Tumour Necrosis Factor Therapy Is Associated with Reduced Mortality From Ruptured Abdominal Aortic Aneurysm: Results From the British Society for Rheumatology Biologics Register. Audrey SL Low1, James B. Galloway1, Louise K. Mercer1, Rebecca Davies1, Mark Lunt1, Kath D. Watson1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium1, Kimme L. Hyrich1, William G. Dixon1, Deborah PM Symmons1 and On behalf of the BSRBR2, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2British Society for Rheumatology, London, United Kingdom 427. Tocilizumab Monotherapy and Tocilizumab Plus DiseaseModifying Antirheumatic Drugs in a US Rheumatoid Arthritis Population with Inadequate Response to AntiTumor Necrosis Factor Agents. Michael E. Weinblatt1, Joel M. Kremer2, John J. Cush3, William Rigby4, Lichen Teng5, Natasha Singh5, Raymond L. Malamet6 and Mark C. Genovese7, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Baylor Research Institute, Dallas, TX, 4Dartmouth Medical School, Lebanon, NH, 5Roche, Nutley, NJ, 6Genentech, South San Francisco, CA, 7Stanford University, Palo Alto, CA 428. 14-3-3η, a Novel Mediator Upregulated by TNFα, Reflects Clinical Response to Anti-TNFα Therapy. Walter P. Maksymowych1 and Anthony Marotta2, 1University of Alberta, Edmonton, AB, 2Augurex Life Sciences Corp, North Vancouver, BC 429. Evaluation of the Association Between Disease Activity and Risk of Serious Infections in Subjects with Rheumatoid Arthritis When Treated with Etanercept or DMARDs. Paul Emery1, G. Gallo2, C. L. Morgan3, C. J. Currie4, C. D. Poole3 and Henk Nab5, 1Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 2Pfizer, Rome, Italy, 3Pharmatelligence, Cardiff, United Kingdom, 4Cardiff University, Cardiff, United Kingdom, 5Pfizer Europe, Rome, Italy 430. A Nationwide Survey on patient’s Versus physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study. Jan Lenaerts1, Bert Vander Cruyssen2, H. Mielants3, Rene Westhovens4, Patrick Durez5 and Dirk Elewaut6, 1Department of Rheumatology, Catholic University Leuven,Belgium, Reuma-instituut Hasselt Belgium., Hasselt, Belgium, 2OLV Hospital Aalst and St-josephs hospital Bornem, Aalst, Belgium, 3University Hospital, Gent, Belgium,

University Hospital KU Leuven, Leuven, Belgium, 5Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, 6Gent University Hospital, Ghent, Belgium

4

431. Combination of Disease-Modifying Antirheumatic Drugsprohibits the Need of Early Initiation of Biologicals, Independent of Glucocorticosteroids. A clinical trial to Investigate Different Induction Therapies in Early Rheumatoid Arthritis. P.H.P. de Jong1, Johanna Hazes2, P.J. Barendregt3, A.M. Huisman4, D. van Zeben4, P.A. van der Lubbe5, A.H. Gerards5, M.H. de Jager6, P.B. de Sonnaville7, B.A. Grillet8, Jolanda J. Luime9 and A.E.A.M. Weel3, 1University Medical Center, Rotterdam, Netherlands, 2 Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, 3Maasstad Hospital, Rotterdam, Netherlands, 4 Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5 Vlietland Hospital, Schiedam, Netherlands, 6Albert Schweitzer Hospital, Dordrecht, Netherlands, 7Admiraal de Ruyter hospital, Goes, 8Zorgsaam hospital, Terneuzen, Netherlands, 9Erasmus MC - University Medical Center, Rotterdam, Netherlands 432. Sustained Remission in Anti-TNF Treated Rheumatoid Arthritis Patients. Observational Data From Southern Sweden. Jon T. Einarsson, Pierre Geborek, Tore Saxne and Meliha C. Kapetanovic, Dept of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Sweden, Lund, Sweden 433. Risk of Fatal Infection and Malignancy Related to Use of Anti-Tumor Necrosis Factor-Alpha Biologics by Rheumatoid Arthritis Patients. Veena Thyagarajan1, Heather Norman2, Kimberly Alexander3, Pavel Napalkov3 and Cheryl Enger1, 1 OptumInsight, Ann Arbor, MI, 2OptumInsight, Waltham, MA, 3Genentech, Inc., South San Francisco, CA 434. Early Reductions in Tissue Inflammation with Tocilizumab As Either Monotherapy or in Combination with Methotrexate: 12-Week Unblinded Results From a Magnetic Resonance Imaging Substudy of a Randomized Controlled Trial. Philip G. Conaghan1, Charles G. Peterfy2, Julie DiCarlo2, Ewa Olech3, Alan R. Alberts4, Jeffrey A. Alper5, Jenny Devenport6, Andrew M. Anisfeld6 and Orrin M. Troum7, 1NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 2Spire Sciences LLC, San Francisco, CA, 3 Oklahoma Medical Research Foundation, Oklahoma City, OK, 4West Broward Rheumatology Associates, Inc., Tamarac, FL, 5Jeffrey Alper MD Research, Naples, FL, 6Genentech, South San Francisco, CA, 7USC Keck School of Medicine, Santa Monica, CA 435. Infliximab Versus Placebo in Adult Patients with ACPA Positive Undifferentiated Arthritis. Patrick Durez1, Laurent Meric de Bellefon1, Genevieve Depresseux1, Adrien Nzeusseu Toukap1, Bernard Lauwerys1 and Frédéric. A. Houssiau2, 1Cliniques Universitaires St Luc, Brussels, Belgium, 2Université catholique de Louvain, Brussels, Belgium 2011 Program Book

167

ACR Poster Session A 436. Predicted Versus Observed Radiographic Progression in a Randomized Trial. Ronald F. van Vollenhoven1, Heléne Hanses1, Kristina Forslind2, Pierre Geborek3, Ingemar F. Petersson3, Sofia Ernestam4 and Johan Bratt4, 1The Karolinska Institute, Stockholm, Sweden, 2Helsingborgs Lasarett and Lund University, Lund, Sweden, 3Lund University, Lund, Sweden, 4Karolinska University Hospital, Stockholm, Sweden 437. A Novel SYK Specific Inhibitor for the Treatment of Rheumatoid Arthritis. Eun-Ho Lee1, Sun-Hwa Chang1, Hae Jun Hwang1, Jang-Sik Choi1, Dong Sik Jung1, Sung Ho Park1, Sun Ju Wang1, Il Hwan Yang1, Sang Yeop Lee1, Jung-Ho Kim1, Ho-Juhn Song2, Jaekyoo Lee2, Jong Sung Koh2, Se Won Kim1 and Jung Kun Kim1, 1OSCOTEC Inc., Choongnam, South Korea, 2GENOSCO, Cambridge, MA 438. Comparative Effectiveness of Rituximab and Abatacept in 1192 Patients with Rheumatoid Arthritis Included in the French Society of Rheumatology AIR and ORA Registries. Jacques-Eric Gottenberg1, Philippe Ravaud2, Thomas Bardin3, Patrice Cacoub4, Alain G. Cantagrel5, Bernard G. Combe6, Maxime Dougados7, Rene-Marc Flipo8, Bertrand Godeau9, Loic Guillevin10, Xavier X. Le Loet11, Eric Hachulla12, Thierry Schaeverbeke13, Jean Sibilia14, Isabelle Pane15, Gabriel Baron16 and Xavier Mariette17, 1Strasbourg University Hospital, Strasbourg, France, 2Hotel Dieu University hospital, France, 3Service de Rhumatologie. Centre Viggo Petersen. Hôpital Lariboisiere, Paris, France, 4CHU PitiéSalpêtrière, Paris, France, 5Hopital Purpan, Toulouse CEDEX 9, France, 6Hopital Lapeyronie, Montpellier, France, 7 Paris-Descartes University, Cochin Hospital, Paris, France, 8 Hopital R Salengro CHRU, Lille CEDEX, France, 9Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 10Cochin University Hospital, Paris, France, 11CHU de ROUEN, Rouen CEDEX, France, 12Internal Medicine, Lille CEDEX, France, 13Pellegrin Hospital, Bordeaux, France, 14Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 15France, 16Epidemiology, Paris, France, 17 Université Paris-Sud, Le Kremlin Bicetre, France 439. Interferon Type I Signature Predicts Non Response to Rituximab in Rheumatoid Arthritis. Hennie G. Raterman1, Saskia Vosslamber1, Michael T. Nurmohamed2, Willem F. Lems1, Maarten Boers1, Ben A.C. Dijkmans3, Cornelis L. Verweij1 and Alexandre E. Voskuyl1, 1VU University medical center, Amsterdam, Netherlands, 2Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, 3 Reade, Centre for Rehabilitation and Rheumatology and VU University Medical Centre, Department of Rheumatology, Amsterdam, Netherlands 440. Remission Induction Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid and Undifferentiated Arthritis. K.V.C. Wevers-de Boer1, L. Heimans1, K. Visser1, H.K. Ronday2, T.H.E. Molenaar3, P.E.H. Seys4, C. Bijkerk5, M.L. Westedt6, W. De Beus7, P.B. de

168

2011 Program Book

Sonnaville8, T. Huizinga1 and C.F. Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2Haga Hospital, The Hague, Netherlands, 3Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, Netherlands, 5 Reinier de Graaf Gasthuis, Delft, Netherlands, 6Bronovo Hospital, The Hague, Netherlands, 7MCH, The Hague, Netherlands, 8Admiraal de Ruyter Hospital, Goes 441. Treatment Outcomes Based on Methotrexate Dose Range in Patients with Rheumatoid Arthritis Receiving Etanercept Plus Methotrexate Versus Methotrexate Alone. Roy Fleischmann1, Andrew S. Koenig2, Ronald Pedersen2, Tahmina Ferdousi2 and Eustratios Bananis2, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Pfizer Inc., Collegeville, PA 442. No Increased Malignancy Risk in Tumor Necrosis Factor-α Antagonists Treated Adult Rheumatoid Arthritis Patients: A Meta-Analysis of 29 Randomized Controlled Trials. Guillaume Moulis, Agnès Sommet, François Montastruc, Laurent Sailler, Jean-Louis Montastruc and Maryse LapeyreMestre, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France 443. RISK of HERPES VIRUSES INFECTIONS (HSV,VZV) DURING ANTI-TNF THERAPY In PATIENTS with INFLAMMATORY RHEUMATIC DISEASES Systematic Review and MetaAnalysis. Hélène Che, Jacques Morel, Bernard G. Combe and Cédric Lukas, Hopital Lapeyronie, Montpellier, France 444. Early Versus Delayed Retreatment with Rituximab (RTX) in Relation to Long Term Clinical Response – Data From the CERERRA Collaboration. Elisabeth Lie1, Katerina Chatzidionysiou2, Evgeny L. Nasonov3, Galina Lukina3, Karel Pavelka4, Dan C. Nordström5, Matija Tomsic6, Cem Gabay7, Ioan Ancuta8, Piet LC van Riel9, Juan J. Gomez-Reino10, João E. Fonseca11, Merete L. Hetland12, Ulrik Tarp13, Ronald F. van Vollenhoven2 and Tore K. Kvien1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Karolinska Institute, Stockholm, Sweden, 3Institute of Rheumatology, Moscow, Russia, 4 1Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 5ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 6University Medical Centre Ljubjana, Ljubljana, Slovenia, 7Geneva University Hospitals, for the SCQM registry, Geneva, Switzerland, 8Cantacuzino Hospital, Bucharest, Romania, 9 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 10Hospital Clinico Universitario, Santiago, Spain, 11Lisbon Academic Medical Center, on behalf of Rheumatic Diseases Portuguese Register (Reuma.pt), Lisbon, Portugal, 12Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 13Aarhus University Hospital, Aarhus, Denmark 445. RAPID3 (Routine Assessment of Patient Index Data 3) At Week 12 Predicts Progression of Joint Damage At Year 1 in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol Plus Methotrexate. Edward Keystone1, Owen Davies2

ACR Poster Session A and Kristel Luijtens2, 1University of Toronto, Toronto, ON, 2 UCB, Brussels, Belgium 446. Pretreatment Synovial Transcriptional Profile Predicts Early and Late Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab. Vanessa E. Hogan1, Cecile TJ Holweg2, David F. Choy2, Sarah Kummerfeld2, Jason Hackney2, Yko Teng3, Michael J. Townsend2 and Jacob M. van Laar4, 1Newcastle University, Newcastle, United Kingdom, 2 Genentech Research and Early Development, South San Francisco, CA, 3Leiden University Medical Centre, Leiden, Netherlands, 4Musculoskeletal Research Group, Newcastle, United Kingdom 447. Sulfasalazine and Its Metabolites Inhibit Platelet Function in Patients with Inflammatory Arthritis. Paul A. MacMullan1, Anne M. Madigan1, Nevin Paul2, Aaron J. Peace2, Paola M. Bagaglia1, Ahmed Alagha2, Kevin B. Nolan2, Dermot Kenny3 and G M. McCarthy1, 1Mater Misericordiae University Hospital, Dublin 7, Ireland, 2RCSI, Dublin 2, 3RCSI, Dublin 2, Ireland 448. Impact of Tumor Necrosis Factor Inhibition on Healthcare Costs in Patients with Rheumatoid Arthritis. Walter P. Maksymowych1, Nguen Xuan Thanh2, Joanne Homik1, Cheryl CM Barnabe3, Liam Martin3, Susan G. Barr3 and Arto Ohinmaa1, 1University of Alberta, Edmonton, AB, 2Institute of Health Economics, Edmonton, AB, 3University of Calgary, Calgary, AB 449. Trend of Tumor Necrosis Factor Inhibitors Use Among Patients with Rheumatoid Arthritis: Analysis From the Consortium of Rheumatology Researchers of North America Registry. Pim Jetanalin1, Susan P. Messing2, Kimberly Kaukeinen2, Joel M. Kremer3 and Susan J. Lee1, 1University of California San Diego, La Jolla, CA, 2 University of Rochester School of Medicine and Dentistry, Rochester, NY, 3Albany Medical College and The Center for Rheumatology, Albany, NY 450. Dermatologicals Manifestations Induced by Tumor Necrosis Factor Antagonists Therapy in Rheumatic Diseases. Incidence Rate in BIOBADASER 2.0 Registry. Maria Victoria Hernández Miguel1, Miguel A. Descalzo2, Loreto Carmona3, Melina Meineri1, Sonia Cabrera4, Maria Eugenia Gomez Caballero4, Jose Alfredo Gomez Puerta1, Virginia Ruiz Esquide1, Julio Ramirez1, Juan D. Cañete5 and Raimon Sanmarti1, 1Hospital Clinic of Barcelona, Barcelona, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3 Universidad Camilo José Cela, Villanueva de la Cañada, Spain, 4Hospital Clinic of Barcelona., Barcelona, Spain, 5 Hospital Clínic de Barcelona., Barcelona, Spain 451. Tofacitinib Reduces Interleukin-6 and Matrix Metalloproteinase-3 Production and Inhibits Cartilage Destruction in Rheumatoid Arthritis. Kunihiro Yamaoka1, Satoshi Kubo1, Keisuke Maeshima2, Koshiro Sonomoto1, Kazuhisa Nakano3, Norifumi Sawamukai1, Masao Nawata1, Kazuyoshi Saito1 and Yoshiya Tanaka1, 1University of Occupational and Environmental Health, Japan, Kitakyushu,

Japan, 2Oita University, Faculty of Medicine, Yufu, Japan, University of California San Diego, La Jolla, CA

3

452. One Single Infusion of Rituximab 1g Might Be Sufficient in the Long-Term Management of Rheumatoid Arthritis Patients Responding to a First Cycle of Rituximab (2 x 1g): Results of a 2-Year Multi-Center Randomized Controlled Trial. Maxime Dougados1, Stephanie Rouanet2, Jean Sibilia3, Bernard G. Combe4, Xavier X. Le Loet5, Jacques G. Tebib6, Rosemary Jourdan7 and Xavier Mariette8, 1Paris-Descartes University, Cochin Hospital, Paris, France, 2Roche, Neuilly sur Seine, France, 3Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 4Hopital Lapeyronie, Montpellier, France, 5CHU de ROUEN, Rouen CEDEX, France, 6Centre Hosp Lyon Sud, Pierre Benite, France, 7Roche, Neuilly Sur Seine, France, 8 Université Paris-Sud, Le Kremlin Bicetre, France 453. Patients’ Preferences for the Treatment of Moderate to Severe Rheumatoid Arthritis. A. Brett Hauber1, Christine Poulos1, Juan Marcos Gonzalez1, Sarika Ogale2, Dalia Moawad2 and Adam Turpcu2, 1RTI Health Solutions, Research Triangle Park, NC, 2Genentech, South San Francisco, CA 454. Simvastatin and Toll-Like Receptor-2 Mediated Signaling Augment Apoptosis and reactive Oxygen Species Associated Gene Expression in Rheumatoid Arthritis Synoviocytes. Mohammad Saeed Khan1, Krishnaswamy Kannan1 and Robert Ortmann2, 1University of Arkansas for Medical Sciences, Little Rock, AR, 2University of Arkansas, Little Rock, AR 455. Symptomatic Subcutaneous Anti-Tumor Necrosis Factor-Treated Rheumatoid Arthritis Patients Improve Following An Active Switch to Golimumab: An Initial 14 Week Assessment. J. Eugene Huffstutter1, Rebecca Bolce2, Shelly P. Kafka3, Lawrence H. Brent4, Jim Wang5, Raphael J. DeHoratius2, Trev Sprabery2 and Dennis Decktor2, 1Arthritis Associates PLLC, Hixson, TN, 2Janssen Services, LLC, Horsham, PA, 3Mountain State Rheumatology, Clarksburg, WV, 4Albert Einstein Med Ctr, Philadelphia, PA, 5Johnson & Johnson Pharmaceutical Research and Development, LLC, Belle Mead 456. Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis. Rachna Aggrawal1, Beverly S. Franek1, Marlena Kern2, Peter K. Gregersen2 and Timothy B. Niewold1, 1University of Chicago, Chicago, IL, 2Feinstein Institute for Medical Research, Manhasset, NY 457. Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission Criteria for Infliximab or Etanercept-Treated RA Patients Using Multiple Medical Cohorts. Tsukasa Matsubara1, Satoru Koyano2, Keiko Funahashi2, Takafumi Hagiwara1, Takako Miura1, Kosuke Okuda1, Takeshi Nakamura1, Akira Sagawa3, Takeo Sakurai4, Hiroaki Matsuno5, Tomomaro Izumihara6, Eisuke Shono7, Kou Katayama8, Toyomitsu Tsuchida9, Mitsuyoshi Iwahashi10, 2011 Program Book

169

ACR Poster Session A Tomomi Tsuru11 and Motohiro Oribe12, 1Matsubara Mayflower Hospital, Kato, Japan, 2Research Institute of Joint Diseases, Kobe, Japan, 3Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 4Inoue Hospital, Takasaki, Japan, 5Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 6Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, 7Shono Rheumatology Clinic, Fukuoka, Japan, 8Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, 9Tsuchida Clinic, Chiba, Japan, 10Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, 11PS Clinic, Fukuoka, Japan, 12Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan 458. 52-Week Results of Clinical, Radiographic and Pharmacokinetic Assessments: Golimumab, a Human AntiTNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Yoshiya Tanaka1, Masayoshi Harigai2, Tsutomu Takeuchi3, Hisashi Yamanaka4, Naoki Ishiguro5, Kazuhiko Yamamoto6, Minoru Kanazawa7, Yoshinori Murakami8, Toru Yoshinari9, Daniel G. Baker10, Nobuyuki Miyasaka11 and Takao Koike12, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 2Tokyo Medical and Dental Univ, Tokyo, Japan, 3Keio University School of Medicine, Tokyo, Japan, 4 Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 5Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 6 Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 7Director of Respiratory Center Professor of Respiratory, Medicine Saitama Medical University, Moroyama, Iruma-Gun, Saimata, Japan, 8Janssen Pharmaceutical KK, Tokyo, Japan, 9Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, 10Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research and Development, LLC, Malvern, PA, 11Tokyo Medical and Dental University, Tokyo, Japan, 12Hokkaido University Graduate School of Medicine, Sapporo, Japan 459. Sick Leave and Disability Pension in Patients with Early Rheumatoid Arthritis Randomized to Infliximab Plus Methotrexate or Triple Therapy: One-Year Results. Jonas Eriksson1, Martin Neovius2, Johan Bratt3, Ingemar F. Petersson4, R.F. van Vollenhoven5, Pierre Geborek6 and Sofia Ernestam7, 1Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, 3Karolinska Univ Hosp Huddinge, Stockholm, Sweden, 4Musculoskeletal Sciences, Dept of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, 5The Karolinska Institute, Clinical Trials Unit, Stockholm, Sweden, 6 Lund University, Lund, Sweden, 7Karolinska University Hospital, Huddinge, Sweden 460. Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks As Monotherapy in Patients with Active Rheumatoid Arthritis Despite DMARD Therapy: 52-Week Results of Clinical, Radiographic and Pharmacokinetic Assessments.

170

2011 Program Book

Tsutomu Takeuchi1, Masayoshi Harigai2, Yoshiya Tanaka3, Hisashi Yamanaka4, Naoki Ishiguro5, Kazuhiko Yamamoto6, Minoru Kanazawa7, Yoshinori Murakami8, Toru Yoshinari9, Daniel G. Baker10, Nobuyuki Miyasaka11 and Takao Koike12, 1 Keio University School of Medicine, Tokyo, Japan, 2Tokyo Medical and Dental Univ, Tokyo, Japan, 3University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 5Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 6Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 7Director of Respiratory Center Professor of Respiratory, Medicine Saitama Medical University, Moroyama, Iruma-Gun, Saimata, Japan, 8Janssen Pharmaceutical KK, Tokyo, Japan, 9Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, 10Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research and Development, LLC, Malvern, PA, 11Tokyo Medical and Dental University, Tokyo, Japan, 12Hokkaido University Graduate School of Medicine, Sapporo, Japan 461. Impact of Different Biologic Agents on the Improvement of Fatigue. Anja Strangfeld1, Matthias Schneider2, Jörg Kaufmann3, Andreas Krause4, Angela Zink5 and Joachim Listing6, 1Deutsches Rheumaforschungszentrum, Berlin, Germany, 2Heinrich-Heine-University, Duesseldorf, Germany, 3 Rheumatologist, Ludwigsfelde, Germany, 4Immanuel Krankenhaus Berlin-Buch, Berlin, Germany, 5Deutsches Rheumaforschungszentrum and Charité University Medicine, Berlin, Germany, 6German Rheumatism Research Centre, Berlin, Germany 462. Does the Association Between Anti-TNF Biologics and Serious Infections in Rheumatoid Arthritis Patients Vary by Comorbidity Burden? Jeffrey R. Curtis1, Fenglong Xie2, Paul M. Muntner2, Lang Chen2, Kenneth G. Saag2 and Elizabeth S. Delzell2, 1Univ of Alabama-Birmingham, Birmingham, AL, 2 University of Alabama at Birmingham, Birmingham, AL 463. A Preliminary Report of Remission Induction with Two Therapeutic Strategies with Infliximab or High Dose Intravenous Steroids for the Treatment of Rheumatoid Arthritis. Jackie L. Nam1, Edith Villeneuve2, Philip G. Conaghan3, Elizabeth Hensor4, Helen I. Keen5, Roshan Amarasena6, Andrew K. Gough7, Philip Helliwell3, Ann W. Morgan3, Mark Quinn8, Michael J. Green9, Richard Reece10, Richard Wakefield3 and Paul Emery3, 1NIHR Leeds Musculoskeletal Biomedical Research Unit , LIMM, University of Leeds., Leeds, United Kingdom, 2NIHRLeeds Musculoskeletal Biomedical Unit, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 3NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 4NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 5UWA, Perth, Australia, 6Salford Royal Foundation trust, Manchester, United Kingdom, 7Harrogate District Hospital, Harrogate,

ACR Poster Session A United Kingdom, 8The York Hospital, York Teaching Hospital NHS Foundation Trust, York, United Kingdom, 9York Teaching Hospital NHS Foundation Trust, Harrogate, United Kingdom, 10 University of Leeds, Leeds, United Kingdom 464. The Immunogenicity of Infliximab, Adalimumab and Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn’s Disease and Ulcerative Colitis - a Quantitative and a Qualitative Review. Sandra Garcês1, Jocelyne Demengeot2, Gj Wolbink3, L. Aarden4 and Elizabeth Benito-Garcia5, 1Instituto Gulbenkian Ciência; Hospital Garcia de Orta, Oeiras, Portugal, 2Instituto Gulbenkian Ciência, Oeiras, Portugal, 3Reade/Jan van Breemen Institute Research Center, Amsterdam, Netherlands, 4Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands, 5BioEpi, Research Center, Oeiras, Portugal

Sjögren’s Syndrome 465. Effect of Caphosol® On the Symptoms of Xerostomia Associated with Primary and Secondary Sjögren’s Syndrome. Stephanie Mathew1, Angelique N. Collamer2, Athena S. Papas3 and Daniel F. Battafarano4, 1United States Air Force SAUSHEC, Fort Sam Houston, TX, 2Langley AFB Hospital, Langley AFB, VA, 3Tufts School of Dental Medicine, Boston, MA, 4Brooke Army Medical Ctr, San Antonio, TX 466. Responsiveness of Disease Activity Indices (ESSPRI, ESSDAI) in Patients with Primary Sjögren’s Syndrome Treated with Rituximab. Petra M. Meiners, Suzanne Arends, Elisabeth Brouwer, Arjan Vissink and Hendrika Bootsma, University Medical Center Groningen, Groningen, Netherlands 467. Characterization of Anti Sjögren’s Syndrome Nuclear Antigen-1 (SSNA-1) Novel Autoantibody in Patients with Primary Sjögren’s Syndrome. Kaori Hiruma1, Kazuhisa Nozawa1, Keigo Ikeda2, Ayako Yamaguci1, Iwao Sekigawa2, Edward K.L. Chan3 and Yoshinari Takasaki1, 1Juntendo University School of Medicine, Tokyo, Japan, 2Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, 3 University of Florida, Gainesville, FL 468. Early Reconstitution of Autoreactive B-Cells After Rituximab Treatment in Primary Sjögren’s Syndrome. Wayel H. Abdulahad, Henko Tadema, Arjan Vissink, Minke G. Huitema, Jetske Anema, Petra M. Meiners, Pieter C. Limburg, Cees GM Kallenberg, Frans Kroese and Hendrika Bootsma, University Medical Center Groningen, Groningen, Netherlands 469. A Novel Cell-Based Assay for Inhibitory Anti-Muscarinic Type 3 Receptor Antibodies in Patients with Sjögren’s Syndrome. Michael W. Jackson1, Isabell Bastian1 and Thomas P. Gordon2, 1Flinders University and Flinders Medical Centre, Adelaide, Australia, 2Flinders Medical Centre, Bedford Park, Australia 470. Immunological Differences in Sicca Patients Based on Age. Andreea Coca, Tracey Sanford, Mustimbo Roberts, Jason Englert, Jennifer H. Anolik and Ignacio Sanz, University of Rochester, Rochester, NY

471. In Vivo Confocal Microscopic Evaluation of Corneal Morphology and Innervation in Primary Sjögren’s Syndrome and Non-SS Dry Eye: A Monocentric Cross Sectional Study. Chiara Baldini1, Giovanna Gabbriellini2, Pasquale Pepe1, Valentina Varanini2, Francesco Ferro1, Francesca Fanucci2, Chiara Notarstefano2 and Stefano Bombardieri1, 1Rheumatology Unit, Pisa, Italy, 2 Opthalmology Unit, Pisa, Italy 472. Assessment of Minor Salivary Gland Innervation in Sjögren’s Syndrome: A Feasibility Study. Alan N. Baer1, Ying Liu1, Anthony L. Keyes2, Jean Kim1 and Michael Polydefkis1, 1 Johns Hopkins University, Baltimore, MD, 2John Hopkins, Baltimore, MD 473. Improved Assessment of Parotid Gland Dysfunction with Scintigraphy in Sjögren’s Syndrome. Anthony L. Keyes, Rebecca L. Manno, Margaret Mills, John Petronis and Alan N. Baer, Johns Hopkins University, Baltimore, MD 474. Diagnostic Validity of Major Salivary Gland Ultrasonography for Sjögren’s syndrome: Echostructure, Gland Size and Döppler Waveform Analysis. Divi Cornec1, Sandrine Jousse-Joulin2, Alain Saraux1, Luc Bressollette1, Jacques-Olivier Pers1, Thierry Marhadour3, Sylvie BoisraméGastrin1, Pierre Y. Youinou4 and Valerie Devauchelle-Pensec5, 1 Brest Occidentale University, Brest, France, 2Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, 3CHU La Cavale Blanche, Brest, France, 4 Brest Univ Medical School, Brest, France, 5Brest University Medical School, Brest, France 475. Nailfold Capillary Changes in Patients with Primary Sjögren’s Syndrome: Comparison to Controls. Richa Mishra1, Anupama Shahane1, Liang Wu2 and Frederick B. Vivino2, 1University of Pennsylvania, Philadelphia, PA, 2Penn Presbyt Med Ctr, Philadelphia, PA 476. A Step Toward New Diagnostic Criteria in Sjögren’s Syndrome: Contribution of Major Salivary Gland Ultrasonography and Blood B-Cell Subset Profiling. Divi Cornec1, Alain Saraux1, Sandrine Jousse-Joulin2, Thierry Marhadour3, Jacques-Olivier Pers1, Beatrice Cochener1, Pierre Youinou1 and Valerie Devauchelle-Pensec4, 1Brest Occidentale University, Brest, France, 2Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, 3CHU La Cavale Blanche, Brest, France, 4Brest Occidentale university, Brest, France 477. High Risk of Human Papillomavirus Type 58 Infections and of Cervical Squamous Intraepithelial Lesions in Sjogren’s Syndrome Patients. Miansong Zhao Sr., Beijing Shijitan Hospital,Capital Medical University, Beijing, China 478. Monoclonal Gammapathy Is Associated with Ten-Fold Risk of Hematologic Disorders in Primary Sjögren Syndrome. Anne-Laurence Tomi1, Raphaèle Seror2, Stephan Pavy3, Corinne Miceli-Richard4 and Xavier Mariette5, 1Bicetre university hospital, Le Kremlin-Bicêtre, France, 2Bicetre university hospital, LE Kremlin-Bicetre, France, 3Hopital Bicetre, Paris, France, 4Hopital Bicêtre, Le Kremlin Bicêtre, France, 5Université Paris-Sud, Le Kremlin Bicetre, France 2011 Program Book

171

ACR Poster Session A 479. Follow up of Primary Sjögren Syndrome Patients Presenting Positive Anti-Cyclic Citrullinated Peptides Antibodies. Yang-Seon Ryu1, Eun-Ji Kim1, Ji-Min Kim1, Jennifer Lee1, Seung-Ki Kwok1, Ji Hyeon Ju2, Sung Hwan Park3 and Ho-Youn Kim2, 1Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Rhematism Research Center, Seoul, South Korea 480. Low Levels of Vitamin-D are Associated with Neuropathy and Lymphoma Among Patients with Sjögren’s Syndrome. Nancy Agmon-Levin1, Howard Amital2, Athanasios G. Tzioufas3, Marcus López Hoyos4, Blaz Rozman5, Shaye Kivity1, Ilan Ben Zvi1, Inga Efes1, Yinon Shapira1 and Yehuda Shoenfeld6, 1Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, Tel-Hashomer, Israel, 2 Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, Tel-hashomer, Israel, 3Medical SchoolUniv of Athens, Athens, Greece, 4Servicio Inmunología Hospital Universitario Marqués de Valdecilla Santander Spain, Santander, Spain, 5University Medical Centre, Ljubljana, Slovenia, 6Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, Ramat Gan, Israel 481. A High-Density Genome-Wide Association Study by the Sjögren’s Genetics Network Identifies Five Novel Susceptibility Loci for Primary Sjögren’s Syndrome and Confirms Association with MHC, IRF5, and BLK. Christopher J. Lessard1, John A. Ice1, Indra Adrianto1, Jennifer A. Kelly1, Roland Jonsson2, Gabor G. Illei3, Maureen Rischmueller4, Gunnel Nordmark5, Xavier Mariette6, Corinne MiceliRichard6, Marie Wahren Herlenius7, Torsten Witte8, Michael T. Brennan9, Roald Omdal10, Timothy J. Vyse11, James A. Lessard12, Wan-Fai Ng13, Nelson L. Rhodus14, Barbara M. Segal15, R. Hal Scofield1, Benjamin A. Rybicki for ACCESS16, Juan-Manuel Anaya17, John B. Harley18, Courtney G. Montgomery1 and Kathy L. Moser19, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Bergen, Bergen, Norway, 3NIDCR/ NIH #10 1N110, Bethesda, MD, 4Queen Elizabeth Hospital, Adelaide, Australia, 5 Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 6Bicêtre University Hospital, Le Kremlin Bicêtre, France, 7Karolinska Institute, Stockholm, Sweden, 8Hannover Medical School, Hanover, Germany, 9Carolinas Medical Center, Charlotte, NC, 10Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 11Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 12Valley Bone & Joint Clinic, Grand Forks, ND, 13Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle, England, 14University of Minnesota, Minneapolis, MN, 15Hennepin County Medical Center, Minneapolis,

172

2011 Program Book

MN, 16Henry Ford Hospital, Detroit, MI, 17Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 18Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 19Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 482. Sympathetic and Parasympathetic Abnormalities in Primary Sjögren’s Syndrome (pSS) Patients Assessed in Outpatients Using Real-Time Digital Autonomic Nervous System (ANS) Monitoring. Nikolay P. Nikolov1, Stanley R. Pillemer1, Vladimir Bakalov2, Lolita Bebris1, Joe Colombo3 and Gabor G. Illei1, 1NIDCR/NIH, Bethesda, MD, 2 NIH, Bethesda, MD, 3Ansar Medical Technologies, Inc, Philadelphia, PA 483. Fine Specificity of Antibodies Against Ro52, Ro60, and La Antigens in Sjögren’s Patients with Neuropathies and Demyelinating Syndromes. Julius Birnbaum, Livia CasciolaRosen, Laura Gutierrez and Alan N. Baer, Johns Hopkins University, Baltimore, MD 484. Salivary Genomic Biomarkers for Primary Sjögren’s Syndrome: Correlation with Minor Salivary Gland Lymphocyte Focus Score and Serum Interleukin-17, 21, 23 Level. Sung-Hoon Park1, Ji Hun Kim1, Seong-Kyu Kim2, Jung-Yoon Choe3, Sang-Hyon Kim4 and Ji-Yoon Kim5, 1Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 2Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegue, South Korea, 3Arthritis and Autoimmunity Research Center, Catholic university of Daegu, School of mediine, Daegu, 4Dongsan Medical Center, Keimyung University, Daegu, South Korea, 5Dongsan Medical Center, Keimyung University, School of medicine, Daegu, South Korea 485. BLK Polymorphisms Are Associated with Sjögren’s Syndrome Only in Patients with Anti-SSA Antibodies. Corinne Miceli-Richard1, Joanne Nititham2, Kimberly E. Taylor3, Céline Verstuyft1, Laurent Becquemont1, Ryad Tamouza4, Xavier Puechal5, Eric Hachulla6, Jacques-Eric Gottenberg7, Lindsey A. Criswell8 and Xavier Mariette9, 1 Hopital Bicêtre, Le Kremlin Bicêtre, France, 2University of California, CA, 3University of California, San Francisco, San Francisco, CA, 4Paris, France, 5Le Mans General Hospital, Le Mans, France, 6Internal Medicine, Lille CEDEX, France, 7 Strasbourg University Hospital, Strasbourg, France, 8 University of California San Francisco, San Francisco, CA, 9 Université Paris-Sud, Le Kremlin Bicetre, France 486. Interferon-Alpha Activation in Relation to ProInflammatory Cytokines and Anti-Ro/La Response in Primary Sjøgren’s Syndrome. Johannes C. Nossent1, Maureen Rischmueller2, Andrea Becker-Merok1 and Sue Lester2, 1University of Tromsø, Tromso, Norway, 2Queen Elizabeth Hospital, Adelaide, Australia

ACR Poster Session A 487. Cathepsin S Activity Measurements in Tears As a Putative Marker of Sjögren’s Syndrome. Jay Zhu1, Daniel G. Arkfeld1, W. Stohl1, Srikanth R. Janga2, J. Martin Heur3, John Irvine3 and Sarah F. Hamm-Alvarez2, 1USC Keck School of Medicine, Los Angeles, CA, 2University of Southern California School of Pharmacy, Los Angeles, CA, 3Doheny Eye Institute, Los Angeles, CA 488. Serum IL-21 Is Increased and Associated with Higher Disease Activity and Higher Serum Levels of Markers of B-Cell Activation in Primary Sjögren’s Syndrome. JacquesEric Gottenberg1, Ghada Alsaleh1, Corinne Miceli-Richard2, Raphaèle Seror3, Joelle Benessiano4, Valerie DevauchellePensec5, Philippe Dieude6, Jean Jacques Dubost7, AnneLaure Fauchais8, Vincent Goeb9, Eric Hachulla10, Pierre yves Hatron11, C. Larroche12, Véronique Le Guern13, Jacques Morel14, Aleth Perdriger15, Xavier Puechal16, Stephanie Rist17, Alain Saraux18, Damien Sène19, Jean Sibilia20, Karine Inamo21, Philippe Ravaud22 and Xavier Mariette23, 1Strasbourg University Hospital, Strasbourg, France, 2Hopital Bicêtre, Le Kremlin Bicêtre, France, 3Bicetre university hospital, LE Kremlin-Bicetre, France, 4Rheumatology, Paris Unervisity Hospital BICHAT, France, 5Brest Occidentale university, Brest, France, 6APHP, Hopital Bichat, Paris, France, 7CHU Gabriel Montpied, Clermont-Ferrand, France, 8Hospital, Limoges, France, 9Rheumatology, Rouen Unervisity Hospital, France, France, 10Internal Medicine, Lille CEDEX, France, 11 Service de médecine interne, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, 12Hospital University Bobigny, France, 13Cochin Hospital, Paris, France, 14 Hopital Lapeyronie, Montpellier, France, 15Hôpital Sud, Rennes, France, 16Le Mans General Hospital, Le Mans, France, 17Hospital University Orléans, France, 18CHU de la Cavale Blanche, Brest Cedex, France, 19Pitie-Salpetriere Hospital, Paris, France, 20Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 21Nihon Univ Hikarigoaka Hosp, Nerima-ku Tokyo, Japan, 22Hopital Hotel Dieu, Paris Descartes University, Paris, France, 23Université Paris-Sud, Le Kremlin Bicetre, France 489. Gene Expression Profiling in a Cohort of 275 European American Sjögren’s Syndrome Patients and Controls. Jennifer A. Kelly1, Christopher J. Lessard1, Indra Adrianto1, John A. Ice1, He Li1, Stuart B. Glenn1, Kimberly Hefner2, Evan Glenn Vista3, Donald U. Stone4, Raj Gopalakrishnan5, Glen D. Houston4, David M. Lewis4, Michael Rohrer5, Pamela Hughes5, John B. Harley6, Courtney G. Montgomery1, James Chodosh7, James A. Lessard8, Juan-Manuel Anaya9, Barbara M. Segal10, Nelson L. Rhodus5, Lida Radfar4, M. Bart Frank1, Robert H. Scofield11 and Kathy L. Moser1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Hefner Eye Care and Optical Center, Oklahoma City, OK, 3University of Santo Tomas, Taguig City, Philippines, 4University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5University of Minnesota, Minneapolis, MN, 6Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7Harvard Clinical

and Translational Science Center, Boston, MA, 8Valley Bone & Joint Clinic, Grand Forks, ND, 9Universidad del RosarioCorporacion para Investigaciones Biologicas, Bogota, Colombia, 10Univ of Minnesota, Minneapolis, MN, 11Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 490. Cellular microRNAs and Sjögren’s Syndrome: Candidate Regulators of Autoimmune Response and Autoantigen Expression. Efstathia K. Kapsogeorgou, Vasiliki C. Gourzi, Nikolaos C. Kyriakidis, Menelaos N. Manoussakis, Haralampos M. Moutsopoulos and Athanasios G. Tzioufas, Pathophysiology Dept, School of Medicine, National University of Athens, Greece, Athens, Greece 491. Autoantibodies in Primary Sjögren Syndrome Patients Induce Internalization of Muscarinic Type 3 Receptors. Meihong Jin1, Sung-Min Hwang1, Alexander J. Davies1, Yonghwan Shin1, Jun-Seok Bae1, Chongho Lee1, Byoong-Yong Choi2, Eun Young Lee2, Yeong Wook Song2 and Kyungpyo Park1, 1Seoul National University and Dental Research Institute, Seoul, South Korea, 2Seoul National University Hospital, Seoul, South Korea 492. Analysis of M3R Reactive T Cell Epitopes in M3R Induced Autoimmune Sialoadenitis. Naomi Matsuo, Hiroto Tsuboi, Mana Iizuka, Yuya Kondo, Isao Matsumoto and Takayuki Sumida, Division of Clinical Immunology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan 493. The Sjogren’s Syndrome-Related Autoantigen Ro52 Is a Pro-Apoptotic Molecule Upon Oxidative Stress. Siti NA Jauharoh1, Seiji Kawano1, Jun Saegusa1, Takeshi Sugimoto1, Daisuke Sugiyama1, Osamu Tokuno1, Chiyo Kurimoto1, Yumiko Nobuhara2, Yuji Nakamachi1, Bambang Ardianto3 and Shunichi Kumagai1, 1Kobe University Graduate School of Medicine, Kobe, Japan, 2Saiseikai Nakatsu Hospital, Osaka, Japan, 3Gadjah Mada University Faculty of Medicine Department of Child Health, Yogyakarta, Indonesia 494. VIP / VPAC System Involved in the Interaction of Primary Sjögren Syndrome Immune Cells and a Human Salivary Gland Epithelial Cell Line. Vanesa C. Hauk1, Laura Fraccaroli1, Esteban Grasso1, Rosanna Ramhorst1, Alicia Eimon2, Osvaldo Hubscher2 and Claudia Perez Leiros1, 1 School of Exact and Natural Sciences-CONICET, Buenos Aires, Argentina, 2CEMIC, Buenos Aires, Argentina 495. Regulatory T Cell Subset Defect in a Mouse Model of Sjögren Syndrome. Scott M. Lieberman1, Portia A. Kreiger2 and Gary A. Koretzky3, 1The Children’s Hospital of Philadelphia, Philadelphia, PA, 2Nemours/A.I. DuPont Hospital for Children, Wilmington, DE, 3University of Pennsylvania, Philadelphia, PA

2011 Program Book

173

ACR Poster Session A 496. A Chimeric Human-Mouse Model of Sjögren’s Syndrome. Nicholas Young, Alexandra Friedman and Wael N. Jarjour, The Ohio State University Medical Center, Columbus, OH 497. The Majority of Micrornas in Serum and Saliva Is Concentrated in Exosomes. Alessia Gallo1, Mayank Tandon1, Gabor G. Illei2 and Ilias Alevizos1, 1NIDCR, Bethesda, MD, 2 NIDCR/ NIH #10 1N110, Bethesda, MD 498. Deep Sequencing of Small RNAs Reveals Novel MicroRNAs in Minor Salivary Glands of Sjögren’s Syndrome Patients. Mayank Tandon1, Alessia Gallo1, Gabor G. Illei2 and Ilias Alevizos2, 1NIDCR, Bethesda, MD, 2NIDCR/ NIH #10 1N110, Bethesda, MD

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I 499. Subclinical Peripheral Synovitis Detected by ultrasound In Patients with Axial Spondyloarthritis. Pascal Zufferey1, Cecile Mouly Jr.1, Hans Rudolf Ziswiler2 and Jean Dudler3, 1 Rheumatology, Lausanne, Switzerland, 2Rheumatology, Bern, Switzerland, 3HFR Fribourg - Hôpital Cantonal, Fribourg, Switzerland 500. Cardiometabolic Abnormalities in Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis: The PRISTINE Trial. M. Elaine Husni1, Abrar A. Qureshi2, Annette Szumski3, Andrew S. Koenig3 and Debbie H. Robertson3, 1 Cleveland Clinic Foundation, Cleveland, OH, 2Brigham and Women’s Hospital, Boston, MA, 3Pfizer Inc., Collegeville, PA 501. Impact of Uveitis On the Phenotype of Patients with Recent Inflammatory Back Pain. Data From the DESIR Cohort. Daniel Wendling1, Clément Prati2, Christophe Demattei3, Corinne Miceli-Richard4, Jean-Pierre Daures3 and Maxime Dougados5, 1Minjoz University Hospital, Besancon, France, 2CHU J Minjoz, Besancon, France, 3CHU, Nimes, France, 4Hopital Bicêtre, Le Kremlin Bicêtre, France, 5ParisDescartes University, Cochin Hospital, Paris, France 502. Cardiovascular Events Are Related to High Levels of HDL-Cholesterol In Ankylosing Spondylitis. Anne Grete Semb1, Tore K. Kvien1, Rana Fayyad2, David A. DeMicco2, John LaRosa3, John Betteridge4, Terje R. Pedersen5 and Ingar Holme5, 1Diakonhjemmet Hospital, Oslo, Norway, 2Pfizer Inc, New York, 3State University of New York health Science Centre, New York, 4Middelsex Hospital, London, United Kingdom, 5Oslo University Hospital-Ullevaal, Oslo, Norway 503. The Degree of Spinal Inflammation Is Similar in Patients with Axial Spondyloarthritis Who Report High or Low Levels of Disease Activity – a Cohort Study. Uta Kiltz1, Xenofon Baraliakos1, Pantelis Karakostas1, Manfred Igelmann2, Ludwig H. Kalthoff3, Claudia Klink4, Dietmar MJ Krause4, Elmar Schmitz-Bortz5, Martina Floerecke1, Matthias Bollow6 and Juergen Braun1, 1Ruhr-University Bochum, Herne, Germany, 2Private Rheumatology office, Bochum, Germany, 3Private rheumatology office, Herne, Germany, 4Private rheumatology office, Gladbeck, Germany, 5 Private rheumatology office, Hattingen, Germany, 6Augusta Krankenanstalten, Bochum, Germany

174

2011 Program Book

504. The Swedish Early Psoriatic Arthritis (SwePsA) Registry. 5-Year Follow-up: Higher Disease Activity, Greater Functional Impairment and Worse Outcome for Women Compared to Men. Elke Theander1, Tomas Husmark2, Gerd-Marie Alenius3, Per Larsson4, Annika Teleman5, Mats Geijer6 and Ulla R. C. Lindqvist7, 1Department of Rheumatology, Skåne University Hospital, Lund University, Malmö, Sweden, 2Department of Rheumatology, Falu Hospital, Falun, Sweden, 3Department of Public Health and Clinical Medicine, Rheumatology, Umeå University Hospital, Umeå, Sweden, 4Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, 5 Spenshult Rheumatological Hospital, Oskarstrom, Sweden, 6 Department of Radiology, Skåne University Hospital, Lund University, Lund, Sweden, 7Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden 505. Gender Differences in the Correlation of Self-Reported Functional Status with Spinal Mobility in Patients with Ankylosing Spondylitis. Pooja N. Patel1, Roozbeh Sharif2, Shervin Assassi3, Lianne S. Gensler4, Laura A. Diekman5, Thomas J. Learch6, Michael H. Weisman7, Michael M. Ward8 and John D. Reveille2, 1University of Texas, Houston, Houston, TX, 2University of Texas Health Science Center at Houston, Houston, TX, 3Univ of Texas Health Science, Houston, TX, 4UCSF, San Francisco, CA, 5UT Health Science Center, Houston, TX, 6Cedars-Sinai, Los Angeles, CA, 7Cedars Sinai Med Ctr, Los Angeles, CA, 8NIAMS/NIH, Bethesda, MD 506. Patients with Non-Radiographic Axial Spondyloarthritis Differ From Patients with Ankylosing Spondylitis in Several aspects– Results of a Cross-Sectional Cohort Study. Uta Kiltz1, Xenofon Baraliakos2, Pantelis Karakostas2, Manfred Igelmann3, Ludwig H. Kalthoff4, Claudia Klink5, Dietmar MJ Krause6, Elmar Schmitz-Bortz7, Martina Floerecke2, Matthias Bollow8 and Juergen Braun2, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Ruhr-University Bochum, Herne, Germany, 3Private Rheumatology office, Bochum, Germany, 4 Private rheumatology office, Herne, Germany, 5Private rheumatology office, Gladbeck, Germany, 6Gladbeck, Germany, 7Private rheumatology office, Hattingen, Germany, 8 Augusta Krankenanstalten, Bochum, Germany 507. Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients Under Biological Therapies in Daily Practice – Results From the Portuguese Register Reuma.Pt. Sofia Ramiro1, Pedro Machado2, Raquel Roque3, Helena Santos4, Joaquim Polido-Pereira5, Daniela Peixoto6, Cátia Duarte7, Fernando Pimentel-Santos8, Cândida Silva4, J. E. Fonseca5, Filipa Teixeira6, Andrea Marques7, Filipe Araújo8, Jaime C. Branco8, José Pereira Da-Silva7, José Costa6, Jose A. Pereira Da Silva9, Luis Cunha Miranda4, J. Canas da Silva3, Helena Canhão5, A.M. Van Tubergen10, Desirée van der Heijde11, Robert Landewé12 and MJ Santos3, 1Hospital Garcia de Orta, Almada, Portugal and Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2 Hospitais da Universidade de Coimbra, Coimbra, Portugal and Leiden University Medical Center, Leiden, Netherlands,

ACR Poster Session A Hospital Garcia de Orta, Almada, Portugal, 4Instituto Português de Reumatologia, Lisboa, Portugal, 5Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 6Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, 7 Hospitais da Universidade de Coimbra, Coimbra, Portugal, 8 Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, 9Centro Hospitalar de Lisboa Norte, Hospital de Santa Maria, Lisboa, Portugal, 10Maastricht University Medical Center, Maastricht, Netherlands, 11Leiden University Medical Center, Leiden, Netherlands, 12Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 3

508. Prevalence and Treatment Patterns of Psoriatic Arthritis in the Health Improvement Network. Alexis Ogdie1, Thorvardur Love2, Kevin Haynes3, Yiding Yu3, Nicole Seminara3, Hyon K. Choi4 and Joel Gelfand3, 1University of Pennsylvania, Philadelphia, PA, 2Landspitali University Hospital, Reykjavík, Iceland, 3University of Pennsylvania., Philadelphia, PA, 4Boston University School of Medicine, Boston, MA 509. The Risk of Malignancy in a Large Cohort of Patients with Psoriatic Arthritis. Rachel L. Gross1, Julie S. SchwartzmanMorris1, Michael Krathen2, George Reed3, Hong Chang2, Katherine C. Saunders4, Mark C. Fisher5, Chaim Putterman1, Philip J. Mease6, Alice B. Gottlieb2 and Anna R. Broder1, 1 Albert Einstein College of Medicine, Bronx, NY, 2Tufts Medical Center, Boston, MA, 3University of Massachusetts, Worcester, MA, 4CORRONA, Inc., Southborough, MA, 5 Massachusetts General Hospital, Boston, MA, 6Seattle Rheumatology Associate, Seattle, WA 510. Hand Bone Loss in Patients with Psoriatic Arthritis: Sub Analysis From IMPACT-2 Study Comparing Infliximab and Placebo. Mari Hoff1, Arthur Kavanaugh2 and Glenn Haugeberg3, 1PhD, Trondheim, Norway, 2University of California San Diego, San Diego, CA, 3PhD, Kristiansand, Norway 511. Early Disease Characteristics of Enthesitis-Related Arthritis Reveals Elevated TGF-Beta. Hemalatha Srinivasalu1, Michael Barnes2, Gerlinde Layh-Schmitt3, Michael M. Ward4 and Robert A. Colbert3, 1NIAMS NIH, Nemours/Alfred I duPont Hospital for Children, Bethesda, MD, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3NIAMS NIH, Bethesda, MD, 4NIAMS/NIH, Bethesda, MD 512. Clinical Predictors Associated with Severe Radiographic Sacroilitis in Axial Spondyloarthritis. Grace Yoon1, Thomas J. Learch2, John C. Davis3 and Lianne S. Gensler4, 1UCSF, San Franciscao, CA, 2Cedars-Sinai, Los Angeles, CA, 3Genentech Inc, South San Francisco, CA, 4UCSF, San Francisco, CA 513. Increased Risk of Cardiovascular Disease in Patients with Active Ankylosing Spondylitis. Inger Jorid Berg1, Sella Provan2, Hanne Dagfinrud3, D.M.F.M. van der Heijde4, Tore

K. Kvien3 and Anne Grete Semb3, 1Diakonhjemmet Hospital, 0319 Oslo, Norway, 2Diakonhjemmet hospital, Oslo, Norway, 3 Diakonhjemmet Hospital, Oslo, Norway, 4Leiden University Medical Center, Leiden, Netherlands 514. Differences Between Women and Men with Recent Onset Axial Spondyloarthritis: Results From the DESIR Cohort. Anne Tournadre1, Bruno Pereira1, Agnes Lhoste1, Jean Jacques Dubost1, Jean Michel Ristori1, Pascal Claudepierre2, Maxime Dougados3 and Martin Soubrier1, 1CHU CLERMONTFERRAND, Clermont-Ferrand, France, 2Paris-Est University; LIC EA4393; APHP, Henri Mondor Hospital, Creteil, France, 3 Paris-Descartes University, Medicine Faculty; UPRES EA4058; APHP, Cochin Hospital, Paris, France 515. Poor Agreement Between Enthesitis on Whole-Body Magnetic Resonance Imaging and Enthesitis on Clinical Examination in Patients with Early Axial Spondyloarthritis – Results From the ESTHER Trial At Baseline. In-Ho Song1, Kay-Geert Hermann2, Hildrun Haibel1, Christian Althoff2, Denis Poddubnyy1, Joachim Listing3, Anja Weiß3, Bruce Freundlich4, Martin Rudwaleit5 and Joachim Sieper1, 1Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 2Charite Medical School, Berlin, Germany, 3German Rheumatism Research Centre, Berlin, Germany, 4University of Pennsylvania, Philadelphia, PA, 5Ev. Krankenhaus Hagen-Haspe, Hagen, Germany 516. Difference in Clinical Presentation of Patients with Spondyloarthritis with a Positive MRI of the SI Joints and/ or HLA-B27 Positivity. R. van den Berg, M. Reijnierse, T.W.J. Huizinga and D.M.F.M. van der Heijde, Leiden University Medical Center, Leiden, Netherlands 517. Comparing 2 Referral Strategies to Diagnose Axial Spondyloarthritis: The Recognizing and Diagnosing Ankylosing Spondylitis Reliably Study. J. Sieper1, S. Srinivasan2, O. Zamani3, H. Mielants4, D. Choquette5, Karel Pavelka6, Anne Gitte Loft7, P. Gehér8, D. Danda9, T. Reitblat10, Fabrizio Cantini11, C. Ancuta12, S. Erdes13, H. Raffayova14, AC Keat15, JS Hill Gaston16 and N. Vastesaeger17, 1Charitè Berlin, Campus Benjamin Franklin, Berlin, Germany, 2Merck, Sharp & Dohme Corporation, Rahway, NJ, 3Rheumazentrum Favoriten, Wien, Austria, 4University Hospital, Gent, Belgium, 5Institute of Rheumatology of Montreal, Montreal, QC, 61Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 7Vejle Hospital, Vejle, Denmark, 8Semmelweis University, Budapest, Hungary, 9Christian Medical College, Vellore, India, 10 Barzilai Medical Centre, Ashkelon, Israel, 11Stabilimento Ospedaliero Misericordia, Prato, Italy, 12G.T.Popa Center for Biomedical Research, Iasi, Romania, 13Scientific Institute of Rheumatology, Moscow, Russia, 14National Institute of Rheumatic Diseases, Pieš any, Slovakia, 15Northwick Park Hospital, Harrow, United Kingdom, 16Univ of Cambridge/Clin Med, Cambridge, United Kingdom, 17Merck, Sharp & Dohme Corporation, Brussels, Belgium

2011 Program Book

175

ACR Poster Session A 518. Associations Between Axial and Peripheral Signs of Ankylosing Spondylitis and the Acute Phase Response: A Prospective Longitudinal Study in 411 Patients. Siddharth Bethi1, Abhijit Dasgupta1, Michael H. Weisman2, Thomas J. Learch3, Lianne S. Gensler4, John C. Davis5, John D. Reveille6 and Michael M. Ward1, 1NIAMS/NIH, Bethesda, MD, 2Cedars Sinai Med Ctr, Los Angeles, CA, 3Cedars-Sinai, Los Angeles, CA, 4UCSF, San Francisco, CA, 5Genentech Inc, South San Francisco, CA, 6University of Texas Health Science Center at Houston, Houston, TX 519. Low Lipid Levels are related to Disease activity in Ankylosing Spondylitis. Inger Jorid Berg1, Anne Grete Semb2, Désirée van der Heijde3, Hanne Dagfinrud2, Sella Provan4 and Tore K. Kvien2, 1Diakonhjemmet Hospital, 0319 Oslo, Norway, 2Diakonhjemmet Hospital, Oslo, Norway, 3 Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Diakonhjemmet hospital, Oslo, Norway 520. Circulating Mediators of Bone Remodelling in Patients with Psoriatic and Rheumatoid Arthritis Treated with Anti-TNFAlpha Therapy. Agnes Szentpetery1, Harjit P. Bhattoa2, Peter Antal-Szalmas2, Zoltan Szekanecz3 and Oliver M. FitzGerald1, 1 St. Vincent’s University Hospital, Dublin, Ireland, 2University of Debrecen, Medical and Health Science Center, Debrecen, Hungary, 3University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary 521. Spondyloarthritis: A Clinical Comparison Between Men and Women. Jacqueline E. Paramarta, Leen E. De Rycke, Carmen A. Ambarus, Paul P. Tak and Dominique L. Baeten, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands 522. Evidence for a Link Between Inflammation and Radiographic Progression in Ankylosing Spondylitis. Nigil Haroon1, Nathalie Morency2, Richard J. Cook3, Ker-Ai Lee3, Stephanie Wichuk2, Proton Rahman4, Dafna D. Gladman1, Robert D. Inman1 and Walter P. Maksymowych2, 1Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 2University of Alberta, Edmonton, AB, 3University of Waterloo, Waterloo, ON, 4St. Claires Mercy Hospital, St. Johns, NF 523. WITHDRAWN. 524. Serum Levels of Adiponectin and Insulin Resistance Are Increased in Patients with Psoriatic Arthritis Compared to Those with Psoriasis Alone. Lihi Eder1, Remy Pollock1, Fawnda Pellett2, Jai Jayakar3, Arane Thavaneswaran1, Daniel Pereira2, Cheryl Rosen2, Vinod Chandran2 and Dafna D. Gladman1, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3University of Western Ontario, London, ON 525. Anti TNFα Agents Are More Effective Than Methotrexate in Preventing Radiographic Joint Damage Among Patients with Psoriatic Arthritis in a Clinic Setting. Lihi Eder1, Arane

176

2011 Program Book

Thavaneswaran1, Vinod Chandran2 and Dafna D. Gladman1, 1 Toronto Western Hospital, University of Toronto, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON 526. Association Between Clinical Factors and Radiographic Severity in Ankylosing Spondylitis. Tae-Jong Kim1, SeungHun Lee2, Kyung-Bin Joo3 and Tae-Hwan Kim4, 1Chonnam National University Medical School and Hospital, Gwangju, South Korea, 2South Korea, 3Hanynag University, Seoul, South Korea, 4Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 527. Rheumatologist’s Expert Opinion Is An Important Determinant of Tumor Necrosis Factor Blocking Agent Prescription in Axial Spondyloarthritis: Results From the Swiss Clinical Quality Management Axial Spondyloarthritis Cohort. Almut Scherer1, Ulrich Weber2, Pascale Exer3, Juerg Bernhard4, Jean Dudler5, Giorgio Tamborrini6, Bettina Weiss2, Ruediger Mueller7, Beat A. Michel6, Rudolf O. Kissling2, Adrian Ciurea6 and on behalf of the SCQM Rheumatologists8, 1 SCQM Foundation, Zurich, Switzerland, 2Balgrist University Hospital, Zurich, Switzerland, 3Private Rheumatology Practice, Basel, Switzerland, 4Buergerspital, Solothurn, Switzerland, 5Hôpital Cantonal, Fribourg, Switzerland, 6 Department of Rheumatology, University Hospital, Zurich, Switzerland, 7Cantonal Hospital, St. Gallen, Switzerland, 8 Scqm, Switzerland 528. WITHDRAWN. 529. Dyslipidemia in Patients with Seronegative Spondyloarthropathies. Charalampos Papagoras1, Theodora E. Markatseli1, Ioanna Saougou1, Haralampos J. Milionis2 and Alexandros A. Drosos3, 1Fellow in Rheumatology, Ioannina, Greece, 2Assistant Professor of Internal Medicine, Ioannina, Greece, 3Professor of Medicine/Rheumatology, Ioannina, Greece 530. Body Mass Index Influences the Response to Infliximab in Ankylosing Spondylitis. Sébastien Ottaviani1, Yannick Allanore2, Florence Tubach3, Blandine Pasquet3, Olivier Meyer4 and Philippe Dieude5, 1APHP, Paris, France, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3APHP, Hôpital Bichat, Paris, France, 4 Hopital Bichat, Paris, France, 5APHP, Hopital Bichat, Paris, France 531. The Role of CRP and Peripheral Disease in Achieving ASDAS Response to Anti-TNF Therapy in 397 Patients with Ankylosing Spondylitis. Karen Minde Fagerli1, Elisabeth Lie2, D.M.F.M. van der Heijde3, Marte S. Heiberg1, Erik Rødevand4, Cecillie Kaufmann5, Knut Mikkelsen6, Synnøve Kalstad7 and Tore K. Kvien2, 1Diakonhjemmet hospital, Oslo, Norway, 2 Diakonhjemmet Hospital, Oslo, Norway, 3Leiden University Medical Center, Leiden, Netherlands, 4Trondheim, Norway, 5 Vestre Viken, Drammen, Norway, 6Lillehammer Hosp for Rheumatic Diseases, Lillehammer, Norway, 7Tromsø, Norway

ACR Poster Session A 532. Prevalence of Psoriatic Arthritis in Dermatological Patients with Psoriasis. Joerg C. Henes1, Michael Eisfelder2, Anette Adamczyk3, Björn Knaudt3, Felix Jacob3, Eva-Maria Zuipa1, Ralf Denfeld4, Jürgen Lux5, Armin Philipp4, Carolin Steigleder4, Martin Kleinhans4, Nicole Oster4, Gerhard Fierlbeck3 and Ina Kötter6, 1University Hospital Tuebingen, Tuebingen, Germany, 2Private practice, Rottweil, Rottweil, Germany, 3University Hospital Tuebingen, Department of dermatology, Tuebingen, Germany, 4Private practice, Stuttgart, Germany, 5Private practice, Tuebingen, Germany, 6 Department of Internal Medicine II, Rheumatology Division, Tübingen, Germany 533. Predictors of ASDAS Major Improvement in Patients with Ankylosing Spondylitis Receiving Their First TNF Inhibitor. Results From a Longitudinal Observational Study. Karen Minde Fagerli1, Elisabeth Lie2, Marte S. Heiberg1, D.M.F.M. van der Heijde3, Synnøve Kalstad4, Knut Mikkelsen5, Cecillie Kaufmann6, Erik Rødevand7 and Tore K. Kvien2, 1 Diakonhjemmet hospital, Oslo, Norway, 2Diakonhjemmet Hospital, Oslo, Norway, 3Leiden University Medical Center, Leiden, Netherlands, 4Tromsø, Norway, 5Lillehammer Hosp for Rheumatic Diseases, Lillehammer, Norway, 6Vestre Viken, Drammen, Norway, 7Trondheim, Norway 534. Differences in Comorbidities Related to Rheumatoid Arthritis and Psoriatic-Arthritis: Data From Large Prospective Observational Studies. Frank Behrens1, Diamant Thaci2, Hanns-Martin Lorenz3, Brigitte KrummelLorenz4, Lothar Meier5, Holger Gnann6, Gerd Greger7, Bianca Wittig7 and Harald Burkhardt1, 1CIRI/Rheumatology, J.W. Goethe University, Frankfurt/Main, Germany, 2Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, 3Medizinische Klinik und Poliklinik, Universität, Heidelberg, Germany, 4 CIRI/Endokrinologikum, Frankfurt/Main, Germany, 5 CIRI/Rheumatologische Schwerpunktpraxis, Hofheim, Germany, 6Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, 7Abbott GmbH & Co KG, Wiesbaden, Germany 535. Sustained Improvement of Spinal Mobility, Physical Function, and Quality of Life in Patients with Ankylosing Spondylitis: 5-Year Results. Désirée van der Heijde1, Maxime A. Breban2, Dale G. Halter3, Gino DiVittorio4, Johan Bratt5, Fabrizio Cantini6, Sonja Kary7, L. Steven Brown8, Hartmut Kupper7, Tracy F. Nicholson9 and Philip J. Mease10, 1 Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Hopital Ambroise Pare, Boulogne, France, 3Houston, TX, 4Mobile, AL, 5Karolinska Univ Hosp Huddinge, Stockholm, Sweden, 6Stabilimento Ospedaliero Misericordia, Prato, Italy, 7Abbott GmBH & Co KG, Ludwigshafen, Germany, 8Abbott Laboratories, Abbott Park, IL, 9Abbott Laboratories, 10Seattle Rheumatology Associate, Seattle, WA

536. Adenosine Receptor Signaling in Keratinocyte Proliferation and Implications for Caffeine and Methotrexate Therapy. Gideon Smith1, Andrew G. Franks2, Bruce N. Cronstein3 and Edwin SL Chan1, 1New York University School of Medicine, New York, NY, 2New York University, New York, NY, 3New York Univ Medical Center, New York, NY 537. The Prevalence of Carotid Artery Plaques Is Higher in Patients with Psoriatic Arthritis Compared to Those with Psoriasis Alone. Lihi Eder1, Jai Jayakar2, Sutharshini Shanmugarajah2, Arane Thavaneswaran1, Daniel Pereira2, Vinod Chandran2, Cheryl Rosen2 and Dafna D. Gladman1, 1 Toronto Western Hospital, University of Toronto, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON 538. Sclerostin Predicts Radiographic Progression in Patients with Ankylosing Spondylitis on Standard Therapies but Not in Patients on Tumor Necrosis Factor Blockers. Walter P. Maksymowych1, Nathalie Morency1, Stephanie Wichuk1, Barbara Conner-Spady1 and Georg Schett2, 1University of Alberta, Edmonton, AB, 2University of Erlangen-Nuremberg, Erlangen, Germany 539. WITHDRAWN. 540. Clinical Features of Pustulotic Arthro-Osteitis. Jun-ichi Fukushi, Yasuharu Nakashima, Ken Okazaki, Taro Mawatari, Masanobu Ohishi, Yasutaka Tashiro and Yukihide Iwamoto, Kyushu University, Fukuoka, Japan 541. High Prevalence of Spondyloarthritis Among First Degree Relatives of Patients with Familial Mediterranean Fever: Further Evidence for a Link Between the Two Disorders. Servet Akar1, Ozgul Soysal2, Dilek Solmaz2, Vedat Gerdan2, Fatos Onen1 and Nurullah Akkoc1, 1Professor, Izmir, Turkey, 2 MD, Izmir, Turkey 542. The Presence of HLA-B15 Determines the Clinical Presentation and Outcome in Colombian`s Patients with Spondyloarthropathies. John Londono1, Paola Peña2, Ana Santos3, Wilson Bautista - Molano2, Consuelo Romero Sanchez2, Mabel Avila4, Marlon Porras4, Calos Jaramillo3, G. Vargas-Alarcon5 and Rafael Valle-Oñate6, 1Universidad de La Sabana, Chía, Colombia, 2Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/ Universidad de La Sabana. Bogotá. Colombia, Bogotá, Colombia, 3Universidad de Los Andes, Bogota, Colombia, 4 Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogota, Colombia, 5Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico DF, Mexico, 6Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/ Universidad de La Sabana, Bogotá, Colombia 543. Rituximab (RTX) Therapy for Psoriatic Arthritis (PsA). M. Esther Jimenez Boj1, Jozef Rovensky2, Tanja A. Stamm1, H. Raffayova3, Burkhard F. Leeb4, Klaus P. Machold5 and Josef Smolen6, 1Medical University of Vienna, Vienna, Austria, 2 Vurch, Piestany, 3National Institute of Rheumatic Diseases,

2011 Program Book

177

ACR Poster Session A Piestany, Slovakia, 4State Hospital Weinviertel ,Lower Austrian Centre for Rheumatology, Stockerau, Austria, 5 Vienna Med Univ, Vienna, Austria, 6Medical University of Vienna and Hietzing Hospital, Vienna, Austria 544. Expression of Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) and Osteoclast Precursor (OCP) Frequency in Psoriasis (PsC) Patients Who Develop Psoriatic Arthritis (PsA). Yahui Grace Chiu1, Sutharshini Shanmugarajah2, Dafna D. Gladman2, Ben Panepento1, Sharon Moorehead1, Lihi Eder2, Vinod Chandran2, Rick Barrett1 and Christopher T. Ritchlin3, 1University of Rochester, Rochester, NY, 2Toronto Western Hospital, Toronto, ON, 3University of Rochester Medical Center, Rochester, NY 545. WITHDRAWN. 546. Radiographic Progression in Ankylosing Spondylitis – Results After up to 8 Years of Infliximab Treatment. Xenofon Baraliakos1, Hildrun Haibel2, Joachim Listing3, Joachim Sieper4 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 3German Rheumatism Research Centre, Berlin, Germany, 4Charité – Campus Benjamin Franklin, Berlin, Germany 547. Cardio-Metabolic Risk Profile of Patients with Psoriatic Arthritis and Psoriasis. Yih Chang Lin1, Kiyoko Uno1, Neil J. Korman2, Neil Borkar2, Katherine Wolski1, Danielle Brennan1, Vaibhav Pawar2, Stephen J. Nicholls3 and M. Elaine Husni1, 1 Cleveland Clinic Foundation, Cleveland, OH, 2University Hospitals - Case Medical Center, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland 548. Approaching Psoriatic Arthritis - Comparing the Patients’s Perspective to Physicians’ Evaluations. Matthias Englbrecht, Stefan W. H. Dandorfer, Monika R. Ronneberger, Veronika Lang and Georg Schett, University of Erlangen-Nuremberg, Erlangen, Germany 549. Radiological Characteristics of the Calcaneal Spurs in Psoriatic Arthritis. Mohammed Abufayyah1, David Salonen2, Arane Thavaneswaran3, Vinod Chandran1 and Dafna D. Gladman3, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2University Health Network, Toronto, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON 550. Smoking Is Associated with Syndesmophyte Development in Ankylosing Spondylitis. Dilek Solmaz1, Servet Akar2, Ismail Sari3, Ozgul Soysal1, Vedat Gerdan1, Fatos Onen2 and Nurullah Akkoc2, 1MD, Izmir, Turkey, 2Professor, Izmir, Turkey, 3 DOKUZ EYLUL UNIVERSITY SCHOOL OF MEDICINE, Izmir, Turkey 551. Three Phenotype Profiles Are Revealed by Cluster Analysis in Early Inflammatory Back Pain Suggestive of Spondyloarthritis (SPA). Results From the DEvenir Des Spondyloarthropathies Indifferenciées Récentes (DESIR) Cohort. Maria-Antonietta D’Agostino1, Philippe Aegerter2,

178

2011 Program Book

Maxime A. Breban3 and Maxime Dougados4, 1VersaillesSaint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France, 2Versailles-Saint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital,, Boulogne-Billancourt,, France, 3Hopital Ambroise Pare, Boulogne, France, 4Paris-Descartes University, Paris, France 552. Atherosclerotic Burden In Patients with Psoriatic Arthritis and Psoriasis: Do They Differ? Yih Chang Lin1, Kiyoko Uno1, Neil Borkar2, Danielle Brennan1, Vaibhav Pawar2, Katherine Wolski1, Neil J. Korman2, Stephen J. Nicholls3, Soo Hyun Kim4 and M. Elaine Husni1, 1Cleveland Clinic Foundation, Cleveland, OH, 2University Hospitals - Case Medical Center, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland, 4 Cleveland Clinic, Cleveland, OH

Systemic Lupus Erythematosus - Animal Models 553. Inhibition of Hyaluronan Synthesis with 4-Methylumbelliferone In NZBWF1/J Mice Is Associated with Improved Renal Function and Reduced Renal Inflammation. Susan Yung, Wan Wai Tse, Mel Chau and Tak Mao Chan, The University of Hong Kong, Hong Kong SAR, Hong Kong 554. Carabin, a Negative Regulator of B Cells, Points Out a New Defective Biological Pathway In Systemic Lupus Erythematosus. Jean-Nicolas Schickel1, Jean-Louis Pasquali1, Anne Soley1, Anne-Marie Knapp1, Marion Decossas1, Luc Marcellin2, Anne-Sophie Korganow1, Thierry Martin1 and Pauline Soulas-Sprauel1, 1IBMC, Strasbourg, France, 2 Hôpitaux Universitaires de Strasbourg, Strasbourg, France 555. TWEAK/Fn14 Pathway Blockade Attenuates Renal Disease In Autoantibody-Induced Nephritis. Yumin Xia1, Sean Campbell1, Leal Herlitz2, Jennifer S. Michaelson3, Linda C. Burkly3 and Chaim Putterman4, 1Albert Einstein College of Med, Bronx, NY, 2Columbia Presbyterian Medical Center, 3 Biogen Idec, Cambridge, MA, 4Albert Einstein College of Medicine, Bronx, NY 556. Deficiency of the TWEAK Receptor Fn14 Is Protective In the MRL-Lpr/Lpr Mouse Model of Lupus Nephritis. Yumin Xia1, Jing Wen1, Jennifer S. Michaelson2, Linda C. Burkly2 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY 557. Interferon Regulatory Factor-4 deficient Lupus-Prone MRL/Lpr Mice Show Strong Propensity for Th1 Polarity and Develop Granulomatous Lesions in Multiple Organs. Hidemaru Sekine1, Takeshi Machida1, Eiji Suzuki2, Christopher Reilly3, Xian Zhang4, Phil Ruiz5 and Gary S. Gilkeson6, 1Fukushima Medical University, Fukushima, Japan, 2Medical University of South Carolina, Charleston, SC, 3Virginia Tech, Blacksburg, VA, 4Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, 5University of Miami, Miami, FL, 6Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC

ACR Poster Session A 558. TNFα Inhibition Prevents Peri-Glomerular Resident Renal Macrophage Accumulation and Activation in SLE Nephritis. Ramalingam Bethunaickan1, Yiting Tang2 and Anne Davidson3, 1Feinstein Institute for Medical research, Manhasset, NY, 2Feinstein Institute for Medical Research, Manhasset, 3Feinstein Institute for Medical Research, Manhasset, NY 559. Increased Expression of Ribonuclease Prolongs Survival in Murine Lupus. Xizhang Sun1, Nalini Agrawal1, Lena Tanaka1, Martha Hayden-Ledbetter1, Kelly L. Hudkins1, Charles E. Alpers1, Silvia Bolland2, Jeffrey A. Ledbetter1 and Keith B. Elkon1, 1University of Washington, Seattle, WA, 2NIH, NIAID, Rockville, MD 560. Laquinimod Inhibits Disease Severity and Progression in Mouse Models of Lupus: Alone and in Combination with Standard of Care Agents. Joel F. Kaye, Revital Etzyoni, Rotem Keshet-Katz, Emanuel Raymond and Eran Blaugrund, Teva Pharmaceuticals Ltd, Netanya, Israel 561. Impaired Inhibition on B Cell Activation by Bone MarrowDerived Mesenchymal Stem Cells with Decreased CCL2 Expression in MRL/Lpr Mice. Nan Che, Xia Li and Lingyun Sun, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Jiangsu 210008, China P.R, Nanjing, China 562. Yaa-Mutation Induces Phenotype Shift From Rheumatoid Arthritis to Systemic Lupus Erythematosus in FcgRIIBDeficient B6 Mice. Hirofumi Amano, Shinya Kawano, Toshiyuki Kaneko, Aya Sato-Hayashizaki, Lin Qingshun, Yoshinari Takasaki and Sachiko Hirose, Juntendo University School of Medicine, Tokyo, Japan 563. Anti-Interleukin 23 Antibody Alleviates Nephritis in MRL/ Lpr lupus-Prone Mice. Ourania Kampagianni, George C. Tsokos and Vasileios C. Kyttaris, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 564. Dysregulation of Clade A Serine Protease Inhibitor Expression in Murine and Human Lupus. Jack Hutcheson1, Kamala Vanarsa1, Soyoun Min1, Tianfu Wu1 and Chandra Mohan2, 1University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 2University of Texas Southwestern Medical Center, Dallas, TX 565. IL-21R Is Required for the Systemic Accumulation of Activated B and T Lymphocytes in MRLlpr Mice. Andrew L. Rankin1, Tatyana Andreyeva1, Yijun Carrier2, Mary Collins3, Cheryl L. Nickerson-Nutter3, Deborah Young2 and Kyri Dunussi-Joannopoulos3, 1Pfizer, Inc., Cambridge, MA, 2 Colleague, Cambridge, MA, 3Pfizer, Cambridge, MA 566. Role of CD5+ B Cells in the Suppression of Fatal Autoimmunity in Lupus-Prone Mice. Yuriy Baglaenko1, NanHua Chang2, Evelyn Pau3 and Joan E. Wither2, 1University of Toronto, Toronto, ON, 2Toronto Western Research Institute, University Health Network, Toronto, ON, 3Toronto Western Research Institute, Toronto, ON

567. Effects of Fasudil Treatment on Lupus Pathogenesis in NZB/W F1 Female Mice. Roslynn A. Stirzaker1, Partha S. Biswas1, Sanjay Gupta1, Weijia Yuan1, Li Song1, Uma Chandrasekaran1, Govind Bhagat2 and Alessandra B. Pernis1, 1 Hospital for Special Surgery, New York, NY, 2Columbia University, New York, NY 568. The PD-1 Pathway Promotes Survival and Continuing Function of CD4+ regulatory T Cells in (New Zealand Black x New Zealand White) F1 Lupus-Prone Mice. Maida Wong1, Antonio La Cava2 and Bevra H. Hahn3, 1UCLA, Los Angeles, CA, 2Univ of California Los Angeles, Los Angeles, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA 569. Differential Effect of Autologous Versus Allogeneic Mesenchymal Stem Cell Transplantation in Lupus Prone Mice. Fei Gu1, Ivan Molano2, Lingyun Sun3 and Gary S. Gilkeson4, 1Division of Rheumatology and Immunology,Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, SC, 3The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 4Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC 570. Enhanced Survival of Anergic Self-Reactive B Cells in New Zealand Black Chromosome 1 Congenic Mice. Nan-Hua Chang, Christina Loh, Evelyn Pau, Yuriy Baglaenko and Joan E. Wither, Toronto Western Research Institute, University Health Network, Toronto, ON 571. Mirna-Let-7a Increases IL-6 Production in Mouse Mesangial Cells. Cristen Chafin, Nicole Regna and Christopher Reilly, Virginia Tech, Blacksburg, VA 572. Oral Delivery of a Tolerogenic Peptide Reduces Disease Severity and Prolongs Survival in SLE-Prone Mice. Brian Skaggs, Elaine Lourenco and Bevra H. Hahn, UCLA David Geffen School of Medicine, Los Angeles, CA 573. Negative Regulatory Role of TCR zeta Chain in the Pathogenesis of Systemic Lupus Erythematosus Through Lipid Rafts. Guo-Min Deng, Jessica Beltran and George C. Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 574. Leptin Impinges on the Clearance of Autoimmune T Cells in Murine Lupus. Gil Amarilyo1, Noriko Iikuni2, Bevra H. Hahn3 and Antonio La Cava4, 1University of California, Los Angeles, Los Angeles, CA, 2UCLA, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Univ of California Los Angeles, Los Angeles, CA 575. Dispensability of APRIL to Development of Systemic Lupus Erythematosus (SLE) In SLE-Prone NZM 2328 Mice. Chaim O. Jacob1, Shunhua Guo1, Noam Jacob1, Rahul Pawar2, Chaim Putterman3, William J. Quinn III4, Michael P. Cancro4, Thi-Sau Migone5 and William Stohl1, 1University of Southern California Keck School of Medicine, Los Angeles, CA, 2Albert Einstein College of Med, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4University of Pennsylvania School of Medicine, Philadelphia, PA, 5Human Genome Sciences, Rockville, MD 2011 Program Book

179

ACR Poster Session A 576. Fn14 Deficiency Ameliorates Neuropsychiatric Disease In MRL-Lpr/Lpr Lupus Prone Mice. Jing Wen1, Yumin Xia1, Jennifer S. Michaelson2, Linda C. Burkly2, Maria Gulinello1 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY

Systemic Lupus Erythematosus - Clinical Aspects I 577. Restoration of Regulatory T Cells-Th17 Cells Balance in Systemic Lupus Erythematosus Through Vitamin D Supplementation. Benjamin Terrier1, Yoland Schoindre2, Guillaume Geri3, David Saadoun4, Kubéraka Mariampillai5, Michelle Rosenzwajg6, David Klatzmann6, Jean-Charles Piette3, Patrice Cacoub3 and Nathalie CostedoatChalumeau3, 1Pitié-Salpêtrière Hospital, Paris, France, 2Foch Hospital, Suresnes, France, 3CHU Pitié-Salpêtrière, Paris, France, 4Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier PitiéSalpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 5Pitié-Salpétrière Hospital, Paris, France, 6Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Paris, France 578. Safety Profile of Belimumab, a B-Lymphocyte Stimulator– Specific Inhibitor, in Phase 2 and 3 Clinical Trials of Patients with Active Systemic Lupus Erythematosus. D.J. Wallace1, S. Navarra2, M. Petri3, A. Gallacher4, R. Gúzman5, M. Thomas6, R.A. Furie7, O. Zamani8, R.A. Levy9, R.F. van Vollenhoven10, S. Cooper11, Z.J. Zhong11, W. Freimuth11, L. Pineda11, R. Cervera12 and BLISS-52 and -76 and LBSL02/99 Study Groups13, 1Cedars-Sinai/UCLA, Los Angeles, CA, 2University of Santo Tomas Hospital, Manila, Philippines, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Hospital Británico de Buenos Aires, Buenos Aires, Argentina, 5 IDEARG, SaludCoop, Bogotá, Colombia, 6Kerala Institute of Medical Sciences, Kerala, India, 7North Shore-LIJ Health System, Lake Success, NY, 8Rheumazentrum Favoriten, Wien, Austria, 9Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, 10The Karolinska Institute, Stockholm, Sweden, 11Human Genome Sciences, Inc., Rockville, MD, 12 Hospital Clinic, Barcelona, Spain, 13Multicenter 579. Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients with Systemic Lupus Erythematosus. Chi Chiu Mok1, Pak To Chan1, Ling Yin Ho2, Ka Lung Yu1 and Chi Hung To1, 1Tuen Mun Hospital, Hong Kong, Hong Kong, 2 Tuen Mun Hospital, Hong Kong SAR, Hong Kong 580. A Risk Management Program Led by a Nurse Improves Cardiovascular and Osteoporosis Risk Management in a Specialized Lupus Clinic. Anne Cymet1, Carolina LandoltMarticorena2, Dafna D. Gladman3, Paul R. Fortin2 and Murray B. Urowitz2, 1University Health Network, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON

180

2011 Program Book

581. Antimalarials: A Window of Opportunity to Improve the Influenza A/H1N1 Vaccine Response in Lupus Patients Under Immunosuppressive Agents. Eduardo F. Borba1, Carla G.S. Saad1, Sandra G. Pasoto1, Ana L. G. Calich1, Nadia E. Aikawa1, Ana C. M. Ribeiro2, Julio C. B. Moraes2, Elaine P. Leon1, Luciana P.C. Seguro1, Lissiane K. N. Guedes1, Clovis A. Silva1, Celio Goncalves2, Ricardo Fuller3, Suzimara A. Oliveira1, Maria A. Ishida4, Alexander R. Precioso5 and Eloisa Bonfa6, 1University of Sao Paulo, Sao Paulo, Brazil, 2 Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3University of Sao Paulo, São Paulo, Brazil, 4 Adolfo Lutz Institute, Sao Paulo, Brazil, 5Butantan Institute, Sao Paulo, Brazil, 6Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil 582. Defensins and Cardiovascular Disease In Systemic Lupus Erythematosus. Stefan Vordenbäumen, Oliver Sander, Ellen Bleck, Matthias Schneider and Rebecca Fischer-Betz, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany 583. Differences Between Male and Female Systemic Lupus Erythematosus In a Multi-Ethnic Population. Tan Tze Chin1, Hong Fang1, Laurence S. Magder2 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of Maryland, Baltimore, MD 584. Sustained Disease Improvement and Safety Profile Over the 1500 Patient-Year Experience (6 years) with Belimumab in Patients with Systemic Lupus Erythematosus. J.T. Merrill1, R.A. Furie2, D.J. Wallace3, W. Stohl4, W. Winn Chatham5, A. Weinstein6, J. Mckay7, E.M. Ginzler8, Z.J. Zhong9, L. Pineda9, J. Klein9, W. Freimuth9, M. Petri10 and LBSL02/99 Study Group11, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2North Shore-LIJ Health System, Lake Success, NY, 3Cedars-Sinai/UCLA, Los Angeles, CA, 4USC/Keck School of Medicine, Los Angeles, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6Washington Hospital Center, Washington, DC, 7Oklahoma State University Center for Health Sciences, Tulsa, OK, 8SUNY Downstate Medical Center, Brooklyn, NY, 9Human Genome Sciences, Inc., Rockville, MD, 10Johns Hopkins University School of Medicine, Baltimore, MD, 11Multicenter 585. Association between B-Cell Activating Factor Gene Expression and Disease Characteristics in Systemic Lupus Erythematosus. Michelle Petri1, Wenzheng Hu1, Hong Fang1, Jie Xu1, Jadwiga Bienkowska2, Norm Allaire2, John Carulli2 and Matthew D. Linnik3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Biogen Idec Inc., Cambridge, MA, 3 Biogen Idec Inc., Solana Beach, CA 586. Decreased Breast Cancer Risk In SLE: Can a Genetic Basis Be Determined? Sasha Bernatsky1, Douglas Easton2, Alison M. Dunning2, Rosalind Ramsey-Goldman3, Caroline Gordon4, William Foulkes5, Kyriaki Michailidou2 and Ann E. Clarke6, 1 McGill UHC/RVH, Montreal, QC, 2University of Cambridge, United Kingdom, 3Northwestern University, Chicago, IL, 4 University of Birmingham, Birmingham, United Kingdom, 5 McGill University, Montreal, QC, 6Research Institute of the McGill Univ. Health, Montreal, QC

ACR Poster Session A 587. Cystatin C Is Associated with Inflammation but Not Atherosclerosis In Systemic Lupus Erythematosus. Ratchaya Lertnawapan1, Aihua Bian2, Young Hee Rho1, Paolo Raggi3, Annette Oeser4, Joseph F. Solus4, Tebeb Gebretsadik2, Ayumi Shintani2 and C. Michael Stein4, 1Div.of Clinical Pharmacology and Rheumatology, Dept.of Medicine and Pharmocology, School of Medicine, Vanderbilt University, Nashville, TN, 2 Vanderbilt Medical Center, Nashville, TN, 3Div.of Cardiology, Emory University, Atlanta, GA, 4Vanderbilt University, Nashville, TN 588. A New 30-Year Cardiovascular Risk Prediction Score Does Not Differ in Women with Systemic Lupus Erythematosus and Control Subjects. Vivian K. Kawai1, Joseph F. Solus1, Annette Oeser1, Young Hee Rho1, Paolo Raggi2, Aihua Bian3, Tebeb Gebretsadik3, Ayumi Shintani3 and C. Michael Stein1, 1 Vanderbilt University, Nashville, TN, 2Div.of Cardiology, Emory University, Atlanta, GA, 3Vanderbilt Medical Center, Nashville, TN 589. Development of Damage and Death in a Large Cohort of SLE Patients. Chee-Seng Yee1, Deva Situnayake2, Simon J. Bowman3, Veronica Toescu1, Richard A. Hickman1 and Caroline Gordon1, 1University of Birmingham, Birmingham, United Kingdom, 2Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom, 3University Hospital Birmingham, Birmingham, United Kingdom 590. Depression in Systemic Lupus Erythematosus, Dependent or Independent of Severity of Disease. Eric van Exel1, Jonathan Jacobs1, Lindy-Anne Korswagen1, Alexandre Voskuyl1, Max Stek1, Joost Dekker2 and Irene Bultink1, 1 VU University Medical Center, Amsterdam, Netherlands, 2 Reade, Centre for Rehabilitation and Rheumatology, VU University Medical Centre, Department of Rehabilitation Medicine, EMGO Institute and Department of Psychiatry, Amsterdam, Netherlands 591. A Prospective Study of Seizures in Systemic Lupus Erythematosus. John G. Hanly1, Murray B. Urowitz2, Li Su3, Caroline Gordon4, Sang-Cheol Bae5, Jorge SanchezGuerrero6, Juanita Romero-Diaz7, Daniel Wallace8, Ann Clarke9, Sasha Bernatsky10, E.M. Ginzler11, Joan T. Merrill12, David A. Isenberg13, Anisur Rahman14, M. Petri15, Paul R. Fortin16, Dafna D. Gladman17, Ian N. Bruce18, Kristjan Steinsson19, M.A. Dooley20, Munther A. Khamashta21, Graciela S. Alarcon22, Barri J. Fessler23, Rosalind RamseyGoldman24 and Susan Manzi25, 1Dalhousie University, Halifax, NS, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6 Mount Sinai Hospital/University Health Network, Toronto, ON, 7INCMNSZ, Mexico city, Mexico, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9Montreal General Hospital, Montreal,

QC, 10McGill UHC/RVH, Montreal, QC, 11SUNY-Downstate Medical Center, Brooklyn, NY, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13University College London, London WC1E 6JF, United Kingdom, 14University College London, London, United Kingdom, 15Johns Hopkins University School of Medicine, Baltimore, MD, 16Toronto Western Hospital, Toronto, ON, 17Toronto Western Hospital, University of Toronto, Toronto, ON, 18A, Manchester, United Kingdom, 19Landspital Univ Hospital, Reykjavik, Iceland, 20 University of North Carolina at Chapel Hill, Chapel Hill, NC, 21 Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 22 University of Alabama at Birmingham, Birmingham, AL, 23Univ of Alabama-Birmingham, Birmingham, AL, 24 Northwestern University Feinberg School of Medicine, Chicago, IL, 25Allegheny Singer Research Institute, Pittsburgh, PA 592. Predictors of Seizures in Systemic Lupus Erythematosus. John G. Hanly1, Murray B. Urowitz2, Li Su3, Caroline Gordon4, Sang-Cheol Bae5, Jorge Sanchez-Guerrero6, Juanita RomeroDiaz7, Daniel Wallace8, Ann E. Clarke9, Sasha Bernatsky10, E.M. Ginzler11, Joan T. Merrill12, David A. Isenberg13, Anisur Rahman14, M. Petri15, Paul R. Fortin16, Dafna D. Gladman17, Ian N. Bruce18, Kristjan Steinsson19, M.A. Dooley20, Munther A. Khamashta21, Graciela S. Alarcon22, Barri J. Fessler23, Rosalind Ramsey-Goldman24 and Susan Manzi25, 1Dalhousie University and Capital Health, Halifax, NS, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, 4 University of Birmingham, Birmingham, United Kingdom, 5 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Mount Sinai Hospital/University Health Network, Toronto, ON, 7INCMNSZ, Mexico city, Mexico, 8 Cedars-Sinai/UCLA, Los Angeles, CA, 9Research Institute of the McGill Univ. Health, Montreal, QC, 10McGill UHC/ RVH, Montreal, QC, 11SUNY-Downstate Medical Center, Brooklyn, NY, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13University College London, London WC1E 6JF, United Kingdom, 14University College London, London, United Kingdom, 15Johns Hopkins University School of Medicine, Baltimore, MD, 16Toronto Western Hospital, Toronto, ON, 17Toronto Western Hospital, University of Toronto, Toronto, ON, 18A, Manchester, United Kingdom, 19 Landspital Univ Hospital, Reykjavik, Iceland, 20University of North Carolina at Chapel Hill, Chapel Hill, NC, 21Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 22University of Alabama at Birmingham, Birmingham, AL, 23Univ of Alabama-Birmingham, Birmingham, AL, 24Northwestern University Feinberg School of Medicine, Chicago, IL, 25 Allegheny Singer Research Institute, Pittsburgh, PA

2011 Program Book

181

ACR Poster Session A 593. Plasma Levels of Osteopontin Identify Patients At Risk for Organ Damage in Systemic Lupus Erythematosus. Ornella J. Rullo1, Jennifer MP Woo1, Alice DC Hoftman1, Miriam F. Parsa1, David Elashoff2, Paul Maranian3, Jennifer M. Grossman4, Bevra H. Hahn4, Maureen A. McMahon3, Deborah K. McCurdy1 and Betty P. Tsao3, 1Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, CA, 3 David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 4UCLA David Geffen School of Medicine, Los Angeles, CA 594. All-Trans Retinoic Acid Sustains the Stability and Function of Natural Regulatory T Cells From Human and Patients with SLE. Qin Lan1, Julie Wang1, Hui-Ming Fan2, David Brand3, Hejian Zou4, Zhong-Min Liu2 and Song G. Zheng1, 1 University of Southern California, Los Angeles, CA, 2 Shanghai East Hospital, Tonji University, Shanghai, China, 3 VA Medical Center, Memphis, TN, 4Huashan Hospital, Shanghai, China 595. Monocyte Chemoattractant Protein-1 and Pentraxin in Systemic Lupus Erythematosus. Adnan Kiani1, Thor Ueland2, Pal Aukrust2, Laurence S. Magder3, Ivana Hollan4 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2The Oslo University, Oslo, Norway, 3University of Maryland, Baltimore, MD, 4 Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway 596. Increase In Vitamin D Improves Urine Protein/Creatinine Ratio and Complement In Systemic Lupus Erythematosus. Michelle Petri1, Kayode J. Bello1, Hong Fang1 and Laurence S. Magder2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD 597. The Contribution of Cell Bound Complement Activation Products to the Diagnosis of Systemic Lupus Erythematosus. Kenneth C. Kalunian1, W. Chatham2, Elena M. Massarotti3, Cole Harris4, R.A. Furie5, Jill P. Buyon6, Eliza F. Chakravarty7, Emily C. Somers8, Puja Chitkara9, Rachel L. Gross10, Kyriakos A. Kirou11, Joyce Reyes-Thomas12, Rosalind Ramsey-Goldman13, Christine Hsieh14, Chaim Putterman15, Thierry Dervieux16 and A. Weinstein17, 1UCSD School of Medicine, La Jolla, CA, 2UAB Arthritis Clinical Intervention Program, Birmingham, AL, 3Brigham and Women’s Hospital, Boston, MA, 4Exagen Diagnostics, 5North Shore-LIJ Health System, Lake Success, NY, 6NYU School of Medicine, New York, NY, 7Stanford University, Palo Alto, CA, 8University of Michigan, Ann Arbor, MI, 9SDAMC, San Diego, CA, 10 Albert Einstein College of Medicine, New York, NY, 11 Mary Kirkland Center for Lupus Care, Hospital for Special Surgery, New York, NY, 12Albert Einstein College of Med, Bronx, NY, 13Northwestern University Feinberg School of Medicine, Chicago, IL, 14University of Chicago, Chicago, IL, 15 Albert Einstein College of Medicine, Bronx, NY, 16Exagen Diagnostics, Albuquerque, NM, 17Washington Hospital Center, Washington, DC

182

2011 Program Book

598. Predictors of Organ Damage At the Time of Systemic Lupus Erythematosus Diagnosis, and of Rates of Increase in Damage After Diagnosis. Sneha Purvey1, Hong Fang1, Laurence S. Magder2 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD 599. Time to Recovery From Proteinuria in Lupus Nephritis Patients Receiving Standard of Care Treatment. Zahi Touma1, Murray B. Urowitz1, Dominique Ibanez1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 600. Proposal for a Reliable and Feasible Algorithm for the Identification of Antinuclear Antibodies. Kaline M.C. Pereira, Alessandra Dellavance and Luis E. C. Andrade, Universidade Federal de São Paulo and Fleury Health and Medicine Laboratories, Sao Paulo, Brazil 601. Longitudinal Assessment of SLE Disease Activity: BILAG-2004, SLEDAI-2000 or Both? Chee-Seng Yee1, Caroline Gordon1, David A. Isenberg2, Bridget Griffiths3, Lee- Suan Teh4, Ian N. Bruce5, Yasmeen Ahmad6, Anisur Rahman7, Athiveeraramapandian Prabu1, Mohammed Akil8, Neil J. McHugh9, Christopher Edwards10, DP. D’Cruz11, Munther A. Khamashta12 and Vernon Farewell13, 1University of Birmingham, Birmingham, United Kingdom, 2University College London, London WC1E 6JF, United Kingdom, 3 Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 4 Royal Blackburn Hospital, Blackburn, United Kingdom, 5 A, Manchester, United Kingdom, 6The Department of Rheumatology, Betsi Cadwaladr University Health Board (West), Llandudno, LL30 1LB, UK, Wales, United Kingdom, 7 University College London, London, United Kingdom, 8 Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, 9Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 10Southhampton General Hospital, Southampton, United Kingdom, 11St. Thomas’ Hospital, London, United Kingdom, 12Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 13MRC Biostatistics Unit, Cambridge, United Kingdom 602. Post Hoc British Isles Lupus Assessment Group Index Mucocutaneous Organ Domain Item Analysis of Systemic Lupus Erythematosus Patients Treated in Phase 3 Belimumab Clinical Trials. Susan Manzi1, Dafna Gladman2, Sandra Navarra3, Jorge Sanchez-Guerrero4, David D’Cruz5, William Freimuth6, Z. John Zhong6, Greg Keenan6 and BLISS-52 and BLISS-76 Study Groups7, 1Allegheny Singer Research Institute, Pittsburgh, PA, 2Toronto Western Hospital, Toronto, ON, 3University of Santo Tomas Hospital, Manila, Philippines, 4University Health Network/Mount Sinai Hospital, Toronto, ON, 5St. Thomas’ Hospital, London, United Kingdom, 6Human Genome Sciences, Inc., Rockville, MD, 7 Multicenter

ACR Poster Session A 603. Vascular Cell Adhesion Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin in Systemic Lupus Erythematosus. Adnan Kiani1, Hong Fang1, Tianfu Wu2, Laurence S. Magder3, Chandra Mohan4 and Michelle Petri1, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 3University of Maryland, Baltimore, MD, 4 University of Texas Southwestern Medical Center, Dallas, TX 604. Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry: Prevalence and Risk Factors of Pulmonary Arterial Hypertension and Interstitial Lung Disease in Chinese Patients with Systemic Lupus Erythematosus. Qian Wang Jr.1, Mengtao Li1, Jiuliang Zhao1, Xiaofeng Zeng2 and Chinese SLE Treatment and Research Group (CSTAR)3, 1Peking Union Medical College Hospital, Beijing, China, 2Peking Union M edical College Hospital , Peking Union M edical College,, Beijing, China, 3Beijing, China 605. The BILAG-2004 Systems Tally - a Novel Way of Analysing the BILAG-2004 Scores. Chee-Seng Yee1, Caroline Gordon1, David A. Isenberg2, Bridget Griffiths3, Lee- Suan Teh4, Ian N. Bruce5, Yasmeen Ahmad6, Anisur Rahman7, Athiveeraramapandian Prabu1, Mohammed Akil8, Neil J. McHugh9, Christopher Edwards10, DP. D’Cruz11, Munther A. Khamashta12 and Vernon Farewell13, 1University of Birmingham, Birmingham, United Kingdom, 2University College London, London WC1E 6JF, United Kingdom, 3 Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 4 Royal Blackburn Hospital, Blackburn, United Kingdom, 5 A, Manchester, United Kingdom, 6The Department of Rheumatology, Betsi Cadwaladr University Health Board (West), Llandudno, LL30 1LB, UK, Wales, United Kingdom, 7 University College London, London, United Kingdom, 8 Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, 9Royal National Hospital, Bath, United Kingdom, 10University of Southampton, Southampton, United Kingdom, 11St. Thomas’ Hospital, London, United Kingdom, 12Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 13MRC Biostatistics Unit, Cambridge, United Kingdom 606. Seasonal Variation In the Activity of Systemic Lupus Erythematosus. Alí Duarte-García1, Hong Fang1, Chi Hung To2, Laurence S. Magder3 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Chelsea Heights, Hong Kong, Hong Kong, 3University of Maryland, Baltimore, MD 607. Predictors of Corticosteroid Tapering in Systemic Lupus Erythematosus Patients. Zaki Abou Zahr1, Hong Fang1, Laurence S. Magder2 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD

608. Results of a French Multicenter Randomized Prospective Study (the PLUS Study) on Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-Blood Concentration. Nathalie Costedoat-Chalumeau1, L. Galicier1, O. Aumaitre1, C. Francès1, Véronique Le Guern2, F. Lioté1, A. Smail1, N. Limal1, L. Perard1, H. Desmurs-Clavel1, B. Asli1, C. Grandpeix1, Olivier Pourrat3, F. Ackermann1, T. Papo1, B. Brihaye1, O. Fain1, J. Stirnemann1, Moez Jallouli1, J. Cohen1, Marie-Laure Tanguy1, Js Hulot1, L. Musset1, Zahir Amoura1 and . the investigators of the PLUS study1, 1CHU Pitié-Salpêtrière, Paris, France, 2Cochin Hospital, Paris, France, 3CHU poitiers, Poitiers, France 609. Biologics use in SLE in 23 Centers - Data from the International Registry for Biologics In SLE (IRBIS). R.F. van Vollenhoven1, Søren Jacobsen2, Daniel Wallace3, John G. Hanly4, Michelle Petri5, David A. Isenberg6, Sasha Bernatsky7, Sang-Cheol Bae8, Manuel Ramos-Casals9, Guillermo RuizIrastorza10, Francisco J. García-Hernández11, Luis Saez12, José Luis Callejas13, Javier Rascón14, Enrique de Ramón15, Mª Mar Ayala-Gutiérrez15, Maite Camps15, Melinda Mild16, Murat Inanç17, Bahar Artim-Esen17, Rosalind Ramsey-Goldman18, Christine A. Peschken19, Danilo Squatrito20, László Kovács21, Andrea Doria22, Zoltan Szekanecz23, Elisa Gremese24 and Emilia I. Sato25, 1Karolinska University Hospital, Stockholm, Sweden, 2Rigshospitalet - 4242, Copenhagen, Denmark, 3 Cedars-Sinai/UCLA, Los Angeles, CA, 4Dalhousie University and Capital Health, Halifax, NS, 5Johns Hopkins Hospital, Baltimore, MD, 6University College London, London WC1E 6JF, United Kingdom, 7McGill UHC/RVH, Montreal, QC, 8 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 9Hospital Clínic, Barcelona, Spain, 10 Hospital de Cruces, Bizkaia, Spain, 11Hospital Virgen del Rocío, Sevilla, Spain, 12Hospital Miguel Servet, Zaragoza, Spain, 13Hospital San Cecilio, Granada, Spain, 14Hospital Son Dureta, Palma de Mallorca, Spain, 15Hospital Carlos Haya, Málaga, Spain, 16Karolinska Institutet, Stockholm, Sweden, 17 Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey, 18Northwestern University Feinberg School of Medicine, Chicago, IL, 19Univ of Manitoba, Winnipeg, MB, 20 Careggi Hospital- Florence, Florence, Italy, 21University of Szeged, Szeged, Hungary, 22University of Padova, Padova, Italy, 23University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, 24Rheumatology Unit, Catholic University, Roma, Italy, 25Escola Paulista de Medicina Universidade Federal de São Paulo, Sao Paulo, Brazil 610. Differences in Autoantibody Profiles, Disease Activity (SLEDAI) and Damage (SDI) Scores Between ChildhoodOnset Lupus and Adult-Onset Lupus: A Meta-Analysis. Brieanna Livingston1, Ashley Bonner2 and Janet E. Pope3, 1 University of Western Ontario, London, ON, 2McMaster University, Hamilton, ON, 3St. Joseph Health Care London, London, ON

2011 Program Book

183

ACR Poster Session A 611. Why Do Lupus Patients Go to the Emergency Department in the United States? Marina Scolnik1, Ajitha Mannalithara2, Enrique R. Soriano1 and Gurkirpal Singh2, 1Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Stanford University School of Medicine, Palo Alto, CA 612. Achieving Consensus on Quality Indicators for Pediatric Systemic Lupus Erythematosus. Joshua D. Pendl1, Matthew C. Hollander2, Shannen L. Nelson1, Xolti Morgan3, Nicolino Ruperto4, Michael W. Beresford5, Marisa Klein-Gitelman6, Marilynn G. Punaro7, Anne M. Stevens2, Tadej Avcin8, Graciela Espada9, Tsz-Leung Lee10, Yu-Lung Lau10, Jennifer L. Huggins1, Esi Morgan Dewitt1 and Hermine Brunner1, 1 Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Seattle Children’s Hospital, Seattle, WA, 3University of Cincinnati, Cincinnati, OH, 4PRINTO-IRCCS, Genova, Italy, 5 Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom, 6Children’s Memorial Hospital, Chicago, IL, 7Texas Scottish Rite Hospital, Dallas, TX, 8University Children’s Hospital Ljubljana, Ljubljana, Slovenia, 9Childrens Hosp Ricardo Gutierrez, Buenos Aires, Argentina, 10The University of Hong Kong, Hong Kong, Hong Kong 613. Effect of Hydroxychloroquine and Statin Therapy on ProInflammatory Cytokines and Disease Activity in a Lupus Cohort. Rohan Willis1, Praveen Jajoria1, Brock E. Harper1, Emilio B. Gonzalez1, M. Petri2, Ehtisham Akhter2, Hong Fang2 and Silvia S. Pierangeli1, 1University of Texas Medical Branch, Galveston, TX, 2Johns Hopkins University School of Medicine, Baltimore, MD 614. Increased Disease Activity Measure in Systemic Lupus Erythematosus Is Adversely Associated with Pregnancy and Pregnancy Outcomes. Lisa A. Davis1, Vincent M. Davis1, Laura Trupin2, Jinoos Yazdany3, Edward Yelin4 and Joann Zell5, 1Univ of Colorado School of Med, Aurora, CO, 2UC San Francisco, San Francisco, CA, 3University of California San Francisco, San Francisco, CA, 4UCSF, San Francisco, CA, 5 National Jewish Health, Denver, CO 615. Urinary λ Free Light Chain Concentration Is Associated with Disease Activity and Response to Treatment in Proliferative Lupus Nephritis. Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Yumi Koseki, Yasuhiro Katsumata, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota, Sayuri Kataoka and Hisashi Yamanaka, Tokyo Women’s Medical University, Tokyo, Japan 616. Lymphoproliferative Disorders in Patients with Systemic Lupus Erythematosus At the University of Michigan. Jason S. Knight and Emily C. Somers, University of Michigan, Ann Arbor, MI 617. Disease Activity and Quality of Life in Refractory Cutaneous Lupus Erythematosus Patients Initiated on Immunosuppressive Therapy. Aileen Y. Chang1, Elizabeth Ghazi2, Joyce Okawa1 and Victoria P. Werth1, 1Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, 2UMDNJRobert Wood Johnson Medical School, Piscataway, NJ

184

2011 Program Book

618. Higher Education Level is Associated with Decreased Compliance in an Urban Multi-Ethnic Lupus Cohort. Rachel L. Gross, Dawn M. Wahezi, Chaim Putterman and Irene Blanco, Albert Einstein College of Medicine, Bronx, NY 619. Distribution of Urine Protein/Creatinine Ratio by Urinalysis Protein Dipstick Score In Systemic Lupus Erythematosus. Hong Fang1, Laurence S. Magder2 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of Maryland, Baltimore, MD 620. Avoidance of Major Bleeding Complications Post Renal Biopsy In Lupus Nephritis Patients with Co-Existing Antiphospholipid Syndrome. Natasha Jordan, Ahlem I. Chaib, Shirish Sangle, Fahim Tungekar, Munther Khamastha, Tarun Sabharwal, Ian Abbs and David P. D’Cruz, Louise Coote Lupus Unit, St Thomas’ Hospital, London, United Kingdom 621. Serum Macrophage Migration Inhibitory Factor In Systemic Lupus Erythematosus with Long-Term Remission and Its Relationship to Chronic Glucocorticoid Exposure. Yoko Wada1, Hiroe Sato1, Daisuke Kobayashi1, Takeshi Nakatsue1, Shuichi Murakami1, Takeshi Kuroda1, Masaaki Nakano2 and Ichiei Narita1, 1Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Niigata University School of Medicine, Niigata, Japan 622. Association of Lupus Nephritis Class with Poor Longterm Outcomes. Michelle Petri and Hong Fang, Johns Hopkins University School of Medicine, Baltimore, MD 623. Ultrasound Assessment of Erosive hand arthritis In Systemic Lupus Erythematosus. Elisabeth M.A Ball1, Madeleine Rooney2 and Aubrey Bell3, 1Musgrave Park Hospital/Queens’ University, Belfast, United Kingdom, 2 Arthritis Research Group, Queen’s University, Belfast, United Kingdom, 3Musgrave Park Hospital/Queens’ University, Belfast, Ireland 624. Human CD8 regulatory T cells generated Ex-Vivo have Potent Protective Activity In Vivo. Qin Lan, Stephanie Pan, Dixon Gray, Julie Wang, Song G. Zheng and David A. Horwitz, USC Keck School of Medicine, Los Angeles, CA 625. Higher Frequency and Worse Outcome of Lupus Nephritis in Korean Male. Jiwon Hwang1, Jaejoon Lee1, Joong Kyong Ahn2, Chan Hong Jeon3, Hoon-Suk Cha1 and Eun-Mi Koh1, 1 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Soonchunhyang University College of Medicine, Bucheon, South Korea 626. Impact of Health Literacy on Treatment Adherence and Clinical Outcomes in Patients with Systemic Lupus Erythematosus. Maria F. Marengo1, Michael A. Kallen1, Sofia De Achaval2, Vanessa Cox1, Araceli Garcia3, Marsha Richardson4 and Maria E. Suarez-Almazor5, 1UT MD Anderson Cancer Center, Houston, TX, 2U.T. MD Anderson Cancer Center, Houston, TX, 3UT MD Anderson, Houston, 4 UT MD Anderson, Houston, TX, 5University of Texas. M.D Anderson Cancer Center, Houston, TX

ACR Poster Session A 627. Risk Factors to Predict the Development of Chronic Kidney Disease In Patients with Lupus Nephritis. Dong-Jin Park1, Sung-Ji Lee1, Tae-Jong Kim2, Yong-Wook Park2 and ShinSeok Lee1, 1Chonnam National University Medical School, Gwangju, South Korea, 2Chonnam National University Medical School and Hospital, Gwangju, South Korea 628. Emergency Room Visits and Hospitalizations in Systemic Lupus Erythematosus. Jie Xu, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 629. Eltrombopag As Steroid Sparing Therapy for Immune Thrombocytopenic Purpura (ITP) in Systemic Lupus Erythemathosus (SLE), Report of Three Cases. Marie Claire Maroun1, Rosanne Ososki2, Judith Andersen1, Frank B. Vasey1 and J. Patricia Dhar1, 1Wayne State University, Detroit, MI, 2Detroit Medical Center, Detroit, MI 630. How Does Cutaneous Lupus Disease Area and Severity Index (CLASI) Compare with Physician Assessments of Cutaneous Activity and Damage in Lupus? Meenakshi Jolly, Nazia Kazmi, Rachel A. Mikolaitis and Joel A. Block, Rush University Medical Center, Chicago, IL 631. Clinical Outcomes In SLE Patients Since the introduction of the 2003 ISN/RPS Classification of Lupus Nephritis. Natasha Jordan, Shirish Sangle, Yousuf Karim, Fahim Tungekar, Ian Abbs and David P. D’Cruz, Louise Coote Lupus Unit, St Thomas’ Hospital, London, United Kingdom

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I: Susceptibility and Pathogenic Mechanisms 632. Phenotypic Associations of Genetic Susceptibility Loci In Systemic Lupus Erythematosus. Elena Sanchez1, Ajay Nadig1, Bruce C. Richardson2, Barry I. Freedman3, Kenneth Kaufman4, Timothy B. Niewold5, Diane L. Kamen6, Gary S. Gilkeson7, Carl D. Langefeld3, Robert P. Kimberly8, J.T. Merrill1, Juan-Manuel Anaya9, Judith A. James10, Bernardo Pons-Estel11, Javier Martin12, Sang-Cheol Bae13, Kathy L. Moser14, Tomothy J. Vyse15, Lindsey A. Criswell16, Patrick M. Gaffney14, Betty P. Tsao17, Chaim O. Jacob18, John B. Harley19, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS and GENLES20 and Amr H. Sawalha1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Michigan, Ann Arbor, MI, 3Wake Forest University Health Sciences, Winston-Salem, NC, 4Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 5University of Chicago, Chicago, IL, 6Medical University of SC, Charleston, SC, 7Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 8University of Alabama at Birmingham, Birmingham, AL, 9Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Rosario, Argentina, 12Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 13Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 14Arthritis and Clinical Immunology

Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 15King’s College London, Guy’s Hospital, London, United Kingdom, 16University of California San Francisco, San Francisco, CA, 17UCLA School of Medicine, Los Angeles, CA, 18Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 19 Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 20Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK 633. Genetic Associations with Serologic Autoimmunity in a Large Multi-Ancestral Systemic Lupus Erythematosus Cohort. Silvia Kariuki1, Beverly S. Franek1, Akaash A. Kumar1, Marissa Kumabe1, Kenneth M. Kaufman2, Juan-Manuel Anaya3, Marta E. Alarcón-Riquelme4, Sang-Cheol Bae5, Elizabeth E. Brown6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly11, Javier Martin12, Joan T. Merrill13, Bernardo Pons-Estel14, Betty P. Tsao15, Timothy J. Vyse16, Carl D. Langefeld7, John B. Harley17, Kathy L. Moser18, Patrick M. Gaffney18, Andrew D. Skol1 and Timothy B. Niewold1, 1University of Chicago, Chicago, IL, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica Pfizer-Universidad de GranadaJunta de Andalucía (GENYO), Granada, Spain, on behalf of the BIOLUPUS and GENLES networks, Oklahoma City, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 7Wake Forest School of Medicine, Winston-Salem, NC, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11University of Alabama at Birmingham, Birmingham, AL, 12Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 13Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Sanatorio Parque, Rosario, Argentina, 15David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 16Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 17Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 18Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

2011 Program Book

185

ACR Poster Session A 634. Association of a Functional Variant in TLR7 with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Multiple Ancestries. Yun Deng1, Jian Zhao1, Wenfeng Tan1, Kenneth M. Kaufman2, Elizabeth E. Brown3, Jeffrey C. Edberg4, Diane L. Kamen5, Gary S. Gilkeson6, Chaim O. Jacob7, Robert H. Scofield8, Robert P. Kimberly on behalf of PROFILE investigators4, Carl D. Langefeld9, Marta E. Alarcόn-Riquelme on behalf of the BIOLUPUS and GENLES10, John B. Harley11, Timothy J. Vyse12, Patrick M. Gaffney13, Kathy L. Moser13, Judith A. James14, Ji-Yih Chen15, Ted R. Mikuls16, Nancy A. Shadick17, Michael E. Weinblatt17, S. Louis Bridges Jr.18, Harold E. Paulus1 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Medical University of SC, Charleston, SC, 6Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 7Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 8Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 10Center for Genomics and Oncological Research, Pfizer-University of Granada-Junta de Andalucia, Granada, Spain and Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 12Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 13Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 15Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Taipei, Taiwan, 16Omaha VA and University of Nebraska, Omaha, NE, 17Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 18Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 635. The Association Between the TNFAIP3 Gene Polymorphisms and Systemic Lupus Erythematosus: A Meta-Analysis. Young Ho Lee1, Sung Jae Choi1, Jong Dae Ji1 and Gwan Gyu Song2, 1Korea University Medical Center, Seoul, South Korea, 2Korea University Medical Center, Seoul

186

2011 Program Book

636. A Single Risk Haplotype in the Region of UBE2L3 Is Associated with Systemic Lupus Erythematosus in Multiple Ethnic Populations. Shaofeng Wang1, Indra Adrianto1, Graham B. Wiley1, Kenneth M. Kaufman2, JuanManuel Anaya3, Marta E. Alarcón-Riquelme on behalf of the BIOLUPUS and GENLES networ4, Sang-Cheol Bae5, Elizabeth E. Brown6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly on behalf of PROFILE investigators11, Javier Martin12, Joan T. Merrill1, Timothy B. Niewold13, Bernardo Pons-Estel14, Betty P. Tsao15, Tomothy J. Vyse16, Carl D. Langefeld7, John B. Harley17, Edward Wakeland18, Kathy L. Moser19, Courtney G. Montgomery1 and Patrick M. Gaffney19, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3 Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation; Center for Genomics and Oncological Research, Oklahoma City; Granada, Spain, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6 University of Alabama at Birmingham, Birmingham, AL, 7 Wake Forest School of Medicine, Winston-Salem, NC, 8 Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 12 Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 13University of Chicago, Chicago, IL, 14Sanatorio Parque, Rosario, Argentina, 15David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 16King’s College London, Guy’s Hospital, London, United Kingdom, 17Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 18Univ of Texas SW Med Ctr, Dallas, TX, 19Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 637. A Functional Haplotype in the Region of TNIP1 Is Associated with Systemic Lupus Erythematosus in Multiple Populations. Indra Adrianto1, Graham B. Wiley1, Shaofeng Wang1, Kenneth M. Kaufman2, Juan-Manuel Anaya3, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES networks4, Sang-Cheol Bae5, Elizabeth E. Brown for PROFILE6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly6, Javier Martin11, Joan T. Merrill1, Timothy B. Niewold12, Betty P. Tsao13, Timothy J. Vyse14, Carl D. Langefeld7, John B. Harley15, Edward K. Wakeland16, Kathy L. Moser17, Courtney G. Montgomery1 and Patrick M. Gaffney17, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical

ACR Poster Session A Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica PfizerUniversidad de Granada-Junta de Andalucía (GENYO), Granada, Spain, Oklahoma City, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6 University of Alabama at Birmingham, Birmingham, AL, 7 Wake Forest School of Medicine, Winston-Salem, NC, 8 Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 12University of Chicago, Chicago, IL, 13David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 14Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 15Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 16Univ of Texas SW Med Ctr, Dallas, TX, 17Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 638. The Role of BsmI and FokI Vitamin D Receptor Gene Polymorphisms and Serum 25-Hydroxyvitamin D in Systemic Lupus Erythematosus. Odirlei A. Monticielo1, Jose A. B. Chies1, Guilherme G. Rucatti2, Maria G. F. Longo1, R. Scalco3, João Carlos T. Brenol1 and Ricardo M. Xavier1, 1 Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Universidade Federal do Rio Grande do Sul, Porto A legre, Brazil, 3Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil 639. SLE-Risk Alleles of SNPs in the NMNAT2/SMG7 Region Are Associated with Lower mRNA Levels of SMG7. Jian Zhao1, Daisuke Sakurai1, Yun Deng1, Andrea L. Sestak2, Carl D. Langefeld3, Kenneth M. Kaufman4, Jennifer A. Kelly5, Patrick M. Gaffney6, Kathy L. Moser6, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network7, John B. Harley8, Sang-Cheol Bae9, Timothy J. Vyse10, Chaim O. Jacob11, Robert P. Kimberly on behalf of PROFILE investigators12, Lindsey A. Criswell13, Judith A. James14, Gary S. Gilkeson15, Juan-Manuel Anaya16, Deh-Ming Chang17, Yeong W. Song18, Jennifer M. Grossman19, Bevra H. Hahn19, Rita M. Cantor20 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3 Wake Forest University Health Sciences, Winston-Salem, NC, 4US Department of Veterans Affairs Medical Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Arthritis and Clinical Immunology Research

Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain and Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 9 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 10Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 11Keck School of Medicine University of Southern California, Los Angeles, CA, 12University of Alabama Birmingham, Birmingham, AL, 13Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California San Francisco, San Francisco, CA, 14Department of Medicine, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 16Universidad del RosarioCorporacion para Investigaciones Biologicas, Bogota, Colombia, 17National Defense Medical Center, Taipei, 18Seoul National University, Seoul, 19UCLA David Geffen School of Medicine, Los Angeles, CA, 20University of California Los Angeles, Los Angeles, CA 640. Association of Androgen Receptor Gene Polymorphism with Damage in Systemic Lupus Erythematosus. Yun Deng1, Jennifer M. Grossman2, Qiong Fu1, William Martin1, Matthew Quirk1, Ornella J. Rullo3, Susan A. Boackle4, Chaim Putterman5, Jane E. Salmon6, Vasileios C. Kyttaris7, George C. Tsokos7, Erika Magdangal1, Lori Sahakian2, Weiling Chen1, Jennifer MP Woo3, Deborah K. McCurdy3, Chack-Yung Yu8, Bevra H. Hahn2, Maureen A. McMahon1 and Betty P. Tsao1, 1 David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2UCLA David Geffen School of Medicine, Los Angeles, CA, 3Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA, 4 University of Colorado Denver School of Medicine, Aurora, CO, 5Albert Einstein College of Medicine, Bronx, NY, 6Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 7Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 87Center for Molecular and Human Genetics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Columbus, OH 641. Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus (SLE) Varies Across Populations with Different African Ancestries. Paula S. Ramos1, James C. Oates2, Diane L. Kamen2, Patrick M. Gaffney3, Carl D. Langefeld1, Jennifer A. Kelly3, Kenneth M. Kaufman3, Robert P. Kimberly4, Timothy B. Niewold5, Chaim O. Jacob6, Betty P. Tsao7, Elizabeth Brown for PROFILE4, Judith A. James8, Joel Guthridge3, Joan T. Merrill3, Susan A. Boackle9, Barry I. Freedman1, R. Hal Scofield3, Anne M. Stevens10, Timothy J. Vyse11, Lindsey A. Criswell12, Kathy L. Moser3, Marta E. 2011 Program Book

187

ACR Poster Session A Alarcon-Riquelme13, John B. Harley14 and Gary S. Gilkeson2, 1 Wake Forest School of Medicine, Winston-Salem, NC, 2 Medical University of South Carolina, Charleston, SC, 3 Oklahoma Medical Research Foundation, Oklahoma City, OK, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Chicago, Chicago, IL, 6Keck School of Medicine, University of Southern California, Los Angeles, CA, 7 David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 8Oklahoma Medical Research Foundation and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9 University of Colorado Denver School of Medicine, Aurora, CO, 10University of Washington, Seattle, WA, 11King’s College London, Guy’s Hospital, London, United Kingdom, 12 University of California San Francisco, San Francisco, CA, 13Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 14Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH 642. Fine Mapping of Xq28: Both MECP2/IRAK1 and NAA10/ RENBP Contribute to Risk for SLE in Multiple Ancestral Groups. Kenneth M. Kaufman1, Jennifer A. Kelly2, Travis Hughes2, Adam Adler2, Elena Sanchez2, Joshua O. Ojwang2, Carl D. Langefeld3, Julie T. Ziegler3, Judith A. James4, Elizabeth E. Brown5, Robert P. Kimberly6, Jeffrey C. Edberg7, Lindsey A. Criswell8, Deh-Ming Chang9, Gary S. Gilkeson10, Timothy B. Niewold11, Sang-Cheol Bae12, Marta E. Alarcón-Riquelme13, Chaim O. Jacob14, Kathy L. Moser15, Patrick M. Gaffney15, John B. Harley16, Amr H. Sawalha2 and Betty P. Tsao17, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Wake Forest University Health Sciences, Winston-Salem, NC, 4 Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 5 Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 6 University of Alabama at Birmingham, Birmingham, AL, 7Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 8University of California San Francisco, San Francisco, CA, 9National Defense Medical Center, Taipei, 10Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 11 University of Chicago, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13 Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain, on behalf of the BIOLUPUS and GENLES networks, Oklahoma City, OK, 14Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 15Arthritis and Clinical Immunology Research Program,

188

2011 Program Book

Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 17David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA 643. Triple X Syndrome (47,XXX) Increases the Risk and Accelerates the Onset of Systemic Lupus Erythematosus and Sjögren’s Syndrome: Support for a Gene-Dose Effect From the X Chromosome. Skyler P. Dillon1, Lydia Kao1, Kenneth M. Kaufman2, John A. Ice2, Roald Omdal3, Xavier Mariette4, Torsten Witte5, Gabor G. Illei6, Maureen Rischmueller7, Gunnel Nordmark8, Roland Jonsson9, Marie Wahren Herlenius10, Timothy J. Vyse11, Michael T. Brennan12, Benjamin A. Rybicki13, Wan-Fai Ng14, Barbara M. Segal15, Nelson L. Rhodus16, Joan T. Merrill2, Courtney G. Montgomery2, Christopher J. Lessard2, John B. Harley17, Kathy L. Moser18, Patrick M. Gaffney18 and R. Hal Scofield2, 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 4Université Paris-Sud, Le Kremlin Bicetre, France, 5Hannover Medical School, Hanover, Germany, 6NIDCR/ NIH #10 1N110, Bethesda, MD, 7Queen Elizabeth Hospital, Adelaide, Australia, 8Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 9University of Bergen, Bergen, Norway, 10CMM L8204 Karolinska Hosp, Stockholm, Sweden, 11Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom, 12Carolinas Medical Center, Charlotte, NC, 13Henry Ford Health System, Detroit, MI, 14Newcastle University, Newcastle upon Tyne, United Kingdom, 15Hennepin County Medical Center, Minneapolis, MN, 16University of Minnesota, Minneapolis, MN, 17Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 18Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 644. Effects of OAZ In Regulating B-Cell Proliferation by Mesenchymal Stem Cells From Patients with Systemic Lupus Erythematosus. Xuebing Feng1, Yan Liu1, Nan Che1, Dandan Wang1, Betty P. Tsao2 and Lingyun Sun1, 1Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2UCLA School of Medicine, Los Angeles, CA 645. Differential DNA Methylation Associated with AntidsDNA Autoantibody Production In Systemic Lupus Erythematosus. Sharon A. Chung1, Kimberly E. Taylor1, Hong L. Quach2, Lisa F. Barcellos2 and Lindsey A. Criswell1, 1 University of California, San Francisco, San Francisco, CA, 2 University of California, Berkeley, Berkeley, CA 646. Circulating T Helper Cells in Patients with Systemic Lupus Erythematosus Share the Phenotypic Property with Lymphoid T Follicular Helper Cells. Elvira Lindwall1, Carl

ACR Poster Session A Gauthier1, Anika Alarakhia1, Gwendoline Menga1, Jerald M. Zakem1, William E. Davis1, Tamika A. Webb-Detiege1, Young Sung Choi1, Robert Quinet2 and Xin Zhang1, 1Ochsner Medical Center, New Orleans, LA, 2Ochsner Medical Center New Orleans, New Orleans, LA

Statens Serum Institut, Copenhagen S, Denmark, 2Statens Serum Institute, Copenhagen S, Denmark, 3Dept of Clinical Sciences Lund, Section of Microbiology, Immunology and Glycobiology, Lund, Sweden, 4Rigshospitalet - 4242, Copenhagen, Denmark

1

647. Microarray Analysis of the autologous Hematopoietic Stem Cell Transplantation Induced Remission Associated CD8 Treg Cells Gene Expression Profile. Li Zhang, Anne M. Bertucci, Richard K. Burt and Syamal K. Datta, Northwestern University FSM, Chicago, IL

653. Enhanced Apoptosis and Senescence of Bone MarrowDerived Mesenchymal Stem Cells From Patients with Systemic Lupus Erythematosus. Lei Liu, Defang Meng, Xia Li and Lingyun Sun, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

648. Peptides Inducing Potent Autoantigen-Specific Treg Cells in Human Lupus. Li Zhang1, Anne M. Bertucci1, Rosalind Ramsey-Goldman2, Richard K. Burt1 and Syamal K. Datta1, 1 Northwestern University FSM, Chicago, IL, 2Northwestern University Feinberg School of Medicine, Chicago, IL

654. Activated NF-Kb in Mesenchymal Cells From SLE Patients Inhibits Osteogenic Differentiation Through DownRegulating Smad Signaling. Yu Tang, Jiyun Zhang and Lingyun Sun, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

649. Genome-Wide Association Scan of Antigenic Epitopes of Lupus Specific Autoantibodies in European Americans. Chee Paul Lin1, Indra Adrianto1, Jessica J. Hale1, Jennifer A. Kelly1, Stuart B. Glenn1, Jourdan Anderson1, Kenneth M. Kaufman2, John B. Harley3, Tomothy J. Vyse4, Robert P. Kimberly5, Marta E. Alarcón-Riquelme1, Carl D. Langefeld6, Betty P. Tsao7, Lindsey A. Criswell8, Chaim O. Jacob9, Patrick M. Gaffney1, Kathy L. Moser1, Judith A. James1 and Courtney G. Montgomery1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Cincinnati, OK, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4King’s College London, Guy’s Hospital, London, United Kingdom, 5University of Alabama at Birmingham, Birmingham, AL, 6Wake Forest University Health Sciences, Winston-Salem, NC, 7David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 8Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California San Francisco, San Francisco, CA, 9 Keck School of Medicine University of Southern California, Los Angeles, CA

655. High Oxidation Status Induced the Rearrangement of F-Actin Cytoskeleton of Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus Via Downregulation of RhoA Signaling Pathway. Dongyan Shi, Xia Li and Lingyun Sun, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

650. Inhibited Expression of HPK1 Associated with Loss of JMJD3 Promoter Binding Contributes to Autoimmunity in Systemic Lupus Erythematosus. Qing Zhang, Hai Long, Jieyue Liao, Ming Zhao, Gongping Liang, Xiaoyan Wu, Peng Zhang, Shu Ding, Shuangyan Luo and Qianjin Lu, Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Medical Epigenomics, Changsha, China 651. Increased IL-21R Expression and Signaling in B Cells From Patients with Systemic Lupus Erythematosus. Vinh Nguyen1, Horea Rus2 and Violeta Rus2, 1Univ of Maryland Schl of Med, Baltimore, MD, 2University of Maryland School of Medicine, Baltimore, MD 652. High Plasma Microparticle-IgG Burden Characterizes Systemic Lupus Erythematosus Patients and Is Associated with Autoantibodies Against DNA and C1q and Activation of the Complement System. Christoffer T. Nielsen1, Ole Østergaard2, Line Stener1, Line V. Iversen1, Lennart T. Truedsson3, Søren Jacobsen4 and Niels H.H. Heegaard1,

656. A Paradoxical Increase in Th17 Cells in Patients with High Interferon Activity in Systemic Lupus Erythematosus. Vivian V. Stone, Thomas H. Teal, Pradipta Ghosh, Jeffrey A. Ledbetter and Keith B. Elkon, University of Washington, Seattle, WA 657. Abnormal Electron Transport Chain Activity in Mitochondria of Peripheral Blood Lymphocytes From Patients with Systemic Lupus Erythematosus. Edward Doherty1 and Andras Perl2, 1SUNY Upstate, Syracuse, NY, 2 Upstate Medical University, Syracuse, NY 658. The Monitoring of FoxP3 Expressing CD4+ T Cell Subsets May Be Helpful for the Prediction of Systemic Lupus Erythematosus Flares. Makoto Miyara1, Alexis Mathian1, Julien Haroche1, Laurent Arnaud2, Driss Chader1, Lucile Musset1, Guy Gorochov1 and Zahir Amoura1, 1CHU PitiéSalpêtrière, Paris, France, 2Paris, France 659. Hypermethylation of CD3Z Promoter CpG Islands in Patients with Autoimmune Diseases Including Systemic Lupus Erythematosus. Kyeong-Man Hong1, Hyun-Kyoung Kim1, Seong-Yeol Park1, Yong-Bock Choi1, Mi-Kyeong Kim1, Ji Ah Park2, Eun Young Lee2, Eun Bong Lee2 and Yeong Wook Song2, 1National Cancer Center, Goyang, South Korea, 2Seoul National University Hospital, Seoul, South Korea 660. Comprehensive Screening for Primary Immunodeficiencies Shows Unexpectedly High Frequency of Selective IgM Deficiency in Systemic Lupus Erythematosus. Sandro F. Perazzio1, Neusa P. Silva2, Reinaldo Salomao1 and Luis Eduardo C. Andrade3, 1Federal University of Sao Paulo, Sao Paulo, Brazil, 2Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 3Universidade Federal de São Paulo and Fleury Health and Medicine 2011 Program Book

189

ACR Poster Session A Laboratories, Sao Paulo Brazil, Sao Paulo, Brazil 661. Altered Selection Leads to Expansion of the Anergic IgM- B Cell Population in SLE. Julie Kim1, Nan-Hua Chang1, Murray B. Urowitz2, Dafna D. Gladman3, Paul R. Fortin2 and Joan E. Wither1, 1Toronto Western Research Institute, University Health Network, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON 662. Auto-Reactive IgEs and Basophils in Systemic Lupus Erythematosus. Barbara Dema1, Sarfaraz A. Hasni2, Chao Jiang1, Donna F. Hardwick3, Nicolas Charles4, Gabor G. Illei5 and Juan Rivera1, 1Laboratory of Molecular Immunogenetics, NIAMS, NIH, Bethesda, MD, 2National Institutes of Health, Bethesda, MD, 3NIH MSC 1616, Bethesda, MD, 4Institut national de la Sante et de la Reserche Medicale, Paris, France, 5NIDCR/ NIH #10 1N110, Bethesda, MD 663. ZAS3 Is Overexpressed in Peripheral Blood Mononuclear Cells in Systemic Lupus Erythematosus Patients and Is Regulated by Estrogen: A Cause of the Dysreguated IL-2 Response? Nicholas Young, Alexandra Friedman, Francesca Madiai, Benjamin Kaffenberger, Lai-Chu Wu and Wael N. Jarjour, The Ohio State University Medical Center, Columbus, OH 664. Elevated IgE Anti-Ds-DNA Levels Are Associated with Serological Disease Activity in Patients with SLE: Potential for a New Treatment Target. Sarfaraz A. Hasni1, Barbara Dema2, Donna F. Hardwick3, Gema Souto-Adeva4, Chao Jiang5, Juan Rivera2 and Gabor G. Illei4, 1National Institutes of Health, Bethesda, MD, 2Laboratory of Molecular Immunogenetics, NIAMS, NIH, Bethesda, MD, 3NIH MSC 1616, Bethesda, MD, 4NIDCR/ NIH #10 1N110, Bethesda, MD, 5Laboratory of Immunogenetics, NIAMS, NIH, Bethesda, MD

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Clinical Aspects and Therapeutics 665. SELF-Administered Systemic Sclerosis Questionnaire. Validation of A SPANISH Version (SYSQ) In Mexicans. Maria Pilar Cruz-Dominguez1, Moises Casarrubias-Ramirez1, Victor Gasca Martínez1, Olga Lidia Vera Lastra1, Luis J. Jara Quezada2 and Daniel Hector Montes-Cortes3, 1Hospital de Especialidades CMN La Raza, IMSS, Mexico, DF, Mexico, 2 Hospital de Especialidades CMN La Raza, IMSS, Mexico City, Mexico, 3Hospital General CMN La Raza, IMSS, Mexico DF, Mexico 666. Marital Status in Systemic Sclerosis: Association with Pulmonary Function and Skin Involvement. Brock E. Harper1, Shervin Assassi2, Giovanni Geslani3, Joanna Leung3, Holly Bentz1, Emilio B. Gonzalez1, Hilda T. Draeger4, Deepthi Nair2 and Maureen D. Mayes2, 1University of Texas Medical Branch, Galveston, TX, 2University of Texas Health Science Center at Houston, Houston, TX, 3Galveston, TX, 4Univ of TX Health Sci Ctr, San Antonio, TX 667. Cancer in Systemic Sclerosis: Results From a Single Centre

190

2011 Program Book

Cohort Report. Giuseppina Abignano, Hannah Lee Evans, Paul Emery, Francesco Del Galdo and Maya H. Buch, University of Leeds, Leeds, United Kingdom 668. Effect of the ETA Selective Endothelin Receptor Antagonist Ambrisentan on Digital Ulcers in Patients with Systemic Sclerosis: Results of a Prospective Pilot Study. Lorinda Chung1, Kait Arefiev2, Aaliya Yaqub2, Deborah Strahs2, Bharathi Lingala2 and David Fiorentino1, 1Stanford Univ Medical Center, Palo Alto, CA, 2Stanford Univ Medical Center, Palo Alto 669. Successful Pregnancies but Higher Risk of Preterm Delivery in Systemic Sclerosis Women. IMPRESS: The Italian Multicentric Study on Pregnancy in Systemic Sclerosis. A. Brucato1, Mara Taraborelli2, Véronique Ramoni3 and Angela Tincani4, 1Ospedali Riuniti, Bergamo, Italy, 2University of Brescia and Spedali Civili, Brescia, Italy, 3Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 4Rheumathology Unit, University of Brescia, Brescia, Italy, Brescia, Italy 670. Increased Risk of Osteoporosis and Fracture in Patients with Systemic Sclerosis. A Comparison to Rheumatoid Arthritis. Jérôme Avouac, Eugénie Koumakis, Emese Toth, Marine Meunier, Emilie Maury, Catherine Cormier, Andre Kahan and Yannick Allanore, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France 671. Serum Estradiol and Estrone Levels in Patients with Systemic Sclerosis: Relationship to Disease Specific Clinical Manifestations. Christine Peoples1, Mary Lucas1, Yona Cloonan2, Thomas A. Medsger Jr.1 and Carol A. FeghaliBostwick1, 1University of Pittsburgh Scleroderma Center, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA 672. Burden of Disease in Dutch Patients with Systemic Sclerosis and Digital Ulcers; Data From Thedata From the Dutch National Registry. Madelon C. Vonk1, Alexandre E. Voskuyl2, Michel Walravens3, Pieter Paassen4 and Annemie Schuerwegh5, 1Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2VU University Medical Center, Amsterdam, Netherlands, 3Maasstad hospital, Rotterdam, Netherlands, 4 University Medical Centre Maastricht, Maastricht, Netherlands, 5Leids Univ Medisch Centrum, Leiden, Netherlands 673. Development and Validation of a New Clinical Prediction Rule for 5-Year Survival in Early Scleroderma, a EUSTAR Study. Delia diaconu-Popa1, Madelon C. Vonk2, Roger Hesselstrand3, Patricia E. Carreira4, Gabriele Valentini5, Lorenzo Beretta6, Paolo Airo7, Murat Inanc8, Alexandra Balbir-Gurman9, Stanislaw Sierakowski10, Yannick Allanore11, Laszlo Czirjak12, Valeria Riccieri13, Roberto Giacomelli14, Armando Gabrielli15, Gabriela Riemekasten16, Marco Matucci-Cerinic17, Dominique Farge18, Nicolas Hunzelmann19, Frank H.J. van den Hoogen20 and Jaap Fransen21, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen,

ACR Poster Session A Netherlands, 3Lund University & Skåne University Hopsital, Lund, Sweden, 4Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 5Second Univ of Napoli, Napoli, Italy, 6IRCCS Fondazione Policlinico-MangiagalliRegina Elena & University of Milan, Milan, Italy, 7Brescia, Italy, 8Istanbul University, Istanbul Faculty of Medicine,, Istanbul, Turkey, 9Rambam Health Care Campus, Haifa, Israel, 10Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland, 11Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 12Hungary, 13University of Rome, Medical Clinic and Therapy Department, 14Rheumatology Unit, University of Aquila, L’Aquila, Italy, 15Clinica Universitaria Ancona, Ancona, Italy, 16Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 17University of Florence, Florence, Italy, 18EBMT, Paris, France, 19University of Cologne, Cologne, Germany, 20Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 21Radboud University Nijmegen Medical Center, Nijmegen, Netherlands 674. Periungueal Capillaroscopy Using Conventional Dermoscopy: Easily Available Method and Simple to Perform During the Regular Office Consult in Patients with Systemic Sclerosis. Nicolle Mazzotti1, Claiton Brenol1, Markus Bredemeier2, João Carlos T. Brenol1, Ricardo M. Xavier1 and Tania Cestari1, 1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil 675. Increased Expression of NOX4 in Systemic Sclerosis Dermal Fibroblasts. Regulation by TFG-ß, Protein Kinase C Delta and c-Abl Kinase. Sonsoles Piera-Velazquez, Alma Makul and Sergio A. Jimenez, Jefferson Insititute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA 676. Construct Validity of the Saint George’s Respiratory Questionnaire in An Observational Cohort of Patients with Early Diffuse Systemic Sclerosis. Dinesh Khanna1, James R. Seibold2, Peter A. Merkel3, Maureen D. Mayes4, Kristine Phillips5, Robert W. Simms6, Shervin Assassi7, Philip J. Clements8 and Daniel E. Furst9, 1University of Michigan, Ann Arbor, MI, 2Scleroderma Research Consultants LLC, Avon, CT, 3Boston University School of Medicine, Boston, MA, 4University of Texas Health Science Center at Houston, Houston, TX, 5University of Michigan Medical School, Ann Arbor, MI, 6Boston University School Medical, Boston, MA, 7 Univ of Texas Health Science, Houston, TX, 8UCLA School of Medicine, Los Angeles, CA, 9UCLA Medical School, Los Angeles, CA 677. Progression of Isolated Raynaud’s Phenomenon to Systemic Sclerosis: Impact of ANA Subtype and Disease Subset. Pia Moinzadeh1, Kevin J. Howell2, Voon Ong3, Svetlana Nihtyanova2 and Christopher D. Denton2, 1Royal Free Hospital, Medical School, London, United Kingdom, 2 Royal Free Hospital, Medical School, London, England, 3UCL Medical School, London, England

678. Efficacy and Safety of Intravenous Cyclophosphamide In the Treatment of Scleroderma Lung Disease: 7-Year Follow-up. Alexandra Balbir-Gurman1, Ludmila Guralnik2, Mordehai Yigla3, Menahem A. Nahir1, Alexander P. Rozin4, Kohava Toledano1, Doron Markovits4 and Yolanda BraunMoscovici1, 1B. Shine Rheumatology Unit, Rambam Health Care Campus, The Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel, 2Department of Diagnostic Imaging, Rambam Health Care Campus, The Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Israel, 3Division of Pulmonary Medicine, Rambam Health Care Campus, The Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel, 4 B. Shine Rheumatology Unit, Rambam Health Care Campus, Haifa, Israel 679. Preliminary Steps to a Health Index for Systemic Sclerosis Based on the World Health Organization’s International Classification of Functioning, Disability and Health: A European League Against Rheumatism Scleroderma Trials and Research Initiative. Lesley Ann Saketkoo1, Reuben Escorpizo2, Kevin J. Keen3 and Oliver Distler4, 1LSU Health Science Center, New Orleans, LA, 2ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications Department of Health Sciences; and Health Policy, University of Lucerne, Switzerland, 3University of Northern British Columbia, Prince George, BC, 4University Hospital Zurich, Zurich, Switzerland 680. Evaluation of Nutritional Status and Dietary Intake in Women with Systemic Sclerosis. Thais F. Marighela1, Ligia A. Martini2, Vera Szejnfeld1, Marcelo M. Pinheiro1 and Cristiane Kayser1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Universidade de São Paulo, São Paulo, Brazil 681. Evaluation of the Impact of Recurrent Ischemic Digital Ulcers on Hand Disability in Patients with Systemic Sclerosis (ECLIPSE). Report of the Cohort At the Time of Inclusion. Luc Mouthon1, Patrick Carpentier2, Catherine Lok3, Eve Puzenat4, Pierre Clerson5, Virginie Gressin6 and Marie-Aleth Richard7, 1Hopital Cochin, Paris, France, 2CHU Grenoble, Grenoble, France, 3Amiens Hospital, France, 4 Besançon, Besançon, France, 5Orgametrie, Roubaix, 6 Actelion France, Paris, France, 7Marseille, Paris, France 682. Survival and Causes of Death of 312 Norwegian Patients with Systemic Sclerosis. Anna-Maria Hoffmann-Vold, Oyvind Midtvedt, Oyvind Molberg, Torhild Garen and Jan Tore Gran, Oslo University Hospital, Oslo, Norway 683. Characteristics and Impact of Pain in Systemic Sclerosis: Comparison with Rheumatoid Arthritis. Serge Perrot1, Philippe Dieude2 and Yannick Allanore3, 1Hopital Hotel Dieu, Paris Descartes University, Paris, France, 2APHP, Hopital Bichat, Paris, France, 3Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France 684. Esophageal Involvement in Systemic Sclerosis and Rheumatoid Arthritis: Prevalence of Esophagitis and Barrett’s Esophagus. Andrey E. Karateev, Mikael M. 2011 Program Book

191

ACR Poster Session A Movsisyan, Lidiya P. Ananieva and Stefka G. RadenskaLopovok, Research Institute of Rheumatology RAMS, Moscow, Russia 685. Ultra Sensitive Troponin in Systemic Sclerosis. Christophe Meune1, Jérôme Avouac2, Camille Gobeaux3, Marine Meunier2, Andre Kahan2 and Yannick Allanore2, 1Paris Descartes University, Cardiology department, Cochin Hospital, Paris, France, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3 Paris Descartes University, Biochemistry A department, Cochin Hospital, Paris, France 686. Hypergammaglobulinemia in Systemic Sclerosis. Nicole Saddic1, Donna Rose Swistowski2, Victoria K. Shanmugam3 and Virginia D. Steen4, 1Georgetown University Hospital, Washington DC, DC, 2Martinsburg Veterans Affairs Medical Center, Martinsburg, WV, 3Georgetown University Hospital, Washington, DC, 4Georgetown Univ Medical Center, Washington, DC 687. Mycophenolate Mofetil Is An Effective, Well-Tolerated, Steroid-Sparing Agent for a Diverse Spectrum of Connective Tissue Disease-Associated Interstitial Lung Disease. Aryeh Fischer, Mahalakshmi Krishnamoorthy, Amy L. Olson, Joshua J. Solomon, Evans R. Fernandez-Perez, Tristan J. Huie, Kevin K. Brown and Jeffery J. Swigris, National Jewish Health, Denver, CO 688. Scleroderma Digital Ulcers Complicated by Infection with Fecal Pathogens. Dilia Giuggioli1, Andreina Manfredi1, Michele Colaci1, Federica Lumetti2, Marco Sebastiani1 and Clodoveo Ferri3, 1University of Modena and Reggio Emilia, Modena, Italy, 2Universitu of Modena and Reggio Emilia, 3 Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy 689. Lung and Breast Cancer in Systemic Sclerosis: Correlations with the Disease’s Features. Michele Colaci, Dilia Giuggioli, Marco Sebastiani, Andreina Manfredi, Caterina Vacchi and Clodoveo Ferri, University of Modena and Reggio Emilia, Modena, Italy 690. Incomplete Thymic Involution in Systemic Sclerosis and Rheumatoid Arthritis. Marine Meunier1, Ramin Bazeli2, Jerome Avouac1, Antoine Feydy2, jean-Luc Drape2, Andre Kahan1 and Yannick Allanore1, 1Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 2 Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France

Carmona2, Beatriz E. Joven3, Christopher D. Denton4, Yannick Allanore5, Ulrich A. Walker6, Marco Matucci-Cerinic7, Ulf Muller-Ladner8 and EUSTAR coauthors9, 1Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 2 Fundación Española de Reumatología, Madrid, Spain, 3 HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, MADRID, Spain, 4 Royal Free Hospital, Medical School, London, England, 5 Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 6Dept. of Rheumatology at Basel University, Felix-Platter Spital, Basel, Switzerland, 7 University of Florence, Florence, Italy, 8Justus-Liebig Universität Gießen, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 9Florence 693. Correlation Between Exercise Echocardiography and Right Heart Catheterization in Scleroderma Patients At Risk for Pulmonary Hypertension. Ami A. Shah1, Susan Mayer1, Reda Girgis1, James Mudd2, Laura K. Hummers1 and Fredrick M. Wigley1, 1Johns Hopkins University, Baltimore, MD, 2Oregon Health & Science University, Portland, OR 694. Positive Predictive Value of Anti-Centromere and AntiScl-70 Antibody Multiplex Assays in a Rheumatology Practice Setting. Svetlana Meier1 and Ted R. Mikuls2, 1Univ of Nebraska Med Center, Omaha, NE, 2Omaha VA and University of Nebraska, Omaha, NE 695. Severe Interstitial Lung Disease within the PHAROS Registry: Baseline Characteristics and Clinical Features. Aryeh Fischer1, Jerry A. Molitor2, Laura K. Hummers3, Vivien M. Hsu4, Monique E. Hinchcliff5 and Virginia D. Steen6, 1 National Jewish Health, Denver, CO, 2Univ of MN MMC108, Minneapolis, MN, 3Johns Hopkins University, Baltimore, MD, 4RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 5 Northwestern University, Chicago, IL, 6Georgetown Univ Medical Center, Washington, DC 696. Clinical Significance of Antibodies to Ro52/TRIM21 in Systemic Sclerosis. Marie Hudson1, Janet Pope2, Solene Tatibouet1, Russell Steele1, Murray Baron3 and Marvin J. Fritzler4, 1McGill University, Montreal, QC, 2Univ of Western Ontario, London, ON, 3Jewish General Hospital, Montreal, QC, 4University of Calgary, Calgary, AB

691. SHOCK Wave THERAPY: A NOVEL TREATMENT for Systemic Sclerosis? Laura Belloli1, Nicola Ughi1, Maria-Cristina D’Agostino1, Alberto Tedeschi2, Marco Massarotti1, Massimo Cugno2 and Bianca Marasini1, 1IRCCS Humanitas Clinical Institute, Rozzano (Milan), Italy, 2Fondazione IRCCS Ca’ Granda, University of Milan, Milan, Italy

697. Elevated Pulmonary Vascular Resistance At Rest Is Associated with Exercise Pulmonary Arterial Hypertension in Systemic Sclerosis Patients without Pulmonary Hypertension Hemodynamics At Rest. Jonathan Kushi1, Mary Ellen Csuka1, Laura K. Hummers2, Fredrick M. Wigley2, Vivien M. Hsu3, Dinesh Khanna4, Jerry A. Molitor5 and Virginia D. Steen6, 1Medical College of Wisconsin, Milwaukee, WI, 2Johns Hopkins University, Baltimore, MD, 3RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 4University of Michigan, Ann Arbor, MI, 5Univ of MN MMC108, Minneapolis, MN, 6Georgetown Univ Medical Center, Washington, DC

692. Clinical Associations of Elevated Acute Phase Response, Proteinuria and Low Dlco In Early Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database. Patricia E. Carreira1, Loreto

698. A Panel of Serum Biomarkers Including Type I InterferonRelated Chemokines Distinguishes Clinical and Autoantibody Status of Patients with Systemic Sclerosis. Emily Baechler Gillespie1, Jane Hoyt Buckner2, Joseph C.

192

2011 Program Book

ACR Poster Session A Wilson3 and Jerry A. Molitor3, 1University of Minnesota, Minneapolis, MN, 2Benaroya Research Institute, Seattle, WA, 3 Univ of MN MMC108, Minneapolis, MN 699. Myocardial Involvement in Systemic Sclerosis As Assessed by Ultrasonography and Scintigraphic Perfusion Imaging. Niki Tsifetaki1, Charalampos Papagoras2, Kersten Achenbach3, Athanasia Georgiou4, Spyridon Tsiouris5, Andreas Fotopoulos6 and Alexandros A. Drosos7, 1Registrar in Rheumatology, Ioannina, Greece, 2Fellow in Rheumatology, Ioannina, Greece, 3Cardiologist, Ioannina, Greece, 4Fellow in Nuclear Medicine, Ioannina, Greece, 5Registrar of Nuclear Medicine, Greece, 6Associate Professor of Nuclear Medicine, Greece, 7Professor of Medicine/Rheumatology, Ioannina, Greece 700. Prevalence of Celiac Antibodies in Patients with Systemic Sclerosis. Lindsy J. Forbess1, Jessica K. Gordon1, Kamini Doobay2, Brian Bosworth3, Morgana L. Davids1 and Robert Spiera1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, 3New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY 701. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma: Racial Differences in Systemic Sclerosis-Related Pulmonary Hypertension. Christine Peoples1, Robyn T. Domsic1, Thomas A. Medsger Jr.1, Virginia D. Steen2 and PHAROS Investigators3, 1Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Georgetown Univ Medical Center, Washington, DC, 3Washington, DC 702. Effects and Safety of Rituximab in Systemic Sclerosis: An Analysis From the European Scleroderma Trial and Research Group. Suzana Jordan1, Jorg HW Distler2, Britta Maurer1, Jacob M. van Laar3, Yannick Allanore4, Oliver Distler1 and EUSTAR Rituximab Group5, 1University Hospital Zurich, Zurich, Switzerland, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3 Musculoskeletal Research Group, Newcastle, United Kingdom, 4Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 5Florence, Italy 703. B Cell Depletion Therapy in Systemic Sclerosis: a Follow-up Study of 4 Years on Skin and Lung Involvement in Fourteen Patients. Silvia L. Bosello1, Antonella Laria1, Manuela Rucco1, Mario Bocci1, Giacomo De Luca1, Annunziata Capacci1, Matteo Falcione2, Francesco Maria Danza2 and Gianfranco Ferraccioli1, 1Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 2Institute of Radiology, Catholic University of the Sacred Heart, Rome, Italy 704. ELF Score: A Validated Serum Test Strongly Predictive of Fibrosis in Systemic Sclerosis. Giuseppina Abignano1, Giovanna Cuomo2, Maya H. Buch1, William M. Rosenberg3, Gabriele Valentini4, Paul Emery5 and Francesco Del Galdo1, 1 University of Leeds, Leeds, United Kingdom, 2Second University of Naples, Naples, Italy, 3Centre for Hepatology - UCL, London, United Kingdom, 4Second Univ of Napoli, Napoli, Italy, 5Leeds Institute of Molecular Medicine,

University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom 705. Optical Coherence Tomography: A New Imaging Technique That Allows Detailed Visualization of Affected Scleroderma Skin. Giuseppina Abignano1, Sibel Aydin2, Concepcion Castillo-Gallego Jr.3, Maya H. Buch1, Paul Emery4 and Francesco Del Galdo1, 1University of Leeds, Leeds, United Kingdom, 2Goztepe Training and Research Hospital, Istanbul, Turkey, 3Hospital Universitario La Paz, Madrid, Spain, 4 NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom 706. Decreased Plasma Ghrelin Levels in Patients with Systemic Sclerosis. Yuko OTA, Yasushi Kawaguchi, Kae Takagi, Takahisa Gono, Masanori Hanaoka and Hisashi Yamanaka, Tokyo Women’s Medical University, Tokyo, Japan 707. A Pilot Study of Abatacept for the Treatment of Patients with Diffuse Cutaneous Systemic Sclerosis. Eliza F. Chakravarty1, David Fiorentino2, Mihoko Bennett3 and Lorinda Chung4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Stanford, Stanford, CA, 3Stanford University, Palo Alto, CA, 4Stanford Univ Medical Center, Palo Alto, CA 708. Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Systemic Sclerosis Patients. Marie Hudson1, Michael Mahler2, Janet Pope3, Daniel You4, Solene Tatibouet1, Russell Steele1, Murray Baron5 and Marvin J. Fritzler4, 1McGill University, Montreal, QC, 2INOVA Diagnostics, Inc., San Diego, CA, 3Univ of Western Ontario, London, ON, 4University of Calgary, Calgary, AB, 5Jewish General Hospital, Montreal, QC 709. Influenza H1N1 Vaccination in Mixed Connective Tissue Disease: Effectiveness and Safety Independent of Disease or Therapy. Renata Miossi1, Ricardo Fuller1, Julio C. B. Moraes1, Ana Cristina Medeiros1, Carla G.S. Saad1, Nadia E. Aikawa1, Joao Miraglia2, Maria A. Ishida3, M.Teresa C. Caleiro1 and Eloisa Bonfa1, 1University of Sao Paulo, Sao Paulo, Brazil, 2Fundação Butantan, São Paulo, Brazil, 3Adolfo Lutz Institute, Sao Paulo, Brazil 710. How Do Physicians Make a Global Assessment of Raynaud’s Phenomenon in a Clinical Trial? Richard W. Martin1, Andrew J. Head2, James D. Birmingham1 and Aaron T. Eggebeen1, 1Michigan State University College of Human Medicine, Grand Rapids, MI, 2College of Human Medicine, Michigan State University, Grand Rapids, MI 711. Tendon and Joint Involvement in Diffuse Systemic Sclerosis: An Ultrasound and Magnetic Resonance Imaging Study. Maria S. Stoenoiu1, Frederic E. Lecouvet1 and Frédéric. A. Houssiau2, 1Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Université catholique de Louvain, Brussels, Belgium 712. Iloprost Enhances Th17 and Th22 While Decreasing 2011 Program Book

193

ACR Poster Session A Th1 Cells Expansion in Healthy and Systemic Sclerosis Mononuclear Cells. Marie-Elise Truchetet1, Yannick Allanore2, Carlo Chizzolini1 and Nicolò Costantino Brembilla1, 1 University hospital of Geneva, Geneva, Switzerland, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France 713. Evaluation of the Effect of Ambrisentan On Digital Microvascular Flow In Patients with Systemic Sclerosis Using Laser Doppler Perfusion Imaging. Nilanjana Bose1, James Bena1, Charles Trunick1, John Petrich2, Debora J. Bork3, Geetha Krishnan1 and Soumya Chatterjee1, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, 3The Cleveland Clinic Found A50, Cleveland, OH 714. Echo-Doppler Evaluation Does Not Show Abnormal Diastole In Scleroderma Patients with Pulmonary Venous Hypertension. Santhanam Lakshminarayanan1, Nada Shaban1, Diane Tran2, Jason W. Ryan2, Irina Collins2, David Hager1 and Naomi F. Rothfield1, 1University of Connecticut School of Medicine, Farmington, CT, 2University of Connecticut School of Medicine, Farmington, CT 715. Nutrition In Systemic Sclerosis Patients. Maureen Murtaugh1 and Tracy M. Frech2, 1University of Utah, Salt Lake, 2University of Utah School of Medicine, SLC, UT 716. Associations Between the UCLA SCTC GIT 2.0 Vs. Objective Tests of Upper Gastrointestinal Involvement in Systemic Sclerosis. Sangmee Bae1, Yannick Allanore2, Daniel E. Furst3, Vijay Bodukam4, Baptiste Coustet5, Olga Morgaceva6, Paul Maranian3 and Dinesh Khanna7, 1David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3UCLA Medical School, Los Angeles, CA, 4 Crozer Chester Medical Center, Upland, PA, 5Université Paris Descartes, Hopital Cochin, Paris, France, 6UCLA, Los Angeles, CA, 7University of Michigan, Ann Arbor, MI 717. Reactive Hyperemia Index Is Associated with Macroangiopathy and Lung Involvement in Systemic Scleroderma. Alain Meyer1, Bernard Geny2, Emmanuel Chatelus3, Olivier Rouyer2, Arnaud Theulin4, Christelle Sordet4, Rose-Marie Javier4, Jean Sibilia5 and Jacques-Eric Gottenberg6, 1Hautepierre Strasbourg university, Strasbourg, France, 2Medicine faculty, Strasbourg university, Strasbourg, France, 3Hopital Hautepierre, Strasbourg, France, 4 Hautepierre Strasbourg Hospital University, Strasbourg, France, 5CHU Hautepierre, Strasbourg, France, 6Strasbourg University Hospital, Strasbourg, France

194

2011 Program Book

ACR/ARHP Poster Session B MONDAY, NOVEMBER 7, 2011

Hall F2 - Poster Hall Epidemiology and Health Services Research II: Osteoarthritis/ Osteoporosis/Gout/Cost 875. Osteoarthritis Severity Is Associated with Increased Risk for Diabetes and Heart Disease. Gillian A. Hawker, Andrew Warner and Taryn Simms, Women’s College Hospital, Toronto, ON 876. Serum 25 Hydroxy Vitamin D (25OHD) and Incident or Worsening Knee Pain In Older Adults: A Five Year Longitudinal Study. Laura Laslett1, Chang-Hai Ding2, Stephen Quinn3, John Burgess4, Venkat Parameswaran4, Tania Winzenberg1 and Graeme Jones1, 1University of Tasmania, Hobart, Australia, 2University of Tasmania & Monash University, Hobart, Australia, 3Flinders University, Australia, 4 Royal Hobart Hospital, Hobart, Australia 877. Trends in the Prevalence of Symptomatic Knee OA From 2002 to 2009. William M. Reichmann1, Jeffrey N. Katz2, Sara A. Burbine3, Meghan E. Daigle3, Benjamin N. Rome3, Alexander M. Weinstein3 and Elena Losina3, 1Brigham and Womens Hospital, Boston, MA, 2Brigham & Womens Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA 878. Impact of Psychosocial Determinants on Total Knee Replacement Costs: Results From the Patient Expectations about Knee Surgery Cohort. Christian A. Waimann1, Rodrigo J. Fernandez-Mazarambroz1, Scott B. Cantor1, Maria LopezOlivo1, Hong Zhang1, Glenn C. Landon2, Sherwin J. Siff2 and Maria E. Suarez-Almazor1, 1University of Texas. M.D Anderson Cancer Center, Houston, TX, 2St. Luke’s Episcopal Health System, Houston, TX 879. Incidence of Hip Symptoms and Radiographic and Symptomatic Hip Osteoarthritis in African Americans and Caucasians: The Johnston County Osteoarthritis Project. Barbara T. Do1, Louise Murphy1, Charles G. Helmick1, Kamil E. Barbour1, Yiling J. Cheng1 and Joanne M. Jordan2, 1Centers for Disease Control and Prevention, Atlanta, GA, 2UNC Thurston Arthritis Center, Chapel Hill, NC 880. Back Pain. Gary J. Macfarlane1, Marcus Beasley1, Elizabeth A. Jones1, Karina Lovell2, Gordon J. Prescott1, Philip Keeley2, John McBeth2, Gareth T. Jones1 and MUSICIAN study team1, 1 University of Aberdeen, Aberdeen, United Kingdom, 2 University of Manchester, Manchester, United Kingdom 881. Association of Lumbar Spine Individual Radiographic Features with Serum C-Propeptide (sCPII) and Serum Collagen Neoepitope (sC2C) of Type II Collagen: The Johnston County Osteoarthritis Project. Adam P. Goode1, Virginia B. Kraus1, Yvonne M. Golightly2, Stephen W. Marshall3, Debra E. Irwin3 and Joanne M. Jordan2, 1Duke University Medical Center, Durham, NC, 2University of North Carolina Thurston Arthritis Center, Chapel Hill, NC, 3 University of North Carolina, Chapel Hill, NC

882. To What Degree Is the Rise in US Total Knee Replacement Rates Attributable to Aging of the Population? Louise Murphy1, Gillian A. Hawker2, Erica Odom1 and Charles G. Helmick1, 1Centers for Disease Control and Prevention, Atlanta, GA, 2Women’s College Hospital, Toronto, ON 883. Patterns of Population Use of Total Joint Arthroplasty: Focus on Outcomes Following a Single primary TJA Is Too Narrow. Ruth Croxford1 and Gillian A. Hawker2, 1Institute for Clinical and Evaluative Science, Toronto, ON, 2Women’s College Hospital, Toronto, ON 884. How Many Americans Are Currently Living with Total Knee Replacement? Alexander M. Weinstein, Benjamin N. Rome, William M. Reichmann, Jamie E. Collins, Sara A. Burbine, Thomas S. Thornhill, John Wright, Jeffrey N. Katz and Elena Losina, Brigham and Women’s Hospital, Boston, MA 885. Impact of Slow Recovery and Poor Functional Outcomes on Direct and Indirect Costs After Total Knee Replacement in Osteoarthritis Patients. Christian A. Waimann1, Rodrigo J. Fernandez-Mazarambroz1, Scott B. Cantor1, Maria LopezOlivo1, Hong Zhang1, Glenn C. Landon2, Sherwin J. Siff2 and Maria E. Suarez-Almazor1, 1University of Texas. M.D Anderson Cancer Center, Houston, TX, 2St. Luke’s Episcopal Health System, Houston, TX 886. Predictors of Suboptimal Patient Outcome Following Total Joint Arthroplasty. Gillian A. Hawker1, Ruth Croxford2, A. M. Davis3, Sheila Dunn1, Joy G. Elkayam1, Melissa R. French1, M. A. Gignac4, Susan B. Jaglal5 and Joanna Sale5, 1Women’s College Hospital, Toronto, ON, 2Institute for Clinical and Evaluative Science, Toronto, ON, 3Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, 4Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 5University of Toronto, Toronto, ON 887. Alcohol Intake Is Associated with Incident Gout Among Black and White, Men and Women in the Atherosclerosis Risk in Communities Study. Mara McAdams DeMarco1, Janet W. Maynard2, Alan N. Baer2 and Josef Coresh1, 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2 Johns Hopkins University, Baltimore, MD 888. Gout Treatment Gaps and Factors Associated with Incident Patients Having Uric Acid Goal Attainment: A Retrospective Cohort Study in An Integrated Healthcare System. Nazia Rashid1, T. Craig Cheetham1, Jeffery R. Curtis2, Gerald D. Levy3, Kenneth G. Saag2 and Ted R. Mikuls4, 1Kaiser Permanente Pharmacy Analytic Services, Downey, CA, 2 University of Alabama at Birmingham, Birmingham, AL, 3 Southern California Permanente Medical Group, Downey, CA, 4Omaha VA and University of Nebraska, Omaha, NE 889. Evaluation of Healthcare Costs for Patients with Gout by Serum Uric Acid. Karen Rascati1, Karim Prasla2, Haesuk Park1 and Tyrone McBayne3, 1University of Texas at Austin

2011 Program Book

195

ACR/ARHP Poster Session B College of Pharmacy, Austin, TX, 2Scott and White Health Plan, Temple, TX, 3Takeda Pharmaceuticals America, Inc., Deerfield, IL 890. Total Health-Care Costs Among Gout Patients On Allopurinol or Febuxostat. Brett W. Pinsky1, Bhavik J. Pandya2, Gabriel Gomez Rey3 and Jasvinder A. Singh4, 1 Innovus, O’Fallon, MO, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, 3Innovus, Eden Prairie, MN, 4 University of Alabama at Birmingham, Birmingham, AL 891. Serum Urate−Lowering Effectiveness of Febuxostat Compared with Allopurinol and Switching to Febuxostat From Allopurinol In the Real-World Setting. Bhavik J. Pandya1, Brett W. Pinsky2, Gabriel Gomez Rey3 and Jasvinder A. Singh4, 1Takeda Pharmaceuticals International, Inc., Deerfield, IL, 2Innovus, O’Fallon, MO, 3Innovus, Eden Prairie, MN, 4University of Alabama at Birmingham, Birmingham, AL 892. Multinational, Prospective, Observational Study to Characterize and Assess the Burden of Refractory Gouty Arthritis on Patients Over One Year: Global Baseline Results. Pascal Lecomte1, Louis Bessette2, Alberto Ferreira1, Hans-Peter Goertz1, Paula Jones3 and Jasvinder A. Singh4, 1 Novartis Pharma AG, Basel, Switzerland, 2CHUL, Quebec, 3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4 University of Alabama at Birmingham, Birmingham, AL 893. Frequency of Gouty Arthritis Attacks and Presence of Comorbid Conditions Have An Impact on Gout-Related Healthcare Resource Utilization and Costs. Joseph J. Saseen1, Neetu Agashivala2, Richard R. Allen3, Vahram Ghushchyan1 and Kavita V. Nair1, 1University of Colorado, Aurora, CO, 2Novartis Pharmaceutical Corporation, East Hanover, NJ, 3Peakstat Statistical Services, Evergreen, CO 894. Multinational, Prospective, Observational Study to Characterize and Assess the Burden of Refractory Gouty Arthritis on Patients Over One Year: US Baseline Results. Pascal Lecomte1, Louis Bessette2, Alberto Ferreira1, HansPeter Goertz1, Paula Jones3 and Jasvinder Singh4, 1Novartis Pharma AG, Basel, Switzerland, 2CHUL, Quebec, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4University of Alabama and VA Medical Center, Birmingham, AL 895. Gout Characteristics, Health-Related Quality of Life and Health Care Utilization: Caucasians Vs. Non-Caucasians In An Observational Cohort of Patients with Gout. Puja Khanna1, Jan Hirsch2, Susan J. Lee3, Robert Terkeltaub4, Jasvinder Singh5, Arthur F. Kavanaugh6, Andrew Sarkin7 and Dinesh Khanna1, 1University of Michigan, Ann Arbor, MI, 2 Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego, San Diego, CA, 3Univ of California San Diego, La Jolla, CA, 4VA Medical Ctr, San Diego, CA, 5University of Alabama and VA Medical Center, Birmingham, AL, 6University of California San Diego, San Diego, CA, 7Health Services Research, University of California San Diego, San Diego, CA

196

2011 Program Book

896. Ambulatory Resource Utilization for Gouty Arthritis and Gouty Arthritis Attacks. Chenghui Li1, Bradley C. Martin1, Dosha F. Cummins1, L.M. Andrews2, Feride Frech-Tamas2 and Anthony Yadao2, 1University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ 897. Health Care Resource Utilization Is Associated with Attack Frequency in Patients with Gouty Arthritis. Prakash Navaratnam1, Carl deMoor1, Michael Shaffer2, Paula Chakravarti3, L.M. Andrews3 and Anthony Yadao3, 1DataMed Solutions LLC, Hilliard, OH, 2BioTrends Research Group LLC, Exton, PA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ 898. Hypertension, but Not Pre-Hypertension, Is Associated with Incident Gout in White and Black, Men and Women From the Atherosclerosis Risk in Communities Study. Mara McAdams DeMarco1, Janet W. Maynard2, Alan N. Baer2 and Josef Coresh1, 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD 899. Prevalence and Risk Factors of Sarcopenia Among Community-Dwelling Older Women with High Frequency of Overweight/Obesity. Diogo S. Domiciano1, Camille Figueiredo1, Jaqueline B. Lopes1, Valéria Caparbo1, Liliam Takayama2, Eloisa Bonfa3 and Rosa M.R. Pereira4, 1University of São Paulo, São Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, 4Disciplina de Reumatologia da FMUSP, Sao Paulo, Brazil 900. Adherence to Physical Activity Guidelines and Its Relationship with Self-Rated Health Among Persons with Doctor-Diagnosed Arthritis. William M. Reichmann1, Jeffrey N. Katz2, Sara A. Burbine3, Meghan E. Daigle3, Benjamin N. Rome3, Alexander M. Weinstein3 and Elena Losina3, 1 Brigham and Womens Hospital, Boston, MA, 2Brigham & Womens Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA 901. Do Climatological Changes Affect Arthritic Pain Severity in Patients with Rheumatic Diseases? K. Deftereou1, B. Haidich2, A. Benos2, M. Trachana3 and A. Garyfallos1, 14 th Department of Internal Medicine,Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, 2 Department of Hygiene, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, 31st Department of Paediatrics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece 902. Economic Burden of Fibromyalgia: A Systematic Review and Meta-Analysis. John B. Wong, Marcia P. Griffith and Chenchen Wang, Tufts Medical Center, Boston, MA 903. Bone Mineral Density Across Age and Gender in Navajo People Compared to the National Health and Nutrition Examination Surveys III: the Education and Research

ACR/ARHP Poster Session B Toward Health Study. Karla L. Miller, Tracy M. Frech, Tom Greene, Khe-ni Ma, Molly McFadden, Lillian Tom-Orme, Laurie J. Moyer-Mileur, Martha Slattery and Maureen Murtaugh, University of Utah School of Medicine, SLC, UT 904. Prevalence of Anti-Osteoporotic Medication Use in a Cohort of Older Women with Both Rheumatoid Arthritis and Postmenopausal Osteoporosis. Gregory Cherkowski, Cynthia O’Malley and Primal P. Kaur, Amgen, Inc., Thousand Oaks, CA 905. Prevalence of Low Bone Mass and Osteoporosis in Navajo People Older Than 50 Across Age, Gender, and Body Mass Index. Karla L. Miller, Tracy M. Frech, Tom Greene, Khe-ni Ma, Molly McFadden, Lillian Tom-Orme, Laurie J. MoyerMileur, Martha Slattery and Maureen Murtaugh, University of Utah School of Medicine, SLC, UT 906. Health-Related Quality of Life Among Patients with Osteoporotic Fractures In Mexico. Patricia Clark1, Fernando Carlos2, Gabriela Chico1, Oskar Ström3, Ingrid Lekander3 and Fredrik Borgström3, 1Hospital Infantil de México Federico Gómez, Mexico City, Mexico, 2RAC Salud Consultores, S.A. de C.V., Mexico, Mexico, 3Innovus, Sweden 907. Disparities in the Prevention/Treatment of GlucocorticoidInduced Osteoporosis. Florina M. Constantinescu1, Primal Bhatia2, Lenore M. Buckley3, Paul Falzer4 and Liana Fraenkel5, 1Washington Hospital Ctr/Georgetown University, Washington, DC, 2Washington Hospital Center, Washington, DC, 3VCU School of Medicine, Richmond, VA, 4 VA Connecticut Healthcare System, New Haven, CT, 5Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 908. Obesity Increases the Risk of Adhesive Capsulitis. Yuqing Zhang1, Christine Peloquin1, Daniel K. White1, Yanyan Zhu1, Young Hee Rho2 and Hyon K. Choi1, 1Boston University School of Medicine, Boston, MA, 2Vanderbilt Medical Center, Nashville, TN 909. Prevalence and Impact of Extreme Obesity (Class III) Among US Adults with Arthritis. Jennifer M. Hootman1, Charles G. Helmick2 and Casey Hannan2, 1Centers for Disease Control and Prevention, Kennesaw, GA, 2Centers for Disease Control and Prevention, Atlanta, GA 910. A Patient Reported Frailty Index That Can Predict Mortality Outcomes Among Patients with Arthritis. Eswar Krishnan1, James F. Fries2 and Bharathi Lingala3, 1Stanford University, Stanford, CA, 2Stanford Univ Medical Center, Palo Alto, CA, 3 Stanford 911. Unintended Consequences; Increased Prescription of Narcotic Analgesics for OA in the Elderly Is Associated with Increased Falls and Fractures in the Post-Vioxx Era. Lydia Rolita1, Adele Spegman2 and Bruce N. Cronstein3, 1NYU School of Medicine, New York, NY, 2Geisinger Health System, Danville, PA, 3New York Univ Medical Center, New York, NY

912. The Impact of Biologics for the Treatment of Rheumatoid Arthritis: The Case of Total Hip and Knee Replacement Surgery. Neeta Tandon1, Guy David2, Arthur Kavanaugh3 and Candace Gunnarsson4, 1Janssen Services, LLC, Horsham, PA, 2 University of Pennsylvania Wharton School of Business, Philadelphia, PA, 3University of California San Diego, San Diego, CA, 4S2 Statistical Solutions, Inc, Cincinnati, OH 913. Costs and Absences Associated with Rheumatoid Arthritis On Work Productivity: A Comparison Between Employees with and without Rheumatoid Arthritis In a United States Population. Nathan L. Kleinman1, Richard A. Brook2, Stephanie E. Kirbach3 and Mary A. Cifaldi3, 1HCMS Group, Cheyenne, WY, 2The JeSTARx Group, Newfoundland, NJ, 3 Abbott Laboratories, Abbott Park, IL 914. A Simple Model That Suggests Possible Cost Savings When Modified-Release Prednisone 5mg/Day Is Added to Current Treatment In Patients with Active Rheumatoid Arthritis. Maarten Boers1 and Frank Buttgereit2, 1VU University Medical Center, Amsterdam, Netherlands, 2 Charité University Medicine, Berlin, Germany 915. Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in US Commercially-Insured Population. Vernon F. Schabert1, Shravanthi R. Gandra2, Crystal Watson2, Jason Yeaw1, Seth Goodman1, Kathy M. Fox3, Sandra Milev4 and David J. Harrison2, 1IMS Consulting Group, Alexandria, VA, 2 Amgen Inc, Thousand Oaks, CA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, 4IMS Brogan, Ottawa, ON 916. Direct Costs in Newly Diagnosed and Established Rheumatoid Arthritis Patients, and Comparison with NonRA Controls in An Insurance Claims Database. Martin M. Crane1, Stephanie Manson2, Maneesh Juneja3, Jeffery Allen1, Regina H. Kurrasch4, Myron E. Chu5, Emilia Quattrocchi2 and David J. Chang5, 1GlaxoSmithKline, Research Triangle, NC, 2 London, United Kingdom, 3GlaxoSmithKline, Stockley Park, United Kingdom, 4Medicines Development, GlaxoSmithKline, King of Prussia, PA, 5Medicines Development GlaxoSmithKline, King of Prussia, PA 917. Healthcare Utilization of Patients with Systemic Lupus Erythematosus In a U.S. Medicaid Population. Xue Song1, Hong Kan2, Barbara H. Johnson3, Benno Bechtel4, Donna O’Sullivan3 and Charles T. Molta5, 1Thomson Reuters, Cambridge, MA, 2GlaxoSmithKline, Research Triangle Park, NC, 3Thomson Reuters, Washington, DC, 4GlaxoSmithKline, Munich, Germany, 5GlaxoSmithKline, Philadelphia, PA 918. WITHDRAWN. 919. Economic Burden of Psoriatic Arthritis and Diabetes in Patients with Psoriatic Arthritis in the United States. Annie Guerin1, Genevieve Gauthier1, Robert Day2, Zeba Khan2 and Frank Zhang2, 1Analysis Group, Inc., Montreal, QC, 2Celgene Corporation, Summit,, NJ

2011 Program Book

197

ACR/ARHP Poster Session B 920. Economic Burden of Psoriatic Arthritis and Obesity in Patients with Psoriatic Arthritis in the United States. Frank Zhang1, Annie Guerin2, Dominick Latremouille-Viau2, Robert Day1 and Zeba Khan1, 1Celgene Corporation, Summit,, NJ, 2 Analysis Group, Inc., Montreal, QC

929. Designing a Fibromyalgia Screening Questionnaire for Primary Care Settings. Robert S. Katz1, Alexandra Small2, Lauren Kwan3, Patricia Kuenzi1 and Jessica L. Polyak3, 1Rush University Medical Center, Chicago, IL, 2University of Illinois Medical School, 3Rheumatology Associates, Chicago, IL

921. Musculoskeletal Corticosteroid and Local Anesthetic Injections; A Survey of Practice Patterns Among Members of the American College of Rheumatology. Leah Alon1, Nina Ramessar1, Jenny Cabas-Vargas2, Dimitre Stefanov1 and Deana M. Lazaro3, 1SUNY Downstate Medical Center, Brooklyn, NY, 2SUNY Downstate, Brooklyn, NY, 3Brooklyn VA, Brooklyn, NY

930. The Effectiveness of Long-Term and Short-Term Interdisciplinary Treatment Approaches in Female Patients with Fibromyalgia. Ilknur Saral1, Dilsad Sindel1, Ozlem S. Berk2 and Sina Esmaeilzadeh1, 1Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Istanbul University, Faculty of Letters, Istanbul, Turkey

922. Cost Per Placebo Adjusted Response of Golimumab, Adalimumab, and Etanercept in Patients with Active Ankylosing Spondylitis. Atul Deodhar1, J. Braun2, R. D. Inman3, Désirée van der Heijde4, Benjamin Hsu5, Neeta Tandon6 and Chenglong Han7, 1Oregon Health & Science University, Portland, OR, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, 4 Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/Philadelphia, PA, 6Janssen Services, LLC, Horsham, PA, 7Janssen Services, LLC, Malvern, PA 923. The “Table-1 p Value” Issue; Baseline Group Comparison Is Inappropriately Omitted in Non-Randomized Studies. Koray Tascilar, Emine Atac, Fehim Esen and Hasan Yazici, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey 924. Seasonal Variation in Mortality of Six Rheumatic Diseases in Hong Kong, China: An Analysis of 2772 Deaths. Chi Hung To, Ka Lung Yu and Chi Chiu Mok, Tuen Mun Hospital, Hong Kong, Hong Kong

Fibromyalgia and Soft Tissue Disorders 925. Milnacipran Improves Health Outcomes in Fibromyalgia Patients Who Have Had An Inadequate Response to Duloxetine Treatment As Measured by PROMIS Computer Adaptive Testing. Steven I. Blum, Stavros Tourkodimitris and Allan Spera, Forest Research Institute, Jersey City, NJ 926. The FREQUENCY of FIBROMYALGIA SYNDROME and the QUALITY of LIFE IN PATIENTS with Periton Dialysis. Muyesser Okumus, Hulya Parpucu, Seher Kocaoglu, Esma Ceceli, Pinar Borman and Murat Duranay, Ministry of Health Ankara Education and Training Hospital, Ankara, Turkey

931. Continuing Efficacy of Milnacipran Demonstrated After Long-Term Treatment of Fibromyalgia. Daniel J. Clauw1, Philip J. Mease2, Yimin Ma3, Arlene Baldecchi3, Robert H. Palmer3 and Joel M. Trugman3, 1University of Michigan, Ann Arbor, MI, 2Seattle Rheumatology Associates and Swedish Medical Center, Seattle, WA, 3Forest Research Institute, Jersey City, NJ 932. The Care Gap in Management of Fibromyalgia: A Needs Assessment Prompting the Development of Clinically Relevant Guidelines for the Diagnosis, Management and Follow-up of Patients. Peter A. Ste-Marie1, Mary-Ann Fitzcharles2, Pantelis Panopalis2, John Pereira3 and Yoram Shir2, 1University of Montreal, Montreal, QC, 2McGill University, Montreal, QC, 3University of Calgary, Calgary, AB 933. Supporting Evidence for the Clinical Utility of the Pain Subscale of the American College of Rheumatology 2010 Preliminary Diagnostic Criteria for Fibromyalgia. Peter A. Ste-Marie1, Marc-Olivier Martel2, Mary-Ann Fitzcharles2 and Yoram Shir2, 1University of Montreal, Montreal, QC, 2McGill University, Montreal, QC 934. Fibromyalgia Syndrome in the General Population of Israel: A Prevalence Study. Jacob N. Ablin1, Anat Oren2, Sarit Cohen3, Valerie Aloush1, Ori Elkayam4, Yonatan Wolman1 and Mark Berman1, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3Carmel Medical Center, Haifa, Israel, 4Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 935. Concordance Between Subjective Dry Eye Symptoms and Objective Findings in Fibromyalgia Patients. Marco Antivalle, Michele Battellino, Alberto Batticciotto, Maria Chiara Ditto, Alessandra Mutti, Gabriella Santalena, Valentina Varisco and Piercarlo Sarzi-Puttini, L. Sacco University Hospital, Milano, Italy

927. Correlates of Word Finding Deficits in Fibromyalgia. Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL

936. High Prevalence of Fibromyalgia Symptoms Among Healthy Full Term Pregnant. Sharon Saad, Ariel Many, Giris Jacob and Jacob N. Ablin, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

928. Carpal Tunnel Syndrome in Fibromyalgia: Evidence of a Subclinical Neuropathy? Robert S. Katz1 and Bhagwan Shahani2, 1Rush University Medical Center, Chicago, IL, 2 University of Chicago Hospital, Chicago

937. Fibromyalgia: Can Online Cognitive Behavioral Therapy Help? Gwendoline Menga1, Bobby J. Dupre2, Carl Gauthier3, William E. Davis4, Tamika A. Webb-Detiege5, Eve Scopelitis3, Jerald M. Zakem4 and Robert Quinet6, 1Ochsner Clinic

198

2011 Program Book

ACR/ARHP Poster Session B Center, New Orleans, LA, 2Ochsner Health System, Baton Rouge, LA, 3Ochsner Clinic Foundation, New Orleans, LA, 4 Ochsner Clinic, New Orleans, LA, 5Ochsner Medical Ctr, New Orleans, LA, 6Ochsner Medical Center - New Orleans, New Orleans, LA 938. The 2010 American College of Rheumatology Fibromyalgia Survey Diagnostic Criteria and Symptom Severity Scale Is Valid and Reliable in a French Speaking Fibromyalgia Cohort. Peter A. Ste-Marie1, Pantelis Panopalis2, Mary-Ann Fitzcharles2, Henri A. Menard3, Yoram Shir2 and Frederick Wolfe4, 1University of Montreal, Montreal, QC, 2McGill University, Montreal, QC, 3Montreal General Hospital, Montreal, QC, 4National Data Bank for Rheumatic Diseases, Wichita, KS 939. The Michigan Body Map and Its Use in Assessing the American College of Rheumatology Survey Criteria for Fibromyalgia. Chad M. Brummett1, Afton L. Hassett2, Katherine A. Brummett1, Daniel J. Clauw3 and David A. Williams4, 1University of Michigan Health System, Ann Arbor, MI, 2University of Michigan Medical School, Ann Arbor, MI, 3 University of Michigan, Ann Arbor, MI, 4Univ of MI Hlth System-Lobby M, Ann Arbor, MI 940. Longitudinal Assessment of Fibromyalgia in Young Adults Previously Diagnosed with Juvenile Fibromyalgia. Tracy V. Ting1, Daniel Strotman1, Emily Verkamp1, Anjali Desai1, Anne Lynch-Jordan1, Lesley M. Arnold2 and Susmita KashikarZuck1, 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2University of Cincinnati College of Medicine, Cincinnati, OH 941. Prevalence of Physician-Diagnosed Fibromyalgia and Fibromyalgia-Related Fatigue in Olmsted County. Ann Vincent1, Debra L. Barton2, Daniel J. Clauw3, Mary Whipple1, Brian Lahr4, Eric Hawkins1, Terry H. Oh2, Connie Luedtke1 and Jennifer St.Sauver4, 1Mayo Clinic, Rochester, MN, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3University of Michigan, Ann Arbor, MI, 4Mayo Clinic, Rochester 942. What Does Affect the Sexual Behaviour in Fibromyalgic Patients? Laura Bazzichi1, Alessandra Rossi2, Ciro Conversano2, Camillo Giacomelli2, Claudia Ferrari1, Francesca De Feo2, Francesca Sernissi2, Marica Doveri2, Linda Carli2 and Stefano Bombardieri1, 1Rheumatology Unit, Pisa, Italy, 2 University of Pisa, Pisa, Italy 943. Functional MRI (fMRI) in Patients with Cognitive Dysfunction Related to Fibromyalgia (Fibrofog). Robert S. Katz1, Vy T. Dinh1, Glen Stebbins2 and Frank Leavitt1, 1Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, Chicago

Imaging of Rheumatic Disease: X-ray, Magnetic Resonance Imaging, Computed Tomography and Positron Emission Tomography 944. MRI Synovitis Is Prevalent in ACPA Positive Patients with Musculoskeletal Symptoms. Jackie L. Nam1, Edith Villeneuve1, Sudipto Das1, Dennis McGonagle1, Richard Hodgson1, Andrew Grainger1, Richard J. Wakefield1, Philip G.

Conaghan1 and Paul Emery2, 1University of Leeds and Leeds Teaching Hospitals, Leeds, United Kingdom, 2Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom 945. Comparison of High-Resolution Multi-Pinhole SPECT and MRI for Monitoring Early Arthritis Patients Under Methotrexat Therapy: First Results. Christian Buchbender1, Philipp Sewerin1, Axel Scherer1, Falk Miese1, Oliver Sander1, Katalin Mattes-György1, Hans-Jörg Wittsack1, Christof Specker2, Gerald Antoch1, Matthias Schneider1 and Ben Ostendorf1, 1Heinrich-Heine-University, Düsseldorf, Germany, 2Kliniken Essen Süd, Essen, Germany 946. Construct Validity and Responsiveness of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Early Rheumatoid Arthritis – A Comparison with Conventional Magnetic Resonance Imaging and Clinical Measures of Disease Activity. Mette Bjørndal Axelsen1, Bo J. Ejbjerg2, Merete L. Hetland1, Kim Hørslev-Petersen3, Mikael Boesen4, Olga Kubassova5, Ulrik B. Lauridsen1, Ole Majgaard2, Henning Bliddal4, Niels Steen Krogh6 and Mikkel Østergaard1, 1 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 2Copenhagen University Hospital at Slagelse, Slagelse, Denmark, 3University of Southern Denmark, Graasten, Denmark, 4The Parker Institute, Copenhagen University Hospital at Frederiksberg, Frederiksberg, Denmark, 5Image Analysis Ltd., Leeds, United Kingdom, 6 ZiteLab ApS, Copenhagen, Denmark 947. Evaluation of Activity, Making Diagnosis and Prediction of Future Bone Destruction by Using Low Field Compact Magnetic Resonance Imaging Machine in Patients with Rheumatoid Arthritis. Makoto Sugihara1, Takeshi Suzuki1, Yoshikazu Okamoto2, Masanobu Horikoshi1, Masahiro Yokosawa1, Shinya Hagiwara1, Tomoya Hirota1, Yohei Takano1, Naoto Umeda1, Yuya Kondo1, Hiroto Tsuboi1, Hiroshi Ogishima1, Taichi Hayashi1, Yusuke Chino1, Daisuke Goto1, Isao Matsumoto1 and Takayuki Sumida1, 1Division of Clinical Immunology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan, 2Division of Radiology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan 948. Is Experience Necessary to Accurately Score Low-Field Non-Contrast Magnetic Resonance Imaging of Rheumatoid Arthritis Joints? Comparison of Readings by Inexperienced Rheumatology Fellow to Scores of Experienced Musculoskeletal Radiologist. Fahed Hamadeh1 and Ewa Olech2, 1University of Oklahoma, Oklahoma City, OK, 2 Oklahoma Medical Research Foundation, Oklahoma City, OK 949. Stability of Automated Quantitation of Dynamic Contrast Enhanced (DCE) 3T Wrist Magnetic Resonance Imaging (MRI) in Healthy Volunteers; A Year Long Longitudinal 2011 Program Book

199

ACR/ARHP Poster Session B Study. A. Rastogi1, Olga Kubassova2, Mikael Boesen3, J.V. Hajnal4 and Peter Taylor5, 1Barts and the London NHS Trust, London, United Kingdom, 2Image Analysis Ltd., Leeds, United Kingdom, 3The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark, 4 Imperial College, London, United Kingdom, 5Kennedy Institute of Rheumatology, London, United Kingdom 950. Importance of Field Strength, Coil Type and Image Resolution for Visualization of Bone Marrow Edema in Magnetic Resonance Imaging (MRI) - a Comparison of Contrast-to-Noise Ratio, Signal-to-Noise Ratio and Contrast on 0.23 T, 0.6 T, 1.5 T and 3 T MRI Units. Simon Krabbe1, Susanne Juhl Pedersen2, Pernille Bøyesen3, J.M. Møller4, Flemming R. Therkildsen5, Ole Rintek Madsen2 and Mikkel Østergaard1, 1Copenhagen University Hospital in Glostrup, Glostrup, Denmark, 2Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, 3Diakonhjemmet Hospital, Oslo, Norway, 4Copenhagen University Hospital in Herlev, Copenhagen, Denmark, 5Copenhagen, Denmark 951. Tocilizumab Improves in Rheumatoid Arthritis Patients with Longstanding but Still Active Disease the Clinical Disease Activity (DAS28) and Ameliorates MRI Findings within the First Three Months of Therapy. Herbert Kellner1 and Wolfgang Kellner2, 1Centre for Inflammatory Joint Diseases, Munich, Germany, 2Radiologische Praxis im Josephinum, Munich, Germany 952. Early Response to Tocilizumab in Patients with Treatment Resistant Rheumatoid Arthritis – Assessment Using 3 Tesla MRI. Joerg C. Henes1, Marius Horger1, Florian Haas1, Gunther Zeh1, Daniel Spira1 and Ina Kötter2, 1University Hospital Tuebingen, Tuebingen, Germany, 2University Hospital Tuebingen, Tübingen, Germany 953. Reduction In MRI Inflammation During Adalimumab Therapy In Patients with Psoriatic Arthritis – Implementation of the OMERACT PsAMRIS Scoring Method In a Follow-up Study. René Panduro Poggenborg1, Pernille Bøyesen2, Charlotte Wiell3, Susanne Juhl Pedersen3, Inge Juul Sørensen1, Ole Rintek Madsen3, Ole Slot1, Jakob M. Møller4, Maria Hasselquist4 and Mikkel Østergaard1, 1 Copenhagen University Hospital in Glostrup, Copenhagen, Denmark, 2Diakonhjemmet Hospital, Oslo, Norway, 3 Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, 4Copenhagen University Hospital in Herlev, Copenhagen, Denmark 954. Diffusion Tensor and Perfusion Magnetic Resonance Imaging Delineates Microstructural Changes of Inflammation and Differentiates Between Tuberculosis and Chronic Inflammatory Arthritis. Vikas Agarwal1, Rishi Awasthi2, Deepak Tripathi3, Vinita Agrawal3, Ram Kishore Singh Rathore4, Prativa Sahoo4, Kusum Sharma5, CM Pandey3 and Rakesh K. Gupta3, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India, 2Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India,, Lucknow, India, 3Sanjay Gandhi

200

2011 Program Book

Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, 4Indian Institute of Technology, Kanpur, India, 5Postgraduate Institute of Medical Education and Research, Chandigarh, India 955. Erosions on MRI of the Sacroiliac Joints in Patients with Ankylosing Spondylitis: Can They Be Reliably Detected? Ulrich Weber1, Susanne Juhl Pedersen2, Mikkel Ostergaard3, Kaspar Rufibach4, Robert GW Lambert1 and Walter P. Maksymowych1, 1University of Alberta, Edmonton, AB, 2 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 3Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 4University of Zurich, Zurich, Switzerland 956. The Reliability of a New Juvenile Arthritis MRI Scoring System for the Knee; JAMRIS. Robert Hemke1, Marion A.J. Van Rossum2, Mira van Veenendaal2, J. Merlijn van den Berg2, Koert M. Dolman3, Taco W. Kuijpers2 and Mario Maas4, 1Academic Medical Center (AMC) / Emma Children’s Hospital, Amsterdam, Netherlands, 2Emma Children’s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 3St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, 4Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 957. Non-Invasive MRI by Omitting Intravenous Contrast Injection; Does It Change the Radiologic Assessment of Knee Joint Pathologies in JIA? Robert Hemke1, Taco W. Kuijpers2, Mira van Veenendaal2, J. Merlijn van den Berg2, Koert M. Dolman3, Marion A. J. van Rossum2 and Mario Maas4, 1Academic Medical Center (AMC) / Emma Children’s Hospital, Amsterdam, Netherlands, 2Emma Children’s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 3St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, 4Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 958. Patients with Juvenile Idiopathic Arthritis and Rheumatoid Arthritis in “Physician Determined Clinical Remission” Have Evidence of Persistent Inflammation Revealed by 3T MRI. Amanda G. Brown1, Raphael Hirsch2, Tal Laor3, Kimberly A. Francis4, Michael J. Hannon5 and C. Kent Kwoh6, 1Children’s Hospital Pittsburgh of UPMC, Pittsburgh, PA, 2Children’s Hospital Pittsburgh, Pittsburgh, PA, 3Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, 4Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 5University of Pittsburgh School of Medicine, Pittsburgh, PA, 6University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA 959. Identification of Magnetic Resonance Imaging Morphologic Features Associated with Different Knee Pain Patterns. C. Kent Kwoh1, Ali Guermazi2, Michael J. Hannon3, Robert M. Boudreau4, Stephanie M. Green4, John M. Jakicic5 and Frank Roemer6, 1University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare,

ACR/ARHP Poster Session B Pittsburgh, PA, 2Boston Medical Center, Boston, MA, 3 University of Pittsburgh School of Medicine, Pittsburgh, PA, 4University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, PA, 6Boston University, Boston, MA 960. Progression of the MRI-Detected Osteoarthritis Features in Radiographic ‘end-Stage’ Knee Osteoarthritis (KellgrenLawrence grade 4) - the Multicenter Osteoarthritis Study. Ali Guermazi1, Daichi Hayashi1, Frank Roemer1, David T. Felson1, Ke Wang1, John Lynch2, Shreyasee Amin3, James Torner4, C.E. Lewis5 and Michael C. Nevitt6, 1Boston University, Boston, MA, 2UCSF, San Francisco, CA, 3Mayo Clinic, Rochester, MN, 4University of Iowa, Iowa City, Iowa City, IA, 5University of Alabama, Birmingham City, AL, 6 University of California-San Francisco, San Francisco, CA 961. The Association Between Bone Marrow Lesion Detected by Magnetic Resonance Imaging and Knee Pain in the Community Residents in Korea. Inje Kim1, Yeong Wook Song2, Hyun Ah Kim3 and Ali Guermazi4, 1Hallym University Kangdong Sacred Heart hospital, Seoul, South Korea, 2Seoul National University College of Medicine, Seoul, South Korea, 3 Hallym University Sacred Heart Hospital, Kyunggi, South Korea, 4Boston Medical Center, Boston, MA 962. Correlation of Bony Enlargements with Radiological Findings in Hand Osteoarthritis. Niveditha Mohan1, Michael J. Hannon2 and C. Kent Kwoh3, 1Univ of Pittsburgh Arth Inst, Pittsburgh, PA, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, 3University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA 963. Correlation of Hand Pain and Radiological Findings in Hand Osteoarthritis. Niveditha Mohan1, Michael J. Hannon2 and C. Kent Kwoh3, 1Univ of Pittsburgh Arth Inst, Pittsburgh, PA, 2 University of Pittsburgh School of Medicine, Pittsburgh, PA, 3University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA 964. Biomarkers of Bone Resorption and Bone Formation Are Specifically Linked to Catabolic and Anabolic Skeletal Changes Assessed by High Resolution CT Scans in Patients with Rheumatoid Arthritis. Sophie Aschenberg, Stephanie Finzel, Sarah Schmidt, Matthias Englbrecht, Juergen Rech and Georg Schett, University of Erlangen-Nuremberg, Erlangen, Germany 965. High Resolution Peripheral Quantitative Computed Tomography Bone Health Outcomes in the Metacarpal Head and Ultra-Ultra Distal Radius: A Precision Study Using Novel Scan Acquisition and Custom Semi-Automatic Contour and Evaluation Protocols. Lynne M. Feehan1, Helen R. Buie2, Eric C. Sayre3, Steve K. Boyd2, Heather A. McKay4 and Linda C. Li1, 1Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, 2University of Calgary, Calgary, AB, 3Arthritis Research Centre of Canada, Vancouver, BC, 4University of British Columbia, Vancouver, BC

966. Correlation of [18f]FDG PET Assessments with Disease Activity and Markers of Inflammation in Patients with Early Rheumatoid Arthritis Following Initiation of Antirheumatic Therapy. Anne M. Roivainen1, Sannamari Hautaniemi1, Timo Möttönen1, Pirjo Nuutila1, Vesa Oikonen1, Riitta Parkkola1, Luminita Pricop2, Rudyard Ress2, Nicholas Seneca3, Marko Seppänen1 and Timo Yli-Kerttula1, 1Turku University Hospital, Turku, Finland, 2Hoffmann-La Roche Inc, Nutley, NJ, 3F. Hoffmann-La Roche Ltd., Switzerland 967. Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Is Useful for the Visualization of ReticuloEndotheliao System and Prediction of Steroid-Resistant Cases in Adult Onset of Still’s Disease. Tomohiro Kameda1, Kentaro Susaki1, Yuka Yamamoto2, Miharu Izumikawa3, Junichi Danjo1, Shusaku Nakashima1, Hiromi Shimada1, Yohei Takeuchi1, Yoshihiro Nishiyama2, Hiroaki Dobashi1 and Takuya Matsunaga1, 1Kagawa University, Kagawa, Japan, 2 Kagawa University, Kita-gun, Japan, 3Kagawa University, Kita-Gun, Japan 968. PET-CT, Interleukins and Metalloproteinases to Assess Disease Activity in Takayasu Arteritis Patients. Anne E.D. Arraes1, Alexandre W.S. Souza1, Eduardo N.P. Lima2 and Emilia I. Sato1, 1Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 2Hospital AC Camargo, São Paulo, Brazil 969. The Value of Positron Emission Tomography – Computed tomography in Patients with Large Vessel Vasculitis. Man Wai Tang, Danielle Marie Gerlag, A. Elisabeth Hak, Berthe L.F. van Eck-Smit and Paul-Peter Tak, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands 970. Reduced Insular Gamma-Aminobutyric Acid in Fibromyalgia. Bradley Foerster1, Myria Petrou1, Richard Edden2, Pia Sundgren1, Tobias Schmidt-Wilcke1, Suzan E. Lowe1, Steven Harte1, Daniel J. Clauw1 and Richard E. Harris1, 1 University of Michigan, Ann Arbor, MI, 2Johns Hopkins, Baltimore, MD 971. Pregabalin Reduces Posterior Insula Combined Glutamate and Glutamine in Fibromyalgia. Richard E. Harris1, John P. Huggins2, Lynne Pauer2, Pia Sundgren1, Craig Urwin1, Kathy Scott1 and Daniel J. Clauw1, 1University of Michigan, Ann Arbor, MI, 2Pfizer Inc., Sandwich, United Kingdom 972. Feasibility of Bone Density Evaluation Using Plain Digital Radiography. Margot B. Kinds, Anne C. A. Marijnissen, Koen L. Vincken, Lambertus W. Bartels, Max A. Viergever, Hugo WAM de Jong and Floris P.J.G. Lafeber, University Medical Center Utrecht, Utrecht, Netherlands 973. Alterations of Bone Geometry, Volumetric Density and Microarchitecture in Women with Systemic Lupus Erythematosus on Chronic Corticosteroids: A Case-Control Study Using High Resolution-Peripheral Quantitative Computed Tomography. Xiao Lin Tang, Tracy Y. Zhu, Lai Shan Tam and Edmund K. Li, The Chinese University of Hong Kong, Hong Kong, Hong Kong

2011 Program Book

201

ACR/ARHP Poster Session B 974. Disease Damage Has Deleterious Effect on Trabecualr Bone Microarchitecture in Female Patients with Systemic Lupus Erythematosus On Chronic Corticosteroids. Xiao Lin Tang, Tracy Y. Zhu, Lai Shan Tam and Edmund K. Li, The Chinese University of Hong Kong, Hong Kong, Hong Kong

Innate Immunity and Rheumatic Disease 975. A Toll-Like Receptor 1 Polymorphism Is Associated with Heightened T Helper 1 Responses and Antibiotic-Refractory Lyme Arthritis. Klemen Strle, Junghee J. Shin, Lisa Glickstein and Allen C. Steere, Massachusetts General Hospital, Harvard Medical School, Boston, MA 976. Toll Like Receptor-2 Activation Prevents Cartilage Damage in Osteoarthritis Models That Display Synovial Activation. Arjen Blom, Peter van Lent, Shahla Abdollahi-Roodsaz, Peter M. van der Kraan and Wim B. van den Berg, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

J. Arntz2, Wim van den Berg1 and Fons A. van de Loo1, 1 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Nijmegen, Netherlands 982. Toll-Like Receptor-9 Activation Regulates Macrophage Triggering Receptor Expressed on Myeloid Cells-1 Expression and Shedding. Yair Molad1, Elisheva Shapira2 and Vered Carmon3, 1Felsenstein Medical Reseach Center, Sackler Faculty of Medicine, Tel Aviv University, and Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 2 Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 3Laboratory of Inflammation Research, Felsenstein Medical Research Center, Tel Aviv University, Petah Tikva, Israel 983. A TLR 9 Antagonist Diminishes Arthritis Severity and Inhibits Bone Erosion in a Rat Model of Rheumatoid Arthritis. Sonja Herman1, Anita Fischer1, Markus Hoffmann2 and Gunter Steiner1, 1Medical University of Vienna, Vienna, Austria, 2Karolinska Institutet, Stockholm, Sweden

977. NI-0101, a Therapeutic TLR4 Monoclonal Antibody for Rheumatoid Arthritis. Greg Elson1, Theresa Page2, Vanessa Buatois1, Bruno Daubeuf1, Laurence Chatel1, Laura Cons1, Carla Lippens1, Susana Salgado-Pires1, Walter Ferlin1, Marie Kosco-Vilbois1, Kim Midwood2 and Limin Shang1, 1 NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, 2 Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, United Kingdom

984. Upregulated High Mobility Group Box One Acts in Synergy with Danger Signals Through the Activation of of p38 Mitogen-Activated Protein Kinases to Promote Inflammation in Patients with Lupus Nephritis. Shui-Lian Yu, Chun-Kwok Wong, Da-Peng Chen, cheuk-Chun Szeto, Edmund K. Li and Lai-Shan Tam, The Chinese University of Hong Kong, Hong Kong, China

978. MiR-20a Regulates Negatively TLR4 Signalling Pathway by Targeting ASK1 in Rheumatoid Synoviocytes. Lucas Philippe1, Ghada Alsaleh1, Sébastien Pfeffer2, Jacques-Eric Gottenberg1, Jean Sibilia1, Dominique Wachsmann1 and Philippe Georgel3, 1EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 2Architecture et Réactivité de l’ARN, Université de Strasbourg, Strasbourg, France, 3Laboratoire d’ImmunoGénétique Moléculaire Humaine, Strasbourg, France

985. The Anti-Inflammatory Action of Nerve Growth Factor Is Mediated by Trka Signalling: Modification in Trka Expression in Juvenile Idiopathic Arthritis Mononuclear Cells Create An Unbalance Between Inflammatory and Anti-Inflammatory Pathways? Gaetana Minnone1, Giusi Prencipe1, Raffaele Strippoli1, Loredana De Pasquale1, Ivan Caiello1, Fabrizio De Benedetti1 and Luisa Bracci-Laudiero2, 1 Children Hospital Bambino Gesù, Rome, Italy, 2Institure of Translational Pharmacology-CNR, Rome, Italy

979. TIR-Domain-Containing Adaptor-Inducing Interferon-β (TRIF)-Dependent Toll-Like Receptor 4 Signaling Mediates Antibody Class Switching in a Mouse Model of HistidyltRNA Synthetase-Induced Myositis. Lisa Harlow1, Makoto Soejima2 and Dana P. Ascherman3, 1University of Miami Miller School of Medicine, Miami, FL, 2University of Pittsburgh, Pittsburgh, PA, 3University of Miami, Miami, FL

986. Dysregulation of Pyrin, the Familial Mediterranean Fever Protein, Exacerbates Endotoxin-Induced Uveitis in Mice. Holly L. Rosenzweig1, Jenna S. Clowers2, Jordan Allensworth1, Emily E. Vance1, Stephen R. Planck1, Michael P. Davey2, Jae Jin Chae3, Daniel L. Kastner4 and James T. Rosenbaum1, 1Oregon Health & Science University, Portland, OR, 2Veterans Affairs Medical Center, Portland, OR, 3Medical Genetics Branch, National Human Genome Research Institute, MD, 4National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

980. Presence of Fas Associated Death Domain Protein in the Synovial Fluids and Sera (ESPOIR Cohort) of Rheumatoid Arthritis Patients Mirrors the Inflammatory Attribute of the Disease. Léa Tourneur1, Sylvie Mistou1, Valérie Vilmont1, Nicolas Cagnard2, Jacques-Eric Gottenberg3, Valerie Devauchelle4 and Gilles Chiocchia2, 1Institut Cochin, Paris, France, 2Institut Cochin, 75014 Paris, France, 3Strasbourg University Hospital, Strasbourg, France, 4Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France 981. TLR4 on Resident Cells and Bone Marrow Derived Cells Contribute Equally to Arthritis. Ben T. van Den Brand1, Shahla Abdollahi-Roodsaz1, Miranda B. Bennink2, Onno

202

2011 Program Book

987. Expression and Function of the NALP3 Inflammasome in Behçet’s Disease. En Hyung Kim1, Jae Young Shin2, Mi-Jin Park2, Sun Park2 and Eun-So Lee2, 1Kwan Dong University, Cheil General Hospital and Women’s Healthcare Center, Seoul, South Korea, 2Ajou University School of Medicine, Suwon, South Korea 988. Demographic and Genetic Results From the EUROFEVERS/ EUROTRAPS Consortia in the Largest Series of Patients with TRAPS Yet Reported. Helen J. Lachmann1, Antonella

ACR/ARHP Poster Session B Meini2, Isabelle Touitou3, Laura Obici4, Martina Finetti5, Kirsten Minden6, Luca Cantarini7, Marine Desjonqueres8, Joost Frenkel9, Isabelle Kone-Paut10, Olga Vougiouka11, Maria Jesus Rua Elorduy12, Nicola Ruperto13, Patricia Woo1 and Marco Gattorno14, 1University College London Medical School, London, United Kingdom, 2Dipartimento di Pediatria, University of Brescia, Brescia, Italy, 3CHU Montpellier Hôpital Arnaud de Villeneuve, Montpellier, France, 4IRCCS Policlinico S. Matteo, Pavia, Italy, 5IRCCS Istituto G. Gaslini, Genova, Italy, 6Charite, Berlin, Germany, 7Policlinico le Scotte, Sienna, Italy, 8Hopital Femme Mere Enfant, Groupement Hospitalier Est, Lyon, France, 9University Medical Center Utrecht, Utrecht, Netherlands, 10CHU Le Kremlin Bicetre, Paris, France, 11P. A. Kyriakou Childrens Hospital of Athens University, Athens, Greece, 12Hospital de Cruces, Barakaldo, Spain, 13Paediatric Rheumatology International Trials Organisation – IRCCS [PRINTO], Genova, Italy, 14G Gaslini Institute, Genoa, Italy 989. The Pattern-Recognition Receptor NOD1 Promotes Production of Inflammatory Mediators in Different Cell Types of the Synovium in Rheumatoid Arthritis. Kazuhiro Yokota1, Toshihide Mimura2, Renate E. Gay1, Steffen Gay1, Christoph Kolling3 and Caroline Ospelt1, 1Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Saitama Medical University, Saitama, Japan, 3Schultess Clinic, Zurich, Switzerland 990. Innate Immune Stimulation Triggers Early-Onset Spondyloarthritis in HLA-B27/Human beta2 Microglobulin Transgenic Rats. Leonie M. van Duivenvoorde1, Gleb M. Slobodin2, Nimman Satumtira2, Martha L. Dorris2, Paul P. Tak3, Dominique L. Baeten1 and Joel D. Taurog2, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2UT Southwestern Medical Center, Dallas, TX, 3Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands 991. Dual Signaling Pathways Dependent Upon the Adaptor Protein SLP-76 Lead to Distinct Natural Killer Cell Effector Functions. Rebecca May1, Chih-Jung Hsu1, Mariko Okumura1, Gary A. Koretzky2 and Taku Kambayashi1, 1University of Pennsylvania, Philadelphia, PA, 2University Pennsylvania, Philadelphia, PA 992. Untreated Juvenile Dermatomyositis: Altered Peripheral Blood Natural Killer Cell Receptors Associated with Increased Natural Killer Cell Localization in Inflamed Muscle. Sheela Shrestha1, Maurice O’Gorman2, Jordan Orange3, Chelsea Tessler-Verville1, Katelin Snow1, Gabrielle Morgan1, Deli Wang4 and Lauren M. Pachman2, 1Children’s Memorial Hospital, Chicago, IL, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3Children’s Hospital of Philadelphia, Philadelphia, 4Northwestern University’s Feinberg School of Medicine, Chicago, IL

993. Antigen Cross-Presentation Is Essentially Required for the Pathogenesis of Lupus Nephritis: Essential Role of Endosomal Trafficking. Ken Tsumiyama1, Mai Takimoto1 and Shunichi Shiozawa2, 1Kobe University Graduate School of Health Science, Kobe, Japan, 2Kobe University Graduate School of Health Science and Medicine/ The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan 994. Immune-Complex Induced Inflammation Is Augmented in the Absence Nicotinic Acetylcholine Receptors in Mice. Milena Vukelic1, Gloria Koo1, Patricia M. Redecha1 and Jane E. Salmon2, 1Hospital for Special Surgery, New York, NY, 2 Hospital for Special Surgery, Weill Cornell Medical College, New York, NY 995. Association of Functional Fcgammariic (FCGR2C) Polymorphisms with Rheumatoid Arthritis in African Americans. Jianming Wu1, Xinrui Li2, Rui Lin3, Howard Wiener4, Hemant Tiwari4, Cunren Liu4, Travis Ptacek2, Jeffrey C. Edberg5, S. Louis Bridges Jr.6 and Robert P. Kimberly4, 1 University of minnesota, St. Paul, MN, 2University of Alabama at Birmingham, Brimingham, AL, 3University of Minnesota, St. Paul, MN, 4University of Alabama at Birmingham, Birmingham, AL, 5Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 6 Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 996. Low Copy Number of Fcgamma Receptor 3B Gene Is a Disease Susceptibility and Severity Factor in Primary Sjøgren’s Syndrome. Johannes C. Nossent1, Maureen Rischmueller2, Andrea Becker-Merok1 and Sue Lester2, 1 University of Tromsø, Tromso, Norway, 2Queen Elizabeth Hospital, Adelaide, Australia 997. C1q Diverts Lupus Immune Complexes Away From CD14dimCD16+ “Patrolling” Monocytes. Pradipta Ghosh*, Alice Wiedeman*, Deanna M. Santer, Vivian E. Vlamakis and Keith B. Elkon, University of Washington, Seattle, WA 998. Functional Effects Attributable to the R77H Lupus Susceptibility Variant Encoded by ITGAM. Benjamin Rhodes1, Barbara G. Fürnrohr1 and Timothy J. Vyse2, 1King’s College London, London, United Kingdom, 2Divisions of Genetics and Molecular Medicine and Immunology, King’s College London, London, United Kingdom 999. WITHDRAWN 1000. Anti-Inflammatory Profile of AS2444697, A Novel Interleukin-1 Receptor-Associated Kinase-4 Inhibitor. Junko Imanishi, Takeshi Ishikawa, Emiko Imamura, Hidekazu Mizuhara, Haruna Iwaoka, Ball Evelyn, Hiroshi Inami, Tsuyoshi Mizutani, Junko Watanabe, Hiroyuki Usuda, Shinya Nagashima, Tomonori Ito, Toru Kontani, Yasuaki Shimizu and Seitaro Mutoh, Astellas Pharma Inc., Tsukuba, Japan

2011 Program Book

203

ACR/ARHP Poster Session B 1001. MicroRNA-15a Regulates Etk/BMX Expression and IL-6 Release In Activated Rheumatoid Synoviocytes. Ghada Alsaleh1, Lucas Philippe1, Angélique Pichot1, Sébastien Pfeffer2, Jacques-Eric Gottenberg1, Jean Sibilia1, Philippe Georgel3 and Dominique Wachsmann1, 1EA4438 Laboratoire Physiopathologie des Arthrites, IllkirchStrasbourg, France, 2Architecture et Réactivité de l’ARN, Université de Strasbourg, Strasbourg, France, 3Laboratoire d’ImmunoGénétique Moléculaire Humaine, Strasbourg, France 1002. Knock-Down of Galectin-3 Inhibits Spontaneous and Lipopolysaccharide -Induced IL-6 Secretion In FibroblastLike Synoviocytes. Uri Arad, Avital Angel-Korman, Sharon Amir, Sharon Tzadok, Ortal Seagal, Ori Elkayam and Dan Caspi, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 1003. Vimentin Suppresses the Production of Reactive Oxygen Species and the Antimicrobial Response Via p47phox. Nirit Mor-Vaknin, Maureen Legendre, Yue Yu, Carlos H.C. Serezani, Sanjay Garg, Anna Jatzek, Michael D. Swanson, Seagal Teitz-Tennenbaum, Antonello Punturieri, N. Cary Engleberg, Ruma Banerjee, Marc Peters-Golden and David Markovitz, University of Michigan, Ann Arbor, MI 1004. SNAPIN Is Overexpressed in Rheumatoid Arthritis Synovial Tissue and Involved in Endosomal Lysosomal Pathway. Bo Shi1, Qi Quan Huang1, Andrea Dorfleutner1, Christian Stehlik1, Paul P. Tak2 and Richard M. Pope1, 1Northwestern University, Feinberg School of Medicine, Chicago, IL, 2 Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands 1005. Mechanisms of Human Monocytes and Macrophages to Adapt to Hypoxia. Monique Fangradt1, Timo Gaber1, Martin Hahne1, Paula Hoff1, Manuela Jakstadt1, Cindy Strehl1, Gerd-Rüdiger Burmester2 and Frank Buttgereit1, 1Charité University Medicine, Berlin, Germany, 2Charité University Hospital, Berlin, Germany 1006. The Key Apoptotic Cell Receptor Mer and Its Ligand Gas6 Are Differentially Regulated in M2 Macrophage Subsets. Gaetano Zizzo, Brendan A. Hilliard, Marc Monestier and Philip L. Cohen, Temple University School of Medicine, Philadelphia, PA 1007. Ly-6Chigh Monocytes Are Key Cells in Pathogenesis of Autoimmune Arthritis and May Be An Interesting Target for Immunotherapy. Jessy Presumey1, Gabriel Courties1, Virginie Escriou2, Daniel Scherman2, Diego Kyburz3, Steffen Gay4, Yves-Marie Pers5, Christian Jorgensen5 and Florence Apparailly1, 1Inserm, Montpellier, France, 2Inserm, Paris, France, 3University hospital of Zurich, Zurich, Switzerland, 4 University Hospital of Zürich, Zürich, Switzerland, 5CHU Lapeyronie, Montpellier, France

204

2011 Program Book

1008. Myeloid-Derived Suppressor Cells Present in the Synovial Fluid of Mice with Proteoglycan-Induced Arthritis Are Potent Suppressors of Dendritic Cell Maturation and T Cell Proliferation. Julia Kurko, Colt Egelston, Timea Besenyei, Beata Tryniszewska, Tamas Kobezda, Tibor A. Rauch, Tibor T. Glant and Katalin Mikecz, Rush University Medical Center, Chicago, IL 1009. Analysis of the Expression of Interferon Regulatory Factors on Dendritic Cells From Systemic Lupus Erythematosus Patients. Karina Santana-de Anda, Adriana Elizabeth Monsivais-Urenda, Diana Gomez-Martin, Jose Cruz-Ruiz and Jorge Alcocer-Varela, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico 1010. Expression of Caspase 8 in Dendritic Cells Is More Potent Than in Myeloid Cells in the Prevention of SLE-Like Disease Onset. Carla M. Cuda1, Jaime Chowaniec1, Jack Hutcheson2, G. Kenneth Haines III3, Chandra Mohan2 and Harris R. Perlman4, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2University of Texas Southwestern Medical Center, Dallas, TX, 3Yale University, New Harven, CT, 4 Northwestern University, Chicago, IL 1011. Analysis of the Bioactive Molecules That Promote the Induction of Human Tolerogenic Dendritic Cells. Takuya Matsumoto, Hitoshi Hasegawa, Jin Lei, Koichiro Suemori, Sachiko Onishi and Masaki Yasukawa, Ehime University Graduate School of Medicine, Toon, Japan 1012. Active involvement of “alarmins” S100A8 and A9 in regulation of Synovial Activation and Joint Destruction During Mouse and Human Osteoarthritis. Peter Van Lent1, Arjen Blom1, Rik Schelbergen1, Annet Sloetjes1, Thomas Vogl2, Johannes Roth2, Wim B. Van Den Berg1 and and The NOAC study group3, 1Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, 2University of Munster, Munster, Germany, 3Maartens Clinic, Nijmegen, Netherlands

Metabolic and Crystal Arthropathies Poster II: Anti-Gout Therapy and Outcomes 1013. Rilonacept for Gout Flare Prevention in Patients on Uric Acid-Lowering Therapy: Results of a Double-Blind, Placebo-Controlled, Phase 3, International Safety Study. John S. Sundy1, H. Ralph Schumacher2, Judith Kirstein3, Essack Mitha4, Steven P. Weinstein5, Jian Wang5, Shirletta King-Davis5 and Robert R. Evans5, 1Duke University Medical Center, Durham, NC, 2VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Advanced Clinical Research, West Jordan, UT, 4Newtown Clinical Research, Johannesburg, Gauteng, South Africa, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY 1014. Rilonacept Efficacy for Gout Flare Prevention in Patients with Tophi and/or Polyarticular Disease Who Initiate Uric Acid-Lowering Therapy. Robert Terkeltaub1, H. Ralph Schumacher2, A. Kivitz3, Steven P. Weinstein4, Richard Wu4, Rebecca Gall4 and Robert R. Evans4, 1VA Medical Ctr, San Diego, CA, 2VA Medical Center and University of

ACR/ARHP Poster Session B Pennsylvania, Philadelphia, PA, 3Altoona Center for Clinical Research, Duncansville, PA, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY 1015. Integrated Safety Analysis of Four Trials of Interleukin-1 Blockade with Rilonacept for Gout Flare Prevention in Patients Taking Uric Acid-Lowering Therapy. Robert Terkeltaub1, H. Ralph Schumacher2, Essack Mitha3, John S. Sundy4, Kenneth G. Saag5, Steven P. Weinstein6, Jian Wang6 and Robert R. Evans6, 1VA Medical Ctr, San Diego, CA, 2VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Newtown Clinical Research, Johannesburg, Gauteng, South Africa, 4Duke University Medical Center, Durham, NC, 5 Univ of Alabama-Birmingham, Birmingham, AL, 6Regeneron Pharmaceuticals, Inc., Tarrytown, NY 1016. Long-Term Efficacy and Safety of Canakinumab Versus Triamcinolone Acetonide in Acute Gouty Arthritis Patients. J.P. Brown1, A. So2, A. Dikranian3, R. Alten4, T. Bardin5, H. R. Schumacher6, A. Gimona7, G. Krammer7, A. Karpov7 and N. Schlesinger8, 1CHUQ-CHUL Research Centre, Laval University, Quebec City, QC, 2CHUV, Lausanne, Switzerland, 3San Diego Arthritis Medical Clinic, San Diego, CA, 4Charité Teaching Hospital–Schlosspark-Klinik, Berlin, Germany, 5Hôpital Lariboisière, Paris, France, 6University of Pennsylvania and VA Medical Center, Philadelphia, PA, 7Novartis Pharma AG, Basel, Switzerland, 8UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 1017. No Dosing Adjustments Are Required for Colchicine in Patients Over Age 60 Years Compared to Younger Adults on the Basis of Age and Mild Renal Impairment. Suman Wason1, Robert D. Faulkner1, Darin B. Brimhall2 and Matthew W. Davis1, 1URL Pharma, Philadelphia, PA, 2Novum Pharmaceutical Research Services Clinical Studies Inc., Pittsburgh, PA 1018. BCX4208 Synergistically Lowers Serum Uric Acid (sUA) Levels When Combined with Allopurinol in Patients with Gout: Results of a Phase 2 Dose-Ranging Trial. Alan S. Hollister1, Michael A. Becker2, Robert Terkeltaub3, Anita Waugh1, Scott Lyman1, Amy Flynt4 and David Fitz-Patrick5, 1 BioCryst Pharmaceuticals, Inc., Durham, NC, 2University of Chicago Medical Center, Chicago, IL, 3VA Medical Ctr, San Diego, CA, 4PharPoint Research, Inc., Chapel Hill, NC, 5EastWest Medical Research Institute, Honolulu, HI 1019. Inflammation Suppression Over 24 Weeks in Patients with Gouty Arthritis: Results From Two Phase-III Core and Extension Studies Comparing Canakinumab with Triamcinolone Acetonide. A. So1, R. Alten2, H. R. Schumacher3, T. Bardin4, M. Bloch5, D. Richard6, A. Karpov6, T. Kiechle6 and N. Schlesinger7, 1CHUV, Lausanne, Switzerland, 2Charité Teaching Hospital–Schlosspark-Klinik, Berlin, Germany, 3University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4Hôpital Lariboisière, Paris, France, 5 Holdsworth House Medical Practice, Sydney, Australia, 6 Novartis Pharma AG, Basel, Switzerland, 7UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ

1020. Effect of IL-1β Inhibition with Canakinumab Compared to Triamcinolone Acetonide on Pain Intensity and New Flares in Gouty Arthritis Patients with Chronic Kidney Disease Stage 2-5. P. Sunkureddi1, T. Bardin2, R. Alten3, N. Schlesinger4, M. Bloch5, T. Kiechle6, G. Krammer6, A. Shpilsky7 and A. So8, 1Clear Lake Rheumatology Center, Nassau Bay, TX, 2Hôpital Lariboisière, Paris, France, 3Charité Teaching Hospital–Schlosspark-Klinik, Berlin, Germany, 4 UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 5Holdsworth House Medical Practice, Sydney, Australia, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceutical Corporation, East Hanover, NJ, 8CHUV, Lausanne, Switzerland 1021. Efficacy and SAFETY of Lesinurad (RDEA594), A NOVEL Uricosuric Agent, Given In COMBINATION with ALLOPURINOL In ALLOPURINOL-REFRACTORY Gout PATIENTS: PRELIMINARY RESULTS FROM the RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B Extension STUDY. John Sundy1, Fernando Perez-Ruiz2, Eswar Krishnan3, Vijay Hingorani4, Jody Welp4, Matt Suster4, Kimberly Manhard4, Matt Cravets4, David Hagerty4 and Barry Quart4, 1Duke University Medical Center, Durham, NC, 2 Hospital De Cruces, Baracaldo, Spain, 3Stanford University, Stanford, CA, 4Ardea Biosciences, Inc., San Diego, CA 1022. Febuxostat (vs. Allopurinol) In Treating the Hyperuricemia of Gout In Diabetic Patients. Michael A. Becker1, Patricia A. MacDonald2, Barbara Hunt2 and Robert L. Jackson2, 1 University of Chicago Medical Center, Chicago, IL, 2Takeda Global Research & Development Center, Inc., Deerfield, IL 1023. Rilonacept for Gout Flare Prevention: Subgroup Analysis of Patients Initiating or Continuing Uric Acid-Lowering Therapy in a Randomized, Placebo-Controlled Trial. John S. Sundy1, H. Ralph Schumacher2, Roy M. Fleischmann3, Johannes M. Engelbrecht4, Steven P. Weinstein5, Jian Wang5, Shirletta King-Davis5 and Robert R. Evans5, 1Duke University Medical Center, Durham, NC, 2VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3MCRC, University of Texas, Dallas, TX, 4Vergelegan Medi-Clinic, West Cape, South Africa, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY 1024. Rilonacept for Prevention of Gout Flares Associated with Uric Acid-Lowering Therapy: Response Rate Across Three Phase 3 Clinical Trials. H. Ralph Schumacher1, Robert R. Evans2, Charles A. Birbara3, Leon Fouche4, Steven P. Weinstein2, Jian Wang2 and Robert Terkeltaub5, 1VA Medical Center and University of Pennsylvania, Philadelphia, PA, 2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Univ Mass City Campus, Worcester, MA, 4Limpopo Clinical Research Initiative, Thabazimbi, South Africa, 5VA Medical Ctr, San Diego, CA 1025. Pharmacological Treatment of Acute Gout: A Systematic Review. Puja Khanna1, Manjit K. Singh2, John D. FitzGerald3, Sangmee Bae2, Shraddha Prakash3, Marian Kaldas3, Maneesh Gogia3, Paul Maranian4, Robert Terkeltaub5 and Dinesh 2011 Program Book

205

ACR/ARHP Poster Session B Khanna6, 1University of Michigan, Ann Harbor, MI, 2David Geffen School of Medicine at UCLA, Los Angeles, CA, 3UCLA, Los Angeles, CA, 4UCLA Medical School, Los Angeles, CA, 5 VA Medical Ctr, San Diego, CA, 6University of Michigan, Ann Arbor, MI 1026. Nonclinical Drug-Drug Interaction Profile of BCX4208, An Oral, Once-Daily, Novel Nonmetabolized Enzyme Inhibitor for Chronic Management of Gout. Paul G. Pearson1, Shanta Bantia2 and Leigh Harman2, 1Pearson Pharma Partners, Westlake Village, CA, 2BioCryst Pharmaceuticals, Inc., Birmingham, AL 1027. Efficacy of Combined Treatment with Allopurinol and Benzbromarone in Gout Patients with Chronic Renal Impairment. Ji Seon Oh1, Seung Won Choi1, Bon San Koo2, Min Wook So2, Yong-Gil Kim2, Chang-Keun Lee2 and Bin Yoo2, 1 University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea, 2University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 1028. Comparison of Pain Intensity, Incidence of New Flares, Safety and Tolerability of Canakinumab Vs Triamcinolone Acetonide in Gouty Arthritis Patients with Cardiovascular Diseases or with Cardiovascular Risk Factors. N. Schlesinger1, J. P. Brown2, T. Bardin3, T. Kiechle4, A. Shpilsky5, R. Alten6 and A. So7, 1UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 2CHUQ (CHUL) Research Centre, Laval University, Quebec City, QC, 3Hôpital Lariboisière, Paris, France, 4Novartis Pharma AG, Basel, Switzerland, 5 Novartis Pharmaceutical Corporation, East Hanover, NJ, 6 Charité Teaching Hospital–Schlosspark-Klinik, Berlin, Germany, 7CHUV, Lausanne, Switzerland 1029. Efficacy of Canakinumab on Re-Treatment in Gouty Arthritis Patients with Limited Treatment Options: 24-Week Results From β-RELIEVED and β-RELIEVED-II Studies. R. Alten1, A. So2, A. Kivitz3, T. Bardin4, M. Bloch5, A. Gimona6, A. Widmer6, G. Krammer6, N. Schlesinger7 and H. R. Schumacher8, 1Charité Teaching Hospital–SchlossparkKlinik, Berlin, Germany, 2CHUV, Lausanne, Switzerland, 3 Altoona Center for Clinical Research, Duncansville, PA, 4 Hôpital Lariboisière, Paris, France, 5Holdsworth House Medical Practice, Sydney, Australia, 6Novartis Pharma AG, Basel, Switzerland, 7UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 8University of Pennsylvania and VA Medical Center, Philadelphia, PA 1030. Pharmacokinetics, Efficacy and SAFETY of Lesinurad, A NOVEL URAT1 Inhibitor, In Individuals with Mild to Moderate Renal IMPAIRMENT. David Hagerty, Brad Kerr, Zangong Shen, Li-tain Yeh, Vijay Hingorani, Matt Cravets, Jody Welp, Jeffrey N. Miner, Kimberly Manhard and Barry Quart, Ardea Biosciences, Inc., San Diego, CA 1031. The Impact On Renal Function of Quantitative Serum Urate Reduction In Gout Patients. Andrew Whelton1, Patricia A. MacDonald2, Barbara Hunt2 and Lhanoo Gunawardhana2, 1 The Johns Hopkins University and Universal Clinical Research Center, Inc., Baltimore, MD, 2Takeda Global Research & Development Center, Inc., Deerfield, IL

206

2011 Program Book

1032. Uncontrolled Serum Uric Acid Is Associated with An Increased Risk of Developing Renal Disease In Veterans with Gout. Eswar Krishnan1, Hari Sharma2, Bhavik J. Pandya3, Maryna Marynchenko2, Andrew Yu2, Eric Wu2, Jinan Liu4 and Lizheng Shi4, 1Stanford University, Stanford, CA, 2 Analysis Group, Inc., Boston, MA, 3Takeda Pharmaceuticals International, Inc., Deerfield, IL, 4Tulane University, New Orleans, LA 1033. Clinical Characteristics of Difficult-to-Treat Gout Patients: a Principal Components Analysis. Elizaveta Vaysbrot1, Yoojin Lee1, Sarah McLaughlin1, Neetu Agashivala2, Anthony Yadao3, Timothy E. McAlindon1 and William F. Harvey1, 1 Tufts Medical Center, Boston, MA, 2Novartis Pharmaceutical Corporation, East Hanover, NJ, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ 1034. Predictors of Outcomes in Gout with Comorbid Chronic Kidney Disease. Ankoor Shah and John S. Sundy, Duke University Medical Center, Durham, NC 1035. Patient Management/Treatment and Outcomes of Gout Between Primary Care Physicians and Rheumatologists: A Chart Review of 1,039 Patients with Gout In the United States. Dinesh Khanna1, Anna Forsythe2 and Puja Khanna1, 1University of Michigan, Ann Arbor, MI, 2Savient Pharmaceuticals, Inc., East Brunswick, NJ 1036. Adverse Reactions to Allopurinol Are Not Increased In Patients Exposed to Doses Higher Than Recommended for Creatinine Clearance: A Retrospective Study of A Large Urban Multispecialty Group. Tawatchai Paisansinsup1 and John T. Schousboe2, 1Park Nicollet Health Services, St. Louis Park, MN, 2Park Nicollet Health Services, Minneapolis, MN 1037. Oral Urate Lowering Therapies in Chronic Gout: A Systematic Review and Meta-Analysis. Puja Khanna1, Manjit K. Singh2, Sangmee Bae2, John D. FitzGerald3, Shraddha Prakash4, Marian Kaldas4, Maneesh Gogia4, Paul Maranian5, Robert Terkeltaub6 and Dinesh Khanna1, 1 University of Michigan, Ann Arbor, MI, 2David Geffen School of Medicine at UCLA, Los Angeles, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4UCLA, Los Angeles, CA, 5University of California, Los Angeles, 6VA Medical Ctr, San Diego, CA

Miscellaneous Rheumatic and Inflammatory Diseases 1038. A Case Series of HLA B27 Patients with a Behçet’s Like Syndrome in a UK Population. Nicola Ambrose1 and Dorian O. Haskard2, 1Imperial College London, London, United Kingdom, 2Imperial College, London, United Kingdom 1039. Dual Effects of Testosterone in Behcet’s Disease: Implications for a Role in Disease Pathogenesis. Sule Yavuz1, Tugba Akdeniz2, Muge Bicakcigil2, Haner Direskeneli1 and Gulderen Yanikkaya Demir2, 1Marmara University, Istanbul, Turkey, 2Yeditepe University, Istanbul, Turkey 1040. Major Arterial Involvement in Behçet’s Disease: Results From a Single Centre about 29 Cases. Z. Tazi Mezalek, W. Ammouri, H. Harmouche, M. Maamar, M. Bourkia, M. Adnaoui and M. Aouni, Ibn Sina Hospital, Rabat, Morocco

ACR/ARHP Poster Session B 1041. Treatment with Infliximab Is Effective and Safty in BD Patients with Uveitis. Kayo Terauchi, Mitsuhiro Takeno, Takeaki Uehara, Atsuhisa Ueda, Nobuhisa Mizuki, Etsuko Shibuya and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan 1042. Adverse Events of Immunosuppressive Therapy in Autoimmune Uveitis Patients. Zulema Rosales, Ana B. Rodríguez-Cambrón, Oscar Fontsere, Leticia León, Pedro Arriola, Lydia Abásolo, Cristina Martínez, Cristina Lajas and Esperanza Pato, Hospital Clínico San Carlos, Madrid, Spain 1043. Relationship BETWEEN PATTERNS of CLINICAL PRESENTATION Uveitis and FINAL Inmunologic DIAGNOSIS. Esperanza Pato1, Zulema Rosales1, Esther Toledano1, Pilar Macarron1, Cristina Vadillo1, Rosalía Mendez1, Miguel A. Descalzo2 and Estíbaliz Loza2, 1Hospital Clínico San Carlos, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain 1044. High Dose Intravenous Methylprednisolone Induces Rapid Improvement In Severe Uveitis: A Multicenter Study. Carmen Bejerano1, Ricardo Blanco1, Emma Beltrán2, Alejandro Fonollosa3, Olga Maiz4, Ana Blanco-Esteban4, Miguel Cordero5, Inés Pérez-Martín6, Joaquín Cañal6, Juan Ventosa6 and Miguel Angel González-Gay6, 1Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain, 2Hospital Peset, Valencia, Spain, 3Hospital de Cruces, Barakaldo-Bilbao, Spain, 4Hospital Donostia, San Sebastian, Spain, 5Hospital León, León, Spain, 6Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain 1045. Adalimumab in 107 Refractory Uveitis: A Multicenter Study. Orlando Pompei1, Ricardo Blanco2, Manuel Diazllopis3, David Salom3, Carmen Garcia-Vicuña4, Miguel Cordero-Coma5, Gabriela Ortega-Larrocea6, Norberto Ortego-Centeno7, Marta Suarez-de-Figueroa8, J. Carlos Fernandez-Cid9, Alejandro Fonollosa10, Angel M. GarciaAparicio11, Jose M. Benítez-del-Castillo12, Jose L. Olea13 and J. Fernando Arevalo14, 1Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain, 3La Fe University Hospital of Valencia, Valencia, Spain, 4Hospital Sant Joan de Déu, Barcelona, Spain, 5Hospital de León, León, Spain, 6National Institute of Rehabilitation, D.F Mexico, Mexico, 7Hospital Clínico San Cecilio, Granada, Spain, 8Hospital Ramon y Cajal, Madrid, Spain, 9Hospital de Pontevedra, Pontevedra, Spain, 10Hospital de Cruces, Bilbao, Spain, 11Hospital Virgen de la Salud, Toledo, Spain, 12Hospital Clínico San Carlos, Madrid, 13Hospital Son Dureta, Palma de Mallorca, Spain, 14Ophthalmology Clinic Center of Caracas, Caracas, Venezuela 1046. Recalcitrant Orbital Inflammatory Disease Responsive to Infliximab. Mary Bach and Gregory C. Gardner, University of Washington, Seattle, WA 1047. Giant Cell Tumor of Synovial Sheath: Of Two Cases Treated with Intra-Articular Infiltration of Infliximab. Emanuela Praino, Crescenzio Scioscia, Maria Grazia Anelli, Laura

Coladonato, Michele Covelli, Florenzo Iannone and Giovanni Lapadula, D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy 1048. Distinct Rheumatological Features Induced by Aromatase Inhibitors in Breast Cancer Patients: A Prospective Multicenter Cohort Study of 138 Women with Breast Cancer. Serge Perrot1, Paul Cottu2, Xavier Decleves1, Laure Chauvenet1, Christophe Tournigand3, Jean-Yves Pierga2, Didier Bouhassira4 and Francoise Laroche3, 1Hopital Hotel Dieu, Paris, France, 2Curie Institute, Paris, France, 3Saint Antoine Hospital, Paris, France, 4Ambroise Paré Hospital, Boulogne, France 1049. Treatment of Chemotherapy-Related Arthropathy with Disease Modifying Antirheumatic Drugs: Results of An Open-Labeled Multicenter Pilot Study. Hyoun Ah Kim1, HyoJin Choi2, Hanjoo Baek2, Mie Jin Lim3, Won Park3, Jisoo Lee4, Sung Jae Choi5, Bo Young Yoon6, Sang Tae Choi7, Jung-Soo Song7, Sung Soo Kim8 and Chang-Hee Suh1, 1Ajou University School of Med, Suwon, South Korea, 2Gachon University Gil Hospital, Incheon, South Korea, 3Center for Rheumatism, Inha University Hospital, Incheon, South Korea, 4Ewha Womans University Mokdong Hospital, Seoul, South Korea, 5 Korea University Medical Center, Ansan, South Korea, 6Inje University Ilsan Paik Hospital, Goyang, South Korea, 7ChungAng University College of Medicine, Seoul, South Korea, 8 Ulsan Univ Med Sch Gangneung, Gangneung 1050. Characterizationof Non-Hodgkin Lymphomas in Rheumatic Diseases. Vladimir I. Vasilyev, Research Institute of Rheumatology of RAMS, Moscow, Russia 1051. Colchicine Halves, but Does Not Eliminate Recurrences in Pericarditis: Colchicine for Recurrent Pericarditis. A Randomized, Controlled Trial. A. Brucato1, S. Maestroni1, D. Cumetti1, R. Cemin2, S. Ferrua3, R. Belli4, D. H. Spodick5, Y. Adler6, R. Trinchero4 and M. Imazio4, 1Ospedali Riuniti, Bergamo, Italy, 2San Maurizio Regional Hospital, Bolzano, Italy, 3Savigliano Hospital, Rivoli, Italy, 4Maria Vittoria Hospital, Torino, Italy, 5St. Vincent Hospital, Massachusetts, 6 Sackler Faculty of Medicine, Tel-Aviv, Israel 1052. EDTA Resistant S100A12 Complexes (ERAC) In Serum of Patients with Coronary Artery Disease (CAD) with and without Inflammatory Rheumatic Disease (IRD). Ivana Hollan1, Anita Kåss2, Torstein Lyberg3, Sven M. Almdahl4, Øystein T. Førre3, Knut Mikkelsen5 and Magne Fagerhol3, 1 Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 2Betanien Hospital, Skien, Norway, 3Oslo University Hospital, Oslo, Norway, 4University Hospital of North Norway, Tromsø, Norway, 5Lillehammer Hosp for Rheumatic Diseases, Lillehammer, Norway 1053. The Baseline Characteristics and Survival of Chinese Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension. YanJie Hao1, Wei Zhou1, Xin Jiang2, Yu Wang1, Lan Gao1, GuangTao Li1, Tao Hong1, Yong Wang3, ZhiCheng Jing2 and ZhuoLi Zhang1, 1 Peking University First Hospital, Beijing, China, 2Shanghai 2011 Program Book

207

ACR/ARHP Poster Session B Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, 3Beijing Shijitan Hospital, Capital Medical University, Beijing, China 1054. Overrepresentation of Lifestyle Associated Risk Factors Along the Spectrum of Rheumatic Disease. Inger L. Meek1, H.S.J. Picavet2, Harald E. Vonkeman1 and Mart AF van de Laar3, 1Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, 2 National Institute for Public Health and the Environment, Bilthoven, Netherlands, 3Medisch Spectrum Twente & Twente University, Enschede, Netherlands 1055. Subclinical Atherosclerosis In Inflammatory Rheumatic Diseases. Dan Nemes1, Mihai Dragoi1, Liliana Catan1, Elena Amaricai1, Daniel Popa1, Roxana Onofrei1, Dan Surducan1, George Puenea1, Elena Sarbu2, Andreea Iana2, Mihaela Muntean2, Rodica Mihaescu2, Rares Olariu2 and Camelia Nemes2, 1”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, 2City Universitary and Emergency Hospital, Timisoara, Romania 1056. Nontuberculous Mycobacterial Infections In Rheumatological Diseases. Vivek Nagaraja1, Joel A. Terriquez2, Susan E. Hoover2 and Jeffrey R. Lisse2, 1University of Arizona / University Physicians Healthcare at Kino Campus, Tucson, AZ, 2University of Arizona, Tucson, AZ 1057. A Meta-Analysis: Diagnostic Accuracy of Serum Procalcitonin Concentrations for Detecting Systemic Bacterial Infection In Patients with Rheumatic Diseases. Yoshinori Kogata, Daisuke Sugiyama, Akira Onishi, Ikuko Naka, Kosaku Tsuda, Keisuke Nishimura, Kenta Misaki, Goichi Kageyama and Akio Morinobu, Kobe university graduate school of medicine, Kobe, Japan 1058. Nutritional Deficiencies Linked to Nonspecific Complaints of Joints, Skin, and Nervous System in a University-Based Rheumatology Clinic; A Retrospective Chart Review. Shawn Macalester, University of Virginia, Charlottesville, VA 1059. Vitamin D Deficiency in Patients with Systemic Lupus Erythematosus and Rheumatoid Artrhitis in a Tropical Country. Claudia D.L. Marques, Thiago Sotero Fragoso, Andrea Tavares Dantas, Aline Jurema G. Costa, Henrique A. Mariz, Aline Ranzolin and Angela Luzia B. P. Duarte, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife PE, Brazil

Orthopedics, Low Back Pain, and Rehabilitation 1060. Predictors of Outcomes of Total Knee Replacement Surgery. Andrew Judge1, Nigel K. Arden2, Cyrus Cooper3, M. Kassim Javaid2, Andrew Carr1, Richard E. Field4 and Paul A. Dieppe5, 1Oxford University, Oxford, United Kingdom, 2 Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, 3 Southampton General Hospital, Southampton, United Kingdom, 4Elective Orthopaedic Cnetre, Epsom, United Kingdom, 5University of Exeter, Plymouth, United Kingdom

208

2011 Program Book

1061. Pain After Hip or Knee Joint Replacement for Osteoarthritis: A Systematic Review. Andrew Beswick1, Vikki Wylde2, Ashley Blom2, Rachael Gooberman-Hill1 and Paul A. Dieppe3, 1University of Bristol, Bristol, 2University of Bristol, Bristol, United Kingdom, 3University of Exeter, Plymouth, United Kingdom 1062. Efficacy of Total Arthroplasty Combined with Anti-Tumor Necrosis Factor Agents on Systemic Disease Activity in Patients with Rheumatoid Arthritis. Masatoshi Hayashi1, Toshihisa Kojima2 and Naoki Ishiguro3, 1Nagoya University Graduate School, Nagoya, Japan, 2Nagoya University, School of Medicine, Nagoya, Japan, 3Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan 1063. Peptic Ulcer Disease Is Associated with Periprosthetic Fractures After Total Hip Replacement. Jasvinder A. Singh1 and David Lewallen2, 1University of Alabama at Birmingham, Birmingham, AL, 2Mayo Clinic College of Medicine, Rochester, MN 1064. Prognostic Factors for Surgical Intervention After Steroid Induced Avascular Necrosis of the Femoral Head. Ryo Hiroshima1, Katsunori Ikari1, Ikuko Masuda2 and Shigeki Momohara1, 1Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 2International University of Health and Welfare, Sanno Hospital, Tokyo, Japan 1065. Relationship Between Synovitis and Two-Year Post-Surgical Outcomes in Patients Undergoing Arthroscopic Partial Meniscectomy. Carla R. Scanzello1, Edward F. DiCarlo2, Veero Kanda1, Anthony Albert3, Steven R. Goldring2, John C. Richmond3 and Brian McKeon4, 1Rush University Medical Center, Chicago, IL, 2Hospital for Special Surgery, New York, NY, 3New England Baptist Hospital, MA, 4New England Baptist Hospital, Boston, MA 1066. Ultrasound Guided Hip Joint Injection, Its Safety and Efficacy. Srijana Pandit1, Charles H. Pritchard2, Elana Eisner2 and Mary Naglak1, 1Abington Memorial Hospital, Abington, PA, 2Rheumatic Disease Associates, Willow Grove, PA 1067. Pilates to TREAT CHRONIC NON-SPECIFIC LOW BACK PAIN. Jamil Natour, Andreia S. Baptista, Luciana A. Cazotti, Luiza H. C. Ribeiro and Anamaria Jones, Universidade Federal de Sao Paulo, Sao Paulo, Brazil 1068. Some Clinical Features Are Associated with MODIC I Changes in Patient with Chronic Low Back Pain; Results of a Case Control Study. Florian Bailly1, Jean-Yves Maigne2, Stéphane Genevay3, Marc Marty4, Frédérique Gandjbakhch1, Sylvie Rozenberg5 and Violaine Foltz6, 1Hopital Pitié Salpétrière, Paris, France, 2Hôpital Hôtel Dieu, Paris, France, 3 Hospital-Beau-Sejour, Geneva, Switzerland, 4Hôpital Henri Mondor, Créteil, France, 5Hopital La Pitie, Paris, France, 6 Hôpital Pitié Salpétrière, Paris, France 1069. The Efficacy of ThermaCare Heat Wraps on Relieving Lower Back Pain and Reducing Muscle Stiffness. Jerrold Petrofsky1, Lee Berk1, Gurinder Bains1, Benny Hau1, Geraldine Doyle2, Shijie Chen2 and Jill Stark2, 1Loma Linda University, Loma Linda, CA, 2Pfizer Consumer Healthcare, Madison, NJ

ACR/ARHP Poster Session B Osteoarthritis - Clinical Aspects 1070. Hand Osteoarthritis: A Predictor of Accelerated Progression in Knee OA? Jonathan Samuels1, Catherine Petchprapa2, Elizabeth Carpenter2, Mukundan Attur1, Leon Rybak2, Svetlana Krasnokutsky3, Cheongeun Oh4 and Steven B. Abramson1, 1NYU Hospital for Joint Diseases, New York, NY, 2NYU Langone Medical Center, New York, NY, 3 NYU Hospital for Joint Disease, New York, NY, 4New York University, New York, NY 1071. Erosive Osteoarthritis Is Associated with Preclinical Atherosclerosis. Athanasios Koutroumpas, Athanasios Giannoukas, Aikaterini Exarchou, Aristeidis Baliakos, Konstantinos Makaritsis and Lazaros I. Sakkas, Thessaly University School of Medicine, Larissa, Greece 1072. More Inflammatory Signs on Ultrasound in Interphalangeal Joints in Erosive Hand Osteoarthritis. Marion C. Kortekaas1, Wing-Yee Kwok1, M. Reijnierse1, T.W.J. Huizinga2 and Margreet Kloppenburg3, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Department Rheumatology and Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, Netherlands 1073. The Association Between Erosive Hand Osteoarthritis and Systemic Bone Mineral Density. Ida K. Haugen1, David T. Felson2, Martin Englund3, Ke Wang2, Piran Aliabadi4, Ali Guermazi2, Frank Roemer2 and Tuhina Neogi2, 1 Diakonhjemmet Hospital, Oslo, Norway, 2Boston University, Boston, MA, 3Lund University, Lund, Sweden, 4Brigham and Women’s Hospital, Boston 1074. Magnetic Resonance Imaging in Hand Osteoarthritis: Validation of the Oslo Hand Osteoarthritis MRI-Scoring Method and Association with Pain, Radiographs and Ultrasound. Wing-Yee Kwok1, Marion C. Kortekaas1, M. Reijnierse1, Desirée van der Heijde1, J.L Bloem1 and Margreet Kloppenburg2, 1Leiden University Medical Center, Leiden, Netherlands, 2Department Rheumatology and Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, Netherlands 1075. MRI and Histologic Evidence for the Role of Synovitis in Bone Erosions in Erosive Osteoarthritis. Allen P. Anandarajah1, Laura A. Paxton2, Ellen Giampoli3, Kenneth Badillo3, Johnny Monu3 and Christopher T. Ritchlin4, 1Univ of Rochester Medical Ctr, Rochester, NY, 2University of Rochester Strong Hospital, Rochester, NY, 3University of Rochester Medical Ctr, Rochester, NY, 4University of Rochester Medical Center, Rochester, NY 1076. Cartilage Damage in the Tibio-Femoral and Patello-Femoral Joints and Risk of Progression: Role of Prevalent Damage Severity – the MOST Study. Frank Roemer1, David T. Felson2, Ke Wang1, Michel Crema1, Monica D. Marra1, Michael C. Nevitt3, Yuqing Zhang4, Cora E. Lewis5, James Torner6 and Ali Guermazi7, 1Boston University, Boston, MA, 2Department of Clinical Epidemiology, Boston University School of

Public Health, Boston, MA, USA, Boston, MA, 3University of California-San Francisco, San Francisco, CA, 4Boston University School of Medicine, Boston, MA, 5University of Alabama, Birmingham City, Birmingham, AL, 6University of Iowa, Iowa City, Iowa City, IA, 7Boston Medical Center, Boston, MA 1077. Prevalence of Cam and Pincer-Type Deformities on Hip MRI in a Swiss Female Population: A Cross-Sectional Study. Stephan Reichenbach1, Peter Jüni1, Stefan Werlen2, Andreas Limacher1, Christian W. Pfirrmann3, Reinhold Ganz1 and Michael Leunig4, 1University of Bern, Bern, Switzerland, 2 Hospital Sonnenhof, Bern, Switzerland, 3Balgrist University Hospital, Zurich, Switzerland, 4Schulthess Clinic, Zurich, Switzerland 1078. Systemic Bone Mineral Density Change and Body Mass Index, but Not Bone Mineral Density Are Related to Knee Cartilage Loss in Knee Osteoarthritis. Ji Yeon Lee1, Timothy E. McAlindon1, Lori Lyn Price1 and Eric Miller2, 1Tufts Medical Center, Boston, MA, 2Tufts University, Medford, MA 1079. Adiposity and Serum Inflammatory Markers Are Associated with Increases in Knee Pain Over 5 Years in Old Adults. Chang-Hai Ding1, Oliver Stannus2, Flavia Cicuttini3 and Graeme Jones2, 1University of Tasmania & Monash University, Hobart, Australia, 2University of Tasmania, Hobart, Australia, 3Monash University, Central and Eastern Clinical School, Melbourne, Australia 1080. Serum Adipokines in End-Stage Osteoarthritis; Comparison with Healthy Controls and Relations with Intra-Articular Joint Characteristics. T.N. de Boer1, Simon C. Mastbergen1, A.M. Huisman2, J.W.J. Bijlsma1 and F.P.J.G. Lafeber1, 1 University Medical Center Utrecht, Utrecht, Netherlands, 2 Sint Franciscus Gasthuis, Rotterdam, Netherlands 1081. Synovial Fluid Leptin Levels and Joint Pain in End-Stage Osteoarthritis: A Potential Explanation for Increased Pain in Women and in Obese Patients. Anne Lübbeke1, Axel Finckh2, Gabor J. Puskas1, Domizio Suva1, Alexandre Lädermann1, Sylvette Bas2, Daniel Fritschy1, Cem Gabay1 and Pierre Hoffmeyer1, 1Geneva University Hospitals, Geneva, Switzerland, 2University Hospital of Geneva, Geneva, Switzerland 1082. Comparison of Cytokine Levels in the Synovial Joint Fluid Between Rapidly Destructive Coxopathy, Hip Osteoarthritis, Rheumatoid Arthritis, and Hip Oseteonecrosis. Hirohito Abe1, Takashi Sakai1, Wataru Ando2, Masaki Takao1, Takashi Nishii1, Nobuo Nakamura3, Hideki Yoshikawa1 and Nobuhiko Sugano1, 1Osaka University Graduate School of Medicine, Suita, Osaka, Japan, 2Kansai Rousai Hospital, Amagasaki, Japan, 3Kyowakai Hospital, Suita, Japan 1083. Presence of Gout Is Associated with Increased Osteoarthritis Prevalence and Severity. Rennie N. G. Howard1, Jonathan Samuels1, Soterios Gyftopoulos1, Svetlana Krasnokutsky2, Joseph Leung3, Christopher

2011 Program Book

209

ACR/ARHP Poster Session B Swearingen4 and Michael H. Pillinger1, 1NYU Langone Medical Center/NYU Hospital for Joint Diseases, New York, NY, 2NYU Hospital for Joint Disease, New York, NY, 3New York, NY, 4University of Arkansas for Medical Sciences, Little Rock, AR 1084. Expression of HUMAN Endogenous Retrovirus Herv-K18 In Osteoarthritis PATIENTS. Benjamin Fernandez-Gutierrez1, Marta Garcia-Montojo2, Jose Hoyas1, Inmaculada Dominguez-Mozo2, Esther Villafuertes1, Pilar TorneroEsteban1, Ana Arias-Leal2, Lydia Abasolo1, Roberto AlvarezLafuente2 and Jose Ramon Lamas2, 1Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 2 Hospital clinico San Carlos, Madrid, Spain 1085. Varus Thrust and Knee Frontal Plane Dynamic Motion in Persons with Knee Osteoarthritis. Alison Chang, Joan Chmiel, Kirsten Moisio, Orit Almagor, Yunhui Zhang, September Cahue, Clifton Saurel and Leena Sharma, Northwestern University, Chicago, IL 1086. Shoe Flexibility Reduces Dynamic Joint Loads in Knee Osteoarthritis: Results of a Pilot Study. Najia Shakoor1, Roy H. Lidtke1, Louis F. Fogg2, Markus A. Wimmer1, Kharma C. Foucher1, Rachel A. Mikolaitis1 and Joel A. Block1, 1Rush University Medical Center, Chicago, IL, 2Rush University Medical Center 1087. Sagittal Plane Hip Motion During Gait and Function and Disability in Knee Osteoarthritis. Kirsten Moisio, Carmelita J. Colbert, Orit Almagor, Joan S. Chmiel, Alison Chang, Yunhui Zhang, September Cahue, Karen W. Hayes, Clifton Saurel and Leena Sharma, Northwestern University, Chicago, IL 1088. Vibratory Sense in Patients At High Risk of Knee Osteoarthritis. Jonas B. Thorlund1, Najia Shakoor2, Eva Ageberg3, Louise F. Sandal1, Joel A. Block2 and Ewa M. Roos1, 1Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark, 2Rush University Medical Center, Chicago, IL, 3 Department of Health Sciences, Lund University, Lund, Sweden

Maria Huijbregts7, Carolyn McCullough7, Lily Chen8 and Gino De Angelis9, 1University of Ottawa, Ottawa, ON, 2Univ of Ottawa Faculty of Med, Ottawa, ON, 3School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada, Ottawa, ON, 4University of Ottawa Heart Institute, Ottawa (Ontario), Canada, 5Univ Health Network, Toronto, ON, 6Institute of Population Health, Ottawa, ON, 7Baycrest Centre, (Toronto), Canada, Toronto, ON, 8University of Ottawa Heart Institute, Ottawa (Ontario), Canada, Ottawa, ON, 9University of Ottawa, Ottawa, ON, Ottawa, ON 1091. Self-Efficacy Status Is Associated with Pain, Partially Mediating the Effect of Communication Style in Acupuncture Treatment for Knee Osteoarthritis. Grace H. Lo1, Vanessa Cox2, Richard L. Street Jr.3 and Maria E. SuarezAlmazor4, 1Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, 2UT MD Anderson Cancer Center, Houston, TX, 3Texas A&M University, College Station, TX, 4 University of Texas. M.D Anderson Cancer Center, Houston, TX 1092. Double Blind Cross-Over Study of the Efficacy of a Tart Cherry Juice Blend In Treatment of Osteoarthritis (OA) of the Knee. H. Ralph Schumacher1, Sally W. PullmanMooar2, Smita R. Gupta3, Janet E. Dinnella4, Rosa Kim5 and Malachy McHugh6, 1VA Medical Center and University of Pennsylvania, Philadelphia, PA, 2Philadelphia Veterans Hospital, Philadelphia, PA, 3University of Pennsylvania, Santa Monica, CA, 4University of Pennsylvania, Philadelphia, PA, 5 The Children’s Hospital of Philadelphia, Philadelphia, PA, 6 Nicholas Institute of Sports Medicine and Athletic Trauma, New York, NY 1093. Fish Oil in Knee Osteoarthritis: A Two Year Randomized, Double-Blind Clinical Trial Comparing High Dose with Low Dose. Catherine L. Hill1, Graeme Jones2, Lynette March3, Ruth Battersby1, Kristen Hynes2, Tanya Fedorova4, Sue Lester5, Susanna Proudman6 and Leslie G. Cleland6, 1The Queen Elizabeth Hospital, Woodville, Australia, 2University of Tasmania, Hobart, Australia, 3University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, 4University of Sydney, St Leonards NSW, Australia, 5Queen Elizabeth Hospital, Woodville South, Australia, 6Royal Adelaide Hospital, Adelaide, Australia

1089. Generalized Sensory Deficits in Radiographic Knee Osteoarthritis: The MOST Study. Najia Shakoor1, Tuhina Neogi2, David T. Felson3, Jingbo Niu3, Laura Frey-Law4, Cora E. Lewis5 and Michael C. Nevitt6, 1Rush University Medical Center, Chicago, IL, 2Boston University, Boston, MA, 3Boston University School of Medicine, Boston, MA, 4University of Iowa, Iowa City, IA, 5University of Alabama, Birmingham City, Birmingham, AL, 6University of California-San Francisco, San Francisco, CA

1094. The Efficacy and Safety of Duloxetine Treatment in Older Patients with Osteoarthritis Knee Pain: A Post Hoc, Subgroup Analysis of Data From 2 Placebo-Controlled Trials. Joseph L. Micca1, Richard C. Risser2, Jonna Ahl2 and Madelaine M. Wohlreich2, 1Patient Centered Healthcare, Altanta, GA, 2Lilly USA, Indianapolis, IN

1090. The Impact of a Community-Based Aerobic Walking Program for Older Individuals with Mild to Moderate Knee Osteoarthritis: A Knowledge Translation Randomized Controlled Trial. Lucie Brosseau1, George A. Wells2, Glen Kenny3, Robert Reid4, Andreas Maetzel5, Peter Tugwell6,

1095. A Phase 3 Placebo- and Oxycodone-Controlled Study of Tanezumab in Adults with Osteoarthritis. James Fidelholtz1, Marvin Tark2, Egilius Spierings3, Gernot Wolfram4, Karen Annis4, Michael D. Smith4, Mark T. Brown4 and Christine R. West5, 1Hilltop Physicians, Inc., Cincinnati, OH, 2Pain

210

2011 Program Book

ACR/ARHP Poster Session B Solutions Treatment Centers, Marietta, GA, 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 4 Pfizer, Groton, CT, 5Pfizer, Williamston, MI 1096. Efficacy and Safety of Tanezumab Added on to Diclofenac in Patients with Knee or Hip Osteoarthritis (NCT00864097). Eugen Feist1, Andra Balanescu2, Gernot Wolfram3, Isabelle Davignon3, Michael D. Smith3, Mark T. Brown3 and Christine R. West4, 1Charité Medical School, Berlin, Germany, 2Sf. Maria Hospital, Bucharest, Romania, 3Pfizer, Groton, CT, 4 Pfizer, Williamston, MI

Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis 1097. Is Femoral Neck Fracture Associated with Hip Structural Analysis Measurements? Alexander G. S. Oldroyd1, John P. Halsey2, Bronwen Evans2, Cathi Greenbank2, Nicola Goodson3 and Marwan Bukhari2, 1Lancaster University, Lancaster, United Kingdom, 2Royal Lancaster Infirmary, Lancaster, United Kingdom, 3University Hospital Aintree, Liverpool, United Kingdom 1098. The Analysis of Denosumab Discontinuation and Associated Fracture Incidence in the FREEDOM Trial. Jacques P. Brown1, Jens-Erik Beck Jensen2, Chris Recknor3, Christian Roux4, Ove Tørring5, Matt Austin6, Andrea Wang6, Andreas Grauer6 and Rachel B. Wagman6, 1CHUQCHUL Research Centre, Laval University, Quebec City, QC, 2Hvidovre Hospital, Hvidovre, Denmark, 3United Osteoporosis Centers, Gainesville, GA, 4Paris Descartes University, Paris, France, 5Institution for Clinical Science and Education Södersjukhuset Karolinska Institutet, Stockholm, Sweden, 6Amgen Inc., Thousand Oaks, CA 1099. Vertebral and Femoral Strength Increased In Postmenopausal Women with Osteoporosis Treated with Teriparatide for 18 Months. Tony M. Keaveny1, Michael Maricic2, David Kopperdahl3, Valerie Ruff4, Xiaohai Wan5 and Kelly Krohn6, 1University of California, Berkeley, CA and O.N. Diagnostics, LLC, Berkeley, CA, 2Catalina Pointe Rheumatology, Tucson, AZ, 3O.N. Diagnostics, LLC, Berkeley, CA, 4Lilly USA, LLC, 5Eli Lilly and Company, 6Lilly USA, LLC, Indianapolis, IN 1100. Risk Factors for Osteoporosis in Patients with Rheumatoid Arthritis (TOMORROW STUDY). Tadashi Okano1, Masahiro Tada1, Yuko Sugioka1, Kenji Mamoto2, Shigeyuki Wakitani1, Hiroaki Nakamura1 and Tatsuya Koike1, 1Osaka City University Medical School, Osaka, Japan, 2Higashisumiyoshi Morimoto Hospital, Osaka, Japan 1101. Adherence with Intravenous Zoledronic Acid and Ibandronate for Osteoporosis Among U.S. Medicare Beneficiaries. Jeffrey R. Curtis1, Huifeng Yun2, Robert Matthews2, Kenneth G. Saag1 and Elizabeth S. Delzell2, 1Univ of Alabama-Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL

1102. Glucocorticosteroids but Not Hand Bone Density Is Associated with Distal Radius Fracture Severity in Elderly Women. Alvilde Dhainaut1, Adalstein Odinson2, Kamil Daibes3, Mari Hoff2, Unni Syversen1 and Glenn Haugeberg1, 1 The Norwegian University of Science and Technology, Trondheim, Norway, 2St Olavs Hospital, Trondheim, Norway, 3 Sørlandet Hospital, Kristiansand, Norway 1103. Extended Safety Observations From Denosumab Administration in Postmenopausal Women From the FREEDOM and FREEDOM Extension Trials. J. P. Brown1, H. G. Bone2, R. Chapurlat3, C. Libanati4, M. L. Brandi5, E. Czerwinski6, M.-A. Krieg7, Z. Man8, D. Mellström9, S. C. Radominski10, J.-Y. Reginster11, H. Resch12, J. A. Román Ivorra13, Christian Roux14, N. S. Daizadeh4, A. Grauer4, S. R. Cummings15 and S. Papapoulos16, 1CHUQ-CHUL Research Centre, Laval University, Quebec City, QC, 2Michigan Bone & Mineral Clinic, Detroit, MI, 3Hôpital Edouard Herriot, Lyon, France, 4Amgen Inc., Thousand Oaks, CA, 5 University of Florence, Florence, Italy, 6Krakow Medical Center, Krakow, Poland, 7University Hospital of Lausanne, Lausanne, Switzerland, 8Centro TIEMPO, Buenos Aires, Argentina, 9Sahlgrenska University Hospital, Göteborg, Sweden, 10Universidade Federal do Paraná, Curitiba, Brazil, 11 University of Liège, Liège, Belgium, 12St. Vincent Hospital, Vienna, Austria, 13Hospital Universitario La Fe, Valencia, Spain, 14Paris Descartes University, Paris, France, 15San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA, 16Leiden University Medical Center, Leiden, Netherlands 1104. Strontium Ranelate in the Treatment of Male Osteoporosis. One Year Results of a Placebo Controlled Study. JeanMarc Kaufman1, Maurice Audran2, Gerolamo Bianchi3, Steven Boonen4, Robert Josse5, Roger M. Francis6, Stefan Goemaere1, S. Palacios7, M. Diaz-Curiel8, Johann-Diederich Ringe9 and Dieter Felsenberg10, 1Ghent University Hospital, Ghent, Belgium, 2CHU Angers, Angers, France, 3Ospedale La Colletta, Arenzano-GE, Italy, 4Leuven University Hospital, Leuven, Belgium, 5St Michael’s Hospital, Toronto, 6Institute for Ageing and Health, Newcastle, United Kingdom, 7 Instituto Palacios, Madrid, Spain, 8Fundacion Jimenez Diaz, Madrid, Spain, 9Klinikum Leverkusen, University of Cologne, Cologne, Germany, 10Charité Campus Benjamin Franklin, Berlin, Germany 1105. The Lancaster Osteoporosis Predictor – a Novel Tool to Identify Individuals with Osteoporosis. Alexander G. S. Oldroyd1, John P. Halsey2, Nicola Goodson3, Bronwen Evans2, Cathi Greenbank2, David Gore2 and Marwan Bukhari2, 1 Lancaster University, Lancaster, United Kingdom, 2Royal Lancaster Infirmary, Lancaster, United Kingdom, 3University Hospital Aintree, Liverpool, United Kingdom 1106. Allowing Patient Self-Referral of Dual Energy X-Ray Absorptiometry Significantly Improves Osteoporosis Screening in Two Regional Healthcare Systems. Amy H. Warriner1, Ryan C. Outman1, Jeffery R. Curtis1, Adrianne C.

2011 Program Book

211

ACR/ARHP Poster Session B Feldstein2, Roslin Nelson3, David T. Redden1, Junling Ren3, Mary M. Rix2, Brandi E. Robinson3, Douglas W. Roblin3, A. Gabriela Rosales2, Monika M. Safford1 and Kenneth G. Saag1, 1 University of Alabama at Birmingham, Birmingham, AL, 2 Kaiser Permanente Center for Health Research, Portland, OR, 3Kaiser Permanente Center for Health Research, Atlanta, GA 1107. Effects of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover Over 8 Years. Michael R. McClung1, E. Michael Lewiecki2, Michael A. Bolognese3, Munro Peacock4, Richard L. Weinstein5, Beiying Ding6, Michelle L. Geller6, Andreas Grauer6, Rachel B. Wagman6 and Paul D. Miller7, 1Oregon Osteoporosis Center, Portland, OR, 2New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 3Bethesda Health Research Center, Bethesda, MD, 4Indiana University, Indianapolis, IN, 5 Diablo Clinical Research, Inc., Walnut Creek, CA, 6Amgen Inc., Thousand Oaks, CA, 7Colorado Center for Bone Research, Lakewood, CO 1108. Transitioning to Denosumab Leads to Further Increases in BMD throughout the Skeleton in Postmenopausal Women Who Received 5 or More Years of Continuous Alendronate Therapy. Michael A. Bolognese1, Henry G. Bone2, David L. Kendler3, Maria Luisa Brandi4, Anthony Hodsman5, Philippe Orcel6, Hoi-Shen Radcliffe7, Andreas Grauer8 and Cesar Libanati8, 1Bethesda Health Research Center, Bethesda, MD, 2 Michigan Bone and Mineral Clinic, Detroit, MI, 3University of British Columbia, Vancouver, BC, 4University of Florence, Florence, Italy, 5University of Western Ontario St. Joseph’s Health Center, London, ON, 6Lariboisière University Hospital, Paris, France, 7Amgen Inc., Cambridge, United Kingdom, 8 Amgen Inc., Thousand Oaks, CA 1109. Current Vs. Past Exposure to Corticosteroids: Which Is Most Associated with Osteoporotic Fractures in SLE Patients? Laurence S. Magder1 and Michelle Petri2, 1 University of Maryland, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD 1110. Severe Vitamin-D Deficiency in HIV-Infected Patients: Relationships with Inflammation, Bone Metabolism and Functional Status. Thiphaine Ansemant1, Paul Ornetti1, Christine Piroth1, Sophie Mahy2, Jean C. Guilland3, Laurence Duvillard3, Delphine Croisier2, Stephanie Ewing3, Christian Tavernier1, Pascal Chavanet2, Jean Francis Maillefert1 and Lionel Piroth2, 1Rheumatology, Dijon, France, 2Infectious diseases department, Dijon, France, 3INSERM U866 and laboratory of biochemistry, Dijon, France 1111. Inhibitory EFFECTS of 1’,2’-Dihydrorotenone On Osteoclast Differentiation and BONE Resorption. Chang-Hoon Lee1, Myung-Soon Sung2, Eun-Gyeong Lee2, Myong Joo Hong2 and Wan-Hee Yoo2, 1Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, 2Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea

212

2011 Program Book

1112. Interesting Roles of IL-1 in Osteoclast Differentiation. Chang-Hoon Lee1, Myung-Soon Sung2, Eun-Gyeong Lee2, Myong Joo Hong2 and Wan-Hee Yoo2, 1Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, 2Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea 1113. Application of Combined Algorithms with Peripheral Bone Mineral Density (BMD) and Risk Indeces to Reduce the Requirement for Central Dual X-Ray Absorptometry (DXA). María América López-Lasanta1, Francisco G. Jiménez-Núñez1, Carmen M. Romero-Barco1, Sara Manrique-Arija1, Verónica Rodriguez-García1, Miguel A. Descalzo2, Blanca Panero1, Jose Mancera Romero3, Silvia Mesa González3, Maria Carmen Ordóñez1, Inmaculada Ureña1, Manuel RodríguezPérez1 and Antonio Fernandez-Nebro4, 1Hospital Regional Universitario Carlos Haya., Málaga, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3Health Center “Ciudad Jardín”, Malaga, Spain, 4Hospital Regional Universitario Carlos Haya, Málaga, Spain 1114. Fractures and Mortality in Relation to Different Osteoporosis Treatments. Huifeng Yun1, Elizabeth S. Delzell1, Robert Matthews1, Meredith Kilgore1, Kenneth G. Saag1, Cathleen Colon-Emeric2, Christopher M. O’Connor3, Kenneth W. Lyles3, Michael Morrisey and Jeffrey R. Curtis1, 1 University of Alabama at Birmingham, Birmingham, AL, 2 Duke University Medical Center and the Durham VA GRECC, Durham, NC, 3Duke University School of Medicine, Durham, NC 1115. Bach1 Regulates Osteoclastogenesis Via Heme Oxgenase-1 Dependent and Independent Pathways. Maasa Hama1, Yohei Kirino1, Mitsuhiro Takeno1, Kaoru Takase1, Ryusuke Yoshimi1, Atsuhisa Ueda1, Akihiko Muto2, Kazuhiko Igarashi2 and Yoshiaki Ishigatsubo1, 1Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Tohoku University Graduate School of Medicine, Sendai, Japan 1116. Maintenance of Antifracture Efficacy Over 10 Years with Strontium Ranelate in Postmenopausal Osteoporosis. J.-Y. Reginster1, Jean-Marc Kaufman2, Jean-Pierre Devogelaer3, Claude-Laurent Benhamou4 and Christian Roux5, 1University of Liège, Liège, Belgium, 2Ghent University Hospital, Ghent, Belgium, 3St-Luc University Hospital, Brussels, Belgium, 4 Hopital de la Source, Orleans, 5Paris Descartes University, Paris, France 1117. Analysis of Prevalence of Low Bone Mineral Density and Secondary Causes In Patients Undergoing Bone Density Measurement. Andrew Wilson, Anuj Patel, Toni Peters and Vikas Majithia, University of Mississippi Medical Center, Jackson, MS 1118. Long-Term Warfarin Use Is Not Associated with Fracture Risk. Devyani Misra1, Yuqing Zhang2, Christine Peloquin2, Hyon K. Choi2 and Tuhina Neogi2, 1Boston University Medical Centre, Boston, MA, 2Boston University School of Medicine, Boston, MA

ACR/ARHP Poster Session B 1119. Possible Hypophosphatasia in Personalized Medicine Research Project. Less K. Shrestha, Fergus E. McKiernan, Richard L. Berg and Jay T. Fuehrer, Marshfield Clinic, Marshfield, WI 1120. Acute-Phase Response After Zoledronic Acid: Role of Vitamin D and of Previous Treatment with Oral AminoBisphosphonates. Marco Massarotti, Chiara Crotti, Nicola Ughi, Gianluigi Fabbriciani, Laura Belloli and Bianca Marasini, IRCCS Humanitas Clinical Institute, Rozzano (Milan), Italy 1121. Use of Pharmacologic Agents for the Prevention of Osteoporosis Among Older Women with Low Bone Mass Is Discordant with National Osteoporosis Foundation Guidance. Jie Zhang, Jeffery R. Curtis, Elizabeth S. Delzell and Kenneth G. Saag, University of Alabama at Birmingham, Birmingham, AL 1122. The Relationship Between the Level of Serum Lipids and Bone Metabolism Among Pre and Postmenopausal Women. Yun Sung Kim1, Hae-Rim Kim2, Sang-Hyon Kim3 and Hyun-Sook Kim1, 1Internal Medicine, Chosun University Hospital, Gwangju, South Korea, 2Konkuk University Medical Center, Seoul, South Korea, 3Dongsan Medical Center, Keimyung University, Daegu, South Korea

1128. Effects of Technetium-99 Conjugated with Methylene Diphosphonate on Rats with Glucocorticoid Induced Osteoporosis. Ying Ning, Xuewu Zhang, Jiaxin Zhu, Min Feng and Zhanguo Li, Peking University People’s Hospital, Beijing, China 1129. Prevention of Glucocorticoid-Induced Osteoporosis - We Are Not Doing Enough; What Else to Consider. Lucy E. Durham1, Sima Patel1, Leena Yalakki Jagadeesh1 and Taher Mahmud2, 1Kent and Sussex Hospital, Tunbridge Wells, United Kingdom, 2Pembury Hospital, Tunbridge Wells, United Kingdom

Rheumatoid Arthritis - Animal Models 1130. Modeling Human Rheumatoid Arthritis In Non-Human Primate: Type II Collagen Induced Arthritis In Cynomolgus Macaques. Hong Zhang1, June Liu1, Jilin Deng1, Liangtang Chang1, Hellen Zheng1, Cheng Yu1, Jun Lu1, Alison Bendele2, Yunfeng Fu1 and Jeff Duan1, 1PharmaLegacy Laboratories, Shanghai, China, 2Bolder BioPATH. Inc., Boulder, CO 1131. Interferon Regulatory Factor 7 Deficiency Inhibits CollagenInduced Arthritis: Regulation of Interleukin-6 and Matrix Metalloproteinase 3 Production. Susan E. Sweeney, UCSD School of Medicine, La Jolla, CA

1123. Vitamin D in Obesity (VIDeO): Assessing Vitamin D Deficiency in the Bariatric Population. Arthur N. Lau1, Maria Tiboni1, Zara Khalid1, Roman Jaeschke1, Mehran Anvari1 and Jonathan D. Adachi2, 1McMaster University, Hamilton, ON, 2 Hamilton, ON

1132. Improving Therapy Effect on Arthritic Rats by CoExpression of CD40LIg and IκBα. Ping Fan, Lan He, Dan Pu, Wenxu Zhou, Xiaohong Lv, Yining Sun and Nan Hu, The First Affiliated Hospital Xi’an Jiaotong University School of Medicine, Xi’an, China

1124. Osteogenesis and Osteoclast Inhibition Effects of Bisphosphonates Administered for Over 4 Years Alone or in Combination with Statin in Rheumatoid Arthritis Patients During a 12 Month Follow-up. Masakazu Nagashima, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan

1133. Mimicking Disruption of the Brain – Immune System – Joint Communication Results in Expression of Collagen Type II-Induced Arthritis in Non-Susceptible PVG Rats. Christine Wolff1, Johannes Wildmann2, Anke Randolf2, Hugo O. Besedovsky2, Adriana del Rey2 and Rainer H. Straub1, 1 Laboratory of Exp. Rheumatology and NeuroendocrinoImmunology, Department of Internal Medicine I, University Hospital, Regensburg, Germany, 2Department of Immunophysiology, Institute of Physiology, Philipps University, Marburg, Germany

1125. The Epidemiology of Low and High Energy Distal Radius Fracture in Middle-Aged and Elderly Men and Women in Southern Norway. Andreas P. Diamantopoulos1, Gudrun Rohde1, Inger M. Skoie1, Irene Johnsrud1, Marc Hochberg2 and Glenn Haugeberg1, 1Hospital of Southern Norway, Kristiansand, Norway, 2University of Maryland School of Medicine, Baltimore, MD 1126. The Efficacy and Mechanism of Bisphosphonate on Glucocorticosteroid-Induced Osteoporosis in SLE Patients. Xiao Zhang and Yu-xing Qin, Guang Dong General Hospital, Guang Dong Academy of Medical Sciences, Guangzhou, China 1127. Changes in Serum Receptor Activator for Nuclear Factor κB Ligand and Osteoprotegerin After Glucocorticoid Therapy Reflect Regulation of Their Expression by Glucocorticoid in Osteoblasts in Vitro. Kaichi Kaneko, Natsuko Kusunoki, Nahoko Tanaka, Tatsuhiro Yamamoto, Yoshie Kusunoki, Kenji Takagi, Hirahito Endo and Shinichi Kawai, Toho University School of Medicine, Tokyo, Japan

1134. Regulation of Inflammatory Arthritis by the Upstream Kinase MKK7 in the c-Jun N-Terminal Kinase (JNK) Pathway. Sang-il Lee, David L. Boyle and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA 1135. Gingiva-Derived Mesenchymal Stem Cells-Mediated Therapeutic Intervention for Experimental Arthritis. Maogeng Chen1, Xiao-Shun He2 and Song G. Zheng3, 1 University of Southern California, Los Angeles, CA, 21st Affiliated Hospital of Sun Yat-sen University, 3USC Keck School of Medicine, Los Angeles, CA 1136. VX-509, An Orally Available Janus Kinase 3 (JAK3) Specific Inhibitor, Showed Robust Activity in Pre-Clinical Models of Aberrant Immune/Inflammatory Function. Thomas Hoock1, James Hogan1, Sudipta Mahajan1, Dina Shlyakhter1, Luke Oh2, Larry Park2, George Ku2, Ian Catlett1, Meryll 2011 Program Book

213

ACR/ARHP Poster Session B Corbin1, Francesco Salituro2 and Mark Namchuk1, 1Vertex Pharmaceuticals Incorporated, Cambridge, MA, 2Formerly of Vertex Pharmaceuticals Incorporated, Cambridge, MA 1137. A New Derivative of Roxithromycin Modulates Immunological Responses and Ameliorates CollagenInduced Arthritis. Noriko Otsuki1, Satoshi Iwata1, Emi Kumagai1, Taketo Yamada2, Tomoki Katayose1, Yoshiko Kichikawa1, Osamu Hosono1, Hiroshi Kawasaki1, Hirotoshi Tanaka1, Nam H. Dang3 and Chikao Morimoto1, 1The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 2School of Medicine, Keio University, Tokyo, Japan, 3 University of Florida Shands Cancer Center, Gainesville, FL 1138. IL-6 Overproduction Is Predominantly Related to Arthritis in TNFα-Induced Adipose-Related Protein (TIARP) Deficient Mice. Asuka Inoue1, Isao Matsumoto1, Naoto Umeda1, Yuki Tanaka1, Satomi Tamaki1, Masahiko Mihara2, Satoru Takahashi3 and Takayuki Sumida1, 1University of Tsukuba, Tsukuba city, Ibaraki, Japan, 2Chugai Pharmaceutical, Gotemba, Japan, 3Department of Anatomy and Embryology, Doctoral Program in Biomedical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba city, Ibaraki, Japan 1139. Inhibitory Effect of c-Fos/AP-1 Inhibitor T-5224 on the Levels of Cytokines and Chemokines in the Arthritic Lesion of Mice with Collagen-Induced Arthritis. Tomomi Date1, Yukihiko Aikawa1, Akira Hashiramoto2, Tetsuya Yamamoto1, Masaaki Mikami1, Hirokazu Narita1, Shuichi Hirono3 and Shunichi Shiozawa2, 1Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan, 2Department of Biophysics, Kobe University Graduate School of Health Sciences/Department of Medicine, Kobe University Graduate School of Medicine/The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, 3 Department of Pharmaceutical Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan 1140. Colony Stimulating Factor 1 Receptor Inhibition Has AntiInflammatory and Potent Early Onset Bone and Cartilage Protective Effects. Myew-Ling Toh1, Jean-Yves Bonnefoy1, Nathalie Accart1, Sandrine Cochin1, Christophe Zemmour1, Helene Haegel1, Philippe Ancian1, Bettina Sehnert2, Sandy Pohle2, Falk Nimmerjahn3, Reinhard Voll4 and Georg Schett2, 1 Transgene SA, Illkirch, France, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Erlangen, Germany, 4Freiburg, Germany 1141. Overexpression of T-Bet Gene Regulates Collagen Induced Arthritis Via IFNγ Independent Suppression of IL-6 Signal Transduction. Yuya Kondo, Masahiro Tahara, Mana Iizuka, Hiroto Tsuboi, Satoru Takahashi, Isao Matsumoto and Takayuki Sumida, University of Tsukuba, Tsukuba city, Ibaraki, Japan 1142. Lapatinib Ameliorates Experimental Arthritis in Rats. Metin Ozgen1, Suleyman Serdar Koca1, Ahmet Karatas1, Adile Ferda Dagli2, Fazilet Erman3, Baris Gundogdu1, Kazim Sahin4 and Ahmet Isik1, 1Department of Rheumatology, Faculty

214

2011 Program Book

of Medicine, Firat University, Elazig, Turkey, 2Department of Pathology, Faculty of Medicine, Firat University, Elazig, Turkey, 3School of Health Sciences, Firat University, Elazig, Turkey, 4Department of Animal Nutrition, Faculty of Veterinary Science, Elazig, Turkey 1143. IL-33 Mediates a Mast Cell-Fibroblast Amplification Loop That Primes Mast Cells for Activation Via Immune Complexes. Shinjiro Kaieda1, Jun-Xia Wang1, Ruslan Shnayder1, Richard Lee1, Richard Stevens1 and Peter A. Nigrovic2, 1Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 2Children’s Hospital Boston and Harvard Medical Scool, Boston, MA 1144. A High Fat Diet Causes Fat Uptake by Synovial Lining Macrophages and Enhances Joint Inflammation and Cartilage Destruction During Experimental Arthritis. Peter van Lent, Wouter de Munter, Arjen Blom, Annet Sloetjes and Wim van den Berg, Rheumatology, Nijmegen, Netherlands 1145. Inhibition of Murine Collagen-Induced Arthritis by Overexpression of Glucocorticoid-Induced Leucine Zipper Locally in the Joints Using a Gene Therapy Approach. Devi Ngo1, Elaine Beaulieu1, Scott Loiler2, Margriet Vervoordeldonk3 and Eric Morand1, 1Monash University, Melbourne, Australia, 2Arthrogen B.V, Amsterdan, Netherlands, 3Arthrogen B.V, AMC/University of Amsterdam, Amsterdan, Netherlands 1146. Inhibiting IL-6 Trans-Signalling with Soluble gp130Fc Potently Reduces the Incidence and Severity of CollagenInduced Experimental Arthritis. Shaun Smale1, Sara Carty1, Rhian Goodfellow1, Ernest Choy1, Stefan Rose-John2, Simon Jones3 and Anwen S. Williams4, 1Cardiff University, Cardiff, ENGLAND, United Kingdom, 2Christian Albrechts University, Kiel, Germany, 3Cardiff University, Cardiff, Wales, 4Cardiff University, Cardiff, United Kingdom 1147. Safety and Biodistribution of An Adeno-Associated Virus Vector, AAV5 hIFN beta (ART-I02), Delivered Via IntraArticular Injection to Rhesus Monkeys with CollagenInduced Arthritis. Caroline J. Aalbers1, L. Bevaart1, K. de Cortie1, M.P.M. Vierboom2, J.F. Wright3, Paul P. Tak4 and Margriet Vervoordeldonk5, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2 Biomedical Primate Research Centre, Rijswijk, Netherlands, 3 Children’s Hospital of Philadelphia, Philadelphia, PA, 4 Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands, 5 Arthrogen B.V, Amsterdan, Netherlands 1148. Anti-IL17 and Etanercept Display An Overlapping Gene Profile for Inflammation and Osteoclastogenesis in Mice with Collagen-Induced Arthritis. Daigen Xu1, Yong Kim1, Kai-Yeung Lau2, Mario Giron2, Palanikumar Ravindran2, Holly Hilton2, Hans Bitter2, Catherine Tribouley2, Deborah Cockayne1 and Jay S. Fine1, 1Inflammation Discovery, Hoffmann-La Roche, Nutley, NJ, 2Translational Research Sciences, Hoffman-La Roche, Nutley, NJ

ACR/ARHP Poster Session B 1149. Importance of the Chymase-Family Member Mouse Mast Cell Protease-5 in Inflammatory Arthritis. Richard Stevens1, H. Patrick McNeil2, Kichul Shin3 and David M. Lee4, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2University of New South Wales, Sydney, Australia, 3 Seoul National University Hospital, Seoul, South Korea, 4 Brigham and Womens Hospital, Boston, MA 1150. Deficiency of the Wnt-Inhibitor Sclerostin Promotes Inflammatory Joint Destruction in the Human Tumor Necrosis Factor Alpha Transgenic Mouse Model of Rheumatoid Arthritis. Corinna Wehmeyer1, Christina Wunrau1, Athanasios Stratis1, Ina Kramer2, Michaela Kneissel2, George Kollias3, Thomas Pap1 and Berno Dankbar1, 1 University Hospital Muenster, Muenster, Germany, 2 Basel, Switzerland, 3Biomedical Sciences Research Center ‘Alexander Fleming’, Vari, Greece 1151. Deficiency of TACE in Myeloid Cells Prevents Arthritis in Mice. Priya Issuree1, Thorsten Maretzky2, Kei Horiuchi3, Jane E. Salmon4 and Carl Blobel5, 1Weill Cornell Graduate School of Medical Sciences, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 4Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 5Weill Cornell Medical College, Hospital for Special Surgery, New York, NY 1152. Cell Penetrating Recombinant Foxp3 Protein Enhances Treg Function, Suppresses Th17 Cells and Ameliorate Arthritis. Kentaro Yomogida1, Yong Zhu2, Shili Wu2 and Cong-Qiu Chu3, 1Oregon Health & Science University, Portland, OR, 2 VivoScript, Inc, Costa Mesa, CA, 3Oregon Health & Science Univ, Portland, OR 1153. Macrophage-Specific SHIP-1 Depletion Leads to Greatly Enhanced Arthritis. Shawn M. Rose and Harris R. Perlman, Northwestern University, Chicago, IL

Rheumatoid Arthritis Clinical Aspects: Cardiovascular Disease in Rheumatoid Arthritis; Infection and Rheumatoid Arthritis; Drug Studies and Safety; Risk Factors for Rheumatoid Arthritis 1154. Treatment and Mortality After Myocardial Infarction in Rheumatoid Arthritis- a Cohort Study of Incident Rhematoid Arthritis in Sweden. Marie Holmqvist1, Ängla Mantel1, Tomas Jernberg2, Lennart TH Jacobsson3, Lars Alfredsson4, Stefan James5 and Johan Askling1, 1Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, 2Department of medicine, Section of Cardiology, Karolinska University Hospital, Huddinge, Sweden, 3Section of Rheumatology, Malmo, Sweden, 4 Institute of Environmental Medicine, Karolinska Institutet, Solna, Sweden, 5Department of Cardiology, Uppsala University Hospital 1155. Diastolic Heart Failure in Rheumatoid Arthritis Correlates with Reduction in Global Longitudinal Strain and Occurs Independent From Therapy with Tumor Necrosis Factor Inhibitors. A Study with Tissue Doppler, Strain Imaging, and NTproBNP Measurement. Demian A. Ridjab1, Michael

Gottwald2, Andreas Krause3, Thomas Schau1, Christian Butter1 and Michael Zaenker2, 1Cardiology Dept., Immanuel Klinikum Bernau Heart Center Brandenburg, Bernau, Germany, 2Immanuel Klinikum Bernau, Rheumatology Center North Brandenburg, Bernau, Germany, 3Immanuel Krankenhaus Berlin-Buch, Berlin, Germany 1156. Progression of Subclinical Atherosclerosis Over Five Years in Patients with Early Rheumatoid Arthritis. Anna Södergren1, Kjell Karp2, Kurt Boman3, Catharina Eriksson4, Elisabeth Lundström2, Torgny Smedby5, Bozen Möller6, Solbritt Rantapää Dahlqvist1 and Solveig Wållberg Jonsson1, 1 Dept of Rheumatology, Umeå, Sweden, 2Department of Surgical and Perioperative Sciences, Umeå, Sweden, 3 Department of Medicine, Skellefteå, Sweden, 4Department of Clinical Immunology, Umeå, Sweden, 5Östersunds Rehab Centrum, Östersund, Sweden, 6Department of Rheumatology, Luleå, Sweden 1157. Treat to Target: Normal Cholesterol Values in Low Disease Activity Established RA. Inger L. Meek1, H.S.J. Picavet2, Harald E. Vonkeman1 and Mart AF van de Laar3, 1 Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, 2National Institute for Public Health and the Environment, Bilthoven, Netherlands, 3Medisch Spectrum Twente & Twente University, Enschede, Netherlands 1158. Vitamin D Levels Are Independently Associated with the Metabolic Syndrome and Metabolic Dyslipidemia In Rheumatoid Arthritis. Joshua Baker1, Nehal Mehta2, Gary Toedter3, Daniel G. Baker4, Joan Marie Von Feldt5 and Mary Beth Leonard6, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, PA, 3Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Malvern, PA, 4Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research and Development, LLC, Malvern, PA, 5Univ of Pennsylvania/ Philadelphia VAMC, Philadelphia, PA, 6The Children’s Hospital of Philadelphia, Philadelphia, PA 1159. Endothelial Dysfunction Improves in Patients with Rheumatoid Arthritis by Reducing Disease Activity. Lodewijk de Groot1, Johanna Westra2, Nynke Jager1, Marcel D. Posthumus2 and Marc Bijl2, 1University Medical Centre Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands 1160. Statin Use Is Associated with Decreased Incident Coronary Artery Events in Rheumatoid Arthritis Patients. Chad P. Walker1, Xiaoqin Tang2, H. Lester Kirchner2, Steven Steinhubl3, Stephanie J. Morris4, Jana L. Antohe3 and Androniki Bili5, 1Geisinger, Bloomsburg, PA, 2Geisinger Center for Health Research, Danville, PA, 3Geisinger Health System, Danville, PA, 4Rose Tree Medical Associates---Riddle Memorial Hos, Danville, PA, 5Geisinger Medical Center, Danville, PA

2011 Program Book

215

ACR/ARHP Poster Session B 1161. Endothelial Progenitor Cells and Cardiovascular Risk in Patients with Rheumatoid Arthritis. Nynke Jager, Steven Wenker, Lodewijk de Groot, Marcel D. Posthumus, Marc Bijl and Johanna Westra, University Medical Center Groningen, Groningen, Netherlands 1162. Ischemic Stroke in RA- a Cohort Study of Risks, Relative Risks and Predictors. Marie Holmqvist1, Emma Gränsmark2, Solveig Wållberg Jonsson3, Lennart TH Jacobsson4, Lars Alfredsson1 and Johan Askling5, 1Karolinska Institutet, Stockholm, Sweden, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3 Dept of Rheumatology, Umeå, Sweden, 4Section of Rheumatology, Malmo, Sweden, 5Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden 1163. Myocardial Ischemia in Asymptomatic Patients with Rheumatoid Arthritis: A Comparative Study with Diabetes Mellitus. A. Karanasos1, I. Felekos1, C. Aggeli1, E. Zampeli1, A. Protogerou1, C. Stefanadis1, G. Kitas2, K. Toutouzas1 and PP Sfikakis1, 1Athens University, Medical School, Athens, Greece, 2The Dudley Group of Hospitals NHS Foundation Trust, Dudley, and Arthritis Research Campaign Epidemiology Unit, University of Manchester, UK, Manchester, United Kingdom 1164. Radiographic Joint Damage in Rheumatoid Arthritis Is More Strongly Associated with Peripheral Arterial Stiffness Than with Peripheral or Carotid Artery Obstruction. Jose Felix Restrepo1, Agustin Escalante1, Daniel F. Battafarano2, Daniel H. O’Leary3 and Inmaculada Del Rincon1, 1University of Texas Health Science Center, San Antonio, TX, 2Brooke Army Medical Ctr, San Antonio, TX, 3Tufts University-Boston Campus, Boston, MA 1165. Determinants of Insulin Resistance in Patients with Rheumatoid Arthritis. Seong Hu Park1, SungIl Kim1, Young Eun Park1, Seung Geun Lee1, SeungHoon Baek1, Geun Tae Kim2 and JoungWook Lee3, 1Pusan Nationl University Hospital, Busan, South Korea, 2Kosin University Gopsel Hospital, Pusan, South Korea, 3Busan st. Mary’s Medical Center, South Korea 1166. Inflammation-Dependent Insulin Resistance Is Present in Rheumatoid Arthritis but it Is Not Associated with Retinol Binding Protein 4. Vanesa Hernandez-Hernandez1, Esmeralda Delgado-Frías1, Ivan Ferraz-Amaro1, Jose A. Garcia-Dopico2, Lilian Medina2, Antonieta Gonzalez-Diaz3, Maria A. Gomez- Rodriguez-Bethencourt3, Jose Ramon Muñiz4, Ana I. Rodriguez-Vargas1, M. Angeles Gantes-Mora1, M.Teresa Arce-Franco1, M. Jesus Dominguez-Luis5 and Federico Diaz-Gonzalez1, 1Rheumatology Service, La Laguna, Spain, 2Laboratorio Central, La Laguna, Spain, 3Medicina Nuclear, Spain, 4Resonancia Magnetica IMETISA, 5Hospital Universitario de Canarias, La Laguna, Spain 1167. Low Serum Levels of Soluble Receptor for Advanced Glycation End Products Are Associated with Increased Augmentation Index in Patients with Early Rheumatoid Arthritis. Lai Shan Tam1, Qing Shang1, Edmund K. Li1, Ka Lai

216

2011 Program Book

Lee2, Ying Ying Leung3, King Yee Ying4, Cheuk-wan Yim5, Emily Kun6, Alexander M. Leung7, Martin Li1, Tena K. Li1, Tracy Y. Zhu1, Ricky K. Chui1, Lorraine Tseung1, Shui Lian Yu1, Woon Pang Kuan8 and Cheuk-Man Yu1, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, 3North District Hospital, Hong Kong, Hong Kong, 4Princess Margaret Hospital, Hong Kong, Hong Kong, 5United Christian Hospital, Hong Kong, Hong Kong, 6Tai Po Hospital, Hong Kong, Hong Kong, 7Queen Elizabeth Hospital, Hong Kong, Hong Kong, 8 Hospital Selayang, Kuala Lumpur, Malaysia 1168. Prolonged Hydroxychloroquine Use Is Associated with Decreased Incidence of Cardiovascular Disease in Rheumatoid Arthritis Patients. Androniki Bili1, Xiaoqin Tang2, H. Lester Kirchner2, Jana L. Antohe1, Stephanie J. Morris3 and Mary Chester Wasko4, 1Geisinger Medical Center, Danville, PA, 2Geisinger Center for Health Research, Danville, PA, 3Rose Tree Medical Associates---Riddle Memorial Hos, Danville, PA, 4West Penn Allegheny Health System, Pittsburgh, PA 1169. Vitamin D Deficiency, Interleukin 17, and Vascular Function in Rheumatoid Arthritis. Prabha Ranganathan1, Shokoufeh Khalatbari2, Srilakshmi Yalavarthi3, Wendy Marder4, Robert Brook2 and Mariana J. Kaplan5, 1Washington University School of Medicine, St. Louis, MO, 2University of Michigan at Ann Arbor, MI, 3University of Michgan at Ann Arbor, MI, 4University of Michigan, Ann Arbor, MI, 5University of Michigan Rheumatology, Ann Arbor, MI 1170. Asymptomatic Carotid Plaques in Rheumatoid Arthritis Results in Inadequate Treatment to Lipid Targets in Cardiovascular Prevention. Anne Grete Semb1, Inge Olsen C2, Sella Provan1, Terje R. Pedersen3, Einar Stranden4, Désirée van der Heijde5, Jonny Hisdal4 and Tore K. Kvien1, 1 Diakonhjemmet Hospital, Oslo, Norway, 2Smerud Medical Research, Oslo, Norway, 3Oslo University Hospital-Ullevaal, Oslo, Norway, 4Uslo University Hospital-Aker, Oslo, Norway, 5 Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands 1171. Cardiac Involvement in Patients with secondary Amyloidosis Due to Rheumatoid Arthritis. Daisuke Kobayashi1, Yoko Wada1, Shuichi Murakami1, Takeshi Kuroda2, Masaaki Nakano3 and Ichiei Narita1, 1Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Niigata University, Niigata, Japan, 3Niigata University School of Medicine, Niigata, Japan 1172. Detection of Left Ventricular Regional Dysfunction by Using Cardiac Magnetic Resonance Imaging in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic DMARDs and Biologics Groups. Hitomi Kobayashi1, Isamu Yokoe1, Hiroshi Sato1 and Yasuyuki Kobayashi2, 1Itabashi Chuo Medical Center, Tokyo, Japan, 2St Marianna Univ Sch of Med, Kawasaki, Japan

ACR/ARHP Poster Session B 1173. Effect of Disease Activity on Lipoproteins Levels in Patients with Early Arthritis. Silvia Pérez-Esteban, Ana M. Ortiz, Ana M. Fernández-Ortiz, Santos Castañeda and Isidoro GonzálezAlvaro, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain 1174. Vascular Calcification On Hand and Wrist Radiographs Are Associated with Comorbidity and Overall Mortality In Rheumatoid Arthritis. Zachary Pruhs1, Kaleb D. Michaud2, Alan R. Erickson3, Harlan Sayles4, Gail S. Kerr5, Angelo L. Gaffo6, Liron Caplan7, Grant W. Cannon8, Deana M. Lazaro9, Andreas M. Reimold10, Dannette S. Johnson11, Bogdan Cherascu12, Pascale Schwab13, Nasim A. Khan14 and Ted R. Mikuls15, 1University of Nebraska Medical Center, Omaha, NE, 2Univ of Nebraska Med Ctr & National Data Bank for Rheumatic Diseases, Omaha, NE, 3UNMC Physicians Brentwood, LaVista, NE, 4University of Nebraska Medical School, Omaha, NE, 5Washington DC VA and Georgetown University, Washington, DC, 6Birmingham VA Medical Ctr, Birmingham, AL, 7Denver VA and University of Colorado, Aurora, CO, 8Salt Lake City VA and University of Utah, Salt Lake City, UT, 9Brooklyn VA, Brooklyn, NY, 10Dallas VA and University of Texas Southwestern, Dallas, TX, 11University of Mississippi Med Center, Jackson, MS, 12Iowa City VA and University of Iowa, Iowa City, IA, 13Portland VA and Oregon Health & Science University, Portland, OR, 14University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, 15Omaha VA and University of Nebraska, Omaha, NE 1175. Cardiovascular Risk Models and Carotid Intima-Media Thickness Predict Cardiovascular Disease Events in Rheumatoid Arthritis. Inge A.M. van den Oever1, Alper M. van Sijl1, Hennie G. Raterman2, Maarten Boers3, Mike J.L. Peters2, Yvo M. Smulders2, Alexandre E. Voskuyl3 and Michael T. Nurmohamed4, 1Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2VU University medical center, Amsterdam, Netherlands, 3VU University Medical Center, Amsterdam, Netherlands, 4Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands 1176. Insulin Resistance, a Non-Traditional Cardiovascular Risk Factor Influenced Both by Disease Activity and Adiposity in Rheumatoid Arthritis. Ronan H. Mullan1, Susan Vankerkamp1, Owen Sullivan1, Oliver M. FitzGerald2, Ursula Fearon3 and Douglas J. Veale3, 1St Vincent’s University Hospital, Dublin, Ireland, 2St. Vincent’s University Hospital, Dublin, Ireland, 3Translation Rheumatology Research Group, Dublin, Ireland 1177. Prevalence and Correlates of Metabolic Syndrome in Patients with Rheumatoid Arthritis. Maria Haye Salinas1, Ana M. Bertoli2, Francisco Caeiro3, Luis Lema4, Veronica Bellomio5, Santiago Aguero6, Federico Ceccato7, Carla Saucedo8, Javier Rosa8, R. Quintana9, Marcela Schmid10, Walter Spindler11, Natalia Tamborenea12, Sergio Paira7, Bernardo Pons Estel13, Alberto J. Spindler14, Enrique R. Soriano8, Alejandro J. Alvarellos15 and Veronica Saurit16,

1 Hospital Privado, Córdoba, Argentina, 2Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, 3 Hospital Privado de Cordoba, Cordoba, Argentina, 4 Instituto Modelo de Cardiologia, Cordoba, Argentina, 5 Consultorio, Tucuman, Argentina, 6Centro de Rehabilitación II, Catamarca, Argentina, 7Hospital Jose Maria Cullen, Santa Fe, Argentina, 8Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Hospital Provincial, Rosario, Argentina, 10Hospital Cullen, Santa Fe, Argentina, 11Centro Medico Privado, Tucuman, Argentina, 12Consultorio, Buenos Aires, Argentina, 13 Sanatorio Parque, Rosario, Argentina, 14Universidad Nacional Tucumán, Yerba Buena Tucuman, Argentina, 15 Hospital Privado, Cordoba, Argentina, 16Hospital Privado Córdoba, Córdoba, Argentina

1178. Rate of Progression of Subclinical Atherosclerosis in Femoral Versus Carotid Arteries in Patients with Rheumatoid Arthritis Over 3 Years. E. Zampeli1, A. Protogerou1, K. Stamatelopoulos2, K. Fragiadaki1, C. Katsiari1, K. Kyrkou2, C. Papamichael2, M. Mavrikakis2, G. D Kitas3 and P. P Sfikakis1, 1First Department of Propaedeutic and Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 2Vascular Laboratory, Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School, Athens, Greece, 3The Dudley Group of Hospitals NHS Foundation Trust, Dudley, and Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom 1179. Rheumatoid Arthritis Patients Are Not At Increased Risk for 30-Day Cardiovascular Events or Infections Following Total Joint Arthoplasty. Kaleb Michaud1, Edward Fehringer2, Kevin Garvin2, James R. O’Dell3 and Ted R. Mikuls3, 1National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Omaha VA and University of Nebraska Medical Center, Omaha, NE 1180. High-Density Lipoprotein Subfractions HDL2 and HDL3 Are Reduced in Female Patients with Rheumatoid Arthritis and Do Not Appear to Be Affected by Disease Activity. Elke.E.A. Arts, Jaap Fransen, Heidi Lemmers, Leo A.B. Joosten, Piet L.C.M. Van Riel and Calin Popa, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 1181. Association of Medicaons and Rheumatoid Arthritis Susceptibility Polymorphism with Lipid Profiles in Patients with Rheumatoid Arthritis. Lisa A. Davis1, Lauren M. Pointer2, Roger K. Wolff3, Andreas M. Reimold4, Gail S. Kerr5, Ted R. Mikuls6, Grant W. Cannon7 and Liron Caplan8, 1 Univ of Colorado School of Med, Aurora, CO, 2Denver Veterans Affairs Medical Center, Denver, CO, 3University of Utah, Salt Lake City, UT, 4Dallas VA and University of Texas Southwestern, Dallas, TX, 5Washington DC VA and Georgetown University, Washington, DC, 6Omaha VA and University of Nebraska, Omaha, NE, 7Salt Lake City VA and University of Utah, Salt Lake City, UT, 8Denver VA and University of Colorado, Aurora, CO 2011 Program Book

217

ACR/ARHP Poster Session B 1182. Urine Albumin Excretion Is Associated Differently with Cardiometabolic Risk Factors and Subclinical Atherosclerosis in Rheumatoid Arthritis (RA) Compared with Controls. Amanda Sammut1, Joan M. Bathon1, Roger Blumenthal2, Moyses Szklo3, Steven Shea1, Joseph Polak4, Russell Tracy5 and Jon T. Giles1, 1Columbia University Medical Center, New York, NY, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 4Tufts University School of Medicine, Boston, MA, 5University of Vermont, Colchester, VT 1183. Atrial Fibrillation Is Not More Common in Patients with Rheumatoid Arthritis. A. Kirstin Bacani, Sherine E. Gabriel, Cynthia S. Crowson and Eric L. Matteson, Mayo Clinic, Rochester, MN 1184. Hypothyroidism In Rheumatoid Arthritis and the Development of Cardiovascular Disease. Sara McCoy1, Cynthia S. Crowson2, Sherine E. Gabriel2 and Eric L. Matteson2, 1Mayo Clinic College of Medicine, Rochester, MN, 2Mayo Clinic, Rochester, MN 1185. The Burden of Autoimmunity and Risk for Coronary Artery Disease in Rheumatoid Arthritis. Katherine P. Liao1, Fina Kurreeman1, Raul N. Guzman P.2, Jun Zhang3, Tianxi Cai3, Gang Li1, Grant Duclos1, Namrata Gupta4, Sergey Goryachev5, Vivian Gainer2, Shawn N. Murphy5, Susanne Churchill5, Isaac Kohane1, Elizabeth W. Karlson6 and Robert M. Plenge1, 1 Brigham and Women’s Hospital, Boston, MA, 2Information Systems, Boston, MA, 3Harvard School of Public Health, Boston, MA, 4The Broad Institute, Cambridge, 5Partners Healthcare Systems, Boston, MA, 6Brigham and Womens Hospital, Boston, MA 1186. Treatment to Lipid Targets in a Preventiv Cardio-Rheuma Clinic. Anne Grete Semb1, Silvia Rollefstad1, Terje R. Pedersen2, Ingar Holme2 and Tore K. Kvien1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Oslo University Hospital-Ullevaal, Oslo, Norway 1187. Incidence and Time Trends of Herpes Zoster in Rheumatoid Arthritis: A Population Based Cohort Study. Bharath Manu Akkara Veetil, Eric L. Matteson, Sherine E. Gabriel and Cynthia S. Crowson, Mayo Clinic, Rochester, MN 1188. Validation of An Infection Risk Score in Rheumatoid Arthritis. Cynthia S. Crowson, Deana D. Hoganson, Patrick Fitz-Gibbon and Eric L. Matteson, Mayo Clinic, Rochester, MN 1189. Risk for Herpes Zoster in Patients with Rheumatoid and Psoriatic Arthritis. Dimitrios A. Pappas1, George Reed2, Michele M. Hooper3, Ying Shan2, Bojena Bitman4, Jeffrey D. Greenberg5, Deborah Wenkert3, Jie Zhang6, Joel M. Kremer7 and Jeffrey R. Curtis6, 1Columbia University, College of Physicians & Surge, New York, NY, 2UMass Medical School, Worcester, MA, 3Amgen, Thousand Oaks, CA, 4Amgen Inc., Thousand Oaks, CA, 5New York University School of Medicine, New York, NY, 6University of Alabama at

218

2011 Program Book

Birmingham, Birmingham, AL, 7Albany Medical College and The Center for Rheumatology, Albany, NY 1190. Combining Tuberculin Skin Test and Interferon Gamma Release Assays for Latent Tuberculosis Infection Screening May Be Necessary for the Exclusion of Latent Tuberculosis in a High Risk Individuals with RA. Bella Mehta1, Bret Sohn2 and Petros V. Efthimiou3, 1Lincoln Medical and Mental Health Center, New York, NY, 2Lenox Hill Hospital ,NY, New York, NY, 3LM&MHC/Weill Cornell MC, New York, NY 1191. Cytomegalovirus (CMV) and Rheumatoid Arthritis (RA) – a Critical Role of CMV Specific T Cells? Kathrin Rothe1, Dagmar Quandt1, Matthias Pierer2, Anett Schulz1, Undine Meusch1, Manuela Rossol3, Roger Scholz2, Christoph G. Baerwald4 and Ulf Wagner4, 1University of Leipzig, Leipzig, Germany, 2Haertelstrasse 16-18, Leipzig, Germany, 3 Translationszentrum für Regenerative Medizin (TRM), University of Leipzig, Leipzig, Germany, 4University Hospital, Leipzig, Germany 1192. Outcome of Pulmonary NTM Disease in Patients with Underlying Rheumatic Disease: A Retrospective Observational Study. Jung Won Noh1, Jiwon Hwang1, Jaejoon Lee1, Joong Kyong Ahn2, Chan Hong Jeon3, Jinseok Kim4, Won-Jung Koh1, Eun-Mi Koh1 and Hoon-Suk Cha1, 1 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Soonchunhyang University College of Medicine, Bucheon, South Korea, 4Jeju National University Hospital, Jeju, South Korea 1193. Serodiagnosis of Mycobacterium Avium-Complex Pulmonary Disease with An Enzyme Immunoassay Kit That Detects Anti-Glycopeptidolipid Core Antigen IgA Antibodies In Patients with Rheumatoid Arthritis. Shogo Banno1, Maiko Watanabe2, Kanesige Sasaki2, Taio Naniwa2 and Yoshihito Hayami2, 1Aichi Medical University, Aichiprefecture, Japan, 2Nagoya City University, Nagoya city, Japan 1194. High Expression of Haptoglobin in the Peripheral Blood Mononuclear Cells From Methotrexate-Resistant Rheuamatoid Arthritis Patients. Wenfeng Tan, Fang Wang, Dunming Guo, Xiaoming Zhu, Yao Ke and Miaojia Zhang, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China 1195. Histological Analyses of Surgically Resected Synovial Tissues In Patients with Rheumatoid Arthritis Treated with/without Biological Agents. Yuichi Mochida1, Katsushi Ishii1, Kengo Harigane1, Naoto Mitsugi1 and Tomoyuki Saito2, 1 Yokohama City University Medical Center, Yokohama, Japan, 2 Yokohama City University School of Medicine, Yokohama, Japan 1196. Induced Abortions in Women with Rheumatoid Arthritis on Methotrexate. Evelyne Vinet1, Christian A. Pineau2, Bindee Kuriya3, Ann E. Clarke1, Robert Platt4 and Sasha Bernatsky5,

ACR/ARHP Poster Session B 1 McGill University Health Centre, Montreal, QC, 2McGill Univ Health Center, Montreal, QC, 3University of Toronto, Toronto, ON, 4McGill University, Montreal, QC, 5McGill UHC/ RVH, Montreal, QC

1197. Influence of Baseline Rheumatoid Factor on the Response to Tumor Necrosis Factor Antagonists of Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. Eva Salgado, Jose Ramon Maneiro, Loreto Carmona and Juan J. Gomez-Reino, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain 1198. Factors Affecting Glucocorticoid Use in Early Rheumatoid Arthritis. Results from an Early Arthritis Cohort. Pooneh S.Akhavan1, Glen S. Hazlewood1, Ye Sun2, Edward C. Keystone3, Gilles Boire4, Janet E. Pope5, Carol A. Hitchon6, Boulos Haraoui7, Diane S. Ferland8, V. Bykerk9 and CATCH Investigators10, 1University of Toronto, Toronto, ON, 2Mount Sinai Hospital, Toronto, ON, 3Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, 4CHUS - Sherbrooke University, Sherbrooke, QC, 5St. Joseph’s Health Care, University of Western Ontario, London, ON, 6University of Manitoba, Winnipeg, MB, 7Institut de Rhumatologie, Montreal, QC, 8LaSalle, QC, 9 Brigham & Women’s Hospital, Boston, MA, 10Toronto, ON 1199. No Evidence of Increased Mortality in Rheumatoid Arthritis Patients Treated with Biologics: Results From a Multicenter Cohort in Japan. Ayako Nakajima1, Toshihisa Kojima2, Wataru Fukuda3, Taku Yoshio4, Eisuke Inoue1, Koichi Amano5, Seiji Minota4, Kazuyoshi Saito6, Shigeki Momohara1, Naoki Ishiguro2, Yoshiya Tanaka7, Tsutomu Takeuchi8 and Hisashi Yamanaka1, 1Tokyo Women’s Medical University, Tokyo, Japan, 2Nagoya University, Nagoya, Japan, 3Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 4Jichi Medical University, Tochigi, Japan, 5Saitama Medical University, Saitama Medical Center, Saitama, Japan, 6University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 7University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 8Keio University School of Medicine, Tokyo, Japan 1200. Generalizability of Patients with Rheumatoid Arthritis in Biologic Clinical Trials. Priyanka Vashisht1, Harlan Sayles2, Grant W. Cannon3, Gail S. Kerr4, Pascale Schwab5, Deana M. Lazaro6, Andreas M. Reimold7, Nasim A. Khan8, Bogdan Cherascu9, Angelo L. Gaffo10, Dannette S. Johnson11, Ted R. Mikuls12 and Kaleb Michaud13, 1Creighton University Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Salt Lake City VA and University of Utah, Salt Lake City, UT, 4Washington DC VA and Georgetown University, Washington, DC, 5Portland VA and Oregon Health & Science University, Portland, OR, 6Brooklyn VA, Brooklyn, NY, 7Dallas VA and University of Texas Southwestern, Dallas, TX, 8University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, 9Iowa City VA and University of Iowa, Iowa City, IA, 10Birmingham VA Medical Ctr, Birmingham, AL, 11Jackson VA and University

of Mississippi Medical Center, Jackson, MS, 12Omaha VA and University of Nebraska Medical Center, Omaha, NE, 13 National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE 1201. Predictors, Features and Effects of First Biologic Switch in Rheumatoid Arthritis within GISEA register: Italian 10-Year Experience. Bernd Raffeiner1, Costantino Botsios1, Paolo Sfriso1, Antonio Carletto2, Domenico Biasi2, Elisa Gremese3, Gianfranco Ferraccioli4, Clodoveo Ferri5, Mauro Galeazzi6, Roberto Gerli7, Paola Cipriani8, Roberto Giacomelli8, Tamara Ziglioli9, Roberto Gorla9, Marcello Govoni10, Antonio Marchesoni11, Fausto Salaffi12, Walter Grassi13, Fabiola Atzeni14, Piercarlo Sarzi-Puttini15, AnnaRita Giardina16, Giovanni Triolo16, Florenzo Iannone17, Giovanni Lapadula17 and Leonardo Punzi1, 1Rheumatology Unit, University of Padova, Padova, Italy, 2Rheumatology Unit, University of Verona, Verona, Italy, 3Rheumatology Unit, Catholic University, Roma, Italy, 4Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 5Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy, 6Rheumatology Unit, University of Siena, Siena, Italy, 7Rheumatology Unit, University of Perugia, Perugia, Italy, 8Rheumatology Unit, University of Aquila, L’Aquila, Italy, 9Rheumatology Unit, University of Brescia, Brescia, Italy, 10Rheumatology Unit, University of Ferrara, Ferrara, Italy, 11Rheumatology Unit, Ospedale G Pini, Milano, Italy, 12 Rheumatology Unit, Polytechnic University of the Marche, Jesi, Italy, 13Università Politecnica delle Marche, Jesi, Italy, 14 Rheumatology Unit, L Sacco University Hospital, MiIano, Italy, 15Rheumatology Unit, L Sacco University Hospital, Milano, Italy, 16Rheumatology Unit, University of Palermo, Palermo, Italy, 17Rheumatology Unit, University of Bari, Bari, Italy 1202. Sleep Disturbances and IL-6 Receptor Inhibition in Rheumatoid Arthritis. K. Fragiadaki1, MG Tektonidou1, M. Konsta1, GP Chrousos2 and PP Sfikakis1, 1Laikon Hospital, Athens University Medical School, Athens, Greece, 2First Department of Pediatrics, Athens University Medical School, Athens, Greece 1203. Fatigue in Patients with Rheumatoid Arthritis: Examination of Contributory Factors Post Tumour Necrosing Factor Inhibitor Treatment. Patricia Minnock1, Gabrielle McKee2, Barry Bresnihan3, Oliver M. FitzGerald4 and Douglas J. Veale5, 1Our Lady’s Hospice & Care Services, Dublin, Ireland, 2 Trinity College Dublin, Dublin, Ireland, 3St. Vincent’s University Hospital, Dublin, Ireland, 4St. Vincent’s Univ Hospital, Dublin, Ireland, 5Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland 1204. Pregnancy and the Risk of Rheumatoid Arthritis In a High Risk North American Native Population. Christine A. Peschken1, David B. Robinson1, Irene Smolik1, Carol A. Hitchon1, Donna M. Hart2, Charles N. Bernstein1 and Hani ElGabalawy1, 1University of Manitoba, Winnipeg, MB, 2Health Sciences Centre, Winnipeg, MB

2011 Program Book

219

ACR/ARHP Poster Session B 1205. A Significant Proporcion of Patients with Palindromic Rheumatism and Positive Anti-Citrulinated Protein Antibodies Do Not evolve to Rheumatoid Arthritis after a Long Term Follow-up. S. Cabrera1, J. A. Gomez- Puerta1, M. V. Hernandez1, V. Ruiz -Esquide1, Georgina Salvador2, M.E. Gomez -Caballero1, J. Ramirez1, J. D. Cañete1 and R. Sanmarti1, 1Hospital Clinic of Barcelona, Barcelona, Spain, 2 Hospital Mutua de Terrassa. Barcelona, Barcelona, Spain 1206. Sick Leave and Disability Pension Before and After Initiation of Biologics in Psoriatic Arthritis Patients: FourYear Nationwide Cohort Study. Martin Neovius1, Jonas Eriksson2, Julia F. Simard2, Johan Askling1 and ARTIS Study Group3, 1Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Sweden

Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy II 1207. Treating to Target Matrix Metalloproteinase 3 Normalisation Together with Disease Activity Score Below 2.6 Yields Better Effects Than Each Alone In Rheumatoid Arthritis Patients: Treating to Twin Targets; T-4 Study. Yukitomo Urata1, Ryoko Uesato1, Dai Tanaka1, Yoshihide Nakamura2 and Shigeru Motomura2, 1Seihoku Chuo Hospital, Gosyogawara, Japan, 2Hirosaki University Graduate School of Medicine, Hirosaki, Japan 1208. Risk of Infections In Rheumatoid Arthritis Patients Treated with Tocilizumab – a Retrospective Data-Analysis. Veronika Lang1, Matthias Englbrecht1, Jürgen Rech1, Bernhard Manger2, Georg Schett3 and Jochen Zwerina4, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Medical School Erlangen, Erlangen, Germany, 3Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 4University of Erlangen-Nuremberg, Germany, Erlangen, Germany 1209. Bone Resorption, OsteoClastogenesis and Adalimumab. A Study On the Impact of Anti-Tumor Necrosis Factor Therapy On Osteoclastogenesis In Patients with Rheumatoid Arthritis. Sabrina Guay-Belanger1 and Arthur J. Fernandes2, 1Universite de Sherbrooke, Sherbrooke, QC, 2 Universite de Sherbrooke, Sherbrooke 1210. Golimumab’s Efficacy in Patients with Very Active Disease in Methotrexate-naïve Rheumatoid Arthritis. Paul Emery1, R. M. Fleischmann2, Elizabeth C. Hsia3, Stephen Xu4, Weichun Xu5 and Daniel G. Baker6, 1Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 2University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 3Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 4Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, 5Centocor R&D, a division of Johnson & Johnson Pharmaceutical

220

2011 Program Book

Research & Development, LLC, Malvern, 6Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research and Development, LLC, Malvern, PA 1211. Impact of Rituximab On the Quality of Life and Physical Function of Patients with Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register. Moetaza M. Soliman1, Kimme L. Hyrich2, Mark Lunt2, Kath D. Watson2, Deborah PM Symmons2 and Darren M. Ashcroft1, 1School of Pharmacy and Pharmaceutical sciences, University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom 1212. Mortality and Cause of Death In Young Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: Results From the British Society for Rheumatology Biologics Register. Malack Alachkar, Kath D. Watson, Kimme L. Hyrich and Deborah PM Symmons, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom 1213. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, As Monotherapy in Patients with Active Rheumatoid Arthritis: A Comparison Between Japanese and Global Populations Over 12 Weeks of Dosing in Phase 2b Studies. T. Takeuchi1, Y. Tanaka2, H. Yamanaka3, M. Suzuki4, H. Nakamura4, K. Yazawa4, S. Toyoizumi4, J. D. Bradley5 and S. H. Zwillich5, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 4Pfizer Inc., Tokyo, Japan, 5Pfizer Inc., Groton, CT 1214. Early Aggressive Intervention for Rheumatoid Arthritis Increases Rate of Remission Defined Using a Boolean Approach in Clinical Practice with Tocilizumab. Toshihisa Kojima1, Atsushi Kaneko2, Yuji Hirano3, Hisato Ishikawa4, Yuichiro Yabe5, Hideki Takagi6, Masatoshi Hayashi1, Koji Funahashi1, Daizo Kato1, Hiroyuki Matsubara7, Naoki Ishiguro8 and TBCR Study Group7, 1Nagoya University, School of Medicine, Nagoya, Japan, 2Nagoya Medical Center, Nagoya, Japan, 3Toyohashi Municipal Hospital, Toyohashi, Japan, 4Nagano Red Cross Hospital, Nagano, Japan, 5Tokyo Kosei Hospital, Tokyo, Japan, 6Nagoya Kyoritsu Hospital, Nagoya, Japan, 7Nagoya, Japan, 8Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan 1215. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, As Monotherapy or with Background Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Phase 2/3 Long-Term Extension Study. H. Yamanaka1, Y. Tanaka2, T. Takeuchi3, M. Suzuki4, H. Nakamura4, Y. Komuro4, S. Toyoizumi4, J. D. Bradley5 and S. H. Zwillich5, 1Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 2University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 3Keio University School of Medicine, Tokyo, Japan, 4Pfizer Inc., Tokyo, Japan, 5Pfizer Inc., Groton, CT

ACR/ARHP Poster Session B 1216. Baseline Predictors of Remission with Combination Etanercept-Methotrexate Therapy in Moderately Active Rheumatoid Arthritis: Interim Results of the PRESERVE Trial. Josef Smolen1, Annette Szumski2, Lisa Marshall2 and Andrew S. Koenig2, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Pfizer Inc., Collegeville, PA 1217. Is Long-Term Etanercept Monotherapy Ever An Option in a Patient with Moderate to Severe Rheumatoid Arthritis (RA)? Roy M. Fleischmann1, Michael H. Schiff2, Deborah Wenkert3, Bojena Bitman4, Sandeep Chaudhari5, Jie Liu6, Grace S. Park7 and Debra J. Zack8, 1University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 2Rheumatology Division, University of Colorado, Denver, CO, 3Amgen, Thousand Oaks, CA, 4Amgen Inc., South San Francisco, CA, 5KForce Clinical Research, Tampa, FL, 6SimulStat Incorporated, San Diego, CA, 7Amgen Inc., Thousand Oaks, CA, 8Amgen Inc, Thousand Oaks, CA 1218. Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Japanese Rheumatoid Arthritis Patients with An Inadequate Response to Methotrexate. Kazuhiko Yamamoto1, Tsutomu Takeuchi2, Hisashi Yamanaka3, Naoki Ishiguro4, Yoshiya Tanaka5, Katsumi Eguchi6, Akira Watanabe7, Hideki Origasa8, Toshiharu Shoji9, Yoshiharu Sakamaki10, Nobuyuki Miyasaka11 and Takao Koike12, 1Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 2Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan, 4Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 5 University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 6Sasebo City General Hospital, Sasebo, Nagasaki, Japan, 7Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, 8 University of Toyama School of Medicine, Toyama, Toyama, Japan, 9Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, 10UCB Inc, Chiyoda, Tokyo, Japan, 11Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan, 12Sapporo Medical Center NTT EC, Sapporo, Japan 1219. Integrated Safety Summary of Modified-Release Prednisone and Immediate-Release Prednisone Comparing Doses ≤5mg/Day Versus >5mg/Day. Frank Buttgereit1, Jacek Szechinski2, Gisela Doering3, Stephan Witte4, Christine Knauer4, Amy Y. Grahn5, Kenneth G. Saag6 and Rieke Alten7, 1 Charité University Medicine, Berlin, Germany, 2Wroclaw Medical University, Wroclaw, Poland, 3Merck KgaA, Darmstadt, Germany, 4Horizon Pharma GmbH, Mannheim, Germany, 5Horizon Pharma, Inc., Northbrook, IL, 6University of Alabama at Birmingham, Birmingham, AL, 7Rheumatology Schlossparkklinik, Berlin, Germany

1220. Efficacy and Safety of Certolizumab Pegol without Methotrexate Co-Administration in Japanese Patients with Active Rheumatoid Arthritis. Kazuhiko Yamamoto1, Tsutomu Takeuchi2, Hisashi Yamanaka3, Naoki Ishiguro4, Yoshiya Tanaka5, Katsumi Eguchi6, Akira Watanabe7, Hideki Origasa8, Koichi Iwai9, Yoshiharu Sakamaki10, Nobuyuki Miyasaka11 and Takao Koike12, 1Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 4Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 6Sasebo City General Hospital, Sasebo, Nagasaki, Japan, 7Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, 8University of Toyama School of Medicine, Toyama, Toyama, Japan, 9Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, 10UCB Inc, Chiyoda, Tokyo, Japan, 11Tokyo Medical and Dental University, Tokyo, Japan, 12 Sapporo Medical Center NTT EC, Sapporo, Japan 1221. Dose Escalation Among Rheumatoid Arthritis Patients Treated with Infliximab or Abatacept: Comparison in Claims Data. Theodore Darkow1, Benjamin Chastek2, Lisa Rosenblatt1, Digisha Trivedi1, Tony Hebden1, Henry Henk2 and Fang Liu2, 1Bristol-Myers Squibb, Plainsboro, NJ, 2 Innovus, an Optum Insight Company, Eden Prairie, MN 1222. The Effectiveness of Abatacept in a Large Rheumatoid Arthritis Real World Practice: Changes in the HAQ Over Time and Durability of Response. Janet E. Pope1, Emmanouil Rampakakis2, John S. Sampalis2 and Olivier Desjardins3, 1St. Joseph’s Health Care, University of Western Ontario, London, ON, 2McGill University & JSS Medical Research, Montreal, QC, 3Bristol Myers Squibb Canada, St. Laurent, QC 1223. Drug Survival and Long-Term Dose Comparison of Etanercept and Infliximab in Rheumatoid Arthritis Patients. Brian D. Hanna1 and Alpesh Shah2, 1McMaster University, Ontario, Kitchener, ON, 2Community Rheumatology Clinic, Etobicoke, ON 1224. Remission According to Different Composite Disease Activity Indices in Biologic-naïve Patients with Rheumatoid Arthritis Treated with Abatacept or Infliximab Plus Methotrexate. Josef S. Smolen1, Maxime Dougados2, Corine Gaillez3, Coralie Poncet4, Manuela Le Bars3, Monica Mody5 and Michael H. Schiff6, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Hôpital Cochin, Paris, France, 3Bristol-Myers Squibb, Rueil Malmaison, France, 4 Docs International, Sévres, France, 5Bristol-Myers Squibb, Princeton, NJ, 6University of Colorado, Denver, CO 1225. Pharmacokinetics of IV Abatacept in Systemic Lupus Erythematosus Patients with Active Proliferative Glomerulonephritis. Michael Tagen1, Blisse Vakkalagadda1, Neelima Thanneer1, Stephanie Meadows-Shropshire1, Martin Ullmann1, Robert Wong1, Richard Aranda2 and Bindu 2011 Program Book

221

ACR/ARHP Poster Session B Murthy1, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb [at time of study], Princeton, NJ 1226. Clinical Effect of Abatacept in Patients with Rheumatoid Arthritis, Data From the Swedish Rheumatology Quality Registry. Ralph Nisell1, Leszek Stawiarz2 and Staffan Lindblad1, 1Karolinska University Hospital, Stockholm, Sweden, 2Karolinska Institutet and Carmona AB, Stockholm / Halmstad, Sweden 1227. Sustained Clinical Response with Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of a Randomized, Placebo-Controlled Study. Jürgen Braun1, Desiree van der Heijde2, Atul Deodhar3, Anna Beutler4, Michael Mack4, Benjamin Hsu5 and Robert D. Inman6, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Leiden University Medical Center, Leiden, Netherlands, 3Oregon Health & Science University, Portland, OR, 4Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 5 Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/ Univ. of Pennsylvania, Malvern/Philadelphia, PA, 6Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON 1228. Fatigue and Morning Stiffness Are Correlated in Early Arthritis and Both Are Substantially Improved by Glucocorticoids. Gisela Westhoff1, Angela Zink2 and Frank Buttgereit3, 1German Rheumatism Research Center Berlin, Berlin, Germany, 2Deutsches Rheumaforschungszentrum and Charité University Medicine, Berlin, Germany, 3Charité University Medicine, Berlin, Germany 1229. Different Remission Definitions Capture Different Proportions of patients with Rheumatoid Arthritis Treated in Clinical Practice. Till Uhlig1, Elisabeth Lie1, Cecillie Kaufmann2, Erik Rodevand3, Knut Mikkelsen4, Synnøve Kalstad5 and Tore K. Kvien1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Buskerud Central Hospital, Drammen, Norway, 3St. Olav Hospital, Trondheim, Norway, 4Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 5University Hospital in Northern Norway, Tromsø, Norway 1230. Patient-Reported Disease Activity Including Joint Assessment: A Comparison of RADAI (Rheumatoid Arthritis Disease Activity Index) and RAPID3 (Routine Assessment of Patient Index Data 3) in Patients Treated with Certolizumab Pegol Over 12 Weeks. Michael E. Weinblatt1, Janet E. Pope2, Roy M. Fleischmann3, Clifton O. Bingham4, Geoffroy Coteur5 and Maxime Dougados6, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 2St. Joseph’s Health Care, University of Western Ontario, London, ON, 3MCRC, University of Texas, Dallas, TX, 4Johns Hopkins University, Baltimore, MD, 5UCB, Brussels, Belgium, 6Paris-Descartes University, Cochin Hospital, Paris, France 1231. Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early

222

2011 Program Book

Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial. Ferdinand C. Breedveld1, Edward Keystone2, Désirée van der Heijde3, Robert Landewe4, Josef Smolen5, Benoit Guerette6, Melissa McIlraith6, Hartmut Kupper7, Shufang Liu8, Benjamin Wolfe8 and Arthur Kavanaugh9, 1Leiden Univ Medical Ctr, Leiden, Netherlands, 2University of Toronto, Toronto, ON, 3 Leiden University Medical Center, Leiden, Netherlands, 4 Academic Medical Center, Amsterdam, Netherlands, 5 Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 6Abbott, Rungis, France, 7Abbott GmbH & Co KG, Ludwigshafen, Germany, 8Abbott, Abbott Park, IL, 9University of California San Diego, San Diego, CA 1232. Association Between Leptin, Adiponectin and TNF-α and Response to Treatment in Patients with Rheumatoid Arthritis. Daniel X. Xibille Friedmann1, Sara Eugenia Hernandez Gongora2, Carolina Bustos Bahena3, Liliana Dominguez Hernandez3, Ivan Martinez Rivera3, Marisol Sandoval Rios3, Jorge Eduardo Ortiz Panozo4 and Jose Luis Montiel Hernandez5, 1Hospital General de Cuernavaca, Cuernavaca Morelos, Mexico, 2Postgraduate Research Coordination, School of Medicine, Universidad Latinoamericana, Cuernavaca, México, 3Cytokines and Autoimmunity Laboratory, Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Cuernavaca, México, Cuernavaca, Mexico, 4Center for Population Health Research. Instituto Nacional de Salud Pública, Cuernavaca, México, 5Cytokines and Autoimmunity Laboratory, Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Cuernavaca, México 1233. Safety and Efficacy of Etanercept Over Five Years in a Large, UK Observational Cohort. C. D. Poole1, Paul Emery2, Adam Young3, Duncan Porter4, C. L. Morgan1, H. Walker5, C. J. Currie6 and A. Reynolds7, 1Pharmatelligence, Cardiff, United Kingdom, 2Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 3City Hospital, St Albans, United Kingdom, 4Gartnavel General Hosp, Glasgow, United Kingdom, 5Pfizer UK Ltd, Tadworth, United Kingdom, 6Cardiff University, Cardiff, United Kingdom, 7Reynolds Clinical Sciences Ltd, Eastleigh, United Kingdom 1234. Response with Combination Therapy - Methotrexate, Sulfasalazine, and Hydroxychloroquine - Appears Similar to the Response to Methotrexate and Anti-Tumor Necrosis Factor in US Veterans in the Veterans Affairs Rheumatoid Arthritis Registry. Grant W. Cannon1, Brian C. Sauer1, Candace L. Hayden1, Stephen G. Pickard1, Gail S. Kerr2, J. Steuart Richards2, Dannette S. Johnson3, Liron Caplan4, Ted R. Mikuls5 and Andreas M. Reimold6, 1Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Washington DC VA and Georgetown University, Washington, DC, 3Jackson VA and University of Mississippi Medical Center, Jackson, MS, 4 Denver VA and University of Colorado, Aurora, CO, 5Omaha VA and University of Nebraska, Omaha, NE, 6Dallas VA and University of Texas Southwestern, Dallas, TX

ACR/ARHP Poster Session B 1235. Greater Physical Dysfunction Is a Negative Predictor for Achieving Boolean-Based Remission in Patients with Rheumatoid Arthritis Treated with Tocilizumab. Daisuke Hoshi, Kumi Shidara, Yohei Seto, Eiichi Tanaka, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan 1236. Direct Comparison of Four Biologics in Biologic-naïve Rheumatoid Arthritis Patients. Yukio Yonemoto1, Kimihiko Takeuchi2, Koichi Okamura1, Masatoshi Matsushita2, Tsutomu Kobayashi1, Tetsuo Aramaki2, Tetsuya Kaneko1 and Kenji Takagishi1, 1Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 2Isesaki Fukushima Hospital, Isesaki, Gunma, Japan 1237. Impact of Tocilizumab Therapy for Remission Quartet in Rheumatoid Arthritis –the Result of 104 Weeks Follow up Data of REACTION Study–. Yoshiya Tanaka1, Tsutomu Takeuchi2, Koichi Amano3, Eri Sato4, Masao Nawata5, Hayato Nagasawa6, Daisuke Hoshi7, Kazuyoshi Saito8, Shunsuke Fukuyo5, Kentaro Hanami8, Hideto Kameda2, Takahiko Kurasawa6, Yuko Kaneko9 and Hisashi Yamanaka4, 1 University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6Saitama Medical Ctr, Kawagoe, Japan, 7Tokyo Women’s Medical University, Tokyo, Japan, 8University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 9Keio Univ School of Medicine, Shinjuku-ku, Japan 1238. Clinical Response At Months 1–6 Can Predict Likelihood of Achieving Remission in Abatacept Plus MethotrexateTreated Patients with Early Rheumatoid Arthritis. Yusuf Yazici1, Jurgen Wollenhaupt2, Patrick Durez3, Juan J. GomezReino4, Walter Grassi5, Manuela Le Bars6, Corine Gaillez7, Coralie Poncet8, Ayanbola Elegbe9 and Rene Westhovens10, 1 NYU Hospital for Joint Diseases, New York, NY, 2SchoenKlinik Hamburg-Eilbek, Hamburg, Germany, 3Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, 4Hospital Clinico Universitario, Santiago de Compostela, Spain, 5Università Politecnica delle Marche, Ancona, Italy, 6Bristol-Myers Squibb, Rueil-Malmaison, France, 7Bristol-Myers Squibb, Rueil Malmaison, France, 8 Docs International, Issy les Moulineaux, France, 9BristolMyers Squibb, Princeton, NJ, 10UZ Gasthuisburg, Leuven, Belgium 1239. Impact of Tocilizumab Therapy After Switching From Tumor Necrosis Factor (TNF) inhibitors – Prevention of Joint Damage by Tocilizumab in Patients with Inadequate Response to Anti-TNF Therapies –. Yoshiya Tanaka1, Tsutomu Takeuchi2, Koichi Amano3, Eri Sato4, Masao Nawata5, Hayato Nagasawa6, Daisuke Hoshi7, Kazuyoshi

Saito8, Shunsuke Fukuyo5, Kentaro Hanami8, Hideto Kameda2, Takahiko Kurasawa6, Yuko Kaneko9 and Hisashi Yamanaka4, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6Saitama Medical Ctr, Kawagoe, Japan, 7Tokyo Women’s Medical University, Tokyo, Japan, 8University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 9Keio Univ School of Medicine, Shinjuku-ku, Japan 1240. Comparative Efficacy and Tolerability of Biologic Therapies in Early Rheumatoid Arthritis Utilizing a Bayesian Approach. Yusuf Yazici1, Christopher Swearingen2, Anagha Nadkarni3 and Lisa Rosenblatt3, 1Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 2University of Arkansas, Little Rock, AR, 3Bristol-Myers Squibb, Plainsboro, NJ 1241. Differences in Gene Expression Profiles in Rheumatoid Arthritis Peripheral Blood Mononuclear Cells Suggest Apoptosis As Relevant Mechanism for Response to Methotrexate Monotherapy. RD Oliveira1, V. Fontana, C. Macedo, CM Junta, Eduardo A. Donadi3, GA Passos and Paulo Louzada-Junior1, 1School of Medicine of Ribeirao Preto - University of Sao Paulo, Ribeirao Preto, Brazil, 2Faculty Med of Ribeirao Preto, Ribeirao Preto, Brazil 1242. Comorbidity and Cost Burden of Patients Prior to Initiating Abatacept or Infliximab As First Line Biologic Therapy for the Treatment of Rheumatoid Arthritis. Theodore Darkow, Digisha Trivedi, Brian Meissner, Lisa Rosenblatt and Tony Hebden, Bristol-Myers Squibb, Plainsboro, NJ 1243. Fatigue in Patients with Rheumatoid Arthritis Treated with Tocilizumab (Actemra®) in Real Life: Clinically Relevant Improvement in 62% of Patients At 4 Months and Rapid Onset of Action. The PEPS Study. Laure Gossec1, Stephanie Rouanet2, Ghislaine Steinberg3 and Bernard G. Combe4, 1Cochin Hospital, Paris, France, 2Roche, Neuilly sur Seine, France, 3Roche, Neuilly Sur Seine, France, 4Hopital Lapeyronie, Montpellier, France 1244. Treatment Satisfaction and Adherence of Patients on Biologic Monotherapy. Jörg Kaufmann1, Anne-Eve Roske2, Adrian Kielhorn2, Eugen Feist3 and Wolfgang A. Schmidt4, 1 Rheumatologist, Ludwigsfelde, Germany, 2Roche Pharma AG, Grenzach-Wyhlen, Germany, 3Charité Medical School, Berlin, Germany, 4Med Ctr Rheumatol Berlin Buch, Berlin, Germany 1245. Baseline Tender Joint Count Scores Predict Long-Term Household Productivity in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol Plus Methotrexate. Arthur Kavanaugh1, Oana Purcaru2, Josef Smolen3, Paul Emery4, Vibeke Strand5, Edward Keystone6 and Ronald F. van Vollenhoven7, 1University of California 2011 Program Book

223

ACR/ARHP Poster Session B San Diego, San Diego, CA, 2UCB, Brussels, Belgium, 3Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4 Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 5Stanford University, Palo Alto, CA, 6University of Toronto, Toronto, ON, 7Karolinska Institute, Stockholm, Sweden 1246. Improvement & Maintenance of Hemoglobin Levels Among Rheumatoid Arthritis, Psoriatic Arthritis&Ankylosing Spondylitis Patients with Anemia of Inflammation After Treatment with Golimumab:3 Year Pooled Analysis. Daniel E. Furst1, Tim Gathany2, Jonathan Kay3, Mary Chester Wasko4, Edward Keystone5, Arthur Kavanaugh6, Atul Deodhar7, Frederick T. Murphy8, Chenglong Han9 and Mittie K. Doyle10, 1UCLA, Los Angeles, CA, 2Johnson & Johnson Pharmaceutical Services, LLC, Horsham, PA, 3University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, MA, 4West Penn Allegheny Health System, Pittsburgh, PA, 5University of Toronto, Toronto, ON, 6 University of California San Diego, San Diego, CA, 7Oregon Health & Science University, Portland, OR, 8Altoona Ctr for Clinical Research, Duncansville, PA, 9Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, 10Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC/University of Pennsylvania School of Medicine, Malvern/Philadelphia, PA 1247. Rheumatologists’ Benefit-Risk Preferences for Biologic Treatments for Rheumatoid Arthritis. A. Brett Hauber1, James T. Cross2, David E. Yocum3, F. Reed Johnson1, JuiChen Yang1, Isidro Villaneuva2 and Patricia P. Katz4, 1RTI Health Solutions, Research Triangle Park, NC, 2Genentech, Inc., South SanFrancisco, CA, 3Genentech, Inc, South San Francisco, CA, 4University of California San Francisco, San Francisco, CA 1248. Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients with Rheumatoid Arthritis Receiving Certolizumab Pegol. A. Kivitz1, Joy Schechtman2, Michele Texter3, Andreas Fichtner4 and Elliot Chartash*3, 1 Altoona Center for Clinical Research, Duncansville, PA, 2 SunValley Arthritis Center, Peoria, AZ, 3UCB, Smyrna, GA, 4 UCB Biosciences GmBH, Monheim, Germany 1249. Number of Cardiovascular Risk Factors May be Associated with Higher Disease Activity Severity. Exploratory Analysis of Baseline Data from the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate vs Etanercept Alone in Rheumatoid Arthritis. Janet Pope1, Edward Keystone2, Boulos Haraoui3, J. Carter Thorne4 and Melanie PoulinCostello5, 1Univ of Western Ontario, London, ON, 2University of Toronto, Toronto, ON, 3Institut de Rhumatologie, Montreal, QC, 4Southlake Regional Health Centre, Newmarket, Newmarket, ON, 5Amgen Canada Inc., Mississauga, ON

224

2011 Program Book

1250. Effect on rheumatoid factor and anti-Cyclic Citrullinated Peptide Antibodies Levels of treatment with Infliximab and Adalimumab in patients with Rheumatoid Arthritis. Selene Baos, Chamaida Plasencia, Susana Ramiro, Rosario Moral, Jesús Díez, E. Martin-Mola, Alejandro Balsa and Dora Pascual-Salcedo, La Paz University Hospital, Madrid, Spain 1251. Does Single Nucleotide Polymorphism in Folate Metabolic Pathway Contribute to Methotrexate Efficacy in Indian (Asian) Patients with Rheumatoid Arthritis? Yogita Ghodke1, Arvind Chopra2, Amrutesh S. Puranik1, Pooja Shintre3, Anjali Radkar4, Kalpana Joshi5 and Bhushan Patwardhan5, 1University of Minnesota, Minneapolis, MN, 2Centre for Rheumatic Diseases, Pune 411001, India, 3 Sinhgad College of Engineering, Pune, India, 4Gokhale Institute of Politics and Economics, Pune, India, 5Symbiosis International University, Pune - 411042, India 1252. Association of ACR Clinical Responses with CDAI (Clinical Disease Activity Index) and RAPID3 (Routine Assessment of Patient Index Data 3) Indices of Disease Activity in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol Plus Methotrexate. Michael H. Schiff1, Kristel Luijtens2, Owen Davies2 and Yusuf Yazici3, 1Rheumatology Division, University of Colorado, Denver, CO, 2UCB, Brussels, Belgium, 3Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 1253. Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study. Michael Weinblatt1, Roy M. Fleischmann2, Ronald F. van Vollenhoven3, Paul Emery4, T.W.J. Huizinga5, Maurizio Cutolo6, Ruth Goldermann7, Benjamin Duncan8, Owen Davies9 and Maxime Dougados10, 1Brigham & Women’s Hospital, Boston, MA, 2MCRC, University of Texas, Dallas, TX, 3Karolinska Institute, Stockholm, Sweden, 4University of Leeds, Leeds, United Kingdom, 5Leiden University Medical Centre, Leiden, Netherlands, 6Research Laboratory and Academic Unit of Clinical Rheumatology, University of Genova, Genova, Italy, 7UCB, Monheim, Germany, 8UCB, Raleigh, NC, 9UCB, Brussels, Belgium, 10Rene Descartes University, Paris, France 1254. No Change in Arterial Stiffness After 6 Months of Abatacept Treatment in Rheumatoid Arthritis. Sylvain Mathieu1, Bruno Pereira2, Emilie Rabois1, Anne Tournadre1, Jean Jacques Dubost1 and Martin Soubrier2, 1CHU Gabriel Montpied, Clermont-Ferrand, France, 2CHU CLERMONTFERRAND, Clermont-Ferrand, France 1255. Folate Metabolic Pathway Single Nucleotide Polymorphisms a Predictive Pharmacogenetic Marker of Methotrexate Related Adverse Events in Indian (Asian) Patients with Rheumatoid Arthritis. Yogita Ghodke1, Arvind Chopra2, Amrutesh S. Puranik1, Pooja Shintre3, Anjali Radkar4, Kalpana Joshi5 and Bhushan Patwardhan5, 1 University of Minnesota, Minneapolis, MN, 2Centre for

ACR/ARHP Poster Session B Rheumatic Diseases, Pune, India, 3Sinhgad College of Engineering, Pune, India, 4Gokhale Institute of Politics and Economics, Pune, India, 5Symbiosis International University, Pune - 411042, India 1256. Design of a High Potency CTLA4-Ig with Extended Half-Life for Improved Dosing Convenience. Matthew J. Bernett, Seung Y. Chu, Holly M. Horton, Erik Pong, Irene Leung, Gregory L. Moore, Umesh S. Muchhal, Greg A. Lazar, David E. Szymkowski and John R. Desjarlais, Xencor, Inc., Monrovia, CA 1257. Campylobacter Fetus Infection In Three Patients Treated with Rituximab for Rheumatoid Arthritis. Alain Meyer1, Arnaud Theulin2, Emmanuel Chatelus3, Christelle Sordet2, Rose-Marie Javier2, Helene Chifflot4, Jacques-Eric Gottenberg5 and Jean Sibilia6, 1Hautepierre Strasbourg university, Strasbourg, France, 2Hautepierre Strasbourg Hospital University, Strasbourg, France, 3Hopital Hautepierre, Strasbourg, France, 4Hautepierre Strasbourg Hospital University, 67000, France, 5Strasbourg University Hospital, Strasbourg, France, 6Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France 1258. Short- and Long-Term Effect of Unguided, Intra-Articular Injections with Betamethasone In Early Rheumatoid Arthritis. Impact of Joint Area, Repeated Injections, MRI Findings, Anti-CCP, IgM-RF and CRP. Merete L. Hetland1, Mikkel Østergaard2, Bo J. Ejbjerg3, Søren Jacobsen4, Kristian Stengaard-Pedersen5, Peter Junker6, Tine Lottenburger6, Ib Hansen7, Lis Smedegaard Andersen8, Ulrik Tarp9, Anders Svendsen10, Jens Kristian Pedersen6, Henrik Skjødt11, Torkell Ellingsen12, Hanne M. Lindegaard6 and Kim Hørslev-Petersen13, 1Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 2 Copenhagen University Hospital in Glostrup, Glostrup, Denmark, 3Hospital at Slagelse, Slagelse, Denmark, 4 Rigshospitalet - 4242, Copenhagen, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Odense University Hospital, Odense C, Denmark, 7 Viborg Hospital, Viborg, Denmark, 8Denmark, 9Aarhus University Hospital, Aarhus, Denmark, 10Odense, Denmark, 11 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 12University Hospital, Silkeborg, Denmark, 13 University of Southern Denmark, Graasten, Denmark 1259. Pharmacokinetic-Pharmacodynamic Modeling of Ozoralizumab (ATN-103), a Novel Humanized Nanobody Tumor Necrosis Factor Inhibitor for Rheumatoid Arthritis. Chandrasekhar Udata1, Arnab Mukherjee2, Matt Hutmacher3, Mark Peterson1, Kai-Hsin Liao1, Tina Checchio2, Kathy Shields4, Xu Meng1 and Gail Comer4, 1Pfizer, San Diego, CA, 2Pfizer, Groton, CT, 3A2PG, Ann Arbor, MI, 4Pfizer, Collegeville, PA 1260. Correlation of CDAI and SDAI with DAS in a Large RealLife Cohort of Rheumatoid Arthritis Patients Treated with Infliximab. Denis Choquette1, William G. Bensen2, Milton

F. Baker3, Sophie Elise Michaud4 and Hayssam Khalil5, University of Montreal, Notre-dame Hospital, Montreal, QC, 2McMaster University, Hamilton, ON, Hamilton, ON, 3 VIHA, Victoria, BC, 4Merck Canada Inc, Montreal, QC, 5 Merck Canada Inc, Kirkland, QC 1

1261. Development of a Whole Blood Assay to Determine Rituximab Mediated Complement Dependent Cytotoxicity of B Lymphocytes. Jonathan D. Jones1, B. JoNell Hamilton2, Whitney Hilton3 and William F. C. Rigby4, 1DartmouthHitchcock Medical Center, Lebanon, NH, 2Dartmouth College, Lebanon, NH, 3Dartmouth Hitchcock Med Ctr, Lebanon, NH, 4Dartmouth-Hitchcock Med Ctr, Lebanon, NH 1262. A Profile of Rheumatoid Arthritis Patients Treated with Tocilizumab in a United States Registry Population. Dimitrios A. Pappas1, Alan Rathbun2, George Reed3, Joel M. Kremer4, Isidro Villanueva5, Jenny Devenport6, Sarika Ogale6, Ani John6 and Jeffrey D. Greenberg7, 1Columbia University, College of Physicians & Surge, New York, NY, 2UMASS Medical School, Worcester, MA, 3UMass Medical School, Worcester, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY, 5Viregen Macarena Hospital, Sevilla, Spain, 6Genentech, South San Francisco, CA, 7New York University School of Medicine, New York, NY 1263. SNP Algorithms for Prediction of Efficacy and Adverse Events of Abatacept. Tsukasa Matsubara1, Satoru Koyano2, Keiko Funahashi2, Takafumi Hagiwara1, Takako Miura1, Kosuke Okuda1, Takeshi Nakamura1, Mitsuyoshi Iwahashi3, Tomomi Tsuru4, Shoichi Uchimura5 and Shigeru Honjo6, 1 Matsubara Mayflower Hospital, Kato, Japan, 2Research Institute of Joint Diseases, Kobe, Japan, 3Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, 4PS Clinic, Fukuoka, Japan, 5Kanzaki Municipal General Hospital, Kanzaki, Japan, 6Honjo Rheumatism Clinic, Takaoka, Japan 1264. Low Persistence of Methotrexate Monotherapy in the Veterans Affairs Rheumatoid Arthritis (VARA) Registry. Grant W. Cannon1, Brian C. Sauer1, Katherine L. Martin1, Candace L. Hayden1, Andreas M. Reimold2, Liron Caplan3, J. Steuart Richards4, Gail S. Kerr4, Dannette S. Johnson5 and Ted R. Mikuls6, 1Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Dallas VA and University of Texas Southwestern, Dallas, TX, 3Denver VA and University of Colorado, Aurora, CO, 4Washington DC VA and Georgetown University, Washington, DC, 5Jackson VA and University of Mississippi Medical Center, Jackson, MS, 6Omaha VA and University of Nebraska, Omaha, NE 1265. Effects of TNF-Alpha Inhibitors on Lipid Profile and on SubClinical Atherosclerosis in Rheumatoid Arthritis. Systematic Review and Meta-Analysis. Sylvain Mathieu1, Sarah Payet1, Bruno Pereira2, Eric Bruckert3 and Martin Soubrier2, 1 CHU Gabriel Montpied, Clermont-Ferrand, France, 2CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 3CHU PitiéSalpêtrière, AP–HP, Paris

2011 Program Book

225

ACR/ARHP Poster Session B 1266. Evaluation of A Novel Homogeneous Mobility Shift Assay for the Measurement of Human Antibodies-to-Infliximab and Infliximab Levels in Patient Serum. Shui Long Wang, Linda Ohrmund, Scott Hauenstein, Jared Salbato, Rukmini Reddy, Patrick Monk, Steven Lockton, Nicholas Ling and Sharat Singh, Prometheus Laboratories, San Diego, CA 1267. Tofacitinib Reduces Interferon-γ and Interleukin-17 Production From CD4+ T Cells in Patients with Rheumatoid Arthritis. Satoshi Kubo, Kunihiro Yamaoka, Koshiro Sonomoto, Keisuke Maeshima, Shintaro Hirata, Kazuhisa Nakano, Norifumi Sawamukai, Masao Nawata, Shigeru Iwata, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 1268. A Phase 1, Randomized, Double-Blind, PlaceboControlled, Multiple, Intravenous, Ascending-Dose Study of Sirukumab in Patients with Cutaneous or Systemic Lupus Erythematosus. Jacek C. Szepietowski1, Surasak Nilganuwong2, Anna Wozniacka3, Annegret Kuhn4, Filippa Nyberg5, Jacek Szechinski1, Ronald F. van Vollenhoven6, Anders Bengtsson7, Adam Reich1, Dick de Vries8, Bart van Hartingsveldt8, Bei Zhou9 and Benjamin Hsu10, 1Wroclaw Medical University, Wroclaw, Poland, 2Siriraj Hospital, Bangkok, Thailand, 3Medical University of Lodz, Lodz, Poland, 4University of Münster, Münster, Germany, 5 Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden, 6Karolinska Institute, Stockholm, Sweden, 7 Department of Rheumatology, Lund University Hospital, Sweden, 8Janssen Biologics B.V., Leiden, Netherlands, 9 Centocor Research & Development, a Division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 10Centocor R&D, a division of J&J Pharmaceutical R& D, LLC/Univ. of Pennsylvania, Malvern/ Philadelphia, PA 1269. Meta-Analysis Suggests Intensive Non-Biologic Combination Therapy with Step-Down Prednisolone May Also ‘Disconnect’ Disease Activity and Damage in Rheumatoid Arthritis. Maarten Boers1, Lilian H.D. van Tuyl1, Marianne van den Broek2, Piet J. Kostense1 and Cornelia F. Allaart2, 1VU University Medical Center, Amsterdam, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands 1270. Clinical Response and B Cell Analysis by High-Sensitive Flowcytometry After the Second Course of Rituximab. Hans-Peter Brezinschek1, Franz Rainer2, Kerstin Brickmann1, Raimund Lunzer2 and Winfried B. Graninger1, 1Medical University Graz, Graz, Austria, 2Hospital Barmherzige Brueder, Graz- Eggenberg, Austria 1271. Comparison of Tocilizumab and TNF Inhibitor Therapy in Rheumatoid Arthritis. Jörg Kaufmann1, Susanne Seel2 and Anne-Eve Roske3, 1Rheumatologist, Ludwigsfelde, Germany, 2 Ambulant Centres f. Rheumatology, Ludwigsfelde, Germany, 3 Roche Pharma AG, Grenzach-Wyhlen, Germany

226

2011 Program Book

1272. Efficacy Evaluation of Tocilizumab with the New ACR/ EULAR Remission Criteria and DAS28-ESR. Tomonori Ishii1, Yasuhiko Hirabayashi2 and Michinoku Tocilizumab Study Group3, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Hikarigaoka Spellman Hospital, Sendai, Japan, 3 Senndai 1273. High Levels of Serum IL-6 but Not CRP or TNF-α During Tocilizumab Treatment Induces Myalgia Among the Patients with Rheumatoid Arthritis. Osamu Saiki1 and Hiroshi Uda2, 1Shiraishi Hospital, Imabari, Japan, 2Keiseikai Hospital, Higashiosaka, Japan 1274. Development of a Novel Recombinant Biotherapeutic with Applications in Targeted Therapy of Human Arthritis. Panagiotis Kamperidis1, Tahereh Kamalati1, Mathieu Ferrari1, Lewis Lee1, Rita Jones1, Toby Garrood1, Malcolm D. Smith2, Soraya Diez-Posada1, Chris Hughes1, Ciara Finucane1, Stephen Mather1, Ahuva Nissim1, Andrew J. T. George1 and Costantino Pitzalis3, 1London, United Kingdom, 2 Adelaide, Australia, 3Centre for Experimental Medicine and Rheumatology, QMUL, London, United Kingdom 1275. Gene Expression Profiling of Folate Pathway Related Genes in Methotrexate naïve- and Methotrexate-Treated Rheumatoid Arthritis Patients. Marjolein Blits1, Gerrit Jansen1, Yehuda G. Assaraf2 and Cornelis L. Verweij1, 1VU University Medical Center, Amsterdam, Netherlands, 2 Technion, Haifa, Israel 1276. Retrospective Analysis of the Efficacy of Tacrolimus in Rheumatoid Arthritis: Suggestive Synergistic Effects with Methotrexate. Kenta Hoshi, Sumiaki Tanaka, Tatsuhiko Wada, Junichi Tanaka, Tatsuo Nagai and Shunsei Hirohata, Kitasato University School of Medicine, Sagamihara, Japan 1277. Anti-CCP Titers Are Predictive of the Response to Biological Agents in Patients with Rheumatoid Arthritis. Ryo Takahashi1, Ryo Yanai1, Hidekazu Furuya1, Kuninobu Wakabayashi1, Tsuyoshi Odai1, Takeo Isozaki2, Nobuyuki Yajima1, Yusuke Miwa3 and Tsuyoshi Kasama1, 1Showa University School of Med, Shinagawa-ku Tokyo, Japan, 2 University of Michigan Medical School, Ann Arbor, MI, 3 Division of Rheumatology, Tokto, Japan 1278. Abatacept Reduces N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From a Prospective Cohort Study. Inge A.M. van den Oever1 and Michael T. Nurmohamed2, 1Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 2Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands 1279. Do Impared Memory, Cognitive Dysfonction and Distress Play a Role In Methotrexate-Related Pancytopenia In Rheumatoid Arthritis Patients? Salim Donmez1, Yavuz Pehlivan2, Omer Nuri Pamuk1, Bunyamin Kisacik2, Gulsum Emel Pamuk1, Ahmet Mesut Onat2, Mehmet Sayarlioglu3 and Gözde Yildirim Çetin3, 1Edirne, Turkey, 2Gaziantep, Turkey, 3 Kahramanmaras, Turkey

ACR/ARHP Poster Session B 1280. Acute Pain Relief by a Proprietary, Nano-Formulated Lower-Dose Oral Indomethacin. Roy D. Altman1, Stephen Daniels2 and Garen Manvelian3, 1UCLA, Los Angeles, CA, 2Premier Research Group, Austin, TX, 3Iroko Pharmaceuticals, Poway, CA 1281. A Phase 2 Study Evaluating the Acute Pain Relief of a Nano-Formulated Oral Naproxen. Garen Manvelian1, Stephen Daniels2, Allan Gibofsky3 and Vibeke Strand4, 1Iroko Pharmaceuticals, Poway, CA, 2Premier Research Group, Austin, TX, 3Hospital for Special Surgery, New York, NY, 4 Stanford University, Palo Alto, CA 1282. Application of Nanotechnology to Improve Non-Steroidal Anti-Inflammatory Drugs. Garen Manvelian1, Roy D. Altman2 and Vibeke Strand3, 1Iroko Pharmaceuticals, Poway, CA, 2 UCLA, Los Angeles, CA, 3Stanford University, Palo Alto, CA 1283. Demonstration of the Symptomatic and Structural Effect of Methotrexate in Daily Practice As the First RA-DMARD Despite Its Sub-Optimal Use: Results From the ESPOIR Early Synovitis Cohort. Cécile Gaujoux-Viala1, Simon Paternotte2, Bernard G. Combe3 and Maxime Dougados4, 1Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, 2Hopital Cochin, Paris, France, 3 Hopital Lapeyronie, Montpellier, France, 4Paris-Descartes University, Paris, France

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II 1284. Impact of Etanercept Therapy on Glycemic Control in a Cohort of Psoriatic Patients: The PRISTINE Trial. Andrew S. Koenig, Annette Szumski, Ronald Pedersen and Debbie H. Robertson, Pfizer Inc., Collegeville, PA 1285. Long Term Results of a Remission Induction Approach to Early Axial Spondyloarthritis: Still Looking for the Window of Opportunity. Zoe R. Ash1, Nick Barkham1, Dennis McGonagle1, Elizabeth Hensor2, Paul Emery1 and Helena Marzo-Ortega1, 1University of Leeds, Leeds, United Kingdom, 2 NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom 1286. High Prevalence of Coronary Heart Disease and Its Risk Factors In Veterans with Spondyloarthritides. Trayton Mains, Suhail Kumar and Vikas Majithia, University of Mississippi Medical Center, Jackson, MS 1287. Clinical and Radiological Evaluation of Sacroiliac Joints (SIJ) Compared with Ultrasound (US) Examination in Early Spondiloarthritis. Francesca Bandinelli1, Daniela Melchiorre1, Francesco Scazzariello1, Antonio Candelieri2, Leonardo Giovannini1, Giuliana Salvadorini1, Francesco Porta1 and Marco Matucci-Cerinic1, 1University of Florence, Florence, Italy, 2University of Calabria, Cosenza, Italy 1288. Early Treatment of Psoriatic Arthritis Is Associated with Improved Outcomes: Findings From the Etanercept (Enbrel®) PRESTA Trial. Bruce W. Kirkham1, Wenzhi Li2,

Robert Boggs2, Henk Nab3 and Miriam Tarallo3, 1Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 2 Pfizer Inc., Collegeville, PA, 3Pfizer Europe, Rome, Italy 1289. Efficacy of a Shorter 6-Month Isoniazid treatment in Patients At High Risk for Tubercolosis Treated with Etanercept. Salvatore D’Angelo, Michele Gilio, Maria Stefania Cutro, Pietro Leccese, Angelo Nigro, Carlo Palazzi, Angela Padula and Ignazio Olivieri, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy 1290. Change in Back Pain Over Time As a Function of C-Reactive Protein Across Studies of Ankylosing Spondylitis. Wenzhi Li1, Michelle Stewart2 and Andrew S. Koenig1, 1Pfizer Inc., Collegeville, PA, 2Pfizer Inc., Groton, CT 1291. PASE Tool for Early Screening of Psoriatic Arthritis: Association with Disease Biomarkers and Score Cutoffs. M. Elaine Husni1, Abrar A. Qureshi2, Ronald Pedersen3, Andrew S. Koenig3 and Debbie H. Robertson3, 1Cleveland Clinic Foundation, Cleveland, OH, 2Brigham and Women’s Hospital, Boston, MA, 3Pfizer Inc., Collegeville, PA 1292. Impact of Ankylosing Spondylitis on Sick Leave, Presenteeism and Work Satisfaction in Turkish People. Emel Ozcan1, Ekin Sen1, Sina Esmaeilzadeh1, Aylin Rezvani2, Tugba Baysak1, Ayse Karan1 and Annelies Boonen3, 1 Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Vakif Gureba University Hospital, Istanbul, Turkey, 3 Rheumatology-Medicine, Maastricht, Netherlands 1293. Cardiovascular Outcome and High Dose Statin Treatment in Patients with Inflammatory Joint Disease. Anne Grete Semb1, Tore K. Kvien1, Rana Fayyad2, David A. DeMicco2, John LaRosa3, John Betteridge4, Terje R. Pedersen5 and Ingar Holme5, 1Diakonhjemmet Hospital, Oslo, Norway, 2Pfizer Inc, New York, 3State University of New York health Science Centre, New York, 4Middelsex Hospital, London, United Kingdom, 5Oslo University Hospital-Ullevaal, Oslo, Norway 1294. Epidemiologic Results of Early Rheumatologic Evaluations in a Cohort of Psoriatic Patients Complaining of MusculoSkeletal Symptoms. Gabriele De Marco1, Angelo Cattaneo2, Carlo Carrera2, Simona Tavecchio3, Massimo Ricci4, Claudio Fracchiolla5 and Antonio Marchesoni6, 1Istituto Ortopedico Gaetano Pini, Milano, Italy, 2Fondazione I. R. C. C. S. Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy, 3 Universita’ delgli Studi di Milano, Milano, Italy, 4Universita’ degli Studi di Milano, Milano, Italy, 5A. S. L. Desenzano del Garda, Desenzano del Garda, Italy, 6Rheumatology Unit, Ospedale G Pini, Milano, Italy 1295. Proposal for An Adaptation of the Berlin Algorithm for Diagnosing Spa: Results of the SPondyloArthritis Caught Early (SPACE)-Cohort. R. van den Berg, M. Reijnierse, T.W.J. Huizinga and D.M.F.M. van der Heijde, Leiden University Medical Center, Leiden, Netherlands

2011 Program Book

227

ACR/ARHP Poster Session B 1296. Patient-Perceived Impact of Psoriatic Arthritis Is Due to Pain and Fatigue, but Also to Psychological Aspects- the Psa Impact of Disease Study. Laure Gossec1, Maarten de Wit2, Andra Balanescu3, Peter V. Balint4, Gabor Békés4, Juergen Braun5, Juan D. Canete6, Laurence Carton7, Alina Dinte3, Kurt L. De Vlam8, Turid Heiberg9, Philip Helliwell10, Umut Kalyoncu11, Uta Kiltz12, Thomas Luger13, Mara Maccarone14, Ronan H. Mullan15, Dennis O’Sullivan15, Kati Otsa16, Andrew Parkinson17, Anselm Sanchez Lombarte6, Rossana Scrivo18, Josef Smolen19, Tanja A. Stamm20 and Tore K. Kvien21, 1 Cochin Hospital, Paris, France, 2Dutch Arthritis Patient League, Amersfoort, Netherlands, 3“Sf. Maria” Hospital, Bucharest, Romania, 4National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 5Ruhr-University Bochum, Herne, Germany, 6Hospital Clinic, Barcelona, Spain, 7 Cochin Hospital and Association Française de Lutte AntiRhumatismale, Paris, France, 8University Hospital, Leuven, Belgium, 9Ullevaal Univ Hospital, Oslo, Norway, 10NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 11 Hacettepe University Faculty of Medicine, Ankara, Turkey, 12 Rheumazentrum Ruhrgebiet, Herne, Germany, 13University Hospital Münster, Münster, Germany, 14Associazione per la Difesa degli Psoriasici, Rome, Italy, 15St Vincent’s University Hospital, Dublin, Ireland, 16Tallinn Central Hospital, Tallinn, Estonia, 17University of Leeds, Leeds, United Kingdom, 18 Reumatologia - Sapienza Università di Roma, Rome, Italy, 19Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 20Medical University of Vienna, Vienna, Austria, 21Diakonhjemmet Hospital, Oslo, Norway 1297. Fully Quantitative Syndesmophyte Measurement in Ankylosing Spondylitis Using Computed Tomography: Reliability of Volume and Height Measures. Sovira Tan1, Jianhua Yao1, John A. Flynn2, Lawrence Yao1 and Michael M. Ward3, 1NIH, Bethesda, MD, 2Johns Hopkins University, Baltimore, MD, 3NIAMS/NIH, Bethesda, MD 1298. Fully Quantitative Syndesmophyte Measurement in Ankylosing Spondylitis Using Computed Tomography: Validity of Volume and Height Measures. Sovira Tan1, Jianhua Yao1, John A. Flynn2, Lawrence Yao1 and Michael M. Ward3, 1NIH, Bethesda, MD, 2Johns Hopkins University, Baltimore, MD, 3NIAMS/NIH, Bethesda, MD 1299. Impact of TNFα, Infliximab, and Antibodies Toward Infliximab in AS Activities: Data From a Monocentric Crossectional Study. Elodie Constant1, Florence Chopin1, Béatrice Pallot-Prades1, Thierry Thomas1, Stéphane Paul2 and Hubert Marotte1, 1Inserm U1059, Saint-Etienne, France, 2 GIMAP, EA3064, University Hospital, Saint-Etienne, France 1300. Ultrasound Assessment of Enthesis Thickening in Psoriatic Arthritis Patients Treated with Adalimumab Compared to Methotrexate. Irena Litinsky1, Jonathan Wollman2, Alexandra Balbir-Gurman3, Uri Arad2, Daphna Paran4, Dan Caspi2 and Ori Elkayam2, 1Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty

228

2011 Program Book

of Medicine Tel Aviv University, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Rambam Health Care Campus, Haifa, Israel, 4Tel Aviv Souraski Medical Ctr, Tel Aviv, Israel 1301. Characterization of a Colombian Cohort of Patientes with Reactive Arthritis. Wilson Bautista-Molano1, John Londoño1, Consuelo Romero-Sanchez1, Paola Peña1, Ana Santos2 and Rafael Valle-Oñate1, 1Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana., Bogotá, Colombia, 2Facultad de Ciencias. Universidad de los Andes, Bogotá, Colombia 1302. Anti-TNFá Efficacy Against Spondyloarthropathy without Associated Imaging Signs. Aurélia Bisson-Vaivre1, JeanFrançois Menard1, Didier Alcaix2, Olivier Vittecoq1, Xavier X. Le Loet1, Charles Zarnitsky2 and Vincent Goeb1, 1Rouen University Hospital, Rouen, France, 2Le Havre General Hospital, Le Havre, France 1303. Continuance of Non-Steroidal Anti-Inflammatory Drugs May Reduce Radiographic Progression in Ankylosing Spondylitis Patients on Biological Therapy. Nigil Haroon1, Hua Shen2, Adele Carty3, Ammepa Anton3, Richard J. Cook2 and Robert D. Inman1, 1Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 2University of Waterloo, Waterloo, ON, 3 Toronto Western Hospital, Toronto, ON 1304. Anti-TNF Therapy and Malignancy in Spondyloarthropathythe Leuven Arthritis Biologics Register. Ine Westhovens, Rik Lories, Rene Westhovens, Patrick Verschueren and Kurt L. De Vlam, University Hospitals KULeuven, Leuven, Belgium 1305. Serum Biomarkers to Predict Clinical Response in Proof-of-Concept Trials in Spondyloarthritis. Maureen C. Turina, Nataliya Yeremenko, Jacqueline Paramarta, Bernard Vandooren, Paul-Peter Tak, Leen E. De Rycke and Dominique L. Baeten, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands 1306. Inflammation May Be Associated with An Unfavorable Lipid Profile in Psoriatic Arthritis Patients in the CORRONA Registry. Asena Bahce-Altuntas1, Julie S. SchwartzmanMorris1, Nicole Jordan1, Jeffrey D. Greenberg2, Chaim Putterman1, George Reed3 and Anna R. Broder1, 1Albert Einstein College of Medicine, Bronx, NY, 2New York University School of Medicine, New York, NY, 3UMass Medical School, Worcester, MA 1307. Comparison of Screening Instruments for Psoriatic Arthritis in Patients with Psoriasis. Jessica Walsh1, Daniel O. Clegg2 and Kristina Callis Duffin3, 1University of Utah Hospital, Salt Lake City, UT, 2University of Utah Medical Ctr, Salt Lake City, UT, 3University of Utah, Salt Lake City, UT 1308. Burden of Delay to Diagnosis of Ankylosing Spondylitis. Sarah E. Grigg, Belinda J. Martin, Russell R. Buchanan and Lionel Schachna, Austin Health, Melbourne, Australia

ACR/ARHP Poster Session B 1309. Serum IL-23 Does Not Correlate with Disease Activity in Spondyloarthritis. Hanna Przepiera-Bedzak, Iwona Brzosko, Katarzyna Fischer and Marek Brzosko, Pomeranian Medical University, Szczecin, Poland 1310. Effect of Weight, Body Mass Index and Weight-Based Dosing on Persistency of Anti-TNFs in Psoriatic Arthritis. Jeffrey D. Greenberg1, Rebecca Bolce2, Ying Shan3, Katherine C. Saunders4, George Reed3, Joel M. Kremer5 and Dennis Decktor2, 1New York University School of Medicine, New York, NY, 2Janssen Services, LLC, Horsham, PA, 3 UMass Medical School, Worcester, MA, 4CORRONA, Inc., Southborough, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY 1311. Correlation Biomarkers of Cartilage and BONE Turnover with DISEASE ACTIVITY, Function, QUALITY of LIFE, Radiology and MAGNETIC RESONANCE Imaging IN PATIENTS with EARLY Spondiloarthritis. Raquel Almodovar1, Valeria Ríos2, Sara Ocaña1, Milena Gobbo3, Marisa Casas1, Pedro Zarco4 and Xavier Juanola-Roura5, 1Hospital Universitario Fundación Alcorcón, Alcorcon. Madrid, Spain, 2 Hospital universitario Belvitge,, Barcelona, Spain, 3Spanish Society of Rheumatology, Madrid, Spain, 4Fundación Hopsital Alcorcon, Alcorcon, Madrid, Spain, 5Hospital Universitario de Bellvitge, Barcelona, Spain 1312. Effect of Adalimumab on Function, Health-Related Quality of Life, Work Productivity, and Daily Activities in Patients with Non-Radiographic Axial Spondyloarthritis. Walter P. Maksymowych1, Philip J. Mease2, Sumati Rao3, Aileen Pangan3, L. Steven Brown3, Vipin Arora3 and Mary A. Cifaldi3, 1 University of Alberta, Edmonton, AB, 2Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 3Abbott Laboratories, Abbott Park, IL 1313. Are High Titers of Anti-CCP Antibodies in Psoriatic Arthritis Patients a Biomarker of Erosive Disease? Ignacio GarciaValladares1, Raquel Cuchacovich1, Antonio A. IglesiasGamarra2 and Luis R. Espinoza1, 1Louisiana State University, New Orleans, LA, 2Universidad Nacional, Bogota, Colombia 1314. Does the Change in Season Affect Disease Outcomes in Patients with Psoriatic Arthritis? Zahi Touma1, Arane Thavaneswaran2, Vinod Chandran1 and Dafna D. Gladman2, 1 Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 1315. Changes in Psychological Status in Patients with Chronic Spondyloarthropathy Treated with Infliximab. Rosa M. Morlà1, Hector Corominas2, M. V. Hernandez3, Mireia Moreno4, Miquel Sala5, Vera Ortiz-Santamaria6, Patricia Reyner6, Vicente Torrente-Segarra Jr.7, Agusti Sellas Fernandez8, Georgina Salvador9, Elena Sirvent10, Cristina Masuet11 and Xavier Juanola-Roura12, 1Hospital Sta Tecla, Tarragona, Spain, 2Hospital Moises Broggi, Barcelona, 3 Hospital Clinic of Barcelona, Barcelona, Spain, 4Servei de Reumatologia, Sabadell, Spain, 5Rheumatology Unit, Figueres, Spain, 6Unitat de Reumatologia, Spain, 7Hospital

General de Hospitalet, Barcelona, Spain, 8Senior Consultant, Barcelon, Spain, 9Hospital Mutua de Terrassa. Barcelona, Barcelona, Spain, 10Hospital de Sant Boi, 11Hospital de Bellvitge, Hospitalet de LLobregat, Spain, 12Hospital Universitario de Bellvitge, Barcelona, Spain 1316. Antibody Response to the Standard Hepatitis B Vaccination in Patients with Rheumatoid Arthritis and Ankylosign Spondylitis Treated with Infliximab. María Montoro Álvarez Sr.1, Carlos Gonzalez Fernandez Sr.2 and Ainhoa Gonzalez Expósito Sr.2, 1Gregorio Marañón Hospital, Madrid, Spain, 2 Gregorio Maranon Hospital, Madrid, Spain 1317. Clinical and Radiological Manifestations of Ankylosing Spondylitis: Gender Differences. Fernando PimentelSantos1, Ana F. Mourão2, Célia Ribeiro1, José Costa3, Helena Santos4, Anabela Barcelos5, Patricia Pinto6, Fátima Godinho7, Margarida Cruz8, Elsa Vieira-Sousa9, Jorge Félix10, J. E. Fonseca11, Henrique Guedes-Pinto12 and Jaime C. Branco1, 1 Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, 2Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, Lisbon, Portugal, 3Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, 4 Instituto Português de Reumatologia, Lisboa, Portugal, 5 Hospital Infante D. Pedro, 6Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, 7Hospital Garcia de Orta, 8Centro Hospitalar Oeste Norte, Centro Hospitalar das Caldas da Rainha, 9Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 10 EXIGO Consultores, 11Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 12 Universidade de Trás-os-Montes e Alto Douro 1318. Anti-TNF Agents May Accelerate the Remodeling of Hip Cartilage in Ankylosing Spondylitis. Sang-Hoon Lee1, Jaeho Choi1, Somi Kim2, Ran Song1, Yeon-Ah Lee2, Seung-Jae Hong2 and Hyung-In Yang3, 1Medical Center at Gangdong, School of Medicine, Kyung Hee University, Seoul, South Korea, 2Kyung Hee University, Seoul, South Korea, 3Kyung Hee University Hospital at KANGDONG, Kyung Hee University, Seoul, South Korea 1319. Evaluation of Circulating Endothelial and Platelet Microparticles In Men with Ankylosing Spondylitis. Ismail Sari1, Giray Bozkaya2, Halil Kirbiyik2, Ahmet Alacacioglu2, Halil Ates1, Gulten SOP2, Gercek Sen3, ALI Taylan4, Ozden Piskin1, Yasar Yildiz2 and Nurullah Akkoc1, 1DOKUZ EYLUL UNIVERSITY SCHOOL OF MEDICINE, Izmir, Turkey, 2IZMIR BOZYAKA TRAINING AND RESEARCH HOSPITAL, Izmir, Turkey, 3IZMIR ATATURK TRAINING AND RESEARCH HOSPITAL, Izmir, Turkey, 4 IZMIR TEPECIK TRAINING AND RESEARCH HOSPITAL, Izmir, Turkey

2011 Program Book

229

ACR/ARHP Poster Session B 1320. Diagnostic Utility of Sacroiliac Joint MRI in NonRadiographic Spondyloarthritis: Validation of Three Assessment Methods in Two Inception Cohorts. Ulrich Weber1, Veronika Zubler2, Susanne Juhl Pedersen3, Stanley Chan1, Kaspar Rufibach4, Robert GW Lambert1 and Walter P. Maksymowych1, 1University of Alberta, Edmonton, AB, 2Balgrist University Hospital, Zurich, Switzerland, 3 Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 4University of Zurich, Zurich, Switzerland 1321. Multifocal Inflammatory Lesions in Ankylosing Spondylitis Patients Depicted by Whole Body MRI (WBMRI) Improve by a One Year Therapy with Etanercept. Martina Karpitschka1, Daniel Theisen1, Annie Horng1, Christian Glaser1, Maximilian Reiser1, Sabine Weckbach1 and Herbert Kellner2, 1Munich, Germany, 2Centre for Inflammatory Joint Diseases, Munich, Germany 1322. Improvement in Ankylosing Spondylitis Disease Activity Score in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor-Alpha Blocking Therapy. Suzanne Arends1, Eveline van der Veer1, Pieternella M. Houtman2, Martha K. Leijsma1, Cees G.M. Kallenberg1, Elisabeth Brouwer1 and Anneke Spoorenberg2, 1University Medical Center Groningen, Groningen, Netherlands, 2Medical Center Leeuwarden, Leeuwarden, Netherlands 1323. European SCORE May Underestimate the Cardiovascular Risk in Psoriatic Arthritis: Comparison of Two Indexes and Related Variables. César Magro-Checa, José L. RosalesAlexander, Juan Salvatierra Sr., Jesús Cantero-Hinojosa, Jose Gonzalez-Dominguez and Enrique Raya-Alvarez, University Hospital San Cecilio, Granada, Spain 1324. The Relation Between Daily Physical Activity Measured with the Accelerometer and Clinical Assessments in Patients with Ankylosing Spondylitis. Suzanne Arends1, Marianne Hofman1, Yvo P.T. Kamsma1, Eveline van der Veer1, Martha K. Leijsma1, Pieternella M. Houtman2, Cees G.M. Kallenberg1, Anneke Spoorenberg2 and Elisabeth Brouwer1, 1University Medical Center Groningen, Groningen, Netherlands, 2Medical Center Leeuwarden, Leeuwarden, Netherlands 1325. The effectiveness of Leflunomide in Psoriatic Arthritis. Alhussain Asiri1, Arane Thavaneswaran2, Vinod Chandran1, Gideon Kalman-Lamb1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2 Toronto Western Hospital, University of Toronto, Toronto, ON 1326. Validation of the Patient Acceptable Work State: Establishing Thresholds for Patient-Reported Outcomes in a Longitudinal, Observational Study in Patients with Ankylosing Spondylitis. Walter P. Maksymowych1, Sumati Rao2, Annelies Boonen3, Naijun Chen4 and Mary A. Cifaldi2, 1 University of Alberta, Edmonton, AB, 2Abbott Laboratories, Abbott Park, IL, 3University Hospital Maastricht, Maastricht, Netherlands, 4Abbott Laboratories, Abbott Park, Illinois, Abbott Park, IL

230

2011 Program Book

1327. The Predictors of Infection in Psoriatic Arthritis - Results From a Longitudinal Observational Cohort. Amir Haddad1, Arane Thavaneswaran2, Vinod Chandran1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 1328. A Retrospective Analysis of Anti-TNF Treatment of 146 Ankylosing Spondylitis Patients According to Gender. Yasemin Yalcinkaya, Özlem Pehlivan, Ahmet Omma, Bahar Artim-Esen, Burak Erer, Nihat Hüseyinsinoglu, Sevil Kamali, Murat Inanc, Orhan Aral, Ahmet Gul and Lale Ocal, Istanbul University, Istanbul Faculty of Medicine,, Istanbul, Turkey 1329. Differences in Clinical and Inflammation Outcomes in Patients with Axial Spondyloarthritis of Shorter and Longer Disease Duration After One Year Treatment with Etanercept. Anja Weiß1, In-Ho Song2, Kay-Geert Hermann3, Christian Althoff3, Bruce Freundlich4, Martin Rudwaleit5, Joachim Listing1 and Joachim Sieper6, 1German Rheumatism Research Centre, Berlin, Germany, 2Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 3 Charite Medical School, Berlin, Germany, 4University of Pennsylvania, Philadelphia, PA, 5Ev. Krankenhaus HagenHaspe, Hagen, Germany, 6Charité – Campus Benjamin Franklin, Berlin, Germany 1330. Profiling NSAID Responders in Ankylosing Spondylitis. Khalid A. Alnaqbi1, Nigil Haroon2, Hua Shen3, Richard J. Cook3, Adele Carty4 and R. D. Inman5, 1Toronto Western Hospital- EW 1-420, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON, 3University of Waterloo, Waterloo, ON, 4Toronto Western Hospital, Toronto, ON, 5The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON 1331. Serum Kallikreins As Biomarkers in Psoriatic Disease. Azza Eissa1, Dafna D. Gladman2, Arane Thavaneswaran2, Fawnda Pellett3, Eleftherios Diamandis1 and Vinod Chandran3, 1 Mount Sinai Hospital, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON, 3Toronto Western Hospital and University of Toronto, Toronto, ON 1332. Comparison Between Psoriasis and Psoriatic Arthritis in An International Cohort. Dafna D. Gladman1, Renise Ayearst2, Vinod Chandran2, Jan P. Dutz3, John T. Elder4, Christopher T. Ritchlin5, Cheryl Rosen2 and Proton Rahman6, 1 Toronto Western Hospital, University of Toronto, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3Univ of BC, Vancouver, BC, 4University of Michigan, Ann Arbor, 5University of Rochester Medical Center, Rochester, NY, 6St. Claires Mercy Hospital, St. Johns, NF 1333. Prevalence of Autoimmune Diseases and Other Comorbidities in Patients with Psoriatic Arthritis in the United States. Frank Zhang1, Annie Guerin2, Genevieve Gauthier2, Robert Day1 and Zeba Khan1, 1Celgene Corporation, Summit,, NJ, 2Analysis Group, Inc., Montreal, QC

ACR/ARHP Poster Session B 1334. Does Clinical Examination Underestimate Joint Inflammation In Patients with Psoriatic Arthritis? Dafna D. Gladman1, Richard J. Cook2, Lihi Eder1, Anupam Wakhlu3, Claire Riddell4, Mikkel Ostergaard5, Arane Thavaneswaran1 and Vinod Chandran1, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2University of Waterloo, Waterloo, ON, 3CSM Medical University, Lucknow, India, 4Antrim Area Hospital, Northern Health and Social Care Trust, Antrim BT41 2RL, Northern Ireland, Ireland, 5Copenhagen University Hospital at Glostrup, Glostrup, Denmark 1335. The Natural Course of Radiographic Progression in Ankylosing Spondylitis – Differences Between Genders and Appearance of Characteristic Radiographic Features. Xenofon Baraliakos1, Joachim Listing2, Anna von der Recke1 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2German Rheumatism Research Centre, Berlin, Germany 1336. Comparative Analysis of Outcomes in Ankylosing Spondylitis: 6 Year Data From the DISTILLER Biologic Registry. Leonard C. Harty, Ciara A. Murray, Conor Fearon, Mairead Dockery, Ursula Fearon and Douglas J. Veale, Translation Rheumatology Research Group, Dublin, Ireland

Spondylarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster 1337. Association of Platelet Endothelial Cell Adhesion Molecule-1 and β1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis. Seung Cheol Shim, Donghyuk Sheen, Mi-Kyoung Lim, Jiyoung Kim, Soyoung Lee and Sangkwang Lee, Eulji University Hospital, Daejeon, South Korea 1338. Predictive and Protective Value of Biomarkers in Patients with Ankylosing Spondylitis Who Are At High Risk of Radiographic Spinal Progression. Denis Poddubnyy1, Kristina Conrad2, Gisela Ruiz-Heiland3, Uta Syrbe2, Hildrun Haibel2, Heiner Appel2, Martin Rudwaleit4, Georg Schett3 and Joachim Sieper2, 1Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 2Charité – Campus Benjamin Franklin, Berlin, Germany, 3University of ErlangenNuremberg, Erlangen, Germany, 4Ev. Krankenhaus HagenHaspe, Hagen, Germany 1339. Increased T Cell Receptor Clonotype Sharing Among Ankylosing Spondylitis Patients Revealed by Deep Repertoire Sequence Analysis. Malek Faham1, Victoria Carlton1, Martin Moorhead1, Jianbiao Zheng1, Tom Asbury1 and R. D. Inman2, 1Sequenta, Inc., San Francisco, CA, 2The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON 1340. Family-Based Association Study of SPA3, a New Susceptibility Locus for Spondyloarthritis on 6p11-q11. Félicie Costantino1, Brigitte Izac1, Gilles Chiocchia2, Roula Said-Nahal3, Ariane Leboime3, Elena Zinovieva1, Diana Zelenika4, Maxime A. Breban3 and Henri-Jean Garchon1,

Institut Cochin, Paris, France, 2Institut Cochin, 75014 Paris, France, 3Ambroise Paré Hospital, Boulogne-Billancourt, France, 4Centre National de Génotypage, Evry

1

1341. Highly Expressed HLA-B27 Accumulate in Subcellular Vesicular Compartments and Form Oligomers That Behave Differently From HLA-B7. Cindy Jeanty1, Adèle Sourisce1, Aurore Wielgosik1, Maxime A. Breban2 and Claudine André1, 1 Institut Cochin, 75014 Paris, France, 2Hopital Ambroise Pare, Boulogne, France 1342. Exacerbated Uveitis in the Context of IFN-Gamma Deficiency Is Ameliorated by Blockade of the Th17 Response in a murine model of Proteoglycan-Induced Arthritis and Spondylitis. Holly L. Rosenzweig1, Jelena M. Kezic1, Michael P. Davey2, Stephen R. Planck1, Tibor T. Glant3 and James T. Rosenbaum1, 1Oregon Health & Science University, Portland, OR, 2Veterans Affairs Medical Center, Portland, OR, 3Rush University Medical Center, Chicago, IL 1343. Identification of Immunogenic HLA-B*27:05 Restricted Peptides of Salmonella Outer Membrane Protein (OMP) in Patients with Reactive Arthritis and Undifferentiated Spondyloarthropathy. Ramnath Misra1, Amit Singh1 and Amita Aggarwal2, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Additional Professor Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India 1344. Endoplasmic Reticulum Aminopeptidase 1 Interaction with Human Leukocyte Antigen B27 Influences the Unfolded Protein Response. Nigil Haroon1, Aifeng Lin2, Ali Akram1 and Robert D. Inman1, 1Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 2Toronto Western Research Institute and University Health Network, Toronto, ON 1345. Phenotype of Resting and Activated Monocyte-Derived Dendritic Cells Grown From Peripheral Blood of Patients with Ankylosing Spondylitis. Gleb Slobodin1, Aharon Kessel1, Natalia Kofman2, Elias Toubi1, Itzhak A. Rosner1 and Majed Odeh1, 1Bnai Zion Medical Center, Haifa, Israel, 2 Technion, Haifa, Israel 1346. Chondrocalcin, C-Terminal Propeptide of Type II Collagen, Can Be Found in Sclerotic Lesions of Spine and Its Gene Expression Is Significantly Increased in Patients with Ankylosing Spondylitis. Yong-Jin Kwon, Tae-Yeon Kim, SangWon Lee, Yong-Beom Park, Soo Kon Lee and Min-Chan Park, Yonse University College of Medicine, Seoul, South Korea 1347. Serial Ultrasonography Documents New Bone Formation At Entheses in Spondyloarthritis. Ralf G. Thiele1, Bethany A. Marston1, Darren Tabechian2, Allen P. Anandarajah3 and Christopher T. Ritchlin4, 1University of Rochester, Rochester, NY, 2Univ of Rochester Schl of Med, Rochester, NY, 3Univ of Rochester Medical Ctr, Rochester, NY, 4University of Rochester Medical Center, Rochester, NY

2011 Program Book

231

ACR/ARHP Poster Session B 1348. Syndesmophyte Formation Is Associated with Low-Grade Spine Inflammation and Disconnected From Peripheral Arthritis in Mice Immunized with Recombinant Human Aggrecan G1 Domain. Mohamed Ramez, Toni S. Forde, Elena Kudryavtseva and Vyacheslav A. Adarichev, Albert Einstein College of Medicine, Bronx, NY

and Human Leukocyte Antigen B27 Presenting Abnormal Peptides. Nigil Haroon and Robert D. Inman, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON

1349. Transition From a Cartilage Phenotype Into Bone in the Intervertebral Disc End Plate in Ageing Mice: Role for Bone Morphogenetic Protein 2. Esmeralda N. Blaney Davidson1, Elly Vitters2, Wim B. van den Berg1 and Peter M. van der Kraan1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands

1356. GDF15, a Distinct TGFb Family Member, Is Differentially Regulated in Spondyloarthritides Compared to Other Rheumatic Diseases. Stijn Lambrecht1, Julie Coudenys1, Filip De Keyser2, Gust Verbruggen3, Dieter Deforce4 and Dirk Elewaut5, 1Ghent University, Ghent, Belgium, 2Universitair Ziekenhuis Gent, Gent, Belgium, 3Universitair Ziekenhuis, B-9000 Gent, Belgium, 4Laboratory for Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium, 5Gent University Hospital, Ghent, Belgium

1350. Simultaneous but Spatially Distinct Occurrence of Inflammation, Tissue Destruction and Osteoproliferation in the HLA-B27/Human beta2 Microglobulin Transgenic Rat Model of Spondyloarthritis. Leonie M. van Duivenvoorde1, Martha L. Dorris2, Nimman Satumtira2, Paul P. Tak1, Joel D. Taurog2 and Dominique L. Baeten1, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2 UT Southwestern Medical Center, Dallas, TX

1357. Extended Haplotypes Between Human Leukocyte Antigen C and Tumour Necrosis Factor A Gene Loci Reveal Psoriatic Arthritis Susceptibility Hotspots. Remy Pollock1, Fawnda Pellett2, Renise Ayearst2, Al Amin P. Rahman3, Dafna D. Gladman1 and Vinod Chandran2, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3Memorial University, St Johns, NE

1351. Inhibition of IL-17 by Antibody Administration Improves Onset of Tarsal Ankylosis In a Murine Model. Shin Ebihara and Masao Ono, Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan

1358. Synovial Cytokine Expression in Psoriatic Arthritis and Associations with Lymphoid Neogenesis and Clinical Features. Raquel Celis1, Raimon Sanmarti1, Julio Ramirez2, Antonio Palacin2, Jose L. Pablos3 and Juan D. Cañete4, 1Clinic Hospital, Barcelona, Spain, 2Hospital Clinic, Barcelona, Spain, 3Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 4Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain

1352. HLA Associations Reveal Genetic Heterogeneity in Psoriatic Arthritis and in the Psoriasis Phenotype. Robert Winchester1, Gregory Minevich1, Valeria Steshenko1, Brian Kirby2, David Kane3, David A. Greenberg4 and Oliver M. FitzGerald2, 1Columbia University, New York, NY, 2St. Vincent’s University Hospital, Dublin, Ireland, 3Adelaide, Meath hospital Dublin (incorporating the National Children’s hospital), Dublin 24, Ireland, 4Mailman School of Public Health Columbia University, New York City, NY 1353. Differential Human Leukocyte Allele Association Between Psoriasis and Psoriatic Arthritis – A Family-Based Association Study. Lihi Eder1, Fawnda Pellett2, Vinod Chandran2, Sutharshini Shanmugarajah2, Shelley Bull3 and Dafna D. Gladman1, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3Mount Sinai Hospital, Toronto, ON 1354. Enhanced Expression of KIR3DL2 in Natural Killer and CD3/ CD4 Positive T Cells of Ankylosing Spondylitis Patients Compared to HLA-B*2705 or B*2709 Healthy Subjects. Alberto Cauli1, Grazia Dessole1, Giovanni Porru1, Alessandra Vacca1, Matteo Piga1, Valentina Ibba1, Pietro Garau1, Simon Kollnberger2 and Alessandro Mathieu1, 1University of Cagliari, Cagliari, Italy, 2Weatherall Institute of Molecular Medicine, Oxford, United Kingdom 1355. Binding of Killer Immunoglobulin Receptors 3DL1 and 3DL2 Is Associated with Surface Expression of Major Histocompatibility Complex Class I Free Heavy Chains

232

2011 Program Book

1359. Immunopathogenic Role of IL-22 and Its Receptor In Psoriatic Arthritis: Synergistic Effect of IL-22 and TNF-á In FLS Proliferation. Siba P. Raychaudhuri1, Anupam Mitra2, Ananya Datta Mitra3 and Smriti K. Raychaudhuri3, 1 Sacramento VA Medical Center/ UC Davis School of Medicine, Mather, CA, 2UC Davis School of Medicine/VA Sacramento Medical Center, Mather, CA, 3VA Sacramento Medical Center, Mather, CA 1360. Association Between Human Leukocyte Antigen and KillerCell Immunoglobulin-Like Receptor Gene Variants and Type II Psoriasis and Dactylitis in Psoriatic Arthritis. Vinod Chandran1, Fawnda Pellett1, Arane Thavaneswaran1, Remy Pollock1, Renise Ayearst1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2 Toronto Western Hospital, University of Toronto, Toronto, ON 1361. Investigating the Association Between Endoplasmic Reticulum Aminopeptidase 1 Gene Variants and Psoriatic Arthritis. Vinod Chandran1, Fawnda Pellett2, Remy Pollock1, Al Amin P. Rahman3 and Dafna D. Gladman1, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2 Toronto Western Hospital and University of Toronto, Toronto, ON, 3Memorial University, St Johns, NE

ACR/ARHP Poster Session B 1362. The Association Between Human Leukocyte Antigen and Killer-Cell Immunoglobulin-Like Receptor Gene Variants and the Development of Arthritis Mutilans in Patients with Psoriatic Arthritis. Vinod Chandran, Arane Thavaneswaran, Fawnda Pellett and Dafna D. Gladman, Toronto Western Hospital, University of Toronto, Toronto, ON 1363. The Association Between Human Leukocyte Antigen and Killer-Cell Immunoglobulin-Like Receptor Gene Variants and the Development of Axial Arthritis Among Patients with Psoriatic Arthritis. Vinod Chandran, Arane Thavaneswaran, Fawnda Pellett and Dafna D. Gladman, Toronto Western Hospital, University of Toronto, Toronto, ON 1364. Family Based Association Study Confirms Human Leukocyte Antigen Allele Associations with Psoriatic Arthritis. Vinod Chandran1, Fawnda Pellett1, Proton Rahman2 and Dafna D. Gladman1, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2St. Claires Mercy Hospital, St. Johns, NF 1365. Proteomic Profiling of Synovial Fluid for the Identification of Psoriatic Arthritis Soluble Biomarkers. Daniel Cretu1, Dafna D. Gladman2, Fawnda Pellett3, Eleftherios Diamandis1 and Vinod Chandran3, 1Mount Sinai Hospital, Toronto, ON, 2 Toronto Western Hospital, University of Toronto, Toronto, ON, 3Toronto Western Hospital and University of Toronto, Toronto, ON 1366. Association of ERAP1, IL12B and IL23R Gene Polymorphisms with Subphenotypes of Psoriatic Arthritis. Deepak Jadon1, William Tillett1, Dinny Wallis1, Charlotte Cavill2, Anna Dixon2, Nicola Waldron1, Eleanor Korendowych1, Anne Barton3 and Neil J. McHugh1, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Bath Institute for Rheumatic Disease, Bath, United Kingdom, 3University of Manchester, Manchester, United Kingdom

Systemic Lupus Erythematosus - Clinical Aspects II 1367. Clinical and Laboratory Correlates in Responders (by the Systemic Lupus Erythematosus Responder Index) in Phase 3 Belimumab Clinical Trials. R.A. Furie1, Z.J. Zhong2, W. Freimuth2 and M. Petri3, 1North Shore-LIJ Health System, Lake Success, NY, 2Human Genome Sciences, Inc., Rockville, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD 1368. Retrospective Validation of the 3 Laboratory Organ Systems of Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Responder Index (SRI-50) Over 10 Years. Zahi Touma1, Dafna D. Gladman2, Dominique Ibanez1 and Murray B. Urowitz1, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 1369. Responders in the Phase 3 Belimumab Clinical Trials in Patients with Systemic Lupus Erythematosus Reported Improvements in Fatigue and Health-Related Quality of Life At Week 52. V. Strand1, S. Cooper2, Z.J. Zhong2 and

G. Dennis2, 1Stanford University, Palo Alto, CA, 2Human Genome Sciences, Inc., Rockville, MD 1370. Early Systemic Lupus Erythematosus Specific Antigens Predict Disease Characteristics. Jessica J. Hale1, Jennifer A. Kelly1, Chee Paul Lin1, Stuart B. Glenn1, Jourdan Anderson1, Patrick M. Gaffney2, Kathy L. Moser2, John B. Harley3, Judith A. James4 and Courtney G. Montgomery1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3 Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 4Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK 1371. Inefficient Strategic Planning with Compensatory Recruitment of Neural Pathway for Conflict Processing and Error Detection Despite Sufficient Disease Control in Patients with New Onset Systemic Lupus Erythematosus: A Prospective Functional MRI Study. Anselm Mak1, Tao Ren2, Erin Hui yun Fu1, Alicia AC Cheak1 and Roger CM Ho1, 1 National University of Singapore, Singapore, Singapore, 2 National University of Singapore, Sinagpore, Singapore 1372. The Effects of Smoking on Age of Onset, Autoantibodies and Interferon- α in Systemic Lupus Erythematosus. Kimberly Smith, Stephanie L. Green, Daniel F. Brandt, Beverly S. Franek, Timothy B. Niewold and Tammy O. Utset, University of Chicago, Chicago, IL 1373. 25-Hydroxyvitamin D Levels Are Inversely Correlated with Systemic Lupus Erythematosus Disease Activity Index, but Are Not Associated with Relapse-Free Survival During Six Months Follow-up of 171 Patients Included in a French Prospective Multicentric Cohor. Yoland Schoindre1, Moez Jallouli2, Benjamin Terrier3, Marie-Laure Tanguy2, Zahir Amoura2, Jean-Charles Piette2, Patrice Cacoub2, Jean-Claude Souberbielle4, Nathalie Costedoat-Chalumeau2 and The group PLUS5, 1Foch Hospital, Suresnes, France, 2CHU PitiéSalpêtrière, Paris, France, 3Pitié-Salpêtrière Hospital, Paris, France, 4CHU Necker, Paris, France, 5Paris 1374. Association of Discoid Lupus with Clinical Manifestations and Damage Accrual in PROFILE: A Multiethnic Lupus Cohort. Yesenia C. Santiago-Casas1, Luis M. Vila1, G. McGwin Jr.2, Michelle Petri3, Rosalind Ramsey-Goldman4, John D. Reveille5, Robert P. Kimberly2, Graciela S. Alarcon2 and Elizabeth E. Brown6, 1University of Puerto Rico Medical Sciences Campus, San Juan, PR, 2University of Alabama at Birmingham, Birmingham, AL, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5 University of Texas Health Science Center at Houston, Houston, TX, 6Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

2011 Program Book

233

ACR/ARHP Poster Session B 1375. Anti-C1q Antibody in Systemic Lupus Erythematosus. Ana-Maria Orbai1, Gunnar K. Sturfelt2, Ola Nived3, Hong Fang1, Graciela S. Alarcón4, Caroline Gordon5, Joan T. Merrill6, Paul R. Fortin7, Ian N. Bruce8, David A. Isenberg9, Daniel J. Wallace10, Rosalind Ramsey-Goldman11, SangCheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University Hospital Lund, Lund, Sweden, 3University Hospital, Lund, Sweden, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Birmingham, Birmingham, United Kingdom, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Toronto Western Hospital, Toronto, ON, 8A, Manchester, United Kingdom, 9University College London, London WC1E 6JF, United Kingdom, 10Cedars-Sinai/UCLA, Los Angeles, CA, 11 Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14University Health Network/Mount Sinai Hospital, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago 1376. Comparison of Health-Related Quality of Life, Disease Damage, Disability, Age and Disease Duration in Pediatric Lupus Across Different Continents: An Expanded Sample. Lakshmi N. Moorthy1 and the International SMILEY Collaboprative Group2, 1Robert Wood Johnson Medical School-UMDNJ, New Brunswick, NJ, 2New Brunswick 1377. Systemic Lupus Erythematosus (SLE) and Vitamin D (Vit D) Deficiency Are Associated with Shorter Telomere Length. Brett M. Hoffecker1, Laura M. Tonks2, Tamara K. Nowling1 and Diane L. Kamen1, 1Medical University of SC, Charleston, SC, 2UNC Chapel Hill, NC 1378. Systemic Lupus Erythematosus Responder Index Assessment of Responders in EMBLEM, a Phase IIb Study in Patients with Moderate to Severe Systemic Lupus Erythematosus. Michelle Petri1, Marilyn C. Pike2, Lexy Kelley3, Brian Kilgallen4 and Caroline Gordon5, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2 Med Pharm Consulting Inc, Cambridge, MA, 3UCB, Smyrna, GA, 4UCB, Brussels, Belgium, 5Medical School, Birmingham, United Kingdom

234

2011 Program Book

1379. Corticosteroid Use and Associated Risk of Adverse Events in Patients with Systemic Lupus Erythematosus: A Retrospective Claims Analysis. Manan Shah1, Sham Chaudhari1, Trent McLaughlin1, Hong Kan2, Benno Bechtel3 and Charles T. Molta4, 1Xcenda, LLC, Palm Harbor, FL, 2GlaxoSmithKline, Research Triangle Park, NC, 3 GlaxoSmithKline, Munich, Germany, 4GlaxoSmithKline, Philadelphia, PA 1380. Prevalence and Associated Factors for Asymptomatic Pulmonary Arterial Hypertension in Patients with Systemic Lupus Erythematosus. Ki-Jo Kim1, Ji-Young Kim2, Su-Jung Park2, Hosung Yoon3, Yun-Jung Park4, Chong-Hyeun Yoon1, Jin-Jung Choi5, Wan-Uk Kim6 and Chul-Soo Cho1, 1College of Medicine, Catholic University of Korea, Seoul, South Korea, 2Research Institute of Bone & Joint Diseases, Catholic University of Korea, Seoul, South Korea, 3The Catholic University, Incheon, South Korea, 4The Catholic University of Korea, Suwon, South Korea, 5CHA University, Bundang CHA General Hospital, Seongnam, South Korea, 6St. Vincent’s Hospital, Suwon, South Korea 1381. Feasibility of Implementing a Lifestyle Intervention and Its Effects on Metabolic Parameters and Adipokines in Overweight and Obese Patients with Systemic Lupus Erythematosus. Nehal Shah1, Amy D. Rickman2, Anne E. Mishler2, Nicole L. Wilson3, John M. Jakicic2, Susan Manzi4 and Amy H. Kao4, 1University of Pittsburgh, Pittsburgh, PA, 2 University of Pittsburgh, PA, 3W Penn Allegheny Health System, Pittsburgh, PA, 4Allegheny Singer Research Institute, Pittsburgh, PA 1382. Renal Mir-150 As Potential Biomarker of Chronicity in Lupus Nephritis. Hua Zhou1, Sarfaraz A. Hasni2, Mayank Tandon1, Ilias Alevizos1, Howard A. Austin3, James E. Balow3 and Gabor G. Illei1, 1NIDCR, Bethesda, MD, 2NIH/NIAMS, Bethesda, MD, 3NIH/NIDDK, Bethesda, MD 1383. Prevalence of Direct Coombs Test in Systemic Lupus Erythematosus. Clinical and Immunologic Associations. Ana-Maria Orbai1, Hong Fang1, Graciela S. Alarcón2, Caroline Gordon3, Joan T. Merrill4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, SangCheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Birmingham, Birmingham, United Kingdom, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Toronto Western Hospital, Toronto, ON, 6A, Manchester, United Kingdom, 7University College London, London WC1E 6JF, United Kingdom, 8CedarsSinai/UCLA, Los Angeles, CA, 9University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden,

ACR/ARHP Poster Session B 11 Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14University Health Network/Mount Sinai Hospital, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago

1384. Predictors of Earlier Time to Renal Failure Among Those with Biopsy-Proven Lupus Nephritis. Alí Duarte-García1, Hong Fang1, Laurence S. Magder2 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of Maryland, Baltimore, MD 1385. Do Active Lupus Patients Continue to Improve At 12 Months by Systemic Lupus Erythematous Disease Activity Index 2000 Responder Index 50 (SRI-50)? Zahi Touma1, Murray B. Urowitz1, Dominique Ibanez1, Shahrzad TaghaviZadeh1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 1386. Lupus Disease Activity Does Not Improve Significantly in One System and Worsen in Another System. Zahi Touma1, Dafna D. Gladman2, Dominique Ibanez1, Shahrzad TaghaviZadeh1 and Murray B. Urowitz1, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 1387. Low Placebo Responses and Clinical Components of the Biomarkers of Lupus Disease (BOLD) Study May Provide Useful Insights for SLE Clinical Trial Design. Sudhakar T. Sridharan1, T. Zhou1, F. Immermann1, M. Lehmann1, J.L. Masferrer1, M. Honczarenko1, J.C. Rawdon2, J.A. James2 and J.T. Merrill2, 1Pfizer Inc, Collegeville, PA, 2Oklahoma Medical Research Foundation, Oklahoma City, OK 1388. Frequency and Characteristics of Prolonged Remission in Systemic Lupus Erythematosus. Amanda J. Steiman1, Murray B. Urowitz1, Dominique Ibanez1, Anjali Papneja2 and Dafna D. Gladman3, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2University of Toronto, Toronto, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON 1389. Comparison of the SF-36 Vs. Lupus Qol in Measuring Health-Related Quality of Life in Systemic Lupus Erythematosus Women with and without Activity. Claudia Mendoza-Pinto1, Mario Garcia-Carrasco Sr.1, Socorro Mendez-Martinez1, Oscar Pazarán1, Mario H. Cardiel2 and Aurelio Lopez-Colombo3, 1HGR 36 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Hospital, Morelia, Mexico, 3Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico

1390. Cognitive Dysfunction and Diffusion Tensor Imaging in Systemic Lupus Erythematosus. Elizabeth Kozora1, Aziz Ulug2, Doruk Erkan3, Glendalee Ramon3, An Vo4, Robert Zimmerman5, Emily Duggan1, JoAnn Vega3, Christopher Filley6 and Michael D. Lockshin3, 1National Jewish Health, Denver, CO, 2The Feinstein Institute for Medical Research, Manhasset, NY, 3Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY, 4The Feinstein Institute for Medical Reearch, Manhasset, NY, 5Weill Cornell Medical College, New York, NY, 6University of Colorado School of Medicine, Aurora, CO 1391. Impaired Responses to Aspirin in Patients with Systemic Lupus Erythematosus: The Role of Inflammation and Oxidative Stress. Vivian K. Kawai1, Ingrid B. Avalos2, Annette M. Oeser1, John A. Oates1, Ginger L. Milne1, Cecilia P. Chung3 and C. Michael Stein1, 1Vanderbilt University, Nashville, TN, 2 Harvard University, Boston, MA, 3Vanderbilt Medical Center, Nashville, TN 1392. Infection As a Predictor of Organ System Damage Accrual and/or Death in Systemic Lupus Erythematosus. Amanda Eudy1, Deanna Hill2, Qinggong Fu2, Hong Fang3 and Michelle Petri3, 1UNC Chapel Hill, Chapel Hill, NC, 2GlaxoSmithKline, Collegeville, PA, 3Johns Hopkins University School of Medicine, Baltimore, MD 1393. Low Prevalence of Use of ACEI/ARBS and Lipid Lowering Agents In African American(AA) SLE Patients. Asha Thomas, Madhu-Kalyan Pendurthi and Vikas Majithia, University of Mississippi Medical Center, Jackson, MS 1394. Population Pharmacokinetics of Sifalimumab, An Investigational Anti-Interferon-á Monoclonal Antibody, in Systemic Lupus Erythematosus Patients. Rajesh Narwal, Lorin Roskos, Wendy White, Warren Greth and Gabriel Robbie, MedImmune, Gaithersburg, MD 1395. Do Race/Ethnicity and Geography Affect Outcomes in An Inception Cohort of Patients with Systemic Lupus Erythematosus Followed for At Least 5 Years? D. D. Gladman1, Murray B. Urowitz1, Dominique Ibanez1, Nicole Anderson1 and Systemic Lupus International Collaborating Clinics (SLICC)2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto, ON 1396. Microstructural Abnormalities in White and Deep Gray Matter Visualized within the First Year of Diagnosis in Adolescents with SLE: A Pilot Magnetization Transfer Imaging Study. Eyal Muscal1, Elfrides Traipe1, Elisabeth Wilde1, Douglas R. Bloom1, Barry L. Myones1, Zili D. Chu1, Robin L. Brey2 and Jill Hunter1, 1Baylor College of Medicine, Houston, TX, 2UTHSCSA, San Antonio, TX 1397. Lupus and Body Image: An Intervention That Works. Meenakshi Jolly1, Kristin Peters2, Rachel A. Mikolaitis1, Kali Evans-Raoul3, Thomas F. Cash4 and Joel A. Block1, 1Rush University Medical Center, Chicago, IL, 2University of Missouri Health Care, Columbia, MO, 3The Image Studios, Chicago, 4Old Dominion University, Norfolk, VT

2011 Program Book

235

ACR/ARHP Poster Session B 1398. Clinical-Pathological Correlates of Proliferative Lesions in Lupus Nephritis. Claire Barber1, Murray B. Urowitz2, Dafna D. Gladman3, Joan E. Wither4, Carolina LandoltMarticorena2, Heather Reich5, Wendy Lou6, Jiandong Su7, Jonathan Yip8, Gan Qian6, David Thomas9, Samih Nasr10, Rohan John8, Ellie Aghdassi8 and Paul R. Fortin7, 1Mount Sinai Hospital, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON, 4Toronto Western Research Institute, University Health Network, Toronto, ON, 5The Toronto Western Hospital, Toronto, ON, 6 Dalla Lana School of Public Health, Toronto, ON, 7Toronto Western Hospital, Toronto, ON, 8University Health Network, Toronto, ON, 9Nephrocor, Long Island, NY, 10Division of Anatomic Pathology, Mayo Clinic, Rochester 1399. Chronicity Index, Especially Glomerular Sclerosis, Is An Independent Predictor of Renal Response Following Immunosuppressive Treatment in Patients with Lupus Nephritis. Dong-Jin Park1, Sung-Ji Lee1, Tae-Jong Kim2, Yong-Wook Park2 and Shin-Seok Lee1, 1Chonnam National University Medical School, Gwangju, South Korea, 2 Chonnam National University Medical School and Hospital, Gwangju, South Korea 1400. Asian Ethnicity Is Associated with Increased Disease Severity in An Urban Australian SLE Cohort. Alberta Y. Hoi, Vera Golder and Eric F. Morand, Monash University, Melbourne, Australia 1401. Incidence and Prevalence of Systemic Lupus Erythematosus in Buenos Aires, Argentina: A 11 Years Health Management Organization Based Study. Soledad M. Valeiras1, Martin F. Marchese1, Alejandro S. Talani1, Nicolas L. Avellaneda1, Alvaro Etchepare1, Patricio Etchepare1, Maria S. Plou1 and Enrique R. Soriano2, 1Instituto Universitario, Escuela de Medicina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina 1402. Long-Term Outcome of Lupus Nephritis in Asian Indians Using Standard Therapy. Varun Dhir, Amita Aggarwal, Able Lawrence, Vikas Agarwal and Ramnath Misra, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India 1403. Soluble Form of Herpesvirus Entry Mediator (HVEM) Is Elevated in Sera of Active Collagen-Vascular Diseases and Might Be a New Biomarker of Disease Activity. Satoko Arai, Kazuhiro Kurasawa, Harutsugu Okada, Takayoshi Ohwada, Reika Maezawa and Takeshi Fukuda, Dokkyo Medical University, Mibu-machi, Tochigi-ken, Japan 1404. Utility of IFN-á As Biomarker in Central Neuropsychiatric Involvement in SLE. Hilda Fragoso-Loyo, Yemil AtishaFregoso, Carlos Nuñez-Alvarez, Luis LLorente-Peters and Jorge Sánchez-Guerrero, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico

236

2011 Program Book

1405. Peripheral Arterial Disease in Systemic Lupus Erythematosus. Jose-Gabriel Erdozain1, Irama Villar2, Javier Nieto2, María-Victoria Egurbide2 and Guillermo RuizIrastorza2, 1Hospital de Mendaro, Mendaro, Spain, 2Hospital de Cruces, UPV/EHU, Barakaldo, Spain 1406. Characteristics of Disease Activity and Organ System Involvement in a Cohort of patients with Systemic Lupus Erythematosus Followed for More Than One Year. Marta Mosca1, Chiara Tani2, Linda Carli1, Grazia Maria Rizzelli1, Rossella Neri1, Antonio Tavoni3, Anna d’Ascanio4 and Stefano Bombardieri4, 1University of Pisa, Pisa, Italy, 2University of Pisa, Italy, 3Via Roma 67, Pisa, Italy, 4Rheumatology Unit, Pisa, Italy 1407. Medication Impact on Gene Expression Patterns May Depend on Biologic Subgroups in the Biomarkers of Lupus Disease (BOLD) Study. Margot O’Toole1, Ying Zhang1, Attila Seyhan1, Frederick W. Immermann2, Andrew A. Hill3, Padmalatha S. Reddy3, Sudhakar T. Sridharan2, Monique Lehmann2, Jaime L. Masferrer4, Tianhui Zhou2, William M. Mounts3, Maryann Whitley3, Terry Walker1, Stan Kamp5, Judith A. James6, Marek Honczarenko1 and Joan T. Merrill7, 1 Pfizer, Cambridge, MA, 2Pfizer Inc, Collegeville, PA, 3Pfizer, Cambridge, 4Pfizer Inc, Cambridge, MA, 5Oklahoma Medical Research Fund, Oklahoma City, 6Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 7Oklahoma Medical Research Foundation, Oklahoma City, OK 1408. Treatment Regimens of Patients Enrolled in the Lupus Clinical Trials Consortium (LCTC). Alana B. Levine1, Doruk Erkan2, Jill P. Buyon3 and Michael D. Lockshin2, 1Hospital for Special Surgery, New York, NY, 2Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, 3NYU School of Medicine, New York, NY 1409. Hydroxychloroquine-Induced Hyperpigmentation in Patients with Systemic Lupus Erythematosus. A Series of 23 Cases. Moez Jallouli, C. Francès, Jean-Charles Piette, Du Le Thi Huong, M. Miyara, D. Saadoun, A. Mathian, J. Haroche, C. De Gennes, G. Leroux, C. Chapelon, Bertrand Wechsler, Patrice Cacoub, Zahir Amoura and Nathalie CostedoatChalumeau, CHU Pitié-Salpêtrière, Paris, France 1410. Response to Hydroxychloroquine in Japanese Patients with Cutaneous Lupus Erythematosus Using the Cutaneous Lupus Erythematosus Disease Area and Severity Index. Naoto Yokogawa1, Takaharu Ikeda2, Kyo Aizawa3, Akiko Tanikawa4, Masayuki Amagai4, Yukihiko Kato5, Yoko Momose6, Satoru Arai6, Hikaru Eto6, Fukumi Furukawa2 and Japanese Hydroxychloroquine Study Group7, 1Tokyo Metropolitan Tama Medical Center, Section of Rheumatology, Tokyo, Japan, 2Wakayama Medical University, Department of Dermatology, Wakayama, Japan, 3 Sanofi-Aventis K.K. Biostatistics & Programming, Tokyo, Japan, 4Keio University School of Medicine, Department of Dermatology, Tokyo, Japan, 5Tokyo Metropolitan Tama

ACR/ARHP Poster Session B Medical Center, Section of Dermatology, Tokyo, Japan, 6St. Luke’s International Hospital, Department of Dermatology, Tokyo, Japan, 7Japan 1411. SLE and Sickle Cell Disease (SCD) As Comorbid Conditions. Asha Thomas, Madhu Kalyan Pendurthi, Robert W. McMurray and Vikas Majithia, University of Mississippi Medical Center, Jackson, MS 1412. Ultrasonographic Evaluation of Hand and Wrist in Systemic Lupus Erythematosus without Arthralgia. Hosung Yoon, The Catholic University, Incheon, South Korea 1413. Pregnancy Outcomes and Fetal Complications in Patients with Systemic Lupus Erythematosus:a Retrospective Analysis in Korea. Eun-Jung Park1, Jiwon Hwang1, Jaejoon Lee2, Joong Kyong Ahn3, Chan Hong Jeon4, Hoon-Suk Cha1 and Eun-Mi Koh1, 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2 Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, 3Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4Soonchunhyang University College of Medicine, Bucheon, South Korea 1414. Relationship Between Age of Onset and Clinical Profile In Systemic Lupus Erythematosus Patients. Julia Martínez-Barrio, Juan G. Ovalles, Francisco J. López-Longo, Inmaculada de la Torre, Lina Martínez-Estupiñán, Juan C. Nieto and Luis Carreño, Gregorio Marañón Hospital, Madrid, Spain 1415. Serum Cystatin C Is Affected by Inflammation and Renal Dysfunction in Patients with Systemic Lupus Erythematosus. Christine LY Chew1, Awal Al-M Husain1, Philip Pemberton2, Sahena Haque1, Allen Yates2 and Ian N. Bruce3, 1University of Manchester, Manchester, United Kingdom, 2Manchester Royal Infirmary, Manchester, United Kingdom, 3A, Manchester, United Kingdom 1416. Factors Associated with Belimumab Treatment Benefit: Results From Phase 3 Studies in Patients with Systemic Lupus Erythematosus. R.F. van Vollenhoven1, M. Petri2, R. Cervera3, C. Kleoudis4, Z.J. Zhong5, D. Roth6, W. Freimuth5 and BLISS-52 and BLISS-76 Study Groups7, 1The Karolinska Institute, Stockholm, Sweden, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Hospital Clinic, Barcelona, Spain, 4GlaxoSmithKline, Durham, NC, 5Human Genome Sciences, Inc., Rockville, MD, 6GlaxoSmithKline, King of Prussia, PA, 7Multicenter 1417. Towards a Quantitative Assessment of Renal Biopsies for Lupus Nephritis. Siddharth S. Samsi1, Brad H. Rovin2, Sara Cole3, Don Stredney1 and Wael N. Jarjour4, 1Ohio Supercomputer Center, Columbus, OH, 2Ohio State University Medical Center, Columbus, OH, 3The Ohio State University, Columbus, OH, 4Ohio State University, Columbus, OH

1418. The Relationship Between Pain Coping Skills and Pain, Fatigue, Mood, and Lupus Activity. Preethi Kurakula, Tamara J. Somers, Lisa G. Criscione-Schreiber, Francis J. Keefe and Megan E. B. Clowse, Duke University Medical Center, Durham, NC 1419. Memory Complaints in Lupus Patients: Relationship to Lupus Activity, Symptoms, Quality of Life, Psychological Distress, and Coping. Megan E. B. Clowse1, Lisa G. CriscioneSchreiber1, Meenakshi Jolly2, Francis J. Keefe1 and Tamara J. Somers1, 1Duke University Medical Center, Durham, NC, 2 Rush University Medical Center, Chicago, IL 1420. The Leiden Neuropsychiatric Systemic Lupus Erythematosus Clinic; Establishing Clinical Phenotypes. E. Zirkzee, G. Steup-Beekman, H. Middelkoop, E. Bollen, N. Van der Wee, E. Baptist, R. Van der Mast, M. Huisman, J. Luyendijk, M. Van Buchem and T. Huizinga, Leiden University Medical Center, Leiden, Netherlands 1421. Limited Value of Soluble Urokinase Plasminogen Activator Receptor As a Disease Activity Marker in Patients with Systemic Lupus Erythematosus. Helena Enocsson, Jonas Wettero, Thomas Skogh and Christopher Sjowall, Linkoping University, Linkoping, Sweden 1422. Caregiver Burden Is Associated with Worse Dyadic Relationship and Health Outcomes in Lupus. Amita Thakkar, Rachel A. Mikolaitis, Joel A. Block and Meenakshi Jolly, Rush University Medical Center, Chicago, IL

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Innate Immune System and Organ Damage 1423. Genetic Ancestry, Serum Interferon-α Activity and Autoantibodies in Systemic Lupus Erythematosus. Kichul Ko, Beverly S. Franek and Timothy B. Niewold, University of Chicago, Chicago, IL 1424. Analysis of Longitudinal Gene and Protein Expression Data Classifies SLE Patients Based on Molecular Profiles Associated with Disease Activity, Serology and Specific Organ Manifestations. Mikhail Olferiev1, Kyriakos A. Kirou2, Dorthe Lundsgaard3, Klaus S. Frederiksen3, Jan Fleckner3 and Mary K. Crow1, 1Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, 2Mary Kirkland Center for Lupus Care, Hospital for Special Surgery, New York, NY, 3NovoNordisk, Copenhagen, Denmark 1425. Estrogen Stimulation of Endosomal Toll-Like Receptor Expression Lowers the Threshold of Activation in Peripheral Blood Mononuclear Cells and Contributes to the Gender Bias of Systemic Lupus Erythematosus. Nicholas A. Young, Alexandra Friedman, Benjamin Kaffenberger and Wael N. Jarjour, The Ohio State University Medical Center, Columbus, OH 1426. Genome-Wide Analyses of IRF1 and H4 Acetylation in SLE Monocytes. Kathleen E. Sullivan1, Lihua Shi1, Li Song1, Michelle Petri2 and Zhe Zhang3, 1Children’s Hospital of Philadelphia, Philadelphia, PA, 2Johns Hopkins Hospital,

2011 Program Book

237

ACR/ARHP Poster Session B Baltimore, MD, 3Bioinformatics, Children’s Hospital of Philadelphia, Philadelphia, PA 1427. Poly (ADP-Ribose) Polymerase 1 and Special AT-Rich Sequence Binding Protein 1 Bind to the TT>A System Lupus Erythematosus Associated Regulatory Downstream of TNFAIP3. Feng Wen1, Michael Kinter1, Joel Guthridge1, Mary Beth Humphrey2 and Patrick M. Gaffney3, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 1428. IRF5 Activation in Monocytes of SLE Patients Is Triggered by Circulating Autoantigens Independent of Type I IFN. Rivka Stone1, Di Feng1, Jing Deng1, Sukhwinder Singh1, Lisong Yang1, Patricia Fitzgerald-Bocarsly1, Maija-Leena Eloranta2, Lars Ronnblom3 and Betsy Barnes1, 1University of Medicine and Dentistry of New Jersey, Newark, NJ, 2Section of Rheumatology, Uppsala University, Uppsala, Sweden, 3 Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden 1429. Large Scale Analysis of Serum Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus. Corinna E. Weckerle1, Dorothy Imbuka1, Beverly S. Franek1, Jennifer A. Kelly2, Marissa Kumabe1, Kathy L. Moser3, Judith A. James4, John B. Harley5 and Timothy B. Niewold1, 1 University of Chicago, Chicago, IL, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 5Cincinnati Children’s Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH 1430. Low Programmed Death Ligand-1 Gene Expression in SLE Monocytes Coregulated by IL-10, TNF-α and TGF-β May Contribute to Chronic T Lymphocyte Activation. Jing-Ni Ou1, Gretchen R. Henstorf1, Matthew Crabtree1, Alice Wiedeman2 and Anne M. Stevens1, 1Seattle Children’s Research Institute, Seattle, WA, 2University of Washington, Seattle, WA 1431. Impact of Aberrations In Xenobiotic Metabolism On the Susceptibility to Systemic Lupus Erythematosus. Yedluri Rupasree, Liza Rajasekhar, Addepalli Pavani, Shaik Mohammad Naushad and Vijay Kumar Kutala, Nizam’s Institute of Medical Sciences, Hyderabad, India 1432. Metabolic Underpinnings of Systemic Lupus Erythematosus. Tianfu Wu1, Chun Xie1, Jie Han1, Irene Blanco2, Nancy J. Olsen3, Chaim Putterman2, Ramesh Saxena4 and Chandra Mohan4, 1University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 2Albert Einstein College of Medicine, Bronx, NY, 3Penn State MS Hershey Medical Center, Hershey, PA, 4University of Texas Southwestern Medical Center, Dallas, TX

238

2011 Program Book

1433. Interferon Alpha Strikes Again: Modulation of Inflammasome Activity Results In IL-18 Mediated Vascular Dysfunction In Systemic Lupus Erythematosus. J. Michelle Kahlenberg1, Seth G. Thacker1, Celine C. Berthier1, Jeffrey Hodgin1, Clemens D. Cohen2, Matthias Kretzler1 and Mariana J. Kaplan3, 1University of Michigan, Ann Arbor, MI, 2 University Hospital Zurich, Zurich, Switzerland, 3University of Michigan Rheumatology, Ann Arbor, MI 1434. Retroviral Vector System Identified FLRT2 As a Novel Cell Surface Autoantigen Against Anti-Endothelial Cell Antibodies in Systemic Lupus Erythematosus. Tsuyoshi Shirai1, Hiroshi Fujii1, Masao Ono2, Kyohei Nakamura1, Ryu Watanabe3, Yumi Sasaki1, Naruhiko Takasawa1, Tomonori Ishii1 and Hideo Harigae1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan, 3 Tohoku University Hospital, Sendai, Japan 1435. Binding of Serum IgG to Human Mesangial Cells and Its Correlation with Disease Activity in Patients with Lupus Nephritis. Desmond YH YAP1, Susan Yung2, Owen Chan2, Florence Q. Zhang2 and Tak Mao Chan2, 1Queen Mary Hospital, Hong Kong, Hong Kong, 2The University of Hong Kong, Hong Kong SAR, Hong Kong 1436. Cardiovascular Disease and Cognitive Dysfunction in Systemic Lupus Erythematosus. Sara Murray, Jinoos Yazdany, Rachel Kaiser, Lindsey A. Criswell, Edward H. Yelin, Patricia P. Katz and Laura J. Julian, University of California, San Francisco, San Francisco, CA 1437. Atherosclerosis and Cardiovascular Disease in Systemic Lupus Eryhematosus Are Related to An Inflammatory / Oxidative Status Linked to the Autoimmune Condition and the Clinical Activity of the Disease. Effect of Statins Treatment. Chary Lopez-Pedrera1, Patricia Ruiz-Limon1, Carlos Perez-Sanchez1, Mª Angeles Aguirre1, Nuria Barbarroja1, Antonio Rodriguez-Ariza1, Eduardo CollantesEstevez1, Jose Manuel Villalba2, Francisco Velasco1, Munther A. Khamashta3, Maria Laura Bertolaccini3 and Mª Jose Cuadrado4, 1IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 2 University of Cordoba, Cordoba, Spain, 3Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 4The Rayne Institute, London, United Kingdom 1438. Analysis of Endothelium from Systemic Lupus Erythematosus Patients Demonstrates a Marked Interferon Inducible Signature and an Associated Decrease in Transforming Growth Factor Beta Signaling Genes. Diana Goldenberg1, Mikhail Olferiev1, Duygu Onat2, Ante Harxhi2, Danieli Andrade1, Mary K. Crow1, Paolo Colombo2 and Jane E. Salmon1, 1Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 2Columbia University College of Physicians & Surgeons, New York, NY

ACR/ARHP Poster Session B 1439. Anti NMDAR and Anti-P/NSPA Antibodies Contribute to Cognitive Dysfunction in Lupus Patients. Loreto Massardo1, Patricia Flores2, Jorge Calderón2, Marcela Bravo-Zehnder2, Angel Jurado2, Carla Henríquez2, Oslando Padilla2, Marcela Babul2, Andrea Slachevsky3, Sergio Jacobelli4, Betty Diamond5 and Alfonso Gonzalez6, 1Catholic University of Chile, Santiago 114-D, Chile, 2Pontificia Universidad Catolica de Chile, Santiago, Chile, 3Universidad de Chile, Santiago, Chile, 4Universidad Catolica de Chile, Santiago, Chile, 5 Feinstein Institute Med Rsch, Manhasset, NY, 6Marcoleta 367, Santiago, Chile 1440. A Central Role of Plasmin in Cardiac Injury Initiated by Fetal Exposure to Maternal Anti-Ro Autoantibodies. Paraskevi Briasouli1, Joanne Reed1, Jill P. Buyon1, Robert M. Clancy1, Mark Halushka2 and Lucas Buyon3, 1New York University School of Medicine, New York, NY, 2John Hopkins Pathology, Baltmore, MD, 3New York University School of Medicine, new York, NY 1441. Vascular Events and HLA-DRB1 Genotypes in Systemic Lupus Erythematosus. Elisabet Svenungsson1, Emelie Lundstrom1, Johanna Gustafsson1, Andreas Jonsen2, Dag Leonard3, Agneta Zickert1, Kerstin Elvin4, Gunnar K. Sturfelt2, Gunnel Nordmark3, Anders Bengtsson5, Lars Ronnblom3, Iva Gunnarsson1 and Leonid Padyukov1, 1Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 2Department of Rheumatology, Lund University Hospital, Lund, Sweden, 3 Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 4Department of Clinical Immunology and Transfusion Medicine, Unit of Clinical Immunology, Karolinska University Hospital and Karolinska Institutet /Karolinska University Hospital, Stockholm, Sweden, 5Department of Rheumatology, Lund University Hospital, Sweden 1442. Insulin-Like Growth Factor Binding Protein-4 As a Marker of Chronic Lupus Nephritis. Chun Xie, Tianfu Wu, Jie Han, Ramesh Saxena and Chandra Mohan, University of Texas Southwestern Medical Center, Dallas, TX 1443. Increased Relative Expression of the Interferon-Responsive Gene MX1 Is Present in Pregnant SLE Patients and May Distinguish Flare of SLE From Preeclampsia. Danieli Andrade1, Gloria Koo1, Patricia M. Redecha1, Kyriakos A. Kirou2, Mimi Kim3, Mary K. Crow1 and Jane E. Salmon4, 1 Hospital for Special Surgery, New York, NY, 2Mary Kirkland Center for Lupus Care - Hospital for Special Surgery, New York, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4 Hospital for Special Surgery, Weill Cornell Medical College, New York, NY 1444. Immune Complexes (ICs) From Systemic Lupus Erythematosus (SLE) and Complement Activate ERK1/2 and PI3K/Akt Pathway in Primary Human Mesangial Cells. Anil K. Chauhan1 and Terry L. Moore2, 1Saint Louis University, St. Louis, MO, 2Saint Louis University, Saint Louis, MO

1445. Quantitative Analysis of Pathologic Cell Subsets Involved in Tubulointerstitial Inflammation in Human Lupus Nephritis. Vladimir M. Liarski, Daniel F. Brandt, Christine Hsieh, Natalya Kaverina, Christine Labno and Marcus R. Clark, University of Chicago, Chicago, IL 1446. Gene Expression Profiles in Monocytes and Macrophages From Systemic Lupus Erythematosus Patients and Healthy Controls with and without An Atherosclerosis Phenotype. Benjamin Korman1, Carly Skamra1, Peggy Wu1, Alexander Sandhu1, Qi Quan Huang1, Chiang-Ching Huang1, William Pearce1, Kim Sutton-Tyrrell2, George Kondos3, James Carr1, Daniel Edmundowicz2, Richard Pope1 and Rosalind RamseyGoldman1, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2University of Pittsburgh, 3University of Illinois at Chicago, Chicago, IL

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Clinical Aspects and Therapeutics 1447. Treatment of Systemic Sclerosis: What to Use When First-Line Treatment Fails. A Consensus of Experts. Kyle M. Walker1, Janet E. Pope2, Scleroderma Clinical Trials Consortium (SCTC)3 and Canadian Scleroderma Research Group (CSRG)4, 1Trinity College Dublin, Dublin, Ireland, 2 St. Joseph’s Health Care, University of Western Ontario, London, ON, 3Boston, MA, 4Montreal, QC 1448. Two Years Follow-up Results After Rituximab Treatment (baseline and month 6) in Patients with “Early” Systemic Sclerosis with Diffuse Skin Involvement. Vanessa Smith1, Yves P. Piette1, Saskia Decuman1, Jens T. Van Praet1, Ellen De Schepper2 and Filip De Keyser1, 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 2 Biostatistics Unit, Ghent University, Ghent, Belgium 1449. A Meta-Analysis of Randomized Trials in the Treatment and Prevention of Digital Ulcers (DU) in Systemic Sclerosis (SSc). Theresa Tingey1, Joseph Smuczek1 and Janet E. Pope2, 1 McMaster University, Hamilton, ON, 2St. Joseph’s Health Care, University of Western Ontario, London, ON 1450. Digital Ulcers in Patients with Systemic Sclerosis: Prevalence, Location, Nailfold Capillaroscopy and Functional Impact. Holly Ennis1, A. Vail2, Elizabeth Wragg3, Adrienne Taylor3, Tonia Moore1, Andrea Murray1, Lindsay Muir4, Christopher E.M Griffiths5 and Ariane L. Herrick1, 1School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2School of Community Based Medicine, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3 Rheumatology Directorate, Salford Royal NHS Foundation Trust, Salford, United Kingdom, 4Hand Surgery, Salford Royal NHS Foundation Trust, Salford, United Kingdom, 5 Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

2011 Program Book

239

ACR/ARHP Poster Session B 1451. Elevation of Aldolase in Eosinophilic Fasciitis. Jennifer Nashel1 and Virginia D. Steen2, 1Washington, DC, 2 Georgetown Univ Medical Center, Washington, DC 1452. HLA DQB1*03:02 Is a Marker for Severity of Interstitial Lung Disease in Systemic Sclerosis. Shervin Assassi1, Filemon K. Tan1, Jun Ying2, Olga Y. Gorlova2, Brock E. Harper3, Hilda T. Draeger4, Emilio B. Gonzalez3, Rosa M. Estrada-YMartin1, Julio Charles1, Xiaodong Zhou1, Frank C. Arnett1, John D. Reveille1 and Maureen D. Mayes1, 1University of Texas Health Science Center at Houston, Houston, TX, 2UT M. D. Anderson Cancer Center, Houston, TX, 3University of Texas Medical Branch, Galveston, TX, 4Univ of TX Health Sci Ctr, San Antonio, TX 1453. Treatment of Idiopathic Retroperitoneal Fibrosis: A Single Center Experience. Pietro Tartaro and Renzo Marcolongo, Hematology and Clinical Immunology Unit, Padova, Italy 1454. Prevention of Digital Ulcers in Systemic Sclerosis Patients: A Proposal of Risk Chart. Andreina Manfredi1, Marco Sebastiani1, Roberto D’Amico1, Valeria Carraro2, Mario Bocci3, Sheila Moscatelli4, Michele Iudici5, Michele Colaci1, Dilia Giuggioli1 and Clodoveo Ferri6, 1University of Modena and Reggio Emilia, Modena, Italy, 2Rheumatology Clinic, University of Padova, Padova, Italy, 3Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 4University of Perugia, Perugia, Italy, 5Second University of Naples, Naples, Italy, 6Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy 1455. Clinical Features of Gastrointestinal Involvement in Patients with Systemic Sclerosis. Christiane Strohbeck1, Florian MP Meier1, Gabriela Riemekasten2, Christiane Pfeiffer3, Andrea Himsel4, Ilka Herrgott5, Norbert Blank6, Jorg HW Distler7, Matthias Seidel8, Nicolas Hunzelmann9 and Ulf Müller-Ladner10, 1Justus-Liebig Universität Gießen, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 2Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 3University Hospital Ulm, Ulm, Germany, 4University Hospital Frankfurt, Frankfurt am Main, Germany, 5University Hospital Münster, Münster, Germany, 6University of Heidelberg, Eppelheim, Germany, 7 Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 8University Hospital of Bonn, Bonn, Germany, 9 University of Cologne, Cologne, Germany, 10Justus-LiebigUniversity of Gießen, Bad Nauheim, Germany 1456. Trends in Mortality in Patients with Systemic Sclerosis Over 40 Years: A Systematic Review and Meta-Analysis of Case-Control and Cohort Studies. Muriel Elhai1, Christophe Meune2, Jerome Avouac1, Andre Kahan1 and Yannick Allanore1, 1Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, 2Paris Descartes University, Cardiology department, Cochin Hospital, Paris, France

240

2011 Program Book

1457. Comparison of Wide Field Nailfold Capillaroscopy and Videocapillaroscopy in the Assessment of the Microcirculation in Patients with Raynaud‘s Phenomenon. Juliana Sekiyama, Cintia Camargo, Luis Eduardo C. Andrade and Cristiane Kayser, Universidade Federal de São Paulo, São Paulo, Brazil 1458. Measuring Vascular Burden in Scleroderma and Raynaud Phenomenon. Laura K. Hummers1, Stefan Zimmerman1, Fredrick M. Wigley1, John Carrino1, Erik Schwetje2, Warren Greth3 and Ami A. Shah1, 1Johns Hopkins University, Baltimore, MD, 2MedImmune, LLC, Gaithersburg, MD, 3 MedImmune LLC, Gaithersburg, MD 1459. Watermelon Stomach in Systemic Sclerosis: A EUSTAR Case-Control Study. Etienne Ghrenassia1, Jérôme Avouac1, Chris T. Derk2, Paolo Airo3, Dinesh Khanna4, Alice Berezne5, Kiet Tiev6, Francesca Ingegnoli7, Edoardo Rosato8, Paola Caramaschi9, Roger Hesselstrand10, Valeria Riccieri11, Sharon Bae12, Virginia D. Steen13 and Yannick Allanore1, 1 Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 2Jefferson Medical College, Philadelphia, PA, 3Brescia, Italy, 4University of Michigan, Ann Arbor, MI, 5Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, 6Internal Medicine Department, Saint Antoine Hospital, Paris, France, 7University of Milan, Milan, Italy, 8Department of Clinical Medicine, La Sapienza University, Rome, Italy, 9 Rheumatology Unit, Department of Medicine, Verona, Italy, 10Lund University & Skåne University Hopsital, Lund, Sweden, 11University of Rome, Medical Clinic and Therapy Department, 12Division of Rheumatology, Department of Medicine, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, 13Georgetown Univ Medical Center, Washington, DC 1460. Patient Reported Measures of Skin Activity Associate with Disability in Diffuse Scleroderma. Julie J. Paik1, Laura K. Hummers1, Fredrick M. Wigley1, Sharon R. Ghazarian1, Natalie R. Daya1, Ami A. Shah1 and for the Imatinib Study Group2, 1Johns Hopkins University, Baltimore, MD, 2CH-4002 Basel, Switzerland 1461. Identification of Mesenchymal Cells Expressing Endothelial Markers in Small Pulmonary Arteries of Systemic Sclerosis Associated Pulmonary Fibrosis: Possible Role of Endothelial-Mesenchymal Transition. Fabian A. Mendoza1, Sonsoles Piera-Velazquez1, John L. Farber2 and Sergio A. Jimenez1, 1Scleroderma Center and Jefferson Institute of Molecular Medicine, Philadelphia, PA, 2Department of Pathology and Cell Biology Thomas Jefferson University, Philadelphia, PA 1462. Outcomes of Systemic Sclerosis Associated Polyarthritis Patients Treated by Biotherapies Tocilizumab or Abatacept: A EUSTAR Observational Study. Marine Meunier1, Marco Matucci Cerinic2, Britta Maurer3, Gabriela Riemekasten4, Raffaele Pellerito5, Carlos Alberto von Mühlen6, Alessandra Vacca7, Paolo Airo8, Francesca Bartoli2, Ginevra Fiori2, Oliver

ACR/ARHP Poster Session B Distler9 and Yannick Allanore1, 1Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 2Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Firenze, Italy, 3Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 5Ospedale Mauriziano, Torino, Italy, 6Rheumatology Department, Saint Lucas Hospital, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil, Porto Alegre, Brazil, 7Chair of Rheumatology II, Department of Medical Sciences, University of Cagliari, Italy, Cagliari, Italy, 8Brescia, Italy, 9University Hospital Zurich, Zurich, Switzerland 1463. Features of Acute Denervation in Scleroderma Myopathy. Julie J. Paik, Fredrick M. Wigley, Laura K. Hummers and Andrew L. Mammen, Johns Hopkins University, Baltimore, MD 1464. Medium and Large Vessel Involvements Contribute to Digital Ulcers in Systemic Sclerosis. Christophe Meune1, Marine Meunier2, Jérôme Avouac2, Andre Kahan2 and Yannick Allanore2, 1Paris Descartes University, Cardiology department, Cochin Hospital, Paris, France, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France 1465. Juvenile Systemic Sclerosis Outcomes After Treatment of Pulmonary Fibrosis with Cyclophosphamide or Methotrexate. Gretchen R. Henstorf1 and Anne M. Stevens2, 1Seattle Children’s Research Institute, Seattle, WA, 2 University of Washington, Seattle, WA 1466. The N-Terminal Fragment of Brain Natriuretic Peptide As An Outcome Predictor in Scleroderma Renal Crisis. Cecilia B. Chighizola1, Henry Penn2, Pier Luigi Meroni1, Christopher D. Denton3 and Voon Ong4, 1University of Milan, Milan, Italy, 2Northwick Park Hospital, Harrow, United Kingdom, 3 Royal Free Hospital, Medical School, London, England, 4UCL Medical School, London, England 1467. Systemic Sclerosis-Related Digital Ulcers: Influence of Location, Calcinosis and Perfusion on Time to Healing. Andrea Murray1, Tonia Moore1, Elizabeth Wragg2, Holly Ennis1, Andy Vail3, Adrienne Taylor2, Graham Dinsdale1, Lindsay Muir4, Charles Hutchinson1, Christopher E.M Griffiths5 and Ariane Herrick1, 1School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2 Rheumatology Directorate, Salford Royal NHS Foundation Trust, Salford, United Kingdom, 3School of Community Based Medicine, University of Manchester, Manchester Academic Health Science Centre, Salford, United Kingdom, 4Hand Surgery, Salford Royal NHS Foundation Trust, Salford, United Kingdom, 5University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

1468. Spectrum of Muscle Disease in Scleroderma. Huma Sohail1, Ann J. Impens2, Elena Schiopu2 and Kristine Phillips3, 1 University Of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3University of Michigan Medical School, Ann Arbor, MI 1469. Circulating Endothelial cells and Capillaroscopic Skin Ulcer risk index (CSURI) As Biomarkers of scleroderma microvascular Injury. Silvia L. Bosello, Mario Bocci, Giacomo De Luca, Annunziata Capacci, Barbara Tolusso and Gianfranco Ferraccioli, Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy 1470. Living with Connective Tissue Related Interstitial Lung Disease: Patient Experiences of the Disease Process Over Time. Shikha Mittoo1, Lesley Ann Saketkoo2, Jeffery J. Swigris3, Daphne LeSage4, Aryeh Fischer3 and Sid Frankel5, 1 University of Toronto, Toronto, ON, 2LSU Health Science Center, New Orleans, LA, 3National Jewish Health, Denver, CO, 4Center for CCH at State of Louisiana, New Orleans, LA, 5 University of Manitoba, Winnipeg 1471. Functional Class Change in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Associations with Survival and Exercise Capacity. Lorinda Chung1, Lori S. Parsons2, Paul M. Hassoun3, Michael D. McGoon4, David B. Badesch5, Dave P. Miller2, Mark R. Nicolls6 and Roham T. Zamanian6, 1Stanford Univ Medical Center, Palo Alto, CA, 2ICON Late Phase & Outcomes Research, San Francisco, CA, 3Johns Hopkins University, Baltimore, MD, 4 Mayo Clinic, Rochester, MN, 5University of Colorado Denver, Aurora, CO, 6Stanford University, Stanford, CA 1472. Serum Interleukin-9 Levels Are Increased In Patients with Systemic Sclerosis: Association with Lower Frequency and Severity of Pulmonary Fibrosis. Koichi Yanaba and Shinichi Sato, The University of Tokyo, Tokyo, Japan 1473. High-Dose I.v. N-Acetylcysteine Increases Peripheral Tissue Perfusion and Improves Clinical Symptoms of Systemic Sclerosis Patients. A Pilot Study. Alberto Sulli, Barbara Ruaro, Giuseppe Zampogna, Carmela Ferrone, Francesca Ravera, Bruno Seriolo and Maurizio Cutolo, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy 1474. Progression of Microvascular Damage Through Different Nailfold Capillaroscopic Patterns in Systemic Sclerosis Patients. Alberto Sulli1, Francesca Ravera1, Barbara Ruaro1, Vanessa Smith2, Carmen Pizzorni1, Giuseppe Zampogna1, Elisa Alessandri1 and Maurizio Cutolo1, 1Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 2 Department of Rheumatology, Ghent University Hospital, Ghent, Belgium 1475. Serum Brain Natriuretic Peptide is a Reliable Marker for Survival of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases, Including Systemic

2011 Program Book

241

ACR/ARHP Poster Session B Sclerosis, Mixed Connective Tissue Disease and Systemic Lupus Erythematosus. Sumiaki Tanaka1, Kenta Hoshi1, Junichi Tanaka1, Tatsuhiko Wada1, Jun Okada2, Tatsuo Nagai1 and Shunsei Hirohata1, 1Kitasato University School of Medicine, Sagamihara, Japan, 2Kitasato University, Sagamihara, Japan 1476. Long Term Safety and Effectiveness of Tumour Necrosis Factor Inhibitors In Systemic Sclerosis Patients with Arthritis. Mohammed Omair1, Veerapong Phumethum2 and Sindhu R. Johnson3, 1Mount Sinai hospital, Toronto, ON, 2Prapokklao Hospital, Chantaburi, Thailand, 3Toronto Western Hospital, Toronto, ON 1477. Fascicular Block: A Predictor of Mortality In Early Systemic Sclerosis. Hilda T. Draeger1, Shervin Assassi2, Roozbeh Sharif3, Emilio B. Gonzalez4, Brock E. Harper4, Richard A. Lange1 and Maureen D. Mayes3, 1Univ of TX Health Science Center-San Antonio, San Antonio, TX, 2Univ of Texas Health Science, Houston, TX, 3University of Texas Health Science Center at Houston, Houston, TX, 4University of Texas Medical Branch, Galveston, TX 1478. The Risk of Cancer in Japanese Patients with Systemic Sclerosis. Atsushi Hashimoto1, Hirahito Endo2, Toshihiro Matsui3, Shigeto Tohma3, Sumiaki Tanaka4 and Shunsei Hirohata4, 1Kitasato University School of Medicine, and Sagamihara National Hospital, National Hospital Organization, Sagamihara, Kanagawa, Japan, 2Toho University School of Medicine, Tokyo, Japan, 3Sagamihara National Hospital, National Hospital Organization, Sagamihara, Kanagawa, Japan, 4Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Pathogenesis, Animal Models and Genetics 1479. Topical Vitamin D Analogue Calcipotriol Superinduces TSLP and IL-13 Expression in the Bleomycin Scleroderma Model but Does Not Modify Fibrosis. Alicia Usategui, Manuel J. Del Rey, Elena Izquierdo, Vanessa Miranda, Gabriel Criado and Jose L. Pablos, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain 1480. Bosentan Reverses the Profibrotic Phenotype of Systemic Sclerosis Dermal Fibroblasts Through Increasing the DNA Binding Ability of Transcription Factor Fli1. Kaname Akamata1, Yoshihide Asano2 and Shinichi Sato3, 1University of Tokyo, Bunkyo-Ku, Japan, 2University of Tokyo Graduate School of Medicine, Tokyo, Japan, 3The University of Tokyo, Tokyo, Japan 1481. Expression Profiling of Skin and Lung Tissue and Explanted Fibroblasts in a Transgenic Mouse Model of Scleroderma. Emma Derrett-Smith1, Rachel Hoyles1, Pia Moinzadeh1, Cecilia B. Chighizola1, Korsa Khan1, Voon Ong2, David J. Abraham1 and Christopher P. Denton1, 1UCL Medical School, London, United Kingdom, 2UCL Medical School, London, England

242

2011 Program Book

1482. The Effect of Trichostatin A, One of the Histone Deacetylase Inhibitor, on Skin Fibrosis Mouse Model. Fumihide Ogawa1, Hajime Tomita1, Yutaka Kuwatsuka1, Kazuhiro Shimizu1, Shinichi Sato2 and Atsushi Utani1, 1 Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2The University of Tokyo, Tokyo, Japan 1483. Notch Pathway Is Activated in Systemic Sclerosis (SSc). Kae Takagi1, Yasushi Kawaguchi1, Yuko Ota1, Akiko Tochimoto1, Chikako Fukasawa1, Masanori Hanaoka1, Hisae Ichida1, Takahisa Gono1 and Hisashi Yamanaka2, 1Tokyo Women’s Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan 1484. Mice Lacking the Receptor-Like Protein Tyrosine Phosphatase CD148 Are Protected From BleomycinInduced Pulmonary Fibrosis. Tamiko R. Katsumoto1, Kevin K. Kim2, Alexis N. Brumwell1, John X. Nguyen1, Connor E. Rosen1, Elliott Callahan1, Jing W. Zhu1, Mark R. Looney1, Harold A. Chapman1 and Arthur Weiss3, 1UCSF, San Francisco, CA, 2University of Michigan, Ann Arbor, MI, 3UC San Francisco, San Francisco, CA 1485. Absence of Epithelial to Mesenchymal Transition Despite Activation of Keratinocytes in Scleroderma Skin. Joanna Nikitorowicz Buniak, Xu Shiwen, David J. Abraham, Christopher D. Denton, Carol M. Black DBE and Richard J. Stratton, UCL Medical School, London, United Kingdom 1486. Abnormal Morphology and Excessive Synthesis of Collagen V Affects Skin Thickness and Disease Activity in Systemic Sclerosis. Patricia Martin1, Walcy R. Teodoro1, Ana Paula P. Velosa2, Jymenez de Morais1, Solange Carrasco3, Francine F. R. Braga1, Romy Christmann4, Claudia GoldensteinSchainberg5, Edwin R. Parra1, Vera L. Capelozzi1 and Natalino H. Yoshinari2, 1Universidade de São Paulo, São Paulo, Brazil, 2 Univerdidade de São Paulo, São Paulo, Brazil, 3Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 4Boston University, Boston, MA, 5University of São Paulo, São Paulo, Brazil 1487. The Association Between the PTPN22 C1858T Polymorphism and Systemic Sclerosis: A Meta-Analysis. Young Ho Lee, Sung Jae Choi, Jong Dae Ji and Gwan Gyu Song, Korea University Medical Center, Seoul, South Korea 1488. Augmented Expression of Inducible Costimulator (ICOS) and Its Ligand (ICOSL) in Patients with Systemic Sclerosis. Minoru Hasegawa, Manabu Fujimoto, Takashi Matsushita, Yasuhito Hamaguchi and Kazuhiko Takehara, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan 1489. Impaired In Vivo Neovascularization Capacity of Endothelial Progenitor Cells In Patients with Systemic Sclerosis. Masataka Kuwana, Yuka Okazaki, Hidekata Yasuoka and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan

ACR/ARHP Poster Session B 1490. A Membrane-Associated Adaptor Protein DOK5 Is Upregulated in SSc and Associated with IGFBP-5-Induced Fibrosis. Hidekata Yasuoka, Yukie Yamaguchi and Carol A. Feghali-Bostwick, University of Pittsburgh, Pittsburgh, PA 1491. A Genome-Wide Association Study Follow-up Strategy Reveals the Association of IL12RB2 Gene with Systemic Sclerosis in Caucasian Populations. Lara Bossini-Castillo1, Jose Ezequiel Martin1, Jasper Broen2, Carmen Pilar Simeon3, Lorenzo Beretta4, Madelon C. Vonk2, Patricia E. Carreira5, Spanish Scleroderma Group, Gabriela Riemekasten7, Nicolas Hunzelmann8, Alexandre E. Voskuyl9, Annemie Schuerwegh10, Oyvind Palm11, Roger Hesselstrand12, Annika Nordin13, Claudio Lunardi14, Paul Shiels15, Jacob M. van Laar16, Ariane L. Herrick17, Filemon K. Tan18, Shervin Assassi19, Carmen Fonseca20, Maureen D. Mayes18, Timothy Radstake2 and Javier Martin1, 1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 2Radboud University Nijmegen Medical Centre, Nijmegen, Nijmegen, Netherlands, 3Hospital Valle de Hebron, Barcelona, Spain, 4 IRCCS Fondazione Policlinico-Mangiagalli-Regina Elena & University of Milan, Milan, Italy, 5Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 6Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 7University of Cologne, Cologne, Germany, 8VU University Medical Center, Amsterdam, Netherlands, 9Leids Univ Medisch Centrum, Leiden, Netherlands, 10Rikshospitalet, Oslo University Hospital, Oslo, Norway, 11Lund University & Skåne University Hopsital, Lund, Sweden, 12Karolinska Institute, Stockholm, Sweden, 13Policlinico G B Rossi, Verona, Italy, 14University of Glasgow, Glasgow, United Kingdom, 15Musculoskeletal Research Group, Newcastle, United Kingdom, 16Rheumatic Diseases Centre, Salford, United Kingdom, 17University of Texas Health Science Center at Houston, Houston, TX, 18Univ of Texas Health Science, Houston, TX, 19Royal Free and University College Medical School, London, United Kingdom 1492. The IRF7 Region Is Associated with Anti-Centromere Autoantibody Production in Systemic Sclerosis Patients. F. David Carmona1, Ramana Gutala2, Carmen P. Simeón3, Patricia E. Carreira4, Norberto Ortego-Centeno5, Esther Vicente-Rabaneda6, Francisco J. García-Hernández7, Paloma García de la Peña8, Mónica Fernández-Castro9, Lina Martínez-Estupiñán10, María-Victoria Egurbide11, Spanish Scleroderma Group, Betty P. Tsao13, Pravitt R. Gourh14, Sandeep K. Agarwal15, Shervin Assassi16, Maureen D. Mayes15, Frank C. Arnett15, Filemon K. Tan15 and Javier Martín17, 1Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, 2The University of Texas Health Science Center, Houston, TX, 3Hospital Valle de Hebron, Barcelona, Spain, 4Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 5Hospital Clínico San Cecilio, Granada, Spain, 6Hospital de la Princesa, Madrid, Spain, 7Hospital Virgen del Rocío, Sevilla, Spain, 8Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain, 9 Hospital Puerta de Hierro, Madrid, Spain, 10Gregorio

Marañón Hospital, Madrid, Spain, 11Hospital de Cruces, UPV/ EHU, Barakaldo, Spain, Barakaldo, Spain, 12David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 13UTHSC-Houston Medical School, Houston, TX, 14University of Texas Health Science Center at Houston, Houston, TX, 15Univ of Texas Health Science, Houston, TX, 16 Consejo Superior de Investigaciones Científicas, Granada, Spain 1493. Atherosclerosis Biomarkers in Systemic Sclerosis- A Multiplex Analysis. Karen M. Au1, Dinesh Khanna2, Anagha A. Divekar1, Ram Raj Singh1, Mariana J. Kaplan3, Maureen A. McMahon4, Daniel E. Furst1, Nagesh Ragavendra4, Paul Maranian1 and Wenpu Zhao2, 1UCLA Medical School, Los Angeles, CA, 2University of Michigan, Ann Arbor, MI, 3 University of Michigan Rheumatology, Ann Arbor, MI, 4UCLA David Geffen School of Medicine, Los Angeles, CA 1494. Immunochip Genotyping of 1,884 Systemic Sclerosis Cases and 4,325 Controls Reveals Novel Associations. Maureen D. Mayes1, Olga Y. Gorlova2, Lara Bossini-Castillo3, Jose Ezequiel Martin4, Jun Ying2, Peter K. Gregersen5, Annette T. Lee6, Shervin Assassi1, Sandeep K. Agarwal1, Filemon K. Tan1, John D. Reveille1, Xiaodong Zhou1, Frank C. Arnett1, Fredrick M. Wigley7, Laura K. Hummers7, Marilyn Perry1, Carmen Pilar Simeon8, Patricia Carriera9, Norberto Ortego-Centeno10, Miguel Gonzalez-Gay11, the Spanish Scleroderma Group12 and Javier Martin13, 1University of Texas Health Science Center at Houston, Houston, TX, 2UT M. D. Anderson Cancer Center, Houston, TX, 3Consejo Superior de Investigaciones Científicas (CSIC), Armilla (Granada), Spain, 4Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 5Feinstein Institute Medical Reschearch, Manhasset, NY, 6Feinstein Institute Med Rsch, Manhasset, NY, 7Johns Hopkins University, Baltimore, MD, 8 Hospital Valle de Hebron, Barcelona, Spain, 9Madrid, Spain, 10 Hospital Clínico San Cecilio, Granada, Spain, 11Hospital Marques De Valdecilla, Santander, Spain, 12Granada, Spain, 13 Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain 1495. Systemic Sclerosis As Prototypic Disease for Functional Antibodies Against Vascular Receptors: From Beside to Bench and Mouse Models. Angela Kill1, Reinmar Undeutsch2, Christoph Tabeling3, Martin Witzenrath4, Wolfgang M. Kuebler5, Sebastian Bock6, Rudi Samapati5, Harald Heidecke7, Ivo Lukitsch3, Duska Dragun4 and Gabriela Riemekasten8, 1Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, 2Charité University hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, 3Charité University Hospital, Berlin, 4Charité University Hospital, Berlin, Germany, 5Charité University Hosptial, Berlin, Germany, 6Charité University Hospital and German Rheumatism Research Centre, a Leibiz, Berlin, Germany, 7CellTrend GmbH, Luckenwalde, Germany, 8Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany 2011 Program Book

243

ACR/ARHP Poster Session B 1496. Evidence for the Contribution of the X Chromosome to Systemic Sclerosis Susceptibility: Association with the Functional IRAK1 196Phe/532Ser Haplotype. Philippe Dieude1, Matthieu Bouaziz2, Gabriela Riemekasten3, Paolo Airo4, Martina Müller5, Daniele Cusi6, Gilles Chiocchia7, Catherine Boileau8, Yannick Allanore9 and Genesys Consortium10, 1Hopital Bichat, Paris, France, 2Evry- genopole, France, 3Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 4 Brescia, Italy, 5München, Germany, 6Milano, Italy, 7Institut Cochin, 75014 Paris, France, 8Boulogne, France, 9Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 10Paris 1497. Identification of Novel Genes Associated with Systemic Sclerosis Through Genome Wide Association Study Follow-up. Jose Ezequiel Martin1, Jasper Broen2, Olga Y. Gorlova3, Madelon C. Vonk4, Spanish Scleroderma Group5, Alexandre Voskuyl6, Annemie Schuerwegh7, Marie Vanthuyne8, Vanessa Smith9, Rene Westhovens10, Elfride de Baere11, Alexander Kreuter12, Gabriela Riemekasten13, Roger Hesselstrand14, Annika Nordin15, Oyvind Palm16, Paolo Airo17, Nicolas Hunzelmann18, Lorenzo Beretta19, Filemon K. Tan20, Frank C. Arnett20, Maureen D. Mayes20, Timothy Radstake21, Javier Martin22 and Bobby P.C. Koeleman23, 1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 2Radboud University Nijmegen Medical Centre, Nijmegen, Nijmegen, Netherlands, 3UT M. D. Anderson Cancer Center, Houston, TX, 4Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Granada, 6VU University Medical Center, Amsterdam, Netherlands, 7Leids Univ Medisch Centrum, Leiden, Netherlands, 8Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium, 9Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 10University Hospital KU Leuven, Leuven, Belgium, 11Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium, 12Ruhr University Bochum, Bochum, Germany, 13Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 14Lund University & Skåne University Hopsital, Lund, Sweden, 15Karolinska Institute, Stockholm, Sweden, 16Rikshospitalet, Oslo University Hospital, Oslo, Norway, 17Brescia, Italy, 18University of Cologne, Cologne, Germany, 19IRCCS Fondazione Policlinico-Mangiagalli-Regina Elena & University of Milan, Milan, Italy, 20University of Texas Health Science Center at Houston, Houston, TX, 21 Geert Groote Plein 8, Nymegen, Netherlands, 22Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 23University Medical Center Utrecht, Utrecht, Netherlands 1498. Gut Fibrosis with Associated Diminished Colonic Contractility in a Transgenic Mouse Model of Scleroderma. Nora Thoua, Korsa Khan, Audrey Dooley, Emma DerrettSmith and Christopher P. Denton, UCL Medical School, London, United Kingdom

244

2011 Program Book

1499. Angiogenic Biomarkers Predict the Development of Digital Ulcers in Patients with Systemic Sclerosis. Jérôme Avouac1, Christophe Meune2, Andre Kahan1, Gilles Chiocchia3 and Yannick Allanore1, 1Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 2Paris Descartes University, Cardiology department, Cochin Hospital, Paris, France, 3Institut Cochin, 75014 Paris, France

Vasculitis I 1500. Efficacy and Tolerance of Infliximab In Refractory Takayasu Arteritis: French Multicenter Study. Arsene Mekinian1, Antoine Neel2, Jean Sibilia3, Pascal Cohen4, Jerome Connault5, Marc Lambert6, Laure Federici7, Sabine Berthier8, jean Noel Feissinger9, Bertrand Godeau10, Isabelle Marie11, Loic Guillevin12, Mohamed Hamidou5 and Olivier Fain13, 1Jean Verdier Hospital, Bondy, France, 2Nantes Hospital, Nantes, France, 3Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 4Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, 5Service de médecine interne, Hôpital Universitaire de Nantes, Nantes, France, Nantes, France, 6Service de médecine interne, Hôpital Claude Huriez, Université Lille II, Lille, France, Lille, France, 7Service de médecine interne, Hôpital Pasteur, F-68000 Colmar, France, Colmar, France, 8Service de médecine interne, Hôpital Bocage, Dijon, France., Dijon, France, 9Service de médecine vasculaire et d’hypertension artérielle, Université Paris 5, AP-HP, Hôpital HEGP, France, Paris, France, 10Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 11Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 12Cochin University Hospital, Paris, France, 13Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France 1501. Takayasu Arteritis: Treatment and Outcome. An American Cohort of 126 Patients. Jean Schmidt1, Tanaz A. Kermani2, A. Kirstin Bacani2, Cynthia S. Crowson2, Eric L. Matteson2 and Kenneth J. Warrington2, 1Amiens University Hospital, Amiens, France, 2Mayo Clinic, Rochester, MN 1502. Tumor Necrosis Factor Inhibitors in Patients with Takayasu Arteritis: Experience From a Referral Center with LongTerm Follow-up. Jean Schmidt1, Tanaz A. Kermani2, A. Kirstin Bacani2, Cynthia S. Crowson2, Eric L. Matteson2 and Kenneth J. Warrington2, 1Amiens University Hospital, Amiens, France, 2 Mayo Clinic, Rochester, MN 1503. Distribution of Large Artery Lesions in Takayasu’s Arteritis Compared to Giant Cell Arteritis. Peter C. Grayson1, Kathleen Maksimowicz-McKinnon2, Tiffany M. Clark3, Gunnar Tomasson4, David Cuthbertson5, Simon Carette6, Nader A. Khalidi7, Carol A. Langford8, Paul A. Monach9, Philip Seo10, Kenneth J. Warrington11, Steven R. Ytterberg11, Gary S. Hoffman12 and Peter A. Merkel4, 1Boston University Medical Center, Boston, MA, 2University of Pittsburgh, Pittsburgh, PA, 3 Cleveland Clinic Foundation, Cleveland, 4Boston University

ACR/ARHP Poster Session B School of Medicine, Boston, MA, 5University of South Florida, Tampa, FL, 6Toronto Western Hospital, Toronto, ON, 7McMaster University, Hamilton, ON, 8Cleveland Clinic, Cleveland, OH, 9Boston University, Boston, MA, 10Johns Hopkins Vasculitis Center, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12Cleveland Clinic Found A50, Cleveland, OH 1504. Outcome of Vascular Interventions in Takayasu Arteritis Using the Takayasu Arteritis Damage Score. Sivakumar M. Rajappa, Cerebrovascular and Vasculitis Research Foundation, Chennai, India 1505. Tocilizumab: A Novel Therapy for Patients with LargeVessel Vasculitis. Maria Grazia Catanoso1, Luca Magnani1, Nicolo Pipitone1, Annibale Versari1, Lucia Dardani1, Lia Pulsatelli2, Riccardo Meliconi3, Luigi Boiardi1 and Carlo Salvarani1, 1Arcispedale S Maria Nuova, Reggio Emilia, Italy, 2Istituto Ortopedico Rizzoli, Bologna, Italy, 3Istituto Ortopedico Rizzoli and University of Bologna, Bologna, Italy 1506. Leflunomide in Takayasu Arteritis - Results from an Observational Study. Alexandre W. S. de Souza1, Morgana D. da Silva1, Luiz Samuel G. Machado1, Ana Cecilia D. Oliveira1, Frederico A. G. Pinheiro1 and Emilia I. Sato2, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil 1507. Tocilizumab for the Treatment of Large Vessel Vasculitis (Giant Cell Arteritis, Takayasu Arteritis) and Polymyalgia Rheumatica: A Case Series. Sebastian Unizony1, Luis Arias-Urdaneta1, Eli Miloslavsky2, Sheila L. Arvikar1, Arezou Khosroshahi1 and John H. Stone1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hopsital, Boston, MA 1508. Results of a Randomized Controlled Study of Adalimumab for Steroid Sparing in Patients with Giant-Cell Arteritis. Xavier Mariette1, Gabriel Baron2, Eric Hachulla3, Michel DeBandt4, C. Larroche5, Xavier Puéchal6, Francois Maurier7, B. de Wazieres8, T. Quemeneur9 and Philippe Ravaud10, 1Université Paris-Sud, Le Kremlin Bicetre, France, 2 Epidemiology, Paris, France, 3Internal Medicine, Lille CEDEX, France, 4Abstract Medical Int’l, Boulogne, France, 5Hospital University Bobigny, France, 6Le Mans General Hospital, Le Mans, France, 7Division of internal Medicine, CHR Metz, Metz, Metz, France, 8CHU de Nimes, Nimes, France, 9CHR de Valenciennes, Valenciennes, France, 10Hopital Hotel Dieu, Paris Descartes University, Paris, France 1509. Impairment of the Elastic Properties of Aorta and the Carotid Artery System in Patients with Takayasu’s Arteritis. Selen Yurdakul1, Fatma Alibaz Oner2, Yelda Tayyareci1, Haner Direskeneli2 and Saide Aytekin1, 1Florence Nightingale Hospital, Istanbul, Turkey, 2Marmara University, School of Medicine, Istanbul, Turkey 1510. Giant Cell Arteritis with or without Suspicion of Aortitis At Diagnosis. A Retrospective Study of 22 Patients with a 12Year Follow-up. Olivier Espitia1, Antoine Néel1, Christophe

Leux2, Jerome Connault3, Thierry D. Ponge4, Benoît Dupas2, Mohamed Hamidou3 and Christian Agard1, 1Internal Medicine, Nantes University Hospital, Nantes, France, 2 Nantes University Hospital, Nantes, France, 3Service de médecine interne, Hôpital Universitaire de Nantes, Nantes, France, Nantes, France, 4Hotel-Dieu, Nantes CEDEX 1, France 1511. Increased Mortality in Giant Cell Arteritis with Large Vessel Disease: A Population-Based Cohort Study. Tanaz A. Kermani, Kenneth J. Warrington, Cynthia S. Crowson, Steven R. Ytterberg, Gene G. Hunder, Sherine E. Gabriel and Eric L. Matteson, Mayo Clinic, Rochester, MN 1512. Statin Exposure and Risk of Giant Cell Arteritis: A Case Control Study. Jean Schmidt1, Tanaz A. Kermani2, Cynthia S. Crowson2, Eric L. Matteson2 and Kenneth J. Warrington2, 1 Amiens University Hospital, Amiens, France, 2Mayo Clinic, Rochester, MN 1513. Relapses Among Patients with Giant Cell Arteritis. Tanaz A. Kermani1, Kenneth J. Warrington1, David Cuthbertson2, Simon Carette3, Gary S. Hoffman4, Nader A. Khalidi5, Curry L. Koening6, Carol A. Langford7, Kathleen McKinnonMaksimowicz8, Carol McAlear9, Paul A. Monach9, Philip Seo10, Peter A. Merkel9 and Steven R. Ytterberg1, 1Mayo Clinic, Rochester, MN, 2University of South Florida, Tampa, FL, 3Toronto Western Hospital, Toronto, ON, 4Cleveland Clinic Foundation, Cleveland, OH, 5McMaster University, Hamilton, ON, 6University of Utah, Salt Lake City, UT, 7Cleveland Clinic, Cleveland, OH, 8University of Pittsburgh, Pittsburgh, 9Boston University School of Medicine, Boston, MA, 10Johns Hopkins Vasculitis Center, Baltimore, MD 1514. The Relationship Between the Polymyalgia Rheumatica Activity Score and Patient Reported Outcomes in Polymyalgia Rheumatica. EM McCarthy, Paul A. MacMullan, S. Al-Mudhaffer, A. Madigan, S. Donnelly, Cj McCarthy and G M. McCarthy, Mater Misericordiae University Hospital, Dublin 7, Ireland 1515. Plasma Fibrinogen Better Reflects patients’ Functional Ability in Polymyalgia Rheumatica Than Either ESR or CRP. EM McCarthy, Paul A. MacMullan, S. Al-Mudhaffer, Anne M. Madigan, S. Donnelly, C. J. McCarthy and G M. McCarthy, Mater Misericordiae University Hospital, Dublin 7, Ireland 1516. Sensitivity of the New EULAR/ACR Classification Criteria for Polymyalgia Rheumatica in Comparison with the Former Ones: A Single Centre Study. Pierluigi Macchioni, Maria Grazia Catanoso, Luigi Boiardi and Carlo Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy 1517. Annexin-A1: A Potential Novel Biomarker in Giant Cell Arteritis. Suchita Nadkarni1, Jane Hollywood2, Justin C. Mason3, Bhaskar Dasgupta4 and Mauro Perretti1, 1Barts and the London School of Medicine, London, United Kingdom, 2 Southend Hospital, Southend, United Kingdom, 3Imperial Coll/Hammersmith Hosp, London, United Kingdom, 4 Southend University Hospital, Essex, United Kingdom

2011 Program Book

245

ACR/ARHP Poster Session B 1518. Prospective Evaluation of Aortic Structural Damage (aneurysm/dilatation) Using a Predefined Screening Protocol in Biopsy-Proven Giant-Cell Arteritis Patients with Extended Follow-up. Ana García-Martínez, Pedro Arguis, Sergio Prieto-González, José Hernández-Rodríguez, Georgina Espígol, Marc Corbera, Marco Alba, Itziar Tavera-Bahillo, Ester Planas and María Cinta Cid, Vasculitis research unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain 1519. Clinical Profile and Therapeutic Approaches in Polymyalgia Rheumatica: Is hydroxychloroquine a Useful SteroidSparing Agent in the Management of the Disease? Rosaria Talarico, Nicolò Giusti, Anna d’Ascanio, Pasquale Pepe, Maurizio Mazzantini and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy 1520. Does Ultrasonography Guidance Increase the Yeld of Temporal Artery Biopsy in Patients with Giant Cell Arteritis? Preliminary Results From a Single-Blinded Randomized Study. Giuseppe Germanò, Nicolo Pipitone, Luigi Boiardi, Ilaria Chiarolanza, Luca Cimino, Maria Grazia Catanoso, Andrea Caruso and Carlo Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy 1521. Incidence of Peripheral Vascular Disease and Myocardial Infarction Among Patients with Giant Cell Arteritis. Gunnar Tomasson1, Christine Peloquin1, Thorvardur Love2, Aladdin Mohammad3, Yuqing Zhang1, Hyon K. Choi1 and Peter A. Merkel1, 1Boston University School of Medicine, Boston, MA, 2 Landspitali University Hospital, Reykjavík, Iceland, 3Skåne University Helsingborg, Lund, Sweden 1522. Incidence of Cerebrovascular Accidents Among Patients with Giant Cell Arteritis. Gunnar Tomasson1, Christine Peloquin1, Thorvardur Love2, Aladdin Mohammad3, Yuqing Zhang1, Hyon K. Choi1 and Peter A. Merkel1, 1Boston University School of Medicine, Boston, MA, 2Landspitali University Hospital, Reykjavík, Iceland, 3Skåne University Helsingborg, Lund, Sweden 1523. Age At Onset and Gender Are Associated with Differences in Giant Cell Arteritis (GCA) Initial Presentation and Outcome. Marco A. Alba, Ana García-Martínez, Itziar TaveraBahillo, Sergio Prieto-González, Georgina Espígol, Jose Hernandez-Rodriguez and Maria C. Cid, Vasculitis research unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain 1524. DEVELOPMENT of Ischemic COMPLICATIONS In PATIENTS with Giant CELL Arteritis Presenting with Apparently Isolated Polymyalgia Rheumatica. Paula Estrada, Javier Narvaez, Laura Lopez-Vives, Irene Martín-Esteve, Carmen Gomez-Vaquero and Joan Miquel Nolla, Hospital Universitario de Bellvitge, Barcelona, Spain 1525. Frequency of Pulmonary Arterial Hypertension Is Not Increased in Takayasu’s Arteritis. Melike Kalfa1, Oktay Musayev2, Hakan Emmungil1, Ozgul Soysal3, Zevcet Yilmaz1, Vedat Inal1, Servet Akar3, Nurullah Akkoc3, Fatos Onen3,

246

2011 Program Book

Meral Kayikcioglu2, Gokhan Keser1 and Kenan Aksu1, Dept. of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, 2Dept. of Cardiology,Ege University, Izmir, Turkey, 3Dept. of Internal Medicine, Division of Rheumatology, Dokuz Eylül University, Izmir, Turkey 1

1526. Lower Respiratory Tract Involvement In Relapsing Polychondritis. Elisa Perry1, Shirish Sangle2, Rebecca Preston1 and DP. D’Cruz3, 1St Thomas’ Hospital, London, United Kingdom, 2Louise Coote Lupus Unit, St Thomas’ Hospital, London, United Kingdom, 3St. Thomas’ Hospital, London, United Kingdom 1527. Ischemic Colitis (IC) Associated with Rheumatic Diseases; A Colonoscopic Study of 23 IC Cases. Ikuko Masuda1, Masako Hara1, Hisae Ichida2, Kae Takagi2, Takahisa Gono2, Yasuhiro Katsumata2, Yasushi Kawaguchi2 and Hisashi Yamanaka2, 1 International University of Health and Welfare, Sanno Hospital, Tokyo, Japan, 2Tokyo Women’s Medical University, Tokyo, Japan 1528. Presentation and Outcome of Hepatitis C Virus-Related Mixed Cryoglobulinemia Cardiomyopathy. Benjamin Terrier1, Alexandre Karras2, Philippe Cluzel3, Jean-Philippe Collet4, Damien Sène5, David Saadoun6 and Patrice Cacoub5, 1 Pitié-Salpêtrière Hospital, Paris, France, 2Nephrology, HEGP, Paris, France, 3Radiology, Pitié-Salpétrière, Paris, France, 4 Cardiology, Pitié-Salpétrière, Paris, France, 5CHU PitiéSalpêtrière, Paris, France, 6Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France 1529. Lymphoma Prevalence in Patients with Serum Cryoglobulins with or without Cryoglobulinemic Vasculitis: Data Extrapolated From the Cryoglobulinemic Vasculitis Classification Criteria Database. Luca Quartuccio1, Laura Corazza2, Giuseppe Monti3, Armando Gabrielli4, Athanasios G. Tzioufas5, Clodoveo Ferri6, Gianfranco Ferraccioli7, Manuel Ramos-Casals8, Michael Voulgarelis9, Marco Lenzi10, Maria Teresa Mascia11, Domenico Sansonno12, Patrice Cacoub13, Matija Tomsic14, Antonio Tavoni15, Maurizio Pietrogrande16, Anna Linda Zignego17, Salvatore Scarpato18, Pietro Pioltelli19, Serge D. Steinfeld20, Peter Lamprecht21, Stefano Bombardieri22, Massimo Galli23 and Salvatore De Vita2, 1Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, 2Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, 3Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, 4Clinica Universitaria Ancona, Ancona, Italy, 5Medical School-Univ of Athens, Athens, Greece, 6Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy, 7 Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 8IDIBAPS, Hospital Clínic, Barcelona, Spain, 9Department of Pathophysiology, Athens, Greece, 10 Department of Clinical Medicine, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy, 11Dipartimento

ACR/ARHP Poster Session B Apparato Locomotore, AOU Policlinico di Modena, Modena, Italy, 12Section of Internal Medicine and Clinical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari, Medical School, Bari, Italy, 13CHU PitiéSalpêtrière, Paris, France, 14University Medical Centre Ljubjana, Ljubljana, Slovenia, 15Via Roma 67, Pisa, Italy, 16 Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, 17viale Morgagni 85, Florence, Italy, 18Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, 19 Hematology, S.Gerardo Hospital, Monza, Italy, 20Clinique Saint-Jean, Brussels, Belgium, 21Oskar-Alexander-Street 26 , Bad Bramstedt, Germany, 22Rheumatology Unit, Pisa, Italy, 23Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy 1530. Comparison of Clinical and Laboratory characteristics of Cryoglobulinemic Vasculitis Associated with Primary Sjӧgren’s Syndrome and Hepatitis C Virus Infection. Svetlana G. Palshina1 and Vladimir I. Vasiljev2, 1Scientific research institute of rheumatology of RAMS, Moscow, Russia, 2Scientific research institute of rheumatology of RAMS, Moscow, Russia, Moscow, Russia 1531. Childhood Granulomatosis with Polyangiitis: Prevalence and Treatment of Airway Stenosis. Nicole M. Fowler1, Jocelyn M. Beach2, Paul Krakovitz1 and Steven J. Spalding1, 1 Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 1532. Comparison of CNS Vasculitis in Children and Adults: Is This the Same Disease Entity? Marinka Twilt1, Tania Cellucci2, Carlo Salvarani3, Gene G. Hunder4 and Susanne M. Benseler1, 1The Hospital for Sick Children, Toronto, ON, 2 Hospital for Sick Children, Toronto, ON, 3Arcispedale S Maria Nuova, Reggio Emilia, Italy, 4Mayo Clinic, Rochester, MN 1533. CIRCULATING LEVELS of Klotho In Kawasaki DISEASE: A POSSIBLE NEW MARKER of Vascular DAMAGE? Fernanda Falcini1, Laura Masi2, Francesco Franceschelli2, Gigliola Leoncini2, Serena Capannini1, Francesco La Torre3, Marco Matucci Cerinic1 and Maria Luisa Brandi2, 1Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Firenze, Italy, 2Department of Internal Medicine, Endocrinology Unit, University of Florence, Firenze, Italy, 3DIMIMP-University Rheumatologic Section, Policlinico of University, Bari, Italy 1534. Vessel Remodeling in Childhood Primary CNS Vasculitis: Impact of Corticosteroid Therapy. Gordon S. Soon, Ivanna Yau, Derek Armstrong, Pascal N. Tyrrell, Suzanne Laughlin, Gabrielle deVeber and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON 1535. Systemic Vasculitis and Pregnancy: Maternal and Neonatal Outcome of 20 Prospectively Followed Pregnancies. Micaela Fredi1, Marta Mosca2, Tamara Ziglioli1, Chiara Tani2, Matteo Filippini1, Francesca Strigini2, Laura Andreoli1, Cinzia Casu1, Mario Motta3, Andrea Lojacono4 and Angela Tincani1,

Rheumatology Unit, University of Brescia, Brescia, Italy, University of Pisa, Pisa, Italy, 3Neonathology and NICU, Spedali Civili, Brescia, Italy, 4Obstetric and Gynecology of Brescia, Brescia, Italy 1 2

1536. Infertility Among Patients with Vasculitis. Megan E. B. Clowse1, Rachel Richesson2, Carl Pieper1, Peter A. Merkel3 and Vasculitis Clinical Research Consortium4, 1Duke University Medical Center, Durham, NC, 2University of South Florida, Tampa, FL, 3Boston University School of Medicine, Boston, MA, 4Boston 1537. Pregnancy in Men and Women with Vasculitis. Megan E. B. Clowse1, Rachel Richesson2, Carl Pieper1, Peter A. Merkel3 and Vasculitis Clinical Research Consortium4, 1Duke University Medical Center, Durham, NC, 2University of South Florida, Tampa, FL, 3Boston University School of Medicine, Boston, MA, 4Boston

ARHP Epidemiology and Public Health 1538. The Impact of Pain on Successful Ageing. Ross Wilkie1, Abdelouahid Tajar2 and John McBeth1, 1Keele University, Newcastle-under-Lyme, United Kingdom, 2University of Manchester, Manchester, United Kingdom 1539. Not So Golden Years: Older (≥65 years) Women with Arthritis Are Employed Least and Disabled Most. Kristina A. Theis1 and Sylvia Furner2, 1Centers for Disease Control and Prevention, Atlanta, GA, 2University of Illinois at Chicago, Chicago, IL 1540. A Population-Based Study Comparing the Impact of Arthritis and Chronic Joint Symptoms: Are There Implications for Arthritis Education and Health Care? Mayilee Canizares1 and E. M. Badley2, 1Toronto Western Research Institute, Toronto, ON, 2Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON 1541. Does Important Improvement in Function After Knee Replacement Guarantee Good Absolute Function. Jessica L. Maxwell1, David T. Felson2, Jingbo Niu2, Barton Wise3, Michael C. Nevitt4, Jasvinder Singh5, Laura Frey-Law6 and Tuhina Neogi2, 1Boston University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Ctr for Healthy Aging-UC Davis, Sacramento, CA, 4University of CaliforniaSan Francisco, San Francisco, CA, 5University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, 6University of Iowa, Iowa City, IA 1542. Patterns of WOMAC Function in People with or At High Risk of Knee Osteoarthritis: The Osteoarthritis Initiative. Uyen Sa D. Nguyen1, Bin Zhang2, Jingbo Niu1, Daniel K. White1 and Yuqing Zhang1, 1Boston University School of Medicine, Boston, MA, 2Boston Univ School of Medicine, Boston, MA 1543. Disease Impact of Osteoarthritis in Hands, Hip, Knee or Generalized Osteoarthritis - a Cross Sectional Study. Rikke Helene Moe1, Margreth Grotle1, Ingvild Kjeken2, Kåre Birger 2011 Program Book

247

ACR/ARHP Poster Session B Hagen1, Tore K. Kvien3 and Till Uhlig3, 1National Resource Centre for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway, 2Diakonjemmets Hospital, Oslo, Norway, 3Diakonhjemmet Hospital, Oslo, Norway 1544. Association of Depressive Symptoms and Helplessness with Socioeconomic Status in People with Hip Osteoarthritis. My-Linh Luong, Leigh F. Callahan, Rebecca J. Cleveland, Britta L. Schoster, Jordan Renner and Joanne M. Jordan, University of North Carolina, Chapel Hill, NC 1545. Current Social Position Associated with Rheumatoid Arthritis Severity and Self-Reported Health Outcomes in African Americans. Leigh F. Callahan1, Rebecca J. Cleveland1, Xia Li1, Todd A. Schwartz1, Beth L. Jonas1, Ted R. Mikuls2, Britta L. Schoster1, Graciela S. Alarcon3, Richard Brasington4, Doyt L. Conn5, Edwin A. Smith6, George Howard3, Larry W. Moreland7 and S. Louis Bridges Jr.8, 1University of North Carolina, Chapel Hill, NC, 2Omaha VA and University of Nebraska, Omaha, NE, 3University of Alabama at Birmingham, Birmingham, AL, 4Washington Univ School of Med, St. Louis, MO, 5Emory Univ School of Medicine, Atlanta, GA, 6Med Univ of South Carolina, Charleston, SC, 7University of Pittsburgh, Pittsburgh, PA, 8Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 1546. Early Consultation with a Rheumatologist for Rheumatoid Arthritis: Does It Reduce Subsequent Use of Orthopaedic Surgery? Debbie Ehrmann Feldman1, Sasha Bernatsky2, Michelle Houde3, Marie-Eve Beauchamp2 and Michal Abrahamowicz2, 1Université de Montréal, Montréal, QC, 2 McGill UHC/RVH, Montreal, QC, 3Public Health Department of Montreal, Montreal, QC 1547. Tumor Necrosis Factor Blocker Treatment Patterns After Discontinuation within the First Year of Therapy Initiation in Rheumatoid Arthritis Patients in a Real-World Managed Care Setting. Machaon Bonafede1, Crystal Watson2, Kathy M. Fox3, Nicole Princic1 and Shravanthi R. Gandra2, 1 Thomson Reuters Healthcare, Cambridge, MA, 2Amgen Inc, Thousand Oaks, CA, 3Strategic Healthcare Solutions, LLC, Monkton, MD 1548. Analysis of Radiographic Changes in Patients with Early Psoriatic Arthritis. Majed M. Khraishi1, Rana Aslanov2, Emmanouil Rampakakis3, Anh Duong4 and John S. Sampalis3, 1 Memorial University of Newfoundland, St Johns, NF, 2 Memorial University of Newfoundland, St.John’s, NF, 3 McGill University & JSS Medical Research, Montreal, QC, 4 JSS Medical Research, Westmount, QC 1549. PATIENTS with Polymyositis, Dermatomyositis and Inclusion BODY Myositis Have ACTIVITY Limitations Despite LOW DISEASE ACTIVITY: A REGISTRY STUDY. Li Alemo Munters1, Malin Regardt2, Therese Jansson3, Susanna Johansson3, Christina Ottosson4, Maryam Dastmalchi5, Ingrid E. Lundberg3 and Helene Alexanderson3, 1Rheumatology Unit, , Karolinska University Hospital in Solna, Karolinska

248

2011 Program Book

Institutet, Stockholm, Sweden, 2Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 3 Karolinska Institutet, Stockholm, Sweden, 4Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, 5 Rheumatology Unit, , Karolinska University Hospital in Solna, Karolinska Institutet., Stockholm, Sweden 1550. Influenza Vaccine Intervention in a Rheumatology Clinic Population. Sherece Black1, Sarabjit Brar1, Lee Chang, Sylvia Chico1, Donald Makowski1, Virginia Haiduc1, Steven K. Magid3, Julie A. Pollino-Tanner1, Julita C. Reyes-Canu1, Ann M. Rakowicz1 and Monica C. Richey1, 1Hospital for Special Surgery, New York, NY, 2Hosp for Special Surgery, New York, NY 1551. What Is the Health Literacy and Numeracy in a Rheumatology Veterans Population? Janine A. Galasso, Philadelphia VA Medical Center, Philadelphia, PA 1552. Factors Associated with Hallux Valgus: The Johnston County Osteoarthritis Project. Yvonne M. Golightly1, Marian T. Hannan2, Alyssa B. Dufour3, Jordan Renner4 and Joanne M. Jordan1, 1UNC Thurston Arthritis Research Center, Chapel Hill, NC, 2Hebrew SeniorLife & Harvard Med Sch, Boston, MA, 3Hebrew SeniorLife & Boston Univ, Boston, MA, 4 University of North Carolina at Chapel Hill, Chapel Hill, NC 1553. Foot Type Is Linked to Falls in Older Adults: The Framingham Foot Study. Jody L. Riskowski1, Thomas J. Hagedorn2, Alyssa B. Dufour3, Virginia A. Casey2 and Marian T. Hannan4, 1Hebrew SeniorLife, Boston, MA, 2Hebrew Senior Life, Boston, MA, 3Hebrew SeniorLife & Boston Univ, Boston, MA, 4Hebrew SeniorLife & Harvard Med Sch, Boston, MA 1554. The Effect of Foot Pain on Mobility Disability in Older Adults: The Framingham Foot Study. Virginia A. Casey1, Alyssa B. Dufour2, Jody L. Riskowski3, Thomas J. Hagedorn1, Robert R. McLean4 and Marian T. Hannan5, 1Hebrew Senior Life, Boston, MA, 2Hebrew SeniorLife & Boston Univ, Boston, MA, 3Hebrew SeniorLife, Boston, MA, 4Hebrew Senior Life/ Harvard Medical School, Boston, MA, 5Hebrew SeniorLife & Harvard Med Sch, Boston, MA 1555. Lesser Toe Deformities Are Highly Heritable in Older Men and Women: The Framingham Foot Study. Marian T. Hannan1, Yi-Hsiang Hsu1, Virginia A. Casey2, Gouri Vadali2 and Joanne M. Jordan3, 1Hebrew SeniorLife & Harvard Med Sch, Boston, MA, 2Hebrew Senior Life, Boston, MA, 3UNC Thurston Arthritis Center, Chapel Hill, NC 1556. Factors Affecting Dynamic Foot Function in Older Adults: The Framingham Foot Study. Thomas J. Hagedorn1, Alyssa B. Dufour2, Yvonne M. Golightly3, Jody L. Riskowski4, Howard J. Hillstrom5, Virginia A. Casey1 and Marian T. Hannan6, 1 Hebrew Senior Life, Boston, MA, 2Hebrew SeniorLife & Boston Univ, Boston, MA, 3University of North Carolina, Chapel Hill, NC, 4Hebrew SeniorLife, Boston, MA, 5Hospital Special Surgery (HSS), New York, NY, 6Hebrew SeniorLife & Harvard Med Sch, Boston, MA

ACR/ARHP Poster Session B ARHP Rehabilitation Sciences 1557. Non-Pharmacological Interventions for Fatigue in Rheumatoid Arthritis: A Cochrane Review. Fiona Cramp1, Sarah Hewlett1, Celia Almeida1, John R. Kirwan2, Ernest Choy3, Trudie Chalder4, Jon Pollock1 and Robin Christensen5, 1 University of the West of England, Bristol, United Kingdom, 2 University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, 3Cardiff University, Cardiff, ENGLAND, United Kingdom, 4Department of Psychological Medicine, London, United Kingdom, 5Copenhagen, Denmark 1558. Relationship Between Beliefs, Motivation and Worries about Physical Activity and Physical Activity Participation in Persons with Rheumatoid Arthritis. Linda S. EhrlichJones1, Jungwha Lee2, Pamela A. Semanik3, Cheryl Cox4, Dorothy D. Dunlop5 and Rowland W. Chang2, 1Rehabilitation Institute Chicago, Chicago, IL, 2Northwestern University, Chicago, IL, 3Rehabilitation Institute Chicago, Oak Park, IL, 4St. Jude Children’s Research Hospital, Memphis, TN, 5 Northwestern Univ Med School, Chicago, IL 1559. A Qualitative Study of Exercise Habits of Individuals with Rheumatoid Arthritis Taking Anti-TNFαMedication Sixteen Weeks Following Participation in a Randomised Controlled Trial. Angela Reid1, Audrey Brady1, Catherine Blake2, AnneBarbara Mongey3, Douglas J. Veale3, Oliver M. FitzGerald3 and Tara Cusack2, 1Our Lady’s Hospice and Care Services, Dublin, Ireland, 2University College Dublin, Dublin, Ireland, 3 St. Vincent’s University Hospital, Dublin, Ireland 1560. Muscle Area and Muscle Quality Relate to Physical Activity in Subjects with Rheumatoid Arthritis. Samannaaz S. Khoja, Gustavo JM Almeida, Bret H. Goodpaster and Sara R. Piva, University of Pittsburgh, Pittsburgh, PA 1561. Associations Between Changes in Physical Function and Physical Activity in Response to An Exercise Program in Patients with Rheumatoid Arthritis. Gustavo JM Almeida and Sara R. Piva, University of Pittsburgh, Pittsburgh, PA 1562. Sensorimotor Training Versus Resistance Training in Patients with Knee Osteoarthritis. Aline B. Gomiero1, Virginia M. Trevisani2, Andrea H. Kayo2, Maria Stella Peccin3 and Marcelo Abraão4, 1Federal University of Sao Paulo, São Paulo, Brazil, 2Federal University of São Paulo, São Paulo Brazil, Brazil, 3Federal University of São Paulo, São Paulo, Brazil, 4Federal University of São Paulo, Brazil 1563. Reductions in Knee Joint Loading After Focused Hip Muscle Training. Laura E. Thorp, Markus A. Wimmer, D. Rick Sumner and Joel A. Block, Rush University Medical Center, Chicago, IL 1564. A Survey of Physical Therapists’ Use of Outcome Measures In Total Hip and Knee Arthroplasty. Catherine A. McAuley1, Marie D. Westby1, Alison Hoens2, Ronda Field3, UBC 2011 MPT Students4 and W. Darlene Reid2, 1Mary Pack Arthritis Centre, Vancouver, BC, 2University of British Columbia, Vancouver, BC, 3Richmond Hospital, Richmond, BC, 4 Vancouver, BC

1565. Describing the Interventions in Home Care Physical Therapy for Patients Following Total Knee Replacement. Kimberly Nanovic1, Amy Phillips1, Elizabeth Childs1, Patricia D. Franklin2 and Carol A. Oatis1, 1Arcadia University, Glenside, PA, 2Univ of MA Med Schl, Worcester, MA 1566. Dysautonomia and Chronotropic Incompetence in Fibromyalgia. Roberta P. C. Ribeiro1, Thalita Dassouki2, Luiz A. Perandini2, Guilherme G. Artioli1, Ana L. G. Calich3, Ana Lucia S. Pinto4, Hamilton Roschel5, Fernanda R. Lima6, Eloisa Bonfa7 and Bruno Gualano8, 1University of Sao Paulo,, Sao Paulo, Brazil, 2University of Sao Paulo, Rheumatology Division, LACRE, Sao Paulo, Brazil, 3University of Sao Paulo, Sao Paulo, Brazil, 4University of Sao Paulo, School of Medicine, Rheumatology Division, LACRE, Sao Paulo, Brazil, 5 University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil, 6University of Sao Paulo, School of Medicine, Rheumatology Division, Sao Paulo, Brazil, 7 Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, 8University of Sao Paulo,School of Physical Education and Sport, Sao Paulo, Brazil 1567. Participation in Household and Community Activities by Persons with Systemic Sclerosis. Janet L. Poole1, Betty Skipper2, Kristal Hildebrand1 and Annandhi Chandrasekaran1, 1 University of New Mexico, Albuquerque, NM, 2University of New Mexico, NM 1568. Effect of Physical Exercise in Systemic Sclerosis - A Pilot Study. Jenny Bergegård1 and Helene Alexanderson2, 1 Karolinska University Hospital, Solna, Stockholm, Sweden, 2 Karolinska Institutet, Stockholm, Sweden 1569. Mobility and disease Activity but Not Aerobic Capacity Relate to Functional Disability in Ankylosing Spondylitis. Fabio Jennings, Hilda A. Oliveira, Marcelo C. Sousa, Vaneska G. Cruz and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil 1570. A Multidisciplinary and Multidimensional Program for Hand Osteoarthritis Is Not Effective; Results of a Randomized Controlled Study. Mirelle J. Stukstette1, Joost Dekker2, Alfons A. den Broeder1, Willemijn Noort van der Laan3, Johannes W.J. Bijlsma4 and Cornelia H.M. van den Ende1, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2VU University Medical Centre, EMGO Institute, Amsterdam, Netherlands, 3Maartenskliniek Woerden, Woerden, Netherlands, 4UMC Utrecht, Utrecht, Netherlands 1571. Association of Pinch Strength with Hand Dysfunction, Finger Deformities and Contact Points In Patients with Rheumatoid Arthritis. Kenrin Shi1, Akihide Nampei2, Kosuke Ebina1, Tsuyoshi Murase1, Hideki Yoshikawa1, Makoto Hirao3 and Jun Hashimoto3, 1Osaka University Graduate School of Medicine, Osaka, Japan, 2Osaka Rosai Hospital, Sakai, Japan, 3 Osaka Minami Medical Center, Osaka, Japan

2011 Program Book

249

ACR/ARHP Poster Session B ARHP Clinical Practice/Patient Care 1572. Effects of Maximal Acute Physical Exercise on Prothrombin Time in Patients with Primary Antiphospholipid Syndrome (PAPS) Under Oral Anticoagulation with Warfarin and Exercise Capacity. Carolina B. Garcia1, Luciana N. J. Matos2, Carlos E. Negrao2, Hamilton Roschel3, Ana Lucia S. Pinto4, Jozelio F. Carvalho5, Eloisa Bonfa6 and Fernanda R. Lima1, 1 Rheumatology Department, Sao Paulo, Brazil, 2University of Sao Paulo, InCor, Sao Paulo, Brazil, 3University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil, 4 University of Sao Paulo, School of Medicine, Rheumatology Division, LACRE, Sao Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 6Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil 1573. Effects of Sexual Dysfunction in Men with Scleroderma: Psychological Impact and Interaction with Health Professionals. Tanaka Ngcozana1, Cecilia B. Chighizola2, Louise Parker1, Carol M. Black DBE1, Voon Ong3 and Christopher D. Denton4, 1UCL Medical School and Royal Free Hosp, London, United Kingdom, 2UCL Medical School, London, United Kingdom, 3UCL Medical School, London, England, 4Royal Free Hospital, Medical School, London, England 1574. “Lo Que Me Diga El Doctor”: Patient Reported Interpersonal Processes of Care in An Urban Rheumatology Clinic. Alice Fike1, Katherine Kline2, Jorel Martinez3 and Mark F. Gourley4, 1National Institutes of Health, Bethesda, MD, 2 NIH/NIAMS, Bethesda, MD, 3Chicago, 4Bethesda, MD 1575. Pilates in Juvenile Idiopathic Arthritis. Tania Mendonça IV, Osvaldo Marques da Silva e Valda Maria da Silva, Sao Paulo, Brazil 1576. Ambivalent Attitudes, Accessing Information and DecisionMaking: An Interview Study of Medication Use in Early Rheumatoid Arthritis (RA). Anne F. Townsend1, Paul M. Adam2, Catherine L. Backman3, Linda C. Li3 and ERAHSE Team4, 1Arthritis Research Centre of Canada, Vancouver, BC, 2 Mary Pack Arthritis Centre, Vancouver, BC, 3University of British Columbia, Vancouver, BC, 4Vancouver & Toronto 1577. Conception, Family Size and Miscarriages in Fibromyalgia Patients. Robert S. Katz1, Sharon M. Ferbert2, Patricia Kuenzi1, Jessica L. Polyak3 and Susan Shott1, 1Rush University Medical Center, Chicago, IL, 2Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, 3Rheumatology Associates, Chicago, IL 1578. Participation in Hospital Influenza Collaborative Is “inFLUential” in Improving Vaccination Rates in Patients with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus. Janalee Taylor1, Elaine F. Haddix2, Kim Badinghaus3, Mary Beth Burns1, Terry M. Moore4, Julie V. Ranz1, Amy Anneken1, Pam Fiorini1, EVA Spiegel1, Esi Morgan DeWitt1, Michael Henrickson1, Hermine Brunner1 and Jennifer L. Huggins1, 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children’s Hospital MC,

250

2011 Program Book

Cincinnati, OH, 3Cincinnati Children’s Hospital Center, Cincinnati, OH, 4Cincinnati Chiildren’s Hospital Medical Center, Cincinnati, OH

ARHP Education and Community Programs 1579. Incorporating the Patient Perspective: Developing a Patient-Focused Evaluation for An Early RA Support and Education Program. Meredith K. Wolrich, Adena Batterman, Roberta Horton, Linda Leff, Theodore R. Fields and Vanima Lalsa, Hospital for Special Surgery, New York, NY 1580. Preferences for Arthritis Interventions: Comparison Between Blacks and Whites with Arthritis. Chivon A. Mingo1, Jessica M. McIlvane2 and William E. Haley2, 1 University of North Carolina, Chapel Hill, NC, 2University of South Florida, Tampa, FL 1581. Increased Awareness of Arthritis May Result in Earlier Diagnosis of Rheumatoid Arthritis. Sara Zafar1, Humeira M. Badsha2, Ayman Mofti2, Arlene Delosantos2, Janice Altares2, Gerald Matudio2 and Kok Ooi Kong3, 1University of Edinburgh, Edinburgh, United Kingdom, 2Al Biraa Arthritis Center, Dubai, United Arab Emirates, 3Tan Tong Seck Hospital, Singapre, Singapore 1582. Effects of a Telephone Based OA Self-Management Program on Communication with Health Care Providers. Kelli D. Allen1, Hayden B. Bosworth1, Cynthia Coffman1, Jennifer H. Lindquist1, Nina R. Sperber1, Morris Weinberger2 and Eugene Z. Oddone1, 1Duke and Durham VA Medical Center, Durham, NC, 2University of North Carolina at Chapel Hill & Durham VA Medical Center, Durham, NC 1583. How Do Self-Directed Participants Follow the Arthritis Foundation’s Walk with Ease Program? Kirsten A. Nyrop, Britta L. Schoster, Mary Altpeter, Betsy Hackney and Leigh F. Callahan, University of North Carolina, Chapel Hill, NC 1584. Improving Doctor-Patient Communication Through Let’s Talk RA. Arlene Vinci, Emily L. Creek and Cindy McDaniel, Arthritis Foundation, Atlanta, GA 1585. A Needs Assessment of Hospital for Special Surgery’s Charla De Lupus/Lupus Chat® Teen and Parent Support Group: Gaining a Community Perspective on Nutritional Health to Inform Implementation of a Nutrition Education Intervention. Jillian A. Rose1, Christie Carlstorm2, Roberta Horton1, Sandra Goldsmith1, Robyn Wiesel1 and Lisa F. Imundo3, 1Hospital for Special Surgery, New York, NY, 2 Hospital For Special Surgery, New York, NY, 3Childrens Hospital of New York, Columbia University Medical Center, New York, NY 1586. Citizen Engagement in Arthritis Research for Patient Centered Research: A Model of Success. Louise Bergeron, Dawn Richards, Linda Wilhelm, John Coderre, Delia Cooper, Janet Gunderson, Louise Crane, Christopher DeBow, Simone Hughes, Marie-Eve Veilleux, Iris Maurstad, Neil White, Elaine Wychreschuk and Katy Miller, Canadian Arthritis Network, Toronto, ON

ACR/ARHP Poster Session C TUESDAY, NOVEMBER 8, 2011

Hall F2 - Poster Hall B Cell Biology and Targets in Autoimmune Disease 1733. Reduced Imprints of Receptor Editing At the Immunologlobulin κ and λ Light Chain Loci During Rituximab Treatment. Khalid Muhammad1, Arumugam Palanichamy1, Petra Roll1, Stefan Kleinert1, Thomas Dörner2 and Hans-Peter Tony1, 1University of Würzburg, Würzburg, Germany, 2Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany 1734. The Levels of Memory B-Cells with a Plasmablast-Like Phenotype Are Associated with Response to Anti-CD20 Treatment in Rheumatoid Arthritis. Gururaj Arumugakani1, Andrew Rawstron2, Reuben Tooze1, Paul Emery3 and Dennis McGonagle4, 1University of Leeds, Leeds, United Kingdom, 2 NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 4 University of Leeds and Leeds Teaching Hospitals, Leeds, United Kingdom 1735. B Cell Depletion Therapy After Multiple Cycles of Rituximab in Patients with Rheumatoid Arthritis: B Cell and Plasma Cell Dynamics Measured Using Serology. Geraldine Cambridge1, Maria J. Leandro1, Jonathan CW Edwards1, Harvey M. Parsons1, Marion C. Dickson2 and Hayley Perry2, 1 UCL, London, United Kingdom, 2GSK, Stevenage 1736. Value of Predictive B Cell Markers for EULAR Response to RITUXIMAB in Patients with Rheumatoid Arthritis (FIRST). Hans-Peter Tony1, Petra Roll1, Henrik Mei2, Lara Gnuegge3, Monika Kobialko3, Thomas Dörner4 and FIRST study team5, 1 University of Würzburg, Würzburg, Germany, 2Charite Universitätsmedizin Berlin and DRFZ,, 10117 Berlin, Germany, 3 Roche Pharma AG, 79639 Grenzach-Wyhlen, Germany, 4 Charite Universitätsmedizin Berlin and DRFZ,, Berlin,, Germany, 5Würzburg 1737. B Cell Activating Factor (BAFF) Binding Receptors (BBR) on B Cells: Characterization in Patients with Rheumatoid Arthritis (RA) Receiving B Cell Depletion Therapy (BCDT) Based on Rituximab ( Rtx). Elena Becerra-Fernandez1, Inmaculada de la Torre2, Lara Valor2, Maria J. Leandro1 and Geraldine Cambridge1, 1UCL, London, United Kingdom, 2 Gregorio Marañón Hospital, Madrid, Spain 1738. No Expression of An Alternative CD20 Transcript Variant in B Cells From Patients with Rheumatoid Arthritis. Marina Deschamp1, Béatrice Gaugler1, Philippe Saas1, Christophe Ferrand1 and Eric Toussirot2, 1INSERM UMR645 - IFR 133, Besançon, 2Rheumatology and CIC Biotherapy 506 and EA 4266 Pathogens and Inflammation, Besançon, France

1739. B Cell Function and Cytokine Secretion After B Cell Depletion Therapy in SLE and RA. Arumugam Palanichamy, James Roger, Wensheng Wang, Jennifer Barnard, Jamie Biear, Chungwen Wei, Iñaki Sanz and Jennifer H. Anolik, University of Rochester, Rochester, NY 1740. Rituximab for the Treatment of IgG4-Related Disease: Lessons From Ten Consecutive Patients. Arezou Khosroshahi, Mollie Carruthers, Vikram Deshpande, Sebastian Unizony, Donald B. Bloch and John H. Stone, Massachusetts General Hospital, Boston, MA 1741. Antibody Secreting Cells Arising After Vaccination From Anti-Cardiolipin Positive Individuals Can Produce Antibodies Which Are Bi-Specific and Bind to Both Cardiolipin and the Vaccinating Antigen. Kenneth Smith1, Jennifer Muther1, Angie Duke1, Emily McKee1, Patrick C. Wilson2 and Judith A. James3, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Chicago, Chicago, IL, 3Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK 1742. Epratuzumab Inhibits Upstream B Cell Receptor Signaling and Modulates Ca2+ Flux Upon Activation. N. Sieger1, K. Reiter1, H.E. Mei1, T. Shock2, C. Daridon1 and T. Dörner1, 1 Charité University Medicine Berlin, Berlin, Germany, 2UCB, Slough, United Kingdom 1743. PTPN22 Risk Allele Interferes with the Removal of Developing Autoreactive B Cells in Humans. David Saadoun1, Laurence Menard2, Isabelle Isnardi2, Yen-shing Ng3, Greta Meyers2, Clara Abraham4, Roja Moyaghedi5, Jane Buckner6, Peter K. Gregersen7 and Eric Meffre8, 1Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511, USA;, New haven, 3 Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511, USA;, New Haven, 4 Department of Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06509, USA,, New Haven, 5Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA,, New York, 6Translational Research Program, Benaroya Research Institute, Seattle, WA 98101, USA,, Seattle, 7 Feinstein Institute Medical Reschearch, Manhasset, NY, 8 Yale University School of Medicine, New Haven, CT 1744. Syk Inhibition with Fostamatinib Leads to Transitional B Lymphocyte Depletion. Chungwen Wei, Paul M. Barr, Julia Schaefer-Cutillo, John Jung, James Roger, Jennifer L. Kelly, Alex Rosenberg, Jonathan W. Friedberg and Iñaki Sanz, University of Rochester, Rochester, NY 1745. Carbamoylation of Vimentin in Patients with Rheumatoid Arthritis: Identification of a Novel Protein Modification with a Possible Link to Disease Pathogenesis. Holger Bang1, 2011 Program Book

251

ACR/ARHP Poster Session C Karl Egerer2, Anette Krämer1, Eugen Feist2 and Gerd R. Burmester2, 1Orgentec Diagnostika GmbH, Mainz, Germany, 2 Charité - Universitätsmedizin Berlin, Berlin, Germany 1746. Early Rheumatoid Arthritis (ERA) Has Lower Levels of Plasmablasts and Memory B Cells Compared to LongStanding RA (LSRA) and Responds to Conventional Therapy with a Normalization of B Cell Subsets Abnormalities. Anna Laura Fedele, Barbara Tolusso, Silvia L. Bosello, Silvia Canestri, Elisa Gremese and Gianfranco Ferraccioli, Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy 1747. Identification of Autoantibody Profiles by Monitoring Autoantibody Biomarkers in RA with Microarray Surface Plasmon Resonance Imaging. Joyce J.B.C. Van Beers1, Angelique M.C. Segbers-Lokate1, Wilma T.M. Vree Egberts1, Richard B.M. Schasfoort2 and Ger J.M. Pruijn1, 1Radboud University Nijmegen, Nijmegen, Netherlands, 2University of Twente and IBIS Technologies BV, Enschede, Netherlands 1748. Development of a High-Throughput, Multiplex Assay for Profiling the Autoantibody Fine Specificity in Rheumatoid Arthritis. Xiaoyan Zhao1, P. Scott Eastman1, Ferhan Qureshi1, William C. Manning1, William Robinson2 and Lyndal K. Hesterberg1, 1Crescendo Bioscience, Inc., South San Francisco, CA, 2Stanford Univ School of Med, Stanford, CA 1749. Anti-hnRNP Autoantibodies Detected in Inflammatory Rheumatic Diseases in Use to Close the Sensitivity gap left by Rheumatoid Factor and Anti CCP in Early RA. Bianka Marklein1, Zoltan Konthur2, Gerd-Rüdiger Burmester3 and Karl Skriner1, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Max Planck Institute for Molecular Genetics, Berlin, Germany, 3Charité - University Medicine Berlin, Berlin, Germany 1750. Substantial Influence of Rheumatoid Factor Positivity On the Peripheral Memory B Cells and Its Modulation by TNF Inhibition In RA. Petra Roll1, Khalid Muhammad1, Mathias Schumann1, Stefan Kleinert2 and Hans-Peter Tony1, 1University of Würzburg, Würzburg, Germany, 2 Rheumatology, University of Würzburg, Würzburg, Germany 1751. Dynamic Evolution of a Public Clonotypic Autoantibody Specific for Ro60: Perpetuating Humoral Autoimmunity Through Clonotypic Shift. Rhianna Lindop1, Georgia Arentz1, Tim, K. Chataway2, Lauren A. Thurgood1, Michael W. Jackson1 and Tom P. Gordon1, 1Flinders Medical Centre and Flinders University, Adelaide, Australia, 2Flinders University, Adelaide, Australia 1752. APRIL and BAFF Levels After Rituximab Treatment in Patients with Primary Sjögren’s Syndrome: A PlaceboControlled Clinical Trial. Rodney Pollard, Wayel H. Abdulahad, Minke G. Huitema, Annie Visser, Jiska Meijer, Hans Burgerhof, Fred Spijkervet, Cees GM Kallenberg, Arjan Vissink, Frans Kroese and Hendrika Bootsma, University Medical Center Groningen, Groningen, Netherlands

252

2011 Program Book

1753. Expansion of Functionally Anergic Autoreactive CD21-/ Low Marginal Zone B Cell Clones in Hepatitis C Virus Infection-Related Autoimmunity. Benjamin Terrier1, Florence Joly2, Philippe Benech2, Michelle Rosenzwajg3, Wassila Carpentier4, Pascale Ghillani-Dalbin5, David Klatzmann3, Patrice Cacoub5 and David Saadoun6, 1PitiéSalpêtrière Hospital, Paris, France, 2Prediguard, Marseille, France, 3Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Paris, France, 4Plateforme génomique P3S, Paris, France, 5 CHU Pitié-Salpêtrière, Paris, France, 6Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France 1754. The Sympathetic Neurotransmitter Norepinephrine Inhibits Proinflammatory IL-7-Receptor Alpha Positive B Cells in Arthritis. Georg Pongratz, Judith Anthofer, Madlen Melzer and Rainer H. Straub, University Hospital Regensburg, Regensburg, Germany 1755. Arthritogenic T Cells Regulate the Homeostatic Expansion of Antigen-Specific B Cells, and These B Cells or Antibodies Are Essential for the Development of Arthritis. Katalin Kis-Toth1, Marianna Radacs2, Tamas Kobezda3, Willem van Eden4, Katalin Mikecz3 and Tibor T. Glant3, 1Boston, MA, 2 Szegedi Tudomany Egyetem: JGYPK, Szeged, Hungary, 3 Rush University Medical Center, Chicago, IL, 4Utrecht,, Netherlands 1756. FasL+ Regulatory B Cells Are Expanded by Interleukin-5 and Induce Apoptosis in CD4+ T Cells Via Cell-Cell Contact and Secretion of FasL+ Exosomes. Matthew W. Klinker, Brian Alzua, Tamra Reed, Campbell Shaw, David A. Fox and Steven K. Lundy, University of Michigan, Ann Arbor, MI 1757. Translational Medicine of a Selective Inhibitor of Btk in Rheumatic Diseases: Pharmacology and Early Clinical Development. Erica Evans, Richland Tester, Sharon Aslanian, Prasoon Chaturvedi, Russell Karp, Matt Labenski, Hormoz Mazdiyasni, Mariana Nacht, Michael Sheets, Kathryn Stiede, Steve Witowski, Heather Lounsbury, Russ Petter, Juswinder Singh and William Westlin, Avila Therapeutics, Waltham, MA 1758. A Bruton’s Tyrosine Kinase Inhibitor Prevents AntigenDriven B Cell Activation In Vivo. Micah Benson1, Varenka A. Rodriguez1, Tatyana Andreyeva1, Sean Keegan1, John R. Springer2, Mark E. Schnute2, Kyri Dunussi-Joannopoulos1, Cheryl L. Nickerson-Nutter1, Andrew L. Rankin1, Melanie Ruzek1 and John Douhan III1, 1Pfizer, Cambridge, MA, 2Pfizer, Inc, Cambridge, MA 1759. IL-10-Producing Regulatory B Cells (B10 cells) Inhibit Intestinal Injury In Mice. Koichi Yanaba and Shinichi Sato, The University of Tokyo, Tokyo, Japan

ACR/ARHP Poster Session C 1760. B Cell Depletion Enhances T Regulatory Activity Essential in the Suppression of Arthritis. Susan Ashaye, Keith Hamel, Yanxia Cao, Yumei Wang, Tibor T. Glant and Alison Finnegan, Rush University Medical Center, Chicago, IL 1761. Efficient Depletion of Autoreactive Plasma Cells within the Nephritic Kidneys in a Murine Model of SLE by Bortezomib. Charlotte M. Starke1, Vilma Urbonaviciute1, Silke Frey1, Georg Schett2 and Reinhard E. Voll3, 1Clinical Research Group, Nikolaus-Fiebiger Center of Molecular Medicine, Erlangen, Germany, 2University of Erlangen-Nuremberg, Erlangen, Germany, 3Dept. of Rheumatology and Centre of Chronic Immunodeficiency, University of Freiburg, Freiburg, Germany 1762. TLR7 Overexpression Promotes Accumulation of Autoreactive CD19+ CD11c+ B Cells. Alice Wiedeman and Keith B. Elkon, University of Washington, Seattle, WA 1763. Anti-DNA Antibody Production Is Restricted by the Germline Composition of DH Genes. Aaron Silva-Sanchez1, Cunren Liu1, Pratibha Kapoor1, Yingxin Zhuang1, Trenton R. Schoeb1 and Harry W. Schroeder Jr.2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of AlabamaBirmingham, Birmingham, AL 1764. A Novel Method to Evaluate Autoreactivity by Inducing Antibodies Secretion Allows the Study of Tolerance In Mice. Emiliano Marasco1, Nataly Manjarrez Orduño1, Peter K. Gregersen2 and Betty Diamond3, 1Feinstein Institute for Medical Research, Manhasset, NY, 2Feinstein Institute Medical Reschearch, Manhasset, NY, 3Feinstein Institute Med Rsch, Manhasset, NY 1765. Subtoxic Dose of Mercury Reduces Splenic Marginal Zone B Cells, Resulting in the Increase in Autoantibodies in Murine Mercury-Induced Autoimmunity. Takaji Matsutani1, Miho Murakami1, Hooi-Ming Lee2, Hidehiko Sugino2 and Norihiro Nishimoto1, 1Wakayama Medical University, Ibaraki, Japan, 2 Osaka University, Suita, Japan 1766. Induction of Regulatory B Cells in Healthy Individuals and Patients with Systemic Lupus Erythematosus. Shun-ichiro Ota, Hiroaki Niiro, Naoko Ueki, Hirofumi Tsuzuki, Siamak Jabbarzadeh-Tabrizi, Yasushi Inoue, Yojiro Arinobu and Koichi Akashi, Kyushu University, Fukuoka, Japan 1767. The Comprehensive B Cell Profiling Analysis of a Multicenter SLE Cohort. John Jung1, Jamie Biear1, Youqun Huang1, Bridget Neary1, Elides Marin1, Jennifer Hossler1, Elise Palmer1, Sharleen Smith1, Ehtisham Akhter2, Tracey Sanford1, Jie Xu2, Michelle Petri2, Alex Rosenberg1, Jennifer H. Anolik1, Chungwen Wei1 and Iñaki Sanz1, 1University of Rochester, Rochester, NY, 2Johns Hopkins University School of Medicine, Baltimore, MD 1768. A Novel Circulating CXCR5-CD20++ B Cell Compartment in Patients with Systemic Lupus Erythematosus. Eric S. Sobel, Edward Butfiloski, James Hunt, Mark Segal, Laurence Morel, Westley H. Reeves and Minoru Satoh, University of Florida, Gainesville, FL

1769. Effect of Mycophenolat Mofetil (MMF) on Clinical and Paraclinical Parameters in Systemic Lupus Erythematosus (SLE). Sebastian Eickenberg, Elisabeth Jung, Eva Mickholz and Annett M. Jacobi, University Hospital Münster, Münster, Germany

Biology and Pathology of Bone and Joint: Inflammation and Osteoarthritis 1770. Simultaneous Targeting of IL-1α and IL-1β by a DualVariable-Domain Immunoglobulin (DVD-IgTM) Prevents Cartilage Degradation In Preclinical Models of Osteoarthritis. Rajesh Kamath, Abbott Research Center, Worcester, MA 1771. Enhanced Expression of mRNA for Interleukin 6 and Tumor Necrosis Factor-Alpha In CD34+ Cells of the Bone Marrow In Osteoarthritis. Shunsei Hirohata1, Tamiko Yanagida2, Tetsuya Tomita3 and Hideki Yoshikawa4, 1Kitasato Univ School of Med, Kanagawa, Japan, 2Teikyo University School of Medicine, Tokyo, Japan, 3Osaka University Med School, Suita Osaka, Japan, 4Osaka University Graduate School of Medicine, Osaka, Japan 1772. Transcriptome Analysis Reveals a Robust Profile In Osteoarthritis Synovial Fibroblasts. Manuel J. Del Rey1, Alicia Usategui1, Elena Izquierdo1, Vanessa Miranda1, Juan D. Cañete2, Francisco J. Blanco Sr.3, Gabriel Criado1 and Jose L. Pablos1, 1Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 2Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain, 3INIBIC-CHUAC, La Coruna, Spain 1773. Destabilization of the Medial Meniscus As a Model to Study the Relationship Between Joint Degeneration and Pain. Rachel E. Miller, Phuong Tran, Nayereh GhoreishiHaack, Rosalina Das and Anne-Marie Malfait, Rush University Medical Center, Chicago, IL 1774. IL-1beta Inhibits TNF-Mediated Differentiation of Human Osteoclast Precursors Grown in Presence of Fibroblast-Like Synoviocytes. Bohdan P. Harvey, Farhan A. Syed and Zehra Kaymakcalan, Abbott Laboratories, Worcester, MA 1775. Norepinephrine (NE) Affects Mesenchymal Stem Cell (MSCs) Chondrogenesis and Accordingly the SelfRegeneration Capacity of Cartilage. Zsuzsa Jenei-Lanzl1, Peter Angele2 and Rainer H. Straub3, 11Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, 2Department of Trauma Surgery, University Hospital Regensburg, Germany, Regensburg, Germany, 3University Hospital Regensburg, Regensburg, Germany 1776. Adiponectin Is Associated with Joint Inflammation and Cartilage Degradation in Osteoarthritis. Anna Koskinen1, Sami Juslin1, Katriina Vuolteenaho1, Riina Nieminen1, Teemu Moilanen2 and Eeva Moilanen1, 1The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, 2The Immunopharmacology Research Group, University of 2011 Program Book

253

ACR/ARHP Poster Session C Tampere School of Medicine, Tampere University Hospital, and Coxa Hospital for Joint Replacement, Tampere, Finland

Centre, Nijmegen, Netherlands, 2INSERM U1031, Toulouse, France, 3Hospital Lapeyronie, Montpellier, France

1777. Mast Cell-Restricted, Tetramer-Forming Tryptases Are Novel Mediators of Articular Cartilage Aggrecanolysis by Activating Matrix Metalloprotease Zymogens. Natalia Magarinos1, Katherine J. Bryant1, Amanda J. Fosang2, Richard L. Stevens3 and H. Patrick McNeil1, 1University of New South Wales, Sydney, Australia, 2University of Melbourne, Melbourne, Australia, 3Brigham & Women’s Hospital and Harvard Medical School, Boston, MA

1785. Chondrocytes in a Subset of Osteo-Arthritic Patients with Reduced NuclearFactorkappaB-p65 Levels Are Vulnerable to Apoptosis Induced by Tumor Necrosis Factor Alpha, Which Could Be Released by the Synovium. Onno J. Arntz, Eline A. Vermeij, Esmeralda N. Blaney Davidson, Shahla Abdollahi-Roodsaz, Miranda B. Bennink, Peter M. van der Kraan, Wim B. van den Berg and Fons Van De Loo, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

1778. Calcium Mineral Deposition In the Cultures of FibroblastLike Synoviocytes. Yubo Sun, David Mauerhan, Atiya Franklin, Andrew Sun, Natalia Zinchenko, H. Norton, Edward Hanley Jr. and Helen Gruber, Carolinas Medical Center, Charlotte, NC

1786. Adipokines Leptin and Adiponectin Correlate with Matrix Metalloproteinases and Interleukin-6 in Synovial Fluid From Osteoarthritis Patients and Enhance Their Production in Osteoarthritic Cartilage Ex Vivo. Katriina Vuolteenaho1, Anna Koskinen1, Sami Juslin1, Riina Nieminen1, Teemu Moilanen2 and Eeva Moilanen1, 1The Immunopharmacology Research Group, University of Tampere School of Medicine, and Tampere University Hospital, Tampere, Finland, 2Coxa Hospital for Joint Replacement, Tampere, Finland

1779. Infliximab Does Reverse Cytokine - Mediated AntiApoptotic Effects In CD14+/CD11b+ Circulating Monocytes – Implications for Osteoclastogenesis. Michael Seitz, Daniel Aeberli, Richard K. Kamgang, Willy Hofstetter, Deepak Balani and Peter M. Villiger, University Hospital, Bern, Switzerland 1780. New Alginate-Chitosan Hydrogel Beads with AntiInflammatory and Anabolic Effects on Human Chondrocytes. Frédéric Oprenyeszk1, Christelle Sanchez1, Jean-Emile Dubuc2, Véronique Maquet3 and Yves Henrotin4, 1 University of Liège, Liège, Belgium, 2Clinical University Saint Luc, Bruxelles, Belgium, 3KitoZyme SA, Herstal, Belgium, 4 Univ of Liege/Pathology Inst, Liege, Belgium 1781. Activation of Adenosine A2A Receptors Prevents Wear Particle-Induced Osteolysis. Aranzazu Mediero1, Sally Frenkel2, Tuere Wilder1 and Bruce N. Cronstein3, 1NYU School of Medicine, New York, NY, 2Hospital for Joint Disease, New York, NY, 3New York Univ Medical Center, New York, NY 1782. Heme Oxygenase-1 Lentiviral Transduction of Human Osteoarthritic Osteoblasts Down-Regulates Inflammatory, Degradative and Senescence Markers. Maria Isabel Guillen1, Victoria Clerigues1, Miguel Angel Castejon2, Francisco Gomar3 and Maria Jose Alcaraz1, 1University of Valencia, Burjasot, Valencia, Spain, 2La Ribera Hospital, Alzira, Valencia, Spain, 3University of Valencia and University Hospital, Valencia, Spain 1783. Human End-Stage Osteoarthritic Cartilage is Responsive to Transforming Growth Factor Beta and Contains a Population of Cells That Expresses SMAD2/3P and SMAD1/5/8P. Arjan P. M. van Caam, Esmeralda N. Blaney Davidson, Elly L. Vitters, Wim B. van den Berg and Peter M. van der Kraan, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 1784. A Single Injection of Adipose-Derived Stem cells Protects Against Cartilage Damage and Lowers Synovial Activation in Experimental Osteoarthritis. Menno C. ter Huurne1, Peter L.E.M. van Lent1, Arjen B. Blom1, Roxane Blattes2, Yannick Jeanson2, Louis Casteilla2, Christian Jorgensen3 and Wim B. van den Berg1, 1Radboud University Nijmegen Medical

254

2011 Program Book

1787. Adenosine A1 Receptor Blockade Inhibits Osteoclast Formation of Mouse Bone Marrow Cells by Downregulation RANKL Signaling. Wenjie He1 and Bruce N. Cronstein2, 1NYU, New York, NY, 2New York Univ Medical Center, New York, NY 1788. MAPK-Activated Protein Kinase-2 (MK2) Regulates Bone Homeostasis. Tobias Braun1, Johannes Lepper1, Gisela Ruiz Heiland1, Georg Schett1 and Jochen Zwerina2, 1University of Erlangen-Nuremberg, Erlangen, Germany, 2Hanusch Hospital, Vienna, Austria 1789. Human MSCs Ameliorate Bone Erosion in TNF-Alpha Transgenic Mice. Joy M. Whitbred1, Robert M. Lowe2, Donald P. Lennon3, Joseph Molter4, Chris A. Flask4, Tracey L. Bonfield2, Arnold I. Caplan3 and Nora G. Singer1, 1Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 2Department of Pediatrics, Case Western Reserve University, Cleveland, OH, 3 Skeletal Research Center, Case Western Reserve University, Cleveland, OH, 4Department of Radiology, Case Western Reserve University, Cleveland, OH 1790. The Role of Mir-29 in the Chondrogenic Differentiation of Mesenchymal Stem Cells. D. Guerit1, D. Philipot2, P. Chuchana1, JM Brondello2, Christian Jorgensen3 and Daniele Noel2, 1INSERM U844, Montpellier, France, 2UM1, Montpellier, France, 3CHU Lapeyronie, Montpellier, France 1791. Activation of AMP-Activated Protein Kinase (AMPK) Alleviates Endoplasmic Reticulum (ER) Stress and Inhibits Catabolic Responses to Biomechanical Injury in Chondrocytes. Freyr Petursson1, Xianling Zhao1, Robert Terkeltaub2 and Ru L. Bryan1, 1UCSD/VAMC, San Diego, CA, 2 VA Medical Ctr, San Diego, CA 1792. Apolipoprotein E and Undercarboxylated Osteocalcin Are Associated with Bone Fragility but Not with Bone Mineral Density in Osteoarthritis Patients. Ana M. Rodrigues1,

ACR/ARHP Poster Session C Joana Caetano-Lopes2, Ana Lopes3, Ana Catarina Vale4, Inês Aleixo3, Inês P. Perpétuo2, Ana Sofia Pena3, Alexandra Faustino3, Alexandre Sepriano3, Joaquim Polido-Pereira5, Elsa Vieira-Sousa6, Bruno Vidal7, JC Romeu8, PM Amaral4, Luis G. Rosa4, José A. Pereira da Silva9, Jacinto Monteiro10, Maria Fátima Vaz4, J. E. Fonseca5 and Helena Canhão5, 1 Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon, Portugal, 2 Rheumatology Research Unit, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 3Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 4 Department of Mechanical Engineering, Instituto Superior Técnico, ICEMS, Lisbon, Portugal, 5Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 6Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 7 Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal., Lisbon, Portugal, 8 Hospital de Santa Maria, Lisbon, Portugal, 9Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon, Portugal, 10Orthopaedics Department, Hospital de Santa Maria, Lisbon, Portugal 1793. Alarmins s100a8 and s100a9 Elicit a Higher Catabolic Response in Osteoarthritic Chondrocytes Compared to Normal Chondrocytes That Is Toll Like Receptor 4 Dependent. Rik Schelbergen1, Arjen B. Blom1, Martijn H.J. van den Bosch1, Annet Sloetjes1, Thomas Vogl2, Johannes Roth2, Wim B. van den Berg1 and Peter L.E.M. van Lent1, 1 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2University of Muenster, Munster, Germany 1794. Periostin, An Osteoblast Stimulating Factor, Regulates Cartilage Metabolism Via MMP-13 Activation. Mukundan Attur1, Glyn Palmer1, Yuki Tachida2, Seiichiro Kumakura2, Kohei Shimada2 and Steven B. Abramson1, 1NYU Hospital for Joint Diseases, New York, NY, 2Daiichi-Sankyo Co. Ltd.,, Tokyo, Japan 1795. Sirt1 Deficient Mice Exhibit An Altered Cartilage Phenotype. Odile H. Gabay Engel1, Christelle Sanchez2, Mona dvir-Ginzberg3, Viktoria Gagarina1, Eun Jin Lee1, Kristien J. Zaal1, Michael McBurney4 and David J. Hall1, 1 NIH, Bethesda, MD, 2Bone and Cartilage Research Unit, Liege, Belgium, 3Hebrew University- Hadassah Ein Kerem, Jerusalem, Israel, 4Ottawa Hospital, Ottawa, ON 1796. Rac1 and NADPH Oxidase Regulate NFκB Activity and MMP-13 Expression in Chondrocytes in Response to Integrin Activation. Richard F. Loeser, Elizabeth A. Erickson and David A. Long, Wake Forest University, Winston-Salem, NC

1797. Disease-Specific Induction of Fibroblast Activation Protein Alpha in Rheumatoid Arthritis. Christina Wunrau1, Marianne Heitzmann1, Corinna Wehmeyer1, George Kollias2, Thomas Pap1 and Berno Dankbar1, 1University Hospital Muenster, Muenster, Germany, 2Biomedical Sciences Research Center ‘Alexander Fleming’, Vari, Greece 1798. Theragnostic Nanosomes for Detection and Treatment of Early Osteoarthritis and Cartilage Damage. Karen A. Hasty1, Hongsik Cho2, Eugene Pinkhassik3 and John M. Stuart4, 1 University of Tennessee Health Science Center, VA Medical Center, Memphis, TN, 2University of Tennessee Health Science Center, Memphis, TN, 3University of Memphis, Memphis, TN, 4VA Medical Center, University of Tennessee Health Science Center, Memphis, TN 1799. Sclerostin Levels in RA and Its Relationship to Disease Activity and Radiographic Joint Damage. M. Vis1, K. Britsemmer2, A.C. Heijboer1, N. Bravenboer1, D. van Schaardenburg2 and W. F. Lems1, 1VU University medical center, Amsterdam, Netherlands, 2Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands 1800. A Novel Method of Basic Calcium Phosphate Crystal Quantification in Synovial Fluid Using a Tetracycline Binding Assay. Jonathan Kushi1, Claudia Gohr1, Brian Jubeck1, Peter A. Simkin2 and Ann K. Rosenthal1, 1Medical College of Wisconsin, Milwaukee, WI, 2University of Washington, Seattle, WA 1801. Revisiting Chemical and Morphological Diversity of Calcium-Containing Crystals in Human Osteoarthritic Menisci. Christelle Nguyen1, Frédéric Lioté1, Didier Hannouche2, Valérie Bousson3, Frédéric Velard1, Michel Daudon4, Dominique Bazin5 and Hang-Korng Ea1, 1UMR-S 606, INSERM & Paris Diderot University; PRES Sorbonne Paris-Cité; Lariboisière Hospital, Paris, France, 2Orthopaedic Surgery Department; Lariboisière Hospital (AP-HP); Univ. Paris Diderot, Sorbonne Paris-Cité, Paris, France, 3Radiology Department; Lariboisière Hospital (AP-HP); University Paris Diderot, Paris, France, 4Service de Biochimie A; Necker Hospital (AP-HP), Paris, France, 5Laboratoire de Physique des Solides; Paris Sud University, Orsay, France 1802. Inhibition of p38 Signaling Negatively Affects Chondrogenesis in Vitro, but Does Not Inhibit Ankylosis in a Model of Ankylosing Spondylitis. Kirsten Braem, Frank P. Luyten and Rik Lories, KU Leuven, Leuven, Belgium 1803. Human Chondrocyte Behaviour During In Vitro Over Expression of Normal and Mutated HFE, the Hemochromatosis Gene. Vanessa Martelli1, John A. Di Battista1, Pantelis Panopalis1, John Antoniou2, Michael Sebag1, Brian Gilfix1 and Henri A. Ménard1, 1McGill University Health Center, Montreal, QC, 2Jewish General Hospital, Montreal, QC 1804. Blockade of Delta-like1 Suppresses Osteoclastgenesis and Arthritis. Chiyoko Sekine1, Akemi Koyanagi1, Noriko Koyama1, Katsuto Hozumi2, Shigeru Chiba3 and Hideo Yagita1,

2011 Program Book

255

ACR/ARHP Poster Session C Juntendo University School of Medicine, Tokyo, Japan, Tokai University School of Medicine, Japan, 3University of Tsukuba, Tsukuba, Japan 1 2

Cytokines, Mediators, and Gene Regulation 1805. Induction of Tyrosine Hydroxylase (TH) and Modulation of Cytokine Release by Hypoxia in Mixed Synovial Cells of Patients with Rheumatoid Arthritis and Osteoarthritis. Silvia Capellino1, Zsuzsa Jenei-Lanzl1 and Rainer H. Straub2, 11Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, 2University Hospital Regensburg, Regensburg, Germany 1806. Synovial Tissue Cytokine Expression in Rheumatoid Arthritis and Associations with Lymphoid Neogenesis, Disease Activity and the European League Against Rheumatism Response. Juan D. Canete1, Raquel Celis2, Julio Ramirez1, Sara Marsal3, Gabriel Avila3, Raimon Sanmarti2 and Jose L. Pablos4, 1Hospital Clinic, Barcelona, Spain, 2Clinic Hospital, Barcelona, Spain, 3Hospital Vall de Hebró, Grup de Recerca de Reumatologia, Barcelona, Spain, 4Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain 1807. Mucocutaneous Flares As Opposed to Flares From Other Organs Have the Strongest Association with High Type I Interferon Levels in Patents with Systemic Lupus Erythematosus. Elzbieta E. Jacek1, Mikhail Olferiev2, Vinicius Domingues3, Rolando Duculan1, Nancy Pan4, Mary K. Crow4 and Kyriakos A. Kirou5, 1Mary Kirkland Center for Lupus Research-Hospital for Special Surgery, New York, NY, 2Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, 3Estacio de Sá University, Rio de Janeiro, Brazil, 4Hospital for Special Surgery, New York, NY, 5 Mary Kirkland Center for Lupus Care, Hospital for Special Surgery, New York, NY 1808. Atherogenic Properties of Rheumatoid Arthritis and SLE Plasma Are Attenuated by Interferon-γ Depletion. Allison B. Reiss, Iryna Voloshyna, Michael J. Littlefield, Elise Belilos, Kristina B. Belostocki, Lois A. Bonetti, Gary C. Rosenblum and Steven E. Carsons, Winthrop University Hospital, Mineola, NY 1809. Potentiation of TNF-Induced T Cell Chemokine Expression by Type I Interferon in Fibroblast-Like Synoviocytes: Target for JAK Inhibition. Sanna Rosengren, Gary S. Firestein and David L. Boyle, UCSD School of Medicine, La Jolla, CA 1810. IL-6 and TNF-α Enhance the Expression of U1C and Affect the Splicing of Functional Defective Angiopoietin-1 (Ang1) Gene Mediated by Anti-U1C Antibody in the Patients with MCTD. Tatsuki Okuyama1, Yuka Kosugi1, Koichiro Komai1, Akira Hashiramoto2, Kazuko Shiozawa3 and Shunichi Shiozawa2, 1Graduate School of Health Sciences, Kobe Univ., Kobe, Japan, 2Graduate School of Health Sciences and Medicine, Kobe Univ. / The Center for Rheumatic Diseases, Kobe Univ., Hosp., Kobe, Japan, 3Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan

256

2011 Program Book

1811. Chemerin/ChemR23 Expression and Pro-Inflammatory Effects in Synovitis of Patients with Rheumatoid Arthritis. Hirahito Endo, Makoto Kabraki, Yoshie Kusunoki, Natsuko Kusunoki and Shinichi Kawai, Toho University School of Medicine, Tokyo, Japan 1812. Functional Characterization of An Allosteric Enhancer of the Adenosine A2a Receptor That Inhibits ProInflammatory Cytokine Production. Ajith A. Welihinda and Edward P. Amento, Molecular Medicine Research Institute, Sunnyvale, CA 1813. Mechanism of Fractalkine/CX3CL1 Synthesis and Shedding in Rheumatoid Arthritis Synovial Fibroblasts. Brian Jones, Maria Beamer, Ayesha Rahman, Wissam Ali Aboualaiwi and Salahuddin Ahmed, Department of Pharmacology, University of Toledo College of Pharmacy & Pharmaceutical Sciences, Toledo, OH 1814. Comparison of Anti-Interleukin-6 and Anti-Interleukin-6 Receptor Antibodies Using In Vivo Functional Systems. Stevan Shaw, Diane Marshall, Helen Neale, Kosmas Kretsos, Tim Bourne and Alastair Lawson, UCB, Slough, United Kingdom 1815. Oncostatin M Is a Potent Regulator of Interleukin-6 and RANKL Expression in Mouse Synovial Fibroblasts and Synergises with Interleukin-1. Benoit Le Goff, Brett A. Tonkin, Sofie Singbrant, T. John Martin, Evange Romas, Natalie A. Sims and Nicole C. Walsh, St Vincent’s Institute of Medical Research, Melbourne, Australia 1816. Late Apoptotic Bodies Mediates Sterile Inflammation in Vitro and In Vivo Via IL-1alpha. Yael Berda-Haddad1, Stéphane Robert1, Paul Salers1, Leila Zekraoui2, Catherine Farnarier3, Charles A. Dinarello4, Françoise Dignat-George1 and Gilles Kaplanski1, 1INSERM U608, Marseille, France, 2 Faculté de Médecine-Timone, Marseille, France, 3Hopital de la Conception, Marseille, France, 4Denver, CO 1817. Fatty Acid-Binding Protein (FABP)-4 Is Increased in Patients with Rheumatoid Arthritis and Correlates with Metabolic Rather Than with Disease Activity Status. Lucie Andrés Cerezo1, Hana Hulejová1, Zdenka Vernerová2, Markéta Kuklová1, Ondrej Pecha3, Vlasta Pesáková1, Karel Pavelka1, Jiri Vencovsky1 and Ladislav Senolt1, 1Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 2Department of Pathology, 3rd Medical Faculty, Charles Universityin Prague, Prague, Czech Republic, 3 Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic 1818. Role of Liver X Receptors In the Regulation of Effector Functions of Fibroblast-Like Synoviocytes In Rheumatoid Arthritis. M.Teresa Arce-Franco1, M. Jesus Dominguez-Luis2, Ana Diaz-Martin2, Ada Herrera-Garcia3, Maria Eugenia Miranda-Carus4, Sagrario Bustabad-Reyes3, Antonio Castrillo5 and Federico Diaz-Gonzalez1, 1Rheumatology Service, La Laguna, Spain, 2Hospital Universitario de Canarias, La

ACR/ARHP Poster Session C Laguna, Spain, 3Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 4La Paz Hospital. IdiPaz, Madrid, Spain, 5University of Las Palmas de Gran Canaria (ULPGC), Canary Islands, Las Palmas (Gran Canaria), Spain 1819. Poly I:C, a Ligand for TLR3, Abrogates Stimulation of Fibrotic Response Induced by Transforming Growth Factor-β. Feng Fang1, Kohtaro Ooka2, Swati Bhattacharyya3 and John Varga3, 1Northwestern University, Chicago, IL, 2 Northwestern University, 3Northwestern Univ Med School, Chicago, IL 1820. Visfatin and B-Cell Activating Factor of the TNF Family Serum Levels Correlate with Disease Activity in AntiJo-1 Positive Patients with Idiopathic Inflammatory Myopathies. Hana Hulejová1, Olga Kryštufková1, Klára Kuncová2, Josef Zámecník2, Herman F. Mann1, Ladislav Senolt1 and Jiri Vencovsky1, 1Institute of Rheumatology,1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 22nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic 1821. FMS-Like Tyrosine Kinase 3 Ligand/CD135 in Arthritis: A New Inflammatory System in RA? Maria I. Martins Ramos, Saïda Aarrass, Lisa G.M. van Baarsen, Danielle M. Gerlag, PP. Tak and Maria C. Lebre, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 1822. Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects Exposed to Secukinumab 150 Mg: Preliminary Study Results. Andrea Chioato, Novartis, Basel, Switzerland 1823. Adiponectin Isoforms Differentially Affect Gene Expression, Signaling Transduction and Migration of Rheumatoid Arthritis Synovial Fibroblasts. Klaus Frommer1, Rosel Engel1, Andreas Schäffler2, Christa Büchler2, Jürgen Steinmeyer3, Markus Rickert3, Stefan Rehart4, Fabia Brentano5, Steffen Gay6, Ulf Müller-Ladner1 and Elena Neumann1, 1JustusLiebig-University of Gießen, Bad Nauheim, Germany, 2 University of Regensburg, Regensburg, Germany, 3 University Hospital Gießen and Marburg, Gießen, Germany, 4 Markus-Hospital, Frankfurt, Germany, 5University Hospital Zürich, 6University Hospital of Zürich, Zürich, Switzerland 1824. F-Spondin Mediates Catabolic Effects on Articular Chondrocytes Via Its Thrombospondin Repeat Domain. James Liu1, Glyn Palmer1, Yang Qing2, Daniel Rifkin2, Mukundan Attur1 and Steven B. Abramson1, 1NYU Hospital for Joint Diseases, New York, NY, 2New York University School of Medicine, New York, NY 1825. Adipokine Expression in Osteoarthritis Osteophytes. Susann Junker1, Klaus Frommer1, Grit Krumbholz1, Angela Lehr2, Stefan Rehart2, Markus Rickert3, Jürgen Steinmeyer3, Georg Schett4, Ulf Müller-Ladner1 and Elena Neumann1, 1 Justus-Liebig-University of Gießen, Bad Nauheim, Germany, 2 Markus-Hospital, Frankfurt, Germany, 3University Hospital

Gießen and Marburg, Gießen, Germany, 4University of Erlangen-Nuremberg, Erlangen, Germany 1826. Increasing Serum IL-17F Levels in Pediatric Localized Scleroderma As Disease Enters Remission. Kathryn S. Torok1, Katherine Kurzinski1, Christina Kelsey1 and Carol A. Feghali-Bostwick2, 1Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA 1827. TWEAKing Cutaneous Manifestations In MRL-Lpr/Lpr Lupus Prone mice. Yumin Xia1, Karin Blecher1, Jing Wen1, Jennifer S. Michaelson2, Linda C. Burkly2, Adam Friedman1 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2 Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY 1828. Pro-Inflammatory Cytokine Measurement in Whole Blood Cultures Stimulated with Lipopolysaccharide Predicts Treatment Outcomes of Patients with Rheumatoid Arthritis Treated with Biologics. Ken Kayakabe1, Takashi Kuroiwa2, Noriyuki Sakurai1, Hidekazu Ikeuchi1, Anastasie K.T.1, Toru Sakairi1, Akito Maeshima1, Keiju Hiromura1 and Yoshihisa Nojima1, 1Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 2Jichi Medical University, Saitama Medical Center, Saitama, Japan 1829. Mitochondrial Mutagenesis Correlates with the Local Inflammatory Environment in Arthritis. Leonard C. Harty1, Monika Biniecka1, Edward Fox2, Jacintha N. O’Sullivan3, Ursula Fearon1 and Douglas J. Veale1, 1Translation Rheumatology Research Group, Dublin, Ireland, 2University of Washington, Seattle, WA, 3Trinity University, Dublin, Ireland 1830. Relationship of Serum Tumor Necrosis Factor α, Tumor Necrosis Factor α Receptors and Tumor Necrosis Factor - Weak Inducer of Apoptosis to Clinical Parameters and Therapeutic Response in Rheumatoid Arthritis Patients Treated with Etanercept. Gunther Neeck1, Helmut Dotzlaw2 and Martin Schulz2, 1Rheumazentrum Bad Doberan, Bad Doberan, Germany, 2Center for Rheumatology, Bad Doberan, Germany 1831. The Role of IL-17 in Systemic Lupus Erythematosus. Gil Amarilyo1, Elaine Lourenco2 and Antonio La Cava3, 1 University of California, Los Angeles, Los Angeles, CA, 2UCLA David Geffen School of Medicine, Los Angeles, CA, 3Univ of California Los Angeles, Los Angeles, CA 1832. A Specific Microrna Pattern Discriminates Synovial Macrophages From Rheumatoid Arthritis and Osteoarthritis Patients. Andrea Diaz-Alderete1, Vanessa Miranda2, Ignacio Caballero1, Manuel Tardaguila1, Alberto Pascual-Montano1, Jose L. Pablos2 and Santos Mañes1, 1 Centro Nacional de Biotecnología- CSIC, Madrid, Spain, 2 Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain 1833. The Influence of Interleukin-32γ on Osteoclastogenesis, with a Focus on Fusion-Related Genes. Bon San Koo, Yong-Gil Kim, Min Wook So, Chang-Keun Lee and Bin Yoo, 2011 Program Book

257

ACR/ARHP Poster Session C University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 1834. Identification of Activated Cytokine Pathways in the Blood of Systemic Lupus Erythematosus, Myositis, Rheumatoid Arthritis, and Scleroderma Patients. Brandon W. Higgs1, Wei Zhu1, Laura Richman1, David Fiorentino2, Steven A. Greenberg3, Bahija Jallal1 and Yihong Yao1, 1MedImmune, Gaithersburg, MD, 2Stanford, Stanford, CA, 3Brigham Women’s Hospital, Harvard Medical School, Boston, MA 1835. Systemic Lupus Erythematosus, Myositis, Rheumatoid Arthritis, and Scleroderma Patients Share Activation of a Common Type I Interferon Pathway. Brandon W. Higgs1, Zheng Liu1, Barbara White1, Wei Zhu1, Wendy White1, Chris Morehouse1, Philip Brohawn1, Peter Kiener1, Laura Richman1, David Fiorentino2, Steven A. Greenberg3, Bahija Jallal1 and Yihong Yao1, 1MedImmune, Gaithersburg, MD, 2 Stanford, Stanford, CA, 3Brigham Women’s Hospital, Harvard Medical School, Boston, MA 1836. Extracellular 14-3-3η: A Novel Mediator of Inflammation Associated with Selective Activation of Intracellular Pathways. Anthony Marotta1, Yuan Gui1, Aziz Ghahary2, Ruhangiz Kilani2 and Walter P. Maksymowych3, 1Augurex Life Sciences Corp, North Vancouver, BC, 2University of British Columbia, Vancover, BC, 3University of Alberta, Edmonton, AB 1837. Serum Galectin-3 Level in Patients with Scleroderma. Metin Ozgen1, Suleyman Serdar Koca1, Fatma Akbas1, Nevin Ilhan2, Baris Gundogdu1 and Ahmet Isik1, 1Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey, 2Department of Biochemistry, Faculty of Medicine, Firat University, Elazig, Turkey 1838. Atherogenic Effect of Inflammatory Cytokines in Chronic Inflammatory Diseases. Misato Hashizume and Masahiko Mihara, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan 1839. Follistatin-Like Protein 1 Promotes Arthritis by Enhancing Cytokine/Chemokine Gene Expression. Yury Chaly1, Anthony Marinov1, Leif Oxburgh2, Daniel Bushnell1 and Raphael Hirsch1, 1Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Maine Medical Center Research Institute, Scarborough, ME 1840. Decreased Interleukin-22 in Pulmonary Fibrosis: Potential Role As a Regulatory Cytokine. Minrui Liang1, Xiangjun Chen2, Jiu-Cun Wang3, Min Guan2, Haiyan Chu4 and Hejian Zou5, 1Huashan Hospital,Fudan University,Shanghai, Shanghai, China, 2Huashan Hospital, Fudan University, Shanghai, China, 3Fudan University, Shanghai, China, 4School of Life Science, Fudan University, China, 5Huashan Hospital, Shanghai, China 1841. Bridging ELISA As a Screening Assay to Monitor Immunogenicity in Routine Clinical Practice. Sandra Garcês1, Jocelyne Demengeot2, J. Canas da Silva3 and L. Aarden4, 1Instituto Gulbenkian Ciência; Hospital Garcia

258

2011 Program Book

de Orta, Oeiras, Portugal, 2Instituto Gulbenkian Ciência, Oeiras, Portugal, 3Hospital Garcia de Orta, Almada, Portugal, 4 Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands 1842. In Vivo Gene Transfer of IL-17A Induces Osteoclast Formation in a RANKL-Dependent Manner, Exacerbates Collagen-Induced Arthritis and Induces Epidermal Hyperplasia. Iannis E. Adamopoulos1, Cheng-Chi Chao2 and Eddie P. Bowman3, 1UC Davis, Sacramento, CA, 2Merck, Palo Alto, CA, 3Merck, Palo Alto 1843. FMS-Like Tyrosine Kinase 3 Receptor Inhibition Leads to Decreased Production of Interleukin 6 by Synovial Biopsies, Fibroblast-Like Synoviocytes and Monocytic Cells From Arthritic Patients. Maria I. Martins Ramos, Saïda Aarrass, Danielle M. Gerlag, PP. Tak and Maria C. Lebre, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 1844. Anti-Inflammatory Activity of Apremilast Against T Cells, Chondrocytes, and Rheumatoid Arthritis Synovial Fibroblasts in Vitro. Lori Capone, Audry Rogovitz, Anita Gandhi and Peter Schafer, Celgene Corporation, Summit, NJ 1845. C5orf30 a Candidate Susceptibility Gene in Rheumatoid Arthritis. Sachin Khetan1, Munitta Muthana1 and A. G. Wilson2, 1Dr, Sheffield, United Kingdom, 2Sheffield Uni / Medical School, Sheffield, United Kingdom

Epidemiology and Health Services Research III: CTDs/Vasculitis/ Inflammatory Arthritis 1846. Adult Prevalence of Systemic Autoimmune Rheumatic Diseases (SARDs) in British Columbia, Canada. J. Antonio Avina-Zubieta1, Eric C. Sayre1, Sasha Bernatsky2, Allen J. Lehman1, Kamran Shojania1, John Esdaile3 and Diane Lacaille1, 1Arthritis Research Centre of Canada/University of British Columbia, Vancouver, BC, 2McGill UHC/RVH, Montreal, QC, 3University of Calgary, Calgary, AB 1847. The Georgia Lupus Registry: Differences in Age-Specific Incidence Rates Between Black and White Females with SLE. Cristina M. Drenkard1, Gaobin Bao1, Charles G. Helmick2, C. Gordon3, Rana Bayakly4 and S. Sam Lim1, 1 Emory University, Atlanta, GA, 2Centers for Disease Control and Prevention, Atlanta, GA, 3University of Birmingham, Birmingham, United Kingdom, 4Georgia Department of Public Health, Atlanta, GA 1848. Epidemiology of Systemic Lupus Erythematosus in a Large United States Managed Care Population. Daniel E. Furst1, Ann Clarke2, Ancilla Fernandes3, Tim Bancroft4, Warren Greth3 and Serban R. Iorga4, 1UCLA Medical School, Los Angeles, CA, 2Montreal General Hospital, Montreal, QC, 3 MedImmune LLC, Gaithersburg, MD, 4Innovus, Eden Prairie, MN 1849. Population-Based Incidence Estimates for Systemic Lupus Erythematosus in the USA, 2002-2005: Results From the Michigan Lupus Epidemiology and Surveillance (MILES)

ACR/ARHP Poster Session C Program. Emily C. Somers1, Wendy Marder1, Patricia C. Cagnoli1, Emily E. Lewis1, Peter DeGuire2, Caroline Gordon3, Charles G. Helmick4, Lu Wang1, Jeffrey J. Wing1, J. Patricia Dhar5, James C. Leisen6, W. Joseph McCune1 and MILES Group7, 1University of Michigan, Ann Arbor, MI, 2MI Dept of Community Health, Lansing, MI, 3University of Birmingham, Birmingham, United Kingdom, 4Centers for Disease Control and Prevention, Atlanta, GA, 5Wayne State University, Detroit, MI, 6Henry Ford Hospital, Detroit, MI, 7Ann Arbor, MI 1850. Impact of Autoimmune Diseases on Health Status and Health Care Utilization. Pamela Shea Poynter, KyoungSuk Lee, Heather Bush and Leslie J. Crofford, University of Kentucky, Lexington, KY 1851. Racial Disparities In Treatment Preferences Among Lupus Patients In An Urban Academic Center. Ernest R. Vina, Christopher M. Masi, Stephanie L. Green and Tammy O. Utset, University of Chicago, Chicago, IL 1852. Effort-Reward Imbalance in Patients with Systemic Lupus Erythematodes? Jutta G. Richter, Thomas Muth, Birthe Koerbl, Nicole Hoffmann, Tobias Koch, Johannes Siegrist and Matthias Schneider, Heinrich-Heine-University, Duesseldorf, Germany 1853. Missed Work Days In Systemic Lupus Erythematosus. Jie Xu, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 1854. Life and Job Satisfaction in Patients with Systemic Lupus Erythematosus. Jutta G. Richter, Thomas Muth, Birthe Koerbl, Mia Vidakovic, Tobias Koch and Matthias Schneider, Heinrich-Heine-University, Duesseldorf, Germany 1855. Impact of Systemic Lupus Erythematosus on Employment and Work Productivity in the US. Ellen Sulcs1, Mechele Lee2, Cindy P. Garris3 and Priti M. Jhingran3, 1Harris Interactive Inc., New York, NY, 2Harris Interactive Inc., New York, 3 GlaxoSmithKline R&D, Research Triangle Park, NC 1856. Association of Body Mass Index, Race/Ethnicity and Gender in a Cohort of Systemic Lupus Erythematosus Patients with Diabetes and/or Hypertension. Jonea Lim1, Nasir Mushtaq2, Rachna Aggarwal3 and R. Hal Scofield4, 1 Harold Hamm Oklahoma Diabetes Center, University of Oklahoma Health Science Center, Oklahoma City, OK, 2 University of Oklahoma Health Science Center College of Public Health, Oklahoma City, OK, 3University of Oklahoma Health Science Center; Oklahoma Medical Research Foundation, OK, 4Oklahoma Medical Research Foundation, Oklahoma City, OK 1857. Everyday Stress, C-Reactive Protein, and Systemic Lupus Erythematosus. Amanda Eudy1, Anissa I. Vines1, Charles Poole1, Carolina Lupus Study Investigators2 and Christine G. Parks3, 1University of North Carolina, Chapel Hill, NC, 2USA, 3 NIH/NIEHS, Research Triangle Park, NC

1858. Stressful Life Experiences and Inflammation in the Carolina Lupus Study: An Open-Ended Query on Stress. Christine G. Parks1, Anissa I. Vines2, Amanda Eudy3 and Carolina Lupus Study Investigators4, 1NIH/NIEHS, Research Triangle Park, NC, 2University of North Carolina, Chapel Hill, NC, 3UNC Chapel Hill, Chapel Hill, NC, 4USA 1859. LupusPRO: Cross Cultural Validation Study for Lupus in the Philippines. S. Navarra1, Rachel A. Mikolaitis2, Joel A. Block2 and Meenakshi Jolly2, 1University of Santo Tomas Hospital, Manila, Philippines, 2Rush University Medical Center, Chicago, IL 1860. Spanish LupusPRO: Cross Cultural Validation Study for Lupus. Meenakshi Jolly1, Joel A. Block1, Rachel A. Mikolaitis1, Daniel Wallace2, Sergio Duran-Barragán3, Ana M. Bertoli4, Sergio Toloza5, Ivana Blazevic6, Luis M. Vila7, Dilrukshie Cooray8, Emmanuel P. Katsaros9, Karina Marianne D. Torralba10, Michael H. Weisman11 and Graciela S. Alarcon12, 1 Rush University Medical Center, Chicago, IL, 2Cedars-Sinai/ UCLA, Los Angeles, CA, 3UIECD, Guadalajara, Mexico, Guadalajara, Mexico, 4Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, 5Hospital San Juan Bautista, Catamarca, Argentina, 6University of Buenos Aires, Buenos Aries, Argentina, 7University of PuertoRico Medical Sciences Campus, San Juan, PR, 8Harbor UCLA Medical Center, Torrance, CA, 9Loma Linda Univ, Loma Linda, CA, 10USC Keck Schl of Medicine, Los Angeles, CA, 11Cedars Sinai Med Ctr, Los Angeles, CA, 12University of Alabama at Birmingham, Birmingham, AL 1861. Epidemiology of Systemic Sclerosis in a Large United States Managed Care Population. Daniel E. Furst1, Ancilla Fernandes2, Serban R. Iorga3, Warren Greth2 and Tim Bancroft3, 1UCLA Medical School, Los Angeles, CA, 2 MedImmune LLC, Gaithersburg, MD, 3Innovus, Eden Prairie, MN 1862. Population-Based Prevalence Estimates of Myositis in First Nations Relative to Non-First Nations Canadians. Cheryl CM Barnabe1, Lawrence Joseph2, Patrick Belisle2, Jeremy Labrecque3, Lawrence W. Svenson1, Steven M. Edworthy1, Susan G. Barr1, Marvin J. Fritzler1, Christine A. Peschken4, Brenda Hemmelgarn1 and Sasha Bernatsky3, 1University of Calgary, Calgary, AB, 2McGill University Health Centre, Montreal, QC, 3McGill UHC/RVH, Montreal, QC, 4University of Manitoba, Winnipeg, MB 1863. Development and Content Validity of the Hand Disability in Systemic Sclerosis—Digital Ulcers (HDISS-DU) Scale. Dinesh Khanna1, Serge Poiraudeau2, Heather Gelhorn3, Elke Hunsche4, Kelly Papadakis4, Loic Perchenet4, Maria Stoeckl Mattera5, Margaret Vernon5 and Luc Mouthon2, 1University of Michigan, Ann Arbor, MI, 2Hopital Cochin, Paris, France, 3 United BioSource Corporation, Golden, CO, 4Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 5United BioSource Corporation, Bethseda, Bethesda, US., MD

2011 Program Book

259

ACR/ARHP Poster Session C 1864. Epidemiology of Idiopathic Inflammatory Myopathy in a Large United States Managed Care Population. Daniel E. Furst1, Anthony A. Amato2, Serban R. Iorga3, Kavita Gajria4 and Ancilla Fernandes4, 1UCLA Medical School, Los Angeles, CA, 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 3Innovus, Eden Prairie, MN, 4 MedImmune LLC, Gaithersburg, MD 1865. Descriptive Epidemiology of Granulomatosis with Polyangitis (Wegener’s), Microscopic Polyangitis, Polyarteritis Nodosa and Goodpasture’s Syndrome in the United States. Martin M. Crane1, Vincent X. Rabatin2 and Alfred Mahr3, 1GlaxoSmithKline, Research Triangle, NC, 2 GlaxoSmithKline, Research Triangle Park, NC, 3Hospital Saint-Louis, Paris, France 1866. Prevalence of ANCA Associated Vasculitis and Polyarteritis Nodosa in Southern Sweden-Revisited 2010. Aladdin Mohammad1 and Mårten Segelmark2, 1Skåne University Hospital, Lund, Sweden, 2Linköping University, Linköping, Sweden 1867. Informed Consent for Treatment of ANCA-Associated Vasculitis. Raluca Cozmuta1, Peter A. Merkel2 and Liana Fraenkel3, 1St. Vincent Medical Center, Bridgeport, CT, 2 Boston University School of Medicine, Boston, MA, 3Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 1868. Increased Prevalence of Metabolic Syndrome and Higher Serum Leptin Levels in Patients with Psoriatic Arthritis. Devy Zisman1, S. Nissan1, Lihi Eder1, J. Feld1, M.A Rahat1, Muna Elias1, D. Rimar1, A. Laor1 and H. Bitterman2, 1Carmel Medical Center, Haifa, Israel, 2Carmel Medical Center , The Ruth and Bruce Rappaport Faculty of Medicine Technion, Haifa, Israel 1869. Quantifying the Harmful Effects of Psoriatic Diseases on Quality of Life Outcomes - COMPASS III Study. Deepan Dalal1, Yih Chang Lin1, Danielle Brennan1, Katherine Wolski1, Neil Borkar2, Neil J. Korman2, Diane Dylinski1 and M. Elaine Husni1, 1Cleveland Clinic Foundation, Cleveland, OH, 2 University Hospitals - Case Medical Center, Cleveland, OH 1870. Trends In Lipid Profiles In Patients with Psoriasis: A Population-Based Analysis. Bharath Manu Akkara Veetil, Eric L. Matteson, Hilal Maradit-Kremers, Marian T. McEvoy and Cynthia S. Crowson, Mayo Clinic, Rochester, MN 1871. Cardiovascular Risk In Psoriasis: A Population Based Analysis with Assessment of the Framingham Risk Score. Bharath Manu Akkara Veetil, Eric L. Matteson, Hilal MaraditKremers, Marian T. McEvoy and Cynthia S. Crowson, Mayo Clinic, Rochester, MN 1872. Learned Helplessness Predicts 2-Year Change in Functional Disability in Patients with Inflammatory Polyarthritis. Elizabeth M. Camacho1, Suzanne Verstappen1, Diane K. Bunn2 and Deborah DPM Symmons1, 1University of Manchester, Manchester, United Kingdom, 2University of East Anglia, Norwich, United Kingdom

260

2011 Program Book

1873. Adverse Pregnancy Outcomes Before Symptom Onset Are Associated with a Worse Disease Outcome in Women with Recent-Onset Inflammatory Polyarthritis. Elizabeth M. Camacho1, Suzanne Verstappen1, Mark Lunt1, Diane K. Bunn2 and Deborah P.M. Symmons3, 1University of Manchester, Manchester, United Kingdom, 2University of East Anglia, Norwich, United Kingdom, 3The University of Manchester, Manchester, United Kingdom 1874. Pregnancy Outcomes In Women Exposed to Adalimumab: An Update On the Autoimmune Diseases In Pregnancy Project. Diana Johnson, Yunjun Luo, Kenneth Lyons Jones and Christina Chambers, University of California, San Diego, La Jolla, CA 1875. Maternal Smoking and the Risk of Juvenile Idiopathic Arthritis. Susan Shenoi1, Carol A. Wallace1 and Beth A. Mueller2, 1Seattle Children’s Hospital, University of Washington, Seattle, WA, 2University of Washington,, Seattle, WA 1876. Prevalence of Depression and Concomitant Risk Factors in Children with Rheumatic Disease. Stacey E. Tarvin1, Nicole M. Taylor2, Christine M. Raches2, Lisa M. Macharoni2, Joseph E. Hansel2 and Susan H. Ballinger1, 1Riley Hospital for Children, Indianapolis, IN, 2University of Indianapolis, Indianapolis, IN 1877. Disease Modifying Anti-Rheumatic Drugs Compliance Study. Kateryna Vostretsova1, Pam Rogers1, Darby JS Thompson2 and Diane Lacaille3, 1Arthritis Research Centre, Vancouver, BC, 2Simon Fraser University, Vancouver, BC, 3 Arthritis Research Centre; University of British Columbia, Vancouver, BC 1878. Improving the Assessment of Minimal Important Change by Combining Health State Transition Questions with Patient Acceptable Symptom State and Patient Willingness to Alter Therapy. Jos Hendrikx, Jaap Fransen, Wietske Kievit and Piet LC van Riel, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 1879. The Accuracy of Identifying Kidney Disease in Administrative Databases for Rheumatic Disease Research - A Systematic Review of Validation Studies. Bindee Kuriya1, Ziv Harel2 and Diane Lacaille3, 1University of Toronto, Toronto, ON, 2Division of Nehprology, University of Toronto, Toronto, 3Arthritis Research Ctr Canada, Vancouver, BC 1880. A Systematic Review of Validation Studies of Administrative Data Used to Identify Infections. Claire Barber1, Diane V. Lacaille2, Joan E. Wither3 and Paul R. Fortin4, 1Mount Sinai Hospital, Toronto, ON, 2Arthritis Research Ctr Canada, Vancouver, BC, 3Toronto Western Research Institute, University Health Network, Toronto, ON, 4Toronto Western Hospital and University of Toronto, Toronto, ON 1881. Consensus Statements Concerning the Use of Administrative Data in Rheumatology Research and Surveillance. Diane Lacaille1, Lisa Lix2, Sasha Bernatsky3,

ACR/ARHP Poster Session C Siobhan O’Donnell4, Claire Bombardier5 and Administrative Data Rheumatology Research & Surveillance, 1Arthritis Research Ctr; University of British Columbia, Vancouver, BC, 2University of Saskatchewan, Saskatoon, SK, 3McGill UHC/RVH, Montreal, QC, 4Public Health Agency of Canada, Ottawa, ON, 5Institute for Work & Health, Toronto, ON 1882. An Evaluation of the Extended Item Euroqol Compared with the Standard Euroqol. Kaleb Michaud1 and Frederick Wolfe2, 1National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 2 National Data Bank for Rheumatic Diseases, Wichita, KS 1883. Increased Ability to Meet Occupational, Home or Leisure Requirements in Patients Starting Biologic Agents. Anja Strangfeld1, Diana Pantigoso1, Peter Herzer2, Hans Peter Tony3, Elke Wilden4, Joachim Listing1 and Angela Zink5, 1Deutsches Rheumaforschungszentrum, Berlin, Germany, 2University of Munich, Munich, Germany, 3 Rheumatology, University of Würzburg, Würzburg, Germany, 4Rheumatologist, Köln, Germany, 5Deutsches Rheumaforschungszentrum and Charité University Medicine, Berlin, Germany 1884. Distribution of Tumor Necrosis Factor Inhibitor Use Across Indications in Sweden: Nationwide Register-Linkage Study. Martin Neovius1, Jonas Eriksson1, Julia F. Simard1, Johan Askling1 and ARTIS Study Group2, 1Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Stockholm, Sweden 1885. Cross-Sectional Validation of the Patient Reported Outcome Measurement Information System Pediatric Scales in Juvenile Idiopathic Arthritis, Childhood Systemic Lupus Erythematosus, and Juvenile Dermatomyositis. Esi Morgan DeWitt1, Heather Gross2, Brian D. Stucky3, Yang Liu3, David Thissen3, Daniel J. Lovell1, Carol A. Wallace4, James F. Fries5, Bonnie Bruce6, Egla C. Rabinovich7, Laura E. Schanberg7 and Darren Dewalt2, 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, 4Childrens Hosp & Regional Med, Seattle, WA, 5Stanford Univ Medical Center, Palo Alto, CA, 6Stanford Dept of Medicine, Palo Alto, CA, 7 Duke University Medical Center, Durham, NC 1886. Assesment of Disease Activity in Ankylosing Spondylitis: Comparison of Rapid3, Basdai, Basfi, and Asdas Scores in Routine Care. Muhammet Cinar1, Sedat Yilmaz1, Suleyman Serdar Koca2, Hakan Erdem1, Salih Pay1, Yusuf Yazici3 and Ismail Simsek1, 1Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey, 2Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey, 3Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 1887. Prevention of Latent Tuberculosis and Toxicity of Isoniazid in Patients Treated by Anti-Tumor Necrosis Factor Alpha in the Czech National Register. Katarina Hviscova1, Liliana Sedova1 and Karel Pavelka2, 1Charles University, Prague,

Czech Republic, 21Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic 1888. Internet-Based Patient Registry and Biospecimen Collection: One Year Experience of the Arthritis Internet Registry. Kaleb Michaud1, Kimberly Harp1, Rebecca Schumacher1, Stanley J. Naides2, William F. Patten2, Beth Axtell3 and Robert M. Plenge4, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Quest Diagnostics Nichols Inst, San Juan Capistrano, CA, 3Arthritis Foundation, Atlanta, GA, 4Brigham and Women’s Hospital, Boston, MA 1889. Improving Clinical Trial Recruitment in a Real World Practice. Results From the Canadian Early Arthritis Cohort. Pooneh S.Akhavan1, Vivian Bykerk2, Ye Sun3, Boulos Haraoui4, J. Carter Thorne5, Janet E. Pope6, Carol A. Hitchon7, Diane S. Ferland8, Gilles Boire9, Edward C. Keystone10 and CATCH Investigators11, 1University of Toronto, Toronto, ON, 2 Brigham & Women’s Hospital, Boston, MA, 3Mount Sinai Hospital, Toronto, ON, 4Institut de Rhumatologie, Montreal, QC, 5Southlake Regional Health Centre, Newmarket, Newmarket, ON, 6St. Joseph’s Health Care, University of Western Ontario, London, ON, 7University of Manitoba, Winnipeg, MB, 8LaSalle, QC, 9CHUS - Sherbrooke University, Sherbrooke, QC, 10Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, 11Toronto, ON 1890. Reproducibility of Composite Scores: Disease Activity 28-Joints Score, Simplified Disease Activity Score and Clinical Disease Activity Score In the Evaluation of Rheumatoid Arthritis(Ra) Disease Activity: Pursuit for A Gold Standard. Lissiane K. N. Guedes1, Ana C. M. Ribeiro2, Julio C. B. Moraes2, Carla G.S. Saad3, Nadia E. Aikawa3, Eduardo F. Borba Neto4, Sandra Pasotto2, Jozelio F. Carvalho3, Eloisa Bonfa2 and Ieda Laurindo5, 1University of Sao Paulo, Sao Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 5Universidade de São Paulo, Sao Paulo, Brazil 1891. Doctor-Patient Involvement in Biologic Treatment Choice:the Benefits of a Collaborative Approach. Chris Martin and Katrina Johnson, The Research Partnership, London, United Kingdom 1892. Older Age, Male Gender, Current Smoking and Worse Disease Activity Are Predictors of Respiratory Disease Mortality in Patients with Inflammatory Polyarthritis: Results From the Norfolk Arthritis Register. Suzanne MM Verstappen1, Mark Lunt1, Diane K. Bunn2, Tarnya Marshall3 and Deborah PM Symmons1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 2Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom, 3Norfolk and Norwich University 2011 Program Book

261

ACR/ARHP Poster Session C Hospitals Trust, Norwich, UK, Norwich, United Kingdom, Norwich, United Kingdom 1893. The Association Between Clinical and Lifestyle Factors and the Development of Inflammatory Polyarthritis and Rheumatoid Arthritis. Results From the European Prospective Investigation of Cancer (Norfolk) Study and the Norfolk Arthritis Register. Manjari Lahiri1, Catharine Morgan1, Robert N. Luben2, Diane K. Bunn3, Mark Lunt1, Nick Warehan2, Suzanne M.M. Verstappen1, Deborah P. M. Symmons1, Kay-Tee Khaw2 and Ian N. Bruce4, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 3University of East Anglia, Norwich, United Kingdom, 4A, Manchester, United Kingdom 1894. Low Levels of Formal Education Generally Are As Significant As High Age and Long Duration of Disease to Identify Poor Clinical Status in Patients with Most Rheumatic Diseases. Isabel Castrejón1, Yusuf Yazici2 and Theodore Pincus1, 1NYU Hospital for Joint Diseases, New York, NY, 2Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 1895. Higher Fruit and Fructose Consumption Is Associated with a Reduced Risk of Inflammatory Polyarthritis and Rheumatoid Arthritis in Men. Results From the European Prospective Investigation of Cancer (Norfolk) and the Norfolk Arthritis Register. Manjari Lahiri1, Catharine Morgan1, Robert N. Luben2, Marleen Lentjes3, Diane K. Bunn4, Mark Lunt1, Nick Wareham2, Suzanne M.M. Verstappen1, Deborah P. M. Symmons1, Kay-Tee Khaw2 and Ian N. Bruce5, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2 University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 3Cambridge, United Kingdom, 4 University of East Anglia, Norwich, United Kingdom, 5A, Manchester, United Kingdom

Fibromyalgia and Soft-Tissue Disorders 1896. Response to Local Corticosteroid Injection In Carpal Tunnel Syndrome with Normal Electrodiagnostic Study. Domingo Ly-Pen1, José Luis Andreu2, Isabel Millán3, Gema de Blas4 and Alberto Sánchez-Olaso4, 1SERMAS. CS “Gandhi” / Hospital “Ramón y Cajal”, Madrid, Spain, 2HU, Madrid, Spain, 3HU “Puerta de Hierro Majadahonda”, Madrid, Spain, 4Hospital “Ramón y Cajal”, Madrid, Spain 1897. New Formulation to Improve Tendon Tissue Organization in Tendinopathies. Anna Torrent1, Ramon Ruhí1, Cristina Martínez2, Mar Cid2, Constanze Buhrmann3 and Mehdi Shakibaei3, 1BIOIBERICA S.A., Palafolls, Spain, 2BIOIBERICA S.A., Barcelona, Spain, 3LMU, Institute of Anatomy, Munich, Germany

262

2011 Program Book

1898. Trochanteric Bursitis: Is there Ultrasonographic Evidence to Suggest Inflammation? P. Dundeva-Baleva1, A. AbdelMegid1, A. Borham1 and Naomi Schlesinger2, 1UMDNJ/ Robert Wood Johnson Medical School, New Brunswick, NJ, 2 UMDNJ-Robt Wood Johnson MS, New Brunswick, NJ 1899. Stress Is a Key Modulator of Mood, Coping, Type of Control and Characteristic Symptoms in Females with Fibromyalgia. Katrina Malin1 and Geoffrey O. Littlejohn2, 1 Monash Medical Centre, Clayton, Australia, 2Monash Medical Center, Melbourne, Australia 1900. Fibromyalgia and Parental Medical Histories of Depression and Alcoholism. Robert S. Katz1, Ben J. Small2, Sharon M. Ferbert3, Patricia Kuenzi1 and Susan Shott1, 1Rush University Medical Center, Chicago, IL, 2Rush University Medical School, Chicago, IL, 3Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL 1901. The Survey Diagnostic Criteria of Fibromyalgia Syndrome – Results From the German Fibromyalgia Syndrome Consumer Reports. Winfried Häuser1, Eva Jung1 and Frederick Wolfe2, 1Technische Universität München, Munich, Germany, 2National Data Bank for Rheumatic Diseases, Wichita, KS 1902. Prevalence of FIBROMYALGIA AT the MEDICAL Out Patient Clinic Kenyatta NATIONAL HOSPITAL. Sophia Dokwe and Omondi.G Oyoo, University of Nairobi, Nairobi, Kenya 1903. Fibromyalgia in Systemic Lupus Erythematosus and Association with Fatigue and Disease Activity: Comparison of 2010 Versus 1990 Criteria. Vinicius Domingues, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 1904. Return of Pain and Functional Impairment After Discontinuation of Milnacipran in Patients with Fibromyalgia. Philip J. Mease1, Daniel J. Clauw2, Yimin Ma3, Arlene Baldecchi3, Joel M. Trugman3 and Robert H. Palmer3, 1 Seattle Rheumatology Associates and Swedish Medical Center, Seattle, WA, 2University of Michigan, Ann Arbor, MI, 3 Forest Research Institute, Jersey City, NJ 1905. Safety and Tolerability of Milnacipran in a 3-Year, OpenLabel, Flexible-Dosing Study of Patients with Fibromyalgia. Lesley M. Arnold1, Yimin Ma2, Robert H. Palmer2, Allan Spera2 and Arlene Baldecchi2, 1University of Cincinnati College of Medicine, Cincinnati, OH, 2Forest Research Institute, Jersey City, NJ 1906. Cannabinoid Use in Fibromyalgia Is Associated with Male Gender, Opioid Use and Drug Seeking Behaviour. Peter A. Ste-Marie1, Mary-Ann Fitzcharles2, Ann Gamsa2, Pantelis Panopalis2 and Yoram Shir2, 1University of Montreal, Montreal, QC, 2McGill University, Montreal, QC 1907. 3-Year Efficacy of Milnacipran in Patients with Fibromyalgia: An Open-Label, Flexible-Dosing Study. Lesley M. Arnold1, Yimin Ma2, Robert H. Palmer2, Allan Spera2 and Arlene Baldecchi2, 1University of Cincinnati College of Medicine, Cincinnati, OH, 2Forest Research Institute, Jersey City, NJ

ACR/ARHP Poster Session C 1908. Improvements in Fatigue Are Incompletely Explained by Improvements in Pain in Fibromyalgia Patients Treated with Milnacipran. Philip J. Mease1, Robert H. Palmer2, Yong Wang2 and R. Michael Gendreau3, 1Seattle Rheumatology Associate and Swedish Medical Center, Seattle, WA, 2Forest Research Institute, Jersey City, NJ, 3Cypress Bioscience, Inc., San Diego, CA 1909. Alcohol Consumption and Symptom Severity in Patients with Fibromyalgia. Terry H. Oh, Chul H. Kim, Connie Luedtke, Jeffery Thompson and Ann Vincent, Mayo Clinic, Rochester, MN 1910. Six-Month Treatment Patterns and Outcomes for Patients with Fibromyalgia. Rebecca Robinson1, Kurt Kroenke2, David A. Williams3, Yi Chen4, Madelaine M. Wohlreich5, Bill McCarberg6 and Philip J. Mease7, 1Eli Lilly and Company, Indianapolis, IN, 2Indiana University Regenstrief Institute, Indianapolis, IN, 3Univ of MI Hlth System-Lobby M, Ann Arbor, MI, 4i3, Ann Arbor, MI, 5Lilly USA, Indianapolis, IN, 6 Kaiser Permanente, Escondido, CA, 7Seattle Rheumatology Associate, Seattle, WA 1911. Subgrouping Chronic Pain Patients At a Tertiary Care Center Based on the Presence of Fibromyalgia Symptoms. Afton L. Hassett1, Chad M. Brummett2, Jenna Goesling2, Kevin Rakovitis2, Daniel J. Clauw3 and David A. Williams4, 1 University of Michigan Medical School, Ann Arbor, MI, 2 University of Michigan Health System, Ann Arbor, MI, 3 University of Michigan, Ann Arbor, MI, 4Univ of MI Hlth System-Lobby M, Ann Arbor, MI 1912. Smoking and Fibromyalgia: The Need for a Multidisciplinary Approach to Treatment. Jenna Goesling1, Chad M. Brummett1, Kevin Rakovitis1, Daniel J. Clauw2 and Afton L. Hassett3, 1University of Michigan Health System, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3 University of Michigan Medical School, Ann Arbor, MI 1913. Perspectives on Fibromyalgia From Trainees At An Academic Health Center. Jennifer Lobert1, Xolti Morgan1 and Lesley M. Arnold2, 1University of Cincinnati, Cincinnati, OH, 2 University of Cincinnati College of Medicine, Cincinnati, OH 1914. EpiFibro – A Brazilian Nationwide Databank in Fibromyalgia – Analysis of 500 Women. Roberto E. Heymann1, Eduardo S. Paiva2, Marcelo C. Rezende3, Daniel Feldman4, Milton Helfenstein Jr.1, Jose E. Martinez5, Jose R. Provenza6, Aline Ranzolin7, Luiz S. Ribeiro8 and Eduardo J.R. Souza9, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Universidade Federal do Parana, Curitiba, Brazil, 3 Santa Casa de Campo Grande, Campo Grande, Brazil, 4 Universidade Federal de São Paulo, Sao Paulo, Brazil, 5 Pontifícia Universidade Católica de São Paulo, Sorocaba, Brazil, 6Pontifícia Universidade Católica de Campinas, Campinas, Brazil, 7Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, 8Instituto de Previdência dos Servidores do Estado de Minas Gerais, Belo Horizonte, Brazil, 9Santa Casa de Belo Horizonte, Belo Horizonte, Brazil

1915. EpiFibro – A Brazilian Nationwide Databank in Fibromyalgia – 2010 Fibromyalgia Criteria, “Fibromyalgianess” Score and FIQ Performances. Eduardo S. Paiva1, Roberto E. Heymann2, Marcelo C. Rezende3, Daniel Feldman4, Milton Helfenstein Jr.5, Jose E. Martinez6, Jose R. Provenza7, Aline Ranzolin8, Luiz S. Ribeiro9 and Eduardo J.R. Souza10, 1Universidade Federal do Parana, Curitiba Parana, Brazil, 2UNIFESP - UNIVERSIDADE FEDERAL DE SÃO PAULO, São Paulo, Brazil, 3Santa Casa de Campo Grande, Campo Grande, Brazil, 4Universidade Federal de de São Paulo, Sao Paulo, Brazil, 5Universidade Federal de de São Paulo, São Paulo, Brazil, 6Pontifícia Universidade Católica de São Paulo, Sorocaba, Brazil, 7 Pontifícia Universidade Católica de Campinas, Campinas, Brazil, 8Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, 9Instituto de Previdência dos Servidores do Estado de Minas Gerais, Belo Horizonte, Brazil, 10Santa Casa de Belo Horizonte, Belo Horizonte, Brazil 1916. A Randomized, Double-Blind Comparison of Duloxetine 30 Mg Once Daily (QD) and Placebo in Adult Patients with Fibromyalgia. Lesley M. Arnold1, Shuyu Zhang2 and Beth Pangallo3, 1University of Cincinnati College of Medicine, Cincinnati, OH, 2Eli Lilly and Company, Indianapolis, IN, 3ELi Lilly and Company, Indianapolis, IN 1917. Therapeutic Massage on Pain Relief for Fibromyalgia: A Systematic Review and Meta-Analysis. Lingjun Kong1, Raveendhara R. Bannuru2, Weian Yuan1, Ying-wu Cheng1, Min Fang1, Timothy McAlindon2 and Chenchen Wang2, 1 Shanghai University of Traditional Chinese Medicine of Yueyang Hospital, Shanghai, China, 2Tufts Medical Center, Boston, MA

Genomics, Proteomics, and Genetics 1918. Proteomic Profiling Following Immunoaffinity Capture of HDL Identifies Association of Acute Phase Proteins and Complement Factors with Pro-Inflammatory HDL in Rheumatoid Arthritis. Christina Charles-Schoeman1, Yunan Miao2, Junji Watanabe3, Yuen Yin Lee4, George Katselis2, Terry D. Lee2 and Srinivasa T. Reddy3, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2Beckman Research Institute of the City of Hope, Duarte, CA, 3UCLA, Los Angeles, 4 UCLA, Los Angeles, CA 1919. Association Between Interferon Alpha Gene Expression and Disease Characteristics in Systemic Lupus Erythematosus. Michelle Petri1, Hong Fang1, Wenzheng Hu1, Jadwiga Bienkowska2, Norm Allaire2, John Carulli2 and Matthew D. Linnik3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Biogen Idec Inc., Cambridge, MA, 3 Biogen Idec Inc., Solana Beach, CA 1920. Association Between Plasma Cell Gene Signature and Disease Characteristics in Systemic Lupus Erythematosus. Michelle Petri1, Hong Fang1, Jie Xu1, Wenzheng Hu1, Ehtisham Akhter1, Jadwiga Bienkowska2, Norm Allaire2, John Carulli2, Laurence S. Magder3 and Matthew D. Linnik4, 1Johns Hopkins University School of Medicine, Baltimore, MD,

2011 Program Book

263

ACR/ARHP Poster Session C Biogen Idec Inc., Cambridge, MA, 3University of Maryland, Baltimore, MD, 4Biogen Idec Inc., Solana Beach, CA

2

1921. Narrowing the Protein Tyrosine Phospahatse-22 Locus in Mice with Cartilage Proteoglycan-Induced Arthritis Explores Disease-Promoting and Disease-Suppressive Sub-Loci Neutralizing Their In Vivo Arthritis Susceptibility and Severity. Timea Besenyei1, Andras Kadar1, Beata Tryniszewska1, Vyacheslav A. Adarichev2, Katalin Mikecz1 and Tibor T. Glant1, 1Rush University Medical Center, Chicago, IL, 2 Albert Einstein College of Medicine, Bronx, NY 1922. Identification of microRNA-31 as a novel regulator contributing to impaired IL-2 production in T cells from patients with systemic lupus Erythematosus. Wei Fan1, Yuanjia Tang1, Bo Qu1, Huijuan Cui1, Xinfang Huang1, Brandon W. Higgs2, Yihong Yao2, Bahija Jallal2 and Nan Shen1, 1 Shanghai Ren Ji Hospital, Shanghai, China, 2MedImmune, Gaithersburg, MD 1923. The Passenger Strand of MicroRNA-34a Is Epigenetically Silenced in Rheumatoid Arthritis Synovial Fibroblasts and Mediates Apoptosis Resistance Via Failure of XIAP (X-linked inhibitor of apoptosis protein) Inhibition. Fabienne Niederer1, Caroline Ospelt1, Joanna Stanczyk2, Michelle Trenkmann2, Emmanuel Karouzakis2, Meike Dahlhaus2, Beat A. Michel2, Christoph Kolling3, Renate E. Gay2, Steffen Gay2, Astrid Juengel2 and Diego Kyburz2, 1 Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Center of Exp. Rheumatology, Zurich, Switzerland, 3Schultess Clinic, Zurich, Switzerland 1924. Adoptive Transfer of Induced-Regulatory T Cells Effectively Attenuates Murine Airway Allergic Inflammation. Qin Lan1, Wei Xu2, Julie Wang1, Hui-Ming Fan3, Bernhard Ryffel4, Wei Shi2 and Song G. Zheng5, 1University of Southern California, Los Angeles, CA, 2The Saban Rrsearch Institute of Children’s Hospital Los Angeles, 3Shanghai East Hospital, Tonji University, Shanghai, China, 4University and CNRS, 3b rue de la Ferollerie, F-45071 Orleans, France, 5USC Keck School of Medicine, Los Angeles, CA 1925. Correlations Between S100 Gene Expression Levels and the Local and Systemic Inflammatory Markers (matrix metalloproteinase-3, MMP3; erythrocyte sedimentation rate, ESR) in Rheumatoid Arthritis Patients. Hooi-Ming Lee1, Hidehiko Sugino1, Chieko Aoki2, Miho Murakami2, Takaji Matsutani2, Takahiro Ochi3 and Norihiro Nishimoto2, 1Osaka University, Suita, Japan, 2Wakayama Medical University, Ibaraki, Japan, 3Osaka Police Hospital, Osaka, Japan 1926. Proteomic Characterization of Plasma Microparticles in Autoimmune Diseases. Christoffer T. Nielsen1, Ole Østergaard1, Line V. Iversen1, Søren Jacobsen2 and Niels H.H. Heegaard1, 1Statens Serum Institut, Copenhagen S, Denmark, 2Rigshospitalet - 4242, Copenhagen, Denmark 1927. Feasibility of a Molecular Diagnosis of Arthritis Based on the Identification of Specific Transcriptomic Profiles in Knee Synovial Biopsies. Isabelle Focant1, Daniel Hernandez-

264

2011 Program Book

Lobato2, Julie Ducreux1, Patrick Durez1, Adrien Nzeusseu Toukap1, Dirk Elewaut3, Frédéric. A. Houssiau1, Pierre Dupont2 and Bernard Lauwerys1, 1Université catholique de Louvain, Brussels, Belgium, 2Université catholique de Louvain, Louvain-La-Neuve, Belgium, 3Gent University Hospital, Ghent, Belgium 1928. Selective Inhibition of Epigenetic Factors Provide Potential New Tools for Arthritis Therapy. Timea Besenyei, Júlia Kurkó, Katalin Mikecz, Tibor T. Glant and Tibor A. Rauch, Rush University Medical Center, Chicago, IL 1929. Genome-Wide DNA Methylation Profiling Studies of Lymphocytes in Arthritic Mice. Tamas Kobezda1, Katalin Olasz2, Katalin Mikecz1, Tibor T. Glant1 and Tibor A. Rauch1, 1 Rush University Medical Center, Chicago, IL, 2Pecs, Hungary 1930. The De Novo Revision of TCRα but Not TCRβ Is Responsible for the Generation of Autoantibody-Inducing CD4+ (aiCD4+) T Cell That Causes Systemic Autoimmunity. Kenichi Uto1, Ken Tsumiyama1 and Shunichi Shiozawa2, 1 Kobe University Graduate School of Health Science, Kobe, Japan, 2Kobe University Graduate School of Health Science and Medicine/ The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan 1931. The Transcriptomic Analysis From PBMC Is a Powerful Approach to Identify Specific Signatures Able to Predict Responses for Each TNFalpha Blocking Agent. Romain Normand1, Olivier Vittecoq2, Martine Hiron1, Céline Derambure1, Xavier Le Loët2 and Thierry Lequerré2, 1Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 2Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France 1932. Identification of A SET of 8 Proteins ABLE to PREDICT the RESPONSE to Methotrexate/Etanercept In Rheumatoid Arthritis PATIENTS. Antoine Obry1, Pascal Cosette2, Philippe Chan Tchi Tsong3, Jéremy Siemowski4, Paul Morel4, Olivier Boyer1, Patrice Fardellone5, René-Marc Flipo6, Christian Marcelli7, Xavier Le Loët8, Thierry Lequerré8 and Olivier Vittecoq8, 1Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 2UMR 6270 CNRS, Plate-Forme d’Analyse protéomique de l’IFRMP23, Faculté des Sciences, University of Rouen, Rouen, France, 3Inserm 982, Plate-Forme d’Analyse Protéomique de l’IFRMP23, Faculté des Sciences, University of Rouen, Rouen, France, 4 UMR 6270 CNRS, Faculté des Sciences, University of Rouen, France, 5Rheumatology Department, Amiens University Hospital, Amiens, France, 6Rheumatology Department, Lille University Hospital, Lille, France, 7Rheumatology Department, Caen University Hospital, 8Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France 1933. Salivary Proteomics and Churg-Strauss Syndrome: A Phase IIa Case-Control Study Aimed At Identifying Novel Diagnostic Disease Biomarkers. Chiara Baldini, Daniela

ACR/ARHP Poster Session C Martini, Sara Grossi, Nicoletta Luciano, Francesco Ferro and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy 1934. BAFF and TACI Gene Expression Are Increased in Untreated Very Early Rheumatoid Arthritis Patients. Rita A. Moura1, Helena Canhão2, Joaquim Polido-Pereira2, Ana M. Rodrigues2, Márcio Navalho3, Ana F. Mourão4, Carlos M. Rosa5, Catarina Resende5, Raquel Campanilho-Marques2, João Madruga Dias2, João R. da Silva5, Mário Bexiga5, José A. Pereira da Silva5, Luis Graca6 and João E. Fonseca7, 1 Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 2Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon, Portugal, 3Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Radiology Department, Hospital da Luz, Lisbon, Portugal, 4Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Ocidental, EPE, Hospital Egas Moniz, Lisbon, Portugal, 5Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon, Portugal, 6Cellular Immunology Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 7Lisbon Academic Medical Center, on behalf of Rheumatic Diseases Portuguese Register (Reuma.pt), Lisbon, Portugal 1935. SLC2A9 Gene Expression Is Associated with a Haplotype Tagging Polymorphism. Philip L. Riches, Samuel Gray, Omar Albagha and Stuart H. Ralston, University of Edinburgh, Edinburgh, United Kingdom 1936. Elevated Expression of MMP9 in Plasma of Patients with Symptomatic Knee Osteoarthritic: Correlation with Disease Severity and Progression. Mukundan Attur1, Jeffrey D. Greenberg2, John Todd3, Quynh Ann Lu3, Renita Ramirez3, Cheongeun Oh4, Jonathan Samuels1, Svetlana Krasnokutsky5 and Steven B. Abramson1, 1NYU Hospital for Joint Diseases, New York, NY, 2New York University School of Medicine, New York, NY, 3Singulex, Alameda, California, Alameda, CA, 4 New York University, New York, NY, 5NYU Hospital for Joint Disease, New York, NY 1937. MicroRNA Expression in Vault Particles. Anne Rowzee1, Mayank Tandon1, Alessia Gallo1, John Routsias2, Athanasios G. Tzioufas3 and Ilias Alevizos4, 1NIDCR, Bethesda, MD, 2 National University of Athens, Greece, 3School of Medicine, National University of Athens, Greece, Athens, Greece, 4 NIDCR/ NIH #10 1N110, Bethesda, MD 1938. Regulation of Apoptosis and Matrix Metalloproteinase Expression by Small Ubiquitin Related Modifier-2/3 in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Svetlana Frank1, Simon Strietholt1, Christine Seyfert2, Marvin A. Peters3, Thomas Pauly4, George Kollias5 and Thomas Pap6, 1Institute of Experimental Musculoskeletal Medicine,

University of Muenster, Muenster, Germany, 2Department of Orthopaedic Surgery, Zeisigwaldkliniken, Chemnitz, Germany, 3Kerckhoff- Klinik GmbH, Justus-Liebig-University Gießen, Bad Nauheim, Gießen, Germany, 4Department of Nephrology and Rheumatology, Heinrich-Heine University, Meerbusch, Germany, 5Biomedical Sciences Research Center ‘Alexander Fleming’, Vari, Greece, 6University Hospital Münster, Münster, Germany

Infection-Related Rheumatic Disease 1939. High Expression of GITR and OX-40 Receptors on Memory CD4+25+ T Cells in the Joint Fluid of Patients with Antibiotic-Refractory Lyme Arthritis. Nalini K. Vudattu1, Elise E. Drouin2 and Allen C. Steere3, 1Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 2 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, Charlestown, MA, 3Massachusetts General Hospital and Harvard Medical School, Boston, MA 1940. C Trachomatis Is Present and Metabolically Active During the Remitting Phase in Synovial Tissues From Patients with Chronic Chlamydia-Induced Reactive Arthritis. John D. Carter1, Herve C. Gerard2 and Alan P. Hudson2, 1University of South Florida, Tampa, FL, 2Wayne State Univ Schl of Med, Detroit, MI 1941. Interferon-γ Release Assays In Rheumatic Patients: Baseline Study and In the Course of Anti-Tumor Necrosis Factor-α Agents. Melania Martínez-Morillo1, Sonia Mínguez2, Lourdes Mateo-Soria1, Irene Latorre1, José Domínguez1, Dolors Grados1, Beatriz Tejera1, Susana Holgado1, Alejandro Olivé1 and Xavier Tena1, 1Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 2 Hospital General de Manresa, Manresa, Spain 1942. Xenotropic Murine Leukemia Virus-Related Virus Infection in Italian Patients with Chronic Fatigue Syndrome, Fibromyalgia or Rheumatoid Arthritis. Laura Bazzichi1, Fabrizio Maggi2, Francesca Sernissi3, Pietro Scarpellini3, Camillo Giacomelli3, Arianna Consensi3, Maria Linda Vatteroni3, Mauro Pistello3 and Stefano Bombardieri1, 1 Rheumatology Unit, Pisa, Italy, 2University Hospital, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 3University of Pisa, Pisa, Italy 1943. Dexamethasone Reduces Staphylococcus Aureus-Induced Production of Inflammatory Cytokines and Matrix Metalloproteases in Primary Human Chondrocytes and Synovial Fibroblasts. Frank Hanses1, Irina Fink1, Susanne Graessel1, Bernd Salzberger1 and Martin Fleck2, 1University Hospital Regensburg, Regensburg, Germany, 2Asklepios Klinikum Bad Abbach, Bad Abbach, Germany 1944. The Cellular Response to Vaccination against Pandemic 2009 Influenza A (H1N1) Virus Among Patients with Rheumatic Diseases. Ori Elkayam, Sharon Amir, Uri Arad, Jonathan Wollman, Ayelet Brill, Daphna Paran, David Levartovsky, Irena Wigler and Dan Caspi, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 2011 Program Book

265

ACR/ARHP Poster Session C 1945. Circulating Levels of IL6, sIL6-r, sgp130 and Gamma-IFN in Patients with Hepatitic C Virus Related Arthritis (HCVrA) and Rheumatoid Arthritis (RA). Angelo Spanò1, Loredana Postiglione1, Paola Sabatini2, I. Soriente2, M.G. Sangiolo1, V. Bruner1, Raffaele Scarpa1 and Antonio Riccio1, 1Federico II University Medical School, Naples, Italy, 2Umberto I Hospital, Nocera Inferiore, Italy 1946. Polyarticular Septic Arthritis: A Case Series. Rajni Kalagate1, Sherilyn T. McCollum1, Charles H. Pritchard2 and Lawrence H. Brent1, 1Albert Einstein Medical Center, Philadelphia, PA, 2 Rheumatic Disease Associates, Willow Grove, PA 1947. Four Novel MEFV Gene Mutations in a Population Where the Prevalence of Crimean-Congo Hemorrhagic Fever and MEFV Gene Carrier Status Is Very High. Gulay Ozgon1, Aynur Engin2, Gulen Hatemi3, Serdal Ugurlu3, Elif Akyayla1, Mehmet Bakir2 and Huri Ozdogan3, 1Nesiller Genetic Lab, Istanbul, Turkey, 2MD,Department of of Infectious Diseases, Medical Faculty, University of Cumhuriyet, Sivas, Turkey, 3 MD,Division of Rheumatology, Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey 1948. The Effect of CCR5-DELTA-32 Mutation On ChlamydiaInduced Reactive Arthritis. Jason P. Guthrie1, Aasim Rehman2, Herve C. Gerard3, Jessica Stanich4, Alan P. Hudson3 and John D. Carter5, 1Springfield, IL, 2Tampa, FL, 3Wayne State Univ Schl of Med, Detroit, MI, 4Wayne State University, Detroit, MI, 5University of South Florida, Tampa, FL 1949. Hyperuricemia, Its Prevalence and Correlation with Age, Gender, BMI, Co-Morbidities and Metabolic Syndrome in Anti- Retroviral Naive HIV Cohort. Nirupa J. Patel1, Roy Rajan1, Rebecca Clark2 and Luis R. Espinoza3, 1LSU Health Sciences Ctr, New Orleans, LA, 2LSU Health Sciences Center, New Orleans, 3LSU Medical Center, New Orleans, LA 1950. Outbreak in Syphilis Presenting As Uveitis. Inés PérezMartín1, David de la Hera1, Ricardo Blanco2, Javier Rueda1, Carmen Bejerano2, Orlando Pompei1, Joaquín Cañal1, Juan Ventosa1, Manuel Gutiérrez-Cuadra1, Vanesa Calvo1, Javier Loricera1 and Miguel Angel González-Gay1, 1Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain 1951. Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies with Brucellosis. Bunyamin Kisacik1, Musa Aydinli1, Yavuz Pehlivan1, Muhammet sait Dag1, Mehmet Sayarlioglu2 and Ahmet Mesut Onat3, 1Gaziantep, Turkey, 2Kahramanmaras, Turkey, 3GAZIANTEP UNIVERSITESI, Gaziantep, Turkey 1952. Human Papillomavirus Lesion in Systemic Lupus Erythematosus. Ricardo V. Juarez, Crespo Maria Elena, Buschiazo Emilio, Sanchez Wilde Maria Cristina., Salta, Argentina

266

2011 Program Book

Miscellaneous Rheumatic and Inflammatory Diseases 1953. A Higher Than Expected Prevalence of Autoimmune Disease in a Cohort of Patients with Recalcitrant Leg Ulcers. Victoria K. Shanmugam1, Amber Schilling1, Anthony Germinario1, Mihriye Mete2 and Christopher Attinger3, 1 Georgetown University Hospital, Washington, DC, 2MedStar Health Research Institute, Hyattsville, MD, 3Georgetown University Hosptial, Washington, DC 1954. Prevalence and Significance of Previously Undiagnosed Rheumatic Diseases in Pregnancy. Véronique Ramoni1, Roberto Caporali1, Arsenio Spinillo2, Fausta Beneventi2, Margherita Simonetta2, Elena Locatelli2, Chiara Cavagnoli2, Claudia Alpini3, Giulia Albonico3, Elena Prisco1 and Carlo M. Montecucco1, 1Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, 2Obstetrics and Gynecology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, 3IRCCS Policlinico San Matteo Foundation, Pavia, Italy 1955. Eosinophilic Fasciitis (Shulman Disease): New Insights Into the Therapeutic Management From a Series of 34 Patients. David Lebeaux1, Camille Frances2, Stéphane Barete2, Bertrand Wechsler1, Odile Dubourg1, Jérôme Renoux1, Thierry Maisonobe1, Olivier Benveniste1, Marc Gatfossé3, Pierre Bourgeois1, Zahir Amoura1, Jean-Charles Piette4, Patrice Cacoub4 and Damien Sène1, 1Pitie-Salpetriere Hospital, Paris, France, 2Tenon Hospital, Paris, France, 3 Centre Hospitalier Coulommiers, Coulommiers, France, 4 CHU Pitié-Salpêtrière, Paris, France 1956. Some of Subgroups in Rheumatoid Arthritis Are Difficult to Differentiate with Polymyalgia Rheumatica by a GenomeWide Gene Expression Analysis. Yoshinobu Koyama1, Chinami Era1, Motohiko Tanino2, Daisuke Hidaka1, Toshiyuki Ota1 and Ayumi Uchino1, 1Iizuka Hospital, Iizuka, Japan, 2DNA Chip Research Inc., Yokohama, Japan 1957. Biologics In Relapsing Polychondritis: a Literature Review. Fernando Kemta Lekpa1, Virginia Byers Kraus2 and Xavier Chevalier1, 1Hopital Henri-Mondor, Creteil, France, 2Duke University Medical Center, Durham, NC 1958. HM-018, An Oral Small Molecule JAK Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis (EAE) in Mice. Yu Cai1, Wuzhong Shen1, Qianqian Dong1, Zhipeng Wu1, Xiaoning Yang1, Ping Ren1, Youjun Yu1, Hongxia Shen1, Jia Li1, Jian Wang1, Yang Sai1, James Yan1, Wei Deng1, Jianguo Ji2, Weiguo Su1 and Haoran Zhao1, 1Hutchison Medipharma Limited, Shanghai, China, 2Abott, Shanghai, China 1959. Safety and Efficacy of Mizoribine in Patients with Connective Tissue Diseases Other Than Rheumatoid Arthritis. Ryo Rokutanda1, Mitsumasa Kishimoto1, Hisanori Shimizu1, Atsushi Nomura2, Yasuhiro Suyama1, Yuri Ohara1, Akira Takeda1, Ken-ichi Yamaguchi3 and Masato Okada1, 1St. Luke’s International Hosptal, Tokyo, Japan, 2Chubu-Rosai hospital, Nagoya, Japan, 3St. Luke’s International Hospital, Tokyo, Japan

ACR/ARHP Poster Session C 1960. Idiopathic Hindfoot Problems As An Early Rheumatological Manifestation of Hereditary Hemochromatosis Type I. Elena Becerra-Fernandez1, Pantelis Panopalis2 and Henri A. Menard3, 1University College London, London, United Kingdom, 2McGill University Health Center, Montreal, QC, 3 Montreal General Hospital, Montreal, QC 1961. Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome:A Case Series with Characteristic Features. Qingping Yao, Cleveland Clinic, Cleveland, OH 1962. Atypical Persistent Plaquelike Skin Rash of Adult Onset Still’s Disease. Case Report and Review of Literature. Asha Muthalaly1, Dennis C. Ang2, Steven T. Hugenberg3, Roy Sampson1 and Agith Muthalaly4, 1Indiana University School of Medicine, Indianapolis, IN, 2Indiana University, Indianapolis, IN, 3Indiana Univ Schl of Medicine, Indianapolis, IN, 4St. James School of Medicine, Chicago 1963. Clinical and Genetic Features of Autoinflammatory Syndromes in Hispanic Patients: The Chilean Experience. Cristian Vergara1, Arturo Borzutzky1, Miguel A. Gutierrez1, Sergio Iacobelli1, Eduardo Talesnik1, Maria Eugenia Martinez1, Lilith Stange1, Javier Basualdo2, Viviana Maluje3, Renato Jimenez4, Elena Jarpa5, Roberto Wiener6, Javier Tinoco6, Juan I. Arostegui7, Jordi Yague7 and Manuel AlvarezLobos1, 1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad de Chile, Santiago, Chile, 3Hospital FACH, Santiago, Chile, 4Hospital Gustavo Fricke, Valparaiso, Chile, 5 Hospital Naval Almirante Nef, Vina Del Mar, Chile, 6Hospital Militar, Santiago, Chile, 7Hospital Clínic / IDIBAPS, Barcelona, Spain 1964. Use of Canakinumab in the Routinary Clinical Practice in Severe Cryopyrin-Associated Periodic Syndrome: One Year of Follow-up. Roberta Caorsi1, Loredana Lepore2, Francesco Zulian3, Maria Alessio4, Achille Stabile5, Martina Finetti6, Alberto Martini6 and Marco Gattorno1, 1G. Gaslini Institute, Genova, Italy, 2Ospedale-Infantile Trieste, Trieste, Italy, 3University of Padua, Padova, Italy, 4University of Naples Federico II, Napoli, Italy, 5DipartimentoPediatria, Policlinico Gemelli, Roma, Italy, 6IRCCS G Gaslini, Pediatria II, Reumatologia, Genova, Italy 1965. Classification of Two Subtypes in Adult-Onset Still’s Disease. Hisae Ichida, Yasushi Kawaguchi, Tomoko Sugiura, Takahisa Gono, Kae Takagi, Yuko Ota, Ikuko Masuda and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan 1966. Free Interleukin 18 As a Predictor of Remission and Flare up in Adult-Onset Still’s Disease Patients. Kyong-Hee Jung1, Joo Hyun Lee2, JinJu Kim2, Jin Sook Lee2, Won Park1, TaeHwan Kim2 and Dae-Hyun Yoo2, 1Center for Rheumatism, Inha University Hospital, Incheon, South Korea, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

1967. Study Design of the β-Confident-Registry Aiming to Evaluate the Largest Cohort of Cryopyrin-Associated Periodic Syndromes Patients. Hal M. Hoffman1, Ulrich A. Walker2, Hugh Tilson3, Jasmin B. Kuemmerle-Deschner4 and Philip Hawkins5, 1Division of Rheumatology and Allergy/ Immunology, La Jolla, CA, 2Dept. of Rheumatology at Basel University, Felix-Platter Spital, Basel, Switzerland, 3University of North Carolina, North Carolina, 4University Hospital Tuebingen, Tuebingen, Germany, 5Department of Medicine, University College London Medical School, London, United Kingdom 1968. Anti-TNFα Therapy in 15 Patients with Severe and Refractory Sarcoidosis. Inés Pérez-Martín1, Ricardo Blanco2, Javier Rueda1, Carmen Bejerano2, Orlando Pompei1, M. Carmen González-Vela1, Marcos A. González-López1, Héctor Fernández-Llaca1, Agustín Oterino1, María J. Sedano1, Mario Agudo1, Víctor M. Martínez-Taboada1 and Miguel Angel González-Gay1, 1Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain 1969. Sonographic Detection of a Bifid Median Nerve and Persistent Median Artery Among Patients with Clinical Diagnosis of Carpal Tunnel Syndrome in Rheumatology Office. Francis Luk, Carolyn R. O’Connor, Humaira Hussain, Vincent Zarro and Angel E. Checa, Drexel University College of Medicine, Philadelphia, PA 1970. The Role of Sufficient Starting Dose of Steroids in AdultOnset Still’s Disease. You Jae Kim1, Bon San Koo1, Min Wook So1, Wook Jang Seo2, Ji Seon Oh3, Yong-Gil Kim1, Chang-Keun Lee1 and Bin Yoo1, 1University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Seoul Veterans Hospital, Seoul, South Korea, 3University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea 1971. Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases. Ana Carolina Araújo, Carla Noronha, Ana Grilo, Maria Francisca Moraes-Fontes, Nuno Riso and Manuel Vaz Riscado, Hospital de Curry Cabral, Lisbon, Portugal 1972. Subacromial Steroid Injection Do Not Seems to Increase the Rate of Full-Thickness Rotator Cuff Tear. Julio Ramirez1, Isaac Pomés2, Jaume Pomés2 and Juan D. Cañete3, 1Hospital Clinic, Barcelona, Spain, 2Hospital Clínic, Barcelona, Spain, 3 Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain 1973. Magnetic Resonance Imaging Cartilage Composition As a Potential Early Marker for Degenerative Joint Disease in Patients with Cryopyrinopathies. Clara Malattia1, Martina Finetti1, Maria Beatrice Damasio2, Chiara Mattiuz2, Gabriele Chiusano3, Curzio Basso3, Aldo Naselli1, Alberto Martini1 and Marco Gattorno1, 1IRCCS G Gaslini, Pediatria II, Reumatologia, Genova, Italy, 2IRCCS G Gaslini, U.O. Radiologia, Genova, Italy, 3Dipartimento di Informatica e Scienze dell’Informazione, Università di Genova, Genova, Italy

2011 Program Book

267

ACR/ARHP Poster Session C 1974. E148Q Is Not a Disease Causing Allele in Familial Mediterranean Fever in Populations Where FMF Is Prevalent. Servet Akar1, Dilek Solmaz2, Fatos Onen1, Vedat Gerdan2, Ozgul Soysal2 and Nurullah Akkoc1, 1Professor, Izmir, Turkey, 2MD, Izmir, Turkey 1975. Long Term Follow-up of Infliximab Efficacy in Pulmonary and Extrapulmonary Sarcoidosis Refractory to Conventional Therapy. Eric Russell, Carolyn R. O’Connor and Humaira Hussain, Drexel University College of Medicine, Philadelphia, PA 1976. Early Recognition of Hearing Loss in Muckle-Wells Syndrome. Jasmin B. Kuemmerle-Deschner1, Assen Koitschev2, Pascal N. Tyrrell3, Katharina Ummenhofer1, Peter Lohse4, Sandra Hansmann1, Stefan Plontke5, Christiane Koitschev6 and Susanne M. Benseler3, 1University Hospital Tuebingen, Tuebingen, Germany, 2Department of Otorhinolaryngology, Klinikum Stuttgart, Stuttgart, Germany, 3 The Hospital for Sick Children, Toronto, ON, 4Department of Clinical Chemistry Großhadern, University Munich, Munich, Germany, 5Department of Otorhinolaryngology, University Hospital Halle (Saale), Halle (Saale), Germany, 6Department of Otorhinolaryngology, University Hospital Tuebingen, Tuebingen, Germany

Osteoarthritis - Clinical Aspects 1977. Association Between Sports Participation and the Risk of Knee Osteoarthritis: A Systematic Review. Jeffrey B. Driban1, Jennifer M. Hootman2, Michael R. Sitler3, Kyle P. Harris4 and Nicole M. Cattano5, 1Tufts Medical Center, Boston, MA, 2Centers for Disease Control and Prevention, Kennesaw, GA, 3Temple University, Philadelphia, PA, 4Bucks County Community College, Newtown, PA, 5West Chester University, West Chester, PA 1978. Physical Activity Levels and the Risk of Incident Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project. Kamil E. Barbour1, Jennifer M. Hootman1, Charles G. Helmick2, Louise Murphy1, Yiling Cheng2, Kristina A. Theis1, Barbara Do2 and Joanne M. Jordan3, 1CDC, Atlanta, GA, 2Centers for Disease Control and Prevention, Atlanta, GA, 3UNC Thurston ARC, Chapel Hill, NC 1979. Recent Heavy Physical Activities Trigger Knee Pain Exacerbation in Persons with Symptomatic Knee Osteoarthritis. Yuqing Zhang1, Diane Wheaton2, Jingbo Niu1, Barton Wise3, William Havey4, Joyce Goggins1 and David J. Hunter5, 1Boston University School of Medicine, Boston, MA, 2New England Baptist Hospital, Boston, MA, Boston, MA, 3University of California, Davis School of Medicine, Sacramento, CA, 4New England Baptist Hospital, Boston, MA, 5Royal North Shore Hospital, Sydney, Australia 1980. Sedentary Behavior and Functional Performance Among Participants in the Osteoarthritis Initiative (OAI). Jungwha Lee1, Rowland W. Chang1, Larry Manheim2, Pamela A. Semanik3, Jing Song2 and Dorothy D. Dunlop2, 1Northwestern University, Chicago, IL, 2Northwestern Univ Med School, Chicago, IL, 3Rehabilitation Institute Chicago, Oak Park, IL

268

2011 Program Book

1981. Differences in Patient Acceptable Symptomatic State (PASS) Thresholds and Minimal Clinically Important Improvement (MCII) for Pain At Rest and on Movement in Patients with Lower Limb Osteoarthritis. Serge Perrot1, Philippe Bertin2 and Philippe Ravaud3, 1Hopital Hotel Dieu, Paris, France, 2Chu Dupuytren, Limoges, France, 3Hopital Hotel Dieu, Paris Descartes University, Paris, France 1982. Relationship Between Aspects of the Pain Experience in Knee Osteoarthritis and Function and Disability. September Cahue, Joan Chmiel, Karen W. Hayes, Orit Almagor, Kirsten Moisio, Carmelita J. Colbert, Clifton Saurel, Yunhui Zhang and Leena Sharma, Northwestern University, Chicago, IL 1983. Relationship of Specific Pain Patterns in Knee Osteoarthritis with Severity of Pain and Functional Disability. Nehal Shah1, Michael J. Hannon2, WANG Zhijie3 and C. Kent Kwoh4, 1 University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, 3University of Pittsburgh school of medicine, Pittsburgh, PA, 4University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA 1984. Relation of Knee Cartilage Loss to Pain and Functional Limitation: The Multicenter Osteoarthritis Study. Barton Wise1, Jingbo Niu2, Nancy E. Lane3, Michael C. Nevitt4, Daniel K. White2, James Torner5, Cora E. Lewis6 and Yuqing Zhang2, 1University of California, Davis School of Medicine, Sacramento, CA, 2Boston University School of Medicine, Boston, MA, 3UC Davis School of Medicine, Sacramento, CA, 4 University of California-San Francisco, San Francisco, CA, 5 University of Iowa, Iowa City, Iowa City, IA, 6University of Alabama, Birmingham City, Birmingham, AL 1985. Muscle Parameters and Function Self-Efficacy in Knee Osteoarthritis. Carmelita J. Colbert, Karen W. Hayes, Orit Almagor, Joan S. Chmiel, Alison H. Chang, Kirsten Moisio, September Cahue, Yunhui Zhang, Clifton Saurel and Leena Sharma, Northwestern University, Chicago, IL 1986. Functional Impairment As a Predictor of Knee Replacement in the Multicenter Osteoarthritis Study. Barton Wise1, Jingbo Niu2, Nancy E. Lane3, Michael C. Nevitt4, David T. Felson2, Jean Hietpas5, Alesia Sadosky6, James Torner7, Cora E. Lewis8 and Yuqing Zhang2, 1University of California, Davis School of Medicine, Sacramento, CA, 2Boston University School of Medicine, Boston, MA, 3UC Davis School of Medicine, Sacramento, CA, 4University of California-San Francisco, San Francisco, CA, 5UCSF, San Francisco, CA, 6 Pfizer, Inc., New York, NY, 7University of Iowa, Iowa City, Iowa City, IA, 8University of Alabama, Birmingham City, Birmingham, AL 1987. Clinical Characteristics and Medication Use of Patients with Knee Osteoarthritis Selected for Total Joint Replacement Surgery. T.N. de Boer1, M.J.P.M. Stukstette2, P.M.J. Welsing1, A.M. Huisman3, A.A. Polak3, J.W.J. Bijlsma1, Simon C. Mastbergen1 and F.P.J.G. Lafeber1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands, 3Sint Franciscus Gasthuis, Rotterdam, Netherlands

ACR/ARHP Poster Session C 1988. Psychological Predictors of Failure to Improve After Lower Extremity Joint Arthroplasty. Chad M. Brummett1, Brian Hallstrom1, Andrew Urquhart1, Michelle Morris1, Daniel J. Clauw2 and David A. Williams3, 1University of Michigan Health System, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Univ of MI Hlth System-Lobby M, Ann Arbor, MI 1989. Is the Impact of Knee OA Diminishing Because of Knee Replacements? The Multi-Center Osteoarthritis Study. Jingbo Niu1, Michael C. Nevitt2, Charles E. McCulloch3, James Torner4, Cora E. Lewis5 and David T. Felson1, 1Boston University School of Medicine, Boston, MA, 2University of California-San Francisco, San Francisco, CA, 3Department of Epidemiology and, San Francisco, CA, 4University of Iowa, Iowa City, Iowa City, IA, 5University of Alabama, Birmingham City, Birmingham, AL 1990. Gait Biomechanics As Predictors of Hip Osteoarthritis Progression. Kharma C. Foucher1, Bryan R. Schlink2, Najia Shakoor1 and Markus A. Wimmer1, 1Rush University Medical Center, Chicago, IL, 2University of Illinois at Chicago, Chicago, IL 1991. The Relationship of Toe-Out Walking to Clinical Characteristics of 1st Metatarsophalangeal Joint Osteoarthritis in Older Adults: The MOST Study. K. Douglas Gross1, Howard J. Hillstrom2, Jingbo Niu3, Michael C. Nevitt4, Cora E. Lewis5, James Torner6 and David T. Felson3, 1MGH Institute of Health Professions, Boston, MA, 2Hospital Special Surgery (HSS), New York, NY, 3Boston University School of Medicine, Boston, MA, 4University of CaliforniaSan Francisco, San Francisco, CA, 5University of Alabama, Birmingham City, Birmingham, AL, 6University of Iowa, Iowa City, Iowa City, IA 1992. Relationships Between the Peak Adduction Moment and Symptoms During Walking in Knee OA Patients with Valgus Knee Brace: A Cross-Sectional Study. Paul Ornetti, Clementine Fortunet, Davy Laroche, Claire Morisset, jeanMarie Casillas and jean-Francis Maillefert, Dijon University Hospital, Dijon, France 1993. Consequences of Knee Buckling: The Multicenter Osteoarthritis Study. Uyen Sa D. Nguyen1, David T. Felson1, Jingbo Niu1, Yanyan Zhu1, Daniel K. White1, Neil Segal2, C.E. Lewis3, Margaret Rasmussen4 and Michael C. Nevitt4, 1 Boston University School of Medicine, Boston, MA, 2 University of Iowa, Iowa City, 3University of Alabama, Birmingham City, AL, 4University of California-San Francisco, San Francisco, CA 1994. Is Medial Knee Osteoarthritis Associated with Adverse Effects At the Ankles? Berna Goker1, Abdurrahman Tufan1, Roy H. Lidtke2 and Joel A. Block2, 1Gazi University Medical School, Ankara, Turkey, 2Rush University Medical Center, Chicago, IL 1995. The Association of Vibratory Perception with Foot Plantar Pressures: The MOST Study. Najia Shakoor1, Howard J. Hillstrom2, K. Douglas Gross3, Ke Wang4, David T. Felson5,

Neil Segal6, Cora E. Lewis7 and Michael C. Nevitt8, 1Rush University Medical Center, Chicago, IL, 2Hospital Special Surgery (HSS), New York, NY, 3MGH Institute of Health Professions, Boston, MA, 4Boston University, Boston, MA, 5Boston University School of Medicine, Boston, MA, 6 University of Iowa, Iowa City, 7University of Alabama, Birmingham City, Birmingham, AL, 8University of CaliforniaSan Francisco, San Francisco, CA 1996. Associations Between Pain on Movement, Range of Movement and Radiographic Change in Osteoarthritis of the Knee. Roger Hilfiker1, Peter Juni2, Eveline Nüesch2, Paul A. Dieppe3 and Stephan Reichenbach1, 1University of Bern, Bern, Switzerland, 2University of Bern, Bern, Switzerland, 3 University of Exeter, Plymouth, United Kingdom 1997. Radiographic Joint Damage and Not Clinical Characteristics Are Related to the Actual Cartilage Damage in Severe Knee OA Patients. T.N. de Boer1, Simon C. Mastbergen1, A.M. Huisman2, J.W.J. Bijlsma1 and F.P.J.G. Lafeber1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Sint Franciscus Gasthuis, Rotterdam, Netherlands 1998. Peri-Articular Apparent Bone Volume Fraction Is Associated with Numerous Patient Characteristics in Knees with Osteoarthritis: Data From the Osteoarthritis Initiative. Jeffrey B. Driban1, Lori Lyn Price1, Anna M. Tassinari1, Grace H. Lo2 and Timothy E. McAlindon1, 1Tufts Medical Center, Boston, MA, 2Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Boston, MA 1999. Safety of Diclofenac Sodium Topical Solution Compared with Oral Diclofenac for Osteoarthritis of the Knee in Patients Aged ≥65 Years: Pooled Analysis From 2 Controlled Trials. Sanford H. Roth1 and Philip Fuller2, 1Arizona Research & Education, Paradise Valley, AZ, 2Covidien, Hazelwood, MO 2000. Prevention of Celecoxib Induced Gastrointestinal Events by Concomitant Therapy with Rebamipide, Gastro-Protective Drug. Masahiro Hasegawa1, Kyosuke Tanaka1, Noriyuki Horiki1, Hiroki Wakabayashi1, Yoshiyuki Takei1, Atsumasa Uchida1, Akihiro Sudo1 and GLORIA study group2, 1Mie University Graduate School of Medicine, Tsu City, Mie, Japan, 2Tsu City, Mie, Japan 2001. GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded End Point (PROBE) Trial. Byron Cryer1, Chunming Li2, Lee S. Simon3, Gurkirpal Singh4, Martin Stillman5 and Manuela Berger2, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Pfizer Inc, New York, NY, 3SDG LLC Consulting, West Newton, MA, 4Stanford University School of Medicine, Palo Alto, CA, 5Hennepin County Medical Center, Minneapolis, MN 2002. COX-1 Affinity Determines NSAID - Aspirin Interactions. Inger L. Meek1, Jeannine Kasemier1, Harald E. Vonkeman1, Kris Movig1 and Mart AF van de Laar2, 1Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, 2Medisch Spectrum Twente & Twente University, Enschede, Netherlands

2011 Program Book

269

ACR/ARHP Poster Session C 2003. Effects of Opioid and Neurotoxin Analgesics on Pain Behaviors and Function Over Time in Mice with Collagenase-Induced Osteoarthritis. Hollis E. Krug1, Christopher W. Dorman2, Sandra Frizelle2 and Maren L. Mahowald3, 1Minneapolis VA Health Care System and University of Minnesota Medical School, Minneapolis, MN, 2 Minneapolis VA Health Care System, Minneapolis, MN, 3 University of Minnesota Medical School and Minneapolis VA Health Care System, Minneapolis, MN 2004. Validation of the Longitudinal Reproducibility of Medial Joint Space Width Quantification in Knee Osteoarthritis. Berna Goker1, Tayfun Akalin1 and Joel A. Block2, 1Gazi University Medical School, Ankara, Turkey, 2Rush University Medical Center, Chicago, IL 2005. Validity of within-Grade Scoring of Longitudinal Changes of MRI-Based Cartilage Morphology and Bone Marrow Lesion Assessment - the MOST Study. Frank Roemer1, Michael C. Nevitt2, David T. Felson3, Jingbo Niu1, John Lynch4, Michel Crema1, Cora E. Lewis5, James Torner6 and Ali Guermazi7, 1Boston University, Boston, MA, 2University of California-San Francisco, San Francisco, CA, 3Department of Clinical Epidemiology, Boston University School of Public Health, Boston, MA, USA, Boston, MA, 4San Francisco, CA, 5 University of Alabama, Birmingham City, Birmingham, AL, 6 University of Iowa, Iowa City, Iowa City, IA, 7Boston Medical Center, Boston, MA 2006. Similar Reliability of DESS and TSE Magnetic Resonance Imaging Sequences in the Assessment of Bone Marrow Lesions in Knee Osteoarthritis Patients: Data From the Osteoarthritis Initiative Cohort. Jean-Pierre Raynauld1, Lukas M. Wildi1, François Abram2, Thomas Moser3, Manon Girard2, Johanne Martel-Pelletier1 and Jean Pierre Pelletier1, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 2ArthroVision Inc., Montreal, QC, 3 Department of Radiology, University of Montreal Hospital Centre (CHUM), Notre-Dame Hospital, Montreal, QC

Chicago, IL, 3Cincinnati Children’s Hospital, Cincinnati, OH, University of Cincinnati, Cincinnati, OH, 5University of Oklahoma, Norman, OK

4

2009. Therapeutic APPROACHES for the TREATMENT of NEW Onset and Flared Juvenile Systemic LUPUS Erythematosus with ACTIVE Renal DISEASE: AN International MULTICENTER PRINTO STUDY. Paivi Miettunen, Angela Pistorio, Angelo Ravelli, Sheila Oliveira, Maria Alessio, Ruben Cuttica, Dimitrina Mihaylova, Graciela Espada, Srdjan Pasic, Elisabetta Cortis, Seza Ozen, Oscar Porras, Flavio Sztajnbok, Alberto Martini and Nicolino Ruperto, IRCCS G. Gaslini, Pediatria II, PRINTO, Paediatric Rheumatology, Genova, Italy 2010. Race, Ethnicity and Gender Affect the Severity of Renal Outcomes in Patients with Pediatric Systemic Lupus Erythematosus: An Analysis of the CARRAnet Data At Baseline Visit. Ornella J. Rullo1, Deborah K. McCurdy1, Ora Yadin1, Alice DC Hoftman1, Jennifer M.P. Woo1, Emily von Scheven2 and CARRAnet Investigators3, 1Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA, 2UC San Francisco, San Francisco, CA, 3Durham 2011. Behavior, Executive and Perceived Neuropsychological Functioning with Childhood-Onset Systemic Lupus Erythematosus – Results of a Best-Friend Controlled Study. Adlin Cedeno1, Aimee Baker2, Marisa Klein-Gitelman1, Anna Carmela P. Sagcal-Gironella2, April German2, Cynthia Scharf2, Jun Ying3, Hermine Brunner2, Dean Beebe2 and Frank Zelko1, 1Children’s Memorial Hospital, Chicago, IL, 2 Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati, Cincinnati, OH

Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Rheumatology Systemic Lupus Erythematosus, Juvenile Dermatomyositis, Vasculitis and Other

2012. The PRINTO Provisional Definition of REMISSION In Juvenile Dermatomyositis. Dragana Lazarevic1, Angela Pistorio1, Paivi Miettunen1, Angelo Ravelli1, Clara Malattia1, Clarissa Pilkington1, Nico Wulffraat1, Stella Maris Garay1, Michael Hofer1, Pierre Quartier1, Pavla Dolezalova1, Inmaculada Calvo Penades1, Virginia P.L. Ferriani1, Gerd Ganser2, Ozgur Kasapcopur1, Jose Antonio Melo-Gomes1, Malgorzata Wierzbowska1, Alberto Martini1 and Nicolino Ruperto1, 1IRCCS G. Gaslini, Pediatria II, PRINTO, Paediatric Rheumatology, Genova, Italy, 2Sankt Josef Stift, Sendenhorst, Germany

2007. The Childhood Myositis Assessment Scale (CMAS) Total Score in Healthy Children, Age 4-5 Years, is 46, Not 52. Rebecca Quinones1, Gabrielle Morgan1, Maria Amoruso1, Deli Wang2 and Lauren M. Pachman3, 1Children’s Memorial Hospital, Chicago, IL, 2Northwestern University’s Feinberg School of Medicine, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL

2013. Determination of Pediatric Doses of Colchicine for Familial Mediterranean Fever on the Basis of Population Pharmacokinetics. Yackov Berkun1, Eldad Ben-Chetrit1, Suman Wason2, Robert Faulkner2 and Stephen Levenstein3, 1 Hadassah Hebrew University Medical Center, Jerusalem, Israel, 2URL Pharma, Philadelphia, PA, 3GCP Clinical Studies Ltd., Rosh Ha’Ayin, Israel

2008. The Pediatric Automated Neuropsychological Assessment Metrics Has Reproducibility and Criterion Validity in Childhood-Onset Lupus. Hermine Brunner1, Aimee Baker1, Adlin Cedeno2, Jennifer L. Huggins1, Anna Carmela P. SagcalGironella3, Jun Ying4, Marisa Klein-Gitelman2 and Tresa Roebuck-Spencer5, 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Children’s Memorial Hospital,

2014. Performance of the Systemic Lupus Erythematosus Responder Index in Juvenile Systemic Lupus Erythematosus. Rina Mina1, Marisa Klein-Gitelman2, Shannen L. Nelson3, B. Anne Eberhard4, Gloria C. Higgins5, Nora G. Singer6, Deborah M. Levy7, Karen Onel8, Judyann C. Olson9, Joshua D. Pendl10, Aimee Baker10, Lisa F. Imundo11, Lori B. Tucker12, Laura E. Schanberg13, Marilynn G. Punaro14,

270

2011 Program Book

ACR/ARHP Poster Session C Kathleen M. O’Neil15, Nicolino Ruperto16, Daniel J. Lovell10 and Hermine Brunner10, 1Cincinnati Children’s Med Ctr, Cincinnati, OH, 2Children’s Memorial Hospital, Chicago, IL, 3Cincinnati Children’s Hospital, Cincinnati, OH, 4Cohen Children’s Hospital Medical Center, New Hyde Park, NY, 5 Nationwide Childrens Hosp, Columbus, OH, 6MetroHealth Medical Center, Cleveland, OH, 7The Hospital for Sick Children, Toronto, ON, 8University of Chicago, Chicago, IL, 9 Medical College of Wisconsin, Milwaukee, WI, 10Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 11 Childrens Hospital of New York, Columbia University Medical Center, New York, NY, 12BC Childrens Hospital, Vancouver, BC, 13Duke University Medical Center, Durham, NC, 14Texas Scottish Rite Hospital, Dallas, TX, 15Okla Univ Health Science Ctr, Oklahoma City, OK, 16PRINTO-IRCCS, Genova, Italy 2015. A Secondary Analysis of the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Study Shows That Atorvastatin Therapy Reduces Progression of Carotid Intima Medial Thickening in Pubertal SLE Patients with Higher C Reactive Protein. Stacy P. Ardoin1, Laura E. Schanberg2, Christy I. Sandborg3, Huiman Barnhart4, Eric Yow4, Greg Evans5, Kelly Mieszkalski2, Norman T. Ilowite6, Emily von Scheven7, B. Anne Eberhard8, Lisa F. Imundo9, Deborah M. Levy10, Yuki Kimura11, Earl D. Silverman12, Suzanne L. Bowyer13, Marilynn G. Punaro14, Nora G. Singer15, David D. Sherry16, Deborah K. McCurdy17, Marisa KleinGitelman18, Carol A. Wallace19, Richard M. Silver20, Linda Wagner-Weiner21, Gloria Higgins22 and Hermine Brunner23, 1 Ohio State University, Columbus, OH, 2Duke University Medical Center, Durham, NC, 3Stanford University, Palo Alto, CA, 4Duke Clinical Research Institute, Durham, NC, 5 Winston-Salem, NC, 6Children’s Hospital Montefiore, Bronx, NY, 7UC San Francisco, San Francisco, CA, 8Cohen Children’s Hospital Medical Center, New Hyde Park, NY, 9Childrens Hospital of New York, Columbia University Medical Center, New York, NY, 10The Hospital for Sick Children, Toronto, ON, 11 Pediatrics, Hackensack, NJ, 12Hospital for Sick Children, Toronto, ON, 13James Whitcomb Riley Hospital, Indianapolis, IN, 14Texas Scottish Rite Hospital, Dallas, TX, 15Director, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 16Children’s Hospital of Philadelphia, Philadelphia, PA, 17Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA, 18Children’s Memorial Hospital, Chicago, IL, 19Childrens Hosp & Regional Med, Seattle, WA, 20MUSC, Charleston, SC, 21 University of Chicago Hospital, Chicago, IL, 22NATIONWIDE CHILDRENS HOSPITAL, Columbus, OH, 23Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 2016. Ovarian Reserve in Juvenile Systemic Lupus Erythematosus Patients without Amenorrhea. Nadia E. Aikawa1, Adriana M. Sallum2, Rosa M.R. Pereira3, Eloisa Bonfa4, Lisa Suzuki5, Vilma S.T. Viana1 and Clovis A. Silva6, 1Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo-

SP, Brazil, 3Disciplina de Reumatologia da FMUSP, Sao Paulo, Brazil, 4University of Sao Paulo, Sao Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 6 Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil 2017. Maternal Autoimmunity and Neonatal Brain Abnormalities: Cerebral Dysmaturation, Diencephalon Abnormalities, and Lenticulostriate Vasculopathy. Jennifer D. Frankovich1, Patrick D. Barnes1, Christy I. Sandborg1 and Eliza F. Chakravarty2, 1Stanford University, Palo Alto, CA, 2 Oklahoma Medical Research Foundation, Oklahoma City, OK 2018. Long-Term Methotrexate Efficacy in Juvenile Localized Scleroderma. Francesco Zulian1, Cristina Vallongo1, Fabio Vittadello1, Annalisa Patrizi2, Maria Alessio3, Anna Belloni Fortina1, Silvana Martino4 and Giorgia Martini1, 1University of Padua, Padova, Italy, 2University of Bologna, Bologna, Italy, 3University of Naples Federico II, Napoli, Italy, 4 University of Turin, Italy 2019. Diagnostic Evaluation and Medication Usage in a Cohort of Subjects with Juvenile Dermatomyositis Recruited within the First 11 Months of the Children’s Arthritis and Rheumatology Research Alliance Registry. Angela B. Robinson1, Mark F. Hoeltzel2, ML Becker2, Dawn M. Wahezi3, Adam M. Huber4, Brian M. Feldman5, Ann M. Reed6 and Juvenile Myositis CARRA Subgroup for CARRAnet Investigators7, 1Rainbow Babies and Childrens Hospital, Cleveland, OH, 2Children’s Mercy Hospital, Kansas City, MO, 3Children’s Hospital Montefiore, Bronx, NY, 4Dalhousie University, Halifax, NS, 5The Hospital for Sick Children, Toronto, ON, 6Mayo Clinic, Rochester, MN, 7Varies by Investigator 2020. Influenza A H1N1/2009 Vaccine in Juvenile Dermatomyositis: Reduced Response in Patients Under Immunosuppressive Agents. Vanessa R. Guissa1, Nadia E. Aikawa2, Adriana M. Sallum1, Lucia M.A. Campos3, Rosa M.R. Pereira4, Eloisa Bonfa5 and Clovis A. Silva1, 1Faculdade de Medicina da Universidade de São Paulo, São Paulo-SP, Brazil, 2 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 4Disciplina de Reumatologia da FMUSP, Sao Paulo, Brazil, 5University of Sao Paulo, São Paulo, Brazil 2021. Creation of A COHORT of French PATIENTS with CHRONIC RECURRENT Multifocal OSTEITIS: PRELIMINARY RESULTS. Julien Wipff1, M.-A. Dumitrescu2, Mathie Lorrot3, Albert Faye2, S. lacassagne-Compeyrot4, B. Bader Meunier4, R. Mouy4, Carine H. Wouters5, Marine Desjonqueres6, S. Jean7, V. Despert7, A. Duquesne6, I. Lemelle8, P. Pillet9, M. GrallLerosey10, Pierre Quartier11 and Chantal Job-Deslandre12, 1 Paris descartes Universityn Rheumatology A, Cochin Hospital, Paris, France, 2Paris, France, 3Paediatry, Robert Debré hospital, Paris, France, 4University Paris Descartes, Paediatry, Necker hospital, Paris, France, 5University 2011 Program Book

271

ACR/ARHP Poster Session C Hosp Gasthuisberg, Leuven, Belgium, 6Hopital Femme Mere Enfant, Groupement Hospitalier Est, Lyon, France, 7 Paediatry, CHU, Rennes, France, 8Paediatry, CHU, Nancy, France, 9Paediatry, CHU, Bordeaux, France, 10Paediatry, CHU, Rouen, France, 11Hôpital Necker-Enfants Malades, Paris, France, 12Hopital Cochin, Paris Cedex 14, France 2022. Recurrent Arthritis As the Sole Presenting Manifestation of Hereditary Autoinflammatory Syndromes. Giulia Vigo1, Giorgia Martini1, Fabio Vittadello1, Isabella Ceccherini2, Laura Obici3 and Francesco Zulian1, 1University of Padua, Padova, Italy, 2G. Gaslini Institute, Genova, Italy, 3IRCCS Policlinico S. Matteo, Pavia, Italy 2023. Description of the Localized Scleroderma Subgroup of the CARRAnet Registry. Eveline Y. Wu1, Egla C. Rabinovich2, Kathryn S. Torok3, Suzanne C. Li4, Robert C. Fuhlbrigge5 and CARRANet Investigators6, 1Duke Univ Med Ctr, Durham, NC, 2Duke University Medical Center, Durham, NC, 3Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 4Hackensack Univ Med Ctr, Hackensack, NJ, 5Childrens Hospital, Boston, MA, 6 Stanford 2024. Parents’ Attitudes towards Research and Research Study Participation in Pediatric Rheumatology (PR). America Uribe1, Lori B. Tucker2, Louise Masse1, Jaime Guzman1 and David A. Cabral3, 1BC Children’s Hospital, Vancouver, BC, 2 BC Childrens Hospital, Vancouver, BC, 3University of British Columbia, Vancouver, BC 2025. Long-Term Mental Health Outcomes in Pediatric-Onset Systemic Lupus Erythematosus. Erica F. Lawson1, Aimee O. Hersh2, Laura J. Julian1, Laura Trupin3, Emily von Scheven3, Patricia P. Katz4 and Edward Yelin1, 1University of California San Francisco, San Francisco, CA, 2University of Utah, Salt Lake City, UT, 3UC San Francisco, San Francisco, CA, 4 Univercity of California San Francisco, San Francisco, CA 2026. Quality of Life and Psychosocial Aspects Among School Adolescents with Diffuse Chronic Musculoskeletal Pain in Brazil. AK Nascif1, V. Valim1, M. Dorio2, JR Gomes1, AFA Pereira1, E. Zandonade1 and Claudio Len3, 1Universidade Federal do Espírito Santo, Vitória, Brazil, 2Vitória, Brazil, 3 Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil

Stone3, Anne Jones4, Dawn C. Chapelle Neal5 and Daniel L. Kastner6, 1Drexel University College of Medicine/St Christophers Hosp for Child, Philadelphia, PA, 2NIAID-NIH, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4NIH-NIAMS, Bethesda, MD, 5NIAMS, Bethesda, MD, 6 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 2029. Mycophenolate Mofetil in Children with Lupus: Clinical Findings in Favour of Therapeutic Drug Monitoring. Brigitte Bader-Meunier1, Camille Jurado2, Bruno Ranchin3, Stéphane Decramer4, Michel Fischbach5, Etienne Berard6 and Franck Saint Marcoux2, 1Hôpital Necker, Paris, France, 2INSERM UMR –S850, Limoges, France, 3Hôpital Femme-Mère-Enfant, Lyon, France, 4hôpital Purpan, Toulouse, France, 5Hôpital Hautepierre, Strasbourg, France, 6Hôpital Lenval, Nice, France 2030. Autoantibody Testing for Children on Biologic Therapies for Rheumatological Conditions: Results of Audit. Julie Duncan, Jill Heath, Eileen M. Baildam, Gavin Cleary, Michael W. Beresford and Liza J. McCann, Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom 2031. Effects of Pediatric-Onset Systemic Lupus Erythematosus on Final Linear Height: Evidence From a Large Observational Cohort. Laura Trupin1, Aimee O. Hersh2, Jinoos Yazdany3, Erica F. Lawson1 and Emily von Scheven1, 1 UC San Francisco, San Francisco, CA, 2University of Utah, Salt Lake City, UT, 3University of California San Francisco, San Francisco, CA 2032. “Living Well” Chronic Disease Self-Management Program for Adolescents with Rheumatic Disease. Sheetal Vora1 and Elizabeth L. Roth-Wojcicki2, 1Medical College of Wisconsin, Milwaukee, WI, 2Medical College of WI, Wauwatosa, WI 2033. Ethnic Differences of Early Disease Severity in Pediatric Systemic Lupus Erythematosus At An Urban Tertiary Care Center. Jennifer M.P. Woo1, Peony Liu2, Miriam F. Parsa1, Gil Amarilyo1, Alice DC Hoftman2, Deborah K. McCurdy2 and Ornella J. Rullo2, 1University of California, Los Angeles, Los Angeles, CA, 2Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA

2027. Race Is a Risk Factor for Calcinosis in Patients with Juvenile Dermatomyositis: Early Observations From the Childhood Arthritis and Rheumatology Research Alliance Registry (CARRAnet). Mark F. Hoeltzel1, ML Becker1, Angela B. Robinson2, Adam M. Huber3, Brian M. Feldman4, Ann M. Reed5 and Juvenile Myositis CARRA Subgroup for CARRAnet Investigators6, 1Children’s Mercy Hospital, Kansas City, MO, 2 Rainbow Babies and Childrens Hospital, Cleveland, OH, 3 Dalhousie University, Halifax, NS, 4The Hospital for Sick Children, Toronto, ON, 5Mayo Clinic, Rochester, MN, 6Various

2034. Clinical Characteristics of Children with Juvenile Dermatomyositis Recruited within the First 11 Months of the Children’s Arthritis and Rheumatology Research Alliance Registry (CARRAnet). Mark F. Hoeltzel1, ML Becker1, Angela B. Robinson2, Adam M. Huber3, Brian M. Feldman4, Ann M. Reed5 and Juvenile Myositis CARRA Subgroup for CARRAnet Investigators6, 1Children’s Mercy Hospital, Kansas City, MO, 2Rainbow Babies and Childrens Hospital, Cleveland, OH, 3Dalhousie University, Halifax, NS, 4 The Hospital for Sick Children, Toronto, ON, 5Mayo Clinic, Rochester, MN, 6Various

2028. Anakinra for the Treatment of Hyper-IgD with Periodic Fever Syndrome in Children. Donald P. Goldsmith1, Karyl S. Barron2, Amanda K. Ombrello3, Robert Lembo3, Deborah

2035. Outcome of Babies Born to Mothers with Systemic AutoImmune Diseases. Noemie Abisror1, Arsene Mekinian1, Eric Lachassinne2, Pascale nicaise-Roland3, Jerome Stirnemann4,

272

2011 Program Book

ACR/ARHP Poster Session C Loic de Pontual*2, Lionel Carbillon5 and Olivier Fain4, 1Jean Verdier Hospital, Bondy, France, 2Service de néonatologie et pédiatrie, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, 3Unité Fonctionnelles d’Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, Paris, France, 4 Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, 5 Service de gynécologie-obstétrique, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France 2036. Accrual Damage Assessment In Juvenile-Onset Systemic Lupus Erythematosus. Juan G. Ovalles, Julia MartínezBarrio, Francisco J. López-Longo, Inmaculada de la Torre, Lina Martínez-Estupiñán, Juan C. Nieto and Luis Carreño, Gregorio Marañón Hospital, Madrid, Spain 2037. Low Vitamin D in Juvenile Onset Systemic Lupus Erythematosus: Association with Disease Activity and Low Bone Mineral Density. Luciana P.C. Seguro1, Caio B. Casella1, Liliam Takayama2, Eloisa Bonfa3 and Rosa M.R. Pereira4, 1 University of Sao Paulo, Sao Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3 University of Sao Paulo, São Paulo, Brazil, 4Disciplina de Reumatologia da FMUSP, Sao Paulo, Brazil 2038. Use of Urinary Metabolites to Distinguish Proliferative From Membranous Lupus Nephritis. Shannen L. Nelson1, Rina Mina2, Lindsey Romick-Rosendale3, Hermine Brunner4, Michael Bennett2, Joshua D. Pendl4, Michelle Petri5, Adnan Kiani5, Prasad Devarajan2 and Michael Kennedy6, 1 Cincinnati Children’s Hospital, Cincinnati, OH, 2Cincinnati Children’s Med Ctr, Cincinnati, OH, 3Miami University, Ohio, Oxford, OH, 4Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6Miami University, Oxford, Oxford, OH 2039. Effectiveness of Anti-Tumor Necrosis Factor-α Agents in the Treatment of Refractory Juvenile Dermatomyositis. E.L. Boulter1, L. Beard2, Clive Ryder3, Clarissa Pilkington1 and Juvenile Dermatomyositis Research Group4, 1Great Ormond Street Hospital, London, United Kingdom, 2UCL Institute of Child Health, London, United Kingdom, 3Birmingham Children’s Hospital NHS Foundation Trust, Birmingham, United Kingdom, 4London, United Kingdom 2040. Treatment Delay in Kawasaki Disease – the Role of NonTraditional Risk Factors. Nadia Luca1, Joyce C. Y. Ching1, Cedric Manlhiot2, Brian W. McCrindle2 and Rae SM Yeung1, 1 Hospital for Sick Children, Toronto, ON, 2The Hospital for Sick Children, Toronto, ON 2041. Health Care Transition Improvement Utilizing Learning Collaborative and the New Six Core Transition Elements. Patience H. White1, Peggy McManus2, Jeanne McAllister3 and Carl Cooley3, 1Arthritis Foundation, Washington, DC, 2National Alliance to Advance Adolescent Health, Washington, DC, 3Center for Medical Home Improvement, Concord, NH

2042. Mycophenolate Mofetil (MMF) Versus Azathioprine As Maintenance Therapy Combined with Monthly Intravenous Cyclophsophamide (IVCY) in Juvenile Lupus Nephritis. Toshitaka Kizawa, Tomoyuki Imagawa, Tomo Nozawa, Masako Kikuchi, Tomonori Harada, Takako Miyamae and Shumpei Yokota, Yokohama City University, Yokohama, Japan 2043. Inpatient Treatment Variation of Children Hospitalized with Complex Regional Pain Syndrome. Cara Hoffart1, Pamela Weiss2, Andrew J. Klink3, David D. Sherry3 and Chris Feudtner4, 1The Childrens Hospital of Philadelphia, Philadelphia, PA, 2The Children’s Hospital of Philadelphia, Philadelphia, PA, 3Children’s Hospital of Philadelphia, Philadelphia, PA, 4Division of General Pediatrics, Children’s Hospital of Philadelphia; University of Pennsylvania Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA 2044. Children with Ehlers-Danlos Syndrome and Airway Dysfunction. Sanjay J. Khiani1, Sara Lowe1, Michael Zacharisen1 and Sheetal Vora2, 1Medical College of Wisconsin and the Children’s Research Institute, Wauwatosa, WI, 2Medical College of Wisconsin, Milwaukee, WI 2045. Cytomegalovirus in Pediatric Systemic Lupus Erythematosus: Screening and Therapeutic Implications. Evelyn V. Rozenblyum, Deborah M. Levy, Elizabeth Harvey, Diane Hebert and Earl D. Silverman, Hospital for Sick Children, Toronto, ON 2046. Alveolar Hemorrhage: Distinct Clinical Profile in Adult and Juvenile Systemic Lupus Erythematosus Patients. Daniel B. Araujo1, Eduardo F. Borba Neto1, Clovis A. Silva1, Lucia M.A. Campos1, Rosa M.R. Pereira2, Eloisa Bonfa1 and Samuel K. Shinjo1, 1Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 2Disciplina de Reumatologia da FMUSP, Sao Paulo, Brazil 2047. CD146+ Endothelial Progenitor Cell Number Increases Following 36 Months of Atorvastatin Therapy in Children and Adolescents with SLE: The Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Cohort. Stacy P. Ardoin1, Thomas Povsic2, Laura E. Schanberg3, Christy I. Sandborg4, Huiman Barnhart5, Eric Yow5, Greg Evans6, Kelly L. Mieszkalski3, Norman T. Ilowite7, Emily von Scheven8, B. Anne Eberhard9, Lisa F. Imundo10, Yuki Kimura11, Earl D. Silverman12, Suzanne L. Bowyer13, Marilynn G. Punaro14, Nora G. Singer15, David D. Sherry16, Deborah K. McCurdy17, Marisa Klein-Gitelman18, Carol Wallace19, Richard M. Silver20, Linda Wagner-Weiner21, Gloria C. Higgins22 and Hermine Brunner23, 1Ohio State University, Columbus, OH, 2Duke University, Durham, NC, 3Duke University Medical Center, Durham, NC, 4Stanford University, Palo Alto, CA, 5Duke Clinical Research Institute, Durham, NC, 6Winston-Salem, NC, 7Children’s Hospital Montefiore, Bronx, NY, 8UC San Francisco, San Francisco, CA, 9Cohen Children’s Hospital Medical Center, New Hyde Park, NY, 10Childrens Hospital of New York, Columbia University Medical Center, New York, NY, 11Pediatrics, Hackensack, NJ, 12Hospital for Sick Children, 2011 Program Book

273

ACR/ARHP Poster Session C Toronto, ON, 13James Whitcomb Riley Hospital, Indianapolis, IN, 14Texas Scottish Rite Hospital, Dallas, TX, 15Director, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 16Children’s Hospital of Philadelphia, Philadelphia, PA, 17Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA, 18Children’s Memorial Hospital, Chicago, IL, 19Childrens Hosp & Regional Med, Seattle, WA, 20MUSC, Charleston, SC, 21 University of Chicago Hospital, Chicago, IL, 22Nationwide Childrens Hosp, Columbus, OH, 23Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Quality Measures and Innovations in Practice Management and Care Delivery II 2048. Serum Uric Acid Testing Patterns In Gout Patients: A Need for Improved Monitoring. Michael A. Becker1, Bhavik J. Pandya2, Jason R. Young3, Xiangyang Ye3, Sudhir Unni3, Shawn Yu2 and Carl V. Asche3, 1University of Chicago Medical Center, Chicago, IL, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, 3University of Utah College of Pharmacy, Salt Lake City, UT 2049. Patient Reported Outcomes In a Single Community Based Rheumatology Practice, - Outcomes Not As Good As We Think? Melinda K. Pemberton1, Gary Runde2 and Wendell D. Bronson3, 1Heartland Clinic, St Joseph, MO, 2Heartland Regional Medical Center, Saint Joseph, MO, 3Heartland Clinic, St. Joseph, MO 2050. Less-Experienced Rheumatologists Can Improve Agreement in the Detection of Clinical Synovitis Through Consensus in Rheumatoid Arthritis (RA). Peter Cheung1, Vincent Andre2, Natalie Balandraud3, Gerard H. Chales4, Isabelle Chary-Valckaneare5, Emmanuel Chatelus6, Emmanuelle Dernis2, Ghislaine Gill5, Melanie Gilson7, Sandrine Guis3, Thierry Marhadour8, Gael Mouterde9, Stephan Pavy10, Francois Pouyol11, Pascal Richette12, Adeline Ruyssen-Witrand13, Martin Soubrier14, Maxime Dougados15 and Laure Gossec16, 1Hospital Cochin, Paris, France, 2Centre Hospitalier, Le Mans, France, 3Hopital de la Conception, Marseilles, France, 4CHR - Hopital Sud, Rennes, France, 5Hopital de Brabois, Nancy, France, 6Hopital Hautepierre, Strasbourg, France, 7CH Grenoble Hopital Sud, Grenoble, France, 8CHU La Cavale Blanche, Brest, France, 9 Hopital Lapeyronie, Montpellier, France, 10Hopital Bicetre, Paris, France, 11Hopital de Roger Salengro, Lille, France, 12 Lariboisière Hospital, Paris, France, 13Hopitaux de Toulouse, Toulouse, France, 14CHU CLERMONT-FERRAND, ClermontFerrand, France, 15Paris-Descartes University, Cochin Hospital, Paris, France, 16Cochin Hospital, Paris, France 2051. A Clinical Microsystem Analysis of An Academic Rheumatology Practice Is High-Yield for Identifying Improvement Opportunities. Natalie B. Riblet, Alicia J. Zbehlik, Yvonne Y. Cheung and Daniel A. Albert, DartmouthHitchcock Med Ctr, Lebanon, NH

274

2011 Program Book

2052. Scores for Sleep, Anxiety, and Depression on the Multidimensional Health Assessment Questionnaire (MDHAQ) in the Patient-Friendly HAQ Format Are Higher Than for Any of the 8 Traditional HAQ Queries to Identify Problems in Patients with Rheumatic Diseases. Isabel Castrejón1, Yusuf Yazici2 and Theodore Pincus1, 1NYU Hospital for Joint Diseases, New York, NY, 2Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 2053. A Self-Report RADAI (Rheumatoid Arthritis Disease Activity Index) Count of Painful Joints Can Be Informative in Patients with Rheumatic Diseases Other Than Rheumatoid Arthritis. Isabel Castrejón1, Yusuf Yazici2 and Theodore Pincus1, 1NYU Hospital for Joint Diseases, New York, NY, 2 Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 2054. Teens’ Perception of Reproductive Health Counseling in Pediatric Rheumatology. Tova Ronis1, Jennifer D. Frankovich1, Christy I. Sandborg1 and Peter Chira2, 1Stanford University, Palo Alto, CA, 2Indiana University School of Medicine, Indianapolis, IN 2055. Placing Serious Infection Risk in Perspective. A Randomized Trial Evaluating a Patient Decision Aid to Reduce Focusing Illusion. Richard W. Martin1, Newsha Lajevardi1, Shruti Sevak1, Andrew J. Head1, Aaron T. Eggebeen1 and Donald J. Tellinghuisen2, 1Michigan State University College of Human Medicine, Grand Rapids, MI, 2 Calvin College, Grand Rapids, MI 2056. Measurement of the Quality of the Patient-Physician Interaction in An Outpatient Rheumatology Clinic. Shawnta R. Pittman-Hobbs1 and Andreas M. Reimold2, 1UT Southwestern Medical Center, Dallas, TX, 2Dallas VA and University of Texas Southwestern, Dallas, TX 2057. Are United States Rheumatologists Interested in Using Electronic Mail in Patient Care? Concerns From a National Survey. Gregory Wilson1, Chokkalingam Siva2, Celso Velazquez1, Karen L. Smarr3, John Fresen1 and Marius Petruc1, 1University of Missouri, Columbia, MO, 2Univ of Missouri Sch of Med, Columbia, MO, 3Harry S Truman Mem VA Hospital, Columbia, MO 2058. Routine Assessment of Patient Index Data-3 (RAPID3) Is Informative in Patients with All Rheumatic Diseases to Depict Patient-Reported Information As Quantitative Data, Rather Than As Narrative Descriptions. Isabel Castrejón1, Martin J. Bergman2, Yusuf Yazici3 and Theodore Pincus1, 1 NYU Hospital for Joint Diseases, New York, NY, 2Taylor Hospital, Ridley Park, PA, 3Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 2059. Ethical Issues in Rheumatology: A Survey of the American College of Rheumatology Membership. C. Ronald MacKenzie1, Michele Meltzer2 and Elizabeth A. Kitsis3, 1Hosp for Special Surgery, New York, NY, 2Jefferson University, Philadelphia, PA, 3Albert Einstein College of Med, Bronx, NY

ACR/ARHP Poster Session C 2060. Assessment of Cardiovascular Risk in Rheumatoid Arthritis: Comparison of Two Indices and Related Variables. José L. Rosales-Alexander, César Magro-Checa, Juan Salvatierra, Jesús Cantero-Hinojosa and Enrique Raya-Alvarez, University Hospital San Cecilio, Granada, Spain

2066. Is Having Fibromyalgia Worse Than Having Depression or Both in Lupus: Impact on Health Outcomes? Meenakshi Jolly1, Jessica Cornejo2, Rachel A. Mikoliatis2 and Joel A. Block1, 1Rush University Medical Center, Chicago, IL, 2Rush University, Chicago, IL

2061. Measuring Quality of Care in Juvenile Idiopathic Arthritis: The Pediatric Rheumatology Care and Outcomes Improvement Network. Esi Morgan DeWitt1, Timothy Beukelman2, Beth S. Gottlieb3, Nancy Griffin4, Yukiko Kimura5, Itara Barnes6 and Murray H. Passo7, 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Univ of Alabama-Birmingham, Birmingham, AL, 3Schneider Children’s Hospital, New Hyde Park, NY, 4Cincinnati Children’s Hospital Medical Center, Cincinnati, 5Hackensack Univ Medical Ctr, Hackensack, NJ, 6Atlanta, GA, 7MUSC, Charleston, SC

2067. Hydroxychloroquine Retinopathy in Inflammatory Arthritis: A Retrospective Analysis in Canadian Patients. Mohammed Osman1, Heather Burnett1, Alison Kydd2, Paul Davis1, Christopher Rudnisky1, Matthew Tennant1 and Elaine Yacyshyn1, 1University of Alberta, Edmonton, AB, 2University of British Columbia, Vancouver, BC

2062. Detection of Adverse Events in Routine Rheumatology Practice by a New Computer Application. Zulema Rosales1, Ana B. Rodríguez-Cambrón1, Lydia Abásolo1, Leticia León1, Oscar Fontsere1, Cristina Vadillo1, J.L. Fernández Rueda1 and Juan A. Jover2, 1Hospital Clínico San Carlos, Madrid, Spain, 2 Hospital Clinico San Carlos, Madrid, Spain 2063. A Quality Indicator for Osteoporosis in a Japanese Hospital. Yasuhiro Suyama1, Mitsumasa Kishimoto1, Yuri Ohara1, Ryo Rokutanda1, Atsushi Nomura2, Hisanori Shimizu1, Ken-ichi Yamaguchi1, Yukio Matsui1 and Masato Okada1, 1St. Luke’s International Hospital, Tokyo, Japan, 2Chubu-Rosai hospital, Nagoya, Japan 2064. A Randomized Clinical Trial of a Comprehensive Behavioral Intervention in Systemic Lupus Erythematosus Demonstrates Improvement in Mental Health but Not in Physical Health, Cardiovascular Risks or Endothelial Function At One Year. Paul R. Fortin1, Ellie Aghdassi2, Anne Cymet2, Stacey Morrison3, Jiandong Su3, Willy Wynant4, Janet E. Pope5, Sara Hewitt5, Christian A. Pineau6, Carolyn Neville7, Paula Harvey8, Jean-Claude Tardif9, Michal Abrahamowicz10 and Deborah DaCosta11, 1Toronto Western Hospital, Toronto, ON, 2University Health Network, Toronto, ON, 3The Toronto Western Hospital, Toronto, ON, 4McGill University, Quebec, QC, 5St. Joseph’s Health Care, University of Western Ontario, London, ON, 6McGill Univ Health Center, Montreal, QC, 7Royal Victoria Hospital, Montreal, QC, 8Toronto General Hospital, Toronto, ON, 9Universite de Montreal endowed research chair in atherosclerosis, Quebec, QC, 10McGill UHC/RVH, Montreal, QC, 11Montreal General Hospital, Montreal 2065. Cardiovascular Risk Assessment and Management in a Nationally Representative Sample of Routine Ambulatory Visits for Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus. Laura Tarter1, Laura Trupin1, Gabriela Schmajuk2, Mary Margaretten1, Edward Yelin1 and Jinoos Yazdany1, 1University of California San Francisco, San Francisco, CA, 2Stanford University, Palo Alto, CA

2068. Real-Time, Cohort-Based Clinical Decision Support Using a Novel Bioinformatics Platform to Assess Thrombotic Risk in a Critically Ill Pediatric Patient with Systemic Lupus Erythematosus. Jennifer D. Frankovich, Chris Longhurst, Scott Sutherland and Christy I. Sandborg, Stanford University, Palo Alto, CA 2069. The Juvenile Systemic Sclerosis Clinic: an Interdisciplinary Approach. Marìa M. Katsicas, Erica Hammermuller, Betina Cervini and Ricardo A. Russo, MD, Caba, Argentina 2070. Lipid Testing Gaps in Patients with Rheumatoid Arthritis and Key Cardiovascular-Related Comorbidities. Christie M. Bartels1, Amy J. Kind2, Carolyn Thorpe1, Christine Everett3 and Maureen Smith1, 1Univ of Wisconsin School of Medicine and Public Health, Madison, WI, 2Univ of Wisconsin and William S. Middleton VA, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Madison, WI 2071. Safety, Tolerability, and Immunogenicity of Zoster Vaccine in Patients on Chronic/Maintenance Corticosteroids. Janie Parrino1, Farid Marquez2, Chester L. Fisher Jr.3, Wolfgang Spieler4, Tadeusz Tomala5, Jon E. Stek1, Amy F. Russell1, Kathleen E. Coll1, Shu-Chih Su1, Jin Xu1, Xiaoming Li1, Katia Schlienger1 and Jaffrey L. Silber1, 1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 2Palm Springs Research Institute, Hialeah, FL, 3Health Research of Hampton Roads, Newport News, VA, 4Rheumatology Specialty Practice, Zerbst, Germany, 5Svelvik Medical, Svelvik, Norway 2072. Factors Involved in the Decision to Take Medications to Prevent Rheumatoid Arthritis in First Degree Relatives of Patients with RA. A Discrete Choice Experiment. Axel Finckh1, Monica Escher2, Matthew H. Liang3 and Nick Bansback4, 1University Hospital of Geneva, Geneva, Switzerland, 2University Hospital of Geneva, Geneva 14, Switzerland, 3Brigham & Womens Hospital, Boston, MA, 4 University of British Columbia, Vancouver 2073. Effect of Health Insurance Coverage on Quality of Care in SLE. Edward Yelin1, Jinoos Yazdany2, Laura Trupin3, Chris Tonner1, Patricia P. Katz4, Gabriela Schmajuk2, Joann Zell5, Pantelis Panopalis6, Lindsey A. Criswell2 and Laura J. Julian2, 1UCSF, San Francisco, CA, 2University of California San Francisco, San Francisco, CA, 3UC San Francisco, San Francisco, CA, 4Univercity of California San Francisco, San

2011 Program Book

275

ACR/ARHP Poster Session C Francisco, CA, 5National Jewish Health, Denver, CO, 6McGill University, Montreal, QC 2074. Adherence to Gout Guidelines in a Rheumatology Clinic. Richard Conway, Robert J. Coughlan and John J. Carey, Galway University Hospitals, Galway, Ireland 2075. Rheumatoid Arthritis: Patient Insights, Strategies and Expectations— Dual Survey Offers Physicians Unique Insight Into Patient Experience. Gerd R. Burmester1, Theresa Lupton2, JM Alvaro-Gracia3 and Boulos Haraoui4, 1 Charité - Universitätsmedizin Berlin, Berlin, Germany, 2 Univ of Calgary Medical Clinics, Calgary, AB, 3Hospital Universitario de la Princesa, IIS Princesa,, Madrid, Spain, 4 Institut de Rhumatologie, Montreal, QC 2076. Implementation of An Electronic Interface for Medical Record Documentation in An Academic Pediatric Rheumatology Outpatient Clinic: An 18-Month Update. Jennifer M.P. Woo1, Miriam F. Parsa1, Gil Amarilyo1, Nasim Afsar-manesh1, Ornella J. Rullo2 and Deborah K. McCurdy2, 1 University of California, Los Angeles, Los Angeles, CA, 2 Mattel Children’s Hospital, University of California, Los Angeles, Los Angeles, CA 2077. The Use of Hydroxychloroquine in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus: To Check or Not to Check Glucose-6-Phosphate Dehydrogenase Levels Prior to Its Initiation in Everyday Rheumatology Practice. Mercedes Quinones1, Sharon Dowell1, Archana Sharma2, Raymond Flores1, Marc Hochberg1, Jamal Mikdashi1 and Violeta Rus1, 1University of Maryland School of Medicine, Baltimore, MD, 2Maryland General Hospital, Baltimore, MD 2078. A Pilot Cardiovascular Risk Reduction Clinic for Inflammatory Rheumatic Diseases. Kevin Martell, Michael Sean McMurtry, Finlay McAlister, Gabor Gyenes and Stephanie O. Keeling, University of Alberta, Edmonton, AB 2079. A Screening Tool for Knee Osteoarthritis. C. Kent Kwoh1, Michael J. Hannon2, Stephanie M. Green3, Ali Guermazi4 and Robert M. Boudreau3, 1University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA, 4Boston Medical Center, Boston, MA

Rheumatoid Arthritis - Animal Models 2080. Importance of E3 Ubiquitin Ligase Synoviolin In Fibrogenesis. Naoko Yagishita1, Daisuke Hasegawa1, Satoko Aratani2, Yoshihisa Yamano1 and Toshihiro Nakajima2, 1 St.Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, 2Tokyo Medical University, Tokyo, Japan 2081. Pemetrexed Ameliorates Experimental Arthritis in Rats. Metin Ozgen1, Suleyman Serdar Koca1, Ahmet Karatas1, Adile Ferda Dagli2, Fazilet Erman3, Nuran Sahin4, Kazim Sahin4 and Ahmet Isik1, 1Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey, 2Department

276

2011 Program Book

of Pathology, Faculty of Medicine, Firat University, Elazig, Turkey, 3School of Health Sciences, Firat University, Elazig, Turkey, 4Department of Animal Nutrition, Faculty of Veterinary Science, Firat University, Elazig, Turkey 2082. Increased Density of Sympathetic Nerve Fibers in Metabolically Activated Fat Tissue Surrounding Human Synovium and Mouse Lymph Nodes in Arthritis. Christine Wolff1, Luise Rauch1, Torsten Lowin1, Susanne Klatt2 and Rainer H. Straub1, 1Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, Department of Internal Medicine I, University Hospital, Regensburg, Germany, 2 Laboratory of Exp. Rheumatology and NeuroendocrinoImmunology, University Hospital, Regensburg, Germany 2083. Gemcitabine Ameliorates Experimental Arthritis in Rats. Metin Ozgen1, Suleyman Serdar Koca1, Adile Ferda Dagli2, Ahmet Karatas1, Cemal Orhan3, Mehmet Tuzcu4, Nuran Sahin3, Kazim Sahin3 and Ahmet Isik1, 1Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey, 2Department of Pathology, Faculty of Medicine, Firat University, Elazig, Turkey, 3Department of Animal Nutrition, Faculty of Veterinary Science, Elazig, Turkey, 4Department of Biology, Faculty of Science, Firat University, Elazig, Turkey 2084. A Novel, Highly Selective Syk Kinase Inhibitor Significantly Ameliorates the Severity of Arthritis in Rodents. Zhong Cui Sun1, Yu Cai1, Yan Qiu1, Lei Fang1, Xiaoming Dai1, Zhipeng Wu1, Ping Ren1, Jianlin He1, Changwu Lu1, Yongjuan Yu1, Jian Wang1, Yang Sai1, James Yan1, Jia Li1, Wei Deng1, Weihan Zhang1, Jianguo Ji2, Weiguo Su1 and Haoran Zhao1, 1 Hutchison Medipharma Limited, Shanghai, China, 2Abott, Shanghai, China 2085. A Novel Role of h2-Calponin in the Development of Anti-GPI Serum-Induced Arthritis. M. Moazzem Hossain1, Qi Quan Huang2, Linda D. Hazlet3, Sharon A. McClellan3, Richard M. Pope2 and J.-P. Jin1, 1Departments of Physiology, Wayne State University School of Medicine, Detroit, MI, 2 Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, MI 2086. An Endogenous TLR2 Ligand Promotes Chronicity of Arthritis Which Is Modulated by Fas Signaling. Qi Quan Huang1, Alexander Misharin1, Robert Birtett1, Carla M. Cuda1, Christopher V. Nicchitta2, Harris R. Perlman1 and Richard M. Pope1, 1Northwestern University, Chicago, IL, 2 Duke university Medical Center, Durham, NC 2087. Suppression of Established Rat Collagen-Induced Arthritis and Inhibition of TNF-α with Small Molecule Aminopyridizines. Soo I. Choi1, Lori D. Klaman2, Weiling Chen1 and Ernest Brahn1, 1UCLA School of Medicine, Los Angeles, CA, 2Transition Therapeutics, Toronto, ON 2088. Treatments with Glycogen Synthase Kinase-3β Inhibitor Mitigate the Severity of Arthritis in Mice with CollagenInduced Arthritis. Yong-Jin Kwon, Tae-Yeon Kim, Sang-Won

ACR/ARHP Poster Session C Lee, Yong-Beom Park, Soo Kon Lee and Min-Chan Park, Yonse University College of Medicine, Seoul, South Korea 2089. Pressure and Viscosity Measurements in Efferent Lymphatics to Better Understand the Mechanisms of Arthritic Flare and Response to Therapy. Echoe M. Bouta1, Ronald Wood1, Christopher T. Ritchlin2 and Edward M. Schwarz1, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY 2090. IL-6 Blockade Augments the Therapeutic Effect of MTX in Mice with Glucose-6-Phosphate Isomerase-Induced Arthritis. Hiroto Yoshida1, Misato Hashizume1, Keisuke Tanaka1, Miho Suzuki1, Takayuki Sumida2, Isao Matsumoto2 and Masahiko Mihara1, 1Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, 2Division of Clinical Immunology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan 2091. Laquinimod Inhibits Disease Severity in Murine Collagen Induced Arthritis. Joel F. Kaye and Eran Blaugrund, Teva Pharmaceuticals Ltd, Netanya, Israel 2092. Blocking the Granulocyte Macrophage Colony Stimulating Factor Receptor Alpha Chain Prevents Mechanical Hypersensitivity in a Mouse Model of Inflammatory Pain. John P. Hatcher, Justine Whitworth, Ian K. Anderson, Iain P. Chessell and Matthew A. Sleeman, MedImmune Ltd, Cambridge, United Kingdom 2093. Prophylactic Injection of Non-Citrullinated Alpha-Enolase Has Immunomodulatory Effects in Collagen-Induced Arthritis Mice. Clément Guillou1, Gilles Avenel1, Céline Derambure1, Mathieu Verdet1, Martine Hiron1, Maude Maho1, Xavier Le Loët2, Sahil Adriouch1, Olivier Boyer1, Thierry Lequerré2 and Olivier Vittecoq2, 1Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 2Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France 2094. Preventive and Therapeutic Effects of Epigallocatechin3-Gallate (EGCG) on Collagen-Induced Arthritis in Rats. Metin Ozgen1, Suleyman Serdar Koca1, Adile Ferda Dagli2, Ahmet Karatas1, Cemal Orhan3, Hasan Gencoglu4, Nurhan Sahin3, Kazim Sahin3 and Ahmet Isik1, 1Department of Rheumatology, Faculty of Medicine, Firat University, Elazig, Turkey, 2Department of Pathology, Faculty of Medicine, Firat University, Elazig, Turkey, 3Department of Animal Nutrition, Faculty of Veterinary Science, Elazig, Turkey, 4Department of Biology, Faculty of Science, Firat University, Elazig 2095. Trichostatin A Induces CD8á Positive Tolerogenic Dendritic Cells, Regulatory T Cells in SKG Mice, and Ameliorates the Severe Arthritis. Kenta Misaki, Akio Morinobu, Jun Saegusa, Shimpei Kasagi, Masaaki Fujita, Yoshiaki Miyamoto, Fumichika Matsuki and Shunichi Kumagai, Kobe university graduate school of medicine, Kobe, Japan

2096. Brucellosis-Induced Murine Arthritis and Spondylolisthesis. Elizabeth T. Lyons1, Diogo Magnani2, Toni S. Forde1, Gary Splitter2 and Vyacheslav A. Adarichev1, 1Albert Einstein College of Medicine, Bronx, NY, 2University of Wisconsin, Madison, WI 2097. IL-23 Upregulates IRF5 and Polarizes Inflammatory M1 Macrophages to Promote Inflammation in a Mouse Model of Arthritis. Hao Li1, Hui-Chen Hsu1, Jun Li1, Qi Wu1, PingAr Yang1, Daniel Cua2 and John D. Mountz3, 1University of Alabama at Birmingham, Birmingham, AL, 2Merck Research Laboratory, Palo Alto, CA, 3University of Alabama at Birmingham and Birmingham VAMC, Birmingham, AL 2098. Metformin Attenuated An Autoimmune Arthritis in Animal Models of Rheumatoid Arthritis Via AMP-Activated Protein Kinase Activation. Kwi Young Kang1, Inje Kim2 and Ji Hyeon Ju3, 1Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea, 2Hallym University Kangdong Sacred Heart hospital, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea 2099. SH3BP2 “Cherubism” Gain-of-Function Mutation Exacerbates Inflammation and Bone Erosion in Collagen Induced Arthritis. Tomoyuki Mukai1, Teruhito Yoshitaka1, Keiichiro Nishida2 and Yasuyoshi Ueki1, 1University of Missouri-Kansas City, Kansas City, MO, 2Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan 2100. Skin Fibroblasts Are Potent Suppressors of Inflammation in Experimental Arthritis. C. Bouffi1, C. Bony2, Christian Jorgensen3 and Daniele Noel1, 1UM1, Montpellier, France, 2 INSERM U844, Montpellier, France, 3CHU Lapeyronie, Montpellier, France 2101. Treatment of Collagen Induced Arthritis with Human Adipose-Derived, Bone Marrow-Derived and Cord BloodDerived Mesenchymal Stem Cells. Kyu-Hyung Park, Ji-Hye Kim, Sang-Won Lee, Soo Kon Lee and Yong-Beom Park, Yonse University College of Medicine, Seoul, South Korea 2102. A Novel Mouse Model of Atherosclerosis in Inflammatory Arthritis. Shawn M. Rose and Harris R. Perlman, Northwestern University, Chicago, IL 2103. Arthritic ApoE-Deficient Mice Are Protected From the Development of Atherosclerosis. Shawn M. Rose and Harris R. Perlman, Northwestern University, Chicago, IL

Rheumatoid Arthritis Clinical Aspects: Clinical Features of Rheumatoid Arthritis, Disease Severity, Outcomes Research and Metrology 2104. Chronic Kidney Disease in Rheumatoid Arthritis. Cynthia S. Crowson, LaTonya Hickson, Sherine E. Gabriel, James T. McCarthy and Eric L. Matteson, Mayo Clinic, Rochester, MN

2011 Program Book

277

ACR/ARHP Poster Session C 2105. Increased Activity of the platelet glycoprotein (GP) VI pathway in Patients with Rheumatoid Arthritis. Paul A. MacMullan1, Eimear Dunne2, Anne M. Madigan1, Michael C. Berndt2, Robert K. Andrews3, Elizabeth E. Gardiner3, Dermot Kenny2 and G M. McCarthy1, 1Mater Misericordiae University Hospital, Dublin 7, Ireland, 2RCSI, Dublin 2, Ireland, 3Monash University, Melbourne, Australia 2106. Comparison of Respiratory Function in Patients with Inflammatory Polyarthritis and the General Population in the United Kingdom. Suzanne MM Verstappen1, Mark Lunt1, Robert N. Luben2, Jackie Chipping3, Nick Wareham2, Kay-Tee Khaw2, Ian N. Bruce1 and Deborah PM Symmons1, 1 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 2University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 3 Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom 2107. C-Reactive Protein Associated with Depression in Patients with Rheumatoid Arthritis. Mary E. Margaretten, Laura J. Julian, Vladimir Chernitskiy, Jonathan D. Graf, Patricia P. Katz, John B. Imboden and Edward H. Yelin, University of California San Francisco, San Francisco, CA 2108. Using Genome-wide single Nucleotide polymorphism analysis to Investigate the Possibility of the CYB5R Gene Promoting Interstitial Pneumonia in rheumatoid arthritis patients. Takeshi Nakamura1, Satoru Koyano2, Keiko Funahashi2, Takafumi Hagiwara1, Takako Miura1, Kosuke Okuda3, Akira Sagawa4, Takeo Sakurai5, Hiroaki Matsuno6, Tomomaro Izumihara7, Eisuke Shono8 and Tsukasa Matsubara9, 1Matsubara mayflower hospital, Kato, Japan, 2Research Institute of Joint Diseases, Kobe, Japan, 3 Matsubara Mayflower Hospital, Kato, Japan, 4Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 5Inoue Hospital, Takasaki, Japan, 6Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 7Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, 8Shono Rheumatology Clinic, Fukuoka, Japan, 9Matsubara Mayflower Hospital, Kato-shi HYOGOKEN, Japan 2109. Contraception Use in Women with Rheumatoid Arthritis. Megan E. B. Clowse1, Eliza F. Chakravarty2, Karen H. Costenbader3, Christina Chambers4, Frederick Wolfe5 and Kaleb Michaud6, 1Duke University Medical Center, Durham, NC, 2Stanford University, Palo Alto, CA, 3Brigham and Women’s Hospital, Boston, MA, 4University of California, San Diego, La Jolla, CA, 5National Data Bank for Rheumatic Diseases, Wichita, KS, 6National Data Bank for Rheumatic Diseases, University of Nebraska, Omaha, NE 2110. Ethnic Minority Rheumatoid Arthritis Consortium: A Clinical Registry of Minority Patients with Rheumatoid Arthritis. Gail S. Kerr1, Yvonne R. S. Sherrer2, Raj G. Nair3, Edward L. Treadwell4, Angelia D. Mosley-Williams5, Asia M. Mubashir6, Luis R. Espinoza7, Jeffrey Huang6, Christopher

278

2011 Program Book

Swearingen8 and Yusuf Yazici9, 1Washington DC VAMC and Georgetown University and Howard University Hospital, Washington, DC, 2Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, 3Washington Hospital Center, Washington, DC, 4E Carolina Univ Sch of Med, Greenville, NC, 5John Dingell VAMC, Detroit, MI, 6Howard University Hospital, Washington, DC, 7LSU Medical Center, New Orleans, LA, 8 University of Arkansas for Medical Sciences, Little Rock, AR, 9 Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 2111. Impact of Health Literacy on Treatment Adherence and Clinical Outcomes in Patients with Rheumatoid Arthritis. Maria F. Marengo1, Michael A. Kallen1, Sofia De Achaval2, Vanessa Cox1, Araceli Garcia3, Marsha Richardson4 and Maria E. Suarez-Almazor5, 1UT MD Anderson Cancer Center, Houston, TX, 2U.T. MD Anderson Cancer Center, Houston, TX, 3 UT MD Anderson, Houston, 4UT MD Anderson, Houston, TX, 5 University of Texas. M.D Anderson Cancer Center, Houston, TX 2112. Rheumatoid Arthritis (RA) is Associated with Increased Mortality in Patients Undergoing Total Joint Arthroplasty. Kaleb D. Michaud1, Edward Fehringer2, Kevin Garvin2, James R. O’Dell3 and Ted R. Mikuls3, 1National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Omaha VA and University of Nebraska Medical Center, Omaha, NE 2113. Sex Differences in Cytokine Response of Patients with Rheumatoid Arthritis. Melissa A. Wells, John M. Davis III, Keith L. Knutson, Michael A. Strausbauch, Cynthia S. Crowson, Terry M. Therneau and Sherine E. Gabriel, Mayo Clinic, Rochester, MN 2114. Anemia Is An Independent Indicator of Disease Progression In Rheumatoid Arthritis. Burkhard Moller1, Doris Wisler1, Frauke Foerger1, Peter M. Villiger1 and Axel Finckh2, 1Inselspital-University Hospital, Bern, Switzerland, 2 University of Geneva, Geneva, Switzerland 2115. Assesment of Physical Activity by Accelerometry: Relationship Between Physical Function and Disease Activity in Rheumatoid Arthritis Patients. Vanesa Hernandez-Hernandez1, Esmeralda Delgado-Frías1, Ivan Ferraz-Amaro1, Jose A. Garcia-Dopico2, Lilian Medina2, Inmaculada Alonso1, M.Teresa Arce-Franco1, M. Jesus Dominguez-Luis3 and Federico Diaz-Gonzalez1, 1 Rheumatology Service, La Laguna, Spain, 2Central Laboratory, La Laguna, Spain, 3Hospital Universitario de Canarias, La Laguna, Spain 2116. Gender Differences in Disease Characteristics in Rheumatoid Arthritis, Inflammatory Bowel Disease and Psoriasis: Evidence for a Greater Symptomatic Burden in Females. N. Lesuis1, R. Befrits2, Filippa Nyberg3 and R. F. van Vollenhoven2, 1Radboud University, Nijmegen, Netherlands, 2 Karolinska University Hospital, Stockholm, Sweden, 3 Karolinska Institutet, Stockholm, Sweden

ACR/ARHP Poster Session C 2117. Early Rheumatoid Arthritis in Latin America. Low Socioeconomic Status Relates to High Disease Activity At Baseline. Loreto Massardo1, Bernardo A. Pons-Estel2, Mario H. Cardiel3, Claudio Galarza-Maldonado4, Mónica P. Sacnun5, Enrique R. Soriano6, Ieda Laurindo7, Eduardo M. Acevedo-Vásquez8, Carlo V. Caballero-Uribe9, Oslando Padilla10, Marlene Guibert-Toledano11, Rubén A. Montufar Guardado12, Sergio H. Jacobelli13 and Daniel E. Furst14, 1 Catholic University of Chile, Santiago 114-D, Chile, 2 Hospital Provincial, Rosario, Argentina, 3Hospital General “Dr. Miguel Silva”, Morelia, Mexico, 4Hospital Monte Sinai, Cuenca, Ecuador, 5Hosp. Provincial, Rosario, Argentina, 6 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 7 Universidade de São Paulo, Sao Paulo, Brazil, 8Hospital Nacional “Guillermo Almenara Irigoyen”, Lima, Peru, 9 Continential Med Ctr, Barranquilla, Colombia, 10Pontificia Universidad Catolica de Chile, Santiago, Chile, 11Centro de Investigaciones Médico Quirúrgicas, Habana, Ciudad Habana, Cuba, 12Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador, 13Universidad Catolica de Chile, Santiago, Chile, 14UCLA Medical School, Los Angeles, CA

2123. Lobular Panniculitis: A Characteristic Skin Manifestation in Rheumatoid Arthritis. Takehiko Ogawa, Takehisa Ogura, Kana Ogawa, Ayako Hirata and Norihide Hayashi, Toho University Ohashi Medical Center, Tokyo, Japan

2118. Forefoot Plantar Pressure and Gait Characteristic of Patients with Early Rheumatoid Arthritis: A Case-Control Study. Sze Man Lau1, Chi Chiu Mok2, Chi Hung To2 and Wing Yuk Ip3, 1Pok Oi Hospital, Hong Kong, Hong Kong, 2Tuen Mun Hospital, Hong Kong, Hong Kong, 3University of Hong Kong, Hong Kong, Hong Kong

2126. Disease Activity Levels and Treatment Patterns Amongst Ethnic Minority Rheumatoid Arthritis Consortium Patients. Yusuf Yazici1, Christopher Swearingen2, Yvonne R. S. Sherrer3, Raj G. Nair4, Edward L. Treadwell5, Angelia D. Mosley-Williams6, Luis R. Espinoza7, Asia M. Mubashir8, Jeffrey Huang8 and Gail S. Kerr9, 1Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 2University of Arkansas for Medical Sciences, Little Rock, AR, 3Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, 4Washington Hospital Center, Washington DC, DC, 5E Carolina Univ Sch of Med, Greenville, NC, 6John Dingell VAMC, Detroit, MI, 7LSU Medical Center, New Orleans, LA, 8Howard University Hospital, Washington, DC, 9Washington DC VAMC and Georgetown University and Howard University Hospital, Washington, DC

2119. The Effect of Patient Reported Pain on Disability Is Partially Mediated Through Depression in Vulnerable United States Hispanics with Rheumatoid Arthritis. Soha Dolatabadi1, Rosalinda C. Moran2, Galen Cook-Wiens1, Ning Li1, Michael H. Weisman3, Perry M. Nicassio4 and George A. Karpouzas5, 1 Cedars Sinai Medical Center, Los Angeles, CA, 2Harbor UCLA Medical Center, Carson, CA, 3Cedars Sinai Med Ctr, Los Angeles, CA, 4UCLA, Los Angeles, CA, 5Harbor-UCLA, Torrance, CA 2120. The Public Health Impact of Risk Factors for Physical Inactivity in Adults with Rheumatoid Arthritis. Jungwha Lee1, Dorothy D. Dunlop2, Linda S. Ehrlich-Jones3, Pamela A. Semanik4, Jing Song2, Larry Manheim2 and Rowland W. Chang1, 1Northwestern University, Chicago, IL, 2 Northwestern Univ Med School, Chicago, IL, 3Rehabilitation Institute Chicago, Chicago, IL, 4Rehabilitation Institute Chicago, Oak Park, IL 2121. Aldosterone Is Not Increased in Patients with Rheumatoid Arthritis. Michelle J. Ormseth, Margaret Randels, Annette M. Oeser, Joseph F. Solus and C. Michael Stein, Vanderbilt Medical Center, Nashville, TN 2122. Clinical Characterization of Extensive Interstitial Lung Disease in Rheumatoid Arthritis Patients. Masaomi Yamasaki, Yoshiteru Haga, Makoto Inoue, Kumiko Tonooka and Naooki Katsuyama, St Marianna University, Yokohama City Seibu Hospital, Yokohama, Japan

2124. Low Levels of Vitamin D Level Are Associated with Greater Disease Activity and Disability in Patients with Rheumatoid Arthritis. Uzma J. Haque1, Kevin R. Fontaine2, Clifton O. Bingham3 and Susan J. Bartlett4, 1Johns Hopkins Hospital, Baltimore, MD, 2John Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4McGill University, Montreal, QC 2125. Predictors of Assymetric Dimethyl Arginine in Rheumatoid Arthritis. Theodoros Dimitroulas1, Aamer Sandoo1, Jet JJCS Veldhuijzen van Zanten2, Jacqueline P. Smith1, George Metsios1, Peter Nightingale3, Antonios StavropoulosKalinoglou1 and George Kitas1, 1Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, West Midlands, UK, Dudley, United Kingdom, 2School of Sport and Exercise Sciences, University of Birmingham, Birmingham, UK, Dudley, United Kingdom, 3Dudley, United Kingdom

2127. The Impact of Morning Stiffness on Quality of Life in Early Rheumatoid Arthritis. Karin Britsemmer and Dirkjan van Schaardenburg, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands 2128. Complementary and Alternative Medicine Use in African Americans with Rheumatoid Arthritis. Ashutosh Tamhane1, Gerald McGwin1, David T. Redden1, Elizabeth Brown2, Andrew Westfall1, Richard J. Reynolds1, Laura B. Hughes1, Doyt L. Conn3, Beth L. Jonas4, Edwin A. Smith5, Richard D. Brasington6, Larry W. Moreland7, S. Louis Bridges Jr.8 and Leigh F. Callahan9, 1University of Alabama at Birmingham, Birmingham, AL, 2Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 3Emory Univ School of Medicine, Atlanta, GA, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5Med Univ of South Carolina, Charleston, SC, 6Washington Univ School of Med, St. Louis, MO, 7University of Pittsburgh, Pittsburgh, PA, 8Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, 2011 Program Book

279

ACR/ARHP Poster Session C University of Alabama at Birmingham, Birmingham, AL, 9 University of North Carolina, Chapel Hill, NC 2129. Effect of Treatment of Hypogonadism On Rheumatoid Arthritis In Male Veterans. Farah Mahmood, Robert W. McMurray and Dannette S. Johnson, G.V. Sonny Montgomery VA Medical Center and University of Mississippi Medical Center, Jackson, MS 2130. Extra-Articular Manifestations of Rheumatoid Arthritis in An Ethnically Diverse Cohort: Prevalence and Clinical Associations. Nicole C. Richman1, Jinoos Yazdany1, Jonathan D. Graf2, Vladimir Chernitskiy1 and John B. Imboden3, 1 University of California San Francisco, San Francisco, CA, 2 Univ of Calif-San Francisco, San Francisco, CA, 3University of California, San Francisco, CA 2131. Frequency and Clinical Characteristics of Osteoporosis in Patients with Rheumatoid Arthritis − a Comparison with Healthy Subjects. Seung Geun Lee1, Young Eun Park1, Seong Hu Park2, Sung Il Kim3, Seung Hoon Baek4, Geun Tae Kim5, Joung Wook Lee6 and Jun Hee Lee7, 1Pusan Nationl University Hospital, Busan, South Korea, 2Pusan, South Korea, 3PUSAN NATIONAL UNIVERSITY HOSPITAL, Busan, South Korea, 4PUSAN NATIONAL UNIVERSITY YANGSAN HOSPITAL, Yangsan, South Korea, 5Kosin University Gopsel Hospital, Pusan, South Korea, 6Busan st. Mary’s Medical Center, Busan, South Korea, 7Ilsin Christian Hospital, Pusan, South Korea 2132. Low Vitamin D in Rheumatoid Arthritis Is Associated with Significant Limitations in Social Functioning. Susan J. Bartlett1, Kevin R. Fontaine2, Clifton O. Bingham3 and Uzma J. Haque4, 1McGill University, Montreal, QC, 2John Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4Johns Hopkins Hospital, Baltimore, MD 2133. Ocular Complication and Its Association with Disease Characteristics and Treatment Responses in a Cohort of 295 Rheumatoid Arthritis Patients. Zejin Zhu1, Paul Maranian2 and Harold E. Paulus1, 1University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles 2134. Role of Body Composition Phenotypes and Adiposity in Disease Activity, Endothelial Dysfunction and Radiological Damage in RA Patients. Esmeralda Delgado-Frías1, Vanesa Hernandez-Hernandez1, Ivan Ferraz-Amaro1, Jose A. GarciaDopico2, Lilian Medina2, Antonieta Gonzalez-Diaz3, Maria A. Gomez- Rodriguez-Bethencourt3, Jose Ramon Muñiz4, Ana I. Rodriguez-Vargas1, M. Jesus Dominguez-Luis1, M.Teresa Arce-Franco1, M. Angeles Gantes-Mora1 and Federico DiazGonzalez1, 1Servicio de Reumatología, Hospital Universitario de Canarias, La Laguna, Spain, 2Servicio de Laboratorio Central, Hospital Universitario de Canarias, La Laguna, Spain, 3 Servicio de Medicina Nuclear, Hospital Universitario de Canarias, Spain, 4Resonancia Magnética. IMETISA. Hospital Universitario de Canarias

280

2011 Program Book

2135. Ultrasound Screening for Intestinal Lung Disease in Rheumatoid Arthritis. Sonja Kielhauser1, Florentine Fuerst1, Kerstin Brickmann1, Peter Zechner2, Norbert J. Tripolt3 and Winfried B. Graninger4, 1Med Univ Klinik Graz, Graz, Austria, 2 Cardiology, Graz, Austria, 3Diabetology, Graz, Austria, 4 Medical University Graz, Graz, Austria 2136. Genetic Predisposition of the Severity of Joint Destruction in Rheumatoid Arthritis; A Population Based Study. R. Knevel1, Gerður Gröndal2, Tom W.J. Huizinga1, A. Willemien Visser1, Helgi Jónsson2, Arnór Víkingsson2, Árni Jón Geirsson2, Kristjan Steinsson2 and Annette H.M. van der Helm-van Mil1, 1Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Landspítali, National University Hospital Center for Rheumatology Research, Reykjavik, Iceland, Reykjavik, Iceland 2137. Longitudinal Determinants of Disability in Vulnerable United States Hispanics with Rheumatoid Arthritis. George A. Karpouzas1, Soha Dolatabadi2, Ning Li2, Rosalinda C. Moran3, Perry M. Nicassio4 and Michael H. Weisman5, 1 Harbor-UCLA, Torrance, CA, 2Cedars Sinai Medical Center, Los Angeles, CA, 3Harbor UCLA Medical Center, Carson, CA, 4 UCLA, Los Angeles, CA, 5Cedars Sinai Med Ctr, Los Angeles, CA 2138. Smoking Impact on Radiographic Progression in An Early Rheumatoid Arthritis Cohort. Virginia Ruiz-Esquide1, Jose Alfredo Gomez Puerta2, S. Cabrera1, J. D. Cañete3, M. V. Hernandez2, Eduard Graell4, Guadalupe Ercilla1, Odette Viñas1, M. J. Gómara5, Isabel Haro5 and Raimon Sanmarti2, 1 Hospital Clinic of Barcelona., Barcelona, Spain, 2Hospital Clinic of Barcelona, Barcelona, Spain, 3Hospital Clínic de Barcelona,, Barcelona, Spain, 4Hospital Parc Tauli, Sabadell, Spain, 5IQAC-CSIC, Barcelona, Spain 2139. Environmental and Genetic Contributions to Disease Severity in North American Natives with Early Inflammatory arthritis. Carol A. Hitchon, Christine A. Peschken, Trevor Mailley, Jillian Dooley, Peter Nickerson and Hani S. El-Gabalawy, University of Manitoba, Winnipeg, MB 2140. Discrepancies Between Expert Reading and Standard Radiograph Report in Identifying Boney Erosions and Joint Space Narrowing in Patients with Rheumatoid Arthritis in the Veterans Affairs Rheumatoid Arthritis Registry. Maria P. Martes1, Alan Erickson2, Ted R. Mikuls3, Alyse D. Mann4, Liron Caplan5, Dannette S. Johnson6, J. Steuart Richards7, Gail S. Kerr7, Andreas M. Reimold8 and Grant W. Cannon1, 1 Salt Lake City VA and University of Utah, Salt Lake City, UT, 2 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 3Omaha VA and University of Nebraska, Omaha, NE, 4Denver VA and University of Colorado, Denver, CO, 5 Denver VA and University of Colorado, Aurora, CO, 6Jackson VA and University of Mississippi Medical Center, Jackson, MS, 7Washington DC VAMC and Georgetown University, Washington, DC, 8Dallas VA and University of Texas Southwestern, Dallas, TX

ACR/ARHP Poster Session C 2141. Function (HAQ) and Disease Activity (DAS) Varies by Rheumatoid Factor (RF) Status in Early Inflammatory Arthritis (EIA) with Stronger Associations in RF Positive Patients: Results From the CATCH Cohort. Tristan Boyd1, Vivian Bykerk2, Gilles Boire3, Carol A. Hitchon4, J. Carter Thorne5, Edward Keystone6, Boulos Haraoui7, Diane S. Ferland8, Janet E. Pope9 and CATCH Investigators10, 1 University of Western Ontario, London, ON, 2Brigham & Women’s Hospital, Boston, MA, 3CHUS - Sherbrooke University, Sherbrooke, QC, 4University of Manitoba, Winnipeg, MB, 5Southlake Regional Health Centre, Newmarket, Newmarket, ON, 6Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, 7Institut de Rhumatologie, Montreal, QC, 8 LaSalle, QC, 9St. Joseph’s Health Care, University of Western Ontario, London, ON, 10Toronto, ON 2142. Progression of Joint Damage in a Rheumatoid Arthritis Cohort: Role of the HLA-DRB1 Shared Epitope. Jose Felix Restrepo1, Inmaculada del Rincon1, Daniel F. Battafarano2 and Agustin Escalante1, 1University of Texas Health Science Center, San Antonio, TX, 2Brooke Army Medical Ctr, San Antonio, TX 2143. Comparison of the Patient-Based Routine Assessment of Patient Index 3 in Usual Care of Rheumatoid Arthritis to the Physician-Based Disease Activity Score-28 Joint Count and Clinical Disease Activity Index. Daniel Lupash1, Aarat M. Patel2, Christine L. Amity3, Lynne M. Frydrych3, Derek Sippel3, Donald M. Jones3, Danielle Goudeau3, Heather Eng4, David Kyle4, Melissa Saul4, G.K. Balasubramani4, Daniel H. Solomon5, Stephen R. Wisniewski4, Larry W. Moreland1 and Marc C. Levesque3, 1University of Pittsburgh, Pittsburgh, PA, 2Univ of Pittsburgh Med Ctr / Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 3Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 4Univ of Pittsburgh, Pittsburgh, PA, 5 Brigham & Womens Hospital, Boston, MA 2144. Application of Ultrasound to Treat to Target Management of Rheumatoid Arthritis - Multicentre International Observational Experience. Sibel Aydin1, Maya H. Buch2, Sarah Horton3, Kei Ikeda4, Annamaria Iagnocco5, Marwin Gutierrez6, Walter Grassi7, Esperanza Naredo8, Eugenio De Miguel9, Lene Terslev10, Marina Backhaus11, MariaAntonietta D’Agostino12, Alberto Batticciotto2, Zunaid Karim2, Richard J. Wakefield13 and Paul Emery14, 1Goztepe Training and Research Hospital, Istanbul, Turkey, 2Leeds institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Disease Biomedical Research Unit, Leeds Teaching Hospitals, Leeds, United Kingdom, 3Leeds institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Disease Biomedical Research Unit, Leeds Teaching Hospitals, United Kingdom, 4Chiba University Hospital, Chiba, Japan, 5Uni, Jesi, Italy, 6Sapienza Universita di Roma, Rome, Italy, 7Università Politecnica delle Marche, Jesi, Italy, 8Hosptial Universitario Severo Ochoa, Madrid, Spain, 9La Paz University Hospital, Madrid, Spain, 10 The Parker Institute, Copenhagen, Denmark, 11Charite University Hospital, Berlin, Germany, 12Versailles-Saint

Quentin en Yvelines University- APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France, 13Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals, Leeds, United Kingdom, 14Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom 2145. Assessing the Individual Joint in Rheumatoid Arthritis (RA): Valid Detection of Synovitis in the MTP Joint Warrants Ultrasound Examination. Matthias Witt1, Felix Mueller1, Axel Nigg1, Christiane Reindl2, Hendrik Schulze-Koops2 and Mathias Grunke1, 1University of Munich, Munich, Germany, 2 Division of Rheumatology and Clinical Immunology, Med. Poliklinik, University of Munich, Munich, Germany 2146. Quantifying the Contributors to Global Assessment of Rheumatoid Arthritis Disease Activity by the Patient and the Physician. Paul Studenic1, Josef Smolen2 and Daniel Aletaha1, 1Medical University of Vienna, Vienna, Austria, 2 Medical University of Vienna and Hietzing Hospital, Vienna, Austria 2147. Validity and Reliability Problems with Patient Global As a Component of the American College of Rheumatology/ European League Against Rheumatism Remission Criteria. Karim R. Masri1, Frederick Wolfe2, Timothy S. Shaver3, Shadi H. Shahouri4, Shirley Y. Wang4, James D. Anderson5 and Ruth E. Busch6, 1Wichita, KS, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Arthritis & Rheum Clinics KS, Wichita, KS, 4Arthritis & Rheum Clinic of KS, Wichita, KS, 5Arthritis & Rheum Clinics KS, Leawood, KS, 6Arthritis & Rheum Clinic, Wichita, KS 2148. Changes and Sex Differences in Patient Reported Outcomes in Rheumatoid Factor Positive RA – Results From a Community Based Study. Korosh Hekmat, Lennart TH Jacobsson, Jan-Åke Nilsson, Ylva Lindroth and Carl Turesson, Lund University, Malmö, Sweden 2149. Assessment of Foot Structure in Rheumatoid Arthritis by a Foot Digitizer Reveals Marked Deformities, Even in the Absence of Radiographic Erosions. Sophie De Mits1, Dirk De Clercq1, Jim Woodburn2, Philip Roosen1 and Dirk Elewaut3, 1 Ghent University, Ghent, Belgium, 2Glasgow Caledonian University, Glasgow, United Kingdom, 3Gent University Hospital, Ghent, Belgium 2150. Comparison of Rheumatoid Arthritis Patient Characteristics From Randomized Controlled Trials to a Registry Designed for Rheumatoid Arthritis Comparative Effectiveness Research. Aarat M. Patel1, Christine L. Amity2, Lynne M. Frydrych2, Derek Sippel2, Donald Jones2, Danielle Goudeau2, Heather Eng3, David Kyle3, Melissa Saul3, Daniel Hal Solomon4, Stephen R. Wisniewski3, Larry W. Moreland5 and Marc C. Levesque2, 1Univ of Pittsburgh Med Ctr / Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3Univ of Pittsburgh, Pittsburgh, PA, 4Brigham & Womens Hospital, Boston, MA, 5 University of Pittsburgh, Pittsburgh, PA 2011 Program Book

281

ACR/ARHP Poster Session C 2151. The Accuracy of Patient Reported Current and Past Medications Used to Treat Rheumatoid Arthritis in An Academic Institutional Registry. Sergio Schwartzman1, Dana E. Orange2 and Stephen L. Lyman1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, The Rockefeller University, New York, NY 2152. Discordant Autoantibodies and Clinical Outcomes In Rheumatoid Arthritis. Dannette S. Johnson1, Alan Erickson2, Grant W. Cannon3, Gail S. Kerr4, Liron Caplan5, Andreas M. Reimold6, John S. Richards4, Pascale Schwab7, Deana M. Lazaro8, Nasim A. Khan9, Bogdan Cherascu10 and Ted R. Mikuls11, 1G.V. Sonny Montgomery VA and University of Mississippi, Jackson, MS, 2Omaha VA and University of Omaha, Omaha, NE, 3Salt Lake City VA and University of Utah, Salt Lake City, UT, 4Washington DC VA and Georgetown University, Washington, DC, 5Denver VA and University of Colorado, Aurora, CO, 6Dallas VA and University of Texas Southwestern, Dallas, TX, 7Portland VA and Oregon Health & Science University, Portland, OR, 8Brooklyn VA, Brooklyn, NY, 9University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, 10Iowa City VA and University of Iowa, Iowa City, IA, 11Omaha VA and University of Nebraska, Omaha, NE 2153. Does Clinical Assessment of Swollen and Tender Joints Reflect Inflammatory Synovitis in Rheumatoid Arthritis? A Comparative Study of Physician, Nurse and Patient Clinical Assessments Versus Ultrasonography (US) As the Gold Standard. Peter Cheung1, Laure Gossec2, Adeline RuyssenWitrand3, Catherine Le Bourlout4, Maryse Mezieres4 and Maxime Dougados5, 1National University Hospital, Singapore, Singapore, 2Cochin Hospital, Paris, France, 3 Hopitaux de Toulouse, Toulouse, France, 4Hospital Cochin, Paris, France, 5Paris-Descartes University, Cochin Hospital, Paris, France 2154. Patient Tolerability of Arthroscopic Synovial Biopsy Compared to MRI. Maria J. H. de Hair, Marleen G. H. van de Sande, Mario Maas, Danielle M. Gerlag and Paul P. Tak, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

Rheumatoid Arthritis - Human Etiology and Pathogenesis 2155. Polymorphisms in N-Acetyltransferase 2 Impact Rheumatoid Arthritis Risk Due to Cigarette Smoking in African Americans. Marshall Davis1, Tricia LeVan1, Karen Gould1, Fang Yu1, Geoffrey M. Thiele1, Kimberly Bynote1, Larry W. Moreland2, Doyt L. Conn3, Edwin A. Smith4, Leigh F. Callahan5, Beth L. Jonas6, Richard Brasington7, S. Louis Bridges Jr.8 and Ted R. Mikuls1, 1Univ of Nebraska Med Ctr, Omaha, NE, 2University of Pittsburgh, Pittsburgh, PA, 3Emory Univ School of Medicine, Atlanta, GA, 4Med Univ of South Carolina, Charleston, SC, 5University of North Carolina, Chapel Hill, NC, 6University of North Carolina at Chapel Hill, Chapel Hill, NC, 7Washington Univ School of Med, St. Louis, MO, 8Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology

282

2011 Program Book

and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 2156. Integrative Analyses Demonstrate That Rheumatoid Arthritis Risk Loci Impact Genes with CD4+ Effector Memory T-Cell Function. Xinli Hu1, Hyun Kim1, Eli A. Stahl1, Robert M. Plenge1, Mark Daly2 and Soumya Raychaudhuri1, 1Brigham and Women’s Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA 2157. The Hierarchy of HLA-DRB1 Shared Epitope Risk Genotypes Associated with RA in African-Americans Differs From That in Europeans. Altan F. Ahmed1, Laura B. Hughes1, Doyt L. Conn2, Beth L. Jonas3, Leigh F. Callahan4, Edwin A. Smith5, Richard D. Brasington6, Larry W. Moreland7, S. Louis Bridges Jr.1 and Richard J. Reynolds1, 1University of Alabama at Birmingham, Birmingham, AL, 2Emory Univ School of Medicine, Atlanta, GA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4University of North Carolina, Chapel Hill, NC, 5Med Univ of South Carolina, Charleston, SC, 6 Washington Univ School of Med, St. Louis, MO, 7University of Pittsburgh, Pittsburgh, PA 2158. Apolipoprotein M Polymorphism Is a Novel Risk Factor for Dyslipidemia in Rheumatoid Arthritis: A Possible Link Between Disease Susceptibility and dyslipidemia. YuneJung Park1, Jung-Hwa Lee1, Hosung Yoon2, Daejun Kim1, Chul-Soo Cho3 and Wan-Uk Kim1, 1The Catholic University of Korea, St. Vincent’s Hospital, Suwon, South Korea, 2The Catholic University, Incheon, South Korea, 3The Catholic University of Korea, Seoul 2159. Increased Frequency of Complement C4B Deficiency in Rheumatoid Arthritis (RA): Interaction with the Shared Epitope (SE). William F. C. Rigby1, Y.L. Wu2, Moe T. Zan3, Bi Zhou2, Sanna Rosengren4, Cheryl Carlson5, Whitney Hilton5, Jonathan D. Jones6 and Chack-Yung Yu7, 1DartmouthHitchcock Med Ctr, Lebanon, NH, 2Nationwide Children’s Hospital The Ohio State University, Columbus, OH, Columbus, OH, 3Dartmouth-Hitchcock Clinic, Manchester, NH, 4UCSD School of Medicine, La Jolla, CA, 5Dartmouth Hitchcock Med Ctr, Lebanon, NH, 6Dartmouth-Hitchcock Medical Center, Lebanon, NH, 77Center for Molecular and Human Genetics, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Columbus, OH 2160. The STAT4 rs7574865 Polymorphism Is Associated with Differences in Disease Activity and Disability in Patients Wirh Early Arthritis. Ana M. Ortiz1, Amalia Lamana1, Alejandro Balsa2, Blanca Rueda3, Laura Nuño2, Maria Eugenia Miranda-Carus2, María F. González-Escribano4, Miguel A. López-Nebot5, Dora Pascual-Salcedo2, Javier Martin6 and Isidoro González-Alvaro1, 1Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, 2Hospital La Paz. IdiPaz, Madrid, Spain, 3Facultad de Ciencias de la Salud. Universidad de Granada, Granada, Spain, 4Hospital Universitario Virgen del Rocío, Sevilla, Spain, 5Hospital Universitario Virgen de las Nieves, Granada, Spain, 6Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain

ACR/ARHP Poster Session C 2161. The Complexity of Anti-CCP Positive Rheumatoid Arthritis, in the Context of Gene-Environment Associations. Karin Lundberg, Camilla Bengtsson, Lena Israelsson, Nastya Kharlamova, Iskra Pollak-Dorocic, Rikard Holmdahl, Leonid Padyukov, Vivianne Malmström, Lars Alfredsson and Lars Klareskog, Karolinska Institutet, Stockholm, Sweden

2168. Exposure to Environmental Tobacco Smoke and the Risk of Rheumatoid Arthritis Among Nonsmoking Women. So-Young Bang, Hye-Soon Lee, Jae Hoon Kim, Joo-Hyun Lee, Jin Ju Kim, Young Bin Joo and Sang-Cheol Bae, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

2162. Genome-Wide Association Study and Comparison of Risk Alleles for Rheumatoid Arthritis in An Isolated Dutch Population. Joanne Nitiham1, Kimberly E. Taylor1, Yurii S. Aulchenko2, Ben Oostra2, Robert M. Plenge3, Tom W.J. Huizinga4, Peter K. Gregersen5, Cornelia M. van Duijn2 and Lindsey A. Criswell1, 1University of California, San Francisco, San Francisco, CA, 2Erasmus Medical Center, Rotterdam, Netherlands, 3Brigham and Women’s Hospital, Boston, MA, 4 Leiden University Medical Center, Leiden, Netherlands, 5 Feinstein Institute Medical Reschearch, Manhasset, NY

2169. Smoking and Oxidative Stress Interaction Is Associated with Rheumatoid Arthritis Risk. A Case – Control Study. Victoria Navarro Compán, Enrique Melguizo Madrid, Blanca Hernández Cruz, Christian Leyva Prado, Teresa Arrobas Velilla, Federico Navarro Sarabia and Concepción González Rodríguez, Hospital Universitario Virgen Macarena, Sevilla, Spain

2163. Vitamin D Receptor Polymorphism rs2228570 (Fokl) in North American Natives with Rheumatoid Arthritis and Their Unaffected First Degree Relatives. Carol A. Hitchon1, Ye Sun2, David B. Robinson1, Christine A. Peschken1, Charles N. Bernstein1, Katherine A. Siminovitch2 and Hani S. ElGabalawy1, 1University of Manitoba, Winnipeg, MB, 2Mount Sinai Hospital, Toronto, ON 2164. The I50V IL4R SNP Is Associated with Increased Th17 Cell Frequency and Activity in Autoimmune Arthritis. Jan Leipe1, Iryna Prots2, Markus A. Schramm1, Alla Skapenko1 and Hendrik Schulze-Koops1, 1Division of Rheumatology and Clinical Immunology, Med. Poliklinik, University of Munich, Munich, Germany, 2Junior Research Group III, Nikolaus-Fiebiger Center for Molecular Medicine, FriedrichAlexander-University Erlangen-Nürnberg, Erlangen 2165. Gene Polymorphisms of Signal Transducers and Activator of Transcription 4 and Tumor Necrosis Factor ReceptorAssociated Factor 1 Predict Clinical Response to DiseaseModifying Anti-Rheumatic Drugs in Japanese Patients with Rheumatoid Arthritis. Tetsuya Nishimoto, Noriyuki Seta, Ryusuke Anan, Tatsuya Yamamoto, Yuko Kaneko, Masataka Kuwana and Tsutomu Takeuchi, Keio university, Tokyo, Japan 2166. Fine-Mapping of Autoimmune Susceptibility Loci Using Immunochip Identifies Novel Susceptibility Loci for Psoriatic Arthritis. John Bowes1, Pauline Ho2, Eleanor Korendowych3, Neil J. McHugh3, Helena Marzo-Ortega4, Jonathon Packham5, Ian N. Bruce1 and Anne Barton1, 1 Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK, Manchester, United Kingdom, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4 University of Leeds, Leeds, United Kingdom, 5Haywood Hospital, Stoke on Trent, United Kingdom 2167. The Potential Role of PTPRD Gene Copy Number Variation in Susceptibility to Rheumatoid Arthritis. Seung Cheol Shim, Donghyuk Sheen, Mi-Kyoung Lim, Jiyoung Kim, Soyoung Lee and Sangkwang Lee, Eulji University Hospital, Daejeon, South Korea

2170. Smoking and Periodontal Status Are Associated with ACPA Fine Specificity and Levels of Inflammatory Cytokines in Rheumatoid Arthritis: The ARIC Study. Reuven Bromberg1, Jeremy Sokolove1, Lauren J. Lahey1, Alvaro Alonso2, Mark H. Wener3, Vivian H. Gersuk4, Jane Hoyt Buckner4, James D. Beck5, Bryan S. Michalowicz6, Aaron A. Folsom2, William Robinson7 and Jerry A. Molitor8, 1Stanford University, Palo Alto, CA, 2Minneapolis, 3University of Washington, Seattle, WA, 4Benaroya Research Institute, Seattle, WA, 5Chapel Hill, NC, 6Minneapolis, MN, 7Stanford Univ School of Med, Stanford, CA, 8Univ of MN MMC108, Minneapolis, MN 2171. Relationships Between Smoking, HLA-DRB1 Risk Alleles and the Fine Specificity of Anti-Citrullinated Peptide Antibodies in Korean Patients with Rheumatoid Arthritis. Benjamin A. Fisher1, So-Young Bang2, Hye-Soon Lee2, Joo-Hyun Lee2, Muslima Chowdhury3, Peter J. Charles4, Patrick Venables5 and Sang-Cheol Bae6, 1Kennedy Institute of Rheumatology, Imperial College London, London, United Kingdom, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Imperial College London, London, United Kingdom, 4Kennedy Institute of Rheumatology, Imperial College, London, United Kingdom, London, England, 5Kennedy Institute, Imperial College London, London, United Kingdom, 6Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea 2172. Association of Particulate Air Pollution Exposure with AntiCitrullinated Protein Antibody Elevation in Rheumatoid Arthritis Patients. Gary A. Kunkel1, Ryan L. Ragle1, Daniel O. Clegg1, Ted R. Mikuls2 and Grant W. Cannon1, 1Salt Lake City VA and University of Utah, Salt Lake City, UT, 2Omaha VA and University of Nebraska, Omaha, NE 2173. Childhood Residential Pesticides and Other Environmental Exposures in Relation to Rheumatoid Arthritis (RA) in Adulthood. Christine G. Parks, Aimee D’Aloisio, Lisa DeRoo and Dale Sandler, NIH/NIEHS, Research Triangle Park, NC 2174. Periodontal Disease Is Associated with Increased Risk of Incident Rheumatoid Arthritis in Never-Smokers: Results From the First National Health and Nutrition Examination Survey and Its Epidemiologic Follow-up Study. Ryan T. Demmer1, David R. Jacobs Jr.2, Bryan S. Michalowicz2 and Jerry A. Molitor3, 1New York, 2Minneapolis, MN, 3Univ of MN MMC108, Minneapolis, MN 2011 Program Book

283

ACR/ARHP Poster Session C 2175. Prevalence of Periodontitis Is High in Rheumatoid Arthritis Patients and Correlated to Disease Activity. Menke J. de Smit, Johanna Westra, Arjan Vissink, Berber Doornbos-van der Meer, Pieter A. Roelofs, Elisabeth Brouwer and Arie Jan van Winkelhoff, University Medical Center Groningen, Groningen, Netherlands

2180. A Disease-Modifying Role for Mucosal IgA Antibodies to Citrullinated Antigens? Anna Svärd1, Alf Kastbom2, Yngve Sommarin3 and Thomas Skogh4, 1Linköping University, Falun, Sweden, 2Linköping University, Linköping, Sweden, 3EuroDiagnostica AB, Malmö, Sweden, 4Linkoping University, Linkoping, Sweden

2176. Lung Changes Detected by High Resolution Tomography Are Present in ACPA Positive RA Patients Already At Disease Onset. Gudrun Reynisdottir1, Sven Nyren2, Anders Harju1, Magnus Skold3, Anders Eklund1, Marianne Engström1, Johan Grunewald3, Lars Klareskog4 and Anca Irinel Catrina5, 1Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 2Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 3Respiratory Medicine Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden, 5D2:01, Stockholm, Sweden

2181. The ACPA Recognition Profile and Sub-Grouping of APCA Positive RA Patients. Annemiek Willemze, Stefan Böhringer, Rachel Knevel, E.W.Nivine Levarht, Gerrie StoekenRijsbergen, Jeanine J. Houwing-Duistermaat, Annette H.M. van der Helm-van Mil, Tom W.J. Huizinga, René E.M. Toes and Leendert A. Trouw, Leiden University Medical Center, Leiden, Netherlands

2177. Investigating the Cellular Composition of Lymph Nodes in Preclinical and Early Inflammatory Arthritis: A Feasibility Study. Lisa G.M. van Baarsen1, Maria J. H. de Hair1, Tamara H. Ramwadhdoebe1, Marleen G. H. van de Sande1, IJsbrand A.J. Zijlstra2, Mario Maas2, Danielle M. Gerlag1 and PP. Tak1, 1Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 2178. Type 1 Interferon Signature Predicts Development of Rheumatoid Arthritis. Joyce Lubbers1, Mikael Brink2, Lotte A. van de Stadt3, Saskia Vosslamber1, John G. Wesseling1, Dirkjan van Schaardenburg3, Solbritt M. Rantapaa-Dahlqvist2 and Cornelis L. Verweij1, 1VU University Medical Center, Amsterdam, Netherlands, 2Umeå University, Umea, Sweden, 3 Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands 2179. Identification of Shared Citrullinated Potentially Immunological Targets in the Lungs and Joints of Patients with Rheumatoid Arthritis. Jimmy Ytterberg1, Gudrun Reynisdottir1, Elena Ossipova1, Aase Haj Hensvold2, Anders Eklund3, Magnus Skold3, Johan Grunewald3, Karin Lundberg4, Vivianne Malmström4, Per Johan Jakobsson5, Roman Zubarev4, Lars Klareskog4 and Anca Irinel Catrina1, 1 Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 2Rheumatology unit, 171 76 Stockholm, Sweden, 3Respiratory Medicine Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 4 Karolinska Institutet, Stockholm, Sweden, 5Rheumatology Unit, Karolinska Institutet; Karolinska University hospital, Stockholm, Sweden

284

2011 Program Book

2182. Total Protein, Citrullination and Autoantibodies Are Elevated in Lungs of Patients with Established Rheumatoid Arthritis Compared to Controls: Pilot Study Results. Van Willis1, Mark Parish1, Lezlie A. Derber2, M. Kristen Demoruelle3, Jason R. Kolfenbach4, Chris Striebich3, Peter Sachs3, David Lynch5, Russell Bowler5, Kevin K. Brown6, V. Michael Holers4 and Kevin D. Deane3, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Colorado AMC, Aurora, CO, 3University of Colorado School of Medicine, Aurora, CO, 4Univ of Colorado School of Med, Aurora, CO, 5National Jewish Health, Denver, CO, 6National Jewish Hospital, Denver, CO 2183. A Serological Proteome Approach for Screening of Autoantigens From Korean Rheumatoid Arthritis Patients. Sung-Hoon Park1, Ji Hun Kim1, Seong-Kyu Kim2, Jung-Yoon Choe3, Sang-Hyon Kim4, Yong-Hak Kim5, Yeonkyung Park5 and Mina Choi5, 1Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 2Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegue, South Korea, 3Arthritis and Autoimmunity Research Center, Catholic university of Daegu, School of mediine, Daegu, 4Dongsan Medical Center, Keimyung University, Daegu, South Korea, 5Catholic University of Daegu, School of Medicine, Daegu, South Korea 2184. Could Presence of Antibodies to Citrullinated Proteins Be More Strongly Associated to Bone- Than Cartilage Destruction? Results From a 10-Year Prospective Study. Silje Watterdal Syversen1, Pernille Bøyesen2, Guro Løvik Goll1, D. Van Der Heijde3 and Tore K. Kvien2, 1Oslo, Norway, 2 Diakonhjemmet Hospital, Oslo, Norway, 3Leiden University Medical Center, Leiden, Netherlands 2185. Rheumatoid Arthritis Patients Have Anti-Homocitrullinated Fibrinogen Antibodies. Mathias Scinocca1, David A. Bell1, Janet Pope2, Ewa Cairns1 and Lillian J. Barra1, 1Schulich School of Medicine and Dentistry, London, ON, 2Univ of Western Ontario, London, ON 2186. Heterogeneity in the Memory B Cell Compartment in the Bone Marrow in Human Rheumatoid Arthritis. Arumugam Palanichamy, Christopher A. Cistrone, Jennifer Hossler, Teresa Owen and Jennifer H. Anolik, University of Rochester, Rochester, NY

ACR/ARHP Poster Session C Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy III 2187. Tocilizumab and Tumor Necrosis Factor Inhibitors in Biologic Switchers: Similar Drug Survival and Safety with Different Infection Profile in Routine Practice. Kazuki Yoshida1, Kazuo Matsui1, Hiroto Nakano1, Hideto Oshikawa1, Masako Utsunomiya1, Tatsuo Kobayashi1, Makiko Kimura1 and Mitsumasa Kishimoto2, 1Kameda Medical Center, Kamogawa City, Japan, 2St Luke`s International Hospital, Chuo-ku, Tokyo, Japan 2188. Clinical Efficacy of Infliximab Is Maximized When Both Circulating TNF and IL-6 Are Suppressed In the Treatment of Rheumatoid Arthritis -Results From the RISING Study-. Tsutomu Takeuchi1, Yoshihiko Tatsuki2, Toshiro Yano2, Toru Yoshinari2, Nobuyuki Miyasaka3, Tohru Abe4 and Takao Koike5, 1School of Medicine, Keio University, Tokyo, Japan, 2 Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, 3 Tokyo Med & Dent Univ, Tokyo, Japan, 4Saitama Medical School, Kawagoe-shi Saitama, Japan, 5Sapporo Medical Center NTT EC, Sapporo, Japan 2189. Combination Therapy with Adalimumab+Methotrexate Significantly Improved Work Ability, Physical Function, Fatigue, and Other Patient-Reported Outcomes in Early Rheumatoid Arthritis: Results From a 26-Week Analysis. Paul Emery1, Arthur F. Kavanaugh2, Josef Smolen3, Mary A. Cifaldi4, Leonardo Chaves4, Benoit Guerette5, Vipin Arora4 and Ronald F. van Vollenhoven6, 1Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 2University of California San Diego, San Diego, CA, 3Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4Abbott Laboratories, Abbott Park, IL, 5Abbott, Rungis, France, 6The Karolinska Institute, Stockholm, Sweden 2190. SC Abatacept Is Effective and Well Tolerated with Low Immunogenicity Following Temporary Withdrawal and Reintroduction in the ALLOW LTE (Evaluation of ABA Administered SubcutaneousLy in AduLts With Active RA: Impact of Withdrawal and Reintroduction). Jeffrey L. Kaine1, Geoffrey S. Gladstein2, Ingrid Strusberg3, Manuel Robles4, Ramesh Pappu5, Ingrid Delaet5, Miranda Pans5 and Charles L. Ludivico6, 1Sarasota Arthritis Center, Sarasota, FL, 2 New England Research Associates, Trumbull, CT, 3Instituto Reumatológico Strusberg, Cordoba, Argentina, 4Centro Médico Toluca, Metepec, Mexico, 5Bristol-Myers Squibb, Princeton, NJ, 6East Penn Rheumatology Association, East Stroudsburg, PA 2191. Immunogenicity Is Low and Transient with Intravenous (IV) Abatacept Therapy: Results From a Large Pooled Analysis of 3985 Patients (pts) with Rheumatoid Arthritis (RA) and up to 8 Years’ Exposure. Michael E. Weinblatt1, Mark C. Genovese2, Michael H. Schiff3, Rene Westhovens4, Rieke Alten5, Ingrid Delaet6, Marleen Nys6, James Manning6 and Joel M. Kremer7, 1Department of Medicine, Division

of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 2Stanford University, Palo Alto, CA, 3Rheumatology Division, University of Colorado, Denver, CO, 4University Hospital KU Leuven, Leuven, Belgium, 5Rheumatology Schlossparkklinik, Berlin, Germany, 6 Bristol-Myers Squibb, Princeton, NJ, 7Albany Medical College and The Center for Rheumatology, Albany, NY 2192. Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, As Monotherapy in Japanese Patients with Active Rheumatoid Arthritis: A 12-Week Phase 2b Study. Y. Tanaka1, T. Takeuchi2, H. Yamanaka3, M. Suzuki4, H. Nakamura4, S. Toyoizumi4, J. D. Bradley5 and S. H. Zwillich5, 1University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 4Pfizer Inc., Tokyo, Japan, 5Pfizer Inc., Groton, CT 2193. Use of Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in Quebec, Canada. Jean-Pascal Roussy1, Louis Bessette2, Sasha Bernatsky3, Elham Rahme3, Jean Légaré4 and Jean Lachaine1, 1University of Montreal, Montreal, QC, 2CHUL, Quebec, QC, 3McGill UHC/RVH, Montreal, QC, 4Arthritis Alliance of Canada, Neuville, QC 2194. Remission Induction by Etanercept (ETN) Plus Methotrexate (MTX) Combination Therapy Versus ETN Monotherapy in Patients with Active Rheumatoid Arthritis Despite MTX Treatment. Hideto Kameda1, Ukitaka Ueki2, Kazuyoshi Saito3, Shouhei Nagaoka4, Toshihiko Hidaka5, Tatsuya Atsumi6, Michishi Tsukano7, Tsuyoshi Kasama8, Shunichi Shiozawa9, Yoshiya Tanaka3, Katsuaki Kanbe10, Eri Sato11, Hisashi Yamanaka12 and Tsutomu Takeuchi1, 1Keio University School of Medicine, Tokyo, Japan, 2Rheumatic and Collagen Disease Center, Sasebo, Japan, 3U Occupa & Environ Hlth, Kitakyushu, Japan, 4Yokohama Minami Kyosai Hospital, Yokohama, Japan, 5Zenjinkai Shimin-NoMori-Hospital, Miyazaki, Japan, 6Hokkaido University, Sapporo, Japan, 7Kumamoto Hospital, Kumamoto, Japan, 8 Showa University School of Med, Shinagawa-ku Tokyo, Japan, 9Kobe University Graduate School of Health Science and Medicine/ TThe Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, 10Medical Center East, Tokyo Women’s Medical University, Tokyo, Japan, 11Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 12Tokyo Women’s Medical Univ, Shinjuku-ku , Tokyo, Japan 2195. Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, Improves a Bone Resorption Marker in Postmenopausal Women with Rheumatoid Arthritis. Shigeyoshi Tsuji1, Tetsuya Tomita2, Takao Iwai1, Takanobu Nakase1, Masayuki Hamada1, Hideo Kawai1 and Hideki Yoshikawa2, 1Hoshigaoka Koseinenkin Hospital, Hirakata city, Japan, 2Osaka University Graduate School of Medicine, Suita Osaka, Japan

2011 Program Book

285

ACR/ARHP Poster Session C 2196. Safety of Rituximab in Combination with Other Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: 48-Week Data From SUNDIAL. William Rigby1, Philip J. Mease2, Ewa Olech3, Mark Ashby4 and Swati Tole4, 1Dartmouth Medical School, Lebanon, NH, 2Swedish Medical Center, Seattle, WA, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Genentech, Inc., South San Francisco, CA 2197. Switching of Biologic Disease-Modifying Antirheumatic Drugs During the First Year in Patients with Rheumatoid Arthritis in a Real-World Setting. Brian Meissner, Digisha Trivedi, Min You and Tony Hebden, Bristol-Myers Squibb, Plainsboro, NJ 2198. Real-World Switching Patterns in RA Patients Receiving Abatacept, Adalimumab, Etanercept or Infliximab As Second-Line Biologic Therapy. Brian Meissner, Lisa Rosenblatt, Digisha Trivedi, Min You and Tony Hebden, Bristol-Myers Squibb, Plainsboro, NJ 2199. Long-Term Safety of Rituximab in Rheumatoid Arthritis: Pooled Analysis of Patients in Clinical Trials with up to 9.5 Years of Treatment. Ronald F. van Vollenhoven1, Paul Emery2, Clifton O. Bingham3, Edward Keystone4, Roy M. Fleischmann5, Daniel E. Furst6, Nicola Tyson7, Neil Collinson7 and Patricia B. Lehane7, 1The Karolinska Institute, Stockholm, Sweden, 2Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 3Johns Hopkins University, Baltimore, MD, 4University of Toronto, Toronto, ON, 5University of Texas, Dallas, TX, 6UCLA, Los Angeles, CA, 7Roche Products Limited, Welwyn Garden City, United Kingdom 2200. Eight Year Results of Disease Activity Steered Treatment in a Large Recent Rheumatoid Arthritis Cohort: Clinical and Radiological Outcomes. Linda Dirven1, M. van den Broek1, N.B. Klarenbeek1, K.H. Han2, H.K Ronday3, P.J.S.M. Kerstens4, Tom W.J. Huizinga1, Willem F. Lems5 and C.F. Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2Maasstad Hospital, Rotterdam, Netherlands, 3Haga Hospital, The Hague, Netherlands, 4Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 5VU University medical center, Amsterdam, Netherlands 2201. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BIIB023 (Anti-TWEAK) in Subjects with Rheumatoid Arthritis. Nicolas Wisniacki1, Vishala L. Chindalore2, Christine E. Codding3, Maria W. Greenwald4, Marianne L. Shaw5, Sergey Fitilev6, Olga Ershova7, Xiao Hu8, Timothy S. Zheng9, Lakshmi Amaravadi8, Ray Zhang9 and Linda C. Burkly8, 1Biogen Idec, Maidenhead, United Kingdom, 2Anniston Medical Clinic PC, Anniston, AL, 3Health Research of Oklahoma, Oklahoma City, OK, 4Desert Medical Advances, Palm Desert, CA, 5Duncansville, PA, 6M. Sechenov Moscow Medical Academy, Moscow, Russia, 7Clinical Hospital for Emergency Care, Moscow, Russia, 8Biogen Idec, Cambridge, MA, 9Biogen Idec Inc, Cambridge, MA

286

2011 Program Book

2202. Response to Second-Line DMARDs and TNFi in Seropositive and Seronegative Patients in Early and Late Rheumatoid Arthritis Are Not the Same: Results From the CATCH Cohort and a Large, Established Rheumatoid Arthritis Database. Yang Cao1, Ashley Bonner2, Lillian J. Barra3, J. Carter Thorne4, Boulos Haraoui5, Gilles Boire6, Carol A. Hitchon7, Nicole G. H. Le Riche8, Andrew E. Thompson9, Edward Keystone10, Vivian Bykerk11, Janet E. Pope12 and CATCH Investigators13, 1 University of Western Ontario, London, ON, 2McMaster University, Hamilton, ON, 3Schulich School of Medicine and Dentistry, London, ON, 4Southlake Regional Health Centre, Newmarket, Newmarket, ON, 5Institut de Rhumatologie, Montreal, QC, 6CHUS - Sherbrooke University, Sherbrooke, QC, 7University of Manitoba, Winnipeg, MB, 8St. Joseph’s Hospital, London, ON, 9St. Josephs Health Ctr, London, ON, 10 University of Toronto, Toronto, ON, 11Brigham & Women’s Hospital, Boston, MA, 12St. Joseph’s Health Care, University of Western Ontario, London, ON, 13Toronto, ON 2203. Better Retention Rate of Rituximab Vs Anti-Tnf Agents As Second Line therapy in RA Patients Failing a First Anti-Tnf Agents: Results From the Rhumadata® Registry. D. Choquette, Institute of Rheumatology of Montreal, Montreal, QC 2204. Effect of Tocilizumab on Hematologic Markers Implicates Interleukin-6 Signaling in the Anemia of Rheumatoid Arthritis. John D. Isaacs1, Olivier Harari2, Uwe Kobold3, C. Bernasconi4 and Janet S. Lee5, 1Newcastle University, Newcastle Upon Tyne, United Kingdom, 2Roche, Welwyn, United Kingdom, 3Roche Diagnostics GmbH, Penzberg, Germany, Germany, 4Roche, Basel, Switzerland, 5Roche, Nutley, NJ 2205. Comparison of Disease Characteristics of rheumatoid arthritis patients in Remission According to the DAS Criteria Versus the New ACR/EULAR Criteria in a RealWorld Patient Population. Denis Choquette1, William G. Bensen2, Maqbool K. Sheriff3, John T. Kelsall4, Milton F. Baker5, John S. Sampalis6, Susan M. Otawa7 and Heidi Imhoff7, 1University of Montreal Hospital Research Centre (CRCHUM), Notre Dame Hospital Montreal, Montreal, QC, 2McMaster University, Hamilton, ON, Hamilton, ON, 3 Nanaimo Regional General Hospital, Nanaimo, BC, 4Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, 5University of Victoria, Victoria, BC, 6McGill University & JSS Medical Research, Montreal, QC, 7Merck Canada Inc, Kirkland, QC 2206. Golimumab Treatment Inhibits Progression in Joint Damage in Patients with Psoriatic Arthritis Regardless of Baseline Disease Severity. Arthur Kavanaugh1, Dafna D. Gladman2, Anna Beutler3, Chenglong Han4 and GO-REVEAL Clinical Investigators, 1University of California San Diego, San Diego, CA, 2University of Toronto, Toronto Western Hospital, Toronto, ON, 3Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 4Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA

ACR/ARHP Poster Session C 2207. Optimism and Depressive Scores in Early Arthritis Patients Before and After Treatment with Methotrexate and a Tapered High Dose of Prednisone in the IMPROVED Study. L. Heimans1, K.V.C. Wevers-de Boer1, K. Visser1, Tom W.J. Huizinga1, H.K Ronday2, M.L. Westedt3, T.H.E. Molenaar4, R.C. van der Mast1 and C.F. Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2Haga Hospital, The Hague, Netherlands, 3Bronovo Hospital, The Hague, Netherlands, 4Groene Hart Hospital, Gouda, Netherlands 2208. Sustained Inhibition of Structural Damage in Patients with Rheumatoid Arthritis and An Inadequate Response to Tumor Necrosis Factor Inhibitors Prior to Rituximab Treatment: 5-Year Data From the REFLEX Study. Edward Keystone1, Stanley B. Cohen2, Paul Emery3, Joel M. Kremer4, Maxime Dougados5, James E. Loveless6, Carol Chung7, Patricia B. Lehane8 and Helen Tyrrell8, 1University of Toronto, Toronto, ON, 2Metroplex Clinical Research Center, Dallas, TX, 3 Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 4Albany Medical College, Albany, NY, 5Rene Descartes University, Paris, France, 6St. Luke’s Rheumatology, Boise, ID, 7Genentech, Inc., South San Francisco, CA, 8Roche Products Limited, Welwyn Garden City, United Kingdom 2209. Evaluation of Remission Over 1 Year in Patients (pts) with Early Rheumatoid Arthritis (RA) Treated with Abatacept (ABA) Plus Methotrexate, According to Simplified Disease Activity Index (SDAI). Josef Smolen1, J. Wollenhaupt2, Juan J. Gomez-Reino3, Walter Grassi4, Manuela Le Bars5, Corine Gaillez5, Coralie Poncet6, Ayanbola Elegbe7 and Rene Westhovens8, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Schön Klinik Hamburg-Eilbek, Hamburg, Germany, 3Hospital Clinico Universitario, Santiago de Compostela, Spain, 4Università Politecnica delle Marche, Ancona, Italy, 5Bristol-Myers Squibb, Rueil Malmaison, France, 6Docs International, Sèvres, France, 7Bristol-Myers Squibb, Princeton, NJ, 8UZ Gasthuisburg, Leuven, Belgium 2210. GLPG0634 Shows Selective Inhibition of JAK1 and Maintained JAK-STAT Suppression in Healthy Volunteers. Frédéric Vanhoutte1, René Galien2, Eva Vets3, Florence Namour2, Béatrice Vayssièrre2, Luc Van Rompaey1, Bart Smets1, Reginald Brys1, Piet Wigerinck1 and Gerben van ‘t Klooster1, 1Galapagos NV, Mechelen, Belgium, 2Galapagos SASU, Romainville, France, 3SGS, Antwerp, Belgium 2211. Evaluation of Anti-Tumor Necrosis Factor Levels and AntiTumor Necrosis Factor Antibodies in Rheumatic Diseases Treated with Infliximab and Adalimumab; Preliminary Results From a Local Registry. José Rosas-Gómez de Salazar1, Francisca Llinares-Tello1, José M. Senabre-Gallego1, Gregorio Santos-Soler1, Carlos Santos-Ramírez2, Esteban Salas-Heredia1, Xavier Barber-Vallés3, Mabel SánchezBarrioluengo4, Juan Molina-García1, Nuria Llahí Vidal1 and Catalina Cano Pérez1, 1Hospital Marina Baixa, Villajoyosa, Spain, 2Hospital Marina Salud, Denia, Spain, 3University Miguel Hernández, Elche, Spain, 4Universitat Politècnica de València, Valencia, Spain

2212. Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid ArthritisAssociated Interstitial Pneumonia. Eric L. Matteson1, Paul F. Dellaripa2, Jay H. Ryu1, Cynthia S. Crowson1, Thomas E. Hartman1 and Tim Bongartz1, 1Mayo Clinic, Rochester, MN, 2 Brigham & Womens Hospital, Boston, MA 2213. Efficacy and Safety of Tocilizumab As Monotherapy or in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: A 24-Week Randomized Study in a United States Population. Michael E. Weinblatt1, Joel M. Kremer2, John J. Cush3, William F. C. Rigby4, Lichen Teng5, Natasha Singh5 and Raymond L. Malamet6, 1 Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Baylor Research Institute, Dallas, TX, 4Dartmouth-Hitchcock Med Ctr, Lebanon, NH, 5Roche, Nutley, NJ, 6Genentech, South San Francisco, CA 2214. Efficacy, Safety, and Improvements in Work Productivity and Daily Activities with Certolizumab Pegol After Incomplete Response to Disease-Modifying AntiRheumatic Drugs in Patients with Low to Moderate Disease Activity. Josef Smolen1, Paul Emery2, Gianfranco Ferraccioli3, Francis Berenbaum4, Owen Davies5, Oana Purcaru5, Johann Ambrugeat5, Barbara Bennett6 and Harald Burkhardt7, 1 Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 3Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 4Pierre and Marie Curie University, AP-HP St-Antoine Hospital, Paris, France, 5UCB, Brussels, Belgium, 6 UCB, Smyrna, GA, 7Johan Wolfgang Goethe University, Frankfurt am Main, Germany 2215. Improved Quality of Life and Productivity in Patients with Moderate or Severe Rheumatoid Arthritis Actively Switched to Treatment with Infliximab From Adalimumab or Etanercept Therapy. Roy M. Fleischmann1, Rebecca Bolce2, Jim Wang3, Mike Ingham2, Raphael J. DeHoratius2, Dennis Decktor2 and RESTART Clinical Investigators, 1MCRC, University of Texas, Dallas, TX, 2Janssen Services, LLC, Horsham, PA, 3Johnson & Johnson Pharmaceutical Research and Development, LLC, Belle Mead 2216. Safety and Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis During More Than 5 Years of Therapy Observed in a Phase 3b and Post-Marketing Observational Study. Gerd-Rüdiger Burmester1, Marco Matucci-Cerinic2, Xavier Mariette3, Francisco Navarro-Blasco4, Uemit Oezer5, Sonja Kary5, Kristina Unnebrink5, Theresa Peterson6 and Hartmut Kupper5, 1Charité - University Medicine, Berlin, Germany, 2University of Florence, Florence, Italy, 3 Université Paris-Sud Hôpital Bicêtre, Le Kremlin Bicêtre, France, 4Universitario de Elche, Alicante, Spain, 5Abbott, Ludwigshafen, Germany, 6Abbott, Abbott Park, IL

2011 Program Book

287

ACR/ARHP Poster Session C 2217. Long-Term Safety of Tocilizumab in Rheumatoid Arthritis Clinical Trials. Mark C. Genovese1, Anthony Sebba2, Andrea Rubbert-Roth3, Juan Scali4, Moshe Zilberstein5, Liz Thompson6 and Ronald F. van Vollenhoven7, 1Stanford University Medical Center, Palo Alto, CA, 2University of South Florida, Palm Harbor, FL, 3University of Cologne, Cologne, Germany, 4Durand University Hospital, Buenos Aires, Argentina, 5Roche, Nutley, NJ, 6Roche, Welwyn, United Kingdom, 7Karolinska University Hospital, Stockholm, Sweden 2218. Comparison of Tocilizumab As Monotherapy or with Addon Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and An Inadequate Response to Previous Treatments. Vivian Bykerk1, Andrew Östör2, José Andrés Román Ivorra3, Jürgen Wollenhaupt4, Andrea Stancati5, Corrado Bernasconi5 and Jean Sibilia6, 1Brigham & Women’s Hospital, Boston, MA, 2University of Cambridge, Cambridge, United Kingdom, 3Hospital Universitario La Fe, Valencia, Spain, 4Schön Klinik, Hamburg, Germany, 5Roche, Basel, Switzerland, 6CHU Hautepierre, Strasbourg, France 2219. Effects of Tocilizumab Dose Escalation on Disease Activity in Adult Rheumatoid Arthritis Patients with Inadequate Response At 16 Weeks. Jeffrey R. Curtis1, Sarika Ogale2, Jenny Devenport2 and Denise Lepley2, 1University of Alabama at Birmingham, Birmingham, AL, 2Genentech, South San Francisco, CA 2220. Long Term Anti Tnfa Therapy for Inflammatory Rheumatic Disease Is Associated with Increased Bone Mineral Density and Paradoxical Elevation of TRAP5b Serum Levels. Eric Toussirot1, Laurent Mourot2, Emilie Grandclement3, Daniel Wendling4 and Gilles Dumoulin3, 1Rheumatology and CIC Biotherapy 506 and EA 4266 Pathogens and Inflammation, Besançon, France, 2University of Franche Comté, Besançon, France, 3Department of Physiology, France, 4Minjoz University Hospital, Besancon, France 2221. 12 Month-Retrospective Analysis of Two Different Rituximab Retreatment Regimens in Rheumatoid Arthritis: Retreatment At Clinical Relapse Vs 6th Month Fixed Retreatment. Luca Quartuccio1, Franco Schiavon2, Domenico Biasi3, Valeria Carraro2, Viviana Ravagnani4, Ilaria Dal Forno4, Paola Masolini1, Elisa Mansutti1, Laura Corazza1, Leonardo Punzi5, Silvano Adami4 and Salvatore De Vita1, 1 Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, 2Rheumatology Clinic, University of Padova, Padova, Italy, 3Rheumatology Unit, University of Verona, Verona, Italy, 4Rheumatology Clinic, University of Verona, Verona, Italy, 5Rheumatology Unit, University of Padova, Padova, Italy 2222. The Comparative Efficacy and Toxicity of Initial DiseaseModifying Anti-Rheumatic Drug Choices for Patients with Moderate-Severe Early Rheumatoid Arthritis: A Bayesian Network Meta-Analysis. Glen S. Hazlewood1, Cheryl CM Barnabe2, George A. Tomlinson1, Deborah Marshall3 and Claire Bombardier4, 1University of Toronto, Toronto, ON,

288

2011 Program Book

2 Univ of Calgary Foothills Hosp, Calgary, AB, 3University of Calgary, Calgary, AB, 4Institute for Work & Health, Toronto, ON

2223. Impact of Comorbidities on TNF Inhibitor Persistence in Rheumatoid Arthritis Patients: An Analysis of Korean National Health Insurance Claims Data. Soo-Kyung Cho1, Yoon-Kyoung Sung1, Chan-Bum Choi2, Jae Hoon Kim3, Jin Ju Kim4, Joo-Hyun Lee4, Young Bin Joo4 and Sang-Cheol Bae1, 1Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Disease, Seoul, South Korea, 4 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 2224. Perioperative Use of Anti-TNF Medications in Patients with Rheumatoid Arthritis Undergoing Total Knee Replacement. Beverly Johnson, Susan M. Goodman, Michael Alexiades and Lisa A. Mandl, Hospital for Special Surgery, New York, NY 2225. Undetectable Rheumatoid Factor Following Treatment with Rituximab- What Is Clinical Significance? Pravin Patil1, Julia Flint1, Elena Becerra-Fernandez1, Inmaculada de la Torre2, Geraldine Cambridge1, Maria J. Leandro1 and Jonathan CW Edwards1, 1University College of London, London, United Kingdom, 2Hospital Gregorio Maranon, Madrid, Spain 2226. Definition of Treatment Response in Rheumatoid Arthritis Based on the Simplified and the Clinical Disease Activity Index. Daniel Aletaha1, José Martinez-Avila2, Tore K. Kvien3 and Josef S. Smolen4, 1Medical University of Vienna, Vienna, Austria, 2Medical University of Vienna, Austria, 3 Diakonhjemmet Hospital, Oslo, Norway, 4Krankenhaus Lainz, Vienna, Austria 2227. Golimumab 3-Year Safety Update: An Analysis of Pooled Data From the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Jonathan Kay1, Roy Fleischmann2, Edward Keystone3, Elizabeth C. Hsia4, Mittie K. Doyle4, Benjamin Hsu4, Michael Mack5, Anna Beutler5, Jürgen Braun6 and Arthur Kavanaugh7, 1 University of Massachusetts Memorial Medical Center/ University of Massachusetts Medical School, Worcester, MA, 2University of Texas Southwestern Medical Center, Dallas, TX, 3University of Toronto, Toronto, ON, 4Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC/Univ. of Pennsylvania School of Medicine, Malvern/Philadelphia, PA, 5Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7University of California San Diego, San Diego, CA

ACR/ARHP Poster Session C 2228. Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial. Edward Keystone1, Désirée van der Heijde2, Michael E. Weinblatt3, Neelufar Mozaffarian4, Benoit Guerette5, Hartmut Kupper6, Shufang Liu4, Benjamin Wolfe4 and Arthur Kavanaugh7, 1University of Toronto, Toronto, ON, 2 Leiden University Medical Center, Leiden, Netherlands, 3 Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 4Abbott, Abbott Park, IL, 5Abbott, Rungis, France, 6Abbott GmbH & Co KG, Ludwigshafen, Germany, 7 University of California San Diego, San Diego, CA 2229. Patients with Early Rheumatoid Arthritis (RA) Who Respond Well to Methotrexate Monotherapy Have Less Metacarpal Bone Loss, Measured by Digital X-Ray Radiogrammetry (DXR), Than Those Who Need Add-on Therapy. Findings From a Randomized Trial. Hamed Rezaei1, Saedis Saevarsdottir1, Kristina Forslind2, Pierre Geborek3, Ingemar F. Petersson3, Sofia Ernestam4, Johan Bratt4 and Ronald F. van Vollenhoven1, 1The Karolinska Institute, Stockholm, Sweden, 2Helsingborgs Lasarett and Lund University, Lund, Sweden, 3Lund University, Lund, Sweden, 4 Karolinska University Hospital, Stockholm, Sweden 2230. Relevance of Involvement of Tofacitinib in T Cell Subsets to Clinical Courses in Patients with Rheumatoid Arthritis. Koshiro Sonomoto, Kunihiro Yamaoka, Satoshi Kubo, Keisuke Maeshima, Ippei Miyagawa, Kazuhisa Nakano, Norifumi Sawamukai, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 2231. Improvement in Disease Activity and Treatment Response Over 2 Years of Abatacept Treatment and Shifts to Improved Disease States in Patients with Early RA Who Switch From MTX. Rene Westhovens1, Juan J. GomezReino2, Walter Grassi3, Corine Gaillez4, Manuela Le Bars4, Coralie Poncet5, Ayanbola Elegbe6 and Jurgen Wollenhaupt7, 1 UZ Gasthuisburg, Leuven, Belgium, 2Hospital Clinico Universitario, Santiago de Compostela, Spain, 3Università Politecnica delle Marche, Ancona, Italy, 4Bristol-Myers Squibb, Rueil Malmaison, France, 5Docs International, Sèvres, France, 6Bristol-Myers Squibb, Princeton, NJ, 7SchönKlinik Hamburg-Eilbeck, Hamburg, Germany 2232. Rate of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Seroconversion in Patients with Undifferentiated Arthritis or Early Rheumatoid Arthritis Treated with Abatacept. Tom W.J. Huizinga1, Paul Emery2, Rene Westhovens3, Manuela Le Bars4, Corine Gaillez4, Coralie Poncet5, Ayanbola Elegbe6 and Josef S. Smolen7, 1 Leiden University Medical Center, Leiden, Netherlands, 2 University of Leeds, Leeds, United Kingdom, 3UZ Gasthuisberg, Leuven, Belgium, 4Bristol-Myers Squibb, Rueil Malmaison, France, 5Docs International, Sévres, France, 6 Bristol-Myers Squibb, Princeton, NJ, 7Medical University of Vienna and Hietzing Hospital, Vienna, Austria

2233. Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis in a Real World Routine Care Registry. Yusuf Yazici1, Maria T. Filopoulos2 and Christopher J. Swearingen3, 1Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 2NYU Hospital for Joint Diseases, New York, NY, 3University of Arkansas for Medical Sciences, Little Rock, AR 2234. Switching From Rituximab to Abatacept: Tolerance Data of 203 Patients Prospectively Followed up in the (Orencia) and Rheumatoid Arthritis (ORA) Registry. Jacques-Eric Gottenberg1, Thierry Schaeverbeke2, Philippe Gaudin3, Liana E. Euller-Ziegler4, Thao Pham5, Rene-Marc Flipo6, Alain G. Cantagrel7, Eric Houvenagel8, S. Redecker9, Xavier X. Le Loet10, Pascal Claudepierre11, Isabelle Pane12, Philippe Ravaud13 and Xavier Mariette14, 1Strasbourg University Hospital, Strasbourg, France, 2Pellegrin Hospital, Bordeaux, France, 3CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 4L Archet Hospital (University), Nice CEDEX 3, France, 5Sainte Marguerite Hospital, Marseille, France, 6Hopital R Salengro CHRU, Lille CEDEX, France, 7 Hopital Purpan, Toulouse CEDEX 9, France, 8St Philibert Hospital, Lomme 59462, France, 9Hospital University Abbeville, France, 10CHU de ROUEN, Rouen CEDEX, France, 11 Université Paris Est, Laboratoire d’Investigation Clinique (LIC) EA 4393, AP-HP, Hôpital Henri-Mondor, Rheumatology department, Creteil, France, 12France, 13Hopital Hotel Dieu, Paris Descartes University, Paris, France, 14Université ParisSud, Le Kremlin Bicetre, France 2235. First Year Radiological Erosive Progression Is a New Predictor of Further Erosive Progression in Early Arthritis: Results of the ESPOIR Cohort. Gabriel Tobon1, Alain Saraux2, Cédric Lukas3, Frédérique Gandjbakhch4, Xavier Mariette5, Bernard G. Combe6 and Valerie Devauchelle-Pensec7, 1Unit of immunology, Brest, France, 2Brest Occidentale University, Brest, France, 3Montpellier 1 University, Lapeyronie Hospital, 371, Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France, Montpellier, France, 4Hopital Pitié Salpétrière, Paris, France, 5Université Paris-Sud, Le Kremlin Bicetre, France, 6Hopital Lapeyronie, Montpellier, France, 7Brest Occidentale university, Brest, France 2236. New, Provisional American College of Rheumatology and European League Against Rheumatism Remission Criteria: Results From 2 Randomized, Controlled Golimumab Trials in Patients with Rheumatoid Arthritis. Paul Emery1, Edward Keystone2, R. M. Fleischmann3, M. C. Genovese4, Lars Klareskog5, Stephen Xu6, Chenglong Han7 and Elizabeth C. Hsia8, 1Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom, 2University of Toronto, Toronto, ON, 3University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 4Stanford University Medical Center, Palo Alto, CA, 5Karolinska Institutet, Stockholm, Sweden, 6Centocor R & D, a division of Johnson & Johnson Pharmaceutical 2011 Program Book

289

ACR/ARHP Poster Session C Research & Development, LLC, 7Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, 8Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA 2237. A Twelve-Week Exploratory Phase II Trial of GLPG0259 Versus Placebo in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate. Rene Westhovens1, Filip De Keyser2, Dmitro Rekalov3, Evgeny L. Nasonov4, Johan Beetens5, Annegret Van der Aa5, Piet Wigerinck5, Florence Namour6, Frédéric Vanhoutte5 and Patrick Durez7, 1University Hospital KU Leuven, Leuven, Belgium, 2Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, 4Institute of Rheumatology, Moscow, Russia, 5Galapagos NV, Mechelen, Belgium, 6Galapagos SASU, Romainville, France, 7Université Catholique de Louvain, Brussels, Belgium 2238. Safety and Efficacy of Abatacept in Eight Rheumatoid Arthritis Patients with Chronic Hepatitis B. Paul S. Kim1, Gerald Y. Ho2, Pamela E. Prete3 and Daniel E. Furst4, 1 University of California, Irvine, Orange, CA, 2Arthritis/ Osteoporosis Med Ctr, La Palma, CA, 3Long Beach VA Med Ctr, Long Beach, CA, 4UCLA, Los Angeles, CA 2239. Higher Proportion of Rheumatoid Arthritis Patients Achieve Low Swollen and Tender Joint Counts and No Radiographic Progression with Etanercept Plus Methotrexate Versus Methotrexate Alone. Eustratios Bananis, Tahmina Ferdousi, Ronald Pedersen, Andrew S. Koenig and Thomas V. Jones, Pfizer Inc., Collegeville, PA 2240. Efficacy of TNF Switch After Failure of One TNF Inhibitor – Results From a Nation-Wide Observational Study. Katerina Chatzidionysiou1, Jonas Eriksson2, Johan Askling3 and Ronald F. van Vollenhoven1, 1Karolinska Institute, Stockholm, Sweden, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden 2241. A Safety Analysis of Oral Prednisone As a Pre-Treatment for Rituximab in Rheumatoid Arthritis. John D. Carter1, Nancy Albritton1, S. Alireza Zarabadi2, Louis R. Ricca3, Joanne Valeriano-Marcet1, Frank B. Vasey4 and Anthony Sebba5, 1 University of South Florida, Tampa, FL, 2Tampa Arthritis Center, Tampa, FL, 3University of South Florida College of Medicine, St Petersburg, FL, 4Wayne State Univ. Health Ctr., Detroit, MI, 5University of South Florida, Palm Harbor, FL 2242. Characterization of Long-Term Responders to First Treatment Course of Rituximab (RTX) – Results From the CERERRA Collaboration. Elisabeth Lie1, Katerina Chatzidionysiou2, Evgeny L. Nasonov3, Galina Lukina3, Karel Pavelka4, Dan C. Nordström5, Matija Tomsic6, Cem Gabay7, Ioan Ancuta8, Piet LC van Riel9, Juan J. Gomez-Reino10, João E. Fonseca11, Merete L. Hetland12, Ulrik Tarp13, Tore K. Kvien1 and Ronald F. van Vollenhoven2, 1Diakonhjemmet Hospital, Oslo, Norway, 2Karolinska Institute, Stockholm, Sweden,

290

2011 Program Book

3 Institute of Rheumatology, Moscow, Russia, 41Institute of Rheumatology, Department of Experimental Rheumatology, 1 st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 5ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 6University Medical Centre Ljubjana, Ljubljana, Slovenia, 7University Hospitals of Geneva, on behalf of the SCQM registry, Geneva, Switzerland, 8Cantacuzino Hospital, Bucharest, Romania, 9 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 10Hospital Clinico Universitario, Santiago, Spain, 11Lisbon Academic Medical Center, on behalf of Rheumatic Diseases Portuguese Register (Reuma.pt), Lisbon, Portugal, 12Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 13Aarhus University Hospital, Aarhus, Denmark

2243. Long-Term Tolerability of Tocilizumab for the Treatment of Rheumatoid Arthritis. Yoshihiro Hishitani, Toru Hirano, Yoshihito Shima, Atsushi Ogata, Masashi Narazaki, Keisuke Hagihara and Toshio Tanaka, Osaka University Graduate School of Medicine, Suita, Japan 2244. A Multi-Biomarker Disease Activity Score (Vectra™DA algorithm score) Reflects Clinical Disease Activity and Tracks Response in a Japanese Rheumatoid Arthritis Population Treated with Anti-TNF Therapy. Shintaro Hirata1, Douglas J. Haney2, Guy Cavet2, Lyndal K. Hesterberg2, Norifumi Sawamukai1, Kunihiro Yamaoka3, Kazuyoshi Saito1 and Yoshiya Tanaka1, 1University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 2Crescendo Bioscience, Inc., South San Francisco, CA, 3University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 2245. The Risk of Serious Infection with and without AntiTNF Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: A Meta-Analysis. Hélène Cormier, Thomas Barnetche and Thierry Schaeverbeke, Pellegrin Hospital, Bordeaux, France 2246. Rebalancing the IL-23/Th17 Axis and Regulatory T Cells in Arthritis by Depleting IRF5+ IL-23+ M1 Macrophages Using An Anti-Human DR5 Antibody. Jun Li1, Hui-Chen Hsu1, PingAr Yang1, Qi Wu1, Hao Li1 and John D. Mountz2, 1 University of Alabama at Birmingham, Birmingham, AL, 2 University of Alabama at Birmingham and Birmingham VAMC, Birmingham, AL 2247. Systematic Review and Network Meta-Analysis of Combination Therapy for Methotrexate-Experienced, Rheumatoid Arthritis Patients: Analysis of American College of Rheumatology Criteria Scores 20, 50 and 70. Michelle E. Orme1, Iain Fotheringham2, Stephen A. Mitchell2, Dean Spurden3 and Alex Bird3, 1ICERA consutling, United Kingdom, 2Abacus International, United Kingdom, 3Pfizer Ltd, Surrey, United Kingdom 2248. Fucosylation Inhibitor, 2-D-Gal, Promotes Human Synovial Fibroblast Apoptosis and Is a Potent Suppressor of Arthritis in a TNF-α Tg Mouse Model In Vivo. Jun Li1, Hui-Chen Hsu1,

ACR/ARHP Poster Session C PingAr Yang1, Qi Wu1 and John D. Mountz2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham and Birmingham VAMC, Birmingham, AL 2249. Infliximab Is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis – a Randomized Trial. Lai Shan Tam1, Qing Shang1, Edmund K. Li1, Ka Lai Lee2, Ying Ying Leung3, King Yee Ying4, Cheuk-Wan Yim5, Emily W. Kun6, Alexander M. Leung7, Martin Li1, Tena K. Li1, Tracy Y. Zhu1, Ricky K. Chui1, Lorraine Tseung1, Shui Lian Yu1, Woon Pang Kuan8 and Cheuk-Man Yu1, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, 3 North District Hospital, Hong Kong, Hong Kong, 4Princess Margaret Hospital, Hong Kong, Hong Kong, 5United Christian Hospital, Hong Kong, Hong Kong, 6Tai Po Hospital, Hong Kong, Hong Kong, 7Queen Elizabeth Hospital, Hong Kong, Hong Kong, 8Hospital Selayang, Kuala Lumpur, Malaysia 2250. Golimumab Use and Sustained Clinical Response in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-Tumor Necrosis Factor Alpha Agents. Josef Smolen1, Jonathan Kay2, Robert Landewe3, Eric L. Matteson4, Norman B. Gaylis5, J. Wollenhaupt6, Frederick T. Murphy7, O. Zamani8, Yiying Zhou9, Elizabeth C. Hsia9 and Mittie K. Doyle9, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2University of Massachusetts Medical School, Worcester, MA, 3Academic Medical Center, Amsterdam, Netherlands, 4Mayo Clinic, Rochester, MN, 5 Arthritis & Rheumatic Disease Specialties, Aventura, FL, 6 Eilbeck Hospital, Hamburg, Germany, 7Altoona Ctr for Clinical Research, Duncansville, PA, 8Rheumazentrum Favoriten, Wien, Austria, 9Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA

2253. Pulmonary Adverse Events in a Cohort of Patients with Rheumatoid Arthritis Under Tnfa Blockers. Juan Antonio Martinez-Lopez1, Fredeswinda Romero1, Sandra Bermudez1, Jorge J. González López1, María Pérez Ferro1, Sheila Recuero1, Gema Díaz Moya1, Maria A. Contreras1, Gabriel Herrero-Beaumont2 and Olga Sanchez-Pernaute1, 1Jiménez Díaz Foundation University Hospital, Madrid, Spain, 2 Jiménez Diaz Foundation University Hospital, Madrid, Spain

Systemic Lupus Erythematosus - Clinical Aspects III 2254. Electrocardiographic Abnormalities in a Large Systemic Lupus Erythematosus Inception Cohort. Josiane BourréTessier1, Murray B. Urowitz2, Mori J. Krantz3, Lawrence Joseph4, SLICC investigators5 and Christian A. Pineau6, 1 McGill University Health Center, Montréal, QC, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3 University of Colorado, Denver, CO, 4McGill University Health Centre, Montreal, QC, 5Toronto, 6McGill Univ Health Center, Montreal, QC 2255. Initial Results for the LFA Collective Data Analysis Initiative (LFA CDAI): How Do Subjects From Lupus Clinical Trials Randomized to Standard of Care Respond Over Time? Kenneth C. Kalunian1, Mimi Kim2, Leslie M. Hanrahan3, Jean-Claude P. Becker4, Sabine Bongardt5, Paul Brunetta6, David Close7, Jorn Drappa7, Richard Furie8, Bevra H. Hahn9, Matthew Linnik10, Jane E. Salmon11, Neil Solomons12 and Joan T. Merrill13, 1UCSD School of Medicine, La Jolla, CA, 2 Albert Einstein College of Medicine, Bronx, NY, 3Lupus Foundation of America, Washington, DC, 4Becker Clinical Reearch Consulting LLC, New York, NY, 5UCB Biosciences, 6 Genentech, So San Francisco, CA, 7MedImmune Inc., 8North Shore-LIJ Health System, Lake Success, NY, 9UCLA David Geffen School of Medicine, Los Angeles, CA, 10Lilly Research Laboratories, 11Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 12Vifor Pharma, 13Oklahoma Medical Research Foundation, Oklahoma City, OK

2251. Methotrexate Every Day Is Safe and Effective As Weekly Dosage. Ricardo Moreno-Valdes1, Marco Ulises MartinezMartinez1, Enrique Cuevas-Orta1, Jorge Alcocer-Varela2 and Carlos Abud-Mendoza3, 1Hospital Central,, San Luis Potosí, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, 3Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico

2256. Incidence and Standardized Incidence Ratio (SIR) of Suicide in Southern Chinese Patients with Rheumatic Diseases in Hong Kong, China: 1999-2010. Chi Chiu Mok1, Raymond Kwok2, Ling Yin Ho3 and Paul Yip2, 1Tuen Mun Hospital, Hong Kong, Hong Kong, 2University of Hong Kong, Hong Kong, Hong Kong, 3Tuen Mun Hospital, Hong Kong SAR, Hong Kong

2252. B Cell Biomarkers Allow Prediction of Improving Response on Repeat Cycles of rituximab. Sudipto Das1, Edward M. Vital2, Shouvik Dass2, Maya H. Buch3, Andrew Rawstron2 and Paul Emery4, 1NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3 University of Leeds, Leeds, United Kingdom, 4Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Leeds, United Kingdom

2257. Support Vector Machines Classification of Texture Parameters of White Matter Lesions in Systemic Lupus Erythematosus. Possible Mechanism to Distinguish Between Demyelination and Ischemia. Aline Lapa1, Mariana P. Bento1, Letcia Rittner1, Gabriela Castellano1, Heloisa Ruocco2, Benito Damasceno3, Lilian Costallat4, Roberto Lotufo4, Fernando Cendes1 and Simone Appenzeller5, 1State University of Campinas, Campinas, Brazil, 2Medical Faculty of Jundiai, Campinas, Brazil, 3Medical Faculty of Jundiai, Campinas, United Kingdom, 4State University of Campinas, Campinas, United Kingdom, 5State University of Campinas, São Paulo, Brazil

2011 Program Book

291

ACR/ARHP Poster Session C 2258. sIL-7R Is a Novel Marker of Disease Activity in SLE Nephritis, Which Reflects Target Organ Involvement. Valérie Badot1, Geneviève Depresseux2, Frédéric. A. Houssiau2 and Bernard Lauwerys2, 1CHU-Brugmann & Université catholique de Louvain, Brussels, Belgium, 2 Université catholique de Louvain, Brussels, Belgium 2259. High-Sensitivity C-Reactive Protein As An Independent Risk Factor for Coronary Artery Disease in Systemic Lupus Erythematosus. Mandana Nikpour1, Dafna D. Gladman2, Dominique Ibanez3, Paula Harvey4 and Murray B. Urowitz3, 1 The University of Melbourne, Fitzroy, Australia, 2Toronto Western Hospital, University of Toronto, Toronto, ON, 3 Toronto Western Hospital and University of Toronto, Toronto, ON, 4Women’s College Hospital, Toronto, ON 2260. Effect of Raloxifene, a Selective Estrogen Receptor Modulator, on Disease Activity, Flare and Vascular Biomarkers in Patients with Systemic Lupus Erythematosus (SLE): A 12-Month Double-Blinded Randomized Controlled Trial. Chi Chiu Mok1, King Yee Ying2 and Kwok Man Ma1, 1 Tuen Mun Hospital, Hong Kong, Hong Kong, 2Princess Margaret Hospital, Hong Kong, Hong Kong 2261. Transcriptional Patterns in Whole Blood Diagnostic of Systemic Lupus Erythematosus. Tracy Costello and Cole Harris, Exagen Diagnostics, Houston, TX 2262. Adjusted Framingham Risk Factor Scoring for Systemic Lupus Erythematosus. Murray B. Urowitz1, Dominique Ibanez1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 2263. Damage Accrual in Patients with Systemic Lupus Erythematosus Is Associated with Endothelial Function Detriment: A Prospective Cohort Study. Chiara Tani1, R. Bruno1, Anna d’Ascanio2, Lorenzo Ghiadoni1, Y. Plantinga1, Rossella Neri1, Antonio Tavoni3, Linda Carli1, Stefano Taddei1, Stefano Bombardieri2 and Marta Mosca1, 1University of Pisa, Pisa, Italy, 2Rheumatology Unit, Pisa, Italy, 3AOUP, Pisa, Italy 2264. Transverse Myelitis and Its Relationship with Neuromyelitis Optica in the Michigan Lupus Cohort. Malini Venkatram1, Patricia C. Cagnoli1, Diana Gomez-Hassan2 and W. Joseph McCune1, 1University of Michigan, Ann Arbor, MI, 2Univ of Michigan, Ann Arbor, MI 2265. Evaluation of Treatment Success in Systemic Lupus Erythematosus Clinical Trials: Development of the British Isles Lupus Assessment Group-Based Composite Lupus Assessment Endpoint. D. Wallace1, V. Strand2, R. Furie3, M. Petri4, K. Kalunian5, M. Pike6, L. Kelley7 and C. Gordon8, 1 Cedars-Sinai Medical Center, Los Angeles, CA, 2Stanford University, Palo Alto, CA, 3North Shore-LIJ Health System, Lake Success, NY, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5UCSD School of Medicine, La Jolla, 6Massachusetts General Hospital, Fort ashington, PA, 7 UCB, Symrna, GA, 8Medical School, Birmingham, United Kingdom

292

2011 Program Book

2266. Inpatient Mortality Related to Cerebrovascular Disease in Systemic Lupus Erythematosus: The Impact of Delay in Diagnosis of Neuropsychiatric Lupus. Jamal A. Mikdashi, Univ of Maryland Schl of Med, Baltimore, MD 2267. Predictors of Outcome in Peripheral Nervous System Manifestations of Systemic Lupus Erythematosus. Brandusa Florica1, Jiandong Su2 and Paul R. Fortin1, 1Toronto Western Hospital, Toronto, ON, 2The Toronto Western Hospital, Toronto, ON 2268. Mortality Causes and Associated Factors in a Systemic Lupus Erythematosus Monocentric Cohort: Is the Systolic Pulmonary Artery Pressure A Risk Factor for Death? I. RuaFigueroa, C. Erausquin, MD Fiuza, F. Francisco-Hernández, S. Ojeda, A. Naranjo, JC Quevedo, A. Acosta, R. Lopez -R and C. Rodriguez-Lozano, Hospital de GC Dr Negrin, Las Palmas GC, Spain 2269. Anti-Nucleosome Antibodies Correlate with Temporal Fluctuations in Disease Activity in Systemic Lupus Erythematosus. Li Timothy1, Stacey Morrison2, Wendy Lou3, Heather Reich2, Ellie Aghdassi4, D. D. Gladman5, Murray B. Urowitz1, James Scholey2, Paul R. Fortin1, Joan E. Wither6 and Carolina Landolt-Marticorena1, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2 The Toronto Western Hospital, Toronto, ON, 3University of Toronto, Toronto, ON, 4University Health Network, Toronto, ON, 5The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, 6Toronto Western Research Institute, University Health Network, Toronto, ON 2270. The Substantial Negative Impact of Systemic Lupus Erythematosus on the Working Lives of Patients: Results of the Lupus European Online Survey. M. Schneider1, C. Gordon2, K. Lerstrøm3, M. Govoni4, E. Nikai4 and D.A. Isenberg5, 1Heinrich-Heine-University, Duesseldorf, Germany, 2University of Birmingham, Birmingham, United Kingdom, 3LUPUS EUROPE, Farum, Denmark, 4UCB, Brussels, Belgium, 5University College of London, London, United Kingdom 2271. Is the Heightened Lung Cancer Risk in SLE Decreasing Over Time? Data From a Very Large International Multi-Centre Cohort. Sasha Bernatsky1, Ann E. Clarke2, C. Gordon3, Jeremy Labrecque1, Rosalind Ramsey-Goldman4 and Systemic Lupus International Collaborating Clinic (SLICC).5, 1McGill UHC/RVH, Montreal, QC, 2Research Institute of the McGill Univ. Health, Montreal, QC, 3University of Birmingham, Birmingham, United Kingdom, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Toronto 2272. Risk Factors Associated with Cataracts in SLE Patients. An Inception-Cohort Study. Mariana Chávez-Villa, Juanita Romero-Diaz, Claudia Recillas-Gispert, Carmen Lizana, Francisco Cárdenas and Jorge Sánchez-Guerrero, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico, Mexico

ACR/ARHP Poster Session C 2273. Clinical and Psychosocial Factors Are Associated with Current Work Status and Missing Days At Work in a Large Population of Patients with Systemic Lupus Erythematosus (SLE). Stacey Morrison, Jiandong Su and Paul R. Fortin, Toronto Western Hospital, Toronto, ON 2274. The WHO Fracture Risk Assessment Tool (FRAXR) UnderEstimates the 10-Year Fracture Risk in Chinese Patients with Systemic Lupus Erythematosus (SLE). Chi Chiu Mok, Chi Hung To and Kwok Man Ma, Tuen Mun Hospital, Hong Kong, Hong Kong 2275. Insulin Resistance and Its Association with Phospholipid Profile, Carotid Intimal- Medial Thickness and Carotid Plaque Area in Women with Systemic Lupus Erythematosus. Ellie Aghdassi1, David WL. Ma2, Lihi Eder3, Amaris K. Balitsky4, Stacey Morrison5, Michael Frattasi5, Jiandong Su5, Shayan Ezatollahpour5, D. D. Gladman6 and Paul R. Fortin7, 1University Health Network, Toronto, ON, 2 University of Guelph, Guelph, ON, 3Toronto Western Hospital, University of Toronto, Toronto, ON, 4The University of Toronto, Toronto, ON, 5The Toronto Western Hospital, Toronto, ON, 6The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, 7Toronto Western Hospital, Toronto, ON 2276. Vitamin D Deficiency As Marker for Disease Activity and Organ Damage in Systemic Lupus Erythematosus: A Comparison with Anti-dsDNA and Anti-C1q. Chi Chiu Mok1, Daniel Birmingham2 and Brad H. Rovin2, 1Tuen Mun Hospital, Hong Kong, Hong Kong, 2Ohio State University Medical Center, Columbus, OH 2277. Number of Breastfed Babies Inversely Related to Development of Systemic Lupus Erythematosus Compared to Controls. April Barnado1, Lee Wheless2, Anna K. Meyer2, Gary S. Gilkeson3 and Diane L. Kamen4, 1Duke University Medical Center, Durham, NC, 2Medical University of South Carolina, Charleston, SC, 3Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 4Medical University of SC, Charleston, SC 2278. Predictors of Preterm Birth and Preeclampsia in SLE. Megan E. B. Clowse, Lisa G. Criscione-Schreiber and David S. Pisetsky, Duke University Medical Center, Durham, NC 2279. Nitrated Nucleosome Levels in Patients with Systemic Lupus Erythematosus – Associations with Ethnicity and Autoantibody Status. Sara Croca, Charis Pericleous, Karim Alber, Harry Yong, Ian Giles, David A. Isenberg, Anisur Rahman and Yiannis Ioannou, University College London, London, United Kingdom 2280. Free Fatty Acids Are Associated with Metabolic Syndrome and Endothelial Activation but Not Inflammation in Lupus. Michelle J. Ormseth1, Larry L. Swift1, Sergio Fazio1, MacRae F. Linton1, Cecilia P. Chung1, Paolo Raggi2, Young Hee Rho1, Joseph F. Solus1, Annette M. Oeser1, Aihua Bian1, Tebeb Gebretsadik1, Ayumi Shintani1 and C. Michael Stein1,

1 Vanderbilt Medical Center, Nashville, TN, 2Div.of Cardiology, Emory University, Atlanta, GA

2281. B Cell Depletion therapy and Pregnancy Outcome in Severe Refractory autoimmune Disease. Pamela M.K Lutalo1, Shirish Sangle1, Rachel J. Davies1, Munther A. Khamashta2 and David P. D’Cruz1, 1Louise Coote Lupus Unit, St Thomas’ Hospital, London, United Kingdom, 2Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom 2282. Treatment of Hypertension and Hypercholesterolemia Is Not Successful in the Majority of Patients with Systemic Lupus Erythematosus. Elizabeth A. Pek1, Dafna D. Gladman2, Dominique Ibanez1 and Murray B. Urowitz1, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2 Toronto Western Hospital, University of Toronto, Toronto, ON 2283. Systematic Review and Meta-Analysis of the Association of Systemic Lupus Erythematosus and Malignancy. I.D. Dey1 and David A. Isenberg2, 1University College London Hospital, London, United Kingdom, 2University College London, London WC1E 6JF, United Kingdom 2284. Late Versus Early Development of Lupus Nephritis. Debra Dye-Torrington1, Murray B. Urowitz1, Dominique Ibanez1 and Dafna D. Gladman2, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 2285. Hospitalization in Patients with Systemic Lupus Erythematosus. Alhussain Asiri1, Dafna D. Gladman2, Anne G. MacKinnon1 and Murray B. Urowitz1, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 2286. Few Pregnancies After Cyclophosphamide Treatment Despite Preserved Ovarian Function. Lindsey E. Harward1, Kate Mitchell2, Lisa G. Criscione-Schreiber2 and Megan E. B. Clowse2, 1Medical University of South Carolina, Charleston, SC, 2Duke University Medical Center, Durham, NC 2287. Urinary Exosomal Microrna-192 and -195 As Potential Biomarkers of Renal Disease Activity in Lupus Nephritis. Hua Zhou1, Gema Souto-Adeva2, Donna Hardwick2 and Gabor G. Illei1, 1NIDCR/ NIH #10 1N110, Bethesda, MD, 2 NIH/NIAMS, Bethesda, MD 2288. Nitrated Nucleosome Levels in Patients with Systemic Lupus Erythematosus – Associations with Disease Activity. Sara Croca1, Charis Pericleous1, Karim Alber1, Harry Yong1, Ian Giles1, David A. Isenberg2, Anisur Rahman1 and Yiannis Ioannou1, 1University College London, London, United Kingdom, 2University College London, London WC1E 6JF, United Kingdom 2289. Expression of Interferon-Inducible Genes Are Regulated by Sex Hormones and Gender in SLE. Ravi Dinesh1, Awlad Hossain1, Bevra H. Hahn1 and Ram P. Singh2, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2David Geffen Schl of Med/UCLA, Los Angeles, CA 2011 Program Book

293

ACR/ARHP Poster Session C 2290. The Lupus Damage Index Questionnaire and Its Correlation with the SLICC/ACR Damage Index and the LupusQoL in a Spanish Multicenter Lupus Cohort. Is It Really Measuring Damage? José M. Pego-Reigosa1, Íñigo Rúa-Figueroa2, Teresa Otón-Sánchez1, Manuela Fontanillo-Fontanillo1, María Galindo-Izquierdo3, Esther Uriarte-Isacelaya4, Bruno Aspede la Iglesia5, Laura Cáceres-Martín2 and Félix FranciscoHernández2, 1Hospital do Meixoeiro, Vigo, Spain, 2Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, 3 Hospital 12 de octubre, Madrid, Spain, 4Donosti, Spain, 5 Vigo, Spain 2291. Anti-Dense Fine Speckled 70 Antibodies: Initial Study of Clinical and Laboratory Associations in a US Laboratory Patient Population. Gurpreet Rawat, Kathleen Hutchinson and Mark H. Wener, University of Washington, Seattle, WA 2292. The Workplace Activity Limitations Among Lupus Patients. Ali Al-Dhanhani1, M. A. Gignac2, Dorcas E. Beaton3, Jiandong Su4 and Paul R. Fortin5, 1UAE University, Al Ain, United Arab Emirates, 2Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 3Ontario Workers Comp Institute, Toronto, ON, 4The Toronto Western Hospital, Toronto, ON, 5Toronto Western Hospital, Toronto, ON 2293. Shrinking Lung Syndrome is a Multifactorial Process Featuring Reduced Lung Compliance and Extrinsic Ventilatory Restriction. Lauren A. Henderson1, Stephen H. Loring2, Ritu R. Gill3, Katherine P. Liao3, Matthew L. Stoll4, Susan Kim1, Paul F. Dellaripa3, Deborah Rothman5, Lawrence S. Zemel6, Mary B. Son1 and Peter A. Nigrovic3, 1 Children’s Hospital Boston, Boston, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4University of Alabama at Birmingham, Birmingham, AL, 5Shriners Hosptials for Children, Springfield, MA, 6Connecticut Childrens Med Ctr, Hartford, CT 2294. Socioeconomic Status Is Associated with Disability in Pediatric Systemic Lupus Erythematosus. Mary Beth F. Son1, Aimee O. Hersh2, Hermine Brunner3, B. Anne Eberhard4, Emily von Scheven5 and CARRAnet Investigators6, 1Children’s Hospital Boston, Boston, MA, 2University of Utah, Salt Lake City, UT, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Cohen Children’s Hospital Medical Center, New Hyde Park, NY, 5UC San Francisco, San Francisco, CA, 6 Durham 2295. Performance of Complement C3, C4 and Anti-dsDNA Antibody in Predicting Disease Flare in Systemic Lupus Erythematosus: An Analysis of Data From 6035 Clinical Visits. Chi Hung To, Ka Lung Yu and Chi Chiu Mok, Tuen Mun Hospital, Hong Kong, Hong Kong 2296. Performance of Complement C3, C4 and Anti-dsDNA Antibody in Predicting Disease Flare in Individual Organ Systems in Systemic Lupus Erythematosus: An Analysis of Data From 6035 Clinical Visits. Chi Hung To, Ka Lung Yu and Chi Chiu Mok, Tuen Mun Hospital, Hong Kong, Hong Kong

294

2011 Program Book

2297. Digital Image Analysis Results Show High Reproducibility and Agreement with Human Interpretation on HEp-2 Cells. Gabriella Lakos, Carol E. Buchner, Cassandra C. Bryant, Pieter A. Baker, Rachel A. Rosenblum and Rufus W. Burlingame, INOVA Diagnostics, Inc., San Diego, CA 2298. Serological and Clinical Associations of Anti-PCNA Antibodies in Systemic Lupus Erythematosus Detected by a Novel Chemiluminescence Assay. Michael Mahler1, Marvin J. Fritzler2 and John G. Hanly3, 1INOVA Diagnostics, Inc., San Diego, CA, 2University of Calgary, Calgary, AB, 3Dalhousie University, Halifax, NS 2299. LupusPRO and Responsiveness to Changes in Health Status and Disease Activity Over Time. Meenakshi Jolly, Jessica Cornejo, Rachel A. Mikolaitis and Joel A. Block, Rush University Medical Center, Chicago, IL 2300. Analysis of RISK FACTORS for Relapses and CHRONIC Renal FAILURE In LUPUS Nephritis: Long TERM FOLLOWup of Biopsy Proven 172 PATIENTS Followed AT A SINGLE CENTER. Bahar Artim-Esen1, Yasemin Özlük2, Isin Kilicaslan2, Ahmet Omma1, Özlem Pehlivan1 and Murat Inanç1, 1Istanbul University, Istanbul Faculty of Medicine,Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Department of Pathology, Istanbul, Turkey 2301. Clinical Impact of Frequency of Visits in Systemic Lupus Erythematosus. Dafna D. Gladman1, Dominique Ibanez2 and Murray B. Urowitz2, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2Toronto Western Hospital and University of Toronto, Toronto, ON 2302. Quality of Life Measures Are Not Associated and Have No Discriminative Validity in Lupus Patients for Different Levels of Disease Activity. Zahi Touma1, Dafna D. Gladman2, Dominique Ibanez1, Shahrzad Taghavi-Zadeh1 and Murray B. Urowitz1, 1Toronto Western Hospital and University of Toronto, Toronto, ON, 2Toronto Western Hospital, University of Toronto, Toronto, ON 2303. The Influence of Age of Onset of Systemic Lupus Erythematosus and Disease Duration on Lupus Manifestations. Nayef Al Ghanim1, Jiandong Su2, Ellie Aghdassi3, Wendy Lou1 and Paul R. Fortin4, 1University of Toronto, Toronto, ON, 2The Toronto Western Hospital, Toronto, ON, 3University Health Network, Toronto, ON, 4 Toronto Western Hospital, Toronto, ON 2304. Prescribing Practices of Hydroxychloroquine World Wide. Seema Malani, SUNY Downstate Medical Center, Brooklyn, NY 2305. Cluster Analysis of Autoantibodies in 852 Patients with Systemic Lupus Erythematosus From a Single Center: Four Main Clusters with Prognostic Implications. Bahar ArtimEsen1, Erhan Çene2, Yasemin Sahinkaya1, Semra Ertan1, Özlem Pehlivan1, Sevil Kamali1, Ahmet Gül1, Lale Öcal1, Orhan Aral1 and Murat Inanç1, 1Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology,

ACR/ARHP Poster Session C Istanbul, Turkey, 2Yildiz Technical University, Department of Statistics, Faculty of Arts and Sciences, Istanbul, Turkey 2306. Urine Protein-to-Creatinine Ratio in a Random Spot Urine Collection Is a Reliable Measure of Proteinuria in Lupus Nephritis. In Ah Choi, Eun Young Lee, Yeong Wook Song and Eun Bong Lee, Seoul National University Hospital, Seoul, South Korea 2307. Quasi-homogeneous ANA-HEp-2 Pattern Reflects An Autoantibody Profile Intermediate to the Homogeneous and Dense Fine Speckled Nuclear Patterns. Natália R. França1, Alessandra Dellavance2, Sílvia H. Rodrigues3, Sandro F. Perazzio4, Neusa P. Silva5 and Luis Eduardo C. Andrade3, 1 Federal University, Sao Paulo, Brazil, 2Universidade Federal de São Paulo and Fleury Health and Medicine Laboratories, Sao Paulo, Brazil, 3Universidade Federal de São Paulo and Fleury Health and Medicine Laboratories, Sao Paulo Brazil, Sao Paulo, Brazil, 4Federal University of Sao Paulo, Sao Paulo, Brazil, 5Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil 2308. Cognitive Differences in Systemic Lupus Erythematosus Patients From the Western (Denver, CO) and Eastern (New York, NY) Regions of the United States. Elizabeth Kozora1, Doruk Erkan2, Sterling G. West3, Christopher Filley3, Aziz Ulug4, Glendalee Ramon2, Emily Duggan1, Lening Zhang1, JoAnn Vega2 and Michael D. Lockshin2, 1National Jewish Health, Denver, CO, 2Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY, 3University of Colorado School of Medicine, Aurora, CO, 4 The Feinstein Institute for Medical Research, Manhasset, NY

Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Pathogenesis, Animal Models and Genetics 2309. Hypophosphatemia Is Associated with Nephrogenic Systemic Fibrosis: A Case-Control Study. Elana J. Bernstein1, Tamara Isakova2, Mary E. Sullivan3, Lori B. Chibnik4, Hasan Bazari3, Myles Wolf2 and Jonathan Kay5, 1Hospital for Special Surgery, New York, NY, 2University of Miami, Miami, FL, 3Massachusetts General Hospital, Boston, MA, 4 Brigham & Women’s Hospital, Boston, MA, 5University of Massachusetts Medical School, Worcester, MA 2310. HLA-DRB5* 01:05 Is a Risk Factor for Systemic Sclerosis with Interstitial Lung Disease. Toshio Odani, Shinsuke Yasuda, Ayaka Kubota, Hisako Nakagawa, Yuichiro Fujieda, Kotaro Otomo, Masaru Kato, Tetsuya Horita, Tatsuya Atsumi and Takao Koike, Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan 2311. A Transforming Growth Factor-β Receptor One Variant Is Associated with Constitutively Decreased Transforming Growth Factor-β Signaling and Risk for Systemic Sclerosis. Monique E. Hinchcliff1, Michael Pennison2, Jacquelyn Zimmerman2, Naresh Bellam2, Qinghua Zeng2, Chiang-Ching Huang1, Richard M. Pope1, Maureen Sadim1, Wendy Wolf3, Jeffrey C. Edberg4, Robert P. Kimberly2, Kui Zhang5, Jun Li5,

Nengjun Yi5, Canadian Scleroderma Research Group (CSRG)6, Scleroderma Registry Investigators7, Maureen D. Mayes7, John Varga1 and Boris Pasche2, 1Northwestern Univ Med School, Chicago, IL, 2University of Alabama at Birmingham, Birmingham, AL, 3Harvard Medical School, Boston, MA, 4 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham School of Public Health, Birmingham, AL, 6 SMBD Jewish General Hospital, Montreal, QC, 7University of Texas Health Science Center at Houston, Houston, TX 2312. Anti-AT(1)R and Anti-ET(A)R Autoantibodies in Systemic Sclerosis: Indication of Possible Involvement in Disease Pathology. Angela Kill1, Mike O. Becker2, Jeannine Guenther1, Harald Heidecke3, Duska Dragun2 and Gabriela Riemekasten1, 1Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 2Charité University Hospital, Berlin, Germany, 3 CellTrend GmbH, Luckenwalde, Germany 2313. Identification of Major Histocompatibility Complex Class II Alleles Associated with Systemic Sclerosis Through Imputation Strategy. Jose Ezequiel Martin1, International Scleroderma Group2, Timothy RD Radstake3, Filemon K. Tan4, Frank C. Arnett4, Maureen D. Mayes4, Paul de Bakker5, Bobby P.C. Koeleman6 and Javier Martin7, 1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 2Granada, Spain, 3Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4University of Texas Health Science Center at Houston, Houston, TX, 5 Brigham and Women’s Hospital, Boston, MA, 6University Medical Center Utrecht, Utrecht, Netherlands, 7Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain 2314. FLOW Cytometric Analysis of CIRCULATING Microparticles In Systemic Sclerosis. Line V. Iversen, Statens Serum Institut, Copenhagen S, Denmark 2315. A Peptide Derived From Endostatin Ameliorates Fibrosis Induced by TGF–β and Bleomycin in Multiple Pre-Clinical Models. Yukie Yamaguchi1, Takahisa Takihara2, Roger Chambers2, Adriana T. Larregina2 and Carol A. FeghaliBostwick2, 1Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2University of Pittsburgh, Pittsburgh, PA 2316. Thymic Stromal Lymphopoietin (TSLP) Is Overexpressed in Scleroderma Skin and It Is Induced by TLR3 Activation in Dermal Fibroblasts. Alicia Usategui, Manuel J. Del Rey, Elena Izquierdo, Patricia E. Carreira, Pablo Ortiz and Jose L. Pablos, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain 2317. Oxidation of Protein Tyrosine Phosphatase-1B Leads to Pronounced PDGFR Activation in Scleroderma Fibroblasts. Pei-Suen Tsou1, Adam J. Pinney1, Nadin N. Talia1, Sonsoles Piera-Velazquez2, Sergio A. Jimenez3, James R. Seibold4, Kristine Phillips1 and Alisa E. Koch5, 1University of Michigan Medical School, Ann Arbor, MI, 2Thomas Jefferson 2011 Program Book

295

ACR/ARHP Poster Session C University, Philadelphia, PA, 3Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, 4Scleroderma Research Consultants LLC, Avon, CT, 5 Department of Veteran’s Affairs and University of Michigan, Ann Arbor, MI 2318. The Expression and Activities of Protein Tyrosine Phosphatases in Scleroderma Dermal Fibroblasts: Impact of Oxidative Stress on DEP-1 and SHP-2. Pei-Suen Tsou1, Adam J. Pinney1, Ann Kendzucky2, Sonsoles Piera-Velazquez3, Sergio A. Jimenez4, Kristine Phillips1 and Alisa E. Koch5, 1 University of Michigan Medical School, Ann Arbor, MI, 2 Grand Valley State University, MI, 3Thomas Jefferson University, Philadelphia, PA, 4Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, 5 Department of Veteran’s Affairs and Unversity of Michigan, Ann Arbor, MI 2319. Atorvastatin Attenuates Skin Fibrosis Through the PI3K Pathway. Yuko OTA, Yasushi Kawaguchi, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka and Hisashi Yamanaka, Tokyo Women’s Medical University, Tokyo, Japan 2320. The Role of Adiponectin in the Pathogenesis of Dermal Fibrosis in Systemic Sclerosis. Yoshihide Asano, Yuri Masui, Takafumi Kadono and Shinichi Sato, The University of Tokyo, Tokyo, Japan 2321. Platelet Derived Growth Factor receptor inhibitor ARRY768 Prevents Experimental Dermal Fibrosis and Induces Regression of Pre-Established Dermal Fibrosis. Michal Tomcik1, Nicole Reich2, Katrin Palumbo2, Pawel Zerr2, Jérôme Avouac3, Alfiya Akhmetshina2, Clara Dees2, Christian Beyer4, Radim Becvar1, Ladislav Senolt5, Oliver Distler6, Georg Schett2 and Jorg HW Distler2, 1Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1 st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Department of Internal Medicine 3 and Institute for Clinical Immunology, University of ErlangenNuremberg, Erlangen, Germany, 3Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 4 University of Erlangen-Nuremberg, Erlangen, Germany, 5 Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 6University Hospital Zurich, Zurich, Switzerland 2322. Adenosine A2A Receptor Activation Stimulates Collagen1 and Collagen3 by Different Signaling Pathways in Normal Human Dermal Fibroblasts (NHDF). Miguel Perez-Aso and Bruce N. Cronstein, New York Univ Medical Center, New York, NY 2323. Adenosine-Mediated Dermal Fibrosis and Fli-1 Expression in CD39 and CD73 Knockout Mice. Edwin SL Chan1, Gideon Smith1, Patricia Fernandez2, Hailing Liu1, Andrew G. Franks2, Maria Trojanowska3 and Bruce N. Cronstein4, 1New York University School of Medicine, New York, NY, 2New York University, New York, NY, 3Boston University, Boston, MA, 4 New York Univ Medical Center, New York, NY

296

2011 Program Book

2324. Enhanced IL-6 Trans-Signalling in Early dcSSc May Drive Fibrotic Response Via JAK2/STAT3 Signalling Pathways. Korsa Khan1, Xu Shiwen2, David J. Abraham3, Christopher P. Denton4 and Voon Ong5, 1UCL medical School, London, United Kingdom, 2Royal Free Hospital, London, United Kingdom, 3Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 4 UCL Medical School, London, United Kingdom, 5UCL Medical School, London, England 2325. Estimation of Cellular States From SSc Gene Expression Reveals Heterogeneity of Pathway Expression. J. Matthew Mahoney and Michael L. Whitfield, Dartmouth Medical School, Hanover, NH 2326. The Melanocortin System: A New and Important Actor on the Scene of Systemic Sclerosis. Grethe N. Andersen1, Olga Nagaeva2, Lucia Mincheva-Nilsson3 and Jarl E.S. Wikberg4, 1 Hospital of Vendsyssel/Ålborg University, Hjørring, Denmark, 2University of Umeå, Umeå, Sweden, 3University of Umeå, Sweden, 4Department of Pharmaceutical Pharmacology, Uppsala, Sweden 2327. Identification of a Gene Expression Signature in Limited Cutaneous Systemic Sclerosis That Includes Several Vascular Genetic Factors. Cecilia B. Chighizola1, Pia Moinzadeh2, Korsa Khan3, Tammara A. Wood4, Pier Luigi Meroni5, David J. Abraham6, Michael L. Whitfield4, Voon Ong7 and Christopher P. Denton3, 1University Of Milan, Milan, Italy, 2Royal Free Hospital, Medical School, London, United Kingdom, 3UCL Medical School, London, United Kingdom, 4Dartmouth Medical School, Hanover, NH, 5 University of Milan, Milan, Italy, 6Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 7UCL Medical School, London, England 2328. A Novel Automated Longitudinal In Vivo Assessment of Bleomycin Induced Pulmonary Fibrosis in Mice Using In Vivo High Resolution Micro-Computed Tomography. Ellen De Langhe1, Greetje Vande Velde1, Jeroen Hostens2, Frank P. Luyten1, Ben Nemery1, Uwe Himmelreich1, Jeroen Vanoirbeek1 and Rik Lories1, 1KU Leuven, Leuven, Belgium, 2 Skyscan 2329. Gene-Gene Interactions In Interferon Pathway GeneMutations In European and American Scleroderma Cohorts. Pravitt R. Gourh1, Filemon K. Tan2, Blanca Rueda3, Frank C. Arnett2, Shervin Assassi2, John D. Reveille2, Timothy RD Radstake4, Maureen D. Mayes2, Javier Martin5 and Sandeep K. Agarwal2, 1UTHSC-Houston Medical School, Houston, TX, 2University of Texas Health Science Center at Houston, Houston, TX, 3Facultad de Ciencias de la Salud. Universidad de Granada, Granada, Spain, 4 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain

ACR/ARHP Poster Session C 2330. Human Leukocyte Antigen Alleles in Juvenile Onset Systemic Sclerosis. Anne M. Stevens1, Maureen D. Mayes2, John D. Reveille2, Gretchen R. Henstorf3 and J. Lee Nelson4, 1 University of Washington, Seattle, WA, 2University of Texas Health Science Center at Houston, Houston, TX, 3Seattle Children’s Research Institute, Seattle, WA, 4Fred Hutchinson Cancer Rsch, Seattle, WA

2337. Antigen-Specific Regulatory Tr1 Lymphocytes As New Cell-Therapy Approach for Immunotherapy in Arthritis. Delphine Martire1, Julie Quentin1, Anne-Laure MaussetBonnefont1, Helène Asgnali2, Nathalie Belmonte2, Arnaud Foussat2, Christian Jorgensen3 and Pascale Louis-Plence1, 1 Inserm U844, Montpellier, France, 2TxCell, Valbonne-Sophia Antipolis, France, 3CHU Lapeyronie, Montpellier, France

T cell Biology and Targets in Autoimmune Disease: Lymphocyte Biology and Targets in Autoimmune Disease

2338. Differences in Immune Cell Profile and Related Gene Expression Provide Clues to Susceptibility to Arthritis in Humanized Mice. David Luckey, Behrens Marshall and Veena Taneja, Mayo Clinic, Rochester, MN

2331. Methylprednisolone Modulates MicroRNA and Gene Expression in Human CD4+ T Cells: A Novel Mechanism of Anti-Inflammatory Action. Trevor E. Davis1, Katalin KisToth2, Attila Szanto3, Laurie C. Miller4 and George C. Tsokos5, 1 Floating Hospital for Children at Tufts Medical Center; Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Harvard Medical School; Massachusetts General Hospital, Boston, MA, 4Tufts Medical Center, Boston, MA, 5Beth Israel Deaconess Medical Center; Harvard Medical School, Boston, MA 2332. Deficient Thymic T Lymphopoeisis in Rheumatoid Arthritis Is Not Due to the Lack of CD34+ Lymphoid progenitors. Manuela Rossol1, Anett Schulz1, Annika Schatz2, Undine Meusch2, Dagmar Quandt2, Christoph G. Baerwald3 and Ulf Wagner3, 1Translationszentrum für Regenerative Medizin (TRM), University of Leipzig, Leipzig, Germany, 2University of Leipzig, Leipzig, Germany, 3University Hospital, Leipzig, Germany 2333. Synovial Fluid Vγ9Vδ2 T Cells Activated by Synovial Fibroblasts Induce Their Apoptosis. Anna Bendersky1, Victoria Marcu1, Yackov Berkun2, Itamar Goldstein1, Maya Gerstein1, Shay Padeh1 and Ilan Bank1, 1Sheba Medical Center, Ramat Gan, Israel, 2Hadassah Hebrew University Medical Center, Jerusalem, Israel 2334. Defining Pathogenicity of Human Th17 Cells in RA. Hiroshi Kato1, Judith Endres1 and David A. Fox2, 1University of Michigan, Ann Arbor, MI, 2Univ of Michigan Med Ctr, Ann Arbor, MI 2335. T Cell Receptor Signal Strength Controls Onset and Severity of Arthritis in Antigen (Proteoglycan Epitope)-Specific T Cell Receptor Transgenic Mice. Katalin Olasz1, Ferenc Boldizsar1, Katalin Kis-Toth2, Oktavia Tarjanyi1, Akos Hegyi3, Willem van Eden4, Tibor A. Rauch3, Katalin Mikecz3 and Tibor T. Glant3, 1Pecs, Hungary, 2Boston, MA, 3Rush University Medical Center, Chicago, IL, 4Utrecht,, Netherlands 2336. Short Combination Therapy with Anti-CD3 and Anti-TNF Is Associated with Long Term Inhibition of Established Collagen-Induced Arthritis. Fabien Depis1, Eric Hatterer1, Céline Lamacchia2, Cem Gabay2, Jean-Marc Waldburger2, Walter Reith3, Marie Kosco-Vilbois1 and Yann Dean1, 1 NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, 2 University Hospitals of Geneva, Geneva, Switzerland, 3 University of Geneva Medical School, Geneva, Switzerland

2339. Investigation of Fibrinogen-Reactive T Cells in the Pathogenesis of Mouse Models of Rheumatoid Arthritis. Kristen N. Cordova1, Rocky L. Baker1, Gene Barbour1, Kathryn Haskins1 and V. Michael Holers2, 1University of Colorado, AMC, Aurora, CO, 2Univ of Colorado School of Med, Aurora, CO 2340. Lysophosphatidylcholine Enhances Suppressive Function of Human Naturally Occurring Regulatory T Cells Through TGF-Beta Production. Hitoshi Hasegawa, Jin Lei, Takuya Matsumoto, Sachiko Onishi, Koichiro Suemori and Masaki Yasukawa, Ehime University Graduate School of Medicine, Toon, Japan 2341. Multifunctional T Cell Reactivity to Native and Glycosylated Type-II Collagen in Rheumatoid Arthritis. Vivianne Malmström1, Omri Snir1, Johan Bäcklund2, Lars Klareskog1 and Rikard Holmdahl1, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Stcokholm, Sweden 2342. Circulating CD4+CD161+ T Cells As Biomarker of Disease Activity in Recently Diagnosed, Non- Treated Rheumatoid Arthritis Patients. Paulina Chalan, Wayel H. Abdulahad, Minke G. Huitema, Bart-Jan Kroesen, Elisabeth Brouwer and Annemieke M.H. Boots, University Medical Center Groningen, Groningen, Netherlands 2343. CIRCULATING HUMAN Collagen II- REACTIVE T CELL In EARLY Rheumatoid Arthritis PRODUCE IL17. Anna Laura Fedele1, Chiara Nicolò2, Gabriele Di Sante2, Barbara Tolusso1, Silvia L. Bosello1, Elisa Gremese1, Francesco Ria2 and Gianfranco Ferraccioli1, 1Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 2Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy 2344. A Novel Human Autoantigen Induces T and B Cell Responses in Patients with Antibiotic-Refractory Lyme Arthritis. Elise E. Drouin1, Robert J. Seward2, Chunxiang Yao3, Kianoosh Katchar1, Gail McHugh1, Klemen Strle1, Catherine E. Costello3 and Allen C. Steere1, 1Massachusetts General Hospital and Harvard Medical School, Boston, MA, 2 Massachusetts General Hospital, Harvard Medical School and Boston University School of Medicine, Boston, MA, 3 Boston University School of Medicine, Boston, MA

2011 Program Book

297

ACR/ARHP Poster Session C 2345. IL-2/IL-2mAb Complex Induced Expansion of Treg Cells and Prolonged Suppression of Collagen Induced Arthritis in Mice by Fortifying IL-2 Signaling Pathways. seon Yeong Lee1, Hye Jwa Oh1, Joo-Yeon Jhun1, Jun Geol Ryu1, Mi La Cho1, ji Hyeon Ju1, Sang Heon Lee2, Sung Hwan Park1, Charles D. Surh3 and Ho Youn Kim1, 1Rhematism Research Center, Seoul, South Korea, 2Division of Rheumatology, Seoul, South Korea, 3Department of Immunology 2346. High Density Lipoproteins Stabilize Antigen Presenting Cell:T Cell Conjugates by Altering the T Cell Receptor Signalling Kinetics. A.L. Gomes1, J. Delgado-Alves1 and E.C. Jury2, 1Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisboa, Portugal, 2University College London, London, United Kingdom 2347. The Induction of c-Maf in Th17 Cells and Its Implications in the Development of Memory Th Cells. Kojiro Sato, Fumihiko Miyoshi and Toshihide Mimura, Saitama Medical University, Saitama, Japan 2348. A Novel Role for Vitamin D in Immunosenescence: Is Enough Too Much for Naïve CD8 T Cells? Yong Gil Hwang1, Fei Chu Lim1, Qi Wu1, PingAr Yang1, Gordon Fisher2, Gary Hunter3, Hui-Chen Hsu1 and John D. Mountz4, 1University of Alabama at Birmingham, Birmingham, AL, 2Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA, 3Department of Human Studies, University of Alabama at Birmingham, Birmingham, Alabama, USA, 4University of Albama at Birmingham/ Birmingham VA Medical Center, Birmingham, AL 2349. AKAP79 Expression Is Increased in Systemic Lupus Erythematosus T Cells and Reduces IL2 Production. Gabriel Criado, María Galindo, A. Javier García-González, Jose L. Pablos and María J. Pérez-Lorenzo, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain 2350. Oxidation Impairs PKCä Signaling in Lupus. Gabriela Gorelik and Bruce C. Richardson, University of Michigan, Ann Arbor, MI 2351. Linker for Activation of T Cells Is Displaced From the Immunological Synapse in Lupus T Cells After T Cell Activation. Nursamaa Abdoel1, Carmen Bracho2, Martin A. Rodriguez1 and Ana M. Blasini1, 1Hospital Universitario de Caracas, Caracas, Venezuela, 2Instituto Venezolano de Investigaciones Científicas, Miranda, Venezuela 2352. Effects of Direct Ras Inhibition on Lupus T Cell Cytokine Secretion. Ioana Moldovan, Leticia Ortloff, Adrian Costinescu, Keith K. Colburn and Lora Green, Loma Linda University, Loma Linda, CA 2353. A Progesterone Receptor Regulates T Helper Cell Type 1 Functions and T Cell-Dependent Antibody Responses In Vivo. Alan Wong, Edward A. Clark and Grant C. Hughes, University of Washington, Seattle, WA 2354. The Autoantibody-Inducing CD4 T Cell (aiCD4 T cell) Which Induces Systemic Lupus Erytematosus (SLE) Belongs to CD45RBlo 122lo Subpopulation. Yumi Miyazaki1, Ken

298

2011 Program Book

Tsumiyama1 and Shunichi Shiozawa2, 1Kobe University Graduate School of Health Science, Kobe, Japan, 2Kobe University Graduate School of Health Science and Medicine/ The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan 2355. Sex-Specific Effects of Segmented Filamentous Bacteria In the Autoimmune-Prone NOD Mouse Strain – Segregation with Diabetes Protection In Females but Not Males. Martin A. Kriegel1, Esen Sefik2, Jonathan A. Hill2, Hsin-Jung Wu2, Christophe Benoist2 and Diane Mathis2, 1Brigham & Women’s Hospital/Harvard Medical School, Boston, MA, 2 Harvard Medical School, Boston, MA 2356. Expansions of Interleukin-21-Secreting CD4+ T Helper Cells in Inflammatory Arthritides. Pedro L. Vieira1, Maria C. Lebre2, Saïda Aarrass2, Thomas Newsom-Davis1, PP. Tak2 and Gavin R. Screaton1, 1Imperial College London, London, United Kingdom, 2Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands 2357. Th17 but Not Th22 Cells Display Pathological Behaviour in Rheumatoid Arthritis Synovial Inflammation. Jan Piet van Hamburg, Odilia B.J. Corneth, Sandra M.J. Paulissen, Nadine Davelaar, Patrick S. Asmawidjaja and Erik Lubberts, Erasmus MC, University Medical Center, Rotterdam, Netherlands 2358. HRES-1/Rab4 Lupus Susceptibility Gene Selectively Regulates Mammalian Target of Rapamycin Complexes 1 and 2 in T Lymphocytes. Tiffany Telarico1, Gabriella Miklossy2, David Sabatini3, David Kwiatkowski4, Nahum Sonenberg5 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2Upstate Medical University, Syracuse, NY, 3Whitehead Institute for Biomedical Research, Cambridge, MA, 4Brigham and Women’s Hospital, Boston, MA, 5Goodman Cancer Research Centre, McGill University, Montreal, QC 2359. Abatacept (CTLA-4Ig) Treatment Reduces Activation Induced Cell Death (AICD) and Susceptibility of T Cells to Regulatory T Cell Suppression in Patients with Rheumatoid Arthritis (RA). Michael Bonelli1, Lisa Goeschl1, Stefan Blueml1, Anastasiya Hladik1, Emmi Puujalka1, Carl-Walter Steiner1, Josef Smolen2 and Clemens Scheinecker1, 1Medical University of Vienna, Vienna, Austria, 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria 2360. Do Immune Complexes (ICs) Binding Low Affinity FcγRIIIA/B Bearing CD4+ T Cells Contribute to the Autoimmune Pathology? Anil K. Chauhan1 and Terry L. Moore2, 1Saint Louis University, St. Louis, MO, 2Saint Louis University, Saint Louis, MO 2361. Leptin Modulates Apoptosis of Autoimmune T Cells in Systemic Lupus Erythematosus. Gil Amarilyo1, Noriko Iikuni2, Bevra H. Hahn3 and Antonio La Cava4, 1UCLA, Los Angeles, CA, 2UCLA, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Univ of California Los Angeles, Los Angeles, CA

ACR/ARHP Poster Session C 2362. Identification of a CD62LhiCD44low TFH Precursor Capable of Developing into An IL21hi IL17hi Mature TFH in Autoimmune BXD2 Mice. Yanna Ding1, Hui-Chen Hsu1 and John D. Mountz2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham and Birmingham VAMC, Birmingham, AL 2363. Effects of Altering Fli1 Levels in Lupus T Cells on Disease Expression and T Cell Function in the MRL/Lpr Mouse Model. Fahmin Basher1, Marlene Bunni1, Zainab Amani1, Xian Zhang2 and Tamara K. Nowling2, 1Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina & Ralph H Johnson VA Medical Center, Charleston, SC 2364. DNA Methylation Regulates Gene Expression in CD4+CD28T Cells Through Micrornas. Dipak R. Patel, Anura Hewagama, Gabriela Gorelik, Sushma Yarlagadda, Faith Strickland and Bruce C. Richardson, University of Michigan, Ann Arbor, MI

Vasculitis II 2365. CTLA-4 and TNF-á Promoter –308 A/G Polymorphisms and ANCA-Associated Vasculitis Susceptibility: A Meta-Analysis. Young Ho Lee, Sung Jae Choi, Jong Dae Ji and Gwan Gyu Song, Korea University Medical Center, Seoul, South Korea 2366. How Do Rheumatologists Choose Between Cyclophosphamide and Rituximab? Raluca Cozmuta1, Peter A. Merkel2 and Liana Fraenkel3, 1St. Vincent Medical Center, Bridgeport, CT, 2Boston University School of Medicine, Boston, MA, 3Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 2367. Treatment for ANCA-Associated Vasculitis: What Are the Experts Prescribing? Raluca Cozmuta1, Peter A. Merkel2 and Liana Fraenkel3, 1St. Vincent Medical Center, Bridgeport, CT, 2 Boston University School of Medicine, Boston, MA, 3Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 2368. Are Patients with ANCA-Associated Vasculitis Entered In Clinical Trials Representative of Patients Followed In Observational Cohorts? Christian Pagnoux1, Simon Carette2, Nader A. Khalidi3, David Cuthberston4, Paul R. Fortin5, Gary S. Hoffman6, Carol A. Langford7, Paul A. Monach8, Luc Mouthon9, Philip Seo10, Ulrich Specks11, Steven R. Ytterberg11, Peter A. Merkel12, Loic Guillevin13, French Vasculitis Study Group (FVSG)14 and The Vcrc8, 1University Health Network, Toronto, Canada, Toronto, ON, 2Toronto Western Hospital, Toronto, ON, 3McMaster University, Hamilton, ON, 4University of South Florida, Tampa, FL, 5 Toronto Western Hospital and University of Toronto, Toronto, ON, 6Cleveland Clinic Found A50, Cleveland, OH, 7Cleveland Clinic, Cleveland, OH, 8Boston University, Boston, MA, 9Hopital Cochim, Paris, France, 10Johns Hopkins Vasculitis Center, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12Boston University School of Medicine, Boston, MA, 13 Cochin University Hospital, Paris, France, 14Paris, France

2369. Optimal Definition for the Duration of Sustained Remission in ANCA-Associated Vasculitis. Gunnar Tomasson1, Michael Walsh2, Thomas F. Hiemstra3, Maarten Boers4, Peter A. Merkel1 and EUVAS Investigators5, 1Boston University School of Medicine, Boston, MA, 2McMaster University, Hamilton, 3 Addenbrookexs Hospital University of Cambridge, Cambridge, United Kingdom, 4VU University Medical Center, Amsterdam, Netherlands, 5Cambridge, United Kingdom 2370. Neural Correlates of Chronic Fatigue in Granulomatosis with Polyangiitis (GPA; Wegener’s) – A Functional Magnetic Resonance Imaging (fMRI) Study. Neil Basu1, Gareth T. Jones1, Raashid A. Luqmani2, Alison D. Murray1, David M. Reid1, Gary J. Macfarlane1 and Gordon D. Waiter1, 1 University of Aberdeen, Aberdeen, United Kingdom, 2 University of Oxford, Oxford, United Kingdom 2371. Mental Health As a Predictor of Disease Flare in Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). Morgana L. Davids1, Huong Do1, Gunnar Tomasson2, John C. Davis3, Gary S. Hoffman4, W. Joseph McCune5, Ulrich Specks6, E. William St Clair7, John H. Stone8, Peter A. Merkel9 and Robert F. Spiera1, 1Hospital for Special Surgery, New York, NY, 2Boston University School of Medicine, Boston, MA, 3Genentech Inc, South San Francisco, CA, 4Cleveland Clinic, Cleveland, OH, 5University of Michigan, Ann Arbor, MI, 6Mayo Clinic, Rochester, MN, 7Duke University Medical Center, Durham, NC, 8Massachusetts General Hospital, Boston, MA, 9Boston University, Boston, MA 2372. Patient-Driven On-Line Survey on Granulomatosis with Polyangiitis. Adam Hall1, Marta Rode2, Christian Pagnoux3 and Elaine Yacyshyn1, 1University of Alberta, Edmonton, AB, 2 None, Jasper, AB, 3University of Toronto, Toronto, ON 2373. Rituximab in Relapsing Granulomatosis with Polyangiitis (Wegener’s granulomatosis): A Case Series. Pamela M.K Lutalo, Ian C. Scott, Shirish Sangle and David P. D’Cruz, Louise Coote Lupus Unit, St Thomas’ Hospital, London, United Kingdom 2374. B Cell Depletion by Rituximab Severely Reduces Immunoglobulin Levels in Patients with ANCA-Associated Vasculitis Previously Treated with Cyclophosphamide. Jens Thiel, Nora M. Effelsberg, Hans-Hartmut Peter, Reinhard E. Voll, Klaus Warnatz and Nils Venhoff, Dpt. Rheumatology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany 2375. A Cost Effectiveness Analysis of Weekly Complete Blood Count Monitoring for Leukopenia In Patients with Granulomatosis with Polyangiitis (Wegner’s) On Cyclophosphamide. Atul A. Khasnis1, Richard Wilson2, Gary S. Hoffman1, Alexandra Villa-Forte1 and Carol A. Langford3, 1 Cleveland Clinic Foundation, Cleveland, OH, 2Case Western Reserve University, Cleveland, OH, 3Cleveland Clinic, Cleveland, OH

2011 Program Book

299

ACR/ARHP Poster Session C 2376. Gram-Positive Bacterial Wall Components Inhibit Formation of Osteoclast-Like Multinucleated Giant Cells: Possible Explanation for Their Scarcity in Sinonasal Inflammation of Granulomatosis with Polyangiitis. Jin Kyun Park, Johns Hopkins University, Baltimore, MD 2377. Perspective on Hypoxic Signalling in Granulomatosis with Polyangiitis (Wegener’s) – Increased Expression of HIF-1α and Glut-1 in Granulomatous Lesions of the Nasal Cavity. Nina Kesel1, Antje Müller2, Dorothee Köhler1, Martin Laudien3, Elena Csernok2, Udo Schumacher1 and Sebastian Ullrich1, 1University Medical Center Hamburg, Hamburg, Germany, 2University of Lübeck, Bad Bramstedt, Germany, 3 Christian-Albrechts-University Kiel, Kiel, Germany 2378. CT Imaging Characteristics of the Sino-Nasal Tract and Orbits in granulomatosis with Polyangiitis (Wegener’s) and Churg–Strauss Syndrome. A Cross-Sectional Review. Khaldoun Chaabo1, Shirish Sangle2, Dhiren Shah3, Hema Verma4 and David P. D’Cruz2, 1St Thomas’ Hospital, London, SE1 7EH, United Kingdom, 2Louise Coote Lupus Unit, St Thomas’ Hospital, London, United Kingdom, 3Guy’s and St Thomas’ Hospitals NHS Foundation Trust, London,SE1 9RT, United Kingdom, 4Guy’s and St Thomas’ Hospitals NHS Foundation Trust, London, SE1 9RT, United Kingdom 2379. Churg–Strauss Syndrome: Analysis of 58 patients’ Relapses and Outcomes. Maxime Samson1, Camillo Ribi2, Pascal Cohen3, Marc Stern4, Christian Pagnoux5, Jean-Francois Cordier6, Luc Mouthon7 and Loic Guillevin8, 1Hôpital Cochin, University Paris Descartes, Paris, France, 2Hôpital Universitaire Cantonal de Genève, Geneve, Switzerland, 3 Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, 4Hôpital Foch, Suresnes, France, 5University of Toronto, Toronto, ON, 6 Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, 7Hopital Cochim, Paris, France, 8Cochin University Hospital, Paris, France 2380. IgG4 Immune Response in Churg-Strauss Syndrome. Augusto Vaglio1, Johanna Strehl2, Bernhard Manger2, Federica Maritati1, Federico Alberici1, Christian Beyer2, Juergen Rech2, Jorg HW Distler2, Georg Schett2, Renato Sinico3 and Jochen Zwerina2, 1University of Parma, Parma, Italy, 2University of Erlangen-Nuremberg, Erlangen, Germany, 3Ospedale San Carlo Borromeo, Milano, Italy 2381. Airway Inflammation and Systemic Inflammation During Churg-Strauss Syndrome Natural Course: A Multidisciplinary Monocentric Crosse-Sectional Study. Chiara Baldini1, Sara Grossi1, Manuela Latorre2, Pasquale Pepe1, Valeria Giorgerini1, Alessandra Della Rossa1, Federico Dente2, Silvia Cianchetti2, Pierluigi Paggiaro2 and Stefano Bombardieri1, 1Rheumatology Unit, Pisa, Italy, 2Pneumology Unit, Italy 2382. Cell Clonality in Churg-Strauss Syndrome: What Pathogenetic Role? Chiara Baldini1, Sara Galimberti2, Pasquale Pepe1, Sara Grossi1, Elisabetta Sordi2, Valeria

300

2011 Program Book

Giorgerini1, Alessandra Della Rossa1 and Stefano Bombardieri1, 1Rheumatology Unit, Pisa, Italy, 2Hematology Unit, Pisa, Italy 2383. Cocaine and ANCA Associated Vasculitis-Like Syndromes: A Single Centre Study. Khaldoun Chaabo1, Shirish Sangle2 and David P. D’Cruz3, 1St Thomas’ Hospital, London, SE1 7EH, United Kingdom, 2Louise Coote Lupus Unit, St Thomas’ Hospital, London, United Kingdom, 3St Thomas’ Hospital, London, United Kingdom 2384. Rituximab Therapy for Systemic Vasculitis Associated with Rheumatoid Arthritis in the AutoImmunity and Rituximab Registry. Xavier Puéchal1, Jacques-Eric Gottenberg2, Jean-Marie Berthelot3, Laure Gossec4, Olivier Meyer5, Jacques Morel6, Daniel Wendling7, Michel De Bandt8, Eric Houvenagel9, Bénédicte Jamard10, Thierry Lequerré11, Gauthier Morel12, Pascal Richette13, Jérémie Sellam14, Loic Guillevin4 and Xavier Mariette for the AutoImmunity and Rituximab Registry15, 1Center for Rare Systemic Autoimmune Diseases, Le Mans General Hospital, Le Mans, France, 2Strasbourg University Hospital, Strasbourg, France, 3 Nantes University Hospital, Nantes, France, 4Cochin University Hospital, Paris, France, 5Bichat University Hospital, Paris, France, 6Montpellier University Hospital, Montpellier, France, 7Minjoz University Hospital, Besancon, France, 8R. Ballanger Hospital, Aulnay Sous Bois, France, 9St Philibert Hospital, Lomme, France, 10Toulouse University Hospital, Toulouse, France, 11Rouen University Hospital, Rouen, France, 12Valenciennes Hospital, Valenciennes, France, 13Lariboisière University Hospital, Paris, France, 14 St Antoine University Hospital, Paris, France, 15Bicêtre University Hospital, Le Kremlin Bicetre, France 2385. Assessment of Disease Activity in Behcet Disease: Comparison of Behcet’s Disease Current Activity Form (bdcaf), Behcet’s Syndrome Activity Score (bsas) and Routine Assessment of Patient Index Data (rapid) 3 Scores. Sedat Yilmaz1, Ismail Simsek1, Muhammet Cinar1, Hakan Erdem1, Osman Kose1, Yusuf Yazici2 and Salih Pay3, 1Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey, 2Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 3GATA, Ankara, Turkey 2386. The Impact of Positive Pathergy Test on the Performance of Diagnostic Criteria in Behcet’s Disease. Fereydoun Davatchi, Bahar Sadeghi Abdollahi, Cheyda Chams-Davatchi, Farhad Shahram, Zahra Ghodsi, Tahereh Faezi, Abdolhadi Nadji, Massoomeh Akhlaghi and Roghieh Larimi, Shariati HospitalTehran Univ, Tehran, Iran 2387. A Mucocutaneous Activity Index for Behcet’s Disease. Gonca Mumcu1, Nevsun Inanc2, Haner Direskeneli2 and Tülin Ergun3, 1Marmara University,Faculty of Health Sciences, Department of Health Informatics and Technologies, Istanbul, Turkey, 2Marmara University School of Medicine, Istanbul, Turkey, 3Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey

ACR/ARHP Poster Session C 2388. Gender-Specific Differences in Adamantiades-Behçet’s Disease Presentation and Their Relationship with HLA-B5: An Analysis of 731 Subjects From the German Registry for Adamantiades-Behçet’s Disease. Nikolaos G. Bonitsis1, Liem Binh Luong Nguyen2, Nestor Papoutsis1, Andreas Altenburg1, Ina Kötter3, Alfred Mahr2 and Christos C. Zouboulis1, 1 Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany, 2 Department of Internal Medicine, Hospital Saint-Louis, Paris, France, 3Department of Internal Medicine II, Rheumatology Division, University Hospital Tübingen, Tübingen, Germany 2389. Exploration of Male Gender in Heterogeneity of Association Between HLA-B51/B5 and Behçet’s Disease Using Mixture Models. Michael P. LaValley1, Hailong Cheng2, Mathilde de Menthon3 and Alfred Mahr3, 1Boston University School of Public Health, Boston, MA, 2Sunovion Pharmaceuticals Inc., Marlborough, MA, 3Hospital SaintLouis, Paris, France 2390. CC Chemokine RECEPTOR 5 POLYMORPHISM In BEHÇET’S DISEASE. Fabiola Atzeni1, Luigi Boiardi2, Bruno Casali3, Enrico Farnetti3, Piercarlo Sarzi-Puttini1, Nicolo Pipitone2, Ignazio Olivieri4, Fabrizio Cantini5, Fabrizio Salvi6, Renato La Corte7, Giovanni Triolo8, Davide Filippini9, Giuseppe Paolazzi10 and Carlo Salvarani2, 1Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, 2Arcispedale S Maria Nuova, Reggio Emilia, Italy, 3Molecular Biology Laboratory, Arcispedale S. Maria Nuova,, Reggio Emilia, Italy, 4 Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, 5Stabilimento Ospedaliero Misericordia, Prato, Italy, 6Dept. of Neurological Sciences, Ospedale Bellaria,, Bologna, Italy, 7Chair of Rheumatology, University of Ferrara,, Ferrara, Italy, 8Rheumatology Unit, University of Palermo, Palermo, Italy, 9Rheumatology Unit, Ospedale Niguarda,, Milan, Italy, 10Ospedale Santa Chiara, Trento 2391. Genome-Wide Expression Profiling of CD14+ Monocytes in Behcet’s Disease: An Upregulated TGF-b Signaling and N-Methyltransferase Activity. M. Dozmorov1, F. Ozdemir2, V. Yilmaz3, E. Eksioglu-Demiralp2, J. Wren1, G. Saruhan-Direskeneli3, A. Sawalha1 and H. Direskeneli4, 1 Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Marmara University, School of Medicine, Department of Immunology, Istanbul, Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Department of Physiology, Istanbul, Turkey, 4 Marmara University, School of Medicine, Department of Rheumatology, Istanbul, Turkey 2392. Parvovirus B19 in Behçet’s Disease. Zahra Habibagahi, Mojtaba Habibagahi and Said Mostafa Said Mardani, Shiraz University of Medical Sciences, Shiraz, Iran 2393. Management and Prognosis of Non- Pulmonary Large Arterial Disease in Behcet’s Syndrome: A Reappraisal of 25 Patients From a Single Center. Hasan Tuzun, Emire Seyahi,

Caner Arslan, Vedat Hamuryudan, Kazim Besirli and Hasan Yazici, University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey 2394. Long-Term Outcome of Arterial Lesions in Behçet’s Disease: A Series of 101 Patients. David Saadoun1, B. Asli2, Bertrand Wechsler2, Habib Houman3, Guillaume Geri2, Jean-Charles Piette2, Zahir Amoura2, Mathieu Resche Rigon1 and Patrice Cacoub2, 1Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier PitiéSalpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2CHU Pitié-Salpêtrière, Paris, France, 3 department of internal medicine hôpital la rabta Tunis Tunisie, France 2395. Immunosuppressants Reduce Venous Thrombosis Relapses in Behçet‘s Disease. anne Claire Desbois1, Bertrand Wechsler2, Jean-Charles Piette3, Du Boutin1, Zahir Amoura4, Fabien Koskas1, Patrice Cacoub4 and David Saadoun5, 1 Department of Internal Medicine and 2Laboratory I3 « Immunology, Immunopathology, Immunotherapy », UMR CNRS 7211, INSERM U959, Groupe Hospitalier PitiéSalpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2Hopital de la Pitie, Paris, France, 3 Paris, 4CHU Pitié-Salpêtrière, Paris, France, 5Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France 2396. Difference of Manifestations and Treatment Among Behcet’s Syndrome Patients in the United States and Japan. Yuri Ohara1, Mitsumasa Kishimoto1, Tatsuo Kobayashi2, Christopher Swearingen3, M.T. Filopoulos4, Yasuharu Tokuda5, Hideto Oshikawa2, Kazuki Yoshida2, Masako Utsunomiya2, Makiko Kimura2, Masato Okada1, Kazuo Matsui2 and Yusuf Yazici6, 1St. Luke’s International Hospital, Tokyo, Japan, 2Kameda Medical Center, Kamogawa City, Japan, 3University of Arkansas for Medical Sciences, Little Rock, AR, 4Hospital for Joint Diseases, New York, NY, 5University of Tsukuba, Ibaraki, Japan, 6Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY 2397. Neuro-Behçet´s Disease in Brazil: Higher Incidence in Females and Atypical Manifestations. Livia A. Dutra1, Celio R. Gonçalves2, José L. Pedroso1, Pedro Braga-Neto1, Alberto A. Gabbai1, Orlando G. P. Barsottini1 and Alexandre W. S. de Souza1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Universidade de São Paulo, São Paulo, Brazil 2398. Some Manifestations Disappear Earlier Than Others in Behcet’s Syndrome. F. Sevgi Sacli1, Emire Seyahi2, Serdal Ugurlu3, Yilmaz Ozyazgan2, Cem Mat2 and Hasan Yazici2, 1 Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey, 3Rheumatology, Istanbul, Turkey 2011 Program Book

301

ACR/ARHP Poster Session C 2399. Spectrum of Cardiac Lesions in Behçet’s Disease. Guillaume Geri1, Bertrand Wechsler1, Du Le Thi Huong1, Richard Isnard2, Jean-Charles Piette1, Zahir Amoura1, Mathieu Resche Rigon3, Patrice Cacoub1 and David Saadoun3, 1CHU Pitié-Salpêtrière, Paris, France, 2Department of Cardiology, CHU Pitié-Salpêtrière, 47-83 Boulevard de l’hôpital, 75651 Paris Cedex 13, Paris, France, Paris, France, 3Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France 2400. Is It Possible to Maintain Remission After Suspension of Infliximab for Sight- and Life-Threatening Involvement in Behcet’s Disease? A Proposal of a Tapering Schedule. Rosaria Talarico, Anna d’Ascanio, Laura Bazzichi and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy 2401. Neurological Involvement in Behcet’s Disease: A Worrying Cause of Morbidity and Mortality. Rosaria Talarico, Claudia Ferrari, Anna d’Ascanio and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy 2402. Consensus Statements for Management for Intestinal Behcet’s Disease in Japan. Mitsuhiro Takeno1, Reikou Watanabe1, Hirotoshi Kikuchi2, Masakazu Nagahori3, Kazuyoshi Saito4, Nagamu Inoue5, Michiko Kurosawa6, Yoshiaki Ishigatsubo1 and Behcet’s Disease Reserch Commitee of Japan7, 1Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Teikyo University, Tokyo, Japan, 3Tokyo Medicai Dental University, Tokyo, Japan, 4University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 5Keio University, Tokyo, Japan, 6 Juntendo University, Tokyo, Japan, 7Yokohama, Japan

ARHP Pediatric 2403. Measurement of Pain Perception in Children and Adolescents with Musculoskeletal Pain. Melissa Fraga1, Claudio A. Len1, Rafael Azevedo1, Marcelo I. Yoguim1, Maria Teresa Terreri2 and Maria Odete E. Hilário1, 1Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, 2 Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil

ARHP Psychology/Social Sciences 2404. Development of a Quality Patient-Health Care Provider Communication Scale Based On Patients’ Perspective. Elizabeth G. Salt, Leslie J. Crofford, Jamie L. Studts, Robert W. Lightfoot and Lynne Hall, University of Kentucky, Lexington, KY 2405. “It’s Totally Turned Around the Way I Think”: The Patient Perspective of Cognitive Behavioural Therapy for Fatigue In Rheumatoid Arthritis. Emma Dures1, Karen Kitchen2, Celia Almeida1, Nicholas Ambler3, Alena Cliss1, Alison Hammond4, Bev Knops3, Marianne Morris1, Annette Swinkels1 and Sarah Hewlett1, 1University of the West of England, Bristol, United

302

2011 Program Book

Kingdom, 2University of Bristol, Bristol, United Kingdom, 3 Frenchay Hospital, Bristol, United Kingdom, 4University of Salford, Salford, United Kingdom 2406. Factors Affecting Role Strain In Patients with Newly Diagnosed Rheumatoid Arthritis. Mary-Beth Coty1, John A. Myers1, Elizabeth G. Salt2 and Said K. Abusalem1, 1University of Louisville, Louisville, KY, 2University of Kentucky, Lexington, KY 2407. Integrating An Acceptance-Oriented Cognitive-Behavioural Therapy within Multidisciplinary Rehabilitation for Highly Distressed Patients with Arthritis: A Proof-of-Concept study. Johanna E. Vriezekolk1, Rinie Geenen2, Agnes M.M. Eijsbouts1, Frank H.J. van den Hoogen1, Hanneke Beenackers1, Helma Slot1, Wim G.J.M. van Lankveld1 and Cornelia H.M. van den Ende1, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Utrecht University, Utrecht, Netherlands 2408. Family Stress in Childhood of Patients with Fibromyalgia. Robert S. Katz1, Sharon M. Ferbert2, Ben J. Small3 and Susan Shott1, 1Rush University Medical Center, Chicago, IL, 2 Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, 3Rush University Medical School, Chicago, IL 2409. Childhood Social Ostracism in Fibromyalgia. Afton L. Hassett1, Sharon M. Ferbert2, Susan Shott3 and Robert S. Katz3, 1University of Michigan Medical School, Ann Arbor, MI, 2Advocates for Funding Fibromyalgia Treatment, Education and Research (AFFTER), Libertyville, IL, 3Rush University Medical Center, Chicago, IL 2410. The Role of Pain and Depression in Self-Reported Fatigue/ Energy in Systemic Lupus Erythematosus. Feridey N. Carr1, Perry M. Nicassio2, Dilrukshie Cooray3, Ioana Moldovan4, Emmanuel P. Katsaros5, Karina D. Torralba6, Shuntaro Shinada7, Meenakshi Jolly8, Mariko L. Ishimori9, Alisa L. Wilson9, Daniel J. Wallace10 and Michael H. Weisman11, 1 California School of Professional Psychology at Alliant International University - Los Angeles, Alhambra, CA, 2UCLA, Los Angeles, CA, 3Harbor UCLA Medical Center, Torrance, CA, 4Loma Linda Univ Medical Center, Loma Linda, CA, 5 Loma Linda Univ, Loma Linda, CA, 6University of Southern California-Los Angeles County Medical Center, Los Angeles, CA, 7USC Keck School of Medicine, Los Angeles, CA, 8Rush University Medical Center, Chicago, IL, 9Cedars Sinai Medical Ctr, Los Angeles, CA, 10Cedars-Sinai/UCLA, Los Angeles, CA, 11 Cedars Sinai Med Ctr, Los Angeles, CA 2411. Piloting a Patient Health Questionnaire Depression Screening Tool in a Hospital-Based Multi-Disciplinary Lupus Clinic. Su Jin Kim1, Pretima Persad2, Monica C. Richey2, Mavis Seehaus1, Roberta Horton1, Kyriakos A. Kirou2, Doruk Erkan2 and John Barnhill3, 1Dept. of Social Work Programs - Hospital for Special Surgery, New York, NY, 2Mary Kirkland Center for Lupus Care - Hospital for Special Surgery, New York, NY, 3 Division of Psychiatry - Hospital for Special Surgery, New York, NY

ACR/ARHP Poster Session C 2412. The Challenges of Being a Father with Systemic Sclerosis. Janet L. Poole1, Donna Haygood2 and Cindy F. Mendelson1, 1 University of New Mexico, Albuquerque, NM, 2Bernalillo Public Schools, Bernalillo, NM

ARHP Health Services Research 2413. Development of a Care Pathway for Inflammatory Arthritis. Shona P. Lee1 and David Kane2, 1Adelaide and Meath Hospital Inc National Children’s Hospital, Dublin 24, Ireland, 2Adelaide, Meath hospital Dublin (incorporating the National Children’s hospital), Dublin 24, Ireland 2414. Online Access for Patients to Their Electronic Medical Record: Advantages, Drawbacks and Preconditions According to Care Providers. Rosalie van der Vaart1, Constance H.C. Drossaert1, Erik Taal1 and Mart AF van de Laar2, 1University of Twente, Enschede, Netherlands, 2 Medisch Spectrum Twente & Twente University, Enschede, Netherlands 2415. Anti-Tumor Necrosis Factor Dose Escalation Among Biologic Naïve Rheumatoid Arthritis Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation. Machaon Bonafede1, Kathy M. Fox2, Kathleen L. Wilson1 and Shravanthi R. Gandra3, 1Thomson Reuters Healthcare, Cambridge, MA, 2Strategic Healthcare Solutions, LLC, Monkton, MD, 3Amgen Inc, Thousand Oaks, CA

2420. mtDNA Haplogroups and Serum Levels of SOD2, Catalase and Gelsolin In the Osteoarthritis Disease. Ignacio RegoPérez1, Mercedes Fernández-Moreno1, Sonia Pértega2, Carlos Fernández-López1, Natividad Oreiro1 and Francisco J. Blanco1, 1INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain, 2Epidemiology Unit. INIBIC-Complejo Hosp. Univ. A Coruña, La Coruña, Spain 2421. The Hospital Anxiety and Depression Scale (HADS) Positive Affect Subscale: A Preliminary Evaluation of Its Utility for the Assessment of Resilience in Fibromyalgia. Afton L. Hassett1, Chad M. Brummett2, Jenna Goesling2, Kevin Rakovitis2, Daniel J. Clauw3 and David A. Williams4, 1 University of Michigan Medical School, Ann Arbor, MI, 2 University of Michigan Health System, Ann Arbor, MI, 3 University of Michigan, Ann Arbor, MI, 4Univ of MI Hlth System-Lobby M, Ann Arbor, MI 2422. A Bayesian Mixed Treatment Comparison Demonstrates Differences Between Anti-Tumour Necrosis Factor Agents in Rheumatoid Arthritis. Susanne Schmitz1, Roisin C. Adams2, Michael Barry2, Cathal Walsh3 and Oliver M. FitzGerald4, 1Department of Statistics,Trinity College Dublin, Dublin, Ireland, 2National Centre for Pharmacoeconomics, Dublin, Ireland, 3Trinity College Dublin and National Centre for Pharmacoeconomics, Dublin, Ireland, 4St. Vincent’s University Hospital, Dublin, Ireland

2416. Comparing Costs of Tumor Necrosis Factor Blockers Per Treated Patient for Psoriatic Arthritis Using Real-World Data in US Managed Care. Vernon F. Schabert1, Shravanthi R. Gandra2, Crystal Watson2, Seth Goodman1, Kathy M. Fox3, Jason Yeaw1, Sandra Milev4 and David J. Harrison2, 1IMS Consulting Group, Alexandria, VA, 2Amgen Inc, Thousand Oaks, CA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, 4IMS Brogan, Ottawa, ON

2423. Development of Quality Indicators for Physical Therapy in Hip and Knee Osteoarthritis. Wilfred FH Peter1, Ph van der Wees2, J. Verhoef3, Z. de Jong1, L. Vos1, Wkha Hilberdink4 and Tpm VlietVlieland1, 1Leids University Medical Center, Leiden, Netherlands, 2The Royal Dutch Society of Physical Therapy (KNGF) Amsersfoort, CAPHRI Maastricht University, IQ Healthcare, Nijmegen, Netherlands, 3Hogeschool Leiden, Leiden, Netherlands, 4Paramedical Center for Rheumatology and Rehabilitation, Groningen, Netherlands

ARHP Research Methodology

2424. Patient Preference of Disability in Rheumatoid Arthritis. Li Alemo Munters1, Nina Brodin2, Elin Löfberg2, Sara Stråt2 and Helene Alexanderson3, 1Rheumatology Unit, , Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 2Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden, 3Karolinska Institutet, Stockholm, Sweden

2417. Measuring Fear of Progression in Patients with Systemic Sclerosis. Linda Kwakkenbos1, Frank H.J. van den Hoogen1, José Custers2, Judith Prins3, Madelon C. Vonk4, Wim G.J.M. van Lankveld1, Eni S. Becker2 and Cornelia H.M. van den Ende1, 1Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, Netherlands, 3Department of Medical Psychology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, 4Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 2418. Construct Validity of Three PROMIS Instruments in An Arthritis Sample. Kirsten A. Nyrop, Bryce B. Reeve, Robert F. DeVellis, Darren Dewalt, Rebecca J. Cleveland and Leigh F. Callahan, University of North Carolina at Chapel Hill, Chapel Hill, NC 2419. Validity of SenseWear Armband to Estimate Energy Expenditure During Activities of Daily Living In Rheumatoid Arthritis. Marie Tierney1, Alexander D. Fraser2 and Norelee M. Kennedy1, 1University of Limerick, Limerick, Ireland, 2Mid Western Regional Hospital, Limerick, Ireland

2425. Sensitivity to Change of the Bristol Rheumatoid Arthritis Fatigue Scales. Sarah Hewlett1, Emma Dures1, John R. Kirwan2, Fiona Cramp1, Joanna Nicklin3, Celia Almeida1, Kathryn Mitchell3 and Rosemary Greenwood2, 1University of the West of England, Bristol, United Kingdom, 2University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, 3University of Bristol, Bristol, United Kingdom 2426. Human Amniotic Membrane Stem Cells as an Alternative Cellular Therapy for Articular Cartilage Repair. Emma Muiños1, Silvia Diaz-Prado2, Tamara Hermida-Gómez1, Esther Rendal1, Isaac M. Fuentes2, Francisco J. De Toro1 and Francisco J. Blanco1, 1INIBIC-CHUAC, La Coruña, Spain, 2 INIBIC-CHUAC/University of A Coruña, La Coruña, Spain

2011 Program Book

303

REF Industry Roundtable-supported Symposia Sunday, November 6, 2011 The events listed below are non-CME Programs wholly sponsored and supported by the commercial entities listed. By holding the Programs, the commercial entities have represented that the Programs have been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entities are to observe all guidelines established by federal and state regulatory agencies regarding non-CME educational or promotional presentations throughout the duration of the Program. The content and views expressed during the Program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the Program nor the products discussed and reviewed during the Program.

8:50 - 9:30 pm Panel Discussion and Questions Ian Bruce, MD, FRCP, The University of Manchester, Manchester, UK Peter Lipsky, MD, University of Texas Southwestern Medical Center at Dallas, Dallas, TX (retired) Ronald van Vollenhoven, MD, PhD, The Karolinska University Hospital, Stockholm, Sweden Joan Merrill, MD, Oklahoma Medical Research Foundation, Oklahoma City, OK

6:30 - 9:30 pm

Non-CME Symposium

Hilton Chicago, North International Ballroom Spondyloarthropathies: PsA and AS Challenge

Developed and offered by Janssen Biotech, Inc.

6:30 - 9:30 pm

Non-CME Symposium

Hilton Chicago, Grand Ballroom

Third-Party Organization: Executive Meeting Management

6:30 - 7:00 pm Dinner

Learning Objectives Upon completion of this session, participants should be able to: • discuss the pathogenesis of PsA and AS • identify diagnosis and management strategies for PsA and AS • understand considerations regarding the safety and efficacy of a biologic agent in PsA and AS

7:00 - 7:10 pm Welcome and Introductions

6:30 - 7:00 pm Registration and Dinner

7:10 - 8:50 pm An Overview of BENLYSTA

7:00 - 7:10 pm Welcome and Introductions Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA Atul Deodhar, MD, MRCP, Oregon Health and Science University, Portland, OR

An Overview of BENLYSTA® (belimumab) Developed and offered by Human Genome Sciences, Inc.

304

2011 Program Book

REF Industry Roundtable-supported Symposia 7:10 - 8:20 pm Spondyloarthropathies: PsA and AS Challenge (Interactive Discussion) Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA Atul Deodhar, MD, MRCP, Oregon Health and Science University, Portland, OR 8:20 - 8:30 pm Question and Answer Session Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA Atul Deodhar, MD, MRCP, Oregon Health and Science University, Portland, OR

6:30 - 9:30 pm

Non-CME Symposium

Hilton Chicago, Continental Ballroom

Rheumatoid Arthritis: Predictability in an Unpredictable World Developed and offered by UCB, Inc. Third-Party Organization: Ethos Health Communications Learning Objectives Upon completion of this session, participants should be able to: • define and discuss the unpredictable environment for the US rheumatologist, including the complexities of healthcare reform, clinical environments, disease paradigm, treatment agents and healthcare setting • examine the global impact of healthcare reform and its impact on daily clinical practice • discuss the clinical maintenance of patients being treated for moderate to severe rheumatoid arthritis, including predictability of outcomes and flares; to examine the role of the OMERACT research agenda in providing validated data to aid clinical decisions • explore the ability to predict long-term outcomes based on early responsiveness to therapy • describe the development of clinical tools and techniques for predicting response in patients, including biomarkers and epigenetics 6:30 - 7:00 pm Registration and Dinner 7:00 - 7:05 pm Welcome and Introduction Edward Keystone, MD, FRCPC, University of Toronto, Toronto, Ontario, Canada 7:05 - 7:25 pm Predictability and Unpredictability of US Healthcare Reform in Patient Care Michael Schiff, MD, University of Colorado School of Medicine, Denver, CO

8:25 - 9:00 pm Panel Discussion Question and Answer Session Faculty Panel 9:00 pm Conclusion and Closing Remarks Edward Keystone, MD, FRCPC, University of Toronto, Toronto, Ontario, Canada

6:30 - 9:30 pm

Hilton Chicago, Waldorf Room

Prolia® Update: Expert Discussion of Clinical Data Relevant to the Treatment of Postmenopausal Osteoporosis in Women at High-risk for Fracture Developed and offered by Amgen, Inc. Learning Objectives Upon completion of this session, participants should be able to: • understand bone biology and the role RANK ligand plays in bone remodeling • understand how Prolia’s novel MOA impacts RANK ligand and bone resorption and become familiar with key clinical data • learn about new safety and efficacy data that has been recently published 6:30 - 7:00 pm Registration and Dinner 7:00 - 7:15 pm Introduction 7:15 - 7:45 pm Bone Biology and RANK Ligand David W. Dempster, PhD, Columbia University, New York, NY 7:45 - 8:15 pm Prolia® MOA and Clinical Data Nancy E. Lane, MD, University of California at Davis Medical Center, Sacramento, CA 8:15 - 8:45 pm Discussion of Recently Published Data John P. Bilezikian, MD, Columbia University, New York, NY 8:45 - 9:15 pm Panel Discussion Question and Answer All Faculty

7:25 - 7:45 pm Predictability in Clinical Practice Clifton Bingham, MD, Johns Hopkins University, Baltimore, MD 7:45 - 8:05 pm Early Response as a Predictor of Outcomes: Recent Clinical Evidence Edward Keystone, MD, FRCPC, University of Toronto, Toronto, Ontario, Canada 8:05 - 8:25 pm Rheumatoid Arthritis: Understanding the Present to Better Know the Future? Iain McInnes, FRCP, PhD, FRSE, University of Glasgow, Glasgow, Scotland

Non-CME Symposium

Tuesday, November 8, 2011

6:30 - 9:30 pm

CME-Accredited Symposium

For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit.

Palmer House Hilton, Red Lacquer Room

Enhancing Outcomes in Chronic Pain Associated with Osteoarthritis: Faculty Debate and Clinical Case Discussions Sponsored by Creative Educational Concepts, Inc. Supported by an educational grant from Lilly USA, LLC 2011 Program Book

305

REF Industry Roundtable-supported Symposia Physician (ACCME) Accreditation Statement Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement CEC designates this live activity for up to 2.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Learning Objectives Upon completion of this session, participants should be able to: • identify the social and economic burden of pain associated with osteoarthritis • identify current barriers to successful management of pain associated with osteoarthritis • using a debate format, evaluate safety and efficacy data for the use of traditional and new pharmacologic and nonpharmacologic treatment options for osteoarthritis pain • using a case-based approach, formulate appropriate treatment plans for patients with osteoarthritis pain in real-life clinical scenarios 6:30 - 7:00 pm Registration and Dinner 7:00 - 7:05 pm Welcome and Introductions Marc C. Hochberg, MD, MPH, University of Maryland, Baltimore, MD 7:05 - 7:25 pm Update on Osteoarthritis Chronic Pain I: Recent Changes to Definition, Paradigm, and Mortality Marc C. Hochberg, MD, MPH, University of Maryland, Baltimore, MD 7:25 - 7:45 pm Update on Osteoarthritis Chronic Pain II: Advances in Basic Science of OA Pain Thomas J. Schnitzer, MD, PhD, Northwestern University, Chicago, IL 7:45 - 8:45 pm Evidence-Based Strategies to Enhance Outcomes: A Case-Based Approach to Effective and Optimal OA Treatment Faculty Panel Moderated by Roy D. Altman, MD, University of California, Los Angeles, Los Angeles, CA 8:45 - 9:00 pm Panel Discussion Question and Answer Session All Faculty

Wednesday, November 9, 2011

1:00 - 4:00 pm



McCormick Place West, Room W474a

Osteoarthritis Updates: Pathophysiology and Pharmacologic Management in 2011 Jointly sponsored by Medical Education Resources and Consensus Medical Communications Supported by an educational grant from Bioiberica

306

2011 Program Book

Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Consensus Medical Communications (CMC). MER is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement MER designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Learning Objectives Upon completion of this session, participants should be able to: • discuss the pathologic effects of osteoarthritis in the synovium, cartilage and bone • describe the mechanisms of action of chondroitin sulfate and its effects on the osteoarthritic joint • recognize how the addition of glucosamine to chondroitin sulfate enhances the anti-inflammatory effects of the single components • describe the treatments available for patients with moderate-tosevere knee pain 1:00 - 1:30 pm Registration and Lunch 1:30 - 1:35 pm Welcome and Introduction Marc C. Hochberg, MD, MPH (Program Chair), University of Maryland School of Medicine, Baltimore, MA 1:35 - 1:50 pm The Pathophysiology of Osteoarthritis Virginia Byers Kraus, MD, PhD, Duke University Medical Center, Durham, NC 1:50 - 2:05 pm Mechanisms of Action of Chondroitin Sulfate in the Three Main Joint Tissues Johanne Martel-Pelletier, MD (Program Co-Chair), University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada 2:05 - 2:25 pm Chondroitin Sulfate: Review of Therapeutic Efficacy Jean-Pierre Pelletier, MD, (Program Co-Chair) University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada 2:25 - 2:40 pm Synergistic Effect of the Chondroitin Sulfate and Glucosamine Combination Patrick du Souich, MD, PhD, University of Montreal, Montreal, Quebec, Canada 2:40 - 2:55 pm Treatment of Knee Osteoarthritis in Patients with Moderate-to-Severe Pain Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MA 2:55 - 3:00 pm Question and Answer Session

Industry-supported POST-CONFERENCE Symposia 1:00 - 4:00 pm



McCormick Place West, Room W375a

Pain Management in the Rheumatology Setting: Individualized Multimodal Therapies for Improved Patient Function Jointly sponsored by Asante Communications, LLC, Albert Einstein College of Medicine, and Montefiore Medical Center

2:15 - 2:30 pm Post-activity Questionnaire and Activity Evaluation

1:00 - 4:00 pm



McCormick Place West, Room W475ab

Aggressively Pursuing Remission in RA: Where Will Emerging Therapies Fit into the Treatment Armamentarium?

Supported by an educational grant from Ortho-McNeil Janssen Scientific Affairs, LLC

Sponsored by North American Center for CME (NACCME)

Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine and Montefiore Medical Center, and Asante Communications. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Supported by an educational grant from MedImmune, LLC

Credit Designation Statement Albert Einstein College of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Learning Objectives Upon completion of this session, participants should be able to: • describe the biopsychosocial experience of pain in patients with rheumatic diseases, and the peripheral and central sensitization disease mechanisms that shape its intensity, severity, chronicity, and adverse functional consequences • improve the multidimensional assessment and longitudinal examination of patients with low back pain, pain associated with osteoarthritis, rheumatoid arthritis, and other inflammatory and mixed pain syndromes • individualize therapy with pharmacologic regimens that employ complementary mechanisms of action along the neuraxis • evaluate the clinical profiles of current and emerging pharmacologic agents based in part on pharmacokinetic and pharmacodynamic profiles, analgesic effectiveness, treatment-related side effects, and risk of physical dependence and nonmedical use • collaborate with an interdisciplinary health care team to integrate nonpharmacologic therapy tailored to the biopsychosocial needs of patients with chronic pain 1:00 - 1:15 pm Pre-activity Questionnaire 1:15 - 1:30 pm Poster Gallery Biopsychosocial Construct of Chronic Pain: Disease Mechanisms, Multidimensional Assessment and Multimodal Treatment Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 1:30 - 2:00 pm Meet the Professors Case Based Best Practices in Chronic Pain Management Charles Argoff, MD, Albany Medical Center, Albany, NY Ronald Rapoport, MD, Charlton Memorial Hospital, Fall River, MA 2:00 - 2:15 pm Case-Based Decision Tree Interdisciplinary Management of Chronic Low Back Pain Douglas Schottenstein, MD, New York Presbyterian, New York, NY Chaim Putterman, MD, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY

Physician (ACCME) Accreditation Statement North American Center for Continuing Medical Education, LLC (NACCME), is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement NACCME designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Learning Objectives Upon completion of this session, participants should be able to: • outline changes to RA disease classification and remission criteria to develop appropriate therapeutic strategies for the aggressive pursuit of remission and management of comorbidities • interpret emerging data on the controllable factors that impact patient adherence to therapy • describe current data regarding safety issues associated with biologic therapies, such as risks of serious infections and side effects • compare and contrast the safety, efficacy, and clinical profiles of newer and emerging options for RA management • overcome hesitation to switch biologic therapy in patients receiving an inadequate response 1:00 - 1:30 pm Registration and Lunch 1:30 - 2:00 pm Welcome and Introductions The New RA Disease Classification and Remission Criteria: The Aggressive Pursuit of Remission Daniel Aletaha, MD, Medical University of Vienna, Vienna, Austria 2:00 - 2:30 pm Safety Issues with Biologic Therapies: Optimizing Adherence Paul Emery, MD, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK 2:30 - 3:10 pm An Update on Emerging Treatments in RA Management Josef S. Smolen, MD, Vienna General Hospital, University of Vienna Center for Rheumatic Diseases, Lainz Hospital Vienna, Vienna, Austria 3:10 - 3:30 pm Question and Answer Session All Faculty

2011 Program Book

307

Industry-supported POST-CONFERENCE Symposia 1:00 - 4:00 pm



McCormick Place West, Room W471ab

Advances in the Management of Gout: Issues and Answers Jointly sponsored by the Interstate Postgraduate Medical Association and MedEdRules, LLC. Supported by an educational grant from Savient Pharmaceuticals, Inc. Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Interstate Postgraduate Medical Association (IPMA) and MedEdRules, LLC (MER). IPMA is accredited by the ACCME to provide continuing medical education for physicians. The joint sponsor is MER. Nurses IPMA is approved by the California Board of Registered Nursing, Provider number 6971, for 2.4 contact hours. Each person should retain this certificate for four years after the course has been completed. RNs outside California must verify with their licensing agency for approval of this course. Credit Designation Statement Interstate Postgraduate Medical Association designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Learning Objectives Upon completion of this session, participants should be able to: • review the underlying mechanisms of uric acid production and crystal deposition disease progression • identify the common comorbidities associated in patients with advanced gout and barriers to achieving successful management in those with monosodium urate (MSU) crystal deposition • assess current treatment options, including their safety and efficacy, in patients with chronic and advanced disease • develop and apply a practical, comprehensive and individualized management strategy for patients with advanced and refractory crystal deposition, taking into consideration new and emerging therapies 1:00 - 1:30 pm Registration and Refreshments 1:30 - 1:35 pm Welcome and Introductions Leonard H. Calabrese, DO, Cleveland Clinic, Cleveland, OH 1:35 - 2:05 pm Identifying Impediments to the Successful Treatment of Gout N. Lawrence Edwards, MD, FACP, FACR, University of Florida, Gainesville, FL

308

2011 Program Book

2:05 - 2:35 pm Managing Gout in the Presence of Multiple Co-Morbidities Michael A. Becker, MD, The University of Chicago School of Medicine, Chicago, IL 2:35 - 3:10 pm Advances in the Treatment of Crystal Deposition Disease John Sundy, MD, PhD, Duke University, Durham, NC 3:10 - 3:30 pm Summary Followed by Questions and Answers All Faculty

ACR REF Industry Roundtable The Industry Roundtable brings together the ACR Research and

Education Foundation and pharmaceutical industry leaders in a collaboration to provide training, research and educational opportunities in rheumatology while serving as a forum for dialogue between industry and the REF. Through Industry Roundtable support, the REF continues to increase funding for research and training. The REF would like to thank these organizations for their multi-year commitment to the REF and its programs. Together, the REF and the Industry Roundtable are investing in the future of rheumatology.

CERTIFICATES OF CME CREDIT OR PARTICIPATION Accreditation Statement: The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Therefore, all speakers and moderators participating in an ACR-sponsored activity are required to disclose to the planning committee and audience any financial or other relationships including, but not limited to:

Designation Statement: The ACR designates this live educational activity for a maximum of 47.25 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

None: Nothing to disclose

International Physicians: International physicians who register as part of a group and require AMA PRA Category 1 Credit(s)™, must provide the following information to your tour leader: full name, mailing address, telephone and fax numbers, and e-mail address. The information will be used to verify your meeting attendance.

1. S tock, stock options or bond holdings in a for-profit corporation or self-directed pension plan 2. Research grants 3. Employment (full or part-time) 4. Ownership or partnership 5. C onsulting fees or other remuneration (payment) 6. N on-remunerative positions of influence such as officer, board member, trustee or public spokesperson

The American Medical Association has an agreement of mutual recognition of continuing medical education credit with the European Union of Medical Specialties. International physicians interested in converting AMA PRA Category 1 Credit ™ to EACCME credit should contact the UEMS.

7. Receipt of royalties

Health Professionals: Participants may claim hours to receive a Certificate of Participation for an activity designated for AMA PRA Category 1 Credit(s)™. For non-CME sessions, attendees may also request a certificate of participation.

Speakers, moderators and abstract authors submitted their disclosure online prior to publication. Disclosures for invited speakers are listed in the indices by presenters’ last name.

MEETING EVALUATIONS, CME CREDIT/ CERTIFICATES OF PARTICIPATION Computers are available for you to complete your CME/Certificate of Participation application and meeting evaluation form online during the meeting. In addition, you can complete the evaluation and print your certificate after you return home. If you are an international physician and require a Certificate of Attendance, this is enclosed in your meeting bag. If your country recognizes AMA PRA Category 1 Credit(s)™ in accordance with AMA PRA requirements, please complete a meeting evaluation and CME application. Your evaluation of the meeting is very important. The ACR/ ARHP annual meeting planning committees use feedback from attendees to assist in the development of future educational activities; therefore, we encourage you to complete your evaluation and CME/Certificate application online. Conflict of Interest/Disclosure Statements As an educational provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American College of Rheumatology must ensure balance, independence, objectivity and scientific rigor in all its educational activities.

310

2011 Program Book

8. Speakers’ bureau 9. Other

Abstract author disclosures are published online and in a supplement to the October issue of Arthritis & Rheumatism. Disclosures for the Late-Breaking abstracts are published online and in the December issue of Arthritis & Rheumatism. Any individual who refuses to disclose relevant financial relationships will be disqualified from being a planning committee member, a presenter, an author of a CME activity, and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity. ACR Disclosure Policy It is the policy of the American College of Rheumatology to ensure that its CME activities are independent and free of commercial bias. To ensure content objectivity and balance, and guarantee that the content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control content disclose all relevant financial relationships with any commercial interest if the relationship is financial and occurred within the past 12 months. If there are relationships that create a conflict of interest, these must be resolved in accordance with the ACR’s CME Resolution of Conflict policy prior to the participation of the individual in the development or presentation of CME content.

2011 ACR/ARHP Annual Meeting Leadership Thank You! The ACR/ARHP board of directors extends its gratitude to the ACR Annual Meeting Planning Subcommittee, ACR Abstract Oversight Committee, ACR Abstract Selection Committee, ARHP Abstract Review Panels, ARHP Annual Meeting Program Committee and ARHP Clinical Focus Task Force members for their leadership and volunteering their services to plan the 2011 annual meeting. Their significant contributions and expertise make the annual meeting the premier event for specialists in the field of rheumatology. ACR Annual Meeting Planning Subcommittee

Peter A. Nigrovic, MD

Joel A. Block, MD, Chair

Kathleen M. O’Neil, MD

Chester V. Oddis, MD, Chair-Elect

Christopher Ritchlin, MD, Professional Meetings Committee, Chair

Richard F. Loeser, MD, Basic Science Sub-chair Susan Manzi, MD, MPH, Clinical Sub-chair Robert W. Simms, MD, Meet the Professor/ Workshop/Study Group Sub-chair Carol A. Langford, MD, MHS, Clinical Chair, Abstract Selection

Eric M. Ruderman, MD Elizabeth G. Salt, ARNP, PhD, ARHP Annual Meeting Program Sub-committee Representative Kenneth N. Schikler, MD

George Tsokos, MD, Basic Science Chair, Abstract Selection

Victoria K. Shanmugam, MBBS

Abby Abelson, MD, Committee on Rheumatology Training and Workforce Issues Representative

Jasvinder Singh, MD, MPH

Joan M. Bathon, MD, A&R Editor

John Varga, MD

David G. Borenstein, MD, ACR President Richard Bucala, MD, PhD Robert H. Carter, MD Lindsey A. Criswell, MD, MPH Mary Cronin, MD Kori A. Dewing, DNP, ARNP, ARHP Annual Meeting Program Sub-committee, Chair Fernando E. Figueroa, MD Richard A. Furie, MD, Committee on Education, Chair Gregory C. Gardner, MD Steven Goldring, MD, Committee on Research Representative

Gregg J. Silverman, MD Robert F. Spiera, MD Paul P. Tak, MD, PhD

George Tsokos, MD, Basic Science, Co-Chair 1. Cytokines, Mediators, and Gene Regulation Alison Finnegan, MD, Co-Chair Iain B. McInnes, PhD, Co-Chair Erik Lubberts, PhD Pierre Miossec, MD, PhD Harris Perlman, PhD Shiva Shahrara, PhD 2. Cell-cell Adhesion, Cell Trafficking and Angiogenesis Bruce Cronstein, MD, Co-Chair Zoltan Szekanecz, MD, PhD, Co-Chair

Raymond L. Yung, MD, Committee on Education, Programs Sub-chair

Mariana J. Kaplan, MD

ACR Abstract Oversight Committee Robert Fulbriggee, MD, Chair Kori Dewing, DNP, ARNP David Pisetsky, MD

Christopher D. Buckley, MD Katalin Mikecz, MD, PhD Douglas Veale, MD 3. Innate Immunity and Rheumatic Disease Susan A. Boackle, MD, Co-Chair

Steven Ytterberg, MD

Richard M. Pope, MD, Co-Chair

ARHP Annual Meeting Program Subcommittee

Diego Kyburz, MD

Kori A. Dewing, DNP, ARNP, Chair Atul A. Deodhar, MD, MRCP

Alexei A. Grom, MD Gillian A. Hawker, MD, Quality Measures Committee Representative

Nadine M. Fisher, EdD Yvonne M. Golightly, PT, MS, PhD

Bruce I. Hoffmann, MD

Susan M. Maillard, MSC, SRP, MCSP

Shelly P. Kafka, MD

Linda J. Pine, PharmD

Diane Kamen, MD

Elizabeth G. Salt, PhD, ARNP

Salahuddin Kazi, MD, Committee on Registries and Health Information Technology Representative

Emily C. Somers, PhD, ScM

Anne-Marie Malfait, MD, PhD

Carol A. Langford, MD, MS, Clinical, Co-Chair

Mary-Chester Wasko, MD, MSc

Donna Everix, MPA, BS, PT

Sharon L. Kolasinski, MD

ACR and ARHP Abstract Selection Committees (including category chairs and reviewers)

Mary Wright, BS, OT Karen L. Smarr, PhD, ARHP President ARHP Clinical Focus Task Force

Kevin McKown, MD

Afton L. Hassett, PsyD, Chair

Zsuzsanna McMahan, MD, Fellows Representative

Manuel Chavez, BSN, MSN Jessica F. Farrell, PharmD

Esi Morgan DeWitt, MD, Committee on Research Representative

Karen Huisinga, MN, ARNP, FNP Terence W. Starz, MD

Paul J. Utz, MD Daniel L. Kastner, MD, PhD Wayne M. Yokoyama, MD 4. B-cell Biology and Targets in Autoimmune Disease Chaim Putterman, MD, Co-Chair William Stohl, MD, PhD, Co-Chair Jennifer Anolik, MD, PhD Shu-Man Fu, MD, PhD Chandra Mohan, MD, PhD Yaakov Naparstek, MD 5. T-cell Biology and Targets in Autoimmune Disease C. Garrison Fathman, MD, Co-Chair David Fox, MD, Co-Chair Sujata Sarkar, MD William Robinson, MD, PhD Jeremy Sokolove, MD

2011 Program Book

311

2011 ACR/ARHP Annual Meeting Leadership 6. Biology and Pathology of Bone and Joint Tariq M. Haqqi, MPh, PhD, Co-Chair Mary B. Goldring, PhD, Co-Chair Richard Loeser, MD Hiroshi Asahara, MD, PhD Martin Lotz, MD Mary Beth Humphrey, MD, PhD 7. Osteoarthritis – Clinical Aspects Timothy E. McAlindon, MD, MPH, MRCP, Co-Chair Joanne Jordan, MD, MPH, Co-Chair Amanda Nelson, MD Gillian Hawker, MD, MSc Jeffrey Duryea, PhD Najia Shakoor, MD 8. Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Robin K. Dore, MD, Co-Chair Nancy E. Lane, MD, Co-Chair Jennifer M. Grossman, MD Karen Hansen, MD, MS

Lori Tucker, MD, Co-Chair Edward M. Behrens, MD Abbe de Vallejo, PhD Daniel E. Furst, MD (alternate reviewer) Tariq M. Haqqi, MPh, PhD (alternate reviewer) Raphael Hirsch, MD James Jarvis, MD Kathryn S. Torok, MD John Varga, MD (alternate reviewer) 13. Infection-related Rheumatic Disease John D. Carter, MD, Co-Chair Dimitrios Vassilopoulos, MD, Co-Chair Raquel Cuchacovich, MD Alan P. Hudson, PhD Prashant Kaushik, MD Stanley Naides, MD

17. Rheumatoid Arthritis – Clinical Aspects Jon T. Giles, MD, MPH, Co-Chair Jonathan Kay, MD, Co-Chair Eric L. Matteson, MD, MPH, Co-Chair Deborah Symmons, MD, Co-Chair Neal S. Birnbaum, MD Paul F. Dellaripa, MD Immaculada del Rincon, MD, MS John D. Isaacs, MD, PhD Lennart Jacobsson, MD, PhD Joseph A. Markenson, MD Eric M. Ruderman, MD Charles M. Stein, MD 18. Rheumatoid Arthritis Treatment – Small Molecules, Biologics and Gene Therapy John J. Cush, MD, Co-Chair Daniel E. Furst, MD, Co-Chair Richard W. Martin, MD, Co-Chair Josef S. Smolen, MD, Co-Chair Daniel H. Solomon, MD, MPH, Co-Chair Martin Aringer, MD, Co-Chair

Anthony Woolf, MBBS

14. Metabolic and Crystal Arthropathies Hyon K. Choi, DrPH, MD, Co-Chair

Stuart Silverman, MD

John S. Sundy, MD, PhD, Co-Chair

Vivian Bykerk, MD

Michael A. Becker, MD

Andrew P. Cope, MD, PhD

Robert T. Keenan, MD, MPH

Aaron T. Eggebeen, MD

Kenneth S. O’Rourke, MD (alternate reviewer)

Jeffery D. Greenberg, MD

Peter A. Simkin, MD

Katherine Hobbs, MD

Robert Terkeltaub, MD

Alan Kivitz, MD

Robert A. Yood, MD (alternate reviewer)

Ted R. Mikuls, MD

9. Fibromyalgia and Soft Tissue Disorders Don L. Goldenberg, MD, Co-Chair Daniel Clauw, MD, Co-Chair Manuel Martinez-Lavin, MD Afton Hassett, PsyD Maryanne Fitzcharles, MD Chad S. Boomershine, MD, PhD 10. Orthopedics, Low Back Pain, and Rehabilitation Beth Jonas, MD, Co-Chair Jeffery N. Katz, MD, Co-Chair Aileen M. Davis, PhD Elaine Husni, MD, MPH Alfredo C. Rivadeneira, MD Kenneth S. O’Rourke, MD 11. Pediatric Rheumatology – Clinical and Therapeutic Aspects Norman T. Ilowite, MD, Co-Chair Daniel Lovell, MD, MPH, Co-Chair Rayfel Schneider, MBBCh, Co-Chair Carol A. Wallace, MD, Co-Chair Roger C. Allen, MBBS Timothy Beukelman, MD, MSCE Peter Chira, MD, MS Harry L. Gewanter, MD Michael Henrickson, MD, MPH Lisa F. Imundo, MD Marilynn G. Punaro, MD

312

11. Pediatric Rheumatology – Pathogenesis and Genetics Nora C. Singer, MD, Co-Chair

2011 Program Book

15. Muscle Biology, Myositis and Myopathies Ingrid E. Lundberg, MD, PhD, Co-Chair Frederick W. Miller, MD, PhD, Co-Chair Dana P. Ascherman, MD, PhD Leslie J. Crofford, MD (alternate reviewer) Lauren M. Pachman, MD

Maya H. Buch, MBChB, MRCP, PhD

Andrew J. Head, MD

Stephen A. Paget, MD Harold E. Paulus, MD Michael E. Weinblatt, MD 19. Rheumatoid Arthritis – Human Etiology and Pathogenesis Leslie J. Crofford, MD, Co-Chair

Jiri Vencovsky, MD, PhD

Paul Tak, MD, PhD, Co-Chair

Lucy R. Wedderburn, MD, PhD

S. Louis Bridges, MD, PhD

Robert L. Wortmann, MD (alternate reviewer)

Maridat Corr, MD

16. Imaging of Rheumatic Diseases John A. Carrino, MD, MPH, Co-Chair Wolfgang A. Schmidt, MD, Co-Chair

Kris A. Reedquist, PhD William Rigby, MD 20. Rheumatoid Arthritis – Animal Models Linda K. Myers, MD, Co-Chair

Phillip G. Conaghan, MD, PhD

Charles S. Via, MD, Co-Chair

Harry K. Genant, MD

David Bradley, PhD

Ali Guermazi, MD

Tibor T. Glant, MD, PhD

Eugene Kissin, MD

Veena Taneja, PhD Paul H. Wooley, PhD

2011 ACR/ARHP Annual Meeting Leadership 21. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics Murray Baron, MD, Co-Chair Maureen Mayes, MD, MPH, Co-Chair Robyn Domsic, MD Ariane Herrick, MD Jessica K. Gordon, MD Tatiana S. Rodriguez-Reyna, MD 22. Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics Marco Matucci-Cerinic, MD, PhD, Co-Chair Maria Trojanowska, PhD, Co-Chair David Abraham, PhD Francesco del Galdo, MD, PhD Carol Feghali-Bostwick, PhD Maria E. Suarez-Almazor, MD, PhD (alternate reviewer) Richard W. Martin, MD (alternate reviewer) John Varga, MD 23. Sjögren’s Syndrome Gabor G. Illei, MD, Co-Chair Athanasios G. Tzioufas, MD, Co-Chair Robert Clancy, PhD

26. Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Mary K. Crow, MD, Co-Chair Vasileios C. Kyttaris, MD, Co-Chair Joseph M. Ahearn, MD Jill P. Buyon, MD Insoo Kang, MD Andras Perl, MD, PhD 27. Systemic Lupus Erythematosus – Animal Models Phil Cohen, MD, Co-Chair

Westley H. Reeves, MD Joan E. Wither. MD, PhD 28. Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Robert D. Inman, MD, Co-Chair Christopher T. Ritchlin, MD, MPH, Co-Chair Desiree M. van der Heijde, MD, PhD, Co-Chair Michael H. Weisman, MD, Co-Chair Daniel O. Clegg, MD

Robert Hal Scofield, MD

Dirk Elewaut, MD

Tatsuya Atsumi, MD, PhD Yehuda Shoenfeld, MD 25. Systemic Lupus Erythematosus – Clinical Aspects and Treatment Elena M. Massarotti, MD, Co-Chair Michelle Petri, MD, Co-Chair Rosalind Ramsey-Goldman, MD, Co-Chair Daniel L. Wallace, MD, Co-Chair Cynthia Aranow, MD

Shikha Mittoo, MD, MHS Rachelle Buchbinder, MBBS, PhD Jolanda Cibere, MD, PhD Jeffery Curtis, MD, MPH, MSPH Elena Losina, PhD Kaleb Michaud, PhD Gabriella Schmajuk, MD, MS

Gary S. Gilkeson, MD

Maxime Dougados, MD, PhD

Robert A.S. Roubey, MD

Lisa A. Mandl, MD, MPH, Co-Chair

Tuhina Neogi, MD

Xavier Mariette, MD

Pier Luigi Meroni, MD

Allan C. Gelber, MD, Co-Chair

Anne Davidson, MBBS

Yrjo Konttine, MD, PhD

Barry L. Myones, MD, Co-Chair

Liana Fraenkel, MD, MPH, Co-Chair

Jane E. Salmon, MD, Co-Chair

Atul Deodhar, MD, MRCP (alternate reviewer)

24. Antiphospholipid Syndrome Doruk Erkan, MD, Co-Chair

31. Epidemiology and Health Services Research Karen Costenbader, MD, MPH, Co-Chair

Lianne S. Gensler, MD Artie Kavanaugh, MD Walter P. Maksymowych, MD Jochen Sieper, MD 29. Spondylarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Robert A. Colbert, MD, PhD, Co-Chair Joel D. Taurog, MD, Co-Chair Shervin Assassi, MD, MS James Rosenbaum, MD Judith Smith, MD, PhD Nigil Haroon, MD 30. Vasculitis Rula Hajj-Ali, MD, Co-Chair

32. Quality Measures and Innovations in Practice Management and Care Delivery Gary L. Bryant, MD, Co-Chair Salahuddin Kazi, MD, Co-Chair Eric Newman, MD Catalina Orozco, MD Andreas Reimold, MD Jasvinder Singh, MD, MPH 33. Genetics, Genomics and Proteomics John D. Reveille, MD, Co-Chair Betty Tsao, PhD, Co-Chair Robert Plenge, MD, PhD Sampath Prahalad, MD, MSc Nan Shen, MD Gregg Silverman, MD 34. Education Robert A. Kalish, MD, Co-Chair Joan Von Feldt, MD, MS, Co-Chair Richard Brasington, MD John Flynn, MD, MBA Paulette C. Hahn, MD Michael H. Pillinger, MD 35. Miscellaneous Rheumatic and Inflammatory Diseases Winn Chatham, MD, Co-Chair Kristine M. Lohr, MD, MS, Co-Chair Laura Carbone, MD Katherine K. Temprano, MD Richard Keating, MD

Anca Askanase, MD

Paul Monach, MD, PhD, Co-Chair

John Esdaile, MD, MPH

Gary S. Hoffman, MD

Diane Kamen, MD, MS

Curry L. Koening, MD, MS

Aisha Lateef, MBBS, MRCP, M.MED

Robert Spiera, MD

Matthew H. Liang, MD, MPH (alternate reviewer)

Richard Watts, MD

Debra Bancroft-Rizzo, MSN, FNP-C

Cornelia M. Weyand, MD, PhD

Patricia J. Cornell, ANP

Christian A. Pineau, MD

Chris D. Adams, MD 36. Clinical Practice/Patient Care Atul A. Deodhar, MD, Chair

James Jenkins, PhD

Derrick Todd, MD, PhD

Neil F. Moody, BS, PA-C

Tammy O. Utset, MD, MPH

Doreen Stiskal, PhD, PT

2011 Program Book

313

2011 ACR/ARHP Annual Meeting Leadership 37. Education/Community Programs Kori A. Dewing, DNP, ARNP, Chair Basia Belza, PhD Laura Bilek, PhD, PT Gail C. Davis, RN, EdD Geri Neuberger, RN, EdD Lisa Shelton, RN, BSN, BSc 38. Epidemiology and Public Health Emily Somers, PhD, ScM, Chair Glinda Cooper, PhD Alyssa Dufour, MA Charles Helmick, MD Howard Hillstrom, PhD Robert McLean, DSc, MPH 39. Health Services Research Linda J. Pine, PharmD, Chair Joyce P. Carlone, MN, RN, FNP-BC Lisa Kastanek, RN, CCRC Donald R. Miller, PharmD Kamela M. Nola, PharmD, MS Benjamin J. Smith, PA-C 40. Pediatrics Susan Maillard, MSc, Chair Kelly K. Anthony, PhD Christine W. Kennedy, CPNP, MSN, RN Norma L. Liburd, BSN, RNC Tim Takken, PhD, MSc Janalee Taylor, CNP 41. Psychology/Social Sciences Elizabeth G. Salt, PhD, Chair Mary-Beth Coty, PhD, RN Carol Greco, PhD Vanessa Malcarne, PhD Perry M. Nicassio, PhD Karen Smarr, PhD 42. Rehabilitation Sciences Nadine M. Fisher, EdD, Chair Jill Blitz, PT, DPT Talitha Cox, MA, OTR/L Lori Cyr, BSc, OT Donna Everix, MPA, BS, PT Mary Wright, BS, OT 43. Research Methodology Yvonne M. Golightly, PhD, PT, MS, Chair Nancy A. Baker, ScD, MPH, OTR/L Adam Goode, DPT, PT Mariana T. Hannan, DSc, MPH Nadine T. James, PhD, RN Yuqing Zhang, DSc

314

2011 Program Book

Explore the Exhibit Hall! Sunday, November 6: 10:00 am – 5:00 pm Monday, November 7: 10:00 am – 7:00 pm Tuesday, November 8: 10:00 am – 5:00 pm

Discover the latest rheumatology products and services from over 150 exhibitors Learn about new innovations in the Innovation Theater* View a missed session in the Replay Café Grab a snack at one of the daily refreshment breaks at 10:00 am and 2:00 pm Unwind at the Wine and Cheese Reception on Monday, November 7: 5:00 pm - 7:00 pm Connect with a colleague in a Networking Lounge Choose from a variety of lunch options in the food court Visit exhibitors participating in the passport program to be entered to win an iPad *presentations throughout the day, for the full schedule, please see page 304

EXHIBITORS Abbott Pharmaceuticals Booth # 201 www.abbott.com

Auxilium Pharmaceuticals Pharmaceuticals Booth # 857, 964 www.auxilium.com

Covidien - Mallinckrodt Pharmaceuticals Booth # 339 www.mallinckrodt.com

AccentHealth Digital Media, Educational Materials for Patients Booth # 1050 www.accenthealth.com

Besse Medical Pharmaceuticals Booth # 830 www.besse.com

Crescendo Bioscience, Inc. Diagnostic Equipment/Products Booth # 439 www.crescendobio.com

BioMed Central Publisher Booth # 834 www.biomedcentral.com

CuraScript SD Pharmacy Services Booth # 629 www.curascriptonline.com

Bristol-Myers Squibb Pharmaceuticals Booth # 745 www.bms.com

CVS Caremark/CarePLUS Pharmacy Services Booth # 831 www.cvscaremarkspecialtyrx.com

British Society for Rheumatology Nonprofit Organization Booth # 342 www.rheumatology.org.uk

Daiichi Sankyo Pharmaceuticals Booth # 115 www.dsi.com

Cardinal Health Pharmacy Services Booth # 1129 www.cardinalhealth.com

DePuy Mitek Medical Device Booth # 930 www.depuymitek.com

Cellestis Inc. Diagnostic Equipment/Products Booth # 1113 www.cellestis.com

Dermpath Diagnostics Other: Laboratory Services Booth # 829 www.dermpathdiagnostics.com

Celltrion Healthcare Co., LTD Biotech, Pharmaceuticals Booth # 489 www.celltrionhealthcare.com

Diagnostic Instruments, Inc. Diagnostic Equipment/Products Booth # 639 www.msultrasound.net

Chugai Pharmaceutical Co., Ltd. Pharmaceuticals Booth # 679 www.chugai-pharm.co.jp/hc/chugai_top_ en.jsp

DJO Medical Device Booth # 718 www.djoglobal.com

ACP/Annals of Internal Medicine Nonprofit Organization, Publisher Booth # 238 www.acponline.org ACR Career Connection Booth # 1205 ACR Concierge Center Booth # 601 Actelion Pharmaceuticals Pharmaceuticals Booth # 938, 1039 www.actelion.com American Orthopaedic Association/Own the Bone Nonprofit Organization Booth # 131 www.ownthebone.org American Regent, Inc. Pharmaceuticals Booth # 328 www.americanregent.com Amgen, Inc. Biotech, Pharmaceuticals Booth # 1011 www.amgen.com Amgen, Inc. and Pfizer Inc. Pharmaceuticals Booth # 800 www.pfizer.com Arthritis Foundation Nonprofit Organization Booth # 239 www.arthritis.org Arthritis Self-Management Publisher Booth # 769 www.arthritisselfmanagement.com Autoimmune Diseases Association Nonprofit Organization Booth # 116 www.aarda.org

316

2011 Program Book

Cleveland Clinic Nonprofit Organization Booth # 138 www.clevelandclinic.org Clinical and Experimental Rheumatology Publisher Booth # 838 www.clinexprheumatol.org Computer Recharge Lounge Booth # 456, 927 CORRONA, Inc. Other: Registry Booth # 1048 www.corrona.org

Elliot Health System Nonprofit Organization, Recruitment Booth # 120 www.elliothospital.org Elsevier Publisher Booth # 720 www.us.elsevierhealth.com EMD Serono Pharmaceuticals Booth # 643 www.emdserono.com

EXHIBITORS Esaote North America Diagnostic Equipment/Products Booth # 757 www.esaoteusa.com

GE Healthcare Diagnostic Equipment/Products Booth # 325 www.gehealthcare.com

Innovation Theater Booth # 789 www.rheumatology.org/education/annual/ exhibit_hall/educational_opps.asp

Euroimmun US Biotech Booth # 739 www.euroimmunus.com

Gebauer Company Pharmaceuticals, Topical Anesthetics Booth # 340 www.gebauer.com

Inova Diagnostics, Inc. Biotech, Diagnostic Equipment/Products Booth # 645 www.inovadx.com

European League Against Rheumatism (EULAR) Nonprofit Organization Booth # 226 www.eular.org

Genentech and Roche Biotech Booth # 457 www.gene.com

Internet Center Booth # 124, 1143

Exagen Diagnostics Biotech Diagnostic Equipment/Products Booth # 933 www.exagen.com Excellence in Rheumatology Conference Medical Conference Booth # 526 www.excellence-in-rheumatology.org Exhibitchek Market Research Booth # 835 Exhibit Hall Networking Lounge Booth # 100, 689, 749 Fallene Ltd. Other Booth # 840 www.totalblock.com Ferring Pharmaceuticals Inc. Medical Device Booth # 731 www.euflexxa.com Fidia Pharma USA Medical Device Booth # 1032 www.Hyalgan.com Forest Pharmaceuticals, Inc. Pharmaceuticals Booth # 919 www.frx.com Foundation for Sarcoidosis Research Educational Materials for Patients, Nonprofit Organization Booth # 114 www.stopsarcoidosis.org FujiFilm Medical Systems U.S.A., Inc. Diagnostic Equipment/Products Booth # 1107 www.fujimed.com

Genzyme Biotech Booth # 1029 www.genzyme.com Gilead Sciences, Inc. Pharmaceuticals Booth # 539 www.gilead.com Gout & Uric Acid Education Society (GUAES) Educational Materials for Patients, Nonprofit Organization Booth # 232 www.gouteducation.org Hattiesburg Clinic Recruitment Booth # 1206 www.hattiesburgclinic.com Hologic Diagnostic Equipment/Products Medical Device Booth # 613 www.hologic.com Horizon Pharma, Inc. Pharmaceuticals Booth # 879 www.horizon-pharma.com Hospital for Special Surgery Nonprofit Organization Booth # 334 www.hss.edu Human Genome Sciences, Inc. Biotech Booth # 444 www.hgsi.com

JAMA & Archives Journals Publisher Booth # 1102 pubs.ama-assn.org Janssen Biotech, Inc. Pharmaceuticals Booth # 812, 820 www.janssenbiotech.com Johns Hopkins Arthritis Center Nonprofit Organization Booth # 427 www.hopkins-arthritis.org Journal of Rheumatology, The Publisher Booth # 242 www.jrheum.org Kantor & Kantor Other: Legal Resource Booth # 533 www.kantorlaw.net La Lettre Du Rhumatologue - Edimark Santé Publisher Booth # 873 www.edimark.fr LabCorp Other: Laboratory Testing Service Booth # 528 www.labcorp.com Letter to Editor Rheumatology Nonprofit Organization, Publisher Booth # 118 www.lettertoeditor.org Lilly USA, LLC. Pharmaceuticals Booth # 470, 521 www.lilly.com

INC Research Contract Research Booth # 934 www.incresearch.com

2011 Program Book

317

EXHIBITORS Lippincott, Williams and Wilkins Publisher Booth # 1100 www.lww.com

Nutramax Laboratories, Inc. Nutritional Products Booth # 619 www.nutramaxlabs.com

Purdue Pharma L.P. Pharmaceuticals Booth # 1045 www.purduepharma.com

Lupus Initiative, The Nonprofit Organization Booth # 733 www.thelupusinitiative.org

NYU Hospital for Joint Diseases Nonprofit Organization Booth # 234 www.med.nyu.edu/medicine/rheumatology

Quidel Corporation Diagnostic Equipment/Products Booth # 1109 www.quidel.com

McKesson Specialty Care Solutions Distributor Booth # 928 www.mckesson.com

Ochsner Health System Recruitment Booth # 1204 www.ochsner.org

MedImmune, LLC Biotech Booth # 967 www.medimmune.com

Optasia Medical, Inc Diagnostic Equipment/Products Booth # 1003 www.optasiamedical.com

R. J . Fasenmyer Center for Clinical Immunology Nonprofit Organization Booth # 140 www.clevelandclinic.org/FasenmyerCenter

Merck Pharmaceuticals Booth # 1001 www.merck.com

Organization of Teratology Information Specialists Nonprofit Organization Booth # 142 www.otispregnancy.org

Merit Foundation Nonprofit Organization Booth # 129 www.meteorfoundation.com Metro Medical Supply Pharmacy Services Booth # 531 metromedical.com Metroplex Clinical Research Center Other Booth # 844 www.mcrcdallas.com National Data Bank for Rheumatic Diseases Nonprofit Organization Booth # 243 www.arthritis-research.org National Institute of Arthritis and Musculoskeletal and Skin Diseases Other: Government Booth # 233 www.niams.nih.gov New Balance Athletic Shoe, Inc. Other: Footwear Booth # 1017 www.newbalance.com Novartis Pharmaceuticals Corporation Pharmaceuticals Booth # 314 www.novartis.com

318

2011 Program Book

Ossur Americas Medical Device Booth # 729 www.Össur.com Oxford Immunotec Inc Diagnostic Products Booth # 108 www.oxfordimmunotec.com Oxford University Press Publisher Booth # 716 www.oxfordjournals.org Pan American League of Associations for Rheumatology (PANLAR) Non-profit Organization Booth # 228 www.Panlar.org PBL InterferonSource Contract Research, Laboratory Equipment/ Products Booth # 634 www.interferonsource.com Pfizer, Inc. Pharmaceuticals Booth # 401, 514, 913 www.pfizer.com

RDL Reference Laboratory Diagnostic Products Booth # 527 www.rdlinc.com Regeneron Pharmaceuticals, Inc. Pharmaceuticals Booth # 433 www.regeneron.com Replay Cafe Booth # 180 ReSearch Pharmaceutical Services Contract Research Booth # 738 www.rpsweb.com Rheumatoid Health Network Educational Materials for Patients Booth # 520 rheumatoidhealthnetwork.com Rheumatology News Publisher Booth # 712 www.rheumatologynews.com Rheumatology Nurses Society Nonprofit Organization Booth # 143 www.rns-network.org Rheumatology Practice News Publisher Booth # 735 http://www.rheumatologypracticenews.com Rottapharm Ltd Pharmaceuticals Booth # 728 www.rotta.com

EXHIBITORS Savient Pharmaceuticals Biotech Booth # 1056 www.Savientpharma.com

Swedish Orphan Biovitrum Pharmaceuticals Booth # 773 www.sobi.com

VQ OrthoCare Medical Device Booth # 333 www.vqorthocare.com

Scandinavian Journal of Rheumatology Nonprofit Organization Booth # 240 www.scandjrheumatol.dk

Takeda Pharmaceuticals Pharmaceuticals Booth # 481 www.tpna.com

Wiley Blackwell Publisher Booth # 1105 www.wiley.com

Scleroderma Foundation Nonprofit Organization Booth # 231 www.scleroderma.org

Terason Diagnostic Equipment/Products, Medical Device Booth # 732 www.terason.com

Siemens Medical Solutions USA Inc. Diagnostic Equipment/Products Booth # 633 www.usa.siemens.com/rheumatology Silver Ring Splint Company Medical Device Therapeutic/Patient Aid Products Booth # 714 www.SilverRingSplint.com

The Binding Site Laboratory Equipment/Products Booth # 1007 www.thebindingsite.com TheraTest Laboratories, Inc. Diagnostic Equipment/Products Booth # 949 www.theratest.com

Sjögren’s Syndrome Foundation Nonprofit Organization Booth # 235 www.sjogrens.org

UpToDate Publisher Booth # 828 www.uptodate.com

Smith & Nephew Pharmaceuticals Booth # 849 www.smithnephew.com/us/professionals

URL Pharma Pharmaceuticals Booth # 571 www.urlpharma.com

SonoSite Diagnostic Equipment/Products, Medical Device Booth # 1157 www.sonosite.com

Vasculitis Foundation Nonprofit Organization Booth # 135 www.vasculitisfoundation.org

Spondylitis Association of America Nonprofit Organization, Educational Materials for Patients, Therapeutic/Patient Aid Products Booth # 229 www.spondylitis.org STOP Foodborne Illness Nonprofit Organization Booth # 338 www.stopfoodborneillness.org

Vindico Medical Education Publisher Booth # 1005 www.VindicoMedEd.com Virtual Scopics Contract Research Booth # 865 www.virtualscopics.com Vitamin Health Nutritional Products Booth # 632 www.neoflex.com

2011 Program Book

319

acknowledgements The ACR, the ARHP and the REF wish to thank the following organizations for providing support for the 2011 ACR/ARHP Annual Scientific Meeting. Their support has been used to help offset the cost of the meeting for attendees. Abbott Convention Internet Center Convention Center Banner Convention and Exhibit Hall Map Brochure Amgen, Inc. and Pfizer Inc Scientific Program Book Session Tracker Bristol-Myers Squibb Company Poster Hall Services Computer Recharge Lounges Exhibit Hall Aisle Signs Exhibit Hall Networking Lounges Genentech, A Member of the Roche Group My ACR (Online Itinerary Builder with Abstracts and Scientific Syllabi) Clinical Scenario Challenge Hotel Key Cards SessionSelect Savient Pharmaceuticals, Inc. Conference Shuttle Buses Conference Notepad and Daily Planner Convention Center Banner Exhibit Hall Floor Decals UCB, Inc. Convention Center Banner

320

2011 Program Book

acknowledgements In addition to the support provided for the 2011 ACR/ARHP Annual Scientific Meeting, the ACR, the ARHP and the REF wish to thank the following organizations for providing support for activities and programs held throughout the year.

Musculoskeletal Ultrasound Course for Rheumatologists Pediatric Rheumatology Symposium CARE 2011 ARHP Advanced Rheumatology Course

Abbott Industry Roundtable Member Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors’ Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Integrating Immunology and Biologics into Clinical Practice Musculoskeletal Ultrasound Course for Rheumatologists Pediatric Rheumatology Symposium CARE 2011 ARHP Advanced Rheumatology Course ACR REF/Abbott Medical and Graduate Student Achievement Award ACR REF/Abbott Medical and Pediatric Resident Research Award ACR REF/Abbott Health Professional Graduate Student Research Preceptorship ACR REF/Abbott Medical Student Clinical Preceptorship ACR REF/Abbott Medical Student Research Preceptorship

Human Genome Sciences, Inc. Industry Roundtable Member State-of-the-Art Clinical Symposium Clinical Focus Course: Integrating Immunology and Biologics into Clinical Practice Annual Scientific Meeting Industry Roundtable Symposium

Amgen, Inc. Industry Roundtable Member Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors’ Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Integrating Immunology and Biologics into Clinical Practice Musculoskeletal Ultrasound Course for Rheumatologists Pediatric Rheumatology Symposium CARE 2011 ARHP Advanced Rheumatology Course ACR REF/Amgen Pediatric Rheumatology Visiting Professorship Program ACR REF/Amgen Pediatric Rheumatology Research Award ARHP Networking Forum Annual Scientific Meeting Industry Roundtable Symposium Amgen, Inc. and Pfizer Inc Fellows Education Fund ACR REF/Amgen/Pfizer Rheumatology Fellowship Training Award

Janssen Biotech, Inc. Industry Roundtable Member Annual Scientific Meeting Fellows-In-Training Travel Scholarship ACR REF Rheumatology Scientist Development Award Annual Scientific Meeting Industry Roundtable Symposium MedImmune, LLC Annual Scientific Meeting Industry-Supported Post-Conference Symposium Ortho-McNeil Janssen Scientific Annual Scientific Meeting Industry-Supported Post-Conference Symposium Pfizer Inc Industry Roundtable Member Savient Pharmaceuticals, Inc. Annual Scientific Meeting Industry-Supported Post-Conference Symposium UCB, Inc. Industry Roundtable Member Annual Scientific Meeting Fellows-In-Training Travel Scholarship Rheumatology Maintenance of Certification Course Rheumatology Training Directors’ Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Integrating Immunology and Biologics into Clinical Practice Musculoskeletal Ultrasound Course for Rheumatologists Pediatric Rheumatology Symposium CARE 2011 ARHP Advanced Rheumatology Course Annual Scientific Meeting Industry Roundtable Symposium

Bioiberica Annual Scientific Meeting Industry-Supported Post-Conference Symposium Bristol-Myers Squibb Company Fellows Education Fund Winter Rheumatology Symposium State-of-the-Art Clinical Symposium Eli Lilly and Company Industry Roundtable Member Annual Scientific Meeting Fellows-In-Training Travel Scholarship State-of-the-Art Clinical Symposium Annual Scientific Meeting Industry Roundtable Symposium Genentech, A Member of the Roche Group Industry Roundtable Member Annual Scientific Meeting Fellows-In-Training Travel Scholarship 2011 ACR/ARHP Membership Directory 2011 Annual Scientific Meeting Registration Brochure Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors’ Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Integrating Immunology and Biologics into Clinical Practice

It is with gratitude that the ACR Research and Education Foundation acknowledges those who have demonstrated exemplary support of the Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign. Pinnacle ($5 million +)

Principal ($2.5 million +) Genentech

Partner ($1 million +) Arthritis Foundation, Inc. Centocor Ortho Biotech Services LLC

Pfizer Inc Scott Schweighauser and Liz Ellrodt

Invited Speaker /Moderator Index

A Abelson, Abby, MD ACR REF Special Session: Clinician Scholar Educator Presentations . . . . . . . . . . . . 51 Disclosure: Nothing to Disclose Gender Issues in the Rheumatology Workforce 85 Disclosure: Nothing to Disclose Adams, John S., MD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Quest, 2 Adebajo, Adewale O., MD ILAR Global Health Project . . . . . . . . . . 80 Disclosure: Nothing to Disclose Aggarwal, Rohit, MD Emerging Concepts in the Inflammatory Myopathies . . . . . . . . . . . . . . . . . . . 87 Disclosure: Nothing to Disclose Ahn, Grace, MD Thieves’ Market: Show Me Your Best Cases . 71 Disclosure: Nothing to Disclose Alarakhia, Anika, MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose Albani, Salvatore, MD, PhD Advances in Polyarticular Juvenile Idiopathic Arthritis . . . . . . . . . . . . . . . . . . . . . 64 Disclosure: NIH, 2 Albert, Daniel A., MD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . . 123 Disclosure: Nothing to Disclose Aliprantis, Antonios O., MD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Nothing to Disclose Allada, Gopal, MD Extrarticular Manifestations of Rheumatoid Arthritis: Ophthalmologic, Pulmonary and Cardiovascular . . . . . . . . . . . . . . . . 105 Disclosure: Nothing to Disclose Allaire, Saralynn H., ScD Keep People with Arthritis Working: An Interactive Case-based Discussion . . . . . 106 Disclosure: Nothing to Disclose Allanore, Yannick, MD, PhD Challenging Complications of Systemic Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . .107 Disclosure: Actelion Pharmaceuticals US, 2, 9; Pfizer Inc, 2 Allen, Kelli D., PhD To P or Not to P? Knowing When the P-Value is Less than Useful . . . . . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Altman, Roy D., MD Enhancing Outcomes in Chronic Pain Associated with Osteoarthritis: Faculty Debate and Clinical Case Discussions . . . . . . . . . . . . . . . 306 Disclosure: Nothing to Disclose

322

2011 Program Book

Amin, Shreyasee, MDCM, MPH Metabolic Bone Disease . . . . . . . . . . . 115 Disclosure: Merck Pharmaceuticals, 5 An, Howard, MD Cervical Spine Surgeries in Rheumatic Diseases: 2011 Update . . . . . . . . . . . . . . . . . . 56 Disclosure: Articular Engineering LLC, 4; Baxter Inc, 2; Globus Inc, 2; Life Spine Inc, 5; Pioneer Inc, 5; Spinal Kinetics Inc., 1; Spinalcyte LLC, 2; Synthes Inc, 2; U and I Inc. , 1; Zimmer Spine Inc, 5 Anderson, Mark, MD, PhD Genetic Defects, AIRE and Autoimmunity . 88 Disclosure: Nothing to Disclose Antolini, C. Ryan, MD Mastering Patient Flow to Improve Practice Operations . . . . . . . . . . . . . . . . . . . 94 Disclosure: Nothing to Disclose Apkarian, A. Vania, PhD Pain, the Brain, and Osteoarthritis . . . . . . 29 Disclosure: Nothing to Disclose Arnold, Lesley M., MD Complex Pain Issues: Comorbidities and Special Populations . . . . . . . . . . . . . . . . . . . 23 Disclosure: Astra Zeneca, 5; Boehringer Ingelheim, 2; Cypress Biosciences, Inc., 2, 5; Eli Lilly and Company, 2, 5; Forest Laboratories, 2, 5; Grunenthal, 5; Johnson & Johnson, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2, 5; Sanofi-Aventis Pharmaceutical, 5; Takeda , 5 Ascherman, Dana P., MD Emerging Concepts in the Inflammatory Myopathies . . . . . . . . . . . . . . . . . . . 87 Disclosure: Consultant--Biogen, 5 Askanase, Anca D., MD Biomarkers in Systemic Lupus Erythematosus: Where Do We Stand? . . . . . . . . . . . . . 63 Disclosure: Nothing to Disclose

B Backhaus, Marina, MD, PhD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two . . . . . . . . . . 17 Disclosure: Abbott Laboratories, 5; Bristol-Myers Squibb, 5; MSI, 5; Pfizer Inc, 5; UCB, 5 Backman, Catherine L., OT, PhD Beyond Pain and Fatigue: Expanding Clinician and Researcher Focus to Improve Daily Life 105 Disclosure: Nothing to Disclose Baer, Alan N., MD Controversies in Sjögren’s Syndrome . . . . . 27 Disclosure: Nothing to Disclose Controversies in Sjögren’s Syndrome . . . . . 80 Disclosure: Nothing to Disclose Baker, Nancy A., ScD, MPH, OTR/L Deconstructing the Randomized Controlled Trial: Assessing the Study Quality of Level One Non-Drug Studies . . . . . . . . . . . . . . . 53 Disclosure: Nothing to Disclose Keep People with Arthritis Working: An Interactive Case-based Discussion . . . . . 105 Disclosure: Nothing to Disclose

Balint, Peter V., MD, PhD Musculoskeletal Ultrasound Course for Rheumatologists - Day One . . . . . . . . . . 17 Disclosure: Nothing to Disclose Bancroft-Rizzo, Debra, MSN, APNP Rheumatic Disease Update: Relapsing Polychondritis . . . . . . . . . . . . . . . . . 44 Disclosure: Nothing to Disclose Baraf, Herbert, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two . . . . . . . . . . 20 Disclosure: Nothing to Disclose Contract Negotiations for Physicians . . . . . 62 Disclosure: Nothing to Disclose Barr, Michael S., MD, MBA CORC Forum: Payment Reform Options . . 92 Disclosure: Pfizer, NovoNordisk, Merck, Wyeth, Sanofi, Endo, 2 Barron, Karyl S., MD Periodic Fevers with Aphthous Stomatitis, Pharyngitis, and Adenitis . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Bartlett, Susan J., PhD Behave Yourself! Practical Application of Cognitive Behavioral Theories to Motivate Change in Patients with Arthritis . . . . . . . 54 Disclosure: Nothing to Disclose Introduction to Comparative Effectiveness Research Study Designs for Rheumatology Health Professionals . . . . . . . . . . . . . 125 Disclosure: Nothing to Disclose Bathon, Joan M., MD ACR REF Special Session: Within Our Reach: Finding a Cure for Rheumatoid Arthritis . . . 42 Disclosure: Nothing to Disclose Extrarticular Manifestations of Rheumatoid Arthritis: Ophthalmologic, Pulmonary and Cardiovascular . . . . . . . . . . . . . . . . 105 Disclosure: Nothing to Disclose Heart Disease and Rheumatoid Arthritis . . . 73 Disclosure: Nothing to Disclose Publishing in Peer-Reviewed Medical Journals . . . . . . . . . . . . . . . . . . . . . . . . . 33 Disclosure: Nothing to Disclose Battistone, Michael J., MD ACR REF Special Session: Clinician Scholar Educator Presentations . . . . . . . . . . . . 51 Disclosure: Nothing to Disclose Medical Education: Year in Review . . . . . . 33 Disclosure: Nothing to Disclose Bauer, Douglas C., MD Great Debate: Is too Much Suppression of Turnover Bad for Bone? . . . . . . . . . . . . 42 Disclosure: Amgen, 2; Novartis Pharmaceutical Corporation, 2 Becker, Michael A., MD Crystal: Diagnosis and Management of Gout . . . . . . . . . . . . . . . . . . . . . . . . 55, 86 Disclosure: Takeda, Savient, BioCryst, Ardea, Metabolex, URL/Mutual, Regeneron, Menarini, Teijin, Chugai, 5 Becker, Mara L., MD, MSCE Pediatric Systemic Lupus . . . . . . . . . . . 80 Disclosure: Nothing to Disclose Pediatrics: Juvenile Idiopathic Arthritis for Adult Rheumatologists . . . . . . . . . . . . . . . . 55 Disclosure: Nothing to Disclose

Bennett, Robert M., MD Sleep Disturbance in Fibromyalgia . . . . . . 55 Disclosure: Nothing to Disclose Bergman, Martin J., MD Rheumatoid Arthritis: Outcome Measures in Clinical Practice . . . . . . . . . . . . . . . . . 51 Disclosure: Abbott Laboratories, 2, 5, 8; Bristol-Myers Squibb, 2, 5; Celgene, 5; Janssen Pharmaceutica Product, L.P., 5; Pfizer Inc, 5; Roche Pharmaceuticals, 2, 5; ucb, 8 Berkowitz, Lee, MD Education Redesign for Teaching Rheumatologists . . . . . . . . . . . . . . . . 94 Disclosure: Nothing to Disclose Bernatsky, Sasha, MD, PhD Session II: Methods for Comparative Effectiveness Research . . . . . . . . . . . . . 22 Disclosure: Nothing to Disclose

Bisoendial, Radjesh J., MD, PhD Towards Prevention of Atherosclerosis Progression in Rheumatoid Arthritis: Insights into the Relationship between Inflammation and Cardiovascular Disease . . . . . . . . . . 90 Disclosure: Nothing to Disclose Blitz, Jill R., PT, DPT Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: Nothing to Disclose bloch-Queyrat, Coralie, MD, PhD Plenary Session II . . . . . . . . . . . . . . . . 60 Disclosure: Nothing to Disclose Block, Joel A., MD Plenary Session II . . . . . . . . . . . . . . . . 60 Disclosure: Abbott Laboratories, 5; Adolor, 5 Year in Review . . . . . . . . . . . . . . . . . 26 Disclosure: Abbott Laboratories, 5; Adolor, 5 Bockman, Richard, MD, PhD Efficacy and Safety of Calcium and Vitamin D Supplementation . . . . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose

Berney, Seth M., MD Contract Negotiations for Physicians . . . . . 62 Disclosure: Nothing to Disclose

Boers, Maarten, MD, MSc, PhD Scientific Graphs: An Alternative to PowerPoint and Excel . . . . . . . . . . . . . . . . . . . 106 Disclosure: Epiconsult BV, 4

Beshai, John F., MD Clinicopathologic Conference: A 40 Year-Old Male with Dyspnea on Exertion . . . . . . . . 54 Disclosure: Nothing to Disclose

Boilard, Eric, PhD Platelets as Inflammatory Cells in Arthritis 116 Disclosure: Nothing to Disclose

Beukelman, Timothy, MD, MSCE Advances in Polyarticular Juvenile Idiopathic Arthritis . . . . . . . . . . . . . . . . . . . . . 64 Disclosure: Nothing to Disclose Beyer, Christian, MD Plenary Session II . . . . . . . . . . . . . . . . 60 Disclosure: Nothing to Disclose Bilek, Laura D., PhD, PT Are You Losing It? How to Deal with Loss to Follow Up in Research Studies and Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . 92 Disclosure: Nothing to Disclose Bingham III, Clifton O., MD Vaccinations for Patients on Biologic Therapies . . . . . . . . . . . . . . . . . . . . . . . . .113 Disclosure: Amgen, BMS, Centocor, Genetech/ Roche, Millenium, Pfizer, UCB, 5; BMS, Genentech/Roche, Biogen/IDEC, UCB, 2 Binstadt, Bryce A., MD, PhD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose Birnbaum, Julius, MD, MHS Extra Glandular Manifestations of Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose Peripheral Neuropathies for the Rheumatologist . . . . . . . . . . . . . . . . . . . . . . . . . 23 Disclosure: Nothing to Disclose Bise, Christopher, PT, MS, DPT Lower Extremity Musculoskeletal Assessment of the Rheumatology Patient . . . . . . . . . .129 Disclosure: Nothing to Disclose

Bonewald, Lynda, PhD Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . 119 Disclosure: Nothing to Disclose Bongartz, Tim, MD, MS Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Borenstein, David G., MD ACR Leadership Town Hall Meeting . . . . . 95 Disclosure: Nothing to Disclose ACR Plenary Session I: Discovery 2011 . . . . 30 Disclosure: Nothing to Disclose ACR/ARHP Opening Lecture and Awards . . . 24 Disclosure: Nothing to Disclose Pain: Evaluation and Treatment of Back Pain . . . . . . . . . . . . . . . . . . . . . . . . 27, 87 Disclosure: Nothing to Disclose Bouxsein, Mary L., PhD Session IV: Assessment of Bone Structure and Quality . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Boyle, Dennis J., MD Difficult Patient Interactions . . . . . . . . . 86 Disclosure: Nothing to Disclose Practice Potpourri . . . . . . . . . . . . . . 106 Disclosure: Nothing to Disclose Bozaite-Gluosniene, Rasa, MD ACR Plenary Session I: Discovery 2011 . . . . 30 Disclosure: Nothing to Disclose Bradley, Laurence A., PhD Brain Correlates of Chronic Pain . . . . . . 117 Disclosure: Eli Lilly and Company, 5

Brady, Teresa J., PhD Marketing Community-based Programs to Primary Care Practices: An Approach Based on Centers for Disease Control Audience Research . . . . . . . . . . . . . . . . . . . . . . . . .117 Disclosure: Nothing to Disclose Policy and Environmental Strategies to Support Increased Physical Activity for Adults with Arthritis: Findings from a Centers for Disease Control/Arthritis Foundation Expert Panel . 130 Disclosure: Nothing to Disclose Brey, Robin L., MD Cognitive Function in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose


Belza, Basia, PhD New and Noteworthy: Nursing, Pharmacy and Pedorthics . . . . . . . . . . . . . . . . . . . 55 Disclosure: Nothing to Disclose

Bridges Jr., S. Louis, MD, PhD Adult Pharmacogenomics . . . . . . . . . . . 89 Disclosure: TcLand Expression, Nantes, France, 9 Brown Jr., Calvin R., MD Education Redesign for Teaching Rheumatologists . . . . . . . . . . . . . . . . 94 Disclosure: Nothing to Disclose Broy, Susan B., MD Iatrogenic Misadventures in Osteoporosis Treatment . . . . . . . . . . . . . . . . . . . . 53 Disclosure: Merck, Amgen, Lilly, 5 Bruce, Ian N., MD Lipid-Lowering Therapy 2011 . . . . . . . . . 28 Disclosure: Nothing to Disclose Bucala, Richard J., MD, PhD Innate Immunity . . . . . . . . . . . . . . . . 56 Disclosure: Nothing to Disclose New Concepts in the Autoimmune Pathogenesis of Interstitial Lung Diseases . . . . . . . . . 106 Disclosure: Nothing to Disclose Buckner, Jane Hoyt, MD Rheumatic Disease Update: Relapsing Polychondritis . . . . . . . . . . . . . . . . . 44 Disclosure: Nothing to Disclose T-Cell Regulation and Autoimmune Pathogenesis: Th1, Th2, Th17 and T Regs . . 54 Disclosure: Nothing to Disclose Burke, Allen, MD Histopathology of Vasculitis . . . . . . . . . . 90 Disclosure: Nothing to Disclose Burmester, Gerd-Rüdiger, MD ACR Plenary Session I: Discovery 2011 . . . . 30 Disclosure: Pfizer Inc, 2, 5, 8 Burr, David B., PhD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Amgen, 2, 5; CRC Press, 7; Eli Lilly and Company, 2, 5; NephroGenex, 9; Pfizer Inc, 9; PharmaLegacy, 6; Procter and Gamble Pharmaceuticals, 2; Springer, 7 Butts, Cherie L., PhD Theories on Sex Disparities in Autoimmune Disease: From Estrogen to the X Chromosome 84 Disclosure: Nothing to Disclose Buyon, Jill P., MD Biomarkers in Systemic Lupus Erythematosus: Where do we stand? . . . . . . . . . . . . . . 63 Disclosure: Have consulted for Human Genome Sciences, Galaxo Smith Klein, Bristol Myers Squibb, Gerson Lehrman Consulting Group, Medacorp, 5 2011 Program Book 323


Bykerk, Vivian, MD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Novartis Pharmaceutical Corporation, 1

Christopher-Stine, Lisa, MD, MPH Emerging Concepts in the Inflammatory Myopathies . . . . . . . . . . . . . . . . . . . 87 Disclosure: Patent, 9

C

Chu, Cong-Qiu, MD, PhD Entrapment Neuropathies and Nerve Conduction Studies . . . . . . . . . . . . . . 92 Disclosure: Bristol-Myers Squibb, 8; Covidien, 8

Callahan, Leigh F., PhD Arthritis and Traditional Chinese Medicine . 92 Disclosure: Nothing to Disclose Rubbing Elbows with the Higher Ups: Effective Communications with Administration . . . 117 Disclosure: Nothing to Disclose

Chung, Antanya, CPC, CPC-I, CRHC, CCP ACR Certified Rheumatology Coder Course . 18 Disclosure: Nothing to Disclose ICD-10 & HIPAA 5010 - Ready or Not…It’s Coming! . . . . . . . . . . . . . . . . . . . . 116 Disclosure: Nothing to Disclose

Callen, Jeffrey P., MD The Three Ps of Dermatologic and Autoimmune Disease: Pyoderma, Panniculitis and Pemphigus/ Pemphigoid . . . . . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose

Clancy, Carolyn M., MD Session I: Introduction and Overview of Comparative Effectiveness Research from the Perspective of Government and Insurers . . 22 Disclosure: Nothing to Disclose

Caragher, Timothy E., PhD Practice Potpourri . . . . . . . . . . . . . . 106 Disclosure: Nothing to Disclose

Clauw, Daniel J., MD Evidence-based Non-pharmacological Interventions . . . . . . . . . . . . . . . . . . 24 Disclosure: Cypress Biosciences, Inc., 5; Forest Laboratories, 2, 5; Jazz, 5; Johnson & Johnson, 5; Lilly, 5; Merck Pharmaceuticals, 2; Nuvo, 5; Pfizer Inc, 2, 5 Lessons Learned from Fibromyalgia Regarding the Mechanisms and Treatment of Chronic Pain . . . . . . . . . . . . . . . . . . . . . . . . . 23 Disclosure: Cypress Biosciences, Inc., 5; Forest Laboratories, 2, 5; Jazz, 5; Johnson & Johnson, 5; Lilly, 5; Merck Pharmaceuticals, 2; Nuvo, 5; Pfizer Inc, 2, 5 Pain: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . 24 Disclosure: Cypress Biosciences, Inc., 5; Forest Laboratories, 2, 5; Jazz, 5; Johnson & Johnson, 5; Lilly, 5; Merck Pharmaceuticals, 2; Nuvo, 5; Pfizer Inc, 2, 5

Carlson, Hans L., MD Entrapment Neuropathies and Nerve Conduction Studies . . . . . . . . . . . . . . 92 Disclosure: Nothing to Disclose Carter, John D., MD Spondylarthropathies: Recent Insights . . . . 88 Disclosure: Nothing to Disclose Carter, Robert H., MD Rheumatoid Arthritis: Where Does It Begin? 64 Disclosure: Nothing to Disclose Castillo, Rhina, MD Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: Nothing to Disclose Chang, Alison H., PT, DPT, MS Mechanical Factors in Knee Osteoarthritis: A Plausible Road to Riches . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose

Clayburne, Gilda M., MLT Synovial Fluid Analysis and Crystal Identification Disclosure: Nothing to Disclose . . . 30, 59, 87

Chang, Hyun-Dong, PhD Stem Cell Mediated Therapies in Autoimmune Diseases . . . . . . . . . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose

Clegg, Daniel O., MD Spondylarthropathy: An Update . . . . . . . 27 Disclosure: Nothing to Disclose

Chen, Lan X., MD, PhD Synovial Fluid Analysis and Crystal Identification . . . . . . . . . . . . . . . . . . . . . . . . . 30 Disclosure: Nothing to Disclose

Clemens, Thomas L., PhD Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose

Chhakchhuak, Christine, MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose

Clowse, Megan E. B., MD, MPH Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Pregnancy in Rheumatic Diseases . . . . . . 32 Disclosure: Nothing to Disclose

Chopra, Arvind, MD, DNB ILAR Global Health Project . . . . . . . . . . 81 Disclosure: Nothing to Disclose Christenson, Mary E., PT, PhD Designing Exercise Prescriptions for Individuals with Arthritis and Other Comorbidities: What are the Considerations? . . . . . . . . . . 1115 Disclosure: Nothing to Disclose Lower Extremity Musculoskeletal Assessment of the Rheumatology Patient . . . . . . . . . .129 Disclosure: Nothing to Disclose Christmann, Romy, MD, PhD Challenging Complications of Systemic Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . .107 Disclosure: Nothing to Disclose

324

2011 Program Book

Cohen, Stanley B., MD Rheumatoid Arthritis: Difficult Cases . . . . 127 Disclosure: Pfizer, Roche, Genentech, BristolMyers Squibb, Johnson and Johnson, Centocor, UCB, Merck, Amgen and Novartis, 2, 5 Utilizing Media Relations to Build Your Practice . . . . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Pfizer, Roche, Genentech, BristolMyers Squibb, Johnson and Johnson, Centocor, UCB, Merck, Amgen and Novartis, 2, 5

Conaghan, Philip G., MD, PhD Peripheral Magnetic Resonance Imaging in Rheumatology Practice . . . . . . . . . . . . 30 Disclosure: Amgen, 5; AstraZeneca, 8; Bioiberica, 8; Bristol-Myers Squibb, 5; Centocor, Inc., 2; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 2; Roche Pharmaceuticals, 5 Cooper, Glinda S., PhD ICD Coding - Crash Course for Researchers . 54 Disclosure: Nothing to Disclose Impact of Environmental Health on Autoimmunity . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Costenbader, Karen H., MD, MPH Impact of Environmental Health on Autoimmunity . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Rheumatoid Arthritis: Where Does it Begin? 64 Disclosure: Nothing to Disclose Coty, Mary-Beth, PhD, RN Cognitive Function in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Cox, Talitha, MA, OTR/L Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: Nothing to Disclose Crawford, Donah Z., BS, MA Highlights from the 2011 ARHP Sessions . . 117 Disclosure: Nothing to Disclose Criswell, Lindsey A., MD, MPH Mechanisms of Lymphoma Development in Systemic Autoimmune Disease . . . . . . . . 95 Disclosure: Nothing to Disclose Crofford, Leslie J., MD Complex Pain Issues: Comorbidities and Special Populations . . . . . . . . . . . . . . . . . . . 24 Disclosure: Nothing to Disclose Gender Issues in the Rheumatology Workforce . . . . . . . . . . . . . . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Year in Review . . . . . . . . . . . . . . . . . 26 Disclosure: Nothing to Disclose Cronin, Mary E., MD Adult Inflammatory Myopathy . . . . . . . . 32 Disclosure: Nothing to Disclose Extra Glandular Manifestations of Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose Cronstein, Bruce N., MD Adult Pharmacogenomics . . . . . . . . . . . 89 Disclosure: Canfite Pharma; Bristol-Myers Squibb; Tap Pharmaceuticals; Prometheus laboratories; Regeneration (Westat, DSMB); Endocyte; Savient. , 5; Canfite Piophamaceuticals, 1; Eli Lilly & Co.; UCB , Pfizer,Vilcek Foundation, 6; NIH; Vilcek Foundation; URL Pharma, 2 Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . . . . . . . . . . . . . . 81 Disclosure: Canfite Pharma; Bristol-Myers Squibb; Tap Pharmaceuticals; Prometheus laboratories; Regeneration (Westat, DSMB); Endocyte; Savient. , 5; Canfite Piophamaceuticals, 1; Eli Lilly & Co.; UCB ;Pfizer; Vilcek Foundation, 6; NIH; Vilcek Foundation; URL Pharma, 2

D Dahl, Owen J., MBA, CHBC Mastering Patient Flow to Improve Practice Operations . . . . . . . . . . . . . . . . . . . 94 Disclosure: Nothing to Disclose Daikh, Brian E., MD Thieves’ Market: Show Me Your Best Cases . 71 Disclosure: Nothing to Disclose Daikh, David I, MD, PhD ACR REF Marshall J. Schiff, MD, Memorial Lectureship: Multicenter Orthopaedic Outcomes Network - A Prospective Longitudinal Cohort of ACL Reconstruction Outcomes . . . . . . . . 82 Disclosure: Nothing to Disclose Dasgupta, Bhaskar, MD Polymyalgia Rheumatica . . . . . . . . . . . 32 Disclosure: Nothing to Disclose Davey, Michael P., MD, PhD Extrarticular Manifestations of Rheumatoid Arthritis: Ophthalmologic, Pulmonary and Cardiovascular . . . . . . . . . . . . . . . . 105 Disclosure: Nothing to Disclose Davidson, Anne, MBBS ACR REF Edmond L. Dubois, MD, Memorial Lectureship: “Interfering” with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . 104 Disclosure: Abbott Immunology Pharmaceuticals, 5; Bristol-Myers Squibb, 5 De Vries, Niek, MD, PhD Next-Generation Sequencing Applied to Rheumatic Diseases . . . . . . . . . . . . . . 95 Disclosure: Nothing to Disclose Deal, Chad L., MD Great Debate: Is too Much Suppression of Turnover Bad for Bone? . . . . . . . . . . . . 42 Disclosure: Lilly, Novartis, Amgen, 5; Lilly, Novartis, Amgen, Warner Chilcott, 8 Deane, Kevin D., MD, PhD Rheumatoid Arthritis: Where Does It Begin? 64 Disclosure: Abbott Laboratories, 2 Dees, Clara, MSc Plenary Session III . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Del Fatore, Andrea, PhD Plenary Session II . . . . . . . . . . . . . . . . 60 Disclosure: Nothing to Disclose Dellaripa, Paul F., MD Pulmonary Manifestations of Rheumatic Disease . . . . . . . . . . . . . . . . . . . . . 62 Disclosure: BIogen, Gilead, 2, 9 Pulmonary Manifestations of Rheumatic Disease . . . . . . . . . . . . . . . . . . . . . 93 Disclosure: Nothing to Disclose

Dennis, Gregory J., MD Contract Negotiations for Physicians . . . . . 62 Disclosure: Nothing to Disclose Denton, Christopher P., PhD Scleroderma: Systemic Sclerosis . . . . . 87, 56 Disclosure: Actelion Pharmaceuticals US, 5; GSK, 5; Orion pharmaceuticals, 5; Pfizer Inc, 5; SanofiAventis Pharmaceutical, 5 Denton, G. Dodd, MD, MPH Medical Education: Year in Review . . . . . . 33 Disclosure: Nothing to Disclose Deodhar, Atul A., MD, MRCP Debate: Joints for Joints: Medical Marijuana is Useful for Treating Rheumatic Disease . . . . 72 Disclosure: Nothing to Disclose Joint Injection Techniques . . . . . . . . . . . 30 Disclosure: Nothing to Disclose Reactive Arthritis: An Update . . . . . . . . . 80 Disclosure: Centocor, Inc., 5, 8 Deutsch, Anne, RN, PhD, CRRN Analysis of Large Databases: Rheumatology Research Opportunities . . . . . . . . . . . 124 Disclosure: Nothing to Disclose Dewing, Kori A., DNP, ARNP ARHP Distinguished Lecturer: How Do We Get Policy Makers to Take Musculoskeletal Conditions Seriously? – The Bone and Joint Initiative . . . . . . . . . . . . . . . . . . . . 59 Disclosure: Nothing to Disclose Keynote Address: Sleep for Success! Everything You Must Know About Sleep, but Are Too Tired to Ask . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose Metabolic Bone Disease . . . . . . . . . . . 115 Disclosure: Nothing to Disclose Dixon, William G., MRCP, PhD Heart Disease and Rheumatoid Arthritis . . . 74 Disclosure: Nothing to Disclose Dodge, Carole V., OT, CHT Pregnancy and Child Care Issues for Parents with Arthritis . . . . . . . . . . . . . . . . . . 89 Disclosure: Nothing to Disclose Dooley, M.A., MD, MPH Systemic Lupus Erythematosus: Novel Treatments . . . . . . . . . . . . . . . . . . 100 Disclosure: Human Genome Sciences, GlaxoSmithKline, Vifor Pharma, Lupus Foundation of America Medical Scientific and Advisory Board, 5; Human Genome Sciences, UCB, Genentech, Cephalon, Bristol-Myers Squibb, Eli Lilly, 2 Dore, Robin K., MD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . . 123 Disclosure: Amgen, Takeda, UCB, Roche, SanofeAventis, Eli Lilly, Bristol-Meyers, Squibb reserch grants. Consulting fees for Amgen, Novartis, Takeda, Pfizer, Abbott. Speaker’s bureau for Amgen, Pfizer, UCB, Abbott, Takeda, Novartis, Eli Lilly, Warner-Chilcott, 8 Dowell, Sharon, MBBS Thieves’ Market: Show Me Your Best Cases . 71 Disclosure: Nothing to Disclose

Dufour, Alyssa B., MA Are You Losing It? How to Deal with Loss to Follow Up in Research Studies and Clinical Trials 92 Disclosure: Nothing to Disclose Dugan, Sheila A., MD Gender Issues in the Rheumatology Workforce . . . . . . . . . . . . . . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Dunlop, Dorothy D., PhD Basic Statistical Concepts for the Medical Researcher . . . . . . . . . . . . . . . . . . . 63 Disclosure: Nothing to Disclose Duruoz, Mehmet Tuncay, MD Axial Spondylarthritis: New Concepts . . . . 53 Disclosure: Nothing to Disclose


Cush, John J., MD Rheumatology Roundup: Highlights from the 2011 Annual Scientific Meeting . . . . . . . 111 Disclosure: Abbott Immunology Pharmaceuticals, 5; Allos, 5; Amgen, 5; Auxilum, 5; Celgene, 5; Cellestis, 5; Centorcor, 5; Flexion, 5; Genentech and Biogen IDEC Inc., 5; Human Genome Sen, 5; Ortho Biotech Products L.P., 5; Pfizer Inc, 5; UCB, 2, 4

E Ehrlich-Jones, Linda S., PhD, RN First-time Attendees Orientation . . . . . . . 26 Disclosure: Nothing to Disclose Policy and Environmental Strategies to Support Increased Physical Activity for Adults with Arthritis: Findings from a Centers for Disease Control/Arthritis Foundation Expert Panel . 129 Disclosure: Nothing to Disclose Rubbing Elbows with the Higher Ups: Effective Communications with Administration . . . 117 Disclosure: Nothing to Disclose Eich, Geoffrey Biosimilar Products in the U.S. Market: Fact or Fiction? . . . . . . . . . . . . . . . . . . . . 125 Disclosure: Full Time Employee, 3 El-Gabalawy, Hani S., MD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Elkon, Keith B., MD Apoptosis, Phagocytic Clearance and Autoimmune and Inflammatory Diseases . 116 Disclosure: Resolve Therapeutics, 2 Embi, Peter J., MD, MS Designing a Website for Your Practice . . . . 30 Disclosure: Nothing to Disclose Epstein, Alana, MSW Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 84 Disclosure: Nothing to Disclose Erickson, Alan R., MD CORC Forum: Payment Reform Options . . . 92 Disclosure: Nothing to Disclose Erkan, Doruk, MD Management of Antiphospholipid SyndromeFrom Controversies to Consensus . . . . . . 44 Disclosure: Genentech and Biogen IDEC Inc., 2, 5; Lupus Clinical Trials Consortium, 2 Espinoza, Luis R., MD ILAR Global Health Project . . . . . . . . . . 80 Disclosure: Nothing to Disclose

2011 Program Book

325


Evangelisto, Amy M., MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One . . . . . . . . . . 17 Disclosure: Abbott Laboratories, 8; UCB, Abbott, 2; USSONAR, 6

Firestein, Gary S., MD Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose

Everix, Donna K., MPA, BS, PT Disease Modifying Osteoarthritis Drugs, Glucosamine/Chondroitin and Nonpharmacologic Treatment of Osteoarthritis . 83 Disclosure: Nothing to Disclose Rehabilitation for the Clinician . . . . . . . . 43 Disclosure: Nothing to Disclose

Fisher, Nadine M., EdD Analysis of Large Databases: Rheumatology Research Opportunities . . . . . . . . . . . 124 Disclosure: Nothing to Disclose Designing Exercise Prescriptions for Individuals with Arthritis and Other Comorbidities: What are the Considerations? . . . . . . . . . . . 115 Disclosure: Nothing to Disclose Mechanical Factors in Knee Osteoarthritis: A Plausible Road to Riches . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose The Osteoarthritis Initiative: A Database for Knee Osteoarthritis Research . . . . . . . . . 31 Disclosure: Nothing to Disclose

F Falk-Krzesinski, Holly, PhD Best Practices for Collaboration in Research and Clinical Practice . . . . . . . . . . . . . . . . . 31 Disclosure: Nothing to Disclose Feghali-Bostwick, Carol A., PhD Fibrosis: Novel Paradigms . . . . . . . . . . . 63 Disclosure: Nothing to Disclose New Concepts in the Autoimmune Pathogenesis of Interstitial Lung Diseases . . . . . . . . . 106 Disclosure: Nothing to Disclose Feldman, Brian M., MD The Child with Chronic Pain . . . . . . . . . 108 Disclosure: Nothing to Disclose Felson, David T., MD, MPH Disease Modifying Osteoarthritis Drugs, Glucosamine/Chondroitin and Nonpharmacologic Treatment of Osteoarthritis . 83 Disclosure: Nothing to Disclose Ferguson, Karen M., MS Fiscal Management of Infusion Clinics: Academic and Private Practice Perspectives . . . . . . . 93 Disclosure: Genentech and Biogen IDEC Inc., 8; UCB Speakers Bureau, 8 Chronic Non-bacterial Osteomyelitis . . . . 124 Disclosure: Nothing to Disclose Pediatrics: Periodic Fevers in Children . . . . 62 Disclosure: Nothing to Disclose Ferrari, Jill, PhD, BSc(Hons) Practice Potpourri . . . . . . . . . . . . . . 106 Disclosure: Nothing to Disclose Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Amgen and MSD, 2; Amgen, Eli Lilly, MSD, Novartis, 5 Fett, Nicole, MD Cutaneous Vasculitis . . . . . . . . . . . . . . 32 Disclosure: Amgen, 2; Celgene, 2 Dermatological Manifestations of Rheumatic Diseases . . . . . . . . . . . . . . . . . . 51, 113 Disclosure: Amgen, 2; Celgene, 2 Figueroa, Fernando E., MD Management of Antiphospholipid SyndromeFrom Controversies to Consensus . . . . . . 44 Disclosure: Nothing to Disclose Fiorentino, David, PhD Emerging Concepts in the Inflammatory Myopathies . . . . . . . . . . . . . . . . . . . 87 Disclosure: Nothing to Disclose

326

2011 Program Book

FitzGerald, John D., MD, PhD Developing ACR Guidelines for the Treatment of Gout . . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose Fleischmann, Roy M., MD Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis . . . . . . . . . . . . . 34 Disclosure: AstraZeneca, 2; Pfizer Inc, 2, 5; Sanofi-Aventis Pharmaceutical, 2 Flood, Joseph, MD ACR Leadership Town Hall Meeting . . . . . 95 Disclosure: Nothing to Disclose Fonseca, João E., MD, PhD Towards Prevention of Atherosclerosis Progression in Rheumatoid Arthritis: Insights into the Relationship between Inflammation and Cardiovascular Disease . . . . . . . . . . 90 Disclosure: Abbott Immunology Pharmaceuticals, 2; Pfizer Inc, 2 Fontanarosa, Phil, MD, MBA Publishing in Peer-Reviewed Medical Journals . . . . . . . . . . . . . . . . . . . . . . . . . 33 Disclosure: Employment, 3 Fox, David A., MD Developing ACR Guidelines for the Treatment of Gout . . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Savient, 5 Year in Review . . . . . . . . . . . . . . . . . 26 Disclosure: Genetech, 2 Fraenkel, Liana, MD, MPH Developing ACR Guidelines for the Treatment of Gout . . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose Frank, Michael M., MD Hereditary Angioedema . . . . . . . . . . . 118 Disclosure: CSL Behring, Viropharma, Dyax, Shire and Pharming, 5 Frech, Tracy M., MD Hereditary Angioedema . . . . . . . . . . . 118 Disclosure: Nothing to Disclose

Furst, Daniel E., MD 2011 Updated ACR Rheumatoid Arthritis Guidelines . . . . . . . . . . . . . . . . . . . 63 Disclosure: Abbott, Actelion, Amgen, BMS, BiogenIdec, Centocor, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 5; Abbott, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 2; Abbott, Actelion, UCB , 8; Corrona, 3 Systemic Sclerosis: How to Perform Skin Scores 73 Disclosure: Abbott, Actelion, Amgen, BMS, BiogenIdec, Centocor, CORRONA, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 5; Abbott, Actelion, Amgen, BMS, BiogenIdec, Centocor, Gilead, NIH, Roche/Genentech, 9; Abbott, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 2; Abbott, Actelion, UCB , 8

G Gadea, Carlos, MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose Gall, Eric P., MD, MACR, MACP Rubbing Elbows with the Higher Ups: Effective Communications with Administration . . . 117 Disclosure: Nothing to Disclose Gardner, Gregory C., MD Hyperuricemia and Gout: Mechanisms and Morbidity . . . . . . . . . . . . . . . . . . . . 94 Disclosure: Nothing to Disclose Joint Injections (Knee and Ankle Prosthetics) 56 Disclosure: Nothing to Disclose Joint Injections (Shoulder and Wrist Prosthetics) . . . . . . . . . . . . . . . . . . . . . . . . . 73 Disclosure: Nothing to Disclose Gattorno, Marco, MD, PhD New Auto-inflammatory Syndromes . . . . . 29 Disclosure: Novartis, SOBI, 8 Gay, Steffen, MD Epigenetic Changes in Rheumatic Disease . . 26 Disclosure: Nothing to Disclose MicroRNA in Epigenetic Regulation of Rheumatic Inflammatory Diseases . . . . . . 33 Disclosure: Nothing to Disclose Genovese, Mark C., MD Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis . . . . . . . . . . . . . 34 Disclosure: Lilly, 2; Pfizer Inc, 2; Pharmacyclics, 5; Portola, 5; Vertex, 5 Gerlag, Danielle Marie, MD, PhD Rheumatoid Arthritis: Where Does It Begin? 64 Disclosure: Nothing to Disclose Gignac, Monique A., PhD Beyond Pain and Fatigue: Expanding Clinician and Researcher Focus to Improve Daily Life 105 Disclosure: Nothing to Disclose Giles, Jon T., MD, MPH Cervical Spine Surgeries in Rheumatic Diseases: 2011 Update . . . . . . . . . . . . . . . . . . 56 Disclosure: Genentech and Biogen IDEC Inc., 5 Heart Disease and Rheumatoid Arthritis . . . 74 Disclosure: Genentech and Biogen IDEC Inc., 5

Glass, David N., MD Juvenile Idiopathic Arthritis: Clinical Heterogeneity and the Genome . . . . . . . 59 Disclosure: Nothing to Disclose Gold, Garry, MD Tools for Studying Joint Tissue Changes in Osteoarthritis . . . . . . . . . . . . . . . . . . 34 Disclosure: Arthrocare, Inc, 5; GE Healthcare, 2; Isto, Inc, 5; Zimmer, Inc, 5 Goldberg, Lynne J., MD Dermatopathology of Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . 27, 33 Disclosure: Nothing to Disclose Goldin, Lynn R., PhD Mechanisms of Lymphoma Development in Systemic Autoimmune Disease . . . . . . . . 95 Disclosure: Nothing to Disclose Goldman, John A., MD Immunology 101 and Targeted Therapies for Rheumatology Healthcare Professionals . . . 31 Disclosure: Amgen, Pfizer, UCB, 8; Atlanta Center Clincial Research, 2; BMS, 1 Goldring, Steven R., MD Introduction: Pathophysiology of Bone Remodeling in Rheumatic Diseases . . . . . 18 Disclosure: Boehringer Ingelheim, 2; Bone Therapeutics, 5; Pfizer Inc, 5 Session II: Cross-Talk between Bone and ExtraSkeletal Organs . . . . . . . . . . . . . . . . . 19 Disclosure: Boehringer Ingelheim, 2; Bone Therapeutics, 5; Pfizer Inc, 5 Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 20 Disclosure: Boehringer Ingelheim, 2; Bone Therapeutics, 5; Pfizer Inc, 5 Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Boehringer Ingelheim, 2; Bone Therapeutics, 5; Pfizer Inc, 5

Greenberg, Jeffrey D., MD New Targets in Rheumatoid Arthritis: Syk, Jaks and Btk . . . . . . . . . . . . . . . . . . . . . 28 Disclosure: CORRONA Inc., 1, 5; Pfizer, Astra Zeneca, 5 Session IV: Successes in Rheumatology Comparative Effectiveness Research . . . . . 22 Disclosure: CORRONA Inc., 1, 5; Pfizer, Astra Zeneca, 5 Gregersen, Peter K., MD Moving Forward in the Genome Wide Association Studies Era . . . . . . . . . . . . 54 Disclosure: Nothing to Disclose Next-Generation Sequencing Applied to Rheumatic Diseases . . . . . . . . . . . . . . 95 Disclosure: Nothing to Disclose Grom, Alexei A., MD Juvenile Idiopathic Arthritis: Clinical Heterogeneity and the Genome . . . . . . . 59 Disclosure: Novartis Pharmaceutical Corporation, 5 Grossman, Jennifer M., MD Treatment of Lupus Nephritis . . . . . . . . 60 Disclosure: Genentech, Anthera, Cephalon, Human Genome Sciences, TEVA, 2 Gultekin, Sakir Humayun, MD Muscle Involvement in Rheumatic Diseases . 95 Disclosure: Nothing to Disclose

H Haggart, Ellie, BSc An Update in the Diagnosis and Management of Juvenile Dermatomyositis . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Hahn, Bevra H., MD ACR REF Memorial Lectureship: From Shulman’s Syndrome to Nephrogenic Systemic Fibrosis: Exogenous Factors and Systemic Fibrosing Disorders . . . . . . . . . . . . . . . . . . . . 57 Disclosure: Nothing to Disclose Treatment of Lupus Nephritis . . . . . . . . . 60 Disclosure: Abbott Laboratories, 5; Anthera, Inc, 5; Aspreva, 2; BMS, Inc, 5; UCB, Inc., 5

Hansen, Karen, MD, MS Efficacy and Safety of Calcium and Vitamin D Supplementation . . . . . . . . . . . . . . . 118 Disclosure: NIH grant to study different doses of vitamin D vs. placebo, 2 Vitamin D and Bone Health . . . . . . . . . 33 Disclosure: NIH grant to study different doses of vitamin D vs. placebo, 2 Hant, Faye N., DO, MSCR Did You Brush Your Teeth Today? . . . . . . . 62 Disclosure: Nothing to Disclose Hardin, John A., MD Tools for Studying Joint Tissue Changes in Osteoarthritis . . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Harris, Richard E., PhD Brain Correlates of Chronic Pain . . . . . . 117 Disclosure: Pfizer Inc, 2 Hassett, Afton L., PsyD Evidence-based Non-pharmacological Interventions . . . . . . . . . . . . . . . . . . 24 Disclosure: Bristol-Myers Squibb, 2, 5; Jazz Pharmaceuticals, 5 Improving Health Measurement in Rheumatology . . . . . . . . . . . . . . . . 115 Disclosure: Bristol-Myers Squibb, 2, 5; Jazz Pharmaceuticals, 5 Pain: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . 24 Disclosure: Bristol-Myers Squibb, 2, 5; Jazz Pharmaceuticals, 5 Hayward, Anthony, MD, PhD Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Heaney, Robert P., MD Efficacy and Safety of Calcium and Vitamin D Supplementation . . . . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose Heath, Jonathon, MD Histopathology of Vasculitis . . . . . . . 90, 95 Disclosure: Nothing to Disclose

Goldstein, David, PhD Moving Forward in the Genome Wide Association Studies Era . . . . . . . . . . . . 54 Disclosure: Nothing to Disclose

Hajj-Ali, Rula, MD Central Nervous System Vasculitis . . . . . . 80 Disclosure: Nothing to Disclose Vasculitis: Key Issues for the Clinician in Three Unique Diseases . . . . . . . . . . . . . . . . 96 Disclosure: Nothing to Disclose

Helmick, Charles G., MD ICD Coding - Crash Course for Researchers . 55 Disclosure: Nothing to Disclose

Gourley, Mark F., MD Myopathy: Issues in Diagnosis and Treatment . . . . . . . . . . . . . . . . . . . . . . . . 32, 93 Disclosure: Nothing to Disclose

Hammond, Alison, PhD Pregnancy and Child Care Issues for Parents with Arthritis . . . . . . . . . . . . . . . . . . 89 Disclosure: Nothing to Disclose

Herman, Sonja, MD Plenary Session III . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose

Goyal, Janak R., MD Musculoskeletal Ultrasonography: Basic . . . 27 Disclosure: SonoSite, Abbott, 5

Hannan, Marian T., DSc, MPH Foot Structure, Footwear and Foot Pain Translating Evidence into Practice . . . . . . 73 Disclosure: Nothing to Disclose Publishing in Peer-Reviewed Medical Journals . . . . . . . . . . . . . . . . . . . . . . . . . 33 Disclosure: Nothing to Disclose

Graham, James E., PhD, DC Analysis of Large Databases: Rheumatology Research Opportunities . . . . . . . . . . . 124 Disclosure: Nothing to Disclose Gravallese, Ellen M., MD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 20 Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 2


Giltiay, Natalia V. ACR REF Edmond L. Dubois, MD, Memorial Lectureship: “Interfering” with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . 104 Disclosure: Nothing to Disclose

Henrickson, Michael, MD, MPH The Child with Chronic Pain . . . . . . . . . 108 Disclosure: Nothing to Disclose

Herzog, Erica, MD, PhD New Concepts in the Autoimmune Pathogenesis of Interstitial Lung Diseases . . . . . . . . . 107 Disclosure: Medimmune Inc, 2 Hewlett, Sarah, PhD, MA, RN Behave Yourself! Practical Application of Cognitive Behavioral Theories to Motivate Change in Patients with Arthritis . . . . . . . 54 Disclosure: Nothing to Disclose

2011 Program Book

327


Hillstrom, Howard J., PhD Foot Structure, Footwear and Foot Pain Translating Evidence into Practice . . . . . . 73 Disclosure: Stride Rite, 2 Knee Braces and Foot Orthosis for Knee Osteoarthritis . . . . . . . . . . . . . . . . . . 73 Disclosure: Stride Rite, 2 Hinz, Boris, PhD Fibrosis: Novel Paradigms . . . . . . . . . . . 64 Disclosure: Nothing to Disclose Hobday, Patricia, MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose Hochberg, Marc, MD, MPH Disease Modifying Osteoarthritis Drugs, Glucosamine/Chondroitin and Nonpharmacologic Treatment of Osteoarthritis . 83 Disclosure: Abbott Laboratories, Amgen, AstraZeneca Pharmaceuticals, Bioiberica S.A., Bristol Myers Squibb, Covidien, Eli Lilly, Genentech/ Roche, Iroko Pharmaceuticals, Merck, EMD Serono, NiCox S.A., Novartis Pharma AG, Pfizer, Pozen, Smith and Nephew, Stryker LLC, , 5; Theralogix LLC, 1; U.S. Bone and Joint Initiative, 6 Hoffman, Bruce I., MD Celiac Disease: Immunopathogenesis and Clinical Spectrum Potential . . . . . . . . . . 85 Disclosure: Nothing to Disclose Hogaboam, Cory M., PhD Fibrosis: Novel Paradigms . . . . . . . . . . . 64 Disclosure: Novartis Pharmaceutical Corporation, 2 Holers, V. Michael, MD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Hong, Raymond, MD, MBA CORC Forum: Payment Reform Options . . . 92 Disclosure: Nothing to Disclose ICD-10 & HIPAA 5010 - Ready or Not…It’s Coming! . . . . . . . . . . . . . . . . . . . . 116 Disclosure: Nothing to Disclose Hootman, Jennifer M., ATC, PhD Introduction to Comparative Effectiveness Research Study Designs for Rheumatology Health Professionals . . . . . . . . . . . . . 125 Disclosure: Nothing to Disclose Policy and Environmental Strategies to Support Increased Physical Activity for Adults with Arthritis: Findings from a Centers for Disease Control/Arthritis Foundation Expert Panel . 129 Disclosure: Nothing to Disclose Houssiau, Frédéric A., MD, PhD Systemic Lupus Erythematosus: Lupus Nephritis . . . . . . . . . . . . . . . . . . . . . . 27, 113 Disclosure: Aspreva, 5; BMS, 5; Genentech and Biogen IDEC Inc., 5; GlaxoSmithKline, 5; Human Genome Sciences, Inc., 5; Roche Pharmaceuticals, 5; Serono, 5; UCB, 5

328

2011 Program Book

Huber, Adam, MD Pediatrics: Dermatomyositis . . . . . . . . . 51 Disclosure: Nothing to Disclose Hughes, Graham R. V., MD Antiphospholipid Syndrome . . . . . . . 55, 86 Disclosure: Nothing to Disclose Huisinga, Karen, MN, ARNP Practice Potpourri . . . . . . . . . . . . . . 106 Disclosure: Abbott Immunology Pharmaceuticals, 8; Pfizer Inc, 8 Hummers, Laura K., MD, ScM Challenging Complications of Systemic Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . .107 Disclosure: Nothing to Disclose Curbside Consults - Ask the Professors . . . . 59 Disclosure: Actelion Pharmaceuticals US, 2; Medical & Biological Laboratories, 2; United Therapeutics, 2 Scleroderma Mimics . . . . . . . . . . . . . . 62 Disclosure: Nothing to Disclose Humphrey, Mary Beth, MD, PhD Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . . 18 Disclosure: Nothing to Disclose Hunder, Gene G., MD Temporal Arteritis . . . . . . . . . . . . 51, 93 Disclosure: Nothing to Disclose Husain, Aliya, MD Clinicopathologic Conference: A 40 Year-Old Male with Dyspnea on Exertion . . . . . . . . 54 Disclosure: Nothing to Disclose Husni, M. Elaine, MD, MPH Psoriatic Arthritis . . . . . . . . . . . . . 55, 113 Disclosure: Nothing to Disclose Spondylarthropathies: Recent Insights . . . . 87 Disclosure: Nothing to Disclose Hyrich, Kimme L., MD, PhD Session IV: Successes in Rheumatology Comparative Effectiveness Research . . . . . 22 Disclosure: Nothing to Disclose

I Inman, Robert D., MD Chronic Non-bacterial Osteomyelitis . . . . 124 Disclosure: Sanofi-Aventis Pharmaceutical, Merck, Abbott, Amgen-Wyeth, 5 Isenberg, David A., MD Difficult to Treat Systemic Lupus Erythematosus: Case Studies . . . . . . . . . . . . . . . . . . 73 Disclosure: Nothing to Disclose Ivashkiv, Lionel B., MD Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Iversen, Maura D., DPT, SD, MPH, PT Designing Exercise Prescriptions for Individuals with Arthritis and Other Comorbidities: What are the Considerations? . . . . . . . . . . . 115 Disclosure: Nothing to Disclose

J Jack, Hans-Martin, PhD Epigenetic Changes in Rheumatic Disease . . 26 Disclosure: Nothing to Disclose James, Judith A., MD, PhD Impact of Environmental Health on Autoimmunity . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Sjögren’s Syndrome: Not Just Dryness . . . . 23 Disclosure: Nothing to Disclose James, Nadine, RN, PhD ACR Leadership Town Hall Meeting . . . . . 95 Disclosure: Nothing to Disclose ACR/ARHP Opening Lecture and Awards . . . 24 Disclosure: Nothing to Disclose Janisse, Dennis J., C, Ped New and Noteworthy: Nursing, Pharmacy and Pedorthics . . . . . . . . . . . . . . . . . . . 55 Disclosure: Nothing to Disclose Jarvis, James N., MD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . . 123 Disclosure: Genentech and Biogen IDEC Inc., 5 Jimenez, Richard, MD Disability: Clinical Facts, Legal Fictions, and Practice Strategies . . . . . . . . . . . . . . . 43 Disclosure: Nothing to Disclose ACR REF Memorial Lectureship: From Shulman’s Syndrome to Nephrogenic Systemic Fibrosis: Exogenous Factors and Systemic Fibrosing Disorders . . . . . . . . . . . . . . . . . . . . 57 Disclosure: Nothing to Disclose Jones, Dallas, PhD New Insights into Bone Remodeling . . . . . 85 Disclosure: Nothing to Disclose Jordan, Joanne M., MD, MPH Tools for Studying Joint Tissue Changes in Osteoarthritis . . . . . . . . . . . . . . . . . . 34 Disclosure: Algynomics, Inc., 1; Eli Lilly and Company, 5; Interleukin Genetics, Inc., 5; Johnson and Johnson, Inc., 2, 5 Total Hip and Knee Replacements 2011: An Update for Rheumatologists . . . . . . . . . 74 Disclosure: Algynomics, Inc., 1; Eli Lilly and Company, 5; Interleukin Genetics, Inc., 5; Johnson and Johnson, Inc., 2, 5 Jorgensen, Christian, MD, PhD Stem Cell Mediated Therapies in Autoimmune Diseases . . . . . . . . . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose

K Kaeley, Gurjit S., MBBS, MRCP Musculoskeletal Ultrasonography: Basic . . . 27 Disclosure: equipment grant, 2 Musculoskeletal Ultrasound Course for Rheumatologists - Day One . . . . . . . 17, 18 Disclosure: equipment grant, 2 Kafka, Shelly P., MD The Three Ps of Dermatologic and Autoimmune Disease: Pyoderma, Panniculitis and Pemphigus/ Pemphigoid . . . . . . . . . . . . . . . . . . . 91 Disclosure: Abbott Immunology Pharmaceuticals, 9; Amgen, 9; Johnson & Johnson, 5; Lilly Pharmaceuticals, 9; Novartis Pharmaceutical Corporation, 8; Pfizer Inc, 8, 9; UCB, 5, 9

Katz, Patricia P., PhD Beyond Pain and Fatigue: Expanding Clinician and Researcher Focus to Improve Daily Life 105 Disclosure: Nothing to Disclose

Khanna, Puja, MD, MPH Developing ACR Guidelines for the Treatment of Gout . . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose

Kalish, Robert A., MD ACR/ABIM Maintenance of Certification Learning Session - 2011 Update in Rheumatology . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Rheumatology Physical Examination of Lower Extremity and Lumbosacral Spine: Anatomical Correlates . . . . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Rheumatology Physical Examination of Upper Extremity and Cervical Spine: Anatomical Correlates . . . . . . . . . . . . . . . . . . . . 87 Disclosure: Nothing to Disclose

Kavanaugh, Arthur, MD Debate: Joints for Joints: Medical Marijuana is Useful for Treating Rheumatic Disease . . . . 72 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Centocor, Inc., 2 Psoriatic Arthritis . . . . . . . . . . . . . . . . 51 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Centocor, Inc., 2 Rheumatology Roundup: Highlights from the 2011 Annual Scientific Meeting . . . . . . . 116 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Centocor, Inc., 2 Update on Safety Issues in the Treatment of Rheumatic Diseases – From the FDA and Beyond . . . . . . . . . . . . . . . . . . . . . . . . .125 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Centocor, Inc., 2

King II, Charles M., MD Health Information Technology and Informatics to Promote High Quality Rheumatologic Care . . . . . . . . . . . . . . . . . . . . . . . . . 27 Disclosure: Nothing to Disclose Understanding Medicare Incentive Programs: e-Prescribing & PQRI . . . . . . . . . . . . . 90 Disclosure: Nothing to Disclose

Kamen, Diane L., MD, MS Curbside Consults - Ask the Professors . . . . 59 Disclosure: Nothing to Disclose Efficacy and Safety of Calcium and Vitamin D Supplementation . . . . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose Impact of Environmental Health on Autoimmunity . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Thieves’ Market: Show Me Your Best Cases . 71 Disclosure: Nothing to Disclose Kandiah, David A., MPH, PhD Thieves’ Market: Show Me Your Best Cases . 71 Disclosure: Nothing to Disclose Kaplan, Mariana J., MD ACR REF Edmond L. Dubois, MD, Memorial Lectureship: “Interfering” with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . 104 Disclosure: Nothing to Disclose Karlson, Elizabeth W., MD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Karp, David R., MD, PhD ACR REF Special Session: Within Our Reach: Finding a Cure for Rheumatoid Arthritis . . . 42 Disclosure: Nothing to Disclose Karsenty, Gerard, MD., PhD Session II: Cross-Talk between Bone and ExtraSkeletal Organs . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Kashikar-Zuck, Susmita, PhD The Child with Chronic Pain . . . . . . . . . 108 Disclosure: Nothing to Disclose Katz, James D., MD ACR REF Special Session: Clinician Scholar Educator Presentations . . . . . . . . . . . . 51 Disclosure: Nothing to Disclose Katz, Jeffrey N., MD Total Hip and Knee Replacements 2011: An Update for Rheumatologists . . . . . . . . . 74 Disclosure: Nothing to Disclose

Kay, Jonathan, MD Rheumatoid Arthritis: Challenging Cases . . . . . . . . . . . . . . . . . . . . . . . 27, 93 Disclosure: Array BioPharma, 5; Bristol-Myers Squibb, 2, 5; Centocor Ortho Biotech, 5; Eisai Research Institute, 5; Fidia Farmaceutici SpA, 2; Genentech and Biogen IDEC Inc., 5; Johnson & Johnson, 5; Mallinkrodt, 5; Novo Nordisk, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 2, 5; Sanofi-Aventis Pharmaceutical, 2, 5; UCB, 5 Kazi, Salahuddin, MD Getting Electronic Health Record Right . . . . 63 Disclosure: Nothing to Disclose Understanding Medicare Incentive Programs: e-Prescribing & PQRI . . . . . . . . . . . . . . 90 Disclosure: Nothing to Disclose Kennedy, Christine W., CPNP, MSN, RN Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: Nothing to Disclose Keysor, Julie J., PhD, PT Keep People with Arthritis Working: An Interactive Case-based Discussion . . . . . 105 Disclosure: Nothing to Disclose Keystone, Edward, MD Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders . . . . . . . . . . . 30 Disclosure: Nothing to Disclose Khamashta, Munther A., MD Management of Antiphospholipid SyndromeFrom Controversies to Consensus . . . . . . 44 Disclosure: Nothing to Disclose Khan, Muhammad Asim, MD, MACP Axial Spondylarthritis: New Concepts . . . . 53 Disclosure: Abbott Immunology Pharmaceuticals, 5, 8; Amgen, 8; Genentech and Biogen IDEC Inc., 5; Pfizer Inc, 8 Khanna, Dinesh, MD, MSc Developing ACR Guidelines for the Treatment of Gout . . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: ARDEA pharmaceuticals, 5; NIH/ NIAMS, 2; Novartis Pharmaceutical Corporation, 2; Savient Pharmaceuticals, 2, 5, 8; Takeda Pharmaceuticals, 8; URL pharmaceuticals, 2

Kingsley, Gabrielle H., MBChB, PhD Spondylarthropathies: Recent Insights . . . . 88 Disclosure: Nothing to Disclose


Kaiser, Rachel, MD, MPH Mechanisms of Thrombosis in Systemic Autoimmune Disease . . . . . . . . . . . . 117 Disclosure: Nothing to Disclose

Kirino, Yohei, MD, PhD Plenary Session III . . . . . . . . . . . . . . . 92 Disclosure: Nothing to Disclose Kissin, Eugene Y., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two . . . . . . . . . . 20 Disclosure: SonoSite Inc, 5 Musculoskeletal Ultrasound . . . . . . . 44, 56 Disclosure: SonoSite Inc, 5 Klarenbeek, Paul L., MD, MSc Next-Generation Sequencing Applied to Rheumatic Diseases . . . . . . . . . . . . . . 95 Disclosure: Nothing to Disclose Klareskog, Lars, MD, PhD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose Kolasinski, Sharon L., MD Total Hip and Knee Replacements 2011: An Update for Rheumatologists . . . . . . . . . 74 Disclosure: Nothing to Disclose Koretzky, Gary A., MD, PhD Publishing in Peer-Reviewed Medical Journals . . . . . . . . . . . . . . . . . . . . . . . . . 33 Disclosure: American Society of Clinical Investigation, 9 Kortan, Joyce M., RN Fiscal Management of Infusion Clinics: Academic and Private Practice Perspectives . . . . . . . 93 Disclosure: Nothing to Disclose Kremer, Joel M., MD Omega-3 Fatty Acids in Inflammation and Cardiovascular Health . . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Krohn, Kelly D., MD Knee Braces and Foot Orthosis for Knee Osteoarthritis . . . . . . . . . . . . . . . . . . 73 Disclosure: Lilly USA, LLC, 3 Kubes, Paul, PhD Neutrophil Recruitment by Intravascular Danger Signals . . . . . . . . . . . . . . . . . . . . . . 88 Disclosure: Nothing to Disclose

2011 Program Book

329


L Lacaille, Diane V., MD, MHSc Keep People with Arthritis Working: An Interactive Case-based Discussion . . . . . 106 Disclosure: Nothing to Disclose Lahita, Robert G., MD, PhD Systemic Lupus Erythematosus: Novel Treatments . . . . . . . . . . . . . . . . . . . 80 Disclosure: Nothing to Disclose Laing, Timothy, MD Legislative Update from Capitol Hill . . . . . 51 Disclosure: Nothing to Disclose Lambris, John D., PhD Complimentary Roles for Complement in the Rheumatic Diseases . . . . . . . . . . . . . . 85 Disclosure: producing, 7 Lane, Nancy E., MD ACR REF Oscar S. Gluck, MD, Memorial Lectureship: Everything a Rheumatologist Should Know About Glucocorticoid-Induced Bone Fragility but was Afraid to Ask . . . . . 26 Disclosure: Nothing to Disclose Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Nothing to Disclose Langer, Frederick P. Disability: Clinical Facts, Legal Fictions, and Practice Strategies . . . . . . . . . . . . . . . 43 Disclosure: Nothing to Disclose Langford, Carol A., MD, MHS ACR/ABIM Maintenance of Certification Learning Session - 2011 Update in Rheumatology . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Plenary Session III . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Vasculitis: Key Issues for the Clinician in Three Unique Diseases . . . . . . . . . . . . . . . . 96 Disclosure: Nothing to Disclose Lapidus, Sivia K., MD Periodic Fevers with Aphthous Stomatitis, Pharyngitis, and Adenitis . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Laslop, Andrea, Univ-Prof, MD Biosimilar Products in the U.S. Market: Fact or Fiction? . . . . . . . . . . . . . . . . . . . . 125 Disclosure: Nothing to Disclose Lau, Lester F., PhD Fibrosis: Novel Paradigms . . . . . . . . . . . 64 Disclosure: Nothing to Disclose LaValley, Michael P., PhD To P or Not to P? Knowing When the P-Value is Less than Useful . . . . . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Lawry, George V., MD Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis . . 58 Disclosure: McGraw-Hill medical publishers, 7 Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back . . . . . . . . . . . . . . . . . . . . 87 Disclosure: McGraw-Hill medical publishers, 7 Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee . . . . . . . . . . . . . . . . . . . . 90 Disclosure: McGraw-Hill medical publishers, 7

330

2011 Program Book

Lee, Jungwha, MPH, PhD Basic Statistical Concepts for the Medical Researcher . . . . . . . . . . . . . . . . . . . 63 Disclosure: Nothing to Disclose Lee, Leia A., MD The Three Ps of Dermatologic and Autoimmune Disease: Pyoderma, Panniculitis and Pemphigus/ Pemphigoid . . . . . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Lee, Yvonne C., MD Pain Pathways in Rheumatic Diseases . . . 125 Disclosure: Elan Corporation, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Novartis Pharmaceutical Corporation, 1 Pain: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . 24 Disclosure: Elan Corporation, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Novartis Pharmaceutical Corporation, 1 Legault, Kimberly, MD Thieves’ Market: Show Me Your Best Cases . 71 Disclosure: Nothing to Disclose Leonard, Mary Beth, MD, MSCE Session II: Cross-Talk between Bone and ExtraSkeletal Organs . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Lightfoot, Robert W., MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose Limanni, Alex, MD Insurance Roundtable . . . . . . . . . . . . 113 Disclosure: Nothing to Disclose Lindwall, Elvira, MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose Lioté, Frédéric, MD, PhD Rheumatic Disease Update: Calcium Pyrophosphate Crystal Deposition Disease . 31 Disclosure: LGV, 9; Novartis Pharmaceutical Corporation, 5, 9; SOBI, 9 Little, Christopher B., BSc, MSc, BVMS, PhD Tools for Studying Joint Tissue Changes in Osteoarthritis . . . . . . . . . . . . . . . . . . 34 Disclosure: Pfizer Inc, 2 Lockshin, Michael D., MD Curbside Consults - Ask the Professors . . . . 59 Disclosure: Nothing to Disclose Mechanisms of Thrombosis in Systemic Autoimmune Disease . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose Publishing in Peer-Reviewed Medical Journals . . . . . . . . . . . . . . . . . . . . . . . . . 33 Disclosure: Nothing to Disclose Loeser, Richard F., MD Osteoarthritis: A Disease of the Joint as an Organ . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose Osteoarthritis: Update 2011 . . . . . . . 55, 87 Disclosure: Nothing to Disclose Lohmander, Stefan, MD, PhD Tools for Studying Joint Tissue Changes in Osteoarthritis . . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose

Lories, Rik, MD, PhD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 20 Disclosure: Abbott, Pfizer, 2; Pfizer, MSD, Abbott, Celgene, 5 Lovell, Daniel J., MD, MPH Update on Safety Issues in the Treatment of Rheumatic Diseases – From the FDA and Beyond . . . . . . . . . . . . . . . . . . . . . . . . .125 Disclosure: Abbott, 5; Amgen, 5; Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers Squibb, 5; Centocor, Inc., 5; Hoffmann-La Roche Inc, 5; Novartis, Inc, 5; Pfizer Inc, 5; UBC., 5; Wyeth Pharmaceuticals, 5 Lowik, Clemens, PhD Session IV: Assessment of Bone Structure and Quality . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Lynch, John, PhD The Osteoarthritis Initiative: A Database for Knee Osteoarthritis Research . . . . . . . . . 31 Disclosure: Nothing to Disclose

M Maas, James B., PhD Keynote Address: Sleep for Success! Everything You Must Know About Sleep, but Are Too Tired to Ask . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose Mack, Matthias, MD New Concepts in the Autoimmune Pathogenesis of Interstitial Lung Diseases . . . . . . . . . 106 Disclosure: Nothing to Disclose Maillard, Susan, MSc An Update in the Diagnosis and Management of Juvenile Dermatomyositis . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Maixner, William, DDS, PhD Pain Pathways in Rheumatic Diseases . . . 125 Disclosure: Algynomics, 1; NIH Grant, 2 Maksymowych, Walter P., MD Spondylarthropathies: Recent Insights . . . . 87 Disclosure: Abbott Laboratories, 5; Amgen, 5; Bristol-Myers Squibb, 5; Eli Lilly and Company, 5; Merck Pharmaceuticals, 5; Pfizer Inc, 5 Malfait, Anne-Marie, MD, PhD Cytokine and Chemokine Regulation of Chronic Pain . . . . . . . . . . . . . . . . . . . . . . . 88 Disclosure: Pfizer Inc, 1, 5 Pain Pathways in Rheumatic Diseases . . . 125 Disclosure: Pfizer Inc, 1, 5 Mandelin II, Arthur M., MD, PhD Adult Musculoskeletal Lower Examinations . 87 Disclosure: Nothing to Disclose Adult Musculoskeletal Upper Examinations . 44 Disclosure: Nothing to Disclose Mandell, Brian F., MD, PhD Synovial Fluid Analysis and Crystal Identification . . . . . . . . . . . . . . . . . . . . . 87, 59, 30 Disclosure: Nothing to Disclose Mandl, Lisa A., MD, MPH Total Hip and Knee Replacements 2011: An Update for Rheumatologists . . . . . . . . . 74 Disclosure: Nothing to Disclose

Marder, Wendy, MD Deconstructing the Randomized Controlled Trial: Assessing the Study Quality of Level One Non-Drug Studies . . . . . . . . . . . . . . . 53 Disclosure: Nothing to Disclose Maricic, Michael J., MD Osteoporosis: Novel Treatments . . . . . . . 32 Disclosure: Amgen, 2; Eli Lilly and Company, 2; Genentech and Biogen IDEC Inc., 2; Merck Pharmaceuticals, 2; Novartis Pharmaceutical Corporation, 5; Proctor & Gamble Pharmaceuticals, 2 ACR REF Oscar S. Gluck, MD, Memorial Lectureship: Everything a Rheumatologist Should Know About Glucocorticoid-Induced Bone Fragility but was Afraid to Ask . . . . . 26 Disclosure: Nothing to Disclose Rheumatology Practice 101: Starting Out in Practice for The Graduating Fellow . . . . . 113 Disclosure: Amgen, 2; Eli Lilly and Company, 2; Genentech and Biogen IDEC Inc., 2; Merck Pharmaceuticals, 2; Novartis Pharmaceutical Corporation, 5; Proctor & Gamble Pharmaceuticals, 2 Mariette, Xavier, MD Extra Glandular Manifestations of Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . . 107 Disclosure: GlaxoSmithKline, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5; UCB, 5 Mechanisms of Lymphoma Development in Systemic Autoimmune Disease . . . . . . . . 95 Disclosure: GlaxoSmithKline, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5; UCB, 5 Martinez-Lavin, Manuel, MD Fibromyalgia . . . . . . . . . . . . . . . . . . 80 Disclosure: Nothing to Disclose Fibromyalgia and Dysautonomia . . . . . . . 93 Disclosure: Nothing to Disclose Martini, Alberto, MD Juvenile Idiopathic Arthritis: Clinical Heterogeneity and the Genome . . . . . . . 59 Disclosure: Nothing to Disclose Marzan, Katherine AB, MD Preparing for Transition from Day One of Diagnosis to Adult Care . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Massarotti, Elena M., MD Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus . . . . . . . . 32 Disclosure: EMD Serono, Roche, 2; UCB, Ampimmune, Bristol Myers Squibb, 5

Matsumoto, Alan K., MD Utilizing Media Relations to Build Your Practice . . . . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose McCarthy, G M., MD Crystal: Pseudogout . . . . . . . . . . . . . . 62 Disclosure: Nothing to Disclose Crystals and Arthritis-Mechanisms of Inflammation and Joint Destruction . . . . . 44 Disclosure: Nothing to Disclose McClatchey, William M., MD Effective Use of Technology . . . . . . . . . 113 Disclosure: Nothing to Disclose McClung, Michael, MD Metabolic Bone Disease . . . . . . . . . . . 115 Disclosure: Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5; Warner-Chilcott Pharmaceuticals, 5

Merrell, Victoria A., PA-C, MPT Rehabilitation for the Clinician . . . . . . . . 43 Disclosure: Nothing to Disclose Merrill, J.T., MD Treatment of Lupus Nephritis . . . . . . . . . 60 Disclosure: Aspreva, 2; Aspreva Vifor, Genentech, Bristol Myers Squibb, Pfizer, 5; Bristol Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2 Messier, Stephen P., PhD ACR Plenary Session I: Discovery 2011 . . . . 31 Disclosure: Nothing to Disclose Miceli-Richard, Corinne, MD, PhD Mechanisms of Lymphoma Development in Systemic Autoimmune Disease . . . . . . . . 95 Disclosure: Nothing to Disclose

McDougall, Jason J., PhD Pain Pathways in Rheumatic Diseases . . . 125 Disclosure: Nothing to Disclose

Michaud, Kaleb D., PhD Introduction to Comparative Effectiveness Research Study Designs for Rheumatology Health Professionals . . . . . . . . . . . . . 125 Disclosure: Nothing to Disclose

McGonagle, Dennis, MB, PhD Enthesopathy: Spondylarthropathies and Beyond . . . . . . . . . . . . . . . . . . . . . 23 Disclosure: Nothing to Disclose

Mikuls, Ted R., MD 2011 Updated ACR Rheumatoid Arthritis Guidelines . . . . . . . . . . . . . . . . . . . 63 Disclosure: Nothing to Disclose

McInnes, Iain B., PhD New Targets in Rheumatoid Arthritis: Syk, Jaks and Btk . . . . . . . . . . . . . . . . . . . . . 28 Disclosure: Astra Zeneca, 5; Pfizer Inc, 2

Miller, Frederick W., MD, PhD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . . 123 Disclosure: Nothing to Disclose Impact of Environmental Health on Autoimmunity . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose

McLean, Robert R., DSc, MPH Are You Losing It? How to Deal with Loss to Follow Up in Research Studies and Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . 92 Disclosure: Nothing to Disclose Highlights from the 2011 ARHP Sessions . . 117 Disclosure: Nothing to Disclose Introduction to Comparative Effectiveness Research Study Designs for Rheumatology Health Professionals . . . . . . . . . . . . . 124 Disclosure: Nothing to Disclose McMahan, Zsuzsanna H., MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose Anemia of Inflammatory Disease . . . . . . . 56 Disclosure: Nothing to Disclose Medsger, Thomas A., MD Session IV: Successes in Rheumatology Comparative Effectiveness Research . . . . . 22 Disclosure: Nothing to Disclose Melton, Alton, MD Immunodeficiency Syndromes . . . . . . . . 51 Disclosure: Nothing to Disclose Merkel, Peter A., MD, MPH Vasculitis: Key Issues for the Clinician in Three Unique Diseases . . . . . . . . . . . . . . . . 96 Disclosure: Actelion Pharmaceuticals US, 5; Avila, 5; Bellus Health, 5; Bristol-Myers Squibb, 2; Celgene, 2; Genentech and Biogen IDEC Inc., 2; Human Genome Sciences, Inc., 5; Nordic Group, 5; Protein Therapeutics, 2; Serono, 5 Vasculitis: Update . . . . . . . . . . . . . 62, 87 Disclosure: Actelion Pharmaceuticals US, 5; Avila, 5; Bellus Health, 5; Bristol-Myers Squibb, 2; Celgene, 2; Genentech and Biogen IDEC Inc., 2; Human Genome Sciences, Inc., 5; Nordic Group, 5; Protein Therapeutics, 2; Serono, 5


Manzi, Susan, MD Biomarkers in Systemic Lupus Erythematosus: Where do we stand? . . . . . . . . . . . . . . 63 Disclosure: Anthera, 9; Bristol-Myers Squibb, 2, 9; Cephalon, 2, 9; Cypress Biosciences, Inc., 5; Human Genome Sciences, Inc., 2, 9; Immunomedics, Inc., 2; Medammune, Inc., 9; NIH, 2 Difficult to Treat Systemic Lupus Erythematosus: Case Studies . . . . . . . . . . . . . . . . . . 73 Disclosure: Anthera, 9; Bristol-Myers Squibb, 2, 9; Cephalon, 2, 9; Cypress Biosciences, Inc., 5; Human Genome Sciences, Inc., 2, 9; Immunomedics, Inc., 2; Medammune, Inc., 9; NIH, 2

Miller, Richard J., PhD Cytokine and Chemokine Regulation of Chronic Pain . . . . . . . . . . . . . . . . . . . . . . . 88 Disclosure: Nothing to Disclose Miner, Jeffrey N., PhD Plenary Session II . . . . . . . . . . . . . . . . 60 Disclosure: Ardea Biosciences, 1, 3; Scientific Advisor for Arman Tadbir Afagh - ARTA, 6 Molina, Rodolfo, MD Insurance Roundtable . . . . . . . . . . . . 113 Disclosure: Nothing to Disclose Monach, Paul A., MD, PhD Vasculitis: An Update . . . . . . . . . . . 80, 94 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 5 Moreland, Larry W., MD Rheumatoid Arthritis: Biological Agents 80, 113 Disclosure: Chemocentryx, 5; Crescendo, 5; Pfizer Inc, 5 Morrison, William, MD Musculoskeletal Imaging . . . . . . . . . . . 95 Disclosure: Apriomed, Inc, 9; GE Healthcare, 5 Moskowitz, Roland W., MD ACR REF Paul Klemperer, MD Memorial Lectureship: Osteoarthritis - Quo Vadis - Where are We Now - Where are We Going? . . . . . 89 Disclosure: Bioiberica, 5; Cyperss Bioscience, 5; Cypress Biosciences, Inc., 5; Endo Pharmaceuticals Inc., 5; Iroko Pharmaceuticals, 5; Johnson and Johnson, 5; Lilly Company, 5; Novartis Pharmaceutical Corporation, 8; Pfizer Inc, 8; Smith and Nephew, 5; Wyeth Pharmaceuticals, 5 2011 Program Book

331


Mueller, Daniel L., MD Plenary Session II . . . . . . . . . . . . . . . . 60 Disclosure: Nothing to Disclose Muller-Ladner, Ulf, MD The Role of Extracellular Ribonucleic Acid in Inflammatory Processes . . . . . . . . . . . 129 Disclosure: Nothing to Disclose Murphy, Susan L., OTR Deconstructing the Randomized Controlled Trial: Assessing the Study Quality of Level One Non-Drug Studies . . . . . . . . . . . . . . . 53 Disclosure: Nothing to Disclose Murray, Joseph A., MD Celiac Disease: Immunopathogenesis and Clinical Spectrum Potential . . . . . . . . . . 85 Disclosure: Alba Therapeutics, 2; Alvine Inc., 5; Bayer Inc., 5; Biocard , 2; ImmunosanT, 5; Shire, 5

N Nakamura, Mary C., MD Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Naredo, Esperanza, MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One . . . . . . . . . . 17 Disclosure: Nothing to Disclose Nevitt, Michael C., MPH, PhD The Osteoarthritis Initiative: A Database for Knee Osteoarthritis Research . . . . . . . . . 31 Disclosure: Nothing to Disclose Nigrovic, Peter A., MD Juvenile Idiopathic Arthritis: Clinical Heterogeneity and the Genome . . . . . . . 59 Disclosure: Nothing to Disclose Leveraging Existing Resources for Your Research: Clinical and Translational Science Award Centers and Alternatives . . . . . . . . . . . . . . . . 81 Disclosure: Nothing to Disclose New Insights into Bone Remodeling . . . . . 85 Disclosure: Nothing to Disclose Pediatric Rheumatology for Adult Rheumatologists . . . . . . . . . . . . . . . . 55 Disclosure: Nothing to Disclose Platelets as Inflammatory Cells in Arthritis 116 Disclosure: Nothing to Disclose Nikolaus, Stephanie, MSc Improving Health Measurement in Rheumatology . . . . . . . . . . . . . . . . 115 Disclosure: Nothing to Disclose Noel, Daniele, PhD Stem Cell Mediated Therapies in Autoimmune Diseases . . . . . . . . . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose Nola, Kam, PharmD, MS Complex Pain Issues: Comorbidities and Special Populations . . . . . . . . . . . . . . . . . . . 24 Disclosure: Nothing to Disclose Evidence-based Non-pharmacological Interventions . . . . . . . . . . . . . . . . . . 24 Disclosure: Nothing to Disclose New and Noteworthy: Nursing, Pharmacy and Pedorthics . . . . . . . . . . . . . . . . . . . 55 Disclosure: Nothing to Disclose

332

2011 Program Book

Norris, Jill, MPH, PhD ACR REF Special Session: Within Our Reach: Finding a Cure for Rheumatoid Arthritis . . . 42 Disclosure: Nothing to Disclose

O O’Dell, James R., MD ACR Leadership Town Hall Meeting . . . . . 95 Disclosure: Nothing to Disclose Rheumatoid Arthritis: Early Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . 27, 87 Disclosure: Nothing to Disclose O’Neil, Kathleen M., MD Advances in Polyarticular Juvenile Idiopathic Arthritis . . . . . . . . . . . . . . . . . . . . . 64 Disclosure: Nothing to Disclose New Auto-inflammatory Syndromes . . . . . 29 Disclosure: Nothing to Disclose O’Rourke, Kenneth S., MD Joint Injection Techniques . . . . . . . . . . . 90 Disclosure: Nothing to Disclose O’Shea, John J., MD Epigenetic Changes in Rheumatic Disease . . 26 Disclosure: Pfizer Inc, 9 Oatis, Carol A., PhD, PT Disease Modifying Osteoarthritis Drugs, Glucosamine/Chondroitin and Nonpharmacologic Treatment of Osteoarthritis . 83 Disclosure: Nothing to Disclose Oddis, Chester V., MD Emerging Concepts in the Inflammatory Myopathies . . . . . . . . . . . . . . . . . . . 87 Disclosure: Nothing to Disclose Ogdie, Alexis, MD Diagnostic Errors in Rheumatology: Why They Happen and How We Can Avoid Them . . . . 63 Disclosure: Nothing to Disclose Okada-Yim, Sarah K., MD Update on Safety Issues in the Treatment of Rheumatic Diseases – From the FDA and Beyond . . . . . . . . . . . . . . . . . . . . . . . . .125 Disclosure: Nothing to Disclose Olech, Ewa, MD Peripheral Magnetic Resonance Imaging in Clinical Rheumatology . . . . . . . . . . 33, 63 Disclosure: Abbott Laboratories, 2; Centocor, Inc., 2, 5; Eli Lilly and Company, 2; Genentech and Biogen IDEC Inc., 2, 5; Pfizer Inc, 2, 5; UCB, 2, 5; Vertex, 2 Olenginski, Thomas P., MD Osteoporosis: Applying Fracture Risk Assessment Algorithm Methodology . . . . 62 Disclosure: Amgen, 8; Eli Lily, Inc, 5; Novartis Pharmaceutical Corporation, 8 Olsen, Nancy J., MD ACR REF Special Session: Within Our Reach: Finding a Cure for Rheumatoid Arthritis . . . 42 Disclosure: ArthoChip LLC, 4 Ortiz, Elizabeth C., MD Preparing for Transition from Day One of Diagnosis to Adult Care . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose

Ospelt, Caroline, MD Epigenetic Changes in Rheumatic Disease . . 26 Disclosure: Nothing to Disclose Ostergaard, Mikkel, MD, PhD, DMSc Peripheral Magnetic Resonance Imaging in Rheumatology Practice . . . . . . . . . 30, 106 Disclosure: Nothing to Disclose Oude Voshaar, Martijn, MSc Improving Health Measurement in Rheumatology . . . . . . . . . . . . . . . . 115 Disclosure: Nothing to Disclose

P Pacifici, Maurizio, PhD Osteoarthritis: A Disease of the Joint as an Organ . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose Paiva Sr., Eduardo S., MD Sleep Disturbance in Fibromyalgia . . . . . . 55 Disclosure: Pfizer Inc, Lilly, 8 Passo, Murray H., MD Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis . . . . . . . . . . . . . . . . . . . . . 27 Disclosure: Pfizer Inc, 2, 5 Patel, Amit, MD Clinicopathologic Conference: A 40 Year-Old Male with Dyspnea on Exertion . . . . . . . . 54 Disclosure: Nothing to Disclose Pelletier, Jean Pierre, MD ACR REF Marshall J. Schiff, MD, Memorial Lectureship: Multicenter Orthopaedic Outcomes Network - A Prospective Longitudinal Cohort of ACL Reconstruction Outcomes . . . . . . . . 82 Disclosure: Nothing to Disclose Pernis, Alessandra, MD ACR REF Edmond L. Dubois, MD, Memorial Lectureship: “Interfering” with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . 104 Disclosure: Nothing to Disclose Petri, Michelle, MD, MPH Neuropsychiatric Lupus . . . . . . . . . . . . 22 Disclosure: Nothing to Disclose Pezalla, Edmund, MD, MPH Session I: Introduction and Overview of Comparative Effectiveness Research from the Perspective of Government and Insurers . . 22 Disclosure: Aetna, 3 Pierangeli, Silvia S., PhD Mechanisms of Thrombosis in Systemic Autoimmune Disease . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose Pilkington, Clarissa, MBBS.BSc An Update in the Diagnosis and Management of Juvenile Dermatomyositis . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Pillinger, Michael H., MD Hyperuricemia and Gout: Mechanisms and Morbidity . . . . . . . . . . . . . . . . . . . . 94 Disclosure: Takeda, 2; URL Pharma, 2 MicroRNA in Epigenetic Regulation of Rheumatic Inflammatory Diseases . . . . . . 33 Disclosure: Nothing to Disclose

Pine, Linda J., PharmD New and Noteworthy: Nursing, Pharmacy and Pedorthics . . . . . . . . . . . . . . . . . . . 55 Disclosure: Amgen, 5 Plenge, Robert M., MD, PhD Next-Generation Sequencing Applied to Rheumatic Diseases . . . . . . . . . . . . . . 95 Disclosure: Nothing to Disclose Poole, Janet L., OTR, PhD Marketing Community-based Programs to Primary Care Practices: An Approach Based on Centers for Disease Control Audience Research . . . . . . . . . . . . . . . . . . . . . . . . .117 Disclosure: American College of Rheumatology Research and Education Foundation, 2 Pope, Janet E., MD, MPH Raynaud’s and Digital Ischemia . . . . . . . 113 Disclosure: Actelion Pharmaceuticals US, 2, 5; Mediquest, 2, 5; Pfizer Inc, 2, 5; United Therapeutics, 2 Raynaud’s and Digital Ischemia . . . . . . . . 62 Disclosure: Actelion Pharmaceuticals US, 2, 5; Mediquest, 2, 5; Pfizer Inc, 2, 5; United Therapeutics, 2 Contract Negotiations for Physicians . . . . . 62 Disclosure: Nothing to Disclose Prahalad, Sampath, MD, MSc Juvenile Idiopathic Arthritis: Clinical Heterogeneity and the Genome . . . . . . . 59 Disclosure: Nothing to Disclose Preissner, Klaus T., PhD The Role of Extracellular Ribonucleic Acid in Inflammatory Processes . . . . . . . . . . . 129 Disclosure: Nothing to Disclose Putterman, Chaim, MD ACR REF Edmond L. Dubois, MD, Memorial Lectureship: “Interfering” with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . 104 Disclosure: Nothing to Disclose

Q Quinet, Robert, MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose

R Rader, Daniel J., MD Towards Prevention of Atherosclerosis Progression in Rheumatoid Arthritis: Insights into the Relationship between Inflammation and Cardiovascular Disease . . . . . . . . . . 90 Disclosure: Bristol-Myers Squibb, 5; Eli Lilly and Company, 5; Johnson & Johnson, 5; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5; VascularStrategies, 4

Rahman, Anisur, PhD Difficult to Treat Systemic Lupus Erythematosus: Case Studies . . . . . . . . . . . . . . . . . . 73 Disclosure: Nothing to Disclose

Rosen, Antony, MD Basic Immunology for Clinical Rheumatologists . . . . . . . . . . . . . . . . . . . . . . . 62, 93 Disclosure: Sanofi-Aventis Pharmaceutical, 5

Rao, Smita, PT, PhD Foot Structure, Footwear and Foot Pain Translating Evidence into Practice . . . . . . 73 Disclosure: Nothing to Disclose

Rosen, Clifford J., MD Session II: Cross-Talk between Bone and ExtraSkeletal Organs . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose

Rauch, Joyce, PhD Mechanisms of Thrombosis in Systemic Autoimmune Disease . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose Ravelli, Angelo, MD An Update in the Diagnosis and Management of Juvenile Dermatomyositis . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Ravenel, Michele, DMD Did You Brush Your Teeth Today? . . . . . . . 62 Disclosure: Nothing to Disclose Raychaudhuri, Siba P., MD Chronic Non-bacterial Osteomyelitis . . . 124 Disclosure: Nothing to Disclose Raza, Karim, MD, PhD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Pfizer Inc, 5; Roche Pharmaceuticals, 5; UCB, 5, 8 Remst, Dennis F.G., MSc ACR REF Marshall J. Schiff, MD, Memorial Lectureship: Multicenter Orthopaedic Outcomes Network - A Prospective Longitudinal Cohort of ACL Reconstruction Outcomes . . . . . . . . 82 Disclosure: Nothing to Disclose Richardson, Bruce C., MD, PhD Theories on Sex Disparities in Autoimmune Disease: From Estrogen to the X Chromosome . . . . . . . . . . . . . . . . . . . . . . . . . 84 Disclosure: Nothing to Disclose Richardson, Jan K., PT, PhD, OCS Evidence-based Non-pharmacological Interventions . . . . . . . . . . . . . . . . . . 24 Disclosure: Nothing to Disclose Ritchlin, Christopher T., MD, MPH Neutrophil Recruitment by Intravascular Danger Signals . . . . . . . . . . . . . . . . . . . . . . 88 Disclosure: Nothing to Disclose Robinson, William, MD, PhD Next-Generation Sequencing Applied to Rheumatic Diseases . . . . . . . . . . . . . . 95 Disclosure: Atreca, Inc., 1; NIH RC1 AR05871301, 2 Robling, Alexander, PhD Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Roediger, Joan M., JD, LLM Contract Negotiations for Physicians . . . . . 62 Disclosure: Nothing to Disclose Roos, Ewa M., PT, PhD The Neuromuscular System in Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . 96 Disclosure: Nothing to Disclose

Rosenbaum, James T., MD Extrarticular Manifestations of Rheumatoid Arthritis: Ophthalmologic, Pulmonary and Cardiovascular . . . . . . . . . . . . . . . . 105 Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; Genentech and Biogen IDEC Inc., 2; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 5; Regeneron, 5; Xoma Corporation , 5 Inflammatory Eye Disease and the Rheumatologist . . . . . . . . . . . . . . . . 23 Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; Genentech and Biogen IDEC Inc., 2; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 5; Regeneron, 5; Xoma Corporation , 5 Inflammatory Eye Disease/Uveitis . . . . . . 80 Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; Genentech and Biogen IDEC Inc., 2; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 5; Regeneron, 5; Xoma Corporation , 5


Pincus, Theodore, MD Patient Questionnaires to Monitor Status and Document Improvement in Standard Care: Practical Considerations . . . . . . . . . . . 106 Disclosure: Nothing to Disclose

Rosenthal, Ann K., MD Crystals and Arthritis-Mechanisms of Inflammation and Joint Destruction . . . . . 44 Disclosure: Nothing to Disclose Ross, James M., MD ACR REF Special Session: Clinician Scholar Educator Presentations . . . . . . . . . . . . 52 Disclosure: Nothing to Disclose Roth, Johannes, MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One . . . . . . . . . . 18 Disclosure: Nothing to Disclose Roubey, Robert A. S., MD Management of Antiphospholipid SyndromeFrom Controversies to Consensus . . . . . . 44 Disclosure: Quest Diagnostics, 5 Rovin, Brad H., MD Treatment of Lupus Nephritis . . . . . . . . 60 Disclosure: Biogen-Idec, 5; Genentech and Biogen IDEC Inc., 5; Johnson and Johnson, 5; questcor, 5; Teva Pharmaceuticals, 2 Ruderman, Eric M., MD Biosimilar Products in the U.S. Market: Fact or Fiction? . . . . . . . . . . . . . . . . . . . . 125 Disclosure: Abbott Immunology Pharmaceuticals, 2, 5; Allos Pharmaceuticals, 5; Amgen, 5; Celgene, 5; Centocor, Inc., 2; CVS/ Caremark, 5; Lilly, 5; Pfizer Inc, 5; UCB, 5 Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis . . . . . . . . . . . . . 34 Disclosure: Abbott Immunology Pharmaceuticals, 2, 5; Allos Pharmaceuticals, 5; Amgen, 5; Celgene, 5; Centocor, Inc., 2; CVS/ Caremark, 5; Lilly, 5; Pfizer Inc, 5; UCB, 5 2011 Program Book

333


Omega-3 Fatty Acids in Inflammation and Cardiovascular Health . . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Ruffing, Victoria L., RN Fiscal Management of Infusion Clinics: Academic and Private Practice Perspectives . . . . . . . 93 Disclosure: Nothing to Disclose Russell, R. Graham G., MD, PhD, FRS Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Amgen, Lilly, Novartis, GSK, Roche, Warner Chilcott, 5; Warner Chilcott, 2

S Saag, Kenneth G., MD, MSc 2011 Updated ACR Rheumatoid Arthritis Guidelines . . . . . . . . . . . . . . . . . . . 63 Disclosure: Amgen, 2, 5; Eli Lilly and Company, 2, 5; Genentech and Biogen IDEC Inc., 5; Horizon, 5; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Proctor Gamble, 2; Sanofi Aventis, 2; Takeda, 2; URL, 5 Great Debate: Is too Much Suppression of Turnover Bad for Bone? . . . . . . . . . . . . 42 Disclosure: Amgen, 2, 5; Eli Lilly and Company, 2, 5; Genentech and Biogen IDEC Inc., 5; Horizon, 5; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Proctor Gamble, 2; Sanofi Aventis, 2; Takeda, 2; URL, 5 Salmon, Jane E., MD Mechanisms of Thrombosis in Systemic Autoimmune Disease . . . . . . . . . . . . 117 Disclosure: Nothing to Disclose Salt, Elizabeth G., PhD Antimalarials for Rheumatic Disorders: Historical Perspectives, Clinical Insights and Future Directions . . . . . . . . . . . . . . . . . . . . 57 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Behave Yourself! Practical Application of Cognitive Behavioral Theories to Motivate Change in Patients with Arthritis . . . . . . . 54 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Best Practices for Collaboration in Research and Clinical Practice . . . . . . . . . . . . . . . . . 31 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Daltroy Memorial Lecture: The Role of Cultural Diversity in Patient-Healthcare Provider Communication . . . . . . . . . . . . . . . . 89 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Pain: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . 24 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Sammaritano, Lisa R., MD Management of Antiphospholipid SyndromeFrom Controversies to Consensus . . . . . . 45 Disclosure: Nothing to Disclose

334

2011 Program Book

Sanchez-Guerrero, Jorge, MD, MS Systemic Lupus Erythematosus: Central Nervous System . . . . . . . . . . . . . . . . . . . . . 51 Disclosure: Nothing to Disclose Sawalha, Amr H., MD Theories on Sex Disparities in Autoimmune Disease: From Estrogen to the X Chromosome . . . . . . . . . . . . . . . . . . . . . . . . . 84 Disclosure: Nothing to Disclose Scalapino, Kenneth J., MD Rheumatic Disease Update: Musculoskeletal Manifestiations of Human Immunodeficiency Virus . . . . . . . . . . . . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Scanzello, Carla R., MD, PhD Osteoarthritis: A Disease of the Joint as an Organ . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose Schanberg, Laura E., MD Complex Pain Issues: Comorbidities and Special Populations . . . . . . . . . . . . . . . . . . . 24 Disclosure: AstraZeneca, 5; GlaxoSmithKline, 5; Pfizer Inc, 2; UCB, 5 Session IV: Successes in Rheumatology Comparative Effectiveness Research . . . . . 22 Disclosure: Nothing to Disclose Scher, Jose U., MD T-Cell Regulation and Autoimmune Pathogenesis: Th1, Th2, Th17 and T Regs . . 54 Disclosure: Nothing to Disclose Schett, Georg, MD, PhD Pain Pathways in Rheumatic Diseases . . . 125 Disclosure: Nothing to Disclose Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . . 18 Disclosure: Nothing to Disclose Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 20 Disclosure: Nothing to Disclose Session IV: Assessment of Bone Structure and Quality . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Schikler, Kenneth N., MD Periodic Fevers with Aphthous Stomatitis, Pharyngitis, and Adenitis . . . . . . . . . . . 91 Disclosure: Nothing to Disclose The Child with Chronic Pain . . . . . . . . . 108 Disclosure: Pfizer Inc, Forest Labs, 2 Schlesinger, Naomi, MD Crystal: Diagnosis and Management of Gout . . . . . . . . . . . . . . . . . . . . . . . . . . 51 Disclosure: Advisory boards: Novartis ,Savient, URL Pharma, EnzymeRx , 5; NJ Rheumatology association, 9; Novartis Pharmaceutical Corporation, 2; Savient, Takeda, Novartis, 8

Schmidt, Wolfgang A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day One . . . . . . . . . . 17 Disclosure: Abbott Immunology Pharmaceuticals, 8; Actelion Pharmaceuticals US, 2; Berlin Chemie, 8; Bristol-Myers Squibb, 8; Chugai, 8; Esaote, 2; Medac, 8; Merck Pharmaceuticals, 8; Merck Sharp Dome, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 8; Roche Pharmaceuticals, 8 Musculoskeletal Ultrasound Course for Rheumatologists - Day Two . . . . . . . . . . 20 Disclosure: Abbott Immunology Pharmaceuticals, 8; Actelion Pharmaceuticals US, 2; Berlin Chemie, 8; Bristol-Myers Squibb, 8; Chugai, 8; Esaote, 2; Medac, 8; Merck Pharmaceuticals, 8; Merck Sharp Dome, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 8; Roche Pharmaceuticals, 8 Schneeweiss, Sebastian, MD, ScD Session II: Methods for Comparative Effectiveness Research . . . . . . . . . . . . . 22 Disclosure: Nothing to Disclose Schneider, Rayfel, MBBCh Systemic Arthritis and Still’s Disease . . . . . 51 Disclosure: Consultant, 5 Schrag, Deborah, MD, MPH Session III: Developing Standardized Treatment Algorithms for Registries . . . . . . . . . . . 22 Disclosure: Nothing to Disclose Schwab, Pascale, MD Practice Potpourri . . . . . . . . . . . . . . 106 Disclosure: Nothing to Disclose Schwartz, Lawrence B., MD, PhD Hereditary Angioedema . . . . . . . . . . . 118 Disclosure: GSK: clinical trials, 2; Phadia: tryptase assay, 7 Seibold, James R., MD Pulmonary Hypertension in the Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . 27 Disclosure: Actelion Pharmaceuticals US, 2; Apricus, 5; Celgene, 5; Fibrogen, 5; Genentech and Biogen IDEC Inc., 5; Sanofi-Aventis Pharmaceutical, 5; United Therapeutics, 2 Seo, Philip, MD, MHS Large Vessel Vasculitis 2011 . . . . . . . . . . 22 Disclosure: Nothing to Disclose Serhan, Charles, PhD 2011 Hench Lecture: Resolution of Inflammation . . . . . . . . . . . . . . . . . . 26 Disclosure: Bayer Health Care, 7; NIH, 2; Resolvyx Pharmaceutical Comany, 1 Seton, Margaret, MD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Nothing to Disclose Seymour, Sally M., MD Update on Safety Issues in the Treatment of Rheumatic Diseases – From the FDA and Beyond . . . . . . . . . . . . . . . . . . . . . . . . .126 Disclosure: Nothing to Disclose Shadick, Nancy A., MD, MPH Rheumatoid Arthritis: Difficult Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . 27 Disclosure: Amgen Abbott, Genentech, Crescendo Biosciences, Biogen Idec, 2

Shakoor, Najia, MD Pain, the Brain, and Osteoarthritis . . . . . . 96 Disclosure: Nothing to Disclose The Neuromuscular System in Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose Shane, Elizabeth J., MD Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Eli Lilly and Company, 2; Merck Pharmaceuticals, 2; Novartis Pharmaceutical Corporation, 2 Shanmugam, Victoria K., MBBS, MRCP Challenging Complications of Systemic Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . .107 Disclosure: NIH, 2; Spouse is an attorney with Williams and Connolly LLP and represents various pharmaceutical companies. , 9 Did You Brush Your Teeth Today? . . . . . . . 62 Disclosure: NIH, 2; Spouse is an attorney with Williams and Connolly LLP and represents various pharmaceutical companies. , 9 Hereditary Angioedema . . . . . . . . . . . 118 Disclosure: NIH, 2; Spouse is an attorney with Williams and Connolly LLP and represents various pharmaceutical companies. , 9 Sharif, Roozbeh, MD Plenary Session III . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Sharma, Leena, MD Mechanical Factors in Knee Osteoarthritis: A Plausible Road to Riches . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Shepherd, Rebecca M., MD RAC and Roll – How to Perform Complex Chart Audits . . . . . . . . . . . . . . . . . . . . . . 56 Disclosure: Nothing to Disclose Sherry, David D., MD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . . 123 Disclosure: Nothing to Disclose Shore, Eileen M., PhD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Nothing to Disclose Shubin, Neil H., PhD ACR/ARHP Opening Lecture and Awards . . . 24 Disclosure: Nothing to Disclose Siemons, Liseth, MSc Improving Health Measurement in Rheumatology . . . . . . . . . . . . . . . . 115 Disclosure: Nothing to Disclose Sieper, Joachim, MD Ankylosing Spondylitis: Disease Modification . . . . . . . . . . . . . . . . . . . . . . . . . 86 Disclosure: Abbott Immunology Pharmaceuticals, 8; BMS, 2; Lilly, 5; Merck Pharmaceuticals, 8; Pfizer Inc, 8; Roche Pharmaceuticals, 8; UCB, 8

Silverman, Gregg J., MD Apoptosis, Phagocytic Clearance and Autoimmune and Inflammatory Diseases . 116 Disclosure: Have consulted for Genentech, Roche and Biogen Idec, 5; Wife is employed by Gilead., 3 Complimentary Roles for Complement in the Rheumatic Diseases . . . . . . . . . . . . . . 85 Disclosure: Have consulted for Genentech, Roche and Biogen Idec, 5; Wife is employed by Gilead., 3 Genetic Defects, AIRE and Autoimmunity . . 88 Disclosure: Have consulted for Genentech, Roche and Biogen Idec, 5; Wife is employed by Gilead., 3 Debate: Joints for Joints: Medical Marijuana is Useful for Treating Rheumatic Disease . . . . 72 Disclosure: Nothing to Disclose Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm . . . . . . . . . . . . . . . . . . . . . . . 27, 59 Disclosure: Amgen, Genentech, Lilly, Novartis, Pfizer / Wyeth, Roche Pharmaceuticals, Roche Diagnostics, Warner Chilcott, 5; Amgen, Lilly, Novartis, Pfizer / Wyeth, Roche Pharmaceuticals, 8; Cedars-Sinai Medical Center , 3; Lilly, Pfizer / Wyeth, Warner Chilcott, 2 Simkin, Peter A., MD Rheumatic Disease Update: Calcium Pyrophosphate Crystal Deposition Disease . 31 Disclosure: Nothing to Disclose Simopoulos, Artemis P., MD Omega-3 Fatty Acids in Inflammation and Cardiovascular Health . . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Singh, Jasvinder, MD, MPH 2011 Updated ACR Rheumatoid Arthritis Guidelines . . . . . . . . . . . . . . . . . . . 63 Disclosure: Takeda, Novartis, Savient, URL, 5; Omeract, 6; Takeda, Savient, 2; University of Alabama and Birmingham Veterans Affairs Medical Center, 3 Heart Disease and Rheumatoid Arthritis . . . 73 Disclosure: Takeda, Novartis, Savient, URL, 5; Omeract, 6; Takeda, Savient, 2; University of Alabama and Birmingham Veterans Affairs Medical Center, 3 The Neuromuscular System in Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . 96 Disclosure: Takeda, Novartis, Savient, URL, 5; Omeract, 6; Takeda, Savient, 2; University of Alabama and Birmingham Veterans Affairs Medical Center, 3 Skea, Warren, PhD CORC Forum: Payment Reform Options . . . 92 Disclosure: Nothing to Disclose Slusher, Barbara A., PA-C, MSW Highlights from the 2011 ARHP Sessions . . 117 Disclosure: Nothing to Disclose

Solomon, Daniel H., MD, MPH Introduction of Afternoon Session . . . . . . 22 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Rheumatoid Arthritis: Safety of Novel Therapies . . . . . . . . . . . . . . . . . . . . . . . . . 62 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Session I: Introduction and Overview of Comparative Effectiveness Research from the Perspective of Government and Insurers . . 21 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Session II: Methods for Comparative Effectiveness Research . . . . . . . . . . . . . 22 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Welcome and Introductions . . . . . . . . . . 21 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9


Shah, Ami A., MD, MHS ACR Plenary Session I: Discovery 2011 . . . . 31 Disclosure: Actelion Pharmaceuticals US, 2

Somers, Emily C., PhD, ScM Theories on Sex Disparities in Autoimmune Disease: From Estrogen to the X Chromosome . . . . . . . . . . . . . . . . . . . . . . . . . 84 Disclosure: Nothing to Disclose Spiera, Robert F., MD Curbside Consults - Ask the Professors . . . . 59 Disclosure: Novartis Pharmaceutical Corporation, United Therapeutics, BMS, 2 Difficult Raynaud’s Phenomena . . . . . . . . 33 Disclosure: Novartis Pharmaceutical Corporation, United Therapeutics, BMS, 2 Thieves’ Market: Show Me Your Best Cases . 71 Disclosure: Novartis Pharmaceutical Corporation, United Therapeutics, BMS, 2 Vasculitis: Key Issues for the Clinician in Three Unique Diseases . . . . . . . . . . . . . . . . 96 Disclosure: Roche Pharmaceuticals/Genetech, 5 Spindler, Kurt P., MD ACR REF Marshall J. Schiff, MD, Memorial Lectureship: Multicenter Orthopaedic Outcomes Network - A Prospective Longitudinal Cohort of ACL Reconstruction Outcomes . . . . . . . . 82 Disclosure: Nothing to Disclose St.Clair, E. William, MD ACR Leadership Town Hall Meeting . . . . . 95 Disclosure: Genentech and Biogen IDEC Inc., 2; Medimmune, 2 ACR Plenary Session I: Discovery 2011 . . . . 30 Disclosure: Genentech and Biogen IDEC Inc., 2; Medimmune, 2 ACR REF Paul Klemperer, MD Memorial Lectureship: Osteoarthritis - Quo Vadis - Where are We Now - Where are We Going? . . . . . 89 Disclosure: Genentech and Biogen IDEC Inc., 2; Medimmune, 2 Extra Glandular Manifestations of Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . . 107 Disclosure: Genentech and Biogen IDEC Inc., 2; Medimmune, 2

2011 Program Book

335


Staels, Bart, PhD Towards Prevention of Atherosclerosis Progression in Rheumatoid Arthritis: Insights into the Relationship between Inflammation and Cardiovascular Disease . . . . . . . . . . 90 Disclosure: Nothing to Disclose Steen, Virginia D., MD Challenging Complications of Systemic Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . .107 Disclosure: Nothing to Disclose Stein, Brady L., MD Anemia of Inflammatory Disease . . . . . . . 56 Disclosure: Nothing to Disclose Stern, Sara M., MD Chronic Non-bacterial Osteomyelitis . . . 124 Disclosure: Nothing to Disclose Stetson, Dan, PhD Innate Immunity . . . . . . . . . . . . . . . . 56 Disclosure: Nothing to Disclose Stone, John H., MD, MPH Plenary Session III . . . . . . . . . . . . . . . 92 Disclosure: Genentech and Biogen IDEC Inc., 5 Vasculitis Mimics . . . . . . . . . . . . . . . . 51 Disclosure: Genentech and Biogen IDEC Inc., 2, 5 Lipid-Lowering Therapy 2011 . . . . . . . . . 28 Disclosure: Aurora Healthcare, 9 Strand, Vibeke, MD Biosimilar Products in the U.S. Market: Fact or Fiction? . . . . . . . . . . . . . . . . . . . . 125 Disclosure: Abbott Immunology, Alder, Amgen Corporation, 5 Stroes, Erik, MD, PhD Towards Prevention of Atherosclerosis Progression in Rheumatoid Arthritis: Insights into the Relationship between Inflammation and Cardiovascular Disease . . . . . . . . . . 90 Disclosure: Nothing to Disclose Suarez-Almazor, Maria E., MD, PhD Daltroy Memorial Lecture: The Role of Cultural Diversity in Patient-Healthcare Provider Communication . . . . . . . . . . . . . . . . 89 Disclosure: Nothing to Disclose Sweiss, Nadera J., MD Clinicopathologic Conference: A 40 Year-Old Male with Dyspnea on Exertion . . . . . . . . 54 Disclosure: Nothing to Disclose

T Tak, Paul P., MD, PhD The Earliest Phases of Rheumatoid Arthritis: Update on American and European Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . 81 Disclosure: Abbott Laboratories, 5; Arthrogen b.v., 1; AstraZeneca, 2, 5; Bristol-Myers Squibb, 2, 5; GlaxoSmithKline, 3; Merck Pharmaceuticals, 5; MerckSerono, 2; NovoNordisk, 2, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5 Takayanagi, Hiroshi, MD, PhD Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . . 18 Disclosure: Nothing to Disclose

336

2011 Program Book

Taylor, Janalee, MSN, CNS, CPNP Rheumatic Disease Update: Paraneoplastic Rheumatic Disorders . . . . . . . . . . . . . . 73 Disclosure: Nothing to Disclose

Troum, Orrin, MD Peripheral Magnetic Resonance Imaging in Clinical Rheumatology . . . . . . . . . . 33, 63 Disclosure: Nothing to Disclose

Ten Klooster, Peter, PhD Improving Health Measurement in Rheumatology . . . . . . . . . . . . . . . . 115 Disclosure: Nothing to Disclose

Troxell, Megan, MD Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis . . . . . . 44, 56 Disclosure: Nothing to Disclose

Terkeltaub, Robert, MD Crystals and Arthritis-Mechanisms of Inflammation and Joint Destruction . . . . . 44 Disclosure: ARDEA, 5; BioCryst, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Regeneron, 5; Takeda, 5; URL, 5 Developing ACR Guidelines for the Treatment of Gout . . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: ARDEA, 5; BioCryst, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Regeneron, 5; Takeda, 5; URL, 5

Tsai, Jeffrey, MBBS Thieves’ Market: Show Me Your Best Cases . 71 Disclosure: Various Scientific Meetings, Seminars and Symposium, 9

Theis, Kristina A., BA, MPH Keep People with Arthritis Working: An Interactive Case-based Discussion . . . . . 105 Disclosure: Nothing to Disclose Thiele, Ralf G., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two . . . . . . . . . . 20 Disclosure: SonoSite, 8 Musculoskeletal Ultrasound Course for Rheumatologists - Day One . . . . . . . . . . 17 Disclosure: SonoSite, 8 Thomas, Jana Leigh, MPA Utilizing Media Relations to Build Your Practice . . . . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose Thorp, Laura E., MPT, PhD The Neuromuscular System in Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . 96 Disclosure: Nothing to Disclose Tillman, Melesia, CPC, CRHC, CHA ACR Certified Rheumatology Coder Examination . . . . . . . . . . . . . . . . . . . . . . . . . 24 Disclosure: Nothing to Disclose RAC and Roll – How to Perform Complex Chart Audits . . . . . . . . . . . . . . . . . . . . . . 56 Disclosure: Nothing to Disclose Ting, Tracy V., MD, MSc The Child with Chronic Pain . . . . . . . . . 108 Disclosure: Nothing to Disclose Torgerson, Troy R., MD, PhD Immunology 101 and Targeted Therapies for Rheumatology Healthcare Professionals . . . 31 Disclosure: Nothing to Disclose When Your Defense Can’t Go on the Offense: Immunodeficiencies for the Practicing Rheumatologist . . . . . . . . . . . . . . . . 23 Disclosure: Nothing to Disclose Torralba, Karina Marianne D., MD ACR REF Special Session: Clinician Scholar Educator Presentations . . . . . . . . . . . . 52 Disclosure: Nothing to Disclose Towler, Dwight A., MD, PhD Session II: Cross-Talk between Bone and ExtraSkeletal Organs . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose

Tse, Shirley, MD Pediatrics: Spondylarthritis in Children . . . 55 Disclosure: SpA Advisory Board Meeting for Merck, Pfizer, Abbott, 5 Tsokos, George C., MD Plenary Session II . . . . . . . . . . . . . . . . 60 Disclosure: Nothing to Disclose Tsuji, Wayne H., MD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . . 123 Disclosure: Amgen, 1, 3; Immunex, 3 Tyndall, Alan G., MD Stem Cell Mediated Therapies in Autoimmune Diseases . . . . . . . . . . . . . . . . . . . . 118 Disclosure: Ad hoc consultant to Celerix, Celgene and Athersys, 5

U Uknis, Audrey B., MD ACR Leadership Town Hall Meeting . . . . . 95 Disclosure: Nothing to Disclose Uslan, Donald, MA, MBA, LMHC, CRC Disability: Clinical Facts, Legal Fictions, and Practice Strategies . . . . . . . . . . . . . . . 43 Disclosure: Nothing to Disclose Utrie, Paul C., MD Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis . . 58 Disclosure: Nothing to Disclose Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back . . . . . . . . . . . . . . . . . . . . 87 Disclosure: Nothing to Disclose Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee . . . . . . . . . . . . . . . . . . . . 90 Disclosure: Nothing to Disclose

V Van Den Berg, Wim B., PhD Osteoarthritis: A Disease of the Joint as an Organ . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose

van Laar, Jacob M. Stem Cell Mediated Therapies in Autoimmune Diseases . . . . . . . . . . . . . . . . . . . . 118 Disclosure: Nothing to Disclose van Vollenhoven, R.F., MD, PhD Difficult to Treat Systemic Lupus Erythematosus: Case Studies . . . . . . . . . . . . . . . . . . 73 Disclosure: Abbott, GSK, MSD, Pfizer, Roche, UCB Pharma, 2, 5 Varga, John, MD 2011 Hench Lecture: Resolution of Inflammation . . . . . . . . . . . . . . . . . . 26 Disclosure: Nothing to Disclose Fibrosis: Novel Paradigms . . . . . . . . . . . 63 Disclosure: Nothing to Disclose Venables, Patrick, MD Rheumatoid Arthritis: Where Does It Begin? . . . . . . . . . . . . . . . . . . . . . . . . . 64 Disclosure: Nothing to Disclose Villasenor Ovies, Pablo, MD ILAR Global Health Project . . . . . . . . . . 81 Disclosure: Nothing to Disclose Rheumatology Physical Examination of Lower Extremity and Lumbosacral Spine: Anatomical Correlates . . . . . . . . . . . . . . . . . . . . 34 Disclosure: Nothing to Disclose Rheumatology Physical Examination of Upper Extremity and Cervical Spine: Anatomical Correlates . . . . . . . . . . . . . . . . . . . . 87 Disclosure: Nothing to Disclose Von Feldt, Joan Marie, MD, MS Diagnostic Errors in Rheumatology: Why They Happen and How We Can Avoid Them . . . . 63 Disclosure: Abbott Immunology Pharmaceuticals, 1; American Board of Internal Medicine, 6; Amgen, 1; HGS, 1; Incyte, 1; Novartis Pharmaceutical Corporation, 1; Pfizer Inc, 1; Rigel Pharma, 1; Roche Pharmaceuticals, 1; Teva Pharmaceuticals, 1; Vertex, 1

W Wallace, Carol, MD ACR Plenary Session I: Discovery 2011 . . . . 31 Disclosure: Amgen, 2; Bristol Myers Squibb, 5; Pfizer Inc, 2 Advances in Polyarticular Juvenile Idiopathic Arthritis . . . . . . . . . . . . . . . . . . . . . 64 Disclosure: Amgen, Pfizer, Centocor, Novartis, BMS, 2 Introduction of Afternoon Session . . . . . . 22 Disclosure: Nothing to Disclose Session III: Developing Standardized Treatment Algorithms for Registries . . . . . . . . . . . 22 Disclosure: Nothing to Disclose Welcome and Introductions . . . . . . . . . . 21 Disclosure: Nothing to Disclose

Wallace, Daniel J., MD ACR REF Edmond L. Dubois, MD, Memorial Lectureship: Interfering with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . 104 Disclosure: Pfizer, UCB, Abbott, Amgen, TEVA, Cephalon, Remmunix, Human Genome Sciences, 5 Antimalarials for Rheumatic Disorders: Historical Perspectives, Clinical Insights and Future Directions . . . . . . . . . . . . . . . . . . . . 57 Disclosure: non Pfizer, UCB, Abbott, Amgen, TEVA, Cephalon, Remmunix, Human Genome Sciencese, 5 Wampler Muskardin, Theresa, MD ACR/ARHP Knowledge Bowl . . . . . . . . . 113 Disclosure: Nothing to Disclose Wanchu, Ajay, MD Rheumatic Disease Update: Musculoskeletal Manifestiations of Human Immunodeficiency Virus . . . . . . . . . . . . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Wang, Chenchen, MD, MSc Arthritis and Traditional Chinese Medicine . 92 Disclosure: Nothing to Disclose Ward, Michael M., MD ICD Coding - Crash Course for Researchers . 55 Disclosure: Nothing to Disclose Warman, Matthew L., MD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Nothing to Disclose Warren, Robert W., MD, PhD, MPH The Road to Meaningful Use and Beyond: A Simple Overview of a Complex Topic . . . . . 60 Disclosure: Nothing to Disclose Warrington, Kenneth J., MD Thieves’ Market: Show Me Your Best Cases . 72 Disclosure: Nothing to Disclose Wasko, Mary Chester, MD, MSc ACR/ABIM Maintenance of Certification Learning Session - 2011 Update in Rheumatology . . . . . . . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Cervical Spine Surgeries in Rheumatic Diseases: 2011 Update . . . . . . . . . . . . . . . . . . 56 Disclosure: Nothing to Disclose Watcher, Sandra J., RN, BSN Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: Gentech, 5 Preparing for Transition from Day One of Diagnosis to Adult Care . . . . . . . . . . . . 58 Disclosure: Gentech, 5 Wechsler, Michael E., MMSc, MD Vasculitis: Key Issues for the Clinician in Three Unique Diseases . . . . . . . . . . . . . . . . 96 Disclosure: Nothing to Disclose

Wedderburn, Lucy R., MD, PhD Advances in Polyarticular Juvenile Idiopathic Arthritis . . . . . . . . . . . . . . . . . . . . . 64 Disclosure: Nothing to Disclose Juvenile Idiopathic Arthritis: Clinical Heterogeneity and the Genome . . . . . . . 59 Disclosure: Nothing to Disclose Weinans, Harrie, PhD Osteoarthritis: A Disease of the Joint as an Organ . . . . . . . . . . . . . . . . . . . . . 107 Disclosure: Nothing to Disclose Weinblatt, Michael E., MD Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis . . . . . . . . . . . . . 34 Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; astellas, 5; Astrazeneca, 5; Biogen Idec, 2; Biogen/idec, 5; BristolMyers Squibb, 2; Centocor, Inc., 5; crescendo bioscience, 2, 5; Eisai, 5; GlaxoSmithKline, 5; horizon therapeutics, 5; idera, 5; lilly, 5; lycera, 5; Medimmune, 5; Merck Pharmaceuticals, 5; Pfizer Inc, 5; portola, 5; Rigel Pharma, 5; Roche Pharmaceuticals, 2, 5; Sanofi-Aventis Pharmaceutical, 5; ucb, 5; VBL, 5; Vertex, 5


van der Heijde, Desiree, MD, PhD Ankylosing Spondylitis: 2011 Update . . . . . 32 Disclosure: Abbott, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, ScheringPlough, UCB, Wyeth, 5; UCB, 8 Ankylosing Spondylitis: 2011 Update . . . . . 93 Disclosure: Abbott, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, ScheringPlough, UCB, Wyeth, 5; UCB, 8

Werth, Victoria P., MD Difficult to Treat Systemic Lupus Erythematosus: Case Studies . . . . . . . . . . . . . . . . . . 73 Disclosure: Amgen, 2; Astion, 5; Biogen Idec, 5; Celgene, 2; Cephalon, 5; CLASI, 9; Genentech and Biogen IDEC Inc., 5; ISW Group, INc., 5; Lupus Foundation of America, 6; Medimmune, 5; Pfizer Inc, 5; Rigel Pharma, 5; UV Therapeutics, 5 The Three Ps of Dermatologic and Autoimmune Disease: Pyoderma, Panniculitis and Pemphigus/ Pemphigoid . . . . . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose White, Daniel K., PT, ScD To P or Not to P? Knowing When the P-Value is Less than Useful . . . . . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Wigley, Fredrick M., MD Difficult Raynaud’s Phenomena . . . . . . . . 33 Disclosure: Actelion, Amira, Kinemed, Medimmune, Novartis, Orion, Pfizer, United Therapeutic, 2; Amira, Mediquest, Novartis, Orion, United Therapeutics, 5; Actelion; 8 Wilkie, Ross, PhD Beyond Pain and Fatigue: Expanding Clinician and Researcher Focus to Improve Daily Life . . . . . . . . . . . . . . . . . . . . . . . . .105 Disclosure: Nothing to Disclose Williams, Charlene, PhD Crystals and Arthritis-Mechanisms of Inflammation and Joint Destruction . . . . . 44 Disclosure: Nothing to Disclose Williams, David A., PhD Evidence-based Non-pharmacological Interventions . . . . . . . . . . . . . . . . . . 24 Disclosure: Bristol Meyers Squibb, 5; Eli Lilly and Company, 5; Forest Pharmaceuticals, 5; Jazz Pharmaceuticals, 5; Pfizer Inc, 5

2011 Program Book

337


Williams Judge, Susan L., MN, ARNP Iatrogenic Misadventures in Osteoporosis Treatment . . . . . . . . . . . . . . . . . . . . 53 Disclosure: UCB, Amgen, 8 Wolfe, Frederick, MD Session IV: Successes in Rheumatology Comparative Effectiveness Research . . . . . 22 Disclosure: Nothing to Disclose Woolf, Anthony D., MBBS ARHP Distinguished Lecturer: How Do We Get Policy Makers to Take Musculoskeletal Conditions Seriously? – The Bone and Joint Initiative . . . . . . . . . . . . . . . . . . . . 59 Disclosure: Nothing to Disclose Wortmann, Robert L., MD Curbside Consults - Ask the Professors . . . . 59 Disclosure: Nothing to Disclose Wright, Mary, BS, OT Foot Structure, Footwear and Foot Pain Translating Evidence into Practice . . . . . . 72 Disclosure: Nothing to Disclose Pregnancy and Child Care Issues for Parents with Arthritis . . . . . . . . . . . . . . . . . . 89 Disclosure: Nothing to Disclose Rehabilitation for the Clinician . . . . . . . . 43 Disclosure: Nothing to Disclose

Y Yazici, Hasan, MD Behcet’s Disease . . . . . . . . . . . . . . . . 27 Disclosure: Nothing to Disclose Yazici, Yusuf, MD Rheumatic Disease Update: Paraneoplastic Rheumatic Disorders . . . . . . . . . . . . . . 73 Disclosure: BMS, Celgene, Centocor, Genentech, UCB, Pfizer, Merck, 5; Centocor, Genentech, BMS, 2 Yeremenko, Nataliya, PhD Plenary Session II . . . . . . . . . . . . . . . . 60 Disclosure: Nothing to Disclose York, Michael R., MD Scleroderma: Systemic Sclerosis . . . . . . . 56 Disclosure: Nothing to Disclose

Z Zaremba, Laura, BA, MA The Road to Meaningful Use and Beyond: A Simple Overview of a Complex Topic . . . . . 61 Disclosure: Nothing to Disclose Zheng, Song G., MD ACR REF Edmond L. Dubois, MD, Memorial Lectureship: “Interfering” with Vascular Health: How Innate Immunity Promotes Premature Organ Damage in Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . 104 Disclosure: Nothing to Disclose Zuraw, Bruce L., MD Hereditary Angioedema . . . . . . . . . . . 118 Disclosure: CSL Behring, 5; Dyax, 5; Pharming, 2; Robert Michael Educational Institute, 8; Santarus, 5; Shire, 2, 5

338

2011 Program Book

A Aalbers, CJ 1147 Aarden, L 464, 1841 Aarrass, S 1821, 1843, 2356 Aati, O 1618 Abaci, N 166 Abasolo, L 383, 1042, 1084, 2062

Adarichev, VA 1348, 1637, 1921, 2096

Akar, S 541, 550, 1525, 1974

Albertsson, K 348, 2513

Addimanda, O 33

Akashi, K 1766

Albonico, G 1954

Akbas, F 1837

Albritton, N 2241

Akdeniz, T 1039

Alcaix, D 1302

Akerman, M 2550

Alcaraz, MJ 1782

Akhlaghi, M 2386

Alcocer, P 355

Akhmetshina, A 1588, 2321, 2427, 2535, 2538, 2539, 2540, 2606

Alcocer-Varela, J 854, 1009, 2251

Akhtar, N 2437

Alegre, JJ 191

Addya, S 2608 Adkins, D 861 Adler, A 150, 157, 642, 1680 Adler, Y 1051

Abbe, A 1641

Adnaoui, M 1040

Abbs, I 620, 631

Adoue, DFP 230

Abdel-Gadir, A 1662 Abdel-Megid, A 1898

Adrianto, I 481, 489, 636, 637, 649, 773, 1680, 2475

Abdoel, N 2351

Adriouch, S 2093

Abdollahi-Roodsaz, S 976, 981, 1785

Aeberli, D 1779

Abdulahad, DA 1659

Aelion, JA 401

Akkoc, N 541, 550, 1319, 1525, 1974

Abdulahad, WH 468, 794, 1752, 2342

Afsar-manesh, N 2076

Akram, A 1344

Abe, H 1082

Agard, C 1510

Aksentijevich, I 170, 306

Abe, T 44, 2188

Agarwal, SK 1492, 1494, 2329, 2429

Aksu, K 1525

Abignano, G 200

Agarwal, V 954, 1402

Abignano, G 667, 704, 705

Agashivala, N 893, 1033

Al Ghanim, N 2303

Abisror, N 2035

Ageberg, E 1088

Ablin, JN 934, 936

Aggarwal, A 294, 1343, 1402, 1654

Aboualaiwi, WA 1813

Aggarwal, R 1856

Abraão, M 1562

Aggarwal, R 229, 240

Abraham, C 1743

Aggeli, C 1163

Abraham, DJ 1481, 1485, 2324, 2327, 2603

Aggrawal, R 456

Aegerter, P 551, 807

Abraham, S 1652

Aghdassi, E 22, 1398, 2064, 2269, 2275, 2303, 2639

Abrahamowicz, M 1546, 2064, 2463, 2577

Agmon-Levin, N 480

Abram, F 1625, 2006

Agrawal, V 954

Abramson, SB 52, 61, 169, 171, 1070, 1794, 1824, 1936, 2434, 2518 Abud-Mendoza, C 2251 Abufayyah, M 549 Abujam, B 1654 Abusalem, SK 2406 Accart, N 1140 Accogli, A 273 Acevedo-Vásquez, EM 2117 Achenbach, K 699 Achenbach, SJ 1632 Ackerman, IN 796 Ackermann, F 608 Acosta, A 2268 Adachi, JD 1123 Adachi, R 1639 Adam, PM 1576, 1669 Adamczyk, A 532 Adami, S 2221 Adamopoulos, IE 1842 Adams, BS 266 Adams, M 96 Adams, RC 2422

Agrawal, N 559 Agudelo-Hernandez, A 229 Agudo, M 1968 Aguero, S 1177 Aguilar Arreola, J 250 Aguilar-Valenzuela, R 723 Aguirre, D 1705 Aguirre, MA 725, 1437 Ahl, J 1094 Ahlqvist, P 394 Ahmad, Y 601, 605, 2566 Ahmed, AF 2157 Ahmed, S 370, 1813 Ahn, JK 377, 625, 1192, 1413 Aikawa, NE 581, 709, 821, 865, 1890, 2016, 2020, 2619

Akhter, E 613, 1767, 1920 Akil, M 601, 605 Akiva, P 399 Akkara Veetil, BM 121, 213, 1187, 1617, 1870, 1871 Akkineni, R 1603

Akyayla, E 168, 1947 Al-Dhanhani, A 2292 Al-Mudhaffer, S 1514, 1515 Al-Otaiby, M 27 Alacacioglu, A 1319 Alachkar, M 1212 Alagha, A 447 Alarakhia, A 646 Alarcόn-Riquelme on behalf of the BIOLUPUS and GENLES, ME 634 Alarcon, GS 4, 591, 592, 783, 1374, 1375, 1383, 1545, 1708, 1860, 2642 Alarcon-Riquelme, ME 150, 157, 633, 641, 642, 649, 2475, 2476, 2479 Alarcon-Riquelme on behalf of BIOLUPUS, ME 1681

Aldag, JC 112, 740 Aleixo, I 1792 Alemo Munters, L 1549, 2424 Alenius, G 504 Alessandri, E 1474 Alessio, M 283, 1964, 2009, 2018 Aletaha, D 328, 1614, 2146, 2226 Alevizos, I 497, 498, 775, 1382, 1937 Alexander, K 113, 433 Alexander, MY 78 Alexanderson, H 1549, 1568, 2424 Alexeeva, E 292, 2626 Alexiades, M 1694, 2224 Alfredsson, L 104, 167, 1154, 1162, 1682, 2161, 2574 Ali, A 856 Aliabadi, P 1073 Alibaz Oner, F 1509 Aliferis, CF 169 Alivernini, S 1673 Allaart, C 354, 416, 418, 440, 2200, 2207 Allaart, CF 351, 1269, 1613 Allaire, N 585, 1919, 1920 Allanore, Y 530, 670, 673, 683, 685, 690, 692, 702, 712, 716, 1456, 1459, 1462, 1464, 1496, 1499, 1718, 2540 Allegri, F 9

Alarcon-Riquelme on behalf of BIOLUPUS and GENLES, ME 632

Allen, J 916

Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network, ME 639

Allen, NB 2432

Alarcón-Riquelme on behalf of BIOLUPUS and GENLES networks, ME 637 Alarcón-Riquelme on behalf of the BIOLUPUS and GENLES networ, ME 636, 2477

abstract author Index

Abbas, AR 837

Administrative Data Rheumatology Research & Surveillance 1881

Allen, KD 1582, 2542 Allen, RR 893 Allen, R 2621 Allensworth, J 986 Almagor, O 1085, 1087, 1982, 1985 Almas, E 2559C Almdahl, SM 1052

Alavi, A 14

Almeida, C 1557, 2405, 2425

Aikawa, Y 1139

Alba, M 1518

Almeida, GJ 1560, 1561

Airo, P 673, 1459, 1462, 1496, 1497

Alba, MA 1523

Almodovar, R 1311

Alba, MI 136, 143

Alnaqbi, KA 1330

Aittomäki, S 2570

Albagha, O 1935

Aloisi, F 375

Aizawa, K 1410

Alber, K 2279, 2288

Alon, L 921

Aizer, J 93

Alberici, F 2380

Alonso, A 2170

Akaike, H 267, 297

Albert, A 1065

Alonso, I 2115

Akalin, T 2004

Albert, DA 1603, 2051

Aloush, V 934

Akamata, K 1480

Alberts, AR 434

Alper, JA 434 2011 Program Book

339

Alpers, CE 559

Amoruso, M 2007

Ansemant, T 1110

Armaka, M 1640

Alpigiani, MG 283

Amos, C 1677, 1678

ANSWER Team 1669

Armbrust, W 258, 286

Alpini, C 1954

Amoudruz, P 1658

Antal-Szalmas, P 520

Armstrong, D 1534

Alsaleh, G 488, 774, 978, 1001

Amoura, Z 19, 20, 230, 608, 658, 859, 1373, 1409, 1955, 2394, 2395, 2399, 2450

Anthofer, J 1754

Arnaud, L 19, 20, 658

Antivalle, M 935

Arneson, C 2483

Antoch, G 945

Arnett, FC 1452, 1492, 1494, 1497, 2313, 2329, 2429

Altaf, S 212 Altares, J 1581 Alten, R 1016, 1019, 1020, 1028, 1029

Amram, L 2568

Alten, R 342, 363, 402, 403, 1219, 1697, 2191

An, Y 2526

Altenburg, A 2388

Anandarajah, AP 1075, 1347

Althoff, C 515, 1329, 2534

Ananieva, LP 684

Altman, RD 1280, 1282

Anaya, J 481, 489, 632, 633, 636, 637, 639, 773, 2475

Altpeter, M 1583 Alvarellos, AJ 783, 1177


Ampel, NM 2466

Alvarez-Lafuente, R 383, 1084 Alvarez-Lobos, M 1963 Álvarez-Rodríguez, L 16, 17, 81 Alvaro-Gracia, J 2075 Alzua, B 1756 Amador, LF 321 Amagai, M 1410 Amani, Z 2363 Amano, H 562 Amano, K 395, 396 Amano, K 1199, 1237, 1239 Amaral, P 1792 Amarasena, R 463 Amaravadi, L 2201

Anan, R 2165

Ancian, P 1140 Ancuta, C 517 Ancuta, I 444, 1645, 1646, 2242 Andersen, GN 2326 Andersen, J 629 Andersen, LS 1258 Anderson, D 756 Anderson, IK 2092 Anderson, JD 2147 Anderson, J 649, 1370, 2601 Anderson, M 749 Anderson, N 785, 1395 Andersson, M 356 Andersson, ML 348 Andhivarothai, N 265

Amaricai, E 1055

Ando, W 1082

Amarilyo, G 98, 574, 1831, 2033, 2076, 2361

Andrade, D 1438, 1443 Andrade, LEC 600

Amato, AA 235, 1864

Andrade, LEC 660, 1457, 2307

Amato, M 1675, 2597

André, C 1341

Ambarus, CA 521

Andre, V 2050

Ambler, N 2405

Andreo, AB 1719

Ambrose, N 1038

Andreoli, L 9, 1535

Ambrugeat, J 2214

Andrés Cerezo, L 53, 1817

Ambudka, I 776

Andreu, JL 1896

Ambudkar, I 775

Andrews, L 896, 897

Amengual, O 15

Andrews, RK 2105

Amento, EP 1812

Andreyeva, T 565, 1758

Ames, R 207

Andrianakos, AA 126

Amezcua-Guerra, LM 340

Anelli, MG 1047

Amezega, M 756

Anema, J 468

Amigo, M 8

Ang, DC 1607, 1962

Amigues, I 1709

Ang, L 1601

Amin, MA 731, 1619

Angel-Korman, A 1002

Amin, S 820, 960, 1632

Angele, P 1775

Amir, S 1002, 1944

Angeles-Han, S 271, 281, 289, 293

Amit-Vazina, M 2568

Anink, J 286

Amital, H 480, 2628

Anisfeld, AM 434

Amity, CL 135, 393, 844, 2143, 2150, 2516

Ankri, A 19, 20

Ammendola, A 397

Annis, K 1095

Ammitzbøll, CG 394 Ammouri, W 1040

340

2011 Program Book

Anneken, A 1578 Anolik, JH 470, 1739, 1767, 2186, 2504

Antoft, R 1665 Antohe, J 753 Antohe, JL 719, 1160, 1168 Anton, A 1303 Antonelli, M 870 Antoniou, J 1803 Anvari, M 1123 Aoki, C 2625 Aoki, C 1925 Aouni, M 1040 Aoyagi, K 318 Apparailley, F 2428 Apparailly, F 1007 Appel, H 1338 Appenzeller, S 2257 Arad, U 1002, 1300, 1944 Arai, S 1403 Arai, S 1410 Aral, O 1328, 2305 Aramaki, T 1236 Aranda, R 1225, 2469 Aranow, C 2472 Aranow, C 4, 1375, 1383, 1708 Aratani, S 2080 Araújo, AC 1971 Araujo, DB 2046 Araújo, F 507 Arbab, AS 731 Arbelaez, AM 321 Arce-Franco, M 30, 1166, 1818, 2115, 2134 Arden, NK 829, 1060 Ardianto, B 493 Ardoin, SP 2015, 2047, 2624 Arefiev, K 668 Arends, S 466, 1322, 1324 Arendt-Nielsen, L 1627 Arentz, G 1751 Arevalo, JF 1045 Arguis, P 1518 Arias-Leal, A 1084 Arias-Urdaneta, L 1507

Arnold, JL 94 Arnold, LM 940, 1608, 1905, 1907, 1913, 1916 Arntz, OJ 205, 981, 1785 Arora, T 122 Arora, V 1312, 2189 Arostegui, JI 1963 Arraes, AE 968 Arriens, C 1638 Arriola, P 1042 Arrobas Velilla, T 2169 Arslan, C 2393 Artim-Esen, B 609, 1328, 2300, 2305 Artioli, GG 1566 ARTIS Study Group 1206, 1884 Arts, E 1180, 2585 Arumugakani, G 1734 Arvikar, SL 1507 Asano, Y 1480, 2320 Asare, A 789, 2432 Asavatanabodee, P 409 Asbury, T 1339 Asche, CV 2048 Aschenberg, S 964 Ascherman, DP 823, 979 Asgnali, H 2337 Ash, ZR 200, 1285, 2486F Ashaye, S 1760 Ashby, M 2196 Ashcroft, DM 1211 Asiri, A 1325, 2285 Askanase, AD 2472 Askling, J 767, 1154, 1162, 1206, 1884, 2240, 2515, 2523 Aslanian, S 1757 Aslanov, R 1548 Asli, B 608, 2394 Asmawidjaja, PS 50, 2357, 2499 Aspe-de la Iglesia, B 2290 Assaraf, YG 1275

Arima, K 318, 2447

Assassi, S 153, 505, 666, 676, 1452, 1477, 1491, 1492, 1494, 2329, 2429, 2531

Arimura, Y 793

Assirelli, E 33

Aringer, M 2460

Atac, E 923

Arinobu, Y 1766

Atamas, SP 2607

Arisoy, N 166

Ates, H 1319

Arkachaisri, T 308

Atisha-Fregoso, Y 1404

Arkema, EV 101

Atkinson, EJ 1632

Arkfeld, DG 487

Atsumi, T 15, 2194, 2310

Arikan, M 166

Bader-Meunier, B 298, 2029

Baldi, M 2452

Barnes, B 1428, 2478

Attur, M 52, 61, 169, 171, 1070, 1794, 1824, 1936, 2434, 2518

Badesch, DB 1471

Baldini, C 471, 1933, 2381, 2382

Barnes, I 122, 2061

Atzeni, F 1201, 2390

Badillo, K 1075

Baliakos, A 1071

Barnes, J 160

Badinghaus, K 1578

Baliga, R 2603

Barnes, M 511

Audran, M 1104

Badley, EM 114, 798, 1540, 1727, 2612

Balint, PV 174, 1296

Barnes, PD 2017

Aukrust, P 595

Badot, V 2258

Balitsky, AK 22, 2275, 2639

Barnetche, T 2245

Aulchenko, YS 2162

Badsha, HM 1581

Ball, EM 194, 623

Barnhart, H 2015, 2047

Aumaitre, O 608

Bae, GB 2587

Ball, S 196

Barnhart, SM 2442

Aumaître, O 858

Bae, J 491

Ballantine, L 1673

Barnhill, J 2411

Aurousseau, M 728

Bae, S 4, 103, 109, 125, 591, 592, 609, 632, 633, 636, 637, 639, 642, 1375, 1383, 1708, 2168, 2171, 2223, 2475, 2477

Ballinger, SH 1876

Barohn, RJ 235

Balogh, B 38

Baron, G 438, 1508, 1641

Balogh, E 391

Baron, M 696, 708, 1717, 2489

Balogh, Z 283

Barr, PM 1744

Bae, S 716, 1025, 1037

Balow, JE 1382

Barr, SG 105, 140, 448, 1862, 2545

Bae, S 1459

Balsa, A 355, 1250, 2160, 2636

Barra, LJ 338, 2185, 2202

Bae on behalf of Korean Investigators, S 1681

Bananis, E 441, 2239

Barragan, A 8

Bancroft, T 1848, 1861

Barrera, P 165

Avellaneda, NL 1401

Baechler Gillespie, E 698, 820, 1655

Bandinelli, F 1287

Barrett, A 141

Avenel, G 2093

Baek, H 1049

Banerjee, R 1003

Barrett, JM 755

Avila, G 1806

Baek, SH 77, 2131

Banerjee, S 2591

Barrett, R 544, 1704

Avila, M 542

Baek, S 1165

Bang, H 839, 1745

Barrio del, R 16, 17

Avina-Zubieta, JA 1846

Baer, AN 472, 473, 483, 887, 898, 1600

Bang, S 1681, 2168, 2171

Barron, KS 2028, 2445

Bank, I 2333

Barry, M 2422

Bank, RA 1726

Barsalou, J 269

Banno, S 1193

Barsness, LO 1590

Bannuru, RR 1917

Barsottini, OGP 2397

Au, KM 1493

Austad, C 128 Austermann, J 306 Austin, HA 1382 Austin, M 1631 Austin, M 1098 Avalos, IB 1391 Avcin, T 612, 728

Avitable, M 1593 Avouac, J 670, 685, 690, 1456, 1459, 1464, 1499, 1718, 2321, 2538, 2540

Baerlecken, NT 790, 2529 Baerwald, CG 56, 1191, 1691, 2332

Awasthi, R 954

Baeten, D 2486D

Bansback, N 2072

Bartels, CM 2070

Axelsen, MB 946

Baeten, DL 521, 990, 1305, 1350, 1591

Bantia, S 1026

Bartels, LW 972

Bao, G 1847, 2444

Bartlett, SJ 342, 2124, 2132

Baeuerle, M 387

Baos, S 1250

Bartok, B 37

Bagaglia, PM 447

Baptist, E 1420

Bartoli, F 1462

Baglaenko, Y 566, 570

Baptista, AS 1067

Bahce-Altuntas, A 1306, 2634

Baraf, H 2582

Barton, A 160, 162, 164, 344, 1366, 1677, 2166

Bahner, M 198

Baraliakos, X 423, 503, 506, 546, 1335, 2486D

Barton, DL 941

Baildam, EM 257, 290, 2030

Bartos, A 2599

Bailly, F 1068

Barbaglia, AL 2563

Bas, S 160, 1081

Bainbridge, L 2562

Barbarroja, N 725, 1437

Basher, F 2363

Bains, G 1069

Barber, C 1398, 1880

Basra, G 726

Bajocchi, G 189

Barber-Vallés, X 2211

Bass, AR 93

Bakalov, V 482

Barbhaiya, M 7

Basso, C 1973

Baker, A 751, 2008, 2011, 2014, 2456

Barbour, G 2339

Bastian, H 1697

Barbour, KE 879, 1978, 2508

Bastian, I 469

Baan, H 2459

Baker, DG 389, 458, 460, 1158, 1210

Barcellos, LF 645

bastuji-Garin, S 2638

Baba, S 227, 615

Baker, J 218, 389, 1158

Barcelos, A 1317

Basu, N 2370

Babul, M 1439

Baker, MF 1260, 2205

Barclay, M 2467

Basualdo, J 1963

Babyn, PS 749

Baker, PA 2297

Bardin, T 1016, 1019, 1020, 1028, 1029

Bateman, L 1609

Bacani, AK 213, 1183, 1501, 1502, 1617

Baker, RL 2339

Bardin, T 438, 1641

Bakir, M 168, 1947

Bach, M 1046

Barendregt, P 431

Battafarano, DF 111, 465, 1164, 2142

Bakker, MF 1695

Backhaus, M 174, 176, 178, 198, 327, 2144, 2460

Barete, S 1955

Battellino, M 935

Balandraud, N 2050

Barilaro, G 726

Batterman, A 1579

Backhaus, TM 176

Balanescu, A 1096, 1296

Barile, LA 8

Battersby, R 1093

Balani, D 1779

Barkham, N 1285

Batticciotto, A 935, 2144

Balasubramani, G 2143

Barnabe, CC 105, 140, 448, 1862, 2222, 2545

Baum, P 1691

Barnado, A 2277

Bautista - Molano, W 542

Axford, JS 14 Axtell, B 1888 Ayala-Gutiérrez, MM 609 Ayanian, JZ 123 Aydin, S 200, 705, 2144, 2486F Aydinli, M 1951 Ayearst, R 1332, 1357, 1360 Ayoub, WT 753, 755 Aytekin, S 1509 Azakli, H 166 Azevedo, R 2403 Aziz, F 1709

B

Backman, CL 1576, 1669 Badawi, RD 206 Baddley, J 801 Bader Meunier, B 2021

Balbir-Gurman, A 673, 678, 1300 Baldecchi, A 931, 1904, 1905, 1907

Barnard, J 1739, 2504


Attinger, C 27, 1953

Bathon, JM 1182, 1642

Baumgartner, S 811 Bautista-Molano, W 1301 2011 Program Book

341


Bawa, WA 259

Belli, R 1051

Beretta, L 673, 1491, 1497

Betteridge, J 502, 1293

Baxendale, RW 170

Bello, KJ 596, 786, 2471

Berezne, A 1459

Betteridge, Z 824

Baxter, D 1673

Belloli, L 691, 1120

Berg, IJ 513, 519

Bayakly, R 1847, 2444

Bellomio, V 1177, 2563

Berg, KH 2559C

Beukelman, T 264, 278, 280, 282, 801, 2061

Baysak, T 1292

Belloni Fortina, A 2018

Berg, RL 1119

Bazari, H 2309

Belmonte, N 2337

Bergegård, J 1568

Bazeli, R 268, 690, 1718

Belmonte Serrano, MA 343

Berger, M 2001

Bazin, D 1801

Belostocki, KB 1808

Bergeron, L 1727

Bazzichi, L 942, 1942, 2400

Beltrán, E 1044

Bergeron, L 1586

Beach, JM 1531

Beltran, J 573

Berggren, O 2496

Beamer, M 370, 1813

Belza, B 869

Berglin, EH 312

Beard, L 234, 2039

Ben Zvi, I 480

Berglund, A 104

Beasley, M 880

Ben-Chetrit, E 2013

Bergman, MJ 142, 331, 2058

Beaton, CA 221

Bena, J 237, 238, 713

Bergman, P 2613

Beaton, DE 2292

Benaglio, F 350

Bergman, S 356

Beattie, KA 88

Benbara, A 728

Bergmann, C 2535, 2539

Beauchamp, M 1546, 2463

Benchaala, I 2617

Bergmann, M 817

Beaulieu, E 1145

Benda, B 718, 2592

Berk, L 1069

Beaupre, LA 745

Bendele, A 1130

Berk, OS 930

Bebris, L 482

Benderdour, M 80

Berkun, Y 2013, 2333, 2622

Becerra-Fernandez, E 1737, 1960, 2225

Bendersky, A 2333

Berman, A 2563, 2591

Bechtel, B 917, 1379

Bendran, Z 2563

Berman, J 93

Benech, P 1753

Berman, M 934

Benegas, M 2563

Bermas, BL 1667

Benessiano, J 488

Bermudez, S 2253

Benestad, EE 2559C

Bernasconi, C 2204

Beneventi, F 1954

Bernasconi, C 2218, 2628

Bengtsson, A 1268, 1441

Bernatsky, S 256, 586, 591, 592, 609, 1196, 1546, 1846, 1862, 1881, 2193, 2271, 2455, 2463

Beck, JD 2170 Beck Jensen, J 1098 Becker, ES 2417, 2487 Becker, JP 2255 Becker, ML 750 Becker, MA 1018, 1022, 2048, 2582 Becker, MO 2312 Becker, M 255, 2019, 2027, 2034 Becker-Merok, A 486, 996 Beckwith, T 751 Becquemont, L 485 Becvar, R 2321, 2538 Beebe, D 751, 2011, 2456 Beenackers, H 2407 Beetens, J 2237 Befrits, R 2116 Behbahani-Nejad, N 2572 Behcet’s Disease Reserch Commitee of Japan 2402 Behrens, EM 1683, 2502 Behrens, F 363, 534 Behrens, TW 837, 2479, 2480 Beier, F 2434 Beirnaert, E 834 Bejerano, C 81, 1044, 1950, 1968 Békés, G 1296 Belenotti, P 857, 860 Belilos, E 1808 Belisle, P 1862 Bell, A 623 Bell, DA 2185 Bellam, N 2311 Bellando-Randone, S 2604

342

2011 Program Book

Bengtsson, C 104, 2161 Benham, H 1705 Benhamou, C 1116 Benítez-del-Castillo, JM 1045 Benito-Garcia, E 464 Bennett, B 2214 Bennett, M 2038 Bennett, M 707 Bennett, RM 735 Benninghoff, S 35 Bennink, MB 981, 1785 Benoist, C 2355 Benos, A 901 Benseler, SM 291, 748, 749, 1532, 1534, 1976 Bensen, WG 1260, 2205 Benson, C 194 Benson, M 1621, 1758 Bentin, J 180 Bento, MP 2257 Bentz, H 666 Benveniste, O 230, 1587, 1955 Berard, E 2029 Berard, RA 863 Berda-Haddad, Y 1816 Berdasco, M 366 Berenbaum, F 2214 Beresford, MW 290, 612, 2030, 2454

Beutler, A 423, 1227, 2206, 2227 Bevaart, L 1147 Bexiga, M 1934 Beyer, C 1588, 2321, 2380, 2535, 2538, 2539, 2540 Bezerra, ELM 1598 Bezerra Neto, FA 1598 Bhagat, G 567, 2549 Bhagat, S 861 Bhangale, T 2479 Bharat, A 122 Bharatwaj, BS 2617 Bhatia, P 907 Bhattacharyya, S 1819, 2537 Bhattoa, HP 520 Bian, A 587, 588, 2280 Bianchi, G 1104 Biasi, D 1201, 2221 Bica, BE 304 Bicakcigil, M 1039 Biear, J 1739, 1767, 2504 Bienkowska, J 585, 1919, 1920 Bienvenu, B 858 Bierma-Zeinstra, SM 187 Bijkerk, C 440 Bijl, M 1159, 1161, 1659

Berndt, MC 2105

Bijlsma, J 127, 1080, 1987, 1997

Bernett, MJ 1256

Bijlsma, JW 419, 1570, 1695

Bernhard, J 527, 2637

Bilgic, H 820

Bernie, C 861

Bili, A 719, 753, 755, 1160, 1168

Bernstein, CN 152, 765, 1204, 2163, 2573

Bingham, III, CO 342, 1230, 2124, 2132, 2199

Bernstein, EJ 2309

Biniecka, M 391, 1829

Bernstein, J 306

Birbara, CA 1024

Berthelot, J 2384

Birch, H 2443

Berthier, CC 1433

Bird, A 2247

Berthier, S 1500

Birkelund, B 172

Bertin, P 1981

Birkett, R 367

Bertolaccini, ML 24, 25, 26, 725, 1437

Birmingham, D 2276

Bertoli, AM 1177, 1860

Birnbaum, J 483

Bertolino, A 779 Bertone, M 768 Bertrand, K 101 Bertsias, G 2431 Bertucci, AM 647, 648 Besedovsky, HO 1133 Besenyei, T 1008, 1921, 1928 Besirli, K 2393 Bessette, L 892, 894, 2193 Beswick, A 1061 Bethi, S 518 Bethunaickan, R 558, 2550

Birmingham, JD 710 Birtett, R 2086 Birtwhistle, R 1727 Bischof, S 260 Bischoff, S 2460 Bishop, R 2451 Bisson-Vaivre, A 1302 Biswas, PS 567, 2549 Bitman, B 1189, 1217 Bitter, H 1148 Bitterman, H 1868 Biundo, J 95 Bjerre, M 299

Bjornsson, J 2439, 2546

Boggs, R 1288

Borte, M 2623

Brahn, E 2087

Blachier, M 2638

Bohnsack, JF 1686

Borup, R 253

Bramson, C 741

Black, S 1550

Boiardi, L 189, 855, 1505, 1516, 1520, 2390

Borzutzky, A 1963

Branch, W 1707

Boileau, C 1496

Bos, W 770

Branco, JC 507, 1317

Bose, N 713

Brand, D 594, 849

Bosello, SL 703, 1469, 1746, 2343

Brandi, ML 1103

Bosma, A 1662

Brandi, ML 1108, 1533

Bossini-Castillo, L 1491, 1494, 2429

Brandt, DF 1372, 1445

Bosworth, B 700 Bosworth, HB 1582

Brasington, R 337, 1545, 2155, 2642

Botsios, C 1201

Brasington, RD 2128, 2157

Bottai, M 235

Bratt, J 436, 459, 535, 2229, 2513

Bottaro, A 2493

Brault, Y 174

Botusan, IR 55

Braun, D 2591

Bouaziz, M 1496

Braun, J 779, 922, 2486D

Boudaoud, S 161

Braun, J 503, 506, 546, 1296, 1335

Boudreau, RM 959, 2079

Braun, J 423, 777, 1227, 2227, 2486B

Black DBE, CM 1485, 1573 Blake, C 1559 Blanco, Sr., FJ 48, 1772, 2420, 2426, 2554

Boin, F 2486

Blanco, I 618, 1432, 1655

Boire, G 325, 338, 339, 347, 736, 1198, 1889, 2141, 2202, 2457

Blanco, R 718

Boinot, C 728

Blanco, R 81, 1044, 1045, 1950, 1968

Boisramé-Gastrin, S 474

Blanco-Esteban, A 1044

Boldizsar, F 2335

Blaney Davidson, EN 1349, 1726, 1783, 1785, 2435

Bolge, S 129

Blank, N 1455

Bollen, E 1420

Blattes, R 1784 Blaugrund, E 560, 2091 Blazevic, I 1860 Blecher, K 1827

Bolland, S 559 Bollow, M 503, 506 Bolognese, MA 1107, 1108 Bolster, MB 1594, 1716, 2589 Boman, K 1156

Bleck, E 582

Bombardier, C 118, 863, 1881, 2222

Bliddal, H 384, 946

Bombardieri, M 374, 375

BLISS-52 and -76 and LBSL02/99 Study Groups 578

Bombardieri, S 185, 471, 942, 1406, 1519, 1529, 1933, 1942, 2263, 2381, 2382, 2400, 2401

BLISS-52 and BLISS-76 Study Groups 602, 1416

Bouffi, C 2100 Bouhaddi, M 424 Bouhassira, D 1048 Boulter, E 2039 Boumier, P 315 Bourgeois, P 132, 1955

Bommireddy, S 2501

Bourkia, M 1040

BLISS-52/-76 Study Groups 2472

Bonafede, M 1547, 2415

Bourne, T 1814

Blits, M 1275

Bone, HG 1103

Bourré-Tessier, J 2254

Blobel, C 1151

Bone, HG 1108

Bousson, V 1801

Bloch, DB 1740

Bonelli, M 31, 817, 1657, 2359

Bouta, EM 2089

Bloch, M 1019, 1020, 1029

Bonetti, LA 1808

Boutin, D 19, 20, 2395

Bloch, O 2568

Bonfa, E 581, 709, 812, 821, 865, 899, 1566, 1572, 1647, 1723, 1890, 2016, 2020, 2037, 2046, 2614, 2619

Boutroy, S 1631

bloch-Queyrat, C 1587 Block, JA 630, 1086, 1088, 1397, 1422, 1563, 1859, 1860, 1994, 2004, 2066, 2299 Bloem, J 1074 Blom, A 976, 1012, 1144 Blom, AB 1784, 1793, 2435 Blom, A 1061 Bloom, AC 2433 Bloom, DR 1396 Blueml, S 817, 2359 Blum, SI 925 Blumbergs, P 251 Blumenthal, DR 1593 Blumenthal, R 1182 Boackle, SA 640, 641 Bocci, M 703, 1454, 1469 Bock, S 1495 Bode, BY 2466 Bodukam, V 716 Boers, M 378, 439, 914, 1175, 1269, 2369 Boesen, M 946, 949 Boevin, T 2599 Boffa, M 728 Bogado, CE 1631

Bonfield, TL 1789 Bongardt, S 2255 Bongartz, T 213, 1617, 1676, 2212, 2530

Bowes, J 1677, 1688, 2166 Bowler, R 2182 Bowman, EP 1842 Bowman, SJ 589 Bowyer, SL 2015, 2047 Box, JH 402

Bonilla, E 2599

Boyce, B 1635

Bonilla, MG 2636

Boyd, SK 1631

Bonilla, N 1706

Boyd, SK 965

Bonitsis, NG 2388

Boyd, T 2141

Bonnefoy, J 1140

Boyer, O 372, 1587, 1932, 2093

Bonner, A 610, 2202

Boyle, DL 196, 385, 1134, 1630, 1809, 2517

Bonnet, F 857, 860 Bony, C 2100 Boone, JM 206 Boonen, A 342, 1292, 1326 Boonen, S 1104 Boots, AM 2342 Bootsma, H 466, 468, 1752 Borba, EF 581, 2614 Borba Neto, EF 1890, 2046 Borgström, F 906 Borham, A 1898 Bork, DJ 713 Borkar, N 547, 552, 1869 Borman, P 926

Bozaite-Gluosniene, R 719, 753 Bozkaya, G 1319 Bracci-Laudiero, L 985 Bracho, C 2351 Bradley, J 409 Bradley, JD 407, 408, 718, 1213, 1215, 2192, 2592, 2627 Bradley, L 1627 Bradley, LA 744 Brady, A 1559 Braem, K 1802 Braga, FFR 1486 Braga-Neto, P 2397

Braun, T 1697 Braun, T 1788 Braun-Moscovici, Y 678 Bravenboer, N 1799 Bravo-Zehnder, M 1439


Blasini, AM 2351

Bolce, R 455, 826, 1310, 2215

Brar, S 1550

Breban, MA 535, 551, 1340, 1341, 1701, 1706 Bredemeier, M 674 Bree, A 1621 Breedveld, FC 1231 Brembilla, NC 712 Brennan, A 1722 Brennan, A 2443 Brennan, D 547, 552, 1869 Brennan, MT 481, 643, 773 Brenol, C 674 Brenol, JCT 638, 674 Brent, LH 455, 1946 Brentano, F 1823 Bresnihan, B 1203 Bressollette, L 474 Bretz, W 2518 Brewer, C 2451 Brewer, JM 203 Brey, RL 1396 Brezinschek, H 1270 Briasouli, P 1440 Brickmann, K 1270, 2135 Bridges, Jr., SL 337, 392, 412, 634, 995, 1545, 1696, 2128, 2155, 2157, 2642 Brihaye, B 608 Brik, R 2622 Brill, A 1944 Brimhall, DB 1017 Brink, M 2178 Britsemmer, K 1799 Britsemmer, K 425, 2127 Brock, M 1671, 2536, 2605 2011 Program Book

343

Broder, AR 21, 509, 1306, 1693, 2634

BSRBR, OBOT 426, 2525

Bushnell, T 1704

Calamia, V 2554

Brodin, N 2424

(BSRBR) control centre consortium, BSFRBR 426, 2524, 2525

Bustabad-Reyes, S 1818

Calcagni, M 2536, 2605

Brodsky, JE 86

Buatois, V 63, 977

Bustos Bahena, C 1232

Calcagno, G 283, 2452

Broen, J 1491, 1497

Buch, MH 667, 704, 705, 1643, 2144, 2252

Butfiloski, E 1768

Calderón, J 1439

Butler Browne, G 1587

Calderón-Aranda, E 11

Butman, J 2451

Caleiro, MC 709

Butter, C 1155

Calich, ALG 581, 1566, 2619

Buttgereit, F 28, 373, 914, 1005, 1219, 1228, 1697

Caliendo, J 32

Butz, S 34

Buckley, D 197

Buyon, JP 305, 597, 752, 771, 772, 1408, 1440, 1675, 1707, 2597

Callahan, LF 337, 1544, 1545, 1583, 1594, 2128, 2155, 2157, 2418, 2642

Buckley, LM 907

Buyon, L 1440

Callejas, JL 609

Brosseau, L 1090

Buckner, J 1743

Buzio, C 855

Callis Duffin, K 1307

Brouwer, E 352, 466, 1322, 1324, 2175, 2342

Buckner, JH 698, 2170

Büchler, C 1823

Callon, KE 210

Budoff, M 759, 762

Bykerk, V 338, 1198

Calvo, V 1950

Brown, AG 958

Budoff, S 314

Calvo Penades, I 2012

Brown, D 2621

Buechler, MB 2548

Bykerk, V 118, 325, 339, 342, 378, 736, 1889, 2141, 2202, 2218

Brown, E 337, 2128

Bueno, VC 862

Bykerk, VP 333, 2457

Camacho, EM 1872, 1873

Brown, EE 633, 634, 636, 642, 1374, 2479

Bugatti, S 350

Brohawn, P 1835 Bromberg, R 2170 Brondello, J 1790 Bronson, WD 2049 Brook, RA 913 Brook, R 1169 Brookhart, MA 123


Brooks, EB 276

Brown, JP 1028, 1103 Brown, J 1016 Brown, JP 1098 Brown, KK 687, 1714, 2182 Brown, LS 535, 1312, 2486A Brown, MT 741, 828, 1095, 1096 Brown, MA 153 Brown for PROFILE, E 150, 641 Brown for PROFILE, EE 157, 637, 2475, 2476 Brown* on behalf of PROFILE, AEE 1681 Brucato, A 669, 1051 Bruce, B 1885, 2556 Bruce, IN 4, 78, 591, 592, 601, 605, 1375, 1383, 1415, 1708, 1893, 1895, 2106, 2166, 2588

Buchanan, RR 1308 Buchbender, C 945 Buchbinder, R 411 Buchner, CE 2297 Buckley, CD 349, 366, 374

Bugge, T 776 Bugni, VM 862 Buhrmann, C 1897 Buie, HR 965 Buischi, Y 2518 Bukh, G 872 Bukhari, M 1097, 1105

Byun, J 850

Cameron, G 2591

Bzarova, T 292, 2626

Cameron-Fiddes, V 2609

Bäcklund, J 2341

Camici, G 46

Böhringer, S 2181

Campanilho-Marques, R 1934

Bøyesen, P 950, 953, 1623, 2184

Campbell, RC 241, 242, 243

C Caballero, I 1832

Bunn, DK 1872, 1873, 1892, 1893, 1895, 2588

Caballero-Uribe, CV 2117

Bunney, TD 170

Cabral, AR 5

Buoncompagni, A 273 Buonocore, MH 206 Burbine, SA 877, 884, 900, 2510

Brummett, CM 939, 1911, 1912, 1988, 2421

Burgess, J 876

Brummett, KA 939

Burkhardt, H 363, 534, 2214

Brumwell, AN 1484 Brunck, M 2430

Burkly, LC 555, 556, 576, 1827, 2201

Bruner, V 1945 Brunetta, P 789, 837, 2255, 2432

Burgos-Vargas, R 2469

Cabas-Vargas, J 921 Cabral, DA 1633, 2024 Cabrera, S 1205, 2138 Cabrera, S 316, 450 Cabrera-Perez, J 776 Cáceres-Martín, L 2290 Cacoub, P 230, 438, 577, 791, 857, 860, 1373, 1409, 1528, 1529, 1641, 1753, 1955, 2394, 2395, 2399, 2450, 2620

Campbell, S 555 Campos, LM 865, 2020, 2046 Camps, M 609 Cañal, J 1044, 1950 Canas da Silva, J 507, 1841 Cancro, MP 575 Candelieri, A 1287 Canestri, S 1746 Cañete, JD 1205, 2138 Cañete, JD 182, 316, 450, 1296, 1358, 1591, 1772, 1806, 1972 Canhão, H 414, 507, 1645, 1646, 1792, 1934 Canizares, M 1540 Canna, S 2502

Cacoub, PP 859

Canna, SW 1683

Burlingame, RW 302, 2297

Cadzow, M 211

Cannizzaro, E 284

Burmester, GR 176, 198, 373, 839, 840, 1644, 1697, 1745, 2075

Caeiro, F 1177, 2563 Caetano-Lopes, J 414, 1792

Burmester, G 28, 718, 1005, 1749, 2216

Caffrey, A 1722

Cannon, GW 134, 1174, 1181, 1200, 1234, 1264, 2140, 2152, 2172

Burnett, H 2067

Cagnoli, PC 1849, 2264, 2442

Bruno, R 2263

Burns, A 1702

Brus, HL 2459

Burns, J 194

Brusi, V 33

Burns, MB 1578

Bryan, RL 1791

Burt, RK 647, 648

Bryant, CC 2297

Bury, R 1702

Bryant, KJ 1777

Busch, RE 2147

Brys, R 2210

Bush, H 1850

Brzosko, I 1309

Bush-Joseph, C 816

Brzosko, M 1309

Bushnell, D 1839

2011 Program Book

Cambridge, G 390, 1735, 1737, 2225, 2521

Bultink, I 590

Bruckert, E 1265

344

Byron, J 843

Bull, S 1353

Bunni, M 2363

Calvo-Alen, J 16, 17 Camargo, C 1457

Byrne, R 31

Bukulmez, H 276

Burgerhof, H 1752

Brunner, H 612, 721, 751, 754, 1578, 2008, 2011, 2014, 2015, 2038, 2047, 2294, 2454, 2456, 2621, 2622, 2624

Bynote, K 2155

Callahan, E 1484

Cagnard, N 980, 1701 Cahue, S 1085, 1087, 1982, 1985 Cai, T 1185 Cai, Y 1958, 2084 Caiello, I 985 Cairns, A 159 Cairns, E 2185 Cakar, A 166 Cakiris, A 166 Calabrese, LH 2448

Cano Pérez, C 2211 Canoso, JJ 95, 1595 canoui-Poitrine, F 2638 Cantagrel, AG 438, 1641, 2234 Cantarini, L 988 Canteli, B 208 Cantero-Hinojosa, J 1323, 2060 Cantini, F 517, 535, 2390 Cantor, RM 639, 2477 Cantor, SB 878, 885 Cao, K 184

Carretero, RM 725

Cavill, C 1366

Cao, Y 1760

Carrier, Y 565

Cazotti, LA 1067

Caorsi, R 1964, 2452

Carriera, P 1494

Ceccarelli, C 2604

Capacci, A 703, 1469

Carrino, J 1458

Ceccato, F 1177, 2563

Chandran, V 524, 525, 537, 544, 549, 781, 1314, 1325, 1327, 1331, 1332, 1334, 1353, 1357, 1360, 1361, 1362, 1363, 1364, 1365, 1651, 2486E, 2486C

Capannini, S 1533

Carroll, D 2542

Ceccherini, I 2022, 2452

Chandrasekaran, A 1567

Capannolo, M 1589

Carruthers, M 1740

Ceceli, E 926

Chandrasekaran, U 567

Caparbo, V 812, 899

Carsons, SE 1808

Cedeno, A 751, 2008, 2011, 2456

Chang, AY 617

Capellino, S 1805

Carter, JD 1940, 1948, 2241

Celis, R 1358, 1806

Chang, A 1085, 1087

Capelozzi, VL 1486

Carton, L 1296

Cellucci, T 748, 1532

Chang, AH 1985

Capini, C 2430

Carty, A 1303, 1330

Cemin, R 1051

Chang, DJ 916

Caplan, AI 1789

Carty, S 1146

Cendes, F 2257

Chang, D 639, 642, 2477

Caplan, L 134, 145, 1174, 1181, 1234, 1264, 2140, 2152

Carulli, J 585, 1919, 1920

Çene, E 2305

Chang, H 326, 509

Capone, L 1844

Caruso, A 189, 1520

Centola, M 347, 351, 1613

Chang, J 137

Carvalho, JF 865, 1572, 1890

Ceribelli, A 228, 231, 232, 845

Chang, L 1550

Casadevall, A 2552

Cervera, R 578, 1416

Chang, L 1130

Casali, B 2390

Cervini, B 2069

Chang, N 566, 570, 661, 852

Casalla, L 2563

Cestari, T 674

Casarrubias-Ramirez, M 665

Çetin, GY 1279

Chang, RW 1558, 1980, 2120, 2505, 2558

Casas, M 1311

Cevallos, R 858

Chang, S 437

Casas, S 19, 20

Cha, H 109, 125, 377, 625, 1192, 1413

Chang, SH 324

Casella, CB 2037

Chaabo, K 2378, 2383

Chang, Y 322, 388

Chaara, W 791

Chao, C 1842

Carette, S 95, 1503, 1513, 2368

Casey, VA 800, 1553, 1554, 1555, 1556, 2543

Chader, D 658

Chao, JH 196

Carey, JJ 87, 2074

Cash, TF 1397

Chae, JJ 986

Chapelle, D 818

Carlens, C 767

Casillas, J 1992

Chafin, C 571

Chapelle Neal, DC 310, 2028, 2451

Carletto, A 1201

Caspi, D 1002, 1300, 1944

Chaib, AI 620

Chapelon, C 1409

Carli, L 942, 1406, 2263

Castañeda, S 1173

Chaitow, J 2621

Chapman, HA 1484

Carlos, F 906

Castaño, M 191

Chakravarti, P 897

Chapman, PT 2467

Carlson, C 2159

Casteels, P 834

Chapurlat, R 1103

Carlstorm, C 1585

Casteilla, L 1784

Chakravarty, EF 597, 707, 2017, 2109

Carlton, V 1339

Castejon, MA 1782

Chakravarty, K 224

Charles, N 662

Carmon, V 982

Castellano, G 2257

Carmona, FD 1492

Castillo-Gallego, C 200, 705, 2486F

Chalarakis, N 739

Carmona, L 343, 450, 692, 1197

Castrejón, I 124, 331, 343, 1894, 2052, 2053, 2058

Chalder, T 1557 Chalès, G 180

Charles-Schoeman, C 763, 764, 788, 1918

Caroli, F 2452

Castrillo, A 1818

Chales, GH 2050

Chartash*, E 1248

Carolina Lupus Study Investigators 1857, 1858

Casu, C 1535

Chaly, Y 1839

Charuel, JL 1587

Catalan Pellet, A 2563

Chary-Valckaneare, I 2050

Carpenter, E 1070

Catan, L 1055

Chamberlain, ND 364, 365, 729, 730, 835

Carpentier, P 681

Catanoso, MG 189, 1505, 1516, 1520

Chambers, C 1874, 2109 Chambers, R 2315

Chastek, B 1221

CATCH Investigators 339, 1198, 1889, 2141, 2202, 2457

Chammas, MC 222

Catlett, I 1136

Chan, EK 228, 231, 232, 467, 845

Caporali, R 350, 1954 Cappariello, A 1589 CAPS Study 257 Caramaschi, P 1459 Carbillon, L 728, 2035 Cárdenas, F 2272 Cardenas, S 30 Cardiel, M 2592 Cardiel, MH 1389, 2117

Carneiro-Sampaio, M 304

Carpentier, W 1753 Carr, A 1060 Carr, FN 2410 Carr, JJ 722 Carr, J 787, 1446 CARRANet Investigators 280, 281, 289, 747, 2010, 2023, 2294 Carraro, V 1454, 2221 Carrasco, R 257 Carrasco, S 303, 1486 Carreira, P 1717

Casciola-Rosen, L 483

Catrina, AI 55, 767, 2176, 2179 Catrina, S 55 Cats-Baril, WL 93 Cattalini, M 2452 Cattaneo, A 1294 Cattano, NM 1977 Cauli, A 1354

Carreira, PE 673, 692, 1491, 1492, 2316

Cavagnoli, C 1954

Carreño, L 390, 1414, 2036

Cavazza, A 189

Carrera, C 1294

Cavazzana, I 231, 232

Carrera-Marin, AL 12, 13

Cavet, G 323, 351, 361, 838, 1613, 2244

Cavalcanti, A 304

Chalan, P 2342

Chams-Davatchi, C 2386 Chan, ES 536, 2323 Chan, J 43 Chan, JY 228, 232 Chan, MO 262


Cao, Y 2202

Chang, TC 391

Charles, J 1452 Charles, PJ 59, 1652, 2171, 2522 Charles-Schoeman, C 718

Chary-Valckenaere, I 180 Chataway, TK 1751 Chatel, L 63, 977 Chatelus, E 717, 774, 1257, 2050 Chatham, W 597 Chatham, WW 584 Chatterjee, S 237, 238, 713, 2483 Chaturvedi, P 1757

Chan, O 1435

Chatzidionysiou, K 444, 1645, 1646, 2240, 2242

Chan, PT 579

Chau, M 553

Chan, S 1320

Chaudhari, AJ 206

Chan, TM 553, 1435

Chaudhari, S 1217

Chan Tchi Tsong, P 1932

Chaudhari, S 1379

Chandran, A 1608

Chauhan, AK 300, 309, 1444, 2360 Chauvenet, L 1048 Chavanet, P 1110 2011 Program Book

345

Chaves, L 2189

Childs, E 1565

Choquette, D 517, 2203

Clark, TM 1503

Chávez-Villa, M 2272

Chin, TT 583

Choquette, D 126, 1260, 2205

Clarke, A 591, 1848

Che, H 443

Chindalore, VL 2201

Chow, K 843

Che, N 561, 644

Chinese SLE Treatment and Research Group (CSTAR) 604

Chowaniec, J 1010

Clarke, AE 4, 256, 586, 592, 1196, 1375, 1383, 1708, 2271, 2455

Ching, JCY 2040

Choy, DF 446

Cheak, AA 1371 Checa, AE 183, 1969 Checchio, T 1259 Cheetham, TC 888 Chegudi, R 219 Chen, D 984 Chen, H 2573 Chen, J 634 Chen, L 335, 462, 801, 803, 806, 2514


Chen, L 1090 Chen, L 2497 Chen, M 1135 Chen, N 1326 Chen, S 1069 Chen, S 2469 Chen, W 1678 Chen, W 640, 2087 Chen, X 1840 Chen, Y 1910 Chen, Y 819 Chen, Y 71 Chen, Y 60, 310, 818 Cheng, H 2389 Cheng, Q 29 Cheng, T 2469 Cheng, Y 1978 Cheng, YJ 879, 2508 Cheng, Y 1917 Cherascu, B 1174, 1200, 2152 Cherkowski, G 904 Chernitskiy, V 2107, 2130, 2610 Chernoff, D 1613 Chessell, IP 2092 Cheung, P 2050, 2153 Cheung, YY 2051 Chevalier, X 1957 Chew, CL 1415 Chhana, A 210 Chiapas-Gasca, K 340 Chiarolanza, I 189, 1520 Chiba, S 1804 Chibnik, LB 2309 Chico, G 906 Chico, S 1550 Chieng, A 257 Chies, JAB 638 Chiesa, S 273 Chifflot, H 1257 Chighizola, CB 1466, 1481, 1573, 2327 Childhood Arthritis Prospective Study (CAPS) 290

346

2011 Program Book

Chino, Y 947

Chowdhury, M 1652, 2171, 2522

Chinoy, H 824, 1678

Choy, E 224, 342, 1146, 1557, 2433

Chioato, A 1822

Christensen, R 342, 1557

Chiocchia, G 980, 1340, 1496, 1499, 1701, 1706, 2494

Christianson, D 1594

Chiorini, JA 776

Chrousos, G 1202

Chipping, J 2106 Chira, P 721, 2054 Chitkara, P 597 Chiu, B 2615, 2616 Chiu, YG 544, 1704 Chiu, YH 737 Chiusano, G 1973 Chizzolini, C 712 Chmiel, J 1085, 1982 Chmiel, JS 1087, 1985

Christmann, R 1486, 1714 Chu, C 1152 Chu, CR 1626 Chu, H 1840 Chu, ME 916 Chu, SY 1256 Chu, ZD 1396 Chubinskaya, S 816 Chuchana, P 1790 Chui, RK 1167, 2249 Chung, C 142, 2208

Claudepierre, P 514, 2234, 2638 Clauw, DJ 735, 738, 931, 939, 941, 970, 971, 1904, 1911, 1912, 1988, 2421 Clayburne, GM 218 Cleary, G 290, 2030 Clegg, DO 1307, 2172 Cleland, LG 1093 Clements, PJ 676 Clerigues, V 1782 Clerson, P 681 Cleveland, RJ 1544, 1545, 2418, 2642 Cleynen, I 298 Cliss, A 2405 Cloonan, Y 671 Close, D 2255 Clowers, JS 75, 986

Chung, CP 1391, 2280

Clowse, MEB 1418, 1419, 1536, 1537, 2109, 2278, 2286

Chung, HY 1650

Cluzel, P 1528

Cho, ML 77, 2345

Chung, L 244, 668, 707, 1471, 1715, 2483

Cobb, J 257, 1688

Cho, M 850, 1636

Chung, S 720

Cho, M 72

Chung, SA 645, 2479

Coca, A 470

Cho, M 76

Chung, W 109, 125

Cho, S 103, 109, 125, 2223

Churchill, S 1185

Cho, Y 1620

Cianchetti, S 2381

Chodosh, J 489

Cibere, J 2507

Choe, J 109, 125, 484, 2183

Cicuttini, F 1079, 1625

Choi, B 491

Cid, M 1897

Choi, BY 324

Cid, MC 1523

Choi, C 103, 109, 125, 1681, 2223

Cid, MC 1518

Choi, D 856

Cifaldi, MA 108, 259, 913, 1312, 1326, 2189

Cho, CS 2591 Cho, C 1380, 1648, 2158 Cho, H 1798

Choi, H 1049 Choi, HK 217, 508, 908, 1118, 1521, 1522, 1599, 1603, 2533, 2576, 2577, 2583, 2643

Cimaz, R 288, 298

Choi, IA 324, 2306

Cioffi, E 185

Choi, J 1318 Choi, J 437 Choi, J 1380, 1648 Choi, M 2183 Choi, ST 215, 360, 1049 Choi, SW 1027 Choi, SI 2087

Cimino, L 1520 Cinar, M 1886, 2385 Cipriani, P 1201 Cistrone, CA 2186 Citera, G 2563 Ciurea, A 527, 2637 Cividino, AA 88 Clair, B 1660, 1661, 2599

Choi, SJ 635, 1049, 1487, 2365

Clancy, RM 305, 752, 771, 772, 1440, 1675, 2597, 2602

Choi, Y 659

Clark, AR 49

Choi, YS 646

Clark, CA 1, 2

Choi, Y 2584

Clark, EA 2353, 2548

chollet-Martin, S 728

Clark, MR 1445

Chong, J 219

Clark, P 906

Chopin, F 1299

Clark, R 1949

Chopra, A 1251, 1255

Clark, SJ 266

Cobelli, R 855 Coccia, EM 375 Cochener, B 476 Cochin, S 1140 Cockayne, D 1148 Codding, CE 401, 2201 Coderre, J 1586 Coenen, MJ 165 Coert, JH 187 Coffman, C 1582 Cofield, S 392, 412, 1696 Coghlan, JG 2482 Cohen, CD 1433 Cohen, H 12 Cohen, J 608 Cohen, P 858, 1500, 2379 Cohen, PL 1006 Cohen, S 409 Cohen, SB 408, 2592 Cohen, S 934 Cohen, SB 2208 Colaci, M 688, 689, 1454 Coladonato, L 1047 Colbert, CJ 1087, 1982, 1985 Colbert, RA 280, 511, 1701, 1703 Colburn, KK 2352 Cole, S 1417 Coll, KE 2071 Collamer, AN 465 Collantes-Estevez, E 725, 1437 Collet, J 1528

Collier, DH 326

Cornec, D 474, 476

Collins, CE 85, 1596

Cornejo, J 2066, 2299

Collins, I 714

Cornelissen, F 50

Collins, JE 884, 2510

Cornell, PJ 2561

Collins, M 565, 834

Corneth, OB 50, 2357, 2499

Collinson, N 2199

Cornish, J 210

Colombo, J 482

Corominas, H 1315

Colombo, P 1438

Corona-Sánchez, E 250

Colon-Emeric, C 1114, 2589

Corr, M 833

Comarmond, C 858

Cortis, E 283, 2009

Combe, BG 311, 353, 438, 443, 452, 1243, 1283, 1641, 2235, 2458, 2494, 2528

Cosan, F 166

Comeau, ME 2476 Comer, G 1259, 2630

Conforti, ML 2604 Conn, DL 130, 337, 1545, 2128, 2155, 2157, 2642 Connault, J 1500, 1510 Connell, CA 2592 Conner-Spady, B 538, 778 Connolly, M 41, 42, 47, 1672 Conrad, K 1338 Cons, L 63, 977 Consensi, A 1942 Constant, E 1299 Constantin, T 2622 Constantinescu, FM 907 Contreras, MA 2253 Conversano, C 942 Conway, R 87, 2074 Cook, RJ 522, 1303, 1330, 1334, 1649, 2486E Cook-Mills, J 32 Cook-Wiens, G 2119 Cooley, C 2041 Coon, C 1608 Cooney, JK 2566 Cooper, C 829, 1060 Cooper, D 1586 Cooper, RG 224, 824, 1678 Cooper, S 578, 1369 Cooray, D 1860, 2410 Cope, AP 361 Corazza, L 1529, 2221 Corbera, M 1518 Corbin, M 1136 Corbo, M 404 Cordero, M 1044 Cordero-Coma, M 1045 Cordier, J 858, 2379 Cordingley, L 290, 344 Cordova, KN 2339 Coresh, J 887, 898, 1600 Cormier, C 670 Cormier, H 2245

Cristol, J 2528 Criswell, LA 161, 485, 632, 639, 641, 642, 645, 649, 799, 1436, 1679, 2073, 2162, 2479, 2640

Cusack, T 1559, 1722

Croca, S 2279, 2288

Custers, J 2417

Crofford, LJ 1674, 1850, 2404 Croia, C 375 Croisier, D 1110 Cron, RQ 277

Cosette, P 1932

Cronstein, BN 536, 911, 1781, 1787, 2322, 2323, 2436

Costa, AJG 1059

Cross, JT 1247

Costa, J 507, 1317

Crotti, C 1120

Costallat, L 783, 2257 Costantino, F 1340, 1706

Crow, MK 59, 93, 816, 1424, 1438, 1443, 1709, 1807

Costanzo, D 276

Crowley, S 756

Costas, C 57

Crowson, CS 121, 761, 820, 1183, 1184, 1187, 1188, 1501, 1502, 1511, 1512, 1870, 1871, 2104, 2113, 2212

Costedoat-Chalumeau, N 19, 20, 577, 608, 791, 1373, 1409, 2450 Costello, CE 2344 Costello, T 2261 Costenbader, KH 101, 1667, 2109, 2441, 2544, 2574 Costinescu, A 2352 Costner, MI 4, 1375, 1383, 1708 Coteur, G 1230 Cotofana, S 827 Cott, C 1727 Cottu, P 1048 Coty, M 2406 Coudenys, J 1356 Couderc, Sr., M 810 Coughlan, RJ 87, 2074 Coughlin, NK 276 Courties, G 1007 Coustet, B 716 Coutanceau, B 2638 Covarrubias Cobos, A 402 Covelli, M 1047 Cowen, E 310 Cox, C 1558 Cox, SR 251, 2465 Cox, V 626, 743, 1091, 2111 Coyne, K 133 Cozmuta, R 1867, 2366, 2367 Crabtree, M 1430 Craft, JE 83 Cramp, F 1557, 2425 Crane, L 1586 Crane, MM 916, 1865 Cravets, M 1021, 1030 Crawford, L 1673 Creek, EL 1584 Crema, M 1076, 1616, 2005 Cretu, D 1365 Criado, G 1479, 1772, 2349

Curtis, JR 122, 392, 412, 462, 801, 803, 806, 1101, 1114, 1189, 1696, 2219, 2514, 2595

Croxford, R 883, 886, 2506 Cruz, M 1317 Cruz, VG 1569 Cruz-Dominguez, MP 665 Cruz-Reyes, C 250 Cruz-Ruiz, J 854, 1009 Cryer, B 2001 Csernok, E 2377 Csiki, Z 201 Csuka, ME 697, 2483 Cua, D 2097 Cuadrado, MJ 725, 1437

Cush, JJ 427, 2213 Cusi, D 1496 Cuthberston, D 2368 Cuthbertson, D 1503, 1513 Cutolo, M 1253, 1473, 1474 Cutro, MS 1289 Cuttica, R 2009 Cuttica, RJ 2454 Cuttler, AS 1637 Cymet, A 580, 2064 Czerwinski, E 1103 Cziriak, L 2606 Czirjak, L 673

D D’Agostino, EMA 180 D’Agostino, M 174, 551, 807, 1650, 2144 D’Agostino, M 691


Conaghan, PG 434, 463, 944, 2465, 2628

Criscione-Schreiber, LG 84, 1418, 1419, 1594, 2278, 2286

D’Aloisio, A 2173 D’Amico, R 1454 D’Angelo, S 1289 D’Antona, G 270 d’Ascanio, A 1406, 1519, 2263, 2400, 2401 D’Cruz, D 2472 D’Cruz, D 602

Cubides, MF 321

D’Cruz, DP 620, 631, 2281, 2373, 2378, 2383

Cuchacovich, R 1313

D’Cruz, D 601, 605, 1526

Cucho-Venegas, M 783

D’Lima, D 2438

Cuda, CM 1010, 2086

D’Souza, C 786

Cuddy, V 1722

da Rocha, SR 2617

Cuevas-Orta, E 2251

da Silva, JR 1934

Cugno, M 691

da Silva, MD 1506

Cui, H 1922

Dabelea, DM 100

Cui, J 1679

DaCosta, D 2064

Culler, SD 130

Dag, MS 1951

Cumetti, D 1051

Dagfinrud, H 513, 519

Cummings, SR 1103

Dagli, AF 1142, 2081, 2083, 2094

Cummins, DF 896

Daha, N 352

Cunha Miranda, L 507

Dahlhaus, M 45, 1923

Cuningham, D 758

Dahmen, G 779

Cunnane, G 92

Dai, X 2084

Cunningham, M 107

Daibes, K 1102

Cunningham, T 254, 295

Daien, C 2528

Cuomo, G 704

Daien, V 2528

Curran, M 415

Daigle, ME 877, 900

Curran, ML 264

Daizadeh, NS 1103

Currie, CJ 429, 1233

Dal Forno, I 2221

Curtis, JR 102, 335, 888, 1106, 1121, 2541

Dal Pra, F 2563 Dalal, D 1869 2011 Program Book

347

Dalbeth, N 207, 210, 211, 212, 219, 1618, 1622, 2579

Davis, P 2067

de Smit, MJ 2175

DeMicco, DA 502, 1293

Daly, M 2156

Davis, T 278, 293

de Sonnaville, P 431, 440

Demirci, FY 2479

Davis, TE 2331

de Souza, AWS 1506, 2397

Demirkaya, E 272

Davis, VM 614

De Toro, FJ 2426

Demmer, RT 2174

Davis, WE 646, 937

de Toro-Santos, FJ 95

deMoor, C 897

Dawood, MM 2599

De Vera, M 2577

Demoruelle, MK 769, 2182

Day, R 919, 920, 1333

de Visser, M 235

den Broeder, A 1700, 2585, 2596

Daya, NR 1460

De Vita, S 1529, 2221

den Broeder, AA 1570

Dang, NH 1137

De Achaval, S 626, 743, 2111, 2559A

De Vlam, KL 1296, 1304

den Uyl, D 419

Dani, L 824

De Angelis, G 1090

de Vries, D 1268

Denfeld, R 532

Daniels, S 1280, 1281

de Baere, E 1497

de Vries-Bouwstra, J 418

Deng, G 573

Danjo, J 967

de Bakker, P 167, 1682, 2313

de Wazieres, B 1508

Deng, J 1130

Dankbar, B 1150, 1797

De Bandt, M 2384

de Wit, M 1296

Deng, J 1428

Danko, K 224, 1678

De Benedetti, F 985, 1589, 2621

Dean, Y 2336

Deng, W 1958, 2084

Dantas, AT 1059

De Beus, W 440

Deane, KD 100, 322, 388, 766, 769, 2182

Deng, Y 634, 639, 640, 2477

Danza, FM 703

de Blas, G 1896

DeBandt, M 1508

Daragon, A 315

de Boer, T 1080, 1987, 1997

DeBow, C 1586

Denis, MC 832

Dardani, L 189, 1505

de Carolis, S 728

Dechant, C 387, 1689

Daridon, C 1742

De Clercq, D 2149

Decktor, D 455, 1310, 2215

Darkow, T 1221, 1242

de Cortie, K 1147

Decleves, X 1048

Das, R 1773

De Feo, F 942

Decossas, M 554

Das, S 944, 1643, 2252

De Gennes, C 1409

Decramer, S 2029

Dasgupta, A 518

de Groot, L 1159, 1161

Decuman, S 1448

Dasgupta, B 1517

de Hair, MJH 313, 371, 770, 2154, 2177

Dees, C 1588, 2321, 2427, 2535, 2538, 2539, 2540, 2606

De Hertogh, G 298

Deforce, D 1356

Depis, F 2336

de Jager, M 431

Deftereou, K 901

Depresseux, G 435, 2258

de Jong, HW 972

DeGuire, P 1849, 2442

Derambure, C 372, 1931, 2093

de Jong, P 431

Dehlendorf, A 300

Derber, LA 100, 766, 769, 2182

de Jong, Z 1668, 2423

DeHoratius, RJ 455, 2215

Derk, CT 1459, 1716

De Keyser, F 1356, 1448, 2237

Dehpoor, A 418

Dernis, E 2050

de Koning, HD 73, 2446

Dei, Y 1711

DeRoo, L 2173

de la Hera, D 1950

Dejaco, C 811

Derrett-Smith, E 1481, 1498, 2603

de la Torre, I 390, 1414, 1737, 2036, 2225, 2521

Dekker, JM 760

Dervieux, T 329, 421, 597, 841, 842, 2467

de Laat, B 1684

Del Fatore, A 1589

Dam, MY 394 Damasceno, B 2257 Damasio, MB 1973 Dancea, S 753 Danda, D 517


Dandorfer, SWH 548

Dass, S 1643, 2252 Dassouki, T 1566, 1723, 2614 Dastmalchi, M 1549 Datta, I 1680 Datta, S 170 Datta, SK 647, 648 Datta Mitra, A 1359 Daubeuf, B 977 Daudon, M 1801 Daures, J 501 Dávalos, I 250 Davatchi, F 2386 Davelaar, N 2357 Davey, MP 986, 1342 David, G 912 David, J 1630 Davids, ML 700, 2371 Davidson, A 558, 2547, 2550 Davidson, J 257 Davies, AJ 491 Davies, O 445, 1252, 1253, 2214 Davies, RJ 2281 Davies, R 426 Davignon, I 1096 Davis, AM 886, 1727, 2506, 2612 Davis, JC 512, 518, 2371 Davis, III, JM 213, 761, 1617, 2113 Davis, LA 134, 614, 1181 Davis, MM 851 Davis, M 2155 Davis, MM 266 Davis, MW 1017, 2581

348

2011 Program Book

De Langhe, E 2328 de Launay, D 82 De Luca, G 703, 1469 De Marco, G 1294 de Menthon, M 2389 De Miguel, E 174, 2144 de Min, C 63 De Mits, S 2149 de Morais, J 1486 de Munter, W 1144 de Pablo, P 349 De Pasquale, L 985 de Pontual*, L 2035 de Punder, YM 341 de Ramón, E 609

Dekker, J 590, 1570 Del Galdo, F 200, 667, 704, 705 del Rey, A 1133 Del Rey, MJ 1479, 1772, 2316 Del Rincon, I 111, 1164, 2142 Delaet, I 402, 403, 404, 2190, 2191 Delaval, P 858 Delgado-Alves, J 2346 Delgado-Frías, E 1166, 2115, 2134 Delicha, E 739 Della Rossa, A 2381, 2382 Dellaripa, PF 1714, 2212, 2293 Dellavance, A 600, 2307 Delle Sedie, A 185 Delosantos, A 1581

Denio, AE 753 Denisova, R 292, 2626 Dennis, G 1369 Dent, PB 1633 Dente, F 2381 Denton, CD 677, 692, 1466, 1485, 1573, 2483 Denton, CP 1481, 1498, 1714, 2324, 2327, 2482, 2603 Deodhar, A 423, 922, 1227, 1246

Desai, A 940 Desai, SS 2590 Desale, S 96 Desbois, AC 2395 Descalzo, MA 450, 1043, 1113 Deschamp, M 1738 Deshpande, V 1713, 1740 Desjardins, O 1222 Desjarlais, JR 1256 Desjonqueres, M 988, 2021 Desjuzeur, M 126 Desmet, VJ 298 Desmurs-Clavel, H 608 Despert, V 2021 Dessole, G 1354

DelVecchio, B 753

Detert, J 373, 1697

Delzell, ES 122, 462, 801, 806, 1101, 1114, 1121, 2514, 2541

Devarajan, P 2038

de Rooy, DP 352, 359

Devauchelle, V 180, 980

De Rycke, LE 521, 1305

Dema, B 662, 664

de Saint-Martin, L 857, 860

Demattei, C 501

Devauchelle-Pensec, V 474, 476, 488, 2235

De Schepper, E 1448

Demengeot, J 464, 1841

De Roos, AJ 102

deVeber, G 1534

DeVellis, RF 2418

Dinh, VT 943

Dooley, A 1498, 2603

Duclos, G 1185

Devenport, J 434, 1262, 2219

Dinnella, JE 218, 1092

Dooley, J 2139

Ducreux, J 1927

Devilliers, H 230

Dinsdale, G 197, 1467

Dooley, M 591, 592, 2472

Duculan, R 1709, 1807

DeVita, P 722

Dinte, A 1296

Duda, G 28

Devlin, C 2621

Diogo, D 1677

Doornbos-van der Meer, B 794, 2175

Devogelaer, J 1116

Dion, J 317

Dopazo Gonzalez, N 192

Duewell, S 2633

Dewalt, D 1885, 2418

DiPietro, L 2558

Dewing, KA 869

Direskeneli, H 2391

Dey, I 2283

Direskeneli, H 1039, 1509, 2387

DeZordo, T 811

Dirven, L 354, 416, 418

Dhainaut, A 1102 Dhar, JP 629, 1849, 2442

Doré, A 846 Dorfleutner, A 367, 1004 Doria, A 609

Dudler, J 499, 527 Dufat, L 19, 20 Duffy, CM 256, 269, 2455 Dufour, AB 800, 1552, 1553, 1554, 1556, 2543

Dirven, L 351, 1613, 2200

Dorman, CW 2003

Duggan, E 1390, 2308

Distler, JH 702, 1455, 1588, 2321, 2380, 2427, 2535, 2536, 2538, 2539, 2540, 2606

Dorris, ML 990, 1350

Duggen, D 830

Dotzlaw, H 1830

Duke, A 1741

Douek, DC 170

Dumitrescu, M 2021

diaconu-Popa, D 673

Ditto, MC 935

Dougados, M 174, 180, 438, 452, 501, 514, 551, 1224, 1230, 1253, 1283, 1641, 1650, 2050, 2153, 2208, 2486A, 2494, 2628, 2638

Dummer, W 837

Di Sante, G 2343

Distler, O 679, 702, 1462, 1588, 1714, 2321, 2427, 2535, 2536, 2538, 2539, 2540, 2605, 2606

Diamandis, E 1331, 1365

Divekar, AA 1493

Douglas, KM 349

Diamant, M 419

DiVittorio, G 535

Douhan, III, J 1758

Diamantopoulos, AP 1125

Dixon, A 1366

Doveri, M 942

Diamond, B 1439, 1764, 2474

Dixon, WG 426, 2463, 2524, 2525

Dowell, S 2077

Díaz Moya, G 2253

Do, B 1978

Dower, K 1621

Diaz-Alderete, A 1832

Do, BT 879, 2508

Doyle, A 1618

Diaz-Curiel, M 1104

Do, H 2371

Doyle, G 1069

Diaz-Gonzalez, F 30, 1166, 1818, 2115, 2134

Dobashi, H 967

Doyle, MK 1246, 2227, 2250

Diaz-llopis, M 1045

Dockerty, JL 2579

Dozmorov, M 2391

Dockery, M 1336

Draeger, HT 666, 1452, 1477, 2429

Dodé, C 2450

Dragoi, M 1055

Doerfler, A 2527

Dragun, D 1495, 2312

Doering, G 1219

Drake, J 2579

Doherty, E 657, 1660, 2599

Drape, J 690, 1718

Doherty, M 825

Drappa, J 2255

Doi, H 202

Dray, M 210

Dokoupilova, E 401

Drenkard, CM 1847, 2444

Dokwe, S 1902

Dressler, F 283

Dolan, JG 2451

Drews-Botsch, C 271

Dolatabadi, S 2119, 2137

Driban, JB 1977, 1998

Dolezalova, P 2012

Driscoll, PC 23

Díez, J 1250

Dolman, KM 258, 286, 864, 956, 957

Drosos, AA 529, 699

Díez-Pérez, A 829

Dolzani, P 33

Drossaert, CH 2414

Durez, P 401, 402, 430, 435, 1238, 1699, 1927, 2237

Diez-Posada, S 1274

Domiciano, DS 812, 899

Drouin, EE 1939, 2344

Durham, LE 1129

Difrancesco, M 751, 2456

Domingues, V 3, 1807, 1903

Drouot, L 1587

Dutmer, EA 165

Dignat-George, F 1816

Domínguez, J 1941

Drozd, J 756

Dutra, LA 2397

Dijkmans, B 1613

Dominguez Hernandez, L 1232

Du, H 54, 2571

Dutz, JP 1332

Dijkmans, BA 419, 439

Du, P 2478

Duvillard, L 1110

Dikranian, A 1016

Dominguez-Luis, MJ 30, 1166, 1818, 2115, 2134

Du, Y 1638

dvir-Ginzberg, M 1795

Dillon, SP 643

Dominguez-Mozo, I 1084

du Cailar, G 2528

Dwivedi, A 1666

Dimitroulas, T 2125

Domsic, RT 701, 844, 846, 847, 1715, 2485

Duan, J 1130

Dye-Torrington, D 2284

Duarte, AJ 865

Dyer, A 787

Duarte, ALBP 1059

Dylinski, D 1869

Duarte, C 507

Dörner, T 1742

Duarte-García, A 606, 1384

Dörner, T 1733, 1736

Dhellin, O 2470 Dhir, V 1402 Di Battista, JA 1803

Diaz-Martin, A 1818 Diaz-Prado, S 2426 Diaz-Zamudio, M 854 DiCarlo, EF 1065 DiCarlo, J 434 Dickinson, M 197 Dickson, MC 1735 Diekman, LA 505, 2531 Diemert, M 19, 20 Dieppe, PA 746, 1060, 1061, 1996 Dietrich, B 397 Dieude, P 488, 530, 683, 1496

Dina, B 751, 2456 Dinarello, CA 1816 Dinesh, R 2289 Ding, B 1107 Ding, C 876, 1079, 1625 Ding, L 789, 792, 2432 Ding, S 650 Ding, Y 2362

Donadi, EA 1241 Dong, H 1674 Dong, Q 1958 Donmez, S 1279 Donnelly, R 2478 Donnelly, S 1514, 1515 Doobay, K 700, 1716

Dumont, F 2494 Dumont, F 1706 Dumoulin, G 424, 2220 Duncan, B 1253 Duncan, J 2030 Dundeva-Baleva, P 1898 Dunlop, DD 1558, 1980, 2120, 2505, 2558 Dunn, S 886, 2506 Dunne, E 2105 Dunning, AM 586 Dunussi-Joannopoulos, K 565, 834, 1758 Duong, A 1548 Dupas, B 1510 Dupont, P 1927 Dupre, BJ 937 Dupuy, A 2528 Duquesne, A 2021 Duran-Barragán, S 1860 Duranay, M 926 Duransoy, L 115 Durcan, L 92 Dures, E 2405, 2425

Dubost, JJ 161, 488, 514, 1254

E

Dubourg, O 1955 Dubreuil, M 193 Dubuc, J 1780


Dorio, M 2026

Ea, H 1801 Easley, K 130, 2444 2011 Program Book

349

Eastman, PS 361, 1748

Elders, LM 73

Easton, D 586

Eldridge, H 129

Eberhard, BA 2014, 2015, 2047, 2294, 2454, 2624

Elegbe, A 1238, 2209, 2231, 2232

Ebihara, S 1351

Elhai, M 268, 1456, 1718

Ebina, K 1571 Ebisawa, M 376 Eckel, RH 100 Eckstein, F 722, 827 Edberg, JC 634, 642, 995, 2311, 2476 Edden, R 970 Edelmann, E 327


Eder, L 524, 525, 537, 544, 1334, 1353, 1868, 2275, 2486E, 2486C Edgar, M 833, 1630 Edison, JD 89 Edmundowicz, D 787, 1446 Edwards, C 601, 605 Edwards, JC 1735, 2225, 2521 Edworthy, SM 1862 Efes, I 480 Effelsberg, NM 814, 2374, 2600 Efthimiou, PV 1190

Elewaut, D 430, 1356, 1927, 2149 Elias, M 1868 Elkayam, JG 886, 2506 Elkayam, O 934, 1002, 1300, 1944 Elkon, KB 559, 656, 997, 1762, 2548 Ellingsen, T 394, 1258 Ellsworth, JE 1633 Eloranta, M 1428, 2478, 2496 Elson, G 63, 977 Elvin, K 1441

Eriksson, J 459, 1206, 1884, 2240, 2515, 2523 Eriksson, KG 2480 Erkan, D 7, 726, 727, 867, 1390, 1408, 1666, 2308, 2411 Erman, F 1142, 2081 Ernestam, S 436, 459, 2229, 2513 Ernet, C 1611 Ershova, O 2201 Ertan, S 2305 Esber, A 1691 Escalante, A 111, 1164, 2142 Escher, M 2072 Escorpizo, R 679 Escriou, V 1007

Emery, P 126, 200, 429, 463, 667, 704, 705, 779, 944, 1210, 1233, 1245, 1253, 1285, 1612, 1643, 1698, 1699, 1702, 1734, 2144, 2189, 2199, 2208, 2214, 2232, 2236, 2252, 2465, 2486D, 2486F

Esdaile, J 804, 1846

Emmerich, J 859

Espericueta-Arriola, G 5

Emmungil, H 1525

Espígol, G 1518, 1523

Emrence, Z 166

Espinosa-Cuervo, G 8

Encinas, J 202

Espinoza, LR 1313, 1949, 2110, 2126

Esen, F 923 Esmaeilzadeh, S 930, 1292 Espada, G 612, 2009, 2454, 2621 Esparza-Lopez, J 854

Eyre, S 1677 Ezatollahpour, S 2275

F Fabbriciani, G 1120 Faezi, T 2386 Fagerhol, M 1052 Fagerli, KM 531, 533, 2532 Faham, M 1339 Fahmi, H 67, 80 Fain, O 608 Fain, O 728, 858, 1500, 2035 Falcini, F 283, 1533 Falcione, M 703 Falen, SW 206 Fall, N 1685, 1687 Fallon, N 737 Falzer, P 107, 907 Fan, H 594, 1924 Fan, M 2552 Fan, P 1132 Fan, W 1922 Fang, F 1819

Egerer, K 839, 1697, 1745

Endo, H 382, 1127, 1478, 1811, 2565

Eggebeen, AT 710, 2055

Endres, J 2334, 2572

ESPOIR Scientific Committee 353

Egger, P 1712

Eng, H 135, 393, 2143, 2150, 2516

Essioux, L 399

Fang, H 3, 4, 583, 585, 596, 598, 603, 606, 607, 613, 619, 622, 628, 786, 1375, 1383, 1384, 1392, 1656, 1708, 1712, 1853, 1903, 1919, 1920, 2443, 2471

Eguchi, K 318, 1218, 1220

Engel, R 1823

Esteller, M 366

Fang, L 2084

Egurbide, M 1405, 1492

Engelbrecht, JM 1023

Esteva-Spinetti, MH 783

Fang, M 1917

Ehrenstein, BP 178

Engelke, K 1611, 1615

Estrada, P 1524

Fang, Y 1710

Ehrlich-Jones, LS 1558, 2120

Enger, C 433

Estrada-Y-Martin, RM 1452

Fanget, B 2470

Eicher, JL 1670

Engin, A 168, 1947

Etchepare, A 1401

Fangradt, M 28, 373, 1005

Eickenberg, S 1769

Etchepare, F 180

Fanucci, F 471

Eijsbouts, AM 2407

Englbrecht, M 548, 964, 1208, 1611, 1615, 2527

Faraone, S 2599

Eilat, D 2550

Engleberg, NC 1003

Etchepare, P 1401

Farber, JL 1461

Eimon, A 494

Englert, J 470

Eto, H 1410

Fardellone, P 132, 315, 1932

Einarsson, JT 432

Englund, M 1073, 2509, 2515

Etzyoni, R 560

Fardipour, P 2630

Einstadter, D 870

Engström, A 2513

Eudy, A 1392, 1857, 1858

Farewell, V 601, 605

Eisfelder, M 532

Engström, M 2176

Euller-Ziegler, LE 2234

Farge, D 673

Eisner, E 1066

Ennis, H 1450, 1467

EUSTAR coauthors 692

Farnarier, C 1816

Eissa, A 1331

Enocsson, H 1421

EUSTAR Rituximab Group 702

Farnetti, E 2390

Eitzman, DT 2547

Equinda, M 2518

EUVAS Investigators 2369

Farrell, J 2492

Ejbjerg, BJ 946, 1258

Era, C 1956

Evans, B 1097, 1105

Fasth, A 822

Ekholm, L 59

ERAHSE Team 1576

Evans, DM 153

Fathman, CG 54, 2571

Eklund, A 2176, 2179

Erar, A 115

Evans, E 1757

Fauchais, A 488

Ekman, EF 828

Erausquin, C 2268

Evans, G 2015, 2047

Faulkner, R 2013

Eksioglu-Demiralp, E 2391

Ercilla, G 2138

Evans, J 83

Erdem, H 1886, 2385

Faulkner, RD 1017, 2581

El Gaafary, M 808, 1690

Evans, RR 1013, 1014, 1015, 1023, 1024

El Mansouri, FE 80

Erdes, S 517

Evans-Raoul, K 1397

Erdozain, J 1405

Evelyn, B 1000

Fautrel, B 132, 230, 317, 353

El Miedany, YM 808, 1690 El-Gabalawy, H 1204

Erer, B 1328

Everett, C 2070

El-Gabalawy, HS 152, 347, 362, 765, 768, 2139, 2163, 2573

Ergun, T 2387

Everett, S 1666

Erickson, A 2140, 2152

Ewing, S 1110

El-hallak, M 757

Erickson, AR 1174

Exarchou, A 1071

Elashoff, D 254, 593

Erickson, EA 1796

Exer, P 527

Fearon, U 41, 47, 391, 732, 1176, 1336, 1672, 1829

Elder, JT 1332

Eriksson, C 1156

Eyal, R 98

Fedele, AL 1746, 2343

Egelston, C 734, 1008

350

2011 Program Book

Espitia, O 1510

Faustino, A 1792 Faye, A 2021 Fayyad, R 502, 1293 Fazio, S 2280 Fearon, C 1336

Federici, L 1500 Federici, S 2452 Fedorova, T 1093 Fedorova, T 2569 Feehan, LM 965 Feghali-Bostwick, CA 308, 671, 1490, 1826, 2315, 2537 Fehringer, E 1179, 2112

Ferraccioli, G 270, 703, 1201, 1469, 1529, 1673, 1746, 2214, 2343

Finzel, S 807, 964, 1611, 1615, 2527

Foeldvari, I 274, 283, 2453, 2623

Ferrand, C 1738

Fiocco, M 1668

Foerger, F 2114

Ferrandiz, MA 2622

Fiorentino, D 244, 668, 707, 1834, 1835

Ferrari, C 942, 2401

Fiori, G 1462

Ferrari, M 1274

Fiorini, P 1578

Ferraz-Amaro, I 1166, 2115, 2134

Firestein, GS 37, 196, 385, 833, 1134, 1630, 1809, 2517

Feissinger, JN 1500

Ferreira, A 892, 894

Feist, E 839, 1096, 1244, 1644, 1745

Ferrero, A 206 Ferretti, S 855

Feld, J 1868

Ferri, C 688, 689, 1201, 1454, 1529

Feldman, BM 240, 863, 2019, 2027, 2034, 2481

Ferriani, VP 304

Feldman, CH 1667, 2441

Ferro, F 471, 1933

Feldman, DE 1546 Feldstein, AC 1106 Felekos, I 1163 Félix, J 1317 Felsenberg, D 1104 Felson, DT 742, 744, 802, 960, 1073, 1076, 1089, 1541, 1616, 1624, 1627, 1628, 1724, 1986, 1989, 1991, 1993, 1995, 2005, 2557, 2560

Ferrone, C 1473 Ferrua, S 1051 Fert, I 1701 Fertig, N 229 Fervenza, F 792, 2432 Fesler, P 2528

Fischbach, M 2029 Fischer, A 983 Fischer, A 687, 695, 1470 Fischer, HD 86 Fischer, K 1309 Fischer, MA 2441 Fischer-Betz, R 6, 582 Fisher, BA 2171 Fisher, Jr., CL 2071 Fisher, G 2348 Fisher, MC 509

Fessatou, S 306

Fitilev, S 2201

Fessler, BJ 591, 592, 789, 792, 2432

Fitter, S 2623 Fitz, L 834

Feudtner, C 2043

Fitz-Gibbon, P 1188

Feng, D 1428, 2478

Feydy, A 268, 690

Fitz-Patrick, D 1018

Feng, M 1128

Fichtner, A 1248

Feng, M 2567

Fidelholtz, J 1095

Fitzcharles, M 932, 933, 938, 1605, 1906

Feng, X 644, 2473

Field, RE 1060

Ferbert, SM 1577, 1900, 2408, 2409, 2564

Field, R 1564

Ferdousi, T 330, 441, 2239

Fields, K 1716

Ferguson, PJ 299

Fields, TR 1579

Feria, M 30

Fierlbeck, G 532

Ferland, DS 325, 338, 339, 736, 1198, 1889, 2141, 2457

Figueiredo, C 812, 899

Ferlet, JF 180 Ferlin, W 63, 977 Fernandes, A 141, 1848, 1861, 1864 Fernandes, AJ 1209 Fernandez, I 823 Fernandez, P 2323 Fernández Rueda, J 2062 Fernández-Castro, M 1492 Fernandez-Cid, JC 1045 Fernández-Costa, C 2554 Fernandez-Gutierrez, B 383, 1084 Fernandez-Llaca, H 81, 1968 Fernández-López, C 2420, 2554 Fernandez-Mazarambroz, RJ 878, 885 Fernández-Moreno, M 2420 Fernandez-Nebro, A 1113 Fernández-Ortiz, AM 319, 1173 Fernandez-Perez, ER 687 Fernández-Puente, P 2554 Ferner, E 817

Fielder, P 837

Fiirgaard, B 299 Fike, A 1574 Filer, A 366, 374 Filipow, PL 2633 Filippini, D 2390 Filippini, M 1535 Filková, M 42, 53, 2519 Filley, C 1390, 2308 Filocamo, G 283 Filopoulos, M 2396 Filopoulos, MT 314, 2233, 2461 Finckh, A 126, 1081, 2072, 2114, 2637 Fine, JS 1148 Fine, MJ 2485 Finetti, M 273, 988, 1964, 1973, 2452

FitzGerald, JD 764, 788, 1025, 1037 FitzGerald, OM 520, 1176, 1203, 1352, 1559, 1722, 2422 Fitzgerald-Bocarsly, P 1428 Fitzpatrick, M 1722 Fiuza, M 2268 Flaherty, K 1714 Flannery, J 2612 Flask, CA 1789 Flatø, B 2621 Fleck, M 178, 1943 Fleckner, J 1424 Fleischmann, RM 408, 1210, 2236 Fleischmann, R 441, 1699, 2227, 2592, 2630 Fleischmann, RM 1023, 1217, 1230, 1253, 1698, 2199, 2215, 2593, 2627

Foerster, B 970 Fogg, LF 1086 Folsom, AA 2170 Foltz, V 1068 Fonollosa, A 1044, 1045 Fonseca, C 1491 Fonseca, JE 507, 1317, 1792 Fonseca, JE 414, 444, 1934, 2242 Fontaine, KR 2124, 2132 Fontana, V 1241 Fontanillo-Fontanillo, M 2290 Fontsere, O 1042, 2062 Foo, J 194 Foocharoen, C 814, 2600 for the CARRAnet investigators 271, 278 for the Imatinib Study Group 1460 for the RAVE-ITN Research Group 2432 Forbess, LJ 700 Forde, TS 1348, 1637, 2096 Forejtova, S 408 Forslind, K 348, 436, 2229, 2513 Forslund, E 235 Forsythe, A 216, 1035, 2583 Fortin, PR 4, 22, 580, 591, 592, 661, 1375, 1383, 1398, 1667, 1708, 1880, 2064, 2267, 2269, 2273, 2275, 2292, 2303, 2368, 2639 Fortunet, C 1992 Fosang, AJ 1777 Foster, H 257 Fotheringham, I 2247 Fotopoulos, A 699 Fouche, L 1024 Foucher, KC 1086, 1990 Foulkes, W 586 Fournie, B 230 Fourret, P 791 Foussat, A 2337 Fowler, NM 1531 Fox, A 1652 Fox, DA 1756, 2334, 2572

Fleming, S 106

Fox, E 750

Flint, J 2225

Fox, E 391, 1829

Flipo, R 132, 438, 1641, 1932, 2234

Fox, KA 747

Floerecke, M 503, 506

Fox, KM 146, 915, 1547, 2415, 2416

Flores, P 1439

Fraccaroli, L 494

Fink, I 1943

Flores, R 2077

Fracchiolla, C 1294

Finkel, R 235

Florica, B 2267

Finnegan, A 816, 1760

Flynn, E 160

Fraenkel, L 83, 107, 110, 120, 743, 756, 907, 1721, 1867, 2366, 2367

Finnegan, S 307

Flynn, JA 1297, 1298

Finucane, C 1274

Flynt, A 1018 Focant, I 1927


Feldman, D 1914, 1915

Ferriani, VP 2012

FIRST study team 1736

Foell, D 306

Fraga, M 2403 Fragiadaki, K 1178, 1202 Fragoso, TS 1059 2011 Program Book

351

Fragoso-Loyo, H 1404

Fridén, C 2613

Frampton, C 2579

Friedberg, JW 1744

França, IL 865, 2619

Friedman, A 1827

França, NR 2307

Friedman, A 496, 663, 1425

Francès, C 608, 1409

Fries, JF 910, 1885, 2556

Frances, C 1955

Frits, MA 333, 2575

Franceschelli, F 1533

Fritschy, D 1081

Franceschini, F 231, 232

Fritz, J 866

Francis, KA 958

Fritzler, MJ 696, 708, 765, 1862, 2298

Francis, L 2599 Francis, RM 1104 Francisco-Hernández, F 2268 Francisco-Hernández, F 2290


Franek, BS 456, 633, 1372, 1423, 1429 Frank, C 1727 Frank, MB 489 Frank, M 42, 45, 2519 Frank, S 1938 Franke, B 165 Frankel, S 1470 Franklin, A 1778 Franklin, PD 1565 Frankovich, JD 2017, 2054, 2068 Franks, AG 536, 2323

Frizelle, S 2003 Frleta, M 82 Frolov, A 1674 Frommer, K 1823, 1825 Frydrych, LM 135, 393, 844, 2143, 2150, 2516 Fu, C 2630 Fu, EHY 1371 Fu, Q 1392, 1712 Fu, Q 640 Fu, Y 1130 Fuehrer, JT 1119 Fuentes, IM 2426 Fuerst, F 2135 Fuhlbrigge, RC 2023

Fransen, J 341, 673, 1180, 1717, 1878, 2585, 2596

Fujieda, Y 15, 2310

Frantal, S 31

Fujii, H 1434

Fraser, AD 2419, 2641

Fujii, T 225

Fraser, PA 1667

Fujimoto, M 1488

Frattasi, M 2275, 2639

Fujio, K 853

Frazier, SK 868

Fujita, M 2095

Frech, TM 715, 903, 905, 1716, 2483

Fujita, T 226, 236

Frech-Tamas, F 896

Fukuda, S 376

Frederiksen, KS 1424 Fredi, M 231, 1535 Freedman, BI 632, 633, 636, 637, 641, 2476, 2479 Freeman, AF 170 Freiman, J 2593 Freimuth, W 578, 584, 1367, 1416, 2472 Freimuth, W 602 Freire, V 268, 1718 French, HP 1722 French, M 1628 French, MR 886, 2506 French Vasculitis Study Group (FVSG) 2368 French Vasculitis Study Group (FVSG)* 858 Frenkel, J 988 Frenkel, S 1781 Fresen, J 2057 Freundlich, B 515, 1329, 2534 Frey, S 1761 Frey-Law, L 742, 1089, 1541, 1627

352

2011 Program Book

Fujihira, E 304

Fukasawa, C 1483 Fukuda, T 1403 Fukuda, W 1199 Fukushi, J 540 Fukuyo, S 1237, 1239, 2468 Fuller, P 1999 Fuller, R 222, 581, 709 Funahashi, K 457, 1263, 2108 Funahashi, K 1214 Furer, V 52, 223 Furie, R 2265 Furie, R 578, 584, 597, 1367 Furie, R 2255, 2469 Furner, S 1539 Furst, DE 98, 221, 342, 676, 716, 1246, 1493, 1848, 1861, 1864, 2117, 2199, 2238, 2429, 2464, 2511 Furtado, RV 1719 Furukawa, F 1410 Furuya, H 66, 1277 Furuya, T 1629 Fürnrohr, BG 998 Førre, ØT 1052

G Gabay, C 160, 444, 1081, 1645, 1646, 2242, 2336, 2637 Gabay Engel, OH 1795 Gabbai, AA 2397 Gabbriellini, G 471 Gaber, T 28, 373, 1005

Gao, W 47, 732 Garabet, L 1707 Garau, P 1354 Garay, SM 2012 Garcês, S 464, 1841 Garchon, H 1340, 1706 Garcia, A 626, 2111

Gabler, M 63

Garcia, CB 1572

Gabriel, SE 121, 761, 1183, 1184, 1187, 1511, 1632, 2104, 2113

Garcia, D 60, 310, 818 Garcia, MV 175

Gabrielli, A 673, 1529

Garcia, R 2599

Gadina, M 818

García Carazo, S 355

Gaffney, PM 150, 157, 632, 633, 634, 636, 637, 639, 641, 642, 643, 649, 773, 1370, 1427, 2475, 2476, 2477, 2479

García de la Peña, P 1492 Garcia Monaco, R 175, 188 Garcia Salinas, R 2563

Gaffney on behalf of LLAS2, PM 1681

Garcia-Aparicio, AM 1045

Gaffo, AL 1174, 1200

Garcia-Carrasco, Sr., M 1389

Gagarina, V 1795

Garcia-Dopico, JA 1166, 2115, 2134

Gaillez, C 1224, 1238, 2209, 2231, 2232

García-Arias, M 355

Garcia-Fernandez, C 25

Gainer, V 1185

García-González, AJ 2349

Gajria, K 133, 141, 1864

García-Hernández, FJ 609, 1492

Galarza-Maldonado, C 2117

García-Iglesias, T 250

Galasso, JA 1551

García-Martínez, A 1518, 1523

Galasso, R 272

Garcia-Montojo, M 1084

Galbo, H 253

Garcia-Valladares, I 1313

Galeazzi, M 1201

Garcia-Vicuña, C 1045

Galgiani, J 2466

Garcia-Vicuña, R 319

Galicier, L 608

Gardam, M 118

Galien, R 2210

Gardiner, EE 2105

Galimberti, S 2382

Gardner, GC 1046

Galindo, M 2349

Gardner-Medwin, J 257

Galindo-Izquierdo, M 2290

Garen, T 682

Gall, EP 2466

Garg, S 84, 1003

Gall, R 1014

Garland, A 2573

Gallacher, A 578

Garment, AR 1666

Galletti, S 33

Garneau, K 119

Galli, M 1529

Garrelfs, M 82

Gallizzi, R 2452

Garrido, J 191

Gallo, A 497, 498, 775, 1937

Garris, CP 1855

Gallo, G 429

Garrood, T 1274

Galloway, JB 426, 2524, 2525

Garside, P 203

Gamble, G 207, 210, 219

Garvin, K 1179, 2112

Gámez-Nava, I 250

Garyfallos, A 901

Gamsa, A 1605, 1906

Garza-Garcia, A 23

Gandhi, A 1844

Gasca Martínez, V 665

Gandhi, C 170

Gaston, JH 517

Gandjbakhch, F 1068, 2235

Gatfossé, M 1955

Gandra, SR 146, 915, 1547, 2415, 2416

Gathany, T 144, 1246

Ganser, G 274, 2012, 2623

Gattorno, M 273, 306, 988, 1686, 1964, 1973, 2452

Gantes-Mora, MA 1166, 2134

Gaudin, P 180, 2234

Ganz, R 1077

Gaugler, B 1738

Gao, A 1618

Gaujoux-Viala, C 132, 1283

Gao, J 285

Gauthier, C 646, 937

Gao, L 1053

Gauthier, G 919, 1333

Gay, RE 42, 45, 46, 366, 989, 1671, 1672, 1923, 2519, 2520, 2536, 2605

Ghinoi, A 189

Gaylis, NB 2250

Ghoreishi-Haack, N 1773

Gebhardt, C 1689

Ghosh, P 656

Gladman, DD 4, 522, 524, 525, 537, 544, 549, 580, 591, 592, 599, 661, 781, 1314, 1325, 1327, 1331, 1332, 1334, 1353, 1357, 1360, 1361, 1362, 1363, 1364, 1365, 1368, 1375, 1383, 1385, 1386, 1388, 1398, 1649, 1651, 1708, 2206, 2259, 2262, 2282, 2284, 2285, 2301, 2302, 2486C, 2486E

Geborek, P 398, 432, 436, 459, 1692, 2229, 2513, 2515

Ghosh*, P 997

Gladstein, GS 2190

Gomez Rey, G 890, 891, 1604

Ghrenassia, E 1459

Gebretsadik, T 587, 588, 2280

Gomez- Puerta, JA 1205

Ghushchyan, V 893

Geenen, R 2407

Giacomelli, C 942, 1942

Glant, TT 734, 816, 1008, 1342, 1755, 1760, 1921, 1928, 1929, 2335

Geetha, D 2432

Giacomelli, R 673, 1201

Glaser, C 1321

Gómez-Bañuelos, E 11

Glass, D 283

Gomez-Hassan, D 2264

Glass, DN 1686, 1688

Gomez-Martin, D 854, 1009

Glatigny, S 1701

Gomez-Reino, JJ 192, 444, 1197, 1238, 1645, 1646, 2209, 2231, 2242

Gay, S 42, 45, 46, 366, 832, 989, 1007, 1671, 1672, 1823, 1923, 2519, 2520, 2536, 2605

Ghio, D 290 Ghodke, Y 1251, 1255 Ghodsi, Z 2386 Ghomrawi, H 1666, 1694

Giampoli, E 1075

Geijer, M 504

Giannini, EH 265, 721, 2445, 2454

Geirsson, ÁJ 2136

Giannoukas, A 1071

Gelber, AC 2486

Giardina, A 1201

Gelfand, J 508, 782, 2533

Gibofsky, A 1281

Gelhorn, H 1863

Gibson, DS 307

Geller, ML 1107

Gibson, M 750

Gemmen, E 126

Gigante, MR 270

Gencoglu, H 2094

Gignac, MA 886, 2292, 2506

Gendreau, RM 738, 1908

Gilchrist, DS 1673

Genesys Consortium 1496

Giles, I 14, 18, 23, 2279, 2288

Genevay, S 1068

Giles, JT 1182, 1642

Genovese, MC 378, 2236, 2627

Gilfix, B 1803

Genovese, MC 401, 402, 403, 420, 427, 2191, 2217, 2591, 2594

Gilio, M 1289

Glazebrook, KN 213, 1617 Glenn, SB 489, 649, 1370 Glickstein, L 975 Glickstein, SL 334 GLORIA study group 2000 GLOW Investigators 829 Glue, C 1622 Gnann, H 534 Gnuegge, L 1736 GO-RAISE Clinical Investigators 423 GO-REVEAL Clinical Investigators 2206

Gómara, MJ 316, 2138 Gomes, A 2346 Gomes, J 2026 Gomez -Caballero, M 1205 Gomez Caballero, ME 450 Gomez Puerta, JA 316, 450, 2138

Gomez- Rodriguez-Bethencourt, MA 1166, 2134

Gomez-Vaquero, C 1524 Gomiero, AB 1562 Goncalves, C 581, 1647 Gonçalves, CR 2397 Gong, Y 774 Gono, T 227, 615, 706, 1483, 1527, 1965, 2319 Gonzalez, A 1439 Gonzalez, EB 613, 666, 726, 1452, 1477, 2429 Gonzalez, JM 453

Gensler, LS 153, 505, 512, 518, 2531

Gilkeson, GS 68, 150, 157, 557, 569, 632, 633, 634, 636, 637, 639, 641, 642, 1663, 2277, 2476, 2477

Geny, B 717

Gill, G 2050

Godeau, B 438, 858, 1500, 1641

George, AJT 1274

Gill, R 2555

Godinez, F 206

Georgel, P 978, 1001

Gill, RR 2293

Godinho, F 1317

Georgiou, A 699

Gill, TM 1721

Goeb, V 488, 1302

Gerard, HC 1940, 1948, 2617

Gilliam, BE 287, 300, 302, 309

Goekoop-Ruiterman, Y 418

Gerards, A 431

Gillis, M 724

Goemaere, S 1104

Gerdan, V 541, 550, 1974

González-Alvaro, I 57, 319, 343, 1173, 2160

Gilsenan, C 1722

Goertz, H 892, 894

Geri, G 577, 791, 2394, 2399, 2450, 2620

Gonzalez-Diaz, A 1166, 2134

Gilson, M 2050

Goeschl, L 817, 1657, 2359

Gonzalez-Dominguez, J 1323

Giltiay, NV 2548

Goesling, J 1911, 1912, 2421

González-Escribano, MF 2160

Gimbel, J 741

Goggins, J 1979

Gonzalez-Gay, M 790, 1494

Gimona, A 1016, 1029

Gogia, M 1025, 1037

Ginzler, E 584, 591, 592, 2472, 2602

GOGO Investigators 825

González-Gay, MA 1044, 1950, 1968

Gohr, C 1800

Gonzalez-Lopez, L 250

Giorgerini, V 2381, 2382

Goins, RT 1670

González-López, MA 1968

Giovannini, L 1287

Goker, B 1994, 2004

Gonzalez-Malaver, F 321

Girard, M 2006

Gokhale, A 40

Gonzalez-Reyes, JA 725

Girgis, R 693

Goldbach-Mansky, RT 60, 310, 818, 2451

González-Vela, MC 1968

Giron, M 1148 Gisondi, P 2486F

Goldenberg, D 1438

Goode, AP 881

Gitelman, D 751, 2456

Goldenstein-Schainberg, C 222, 303, 1486

Goodfellow, R 1146

Gerlag, D 82, 279 Gerlag, DM 58, 313, 371, 770, 1821, 1843, 2154, 2177 Gerlag, DM 969 Gerli, R 1201 German, A 2011 German BIKER Registry collaborative group 260 Germanò, G 189, 1520 Germinario, A 1953 Gerstein, M 2333 Gersuk, VH 2170 Geslani, G 666 Geurts, MA 1695 Ghahary, A 1836 Ghassemi-Nejad, S 734 Ghazarian, SR 1460 Ghazi, E 249, 617 Ghiadoni, L 2263 Ghillani-Dalbin, P 19, 20, 1753

Giuggioli, D 688, 689, 1454

Gobbo, M 1311 Gobeaux, C 685

Giusti, N 1519

Golder, V 1400

Gladman, DD 785, 1395, 2269, 2275

Goldermann, R 1253 Goldring, SR 1065

Gladman, D 602

Goldsmith, DP 2028 Goldsmith, S 1585 Goldstein, I 2333 Golightly, YM 881, 1552, 1556 Goll, GL 2184


Gehér, P 517

Gomar, F 1782

Gonzalez Expósito, Sr., A 1316 Gonzalez Fernandez, Sr., C 1316 González López, JJ 2253 González López, M 81 González Rodríguez, C 2169 Gonzalez Vela, MDC 81

Gooberman-Hill, R 1061

Goodfield, M 2486F Goodman, S 915, 2416 Goodman, SM 1694, 2224 Goodpaster, BH 1560, 2611 Goodson, N 1097, 1105 Gopalakrishnan, R 489 Gordon, C 1847, 2265, 2270, 2271, 2442, 2444 2011 Program Book

353

Gordon, C 4, 586, 589, 591, 592, 601, 605, 1375, 1378, 1383, 1708, 1849 Gordon, JK 700, 1716 Gordon, P 224, 241, 242, 243 Gordon, RA 2503 Gordon, TP 469 Gordon, TP 1751 Gore, D 1105 Gorelik, G 2350, 2364 Gorelik, M 1687 Goren, A 216 Gorla, R 1201 Gorlova, O 2429


Gorlova, OY 1452, 1494, 1497 Gorn, AH 788 Gorochov, G 658 Gorostiza, D 208 Gorter, SL 258, 286 Goryachev, S 1185 Goss, PE 1676 Gossec, L 1243, 1296, 2050, 2153, 2384 Goto, D 947 Gottenberg, J 126, 161, 438, 485, 488, 717, 774, 978, 980, 1001, 1257, 1641, 2234, 2384 Gottlieb, AB 509 Gottlieb, BS 721, 2061 Gottwald, M 1155 Goudeau, D 135, 393, 844, 2143, 2150, 2516 Gough, AK 463, 2465 Goulas, A 49 Gould, K 2155 Gourh, PR 1492, 2329

Granger, B 353

Gross, RL 509, 597, 618

Guo, D 1194

Graninger, WB 811, 1270, 2135

Gross, WL 790

Guo, S 575

Granton, JT 2481

Grossbard, EB 420, 2594

Gupta, N 1185

Grassi, W 174, 1201, 1238, 2144, 2209, 2231

Grossi, S 1933, 2381, 2382

Gupta, RK 954

Grasso, E 494

Grossman, JM 593, 639, 640, 788, 2477

Gupta, S 567, 2549

Grau, RG 2466

Grotle, M 1543

Grauer, A 1103

Grouard-Vogel, G 2470

Gupta, V 1675

Grauer, A 1098, 1107, 1108

Gruben, D 407, 408, 409, 718, 2592, 2627

Gray, D 624 Gray, S 1935 Grayson, PC 1503 Greco, CM 2488 Green, L 2352 Green, MJ 463 Green, MJ 2465 Green, SL 1372, 1851 Green, SM 959, 2079 Greenbank, C 1097, 1105 Greenberg, DA 1352 Greenberg, HS 828 Greenberg, JD 52, 108, 169, 326, 335, 1189, 1262, 1306, 1310, 1936, 2464, 2511, 2595, 2634

Gruber, H 1778 Grunewald, J 2176, 2179 Grunke, M 387, 1689, 2145 Grupo de Estudos e Pesquisas em Educação Médica - UFRN 1598 Grünke, M 186 Gränsmark, E 1162 Gröndal, G 2136 Gsteiger, S 779, 2486D Gu, F 569 Gualano, B 1566, 1723, 2614 Guan, M 1840 Guay-Belanger, S 1209 Guchelaar, H 165, 841, 842

Greenberg, SA 1834, 1835

Gudnason, V 2439, 2546

Greene, T 903, 905

Guedes, LKN 581, 1890

Greenwald, MW 2201, 2591

Guedes-Pinto, H 1317

Greenwood, R 2425

Guenther, J 2312

Greger, G 534

Guerette, B 417, 1231, 1698, 1699, 2189, 2228

Greger, S 193 Gregersen, PK 165, 167, 456, 1494, 1677, 1678, 1682, 1743, 1764, 2162, 2479

Guerin, A 919, 920, 1333

Gregorich, S 799

Guermazi, A 959, 960, 961, 1073, 1076, 1616, 1624, 2005, 2079

Greidinger, EL 823

Guerini, H 1718 Guerit, D 1790

Gourley, MF 1574

Gremese, E 270, 609, 1201, 1673, 1746, 2343

Guerra, MM 1707

Gourzi, VC 490

Gremmelsbacher, E 1697

Govoni, M 2270

Gressin, V 681

Guibert-Toledano, M 783, 2117

Govoni, M 1201

Greth, W 1394, 1458, 1848, 1861

Gow, PJ 211, 212, 1622

Griffin, M 801, 803

Goycochea, M 8

Griffin, N 2061

Goycochea-Robbles, MV 138

Griffith, MP 902

Grabiec, A 82

Griffiths, B 224, 601, 605

Graca, L 1934

Griffiths, CE 1450, 1467

Guillevin, L 438, 858, 1500, 1641, 2368, 2379, 2384

Gracey, E 2616

Grigg, SE 1308

Guillou, C 2093

Grados, D 1941

Grigoriev, G 2503

Guirola, R 94

Graell, E 316, 2138

Grijalva, C 801

Guis, S 2050

Graessel, S 1943

Grijalva, V 764

Guissa, VR 2020

Graf, JD 2107, 2130

Grillet, B 431

Gul, A 166, 1328, 1686, 2431

Graham, D 803

Grilo, A 1971

Gulanski, B 756

Graham, RR 2479, 2480

Grogan, S 2438

Gulinello, M 576

Grahn, AY 1219

Grom, AA 1685, 1686, 1687

Guma, M 833

Grainger, A 944

Grootenhuis, MA 279, 864

Gunawardhana, L 1031

Grall-Lerosey, M 2021

Grosbein, H 2481

Gunderson, J 1586

Gran, JT 682

Gross, H 1885

Gundogdu, B 1142, 1837

Grandclement, E 2220

Gross, KD 1624, 1724, 1991, 1995, 2560

Gunnarsson, C 912

Grandpeix, C 608

354

2011 Program Book

Gui, Y 1836 Guiducci, S 2604 Guilhot, F 63 Guilland, JC 1110 Guillemin, F 10, 132 Guillen, MI 1782

Gunnarsson, I 1441, 1658, 2480

Gupta, SR 1092 Guralnik, L 678 Gurka, MJ 1670 Gustafsson, J 1441 Gutala, R 1492 Guthridge, J 54, 641, 1427, 2571 Guthridge, JM 1663 Guthrie, JP 1948 Guthrie, LC 136, 143 Gutierrez, L 483 Gutierrez, M 2144 Gutierrez, MA 1963 Gutiérrez-Cuadra, M 1950 Gutierrez-Polo, R 191 Guzman, J 262, 2024 Gúzman, R 578 Guzman P., RN 1185 Guzman-Saltis, C 321 Gyenes, G 2078 Gyftopoulos, S 1083 Gül, A 2305 Günther, A 35

H Haas, F 952 Haas, JP 274, 1688 Haavardsholm, EA 2575 Habal, N 310 Habibagahi, M 2392 Habibagahi, Z 2392 Hachulla, E 161, 230, 438, 485, 488, 1508, 1641, 2470 Hackney, B 1583 Hackney, J 446 Haddad, A 1327, 1651 Haddix, EF 1578 Haegel, H 1140 Hafstrom, I 348 Haga, Y 2122 Hagberg, N 2496 Hagedorn, TJ 1553, 1554, 1556, 2543 Hagen, KB 1543 Hager, D 714 Hagerty, D 1021, 1030 Haggart, E 861 Hagge, R 206 Hagihara, K 2243 Hagiwara, S 947 Hagiwara, T 457, 1263, 2108

Hahn, BH 568, 572, 574, 593, 639, 640, 788, 2255, 2289, 2361, 2477

Hanley, DA 1631

Harris, KP 1977

Hauser, R 284

Hahne, M 28, 373, 1005

Hanley, Jr., E 1778

Harris, RE 738, 970, 971

Hausfater, P 2450

Hanly, JG 4, 591, 592, 609, 1375, 1383, 1708, 2298

Harrison, A 211, 212, 1622

Hautaniemi, S 966

Hanna, BD 1223

Harrison, DJ 915, 2416

Haverman, L 279, 864

Harrold, LR 108, 326, 803, 2595

Havey, W 1979

Hart, DM 152, 765, 768, 1204

Hawker, GA 875, 882, 883, 886, 1628, 2481, 2506

Haibel, H 515, 546, 777, 1338, 2486B, 2534 Haidich, B 901 Haiduc, V 1550, 1666 Haines, III, GK 36, 1010 Haines, KA 2453 Haj Hensvold, A 767, 2179 Hajnal, J 949 Hak, AE 969 Hakendorf, P 251 Hakim, A 224 Hale, JJ 649, 1370, 1680 Hali, M 2617 Hall, A 2372 Hall, DJ 1795 Hall, J 1625 Hall, L 2404 Hall, S 2627 Hallstrom, B 1988 Halsey, JP 1097, 1105

Hannan, MT 797, 800, 1552, 1553, 1554, 1555, 1556, 2543 Hannon, MJ 958, 959, 962, 963, 1983, 2079 Hannouche, D 1801 Hanrahan, LM 2255 Hansel, JE 1876 Hansen, I 394, 1258 Hansen, MS 872 Hanses, F 1943 Hanses, H 436 Hansmann, S 1976 Hansson, M 767 Hao, Y 1053 Haqqi, TM 2437 Haque, S 1415 Haque, UJ 2124, 2132 Hara, M 1527

Hart, JE 2574 Harta, N 106 Harte, S 970 Harte, SE 738 Hartkamp, A 2596 Hartman, TE 2212 Hartung, W 176, 178 Harty, LC 1336, 1829 Harvey, BP 1774 Harvey, E 2045 Harvey, P 2064, 2259 Harvey, WF 1033 Harward, LE 2286 Harxhi, A 1438 Hasegawa, D 2080 Hasegawa, EM 222 Hasegawa, H 1011, 2340

Hawkins, E 941 Hawkins, P 1967 Hawse, JR 1676 Hayami, Y 1193 Hayashi, D 960 Hayashi, M 1062, 1214 Hayashi, N 2123 Hayashi, T 947 Hayden, CL 1234, 1264 Hayden-Ledbetter, M 559 Haye Salinas, M 1177 Hayes, KW 1087, 1982, 1985 Hayes, O 259 Haygood, D 2412 Haynes, K 508 Hays, RD 221 Hazes, J 181, 431

Harada, T 2042

Hasegawa, M 2000

Haraoui, B 325, 338, 339, 417, 736, 1198, 1249, 1612, 1889, 2075, 2141, 2202, 2457

Hasegawa, M 1488 Hashimoto, A 1478

Harari, O 2204

Hashiramoto, A 379, 1139, 1810

Hardin, JA 1693

Hashizume, M 1838, 2090

Hardwick, D 2287

Hashkes, P 721

Hardwick, DF 662, 664, 2498

Hashkes, PJ 2445

Harel, Z 1879

Haskard, DO 1038

Hargrove, JB 735

Haskins, K 2339

Harigae, H 1434

Hasle, H 299

Harigai, M 117, 458, 460, 2629

Hasler, P 814, 2600

Harigane, K 1195

Hasni, SA 662, 664, 1382

Harjacek, M 298

Hasselquist, M 953

Harju, A 2176

Hasserjian, RP 1713

Heeringa, P 794

Harley, JB 150, 157, 481, 489, 632, 633, 634, 636, 637, 639, 641, 642, 643, 649, 773, 1370, 1429, 1663, 1681, 2475, 2476, 2477, 2479, 2601

Hassett, AL 939, 1911, 1912, 2409, 2421

Hefner, K 489 Hegen, M 834

Hassoun, PM 1471

Hegyi, A 2335

Hastings, L 1652

Heiberg, MS 531, 533, 2532

Harlow, L 823, 979

Hasty, KA 1798

Heiberg, T 1296

Harman, L 1026

Hatakeyama, S 15

Heidecke, H 1495, 2312

Harmouche, H 1040

Hatcher, JP 2092

Heijboer, A 1799

Harmsen, WS 2530

Hatemi, G 166, 168, 1947

Heimans, L 416, 440, 2207

Haro, I 316, 2138

Hatron, PY 488, 859

Hein, M 820

Haroche, J 1409

Hatta, K 395, 396

Heinegard, D 348

Haroche, J 19, 20, 658

Hatterer, E 63, 2336

Heinlen, L 2601

Han, Y 2567

Haroon, N 522, 1303, 1330, 1344, 1355, 1649

Hatzigeorgiou, A 832

Heitzmann, M 34, 1797

Hanami, K 369, 1237, 1239

Hau, B 1069

Hekmat, K 2148

Harp, K 1888

Hanaoka, M 227, 615, 706, 1483, 2319

Hauber, AB 453, 1247

Helfenstein, Jr., M 1914, 1915

Harper, BE 613, 666, 1452, 1477

Hauenstein, S 1266

Helliwell, P 463, 1296, 2486E

Harrington, A 769 Harrington, TM 753, 1597

Haugeberg, G 510, 1102, 1125, 2559C

Harrington, WL 1670

Haugen, IK 1073, 1623

Helmick, CG 795, 879, 882, 909, 1847, 1849, 1978, 2442, 2444, 2508

Harris, C 329, 597, 2261

Hauk, VC 494

Halter, DG 535 Halushka, M 1440 Hama, M 190, 809, 1115 Hamada, M 2195 Hamadeh, F 948 Hamaguchi, Y 1488 Hamel, K 1760 Hamerman, JA 2548 Hamidou, M 230, 858, 1500, 1510 Hamilton, BJ 1261 Hamilton, B 2522 Hamilton, MJ 1639 Hamilton, S 721 Hamm-Alvarez, SF 487 Hammaker, D 37, 833 Hammer, HB 172 Hammermuller, E 2069 Hammitzsch, A 1689 Hammock, B 1674 Hammond, A 2405, 2555 Hamuryudan, V 2393 Han, C 144, 922, 1246, 2206, 2236 Han, J 1432, 1442, 1664 Han, K 354, 2200 Han, L 1721 Han, T 285

Hanczko, R 2599 Handler, C 2482 Haney, DJ 323, 361, 2244

Hashimoto, J 1571


Haley, WE 1580

Hannan, C 909

Hazlet, LD 2085 Hazlewood, GS 118, 1198, 2222 He, J 2084 He, L 1132 He, W 1787 He, X 1135 He, X 285 Head, AJ 710, 2055 Heath, J 2030 Hebden, T 1221, 1242, 2197, 2198 Heber, D 811 Hebert, D 2045 Heegaard, NH 652, 1926

Hemke, R 956, 957 2011 Program Book

355

Hemmati, I 138

Hewagama, A 2364

Hiroshima, R 1064

Hollander, MC 612, 2624

Hemmelgarn, B 1862

Hewitt, S 2064

Hirota, T 947

Hollis, S 2594

Henderson, LA 2293

Hewlett, S 342, 1557, 2405, 2425

Hirsch, J 895

Hollis-Moffatt, JE 211, 212

Hendrickson, P 252, 819

Heymann, RE 1914, 1915

Hirsch, R 958, 1687, 1839

Hollister, AS 1018

Hendriks, RW 2499

Heymans, HS 279

Hirsh, JM 145

Hollywood, J 1517

Hendrikx, J 1878

Hickey, M 29

Hiruma, K 467

Holmdahl, R 767, 2161, 2341

Henes, JC 532, 790, 952

Hickman, RA 589

Hisdal, J 1170

Holme, I 502, 1186, 1293

Hengstman, GJD 235

Hickson, L 2104

Hishitani, Y 2243

Henk, H 1221

Hidaka, D 1956

Holmqvist, M 104, 1154, 1162, 2523, 2574

Hennessy, S 2580

Hidaka, T 2194

Henrickson, M 1578

Hiemstra, TF 2369

Henríquez, C 1439

Hietpas, J 1986

Hitchon, CA 152, 325, 338, 339, 347, 362, 736, 768, 1198, 1204, 1889, 2139, 2141, 2163, 2202, 2457, 2573

Henrotin, Y 1780

Higgins, G 245, 246, 265, 721, 2015, 2454


Hensor, E 463, 1285, 1702, 2465 Henstorf, GR 1430, 1465, 2330 Hentsch, B 397 Herlin, T 283, 299 Herlitz, L 555 Herman, S 983, 2428 Hermann, J 811 Hermann, K 423, 515, 1329, 2534 Hermans, G 834 Hermida-Carballo, L 48 Hermida-Gómez, T 2426 Hernandez, D 390

Higgins, GC 2014, 2047, 2453 Higgs, BW 1834, 1835, 1922 Highton, J 211, 212, 1622 Hilario, MO 304 Hilário, MOE 862, 2403 Hilberdink, W 1668, 2423 Hildebrand, K 1567 Hilfiker, R 1996 Hilkens, C 386 Hill, AA 1407 Hill, CL 843, 1093

Hernandez, MV 316, 1205, 1315, 2138

Hill, D 1392, 1712

Hernández Cruz, B 2169

Hill, M 2489

Hernandez Gongora, SE 1232

Hilliard, BA 1006

Hernández Miguel, MV 450

Hillman, J 196

Hernández-Díaz, C 95, 1595

Hillson, JL 2474

Hernandez-Hernandez, V 1166, 2115, 2134

Hillstrom, HJ 1556, 1991, 1995

Hernandez-Lobato, D 1927

Hilton, W 1261, 2159

Hernandez-Molina, G 5 Hernandez-Reyes, P 2484 Hernandez-Rodriguez, J 1518, 1523 Herren, S 63 Herrera-Garcia, A 30, 1818 Herrero-Beaumont, G 2253 Herrgott, I 1455 Herrick, A 197, 1467 Herrick, AL 1450, 1491, 2483 Herrinton, L 801 Hersh, AO 2025, 2031, 2294 Hershko, A 2495 Herson, S 1587 Hervier, B 230 Herzer, P 1883 Hess, A 2527 Hesselstrand, R 673, 1459, 1491, 1497 Hesterberg, LK 838, 1613, 1748, 2244 Hetland, ML 394, 399, 444, 946, 1258, 1645, 1646, 2242 Heur, JM 487

356

2011 Program Book

Hill, JA 2355

Hilton, H 1148 Himes, M 1670 Himmelreich, U 2328 Himsel, A 1455

Hladik, A 31, 817, 1657, 2359 Ho, C 837 Ho, GY 2238 Ho, J 170 Ho, K 836 Ho, LY 579, 2256 Ho, MJ 291 Ho, P 2166 Ho, RC 1371 Hobbs, A 2603 Hochberg, M 825, 830, 1125, 2077, 2505, 2595 Hodgin, J 1433 Hodgson, R 944 Hodler, J 2633 Hodsman, A 1108 Hoehle, M 173 Hoeltzel, MF 2019, 2027, 2034 Hoens, A 1564 Hoes, JN 419 Hofer, M 2012 Hoff, M 510, 1102 Hoff, P 28, 373, 1005 Hoffart, C 2043 Hoffecker, BM 1377

Hinchcliff, ME 695, 2311

Hoffman, GS 789, 792, 1503, 1513, 2368, 2371, 2375, 2432

Hingorani, V 1021, 1030

Hoffman, HM 170, 1967

Hinks, A 1688

Hoffmann, M 983

Hinschberger, O 857, 860

Hoffmann, N 131, 1852

Hinson, G 826

Hoffmann-Vold, A 682

Hinz, M 2630

Hoffmeyer, P 1081

Hirabayashi, Y 1272

Hofman, M 1324

Hiraki, LT 2441

Hofstetter, W 1779

Hirano, T 2243

Hoftman, AD 98, 593, 2010, 2033

Hirano, Y 1214

Hogan, J 1136

Hirao, M 1571

Hogan, VE 446

Hirata, A 2123

Hoganson, DD 213, 1188, 1617

Hirata, S 351, 1267, 1613, 2244, 2468

Hogg-Johnson, S 798, 2612

Hirohata, S 1276, 1475, 1478, 1711, 1771

Holers, VM 100, 322, 388, 766, 769, 2182, 2339

Hiromura, K 1828 Hiron, M 372, 1931, 2093 Hirono, S 1139 Hirose, S 562

Hoi, AY 1400

Holgado, S 1941 Hollan, I 595, 1052 Holland, GN 295 Holland, S 170, 306

Holweg, CT 446, 837 Holzinger, D 306 Homik, J 105, 140, 448, 2545 Honczarenko, M 1387 Honczarenko, M 1407 Hong, K 659 Hong, MJ 1111, 1112 Hong, S 74, 109, 1318 Hong, T 1053 Hong, YJ 324 Honjo, S 151, 1263 Hoock, T 1136 Hooper, MM 1189 Hootman, JM 795, 909, 1977, 1978, 2542 Hoover, SE 1056, 2466 Hoppenreijs, EP 258, 286 Horger, M 866, 952 Horiki, N 2000 Horikoshi, M 947 Horita, T 15, 2310 Horiuchi, K 1151 Horn, A 2427, 2535, 2538 Horn, E 1716 Horn, HC 394 Horne, A 207, 219, 1618 Horneff, G 260, 274, 2621, 2622, 2623 Horng, A 1321 Horowitz, ZD 2582 Horst, G 1659 Horton, HM 1256 Horton, R 1579, 1585, 2411 Horton, S 2144 Horwitz, DA 624, 849, 2551 Hoshi, D 1235, 1237, 1239 Hoshi, K 1276, 1475 Hosoi, T 1629 Hosono, O 1137 Hosono, Y 225 Hossain, A 2289 Hossain, MM 2085 Hossler, J 1767, 2186 Hostens, J 2328 Houde, M 1546 Houghton, KM 1633 Houman, H 2394 House, M 219, 1618

Houssiau, F 2472

Hugenberg, ST 1962

Hwang, YG 2348

Imagawa, T 2042, 2625

Houssiau, F 2469

Huggins, JL 612, 754, 757, 1578, 2008

Hyde, C 2430

Imai, T 376

Huggins, JP 971

Hyndman, D 1592

Imamura, E 1000

Hynes, K 1093

Imanaka, H 267, 297

Hyrich, K 290

Imanishi, J 1000 Imazio, M 1051 Imbuka, D 1429

Houssiau, FA 435, 1927, 2258, 2470 Houssiau, FA 711

Hughes, C 1274

Houston, GD 489

Hughes, GC 72, 2353

Houtman, P 341

Hughes, LB 337, 2128, 2157

Hyrich, KL 257, 426, 1211, 1212, 2524, 2525

Houtman, PM 1322, 1324

Hughes, P 489

Hüseyinsinoglu, N 1328

Houvenagel, E 2234, 2384

Hughes, S 1586

Häuser, W 1610, 1901

Houwing-Duistermaat, JJ 2181

Hughes, T 150, 156, 157, 642

Höhne-Zimmer, V 1697

Howard, BV 102

Hughes-Austin, JM 100

Howard, G 1545, 2642

Hugot, S 401

Hørslev-Petersen, K 394, 946, 1258, 1665

Howard, RNG 223, 1083

Huie, TJ 687

Howell, KJ 677

Huijbregts, M 1090

Hoyas, J 383, 1084

Huisman, A 431, 1080, 1987, 1997

Iacobelli, S 1963

Imundo, LF 1585, 2014, 2015, 2047

Hoyles, R 1481

Huisman, M 1420

Iagnocco, A 2144

Inaba, Y 2625

Hozumi, K 1804

Huitema, MG 468, 794, 1752, 2342

Iana, A 1055

Inada, S 320

Huizinga, T 440, 842, 1420

Iannaccone, CK 333, 2575

Inal, V 1525

Iannone, F 1047, 1201

Inami, H 1000

Iannuzzi, MC 1680

Inamo, K 488

Ibanez, D 599, 785, 1368, 1385, 1386, 1388, 1395, 2259, 2262, 2282, 2284, 2301, 2302

Inanç, M 609, 673, 1328, 2300, 2305

Ibarra-Sanchez, MJ 854

Ingegnoli, F 1459

Hsieh, C 597, 1445 Hsu, B 415, 423, 922, 1227, 1268, 2227, 2631, 2632 Hsu, C 991 Hsu, E 726 Hsu, H 2097, 2246, 2248, 2348, 2362 Hsu, JJ 2624 Hsu, VM 695, 697 Hsu, Y 1555 Hu, A 780 Hu, N 1132 Hu, W 585, 1919, 1920 Hu, X 2201 Hu, X 2156 Huang, B 721, 2445 Huang, BK 196 Huang, C 819, 1446, 2311 Huang, C 71 Huang, J 2110, 2126 Huang, QQ 367, 1004, 1446, 2085, 2086 Huang, W 2550 Huang, X 171 Huang, X 1922 Huang, Y 1767, 2498 Huber, A 234 Huber, AM 240, 1633, 2019, 2027, 2034 Huber, LC 1671, 2519 Hubertsson, J 2509 Hubscher, O 494 Hudkins, KL 559 Hudson, AP 1940, 1948, 2617 Hudson, M 696, 708, 2489 Hueber, W 779, 2486D Huerta-Yáñez, GF 783 Huffman, KM 214 Huffstutter, JE 455

Huizinga, T 323, 416, 516, 838, 1072, 1253, 1295, 1613, 2628 Huizinga, TW 351, 352, 354, 359, 418, 841, 2136, 2162, 2181, 2200, 2207, 2232, 2458 Hulejová, H 53, 1817, 1820 Hulot, J 608 Hum, D 1725 Hummers, LK 693, 695, 697, 720, 1458, 1460, 1463, 1494, 1716, 2429, 2486

Ibba, V 1354 Ibba-Manneschi, L 2604 Ibrahim, A 2486E Ibrahim, F 224

Imhof, BA 38 Imhoff, H 2205 Immermann, F 1387 Immermann, FW 1407 Impens, AJ 1468

Inanc, N 2387 Ingham, M 129, 2215 Ingle, JN 1676 Inman, RD 922, 1330, 1339

Ibrahim, S 2612

Inman, RD 423, 522, 1227, 1303, 1344, 1355, 1649, 2615, 2616

Humphrey, MB 1427

Ice, JA 481, 489, 643, 773, 2475

Inokuma, S 2629

Hunder, GG 1511, 1532

Ichida, H 227, 615, 1483, 1527, 1965, 2319

Inoue, A 1138

Ichinose, K 318

Inoue, M 2122

Hunsche, E 1863 Hunt, B 1022, 1031 Hunt, J 1768 Hunter, DJ 722, 1979 Hunter, G 2348 Hunter, J 1396 Hunter, J 1673

Ida, H 318, 2447 Ierna, M 203 Igarashi, K 1115 Igelmann, M 503, 506 Iglesias-Gamarra, AA 783, 1313

Hunter, JC 206

Ihata, A 190, 809

Hunzelmann, N 673, 1455, 1491, 1497

Iikuni, N 574, 2361 Iizuka, M 492, 1141

Huppertz, H 274, 2623

Ikari, K 151, 163, 1064

Husa, MR 2438

Ikawa, T 401

Husain, AA 1415

Ikeda, K 179, 2144

Huscher, D 373, 1714

Ikeda, K 467

Huscher, D 2460

Ikeda, T 1410

Husmark, T 504

Ikenoya, K 406

Husni, ME 500, 547, 552, 1291, 1869

Ikeuchi, H 1828

Hussain, H 183, 1969, 1975

Ikle, D 789, 792, 2432

Hutcheson, J 564, 1010 Hutchinson, C 1467 Hutchinson, K 2291 Hutmacher, M 1259 Hviscova, K 1887 Hwang, HJ 437 Hwang, J 377, 625, 1192, 1413 Hwang, S 491

Iking-Konert, C 176


Hsia, EC 144, 1210, 2227, 2236, 2250

I

Imboden, JB 2107, 2130

Inoue, E 332, 336, 1199, 1629 Inoue, N 2402 Inoue, Y 1766 Insalaco, A 2452 Insua Vilariño, S 192 Intema, F 827 International Childhood Arthritis Genetics Consortium 1686 International Scleroderma Group 2313 Investigators, SR 2311 Ioannou, Y 14, 23, 2279, 2288 Iorga, SR 1848, 1861, 1864 Ip, WY 2118 Irvine, J 487 Irwin, DE 881 Isaacs, J 779, 2627 Isaacs, J 344

Ilhan, N 1837

Isaacs, JD 386, 2204

Illei, GG 481, 482, 497, 498, 643, 662, 664, 773, 775, 1382, 2287, 2498

Isakova, T 2309 Isayeva, K 292, 2626

Ilowite, NT 282, 721, 747, 1684, 2015, 2047, 2624 Im, CH 2587

Isenberg, DA 4, 23, 224, 591, 592, 601, 605, 609, 1375, 1383, 1662, 1678, 1708, 2279, 2283, 2288

IMACS and PRINTO 240

Ishida, MA 581, 709, 2619

Isenberg, D 2270

2011 Program Book

357

Ishigatsubo, Y 190, 809, 1041, 1115, 2402, 2431

Jacobi, AM 1769

Jehan, F 2620

Jones, A 1727

Ishiguro, N 458, 460, 1062, 1199, 1214, 1218, 1220, 2629

Jacobs, Jr., DR 2174

Jenei-Lanzl, Z 1775, 1805

Jones, A 1067

Jacobs, JW 181, 1695

Jenkins, BJ 2500

Jones, A 2028

Jacobs, J 590

Jennings, F 1569

Jones, B 1813

Jacobsen, S 609, 652, 1258, 1926

Jeon, CH 377, 625, 1192, 1413

Jones, CA 745

Jacobson, CJ 2492

Jeon, E 850

Jones, C 2562

Jacobsson, LT 1154, 1162, 2148, 2440, 2515

Jeong, H 850

Jones, DA 420

Jacques, S 1701, 1706

Jepson, B 789, 2432

Jones, DL 1670

Jernberg, T 1154

Jones, D 135, 2150, 2516

Jessberger, R 2549

Jones, DM 393, 844, 2143

Jesus, AA 304

Jones, EA 880

Jetanalin, P 449

Jones, GT 288, 880, 2370

Jhangri, GS 745

Jones, GW 2500

Jhingran, PM 1855

Jones, G 876, 1079, 1093, 1625

Jhun, J 850, 2345

Jones, GT 211

Ji, J 1958, 2084

Jones, JB 753

Ji, JD 635, 1487, 2365

Jones, J 2566

Jia, X 1682

Jones, JD 1261, 2159

Jiang, C 662, 664

Jones, KL 1874

Jiang, M 1674

Jones, OY 265

Jiang, X 1053

Jones, P 892, 894

Jilkine, K 152

Jones, PBB 211, 212, 1622, 1720, 2579

Ishii, K 1195 Ishii, T 1272, 1434 Ishikawa, H 1214 Ishikawa, T 1000 Ishimori, ML 1663, 2410 Isidor, B 306 Isik, A 1142, 1837, 2081, 2083, 2094 Isnard, R 2399 Isozaki, T 36, 66, 731, 1277, 1619


Jaeschke, R 1123 Jager, N 1159, 1161 Jaglal, SB 886, 2506

Isnardi, I 1743 Israelsson, L 767, 2161 Issuree, P 1151

Jahangier, Z 1695 Jain, M 1675, 2597 Jajoria, P 613, 726 Jakicic, JM 959, 1381, 2488

Itami, Y 357

Jakobsson, PJ 770, 2179

Ito, H 1606

Jakobsson, P 767

Ito, T 1000

Jakstadt, M 28, 373, 1005

Iudici, M 1454 Ivanco, D 846, 847 Ivashkiv, LB 2503 Iversen, LV 652, 1926, 2314 Iversen, MD 119 Iwahashi, M 51, 457, 1263 Iwai, K 1220 Iwai, T 2195 Iwamoto, M 406 Iwamoto, N 318, 2536, 2605 Iwamoto, T 179

Jalal, H 2576 Jallal, B 1834, 1835, 1922 Jallouli, M 608, 1373, 1409 Jamard, B 2384 James, J 1387 James, JA 54, 150, 157, 632, 633, 634, 636, 637, 639, 641, 642, 649, 773, 1370, 1407, 1429, 1663, 1741, 2475, 2476, 2477, 2571, 2601 James, S 1154 Jang, S 775 Janga, SR 487

Iwamoto, Y 540

Jansen, AV 240

Iwaoka, H 1000

Jansen, G 1275

Iwata, S 1137

Jansen, TL 165

Iwata, S 1267

Janssen, CE 298

Izac, B 1340 Izmirly, PM 2518, 2597, 2602 Izquierdo, E 1479, 1772, 2316 Izumihara, T 457, 2108 Izumikawa, M 967

J Jabbarzadeh-Tabrizi, S 1766 Jacek, EE 1807 Jackson, MW 469, 1751 Jackson, R 830 Jackson, RD 102 Jackson, RL 1022 Jacob, CO 575, 632, 633, 634, 636, 637, 639, 641, 642, 649, 2475, 2476, 2477, 2479 Jacob, F 532 Jacob, G 936 Jacob, N 575 Jacobe, H 2453 Jacobelli, S 1439 Jacobelli, SH 2117

358

Jadon, D 1366

2011 Program Book

Jimah, J 2599 Jimenez, R 1963

Jones, R 1274

Jimenez, SA 675, 848, 1461, 2317, 2318, 2608

Jones, S 63, 1146 Jones, SA 2500

Jimenez Boj, ME 543

Jones, TV 330, 410, 2239, 2512

Jiménez-Núñez, FG 191, 1113

Jonsen, A 1441

Jin, H 1620

Jónsson, H 2136

Jin, J 2085

Jonsson, R 481, 643, 773

Jin, L 2591

Joo, K 526

Jin, M 491

Joo, YB 103, 2168, 2223

Jing, Z 1053

Joosten, LA 1180

Job-Deslandre, C 268, 2021

Jordan, C 310

Johansen, J 394

Jordan, JM 825, 879, 881, 1544, 1552, 1555, 1978, 2508

Jansson, T 1549

Johansen, JS 399

Japanese Hydroxychloroquine Study Group 1410

Johansson, S 1549 John, A 1262

Jara, LJ 11

John, R 1398

Jara Quezada, LJ 665

Johnson, A 721

Jara-Quezada, L 250

Johnson, BH 917

Jara-Quezada, LJ 8

Johnson, B 1694, 2224

Jaramillo, C 542

Johnson, DS 1174, 1200, 1234, 1264, 2129, 2140, 2152

Jarjour, WN 496, 663, 1417, 1425 Jarosova, K 53 Jarpa, E 1963 Jatwani, S 726 Jatzek, A 1003 Jauharoh, SN 493 Javaid, MK 829, 1060 Javier, R 717, 1257 Jayakar, B 155 Jayakar, J 524, 537 Jean, S 2021 Jeanson, Y 1784 Jeanty, C 1341 Jeavons, A 1702

Johnson, D 1874 Johnson, FR 1247 Johnson, K 1891 Johnson, KJ 792 Johnson, SR 1476, 1717, 2481 Johnsrud, I 1125

Jordan, N 620, 631 Jordan, N 1306, 2634 Jordan, S 702 Jorgensen, C 1007, 1784, 1790, 2100, 2337, 2470 Joseph, L 1862, 2254 Joshi, K 1251, 1255 Joshi, RK 153 Josse, R 1104 Jourdan, R 452 Jousse-Joulin, S 180, 474, 476 Joven, BE 692 Jover, JA 2062 Joyal, E 60

Johnston, S 113

Joyce, AT 146

Jolly, M 630, 1397, 1419, 1422, 1859, 1860, 2066, 2299, 2410

Ju, JH 479, 2098, 2345 Ju, Y 204

Joly, F 1753

Juanola-Roura, X 1311, 1315

Jonas, BL 337, 1545, 1594, 2128, 2155, 2157, 2642

Juarez, RV 1952

Joneja, M 91

Judge, A 1060

Jubeck, B 1800

Juengel, A 1923

Kallen, MA 626, 2111

Kaplanski, G 1816

Julian, LJ 1436, 2025, 2073, 2107, 2490, 2491, 2640

Kallenberg, CG 789, 1322, 1324

Kapoor, M 67, 1725

Jun, JB 109, 125

Kallenberg, CG 468, 792, 794, 1659, 1752, 2432

Kapoor, P 1763

June, R 2438

Kallinich, T 2622

Juneja, M 916

Kalliolias, GD 2503

Karagianni, N 832

Jung, DS 437

Kalman-Lamb, G 1325

Jung, E 1769

Kalstad, S 531, 533, 1229, 2532

Jung, E 1901

Kalthoff, LH 503, 506

Jung, J 1744, 1767, 2498

Kalunian, K 2265

Jung, K 1966

Kalunian, KC 4, 196, 597, 1375, 1383, 1708, 2255

Jung, LK 265

Kalyoncu, U 1296

Jung, YO 76 Jungel, A 42, 46, 366, 2536 Juni, P 1996 Junker, S 1825

Kamalati, T 1274 Kamali, S 1328, 2305 Kamath, R 1770 Kambayashi, T 991

Junta, C 1241 Jurado, C 2029 Jurencak, R 97, 1633 Jurik, AG 2633 Jury, E 1662, 2346 Juslin, S 1776, 1786 Juvenile Dermatomyositis Research Group 2039

Karam, E 68 Karan, A 1292 Karanasos, A 1163 Karasawa, R 296 Karatas, A 1142, 2081, 2083, 2094 Karateev, AE 684 Karim, Y 631 Karim, Z 2144 Kariuki, S 633 Karlson, EW 101, 1185, 1679, 2544, 2574

Karpf, DB 2584

Kaminsky, P 10 Kamp, S 1407

Karp, R 1757 Karpitschka, M 1321

Kary, S 535, 2216

Kan, H 917, 1379

Kasagi, S 2095

Kaname, S 793

Kasama, T 66, 1277, 2194

Kanazawa, M 458, 460

Kasapcopur, O 166, 2012

Kanazawa, N 2447

Kasemier, J 2002

Kanbe, K 2194

Kashikar-Zuck, S 940, 2492

Kanda, V 816, 1065

Kastbom, A 2180

K.T., A 1828

Kane, D 62, 195, 1352, 1722, 2413

Kabraki, M 1811

Kaneko, A 1214

Kastner, DL 170, 986, 1686, 2028, 2431, 2445

Kadar, A 1921

Kaneko, H 615

Kadono, T 2320

Kaneko, K 1127, 2565

Kaffenberger, B 663, 1425

Kaneko, K 376

Kafka, SP 455

Kaneko, T 1236

Kageyama, G 1057

Kaneko, T 562

Kahan, A 268, 670, 685, 690, 1456, 1464, 1499, 1718

Kaneko, Y 1237, 1239, 2165

Kahlenberg, JM 1433

Kang, E 360

Kalagate, R 1946 Kaldas, M 1025, 1037 Kaleth, A 1607

Kang, C 1681 Kang, JW 2587 Kang, KY 2098 Kang, YM 2587 Kannan, K 454 Kao, AH 1381, 2488 Kao, L 1600 Kao, L 643

Katan, M 170 Kataoka, S 227, 615 Katayama, K 457 Katayama, M 151 Katayose, T 1137 Katchar, K 2344 Kato, D 1214 Kato, H 2334 Kato, M 15, 2310 Kato, Y 1410 Katsaros, EP 1860, 2410 Katselis, G 1918 Katsiari, C 1178 Katsicas, MM 2069 Katsumata, Y 227, 615, 1527

Kapetanovic, MC 398, 432, 1692

Katsumoto, TR 1484

Kallakury, B 27

Kaplan, MJ 1169, 1433, 1493, 2547, 2590

Katz, JN 123, 877, 884, 900, 2510

Kallberg, H 167, 1679

Kaplan, S 799, 2640

Kalfa, M 1525 Kalish, RA 95, 1595

Kausar, F 2449

Kamgang, RK 1779

Kamsma, YP 1324

Kaiser, R 1436

Kaur, PP 904

Karp, K 1156

Jüngel, A 45, 2519

Kaine, JL 403, 404, 2190

Kaukeinen, K 449

Kamen, DL 632, 634, 641, 1377, 1663, 2277, 2476, 2477

Karras, A 1528

Kaieda, S 1143

Kaufmann, J 177, 461, 1244, 1271

Karp, DR 1663

Kamradt, T 63

Kahn, J 857, 860

Kaufmann, C 531, 533, 1229, 2532

Kameda, T 967

Karpov, A 1016, 1019

K

Kaufman, KM 633, 634, 636, 637, 639, 641, 642, 643, 649, 1680, 1681, 2475

Kavanagh, R 87

Kamperidis, P 1274

Jørgensen, A 394

Kaufman, K 150, 157, 632, 2476, 2477

Kameda, H 44, 1237, 1239, 2194

Juvenile Myositis CARRA Subgroup for CARRAnet Investigators 2019, 2027, 2034

Jönsson, G 398, 1692

Kaufman, J 1104, 1116

Kautiainen, H 2570

Karpouzas, GA 759, 762, 2119, 2137

Jönsen, A 2480

Katzavian, G 2495

Karouzakis, E 366, 1672, 1923, 2520

Kampagianni, O 563

Jüni, P 1077

Katz, SJ 90

Karonitsch, T 817

Kamboh, MI 2479

Jurado, A 1439

Karakostas, P 503, 506

Katz, RS 927, 928, 929, 943, 1577, 1610, 1900, 2408, 2409, 2564

Katsuyama, N 2122

Kavanaugh, A 154, 417, 420, 510, 912, 1231, 1245, 1246, 1612, 1698, 1699, 2206, 2227, 2228, 2594 Kavanaugh, AF 895, 2189 Kaverina, N 1445


Junker, P 394, 1258

Kam, YN 374

Kapsogeorgou, EK 490

Katz, PP 799, 800, 1247, 1436, 2025, 2073, 2107, 2490, 2491, 2610, 2640

Kavros, SJ 213, 1617 Kawabata, D 225 Kawaguchi, Y 227, 615, 706, 1483, 1527, 1965, 2319 Kawai, H 2195 Kawai, S 382, 400, 1127, 1811, 2565 Kawai, VK 588, 1391 Kawakami, A 318, 368 Kawakita, T 99 Kawano, S 493 Kawano, S 562 Kawano, Y 297 Kawasaki, H 1137 Kawashima, S 793 Kawashiri, S 318, 368 Kay, J 1246, 2227, 2250, 2309, 2511 Kay, R 347 Kayakabe, K 1828 Kaye, JF 560, 2091 Kayikcioglu, M 1525 Kaymakcalan, Z 1774 Kayo, AH 1562 Kayser, C 680, 1457 Kazmi, N 630 Ke, Y 1194 Keat, A 517, 1652 Keaveny, TM 1099 Keddache, M 1688 Kee, S 1620 Keefe, FJ 1418, 1419 Keegan, S 1758 Keeley, P 880 2011 Program Book

359

Keeling, SO 2078 Keen, HI 463 Keen, KJ 679


Keenan, G 602

Keystone, E 325, 338, 339, 403, 417, 445, 736, 1231, 1245, 1246, 1249, 2141, 2199, 2202, 2208, 2227, 2228, 2236

Kim, E 479

Kim, W 1380, 1648, 2158

Kim, GT 77, 1165, 2131

Kim, Y 1148

Kim, HJ 2451

Kim, Y 1027, 1833, 1970 Kim, Y 2183

Keidel, S 301

Keystone, EC 1198, 1889, 2457, 2592

Kim, H 64, 76, 1122 Kim, HY 1636, 2345

Kim, YJ 1970

Keir, G 2482

Kezic, JM 1342

Kim, H 76, 479, 850

Kim, YS 1122

Keiserman, MW 402

Khalatbari, S 1169

Kim, HS 170

Kim*, K 1681

Keith, MP 2601

Khalid, Z 1123

Kim, HW 324

Kekow, J 147

Khalidi, NA 1503, 1513, 2368

Kim, HA 1049

Kelleher, K 758

Khalil, H 1260

Kim, H 2156

Kimberly, RP 632, 633, 637, 641, 642, 649, 995, 1374, 1681, 2311, 2476, 2479

Kellenberger, C 284

Kim, HA 346, 961

Keller, D 741

Khamashta, MA 24, 25, 26, 591, 592, 601, 605, 725, 1437, 2281

Kim, H 659

Kelley, L 2265

Khamastha, M 620

Kimberly on behalf of PROFILE investigators, RP 634, 636, 639, 2477

Kim, H 1122

Khan, K 1481, 1498, 2324, 2327

Kimura, M 2187, 2396

Kelley, L 1378

Kim, I 346, 961, 2098

Khan, MS 454

Kimura, Y 2015, 2047

Kellner, H 2486D

Kim, JH 103, 2168, 2223, 2635

Khan, NA 139, 1174, 1200, 2152, 2462

Kimura, Y 278, 280, 282, 721, 2061

Kellner, H 176, 178, 401, 951, 1321

Kim, J 472

Kinaszczuk, M 2469

Kim, JH 484, 2183, 2587

Kind, AJ 2070

Kim, J 2101

Kinds, MB 972

Kim, J 479, 1636

King, K 2451

Kim, J 484

King-Davis, S 1013, 1023

Kim, J 1380, 1648

Kingsley, GH 361

Kim, JJ 103, 2168, 2223

Kinter, M 1427

Kim, J 1966, 2635

Kirbach, SE 259, 913

Kim, J 2548

Kirbiyik, H 1319

Kim, J 1192

Kirby, B 1352

Kim, J 1337, 2167

Kirchner, HL 719, 1160, 1168

Kim, J 661

Kireva, T 1588

Kim, JK 437

Kirino, Y 1115, 2431

Kim, J 437

Kirkham, BW 1288

Kim, KK 1484

Kiroglu, G 115

Kim, K 1380, 1648 Kim, KS 74

Kirou, KA 597, 867, 1424, 1443, 1709, 1807, 2411

Kim, K 64

Kirstein, J 1013

Kim, M 659

Kirwan, JR 79, 1557, 2425

Kim, M 1443, 1707, 2255

Kis-Toth, K 1755, 2331, 2335

Kim, M 51

Kisacik, B 1279, 1951

Kim, NR 2587

Kishimoto, D 809

Kim, PS 2238

Kishimoto, M 99, 1959, 2063, 2187, 2396

Kellner, W 951 Kelly, JA 150, 157, 481, 489, 639, 641, 642, 649, 773, 1370, 1429, 1680, 1681, 2475, 2476, 2477 Kelly, JL 1744 Kelly, K 2537

Khan, Z 919, 920, 1333 Khanna, D 216, 221, 676, 697, 716, 895, 1025, 1035, 1037, 1459, 1493, 1714, 1716, 1717, 1863, 2429, 2483

Kelly, S 375

Khanna, P 216, 221, 895, 1025, 1035, 1037

Kelman, A 837

Kharlamova, N 2161

Kelsall, JT 2205

Khasnis, AA 2375

Kelsey, C 308, 1826

Khaw, K 1893, 1895, 2106

Kemta Lekpa, F 1957

Khellaf, M 858

Kendler, DL 1108

Khetan, S 1845

Kendzucky, A 2318

Khiani, SJ 2044

Kennedy, A 391

Khodzhigorova, A 2538

Kennedy, C 1729, 1730, 1731, 1732

Khoja, SS 1560, 2611

Kennedy, CW 271, 281, 289 Kennedy, M 2038 Kennedy, NM 2419, 2641 Kennish, LM 171, 314 Kenny, D 447, 2105 Kenny, G 1090 Kent, PD 334 Kenwright, A 2621 Keogh, K 2432 Kerekes, G 201 Kermani, TA 213, 1501, 1502, 1511, 1512, 1513, 1617 Kern, M 456 Kerndrup, G 299 Kerr, B 1030 Kerr, GS 134, 1174, 1181, 1200, 1234, 1264, 2110, 2126, 2140, 2152

Khosroshahi, A 1507, 1713, 1740 Khraishi, MM 1548 Kiani, A 595, 603, 784, 2038 Kichikawa, Y 1137 Kicker, P 2451 Kiechle, T 1019, 1020, 1028 Kiel, DP 797 Kielhauser, S 2135 Kielhorn, A 1244 Kiely, PD 241, 243 Kiener, HP 817 Kiener, P 1835 Kievit, W 110, 165, 341, 1878, 2596 Kikuchi, H 2402 Kikuchi, M 2042 Kilani, R 1836 Kilgallen, B 1378

Kerstens, P 354, 416, 418, 1613, 2200

Kilgore, M 1114

Kesel, N 381, 2377

Kill, A 1495, 2312

Keser, G 1525

Kiltz, U 503, 506, 1296

Keshet-Katz, R 560

Kim, CH 1909

Kessel, A 1345

Kim, D 2158

Keyes, AL 472, 473

Kim, EH 987

Kilicaslan, I 2300

Kim, E 32, 819

360

2011 Program Book

Kim, R 1092 Kim, S 484, 1122, 2183 Kim, SW 437 Kim, SY 116, 2580 Kim, S 484, 2183 Kim, SM 74 Kim, S 1318 Kim, SH 552 Kim, SJ 867, 2411 Kim, SI 77, 2131 Kim, SS 1049 Kim, S 1165 Kim, S 2644 Kim, S 2293 Kim, T 109, 125, 526, 1966, 2635 Kim, T 109, 125, 526, 627, 1399, 1620 Kim, T 1346, 2088 Kim, T 1681

Kiss, MHB 303 Kissel, K 2628 Kissin, EY 193, 2432 Kissling, RO 527, 2633 Kita, J 318 Kitas, G 1163 Kitas, GD 1178 Kitas, G 224, 349, 2125 Kitchen, J 62, 195 Kitchen, K 2405 Kitsis, EA 2059 Kivity, S 480 Kivitz, AJ 741, 1014, 1029, 1248 Kizawa, T 2042 Kjeken, I 1543 Klaman, LD 2087 Klarenbeek, N 2200

Klareskog, L 104, 767, 842, 1677, 1679, 1682, 2161, 2176, 2179, 2236, 2341, 2574

Koenig, AS 326, 330, 410, 441, 500, 1216, 1284, 1290, 1291, 2239, 2512

Klatt, S 2082

Koening, CL 1513

Klatzmann, D 577, 791, 1753

Koerbl, B 131, 1852, 1854

Klearman, M 1642

Koessler, RE 367

Klein, J 584

Kofman, N 1345

Klein-Gitelman, M 612, 751, 2008, 2011, 2014, 2015, 2047, 2454, 2456, 2624

Koga, T 318, 368

Klein-Gitelman, MS 264 Kleinert, S 363, 1733, 1750 Kleinhans, M 532 Kleinman, NL 913 Kleinrensink, G 181 Klimas, M 31 Kline, K 1574

Koh, E 109, 125, 377, 625, 1192, 1413 Koh, JS 437 Koh, W 1192 Koh, W 1601 Kohane, I 1185 Kohler, M 756 Kohler, MJ 83 Kohlmann, T 147

Korb-Pap, A 34 Korendowych, E 1366, 2166 Koretzky, GA 495, 991 Korganow, A 554 Korhonen, R 49 Korman, B 1446 Korman, NJ 547, 552, 1869 KORONA investigators 109, 125 Korotkova, M 770 Korswagen, L 590 Kortekaas, MC 1072, 1074 Kosa, P 776 Kosco-Vilbois, M 63, 977, 2336 Kose, O 2385 Koseki, Y 615 Koskas, F 2395

Koike, R 117

Koskinen, A 1776, 1786 Kostense, PJ 1269

Klink, C 503, 506

Koike, T 15, 117, 458, 460, 1218, 1220, 2188, 2310, 2629

Kosugi, Y 1810

Klinker, MW 1756

Koike, T 405, 1100

Kottgen, A 1600

Kloppenburg, M 1072, 1074

Koitschev, A 1976

Koumakis, E 670

Klopsch, T 147

Koitschev, C 1976

Koutroumpas, A 1071

Knafo, R 2489

Kojima, T 1062, 1199, 1214

Kovács, L 609

Knapp, A 554

Kojuma, M 44

Kowal, M 803

Knaudt, B 532

Kolfenbach, JR 769, 2182

Kowal-Bielecka, OM 1714

Knauer, C 1219

Kolhatkar, N 2548

Kowalczyk, A 224

Kneissel, M 1150

Kollias, G 34, 832, 1150, 1640, 1797, 1938

Koyama, N 1804

Kolling, C 42, 45, 46, 989, 1671, 1672, 1923, 2519, 2520

Koyanagi, A 1804

Kling, MA 249 Klink, AJ 2043

Knevel, R 311, 352, 2136, 2458 Knevel, R 323, 838, 2181 Knight, JS 616 Knops, B 2405 Knops, E 1644 Knowles, S 2466 Knutson, KL 2113 Ko, K 1423 Kobayashi, D 621, 1171 Kobayashi, H 1172 Kobayashi, K 51 Kobayashi, T 2187, 2396 Kobayashi, T 1236 Kobayashi, Y 1172 Kobezda, T 734, 1008, 1755, 1929 Kobialko, M 1736 Kobie, J 2504 Kobold, U 2204 Koca, SS 1142, 1837, 1886, 2081, 2083, 2094 Kocaoglu, S 926

Kollnberger, S 1354 Komagata, Y 793 Komai, K 1810 Komano, Y 117 Komarow, H 170 Kompella, U 831 Komuro, Y 407, 1215 Konai, M 1719 Koncz, T 408, 718, 2627 Kondo, Y 492, 947, 1141 Kondos, G 787, 1446 Koné-Paut, I 265, 988 Kong, KO 1581 Kong, L 1917 Konsta, M 1202 Konstantellis, L 1666 Kontani, T 1000 Konthur, Z 840, 1749

Koch, AE 36, 38, 731, 1619, 2317, 2318, 2547, 2569

Konttinen, YT 414

Koch, T 131, 1852, 1854

Koo, BS 1027, 1833, 1970

Kochi, Y 151

Koo, G 994, 1443

Koehm, M 363

Koontz, D 229

Koehoorn, M 2507

Koopman, FA 371

Koeleman, BP 1497, 2313

Koopman-Keemink, Y 258, 286

Kontzias, A 60

Kopec, JA 2507, 2577

Koyama, Y 1956 Koyano, S 457, 1263, 2108 Koziel, J 2618 Kozora, E 727, 1390, 2308 Krabbe, S 950 Krabben, A 352 Kraft, P 167 Krakovitz, P 1531 Kramer, A 373 Kramer, I 1150 Krammer, G 1016, 1020, 1029 Krantz, MJ 2254 Krasnokutsky, S 169, 171, 1070, 1083, 1936 Krastinova, E 857, 860 Krathen, M 509 Kraus, VB 881 Kraus, VB 214, 825, 1957 Kraus, WE 214 Krause, A 461, 1155 Krause, DM 503, 506 Krause, L 1701 Kreiger, P 1683, 2502 Kreiger, PA 495 Kreiner, F 253 Kreitz, S 2527 Kremer, JM 421, 841, 842, 2592, 2627

Kremer, JM 108, 326, 329, 427, 449, 1189, 1262, 1310, 2191, 2208, 2213, 2467, 2511, 2595 Kretsos, K 43, 1814 Kretzler, M 1433 Kreuter, A 1497 Krieg, M 1103 Kriegel, MA 2355 Krilis, S 1639 Krintel, SB 394 Krintel, SB 399 Krischer, J 792 Krishnamoorthy, M 687 Krishnamurthy, A 55 Krishnan, E 244, 910, 1021, 1032, 1602 Krishnan, G 713 Krishnaswami, S 408, 718, 2627 Kristiansen, TM 1665 Kroenke, K 1910 Kroese, F 468, 1752 Kroesen, B 2342 Krogh, BO 384 Krogh, NS 946


Kleoudis, C 1416

Kogata, Y 1057

Kopperdahl, D 1099

Krohn, K 1099 Kroon, H 354 Krug, HE 2003 Krumbholz, G 1825 Krummel-Lorenz, B 534 Krüger, K 1697 Kryštufková, O 1820 Krämer, A 1745 Ku, G 1136 Ku, J 856 Kuan, WP 1167, 2249 Kuang, W 285 Kubassova, O 946, 949 Kubo, S 451, 1267, 2230, 2468 Kubota, A 2310 Kubota, T 267, 297 Kudryavtseva, E 1348 Kuebler, WM 1495 Kuemmerle-Deschner, JB 1967, 1976, 2623 Kuenzi, P 929, 1577, 1900, 2564 Kuester, RM 2623 Kuhn, A 1268 Kuhn-Sherlock, B 207 Kuijpers, TW 864, 956, 957 Kuklová, M 1817 Kuller, L 322, 388 Kumabe, M 633, 1429 Kumagai, E 1137 Kumagai, S 493, 2095 Kumakura, S 1794 Kumar, AA 633 Kumar, S 1286 2011 Program Book

361

Kumar, V 2549

Kåss, A 1052

Kume, K 395, 396

Källberg, H 2574

Kummerfeld, S 446

Köhler, D 2377

Kun, E 1167

Köpke, K 840

Kun, EW 2249

Kötter, I 532, 790, 952, 2388, 2460

Kuncová, K 1820

L

Kunkel, GA 2172 Kuntz, K 2576 Kunzler, P 46

La Cava, A 65, 70, 568, 574, 1831, 2361

Kuper, IH 2459

La Corte, R 2390

Kupper, H 154, 265, 535, 1231, 1612, 1698, 1699, 2216, 2228

La Torre, F 1533

Kurakula, P 1418

Labitigan, M 314

Kurasawa, K 1403, 1711


Kurasawa, T 1237, 1239 Kurimoto, C 493 Kuriya, B 325, 803, 1196, 1879

Labenski, M 1757 Labno, C 1445 Labrecque, J 256, 1862, 2271, 2455

Landewe, R 358, 378, 507, 1231, 2250

Lawrence, S 97

Landolt-Marticorena, C 580, 852, 1398, 2269

Lawson, EF 2025, 2031

Landon, GC 878, 885 Landry, M 1727 Landstein, D 2495 Lane, NE 206, 1984, 1986 Lang, BA 1633 Lang, V 548, 1208 Langan, S 782 Lange, J 2541 Lange, RA 1477 Langefeld, CD 150, 157, 305, 632, 633, 634, 636, 637, 639, 641, 642, 649, 771, 1681, 1686, 1688, 2475, 2476, 2477, 2479

Lawson, A 1814 Laxer, RM 269, 2453 Layh-Schmitt, G 511, 1703 Lazar, GA 1256 Lazarevic, D 2012 Lazaro, DM 921, 1174, 1200, 1593, 2152 Lazaro, E 2470 Lazure, T 161 LBSL02/99 Study Group 584 Le, J 2431 Le, T 2481 Le Bars, M 1224, 1238, 2209, 2231, 2232

Langer, H 198, 199

Le Bourlout, C 2153 Le Guern, V 488, 608

Kurkó, J 1008, 1928

Lacaille, D 137, 138, 804, 1669, 1846, 1877, 1879, 1881, 2577

Kuroda, T 621, 1171

Langford, CA 789, 792, 1503, 1513, 2368, 2375, 2432

Le Goff, B 1815

Lacaille, DV 1880

Kuroiwa, T 1828

lacassagne-Compeyrot, S 2021

Langui, D 1587

Kurosawa, M 2402

Lachaine, J 2193

Laor, A 1868

Le Loët, X 315, 372, 1931, 1932, 2093, 2494

Kurowska-Stolarska, M 1673

Lachassinne, E 728, 2035

Laor, T 958

Kurrasch, RH 916

Lachenbruch, PA 240

Lapa, A 2257

Kurreeman, F 167, 1185

Lachmann, HJ 988

Lapadula, G 1047, 1201

Kurtz, B 198

Lacraz, A 857, 860

Lapeyre-Mestre, M 442

Kurzinski, K 308, 1826

LaCroix, A 869

Laplante, P 724

Kushi, J 697, 1800

Laden, F 101, 2574

Larché, M 1633

Kusunoki, N 382, 1127, 1811

Lafeber, F 127, 1080, 1987, 1997

Laria, A 703

Kusunoki, Y 1127, 1811, 2565

Lafeber, F 827

Larimi, R 2386

Kutala, VK 1431

Lafeber, FP 972, 1695

Laroche, D 1992

Kuuliala, A 2570

Lafforgue, P 149

Laroche, F 1048

Kuuliala, K 2570

Lafyatis, R 2537

LaRosa, J 502, 1293

Kuwada, N 267

Lahey, LJ 2170

Larregina, AT 2315

Kuwana, M 226, 227, 236, 1489, 2165

Lahiri, M 1893, 1895, 2588

Larroche, C 488, 1508

Lahr, B 941

Larsen, S 872

Kuwatsuka, Y 1482

Lai, B 71

Larsson, P 504

Kuzin, I 1704

Lai, Z 776

Laskin, CA 1, 2, 1707

Kvien, TK 128, 172, 444, 502, 513, 519, 531, 533, 1170, 1186, 1229, 1293, 1296, 1543, 1623, 1645, 1646, 2184, 2226, 2242, 2532, 2575

Lai, Z 2599

Laslett, L 876, 1625

Lail, A 789, 2432

Lassere, MN 411

Lajas, C 1042

Latorre, I 1941

Lajevardi, N 2055

Latorre, M 2381

Kwakkenbos, L 2417, 2487

Lakos, G 2297

Latremouille-Viau, D 920

Kwan, L 929

Lakshminarayanan, S 714

Lau, AN 1123

Kwiatkowski, D 2358

Lal, P 837

Lau, K 1148

Kwoh, CK 958, 959, 962, 963, 1983, 2079, 2485

Lales, G 264

Lau, SM 2118

Kwok, C 2486F

Lalsa, V 1579

Lau, Y 612

Lamacchia, C 2336

Laudien, M 2377

Lamana, A 57, 2160

Laughlin, S 1534

Lamas, JR 383, 1084

Launay, D 857, 860

Lamb, J 1678

Laurent, DD 2486D

Lambert, M 859, 1500

Lauridsen, UB 946

Lambert, RG 778, 955, 1320, 2633

Laurindo, I 1890, 2117, 2619

Lambrecht, S 1356

Lauwerys, B 435, 1927, 2258, 2470

Lamprecht, P 1529

LaValley, MP 193, 2389, 2439, 2546

Kwok, R 2256 Kwok, S 479 Kwok, W 1072, 1074 Kwon, Y 1346, 2088 Kyburz, D 45, 1007, 1923 Kydd, A 2067 Kyle, D 135, 393, 2143, 2150, 2516 Kyriakidis, NC 490 Kyrkou, K 1178 Kyttaris, VC 563, 640

362

2011 Program Book

Lan, Q 594, 624, 849, 1924 Landewe, R 2486D

Law, S 2430 Lawrence, A 1402

Le Loet, XX 353, 438, 452, 1302, 1641, 2234 Le Quellec, A 858 Le Riche, NGH 2202 Le Thi Huong, D 1409, 2399 Leandro, MJ 390, 1735, 1737, 2225, 2521 Learch, TJ 505, 512, 518, 2531 Learmonth, I 746 Leavitt, F 927, 943 Lebeaux, D 1955 LeBlanc, CM 1633 Leboime, A 1340 Lebre, MC 58, 1821, 1843, 2356 Lebrecht, D 814, 2600 Leccese, P 1289 Lecky, B 224 Leclerc, P 770 Lecompte, T 10 Lecomte, P 892, 894 Lecouvet, FE 711 Ledbetter, JA 559, 656 Lee, A 1603 Lee, AT 165, 1494, 1677, 1678 Lee, C 1111, 1112 Lee, C 1027, 1833, 1970 Lee, C 491 Lee, C 310 Lee, DM 844, 1149 Lee, EB 407, 408 Lee, EB 324, 659, 2306 Lee, EJ 1795 Lee, EY 324, 491, 659, 2306 Lee, E 1111, 1112 Lee, E 437 Lee, E 987 Lee, H 170

Lee, YC 422, 736, 1610

Lee, H 1681, 2168, 2171

Lee Evans, H 667

Lee, J 377, 625, 1192, 1413

Leeb, BF 543

Lee, J 437

Leeder, JS 255

Lee, JS 1642, 2204

Leeder, J 750

Lee, JB 848

Lefevre, S 35

Lee, J 479

Leff, L 1579

Lee, JL 256

Légaré, J 2193

Lee, JY 1078

Legault, C 722

Lee, J 2635

Legendre, M 1003

Lee, JS 1966

Legerton, III, CW 402

Lee, J 109, 125, 1049

Lehane, PB 2199, 2208

Lee, JH 1966

Lehman, AJ 1846

Lee, J 103, 2168, 2171, 2223, 2635

Lehmann, KA 313

Lee, JW 77, 2131

Lehmann, M 1387

Lee, J 1165

Lehmann, M 1407

Lee, JA 240

Lehr, A 35, 381, 1825

Lee, J 834

Lehrach, H 840

Lee, JH 77, 2131

Lei, J 1011, 2340

Lee, J 64, 2158

Lei, X 239

Lee, J 1558, 1980, 2120, 2505, 2558

Leijsma, MK 1322, 1324

Lee, KL 1167, 2249

Leirisalo-Repo, M 2570

Lee, K 1621 Lee, K 522, 1649 Lee, K 1850 Lee, L 1274 Lee, M 1855 Lee, P 2481 Lee, R 1143 Lee, SH 1636, 2345 Lee, SY 437 Lee, S 64, 76, 401, 850 Lee, S 74, 1318 Lee, S 1134 Lee, S 1346, 2088, 2101 Lee, S 1337, 2167 Lee, SY 2345 Lee, SG 77, 1165, 2131 Lee, S 526 Lee, S 109, 125, 627, 1399, 1620 Lee, SP 2413 Lee, S 1619 Lee, SK 1346, 2088, 2101 Lee, S 1337, 2167 Lee, SW 109 Lee, S 627, 1399, 1620 Lee, SJ 449, 895 Lee, TD 1918 Lee, T 612 Lee, Y 74, 1318 Lee, Y 836 Lee, Y 1033 Lee, YS 377 Lee, YH 635, 1487, 2365 Lee, YY 763, 764, 1918 Lee, YJ 324

Leipe, J 387, 2164 Leisen, JC 1849, 2442 Lekander, I 906 Lell, M 209 Lema, L 1177 Lembo, R 2028 Lemelle, I 2021 Lemmers, H 1180 Lemmey, A 2566 Lems, WF 354, 418, 425, 1799 Lems, W 416 Lems, WF 351, 419, 439, 2200 Len, C 304, 2026 Len, CA 862, 2403 Lenaerts, J 430

Lequerré, T 372, 1931, 1932, 2093, 2384

Lhoste, A 514, 810

Lerch, V 753

Li, C 285

Leroux, G 1409 Lerstrøm, K 2270 Lertnawapan, R 587 Lertratanakul, A 787 LeSage, D 1470 Lesch, CA 731 Lessard, CJ 481, 489, 643, 773, 1680, 2475 Lessard, JA 481, 489, 773 Lesser, M 2550 Lester, S 486, 996, 1093 Lesuis, N 2116 Letourneau, J 836 Letourneur, F 1701, 1706, 2494 Leung, AM 1167, 2249 Leung, I 1256 Leung, J 666 Leung, J 1083 Leung, W 219 Leung, YY 1167, 2249 Leunig, M 1077 Leux, C 1510 LeVan, T 2155 Levarht, E 2181 Levartovsky, D 1944 Leveille, SG 797 Levenstein, S 2013 Levesque, MC 135, 148, 393, 844, 2143, 2150, 2516 Levin, AM 1680 Levine, AB 1408 Levine, JS 724 Levinson, RD 295 Levis, B 2489

Li, C 285 Li, C 896 Li, C 2001 Li, D 759, 762 Li, EK 973, 974, 984, 1167, 2249 Li, G 1185 Li, G 1053 Li, H 2097, 2246 Li, H 489, 2475 Li, J 1958, 2084 Li, J 2493 Li, J 2097, 2246, 2248, 2311 Li, L 1727 Li, LC 965, 1576, 1669 Li, M 1167, 2249 Li, M 604 Li, N 2119, 2137 Li, S 218 Li, SC 2023, 2453 Li, TK 1167, 2249 Li, W 1288, 1290, 2512 Li, X 380, 561, 653, 655, 1545, 2473, 2598 Li, X 2071 Li, X 737 Li, X 995 Li, X 863 Li, Y 228, 232 Li, ZG 2627 Li, Z 380, 1128, 2526 Li, Z 169 Lian, J 805 Liang, G 650 Liang, MH 235, 2072 Liang, M 1840

Lencina, V 2563

Levy, DM 2014, 2015, 2045, 2454, 2624

Lennon, DP 1789

Levy, GD 888

Lentjes, M 1895

Levy, R 578

Lentle, B 1633

Levy Neto, M 821

Lenzi, M 1529

Lewallen, D 1063

Leo-Summers, L 1721

Lewiecki, EM 1107

Leon, EP 581

Lewin-Koh, N 837

Leon, G 402

Lewis, B 2569

León, L 1042, 2062

Lewis, C 871, 960, 1628, 1724, 1993, 2560

Lie, E 444, 531, 533, 1229, 1645, 1646, 2242, 2532

Lewis, CE 744, 1076, 1089, 1616, 1624, 1984, 1986, 1989, 1991, 1995, 2005

Lieberman, SM 495 Liebhaber, A 1697

Lewis, DM 489

Ligozio, G 401

Leonard, D 1441 Leonard, MB 1158 Leoncini, G 1533 Leong, AL 342 Leong, D 837 Leong, T 271 Lepley, D 2219

Lewis, EE 1849, 2442 Lewis, J 801, 803

Lepore, L 283, 1964

Lexicon Pharmaceuticals RA Clinical Development 2593

Lepper, J 1788

Leyva Prado, C 2169

Lepse, N 794

Lheritier, K 2622


Lee, H 1765, 1925

Liang, Q 1635 Liao, J 650 Liao, K 1259 Liao, KP 1185, 2293 Liarski, VM 1445 Libanati, C 1103, 1631 Libanati, C 1108 Lidtke, RH 1086, 1994

Lightfoot, RW 2404 Lii, H 803 Lillegraven, S 333, 2575 Lim, C 2457 Lim, FC 2348 Lim, J 1856 Lim, M 850 2011 Program Book

363


Lim, M 1337, 2167

Liu, J 1217

Long, H 650

Lu, TT 2549

Lim, MJ 1049

Liu, J 1032, 1602

Longhurst, C 2068

Lubbers, J 2178

Lim, N 789, 2432

Liu, J 116

Longo, MGF 638

Lubberts, E 50, 2357, 2499

Lim, SS 1847, 2444

Liu, J 1130

Looney, MR 1484

Luben, RN 1893, 1895, 2106

Lima, EN 968

Liu, J 2551

Lopes, A 414, 1792

Luca, N 2040

Lima, FR 1566, 1572, 1723, 2614

Liu, L 653

Lopes, JB 812, 899

Lucas, M 671, 846, 847, 2485

Lima, J 784

Liu, L 801, 803

Lopez -R, R 2268

Luciano, N 1933

Limacher, A 1077

Liu, M 1676

López Hoyos, M 480

Luckey, D 2338

Limal, N 608

Liu, P 2033

López-Armada, MJ 48

Ludivico, CL 404, 2190

Limaye, V 251

Liu, Q 1618

Luedtke, C 941, 1909

Limburg, PC 468, 794, 1659

Liu, R 380

Lopez-Benitez, JM 261, 271, 281, 293

Lin, A 1344

Liu, S 417, 1231, 2228

Lopez-Colombo, A 1389

Luger, T 1296

Lin, A 2551

Liu, X 2526

Lin, CP 649, 1370, 1680

Liu, X 776

Lin, HY 413

Liu, Y 2551

Lin, J 1609

Liu, Y 644

Lin, R 995

Liu, Y 1885

Lin, TH 836

Liu, Y 65, 70

Lin, YC 547, 552, 1869

Liu, Y 310, 818

Linauskas, A 394

Liu, Y 472

Lind-Albrecht, G 199

Liu, Z 1835

Lindblad, S 1226

Liu, Z 594, 849

Lindegaard, HM 394, 1258

Liu-Bryan, R 2438

Lindner, V 1637

Livingston, B 610

Lindop, R 1751

Lix, L 1881

Lindquist, JH 1582

Lizana, C 2272

Lindqvist, E 352

Ljung, L 839

Lindqvist, URC 504

Llahí Vidal, N 2211

Lindroth, Y 2148

Llinares-Tello, F 2211

Lindsley, HB 826

LLorente-Peters, L 1404

Lindwall, E 646

Lloyd, A 347

Lineker, SC 1729, 1730, 1731, 1732

Lloyd, O 290

Ling, N 1266

Lo, GH 1091, 1998

Lingala, B 668, 910, 1715

Lo, MS 2624

Linnemann, A 790

Lobert, J 1913

Linnik, M 2255

Lobo-Mueller, E 749

Linnik, MD 585, 1919, 1920

Locatelli, E 1954

Linton, MF 2280

Lock, M 52

Lioté, F 608

Lockshin, MD 7, 727, 1390, 1408, 1707, 2308

Lioté, F 1801 Liphaus, B 303 Lipp, R 811 Lippens, C 977

Lockton, S 1266 Loeffler, A 46 Loell, IM 233

Lisse, JR 1056, 2466

Loeser, RF 722, 1796

Listing, J 147, 461, 515, 546, 777, 1329, 1335, 1697, 1883, 2486B, 2534

Loft, AG 517 Loftus, Jr., EV 2530

Litinsky, I 1300

Loh, C 570

Littlefield, MJ 1808 Littlejohn, GO 1899 Littman, DR 2518 Liu, A 71 Liu, C 995, 1763 Liu, F 1221 Liu, H 2323 Liu, H 2598 Liu, J 1824, 2434

364

2011 Program Book

Logeart, I 174 Lohanatha, FL 373 Lohse, P 306, 1976 Loiler, S 1145 loire-Berson, P 728 Lojacono, A 1535 Lok, C 681 Londoño, J 542, 1301 Long, DA 1796 Long, E 170

López-Hoyos, M 16, 17, 81 López-Lasanta, MA 1113 López-Longo, FJ 1414, 2036 López-Nebot, MA 2160 Lopez-Olivo, M 878, 885 Lopez-Pedrera, C 725, 1437 López-Santalla, M 57 Lopez-Vives, L 1524 Lorenco, E 788 Lorenz, H 534 Loricera, J 1950

Luetkecosmann, S 28 Lugli, EB 2522 Luijtens, K 445, 1252 Luime, JJ 181, 187, 192, 431 Luk, F 1969 Lukas, C 311, 443, 2235, 2458 Lukina, G 444, 1645, 1646, 2242 Lukitsch, I 1495 Lumetti, F 688 Lunardi, C 1491 Lund, OI 98

Lories, R 1304, 1802, 2328

Lundberg, IE 59, 233, 235, 822, 824, 1549, 1678, 2606

Loring, SH 2293

Lundberg, K 2161, 2179

Lorrot, M 2021

Lundon, K 1729, 1730, 1731, 1732

Losina, E 877, 884, 900, 2510

Lundsgaard, D 384, 1424

Lottenburger, T 1258

Lundstrom, E 1441

Lotufo, R 2257

Lundström, E 1156

Lotz, MK 2438

Lundy, SK 1756

Lou, W 1398, 2269, 2303

Lunt, M 160, 426, 1211, 1873, 1892, 1893, 1895, 2106, 2524, 2525, 2588

Louis-Plence, P 2337 Lounsbury, H 1757 Lourenco, E 572, 1831 Louw, I 2630 Louzada-Junior, P 1241 Love, T 508, 1521, 1522, 2533 Loveless, JE 2208 Lovell, D 2621 Lovell, DJ 265, 721, 754, 1885, 2014, 2445, 2622 Lovell, K 880 Low, AS 426, 2524, 2525 Lowe, RM 1789 Lowe, S 2044 Lowe, SE 970 Lowes, M 310 Lowin, T 39, 2082 Loza, E 1043 LU, B 123, 333, 736, 2544 Lu, C( 830 Lu, C 2084 Lu, J 1130 Lu, L 413 Lu, P 757 Lu, Q 650 Lu, QA 52, 1936

Lunzer, R 1270 Luo, S 650 Luo, W 2547 Luo, Y 1874 Luong, M 1544 Luong Nguyen, LB 2388 Lupash, D 2143 Lupton, T 2075 Luqmani, RA 2370 Lussier, B 1725 Lutalo, PM 2281, 2373 Lutfi, A 811 Lux, J 532 Luyendijk, J 1420 Luyten, FP 1802, 2328 Luzina, IG 2607 Lv, X 1132 Ly-Pen, D 1896 Lübbeke, A 1081 Lyberg, T 1052 Lydon, C 290 Lyles, KW 1114, 2589 Lyles, M 722 Lyman, S 1018

Lyman, SL 1709, 2151

Maffia, P 203

Maldonado Ficco, H 2563

March, L 411, 1093

Lynch, D 769, 2182

Magarinos, N 1777

Malfait, A 816, 1773

Marchese, MF 1401

Lynch, J 960, 2005

Magdangal, E 640

Malin, K 1899

Marchesoni, A 1201, 1294

Lynch-Jordan, A 940

Magder, LS 4, 583, 595, 596, 598, 603, 606, 607, 619, 784, 786, 1109, 1375, 1383, 1384, 1653, 1656, 1708, 1920, 2471

Malinge, P 63

Marcinska, K 2618

Malmström, V 233, 767, 822, 1658, 2161, 2179, 2341

Marcolongo, R 1453

Malorni, W 1660

Marcos, J 2563

Lyons, ET 2096 Lädermann, A 1081 Löfberg, E 2424

Maggi, F 1942

M

Magid, SK 1550 Magilavy, DB 420, 2594 Magistrelli, G 63

Ma, K 903, 905

Magnani, D 2096

Ma, KM 2260, 2274

Magnani, L 189, 1505

Ma, MH 361

Magnusson, PK 767

Ma, Y 931, 1904, 1905, 1907

Magrey, MN 870

Maamar, M 1040

Magrini, F 141

Maas, M 770, 956, 957, 2154, 2177

Magro-Checa, C 1323, 2060

Macalester, S 1058

Mahajan, S 1136

Macarrón, MP 191 Macarron, P 1043 Macaubas, C 263 Maccarone, M 1296 Macchioni, P 189, 1516 MacDonald, D 1594 MacDonald, PA 1022, 1031 MacDougald, OA 2535 Macedo, C 1241 Macfarlane, GJ 288, 880, 2370 MacGibbon, A 207 Machado, LSG 1506 Machado, P 507, 1650 Macharoni, LM 1876 Machida, T 557 Machin, S 12 Machold, KP 543 MacIntyre, NJ 88 Mack, M 423, 1227, 2227 MacKenzie, CR 2059 Mackevic, Z 2606 Mackey, R 102, 322, 388 MacKinnon, AG 2285 Mackman, N 13

Magyar, M 811 Mahler, M 708, 2298 Mahmood, F 2129 Mahmud, T 1129 Maho, M 2093 Mahomed, NN 2612 Mahoney, JM 2325 Mahowald, ML 2003 Mahr, A 858, 1865, 2388, 2389 Mahy, S 1110 Maier, B 373 Maigne, J 1068 Maijer, K 313 Maillard, S 861 Maillefert, JF 1110 Maillefert, J 1992 Mailley, T 2139 Mains, T 1286 Maisonobe, T 1955 Maisonpierre, P 43 Maiz, O 1044 Maizus, K 1644 Majgaard, O 946 Majithia, V 1117, 1286, 1393, 1411

MacMullan, PA 447, 1514, 1515, 2105

Mak, A 1371

Macrae, J 1593

Makkinje, RR 165

Maddison, P 2566 Madiai, F 663 Madigan, A 1514 Madigan, AM 447, 1515, 2105 Madruga Dias, J 1934 Madsen, OR 950, 953 Maecker, HT 54, 2571 Maeshima, A 1828 Maeshima, K 451, 1267, 2230 Maestroni, S 1051 Maetzel, A 1090 Maezawa, R 1403

Makaritsis, K 1071 Makowski, D 1550 Makris, UE 1721 Maksimowicz-McKinnon, K 1503 Maksymowych, WP 105, 140, 358, 378, 428, 448, 522, 538, 778, 955, 1312, 1320, 1326, 1649, 1836, 2545, 2633 Makul, A 675 Malamet, RL 427, 2213 Malani, S 2304 Malattia, C 283, 1973, 2012 Malchus, AM 186

Maluje, V 1963 Malysheva, O 1691 Mammen, AL 1463 Mamoto, K 405, 1100 Man, Z 1103 Mancarella, L 33 Mancera, AE 111 Mancera Romero, J 1113 Mandelin, II, AM 364, 365, 730 Manders, SH 110 Mandl, KD 747 Mandl, LA 1694, 2224 Mandl, P 174 Maneiro, JR 1197 Manek, NJ 213, 1617 Mañes, S 1832 Manetti, M 2604 Manfredi, A 688, 689, 1454 Manger, B 209, 1208, 2380 Manhard, K 1021, 1030 Manheim, L 1980, 2120, 2505, 2558 Manjarrez Orduño, N 1764 Manlhiot, C 2040 Mann, AD 2140 Mann, HF 53, 824, 1820 Mannalithara, A 611 Manning, J 2191 Manning, WC 323, 838, 1748 Manno, RL 473, 2486 Manoussakis, MN 490 Manrique-Arija, S 1113 Manson, S 916 Mansutti, E 2221 Mantel, Ä 1154 Mantonakis, L 739 Manvelian, G 1280, 1281, 1282 Many, A 936 Manzi, S 4, 591, 592, 602, 1375, 1381, 1383, 1708, 2479, 2488 Manzo, A 350 Maquet, V 1780

Marcos, JC 2563 Marcu, V 2333 Marcuz, J 749 Marder, RA 2644 Marder, W 1169, 1849, 2442 Marengo, MF 626, 2111, 2559A Maresz, K 2618 Maretzky, T 1151 Margaretten, M 2065 Margaretten, ME 799, 2107, 2610 Margolis, D 2580 Marhadour, T 474, 476, 2050 Mariampillai, K 577 Marian, V 2498 Maricic, M 1099 Marie, I 857, 860, 1500 Marie, SKN 247


Ma, DW 22, 2275, 2639

Malpeso, J 759, 762

Marcos, AI 783

Mariette, X 161, 180, 438, 452, 478, 481, 485, 488, 643, 773, 1508, 1641, 2216, 2234, 2235, 2470, 2494 Mariette for the AutoImmunity and Rituximab Registry, X 2384 Marighela, TF 680 Marijnissen, ACA 827, 972 Marin, E 1767 Marini, R 304 Marinov, A 1839 Marion, MC 305, 771, 1688 Marion-Thore, S 2494 Maritati, F 2380 Mariz, HA 1059 Markatseli, TE 529 Marklein, B 1749 Markovic, SN 1676 Markovits, D 678 Markovitz, D 1003 Marotta, A 358, 378, 428, 1836 Marotte, H 1299, 2569 Maroun, MC 629 Marques, A 507 Marques, CD 1059 Marquez, F 2071

Maradit-Kremers, H 1870, 1871

Marra, MD 1076, 1616

Maranian, P 221, 593, 716, 1025, 1037, 1493, 2133

Marrie, RA 2573 Marsal, S 1806

Marasco, E 1764

Marschke, KB 836

Marasini, B 691, 1120

Marshall, B 2338

Marcelli, C 1932

Marshall, B 2630

Marcellin, L 554

Marshall, D 2222 2011 Program Book

365

Marshall, D 1814

Martire, D 2337

Matsushita, M 1236

Marshall, L 1216

Marty, M 1068

Matsushita, T 1488

Marshall, SW 881

Maruya, E 151

Matsutani, T 1765, 1925

Marshall, T 1892, 2588

Marynchenko, M 1032, 1602

Mattera, MS 1863

Marsmann, B 1697

Marzo-Ortega, H 200, 1285, 2166, 2486F

Mattes-György, K 945

Marston, BA 1347 Martel, M 933, 1605 Martel-Pelletier, J 67, 2006 Martell, K 2078 Martelli, V 1803 Martes, MP 2140 Martin, BJ 1308

Masferrer, J 1387 Masferrer, JL 1407 Masi, AT 112 Masi, CM 1851 Masi, L 1533

Matteson, EL 121, 761, 1183, 1184, 1187, 1188, 1501, 1502, 1511, 1512, 1714, 1870, 1871, 2104, 2212, 2250, 2530 Matthews, C 159 Matthews, R 1101, 1114 Mattiuz, C 1973

Maskell, D 344

Matucci-Cerinic, M 673, 692, 1287, 1462, 1533, 1717, 2216, 2604

Martin, J 150, 157, 632, 633, 636, 637, 790, 1491, 1492, 1494, 1497, 2160, 2313, 2329, 2429, 2475

Masolini, P 2221

Matudio, G 1581

Mason, JC 1517

Matzinger, M 1633

Martin, JE 1491, 1494, 1497, 2313

Mason, II, TG 213, 1617

Mauerhan, D 1778

Masri, KR 2147

Maurer, B 702, 1462, 2536, 2605

Massardo, L 1439, 2117

Mauri, C 1662

Massardo, ML 783

Maurice-Stam, H 279

Massarotti, EM 597, 1667

Maurier, F 858, 1508

Massarotti, M 691, 1120

Maurstad, I 1586

Masse, L 2024

Maury, E 670

Mastbergen, S 827

Mausset-Bonnefont, A 2337

Mastbergen, SC 1080, 1987, 1997

Mavragani, CP 59

Masuda, I 1064, 1527, 1965

Mavrikakis, M 1178

Masuet, C 1315

Mawatari, T 540

Masui, Y 2320

Maxwell, JL 742, 1541

Mat, C 2398

May, R 991

Mateo-Soria, L 1941

Mayer, S 1689

Mateos, J 2554

Mayer, S 693

Mather, S 1274

Mayes, MD 666, 676, 1452, 1477, 1491, 1492, 1494, 1497, 1716, 2311, 2313, 2329, 2330, 2429, 2483

Martin, BC 896 Martin, C 1891


Mascia, MT 1529

Martin, KL 1264 Martin, L 105, 140, 448, 2545 Martin, P 1486 Martin, RW 710, 2055 Martin, S 1608 Martin, TJ 1815 Martin, TM 298 Martin, T 554 Martin, W 640 Martín Mola, E 355 Martín-Esteve, I 1524 Martín-Márquez, BT 250 Martin-Mola, E 1250, 2627 Martin-Mola, E 2628, 2636 Martínez, C 1042, 1897 Martinez, J 1574 Martinez, JE 1914, 1915 Martinez, ME 1963 Martinez, RJ 1590 Martinez Rivera, I 1232 Martinez-Avila, J 1614, 2226 Martínez-Barrio, J 1414, 2036 Martínez-Estupiñán, L 390, 1414, 1492, 2036 martínez-López, JA 343 Martinez-Lopez, JA 2253 Martinez-Martinez, LA 8, 726 Martinez-Martinez, MU 2251 Martínez-Morillo, M 1941 Martinez-Reyes, C 2484 Martinez-Taboada, VM 16, 17, 81, 1968 Martini, A 265, 272, 273, 283, 1686, 1964, 1973, 2009, 2012, 2452, 2454, 2621, 2622

Maska, L 392

Mathew, S 465 Mathian, A 1409 Mathian, A 19, 20, 658 Mathieu, A 1354 Mathieu, S 1254, 1265 Mathis, D 2355 Matnani, R 1674 Matos, LNJ 1572

Mazuch, J 373 Mazzantini, M 1519 Mazzotti, N 674

McClellan, SA 2085 McClinton, C 1652 McClung, MR 1107 McCollough, CH 213, 1617 McCollum, ST 1946 McCormick, J 41, 732 McCoy, S 1184 McCrindle, BW 2040 McCulloch, CE 1989 McCullough, C 1090 McCune, WJ 1849, 2264, 2371, 2442 McCurdy, DK 98, 254, 295, 593, 640, 2010, 2015, 2033, 2047, 2076 McDaniel, C 1584 McDonnell, E 771 McEvoy, MT 1870, 1871 McFadden, M 903, 905 McGarry, T 41 McGonagle, D 95, 200, 944, 1285, 1702, 1734, 2486F McGoon, MD 1471 McGowan, J 1669 McGuckin, M 1705 McGuinness, B 836 McGwin, Jr., G 1374 McGwin, G 337, 2128 McHugh, G 2344 McHugh, M 1092 McHugh, NJ 601, 605, 824, 1366, 2166 McIlraith, M 1231 McIlraith, MJ 265 McIlvane, JM 1580 McInnes, I 779, 2486D McInnes, IB 203, 1673 McIntyre-Patton, G 757 McKay, HA 965

McAdams DeMarco, M 887, 898, 1600

Mckay, J 584

Matsubara, T 457, 1263, 2108

McKee, E 1741

Matsuda, F 151

McAlear, C 1513

McKee, G 1203

Matsui, K 2187, 2396

McAlindon, T 1917

McKeeman, HM 194

Matsui, T 1478

McAlindon, TE 1033, 1078, 1998

McKenna, S 264

Matsui, Y 2063

McAlister, F 2078

McKeon, B 1065

Matsuki, F 2095

McAllister, J 2041

McKiernan, FE 1119

Matsumoto, I 492, 947, 1138, 1141, 2090

McAuley, CA 1564

McKinnon-Maksimowicz, K 1513

McBayne, T 889

McKnight-Eily, L 2542

McBeth, J 880, 1538

McLaughlin, S 1033

McBride, D 393

McLaughlin, T 1379

McBurney, M 1795

McLean, RR 800, 1554

McCann, LJ 234, 290, 2030

McLeod, L 1608

McCarberg, B 1910

McMahon, MA 593, 640, 764, 788, 1493

Matsumoto, M 15 Matsumoto, T 1011, 2340 Matsunaga, T 967 Matsuno, H 457, 2108

Martini, G 2018, 2022

Matsuo, K 151

Martini, LA 680

Matsuo, K 1725

Martino, S 2018

Matsuo, N 492

Martins Ramos, MI 1821, 1843

Matsushima, K 376

2011 Program Book

Mazdiyasni, H 1757

McCarthy, JT 2104

Mazzuca, SA 1607

Matsubara, H 1214

Martini, D 1933

366

Maynard, JW 887, 898, 1600

McCarthy, GM 447, 1514, 1515, 1722, 2105

McCarthy, CJ 1515 McCarthy, C 1514 McCarthy, E 1514, 1515

McManus, P 2041 McMurray, RW 1411, 2129

McMurtry, MS 2078

Mendoza-Pinto, C 1389

Michet, CJ 213, 1617

Milojevic, D 721

McNeil, HP 1149, 1777

Meng, D 653

Miloslavsky, E 1507

McQueen, FM 207, 210, 219, 1618

Meng, X 1259

Michinoku Tocilizumab Study Group 1272

McVie, T 412

Menga, G 646, 937

Mickholz, E 1769

Mimura, T 989, 2347

Meadows Shropshire, S 2474

Mera, A 192

Meadows-Shropshire, S 1225, 2469

Mercer, LK 426, 2524, 2525

Mealia, S 755

Meric de Bellefon, L 435

Mease, PJ 509, 535, 931, 1312, 1904, 1908, 1910, 2196, 2486A Mebus, CA 718 Medeiros, AC 709 Mediero, A 1781, 2436 Medina, G 8, 11 Medina, L 1166, 2115, 2134

Meek, IL 1054, 1157, 2002 Meffre, E 170, 1743 Mehta, B 1190 Mehta, N 1158 Mei, H 1742 Mei, H 1736 Meier, FM 1455 Meier, L 534 Meier, S 694 Meijer, J 1752 Meijide, G 408 Meiklejohn, G 203 Meineri, M 450 Meiners, PM 466, 468

Meriwether, D 763 Merkel, PA 676, 789, 792, 1503, 1513, 1521, 1522, 1536, 1537, 1867, 2366, 2367, 2368, 2369, 2371, 2432, 2439, 2440, 2546 Meroni, PL 9, 1466, 2327 Merrill, J 150, 157, 584, 632, 1387, 2476

Miese, F 945 Mieszkalski, K 2015 Mieszkalski, KL 747, 2047 Miettunen, P 2009, 2012 Miettunen, PM 1633 Migone, T 575

Mihaylova, D 2009

Merriman, TR 211, 212, 1622

Mikami, M 1139

Merry, SP 213, 1617

Mikdashi, J 2077

Mertens, B 359

Mikdashi, JA 2266

Mesa González, S 1113 Messier, SP 722

Mikecz, K 734, 816, 1008, 1755, 1921, 1928, 1929, 2335

Messing, SP 449, 2511

Mikita, J 89

Messuti, L 270

Mikkelsen, K 531, 533, 1052, 1229, 2532

Mete, M 27, 1953 Metsios, G 2125 Mettler, S 199 Meune, C 685, 1456, 1464, 1499

Meusch, U 56, 1191, 2332

Mejjad, O 315

Mewshaw, EA 89

Mekinian, A 728, 1500, 2035

Meyer, A 717, 1257

Melamed, ML 102, 1693

Meyer, AK 2277

Melchers, I 790

Meyer, CG 84

Melchiorre, D 1287

Meyer, O 530, 2384

Mellado, M 57

Mieras, K 789, 2432

Merriman, ME 211, 212, 1622

Meissner, B 1242, 2197, 2198

Meliconi, R 33, 1505

Mielants, H 430, 517

Merrill, JT 4, 591, 592, 633, 636, 637, 641, 643, 1375, 1383, 1407, 1707, 1708, 2255, 2469, 2571

Meini, A 988, 2452

Melichian, DS 2537

Midwood, K 977

Mihaescu, R 1055

Meunier, M 670, 685, 690, 1462, 1464

Melguizo Madrid, E 2169

Midtvedt, O 682

Meyers, G 1743 Meyers, JE 116 Meyuhas, R 2495 Mezieres, M 2153

Mihalko, S 722 Mihara, M 51, 1138, 1838, 2090

Min, S 564, 1638 Mina, R 2014, 2038, 2454, 2624 Mincheva-Nilsson, L 2326 Minden, K 274, 988, 2623 Mineau, F 67 Miner, JN 1030, 1592 Minevich, G 1352 Mingo, CA 1580 Mínguez, S 1941 Minnock, P 1203 Minnone, G 985 Minota, S 406, 1199, 1711 Minson, R 843 Miossi, R 709, 1723, 2614 Miraglia, J 709, 865, 2619 Miranda, V 1479, 1772, 1832 Miranda-Carus, ME 1818, 2160 Mirault, T 859 Mirjafari, H 2588 Misaki, K 1057, 2095 Misharin, A 2086 Mishler, AE 1381, 2488

Miklossy, G 2358, 2599

Mishra, R 475

Mikolaitis, RA 630, 1086, 1397, 1422, 1859, 1860, 2299

Misra, D 1118 Misra, R 1343, 1402

Mikoliatis, RA 2066

Mistou, S 980

Mikuls, TR 134, 392, 412, 634, 694, 766, 888, 1174, 1179, 1181, 1200, 1234, 1264, 1545, 1696, 2112, 2140, 2152, 2155, 2172, 2522

Mitchell, B 825, 830

Mild, M 609

Mitenko, E 292, 2626

MILES Group 1849, 2442

Mitha, E 1013, 1015

Milev, S 915, 2416

Mitra, A 1359

Milionis, HJ 529

Mitsikostas, D 739

Millán, I 1896

Mitsugi, N 1195

Miller, DP 1471

Mittoo, S 1470

Miller, DR 802

Miura, T 457, 1263, 2108

Miller, E 1078

Miwa, Y 1277

Miller, FW 235, 240, 1678

Mix, K 61

Mitchell, K 2286 Mitchell, K 2425 Mitchell, SA 2247

Mellins, ED 263, 1686

Mhatre, A 237, 238

Mello, FM 222

Miao, Y 1918

Mellström, D 1103

Micca, JL 1094

Miller, GD 722

Miyabe, C 376

Melo-Gomes, JA 2012

Miceli-Richard, C 161, 478, 481, 485, 488, 501, 773

Miller, KL 903, 905

Miyabe, Y 376

Miller, KL 1603

Miyagawa, I 2230

Michaelson, JS 555, 556, 576, 1827

Miller, K 1586

Miyamae, T 2042, 2625 Miyamoto, Y 2095

Michailidou, K 586

Miller, LC 261, 293, 2331 Miller, ML 264

Miyara, M 1409

Miller, PD 1107

Miyara, M 19, 20, 317, 658

Miller, RE 1773

Miyasaka, N 117, 376, 400, 458, 460, 1218, 1220, 2188

Melton, III, LJ 1632 Meltzer, M 2059 Melzer, M 1754 Ménard, HA 938, 1803, 1960 Menard, J 315, 1302 Menard, L 1743 Mendelson, CF 2412

Michalowicz, BS 2170, 2174 Michaud, K 1179, 1200, 1882, 1888, 2109, 2576, 2586, 2589

Mills, D 184

Mendez, R 1043

Michaud, KD 145, 422, 1174, 1610, 2112

Mendez-Martinez, S 1389

Michaud, SE 1260

Millson, D 2594

Mendonça, IV, T 1575

Michel, BA 42, 45, 46, 366, 527, 1671, 1672, 1923, 2519, 2520

Milner, JD 170

Mendoza, FA 848, 1461

Mills, M 473 Milne, GL 1391


Medsger, TA 671, 701, 844, 846, 847, 1717, 2483, 2485

Merhi, Y 724

Middelkoop, H 1420

Mimori, T 151, 225

Miyazaki, Y 2354 Miyoshi, F 2347 Mizuhara, H 1000 Mizuki, N 1041, 2431 Mizutani, T 1000 2011 Program Book

367

MMF/AZA Lupus Nephritis Main Trial, OBOTIIT 2602

Monti, G 1529

Morinobu, A 1057, 2095

Muller-Ladner, U 39, 692

Moallem, E 2495

Monticielo, OA 638

Morisset, C 1992

Mumcu, G 2387

Montiel Hernandez, JL 1232

Morlà, RM 1315

Muñiz, JR 1166, 2134

Montoro Álvarez, Sr., M 1316

Morris, M 2405

Munoz, S 759, 762

Montufar Guardado, RA 2117

Morris, M 1988

Munroe, ME 1663

Monu, J 1075

Morris, SJ 719, 1160, 1168

Muntean, M 1055

Mookherjee, N 362

Morrisey, M 122, 1114

Muntner, PM 462, 2514

Moon, Y 850

Morrison, M 1705

Muradin, GS 187

Moore, GL 1256

Morrison, S 22, 2064, 2269, 2273, 2275, 2639

Murakami, M 1765, 1925

Moore, O 194

Mosca, M 1406, 1535, 2263 Moscatelli, S 1454

Murakami, Y 458, 460

Moore, TL 287, 300, 302, 309, 1444, 2360

Moser, DW 754, 757

Moore, TM 757, 1578

Moser, KL 150, 157, 481, 489, 632, 633, 634, 636, 637, 639, 641, 642, 643, 649, 773, 1370, 1429, 1663, 1680, 2475, 2477, 2479

Moawad, D 113, 453 Mochida, Y 1195 Mody, M 1224 Mody, S 129 Moe, RH 1543 Mofti, A 1581 Mohammad, A 1521, 1522, 1866, 2440 Mohammad, J 2440 Mohan, C 564, 603, 1010, 1432, 1442, 1638, 1664


Mohan, N 962, 963 Moilanen, E 49, 1776, 1786 Moilanen, T 1776, 1786 Moinzadeh, P 677, 1481, 2327 Moir, S 170 Moisini, I 2550 Moisio, K 1085, 1087, 1982, 1985 Mok, CC 579, 924, 2118, 2256, 2260, 2274, 2276, 2295, 2296 Molad, Y 982, 2568 Molano, I 569 Molberg, O 682 Moldovan, I 2352, 2410 Molenaar, T 440, 2207 Molina, J 862 Molina-García, J 2211 Molitor, JA 695, 697, 698, 2170, 2174, 2483 Moller, B 2114, 2637 Molloy, ES 2448 Molta, CT 917, 1379 Molter, J 1789 Momohara, S 151, 163, 332, 336, 1064, 1199, 1235, 1629 Momose, Y 1410 Monach, PA 792, 1503, 1513, 2368, 2432 Monestier, M 1006, 2552 Mongey, A 1559 Monk, P 1266 Monsivais-Urenda, AE 1009 Montastruc, F 442 Montastruc, J 442 Montealegre Sanchez, GA 276 Monteanu, M 2620

Moore, J 2566

Moore, T 197, 1450, 1467 Moorehead, S 544, 1704 Moorhead, M 1339 Moorthy, LN 1376, 2624 Moosig, F 790 Moots, RJ 126 Mor-Vaknin, N 1003 Moraes, JCB 581, 709, 821, 1647, 1890, 2619 Moraes-Fontes, MF 1971 Moraes-Vasconcelos, D 304 Moral, R 1250 Morales-Blanhir, J 2484 Moran, RC 2119, 2137 Morand, E 29, 1145 Morand, EF 1400 Morehouse, C 1835 Morel, G 2384

Murphy, L 879, 882, 1978, 2508

Motamedi, K 254

Murphy, SN 1185

Motomura, S 1207

Murray, AD 2370

Motta, M 728, 1535

Murray, A 197, 1450, 1467

Moulis, G 442

Murray, CA 1336

Mouly, Jr., C 499

Murray, S 1436

Mounts, WM 1407

Murru, V 24, 25, 26

Mountz, JD 2097, 2246, 2248, 2348, 2362

Murtaugh, M 715, 903, 905

Moura, RA 1934, 2521

Murthy, NS 213, 1617

Mourão, AF 1317, 1934 Mourot, L 424, 2220 Mouterde, G 2050

Mouy, R 2021

Moreland, LW 135, 148, 322, 337, 388, 392, 393, 412, 844, 1545, 1696, 2128, 2143, 2150, 2155, 2157, 2516, 2642

Movig, K 2002

Morgan, A 861 Morgan, AW 344, 463 Morgan, BP 2433 Morgan, CL 429, 1233

Movsisyan, MM 684 Moyaghedi, R 1743 Moyer-Mileur, LJ 903, 905 Mozaffarian, N 417, 2228 Mpofu, C 126 Mpofu, S 401 Mubashir, AM 2110, 2126 Muchhal, US 1256 Mudd, J 693 Mueller, BA 1875 Mueller, DL 1590

Morgan, C 1893, 1895

Mueller, F 1689, 2145

Morgan, G 32, 248, 252, 819, 992, 2007

Mueller, M 789, 792, 2432 Mueller, R 527, 2637

Morgan, R 2572

Muhammad, K 1733, 1750

Morgan, X 612, 1913

Muiños, E 2426

Montes-Cortes, DH 665

Morgan DeWitt, E 282, 612, 1578, 1885, 2061, 2492

Muir, L 1450, 1467

Montgomery, C 773, 2475

Morgan DeWitt, EM 278, 754

Montgomery, CG 481, 489, 636, 637, 643, 649, 1370, 1680

Mori, M 2625

Mukherjee, A 1259

Montecucco, CM 1954 Montecucco, C 350 Monteiro, CMC 2559B Monteiro, J 414, 1792 Montero-Duarte, K 2484

368

2011 Program Book

Morimoto, C 1137

Muratore, F 189 Murphy, FT 1246, 2250

Morel, P 1932

Morgaceva, O 716

Murase, T 1571

Mosley-Williams, AD 2110, 2126

Moutsopoulos, HM 490

Moreno-Valdes, R 2251

Murasawa, A 151

Murfitt, L 23

Morel, L 1768

Moreno, M 1315

Muraoka, S 382

Mosialos, G 1640

Morel, J 443, 488, 2384, 2528

Morency, N 522, 538, 778, 1649

Muramoto, K 376

Moser, T 2006

Mouthon, L 681, 858, 1863, 2368, 2379

Morelos-Guzman, M 2484

Murakami, S 621, 1171

Mukai, T 2099 Mullan, RH 1176, 1296 Muller, L 284

Murthy, B 404, 1225 Murthy, VL 726 Mus, A 50, 2499 Musayev, O 1525 Muscal, E 94, 1396, 2624 Mushtaq, N 1856 MUSICIAN study team 880 Musselman, D 1642 Musser, TK 420, 2594 Musset, L 608 Musset, L 1587 Musset, L 19, 20, 230, 658, 791 Muth, T 131, 1852, 1854 Muthalaly, A 1962 Muthalaly, A 1962 Muthana, M 1845 Muther, J 1741 Muto, A 1115 Mutoh, S 1000 Mutti, A 935 Mydel, P 2618 Myers, JA 2406 Myles, A 294 Myles, JD 2590 Müller, A 2377 Müller, M 1496 Müller-Ladner, U 35, 381, 1455, 1823, 1825 Myones, BL 1396

Nakano, K 369, 385, 451, 1267, 2230, 2517

Neary, B 1767, 2498

Nicklin, MJ 75

Mysler, EF 402

Nakano, M 621, 1171

Nebbaki, SS 80

Nicolau, Jr., J 315

Märker-Hermann, E 777, 2486B

Nakase, T 2195

Neeck, G 1830

Nicolls, MR 1471

Möller, B 1156

Nakashima, R 225

Neel, A 1500, 1510

Nicolò, C 2343

Möttönen, T 966

Nakashima, S 967

Negrao, CE 1572

Niederer, F 46, 1923

Møller, J 950

Nakashima, Y 540

Neidhart, M 366, 2520

Niederreiter, B 31

Møller, JM 953

Nakatsue, T 621

Nelson, JL 2330

Nielsen, CT 652, 1926

Nelson, R 1106

Nielsen, FC 253

Nelson, SL 612, 2014, 2038, 2454

Nielsen, S 283

Nelson, S 170

Nielson, W 2489

Nemery, B 2328

Nieminen, R 49, 1776, 1786

Nemes, C 1055

Nieto, J 1405

Nemes, D 1055

Nieto, JC 1414, 2036

Nemeth, MA 741

Niewold, TB 456, 632, 633, 636, 637, 641, 642, 1372, 1423, 1429, 1663, 2475, 2476, 2477, 2601

N Nab, H 429, 1288 Nacht, M 1757 Nader, G 822 Nadig, A 632 Nadji, A 2386 Nadkarni, A 1240 Nadkarni, S 1517 Nagaeva, O 2326 Nagahori, M 2402 Nagai, T 1276, 1475 Nagai, Y 320 Nagakura, Y 1606 Nagaoka, S 2194 Nagaraja, V 1056 Nagasawa, H 1237, 1239 Nagashima, M 1124 Nagashima, S 1000 Nagatani, K 406 Naglak, M 1066 Nagle, SJ 848 Naguwa, SM 206 Nahir, MA 678 Naides, SJ 1888 Naimark, D 118 Nair, A 816 Nair, D 666 Nair, KV 893 Nair, RG 2110, 2126 Nair, SC 127 Naka, EL 2559B Naka, I 1057 Nakagawa, H 15, 2310 Nakagomi, D 179 Nakajima, A 332, 336, 1199, 1235 Nakajima, H 179 Nakajima, T 2080 Nakamachi, Y 493 Nakamura, H 407, 1213, 1215, 2192 Nakamura, H 318, 368 Nakamura, H 405, 1100 Nakamura, K 1434 Nakamura, N 1082 Nakamura, T 457, 1263, 2108 Nakamura, Y 1207 Nakano, H 2187

Nakouzi, AS 2552 Nam, EJ 2587 Nam, JL 463, 944, 2465 Namchuk, M 1136 Namour, F 2210, 2237 Nampei, A 1571 Nanda, K 276 Naniwa, T 1193 Nanki, T 117, 376 Nanovic, K 1565 Naot, D 210 Napalkov, P 433 Naparstek, Y 2495 Narang, N 244 Naranjo, A 298, 2268 Narazaki, M 2243 Naredo, E 2144 Narita, H 1139 Narita, I 621, 1171 Narvaez, J 1524 Narwal, R 1394 Nascif, A 2026 Naselli, A 273, 1973 Nash, PT 2592 Nash, PT 402, 403, 404 Nashel, J 1451 Nasonov, EL 402, 444, 1645, 1646, 2237, 2242, 2628 Nasr, S 1398 Nath, S 1681 Natour, J 1067, 1569, 1719 Natter, MD 747 Naushad, SM 1431 Navalho, M 1934 Navaratnam, P 897 Navarra, S 413, 578, 1859 Navarra, S 602 Navarro Compán, V 2169 Navarro Sarabia, F 2169 Navarro-Blasco, F 2216 Navarro-Millan, I 335 Navarro-Zarza, JE 95, 1595 Navarta, DA 175, 188 Nawata, M 451, 1237, 1239, 1267, 2468 Nayiager, S 2630 Nazarian, A 414 Nduaka, CI 407, 409 Neale, H 1814

Neogi, T 742, 744, 871, 1073, 1089, 1118, 1541, 1627, 1628, 1724, 2560

Nigg, A 1689, 2145

Neovius, M 459, 1206, 1884, 2515, 2523

Nigg, AP 186, 387

Neri, R 1406, 2263

Nigro, A 1289

Nerome, Y 267, 297 Neumann, E 35, 39, 381, 1823, 1825 Nevarez, S 2504 Neville, C 2064 Nevitt, MC 742, 744, 871, 960, 1076, 1089, 1541, 1616, 1624, 1627, 1628, 1724, 1984, 1986, 1989, 1991, 1993, 1995, 2005, 2560 Newcomb, C 2580 Newkirk, MM 765 Newman, ED 753, 755 Newsom-Davis, T 2356 Ng, CT 391 Ng, J 2430 Ng, W 481, 643, 773 Ng, Y 1743 Ngcozana, T 1573 Ngian, G 843 Ngo, D 1145 Nguyen, C 1801 Nguyen, JX 1484 Nguyen, NU 424 Nguyen, USD 797, 1542, 1993, 2553, 2643 Nguyen, V 651 nicaise-Roland, P 728, 2035 Nicassio, PM 2119, 2137, 2410 Nicchitta, CV 367, 2086

Nightingale, P 2125 Nigrovic, PA 282, 1143, 1639, 2293 Nihtyanova, S 677 Niiro, H 1766 Nijpels, G 760 Nikai, E 2270 Nikitorowicz Buniak, J 1485 Nikolov, NP 482 Nikpour, M 843, 2259 Nilganuwong, S 1268 Nilsson, J 2148, 2440 Nimmerjahn, F 1140 Ning, T 214, 1594 Ning, Y 1128, 2526 Nisell, R 1226 Nishida, K 2099 Nishida, N 163 Nishii, T 1082 Nishimoto, N 1765, 1925 Nishimoto, T 2165 Nishimura, K 1057 Nishiyama, KK 1631 Nishiyama, Y 967 Nishizaki, Y 99 Nissan, S 1868 Nissen, MJ 2637 Nissim, A 1274 Nitiham, J 2162 Nititham, J 161, 485

Nicholson, TF 535, 1612, 2486A

Niu, J 742, 797, 871, 1089, 1541, 1542, 1624, 1627, 1628, 1724, 1979, 1984, 1986, 1989, 1991, 1993, 2005, 2553, 2560, 2643

Nickerson, K 723

Niu, S 71

Nickerson, P 362, 2139

Nived, O 4, 1375, 1383, 1708

Nickerson-Nutter, CL 565, 834, 1621, 1758

NOAC study group, AT 1012

Nicklas, BJ 722

Nobuhara, Y 493

Nicklin, J 2425

Nocturne, G 161

Nicholls, K 2469 Nicholls, SJ 547, 552


Myositis Genetics Consortium 1678

Noamani, B 852

2011 Program Book

369

Noel, D 1790, 2100

O’Malley, C 904

Oikonen, V 966

Nogués, X 829

O’Neil, KM 256, 721, 2014, 2453, 2454, 2455

Ojeda, S 2268

O’Neill, T 78

Okada, A 318, 368

Noh, JW 1192 Nojima, Y 1828

O’Rourke, KS 1594

Nolan, KB 447

O’Sullivan, B 2430

Nolla, JM 1524 Nomura, A 1959, 2063 Nonaka, Y 267, 297 Noort, A 733 Noort van der Laan, W 1570 Nordenskiold, U 2555 Nordgren, B 2613


Nordin, A 1491, 1497

O’Sullivan, D 1296 O’Sullivan, D 917 O’Sullivan, JN 391, 1829 O’Toole, J 1728 O’Toole, M 1407 OAI Investigators 830 Oates, JC 641

Nordmark, G 481, 643, 773, 1441, 2480

Oates, JA 1391

Nordström, DC 444, 1645, 1646, 2242

Obici, L 988, 2022

Norman, H 433

Ocal, L 1328

Normand, R 1931 Noronha, C 1971 Norris, J 769 Norris, JM 100, 766, 1663 Norton, H 1778 Nossent, JC 486, 996 Notarstefano, C 471 Nourjah, P 801 Nowell, MA 2500 Nowling, TK 1377, 2363 Nozaki, S 202

Oatis, CA 797, 1565 Obry, A 1932 Öcal, L 2305 Ocaña, S 1311 Ochi, T 1925 Odai, T 1277 Odani, T 2310 Oddis, CV 229, 240, 1714 Oddone, EZ 1582 Odeh, M 1345 Odinson, A 1102 Odom, E 882

Nozawa, K 467

Oen, K 152, 256, 269, 863, 1633, 2455

Nozawa, T 2042

Oeser, A 587, 588

Nunes, H 230

Oeser, AM 1391, 2121, 2280

Nuñez-Alvarez, C 1404

Oezer, U 2216

Nuño, L 2160, 2636

Ogale, S 453, 1262, 2219

Nunokawa, T 320

Ogata, A 2243

Nurmikko, T 737

Ogata, H 44

Nurmohamed, MT 419, 425, 439, 760, 1175, 1278

Ogawa, F 1482

Nuutila, P 966

Ogawa, T 2123

Nyberg, F 1268, 2116 Nüesch, E 1996 Nyirenda, T 2453 Nyren, S 2176 Nyrop, KA 1583, 2418 Nys, M 2191 Nzeusseu Toukap, A 435, 1927

O

Ogawa, K 2123

Okamoto, A 853 Okamoto, H 1711 Okamoto, KYK 862 Okamoto, Y 947 Okamoto, Y 227, 615 Okamura, K 1236 Okano, T 405, 1100 Okawa, J 249, 617 Okazaki, K 540 Okazaki, Y 1489 Oksanen, S 2570 Okubo, A 179 Okuda, K 457, 1263, 2108 Okumura, M 991 Okumus, M 926 Okuyama, T 1810 Olariu, R 1055 Olasz, K 1929, 2335 Oldroyd, AGS 1097, 1105 Olea, JL 1045 Olech, E 434, 948, 2196 Olejeme, KA 239 Olenginski, TP 753, 1597 Olferiev, M 1424, 1438, 1807 Olivé, A 1941 Oliveira, ACD 1506 Oliveira, HA 1569 Oliveira, JB 304 Oliveira, R 1241 Oliveira, RM 1647 Oliveira, S 2009

Onel, K 282, 2014, 2454 Onen, F 541, 550, 1525, 1974 Ong, HL 775 Ong, V 677, 1466, 1481, 1573, 2324, 2327 Onishi, A 1057 Onishi, S 1011, 2340 Ono, M 1351, 1434 Onofrei, AU 2595 Onofrei, R 1055 Ooka, K 1819, 2537 Oostra, B 2162 Opava, CH 2613 Oppermann, BP 753 Oprenyeszk, F 1780 Orange, DE 2151 Orange, J 992 Oravecz, T 2593 Orbai, A 4, 1375, 1383, 1653, 1708 Orcel, P 1108 Ordóñez, MC 1113 Oreiro, N 2420, 2554 Orellana, C 104 Oren, A 934 Orhan, C 2083, 2094 Oribe, M 457 Origasa, H 1218, 1220 Origuchi, T 318, 368 Orme, ME 2247 Ormseth, MJ 2121, 2280 Ornetti, P 1110, 1992 Ortega-Larrocea, G 1045

Ortiz, AM 57, 343, 1173, 2160 Ortiz, P 2316

Ollier, WE 1678

Ortiz Garcia, AM 319

Olofsson, T 2515

Ortiz Panozo, JE 1232

Olsen, NJ 1432

Ortiz-Santamaria, V 1315

Olsen C, I 1170

Ortloff, L 2352

Olson, AL 687

Ortmann, R 454

Olson, JC 2014

Ortmann, W 837, 2480

Omair, M 1476

Osborne, RH 796

Ombrello, AK 302, 2028

Oshikawa, H 2187, 2396

Ombrello, MJ 170, 1686, 2431

Osman, M 2067

Omdal, R 481, 643, 773

Ososki, R 629

OMERACT Flare Working Group 342

Ospelt, C 46, 366, 832, 989, 1672, 1923, 2520

Ohtsuka, K 66

OMERACT Ultrasound Task Force 807

Ossipova, E 2179

Ohwada, T 1403

Omma, A 1328, 2300

Oster, N 532

Ogura, T 2123 Oh, C 169, 171, 1070, 1936 Oh, HJ 2345 Oh, H 76, 850 Oh, JS 1027, 1970 Oh, L 1136

O’Connor, CM 1114, 2589

Ohinmaa, A 140, 448, 2545

O’Dell, JR 392, 412, 766, 1179, 1696, 2112

Ohishi, M 540

O’Donnell, S 1881

Ohrmund, L 1266

2011 Program Book

Okada, T 400

Onat, D 1438

Olivieri, I 1289, 2390

Ohara, Y 1959, 2063, 2396

370

Okada, M 99, 1959, 2063, 2396

Onat, AM 1279, 1951

Oliveira, SA 581

Ogishima, H 947

O’Connor, CR 1969, 1975

O’Leary, DH 1164

Okada, J 1475

on behalf of the SCQM Rheumatologists 527

Ortego-Centeno, N 1045, 1492, 1494

Ogino, S 1606

Oh, TH 941, 1909

O’Hanlon, T 1678

Okada, H 1403

on behalf of the BSRBR, . 2524

Oliveira, SK 304

Ogdie, A 508, 782, 2533

O’Connell, PG 1722

O’Gorman, M 992

Ojwang, JO 642

on behalf of DISTOL Investigators 2483

Ohmura, K 151, 225 Ohrndorf, S 176, 198

Ostendorf, B 945

Ostergaard, M 955, 1334

Pagnoux, C 858, 2368, 2372, 2379

Papo, T 608

Parsons, HM 1735

Østergaard, M 394, 399, 946, 950, 953, 1258

Pahau, H 2430

Papoutsis, N 2388

Parsons, LS 1471

Østergaard, O 652, 1926

Paik, JJ 1460, 1463

Pappas, DA 1189, 1262

Pasche, B 2311

Paira, S 1177, 2563

Pappu, R 402, 2190

Pascoli, L 275

Paisansinsup, T 334, 1036

PARA 2010 Study group 2613

Pascual-Montano, A 1832

Paiva, ES 1914, 1915

Paramarta, J 1305

Palacin, A 1358

Paramarta, JE 521

Pascual-Salcedo, D 355, 1250, 2160, 2636

Palacios, S 1104

Parameswaran, V 876

Palanichamy, A 1733, 1739, 2186, 2504

Paran, D 1300, 1944

Palazzi, C 1289

Paringe, V 2433

Östör, A 2218 Ostrowski, RA 2449 Ota, S 1766 Ota, T 1956 Ota, Y 227, 615, 706, 1483, 1965, 2319 Otawa, SM 2205 Oterino, A 1968 Otomo, K 15, 2310 Otón-Sánchez, T 2290 Otsa, K 1296

Palermo, G 399 Paller, A 818 Pallot-Prades, B 1299 Palm, O 1491, 1497 Palmano, K 207

Ottaviani, S 530 Otten, MH 258, 286 Ottery, FD 2582 Ottosson, C 1549

Palmer, D 808, 1690 Palmer, E 1767 Palmer, G 61, 1794, 1824, 2434

Ou, J 263, 1430

Palmer, RH 738, 931, 1609, 1904, 1905, 1907, 1908

Outman, RC 1106

Palmer, S 746

Ovalles, JG 1414, 2036

Palmisani, E 272

Owczarczyk, K 837

Palmisano, A 855

Owen, T 2186

Palshina, SG 1530

Oxburgh, L 1839

Palumbo, K 2321, 2427, 2535, 2538, 2539, 2540

Oyoo, O 1902

Pamer, EG 2518

Ozaki, LS 862

Pamuk, GE 1279

Ozaki, N 202

Pamuk, ON 1279

Ozcan, E 1292

Pan, N 1709, 1807

Ozdemir, F 2391 Ozdogan, H 166, 168, 1947

Pan, S 624

Parish, M 2182 Park, D 627, 1399, 1620 Park, E 1413 Park, G 2445 Park, GS 326, 1217 Park, H 889 Park, JL 1686 Park, JA 659 Park, JK 2376 Park, J 850 Park, K 2101 Park, K 1636 Park, K 491 Park, L 1136 Park, M 987 Park, MJ 1636 Park, M 1346, 2088 Park, SH 77, 1165, 2131 Park, S 1620 Park, S 659 Park, S 109, 125

Ozen, S 1686, 2009

Pan, Y 130

Ozgen, M 1142, 1837, 2081, 2083, 2094

Pandey, C 954 Pandis, I 832

Ozgon, G 168, 1947

Pandit, S 1066

Park, SH 437

Özlük, Y 2300

Pandya, BJ 890, 891, 1032, 1602, 1604, 2048

Park, SH 125 Park, SH 479, 2345

Pandya, J 233, 822

Park, S 484, 2183

Pane, I 438, 1641, 2234

Park, S 76

Panepento, B 544, 1704, 2504

Park, W 1049, 1966

Panero, B 1113

Park, Y 2183

Pangallo, B 1916

Park, Y 1346, 2088, 2101

Pangan, A 1312, 2486A

Park, Y 627, 1399, 1620

Panopalis, P 932, 938, 1605, 1803, 1906, 1960, 2073

Park, YE 77, 1165, 2131

Panoulas, VF 349

Park, Y 2158

Ozyazgan, Y 2398

P Paassen, P 672 Pablos, JL 1358, 1479, 1772, 1806, 1832, 2316, 2349 Pachman, LM 32, 248, 252, 819, 992, 1678, 2007 Packham, J 2166 Padeh, S 2333 Padilla, O 1439, 2117

Pans, M 2190

Padula, A 1289

Pantigoso, D 1883

Padyukov, L 59, 842, 1441, 1677, 1678, 1682, 2161

Paolazzi, G 2390 Pap, T 34, 1150, 1797, 1938

Paediatric Rheumatology International Trials Organisation 2622

Papadakis, K 1863

Paessler, ME 1683 Page, T 977 Paget, SA 93 Paggiaro, P 2381

Papagoras, C 529, 699 Papalardo, E 726 Papamichael, C 1178 Papapoulos, S 1103 Papas, AS 465 Papneja, A 1388

Park, S 1380, 1648 Park, S 987

Park, Y 1380 Parker, L 1573

Pasic, S 2009 Pasoto, SG 581 Pasotto, S 1890 Pasparakis, M 1640 Pasquali, J 554 Pasquet, B 530 Passalent, LA 1729, 1730, 1731, 1732 Passo, MH 2061 Passos, G 1241 Patel, AM 135, 148, 393, 844, 2143, 2150, 2516 Patel, A 1117 Patel, DR 2364 Patel, J 169 Patel, NJ 1949


Otsuki, N 1137

Pardeo, M 2621

Pashinian, N 2445

Patel, PN 505, 2531 Patel, S 1129 Paternotte, S 1283 Paterson, E 1652 Pathan, E 1652 Patil, P 2225 Patkar, NM 801 Pato, E 1042, 1043 Patrizi, A 2018 Patten, WF 1888 Patterson, C 194 Patton, EP 86 Patwardhan, A 245, 246, 758 Patwardhan, B 1251, 1255 Patwardhan, K 184 Pau, E 566, 570, 852 Paudyal, P 288 Pauer, L 971 Paul, N 447 Paul, S 2430 Paul, S 1299 Pauley, BA 231, 232 Paulissen, SM 2357

Parker, R 1680

Paulus, HE 221, 235, 254, 634, 764, 2133

Parkinson, A 1296

Pauly, T 1938

Parkkola, R 966

Pavani, A 1431

Parks, CG 102, 1857, 1858, 2173 Parpucu, H 926

Pavelka, K 53, 444, 517, 1645, 1646, 1699, 1817, 1887, 2242

Parra, ER 1486

Pavenstädt, H 34

Parrino, J 2071

Pavlov, A 1642

Parrish, EJ 93

Pavy, S 478, 2050

Parsa, MF 98, 254, 295, 593, 2033, 2076

Pawar, R 575, 2552 Pawar, V 547, 552 2011 Program Book

371

Pawlita, M 1644

Perchenet, L 1863

Peters, T 1117

Paxton, LA 1075

Perdriger, A 488

Peters-Golden, M 1003

Pay, S 1886, 2385

Pereira, A 2026

Petersen, B 769

Payet, S 1265

Pereira, B 514, 810, 1254, 1265

Peterson, EJ 820

Payne, J 766

Pereira, D 524, 537

Peterson, M 1259

Pazarán, O 1389

Pereira, J 932

Peterson, T 154, 265, 1699, 2216

Peace, AJ 447

Pereira, KM 600

Peacock, M 1107

Pereira, RM 304, 812, 865, 899, 1647, 2016, 2020, 2037, 2046

Petersson, IF 348, 436, 459, 2229, 2509, 2513, 2515

Pearce, W 787, 1446 Pearson, PG 1026 Peccin, MS 1562 Pecha, O 53, 1817 Pedersen, JK 1258


Pedersen, R 441, 1284, 1291, 2239 Pedersen, SJ 950, 953, 955, 1320 Pedersen, TR 502, 1170, 1186, 1293

Pereira da Silva, JA 507, 1792, 1934 Pereira Da-Silva, J 507 Perez Alamino, R 2563 Pérez Ferro, M 2253 Perez Leiros, C 494 Perez-Aso, M 2322 Pérez-Esteban, S 319, 1173

Petri, M 578, 584, 591, 592, 613, 1367, 1416, 2265, 2476, 2479 Petri, M 228, 250

Piera-Velazquez, S 675, 1461, 2317, 2318 Pierangeli, SS 12, 13, 14, 23, 613, 723, 726 Pierer, M 1191 Pierga, J 1048 Pietrogrande, M 1529 Piette, J 19, 20, 577, 1373, 1409, 1955, 2394, 2395, 2399, 2450 Piette, YP 1448 Piga, M 1354

Petri, M 3, 4, 583, 585, 595, 596, 598, 603, 606, 607, 609, 619, 622, 628, 784, 786, 1109, 1374, 1375, 1378, 1383, 1384, 1392, 1426, 1653, 1655, 1656, 1707, 1708, 1712, 1767, 1853, 1903, 1919, 1920, 2038, 2443, 2471

Pike, M 2265

Petricca, L 270

Pillet, P 2021

Petrich, J 713

Pillinger, MH 223, 1083, 2518

Petrie, KJ 219

Pimentel-Santos, F 507, 1317

Pike, MC 1378 Pilkington, C 861, 2012, 2039 Pilkington, CA 234, 235 Pill, M 146 Pillemer, SR 482

Pediatric Rheumatology Collaborative Study Group [PRCSG] 2622

Pérez-Lorenzo, MJ 2349

Pedraza, I 769

Perez-Pampin, E 192

Petrofsky, J 1069

Pedroso, JL 2397

Perez-Ruiz, F 208, 220, 1021

Petronis, J 473

Pincus, T 124, 331, 1894, 2052, 2053, 2058

Peeters, A 418

Perez-Sanchez, C 725, 1437

Petrou, M 970

Pineau, CA 1196, 2064, 2254

Pego-Reigosa, JM 2290

Pericleous, C 14, 23, 2279, 2288

Petruc, M 2057

Pineda, L 578, 584

Pehlivan, Y 1279, 1951

Perl, A 657, 1660, 1661, 2358, 2599

Petter, R 1757

Pinheiro, FAG 1506

Pettinger, M 102

Pinheiro, MM 680

Perlman, HR 1010, 1153, 2086, 2102, 2103

Petturson, F 2438

Pinkhassik, E 1798

Pernis, A 2549

Petty, RE 262

Pinney, AJ 2317, 2318, 2569

Petursson, F 1791

Pinsky, BW 890, 891, 1604

Pfatschbacher, J 2428

Pinto, ALS 1566, 1572, 1723, 2614

Pfeffer, S 978, 1001

Pinto, P 1317

Pfeiffer, C 1455

Pioltelli, P 1529

Pfirrmann, CW 1077

Pipitone, N 189, 1505, 1520, 2390

Pfister, H 1644

Piroth, C 1110

Pham, T 149, 2234

Piroth, L 1110

Pehlivan, Ö 1328, 2300, 2305 Peikert, T 2432 Peixoto, D 507 Pek, EA 2282 Pelajo, C 271 Pelajo, CF 261, 278, 281, 293 Pellerito, R 1462 Pelletier, JP 67, 80, 1625, 1725, 2006

Pérez-Martín, I 81, 1044, 1950, 1968

Pernis, AB 567 Perno, JR 218 Perpétuo, IP 414, 1792 Perretti, M 1517 Perrot, S 683, 1048, 1981

Pelletier, JM 80, 1625, 1725

Perruccio, AV 2612

Pellett, F 524, 781, 1331, 1353, 1357, 1360, 1361, 1362, 1363, 1364, 1365

Perry, E 1526 Perry, H 1735

PHAROS Investigators 701, 1715, 1716

Pisetsky, DS 45, 2278

Peloquin, C 908, 1118, 1521, 1522, 1599, 2643

Perry, M 1494

Philipot, D 1790

Pers, J 474, 476

Pistello, M 1942

Philipp, A 532

Pers, Y 1007

Pistorio, A 272, 2009, 2012

Philippe, L 978, 1001

Persad, P 2411

Pittman-Hobbs, SR 2056

Phillips, A 1565

Persad, PG 867

Pittrow, D 1714

Phillips, K 1621

Persselin, JE 221

Pitts-Kiefer, MA 414

Pértega, S 2420

Phillips, K 676, 1468, 1714, 2317, 2318

Pitzalis, C 374, 375, 1274

Peruzzi, B 1589

Phillips, PE 2599

Pesáková, V 1817

Phillips, Z 2451 Phippard, DJ 789, 2432

Penn, H 1466

Peschken, CA 152, 362, 609, 768, 1204, 1717, 1862, 2139, 2163, 2573

Pennathur, S 2547

Petchprapa, C 1070

Pennison, M 2311

Peter, H 2374

Piantoni, S 9

Peoples, C 671, 701

Peter, W 1668

Pepe, P 471, 1519, 2381, 2382

Peter, WF 2423

Pepmueller, PH 302

Peterfy, CG 434, 1612

Peralta, MV 759, 762

Peters, E 120

Perandini, LA 1566, 1723, 2614

Peters, K 1397

Perard, L 608

Peters, MA 1938

Perazzio, SF 660, 2307

Peters, MJ 760, 1175

Pemberton, MK 2049 Pemberton, P 1415 Pena, AS 1792 Peña, P 542, 1301 Pendl, JD 612, 2014, 2038 Pendurthi, MK 1411 Pendurthi, M 1393 Peng, B 1678

372

2011 Program Book

Phipps-Green, A 211, 212 Phumethum, V 1476 Piao, C 98 Picavet, H 1054, 1157 Picco, P 273 Pichot, A 1001 Pickard, SG 1234

Piskin, O 1319

Piva, SR 1560, 1561, 2611 Pizzorni, C 1474 Plaisier, E 857, 860 Planas, E 1518 Planck, SR 75, 986, 1342 Plant, D 164, 344 Plantinga, Y 2263 Plasencia, C 1250, 2636 Plass, N 60, 310, 2451 Plass, P 818 Platt, R 1196

Pickens, SR 729, 730

Plenge, RM 167, 1185, 1677, 1679, 1682, 1888, 2156, 2162

Pieper, C 214, 1536, 1537

Plestilová, L 53, 824 Plontke, S 1976

Plou, MS 1401

Porta, F 1287

Przepiera-Bedzak, H 1309

Poddubnyy, D 515, 777, 1338, 2486B, 2534

Porter, D 1233

Ptacek, T 995

Poggenborg, RP 953

Possemato, N 185

Pu, D 1132

Posthumus, M 352

Puechal, X 485, 488, 858, 1508, 2384

Pohl, C 342 Pohle, S 1140 Poiley, JE 2593 Pointer, LM 1181 Poiraudeau, S 1863 Polak, A 1987 Polak, J 1182 Polido-Pereira, J 507, 1792, 1934 Pollak-Dorocic, I 2161 Pollard, R 1752 Pollino-Tanner, JA 1550 Pollock, R 524, 1357, 1360, 1361 Polyak, JL 929, 1577 Polydefkis, M 472 Pomés, I 182, 1972 Pomés, J 182, 1972 Pompei, O 16, 17, 81, 1045, 1950, 1968 Ponce, A 191 Poncet, C 1224, 1238, 2209, 2231, 2232 Ponchel, F 1643 Ponder, L 271, 281, 289 Pong, E 1256 Ponge, TD 1510 Pongrácz, V 201 Pongratz, G 1754 Pons Estel, B 1177 Pons-Estel, B 632, 633, 636, 783, 2475 Pons-Estel, BA 2117 Pons-Estel, GJ 783

Postiglione, L 1945 Potempa, J 2522, 2618 Potier, M 372 Poulin-Costello, M 1249 Poulos, C 453 Poulton, K 18 Pouplin, S 315 Pourrat, O 608, 728 Pouyol, F 2050 Povsic, T 2047 Poynard, T 2620 Poynter, PS 1850 Prabu, A 601, 605 Pradel, V 149 Prado, DML 1723, 2614

Raaschou, P 2523

Puenea, G 1055 Pugliese, DM 755 Pullman-Mooar, SW 218, 1092

Radacs, M 1755

Punturieri, A 1003

Radcliffe, H 1108

Punzi, L 1201, 2221

Radenska-Lopovok, SG 684

Puranik, AS 1251, 1255

Radfar, L 489

Purcaru, O 1245, 2214

Radhakrishna, SM 2624

Purvey, S 598

Radkar, A 1251, 1255

Puskas, GJ 1081

Radominski, SC 409, 1103

Putterman, C 21, 509, 555, 556, 575, 576, 597, 618, 640, 1306, 1432, 1655, 1693, 1827, 2552, 2634

Radstake, T 1491, 1497, 1678

Puzenat, E 681

Prajapati, R 344

Q

Prakash, S 1025, 1037

Preiss, R 2622 Prencipe, G 985 Prescott, GJ 880 Preston, R 1526 Prestridge, A 248 Presumey, J 1007, 2428 Prete, PE 2238

Pons-Estel on behalf of GENLES, B 1681

Price, LL 1078, 1998

Pool, B 210

Prieto-Alhambra, D 829

Poole, CD 429, 1233

Prieto-González, S 1518, 1523

Poole, C 1857

Primdahl, J 1665

Poole, JL 1567, 2412

Prince, FH 258, 286, 333, 2575

Popa, C 1180, 2585

Princic, N 1547

Popa, D 1055

Prins, J 2417

Pope, E 2453

Prinz, JC 186

Pope, J 338, 339, 696, 708, 1249, 2185

Prisco, E 1954

Pope, JE 325, 610, 736, 1198, 1222, 1230, 1447, 1449, 1717, 1889, 2064, 2141, 2202, 2457, 2483

Propert, K 249

Pope, R 1446

Proudman, S 843, 1093

Pope, RM 364, 365, 367, 729, 1004, 2085, 2086, 2311

Provan, S 513, 519, 1170

Porawska, W 402

Provenza, JR 1914, 1915

Porras, M 542

Pruhs, Z 1174

Porras, O 2009

Pruijn, GJ 1747

Porru, G 1354

Pruunsild, C 283

Pricop, L 966

Pritchard, CH 1066, 1946 Protogerou, A 1163, 1178 Prots, I 2164

Proven, A 2559C

Rabquer, BJ 36, 38, 2547 Rachlis, AC 749

Pødenphant, J 394

Precioso, AR 581, 821

Rabois, E 1254

Punaro, MG 612, 721, 2014, 2015, 2047, 2453, 2624

Praino, E 1047

Pratt, AG 386

Rabinovich, EC 1885, 2023, 2453

Raches, CM 1876

Puujalka, E 2359

Prati, C 501

Rabinovich, A 2504

Pulsatelli, L 33, 1505

Prahalad, S 271, 281, 282, 289, 293, 1686

Prasla, K 889

Rabatin, VX 1865

Qi, K 403, 404 Qian, G 1398 Qian, Y 1626 Qin, Y 1126 Qing, Y 61, 1824, 2434


Pollock, J 1557

Posthumus, MD 1159, 1161, 2459

R

Radstake, TR 165 Radstake, TR 2313, 2329, 2537 Raffayova, H 517, 543 Raffeiner, B 1201 Rafferty, G 242 Ragavendra, N 788, 1493 Raggi, P 587, 588, 2280 Raghavan, S 233 Ragle, RL 2172 Ragoussis, J 832 Rahat, M 1868 Rahman, AAP 1357, 1361

Qingshun, L 562

Rahman, A 14, 18, 23, 591, 592, 601, 605, 2279, 2288

Qiu, J 69

Rahman, A 1813

Qiu, Y 2084

Rahman, MU 413

Qu, B 1922

Rahman, M 804

Quach, HL 645

Rahman, P 522, 1332, 1364, 1649

Quandt, D 56, 1191, 2332

Rahme, E 2193

Quart, B 1021, 1030

Rainer, F 1270

Quartier, P 298, 2012, 2021, 2622

Rajalingam, R 295

Quartuccio, L 1529, 2221

Rajan, R 1949

Quattrocchi, E 916

Rajappa, SM 1504

Quemeneur, T 1508

Rajasekhar, L 1431

Quentin, J 2337

Rakovitis, K 1911, 1912, 2421

QUEST-RA 2462

Rakowicz, AM 1550

Quevedo, J 2268

Ralston, SH 1935

Quinet, R 646, 937

Ramanujan, S 43, 361

Quinn, M 463, 2465

Ramessar, N 921

Quinn, S 876

Ramez, M 1348

Quinn, III, WJ 575

Ramhorst, R 494

Quinones, M 2077

Ramirez, J 1205

Quinones, R 2007 Quintana, R 1177

Ramirez, J 182, 450, 1358, 1806, 1972

Quintero, MV 304

Ramirez, R 52, 1936

Quirk, M 640

Ramiro, S 507

Quirke, A 2522

Ramiro, S 355, 1250

Quismorio, FP 2551

Ramnoruth, N 2430

Qureshi, AA 101, 500, 1291

Ramon, G 7, 727, 1390, 2308

Qureshi, F 323, 1748

Ramoni, V 669, 1954 2011 Program Book

373

Ramos, I 2599

Raya-Alvarez, E 1323, 2060

Reid, IR 207

Ramos, PS 305, 641, 771, 2479

Raychaudhuri, SP 206, 1359

Reid, R 1090

Ramos-Casals, M 609, 1529

Raychaudhuri, SK 1359

Reid, WD 1564

Ramot, Y 818

Raychaudhuri, S 167, 1677, 1682, 2156

Reiff, A 265, 2445

Rampakakis, E 1222, 1548 Ramsey-Goldman, R 4, 256, 586, 591, 592, 597, 609, 648, 787, 1374, 1375, 1383, 1446, 1708, 2271, 2455, 2476 Ramwadhdoebe, TH 770, 2177 Ranchin, B 2029 Rand, JH 21, 1684 Randels, M 2121 Randolf, A 1133


Ranganath, VK 254, 764 Ranganathan, P 1169 Rankin, AL 565, 1758 Rantapaa-Dahlqvist, SM 312, 2178 Rantapää Dahlqvist, S 839, 1156 Ranz, JV 757, 1578 Ranzolin, A 1059, 1914, 1915 Rao, S 1683 Rao, S 1312, 1326 Rao, V 1642 Rao, V 1621 Rapoport, MJ 2568 Rascati, K 889 Rascón, J 609 Rashid, N 888 Rashkov, R 2470 Rasmussen, A 2475 Rasmussen, M 1993 Rasmussen, SS 872 Rassen, J 803 Rastogi, A 949 Rasu, R 259 Rat, A 132 Raterman, HG 439, 1175 Rath, E 31 Rathbun, A 1262 Rathore, RKS 954 Ratzlaff, CR 2507 Rau, R 1697 Rauch, J 724 Rauch, L 2082 Rauch, TA 1008, 1928, 1929, 2335 Raun, J 394 Ravagnani, V 2221

Reilly, C 557, 571

Raza, K 366

Reimold, AM 134, 1174, 1181, 1200, 1234, 1264, 2056, 2140, 2152

Ribeiro, C 1317

Reindl, C 387, 1689, 2145

Ribeiro, RPC 1566

Razaeian, P 759, 762 ReACCh Out Study Group 269 Reach, JS 83 Reaume, M 749 Rech, Sr., J 209, 964, 1611, 1615, 2380, 2527 Rech, J 1208 Recillas-Gispert, C 2272 Recknor, C 805, 1098 Recknor, J 805 Recuero, S 2253 Reczko, M 832 Redden, D 337 Redden, DT 1106, 2128 Redden, L 1698, 1699 Reddy, PS 1407 Reddy, R 1266 Reddy, SM 2518

Reinhardt, A 818 Reis Neto, ET 2559B Reiser, M 1321 Reiss, AB 1808 Reiss, W 142 Reitblat, T 517 Reiter, K 1742 Reith, W 2336 Rekalov, D 2237 Remmers, E 1686, 2431 Remmers, EF 170 Remst, DF 1726 Ren, J 1106 Ren, P 1958, 2084 Ren, T 1371

Ribeiro, ACM 581, 821, 1647, 1890, 2619 Ribeiro, LS 1914, 1915 Ribeiro, LHC 1067, 1719 Ribi, C 2379 Riblet, NB 2051 Ribstein, J 2528 Ricca, LR 2241 Ricci, M 1294 Riccieri, V 673, 1459 Riccio, A 1945 Richard, D 1019 Richard, M 681 Richards, D 1586 Richards, HB 401 Richards, JS 1234, 1264, 2140 Richards, JS 2152 Richards, S 2561

Rendal, E 2426

Richardson, BC 150, 157, 632, 2350, 2364, 2476

Rennebohm, RM 245, 246

Richardson, M 626, 2111, 2559A

Renner, J 1544, 1552

Richardson, S 386

Renoux, J 1955

Riches, PL 1935

Reece, RJ 2465

Repo, H 2570

Richesson, R 1536, 1537

Reed, AM 820, 1678, 2019, 2027, 2034

Resch, H 1103

Richette, P 2050, 2384

Resche Rigon, M 859, 2394, 2399

Richey, MC 1550, 1666, 2411

Reed, G 108, 326, 509, 1189, 1262, 1306, 1310, 2595, 2634

Research Group (CSRG), CS 1447, 2311

Richman, L 1834, 1835

Reed, J 1440

Resende, C 1934

Reed, JH 752, 772

Ress, R 966

Richmond, JC 1065

Reed, MR 300

RESTART Clinical Investigators 2215

Reddy, ST 763, 764, 1918 Redecha, PM 994, 1443 Redecker, S 2234 Reece, R 463

Reed, T 1756 Reedquist, K 82 Reeve, BB 2418 Reeves, ER 1707 Reeves, WH 228, 232, 1768 Regardt, M 1549 Reginster, J 1103, 1116 Regna, N 571 Regnault, V 10 Rego-Pérez, I 2420

Reich, A 1268

Ravera, F 1473, 1474

Reich, N 2321

Rehman, A 1948 Reich, H 1398, 2269 Reichenbach, S 1077, 1996

Rawdon, J 1387

Reichmann, WM 877, 884, 900, 2510

Rawstron, A 1643, 1734, 2252

Reid, A 1559

Ray, DW 78, 2463

Reid, DM 2370

2011 Program Book

Ria, F 2343

Raynauld, J 2006

Ravelli, A 234, 272, 273, 2009, 2012, 2454

374

Rhodus, NL 481, 489, 643, 773

Raymond, E 560

Rehart, S 35, 381, 1823, 1825

Rawat, G 2291

Rhodes, B 998

Reijnierse, M 516, 1072, 1074, 1295

Ravaud, P 438, 488, 1508, 1641, 1981, 2234

Ravindran, P 1148

Rho, YH 217, 587, 588, 908, 1599, 2280, 2576, 2643

Restrepo, JF 111, 1164, 2142 Restuccia, G 189 Reveille, JD 153, 505, 518, 1374, 1452, 1494, 2329, 2330, 2476, 2531

Richman, NC 2130 Richter, JG 131, 1852, 1854 Rickert, M 381, 1823, 1825 Rickman, AD 1381, 2488 Riddell, C 1334 Ridene, M 317 Rider, LG 235, 240, 1678 Ridjab, DA 1155

Revu, S 55

Riebschleger, MP 266

Reyes-Canu, JC 1550

Rielly, C 242

Reyes-Thomas, J 597

Riemekasten, G 673, 1455, 1462, 1491, 1495, 1496, 1497, 1717, 2312

Reyes-Utrera, C 2484 Reyna, V 120 Reyner, P 1315 Reynisdottir, G 2176, 2179 Reynolds, A 1233 Reynolds, JA 78 Reynolds, RJ 337, 2128, 2157 Rezaei, H 2229, 2513 Rezende, MC 1914, 1915 Rezvani, A 1292

Riente, L 185 Riese, R 2627 Rifkin, D 1824, 2434 Rigby, W 427, 2196 Rigby, WFC 1261, 2159, 2213 Rigolet, A 230 Rigter, GMM 1591 Rillo, O 2563 Rimar, D 1868 Rincheval, N 311

Ringe, J 1104

Rodríguez-Pérez, M 1113

Rose, CD 298

Rubbert-Roth, A 2217

Ringold, S 278, 721

Rodriguez-Reyna, TS 2484

Rose, JA 1585

Rubin, LA 2562

Ríos, V 1311

Rodriguez-Rodriguez, L 383

Rose, SM 1153, 2102, 2103

Rucatti, GG 638

Riscado, MV 1971

Rodriguez-Vargas, AI 1166, 2134

Rose-John, S 1146

Rucci, N 1589

Rischmueller, M 481, 486, 643, 773, 996

Roebuck-Spencer, T 2008

Roseman, C 398

Rucco, M 703

Riskowski, JL 1553, 1554, 1556, 2543

Roelofs, PA 2175

Rosen, C 524, 537, 1332

Rudnisky, C 2067

Roemer, F 959, 960, 1073, 1076, 1616, 1624, 2005

Rosen, CE 1484

Rudwaleit, M 515, 777, 1329, 1338, 2486B, 2534

Roger, J 1739, 1744

Rosenberg, AM 256, 863, 2455

Riso, N 1971 Risser, RC 1094 Rist, S 488

Roger, VL 761 Rogers, P 137, 1877

Rosenbaum, JT 75, 856, 986, 1342 Rosenberg, A 1744, 1767

Rueda, B 2160, 2329 Rueda, J 1950, 1968 Ruff, V 1099

Rosenblatt, L 1221, 1240, 1242, 2198

Rufibach, K 955, 1320, 2633

Rohde, G 1125

Ruhí, R 1897

Rohrer, M 489

Rosenblum, GC 1808

Ruivard, M 858

Roivainen, AM 966

Rosenblum, RA 2297

Ruiz, A 2636

Rojkovich, B 2630

Rosenfeld, A 1719

Ruiz, P 557

Rokutanda, R 1959, 2063

Rosengren, S 196, 1809, 2159

Ruiz -Esquide, V 1205

Rolita, L 911

Rosenthal, AK 1800

Ruiz Esquide, V 316, 450

Roll, P 1733, 1736, 1750

Rosenthal, PB 2518

Ruiz Heiland, G 1788

Rollefstad, S 1186

Rosenzwajg, M 577, 791, 1753

Ruiz-Esquide, V 2138

Rollins, KD 2483

Rosenzweig, HL 75, 986, 1342

Ruiz-Heiland, G 1338

Román Ivorra, JA 1103

Roskams, T 298

Ruiz-Irastorza, G 609, 1405

Román Ivorra, JA 2218

Roske, A 177, 1244, 1271

Ruiz-Limon, P 725, 1437

Romano, E 2604

Roskos, L 1394

Ruiz-Romero, C 2554

Romas, E 1815

Rosner, IA 1345

Rullier, P 857, 860

Romay-Penabad, Z 12, 13, 723

Ross, K 203

Romberg, N 170

Ross, SJ 228, 231, 232

Rullo, OJ 98, 254, 295, 593, 640, 2010, 2033, 2076

Rome, BN 877, 884, 900, 2510

Rossi, A 942

Romero, F 2253

Rossi, F 189

Romero Sanchez, C 542

Rossol, M 56, 1191, 2332

Romero-Barco, CM 1113

Roth, D 1416, 2472

Robinson, BE 1106

Romero-Diaz, J 591, 592, 2272

Roth, J 97, 306, 1012, 1633, 1793

Robinson, DB 152, 765, 768, 1204, 2163

Romero-Sanchez, C 1301

Roth, SH 1999

Romeu, J 1792

Roth-Wojcicki, EL 2032

Robinson, R 1910

Romick-Rosendale, L 2038

Rothe, K 1191

Robinson, W 322, 1748, 2170

Rommel, C 37

Rothfield, NF 714, 2483

Robinson, WH 100, 388, 766

Romo-Tena, J 854

Rothman, D 2293

Robles, M 2190

Ronday, H 2200, 2207

Rouanet, S 452, 1243, 2494

Roblin, DW 1106

Ronday, H 440

Roussy, J 2193

Rockwitz, K 1697

Ronis, T 2054

Routsias, J 1937

Rodd, C 1633

Ronnblom, L 1428, 1441, 2478

Roux, C 1098, 1103, 1116

Roddy, JE 843

Ronneberger, MR 548

Rouyer, O 717

Rode, M 2372

Rooney, M 275, 307, 623

Rovensky, J 543

Rodevand, E 1229

Rooney, P 732

Rovere, P 728

Rodrigues, AM 414, 1792, 1934

Rooney, P 47

Rovin, BH 1417, 2276

Rodrigues, MC 304

Roos, EM 1088

Rowzee, A 1937

Rodrigues, SH 2307

Roosen, P 2149

Roy, J 2580

Rodriguez, MA 2351

Roque, R 507

Rozenberg, S 1068

Rodriguez, VA 1758

Rosa, CM 1934

Rozenblyum, EV 2045

Rodriguez-Almaraz, E 7

Rosa, J 175, 188, 1177

Rozin, AP 678

Rodriguez-Ariza, A 725, 1437

Rosa, LG 1792

Rozman, B 42, 480

Rodríguez-Cambrón, AB 1042, 2062

Rosales, AG 1106

Rozmovits, L 1731

Rodríguez-Gallego, C 306

Rosales, Z 1042, 1043, 2062

Rua Elorduy, MJ 988

Rosales-Alexander, JL 1323, 2060

Rua-Figueroa, I 2268

Rosas-Gómez de Salazar, J 2211

Rúa-Figueroa, Í 2290

Rosato, E 1459

Ruaro, B 1473, 1474

Roschel, H 1566, 1572, 1723, 2614

Rubbert, A 1644

Ritchlin, CT 204, 544, 1075, 1332, 1347, 1704, 2089, 2493, 2504 Ritterhouse, LL 54, 2571 Rittner, L 2257 Riveiro-Naveira, RR 48 Rivera, J 662, 664 Rix, MM 1106 Rizzelli, GM 1406 Robbie, G 1394 Robbins, L 93 Robert, S 1816 Roberts, BK 2584 Roberts, JR 89 Roberts, M 470 Roberts, R 421 Roberts-Thomson, PJ 251 Robertson, DH 500, 1284, 1291 Robertson, JM 2601 Robinson, AB 276, 2019, 2027, 2034

Rodriguez-García, V 1113 Rodriguez-Lozano, C 2268 Rodriguez-Pardo, M 30

Rogovitz, A 1844


Rosenberg, WM 704

Ristori, JM 514

Rumba, I 283 Runde, G 2049 Rungta, D 836 Ruocco, H 2257 Rupasree, Y 1431 Ruperto, N 240, 988, 2621 Ruperto, N 265, 272, 283, 612, 2009, 2012, 2014, 2622 Ruprecht, J 264 Rus, H 651 Rus, V 651, 2077 Russell, AF 2071 Russell, E 183, 1975 Russo, RA 2069 Ruta, S 175, 188 Ruth, JH 38, 731, 1619 Ruutu, M 1705 Ruyssen-Witrand, A 2050, 2153 Ruzek, M 1621, 1758 Ryan, JW 714 Rybak, L 1070 Rybicki, BA 643, 1680 Rybicki for ACCESS, BA 481 Ryder, C 2039 Ryffel, B 1924 Ryu, JH 2212 Ryu, JG 2345 Ryu, J 850 Ryu, J 2629 Ryu, Y 479 2011 Program Book

375

Rönnblom, L 2480, 2496 Rönnelid, J 1658 Rødevand, E 531, 533, 2532

S S.Akhavan, P 339, 1198, 1889 Saad, CG 581, 709, 821, 865, 1647, 1890, 2619 Saad, S 936 Saadoun, D 1409


Saadoun, D 577, 791, 859, 1528, 1743, 1753, 2394, 2395, 2399, 2450, 2620 Saag, KG 122, 462, 801, 803, 806, 888, 1015, 1101, 1106, 1114, 1121, 1219, 2514 Saake, M 2527 Saas, P 1738 Saavedra, MA 250 Saavedra-Salinas, MA 95, 1595 Sabatini, D 2358 Sabatini, P 1945 Sabharwal, T 620 Sachs, P 769, 2182 Sacli, FS 2398, 2431 Sacnun, MP 2117 Saddic, N 686 Sadeghi Abdollahi, B 2386 Sadim, M 2311 Sadosky, A 1986 Saegusa, J 493, 2095 Saevarsdottir, S 842, 2229, 2513 Saez, L 609 Safford, MM 1106 Sagawa, A 457, 2108 Sagcal-Gironella, ACP 751, 2008, 2011, 2456 Sague, S 415 Saha, C 1607 Saha, GC 2584 Sahakian, L 640, 788 Sahhar, J 843 Sahin, K 1142, 2081, 2083, 2094 Sahin, N 2081, 2083 Sahin, N 2094 Sahinkaya, Y 2305 Sahoo, P 954 Sahu, R 2550 Sai, Y 1958, 2084 Said Mardani, SM 2392

Saito, K 369, 451, 1199, 1237, 1239, 1267, 2194, 2230, 2244, 2402, 2468 Saito, T 1195, 2625 Saji, H 151 Sajuthi, S 771 Sakai, R 117 Sakai, T 1082 Sakairi, T 1828

Sanchez Lombarte, A 1296

Sasaki, Y 51

Sánchez-Barrioluengo, M 2211

Saseen, JJ 893

Sanchez-Guerrero, J 4, 591, 592, 602, 1375, 1383, 1404, 1708, 2272

Sato, EI 609, 968, 1506, 2559B

Sanchez-Madrid, F 30

Sato, H 621

Sánchez-Olaso, A 1896 Sanchez-Pernaute, O 2253 Sandal, LF 1088

Sander, O 582, 945

Saketkoo, LA 679, 1470, 1714

Sanderson, T 342

Sakkas, LI 1071

Sandhu, A 1446

Sakurai, D 639, 2477

Sandler, D 2173

Sakurai, N 1828

Sandling, JK 2480

Sakurai, T 457, 2108

Sandoo, A 2125

Sala, M 1315

Sandorfi, N 1714

Salaffi, F 1201

Sandoval Rios, M 1232

Salas-Heredia, E 2211

Sandoval- Garcia, F 250

Salazar-Páramo, M 250

Sands, A 2593

Salbato, J 1266

Sanford, T 470, 1767

Sale, J 886, 2506

Sangiolo, M 1945

Salem, D 724

Sangle, S 620, 631, 1526, 2281, 2373, 2378, 2383

Saunders, KC 108, 326, 509, 1310

Sanmarti, R 316, 1205

Saurenmann, RK 284, 291

Salers, P 1816 Salgado, E 1197 Salgado-Pires, S 977 Salituro, F 1136

Sanmarti, R 450, 1358, 1806, 2138 Sanna, G 24, 25, 26

Sallum, AM 247, 2016, 2020

Sano, Y 2629

Salmon, JE 93, 640, 994, 1151, 1438, 1443, 1707, 2255

Sansonno, D 1529 Santalena, G 935

Salom, D 1045

Santana-de Anda, K 1009

Salomao, R 660

Santer, DM 997

Salonen, D 549

Santiago-Casas, YC 1374

Salt, EG 868, 2404, 2406

Santos, A 542, 1301

Saltzherr, MS 187

Santos, H 507, 1317

Salvador, G 1205, 1315

Santos, M 507

Salvadorini, G 1287

Santos-Moreno, P 321

Salvarani, C 189, 855, 1505, 1516, 1520, 1532, 2390

Santos-Ramírez, C 2211

Salvatierra, G 2563

Santra, S 154, 1612, 1698, 1699

Salvatierra, Sr., J 1323, 2060

Santos-Soler, G 2211

Sato, S 1472, 1480, 1482, 1759, 2320 Sato, S 226, 227, 236 Sato-Hayashizaki, A 562 Satoh, M 228, 231, 232, 845, 1768 Satorius, C 1686, 2431 Sattar, N 1642, 2588 Sattler, H 176, 178 Satumtira, N 990, 1350 Satyanarayanajois, S 40 Saucedo, C 175, 188, 1177 Sauer, BC 1234, 1264 Saul, M 135, 148, 393, 2143, 2150, 2516 Saurel, C 1085, 1087, 1982, 1985 Saurit, V 1177 Savage, E 275 Sawalha, A 2391 Sawalha, AH 150, 156, 157, 632, 642, 1681, 2476 Sawamukai, N 451, 1267, 2230, 2244 Sawitzke, AD 1707 Saxena, A 771 Saxena, R 1432, 1442 Saxne, T 352 Saxne, T 348, 432, 1692 Saxne, TV 398 Sayarlioglu, M 1279, 1951 Sayles, H 1174, 1200

Sanz, I 470, 2493

Sayre, EC 138, 965, 1846

Sanz, I 1739, 1744, 1767, 2498, 2504

Scalco, R 638

Salzberger, B 1943

Scali, J 2217

Samapati, R 1495

Saougou, I 529

Scanzello, CR 816, 1065

Sammaritano, LR 1707

Saral, I 930

Scarpa, R 1945

Sammut, A 1182

Saraux, A 180, 474, 476, 488, 2235, 2638

Scarpato, S 1529

Sarbu, E 1055

Scazzariello, F 1287

Salvi, F 2390

Sampalis, JS 1222, 1548, 2205 Sampson, B 306 Sampson, R 1962 Samsi, SS 1417

Sardano, E 185 Sari, I 550, 1319 Sarkin, A 895

Sailler, L 442

Saruhan-Direskeneli, G 2391

Sainani, NI 1713

Samukawa, S 809

Saint Marcoux, F 2029

San Pedro, M 2610

Sarzi-Puttini, P 126, 935, 1201, 2390

Saint-Cyr, C 1633

Sanchez, C 1780, 1795

Sasaki, K 1193

Sanchez, E 150, 157, 632, 642, 2476

Sasaki, Y 1434

2011 Program Book

Sato, M 66

Sakellariou, G 350

Samuels, J 124, 169, 171, 223, 1070, 1083, 1936, 2445, 2518

376

Sato, K 2347

Sakamaki, Y 1218, 1220

Sarkar, S 2501

Saiki, O 1273

Sato, H 1172

Sandborg, CI 747, 2015, 2017, 2047, 2054, 2068

Samson, M 2379

Said-Nahal, R 1340

Sato, E 1237, 1239, 2194

Sasaki, R 51

Scarpellini, P 1942 Schabert, VF 915, 2416 Schachna, L 1308 Schacter, I 768 Schaefer-Cutillo, J 1744 Schaeverbeke, T 438, 1641, 2234, 2245 Schafer, P 1844 Schaid, DJ 1676 Schalkwijk, J 2446

Schanberg, LE 256, 280, 721, 747, 1885, 2014, 2015, 2047, 2454, 2455 Scharbatke, EC 363 Scharf, C 2011 Schasfoort, RB 1747 Schatz, A 2332 Schau, T 1155 Schechtman, J 1248 Scheers-Masters, J 1593 Scheet, P 1678 Scheffer, H 165 Scheinecker, C 31, 817, 1657, 2359 Scheinman, RI 831 Schelbergen, R 1012, 1793 Scher*, JU 2518 Scherer, A 527, 2637 Scherer, A 945

Scholey, J 2269 Scholz, J 1627 Scholz, R 1191 Schoster, BL 1544, 1545, 1583 Schott, P 198 Schouffoer, A 416 Schousboe, JT 334, 1036, 1634 Schramm, A 1588 Schramm, MA 387, 2164 Schreiber, BE 2482 Schreiber, E 399 Schroeder, Jr., HW 1763 Schroeder, S 284 Schue, JR 826 Schuerwegh, A 672, 1491, 1497 Schulz, A 1191, 2332 Schulz, M 1830

SECURE study investigators group 117

Sestak, AL 639

Sedano, MJ 1968

Seth, N 834

Seddighzadeh, M 842 Sedova, L 1887 Seeger, JD 1599 Seehaus, M 2411 Seel, S 177, 1271 Seeman, E 1631 Sefik, E 2355 Segal, BM 481, 489, 643, 773 Segal, M 1768 Segal, N 1624, 1993, 1995 Segbers-Lokate, AM 1747 Segelmark, M 1866 Seguro, LP 581, 2037 Sehnert, B 1140 Seibold, JR 676, 1714, 2317, 2483

Seta, N 2165 Seto, Y 332, 336, 1235 Sevak, S 2055 Severa, M 375 Seward, RJ 2344 Sewerin, P 945 Seyahi, E 2393, 2398, 2431 Seyfert, C 1938 Seyhan, A 1407 Seys, P 440 Sfikakis, PP 1178 Sfikakis, P 739, 1163, 1202 Sfriso, P 1201 Sgarlat, CM 261, 293 Shaban, N 714 Shadick, NA 333, 634, 1679, 2575

Schulze-Koops, H 779

Seid, M 2492

Schulze-Koops, H 154, 186, 387, 1689, 2145, 2164

Seidel, M 1455 Seitz, M 1779

Schumacher, HR 1016, 1019, 1029

Sejismundo, LP 789, 2432

Shah, AA 693, 720, 1458, 1460, 2429, 2486

Schumacher, HR 218, 1013, 1014, 1015, 1023, 1024, 1092

Sekigawa, I 467

Shah, A 1034

Schett, GA 780

Schumacher, R 1888

Sekine, C 1804

Shah, D 2378

Schiavon, F 2221

Schumacher, U 381, 2377

Sekine, H 557

Shah, M 1379

Schickel, J 554

Schumann, M 1750

Sekiyama, J 1457

Shah, N 1381, 1983, 2488

Schieir, O 114, 798

Schwab, P 1174, 1200, 2152

Selamnia, AM 149

Shahane, A 475

Schiff, MH 1217, 1224, 1252, 2191

Schwartz, TA 1545, 2642

Sellam, J 2384, 2494

Shahani, B 928

Schilling, A 96, 1953

Schwartzman, S 2151

Sellas Fernandez, A 1315

Shahouri, SH 2147

Schindler, SC 1588

Schwartzman-Morris, JS 509, 1306, 2634

Selles, RW 187

Shahram, F 2386

Selva O’Callaghan, A 1678

Shahrara, S 364, 365, 729, 730, 835

Scherman, D 1007 Schett, G 209, 327, 538, 548, 807, 964, 1140, 1208, 1338, 1588, 1611, 1615, 1630, 1761, 1788, 1825, 2321, 2380, 2427, 2527, 2535, 2538, 2539, 2540, 2606, 2628

Schiopu, E 1468, 2483 Schjerling, P 253 Schlemmer, A 394 Schlesinger, N 1016, 1019, 1020, 1028, 1029 Schlesinger, N 1898 Schlienger, K 2071 Schlink, BR 1990 Schmajuk, G 2065, 2073, 2578 Schmid, M 1177 Schmidt, J 1501, 1502, 1512 Schmidt, RE 790, 2529 Schmidt, S 964, 1615 Schmidt, WA 176, 178, 1244 Schmidt-Wilcke, T 970 Schmitz, S 2422 Schmitz-Bortz, E 503, 506 Schned, ES 334 Schneeweiss, S 116, 123 Schneider, M 2270 Schneider, M 6, 131, 327, 461, 582, 945, 1852, 1854 Schneider, R 282, 1729, 1730, 1731, 1732, 2621 Schnute, ME 1758 Schoeb, TR 1763

Schwarz, EM 204, 1635, 1704, 2089, 2493 Schwenke, C 198, 199 Schwetje, E 1458 Schäffler, A 1823 Sciascia, S 24, 25, 26 Scinocca, M 2185 Scioscia, C 1047 Scleroderma Clinical Trials Consortium (SCTC) 1447 Scofield, RH 481, 641, 643, 773, 1856 Scofield, RH 157, 489, 634 Scolnik, M 611 Scopelitis, E 937

Semanik, PA 1558, 1980, 2120, 2505, 2558


Schemitsch, E 2612

Schoindre, Y 577, 1373

Shaffer, M 897 Shah, A 1223

Shakibaei, M 1897

Semb, AG 502, 513, 519, 1170, 1186, 1293

Shakoor, N 1086, 1088, 1089, 1990, 1995

Semedo, P 2559B

Shan, Y 108, 1189, 1310

Seminara, N 508, 782

Shang, L 977

Sen, E 1292

Shang, Q 1167, 2249

Sen, G 1319

Shanmugam, VK 27, 96, 686, 1953

Senabre-Gallego, JM 2211

Shanmugarajah, S 537, 544, 1353

Sène, D 488, 1528, 1955, 2450, 2620

Shapira, E 982

Seneca, N 966

Shapiro, LS 1716

Senolt, L 53, 1817, 1820, 2321, 2519, 2538 Sensky, T 106

Scott, DL 224, 241, 242, 243, 361

Seo, P 789, 792, 1503, 1513, 2368, 2432

Scott, IC 2373

Seo, WJ 1970

Scott, K 971

Seppänen, M 966

Screaton, GR 2356

Sepriano, A 1792

Scrivo, R 1296

Serafini, B 375

Scuccimarri, R 1633

Serezani, CH 1003

Seagal, O 1002

Seriolo, B 1473

Seary, ME 2481

Sernissi, F 942, 1942

Sebag, M 1803

Seror, R 478, 488, 858

Sebastiani, M 688, 689, 1454

Servy, H 149

Sebba, A 2217, 2241

Sesseng, S 1623

Shapira, Y 480 Sharif, R 505, 1477, 2429, 2531 Sharma, A 2630 Sharma, A 2077 Sharma, H 1032, 1602 Sharma, K 954 Sharma, L 1085, 1087, 1624, 1982, 1985, 2505 Sharma, P 122 Sharplin, P 1720 Shashkova, S 2618 Shaver, TS 2147 Shaw, C 1756 Shaw, ML 2201 Shaw, S 43, 1814 2011 Program Book

377

Shaykevich, T 123, 2441

Shinjo, SK 247, 821, 2046

Shea, S 1182

Shinozaki, N 357

Sheen, D 1337, 2167

Shintani, A 587, 588, 2280

Sheeran, TP 126

Shintre, P 1251, 1255

Sheets, M 1757

Shiozawa, K 379, 1810

Sheikh, A 818

Shiozawa, S 379, 993, 1139, 1810, 1930, 2194, 2354

Sheikh, S 1594 Sheikh, S 748 Shekhani, MT 1637 Shelton, DK 206 Shen, B 155 Shen, H 1958 Shen, H 1303, 1330


Shen, M 834, 1621 Shen, N 1922 Shen, S 789 Shen, W 1958 Shen, Y 351, 838, 1613 Shen, Z 1030 Shen, Z 2560 Sheng, S 2631, 2632 Shenoi, S 263, 1875 Shenouda, N 1633 Shenvi, N 2444 Sheriff, MK 2205 Sherrer, YRS 2110, 2126 Sherry, DD 2015, 2043, 2047 Shi, B 1004 Shi, D 655 Shi, K 1571 Shi, L 1426

Shir, Y 932, 933, 938, 1605, 1906 Shirai, T 1434 Shirai, Y 236 Shivashankar, R 2530 Shiwen, X 1485, 2324 Shlomchik, MJ 723 Shlyakhter, D 1136 Shmerling, RH 797 Shnayder, R 1143 Shock, T 1742 Shoenfeld, Y 480 Shoindre, Y 859 Shojania, K 1846 Shoji, T 1218 Shono, E 457, 2108 Shott, S 1577, 1900, 2408, 2409, 2564 Shpilsky, A 1020, 1028 Shrestha, LK 1119 Shrestha, S 252, 819, 992 Shu, Q 1619 Shupak, R 1729, 1730, 1731, 1732 Siaton, BC 84 Sibbitt, WL 193

Silverman, ED 2015, 2045, 2047, 2455

Skold, M 2176, 2179

Sim, S 772

Skversky, A 1693

Simard, JF 1206, 1884, 2515, 2523 Simeón, CP 1492 Simeon, CP 1491, 1494 Siminovitch, KA 152, 167, 378, 1682, 2163 Simkin, PA 1800 Simms, RW 676, 2483 Simms, T 875 Simon, A 73, 2446 Simon, C 1697 Simon, I 1591 Simon, LS 2001 Simon Campos, JA 402 Simonetta, M 1954 Simonini, G 288 Sims, NA 1815 Simsek, I 1886, 2385 Sinclair, L 1731 Sindel, D 930 Singbrant, S 1815 Singer, NG 276, 1789, 2014, 2015, 2047, 2454 Singh, A 1343 Singh, G 611, 2001 Singh, J 235, 742, 894, 895, 1541 Singh, JA 744, 890, 891, 892, 1063, 1604 Singh, J 1757 Singh, M 139

Shi, N 113

Sibilia, J 438, 452, 488, 717, 774, 978, 1001, 1257, 1500, 1641, 2218, 2494

Shi, W 1924

Sibley, CH 2451

Singh, RP 2289

Shibanuma, N 379

Sieger, N 1742

Singh, RR 1493

Shibuya, E 1041

Siegrist, J 131, 1852

Singh, S 1266

Shidara, K 332, 336, 1235

Siemowski, J 1932

Singh, S 1428

Shields, K 1259, 2630

Sieper, J 517, 779, 2486D

Singwe-Ngandeu, M 160

Shiels, P 1491

Sinha, I 2617

Shilagard, T 723

Sieper, J 515, 546, 777, 1329, 1338, 2486A, 2486B, 2534

Shim, J 109, 125

Sierakowski, S 397, 673 Siff, SJ 878, 885

Sipe, JD 112

Shim, SC 1337, 2167 Shima, Y 2243

Siitonen, S 2570

Sippel, D 135, 393, 2143, 2150, 2516

Shimada, H 967

Sikora, KA 757, 1685

Sirvent, E 1315

Shimada, K 1794

Silber, JL 2071

Sitler, MR 1977

Shimada, K 151, 320, 345

Silva, AE 2559B

Situnayake, D 589

Shimizu, H 1959, 2063

Silva, C 507

Siva, C 2057

Shimizu, K 1482

Silva, C 2619

Six, A 791

Shimizu, Y 1000, 1606

Silva, CA 247, 304, 581, 821, 865, 2016, 2020, 2046

Sjowall, C 1421

Silva, CAA 303, 1647

Skamra, C 1446

Shi, L 1032, 1602

Shimonaka, Y 51 Shin, JY 987 Shin, JJ 975 Shin, K 324, 1149 Shin, SY 2490, 2491 Shin, Y 491 Shinada, S 2410 Shiner, E 1594 378 2011 Program Book

Silva, NP 660, 2307, 2559B Silva, NA 304, 783 Silva-Sanchez, A 1763 Silver, RM 2015, 2047, 2483 Silverfield, JC 407

Singh, MK 1025, 1037 Singh, N 427, 2213

Sinico, R 2380

Skaggs, B 572, 788 Skapenko, A 154, 387, 2164 Skipper, B 1567 Skjødt, H 1258 Skogh, T 1421, 2180 Skoie, IM 1125 Skol, AD 633

Skriner, K 840, 1749 Slachevsky, A 1439 Slade, K 1683, 2502 Slatkowsky-Christensen, B 1623 Slattery, M 903, 905 Slaven, J 1607 Sleeman, MA 2092 Sleptsova, T 292, 2626 SLICC investigators 2254 Slobodin, G 1345 Slobodin, GM 990 Sloetjes, A 1012, 1144, 1793 Slot, H 2407 Slot, O 953 Smail, A 608 Smale, S 1146 Small, A 929, 2564 Small, BJ 1900, 2408 Smarr, KL 2057 Smedby, T 1156 Smets, B 2210 Smith, DD 826 Smith, EA 337, 1545, 2128, 2155, 2157, 2642 Smith, G 536, 2323 Smith, JP 2125 Smith, K 203 Smith, K 1741 Smith, K 1372 Smith, MD 1274 Smith, M 2070 Smith, M 1594 Smith, MD 828, 1095, 1096 Smith, S 1767 Smith, TW 146 Smith, V 1448, 1474, 1497 Smolen, J 31, 154, 328, 543, 817, 1216, 1231, 1245, 1296, 1614, 1657, 1698, 1699, 2146, 2189, 2209, 2214, 2250, 2359, 2631, 2632 Smolen, JS 410, 1224, 1612, 2226, 2232 Smolik, I 152, 765, 768, 1204 Smuczek, J 1449 Smulders, YM 760, 1175 Snell, E 847 Snir, O 2341 Snow, K 992 Snyder, C 2451 So, A 1016, 1019, 1020, 1028, 1029 So, MW 1027, 1833, 1970 Sobel, ES 228, 232, 1768 Soboleva, N 373 Socci, N 2518

Soejima, M 393, 823, 844, 979

Souza, EJ 1914, 1915

Soever, LJ 1729, 1730, 1731, 1732

Soysal, O 541, 550, 1525, 1974

Sohail, H 1468 Sohn, B 1190 Sokka, T 2462 Sokolove, J 100, 388, 2170 Soley, A 554 Soliman, MM 1211 Solmaz, D 541, 550, 1974 Solomon, DH 119, 123, 333, 736, 801, 803, 2143, 2441, 2544, 2575, 2595

Stanczyk, J 42, 45, 1672, 1923, 2519

Stirnemann, J 728, 2035

Spalding, SJ 276, 721, 1531, 2445

Stanevicha, V 283 Stange, L 1963

Stoehr, A 373

Spanish Scleroderma Group 1491, 1492, 1497

Stanich, J 1948

Spanò, A 1945

Stannard, J 266

Spear, G 816

Stannus, O 1079

Specker, C 6, 945

Staples, MP 411

Specks, U 789, 792, 2368, 2371, 2432

Stark, J 1069

Spegman, A 911

Statnikov, A 169

Speich, R 1671

Starke, CM 1761 Stavropoulos-Kalinoglou, A 2125

Stirzaker, RA 567, 2549 Stoeken-Rijsbergen, G 2181 Stoenoiu, MS 711 Stoffels, M 73, 2446 Stohl, W 487, 584 Stohl, W 575 Stoilov, R 2593 Stoll, M 282 Stoll, ML 2293 Stone, D 310, 818, 2028, 2451

Solomon, DH 116, 135, 2150, 2516

Spencer, CH 245, 246, 758

Solomon, GE 2518

Spencer, H 139

Solomon, JJ 687

Spera, A 925, 1609, 1905, 1907

Ste-Marie, PA 932, 933, 938, 1605, 1906

Solomons, N 2255

Sperber, NR 1582

Stebbins, G 943

Soltész, P 201

Spertini, F 2470

Steele, R 696, 708

Solus, JF 587, 588, 2121, 2280

Speyer, I 416

Soma, K 407, 409

Spiecker, F 199

Steen, VD 686, 695, 697, 701, 1451, 1459, 1715, 1716, 2483

Somers, EC 597, 616, 1849, 2442

Spiegel, E 1578

Somers, TJ 1418, 1419

Spieler, W 2071

Stefanadis, C 1163

Sommarin, Y 2180

Spiera, RF 700, 789, 792, 2371, 2432

Stefanik, JJ 1624 Stefanov, D 921

Spierings, E 1095

Stegeman, C 794, 2432

Spies, CM 373

Stehlik, C 1004

Spijkervet, F 1752

Stehouwer, CD 760

Spindler, AJ 1177

Steigleder, C 532

Spindler, W 1177

Steiman, AJ 1388

Spinillo, A 1954

Stein, CM 587, 588, 1391, 2121, 2280

Strausbauch, MA 2113

Stein, N 1689

Street, Jr., RL 1091, 2559A

Son, KM 346 Son, MB 2293 Son, MBF 2294 Sonenberg, N 2358 Song, GG 635, 1487, 2365 Song, H 437 Song, I 515, 1329, 2534 Song, J 1980, 2120, 2505 Song, J 215, 360, 1049 Song, L 567, 1426 Song, R 1318 Song, X 917

Spira, D 952 Spitzer, KA 1, 2 Splitter, G 2096 Spodick, DH 1051 Spoorenberg, A 1322, 1324 Sprabery, T 455

Song, YW 639

Springer, JR 1758

Song, YW 324, 491, 659, 961, 2306, 2477, 2592

Spurden, D 2247 Squatrito, D 609

Sonomoto, K 451, 1267, 2230

Sridharan, ST 1387, 1407

Soon, GS 748, 1534

Srinivasalu, H 511

SOP, G 1319

Srinivasan, S 517

Sorani, M 837

Sroka, A 2618

Sordet, C 717, 774, 1257

St Clair, EW 792, 2371

Sordi, E 2382

St. Clair, EW 789, 2432

Soriano, E 2563

St.Sauver, J 941

Soriano, ER 175, 188, 611, 1177, 1401, 2117

Stabile, A 1964

Soriente, I 1945

Stach, CM 1611, 1615

Sormani, MP 2452 Sotthewes, BN 770 Souberbielle, J 1373, 2620 Soubrier, M 514, 810, 1254, 1265, 2050 Soulas-Sprauel, P 554 Sourisce, A 1341 Sousa, MC 1569 Souto-Adeva, G 664, 2287, 2498 Souza, AW 968

Stacey, D 1669 Stache, V 822 Stahl, EA 167, 1677, 1682, 2156 Stamatelopoulos, K 1178 Stamm, TA 543, 1296 Stamp, LK 211, 212, 421, 1622, 2467, 2579 Stancak, A 737 Stancati, A 2218 Stanciu, R 230

Steere, AC 975, 1939, 2344

Steinberg, G 1243 Steiner, C 817, 2359 Steiner, G 983, 2428 Steinfeld, SD 1529 Steinhubl, S 1160 Steinmeyer, J 35, 381, 1823, 1825 Steinsson, K 591, 592, 2136 Stek, JE 2071 Stek, M 590 Stener, L 652 Stengaard-Pedersen, K 394, 1258 Stern, M 2379 Steshenko, V 1352 Steup-Beekman, G 1420 Stevens, AM 263, 612, 641, 1430, 1465, 2330 Stevens, R 780 Stevens, R 1143, 1149, 1639 Stevens, RL 1777 Stevens, W 843 Stewart, KG 2453 Stewart, M 1290, 2512 Stewart, W 753 Stiede, K 1757 Stillman, M 2001 Stimec, J 749 Stirnemann, J 608

Stone, DU 489 Stone, JH 792, 1507, 1713, 1740, 2371, 2432 Stone, R 1428, 2478 Stone, VV 656 Strachan, D 164 Strahs, D 668 Strand, V 1369, 2265, 2627 Strand, V 106, 141, 342, 1245, 1281, 1282, 1714, 2593 Stranden, E 1170 Strangfeld, A 147, 461, 1883


Sommet, A 442

Stawiarz, L 1226

Stratis, A 1150 Stratton, RJ 1485 Straub, RH 39, 1133, 1754, 1775, 1805, 2082 Stredney, D 1417 Street, S 2430 Strehl, C 28, 373, 1005 Strehl, J 2380 Strickland, C 769 Strickland, F 2364 Striebich, C 769, 2182 Strietholt, S 1938 Strigini, F 1535 Strippoli, R 985 Strle, K 975, 2344 Strohbeck, C 1455 Strotman, D 940 Strunk, J 176, 178 Strusberg, I 2190 Stråt, S 2424 Ström, O 906 Stuart, JM 1798 Stucky, BD 1885 Studenic, P 328, 2146 Studts, JL 2404 Stukstette, M 1987 Stukstette, MJ 1570 Stummvoll, GH 2529 Sturfelt, GK 4, 1375, 1383, 1441, 1708 Stürz, H 35 2011 Program Book

379

Su, J 22, 1398, 2064, 2267, 2273, 2275, 2292, 2303, 2639

Sunkureddi, P 1020

Su, L 851

Supronik, J 401

Su, LC 155 Su, L 591, 592 Su, S 2071 Su, W 1958, 2084 Suarez-Almazor, ME 239, 626, 743, 745, 878, 885, 1091, 2111, 2559A Suarez-de-Figueroa, M 1045 Subang, R 724 Subramanian, N 170 Sudano, J 276 Sudman, M 1688


Sudo, A 2000 Suemori, K 1011, 2340 Sugano, N 1082 Sugihara, M 947 Sugihara, T 376 Sugii, S 320, 345 Sugimoto, T 493 Sugino, H 1765, 1925 Sugioka, Y 405, 1100 Sugiura, T 1965 Sugiyama, D 493, 1057 Suguro, T 382 Suh, C 1049 Suhler, EB 856 Suissa, S 2463 Sulcs, E 1855 Sulli, A 1473, 1474 Sullivan, KE 1426 Sullivan, ME 2309

Sunkureddi, PR 726 Surducan, D 1055 Surh, CD 2345 Susaki, K 967 Suster, M 1021 Sutherland, S 2068 Sutton-Tyrrell, K 787, 1446 Suva, D 1081 Suyama, Y 1959, 2063 Suzuki, A 151 Suzuki, E 68, 557 Suzuki, K 179 Suzuki, L 2016 Suzuki, M 1213, 1215, 2192 Suzuki, M 202 Suzuki, M 2090 Suzuki, S 202 Suzuki, T 947 Suzuki, T 163 Suzuki, Y 226 Suzuki, Y 179 Svendsen, A 1258 Svenson, LW 1862 Svensson, B 348

Systemic Lupus International Collaborating Clinics (SLICC) 4, 785, 1375, 1383, 1395, 1708 Syversen, SW 2184 Syversen, U 1102 Syvänen, A 2480 Szabo, R 2644

Svärd, A 2180 Swaim, B 776 Swamy, S 1654 Swan, D 386 Swanson, MD 1003

Szczepanik, M 2618 Szechinski, J 1219, 1268 Szejnfeld, V 680 Szekanecz, Z 201, 520, 609 Szentpetery, A 520 Szepietowski, JC 1268 Szer, IS 721 Szeto, C 984 Sztajnbok, F 304, 2009 Szumski, A 410, 500, 1216, 1284 Szücs, G 201 Szymkowski, DE 1256 Södergren, A 1156 Söderlin, MK 356 Søe, NH 384

T Taal, E 2414 Tabechian, D 1347 Tabeling, C 1495 Tachida, Y 1794

Tadema, H 468, 794

Swearingen, CJ 2233, 2461

Tagen, M 1225

Sweeney, C 732

Taggart, AJ 194

Sweeney, SE 1131

Taghavi-Zadeh, S 1385, 1386, 2302

Swen, N 192

Tahara, M 1141

Swift, LL 2280

Taimi, V 49

Swigris, JJ 687, 1470

Tajar, A 1538

Swinkels, A 2405

Tajima, K 151

Sun, X 559, 2548

Swistowski, DR 686

Tak, PP 779

Sun, Y 152, 325, 338, 339, 1198, 1889, 2163, 2457

Syed, FA 1774 Syed, RH 287

Tak, PP 313, 371, 521, 733, 770, 990, 1004, 1147, 1350, 1591, 2154

Sun, Y 1132

Sylvestre, M 2463

Sun, Y 1778

Symeonidou, S 356

Sun, ZC 2084

Symmons, DD 1872

Sundel, RP 721

Symmons, DP 162, 164

Sunderkoetter, C 306

Symmons, DPM 1893, 1895, 2588

Sundgren, P 970, 971

Symmons, DP 1873

Sundy, J 1021

Symmons, DP 426, 1211, 1212, 1892, 2106, 2524, 2525

Sun, G 170 Sun, L 380, 561, 569, 644, 653, 654, 655, 2473, 2598 Sun, P 805 Sun, X 380

Sundy, JS 84, 747, 1013, 1015, 1023, 1034, 2582 Sung, M 1111, 1112 Sung, Y 103, 109, 125, 2223 Sunkari, V 55

380

2011 Program Book

Syrbe, U 1338 Systemic Lupus International Collaborating Clinic (SLICC). 2271

Takasugi, K 151

Takayama, L 812, 899, 1647, 2037 Takayasu, A 376 Takeda, A 1959 Takehara, K 1488 Takei, S 267, 297, 2629 Takei, Y 2000 Takeno, M 190, 809, 1041, 1115, 2402 Takeuchi, K 1236 Takeuchi, T 1213, 1215, 2192 Takeuchi, T 44, 236, 400, 458, 460, 1199, 1218, 1220, 1237, 1239, 1489, 2165, 2188, 2194, 2629 Takeuchi, Y 967 Takezaki, T 267, 297 Takihara, T 2315 Talaei, N 852

Taddei, S 2263

Sun, A 1778

Takase, K 190, 809, 1115

Takimoto, M 993

Sørensen, IJ 953

Swearingen, C 1083, 1240, 2110, 2126, 2396

Sumner, DR 1563

Takasawa, N 1434

Taketo, MM 1588

Szklo, M 1182

Tada, M 405, 1100

Sumida, T 492, 947, 1138, 1141, 2090

Takasaki, Y 467, 562

Takatori, S 406

Szanto, A 2331

Swart, JF 258, 286, 864

Sullivan, O 1176

Takao, M 1082

Takatori, H 179

Szamosi, S 201

Svenungsson, E 1441, 2480

Takano, Y 947

Tak, P 358, 378, 969, 1305 Tak, P 58, 82, 1821, 1843, 2177, 2356 Takabayashi, K 179

Talani, AS 1401 Talarico, R 1519, 2400, 2401 Talesnik, E 1963 Talia, NN 2317 Talpin, A 1706 Tam, LS 973, 974, 1167, 2249 Tam, L 984 Tamai, M 318, 368 Tamaki, H 99 Tamaki, M 296 Tamaki, S 1138 Tamborenea, N 1177 Tamborrini, G 527, 2637 Tamhane, A 337, 2128 Tamouza, R 485 Tan, AL 1702, 2486F Tan, FK 1452, 1491, 1492, 1494, 1497, 2313, 2329, 2429 Tan, JA 251 Tan, PK 1592 Tan, S 1297, 1298 Tan, W 634, 1194

Takagi, H 1214

Tan, X 285

Takagi, K 227, 615, 706, 1483, 1527, 1965, 2319

Tanaka, D 1207 Tanaka, E 332, 336, 1235

Takagi, K 1127, 2565

Tanaka, H 1137

Takagishi, K 1236

Tanaka, J 1276, 1475

Takagishi, TK 2449

Tanaka, K 2090

Takahashi, R 66, 1277

Tanaka, K 2000

Takahashi, S 1138, 1141

Tanaka, L 559

Tanaka, M 44

Tayar, JH 239

Teti, A 1589

Thon, A 2623

Tanaka, M 117

Taylan, A 1319

Tetsuo, M 357

Thorlund, JB 1088

Tanaka, N 1127, 2565

Taylor, A 1450, 1467

Texter, M 1248

Tanaka, S 1276, 1475, 1478

Taylor, J 754, 757, 1578

Thaci, D 534

Thorne, JC 325, 338, 339, 736, 1249, 1889, 2141, 2202, 2457

Tanaka, T 2243

Taylor, JJ 1590

Thacker, SG 1433, 2547

Tanaka, Y 1213, 1215, 2192, 2592

Taylor, KE 161, 485, 645, 1679, 2162

Thakkar, A 1422

Taylor, M 764

Thanh, NX 140

Tanaka, Y 351, 369, 400, 451, 458, 460, 1199, 1218, 1220, 1237, 1239, 1267, 1613, 2194, 2230, 2244, 2468, 2629 Tanaka, Y 1138 Tandon, M 497, 498, 775, 1382, 1937 Tandon, N 144, 912, 922 Taneja, V 40, 2338 Tang, MW 969 Tang, XL 973, 974 Tang, X 719, 1160, 1168 Tang, Y 558 Tang, Y 654 Tang, Y 1922 Tanguy, M 608, 1373 Tani, C 1406, 1535, 2263

Taylor, P 106, 949, 1652 Taylor, W 2579 Taylor, WJ 219 Tayyareci, Y 1509 Tazi Mezalek, Z 1040 TBCR Study Group 1214 Tchao, N 789, 792, 2432 Teal, TH 656

the ORAL Standard investigators 408

Timenetsky, MC 821, 865

Tehrani, R 2449

Telarico, T 1660, 1661, 2358, 2599

Taoufik, Y 2494

Teleman, A 504

Taraborelli, M 231, 669

Teles, FM 862

Tarallo, M 1288

Tellinghuisen, DJ 2055

Tardaguila, M 1832

Ten Cate, DF 181, 192

Tardif, J 2064

Ten Cate, R 258, 286, 298

Tarelli, E 14

Tena, X 1941

Tarjanyi, O 2335

Teng, GG 1601

Tark, M 1095

Teng, J 402

Taroumian, S 2466

Teng, L 427, 2213

Tarp, U 444, 1258, 1645, 1646, 2242

Teng, Y 446

Tartaro, P 1453

Tennant, M 2067

Tausche, A 216 Tavecchio, S 1294 Tavera-Bahillo, I 1518, 1523 Tavernier, C 1110 Tavoni, A 1406, 1529, 2263 Tawfik, O 826

Tiev, K 1459

the ORAL Scan investigators 2592

Tanner, S 1702

Taurog, JD 990, 1350

Tierney, M 2419, 2641

Teh, LS 601, 605

Tektonidou, M 1202

Tatsuki, Y 2188

Tiboni, M 1123

Tily, HI 2599

Tanino, M 1956

Tatibouet, S 696, 708

Thyagarajan, V 433

Tegzova, D 2592

Tekstra, J 1695

Tassinari, AM 1998

Thurgood, LA 1751

Tilson, H 1967

Tanikawa, A 1410

Tassi, E 27

Thoua, N 1498

the investigators of the PLUS study, . 608

Tedeschi, A 691

Tejera, B 1941

Tashiro, Y 540

the Canadian STOPP Consortium 1633

Thorstensson, CA 2509

Tillett, W 1366

Taniguchi, A 163, 332, 336, 1235, 1629

Tascilar, K 115, 923

the ARTIS studygroup 2523

Thorpe, C 2070

the International SMILEY Collaboprative Group 1376

Tebib, JG 452, 2494

Teixeira, F 507

Tas, SW 733

the APPLE Investigators 1684

Thorp, LE 1563

Tiliakos, AN 130

Teitz-Tennenbaum, S 1003

Tarvin, SE 1876

Thavaneswaran, A 524, 525, 537, 549, 781, 1314, 1325, 1327, 1331, 1334, 1360, 1362, 1363, 1651, 2486C, 2486E

Thornton, S 1685

The group PLUS 1373

Tebaldi, J 273

Tani, S 400

Tarter, L 2065

Thanneer, N 1225

Thornhill, TS 884

Tennant, A 2555 Teodoro, WR 1486 ter Huurne, MC 1784 Terao, C 151 Terashima, Y 376 Terauchi, K 809, 1041 Terkeltaub, R 221, 895, 1014, 1015, 1018, 1024, 1025, 1037, 1791, 2438

the ORAL Step investigators 718 the ORAL Sync investigators 2627 the Spanish Scleroderma Group 1494 Theander, E 504 Theis, KA 795, 1539, 1978 Theisen, D 1321 Therkildsen, FR 950 Therneau, TM 761, 2113 Theulin, A 717, 1257 Thiel, J 814, 2374, 2600 Thiele, GM 766, 2155, 2522 Thiele, K 2460 Thiele, RG 184, 1347 Thissen, D 1885 Thom, J 2566 Thomas, A 1393, 1411 Thomas, D 1398 Thomas, E 2464 Thomas, J 757 Thomas, M 578 Thomas, R 1705, 2430 Thomas, SR 1590 Thomas, T 1299, 1631 Thombs, BD 2489

Terreri, MT 304, 862, 2403

Thomée, C 298

Terrier, B 577, 791, 857, 860, 1373, 1528, 1753, 2620

Thompson, AE 2202

Terriquez, JA 1056

Thompson, J 1909

Terslev, L 2144

Thompson, L 2217

Tesar, RD 206

Thompson, S 283

Tessler-Verville, C 992

Thompson, SD 1686, 1687, 1688

Tester, R 1757

Thomson, W 257, 290, 1686, 1688

Thompson, DJ 1877


Tang, B 413

Taylor, NM 1876

Thanh, NX 448, 2545

Thorne, J 295

Tímár, O 201 Timothy, L 2269 Tinazzi, I 2486F Tincani, A 9, 231, 669, 728, 1535 Ting, TV 754, 757, 940 Tingey, T 1449 Tinoco, J 1963 Tiwari, H 995 Tjärnlund, A 59, 235 To, CH 579, 606, 924, 2118, 2274, 2295, 2296 Tobin, JN 21, 1693 Tobon, G 2235 Tochimoto, A 1483 Todd, DJ 1667 Todd, J 52, 1936 Todoerti, M 350 Toedter, G 389, 415, 1158 Toes, RE 352, 2181 Toescu, V 589 Toh, M 1140 Tohma, S 345, 1478 Tokio, S 306 Tokuda, Y 2396 Tokunaga, K 163 Tokuno, O 493 Tole, S 789, 2196 Toledano, E 1043 Toledano, K 678 Tolman, Z 1644 Toloza, S 1860 Tolusso, B 1469, 1673, 1746, 2343 Tom-Orme, L 903, 905 Tomala, T 2071 Tomasson, G 792, 1503, 1521, 1522, 2369, 2371, 2439, 2546 2011 Program Book

381

Tomcik, M 2321, 2427, 2538, 2540

Tran, P 1773

Turesson, C 2148, 2440

Ureña, I 1113

Tomi, A 478

Trauzeddel, R 283, 2623

Turina, MC 1305

Uriarte-Isacelaya, E 2290

Tomita, H 1482

Treadwell, EL 2110, 2126

Turnau, S 1669

Uribe, A 2024

Tomita, T 1771, 2195

Treiger Sredni, S 32, 252, 819

Turnbull, EM 256, 2455

Urien, S 1587

Tomlinson, GA 863, 2222, 2481

Tremaine, WJ 2530

Turpcu, A 113, 142, 453

Urita, Y 2565

Tommasini, A 2452

Trendelenburg, M 2600

Turpeinen, T 49

Tomomi Date 1139

Trenkmann, M 1671, 1672, 1923, 2519, 2520

Tuteja, A 294

Trevisani, VM 1562

Tuzun, H 2393

Urowitz, MB 4, 580, 591, 592, 599, 661, 785, 1368, 1375, 1383, 1385, 1386, 1388, 1395, 1398, 1708, 2254, 2259, 2262, 2269, 2282, 2284, 2285, 2301, 2302

Twilt, M 258, 748, 1532

Urquhart, A 1988

Tyndall, AG 1717

Urresola, A 208

Tyrrell, H 2208

Urwin, C 971

Tyrrell, PN 291, 748, 1534, 1976

Usategui, A 1479, 1772, 2316

Tyson, N 2199

Ustek, D 166, 2431

Tyson, S 2555

Ustianowski, A 2524

Tzadok, S 1002

Usuda, H 1000

Tzaribachev, N 866, 2623

Usui, T 225

Tzioufas, AG 480, 490, 1529, 1937

Utani, A 1482

Tørring, O 1098

Uto, K 1930


Tomsic, M 444, 1529, 1645, 1646, 2242 Tomsik, R 728

Tribouley, C 1148

Ton, E 1695

Trijau, S 149

Tonkin, BA 1815

Trinchero, R 1051

Tonks, LM 1377

Triolo, G 1201, 2390

Tonner, C 2073, 2578

Tripathi, D 954

Tonooka, K 2122

Tripolt, NJ 2135

Tony, HP 363, 1883

Trivedi, AN 2578

Tony, H 1733, 1736, 1750

Trivedi, D 1221, 1242, 2197, 2198

Toonen, EJ 165

Trivedi, R 831

Tooze, R 1734

Trojanowska, M 2323

Topless, R 211, 212, 1622

Troum, OM 434, 2628

Topolewski, K 833

Trouw, LA 2181

Torabi-Parizi, P 170

Truchetet, M 712

Tornehave, D 384

Trudes, G 865

Torner, J 744, 871, 960, 1076, 1616, 1628, 1724, 1984, 1986, 1989, 1991, 2005, 2560

Truedsson, LT 398, 652, 1692

Tornero-Esteban, P 383, 1084 Torok, KS 308, 1826, 2023, 2453 Torralba, KD 139, 2410 Torralba, KMD 1860 Torrelo, A 818 Torrent, A 1897 Torrente-Segarra, Jr., V 1315 Tosevski, C 114 Tosteson, ANA 1603 Toth, E 670 Toubi, E 1345 Touitou, I 988 Touma, Z 599, 1314, 1368, 1385, 1386, 2302 Tourkodimitris, S 925 Tournadre, A 514, 1254 Tourneur, L 980 Tournigand, C 1048 Toussirot, E 424, 1738, 2220 Toutouzas, K 1163 Townsend, AF 1576, 1669 Townsend, MJ 446, 837 Toyama, Y 163 Toyoizumi, S 1213, 1215, 2192 Tracey, R 322 Trachana, M 901 Tracy, R 388, 1182 Traipe, E 1396 Tran, A 843, 2430 Tran, CL 28, 373 Tran, D 714

382

2011 Program Book

Trugman, JM 931, 1609, 1904 Trunick, C 713 Trupin, L 614, 2025, 2031, 2065, 2073, 2578, 2640 Tryniszewska, B 1008, 1921 Tsagaris, KC 96 Tsao, BP 593, 632, 633, 634, 636, 637, 639, 640, 641, 642, 644, 649, 1492, 1681, 2475, 2476, 2477, 2479 Tse, S 749 Tse, WW 553 Tseng, L 2622 Tseung, L 1167, 2249 Tsifetaki, N 699 Tsiouris, S 699 Tsokos, GC 563, 573, 640, 2331 Tsolmon, D 809 Tsou, P 2317, 2318 Tsuboi, H 492, 947, 1141 Tsuchida, T 457 Tsuda, K 1057 Tsuji, S 2195 Tsukamoto, M 1606 Tsukano, M 2194 Tsumiyama, K 993, 1930, 2354 Tsuru, T 457, 1263 Tsuzaka, K 357 Tsuzuki, H 1766 Tubach, F 530 Tucker, LB 269, 2014, 2024, 2454 Tufan, A 1994 Tugwell, P 1090, 1669 Tungekar, F 620, 631

Tuzcu, M 2083

U UBC 2011 MPT Students 1564

Utset, TO 1372, 1851 Utsunomiya, M 2187, 2396 Uzunhan, Y 230

Ubeda*, C 2518

V

Uchida, A 2000 Uchimura, S 1263

Vaamonde-García, C 48

Uchino, A 1956

Vacca, A 1354, 1462

Uda, H 1273

Vacchi, C 689

Udata, C 1259, 2630

Vadali, G 1555

Ueda, A 809, 1041, 1115

Vadillo, C 1043, 2062

Uehara, T 809, 1041

Vaglio, A 855, 2380

Ueki, N 1766

Vail, A 1450

Ueki, U 2194

Vail, A 1467

Ueki, Y 2099

Vaith, P 790

Ueland, T 595

Vajda, EG 836

Uesato, R 1207

Vakkalagadda, B 1225

Uetani, M 318

Valcárcel-Ares, MN 48

Ughi, N 691, 1120

Valdez, H 409

Ugurlu, S 168, 1947, 2398

Vale, AC 414, 1792

Uhlig, T 128, 1229, 1543

Valeiras, SM 1401

Uhm, W 109, 125

Valente, RM 402

Ullmann, M 1225

Valentini, G 673, 704, 2536

Ullrich, S 381, 2377

Valeriano-Marcet, J 2241

Ulmansky, R 2495

Valerio, C 2482

Ulph, F 290

Valieva, S 292, 2626

Ulug, A 1390, 2308

Valim, V 2026

Umeda, N 947, 1138

Valle-Oñate, R 321, 542, 1301

Umicevic-Mirkov, M 165

Vallongo, C 2018

Ummenhofer, K 1976

Valor, L 390, 1737

Undeutsch, R 1495

Valverde-Franco, G 1725

Unizony, S 1507, 1740

van ‘t Klooster, G 2210

Unnebrink, K 2216

van Albada-Kuipers, G 1695

Unni, S 2048

van Baarsen, L 82

Uno, K 547, 552

van Baarsen, LG 58, 1821, 2177

Urata, Y 1207

Van Beers, JJ 1747

Urbonaviciute, V 1761

van Beuningen, HM 2435

Urcelay, E 383

Van Buchem, M 1420

Van der Wee, N 1420

Vance, EE 986

Venkatram, M 2264

van Dartel, S 2596

van der Wees, P 1668, 2423

Váncsa, A 201

Ventosa, J 1044, 1950

van de Laar, MA 165

van der Werf, JH 1695

Vande Velde, G 2328

Vera Lastra, OL 665

van de Laar, MA 341, 2459

Van Doornum, S 411

Vandenberg, WB 2428

Verbruggen, G 1356

van de Laar, MA 1054, 1157, 2002, 2414, 2596

van Duijn, CM 2162

Vandepapelière, P 2470

Verburg, KM 741, 828

Van De Loo, F 1785

van Duivenvoorde, LM 990, 1350

Vander Cruyssen, B 430

Verdet, M 2093

van Eck-Smit, BL 969

Vanderpoel, J 129

Vergara, C 1963

van Eden, W 1755, 2335

VanderWeele, TJ 797

Verheyen, J 1644

van Exel, E 590

Vandhuick, T 372

Verhoef, C 1695

van Haandel, L 255

Vandooren, B 1305

Verhoef, J 1668, 2423

van Halm, VP 760

Vanhoutte, F 2210, 2237

Verhoof, EJ 279

van Hamburg, JP 2357

Vankerkamp, S 1176

Verkamp, E 940, 2492

van Hartingsveldt, B 1268

Vanoirbeek, J 2328

Verma, H 2378

van Hulst, LT 110

Vanthuyne, M 1497

Verma, N 816

van Laar, J 2486D

Varade, J 383

Vermeer, M 2459

van Laar, JM 446, 702, 1491

Varanini, V 471

Vermeij, EA 205, 1785

van den Berg, WB 205, 976, 1012, 1349, 1726, 1783, 1784, 1785, 1793, 2435

van Lankveld, WG 2407, 2417, 2487

Varga, J 1819, 2311, 2537

Vermeulen, SH 165

Van Lent, P 976, 1012, 1144

Vargas, A 8, 340

Vernerová, Z 1817

van den Bosch, MH 2435

van Lent, PL 2435

Vargas, G 723

Vernon, M 1863

van den Bosch, MH 1793

van Lent, PL 205, 1784, 1793

Vargas-Alarcon, G 542

Versari, A 1505

van Den Brand, BT 981

van Neck, JW 187

Vargas-Ramírez, R 250

Verschueren, P 1304

van den Broek, M 354, 416, 418, 2200

Van Nooten, F 133

Vargo, JW 1619 Varisco, V 935

Verstappen, S 162, 1872, 1873, 2588

van den Broek, M 1269 van den Ende, CH 1570, 2407, 2417, 2487

Vasculitis Clinical Research Consortium 1536, 1537

Verstappen, SM 1695, 1893, 1895

van Oosterhout, M 354

Verstappen, SM 1892, 2106

Van Praet, JT 1448

Vasey, FB 629, 2241

Verstuyft, C 485

van Raalte, DH 419

Vashisht, P 1200

Van Riel, P 1700, 2596

Vasiljev, VI 1530

Vervoordeldonk, M 371, 1145, 1147

van Riel, PL 165

Vasilyev, VI 1050

van Riel, PL 1180, 2459, 2585

Vastesaeger, N 517

van Riel, PL 341, 444, 1645, 1878, 2242

Vatteroni, ML 1942

Van Riel, PL 110, 1646

Vayssièrre, B 2210

van de Loo, FA 981, 2435 van de Loo, FA 205 van de Sande, MGH 313, 770, 2154, 2177 van de Stadt, LA 2178 van den Bemt, BJ 1700 van den Berg, JM 258, 286, 864, 956, 957 van den Berg, R 516, 1295 van den Berg, W 981, 1144

Van den Hoogen, F 1717 van den Hoogen, FH 673, 1700, 2407, 2417, 2487 van den Oever, IA 1175, 1278 Van der Aa, A 2237 van der Bijl, AE 2459 van der Coelen, D 58 Van Der Heijde, D 779, 2184, 2486D van der Heijde, D 513, 516, 531, 533, 1295, 2532 van der Heijde, D 174, 311, 358, 378, 423, 507, 519, 535, 922, 1074, 1170, 1227, 1231, 1623, 1650, 2228, 2458, 2486A, 2592 van der Helm-van Mil, AH 311, 323, 352, 359, 838, 2136, 2181, 2458 van der Hurk, K 760

van Oeveren, A 836

van Rij, AM 211 van Roermund, P 827 Van Rompaey, L 2210 van Rossum, MAJ 279, 286, 957 Van Rossum, MA 258, 864, 956 van Schaardenburg, D 1799 van Schaardenburg, D 425, 770, 2127, 2178 van Sijl, AM 760, 1175 Van Suijlekom-Smit, LW 258, 286 Van Tubergen, A 507

van der Kraan, PM 976, 1349, 1726, 1783, 1785, 2435

van Tuyl, LH 1269

van der Leij, C 770

van Vollenhoven, RF 2116

van der Linden, M 352

van Vollenhoven, R 408, 459, 578, 609, 842, 1416

van der Lubbe, P 431

van Veenendaal, M 864, 956, 957

Vaysbrot, E 1033 Vaz, BA 2466 Vaz, MF 414, 1792 Vázquez, G 783 Vazquez-Del Mercado, M 228, 250 Vazquez-Lamadrid, J 2484 Vazquez-Rodriguez, T 790

Vestweber, D 34 Vets, E 2210 Vettori, S 2536, 2605 Viale, A 2518 Viallard, J 858 Viana, VS 865, 2016 Viatte, S 160, 162 Vicaut, E 728 Vicente-Rabaneda, E 1492 Vidakovic, M 1854 Vidal, B 414, 1792

Veale, DJ 41, 47, 391, 732, 1176, 1203, 1336, 1559, 1672, 1829

Vieira, PL 2356 Vieira-Sousa, E 1317, 1792

Vega, J 7, 726, 727, 1390, 2308

Vierboom, M 1147

Végh, E 201

Viergever, MA 972

Veilleux, M 1586

Vigo, G 2022

Velard, F 1801

Víkingsson, A 2136

Velasco, F 725, 1437

Vila, LM 150, 1374, 1860, 2476

Velasco, J 1705

Vilar, MJ 1598

Velazquez, C 2057

Villa, I 81

Veldhuijzen van Zanten, JJ 2125

Villa-Forte, A 2375

Veldi, T 2628

Villafuertes, E 383, 1084

Velosa, APP 1486

Villalba, JM 725, 1437

Venables, P 2171, 2522

Villaneuva, I 1247

Venalis, P 822, 2535, 2606

Villanueva, I 1262 Villar, I 1405 Villaseñor-Ovies, P 95, 1595

van der Mast, R 2207 van der Meer, JWM 73, 2446

van Winkelhoff, AJ 2175

van der Vaart, R 2414

van Zeben, D 431

van der Veen, MJ 1695

van Zoest, KP 733

van der Veer, E 1322, 1324

Van-Rossen, L 1652

Vencovsky, J 53, 824, 1678, 1817, 1820

van der Ven-Jongekrijg, J 2446

Vanarsa, K 564

Venhoff, N 814, 2374, 2600

Van der Mast, R 1420

Verweij, CL 439, 1275, 2178

Vcrc, T 2368

van Vollenhoven, RF 436, 444, 1245, 1253, 1268, 1645, 1646, 1698, 1699, 2189, 2199, 2217, 2229, 2240, 2242, 2513

van der Maas, A 1700


van Caam, APM 1783

Villares, RJ 57 2011 Program Book

383

Villeneuve, E 463, 944, 2465

Vostretsova, K 1877

Villiger, PM 1779, 2114

Vougiouka, O 988

Vilmont, V 980

Voulgarelis, M 1529

Vina, ER 1851

Vree Egberts, WT 1747

Viñas, O 2138

Vriezekolk, JE 2407

Vincent, A 941, 1909

Vudattu, NK 1939

Vinci, A 1584

Vugmeyster, Y 834

Vincken, KL 972

Vukelic, M 994

Vines, AI 1857, 1858

Vuolteenaho, K 1776, 1786

Vinet, E 1196

Vyse, TJ 150, 481, 633, 634, 637, 639, 641, 643, 998, 2475, 2477, 2479

Viola, S 273 Vis, M 1799 Vishnu, A 1670


Visser, AW 2136

Vyse, TJ 157, 632, 636, 649, 2476 Vyse on behalf of SLEGEN, TJ 1681

Visser, A 1752

W

Visser, H 341, 2596 Visser, K 440, 2207

Wachsmann, D 774, 978, 1001

Vissink, A 466, 468, 1752, 2175

Wacker, J 209

Vista, EG 489

Wactawksi-Wende, J 102

Vital, EM 1643, 2252

Wada, T 1276, 1475

Vitale, A 2452

Wada, Y 202

Vitolo, B 350

Wada, Y 621, 1171

Vittadello, F 2018, 2022

Wade, M 2483

Vittecoq, O 315, 372, 1302, 1931, 1932, 2093

Wagegg, M 373

Vitters, E 1349

Wagman, RB 1098, 1107

Vitters, EL 1726, 1783

Wagner, S 408

Vivekanandan-Giri, A 2547

Wagner, U 56, 1191, 2332

Vivino, FB 475 Vlad, SC 802

Wagner-Weiner, L 2015, 2047, 2624

Vlamakis, VE 997

Wahezi, DM 618, 1684, 2019

VlietVlieland, T 1668, 2423

Wahl, D 10

Vo, A 1390

Wahren Herlenius, M 481, 643, 773

Vogel-Claussen, J 784 Vogl, T 1012, 1793 Vogler, LB 271, 281, 289 Volin, M 364, 365, 729, 730, 835 Volk, R 743 Voll, R 1140 Voll, RE 1761, 2374, 2600 Voloshyna, I 1808 von der Recke, A 1335 Von Feldt, JM 389, 1158 von Mühlen, CA 1462 von Scheven, E 256, 2010, 2015, 2025, 2031, 2047, 2294, 2455, 2624

Waghmare, S 159

Waimann, CA 239, 878, 885 Waite, PD 277 Waiter, GD 2370 Wakabayashi, H 2000 Wakabayashi, K 66, 1277 Wakefield, R 463 Wakefield, RJ 174, 944, 2144, 2465, 2486F Wakeland, E 636, 2475 Wakeland, EK 637 Wakhlu, A 1334 Wakitani, S 405, 1100 Waldburger, J 2336

Vonk, MC 672, 673, 1491, 1497, 2417, 2487

Waldron, N 1366

Vonkeman, HE 1054, 1157, 2002

Walker, C 753

Vora, S 2032, 2044

Walker, CP 755, 1160

Vordenbäumen, S 582

Walker, H 1233

Vos, L 1668, 2423

Walker, KM 1447

Voskuyl, A 760

Walker, T 1407

Voskuyl, A 590, 1497

Walker, UA 692, 814, 1967, 2600

Voskuyl, AE 439, 672, 1175, 1491

Wall-Burns, L 2533

Vosslamber, S 439, 2178

Wallace, C 263, 721, 2047, 2624

384

2011 Program Book

Walitt, BT 102, 322, 388, 1610

Wallace, CA 282, 747, 1875, 1885, 2015

Ward, MM 136, 143, 153, 505, 511, 518, 1297, 1298, 2531

Wallace, D 2265

Wareham, N 1895, 2106

Wallace, D 578, 584

Warehan, N 1893

Wallace, D 591, 592, 609, 788, 1860

Warmington, K 1729, 1730, 1731, 1732

Wallace, DJ 4, 1375, 1383, 1663, 1708, 2410

Warnatz, K 2374

Wallaert, B 230

Warner, L 2591

Wallenstein, G 408, 718, 2592, 2627 Waller, M 1702 Wallhagen, MI 2490, 2491 Wallis, D 1366 Walravens, M 672 Walsh, C 2422 Walsh, C 732 Walsh, J 1307 Walsh, M 2369 Walsh, NC 1815 Wan, X 1099 Wanderer, AA 170 Wang, A 1098 Wang, B 836 Wang, C 902, 1917 Wang, D 644, 2473, 2598 Wang, D 248, 992, 2007 Wang, F 1194 Wang, H 213, 1617 Wang, H 96

Warner, A 875 Warner, RL 792 Warriner, AH 1106 Warrington, KJ 213, 1501, 1502, 1503, 1511, 1512, 1513, 1617 Wasko, MC 719, 1168, 1246 Wason, S 1017, 2013, 2581 Wassenberg, S 147, 1697 Watabiki, T 1606 Watanabe, A 1218, 1220 Watanabe, J 1918 Watanabe, J 1000 Watanabe, K 117, 376 Watanabe, M 1193 Watanabe, R 809, 2402 Watanabe, R 1434 Watanabe, Y 202 Watase, MG 304 Waterboer, T 1644 Watson, C 915, 1547, 2416 Watson, KD 426, 1211, 1212, 2524, 2525

Wang, J 1013, 1015, 1023, 1024, 1958, 2084

Watson, P 2443

Wang, J 285

Webb-Detiege, TA 646, 937

Wang, J 455, 2215 Wang, J 61 Wang, J 1840 Wang, J 594, 624, 849, 1924, 2551 Wang, J 1143

Waugh, A 1018 Webber, L 789, 2432 Weber, G 2496 Weber, U 527, 955, 1320, 2633 Wechsler, B 1409, 1955, 2394, 2395, 2399

Wang, K 744, 960, 1073, 1076, 1616, 1995, 2557

Weckbach, S 1321

Wang, L 407, 409 Wang, L 1676

Wedderburn, LR 234, 257, 1678, 1688

Wang, L 2552

Wedrén, S 104

Wang, L 1849

Weel, A 431

Wang, M 69

Wegmann, D 167

Wang, M 252

Wegner, N 2522

Wang, Jr., Q 604

Wehmeyer, C 1150, 1797

Wang, S 636, 637

Wei, C 1739, 1744, 1767, 2498, 2504

Wang, SY 2147 Wang, SL 1266

Weckerle, CE 1429

Weinberger, M 1582

Wang, W 1739

Weinblatt, ME 333, 378, 417, 420, 427, 634, 1230, 1253, 1679, 2191, 2213, 2228, 2575, 2594, 2631, 2632

Wang, Y 1053, 1908

Weinshilboum, RM 1676

Wang, Y 1053

Weinstein, A 584, 597

Wang, Y 1760 Ward, K 242

Weinstein, AM 877, 884, 900, 2510

Ward, LM 1633

Weinstein, RL 1107

Wang, SJ 437 Wang, W 2517

Weinstein, SP 1013, 1014, 1015, 1023, 1024

Whitaker, J 2517

Wilson, A 1117

Wolski, K 547, 552, 1869

Weis, LD 83

Whitbred, JM 1789

Wilson, AG 344

Wolslegel, K 837

White, B 1835

Wilson, C 2486F

Wong, A 2353

White, B 1722

Wilson, G 386

Wong, C 984

White, DK 871, 908, 1542, 1724, 1984, 1993, 2560, 2643

Wilson, G 2057

Wong, J 91

White, N 1586

Wilson, JC 698

Wong, JB 902

Wilson, KL 2415

Wong, K 362

Wilson, NL 1381, 2488

Wong, M 568

Wilson, PC 1741

Wong, P 142

Wilson, R 2375

Wong, R 1727, 2612

Wimmer, MA 1086, 1563, 1990

Wong, R 1225

Winchester, R 1352

Wong, S 207

Winer, J 224

Woo, JM 254, 295, 2010, 2033, 2076

Weisman, MH 153, 505, 518, 769, 788, 1663, 1860, 2119, 2137, 2410, 2445, 2531 Weiss, A 1697 Weiss, A 1484 Weiss, B 527, 2637 Weiss, P 278, 280, 2043 Weissmann, G 2518 Weiß, A 515, 1329, 2534 Welihinda, AA 1812 Wells, AU 1714, 2482 Wells, GA 1090 Wellstein, A 27 Welp, J 1021, 1030 Welsh, P 2588 Welsing, P 127, 1987 Welsing, PM 1695 Wen, F 1427 Wen, J 556, 576, 1827 Wendling, D 424, 501, 2220, 2384 Wener, MH 2170, 2291 Wenker, S 1161 Wenkert, D 1189, 1217 Werlen, S 1077 Wermuth, PJ 2608

White, W 1394, 1835 White-Alao, B 224 Whitfield, ML 2325, 2327 Whitley, M 1407 Whitney-Mahoney, KJ 749 Whittum-Hudson, JA 2617 Whitworth, J 2092 Wichuk, S 522, 538, 1649 Wick, JA 826 Widmer, A 1029 Wiedeman, A 1430, 1762 Wiedeman*, A 997 Wiegant, K 827 Wielgosik, A 1341 Wiell, C 953 Wiener, H 995 Wiener, R 1963 Wierzbowska, M 2012 Wiesel, R 1585 Wigerinck, P 2210, 2237

Wing, H 799, 2640 Wing, JJ 1849 Winkelmayer, WC 2441 Winsor, JR 747 Winthrop, KL 801, 806 Winzenberg, T 876 Wipff, J 268, 2021 Wise, B 1541, 1979, 1984, 1986 Wisler, D 2114

Woo, JM 98, 593, 640 Woo, P 988, 1686, 2621 Wood, R 204, 1635, 2089, 2493 Wood, S 407 Wood, SP 409 Wood, TA 2327 Woodburn, J 2149 Woods, A 2486

Wisniacki, N 2201

Woods, AL 75

Wisniewski, SR 135, 148, 393, 2143, 2150, 2485, 2516

Woodworth, TG 342, 2464 Wool, A 399

Wither, JE 566, 570, 661, 852, 1398, 1880, 2269

Woolf, C 1627

Withrington, R 1652

Wordsworth, P 2486D

Wordsworth, BP 153

Wigler, I 1944

Witowski, S 1757 Witt, M 186, 387, 1689, 2145

Worthington, J 162, 164, 167, 1677, 1682

Wesby van-Sway, E 2594

Wigley, FM 693, 697, 720, 1458, 1460, 1463, 1494, 2429, 2483, 2486

Witte, S 1219

Wouters, CH 298, 2021

Wesley, R 60, 2451

Wikberg, JE 2326

Witte, T 481, 643, 773, 790, 2529

Wozniacka, A 1268

Wesseling, JG 2178

Wilde, E 1396

Wittig, B 534

Wragg, E 1450, 1467

Wessels, J 841, 842

Wilden, E 1883

Wittkowski, KM 2453

Wren, J 2391

Wessels, JA 165

Wilder, T 1781

Wittsack, H 945

Wright, AM 2486D

West, CR 741, 828, 1095, 1096

Wildi, LM 2006

Witzenrath, M 1495

Wright, DA 2445

West, SG 2308

Wildmann, J 1133

Wofsy, D 2474

Wright, GD 159, 194

Westby, MD 1564

Wiley, GB 636, 637, 2475

Wohlreich, MM 1094, 1910

Wright, J 1147

Westedt, M 440, 2207

Wilhelm, L 1586

Wojciechowski, W 1704

Wright, J 884

Westfall, A 337, 2128

Wilkie, R 1538

Wojdyla, D 783

Wright, L 1728

Westhoff, G 327, 1228

Wilkinson, B 408

Wolbink, G 464

Wright, NC 102

Westhovens, I 1304

Wilkinson, N 301

Wolf, M 2309

Wrocklage, C 834

Westhovens, R 430, 1238, 1304, 1497, 2191, 2209, 2231, 2232, 2237

Willemze, A 359, 2181

Wolf, W 2311

Wu, E 1032, 1602

Wolfe, B 417, 1231, 1698, 2228

Wu, EY 2023

Wolfe, F 145, 422, 938, 1610, 1882, 1901, 2109, 2147, 2586, 2589

Wu, H 2355

Werner, SG 198, 199 Werth, VP 235, 249, 617

Westlake, S 2561 Westlin, W 1757 Weston-Davies, W 12 Westra, J 1159, 1161, 1659, 2175 Wettero, J 1421 Wevers-de Boer, K 440, 2207 Weyer, G 363 Wheaton, D 1979 Wheeler, LM 162 Wheless, L 2277 Whelton, A 1031 Whipple, M 941

Williams, A 150, 157 Williams, AH 2479 Williams, AS 1146, 2433, 2500 Williams, AA 1626

Wolff, C 1133, 2082

Williams, DA 939, 1910, 1911, 1988, 2421

Wolff, RK 1181 Wolfram, G 1095, 1096

Williams, P 141

Wolin, SL 772

Williams, S 68

Wollenhaupt, J 407, 718, 779, 2209, 2250, 2486D

Williamson, JD 722 Willis, R 613, 726 Willis, V 2182 Wilson, AG 352, 825, 1845 Wilson, AL 2410

Wollenhaupt, J 1238, 2231 Wollenhaupt, J 2218 Wollman, J 1300, 1944 Wolman, Y 934 Wolrich, MK 1579


Wells, MA 2113

White, PH 2041

Wu, J 995 Wu, L 663 Wu, L 475 Wu, P 1446 Wu, PW 787 Wu, Q 2097, 2246, 2248, 2348 Wu, Q 380 Wu, R 1014 Wu, S 1152 Wu, T 564, 603, 1432, 1442, 1638, 1664 Wu, XX 1684 2011 Program Book

385

Wu, X 650

Yamamoto, T 1127, 2565

Yazici, H 115, 923, 2393, 2398

Wu, X 415

Yamamoto, T 2165

Wu, Y 2159

Yamamoto, T 1139

Wu, Z 1958, 2084

Yamamoto, Y 967

Wulffraat, N 2012

Yamana, J 51

Yazici, Y 115, 124, 314, 828, 1238, 1240, 1252, 1886, 1894, 2052, 2053, 2058, 2110, 2126, 2233, 2385, 2396, 2461

Wulffraat, NM 258, 286

Yamana, S 51

Wunrau, C 34, 1150, 1797

Yamanaka, H 1213, 1215, 2192

Wychreschuk, E 1586

Wyman, B 2592

Yamanaka, H 151, 163, 227, 332, 336, 458, 460, 615, 706, 1199, 1218, 1220, 1235, 1237, 1239, 1483, 1527, 1629, 1965, 2194, 2319, 2629

Wynant, W 2064

Yamano, Y 2080

Wållberg Jonsson, S 1156, 1162

Yamaoka, K 369, 451, 1267, 2230, 2244, 2468

Yelin, EH 1436, 2107

Yamasaki, M 2122

Yerges-Armstrong, L 825, 830

Wylde, V 746, 1061


Wyman, A 829

X Xavier, RM 638, 674 Xia, Y 555, 556, 576, 1827, 2552 Xibille Friedmann, DX 1232 Xie, C 1432, 1442, 1664 Xie, F 462, 801, 806, 2514 Xie, H 252

Yamasaki, Y 228 Yamasaki, Y 267, 297 Yamazaki, H 117 Yan, J 1958, 2084 Yan, M 1638 Yanaba, K 1472, 1759

Xie, L 2591 Xing, L 204, 1635, 2493 Xu, A 2551

Yanagida, T 1771 Yanai, R 66, 1277 Yanes, J 2466

Xu, D 1148 Xu, J 585, 628, 1767, 1853, 1920 Xu, J 2071 Xu, S 1210, 2236 Xu, W 1924 Xu, W 423, 1210

Y Yabe, Y 1214 Yacyshyn, E 2067, 2372 Yada, E 1587 Yadao, A 896, 897, 1033 Yadin, O 2010 Yagishita, N 2080 Yagita, H 1804 Yague, J 1963 Yair, S 2495 Yajima, N 1277 Yalakki Jagadeesh, L 1129 Yalavarthi, S 1169 Yalcinkaya, Y 1328 Yamada, A 793 Yamada, H 228 Yamada, R 151 Yamada, S 395, 396 Yamada, T 1137 Yamaguchi, K 99, 1959, 2063 Yamaguchi, Y 1490, 2315 Yamaguci, A 467 Yamamoto, K 151, 400, 458, 460, 853, 1218, 1220 Yamamoto, S 406

386

Yamasaki, S 318, 368

2011 Program Book

Yang, E 1703

Ye, S 750 Ye, X 2048 Yeaw, J 915, 2416 Yee, C 589, 601, 605 Yeganeh, L 2639 Yeh, L 1030 Yelin, E 614, 799, 2025, 2065, 2073, 2578, 2640 Yeremenko, N 1305, 1591 Yeung, RS 269, 863, 2040 Yew, M 784 Yi, N 2311 Yigla, M 678 Yildiz, Y 1319 Yilmaz, S 1886, 2385 Yilmaz, V 2391 Yilmaz, Z 1525 Yim, C 1167, 2249 Yin, H 776

Yoshikawa, H 1082, 1571, 1771, 2195 Yoshimi, R 809, 1115 Yoshimoto, K 44 Yoshinari, NH 1486 Yoshinari, T 458, 460, 2188 Yoshio, T 1199, 1711 Yoshitaka, T 2099 Yoshiura, K 2447 You, D 708 You, M 2197, 2198 Youinou, P 476 Youinou, PY 474 Young, A 1233 Young, D 43 Young, D 386 Young, D 565 Young, JR 2048 Young, N 496, 663 Young, NA 1425 Yousaf, W 2454 Yousefi, C 1669 Youssef, S 808 Yow, E 2015, 2047 Ytterberg, J 2179 Ytterberg, SR 792, 820, 1503, 1511, 1513, 1678, 2368, 2432

Yang, H 74, 1318

Ying, J 1452, 1494, 2008, 2011, 2429

Yang, IH 437

Ying, KY 1167, 2249, 2260

Yang, J 1247

Yip, J 1398

Yang, K 206

Yip, P 2256

Yang, L 1674

Yli-Kerttula, T 966

Yang, L 1428

Yocum, DE 837, 1247

Yang, P 2097, 2246, 2248, 2348

Yoguim, MI 2403

Yang, S 2514

Yokoe, I 1172

Yang, X 1958

Yokogawa, N 320, 345, 1410

Yanikkaya Demir, G 1039

Yokosawa, M 947

Yano, T 2188

Yokota, K 989

Yao, C 2344

Yokota, S 2042, 2625

Yao, J 1297, 1298

Yokoyama, W 376

Yao, L 1297, 1298

Yomogida, K 1152

Yao, Q 155, 1961

Yona, E 2568

Yao, Y 1834, 1835, 1922

Yonemoto, Y 1236

YAP, DY 1435

Yong, H 2279, 2288

Yaqub, A 668

Yoo, B 1027, 1833, 1970

Yarlagadda, S 2364

Yoo, D 109, 125, 1966

Yasuda, S 15, 2310

Yoo, MC 74

Yasukawa, M 1011, 2340

Yoo, W 1111, 1112

Yasumura, J 267

Yood, RA 2582

Yasuoka, H 1489, 1490

Yoon, BY 109, 125, 1049

Yates, A 1415

Yoon, C 1380

Yau, I 748, 1534

Yoon, C 1648

Yau, MS 825

Yoon, G 512

Yau, WH 194

Yoon, H 1380, 1412, 1648, 2158

Yavuz, S 1039

Yoshida, H 2090

Zaal, KJ 1795

Yazawa, K 1213

Yoshida, K 2187, 2396

Zacharisen, M 2044

Yazdany, J 614, 1436, 2031, 2065, 2073, 2130, 2578, 2640

Yoshida, K 379

Zack, DJ 326, 1217

Yoshifuji, H 225

Zadeh, A 784

Yu, A 1032, 1602 Yu, C 640, 2159, 2477 Yu, C 1130 Yu, C 1167, 2249 Yu, F 2155 Yu, J 2599 Yu, KL 579, 924, 2295, 2296 Yu, S 2048 Yu, SL 1167, 2249 Yu, S 984 Yu, Y 508 Yu, Y 65, 70 Yu, Y 2084 Yu, Y 1958 Yu, Y 1003 Yuan, J 1601 Yuan, W 1917 Yuan, W 567 Yudoh, K 296 Yukawa, N 225 Yun, H 1101, 1114, 2541 Yung, S 553, 1435 Yunus, MB 740 Yurdakul, S 1509

Z

Zaenker, M 1155

Zhang, L 2308

Zhu, TY 973, 974, 1167, 2249

Zafar, S 1581

Zhang, L 647, 648

Zhu, W 1834, 1835

Zahr, ZA 607

Zhang, M 1194

Zhu, X 1194

Zakem, JM 646, 937

Zhang, P 650

Zhu, X 69

Zakout, S 79

Zhang, Q 650

Zalewski, C 2451

Zhang, R 2201

Zhu, Y 217, 908, 1599, 1603, 1993, 2533, 2643

Zamani, O 517, 578, 2250

Zhang, R 1670

Zamanian, RT 1471

Zhang, S 1916

Zambrowicz, B 2593

Zhang, W 2084

Zámecník, J 1820

Zhang, X 68, 557, 2363

Zampeli, E 1163, 1178

Zhang, X 1126

Zampogna, G 1473, 1474

Zhang, X 646

Zan, MT 2159

Zhang, X 1128, 2526

Zanchetta, JR 1631

Zhang, Y 1407

Zandonade, E 2026

Zhang, Y 1085, 1087, 1982, 1985

Zang, Y 823

Zarco, P 1311

Zhang, Y 217, 742, 797, 802, 871, 908, 1076, 1118, 1521, 1522, 1542, 1599, 1616, 1627, 1724, 1979, 1984, 1986, 2439, 2533, 2546, 2553, 2557, 2560, 2643

Zarnitsky, C 1302

Zhang, Z 1426

Zarro, V 1969

Zhang, Z 1053

Zauner, D 811

Zhao, H 1958, 2084

Zavaleta-Muñiz, S 250

Zhao, J 634, 639, 2477

Zayed, N 80

Zhao, J 380

Zbehlik, AJ 2051

Zhao, J 604

Zebaze, RM 1631

Zhao, Sr., M 477

Zechner, P 2135

Zhao, M 650

Zeft, AS 276, 721, 1686

Zhao, W 1493, 2547

Zeggini, E 1686

Zhao, X 1791

Zeh, G 952

Zhao, X 361, 1748

Zeidler, H 777, 2486B

Zheng, H 1130

Zejden, A 2633

Zheng, J 1339

Zekharya, T 399

Zheng, J 72

Zekraoui, L 1816 Zelenika, D 1340

Zheng, SG 594, 624, 849, 1135, 1924, 2551, 2567

Zelko, F 751, 2011, 2456

Zheng, TS 2201

Zell, J 614, 2073

Zhi, L 836

Zemel, LS 2293

Zhijie, W 1983

Zemmour, C 1140

Zhijie, Z 844

Zeng, Q 2311

Zhong, ZJ 602

Zeng, X 604

Zhong, Z 578, 584, 1367, 1369, 1416, 2472

Zarabadi, SA 2241

Zerbe, GO 100 Zerbini, CAF 718, 2592 Zerr, P 2321, 2427, 2535, 2538, 2539, 2540, 2606

Zhou, B 1268 Zhou, B 2159 Zhou, H 1382, 2287

Zhang, B 1542, 2553, 2557

Zhou, L 155

Zhang, C 71

Zhou, T 1387

Zhang, FQ 1435

Zhou, T 1407

Zhang, F 919, 920, 1333

Zhou, W 1053

Zhang, H 878, 885, 1130, 2559A

Zhou, W 1132

Zhang, H 2473

Zhou, X 1452, 1494

Zhang, J 806, 1121, 1189

Zhou, X 2501

Zhang, J 654

Zhou, Y 285

Zhang, J 1185

Zhou, Y 2250

Zhang, J 285

Zhu, J 487

Zhang, K 2311

Zhu, J 1128

Zhang, L 750

Zhu, JW 1484

Zhu, Z 2133 Zhuang, Y 1763 Zibit, M 1667 Zickert, A 1441, 1658, 2480 Ziegler, JT 642, 2479 Zielinski, C 370 Zierler, B 869 Ziglioli, T 1201, 1535


Zappia, B 2456

Zhu, Y 1152

Zignego, AL 1529 Zijlstra, IA 2177 Zilberstein, M 2217 Zimmerman, J 2311 Zimmerman, R 1390 Zimmerman, S 1458 Zimmermann, B 381 Zinchenko, N 1778 Zink, A 147, 327, 461, 1228, 1883, 2460 Zinovieva, E 1340 Zinsmeister, AR 2530 Zirkzee, E 1420 Zisman, D 1868 Ziswiler, HR 499 Zizzo, G 1006 Zlotogorski, Z 818 Zong, M 233 Zou, H 69, 594, 849, 1840 Zou, Q 1710 Zouboulis, CC 2388 Zubarev, R 2179 Zubler, V 1320 Zufferey, P 499 Zuily, S 10 Zuipa, E 532 Zulian, F 283, 1964, 2018, 2022, 2452 Zwerina, J 1208, 1611, 1788, 2380, 2535, 2539 Zwillich, SH 407, 408, 409, 718, 1213, 1215, 2192, 2592, 2627

2011 Program Book

387

1 18FDG PET/CT scan 966

2 25 OH D Vitamin insufficiency 54, 362, 1373 25-hydroxyvitamin D 54, 218, 1110, 1373, 1693, 2037, 2163

5 5-HT 1606

A AA-amyloidosis 1171 abatacept 395, 402, 403, 404, 438, 707, 817, 1221, 1224, 1225, 1226, 1238, 1240, 1242, 1254, 1256, 1263, 1278, 1462, 2190, 2191, 2197, 2198, 2209, 2231, 2232, 2234, 2238, 2359, 2469, 2474, 2595

antimalarial drugs 581, 783, 1049, 1408

anakinra 273, 286, 299, 1957, 1976, 2028, 2451

antinuclear antibodies (ANA) 291, 600, 1765, 1810, 2291, 2307, 2571

analgesics 422, 880, 1999 ANCA 793, 814, 1866, 2378, 2383, 2432 anca associated vasculitis 2374 anemia 2114, 2502 angiogenesis 27, 28, 33, 36, 38, 47, 62, 82, 730, 731, 732, 733, 835, 1489, 1499, 2604 angiopoietin 82, 1810 Angiostatin 1664 animal models 12, 13, 50, 75, 205, 554, 557, 560, 564, 566, 724, 823, 976, 990, 994, 1134, 1147, 1152, 1350, 1479, 1481, 1498, 1588, 1606, 1701, 1725, 1759, 1765, 1773, 1781, 1784, 1794, 1795, 1798, 1921, 2080, 2085, 2086, 2087, 2088, 2090, 2095, 2321, 2335, 2377, 2427, 2434, 2535, 2538, 2539, 2540, 2603, 2606, 2615 ankle-brachial index 1164

activity score 240, 303, 328, 343, 351, 360, 499, 755, 791, 821, 1062, 1166, 1260, 1311, 1368, 1421, 1486, 1613, 1712, 1890, 2037, 2050, 2053, 2115, 2134, 2244, 2288, 2387, 2570, 2597, 2600

ankylosing spondylitis (AS) 153, 358, 423, 502, 503, 505, 506, 507, 512, 513, 515, 517, 518, 519, 522, 526, 530, 531, 533, 535, 538, 541, 546, 550, 777, 778, 806, 922, 1186, 1227, 1246, 1285, 1286, 1290, 1292, 1293, 1297, 1298, 1299, 1303, 1308, 1309, 1317, 1318, 1319, 1321, 1322, 1324, 1326, 1328, 1330, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1344, 1345, 1346, 1351, 1354, 1355, 1366, 1569, 1647, 1648, 1649, 1652, 1701, 1703, 1802, 1886, 2227, 2245, 2486A, 2486B, 2486D, 2529, 2531, 2532, 2534, 2559C, 2623, 2635, 2637

acute-phase reactants 47, 518, 692

annexins 1517, 1684

adalimumab 154, 201, 265, 274, 408, 535, 953, 1045, 1209, 1231, 1236, 1250, 1300, 1312, 1508, 1698, 1699, 1874, 1884, 1931, 2189, 2197, 2198, 2211, 2216, 2228, 2486A, 2619, 2623

anti-CCP antibodies 287, 316, 317, 322, 338, 378, 393, 435, 479, 769, 844, 944, 1277, 1313, 1679, 1748, 1951, 2161, 2162, 2170, 2171, 2176, 2185, 2232

adenosine receptors 536, 1781, 1787, 1812, 2322, 2323, 2436

anti-citrullinated protein/peptide antibodies (ACPA) 104, 151, 393, 767, 839, 844, 1745, 2161, 2170, 2171, 2172, 2181, 2182, 2184

access to care 1546, 1727, 1729, 1731, 2051 ACE-inhibitors 1393, 2541 activation 565 activities of daily living (ADL) 1292, 1567, 2052, 2115, 2412, 2419, 2453, 2555

abstract keyword Index

amyloidosis 304

adhesion molecules 30, 32, 35, 38, 39, 40, 41, 381

anti-centromere antibodies (ACA) 694, 708

anti-DNA 1709, 1764, 2552

adhesive capsulitis 908, 2643

anti-dsDNA 302, 645, 664, 2295, 2307

adipocytokines 74, 382, 389, 424, 750, 1232, 1381, 1776, 1786, 1811, 1823, 1825, 2320

anti-TNF 429, 2525

adjuvant arthritis 990 adolescent patients 279, 2016, 2026, 2032, 2054 adult-onset Still’s Disease 967, 1962, 1965, 1966 adverse events 443, 1042, 2062, 2196, 2199, 2579, 2582 Advisory 1728 aerobic 1090, 1569 Africa 160 African-Americans 281, 337, 641, 830, 879, 1377, 1545, 1667, 1680, 2128, 2155, 2157, 2441, 2476, 2508, 2642 aggregate genetic risk score 160 alcohol use 356, 887, 1909, 2544 alternative medicine 370, 1092, 1917 alveolitis 1714, 2046

388

2011 Program Book

anti-TNF therapy 56, 106, 117, 118, 165, 172, 270, 286, 330, 341, 399, 424, 428, 432, 433, 441, 442, 445, 448, 450, 455, 458, 460, 520, 525, 535, 826, 834, 839, 904, 914, 916, 1062, 1212, 1218, 1220, 1231, 1233, 1234, 1240, 1248, 1252, 1265, 1266, 1289, 1302, 1304, 1312, 1315, 1476, 1508, 1647, 1789, 1884, 1887, 1941, 1968, 1975, 2039, 2189, 2194, 2211, 2222, 2224, 2228, 2239, 2240, 2244, 2250, 2253, 2465, 2486A, 2512, 2515, 2523, 2524, 2528, 2531, 2545, 2576, 2595, 2619, 2630, 2636, 2637 antibodies 24, 25, 43, 226, 464, 470, 483, 486, 845, 996, 1274, 1351, 1370, 1394, 1439, 1590, 1692, 1709, 1814, 1841, 2030, 2211, 2269, 2636 antibody microarray 398 anticardiolipin 3, 7, 8, 12, 13, 723, 726, 727, 1741 antigen-presenting cells 294, 493, 1344 antigens 1370, 1590, 2333

antinucleosome antibodies 2307 antioxidants 725 antiphospholipid syndrome 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 620, 723, 724, 725, 726, 727, 728, 1441, 1572, 1666, 2035 apoptosis 42, 56, 303, 370, 493, 568, 574, 652, 1006, 1010, 1241, 1756, 1779, 1785, 1816, 1923, 1938, 2246, 2248, 2361 A proliferation-inducing ligand (APRIL) 575, 1752 arteriosclerosis 395, 582, 1254, 1265 Arthritis 178 arthrocentesis 86, 89, 277, 2333 arthroplasty 742, 745, 878, 883, 885, 886, 1062, 1063, 1179, 1988, 2112, 2506, 2612 arthroscopy 2154 aspirin 1391, 2002 assessment 124, 939, 956, 957, 1471, 1878, 1894, 1911, 2052, 2053, 2058, 2153, 2411, 2421 asthma 1924, 2044, 2381 atherosclerosis 201, 537, 552, 587, 595, 603, 759, 760, 762, 763, 764, 784, 785, 788, 1052, 1071, 1164, 1167, 1178, 1323, 1433, 1446, 1493, 1808, 1838, 1918, 2047, 2060, 2102, 2103, 2262, 2547, 2587, 2590, 2597 atlanto-axial subluxation 2635 autoantibodies 16, 100, 228, 229, 231, 232, 236, 296, 302, 375, 467, 469, 491, 559, 600, 633, 649, 652, 677, 696, 698, 752, 766, 767, 772, 824, 840, 979, 1010, 1185, 1372, 1423, 1424, 1429, 1433, 1440, 1495, 1587, 1643, 1697, 1741, 1747, 1748, 1749, 1751, 1763, 1764, 1765, 1768, 1921, 1930, 2152, 2180, 2181, 2232, 2291, 2297, 2298, 2305, 2312, 2354, 2496, 2521, 2529, 2571, 2588, 2601 autoantigens 228, 467, 493, 652, 752, 772, 840, 1434, 1749, 1751, 2298, 2344, 2428 autoimmune disease 27, 60, 170, 358, 401, 485, 492, 495, 600, 660, 779, 822, 836, 849, 852, 1011, 1136, 1185, 1491, 1688, 1743, 1751, 1753, 1763, 1765, 1819, 1934, 1953, 1954, 2017, 2281, 2291, 2298, 2307, 2340, 2344, 2346, 2355, 2362, 2448, 2486D, 2499 autonomic disorders 469, 482, 1691 azathioprine 1453

B B cell depletion 2196 B cells 16, 126, 170, 372, 384, 390, 393, 468, 476, 485, 554, 566, 570, 577, 644, 651, 661, 703, 774, 1257, 1261, 1445, 1448, 1488, 1590, 1643, 1662, 1733, 1735, 1736, 1737, 1738, 1739, 1742, 1743, 1744, 1746, 1750, 1753, 1754, 1755, 1756, 1757, 1758, 1759, 1760, 1762, 1763, 1764, 1765, 1766, 1767, 1768, 1769, 1934, 1956, 2186, 2199, 2252, 2281, 2338, 2493, 2494, 2496, 2498, 2499, 2504, 2548, 2549, 2550

back pain 880, 1067, 1068, 1290, 1719, 1721

cadherin-11 77

bacterial infections 801, 1003, 1257, 1940, 1943, 2376, 2518, 2617

calcinosis 231, 246, 2027

B cell-activating factor of the tumor necrosis factor family (BAFF) 44, 575, 585, 1737, 1746, 1752, 1934, 2550

calcium pyrophosphate dihydrate (CPPD) 183, 217, 218, 1801

Barrett’s esophagus 684 Behçet’s syndrome 987, 1038, 1039, 1040, 1041, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2431 belimumab 578, 584, 602, 1367, 1369, 1416, 2472 British Isles Lupus Assessment Group (BILAG) 601, 602, 605, 1378, 2265 bioavailability 2581 biologic 2466 biologic agents 2233 biologic response modifiers 63, 159, 199, 282, 394, 411, 430, 456, 507, 977, 1199, 1200, 1303, 1318, 1584, 1699, 1828, 2075, 2212, 2245, 2252, 2336, 2445, 2591

biomechanical testing 1086, 1556, 1563, 1791, 1990, 1991, 1995, 2438 bisphosphonates 804, 805, 870, 1101, 1114, 1120, 1121, 1124, 1126, 2541 Blau syndrome 155, 298

cancer 2523 cancer treatments 667, 1048, 1049 cannabinoid 39, 1906 capillaroscopy 674, 677, 1454, 1469 cardiovascular 537, 2590 cardiovascular disease 11, 22, 100, 113, 114, 121, 134, 223, 296, 349, 388, 447, 482, 500, 502, 513, 547, 552, 580, 588, 719, 755, 760, 787, 803, 1028, 1054, 1071, 1154, 1155, 1156, 1157, 1159, 1160, 1161, 1162, 1163, 1166, 1168, 1170, 1172, 1174, 1175, 1176, 1178, 1179, 1182, 1183, 1184, 1186, 1249, 1286, 1293, 1323, 1405, 1436, 1437, 1441, 1521, 1528, 1601, 1666, 1871, 2015, 2047, 2060, 2064, 2065, 2070, 2078, 2105, 2121, 2125, 2249, 2254, 2275, 2280, 2399, 2439, 2484, 2528, 2566, 2585, 2587, 2588, 2589 caregivers 1422, 2414 Carotid Plaque 537 carpal tunnel syndrome 928, 1896, 1969 cartilage 80, 827, 960, 976, 1012, 1076, 1078, 1080, 1144, 1318, 1616, 1625, 1626, 1637, 1725, 1770, 1776, 1783, 1784, 1786, 1790, 1795, 1796, 1798, 1801, 1802, 1824, 1973, 1984, 1987, 1997, 2005, 2100, 2426, 2433, 2435, 2554 catastrophic antiphospholipid syndrome 20

collagen 706, 1133, 1346, 1461, 1482, 1486, 1588, 1638, 1897, 2080, 2319, 2320, 2322, 2341, 2343, 2537, 2608 combination biologic therapy 2196 combination therapies 1027, 1234, 1264 committee 1728 community programs 1090, 1583, 1667, 1670 comorbidity 620, 745, 795, 875, 891, 919, 920, 1020, 1028, 1155, 1242, 1284, 1333, 1604, 1880, 2143 complex regional pain syndrome 2043 complimentary and alternative therapy 2128 computed tomography (CT) 206, 784, 807, 965, 1128, 1526, 1611, 1615, 1618, 2176, 2378

coping skills 2064, 2403 coronary artery disease 759, 1185, 1199, 1286, 1319, 2060, 2259, 2439

cell biology 78, 1003, 1341, 1445, 1592, 1675, 1783, 2337, 2438 central nervous system involvement 748, 1404, 1532, 1534, 1711 cerebrovascular disease 6, 1441, 1522

chemokines 29, 350, 373, 698, 730, 731, 820, 975, 1711, 1773, 1809, 1811, 1813, 1839, 2431, 2572

bone disease 807, 1346, 1615, 1802

cholesterol 763, 764, 1157, 1180, 1181, 1808, 1918, 2282, 2346 cholinergic agonists 994

bone metabolism 414, 964, 1100, 1110, 1111, 1112, 1122, 1647, 1702, 1787, 2195, 2220, 2434, 2436

chondrocalcinosis 183, 1119

Bortezomib 1761

chronic recurrent multifocal osteomyelitis (CRMO) 299, 301, 2021

C1q 302, 997

colchicine 1017, 1051, 2013, 2396, 2445, 2581

CD32C 995

cervical spine 95, 268

C-reactive protein (CRP) 349, 400, 428, 522, 969, 1019, 1290, 1515, 1857, 1858, 2107, 2195, 2259, 2511, 2593

cognitive dysfunction 1279, 1371, 1390, 1436, 1439, 2008, 2308, 2397, 2490, 2491, 2640

CD T cells 1939, 1944, 2348, 2354

bone density 396, 869, 870, 903, 965, 972, 1073, 1078, 1097, 1100, 1102, 1107, 1108, 1113, 1116, 1117, 1124, 1589, 1630, 1633, 1647, 1788, 1792, 2037, 2131, 2220, 2260, 2274

C

coccidioidomycosis 2466

connective tissue diseases 677, 1053, 1453, 1471, 1491, 1527, 1637, 1714, 1810, 1846, 1959

certolizumab pegol 106, 445, 1218, 1220, 1230, 1245, 1248, 1252, 1253, 2214, 2527

botulinum toxin 2003

clinical trial 139, 141, 402, 403, 404, 407, 409, 412, 668, 710, 718, 722, 779, 789, 827, 925, 931, 1013, 1014, 1015, 1023, 1024, 1068, 1126, 1200, 1213, 1215, 1219, 1221, 1224, 1225, 1238, 1242, 1253, 1258, 1280, 1281, 1282, 1378, 1387, 1609, 1722, 1889, 1904, 1905, 1907, 1908, 2055, 2064, 2071, 2190, 2191, 2192, 2200, 2209, 2214, 2231, 2232, 2255, 2265, 2369, 2430, 2432, 2469, 2474, 2592, 2593, 2627

catecholamines 1775, 1805

body mass 245, 389, 410, 424, 530, 1078, 1079, 1310, 1856, 2134

bone marrow 368, 950, 960, 961, 981, 1771, 2005, 2006

clinical practice guidelines 2582

chondrocytes 61, 71, 80, 210, 1775, 1780, 1785, 1791, 1793, 1803, 1824, 1943, 2437, 2438

chronobiologic variation 373, 1219 Churg-Strauss syndrome 858, 1933, 2378, 2379, 2380, 2381, 2382, 2383 citrullinated vimentin 2179 citrulline 289, 300, 309, 1250, 1749, 2175, 2176, 2180, 2339, 2521, 2522

corticosteroids 245, 246, 607, 857, 969, 1109, 1133, 1199, 1408, 1453, 1896, 1955, 2071, 2379, 2464


biomarkers 33, 72, 112, 204, 225, 247, 255, 306, 323, 324, 329, 347, 348, 350, 351, 355, 357, 358, 361, 378, 386, 388, 399, 428, 446, 487, 488, 497, 538, 544, 582, 597, 613, 615, 698, 704, 705, 726, 788, 792, 814, 820, 837, 838, 840, 842, 881, 964, 1052, 1080, 1156, 1299, 1305, 1311, 1313, 1331, 1338, 1382, 1387, 1403, 1407, 1421, 1432, 1442, 1488, 1493, 1499, 1515, 1517, 1590, 1613, 1643, 1647, 1649, 1654, 1663, 1664, 1687, 1704, 1736, 1746, 1747, 1748, 1749, 1767, 1776, 1837, 1888, 1926, 2038, 2142, 2159, 2185, 2201, 2210, 2244, 2252, 2261, 2269, 2287, 2314, 2338, 2342, 2344, 2380, 2382, 2420, 2494, 2529, 2554, 2571, 2602

calcitonin 1114

classification criteria 177, 179, 244, 262, 313, 314, 319, 940, 1295, 1708, 1717, 2386, 2458

COX inhibitors 911 cryoglobulinemia 857, 860, 1529, 1530, 1753, 2620 crystal-induced arthritis 183, 210, 1013, 1014, 1015, 1023, 1024, 1778, 1801 cutaneous lupus erythematosus 617, 1410, 1827 cutaneous manifestations 450, 703, 1397, 1409, 1827, 2123 cyclooxygenase 67, 202, 2195 cyclophosphamide 2374 cyclosporine 224 cytokines 17, 29, 37, 43, 49, 50, 54, 56, 57, 60, 62, 66, 80, 81, 112, 195, 196, 225, 307, 308, 347, 361, 364, 365, 367, 374, 387, 388, 486, 511, 565, 613, 646, 726, 765, 772, 791, 818, 833, 975, 1006, 1013, 1014, 1015, 1023, 1024, 1082, 1132, 1133, 1137, 1138, 1139, 1141, 1143, 1145, 1267, 1358, 1403, 1446, 1479, 1488, 1658, 1663, 1672, 1673, 1674, 1676, 1683, 1711, 1739, 1793, 1805, 1806, 1809, 1810, 1814, 1820, 1821, 1826, 1828, 1831, 1834, 1839, 1843, 1945, 2086, 2087, 2088, 2011 Program Book

389

2092, 2113, 2164, 2170, 2201, 2289, 2316, 2329, 2334, 2338, 2341, 2347, 2356, 2357, 2362, 2437, 2499, 2500, 2502, 2503, 2569, 2571, 2629

D

electronic communication 2057 email 2057 endothelial cells 28, 29, 36, 47, 78, 296, 724, 730, 731, 733, 1161, 1319, 1434, 1438, 1461, 1469, 1489, 2559B

damage 2263

endothelial function 2263

death 112, 1154, 1392, 1456, 1599, 1712, 1715, 2443

Enthesitis 280, 515, 1300, 1346, 1347, 1702, 2486F

decision analysis 118, 321, 743, 1851

enthesopathy 182, 213, 550, 2486F

dendritic cells 68, 993, 1008, 1009, 1010, 1011, 1345, 1636, 1673, 1701, 1706, 2095, 2430, 2496, 2504

environmental factors 102, 768, 1372, 1893, 1895, 2139, 2161, 2171, 2172, 2173, 2574

denosumab 1098, 1103, 1107, 1108, 1631 dermatomyositis 224, 225, 226, 227, 228, 231, 234, 236, 241, 242, 243, 247, 249, 820, 822, 1678, 1846 dexamethasone 203 diabetes 99, 1022, 1163, 1284, 1602, 1856, 2355, 2584 diagnosis 19, 20, 148, 189, 200, 244, 284, 322, 357, 358, 378, 471, 551, 597, 600, 674, 811, 1043, 1057, 1105, 1307, 1308, 1320, 1523, 1581, 1608, 1617, 1901, 1927, 1956, 2019, 2022, 2040, 2261, 2291, 2402, 2633, 2638 diagnostic criteria 135, 137, 138, 177, 311, 314, 318, 474, 476, 517, 1033, 2386

Enzyme-Linked Immunoabsorbant Assays (ELISA) 38, 600, 1472, 2522 Eosinophilic Fasciitis (Shulman’s disease) 1451, 1955

ethics 2059 ethnic studies 293, 785, 1400, 2110, 2117

disability 109, 257, 293, 418, 679, 681, 795, 800, 909, 1206, 1539, 1855, 1863, 1872, 1873, 1982, 1983, 2119, 2124, 2137, 2273, 2294, 2490, 2509, 2515, 2612

extracellular matrix proteins 41, 1824, 1897, 1973 extracorporeal shockwave therapy 691

F

Discontinuation 2596

drug interactions 1026 drug toxicity 803, 1219, 2448 dual energy x-ray absorptiometry (DEXA) 209, 213, 812, 869, 1106, 1113, 1617

E economics 132, 133, 140, 448, 628, 679, 878, 885, 889, 890, 895, 896, 902, 913, 914, 916, 919, 920, 1853, 2545, 2576 education, medical 83, 84, 85, 86, 87, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 1593, 1594, 1595, 1596, 1597, 1598, 1732 education, patient 91, 110, 149, 618, 743, 930, 1540, 1579, 1581, 1583, 1584, 1585, 1665, 1669, 2055, 2411

390

2011 Program Book

fracture 670, 805, 812, 829, 906, 1063, 1097, 1102, 1109, 1116, 1118, 1125, 1629, 1632, 1633, 1634, 2644 functional status 108, 147, 332, 333, 449, 505, 665, 742, 745, 811, 871, 1067, 1087, 1515, 1541, 1569, 1722, 1980, 1982, 1984, 1985, 1986, 1989, 1992, 2132, 2460, 2516, 2562

G

gender 514

extraarticular manifestations 717, 2130

Doppler ultrasound 62, 173, 186, 195, 474, 810

foot disorders 194, 800, 1552, 1553, 1554, 1555, 1556, 1960, 1991, 2149, 2543, 2609

etanercept 174, 258, 260, 274, 285, 330, 405, 406, 410, 429, 441, 457, 500, 515, 1216, 1217, 1223, 1233, 1236, 1249, 1284, 1288, 1290, 1321, 1830, 1884, 1931, 1932, 1961, 2030, 2197, 2198, 2239, 2512, 2534, 2619

Digital X-ray Radiogrammetry (DXR) 1102, 2229

dopamine agonists 369

folate 2467

galectin 1002

diffuse idiopathic skeletal hyperostosis (DISH) 2026

disease-modifying antirheumatic drugs (DMARDs) 110, 113, 119, 123, 199, 255, 394, 409, 413, 429, 436, 459, 461, 504, 508, 540, 755, 904, 916, 952, 1179, 1207, 1220, 1229, 1253, 1269, 1581, 1877, 2055, 2133, 2193, 2197, 2198, 2222, 2223, 2247, 2404 , 2466, 2594, 2596, 2627, 2637

943, 970, 971, 1566, 1577, 1605, 1606, 1607, 1608, 1609, 1610, 1899, 1900, 1901, 1902, 1903, 1904, 1905, 1906, 1907, 1908, 1909, 1910, 1911, 1912, 1913, 1914, 1915, 1916, 1917, 1942, 2026, 2066, 2408, 2409, 2421, 2564, 2567

epigenetics 252, 366, 385, 497, 645, 650, 775, 1426, 1427, 1672, 1673, 1922, 1923, 1928, 1929, 2517, 2519, 2520, 2605

exercise 693, 722, 880, 1067, 1381, 1558, 1559, 1561, 1562, 1565, 1566, 1568, 1572, 1575, 1583, 1670, 1722, 1723, 2488, 2505, 2542, 2558, 2559B, 2613, 2614

diet 722


Ehlers-Danlos syndrome 2044

familial Mediterranean fever 168, 297, 304, 541, 986, 1947, 1963, 1974, 2013, 2445, 2450, 2452 family studies 765, 767, 771, 1353, 1364, 1577, 2408, 2412 fatigue 125, 241, 242, 243, 925, 941, 1203, 1228, 1369, 1557, 1584, 1670, 1903, 1908, 2370, 2405, 2410, 2425, 2610 Fc receptors 562, 996, 1256 febuxostat 890, 891, 1022, 1031, 1604, 2048, 2583 female 514 fertility 1536, 2286 fever 306, 1961, 2447, 2452 fibroblast 35, 42, 46, 69, 374, 377, 381, 706, 832, 835, 1461, 1480, 1483, 1490, 1588, 1591, 1671, 1672, 1726, 1772, 1819, 1823, 1923, 2100, 2248, 2315, 2316, 2317, 2318, 2319, 2320, 2322, 2333, 2334, 2536, 2537, 2605, 2606, 2607 fibromyalgia 735, 736, 737, 738, 739, 740, 902, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942,

gastrointestinal complications 700, 716, 1058, 1455, 1459, 1498, 1527, 1961, 2000, 2565 gene therapy 205, 1145, 1147 genetic disorders 155, 166, 301, 304, 305, 306, 641, 830, 1555, 1803, 1921, 1961, 2022, 2099, 2389, 2447 genetics 160 genomics 32, 150, 152, 154, 156, 157, 159, 163, 164, 165, 167, 253, 352, 359, 372, 399, 421, 481, 632, 645, 773, 819, 825, 841, 842, 996, 1340, 1352, 1361, 1366, 1423, 1431, 1446, 1494, 1496, 1497, 1637, 1677, 1678, 1680, 1681, 1682, 1686, 1688, 1701, 1832, 1921, 1927, 1931, 1934, 2139, 2142, 2152, 2156, 2159, 2162, 2165, 2166, 2311, 2313, 2325, 2329, 2390, 2475, 2476, 2478, 2479, 2517 geriatrics 1721 giant cell arteritis 189, 790, 1052, 1503, 1507, 1508, 1510, 1511, 1512, 1513, 1517, 1518, 1521, 1522, 1523, 1524, 2439, 2440, 2546 glomerulonephritis 793, 1417 glucocorticoids 29, 39, 79, 193, 233, 253, 282, 373, 419, 621, 756, 802, 804, 907, 914, 1102, 1126, 1127, 1128, 1129, 1145, 1198, 1219, 1228, 1258, 1269, 1633, 1972, 2131, 2463, 2464 glucosamine 67 glutamate 971 glycoproteins 14 gout 84, 207, 208, 209, 210, 211, 212, 213, 215, 216, 219, 220, 221, 222, 223, 887, 888, 889, 890, 892, 893, 894, 895, 896, 897, 898, 1013, 1014, 1015, 1016, 1017, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1054, 1083, 1592, 1599, 1600, 1601, 1602, 1604, 1617, 1618, 1619, 1620, 1621, 1622, 1935, 2048, 2058, 2074, 2579, 2581, 2582, 2583, 2584 growth factors 28, 35, 1349, 2031

H hand disorders 95, 962, 963, 1070, 1072, 1073, 1543, 1570, 1571, 1623, 1718, 1863 Health Assessment Questionnaire 109, 145, 270, 333, 351, 420, 1207, 1211, 1229, 1514, 1571, 1629, 2052, 2114, 2244, 2418, 2556 health behaviors 270, 626, 867, 868, 1558, 1576, 1850, 2024, 2032, 2111, 2404, 2542, 2558 health education 145, 626, 2111 heart disease 714, 761, 1155, 1171, 1183, 1477, 2121, 2450, 2588, 2606 hemochromatosis 171, 1803, 1960 hepatic disorders 1887 hepatitis 1316, 1528, 1529, 1530, 1753, 1945, 2238, 2620

984, 985, 988, 994, 1003, 1055, 1072, 1079, 1110, 1132, 1136, 1144, 1148, 1149, 1232, 1260, 1306, 1334, 1348, 1421, 1444, 1453, 1639, 1659, 1680, 1759, 1780, 1781, 1782, 1812, 1816, 1818, 1820, 1836, 1843, 1940, 1961, 1967, 2050, 2086, 2092, 2153, 2174, 2336, 2377, 2438, 2447, 2451, 2587 inflammatory arthritis 28, 33, 41, 74, 75, 155, 175, 186, 257, 294, 314, 347, 362, 440, 734, 954, 965, 983, 986, 1007, 1008, 1016, 1019, 1029, 1143, 1146, 1149, 1342, 1476, 1589, 1635, 1637, 1639, 1815, 1821, 1829, 1842, 1893, 1895, 1939, 2078, 2097, 2139, 2141, 2413, 2465, 2500, 2501, 2588 inflammatory bowel disease (IBD) 1266, 1705, 1759, 2116, 2530

histone 46

information technology 90, 264, 753, 758

hormones 663, 671, 876, 1039, 1133, 1425, 2016, 2129, 2353

insulin resistance 220, 419, 524, 1165, 1166, 1176, 2125

HPV-58 477

integrins 39, 41, 831, 998, 1681, 1796

human leukocyte antigens (HLA) 151, 516, 522, 781, 1038, 1341, 1344, 1352, 1353, 1355, 1357, 1360, 1362, 1363, 1364, 1441, 1452, 2157, 2161, 2171, 2310, 2330, 2343, 2396

interferons 59, 72, 78, 439, 456, 467, 486, 656, 698, 773, 820, 831, 853, 1009, 1147, 1372, 1404, 1407, 1423, 1424, 1426, 1428, 1429, 1433, 1438, 1443, 1446, 1655, 1685, 1703, 1762, 1807, 1808, 1812, 1819, 1834, 1835, 1919, 1941, 2178, 2289, 2329, 2353, 2429, 2470, 2475, 2478, 2494, 2496, 2504, 2547, 2601

Hip 1118 hip disorders 870, 879, 883, 1066, 1077, 1318, 1543, 1988, 1990, 2423

human papillomavirus (HPV) 579, 1952 hydroxychloroquine 608, 613, 1168, 1234, 1409, 1410, 2067, 2077, 2304 hypermobility 861 hypertension 898, 1856, 2282 hypertriglyceridemia 2584 hyperuricemia 223, 1022, 1031, 1083, 1592, 1599, 1603, 1935, 2580, 2584 hypogammaglobulinemia 2374

I imaging techniques 31, 175, 184, 186, 187, 197, 198, 199, 200, 203, 204, 205, 206, 503, 506, 705, 734, 737, 787, 811, 945, 950, 954, 958, 964, 965, 968, 1175, 1297, 1298, 1347, 1390, 1467, 1798, 2456

interleukins (IL) 44, 52, 53, 58, 64, 73, 75, 76, 77, 79, 80, 156, 169, 273, 368, 383, 384, 386, 401, 451, 488, 563, 565, 571, 577, 651, 723, 774, 779, 791, 836, 968, 986, 1002, 1013, 1014, 1015, 1016, 1019, 1020, 1023, 1024, 1028, 1029, 1112, 1169, 1237, 1239, 1273, 1309, 1351, 1359, 1433, 1472, 1589, 1615, 1621, 1676, 1687, 1703, 1754, 1759, 1766, 1770, 1774, 1786, 1815, 1816, 1822, 1833, 1838, 1840, 1842, 1922, 1944, 1965, 1966, 1967, 1976, 2090, 2097, 2188, 2258, 2319, 2343, 2347, 2355, 2356, 2357, 2445, 2446, 2451, 2477, 2486D, 2500, 2501, 2607, 2622 intima medial thickness 760, 1071, 1156, 1167, 2587

imatinib 1460

J

immunodeficiency 170, 660, 758 immunoglobulin (IG) 14, 660, 662, 789, 793, 1435, 1641, 1713, 1740, 1822, 1924, 2186, 2380 impact 1538 induced regulatory T cells 849 infection 409, 413, 429, 433, 443, 462, 477, 688, 789, 806, 954, 1056, 1057, 1103, 1179, 1187, 1188, 1189, 1208, 1327, 1392, 1644, 1651, 1880, 1939, 1940, 1946, 1950, 1951, 1952, 2096, 2174, 2187, 2245, 2463, 2514, 2545, 2617, 2618 inflammation 28, 48, 49, 50, 58, 63, 69, 73, 75, 100, 166, 203, 246, 349, 355, 361, 364, 365, 367, 510, 522, 553, 573, 587, 729, 733, 748, 814, 816, 835, 853, 969, 975, 977, 980, 981,

Janus kinase (JAK) 407, 408, 409, 451, 718, 1136, 1213, 1215, 1267, 2192, 2210, 2230, 2569, 2592, 2627 Japan 1218 Japanese 406, 1220, 1965, 2629 job loss 795, 1539, 2292 joint destruction 173, 330, 352, 354, 400, 405, 418, 458, 460, 781, 1191, 1237, 1239, 1611, 1612, 1614, 1781, 1789, 1799, 1836, 2136, 2140, 2142, 2184, 2200, 2239, 2458 joint procedures 193, 921 juvenile arthritis 265, 276, 281, 287, 289, 290, 291, 293, 294, 300, 309, 511, 747, 863, 901, 1575, 2333, 2623

juvenile idiopathic arthritis (JIA) 254, 255, 256, 257, 258, 259, 260, 262, 263, 264, 266, 267, 268, 269, 270, 272, 273, 274, 275, 277, 278, 279, 280, 282, 283, 284, 285, 286, 292, 295, 297, 307, 721, 750, 864, 865, 866, 956, 957, 958, 1578, 1685, 1686, 1688, 1875, 2492, 2621, 2622, 2625, 2626 juvenile idiopathic arthritis-enthesitis (ERA) 271, 1687, 2403 juvenile scleroderma 747, 2023, 2069, 2330 juvenile spondylarthropathy 747, 749

K Kawasaki disease 296, 1533, 2040 kinase 44, 49, 420, 836, 1000, 1757, 1758, 1958, 2084, 2088, 2497, 2568 killer cell immunoglobulin-like receptors (KIR) 295, 781, 1354, 1355, 1362, 1363 knee 86, 89, 745, 797, 827, 830, 876, 877, 878, 883, 884, 885, 956, 957, 959, 960, 961, 1070, 1078, 1079, 1085, 1086, 1087, 1089, 1090, 1093, 1543, 1562, 1624, 1626, 1773, 1977, 1983, 1984, 1986, 1988, 1992, 1993, 1994, 1995, 1996, 1998, 1999, 2004, 2006, 2079, 2423, 2505, 2508, 2509, 2510, 2553, 2557

L laboratory tests 24, 1841, 2600 large joints 178 leukocytes 72, 2570 Leukopenia, leukocytopenia, 1421, 2375, 2502 liability 2057 lipids 21, 121, 502, 519, 788, 1122, 1170, 1173, 1180, 1265, 1306, 1393, 1870, 1871, 2082, 2340, 2346, 2634 longitudinal studies 267, 273, 504, 593, 605, 798, 863, 940, 1392, 1474, 1513, 1542, 1712, 1721, 1888, 2142, 2443


Hispanic patients 111, 1574

infliximab 277, 406, 416, 435, 457, 459, 463, 510, 530, 546, 826, 1041, 1046, 1047, 1221, 1223, 1224, 1236, 1242, 1250, 1260, 1266, 1285, 1299, 1316, 1500, 1700, 1779, 1841, 1957, 1975, 2030, 2188, 2197, 2198, 2205, 2211, 2215, 2249, 2402, 2526, 2619, 2636

juvenile dermatomyositis 32, 234, 245, 246, 247, 248, 252, 303, 747, 819, 992, 2007, 2012, 2019, 2027, 2034, 2039

lung 229, 689, 703, 706, 769, 1470, 1680, 1714, 1892, 2106, 2122, 2176, 2179, 2182, 2212, 2310, 2328, 2449, 2607 lupus dermatitis 1268 lupus nephritis 4, 553, 555, 556, 560, 563, 565, 567, 615, 620, 622, 627, 631, 656, 853, 984, 993, 1010, 1225, 1375, 1382, 1384, 1399, 1402, 1417, 1435, 1442, 1445, 1653, 1654, 1655, 1658, 1664, 1708, 1761, 1769, 2042, 2068, 2284, 2287, 2306, 2354, 2363, 2441, 2469, 2474, 2479, 2480, 2552, 2624 Lyme disease 975 lymph node 204, 734, 1635, 2082, 2089, 2177, 2493 lymphocytes 1959, 2607

M macrophage activation syndrome 831, 833, 1144, 1683, 1687, 2502 2011 Program Book

391

macrophage migration inhibitory factor (MIF) 45, 621, 1619

1456, 1511, 1601, 1892, 2112, 2266, 2268, 2429, 2486, 2546, 2580, 2588

opioids 1605, 2003

macrophages 68, 202, 364, 365, 367, 384, 571, 729, 730, 826, 835, 982, 1003, 1004, 1005, 1006, 1010, 1137, 1138, 1675, 1808, 1832, 1838, 2085, 2086, 2097, 2246, 2616

mouse model 565

oral 465, 1636, 1758, 2170, 2174, 2210, 2518

magnetic resonance imaging (MRI) 173, 198, 208, 277, 284, 318, 515, 516, 711, 749, 751, 778, 866, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 955, 956, 957, 958, 959, 960, 961, 966, 970, 971, 1064, 1074, 1075, 1076, 1077, 1172, 1311, 1320, 1321, 1329, 1371, 1458, 1612, 1616, 1623, 1625, 1626, 1650, 1710, 1973, 1984, 1998, 2005, 2006, 2154, 2486D, 2527, 2534, 2633, 2638 major histocompatibility complex (MHC) 1345, 1678, 1682, 1686, 2313 malignancy 115, 117, 239, 256, 411, 433, 442, 478, 480, 509, 586, 616, 689, 824, 1103, 1304, 1478, 2271, 2283, 2455, 2525

multicenter study 405, 427, 434, 504, 1016, 1049, 1260, 2213, 2218, 2621, 2628 muscle strength 242, 1561, 1985, 2007, 2610 musculoskeletal disorders 89, 176, 253, 711, 822, 1069, 1720 mycophenolate mofetil 687, 848, 1769, 2029, 2042 myositis 59, 224, 229, 230, 233, 235, 237, 238, 240, 241, 242, 243, 247, 248, 251, 252, 702, 820, 821, 822, 823, 824, 979, 992, 1463, 1468, 1587, 1820, 1834, 1835, 1862, 1864, 2027, 2034

N

mast cells 1143, 1149, 1639, 1777, 2316

N-tproBNP 1466

matrix metalloproteinase (MMP) 74, 1776, 1777, 1783, 1786, 1793, 1796, 1936, 1938, 1943, 2320, 2357, 2572

nailfold capillaroscopy 1450, 1457, 1473 nanomedicine 831, 1280, 1281, 1282, 1798

memory 1419

Native Americans 362, 903, 905

meniscal 1625 meniscectomy 816, 1065, 1088, 1801 menopause 1116, 1122


Muckle-Wells syndrome 1964, 1967, 1976, 2451

naproxen 1281 natural killer (NK) cells 294, 373, 991, 992 neonatal disorders 304, 305, 752, 771, 772, 1440, 2017, 2451

mesenchymal stem cells 368, 561, 569, 644, 1126, 1775, 1789, 1790, 2100, 2101, 2426, 2473, 2598

nephritis 558, 625, 852, 1398, 1415, 2038, 2258, 2300, 2602

messenger RNA (mRNA) 386, 1407, 1771, 2331, 2437

Neuroendocrine Immune (NEI) 1133, 1754, 2082

meta-analysis 211, 288, 442, 635, 902, 1037, 1269, 1456, 1487, 1679, 2222, 2245, 2247, 2325, 2365, 2389, 2422, 2479 metabolic syndrome 212, 500, 547, 1158, 1868, 1949, 2280, 2634 methotrexate (MTX) 163, 203, 224, 255, 260, 288, 371, 401, 417, 421, 440, 441, 536, 719, 750, 841, 842, 945, 1194, 1196, 1210, 1231, 1234, 1241, 1249, 1251, 1255, 1264, 1275, 1276, 1279, 1283, 1300, 1669, 1695, 1696, 1697, 1698, 1955, 2018, 2090, 2109, 2165, 2189, 2194, 2207, 2222, 2228, 2231, 2237, 2239, 2251, 2342, 2465, 2467, 2594, 2596 methylation 385, 645, 659, 2364 microRNA 1672 migration 42 mitochondria 48, 391, 657, 725, 1660, 1829, 2420, 2599, 2600 mixed connective tissue disease (MCTD) 467, 709, 1468, 1475

nephrogenic fibrosing dermopathy 2309

neuroimaging 970, 1396, 2017 neurologic involvement 480, 483, 2017, 2267, 2397 neuropsychiatric disorders 576, 591, 592, 1396, 1420, 2266, 2298 neurosarcoidosis 1968 neutrophil gelatinase associated lipocalin (NGAL) 603 neutrophils 30, 31, 793, 1424, 1517 nod-like receptor (NLR) 298, 989 non-human primates (NHPs) 1130 nonsteroidal antiinflammatory drugs (NSAIDs) 30, 266, 911, 1280, 1281, 1282, 1303, 1999, 2001, 2002, 2195, 2486B NT-proBNP 1278 nucleosomes 2269, 2279, 2288 nutrition 102, 370, 715, 1585, 1895, 2275, 2639

O

molecular mimicry 1745 monoclonal antibodies 741, 779, 828, 1095, 1096, 1704, 1814, 1836, 1964, 2422, 2486D, 2495, 2631, 2632

obesity 798, 799, 899, 908, 909, 1081, 1381, 1556, 2533, 2640

monocytes 15, 17, 31, 44, 56, 68, 364, 365, 494, 595, 729, 817, 985, 997, 998, 1005, 1007, 1428, 1430, 1446, 1619, 1673, 1685, 1704, 1706, 1779

ocrelizumab 837

morbidity and mortality 111, 478, 534, 589, 631, 682, 843, 860, 924, 1174, 1199, 1212,

392

2011 Program Book

occupational therapy 1732, 2555 ocular involvement 271, 288, 1041, 1044, 1045, 1046, 1950, 2133, 2272 off-label prescribing 609, 1971 older adults 1538

opportunistic infections 1189, 2448, 2524 orthopaedic 1195, 1546 orthotics 2609 osteoarthritis 71, 80, 169, 171, 187, 196, 321, 544, 741, 743, 744, 746, 796, 797, 805, 816, 825, 826, 827, 828, 829, 830, 871, 875, 877, 878, 879, 881, 882, 884, 885, 901, 960, 962, 963, 976, 1002, 1012, 1054, 1060, 1061, 1065, 1066, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1078, 1079, 1080, 1081, 1082, 1083, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1542, 1543, 1544, 1552, 1562, 1563, 1570, 1580, 1582, 1611, 1616, 1623, 1624, 1625, 1626, 1627, 1628, 1668, 1702, 1719, 1722, 1724, 1725, 1726, 1770, 1771, 1772, 1773, 1775, 1776, 1778, 1780, 1782, 1783, 1784, 1785, 1786, 1791, 1792, 1793, 1794, 1795, 1796, 1798, 1800, 1801, 1803, 1817, 1936, 1960, 1977, 1978, 1979, 1980, 1981, 1983, 1984, 1985, 1986, 1987, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2001, 2002, 2003, 2004, 2006, 2058, 2063, 2079, 2082, 2407, 2420, 2423, 2433, 2435, 2437, 2505, 2507, 2508, 2509, 2510, 2554, 2558, 2560, 2562 osteoarticular 2096 osteoblasts 1782, 1799 osteoclastogenesis 64, 1115, 1124, 1148, 1620, 1703, 1774, 1779, 1787, 1804 osteoclasts 369, 544, 983, 1111, 1112, 1209, 1781, 1788, 1797, 1811, 1833, 1842, 2220, 2376, 2436 osteonecrosis 245, 246, 802, 1064, 1082 osteopenia 1123, 1630 osteopontin 254, 593 osteoporosis 122, 510, 670, 756, 804, 812, 869, 870, 904, 905, 906, 907, 1097, 1098, 1099, 1100, 1101, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1113, 1114, 1116, 1117, 1120, 1121, 1122, 1124, 1125, 1126, 1127, 1128, 1129, 1589, 1597, 1631, 2131, 2274, 2589, 2644 osteoprotegerin 520, 1127, 1589 outcome measures 128, 208, 240, 257, 290, 316, 320, 334, 338, 339, 345, 503, 504, 506, 507, 531, 548, 601, 605, 617, 622, 626, 679, 704, 716, 753, 808, 864, 897, 910, 913, 1034, 1065, 1206, 1368, 1385, 1386, 1395, 1402, 1410, 1465, 1535, 1564, 1578, 1604, 1610, 1618, 1690, 1707, 1714, 1720, 1857, 1860, 1874, 1886, 1889, 1955, 1988, 2018, 2046, 2049, 2111, 2143, 2152, 2200, 2225, 2302, 2369, 2385, 2389, 2461, 2511, 2512, 2532, 2555, 2562 outcomes 2233 ovarian 2016

P pain 124, 261, 280, 422, 683, 735, 738, 741, 742, 744, 745, 746, 828, 861, 876, 901, 926, 931, 933, 936, 939, 959, 961, 970, 1016, 1019,

1020, 1028, 1029, 1048, 1069, 1079, 1081, 1091, 1095, 1096, 1273, 1280, 1282, 1418, 1538, 1584, 1606, 1608, 1623, 1627, 1628, 1670, 1720, 1773, 1899, 1904, 1907, 1908, 1911, 1912, 1917, 1979, 1981, 1982, 1983, 1987, 1992, 1996, 2003, 2043, 2092, 2119, 2124, 2146, 2403, 2410, 2421, 2492, 2543, 2553, 2557, 2562, 2612, 2643 palindromic rheumatism 1205, 2022 parathyroid hormone 1693 parvovirus B19 2392 patient 1728 patient questionnaires 125, 430, 864, 1230, 1296, 1326, 1574, 1579, 1608, 1730, 1863, 1878, 1888, 2024, 2049, 2056, 2058, 2072, 2075, 2143, 2146, 2189, 2270, 2411, 2612 patient reported data 2151 pediatric rheumatology 97, 255, 257, 261, 264, 279, 280, 282, 291, 298, 301, 304, 306, 308, 310, 593, 612, 728, 747, 748, 749, 754, 758, 861, 862, 864, 865, 1376, 1396, 1430, 1465, 1531, 1532, 1534, 1585, 1633, 1684, 1826, 1876, 1885, 1964, 2014, 2015, 2016, 2022, 2024, 2025, 2029, 2031, 2033, 2034, 2035, 2036, 2038, 2041, 2042, 2044, 2045, 2047, 2054, 2061, 2068, 2076, 2294, 2452, 2453, 2454, 2455, 2621, 2624 peptide 648 phagocytosis 574

phospholipase 170 physical examination 88, 1595, 2050, 2153 physical function 214, 797, 800, 900, 925, 1542, 1553, 1554, 1561, 1607, 1904, 1907, 1993, 2115, 2418, 2611, 2613 physical therapy 1563, 1564, 1565, 1668, 1722, 1732, 2043, 2423

pregnancy 6, 25, 26, 104, 614, 669, 728, 936, 1196, 1204, 1413, 1443, 1535, 1537, 1577, 1707, 1873, 1874, 2277, 2278, 2281, 2286 prescribing trends 103, 123, 449, 527, 1234, 2072, 2223 pressure pain threshold 1627 prevention 405, 673, 709, 1029, 1170, 1186, 1550, 2015, 2064, 2065, 2070, 2072, 2178 prognostic factors 171, 323, 347, 353, 838, 847, 860, 1076, 1329, 1415, 1424, 1548, 1613, 1892, 1955, 1970, 1990, 2005, 2114, 2178, 2229, 2235, 2267, 2287, 2485, 2513 prostaglandins 48, 61, 67, 169, 770, 1674, 2483 proteinuria 599, 2306 proteoglycans 1921, 2335 proteomics 15, 296, 323, 838, 1365, 1444, 1613, 1664, 1918, 1926, 1932, 1933, 2179, 2183 pseudogout 217 psoriatic arthritis 176, 182, 185, 186, 199, 200, 206, 262, 500, 502, 504, 508, 509, 510, 520, 524, 525, 532, 534, 536, 537, 543, 544, 547, 548, 549, 552, 779, 780, 781, 782, 806, 919, 920, 953, 1186, 1189, 1206, 1246, 1284, 1286, 1288, 1291, 1293, 1294, 1296, 1300, 1304, 1306, 1307, 1309, 1310, 1313, 1314, 1323, 1325, 1327, 1331, 1332, 1333, 1334, 1351, 1352, 1353, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1548, 1611, 1651, 1702, 1704, 1868, 1869, 1871, 1884, 2166, 2206, 2227, 2416, 2486E, 2486C, 2486F, 2533, 2634, 2636, 2637 psychological status 1315, 2025, 2052, 2207, 2371, 2407, 2417, 2487 psychosocial factors 219, 279, 290, 878, 1091, 1579, 1872, 1899, 1988, 2371, 2405, 2406, 2410, 2487, 2489

polyangiitis 2368

pulmonary complications 226, 227, 236, 237, 238, 248, 604, 687, 693, 695, 697, 701, 720, 843, 1053, 1193, 1380, 1452, 1461, 1465, 1471, 1472, 1475, 1478, 1484, 1715, 1716, 2046, 2108, 2268, 2293, 2429, 2481, 2482, 2603

polyarthritis 839, 1745, 1946, 2355

pyoderma gangrenosum 306

physician perspective 2057 plasma cells 1746, 1761, 1920 platelets 447, 2105

polychondritis 1957 polymerase chain reaction (PCR) 571, 1251, 1255 polymorphism 171, 250, 634, 635, 638, 639, 640, 642, 975, 995, 1181, 1251, 1255, 1337, 1427, 1431, 1487, 1491, 1494, 1496, 1691, 2155, 2158, 2160, 2163, 2329, 2365, 2477, 2480, 2620 polymyalgia rheumatica 79, 188, 790, 1514, 1515, 1516, 1519, 1524, 1956 polymyositis/dermatomyositis (PM/DM) 232, 239, 244, 250, 251, 1549 population studies 478, 532, 767, 800, 877, 880, 884, 897, 900, 1551, 1555, 1556, 1849, 1880, 2442, 2510, 2543, 2573 positron emission tomography (PET) 202, 206, 967, 969, 1702

Q quality of care 110, 122, 131, 149, 342, 612, 753, 754, 755, 757, 867, 872, 1035, 1470, 1574, 1576, 1578, 1586, 1852, 1854, 2041, 2051, 2054, 2055, 2056, 2061, 2063, 2065, 2069, 2070, 2072, 2073, 2076, 2266, 2414, 2423, 2559C, 2578 quality of life 131, 132, 147, 216, 221, 249, 259, 270, 279, 280, 331, 461, 505, 590, 617, 676, 681, 716, 795, 796, 864, 895, 900, 906, 909, 925, 942, 1035, 1067, 1312, 1369, 1376, 1389, 1419, 1422, 1470, 1539, 1543, 1575, 1586, 1670, 1700, 1850, 1854, 1859, 1860, 1869, 1876, 1882, 1883, 1885, 2032, 2048, 2066, 2075, 2129, 2270, 2290, 2299, 2302, 2403, 2488, 2489, 2492, 2516, 2559C, 2565 questionnaires 124, 125, 131, 190, 331, 532,

590, 630, 665, 710, 862, 929, 1307, 1455, 1574, 1852, 1854, 1859, 1882, 1885, 2011, 2052, 2290, 2408, 2425, 2512, 2556, 2558

R race/ethnicity 271, 618, 701, 870, 895, 1395, 1574, 1580, 1847, 1851, 1856, 2010, 2027, 2033, 2073, 2111, 2130, 2486, 2505 radiography 183, 268, 311, 316, 352, 353, 389, 418, 436, 473, 526, 549, 812, 879, 962, 963, 972, 1074, 1164, 1269, 1303, 1311, 1366, 1503, 1548, 1614, 1618, 1649, 1994, 1996, 1997, 2004, 2114, 2136, 2138, 2140, 2208, 2235, 2458, 2486E, 2508, 2513, 2531, 2575, 2625, 2638 randomized trials 405, 459, 608, 707, 914, 1093, 1668, 1697, 1999, 2188, 2483, 2582 range of motion 1996, 2643 RANK/RANKL pathway 55, 64, 520, 1111, 1127, 1620, 1774 Raynaud’s Phenomenon 475, 677, 710, 713, 1457, 1458, 1473 reactive arthritis 542, 1301, 1343, 1940, 1948, 2096, 2615, 2616, 2617 receptor for advanced glycation end product (RAGE) 76, 2597 registry 2151 regulatory cells 495, 566, 568, 577, 594, 624, 658, 850, 851, 1011, 1636, 1638, 1657, 1675, 1756, 1766, 1924, 2095, 2097, 2337, 2340, 2345, 2359, 2551, 2598


pharmacology 370, 404, 803, 834, 1121, 1259, 1610, 1813, 2002, 2043, 2237

prednisolone, prednisone 440, 855, 1044, 1056, 1695, 1970, 2018, 2207

rehabilitation 1067, 1553, 1568, 1570, 1720, 2407, 2562, 2612 reimbursement 2057 remission 105, 147, 181, 245, 254, 266, 323, 325, 326, 328, 332, 333, 335, 336, 340, 341, 345, 346, 361, 394, 432, 440, 809, 1044, 1045, 1207, 1214, 1224, 1229, 1235, 1237, 1271, 1272, 1388, 2127, 2147, 2194, 2200, 2205, 2209, 2214, 2231, 2369, 2454, 2459, 2460, 2462, 2468, 2516, 2534 renal disease 222, 587, 620, 926, 1020, 1027, 1031, 1032, 1034, 1036, 1171, 1879, 2010, 2104, 2480 resveratrol 48, 69 Rheumato 1728 rheumatoid arthritis (RA) 34, 36, 37, 38, 40, 45, 52, 53, 56, 57, 66, 74, 76, 77, 88, 100, 101, 102, 103, 104, 105, 107, 108, 109, 110, 111, 115, 116, 117, 118, 119, 121, 122, 123, 125, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 141, 143, 144, 146, 148, 149, 151, 152, 159, 160, 163, 164, 165, 167, 172, 174, 175, 176, 177, 178, 179, 180, 184, 185, 188, 190, 191, 192, 199, 201, 202, 204, 268, 289, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 363, 367, 368, 369, 371, 373, 377, 380, 382, 383, 385, 386,

2011 Program Book

393

387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 398, 399, 401, 404, 408, 411, 412, 414, 415, 416, 417, 418, 419, 420, 425, 427, 429, 430, 432, 433, 434, 436, 437, 439, 440, 441, 442, 443, 444, 447, 451, 453, 454, 455, 456, 458, 460, 461, 462, 463, 479, 499, 520, 534, 562, 683, 719, 729, 730, 753, 755, 759, 760, 761, 762, 763, 764, 849, 995, 1196, 2151, 2233, 2467, 2525, 2590, 2596 rheumatoid arthritis, animal models 203, 731, 815, 832, 834, 835, 836, 977, 1130, 1131, 1135, 1137, 1139, 1140, 1141, 1142, 1144, 1145, 1148, 1151, 1590, 1636, 1638, 1640, 1749, 1754, 1755, 1757, 1760, 1815, 2081, 2083, 2084, 2087, 2088, 2091, 2094, 2098, 2099, 2101, 2246, 2338 rheumatoid arthritis, pathogenesis 47, 162, 195, 364, 365, 372, 376, 378, 428, 731, 769, 770, 815, 1735, 1805, 1836, 2072, 2093, 2105, 2159, 2160, 2163, 2169, 2170, 2174, 2175, 2176, 2177, 2179, 2182, 2185, 2518, 2521, 2572


rheumatoid arthritis, synovium 58, 374, 375, 379, 384, 733, 770, 1002, 2153, 2248 rheumatoid arthritis, treatment 106, 113, 120, 140, 146, 154, 206, 330, 353, 397, 407, 409, 410, 413, 422, 426, 431, 435, 438, 441, 445, 448, 449, 452, 459, 718, 834, 915, 1135, 1140, 1213, 1214, 1215, 1218, 1219, 1220, 1226, 1230, 1231, 1233, 1236, 1241, 1245, 1248, 1252, 1253, 1258, 1262, 1264, 1271, 1280, 1281, 1547, 1615, 1641, 1695, 1696, 1697, 1698, 1699, 1700, 1738, 1789, 1884, 1887, 1891, 1932, 2095, 2101, 2188, 2192, 2195, 2212, 2214, 2216, 2217, 2218, 2219, 2224, 2228, 2234, 2237, 2243, 2246, 2248, 2407, 2415, 2464, 2494, 2524, 2592, 2593, 2609, 2627

2328, 2329, 2453, 2481, 2483, 2486, 2489, 2565, 2603, 2606, 2607 scleroderma renal crisis 1466 scoring 178 self-management 91, 130, 861, 1540, 1576, 1580, 1582, 2032 sensitization 1627 serologic tests 821, 840, 980, 1057, 1388, 1472, 1646 severity 8, 162, 169, 171, 353, 505, 551, 897, 1102, 1548, 1936, 2117, 2268, 2486C, 2531 sex hormones 72, 2289 shoulder disorders 89, 95, 1972, 2643 sialoadenitis 475 signal transduction 18, 37, 38, 196, 370, 378, 386, 650, 733, 833, 854, 985, 991, 1134, 1153, 1444, 1483, 1484, 1630, 1639, 1640, 1671, 1742, 1809, 1813, 1836, 2319, 2335, 2350, 2351, 2360, 2435, 2436, 2437, 2568, 2570 serum levels of interleukin (SIL) 477 sirtuin 46 Sjögren’s syndrome 161, 465, 466, 467, 468, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 498, 643, 752, 771, 772, 773, 774, 776, 811, 935, 996, 1530, 1752, 2133 sleep disorders 125, 1202, 2542 smoking 46 social support 666 socioeconomic factors 124, 867, 1544, 1545, 1857, 1894, 2073, 2294, 2442, 2642

rheumatoid factor titre 2225

spine involvement 812, 881, 1349, 1719

rheumatoid vasculitis 2384

spondylarthropathy 398, 499, 501, 503, 506, 512, 514, 516, 521, 527, 529, 532, 541, 542, 548, 551, 777, 955, 990, 1038, 1052, 1285, 1286, 1295, 1301, 1302, 1305, 1309, 1311, 1312, 1315, 1320, 1329, 1340, 1341, 1342, 1343, 1347, 1348, 1350, 1351, 1356, 1366, 1591, 1650, 1692, 1701, 1703, 1705, 1706, 1887, 2486B, 2529, 2530, 2633, 2636, 2637, 2638

rheumatologic practice 1550, 1576, 1890 risk assessment 271, 359, 502, 580, 588, 673, 692, 771, 1032, 1063, 1076, 1100, 1157, 1175, 1188, 1247, 1257, 1616, 1629, 1893, 1895, 2027, 2040, 2054, 2078, 2155, 2575, 2585 rituximab 142, 438, 439, 444, 446, 452, 466, 468, 543, 702, 727, 789, 837, 857, 1211, 1257, 1261, 1270, 1448, 1528, 1641, 1643, 1644, 1645, 1646, 1662, 1735, 1736, 1737, 1738, 1739, 1740, 1752, 1957, 2203, 2221, 2225, 2234, 2241, 2242, 2252, 2281, 2367, 2373, 2374, 2384, 2432, 2448, 2494 ribonucleic acid (RNA) 498, 1790, 1832, 1937, 1956, 2548

S

statins 21, 454, 613, 726, 1124, 1160, 1293, 1437, 2015, 2047, 2577 statistical methods 605, 797, 923, 1542, 2389 stem cells 647, 1784, 2332 Still’s disease 273, 282, 1685, 1686, 1970 subchondral bone 1725 successful ageing 1538 susceptibility 160

SAPHO syndrome 540, 1309

synovectomy 1195

sarcoidosis 297, 1680, 1968, 1975, 2449

synovial cells, synovial fluid 37, 41, 48, 64, 74, 76, 300, 366, 382, 385, 446, 729, 816, 978, 980, 989, 1001, 1002, 1008, 1359, 1637, 1674, 1685, 1774, 1784, 1815, 1818, 1927, 2341, 2356, 2357, 2517, 2520

satisfaction 1728 scleroderma 308, 667, 672, 676, 679, 684, 688, 689, 695, 696, 697, 698, 700, 702, 704, 705, 708, 710, 711, 716, 844, 845, 846, 847, 848, 1454, 1468, 1476, 1481, 1483, 1484, 1485, 1493, 1498, 1573, 1716, 1717, 1826, 1837, 2018, 2317, 2318, 2320, 2323, 2324, 2325,

394

2011 Program Book

synovitis 58, 184, 191, 193, 196, 327, 350, 354, 499, 816, 826, 944, 947, 956, 957, 976, 1012, 1047, 1065, 1075, 1358, 1673, 1689, 1793, 1806, 1809, 2050, 2087, 2145, 2179, 2344, 2435

synthetase syndrome 687 systemic lupus erythematosus (SLE) 3, 4, 6, 7, 22, 65, 70, 72, 78, 150, 156, 157, 302, 303, 554, 557, 558, 559, 561, 562, 564, 566, 568, 569, 570, 571, 572, 577, 578, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 593, 594, 595, 596, 597, 598, 599, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 618, 619, 621, 623, 625, 626, 628, 629, 630, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 658, 659, 660, 661, 662, 663, 664, 751, 752, 771, 783, 784, 785, 786, 787, 849, 852, 854, 865, 867, 917, 973, 974, 993, 997, 998, 1009, 1059, 1109, 1367, 1368, 1369, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1400, 1401, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1427, 1429, 1430, 1431, 1432, 1433, 1436, 1437, 1438, 1439, 1441, 1443, 1444, 1475, 1527, 1578 systemic sclerosis 197, 652, 665, 666, 668, 669, 670, 671, 673, 674, 675, 677, 678, 680, 681, 682, 683, 684, 685, 686, 687, 690, 691, 692, 693, 697, 699, 700, 701, 703, 706, 707, 711, 712, 713, 714, 715, 717, 720, 843, 848, 1447, 1448, 1449, 1450, 1452, 1454, 1455, 1456, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466, 1467, 1469, 1472, 1473, 1474, 1475, 1476, 1477, 1478, 1479, 1480, 1482, 1484, 1485, 1486, 1487, 1488, 1489, 1490, 1491, 1492, 1493, 1494, 1495, 1496, 1497, 1499, 1567, 1568, 1588, 1715, 1716, 1717, 1718, 1835, 1846, 1861, 1863, 1926, 1958, 2263, 2275, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2319, 2321, 2326, 2327, 2330, 2412, 2417, 2427, 2429, 2481, 2482, 2484, 2485, 2487, 2535, 2536, 2537, 2538, 2539, 2540, 2604, 2605

T T cells 17, 54, 233, 372, 380, 384, 387, 488, 492, 495, 557, 568, 573, 594, 624, 646, 647, 648, 650, 656, 657, 712, 734, 774, 794, 822, 850, 851, 852, 853, 854, 993, 1008, 1011, 1135, 1137, 1141, 1191, 1267, 1339, 1479, 1488, 1620, 1660, 1661, 1704, 1705, 1755, 1760, 1812, 1922, 1924, 1930, 2156, 2164, 2177, 2230, 2246, 2316, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2341, 2342, 2343, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2382, 2499, 2549, 2567, 2599 tacrolimus 400, 1276 Takayasu’s arteritis 791, 859, 968, 1500, 1501, 1502, 1503, 1504, 1505, 1506, 1507, 1509, 1525 temporomandibular joint 277, 284 tendonitis/bursitis 1897 teriparatide 1099, 1114

TGF-beta 849 thrombocytopenia 727 thrombosis 3, 21, 24, 25, 26, 723, 724, 725, 783, 2068 thyroid 1184 tissue engineering 1780 tissue growth factor (TGF) 1794, 2434, 2536 TNF alpha 558 tobacco use 164, 392, 1650, 1912, 2138, 2155, 2174 tocilizumab 51, 66, 117, 267, 395, 396, 427, 434, 872, 951, 952, 1202, 1208, 1214, 1235, 1236, 1237, 1239, 1243, 1262, 1271, 1272, 1273, 1462, 1505, 1507, 1614, 1615, 1642, 1957, 2187, 2204, 2213, 2217, 2218, 2219, 2243, 2621, 2625, 2628, 2629 total joint replacement 743, 882, 884, 1564, 1565, 1629, 1986 transcription factor 61, 68, 82, 831, 1005, 1139, 1141, 1426, 1427, 1428, 1482, 1813, 2097, 2347, 2477, 2606 transforming growth factor 368, 511, 624, 1481, 1726, 1783, 1819, 1824, 1924, 2311, 2325, 2340, 2427, 2435, 2535, 2537, 2538, 2539, 2551, 2603

vasculitis 189, 790, 791, 792, 793, 814, 855, 856, 857, 858, 859, 860, 969, 1040, 1050, 1403, 1453, 1503, 1513, 1514, 1520, 1524, 1525, 1526, 1527, 1528, 1530, 1531, 1532, 1534, 1535, 1536, 1537, 1753, 1846, 1865, 1866, 1867, 2365, 2366, 2367, 2368, 2371, 2373, 2375, 2377, 2379, 2386, 2390, 2391, 2393, 2394, 2395, 2399, 2432 viruses 375, 443, 775, 865, 1084, 1187, 2045 vitamins 9, 54, 480, 577, 638, 1058, 1120, 1158, 1169, 1377, 1792, 2124, 2132, 2276, 2348, 2620, 2639 vocational rehabilitation 1539

W Warfarin 1118 Wegener’s granulomatosis 794, 814, 1531, 1865, 2368, 2370, 2371, 2372, 2373, 2376, 2377, 2378, 2383 weight loss 722 widespread pain 1538 women’s health 797, 1336, 1539, 2109, 2643 Wrist 1118

X

transplantation 981 tuberculosis 118, 406, 413, 954, 1190, 1193, 1289, 1887, 1941

X-ray 1625


tumor necrosis factor (TNF) 146, 379, 390, 391, 393, 406, 426, 428, 443, 449, 456, 459, 527, 719, 801, 834, 840, 915, 997, 1151, 1155, 1206, 1207, 1239, 1259, 1299, 1306, 1322, 1328, 1329, 1336, 1357, 1429, 1547, 1635, 1697, 1771, 1774, 1785, 1789, 1812, 1813, 1829, 1830, 2165, 2187, 2188, 2223, 2248, 2415, 2416, 2450, 2468, 2591, 2596 type II collagen 309, 1137

U ulcers 27, 668, 672, 681, 688, 1063, 1450, 1454, 1464, 1467, 1469, 1953, 2396, 2483 ultrasound 62, 83, 172, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 188, 189, 190, 191, 192, 193, 195, 196, 197, 198, 204, 222, 254, 275, 327, 350, 474, 476, 499, 623, 711, 807, 808, 809, 811, 1066, 1072, 1074, 1171, 1271, 1287, 1300, 1347, 1516, 1520, 1689, 1718, 1898, 1969, 1972, 2135, 2145, 2153, 2486F uric acid 211, 212, 214, 216, 349, 888, 889, 891, 1018, 1027, 1031, 1032, 1035, 1092, 1592, 1600, 1602, 1604, 1620, 1949, 2048, 2074, 2582, 2584 utilization review 216, 889, 897, 2193, 2285, 2415, 2583

V vaccines 398, 581, 709, 758, 821, 865, 1316, 1550, 1578, 1692, 1741, 1822, 1944, 2020, 2071, 2619

2011 Program Book

395

A Anolik, Jennifer H, MD, PhD B-cell Biology and Targets in Autoimmune Disease Disclosure: MedImmune, 5; UCB, 5 Systemic Lupus Erythematosus - Clinical Aspects: Translational Studies Disclosure: MedImmune, 5; UCB, 5 Aranow, C., MD Systemic Lupus Erythematosus - Clinical Aspects: New Therapies Disclosure: Amgen, 2; Cephalon, 2; Eli Lilly and Company, 2; Genentech and Biogen IDEC Inc, 2; GlaxoSmithKline, 5; Human Genome Sciences, Inc, 2; Medimmune, 5; UCB, 2 Aringer, Martin, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Biomarkers Disclosure: GlaxoSmithKline, 5; Novartis Pharmaceutical Corporation, 5; Roche Pharmaceuticals, 5

B Baker, Nancy A, ScD, MPH, OTR/L ARHP Research Methodology Disclosure: Nothing to Disclose Baron, Murray, MD Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Clinical Aspects and Therapeutics II Disclosure: Nothing to Disclose Bathon, Joan M., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Existing Biologics Disclosure: Nothing to Disclose

Abstract Moderator disclosure

Becker, Michael A., MD Metabolic and Crystal Arthropathies II: AntiGout Medications – Dosing, Adverse Effects, and Economic Burden Disclosure: Takeda, Savient, BioCryst, Ardea, Metabolex, URL/Mutual, Regeneron, Menarini, Teijin, Chugai, 5 Bernatsky, Sasha, MD, PhD Systemic Lupus Erythematosus - Clinical Aspects: Cardiac Disease/Organ Damage Disclosure: Nothing to Disclose Bilek, Laura D., PhD, PT ARHP Education and Community Programs Disclosure: Nothing to Disclose Bingham III, Clifton O., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Existing Diseasemodifying Antirheumatic Drugs - Tight Control, Induction and Drug Withdrawal Trials Disclosure: Amgen, BMS, Centocor, Genetech/ Roche, Millenium, Pfizer, UCB, 5; BMS, Genentech/Roche, Biogen/IDEC, UCB, 2 Blitz, Jill R., PT, DPT ARHP Rehabilitation Science Disclosure: Nothing to Disclose

396

2011 Program Book

Boackle, Susan A., MD Innate Immunity and Rheumatic Disease Disclosure: Nothing to Disclose Bongartz, Tim, MD, MS Epidemiology and Health Services Research V: Drugs Disclosure: Nothing to Disclose Boumpas, Dimitrios T., MD Systemic Lupus Erythematosus - Clinical Aspects: Renal Disclosure: Nothing to Disclose Bradley, David S., PhD Rheumatoid Arthritis - Animal Models I Disclosure: Nothing to Disclose Bykerk, Vivian, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Novel Compounds I Disclosure: Novartis Pharmaceutical Corporation, 1

C Carrino, John, MD, MPH Imaging of Rheumatic Disease II: X-ray, Computed Tomography and Magnetic Resonance Imaging Disclosure: Carestream, 2; Medtronic, 5; Quality Medical Metrics, 5; Siemens, 2; Toshiba, 2 Chatham, W. Winn, MD Miscellaneous Rheumatic and Inflammatory Diseases Disclosure: Human Genome Sciences, GlaxoSmithKline, 2 Chohan, Saima, MD Metabolic and Crystal Arthropathies II: AntiGout Medications – Dosing, Adverse Effects, and Economic Burden Disclosure: Nothing to Disclose Choi, Hyon, MD, PhD Epidemiology and Health Services Research I: Gout Disclosure: Centocor, Inc, 9; Novartis Pharmaceutical Corporation, 5; Takeda, 2; URL, 2 Chu, Cong-Qiu, MD, PhD ARHP Clinical Practice/Patient Care II Disclosure: Bristol-Myers Squibb, 8; Covidien, 8 Cimaz, Rolando, MD ACR/ARHP Combined Pediatrics Abstract Session Disclosure: Nothing to Disclose Clauw, Daniel J., MD Fibromyalgia and Soft Tissue Disorders II Disclosure: Cypress Biosciences, Inc, 5; Forest Laboratories, 2, 5; Jazz, 5; Johnson & Johnson, 5; Lilly, 5; Merck Pharmaceuticals, 2; Nuvo, 5; Pfizer Inc, 2, 5 Clegg, Daniel O., MD Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment II Disclosure: Nothing to Disclose

Cohen, Stanley B., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Novel Compounds II Disclosure: none, 5 Corr, Maripat, MD Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Pathogenesis of Rheumatoid Arthritis - What’s New? Disclosure: Nothing to Disclose Costenbader, Karen H., MD, MPH Epidemiology and Health Services Research VI: Lupus/Vasculitis Disclosure: Nothing to Disclose Cox, Talitha, MA, OTR/L ARHP Rehabilitation Science Disclosure: Nothing to Disclose Cronstein, Bruce N., MD Cell-cell Interactions and Adhesion Disclosure: Canfite Pharma, Bristol-Myers Squibb, Tap Pharmaceuticals, Prometheus Laboratories, Cypress Laboratories, Protalex, Allos, Inc, Gismo Therapeutics, Regeneration (Westat, DSMB), Novartis, Endocyte, Savient, 5; Canfite Piophamaceuticals, 1; Eli Lilly & Co, 9; UCB, 9; Pfizer, 9; Vilcek Foundation; 6; King Pharmaceuticals; NIH; Vilcek Foundation; OSI Pharmaceuticals; Gilead Pharmaceuticals; URL Pharma, 2 Curtis, Jeffrey R., MD, MPH, MSPH Epidemiology and Health Services Research V: Drugs Disclosure: Amgen, 2; Centocor, Inc, 2, 5; Corrona, 2, 5; Roche Pharmaceuticals, 2, 5, 8; UCB, 5, 8 Cush, John J., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Further Insights Into Efficacy and Safety of Tumor Necrosis Factor-Inhibitors Disclosure: Abbott Immunology Pharmaceuticals, 5; Allos, 5; Amgen, 5; Auxilum, 5; Celgene, 5; Cellestis, 5; Centorcor, 5; Flexion, 5; Genentech and Biogen IDEC Inc, 5; Human Genome Sen, 5; Ortho Biotech Products L.P., 5; Pfizer Inc, 5; UCB, 2, 4

D de Vallejo, Abbe N., PhD Pediatric Rheumatology - Pathogenesis Disclosure: Nothing to Disclose Del Galdo, Francesco, MD, PhD Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Pathogenesis, Animal Models and Genetics II Disclosure: Nothing to Disclose Del Rincon, Inmaculada, MD, MSc Rheumatoid Arthritis Clinical Aspects: Cardiovascular Disease Disclosure: Nothing to Disclose Dellaripa, Paul F., MD Rheumatoid Arthritis Clinical Aspects: Clinical Features Disclosure: BIogen, 9

Dore, Robin K., MD Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Disclosure: Amgen, Takeda, UCB, Roche, Sanofe-Aventis, Eli Lilly, Bristol-Meyers, Squibb, 2; Amgen, Novartis, Takeda, Pfizer, Abbott, 5; Pfizer, UCB, Abbott, Takeda, Novartis, Eli Lilly, Warner-Chilcott, 8 Dougados, Maxime, MD Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment III Disclosure: Abbott Laboratories, 5; BMS, 5; Merck Pharmaceuticals, 5; Pfizer Inc, 5; UCB, 5

E Elewaut, Dirk, MD Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment I Disclosure: Nothing to Disclose Emery, Paul, MD, MA Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Existing Disease-modifying Antirheumatic Drugs and Corticosteroids Disclosure: Nothing to Disclose Espinoza, Luis R., MD Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment Disclosure: Nothing to Disclose

F Finnegan, Alison, PhD Cytokines, Mediators, and Gene Regulation I Disclosure: Nothing to Disclose Fitzcharles, Mary-Ann, MD, MBChB Fibromyalgia and Soft Tissue Disorders II Disclosure: Lilly, Janssen, 5; Pfizer Inc, Valeant, Lilly, Purdue, Janssen, 8 Flynn, John A., MD, MBA, MEd Education: Medical Education Disclosure: Nothing to Disclose

Furst, Daniel E., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Existing Disease-modifying Antirheumatic Drugs and Corticosteroids Disclosure: Abbott, Actelion, Amgen, BMS, BiogenIdec, Centocor, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 5; Abbott, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 2; Abbott, Actelion, UCB, 8; Corrona, 3

G Gelber, Allan C., MD ACR/ARHP Combined Rehabilitation Abstract Session Disclosure: Nothing to Disclose

Gensler, Lianne S., MD ARHP Clinical Practice/Patient Care I Disclosure: Nothing to Disclose Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment IV Disclosure: Nothing to Disclose Gerlag, Danielle M., MD Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Pathogenesis of the Earliest Stages of Rheumatoid Arthritis Disclosure: Nothing to Disclose Giles, Jon T., MD, MPH Rheumatoid Arthritis Clinical Aspects: Cardiovascular Disease Disclosure: Genentech and Biogen IDEC Inc, 5 Rheumatoid Arthritis Clinical Aspects: Predictors of Outcome Disclosure: Genentech and Biogen IDEC Inc, 5 Glant, Tibor T., MD, PhD Rheumatoid Arthritis - Animal Models II Disclosure: Nothing to Disclose Goldenberg, Don L., MD Fibromyalgia and Soft Tissue Disorders I Disclosure: Pfizer Inc, Lilly, Forest, 5

Herrick, Ariane Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Clinical Aspects and Therapeutics III Disclosure: Actelion Pharmaceuticals US, 5, 8; Orion, 9; Pfizer Inc, 5, 8; United Therapeutics, 9 Hillstrom, Howard J., PhD ACR/ARHP Combined Epidemiology Abstract Session Disclosure: Stride Rite, 2 Hochberg, Marc, MD, MPH ARHP Epidemiology and Public Health II Disclosure: Abbott Laboratories, Amgen, AstraZeneca Pharmaceuticals, Bioiberica S.A., Bristol Myers Squibb, Covidien, Eli Lilly, Genentech/ Roche, Iroko Pharmaceuticals, Merck, EMD Serono, NiCox S.A., Novartis Pharma AG, Pfizer, Pozen, Smith and Nephew, Stryker LLC,, 5; Theralogix LLC, 1; U.S. Bone and Joint Initiative, 6 Holoshitz, Joseph, MD T-cell Biology and Targets in Autoimmune Disease: Lymphocyte Biology and Targets in Autoimmune Disease Disclosure: Nothing to Disclose

I Illei, Gabor G., MD Sjögren’s Syndrome Disclosure: Nothing to Disclose

Goldring, Mary, PhD Biology and Pathology of Bone and Joint: Molecular Targets For an Effective Therapy Disclosure: Abbott Laboratories, 2, 5; Biomet Biologics, 5; F. Hoffmann-La Roche, Ltd, 5; Fidia Farmaceutici S.p.A., 5; Merck-Serono S.A,, 2

Ilowite, Norman T., MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Treatment Disclosure: Abbott Immunology Pharmaceuticals, 8; Centocor, Inc, 5; Genentech and Biogen IDEC Inc, 8; Novartis Pharmaceutical Corporation, 5; Regeneron, 2

Gordon, Jessica K., MD Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Clinical Aspects and Therapeutics I Disclosure: Nothing to Disclose

Imundo, Lisa F., MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Clinical Characteristics Disclosure: Nothing to Disclose

Greco, Carol M., PhD ARHP Psychology/Social Sciences Disclosure: National Institutes of Health, 2

Inman, Robert D., MD Infection-Related Rheumatic Disease Disclosure: Nothing to Disclose Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment I Disclosure: Nothing to Disclose

H Hajj-Ali, Rula, MD Vasculitis I Disclosure: Nothing to Disclose Hanly, John G., MD Systemic Lupus Erythematosus - Clinical Aspects: Cardiac Disease/Organ Damage Disclosure: Nothing to Disclose Hansen, Karen E., MD, MS Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Disclosure: NIH, 2 Haroon, Nigil, MD, MBBS Spondylarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Disclosure: Nothing to Disclose Helmick, Charles G., MD ARHP Epidemiology and Public Health I Disclosure: Nothing to Disclose

Isaacs, John, PhD Rheumatoid Arthritis Clinical Aspects: Predictors of Outcome Disclosure: Nothing to Disclose

J Jacobsson, Lennart T.H., MD, PhD Rheumatoid Arthritis Clinical Aspects: Risk of Cardiovascular Disease Disclosure: Nothing to Disclose


Frech, Tracy M., MD Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Clinical Aspects and Therapeutics II Disclosure: Nothing to Disclose

Genant, Harry K., MD Imaging of Rheumatic Disease II: X-ray, Computed Tomography and Magnetic Resonance Imaging Disclosure: SAB for Amgern, BMS, Roche, Lilly, Genentech, Servier, Pfizer and Synarc, 5

James, Judith A., MD, PhD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I Disclosure: Nothing to Disclose Jolly, Meenakshi, MD, MS Epidemiology and Health Services Research VI: Lupus/Vasculitis Disclosure: Nothing to Disclose 2011 Program Book

397

Jonas, Beth L., MD Orthopedics and Low Back Pain Disclosure: Nothing to Disclose Jordan, Joanne M., MD, MPH Osteoarthritis - Clinical Aspects I Disclosure: Algynomics, Inc, 1; Eli Lilly and Company, 5; Interleukin Genetics, Inc, 5; Johnson and Johnson, Inc, 2, 5

K Kamphuis, Sylvia, MD, PhD Pediatric Rheumatology - Pathogenesis Disclosure: Nothing to Disclose Karlson, Elizabeth W., MD Epidemiology and Health Services Research III: Rheumatoid Arthritis Disclosure: Nothing to Disclose Katz, Jeffrey N., MD Orthopedics and Low Back Pain Disclosure: Nothing to Disclose Kay, Jonathan, MD Rheumatoid Arthritis Clinical Aspects: Clinical Features Disclosure: Array BioPharma, 5; Bristol-Myers Squibb, 2, 5; Centocor Ortho Biotech, 5; Eisai Research Institute, 5; Fidia Farmaceutici SpA, 2; Genentech and Biogen IDEC Inc, 5; Johnson & Johnson, 5; Mallinkrodt, 5; Novo Nordisk, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 2, 5; Sanofi-Aventis Pharmaceutical, 2, 5; UCB, 5 Keenan, Robert T., MD, MPH Metabolic and Crystal Arthropathies I: Pathogenesis of Gout, a Potential Novel Therapy, and Validity of Dual Energy Computed Tomography Disclosure: Novartis Pharmaceutical Corporation, 2; Savient Pharmaceuticals, 8; Savient Pharmaceuticials, 9


Kirou, Kyriakos A., MD Cytokines, Mediators, and Gene Regulation II Disclosure: Nothing to Disclose Krishnan, Eswar, MD ARHP Clinical Practice/Patient Care I Disclosure: Ardea Inc, 2; Metabolex, 2; Savient, 1; Takeda, 2, 5; URL Pharma, 2 ARHP Clinical Practice/Patient Care III Disclosure: Ardea Inc, 2; Metabolex, 2; Savient, 1; Takeda, 2, 5; URL Pharma, 2 Kyttaris, Vasileios C., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I Disclosure: Nothing to Disclose

L Lafyatis, Robert, MD Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Pathogenesis, Animal Models and Genetics I Disclosure: Actelion Pharmaceuticals US, 2; Genentech/Roche, 5; Novartis Pharmaceutical Corporation, 2; Shire Pharmaceutical, 5

398

2011 Program Book

Lohr, Kristine M., MD, MS Miscellaneous Rheumatic and Inflammatory Diseases Disclosure: American Board of Internal Medicine, 6; MedScape, 5; Pfizer Inc, 2; Takeda, 2; Various Stocks, 2 Losina, Elena, PhD Epidemiology and Health Services Research II: Osteoarthritis Disclosure: Nothing to Disclose Lotz, Martin K., MD Biology and Pathology of Bone and Joint: Molecular Targets For an Effective Therapy Disclosure: NIH, 2; Optimer Pharmaceuticals, 1 Lovell, Daniel J., MD, MPH Pediatric Rheumatology - Clinical and Therapeutic Aspects: Predictors and Outcomes Disclosure: Abbott, 5; Amgen, 5; Astra-Zeneca Pharmaceutical, 5; Bristol-Meyers Squibb, 5; Centocor, Inc, 5; Hoffmann-La Roche Inc, 5; Novartis, Inc, 5; Pfizer Inc, 5; UBC, 5; Wyeth Pharmaceuticals, 5 Lubberts, Erik, PhD Cytokines, Mediators, and Gene Regulation I Disclosure: Nothing to Disclose

M Mahr, Alfred, MD, PhD Vasculitis II Disclosure: Nothing to Disclose Maksymowych, Walter P., MD Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment Disclosure: Abbott Laboratories, 5; Amgen, 5; Bristol-Myers Squibb, 5; Eli Lilly and Company, 5; Merck Pharmaceuticals, 5; Pfizer Inc, 5 Mandl, Lisa A., MD, MPH Epidemiology and Health Services Research II: Osteoarthritis Disclosure: Nothing to Disclose Markenson, Joseph A., MD Rheumatoid Arthritis Clinical Aspects: Diagnostic and Remission Criteria Disclosure: TREG, 4 Martin, Richard W., MA, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Further Insights Into Efficacy and Safety of Tumor Necrosis Factor-Inhibitors Disclosure: Nothing to Disclose Martinez-Lavin, Manuel, MD Fibromyalgia and Soft Tissue Disorders I Disclosure: Nothing to Disclose Matucci-Cerinic, Marco, MD, PhD Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Pathogenesis, Animal Models and Genetics I Disclosure: Nothing to Disclose Mayes, Maureen D., MD, MPH Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Clinical Aspects and Therapeutics I Disclosure: Actelion Pharmaceuticals US, 8; Gilead Sciences, 8; United Therapeutics, 2

McAlindon, Timothy E., MD, MPH Osteoarthritis - Clinical Aspects II Disclosure: EMR Serono, 5; Flexion Therapeutics, 5; Internet Based Clncal Trals, 7; Novartis Pharmaceutical Corporation, 5 McLean, Robert R., DSc, MPH ARHP Epidemiology and Public Health I Disclosure: Nothing to Disclose McMahon, Maureen A., MD Systemic Lupus Erythematosus - Clinical Aspects: General Disclosure: Human Genome Sciences, Inc, 8 Mikecz, Katalin, MD, PhD Rheumatoid Arthritis - Animal Models II Disclosure: Nothing to Disclose Miller, Donald R., PharmD ARHP Health Services Research Disclosure: Nothing to Disclose Miossec, Pierre, MD, PhD Cytokines, Mediators, and Gene Regulation III Disclosure: Nothing to Disclose Mohan, Chandra, MD, PhD Systemic Lupus Erythematosus - Clinical Aspects: Renal Disclosure: Nothing to Disclose Monach, Paul A., MD, PhD Vasculitis II Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc, 5 Morgan DeWitt, Esi, MD Quality Measures and Innovations in Practice Management and Care Delivery I Disclosure: Nothing to Disclose Moser, Kathy L., PhD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Genetics Disclosure: Nothing to Disclose Myones, Barry L., MD Antiphospholipid Syndrome Disclosure: Nothing to Disclose

N Navarra, Sandra Systemic Lupus Erythematosus - Clinical Aspects: New Therapies Disclosure: Human Genome Sciences, GlaxoSmithKline, Pfizer, MSD, Roche, 8; Pfizer, 5 Nelson, Amanda E., MD Osteoarthritis - Clinical Aspects II Disclosure: Nothing to Disclose

O Oddis, Chester V., MD ACR Late-breaking Abstract Presentations Disclosure: Nothing to Disclose Onel, Karen, MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Treatment Disclosure: Nothing to Disclose

P Parks, Christine G., PhD ACR/ARHP Combined Epidemiology Abstract Session Disclosure: Nothing to Disclose Perlman, Harris R., PhD Cytokines, Mediators, and Gene Regulation II Disclosure: Novartis Pharmaceutical Corporation, 5 Pilkington, Clarissa A., MBBS, BSc ACR/ARHP Combined Pediatrics Abstract Session Disclosure: Nothing to Disclose Pillinger, Michael H., MD Education: Medical Education Disclosure: Nothing to Disclose Pine, Linda J., PharmD ARHP Health Services Research Disclosure: Amgen, 5 Plenge, Robert M., MD, PhD Genetics, Genomics, and Proteomics Disclosure: Nothing to Disclose Pope, Richard M., MD Innate Immunity and Rheumatic Disease Disclosure: Nothing to Disclose Punaro, Marilynn G., MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Predictors and Outcomes Disclosure: Nothing to Disclose

R Rahman, Anisur, PhD Systemic Lupus Erythematosus - Clinical Aspects: Translational Studies Disclosure: Nothing to Disclose

Reedquist, Kris, PhD Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Pathogenesis of Rheumatoid Arthritis - What’s New? Disclosure: Nothing to Disclose Rigby, William F. C., MD Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Pathogenesis of the Earliest Stages of Rheumatoid Arthritis Disclosure: Genentech, Inc, 2, 5, 8 Ritchlin, Christopher T., MD, MPH Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment III Disclosure: Nothing to Disclose Rodriguez-Reyna, Tatiana, MD Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Clinical Aspects and Therapeutics III Disclosure: Nothing to Disclose

Ruderman, Eric M., MD Rheumatoid Arthritis Clinical Aspects: Risk of Cardiovascular Disease Disclosure: Nothing to Disclose

S Salvarani, Carlo, MD Vasculitis I Disclosure: Nothing to Disclose Sarkar, Sujata, MD T-cell Biology and Targets in Autoimmune Disease: Lymphocyte Biology and Targets in Autoimmune Disease Disclosure: Nothing to Disclose

Smolen, Josef, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Existing Diseasemodifying Antirheumatic Drugs - Tight Control, Induction and Drug Withdrawal Trials Disclosure: Abbott, BMS, Celgene, CentocorJanssen, MSD, Novo-Nordisk, Pfizer, Roche, UCB, 5; Abbott, BMS, MSD, Pfizer, Roche UCB, 2; Textbook co-editor Elsevier-Mosby), 9 Solomon, Daniel H., MD, MPH Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Novel Compounds I Disclosure: Amgen, Abbott, 2; Corrona, 5 St.Clair, E. William, MD ACR Plenary Session I: Discovery 2011 Disclosure: Genentech and Biogen IDEC Inc, 2; Medimmune, 2

Schmajuk, Gabriela, MD, MS Epidemiology and Health Services Research III: Rheumatoid Arthritis Disclosure: Nothing to Disclose

Stohl, William, MD, PhD B-cell Biology and Targets in Autoimmune Disease Disclosure: Xencor, 2

Schmidt, Wolfgang A., MD Imaging of Rheumatic Disease I: Ultrasonography and Dual-emission X-ray Absorptiometry Disclosure: Abbott Immunology Pharmaceuticals, 8; Actelion Pharmaceuticals US, 2; Berlin Chemie, 8; Bristol-Myers Squibb, 8; Chugai, 8; Esaote, 2; Medac, 8; Merck Pharmaceuticals, 8; Merck Sharp Dome, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 8; Roche Pharmaceuticals, 8

Symmons, Deborah P. M., MD Rheumatoid Arthritis Clinical Aspects: Diagnostic and Remission Criteria Disclosure: Nothing to Disclose

Schneider, Rayfel, MBBCh Pediatric Rheumatology - Clinical and Therapeutic Aspects: Clinical Characteristics Disclosure: Hoffmann-La Roche, 5 Shahrara, Shiva, PhD Cytokines, Mediators, and Gene Regulation III Disclosure: Nothing to Disclose Shakoor, Najia, MD Osteoarthritis - Clinical Aspects I Disclosure: Nothing to Disclose Shen, Nan, MD Genetics, Genomics, and Proteomics Disclosure: MedImmune, 2 Simkin, Peter A., MD Metabolic and Crystal Arthropathies I: Pathogenesis of Gout, a Potential Novel Therapy, and Validity of Dual Energy Computed Tomography Disclosure: Ardea, 5; Takeda, 2 Singh, Jasvinder A., MD, MPH Epidemiology and Health Services Research I: Gout Disclosure: Takeda, Novartis, 5; Takeda, Savient, 2 Smarr, Karen L., PhD ARHP Psychology/Social Sciences Disclosure: Nothing to Disclose

Szekanecz, Zoltan, MD, PhD Cell-cell Interactions and Adhesion Disclosure: Nothing to Disclose

T Theis, Kristina A., MPH ARHP Epidemiology and Public Health II Disclosure: Nothing to Disclose Thiele, Ralf G., MD Imaging of Rheumatic Disease I: Ultrasonography and Dual-emission X-ray Absorptiometry Disclosure: SonoSite, 8 Todd, Derrick J., MD, PhD Systemic Lupus Erythematosus - Clinical Aspects: General Disclosure: Nothing to Disclose Trojanowska, Maria, PhD Systemic Sclerosis Fibrosing Syndromes and Raynaud’s - Pathogenesis, Animal Models and Genetics II Disclosure: Nothing to Disclose Tsao, Betty P., PhD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Genetics Disclosure: Nothing to Disclose Tsokos, George C., MD Plenary Session II Disclosure: Nothing to Disclose Tzioufas, Athanasios G., MD Sjögren’s Syndrome Disclosure: Nothing to Disclose


Ranganath, Veena K,, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Novel Compounds II Disclosure: Bristol-Myers Squibb, 2; Celgene, 2; Centocor, Inc, 2; Forest Laboratories, 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2; UCB, 2

Roubey, Robert A. S., MD Antiphospholipid Syndrome Disclosure: Quest Diagnostics, 5

Smith, Judith A., MD, PhD Spondylarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Disclosure: Nothing to Disclose 2011 Program Book

399

V van der Heijde, Desiree, MD, PhD Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment II Disclosure: Abbott, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, ScheringPlough, UCB, Wyeth, 5 Vencovsky, Jiri, MD, PhD Muscle Biology, Myositis and Myopathies: Insights into the Pathogenesis of Myositis Disclosure: Pfizer, UCB, Abbott, MSD, 8; UCB, 5 Villiger, Peter M., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Existing Biologics Disclosure: Nothing to Disclose

W Wanchu, Ajay, MD ARHP Clinical Practice/Patient Care II Disclosure: Nothing to Disclose Ward, Michael M., MD Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment IV Disclosure: Nothing to Disclose Wedderburn, Lucy R., MD, PhD Muscle Biology, Myositis and Myopathies: Insights into the Pathogenesis of Myositis Disclosure: Nothing to Disclose


Weinblatt, Michael E., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Biomarkers Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; Astellas, 5; AstraZeneca, 5; Biogen Idec, 2; Biogen Idec, 5; BristolMyers Squibb, 2; Centocor, Inc, 5; Crescendo Bioscience, 2, 5; Eisai, 5; GlaxoSmithKline, 5; Horizon Therapeutics, 5; Idera, 5; Lilly, 5; Lycera, 5; Medimmune, 5; Merck Pharmaceuticals, 5; Pfizer Inc, 5; Portola, 5; Rigel Pharma, 5; Roche Pharmaceuticals, 2, 5; Sanofi-Aventis Pharmaceutical, 5; UCB, 5; VBL, 5; Vertex, 5 Wiener, Aimee, ARNP, MSN ARHP Education and Community Programs Disclosure: Nothing to Disclose Wooley, Paul H., PhD Rheumatoid Arthritis - Animal Models I Disclosure: Nothing to Disclose Wright, Mary, BS, OT ACR/ARHP Combined Rehabilitation Abstract Session Disclosure: Nothing to Disclose

Y Yazdany, Jinoos, MD, MPH Quality Measures and Innovations in Practice Management and Care Delivery I Disclosure: Nothing to Disclose Yu, David T. Y., MD Infection-Related Rheumatic Disease Disclosure: Nothing to Disclose

400

2011 Program Book

Z Zhang, Yuqing, DSc ARHP Research Methodology Disclosure: Nothing to Disclose

2011 Fellows Education Fund Through the Fellows Education Fund, the ACR is accelerating the education and training of the next generation of rheumatologists. The ACR Fellows Education Fund has a proven track record of successfully providing rheumatology fellows-in-training with outstanding educational opportunities to advance their knowledge and skills to treat an ever-changing patient population. The ACR would like to recognize the following organizations for their generous support of the 2011 Fellows Education Fund:

Abbott Bristol-Myers Squibb Company

In addition to the Fellows Education Fund supporters, the ACR wishes to thank Genentech, A Member of the Roche Group, Janssen Biotech, Inc., UCB, Inc., and Lilly USA, LLC for their support of the 2011 ACR Fellows-In-Training Scholarship Program.

Notes

402

2011 Program Book

Enbrel® (etanercept) Brief Summary SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

WARNINGS SERIOUS INFECTIONS AND MALIGNANCIES Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel. INDICATIONS AND USAGE Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older. Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone. Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Plaque Psoriasis Enbrel is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS Enbrel should not be administered to patients with sepsis. WARNINGS AND PRECAUTIONS Serious Infections Patients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease. Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection, such as advanced or poorly controlled diabetes [see Adverse Reactions]. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel. Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated. Tuberculosis Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has

developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel. Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating antituberculosis therapy is appropriate for an individual patient. Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis. Invasive Fungal Infections Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel. Neurologic Events Treatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions]. Malignancies Lymphomas In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months). Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity. Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials. Leukemia Cases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia. During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months). Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years.

with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years. Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at ≤ 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports. In clinical trials of 696 patients representing 1282 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported. Postmarketing Use In global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported. Patients With Heart Failure Two clinical trials evaluating the use of Enbrel in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully. Hematologic Events Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9/L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy. Hepatitis B Virus Reactivation Use of TNF-blocking agents has been associated with reactivation of hepatitis B virus (HBV), including very rare cases (< 0.01%) with Enbrel, in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers for patients identified as carriers of HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients who are carriers of HBV and require treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation. Allergic Reactions Allergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated. Caution: The needle cap on the prefilled syringe and on the SureClick autoinjector contains dry natural rubber (a derivative of latex) that may cause allergic reactions in individuals sensitive to latex.

Other Malignancies Information is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies.

Immunizations Live vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions].

For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general US population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown.

Autoimmunity Treatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated.

Melanoma and Non-melanoma skin cancer (NMSC) Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept. Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of melanoma was 0.043 cases per 100 patient-years. Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients treated

Immunosuppression TNF mediates inflammation and modulates cellular immune responses. TNFblocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Adverse Reactions]. Use in Wegener’s Granulomatosis Patients The use of Enbrel in patients with Wegener’s granulomatosis receiving

immunosuppressive agents is not recommended. In a study of patients with Wegener’s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions]. Use with Anakinra or Abatacept Use of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions].

compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions]. Other Adverse Reactions Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA. Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials

Use in Patients with Moderate to Severe Alcoholic Hepatitis In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis. ADVERSE REACTIONS Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions. Clinical Studies Experience Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months. In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied. Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice. Infections Infections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents. In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS, and PsO patients. Rates of infections in RA and PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis, and influenza.

In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions]. Injection Site Reactions In placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given. Immunogenicity Patients with RA, PsA, AS, or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS, or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel. In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72, and 96 weeks ranged from 3.6%–8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown. The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to etanercept with the incidence of antibodies to other products may be misleading. Autoantibodies Patients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive antidouble-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased

Placebo (N = 152) Reaction

Enbrelc (N = 349)

Percent of Patients

Infectiond (total) Upper Respiratory Infectionse Non-upper Respiratory Infections Injection Site Reactions Diarrhea Rash Pruritus Pyrexia Urticaria Hypersensitivity

Active Controlledb (Study III) MTX (N = 217)

Enbrelc (N = 415)

Percent of Patients

39 30

50 38

86 70

81 65

15

21

59

54

11

37

18

43

9 2 1 – 1 –

8 3 2 3 – –

16 19 5 4 4 1

16 13 5 2 2 1

Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms. Study duration of 2 years. c Any dose. d Includes bacterial, viral, and fungal infections. e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza. a

b

In placebo-controlled PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group. Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II. Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II) Placebo (N = 359)

Enbrela (N = 876)

Reaction

Percent of Patients

Infectionb (total) Non-upper Respiratory Infections Upper Respiratory Infectionsc Injection Site Reactions Diarrhea Rash Pruritus Urticaria Hypersensitivity Pyrexia

28 14

27 12

17

17

6

15

2 1 2 – – 1

3 1 1 1 1 –

Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses. b Includes bacterial, viral, and fungal infections. c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis, and sinusitis. a

Adverse Reactions in Pediatric Patients In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions]. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children. Postmarketing Experience Adverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure.

cutaneous lupus erythematous, cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar) Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis, and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use. DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions]. Immune-Modulating Biologic Products In a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9/L). In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions]. Cyclophosphamide The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions]. Sulfasalazine Patients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category B. Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to Enbrel. There are, however, no studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Pregnancy Registry: To monitor outcomes of pregnant women exposed to Enbrel, a pregnancy registry has been established. Physicians are encouraged to register patients by calling 1-877-311-8972. Nursing Mothers It is not known whether Enbrel is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Enbrel, a decision should be made whether to discontinue nursing or to discontinue the drug. Pediatric Use Enbrel is indicated for treatment of polyarticular JIA in patients ages 2 years and older [see Indications and Usage, Warnings and Precautions, Adverse Reactions]. Enbrel has not been studied in children < 2 years of age with JIA. The safety and efficacy of Enbrel in pediatric patients with PsO have not been studied. Rare (